A	O	O
common	O	O
human	O	O
skin	B-Disease	D012878
tumour	I-Disease	D012878
is	O	O
caused	O	O
by	O	O
activating	O	O
mutations	O	O
in	O	O
beta	O	O
-	O	O
catenin	O	O
.	O	O

WNT	O	O
signalling	O	O
orchestrates	O	O
a	O	O
number	O	O
of	O	O
developmental	O	O
programs	O	O
.	O	O

In	O	O
response	O	O
to	O	O
this	O	O
stimulus	O	O
,	O	O
cytoplasmic	O	O
beta	O	O
-	O	O
catenin	O	O
(	O	O
encoded	O	O
by	O	O
CTNNB1	O	O
)	O	O
is	O	O
stabilized	O	O
,	O	O
enabling	O	O
downstream	O	O
transcriptional	O	O
activation	O	O
by	O	O
members	O	O
of	O	O
the	O	O
LEF	O	O
/	O	O
TCF	O	O
family	O	O
.	O	O

One	O	O
of	O	O
the	O	O
target	O	O
genes	O	O
for	O	O
beta	O	O
-	O	O
catenin	O	O
/	O	O
TCF	O	O
encodes	O	O
c	O	O
-	O	O
MYC	O	O
,	O	O
explaining	O	O
why	O	O
constitutive	O	O
activation	O	O
of	O	O
the	O	O
WNT	O	O
pathway	O	O
can	O	O
lead	O	O
to	O	O
cancer	B-Disease	D009369
,	O	O
particularly	O	O
in	O	O
the	O	O
colon	O	O
.	O	O

Most	O	O
colon	B-Disease	D003110
cancers	I-Disease	D003110
arise	O	O
from	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
,	O	O
a	O	O
protein	O	O
required	O	O
for	O	O
ubiquitin	O	O
-	O	O
mediated	O	O
degradation	O	O
of	O	O
beta	O	O
-	O	O
catenin	O	O
,	O	O
but	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
colon	B-Disease	D003110
and	I-Disease	D003110
some	I-Disease	D003110
other	I-Disease	D003110
cancers	I-Disease	D003110
harbour	O	O
beta	O	O
-	O	O
catenin	O	O
-	O	O
stabilizing	O	O
mutations	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
discovered	O	O
that	O	O
transgenic	O	O
mice	O	O
expressing	O	O
an	O	O
activated	O	O
beta	O	O
-	O	O
catenin	O	O
are	O	O
predisposed	O	O
to	O	O
developing	O	O
skin	B-Disease	D012878
tumours	I-Disease	D012878
resembling	O	O
pilomatricomas	B-Disease	D018296
.	O	O

Given	O	O
that	O	O
the	O	O
skin	O	O
of	O	O
these	O	O
adult	O	O
mice	O	O
also	O	O
exhibits	O	O
signs	O	O
of	O	O
de	O	O
novo	O	O
hair	O	O
-	O	O
follicle	O	O
morphogenesis	O	O
,	O	O
we	O	O
wondered	O	O
whether	O	O
human	O	O
pilomatricomas	B-Disease	D018296
might	O	O
originate	O	O
from	O	O
hair	O	O
matrix	O	O
cells	O	O
and	O	O
whether	O	O
they	O	O
might	O	O
possess	O	O
beta	O	O
-	O	O
catenin	O	O
-	O	O
stabilizing	O	O
mutations	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
explore	O	O
the	O	O
cell	O	O
origin	O	O
and	O	O
aetiology	O	O
of	O	O
this	O	O
common	O	O
human	O	O
skin	B-Disease	D012878
tumour	I-Disease	D012878
.	O	O

We	O	O
found	O	O
nuclear	O	O
LEF	O	O
-	O	O
1	O	O
in	O	O
the	O	O
dividing	O	O
tumour	B-Disease	D009369
cells	O	O
,	O	O
providing	O	O
biochemical	O	O
evidence	O	O
that	O	O
pilomatricomas	B-Disease	D018296
are	O	O
derived	O	O
from	O	O
hair	O	O
matrix	O	O
cells	O	O
.	O	O

At	O	O
least	O	O
75	O	O
%	O	O
of	O	O
these	O	O
tumours	B-Disease	D009369
possess	O	O
mutations	O	O
affecting	O	O
the	O	O
amino	O	O
-	O	O
terminal	O	O
segment	O	O
,	O	O
normally	O	O
involved	O	O
in	O	O
phosphorylation	O	O
-	O	O
dependent	O	O
,	O	O
ubiquitin	O	O
-	O	O
mediated	O	O
degradation	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

This	O	O
percentage	O	O
of	O	O
CTNNB1	O	O
mutations	O	O
is	O	O
greater	O	O
than	O	O
in	O	O
all	O	O
other	O	O
human	O	O
tumours	B-Disease	D009369
examined	O	O
thus	O	O
far	O	O
,	O	O
and	O	O
directly	O	O
implicates	O	O
beta	O	O
-	O	O
catenin	O	O
/	O	O
LEF	O	O
misregulation	O	O
as	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
hair	O	O
matrix	O	O
cell	O	O
tumorigenesis	O	O
in	O	O
humans	O	O
.	O	O

.	O	O

HFE	O	O
mutations	O	O
analysis	O	O
in	O	O
711	O	O
hemochromatosis	B-Disease	D016399
probands	O	O
:	O	O
evidence	O	O
for	O	O
S65C	O	O
implication	O	O
in	O	O
mild	O	O
form	O	O
of	O	O
hemochromatosis	B-Disease	D016399
.	O	O

Hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
(	O	O
HH	B-Disease	D006432
)	O	O
is	O	O
a	O	O
common	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
of	O	O
iron	O	O
metabolism	O	O
.	O	O

The	O	O
HFE	O	O
candidate	O	O
gene	O	O
encoding	O	O
an	O	O
HLA	O	O
class	O	O
I	O	O
-	O	O
like	O	O
protein	O	O
involved	O	O
in	O	O
HH	B-Disease	D006432
was	O	O
identified	O	O
in	O	O
1996	O	O
.	O	O

Two	O	O
missense	O	O
mutations	O	O
have	O	O
been	O	O
described	O	O
C282Y	O	O
,	O	O
accounting	O	O
for	O	O
80	O	O
%	O	O
to	O	O
90	O	O
%	O	O
of	O	O
HH	B-Disease	D006432
chromosomes	O	O
,	O	O
and	O	O
H63D	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
milder	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
representing	O	O
40	O	O
%	O	O
to	O	O
70	O	O
%	O	O
of	O	O
non	O	O
-	O	O
C282Y	O	O
HH	B-Disease	D006432
chromosomes	O	O
.	O	O

We	O	O
report	O	O
here	O	O
on	O	O
the	O	O
analysis	O	O
of	O	O
C282Y	O	O
,	O	O
H63D	O	O
,	O	O
and	O	O
the	O	O
193A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
substitution	O	O
leading	O	O
to	O	O
the	O	O
S65C	O	O
missense	O	O
substitution	O	O
in	O	O
a	O	O
large	O	O
series	O	O
of	O	O
probands	O	O
and	O	O
controls	O	O
.	O	O

The	O	O
results	O	O
confirm	O	O
that	O	O
the	O	O
C282Y	O	O
substitution	O	O
was	O	O
the	O	O
main	O	O
mutation	O	O
involved	O	O
in	O	O
hemochromatosis	B-Disease	D016399
,	O	O
accounting	O	O
for	O	O
85	O	O
%	O	O
of	O	O
carrier	O	O
chromosomes	O	O
,	O	O
whereas	O	O
the	O	O
H63D	O	O
substitution	O	O
represented	O	O
39	O	O
%	O	O
of	O	O
the	O	O
HH	B-Disease	D006432
chromosomes	O	O
that	O	O
did	O	O
not	O	O
carry	O	O
the	O	O
C282Y	O	O
mutation	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
our	O	O
screening	O	O
showed	O	O
that	O	O
the	O	O
S65C	O	O
substitution	O	O
was	O	O
significantly	O	O
enriched	O	O
in	O	O
probands	O	O
with	O	O
at	O	O
least	O	O
one	O	O
chromosome	O	O
without	O	O
an	O	O
assigned	O	O
mutation	O	O
.	O	O

This	O	O
substitution	O	O
accounted	O	O
for	O	O
7	O	O
.	O	O

8	O	O
%	O	O
of	O	O
HH	B-Disease	D006432
chromosomes	O	O
that	O	O
were	O	O
neither	O	O
C282Y	O	O
nor	O	O
H63D	O	O
.	O	O

This	O	O
enrichment	O	O
of	O	O
S65C	O	O
among	O	O
HH	B-Disease	D006432
chromosomes	O	O
suggests	O	O
that	O	O
the	O	O
S65C	O	O
substitution	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
mild	O	O
form	O	O
of	O	O
hemochromatosis	B-Disease	D016399
.	O	O

Germline	O	O
BRCA1	O	O
alterations	O	O
in	O	O
a	O	O
population	O	O
-	O	O
based	O	O
series	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
cases	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
provide	O	O
more	O	O
accurate	O	O
frequency	O	O
estimates	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
susceptibility	O	O
gene	O	O
1	O	O
(	O	O
BRCA1	O	O
)	O	O
germline	O	O
alterations	O	O
in	O	O
the	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
population	O	O
.	O	O

To	O	O
achieve	O	O
this	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
prevalence	O	O
of	O	O
BRCA1	O	O
alterations	O	O
in	O	O
a	O	O
population	O	O
-	O	O
based	O	O
series	O	O
of	O	O
consecutive	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
cases	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
population	O	O
-	O	O
based	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
study	O	O
reporting	O	O
BRCA1	O	O
alterations	O	O
derived	O	O
from	O	O
a	O	O
comprehensive	O	O
screen	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
seven	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
cases	O	O
were	O	O
analyzed	O	O
for	O	O
BRCA1	O	O
alterations	O	O
using	O	O
the	O	O
RNase	O	O
mismatch	O	O
cleavage	O	O
assay	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O

Two	O	O
truncating	O	O
mutations	O	O
,	O	O
962del4	O	O
and	O	O
3600del11	O	O
,	O	O
were	O	O
identified	O	O
.	O	O

Both	O	O
patients	O	O
had	O	O
a	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Several	O	O
novel	O	O
as	O	O
well	O	O
as	O	O
previously	O	O
reported	O	O
uncharacterized	O	O
variants	O	O
were	O	O
also	O	O
identified	O	O
,	O	O
some	O	O
of	O	O
which	O	O
were	O	O
associated	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
cancer	B-Disease	D009369
.	O	O

The	O	O
frequency	O	O
distribution	O	O
of	O	O
common	O	O
polymorphisms	O	O
was	O	O
determined	O	O
in	O	O
the	O	O
91	O	O
Caucasian	O	O
cancer	B-Disease	D009369
cases	O	O
in	O	O
this	O	O
series	O	O
and	O	O
24	O	O
sister	O	O
controls	O	O
using	O	O
allele	O	O
-	O	O
specific	O	O
amplification	O	O
.	O	O

The	O	O
rare	O	O
form	O	O
of	O	O
the	O	O
Q356R	O	O
polymorphism	O	O
was	O	O
significantly	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
associated	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
suggesting	O	O
that	O	O
this	O	O
polymorphism	O	O
may	O	O
influence	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
risk	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
some	O	O
uncharacterized	O	O
variants	O	O
and	O	O
rare	O	O
forms	O	O
of	O	O
polymorphisms	O	O
in	O	O
determining	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
risk	O	O
,	O	O
and	O	O
highlight	O	O
the	O	O
necessity	O	O
to	O	O
screen	O	O
for	O	O
missense	O	O
alterations	O	O
as	O	O
well	O	O
as	O	O
truncating	O	O
mutations	O	O
in	O	O
this	O	O
population	O	O
.	O	O

Identification	O	O
of	O	O
APC2	O	O
,	O	O
a	O	O
homologue	O	O
of	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
tumour	I-Disease	D011125
suppressor	O	O
.	O	O

The	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	I-Disease	D011125
APC	I-Disease	D011125
)	I-Disease	D011125
tumour	I-Disease	D011125
-	O	O
suppressor	O	O
protein	O	O
controls	O	O
the	O	O
Wnt	O	O
signalling	O	O
pathway	O	O
by	O	O
forming	O	O
a	O	O
complex	O	O
with	O	O
glycogen	O	O
synthase	O	O
kinase	O	O
3beta	O	O
(	O	O
GSK	O	O
-	O	O
3beta	O	O
)	O	O
,	O	O
axin	O	O
/	O	O
conductin	O	O
and	O	O
betacatenin	O	O
.	O	O

Complex	O	O
formation	O	O
induces	O	O
the	O	O
rapid	O	O
degradation	O	O
of	O	O
betacatenin	O	O
.	O	O

In	O	O
colon	B-Disease	D003110
carcinoma	I-Disease	D003110
cells	O	O
,	O	O
loss	O	O
of	O	O
APC	O	O
leads	O	O
to	O	O
the	O	O
accumulation	O	O
of	O	O
betacatenin	O	O
in	O	O
the	O	O
nucleus	O	O
,	O	O
where	O	O
it	O	O
binds	O	O
to	O	O
and	O	O
activates	O	O
the	O	O
Tcf	O	O
-	O	O
4	O	O
transcription	O	O
factor	O	O
(	O	O
reviewed	O	O
in	O	O
[	O	O
1	O	O
]	O	O
[	O	O
2	O	O
]	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
identification	O	O
and	O	O
genomic	O	O
structure	O	O
of	O	O
APC	O	O
homologues	O	O
.	O	O

Mammalian	O	O
APC2	O	O
,	O	O
which	O	O
closely	O	O
resembles	O	O
APC	O	O
in	O	O
overall	O	O
domain	O	O
structure	O	O
,	O	O
was	O	O
functionally	O	O
analyzed	O	O
and	O	O
shown	O	O
to	O	O
contain	O	O
two	O	O
SAMP	O	O
domains	O	O
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
required	O	O
for	O	O
binding	O	O
to	O	O
conductin	O	O
.	O	O

Like	O	O
APC	O	O
,	O	O
APC2	O	O
regulates	O	O
the	O	O
formation	O	O
of	O	O
active	O	O
betacatenin	O	O
-	O	O
Tcf	O	O
complexes	O	O
,	O	O
as	O	O
demonstrated	O	O
using	O	O
transient	O	O
transcriptional	O	O
activation	O	O
assays	O	O
in	O	O
APC	O	O
-	O	O
/	O	O
-	O	O
colon	B-Disease	D003110
carcinoma	I-Disease	D003110
cells	O	O
.	O	O

Human	O	O
APC2	O	O
maps	O	O
to	O	O
chromosome	O	O
19p13	O	O
.	O	O

3	O	O
.	O	O

APC	O	O
and	O	O
APC2	O	O
may	O	O
therefore	O	O
have	O	O
comparable	O	O
functions	O	O
in	O	O
development	O	O
and	O	O
cancer	B-Disease	D009369
.	O	O

Familial	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
associated	O	O
with	O	O
recurrent	O	O
bacteremic	B-Disease	D016870
infections	I-Disease	D016870
due	I-Disease	D016870
to	I-Disease	D016870
Neisseria	I-Disease	D016870
.	O	O

The	O	O
serum	O	O
of	O	O
a	O	O
29	O	O
-	O	O
year	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
recent	O	O
episode	O	O
of	O	O
disseminated	B-Disease	D004673
gonococcal	I-Disease	D004673
infection	I-Disease	D004673
and	O	O
a	O	O
history	O	O
of	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
and	O	O
arthritis	B-Disease	D001168
as	O	O
a	O	O
child	O	O
was	O	O
found	O	O
to	O	O
lack	O	O
serum	O	O
hemolytic	O	O
complement	O	O
activity	O	O
.	O	O

The	O	O
seventh	O	O
component	O	O
of	O	O
complement	O	O
(	O	O
C7	O	O
)	O	O
was	O	O
not	O	O
detected	O	O
by	O	O
functional	O	O
or	O	O
immunochemical	O	O
assays	O	O
,	O	O
whereas	O	O
other	O	O
components	O	O
were	O	O
normal	O	O
by	O	O
hemolytic	O	O
and	O	O
immunochemical	O	O
assessment	O	O
.	O	O

Her	O	O
fresh	O	O
serum	O	O
lacked	O	O
complement	O	O
-	O	O
mediated	O	O
bactericidal	O	O
activity	O	O
against	O	O
Neisseria	O	O
gonorrhoeae	O	O
,	O	O
but	O	O
the	O	O
addition	O	O
of	O	O
fresh	O	O
normal	O	O
serum	O	O
or	O	O
purified	O	O
C7	O	O
restored	O	O
bactericidal	O	O
activity	O	O
as	O	O
well	O	O
as	O	O
hemolytic	O	O
activity	O	O
.	O	O

The	O	O
absence	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
functional	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
activity	O	O
could	O	O
not	O	O
be	O	O
accounted	O	O
for	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
an	O	O
inhibitor	O	O
.	O	O

Opsonization	O	O
and	O	O
generation	O	O
of	O	O
chemotactic	O	O
activity	O	O
functioned	O	O
normally	O	O
.	O	O

Complete	B-Disease	OMIM:610102
absence	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
was	O	O
also	O	O
found	O	O
in	O	O
one	O	O
sibling	O	O
who	O	O
had	O	O
the	O	O
clinical	O	O
syndrome	O	O
of	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
and	O	O
arthritis	B-Disease	D001168
as	O	O
a	O	O
child	O	O
and	O	O
in	O	O
this	O	O
siblings	O	O
clinically	O	O
well	O	O
eight	O	O
-	O	O
year	O	O
-	O	O
old	O	O
son	O	O
.	O	O

HLA	O	O
histocompatibility	O	O
typing	O	O
of	O	O
the	O	O
family	O	O
members	O	O
did	O	O
not	O	O
demonstrate	O	O
evidence	O	O
for	O	O
genetic	O	O
linkage	O	O
of	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
with	O	O
the	O	O
major	O	O
histocompatibility	O	O
loci	O	O
.	O	O

This	O	O
report	O	O
represents	O	O
the	O	O
first	O	O
cases	O	O
of	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
associated	O	O
with	O	O
infectious	O	O
complications	O	O
and	O	O
suggests	O	O
that	O	O
bactericidal	O	O
activity	O	O
may	O	O
be	O	O
important	O	O
in	O	O
host	O	O
defense	O	O
against	O	O
bacteremic	B-Disease	D016870
neisseria	I-Disease	D016870
infections	I-Disease	D016870
.	O	O

GCH1	O	O
mutation	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
oromandibular	B-Disease	D008538
dystonia	I-Disease	D008538
.	O	O

The	O	O
authors	O	O
report	O	O
a	O	O
mutation	O	O
in	O	O
exon	O	O
5	O	O
of	O	O
GCH1	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
oromandibular	B-Disease	D008538
dystonia	I-Disease	D008538
and	O	O
no	O	O
obvious	O	O
family	O	O
history	O	O
of	O	O
dystonia	B-Disease	D004421
.	O	O

The	O	O
patient	O	O
responded	O	O
positively	O	O
to	O	O
treatment	O	O
with	O	O
L	O	O
-	O	O
dopa	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
that	O	O
GCH1	O	O
mutations	O	O
must	O	O
be	O	O
considered	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
dystonic	B-Disease	D004421
symptoms	O	O
not	O	O
typical	O	O
of	O	O
dopa	B-Disease	C538007
-	I-Disease	C538007
responsive	I-Disease	C538007
dystonia	I-Disease	C538007
.	O	O

The	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
protein	O	O
,	O	O
HFE	O	O
,	O	O
specifically	O	O
regulates	O	O
transferrin	O	O
-	O	O
mediated	O	O
iron	O	O
uptake	O	O
in	O	O
HeLa	O	O
cells	O	O
.	O	O

HFE	O	O
is	O	O
the	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
gene	O	O
mutated	O	O
in	O	O
the	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disease	I-Disease	D030342
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
(	O	O
Feder	O	O
,	O	O
J	O	O
.	O	O

N	O	O
.	O	O

,	O	O
Gnirke	O	O
,	O	O
A	O	O
.	O	O

,	O	O
Thomas	O	O
,	O	O
W	O	O
.	O	O

,	O	O
Tsuchihashi	O	O
,	O	O
Z	O	O
.	O	O

,	O	O
Ruddy	O	O
,	O	O
D	O	O
.	O	O

A	O	O
.	O	O

,	O	O
Basava	O	O
,	O	O
A	O	O
.	O	O

,	O	O
Dormishian	O	O
,	O	O
F	O	O
.	O	O

,	O	O
Domingo	O	O
,	O	O
R	O	O
.	O	O

J	O	O
.	O	O

,	O	O
Ellis	O	O
,	O	O
M	O	O
.	O	O

C	O	O
.	O	O

,	O	O
Fullan	O	O
,	O	O
A	O	O
.	O	O

,	O	O
Hinton	O	O
,	O	O
L	O	O
.	O	O

M	O	O
.	O	O

,	O	O
Jones	O	O
,	O	O
N	O	O
.	O	O

L	O	O
.	O	O

,	O	O
Kimmel	O	O
,	O	O
B	O	O
.	O	O

E	O	O
.	O	O

,	O	O
Kronmal	O	O
,	O	O
G	O	O
.	O	O

S	O	O
.	O	O

,	O	O
Lauer	O	O
,	O	O
P	O	O
.	O	O

,	O	O
Lee	O	O
,	O	O
V	O	O
.	O	O

K	O	O
.	O	O

,	O	O
Loeb	O	O
,	O	O
D	O	O
.	O	O

B	O	O
.	O	O

,	O	O
Mapa	O	O
,	O	O
F	O	O
.	O	O

A	O	O
.	O	O

,	O	O
McClelland	O	O
,	O	O
E	O	O
.	O	O

,	O	O
Meyer	O	O
,	O	O
N	O	O
.	O	O

C	O	O
.	O	O

,	O	O
Mintier	O	O
,	O	O
G	O	O
.	O	O

A	O	O
.	O	O

,	O	O
Moeller	O	O
,	O	O
N	O	O
.	O	O

,	O	O
Moore	O	O
,	O	O
T	O	O
.	O	O

,	O	O
Morikang	O	O
,	O	O
E	O	O
.	O	O

,	O	O
Prasss	O	O
,	O	O
C	O	O
.	O	O

E	O	O
.	O	O

,	O	O
Quintana	O	O
,	O	O
L	O	O
.	O	O

,	O	O
Starnes	O	O
,	O	O
S	O	O
.	O	O

M	O	O
.	O	O

,	O	O
Schatzman	O	O
,	O	O
R	O	O
.	O	O

C	O	O
.	O	O

,	O	O
Brunke	O	O
,	O	O
K	O	O
.	O	O

J	O	O
.	O	O

,	O	O
Drayna	O	O
,	O	O
D	O	O
.	O	O

T	O	O
.	O	O

,	O	O
Risch	O	O
,	O	O
N	O	O
.	O	O

J	O	O
.	O	O

,	O	O
Bacon	O	O
,	O	O
B	O	O
.	O	O

R	O	O
.	O	O

,	O	O
and	O	O
Wolff	O	O
,	O	O
R	O	O
.	O	O

R	O	O
.	O	O

(	O	O
1996	O	O
)	O	O
Nat	O	O
.	O	O

Genet	O	O
.	O	O

13	O	O
,	O	O
399	O	O
-	O	O
408	O	O
)	O	O
.	O	O

At	O	O
the	O	O
cell	O	O
surface	O	O
,	O	O
HFE	O	O
complexes	O	O
with	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
,	O	O
increasing	O	O
the	O	O
dissociation	O	O
constant	O	O
of	O	O
transferrin	O	O
(	O	O
Tf	O	O
)	O	O
for	O	O
its	O	O
receptor	O	O
10	O	O
-	O	O
fold	O	O
(	O	O
Gross	O	O
,	O	O
C	O	O
.	O	O

N	O	O
.	O	O

,	O	O
Irrinki	O	O
,	O	O
A	O	O
.	O	O

,	O	O
Feder	O	O
,	O	O
J	O	O
.	O	O

N	O	O
.	O	O

,	O	O
and	O	O
Enns	O	O
,	O	O
C	O	O
.	O	O

A	O	O
.	O	O

(	O	O
1998	O	O
)	O	O
J	O	O
.	O	O

Biol	O	O
.	O	O

Chem	O	O
.	O	O

273	O	O
,	O	O
22068	O	O
-	O	O
22074	O	O
;	O	O
Feder	O	O
,	O	O
J	O	O
.	O	O

N	O	O
.	O	O

,	O	O
Penny	O	O
,	O	O
D	O	O
.	O	O

M	O	O
.	O	O

,	O	O
Irrinki	O	O
,	O	O
A	O	O
.	O	O

,	O	O
Lee	O	O
,	O	O
V	O	O
.	O	O

K	O	O
.	O	O

,	O	O
Lebron	O	O
,	O	O
J	O	O
.	O	O

A	O	O
.	O	O

,	O	O
Watson	O	O
,	O	O
N	O	O
.	O	O

,	O	O
Tsuchihashi	O	O
,	O	O
Z	O	O
.	O	O

,	O	O
Sigal	O	O
,	O	O
E	O	O
.	O	O

,	O	O
Bjorkman	O	O
,	O	O
P	O	O
.	O	O

J	O	O
.	O	O

,	O	O
and	O	O
Schatzman	O	O
,	O	O
R	O	O
.	O	O

C	O	O
.	O	O

(	O	O
1998	O	O
)	O	O
Proc	O	O
.	O	O

Natl	O	O
.	O	O

Acad	O	O
.	O	O

Sci	O	O
.	O	O

U	O	O
S	O	O
A	O	O
95	O	O
,	O	O
1472	O	O
-	O	O
1477	O	O
)	O	O
.	O	O

HFE	O	O
does	O	O
not	O	O
remain	O	O
at	O	O
the	O	O
cell	O	O
surface	O	O
,	O	O
but	O	O
traffics	O	O
with	O	O
TfR	O	O
to	O	O
Tf	O	O
-	O	O
positive	O	O
internal	O	O
compartments	O	O
(	O	O
Gross	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1998	O	O
)	O	O
.	O	O

Using	O	O
a	O	O
HeLa	O	O
cell	O	O
line	O	O
in	O	O
which	O	O
the	O	O
expression	O	O
of	O	O
HFE	O	O
is	O	O
controlled	O	O
by	O	O
tetracycline	O	O
,	O	O
we	O	O
show	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
HFE	O	O
reduces	O	O
55Fe	O	O
uptake	O	O
from	O	O
Tf	O	O
by	O	O
33	O	O
%	O	O
but	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
endocytic	O	O
or	O	O
exocytic	O	O
rates	O	O
of	O	O
TfR	O	O
cycling	O	O
.	O	O

Therefore	O	O
,	O	O
HFE	O	O
appears	O	O
to	O	O
reduce	O	O
cellular	O	O
acquisition	O	O
of	O	O
iron	O	O
from	O	O
Tf	O	O
within	O	O
endocytic	O	O
compartments	O	O
.	O	O

HFE	O	O
specifically	O	O
reduces	O	O
iron	O	O
uptake	O	O
from	O	O
Tf	O	O
,	O	O
as	O	O
non	O	O
-	O	O
Tf	O	O
-	O	O
mediated	O	O
iron	O	O
uptake	O	O
from	O	O
Fe	O	O
-	O	O
nitrilotriacetic	O	O
acid	O	O
is	O	O
not	O	O
altered	O	O
.	O	O

These	O	O
results	O	O
explain	O	O
the	O	O
decreased	O	O
ferritin	O	O
levels	O	O
seen	O	O
in	O	O
our	O	O
HeLa	O	O
cell	O	O
system	O	O
and	O	O
demonstrate	O	O
the	O	O
specific	O	O
control	O	O
of	O	O
HFE	O	O
over	O	O
the	O	O
Tf	O	O
-	O	O
mediated	O	O
pathway	O	O
of	O	O
iron	O	O
uptake	O	O
.	O	O

These	O	O
results	O	O
also	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
understanding	O	O
of	O	O
cellular	O	O
iron	O	O
homeostasis	O	O
in	O	O
organs	O	O
such	O	O
as	O	O
the	O	O
liver	O	O
,	O	O
pancreas	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
spleen	O	O
that	O	O
are	O	O
iron	O	O
loaded	O	O
in	O	O
hereditary	B-Disease	D006432
hemochromatotic	I-Disease	D006432
individuals	O	O
lacking	O	O
functional	O	O
HFE	O	O
.	O	O

Mutation	O	O
and	O	O
haplotype	O	O
studies	O	O
of	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
reveal	O	O
new	O	O
ancestral	O	O
relationships	O	O
and	O	O
evidence	O	O
for	O	O
a	O	O
high	O	O
carrier	O	O
frequency	O	O
with	O	O
reduced	O	O
penetrance	O	O
in	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
population	O	O
.	O	O

Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
is	O	O
a	O	O
recessive	B-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
episodes	O	O
of	O	O
fever	O	O
with	O	O
serositis	B-Disease	D012700
or	O	O
synovitis	B-Disease	D013585
.	O	O

The	O	O
FMF	B-Disease	D010505
gene	O	O
(	O	O
MEFV	O	O
)	O	O
was	O	O
cloned	O	O
recently	O	O
,	O	O
and	O	O
four	O	O
missense	O	O
mutations	O	O
were	O	O
identified	O	O
.	O	O

Here	O	O
we	O	O
present	O	O
data	O	O
from	O	O
non	O	O
-	O	O
Ashkenazi	O	O
Jewish	O	O
and	O	O
Arab	O	O
patients	O	O
in	O	O
whom	O	O
we	O	O
had	O	O
not	O	O
originally	O	O
found	O	O
mutations	O	O
and	O	O
from	O	O
a	O	O
new	O	O
,	O	O
more	O	O
ethnically	O	O
diverse	O	O
panel	O	O
.	O	O

Among	O	O
90	O	O
symptomatic	O	O
mutation	O	O
-	O	O
positive	O	O
individuals	O	O
,	O	O
11	O	O
mutations	O	O
accounted	O	O
for	O	O
79	O	O
%	O	O
of	O	O
carrier	O	O
chromosomes	O	O
.	O	O

Of	O	O
the	O	O
two	O	O
mutations	O	O
that	O	O
are	O	O
novel	O	O
,	O	O
one	O	O
alters	O	O
the	O	O
same	O	O
residue	O	O
(	O	O
680	O	O
)	O	O
as	O	O
a	O	O
previously	O	O
known	O	O
mutation	O	O
,	O	O
and	O	O
the	O	O
other	O	O
(	O	O
P369S	O	O
)	O	O
is	O	O
located	O	O
in	O	O
exon	O	O
3	O	O
.	O	O

Consistent	O	O
with	O	O
another	O	O
recent	O	O
report	O	O
,	O	O
the	O	O
E148Q	O	O
mutation	O	O
was	O	O
observed	O	O
in	O	O
patients	O	O
of	O	O
several	O	O
ethnicities	O	O
and	O	O
on	O	O
multiple	O	O
microsatellite	O	O
haplotypes	O	O
,	O	O
but	O	O
haplotype	O	O
data	O	O
indicate	O	O
an	O	O
ancestral	O	O
relationships	O	O
between	O	O
non	O	O
-	O	O
Jewish	O	O
Italian	O	O
and	O	O
Ashkenazi	O	O
Jewish	O	O
patients	O	O
with	O	O
FMF	B-Disease	D010505
and	O	O
other	O	O
affected	O	O
populations	O	O
.	O	O

Among	O	O
approximately	O	O
200	O	O
anonymous	O	O
Ashkenazi	O	O
Jewish	O	O
DNA	O	O
samples	O	O
,	O	O
the	O	O
MEFV	O	O
carrier	O	O
frequency	O	O
was	O	O
21	O	O
%	O	O
,	O	O
with	O	O
E148Q	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
.	O	O

Several	O	O
lines	O	O
of	O	O
evidence	O	O
indicate	O	O
reduced	O	O
penetrance	O	O
among	O	O
Ashkenazi	O	O
Jews	O	O
,	O	O
especially	O	O
for	O	O
E148Q	O	O
,	O	O
P369S	O	O
,	O	O
and	O	O
K695R	O	O
.	O	O

Nevertheless	O	O
,	O	O
E148Q	O	O
helps	O	O
account	O	O
for	O	O
recessive	O	O
inheritance	O	O
in	O	O
an	O	O
Ashkenazi	O	O
family	O	O
previously	O	O
reported	O	O
as	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
dominantly	O	O
inherited	O	O
FMF	B-Disease	D010505
.	O	O

The	O	O
presence	O	O
of	O	O
three	O	O
frequent	O	O
MEFV	O	O
mutations	O	O
in	O	O
multiple	O	O
Mediterranean	O	O
populations	O	O
strongly	O	O
suggests	O	O
a	O	O
heterozygote	O	O
advantage	O	O
in	O	O
this	O	O
geographic	O	O
region	O	O
.	O	O

Autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
with	O	O
defective	O	O
Fas	O	O
:	O	O
genotype	O	O
influences	O	O
penetrance	O	O
.	O	O

Autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
(	O	O
ALPS	B-Disease	D056735
)	O	O
is	O	O
a	O	O
disorder	B-Disease	D008232
of	I-Disease	D008232
lymphocyte	I-Disease	D008232
homeostasis	I-Disease	D008232
and	I-Disease	D008232
immunological	I-Disease	D008232
tolerance	I-Disease	D008232
.	O	O

Most	O	O
patients	O	O
have	O	O
a	O	O
heterozygous	O	O
mutation	O	O
in	O	O
the	O	O
APT1	O	O
gene	O	O
,	O	O
which	O	O
encodes	O	O
Fas	O	O
(	O	O
CD95	O	O
,	O	O
APO	O	O
-	O	O
1	O	O
)	O	O
,	O	O
mediator	O	O
of	O	O
an	O	O
apoptotic	O	O
pathway	O	O
crucial	O	O
to	O	O
lymphocyte	O	O
homeostasis	O	O
.	O	O

Of	O	O
17	O	O
unique	O	O
APT1	O	O
mutations	O	O
in	O	O
unrelated	O	O
ALPS	B-Disease	D056735
probands	O	O
,	O	O
12	O	O
(	O	O
71	O	O
%	O	O
)	O	O
occurred	O	O
in	O	O
exons	O	O
7	O	O
-	O	O
9	O	O
,	O	O
which	O	O
encode	O	O
the	O	O
intracellular	O	O
portion	O	O
of	O	O
Fas	O	O
.	O	O

In	O	O
vitro	O	O
,	O	O
activated	O	O
lymphocytes	O	O
from	O	O
all	O	O
17	O	O
patients	O	O
showed	O	O
apoptotic	O	O
defects	O	O
when	O	O
exposed	O	O
to	O	O
an	O	O
anti	O	O
-	O	O
Fas	O	O
agonist	O	O
monoclonal	O	O
antibody	O	O
.	O	O

Similar	O	O
defects	O	O
were	O	O
found	O	O
in	O	O
a	O	O
Fas	O	O
-	O	O
negative	O	O
cell	O	O
line	O	O
transfected	O	O
with	O	O
cDNAs	O	O
bearing	O	O
each	O	O
of	O	O
the	O	O
mutations	O	O
.	O	O

In	O	O
cotransfection	O	O
experiments	O	O
,	O	O
Fas	O	O
constructs	O	O
with	O	O
either	O	O
intra	O	O
-	O	O
or	O	O
extracellular	O	O
mutations	O	O
caused	O	O
dominant	O	O
inhibition	O	O
of	O	O
apoptosis	O	O
mediated	O	O
by	O	O
wild	O	O
-	O	O
type	O	O
Fas	O	O
.	O	O

Two	O	O
missense	O	O
Fas	O	O
variants	O	O
,	O	O
not	O	O
restricted	O	O
to	O	O
patients	O	O
with	O	O
ALPS	B-Disease	D056735
,	O	O
were	O	O
identified	O	O
.	O	O

Variant	O	O
A	O	O
(	O	O
-	O	O
1	O	O
)	O	O
T	O	O
at	O	O
the	O	O
Fas	O	O
signal	O	O
-	O	O
sequence	O	O
cleavage	O	O
site	O	O
,	O	O
which	O	O
mediates	O	O
apoptosis	O	O
less	O	O
well	O	O
than	O	O
wild	O	O
-	O	O
type	O	O
Fas	O	O
and	O	O
is	O	O
partially	O	O
inhibitory	O	O
,	O	O
was	O	O
present	O	O
in	O	O
13	O	O
%	O	O
of	O	O
African	O	O
American	O	O
alleles	O	O
.	O	O

Among	O	O
the	O	O
ALPS	B-Disease	D056735
-	O	O
associated	O	O
Fas	O	O
mutants	O	O
,	O	O
dominant	O	O
inhibition	O	O
of	O	O
apoptosis	O	O
was	O	O
much	O	O
more	O	O
pronounced	O	O
in	O	O
mutants	O	O
affecting	O	O
the	O	O
intracellular	O	O
,	O	O
versus	O	O
extracellular	O	O
,	O	O
portion	O	O
of	O	O
the	O	O
Fas	O	O
receptor	O	O
.	O	O

Mutations	O	O
causing	O	O
disruption	O	O
of	O	O
the	O	O
intracellular	O	O
Fas	O	O
death	O	O
domain	O	O
also	O	O
showed	O	O
a	O	O
higher	O	O
penetrance	O	O
of	O	O
ALPS	B-Disease	D056735
phenotype	O	O
features	O	O
in	O	O
mutation	O	O
-	O	O
bearing	O	O
relatives	O	O
.	O	O

Significant	O	O
ALPS	B-Disease	D056735
-	O	O
related	O	O
morbidity	O	O
occurred	O	O
in	O	O
44	O	O
%	O	O
of	O	O
relatives	O	O
with	O	O
intracellular	O	O
mutations	O	O
,	O	O
versus	O	O
0	O	O
%	O	O
of	O	O
relatives	O	O
with	O	O
extracellular	O	O
mutations	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
location	O	O
of	O	O
mutations	O	O
within	O	O
APT1	O	O
strongly	O	O
influences	O	O
the	O	O
development	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
ALPS	B-Disease	D056735
.	O	O

Mutational	O	O
analysis	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
of	O	O
29	O	O
unrelated	O	O
Japanese	O	O
patients	O	O
with	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
.	O	O

BACKGROUND	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
is	O	O
an	O	O
inherited	B-Disease	D030342
disease	I-Disease	D030342
characterized	O	O
by	O	O
progressive	O	O
neurologic	B-Disease	D009461
dysfunction	I-Disease	D009461
,	O	O
occasionally	O	O
associated	O	O
with	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
.	O	O

The	O	O
classic	O	O
form	O	O
of	O	O
ALD	B-Disease	D000326
usually	O	O
has	O	O
onset	O	O
in	O	O
childhood	O	O
(	O	O
childhood	B-Disease	D000326
cerebral	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
,	O	O
with	O	O
rapid	O	O
neurologic	B-Disease	D009461
deterioration	I-Disease	D009461
leading	O	O
to	O	O
a	O	O
vegetative	O	O
state	O	O
.	O	O

Adult	O	O
-	O	O
onset	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
also	O	O
presents	O	O
with	O	O
rapidly	O	O
progressive	O	O
neurologic	B-Disease	D009461
dysfunction	I-Disease	D009461
.	O	O

Milder	O	O
phenotypes	O	O
such	O	O
as	O	O
adrenomyeloneuropathy	B-Disease	D000326
and	O	O
Addison	B-Disease	D000224
disease	I-Disease	D000224
only	O	O
also	O	O
have	O	O
been	O	O
recognized	O	O
.	O	O

Despite	O	O
discovery	O	O
of	O	O
the	O	O
causative	O	O
gene	O	O
,	O	O
a	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
diverse	O	O
clinical	O	O
presentations	O	O
remains	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

OBJECTIVES	O	O
To	O	O
conduct	O	O
mutational	O	O
analyses	O	O
in	O	O
29	O	O
Japanese	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
from	O	O
29	O	O
unrelated	O	O
families	O	O
,	O	O
to	O	O
obtain	O	O
knowledge	O	O
of	O	O
the	O	O
spectrum	O	O
of	O	O
mutations	O	O
in	O	O
this	O	O
gene	O	O
,	O	O
and	O	O
to	O	O
study	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
Japanese	O	O
patients	O	O
.	O	O

METHODS	O	O
The	O	O
29	O	O
patients	O	O
comprised	O	O
13	O	O
patients	O	O
with	O	O
childhood	B-Disease	D000326
cerebral	I-Disease	D000326
ALD	I-Disease	D000326
,	O	O
11	O	O
patients	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
,	O	O
and	O	O
5	O	O
patients	O	O
with	O	O
adrenomyeloneuropathy	B-Disease	D000326
.	O	O

We	O	O
conducted	O	O
detailed	O	O
mutational	O	O
analyses	O	O
of	O	O
29	O	O
unrelated	O	O
Japanese	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
by	O	O
genomic	O	O
Southern	O	O
blot	O	O
analysis	O	O
and	O	O
direct	O	O
nucleotide	O	O
sequence	O	O
analysis	O	O
of	O	O
reverse	O	O
transcriptase	O	O
-	O	O
polymerase	O	O
chain	O	O
reaction	O	O
products	O	O
derived	O	O
from	O	O
total	O	O
RNA	O	O
that	O	O
was	O	O
extracted	O	O
from	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
,	O	O
lymphoblastoid	O	O
cells	O	O
,	O	O
or	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
.	O	O

RESULTS	O	O
Three	O	O
patients	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
were	O	O
identified	O	O
as	O	O
having	O	O
large	O	O
genomic	O	O
rearrangements	O	O
.	O	O

The	O	O
remaining	O	O
26	O	O
patients	O	O
were	O	O
identified	O	O
as	O	O
having	O	O
21	O	O
independent	O	O
mutations	O	O
,	O	O
including	O	O
12	O	O
novel	O	O
mutations	O	O
resulting	O	O
in	O	O
small	O	O
nucleotide	O	O
alterations	O	O
in	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
.	O	O

Eighteen	O	O
(	O	O
69	O	O
%	O	O
)	O	O
of	O	O
26	O	O
mutations	O	O
were	O	O
missense	O	O
mutations	O	O
.	O	O

Most	O	O
missense	O	O
mutations	O	O
involved	O	O
amino	O	O
acids	O	O
conserved	O	O
in	O	O
homologous	O	O
gene	O	O
products	O	O
,	O	O
including	O	O
PMP70	O	O
,	O	O
mALDRP	O	O
,	O	O
and	O	O
Pxa1p	O	O
.	O	O

The	O	O
AG	O	O
dinucleotide	O	O
deletion	O	O
at	O	O
position	O	O
1081	O	O
-	O	O
1082	O	O
,	O	O
which	O	O
has	O	O
been	O	O
reported	O	O
previously	O	O
to	O	O
be	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
in	O	O
white	O	O
patients	O	O
(	O	O
12	O	O
%	O	O
-	O	O
17	O	O
%	O	O
)	O	O
,	O	O
was	O	O
also	O	O
identified	O	O
as	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
in	O	O
Japanese	O	O
patients	O	O
(	O	O
12	O	O
%	O	O
)	O	O
.	O	O

All	O	O
phenotypes	O	O
were	O	O
associated	O	O
with	O	O
mutations	O	O
resulting	O	O
in	O	O
protein	O	O
truncation	O	O
or	O	O
subtle	O	O
amino	O	O
acid	O	O
changes	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
phenotypic	O	O
expressions	O	O
between	O	O
missense	O	O
mutations	O	O
involving	O	O
conserved	O	O
amino	O	O
acids	O	O
and	O	O
those	O	O
involving	O	O
nonconserved	O	O
amino	O	O
acids	O	O
.	O	O

CONCLUSIONS	O	O
There	O	O
are	O	O
no	O	O
obvious	O	O
correlations	O	O
between	O	O
the	O	O
phenotypes	O	O
of	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
and	O	O
their	O	O
genotypes	O	O
,	O	O
suggesting	O	O
that	O	O
other	O	O
genetic	O	O
or	O	O
environmental	O	O
factors	O	O
modify	O	O
the	O	O
phenotypic	O	O
expressions	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

.	O	O

Absence	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	B-Disease	D008589
meningococcemia	I-Disease	D008589
presenting	O	O
as	O	O
vasculitis	B-Disease	D014657
.	O	O

A	O	O
previously	O	O
healthy	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
presenting	O	O
with	O	O
fever	B-Disease	D005334
,	O	O
arthritis	B-Disease	D001168
,	O	O
and	O	O
cutaneous	B-Disease	D018366
vasculitis	I-Disease	D018366
was	O	O
found	O	O
to	O	O
have	O	O
chronic	B-Disease	D008589
meningococcemia	I-Disease	D008589
.	O	O

Evaluation	O	O
of	O	O
his	O	O
complement	O	O
system	O	O
showed	O	O
an	O	O
absence	O	O
of	O	O
functional	O	O
and	O	O
antigenic	O	O
C7	O	O
,	O	O
compatible	O	O
with	O	O
a	O	O
complete	O	O
deficiency	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
.	O	O

Study	O	O
of	O	O
the	O	O
patients	O	O
family	O	O
spanning	O	O
four	O	O
generations	O	O
showed	O	O
heterozygous	O	O
deficiency	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
in	O	O
five	O	O
members	O	O
.	O	O

Chronic	B-Disease	D016870
neisserial	I-Disease	D016870
infection	I-Disease	D016870
can	O	O
be	O	O
associated	O	O
with	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
and	O	O
must	O	O
be	O	O
distinguished	O	O
from	O	O
other	O	O
causes	O	O
of	O	O
cutaneous	B-Disease	D018366
vasculitis	I-Disease	D018366
.	O	O

.	O	O

Genotype	O	O
and	O	O
phenotype	O	O
in	O	O
patients	O	O
with	O	O
dihydropyrimidine	B-Disease	D054067
dehydrogenase	I-Disease	D054067
deficiency	I-Disease	D054067
.	O	O

Dihydropyrimidine	B-Disease	D054067
dehydrogenase	I-Disease	D054067
(	I-Disease	D054067
DPD	I-Disease	D054067
)	I-Disease	D054067
deficiency	I-Disease	D054067
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disease	I-Disease	D030342
characterised	O	O
by	O	O
thymine	O	O
-	O	O
uraciluria	O	O
in	O	O
homozygous	O	O
deficient	O	O
patients	O	O
and	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
a	O	O
variable	O	O
clinical	O	O
phenotype	O	O
.	O	O

In	O	O
order	O	O
to	O	O
understand	O	O
the	O	O
genetic	O	O
and	O	O
phenotypic	O	O
basis	O	O
for	O	O
DPD	B-Disease	D054067
deficiency	I-Disease	D054067
,	O	O
we	O	O
have	O	O
reviewed	O	O
17	O	O
families	O	O
presenting	O	O
22	O	O
patients	O	O
with	O	O
complete	O	O
deficiency	B-Disease	D054067
of	I-Disease	D054067
DPD	I-Disease	D054067
.	O	O

In	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
,	O	O
7	O	O
different	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
including	O	O
2	O	O
deletions	O	O
[	O	O
295	O	O
-	O	O
298delTCAT	O	O
,	O	O
1897delC	O	O
]	O	O
,	O	O
1	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
[	O	O
IVS14	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
)	O	O
]	O	O
and	O	O
4	O	O
missense	O	O
mutations	O	O
(	O	O
85T	O	O
>	O	O
C	O	O
,	O	O
703C	O	O
>	O	O
T	O	O
,	O	O
2658G	O	O
>	O	O
A	O	O
,	O	O
2983G	O	O
>	O	O
T	O	O
)	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
prevalence	O	O
of	O	O
the	O	O
various	O	O
mutations	O	O
among	O	O
DPD	B-Disease	D054067
patients	O	O
has	O	O
shown	O	O
that	O	O
the	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
point	O	O
mutation	O	O
in	O	O
the	O	O
invariant	O	O
splice	O	O
donor	O	O
site	O	O
is	O	O
by	O	O
far	O	O
the	O	O
most	O	O
common	O	O
(	O	O
52	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
other	O	O
six	O	O
mutations	O	O
are	O	O
less	O	O
frequently	O	O
observed	O	O
.	O	O

A	O	O
large	O	O
phenotypic	O	O
variability	O	O
has	O	O
been	O	O
observed	O	O
,	O	O
with	O	O
convulsive	B-Disease	D004829
disorders	I-Disease	D004829
,	O	O
motor	B-Disease	D019957
retardation	I-Disease	D019957
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
being	O	O
the	O	O
most	O	O
abundant	O	O
manifestations	O	O
.	O	O

A	O	O
clear	O	O
correlation	O	O
between	O	O
the	O	O
genotype	O	O
and	O	O
phenotype	O	O
has	O	O
not	O	O
been	O	O
established	O	O
.	O	O

An	O	O
altered	O	O
beta	O	O
-	O	O
alanine	O	O
,	O	O
uracil	O	O
and	O	O
thymine	O	O
homeostasis	O	O
might	O	O
underlie	O	O
the	O	O
various	O	O
clinical	B-Disease	D013568
abnormalities	I-Disease	D013568
encountered	O	O
in	O	O
patients	O	O
with	O	O
DPD	B-Disease	D054067
deficiency	I-Disease	D054067
.	O	O

Molecular	O	O
characterization	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
by	O	O
natural	O	O
and	O	O
amplification	O	O
created	O	O
restriction	O	O
sites	O	O
:	O	O
five	O	O
mutations	O	O
account	O	O
for	O	O
most	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
cases	O	O
in	O	O
Taiwan	O	O
.	O	O

We	O	O
have	O	O
developed	O	O
a	O	O
rapid	O	O
and	O	O
simple	O	O
method	O	O
to	O	O
diagnose	O	O
the	O	O
molecular	O	O
defects	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Chinese	O	O
in	O	O
Taiwan	O	O
.	O	O

This	O	O
method	O	O
involves	O	O
the	O	O
selective	O	O
amplification	O	O
of	O	O
a	O	O
DNA	O	O
fragment	O	O
from	O	O
human	O	O
G6PD	O	O
gene	O	O
with	O	O
specific	O	O
oligonucleotide	O	O
primers	O	O
followed	O	O
by	O	O
digestion	O	O
with	O	O
restriction	O	O
enzymes	O	O
that	O	O
recognize	O	O
artificially	O	O
created	O	O
or	O	O
naturally	O	O
occurring	O	O
restriction	O	O
sites	O	O
.	O	O

Ninety	O	O
-	O	O
four	O	O
Chinese	O	O
males	O	O
with	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
were	O	O
studied	O	O
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
50	O	O
%	O	O
(	O	O
47	O	O
of	O	O
94	O	O
)	O	O
were	O	O
G	O	O
to	O	O
T	O	O
mutation	O	O
at	O	O
nucleotide	O	O
(	O	O
nt	O	O
)	O	O
1376	O	O
,	O	O
21	O	O
.	O	O

3	O	O
%	O	O
(	O	O
20	O	O
of	O	O
94	O	O
)	O	O
were	O	O
G	O	O
to	O	O
A	O	O
mutation	O	O
at	O	O
nt	O	O
1388	O	O
,	O	O
7	O	O
.	O	O

4	O	O
%	O	O
(	O	O
7	O	O
of	O	O
94	O	O
)	O	O
were	O	O
A	O	O
to	O	O
G	O	O
mutation	O	O
at	O	O
nt	O	O
493	O	O
,	O	O
7	O	O
.	O	O

4	O	O
%	O	O
(	O	O
7	O	O
of	O	O
94	O	O
)	O	O
were	O	O
A	O	O
to	O	O
G	O	O
mutation	O	O
at	O	O
nt	O	O
95	O	O
,	O	O
4	O	O
.	O	O

2	O	O
%	O	O
(	O	O
4	O	O
of	O	O
94	O	O
)	O	O
were	O	O
C	O	O
to	O	O
T	O	O
mutation	O	O
at	O	O
nt	O	O
1024	O	O
,	O	O
1	O	O
.	O	O

1	O	O
%	O	O
(	O	O
1	O	O
of	O	O
94	O	O
)	O	O
was	O	O
G	O	O
to	O	O
T	O	O
mutation	O	O
at	O	O
nt	O	O
392	O	O
,	O	O
and	O	O
1	O	O
.	O	O

1	O	O
%	O	O
(	O	O
1	O	O
of	O	O
94	O	O
)	O	O
was	O	O
G	O	O
to	O	O
A	O	O
mutation	O	O
at	O	O
nt	O	O
487	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
the	O	O
former	O	O
five	O	O
mutations	O	O
account	O	O
for	O	O
more	O	O
than	O	O
90	O	O
%	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
cases	O	O
in	O	O
Taiwan	O	O
.	O	O

Aside	O	O
from	O	O
showing	O	O
that	O	O
G	O	O
to	O	O
T	O	O
change	O	O
at	O	O
nt	O	O
1376	O	O
is	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
,	O	O
our	O	O
research	O	O
indicates	O	O
that	O	O
nt	O	O
493	O	O
mutation	O	O
is	O	O
a	O	O
frequent	O	O
mutation	O	O
among	O	O
Chinese	O	O
in	O	O
Taiwan	O	O
.	O	O

We	O	O
compared	O	O
G6PD	O	O
activity	O	O
among	O	O
different	O	O
mutations	O	O
,	O	O
without	O	O
discovering	O	O
significant	O	O
differences	O	O
between	O	O
them	O	O
.	O	O

Homozygous	B-Disease	D006995
hypobetalipoproteinemia	I-Disease	D006995
:	O	O
a	O	O
disease	O	O
distinct	O	O
from	O	O
abetalipoproproteinemia	B-Disease	D000012
at	O	O
the	O	O
molecular	O	O
level	O	O
.	O	O

apoB	O	O
DNA	O	O
,	O	O
RNA	O	O
,	O	O
and	O	O
protein	O	O
from	O	O
two	O	O
patients	O	O
with	O	O
homozygous	B-Disease	D006995
hypobetalipoproteinemia	I-Disease	D006995
(	O	O
HBL	B-Disease	D006995
)	O	O
were	O	O
evaluated	O	O
and	O	O
compared	O	O
with	O	O
normal	O	O
individuals	O	O
.	O	O

Southern	O	O
blot	O	O
analysis	O	O
with	O	O
10	O	O
different	O	O
cDNA	O	O
probes	O	O
revealed	O	O
a	O	O
normal	O	O
gene	O	O
without	O	O
major	O	O
insertions	O	O
,	O	O
deletions	O	O
,	O	O
or	O	O
rearrangements	O	O
.	O	O

Northern	O	O
and	O	O
slot	O	O
blot	O	O
analyses	O	O
of	O	O
total	O	O
liver	O	O
mRNA	O	O
from	O	O
HBL	B-Disease	D006995
patients	O	O
documented	O	O
a	O	O
normal	O	O
size	O	O
apoB	O	O
mRNA	O	O
that	O	O
was	O	O
present	O	O
in	O	O
greatly	O	O
reduced	O	O
quantities	O	O
.	O	O

ApoB	O	O
protein	O	O
was	O	O
detected	O	O
within	O	O
HBL	B-Disease	D006995
hepatocytes	O	O
utilizing	O	O
immunohistochemical	O	O
techniques	O	O
;	O	O
however	O	O
,	O	O
it	O	O
was	O	O
markedly	O	O
reduced	O	O
in	O	O
quantity	O	O
when	O	O
compared	O	O
with	O	O
control	O	O
samples	O	O
.	O	O

No	O	O
apoB	O	O
was	O	O
detectable	O	O
in	O	O
the	O	O
plasma	O	O
of	O	O
HBL	B-Disease	D006995
individuals	O	O
with	O	O
an	O	O
ELISA	O	O
assay	O	O
.	O	O

These	O	O
data	O	O
are	O	O
most	O	O
consistent	O	O
with	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
coding	O	O
portion	O	O
of	O	O
the	O	O
apoB	O	O
gene	O	O
in	O	O
HBL	B-Disease	D006995
patients	O	O
,	O	O
leading	O	O
to	O	O
an	O	O
abnormal	O	O
apoB	O	O
protein	O	O
and	O	O
apoB	O	O
mRNA	O	O
instability	O	O
.	O	O

These	O	O
results	O	O
are	O	O
distinct	O	O
from	O	O
those	O	O
previously	O	O
noted	O	O
in	O	O
abetalipoproteinemia	B-Disease	D000012
,	O	O
which	O	O
was	O	O
characterized	O	O
by	O	O
an	O	O
elevated	O	O
level	O	O
of	O	O
hepatic	O	O
apoB	O	O
mRNA	O	O
and	O	O
accumulation	O	O
of	O	O
intracellular	O	O
hepatic	O	O
apoB	O	O
protein	O	O
.	O	O

.	O	O

A	O	O
population	O	O
-	O	O
based	O	O
study	O	O
of	O	O
the	O	O
clinical	O	O
expression	O	O
of	O	O
the	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
METHODS	O	O
Hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
is	O	O
associated	O	O
with	O	O
homozygosity	O	O
for	O	O
the	O	O
C282Y	O	O
mutation	O	O
in	O	O
the	O	O
hemochromatosis	B-Disease	D006432
(	O	O
HFE	O	O
)	O	O
gene	O	O
on	O	O
chromosome	O	O
6	O	O
,	O	O
elevated	O	O
serum	O	O
transferrin	O	O
saturation	O	O
,	O	O
and	O	O
excess	B-Disease	D019190
iron	I-Disease	D019190
deposits	I-Disease	D019190
throughout	O	O
the	O	O
body	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
prevalence	O	O
and	O	O
clinical	O	O
expression	O	O
of	O	O
the	O	O
HFE	O	O
gene	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
population	O	O
-	O	O
based	O	O
study	O	O
in	O	O
Busselton	O	O
,	O	O
Australia	O	O
.	O	O

In	O	O
1994	O	O
,	O	O
we	O	O
obtained	O	O
blood	O	O
samples	O	O
for	O	O
the	O	O
determination	O	O
of	O	O
serum	O	O
transferrin	O	O
saturation	O	O
and	O	O
ferritin	O	O
levels	O	O
and	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
the	O	O
C282Y	O	O
mutation	O	O
and	O	O
the	O	O
H63D	O	O
mutation	O	O
(	O	O
which	O	O
may	O	O
contribute	O	O
to	O	O
increased	O	O
hepatic	O	O
iron	O	O
levels	O	O
)	O	O
in	O	O
3011	O	O
unrelated	O	O
white	O	O
adults	O	O
.	O	O

We	O	O
evaluated	O	O
all	O	O
subjects	O	O
who	O	O
had	O	O
persistently	O	O
elevated	O	O
transferrin	O	O
-	O	O
saturation	O	O
values	O	O
(	O	O
45	O	O
percent	O	O
or	O	O
higher	O	O
)	O	O
or	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
C282Y	O	O
mutation	O	O
.	O	O

We	O	O
recommended	O	O
liver	O	O
biopsy	O	O
for	O	O
subjects	O	O
with	O	O
serum	O	O
ferritin	O	O
levels	O	O
of	O	O
300	O	O
ng	O	O
per	O	O
milliliter	O	O
or	O	O
higher	O	O
.	O	O

The	O	O
subjects	O	O
were	O	O
followed	O	O
for	O	O
up	O	O
to	O	O
four	O	O
years	O	O
.	O	O

RESULTS	O	O
Sixteen	O	O
of	O	O
the	O	O
subjects	O	O
(	O	O
0	O	O
.	O	O

5	O	O
percent	O	O
)	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
C282Y	O	O
mutation	O	O
,	O	O
and	O	O
424	O	O
(	O	O
14	O	O
.	O	O

1	O	O
percent	O	O
)	O	O
were	O	O
heterozygous	O	O
.	O	O

The	O	O
serum	O	O
transferrin	O	O
saturation	O	O
was	O	O
45	O	O
percent	O	O
or	O	O
higher	O	O
in	O	O
15	O	O
of	O	O
the	O	O
16	O	O
who	O	O
were	O	O
homozygous	O	O
;	O	O
in	O	O
1	O	O
subject	O	O
it	O	O
was	O	O
43	O	O
percent	O	O
.	O	O

Four	O	O
of	O	O
the	O	O
homozygous	O	O
subjects	O	O
had	O	O
previously	O	O
been	O	O
given	O	O
a	O	O
diagnosis	O	O
of	O	O
hemochromatosis	B-Disease	D006432
,	O	O
and	O	O
12	O	O
had	O	O
not	O	O
.	O	O

Seven	O	O
of	O	O
these	O	O
12	O	O
patients	O	O
had	O	O
elevated	O	O
serum	O	O
ferritin	O	O
levels	O	O
in	O	O
1994	O	O
;	O	O
6	O	O
of	O	O
the	O	O
7	O	O
had	O	O
further	O	O
increases	O	O
in	O	O
1998	O	O
,	O	O
and	O	O
1	O	O
had	O	O
a	O	O
decrease	O	O
,	O	O
although	O	O
the	O	O
value	O	O
remained	O	O
elevated	O	O
.	O	O

The	O	O
serum	O	O
ferritin	O	O
levels	O	O
in	O	O
the	O	O
four	O	O
other	O	O
homozygous	O	O
patients	O	O
remained	O	O
in	O	O
the	O	O
normal	O	O
range	O	O
.	O	O

Eleven	O	O
of	O	O
the	O	O
16	O	O
homozygous	O	O
subjects	O	O
underwent	O	O
liver	O	O
biopsy	O	O
;	O	O
3	O	O
had	O	O
hepatic	B-Disease	D008103
fibrosis	I-Disease	D008103
,	O	O
and	O	O
1	O	O
,	O	O
who	O	O
had	O	O
a	O	O
history	O	O
of	O	O
excessive	B-Disease	D000435
alcohol	I-Disease	D000435
consumption	I-Disease	D000435
,	O	O
had	O	O
cirrhosis	B-Disease	D008103
and	O	O
mild	O	O
microvesicular	B-Disease	D005234
steatosis	I-Disease	D005234
.	O	O

Eight	O	O
of	O	O
the	O	O
16	O	O
homozygous	O	O
subjects	O	O
had	O	O
clinical	O	O
findings	O	O
that	O	O
were	O	O
consistent	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
,	O	O
such	O	O
as	O	O
hepatomegaly	B-Disease	D006529
,	O	O
skin	B-Disease	D010859
pigmentation	I-Disease	D010859
,	O	O
and	O	O
arthritis	B-Disease	D001168
.	O	O

CONCLUSIONS	O	O
In	O	O
a	O	O
population	O	O
of	O	O
white	O	O
adults	O	O
of	O	O
northern	O	O
European	O	O
ancestry	O	O
,	O	O
0	O	O
.	O	O

5	O	O
percent	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
C282Y	O	O
mutation	O	O
in	O	O
the	O	O
HFE	O	O
gene	O	O
.	O	O

However	O	O
,	O	O
only	O	O
half	O	O
of	O	O
those	O	O
who	O	O
were	O	O
homozygous	O	O
had	O	O
clinical	O	O
features	O	O
of	O	O
hemochromatosis	B-Disease	D006432
,	O	O
and	O	O
one	O	O
quarter	O	O
had	O	O
serum	O	O
ferritin	O	O
levels	O	O
that	O	O
remained	O	O
normal	O	O
over	O	O
a	O	O
four	O	O
-	O	O
year	O	O
period	O	O
.	O	O

Overexpression	O	O
of	O	O
DM20	O	O
messenger	O	O
RNA	O	O
in	O	O
two	O	O
brothers	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
is	O	O
a	O	O
rare	B-Disease	D020279	D035583
,	I-Disease	D020279	D035583
sex	I-Disease	D020279	D035583
-	I-Disease	D020279	D035583
linked	I-Disease	D020279	D035583
recessive	I-Disease	D020279	D035583
,	I-Disease	D020279	D035583
dysmyelinating	I-Disease	D020279	D035583
disease	I-Disease	D020279	D035583
of	I-Disease	D020279	D035583
the	I-Disease	D020279	D035583
central	I-Disease	D020279	D035583
nervous	I-Disease	D020279	D035583
system	I-Disease	D020279	D035583
that	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
myelin	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
.	O	O

Only	O	O
25	O	O
%	O	O
of	O	O
patients	O	O
studied	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
have	O	O
exonic	O	O
mutations	O	O
in	O	O
this	O	O
gene	O	O
,	O	O
the	O	O
underlying	O	O
cause	O	O
of	O	O
the	O	O
disease	O	O
in	O	O
the	O	O
remaining	O	O
patients	O	O
is	O	O
unknown	O	O
.	O	O

The	O	O
PLP	O	O
gene	O	O
encodes	O	O
two	O	O
major	O	O
alternatively	O	O
spliced	O	O
transcripts	O	O
called	O	O
PLP	O	O
and	O	O
DM20	O	O
.	O	O

PLP	O	O
messenger	O	O
RNA	O	O
is	O	O
specifically	O	O
expressed	O	O
in	O	O
central	O	O
nervous	O	O
system	O	O
tissue	O	O
,	O	O
whereas	O	O
DM20	O	O
messenger	O	O
RNA	O	O
is	O	O
found	O	O
in	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
cardiac	O	O
,	O	O
and	O	O
other	O	O
tissues	O	O
.	O	O

We	O	O
studied	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
2	O	O
brothers	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
who	O	O
exhibited	O	O
no	O	O
detectable	O	O
exonic	O	O
mutation	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
.	O	O

Examination	O	O
of	O	O
RNA	O	O
from	O	O
these	O	O
cells	O	O
showed	O	O
that	O	O
the	O	O
level	O	O
of	O	O
DM20	O	O
messenger	O	O
RNA	O	O
is	O	O
elevated	O	O
sixfold	O	O
relative	O	O
to	O	O
male	O	O
control	O	O
skin	O	O
fibroblasts	O	O
.	O	O

An	O	O
unrelated	O	O
female	O	O
carrier	O	O
,	O	O
also	O	O
with	O	O
no	O	O
detectable	O	O
exonic	O	O
mutation	O	O
,	O	O
showed	O	O
a	O	O
threefold	O	O
increase	O	O
in	O	O
DM20	O	O
messenger	O	O
RNA	O	O
in	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
in	O	O
some	O	O
patients	O	O
,	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
is	O	O
caused	O	O
by	O	O
overexpression	O	O
of	O	O
PLP	O	O
gene	O	O
transcripts	O	O
,	O	O
and	O	O
that	O	O
in	O	O
these	O	O
families	O	O
a	O	O
50	O	O
%	O	O
increase	O	O
of	O	O
DM20	O	O
messenger	O	O
RNA	O	O
in	O	O
females	O	O
,	O	O
relative	O	O
to	O	O
the	O	O
increase	O	O
in	O	O
affected	O	O
males	O	O
,	O	O
can	O	O
identify	O	O
a	O	O
female	O	O
carrier	O	O
.	O	O

.	O	O

Homozygosity	O	O
for	O	O
a	O	O
novel	O	O
DTDST	O	O
mutation	O	O
in	O	O
a	O	O
child	O	O
with	O	O
a	O	O
'	O	O
broad	O	O
bone	O	O
-	O	O
platyspondylic	O	O
'	O	O
variant	O	O
of	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
.	O	O

Atypical	O	O
or	O	O
variant	O	O
forms	O	O
of	O	O
well	O	O
-	O	O
known	O	O
chondrodysplasias	B-Disease	D010009
may	O	O
pose	O	O
diagnostic	O	O
problems	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
girl	O	O
with	O	O
clinical	O	O
features	O	O
suggesting	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
but	O	O
with	O	O
unusual	O	O
radiographic	O	O
features	O	O
including	O	O
severe	O	O
platyspondyly	B-Disease	D013122
,	O	O
wide	O	O
metaphyses	O	O
,	O	O
and	O	O
fibular	O	O
overgrowth	O	O
,	O	O
which	O	O
are	O	O
partially	O	O
reminiscent	O	O
of	O	O
metatropic	B-Disease	C537356
dysplasia	I-Disease	C537356
.	O	O

The	O	O
diagnosis	O	O
was	O	O
clarified	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
DTDST	O	O
gene	O	O
,	O	O
which	O	O
revealed	O	O
homozygosity	O	O
for	O	O
a	O	O
previously	O	O
undescribed	O	O
mutation	O	O
leading	O	O
to	O	O
a	O	O
Q454P	O	O
substitution	O	O
in	O	O
the	O	O
10th	O	O
transmembrane	O	O
domain	O	O
of	O	O
the	O	O
DTDST	O	O
sulfate	O	O
transporter	O	O
.	O	O

Molecular	O	O
analysis	O	O
may	O	O
be	O	O
of	O	O
particular	O	O
value	O	O
in	O	O
such	O	O
atypical	O	O
cases	O	O
.	O	O

.	O	O

Carrier	O	O
detection	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
using	O	O
a	O	O
combination	O	O
of	O	O
anonymous	O	O
DNA	O	O
polymorphisms	O	O
and	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
cDNA	O	O
.	O	O

We	O	O
report	O	O
carrier	O	O
identification	O	O
and	O	O
a	O	O
prenatal	O	O
diagnosis	O	O
using	O	O
DNA	O	O
polymorphisms	O	O
in	O	O
2	O	O
families	O	O
with	O	O
X	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
linked	I-Disease	OMIM:312080
Pelizaeus	I-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
PMD	B-Disease	OMIM:312080
)	O	O
.	O	O

In	O	O
both	O	O
families	O	O
,	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
in	O	O
the	O	O
single	O	O
affected	O	O
male	O	O
could	O	O
be	O	O
traced	O	O
back	O	O
to	O	O
his	O	O
unaffected	O	O
maternal	O	O
grandfather	O	O
.	O	O

Therefore	O	O
,	O	O
each	O	O
family	O	O
contains	O	O
a	O	O
new	O	O
mutation	O	O
.	O	O

In	O	O
the	O	O
case	O	O
of	O	O
the	O	O
prenatal	O	O
diagnosis	O	O
,	O	O
the	O	O
fetus	O	O
was	O	O
shown	O	O
by	O	O
cytogenetic	O	O
analysis	O	O
to	O	O
be	O	O
a	O	O
female	O	O
,	O	O
who	O	O
we	O	O
predict	O	O
will	O	O
be	O	O
a	O	O
noncarrier	O	O
of	O	O
PMD	B-Disease	OMIM:312080
based	O	O
on	O	O
her	O	O
genotype	O	O
with	O	O
the	O	O
PLP	O	O
intragenic	O	O
polymorphism	O	O
.	O	O

.	O	O

Gardner	B-Disease	D005736
syndrome	I-Disease	D005736
in	O	O
a	O	O
boy	O	O
with	O	O
interstitial	O	O
deletion	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
5	O	O
.	O	O

We	O	O
described	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
Gardner	B-Disease	D005736
syndrome	I-Disease	D005736
(	O	O
GS	B-Disease	D005736
)	O	O
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
craniofacial	B-Disease	D019465
abnormalities	I-Disease	D019465
.	O	O

High	O	O
-	O	O
resolution	O	O
banding	O	O
analysis	O	O
showed	O	O
an	O	O
interstitial	O	O
deletion	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
5	O	O
(	O	O
q22	O	O
.	O	O

1	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q31	O	O
1	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q31	O	O
.	O	O

1	O	O
)	O	O
.	O	O

The	O	O
breakpoints	O	O
in	O	O
the	O	O
present	O	O
case	O	O
and	O	O
in	O	O
3	O	O
previously	O	O
reported	O	O
5q	O	O
-	O	O
patients	O	O
with	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
suggest	O	O
that	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
GS	B-Disease	D005736
/	O	O
or	O	O
familial	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
FPC	B-Disease	D011125
)	O	O
is	O	O
in	O	O
the	O	O
5q22	O	O
region	O	O
,	O	O
a	O	O
result	O	O
consistent	O	O
with	O	O
the	O	O
findings	O	O
of	O	O
linkage	O	O
studies	O	O
Type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
human	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

A	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
gene	O	O
deletion	O	O
causes	O	O
skipping	O	O
of	O	O
exon	O	O
6	O	O
during	O	O
RNA	O	O
splicing	O	O
.	O	O

Two	O	O
variants	O	O
of	O	O
a	O	O
genetic	O	O
deficiency	B-Disease	OMIM:217000
of	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
protein	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
(	O	O
C2D	O	O
)	O	O
have	O	O
been	O	O
previously	O	O
identified	O	O
.	O	O

No	O	O
C2	O	O
protein	O	O
translation	O	O
is	O	O
detected	O	O
in	O	O
type	O	O
I	O	O
deficiency	O	O
,	O	O
while	O	O
type	O	O
II	O	O
deficiency	O	O
is	O	O
characterized	O	O
by	O	O
a	O	O
selective	O	O
block	O	O
in	O	O
C2	O	O
secretion	O	O
.	O	O

Type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
was	O	O
described	O	O
in	O	O
a	O	O
family	O	O
in	O	O
which	O	O
the	O	O
C2	O	O
null	O	O
allele	O	O
(	O	O
C2Q0	O	O
)	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
major	O	O
histocompatibility	O	O
haplotype	O	O
/	O	O
complotype	O	O
HLA	O	O
-	O	O
A25	O	O
,	O	O
B18	O	O
,	O	O
C2Q0	O	O
,	O	O
BfS	O	O
,	O	O
C4A4	O	O
,	O	O
C4B2	O	O
,	O	O
Drw2	O	O
;	O	O
this	O	O
extended	O	O
haplotype	O	O
occurs	O	O
in	O	O
over	O	O
90	O	O
%	O	O
of	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
individuals	O	O
(	O	O
common	O	O
complotype	O	O
/	O	O
haplotype	O	O
)	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
,	O	O
the	O	O
C2	O	O
gene	O	O
and	O	O
cDNA	O	O
were	O	O
characterized	O	O
from	O	O
a	O	O
homozygous	O	O
type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
individual	O	O
with	O	O
the	O	O
common	O	O
associated	O	O
haplotype	O	O
/	O	O
complotype	O	O
.	O	O

We	O	O
found	O	O
a	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
in	O	O
the	O	O
type	O	O
I	O	O
C2Q0	O	O
gene	O	O
,	O	O
beginning	O	O
9	O	O
base	O	O
pairs	O	O
upstream	O	O
of	O	O
the	O	O
3	O	O
-	O	O
end	O	O
of	O	O
exon	O	O
6	O	O
,	O	O
that	O	O
generates	O	O
a	O	O
C2	O	O
transcript	O	O
with	O	O
a	O	O
complete	O	O
deletion	O	O
of	O	O
exon	O	O
6	O	O
(	O	O
134	O	O
base	O	O
pair	O	O
)	O	O
and	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
.	O	O

In	O	O
studies	O	O
of	O	O
eight	O	O
kindred	O	O
,	O	O
the	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
C2Q0	O	O
alleles	O	O
associated	O	O
with	O	O
the	O	O
common	O	O
type	O	O
I	O	O
deficient	O	O
complotype	O	O
/	O	O
haplotype	O	O
;	O	O
this	O	O
deletion	O	O
was	O	O
not	O	O
present	O	O
in	O	O
normal	O	O
C2	O	O
nor	O	O
in	O	O
type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
genes	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
1	O	O
)	O	O
type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
human	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
is	O	O
caused	O	O
by	O	O
a	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
genomic	O	O
deletion	O	O
that	O	O
causes	O	O
skipping	O	O
of	O	O
exon	O	O
6	O	O
during	O	O
RNA	O	O
splicing	O	O
,	O	O
resulting	O	O
in	O	O
generation	O	O
of	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
,	O	O
2	O	O
)	O	O
the	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
in	O	O
the	O	O
type	O	O
I	O	O
C2Q0	O	O
gene	O	O
is	O	O
strongly	O	O
associated	O	O
with	O	O
the	O	O
HLA	O	O
haplotype	O	O
/	O	O
complotype	O	O
A25	O	O
,	O	O
B18	O	O
,	O	O
C2Q0	O	O
,	O	O
BfS	O	O
,	O	O
C4A4	O	O
,	O	O
C4B2	O	O
,	O	O
Drw2	O	O
,	O	O
suggesting	O	O
that	O	O
all	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
individuals	O	O
with	O	O
this	O	O
haplotype	O	O
/	O	O
complotype	O	O
will	O	O
harbor	O	O
the	O	O
28	O	O
-	O	O
base	O	O
pair	O	O
C2	O	O
gene	O	O
deletion	O	O
,	O	O
and	O	O
3	O	O
)	O	O
type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
is	O	O
caused	O	O
by	O	O
a	O	O
different	O	O
,	O	O
as	O	O
yet	O	O
uncharacterized	O	O
,	O	O
molecular	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
.	O	O

.	O	O

(	O	O
Over	O	O
)	O	O
correction	O	O
of	O	O
FMR1	B-Disease	OMIM:300624
deficiency	I-Disease	OMIM:300624
with	O	O
YAC	O	O
transgenics	O	O
:	O	O
behavioral	O	O
and	O	O
physical	O	O
features	O	O
.	O	O

Fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
is	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
involving	O	O
loss	O	O
of	O	O
expression	O	O
of	O	O
the	O	O
FMR1	O	O
gene	O	O
.	O	O

The	O	O
role	O	O
of	O	O
FMR1	O	O
remains	O	O
undetermined	O	O
but	O	O
the	O	O
protein	O	O
appears	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
RNA	O	O
metabolism	O	O
.	O	O

Fmr1	O	O
knockout	O	O
mice	O	O
exhibit	O	O
a	O	O
phenotype	O	O
with	O	O
some	O	O
similarities	O	O
to	O	O
humans	O	O
,	O	O
such	O	O
as	O	O
macroorchidism	B-Disease	D005600
and	O	O
behavioral	O	O
abnormalities	O	O
.	O	O

As	O	O
a	O	O
step	O	O
toward	O	O
understanding	O	O
the	O	O
function	O	O
of	O	O
FMR1	O	O
and	O	O
the	O	O
determination	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
therapeutic	O	O
approaches	O	O
to	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
yeast	O	O
artificial	O	O
chromosome	O	O
(	O	O
YAC	O	O
)	O	O
transgenic	O	O
mice	O	O
were	O	O
generated	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
Fmr1	O	O
knockout	O	O
mouse	O	O
phenotype	O	O
could	O	O
be	O	O
rescued	O	O
.	O	O

Several	O	O
transgenic	O	O
lines	O	O
were	O	O
generated	O	O
that	O	O
carried	O	O
the	O	O
entire	O	O
FMR1	O	O
locus	O	O
with	O	O
extensive	O	O
amounts	O	O
of	O	O
flanking	O	O
sequence	O	O
.	O	O

We	O	O
observed	O	O
that	O	O
the	O	O
YAC	O	O
transgene	O	O
supported	O	O
production	O	O
of	O	O
the	O	O
human	O	O
protein	O	O
(	O	O
FMRP	O	O
)	O	O
which	O	O
was	O	O
present	O	O
at	O	O
levels	O	O
10	O	O
to	O	O
15	O	O
times	O	O
that	O	O
of	O	O
endogenous	O	O
protein	O	O
and	O	O
was	O	O
expressed	O	O
in	O	O
a	O	O
cell	O	O
-	O	O
and	O	O
tissue	O	O
-	O	O
specific	O	O
manner	O	O
.	O	O

Macro	O	O
-	O	O
orchidism	O	O
was	O	O
absent	O	O
in	O	O
knockout	O	O
mice	O	O
carrying	O	O
the	O	O
YAC	O	O
transgene	O	O
indicating	O	O
functional	O	O
rescue	O	O
by	O	O
the	O	O
human	O	O
protein	O	O
.	O	O

Given	O	O
the	O	O
complex	O	O
behavioral	O	O
phenotype	O	O
in	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
patients	O	O
and	O	O
the	O	O
mild	O	O
phenotype	O	O
previously	O	O
reported	O	O
for	O	O
the	O	O
Fmr1	O	O
knockout	O	O
mouse	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
more	O	O
thorough	O	O
evaluation	O	O
of	O	O
the	O	O
Fmr1	O	O
knockout	O	O
phenotype	O	O
using	O	O
additional	O	O
behavioral	O	O
assays	O	O
that	O	O
had	O	O
not	O	O
previously	O	O
been	O	O
reported	O	O
for	O	O
this	O	O
animal	O	O
model	O	O
.	O	O

The	O	O
mouse	O	O
displayed	O	O
reduced	O	O
anxiety	B-Disease	D001008
-	O	O
related	O	O
responses	O	O
with	O	O
increased	O	O
exploratory	O	O
behavior	O	O
.	O	O

FMR1	O	O
YAC	O	O
transgenic	O	O
mice	O	O
overexpressing	O	O
the	O	O
human	O	O
protein	O	O
did	O	O
produce	O	O
opposing	O	O
behavioral	O	O
responses	O	O
and	O	O
additional	O	O
abnormal	O	O
behaviors	O	O
were	O	O
also	O	O
observed	O	O
.	O	O

These	O	O
findings	O	O
have	O	O
significant	O	O
implications	O	O
for	O	O
gene	O	O
therapy	O	O
for	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
since	O	O
overexpression	O	O
of	O	O
the	O	O
gene	O	O
may	O	O
harbor	O	O
its	O	O
own	O	O
phenotype	O	O
.	O	O

.	O	O

Fabry	B-Disease	D000795
disease	I-Disease	D000795
:	O	O
identification	O	O
of	O	O
novel	O	O
alpha	O	O
-	O	O
galactosidase	O	O
A	O	O
mutations	O	O
and	O	O
molecular	O	O
carrier	O	O
detection	O	O
by	O	O
use	O	O
of	O	O
fluorescent	O	O
chemical	O	O
cleavage	O	O
of	O	O
mismatches	O	O
.	O	O

Fabry	B-Disease	D000795
disease	I-Disease	D000795
(	O	O
FD	B-Disease	D000795
)	O	O
(	O	O
angiokeratoma	B-Disease	D000795
corporis	I-Disease	D000795
diffusum	I-Disease	D000795
)	O	O
is	O	O
an	O	O
X	B-Disease	D008052
-	I-Disease	D008052
linked	I-Disease	D008052
inborn	I-Disease	D008052
error	I-Disease	D008052
of	I-Disease	D008052
glycosphingolipid	I-Disease	D008052
metabolism	I-Disease	D008052
caused	O	O
by	O	O
defects	O	O
in	O	O
the	O	O
lysosomal	O	O
alpha	O	O
-	O	O
galactosidase	O	O
A	O	O
gene	O	O
(	O	O
GLA	O	O
)	O	O
.	O	O

The	O	O
enzymatic	O	O
defect	O	O
leads	O	O
to	O	O
the	O	O
systemic	O	O
accumulation	O	O
of	O	O
neutral	O	O
glycosphingolipids	O	O
with	O	O
terminal	O	O
alpha	O	O
-	O	O
galactosyl	O	O
moieties	O	O
.	O	O

Clinically	O	O
,	O	O
affected	O	O
hemizygous	O	O
males	O	O
have	O	O
angiokeratoma	B-Disease	D000794
,	O	O
severe	B-Disease	D010292
acroparesthesia	I-Disease	D010292
,	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
and	O	O
vasculopathy	B-Disease	D014652
of	I-Disease	D014652
the	I-Disease	D014652
heart	I-Disease	D014652
and	I-Disease	D014652
brain	I-Disease	D014652
.	O	O

While	O	O
demonstration	O	O
of	O	O
alpha	B-Disease	D000795
-	I-Disease	D000795
galactosidase	I-Disease	D000795
deficiency	I-Disease	D000795
in	O	O
leukocytes	O	O
is	O	O
diagnostic	O	O
in	O	O
affected	O	O
males	O	O
,	O	O
enzymatic	O	O
detection	O	O
of	O	O
female	O	O
carriers	O	O
is	O	O
often	O	O
inconclusive	O	O
,	O	O
due	O	O
to	O	O
random	O	O
X	O	O
-	O	O
chromosomal	O	O
inactivation	O	O
,	O	O
underlining	O	O
the	O	O
need	O	O
of	O	O
molecular	O	O
investigations	O	O
for	O	O
accurate	O	O
genetic	O	O
counseling	O	O
.	O	O

By	O	O
use	O	O
of	O	O
chemical	O	O
cleavage	O	O
of	O	O
mismatches	O	O
adapted	O	O
to	O	O
fluorescence	O	O
-	O	O
based	O	O
detection	O	O
systems	O	O
,	O	O
we	O	O
have	O	O
characterized	O	O
the	O	O
mutations	O	O
underlying	O	O
alpha	B-Disease	D000795
-	I-Disease	D000795
Gal	I-Disease	D000795
A	I-Disease	D000795
deficiency	I-Disease	D000795
in	O	O
16	O	O
individuals	O	O
from	O	O
six	O	O
unrelated	O	O
families	O	O
with	O	O
FD	B-Disease	D000795
.	O	O

The	O	O
mutational	O	O
spectrum	O	O
included	O	O
five	O	O
missense	O	O
mutations	O	O
(	O	O
C202W	O	O
,	O	O
C223G	O	O
,	O	O
N224D	O	O
,	O	O
R301Q	O	O
,	O	O
and	O	O
Q327K	O	O
)	O	O
and	O	O
one	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
[	O	O
IVS3	O	O
G	O	O
(	O	O
-	O	O
1	O	O
)	O	O
-	O	O
-	O	O
>	O	O
C	O	O
]	O	O
.	O	O

Studies	O	O
at	O	O
the	O	O
mRNA	O	O
level	O	O
showed	O	O
that	O	O
the	O	O
latter	O	O
led	O	O
to	O	O
altered	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
with	O	O
consequent	O	O
alteration	O	O
of	O	O
the	O	O
mRNA	O	O
translational	O	O
reading	O	O
frame	O	O
and	O	O
generation	O	O
of	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
of	O	O
translation	O	O
.	O	O

By	O	O
use	O	O
of	O	O
this	O	O
strategy	O	O
,	O	O
carrier	O	O
status	O	O
was	O	O
accurately	O	O
assessed	O	O
in	O	O
all	O	O
seven	O	O
at	O	O
-	O	O
risk	O	O
females	O	O
tested	O	O
,	O	O
whereas	O	O
enzymatic	O	O
dosages	O	O
failed	O	O
to	O	O
diagnose	O	O
or	O	O
exclude	O	O
heterozygosity	O	O
.	O	O

.	O	O

Evidence	O	O
for	O	O
linkage	O	O
of	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
to	O	O
chromosome	O	O
18	O	O
with	O	O
a	O	O
parent	O	O
-	O	O
of	O	O
-	O	O
origin	O	O
effect	O	O
.	O	O

A	O	O
susceptibility	O	O
gene	O	O
on	O	O
chromosome	O	O
18	O	O
and	O	O
a	O	O
parent	O	O
-	O	O
of	O	O
-	O	O
origin	O	O
effect	O	O
have	O	O
been	O	O
suggested	O	O
for	O	O
bipolar	B-Disease	D001714
affective	I-Disease	D001714
disorder	I-Disease	D001714
(	O	O
BPAD	B-Disease	D001714
)	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
28	O	O
nuclear	O	O
families	O	O
selected	O	O
for	O	O
apparent	O	O
unilineal	O	O
transmission	O	O
of	O	O
the	O	O
BPAD	B-Disease	D001714
phenotype	O	O
,	O	O
by	O	O
using	O	O
31	O	O
polymorphic	O	O
markers	O	O
spanning	O	O
chromosome	O	O
18	O	O
.	O	O

Evidence	O	O
for	O	O
linkage	O	O
was	O	O
tested	O	O
with	O	O
affected	O	O
-	O	O
sib	O	O
-	O	O
pair	O	O
and	O	O
LOD	O	O
score	O	O
methods	O	O
under	O	O
two	O	O
definitions	O	O
of	O	O
the	O	O
affected	O	O
phenotype	O	O
.	O	O

The	O	O
affected	O	O
-	O	O
sibpair	O	O
analyses	O	O
indicated	O	O
excess	O	O
allele	O	O
sharing	O	O
for	O	O
markers	O	O
on	O	O
18p	O	O
within	O	O
the	O	O
region	O	O
reported	O	O
previously	O	O
.	O	O

The	O	O
greatest	O	O
sharing	O	O
was	O	O
at	O	O
D18S37	O	O
64	O	O
%	O	O
in	O	O
bipolar	O	O
and	O	O
recurrent	O	O
unipolar	O	O
(	O	O
RUP	O	O
)	O	O
sib	O	O
pairs	O	O
(	O	O
P	O	O
=	O	O
.	O	O

0006	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
excess	O	O
sharing	O	O
of	O	O
the	O	O
paternally	O	O
,	O	O
but	O	O
not	O	O
maternally	O	O
,	O	O
transmitted	O	O
alleles	O	O
was	O	O
observed	O	O
at	O	O
three	O	O
markers	O	O
on	O	O
18q	O	O
at	O	O
D18S41	O	O
,	O	O
51	O	O
bipolar	O	O
and	O	O
RUP	O	O
sib	O	O
pairs	O	O
were	O	O
concordant	O	O
for	O	O
paternally	O	O
transmitted	O	O
alleles	O	O
,	O	O
and	O	O
21	O	O
pairs	O	O
were	O	O
discordant	O	O
(	O	O
P	O	O
=	O	O
0004	O	O
)	O	O
.	O	O

The	O	O
evidence	O	O
for	O	O
linkage	O	O
to	O	O
loci	O	O
on	O	O
both	O	O
18p	O	O
and	O	O
18q	O	O
was	O	O
strongest	O	O
in	O	O
the	O	O
11	O	O
paternal	O	O
pedigrees	O	O
,	O	O
i	O	O
.	O	O

e	O	O
e	O	O
.	O	O

,	O	O
those	O	O
in	O	O
which	O	O
the	O	O
father	O	O
or	O	O
one	O	O
of	O	O
the	O	O
fathers	O	O
sibs	O	O
is	O	O
affected	O	O
.	O	O

In	O	O
these	O	O
pedigrees	O	O
,	O	O
the	O	O
greatest	O	O
allele	O	O
sharing	O	O
(	O	O
81	O	O
%	O	O
;	O	O
P	O	O
=	O	O
.	O	O

00002	O	O
)	O	O
and	O	O
the	O	O
highest	O	O
LOD	O	O
score	O	O
(	O	O
3	O	O
.	O	O

51	O	O
;	O	O
phi	O	O
=	O	O
0	O	O
.	O	O

0	O	O
)	O	O
were	O	O
observed	O	O
at	O	O
D18S41	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
further	O	O
support	O	O
for	O	O
linkage	O	O
of	O	O
BPAD	B-Disease	D001714
to	O	O
chromosome	O	O
18	O	O
and	O	O
the	O	O
first	O	O
molecular	O	O
evidence	O	O
for	O	O
a	O	O
parent	O	O
-	O	O
of	O	O
-	O	O
origin	O	O
effect	O	O
operating	O	O
in	O	O
this	O	O
disorder	O	O
.	O	O

The	O	O
number	O	O
of	O	O
loci	O	O
involved	O	O
,	O	O
and	O	O
their	O	O
precise	O	O
location	O	O
,	O	O
require	O	O
further	O	O
study	O	O
BRCA1	O	O
mutations	O	O
in	O	O
a	O	O
population	O	O
-	O	O
based	O	O
sample	O	O
of	O	O
young	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

BACKGROUND	O	O
.	O	O

Inherited	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
in	O	O
some	O	O
families	O	O
.	O	O

However	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
contribution	O	O
of	O	O
BRCA1	O	O
mutations	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

We	O	O
analyzed	O	O
DNA	O	O
samples	O	O
from	O	O
women	O	O
enrolled	O	O
in	O	O
a	O	O
population	O	O
-	O	O
based	O	O
study	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
to	O	O
assess	O	O
the	O	O
spectrum	O	O
and	O	O
frequency	O	O
of	O	O
germ	O	O
-	O	O
line	O	O
BRCA1	O	O
mutations	O	O
in	O	O
young	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

METHODS	O	O
.	O	O

We	O	O
studied	O	O
80	O	O
women	O	O
in	O	O
whom	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
was	O	O
diagnosed	O	O
before	O	O
the	O	O
age	O	O
of	O	O
35	O	O
,	O	O
and	O	O
who	O	O
were	O	O
not	O	O
selected	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
family	O	O
history	O	O
.	O	O

Genomic	O	O
DNA	O	O
was	O	O
studied	O	O
for	O	O
BRCA1	O	O
mutations	O	O
by	O	O
analysis	O	O
involving	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphisms	O	O
and	O	O
with	O	O
allele	O	O
-	O	O
specific	O	O
assays	O	O
.	O	O

Alterations	O	O
were	O	O
defined	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
.	O	O

Germ	O	O
-	O	O
line	O	O
BRCA1	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
6	O	O
of	O	O
the	O	O
80	O	O
women	O	O
.	O	O

Four	O	O
additional	O	O
rare	O	O
sequence	O	O
variants	O	O
of	O	O
unknown	O	O
functional	O	O
importance	O	O
were	O	O
also	O	O
identified	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
mutations	O	O
and	O	O
three	O	O
of	O	O
the	O	O
rare	O	O
sequence	O	O
variants	O	O
were	O	O
found	O	O
among	O	O
the	O	O
39	O	O
women	O	O
who	O	O
reported	O	O
no	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

None	O	O
of	O	O
the	O	O
mutations	O	O
and	O	O
only	O	O
one	O	O
of	O	O
the	O	O
rare	O	O
variants	O	O
was	O	O
identified	O	O
in	O	O
a	O	O
reference	O	O
population	O	O
of	O	O
73	O	O
unrelated	O	O
subjects	O	O
.	O	O

CONCLUSIONS	O	O
.	O	O

Alterations	O	O
in	O	O
BRCA1	O	O
were	O	O
identified	O	O
in	O	O
approximately	O	O
10	O	O
percent	O	O
of	O	O
this	O	O
cohort	O	O
of	O	O
young	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

The	O	O
risk	O	O
of	O	O
harboring	O	O
a	O	O
mutation	O	O
was	O	O
not	O	O
limited	O	O
to	O	O
women	O	O
with	O	O
family	O	O
histories	O	O
of	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

These	O	O
results	O	O
represent	O	O
a	O	O
minimal	O	O
estimate	O	O
of	O	O
the	O	O
frequency	O	O
of	O	O
BRCA1	O	O
mutations	O	O
in	O	O
this	O	O
population	O	O
.	O	O

Comprehensive	O	O
methods	O	O
of	O	O
identifying	O	O
BRCA1	O	O
mutations	O	O
and	O	O
understanding	O	O
their	O	O
importance	O	O
will	O	O
be	O	O
needed	O	O
before	O	O
testing	O	O
of	O	O
women	O	O
in	O	O
the	O	O
general	O	O
population	O	O
can	O	O
be	O	O
undertaken	O	O
.	O	O

.	O	O

Retinoschisin	O	O
,	O	O
the	O	O
X	B-Disease	D041441
-	I-Disease	D041441
linked	I-Disease	D041441
retinoschisis	I-Disease	D041441
protein	O	O
,	O	O
is	O	O
a	O	O
secreted	O	O
photoreceptor	O	O
protein	O	O
,	O	O
and	O	O
is	O	O
expressed	O	O
and	O	O
released	O	O
by	O	O
Weri	O	O
-	O	O
Rb1	O	O
cells	O	O
.	O	O

X	B-Disease	D041441
-	I-Disease	D041441
linked	I-Disease	D041441
retinoschisis	I-Disease	D041441
is	O	O
characterized	O	O
by	O	O
microcystic	O	O
-	O	O
like	O	O
changes	O	O
of	O	O
the	O	O
macular	O	O
region	O	O
and	O	O
schisis	O	O
within	O	O
the	O	O
inner	O	O
retinal	O	O
layers	O	O
,	O	O
leading	O	O
to	O	O
visual	B-Disease	C531604
deterioration	I-Disease	C531604
in	O	O
males	O	O
.	O	O

Many	O	O
missense	O	O
and	O	O
protein	O	O
-	O	O
truncating	O	O
mutations	O	O
of	O	O
the	O	O
causative	O	O
gene	O	O
RS1	O	O
have	O	O
now	O	O
been	O	O
identified	O	O
and	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
inactivating	O	O
.	O	O

RS1	O	O
encodes	O	O
a	O	O
224	O	O
amino	O	O
acid	O	O
protein	O	O
,	O	O
retinoschisin	O	O
,	O	O
which	O	O
contains	O	O
a	O	O
discoidin	O	O
domain	O	O
but	O	O
is	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

We	O	O
have	O	O
generated	O	O
a	O	O
polyclonal	O	O
antibody	O	O
against	O	O
a	O	O
peptide	O	O
from	O	O
a	O	O
unique	O	O
region	O	O
within	O	O
retinoschisin	O	O
,	O	O
which	O	O
detects	O	O
a	O	O
protein	O	O
of	O	O
approximately	O	O
28	O	O
kDa	O	O
in	O	O
retinal	O	O
samples	O	O
reduced	O	O
with	O	O
dithiothreitol	O	O
,	O	O
but	O	O
multimers	O	O
sized	O	O
>	O	O
40	O	O
kDa	O	O
under	O	O
non	O	O
-	O	O
reducing	O	O
conditions	O	O
.	O	O

A	O	O
screen	O	O
of	O	O
human	O	O
tissues	O	O
with	O	O
this	O	O
antibody	O	O
reveals	O	O
retinoschisin	O	O
to	O	O
be	O	O
retina	O	O
specific	O	O
and	O	O
the	O	O
antibody	O	O
detects	O	O
a	O	O
protein	O	O
of	O	O
similar	O	O
size	O	O
in	O	O
bovine	O	O
and	O	O
murine	O	O
retinae	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
expression	O	O
pattern	O	O
in	O	O
the	O	O
retina	O	O
of	O	O
both	O	O
RS1	O	O
mRNA	O	O
(	O	O
using	O	O
in	O	O
situ	O	O
hybridization	O	O
with	O	O
riboprobes	O	O
)	O	O
and	O	O
retinoschisin	O	O
(	O	O
using	O	O
immunohistochemistry	O	O
)	O	O
.	O	O

The	O	O
antisense	O	O
riboprobe	O	O
detected	O	O
RS1	O	O
mRNA	O	O
only	O	O
in	O	O
the	O	O
photoreceptor	O	O
layer	O	O
but	O	O
the	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
gene	O	O
was	O	O
present	O	O
both	O	O
in	O	O
the	O	O
photoreceptors	O	O
and	O	O
within	O	O
the	O	O
inner	O	O
portions	O	O
of	O	O
the	O	O
retina	O	O
.	O	O

Furthermore	O	O
,	O	O
differentiated	O	O
retinoblastoma	B-Disease	D012175
cells	O	O
(	O	O
Weri	O	O
-	O	O
Rb1	O	O
cells	O	O
)	O	O
were	O	O
found	O	O
to	O	O
express	O	O
RS1	O	O
mRNA	O	O
and	O	O
to	O	O
release	O	O
retinoschisin	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
retinoschisin	O	O
is	O	O
released	O	O
by	O	O
photo	O	O
-	O	O
receptors	O	O
and	O	O
has	O	O
functions	O	O
within	O	O
the	O	O
inner	O	O
retinal	O	O
layers	O	O
.	O	O

Thus	O	O
,	O	O
X	B-Disease	D041441
-	I-Disease	D041441
linked	I-Disease	D041441
retinoschisis	I-Disease	D041441
is	O	O
caused	O	O
by	O	O
abnormalities	O	O
in	O	O
a	O	O
putative	O	O
secreted	O	O
photoreceptor	O	O
protein	O	O
and	O	O
is	O	O
the	O	O
first	O	O
example	O	O
of	O	O
a	O	O
secreted	O	O
photo	O	O
-	O	O
receptor	O	O
protein	O	O
associated	O	O
with	O	O
a	O	O
retinal	B-Disease	D058499
dystrophy	I-Disease	D058499
.	O	O

.	O	O

Aberrant	O	O
splicing	O	O
of	O	O
the	O	O
CHM	B-Disease	D015794
gene	O	O
is	O	O
a	O	O
significant	O	O
cause	O	O
of	O	O
choroideremia	B-Disease	D015794
.	O	O

Choroideremia	B-Disease	D015794
(	O	O
CHM	B-Disease	D015794
)	O	O
is	O	O
an	O	O
X	B-Disease	D015785
-	I-Disease	D015785
linked	I-Disease	D015785
progressive	I-Disease	D015785
degeneration	I-Disease	D015785
of	I-Disease	D015785
the	I-Disease	D015785
choroid	I-Disease	D015785
and	I-Disease	D015785
retina	I-Disease	D015785
.	O	O

12	O	O
%	O	O
of	O	O
unrelated	O	O
male	O	O
patients	O	O
carry	O	O
deletions	O	O
of	O	O
the	O	O
partially	O	O
cloned	O	O
CHM	B-Disease	D015794
gene	O	O
.	O	O

In	O	O
Finland	O	O
,	O	O
there	O	O
are	O	O
more	O	O
than	O	O
120	O	O
living	O	O
CHM	B-Disease	D015794
patients	O	O
belonging	O	O
to	O	O
eight	O	O
apparently	O	O
unrelated	O	O
pedigrees	O	O
.	O	O

Molecular	O	O
deletions	O	O
involving	O	O
the	O	O
CHM	B-Disease	D015794
gene	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
three	O	O
families	O	O
.	O	O

We	O	O
have	O	O
screened	O	O
the	O	O
remaining	O	O
five	O	O
families	O	O
for	O	O
point	O	O
mutations	O	O
.	O	O

In	O	O
one	O	O
large	O	O
family	O	O
a	O	O
single	O	O
nucleotide	O	O
(	O	O
T	O	O
)	O	O
insertion	O	O
into	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
of	O	O
exon	O	O
C	O	O
leads	O	O
to	O	O
two	O	O
aberrantly	O	O
spliced	O	O
mRNAs	O	O
both	O	O
producing	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
.	O	O

The	O	O
mutation	O	O
can	O	O
be	O	O
assayed	O	O
easily	O	O
by	O	O
amplification	O	O
and	O	O
digestion	O	O
with	O	O
Msel	O	O
.	O	O

Our	O	O
findings	O	O
provide	O	O
additional	O	O
evidence	O	O
for	O	O
the	O	O
pathogenetic	O	O
role	O	O
of	O	O
CHM	B-Disease	D015794
mutations	O	O
and	O	O
provide	O	O
a	O	O
diagnostic	O	O
tool	O	O
for	O	O
one	O	O
fifth	O	O
of	O	O
the	O	O
worlds	O	O
known	O	O
CHM	B-Disease	D015794
patients	O	O
.	O	O

.	O	O

X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
:	O	O
a	O	O
novel	O	O
mutation	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
in	O	O
6	O	O
members	O	O
of	O	O
a	O	O
family	O	O
presenting	O	O
with	O	O
5	O	O
different	O	O
phenotypes	O	O
.	O	O

Fragments	O	O
of	O	O
the	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
cDNA	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
adolescent	B-Disease	D000326
ALD	I-Disease	D000326
were	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
subcloned	O	O
.	O	O

Bidirectional	O	O
sequencing	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
ALD	B-Disease	D000326
gene	O	O
disclosed	O	O
a	O	O
cytosine	O	O
to	O	O
guanine	O	O
transversion	O	O
at	O	O
nucleotide	O	O
1451	O	O
in	O	O
exon	O	O
five	O	O
,	O	O
resulting	O	O
in	O	O
substitution	O	O
of	O	O
proline	O	O
484	O	O
by	O	O
arginine	O	O
.	O	O

Five	O	O
of	O	O
nine	O	O
siblings	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
comprising	O	O
two	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
,	O	O
one	O	O
adrenomyeloneuropathy	B-Disease	D000326
,	O	O
one	O	O
Addison	B-Disease	D000224
only	I-Disease	D000224
as	O	O
well	O	O
as	O	O
the	O	O
symptomatic	O	O
mother	O	O
(	O	O
all	O	O
accumulating	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
)	O	O
carried	O	O
this	O	O
mutation	O	O
,	O	O
which	O	O
was	O	O
not	O	O
found	O	O
in	O	O
the	O	O
unaffected	O	O
persons	O	O
,	O	O
in	O	O
five	O	O
unrelated	O	O
ALD	B-Disease	D000326
patients	O	O
,	O	O
and	O	O
in	O	O
twenty	O	O
controls	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
this	O	O
missense	O	O
mutation	O	O
generated	O	O
the	O	O
disease	O	O
per	O	O
se	O	O
as	O	O
well	O	O
as	O	O
the	O	O
metabolic	O	O
defect	O	O
;	O	O
the	O	O
different	O	O
phenotypes	O	O
,	O	O
however	O	O
,	O	O
must	O	O
have	O	O
originated	O	O
by	O	O
means	O	O
of	O	O
additional	O	O
pathogenetic	O	O
factors	O	O
.	O	O

.	O	O

Statistical	O	O
analysis	O	O
of	O	O
the	O	O
two	O	O
stage	O	O
mutation	O	O
model	O	O
in	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
,	O	O
and	O	O
in	O	O
sporadic	B-Disease	D018325
cerebellar	I-Disease	D018325
haemangioblastoma	I-Disease	D018325
and	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
.	O	O

Analysis	O	O
of	O	O
the	O	O
age	O	O
incidence	O	O
curves	O	O
for	O	O
unilateral	B-Disease	D012175
and	I-Disease	D012175
bilateral	I-Disease	D012175
retinoblastoma	I-Disease	D012175
led	O	O
Knudson	O	O
to	O	O
propose	O	O
that	O	O
hereditary	B-Disease	D009386
tumours	I-Disease	D009386
may	O	O
arise	O	O
by	O	O
a	O	O
single	O	O
event	O	O
and	O	O
sporadic	B-Disease	D009369
tumours	I-Disease	D009369
by	O	O
a	O	O
two	O	O
stage	O	O
mutation	O	O
process	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
recently	O	O
that	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
may	O	O
arise	O	O
from	O	O
a	O	O
two	O	O
stage	O	O
mutation	O	O
process	O	O
.	O	O

We	O	O
analysed	O	O
the	O	O
age	O	O
incidence	O	O
curves	O	O
for	O	O
symptomatic	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
(	O	O
n	O	O
=	O	O
26	O	O
)	O	O
and	O	O
cerebellar	B-Disease	D018325
haemangioblastoma	I-Disease	D018325
(	O	O
n	O	O
=	O	O
68	O	O
)	O	O
in	O	O
109	O	O
patients	O	O
with	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	I-Disease	D006623
VHL	I-Disease	D006623
)	I-Disease	D006623
disease	I-Disease	D006623
,	O	O
and	O	O
compared	O	O
them	O	O
to	O	O
104	O	O
patients	O	O
with	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
and	O	O
43	O	O
patients	O	O
with	O	O
sporadic	B-Disease	D018325
cerebellar	I-Disease	D018325
haemangioblastoma	I-Disease	D018325
.	O	O

The	O	O
age	O	O
incidence	O	O
curves	O	O
for	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
and	O	O
cerebellar	B-Disease	D018325
haemangioblastoma	I-Disease	D018325
in	O	O
VHL	B-Disease	D006623
disease	I-Disease	D006623
were	O	O
compatible	O	O
with	O	O
a	O	O
single	O	O
mutation	O	O
model	O	O
,	O	O
whereas	O	O
the	O	O
age	O	O
incidence	O	O
curves	O	O
for	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
and	O	O
cerebellar	B-Disease	D018325
haemangioblastoma	I-Disease	D018325
suggested	O	O
a	O	O
two	O	O
stage	O	O
mutation	O	O
process	O	O
.	O	O

These	O	O
data	O	O
are	O	O
compatible	O	O
with	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
functioning	O	O
as	O	O
a	O	O
recessive	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
.	O	O

Sporadic	B-Disease	D018325
cerebellar	I-Disease	D018325
haemangioblastoma	I-Disease	D018325
and	O	O
some	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
may	O	O
arise	O	O
from	O	O
somatic	O	O
mutations	O	O
inactivating	O	O
both	O	O
alleles	O	O
at	O	O
the	O	O
VHL	B-Disease	D006623
locus	O	O
.	O	O

.	O	O

Characterization	O	O
of	O	O
a	O	O
germline	O	O
mosaicism	O	O
in	O	O
families	O	O
with	O	O
Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
,	O	O
and	O	O
identification	O	O
of	O	O
seven	O	O
novel	O	O
mutations	O	O
in	O	O
the	O	O
OCRL1	O	O
gene	O	O
.	O	O

The	O	O
oculocerebrorenal	B-Disease	D009800
syndrome	I-Disease	D009800
of	I-Disease	D009800
Lowe	I-Disease	D009800
(	O	O
OCRL	B-Disease	D009800
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disorder	I-Disease	D040181
characterized	O	O
by	O	O
major	O	O
abnormalities	B-Disease	D000015
of	I-Disease	D000015
eyes	I-Disease	D000015
,	I-Disease	D000015
nervous	I-Disease	D000015
system	I-Disease	D000015
,	I-Disease	D000015
and	I-Disease	D000015
kidneys	I-Disease	D000015
.	O	O

Mutations	O	O
in	O	O
the	O	O
OCRL1	O	O
gene	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
disease	O	O
.	O	O

OCRL1	O	O
encodes	O	O
a	O	O
phosphatidylinositol	O	O
4	O	O
,	O	O
5	O	O
-	O	O
biphosphate	O	O
(	O	O
PtdIns	O	O
[	O	O
4	O	O
,	O	O
5	O	O
]	O	O
P2	O	O
)	O	O
5	O	O
-	O	O
phosphatase	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
OCRL1	O	O
gene	O	O
in	O	O
eight	O	O
unrelated	O	O
patients	O	O
with	O	O
OCRL	B-Disease	D009800
and	O	O
have	O	O
found	O	O
seven	O	O
new	O	O
mutations	O	O
and	O	O
one	O	O
recurrent	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
.	O	O

Among	O	O
the	O	O
new	O	O
mutations	O	O
,	O	O
two	O	O
nonsense	O	O
mutations	O	O
(	O	O
R317X	O	O
and	O	O
E558X	O	O
)	O	O
and	O	O
three	O	O
other	O	O
frameshift	O	O
mutations	O	O
caused	O	O
premature	O	O
termination	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

A	O	O
missense	O	O
mutation	O	O
,	O	O
R483G	O	O
,	O	O
was	O	O
located	O	O
in	O	O
the	O	O
highly	O	O
conserved	O	O
PtdIns	O	O
(	O	O
4	O	O
,	O	O
5	O	O
)	O	O
P2	O	O
5	O	O
-	O	O
phosphatase	O	O
domain	O	O
.	O	O

Finally	O	O
,	O	O
one	O	O
frameshift	O	O
mutation	O	O
,	O	O
2799delC	O	O
,	O	O
modifies	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
part	O	O
of	O	O
OCRL1	O	O
,	O	O
with	O	O
an	O	O
extension	O	O
of	O	O
six	O	O
amino	O	O
acids	O	O
.	O	O

Altogether	O	O
,	O	O
70	O	O
%	O	O
of	O	O
missense	O	O
mutations	O	O
are	O	O
located	O	O
in	O	O
exon	O	O
15	O	O
,	O	O
and	O	O
52	O	O
%	O	O
of	O	O
all	O	O
mutations	O	O
cluster	O	O
in	O	O
exons	O	O
11	O	O
-	O	O
15	O	O
.	O	O

We	O	O
also	O	O
identified	O	O
two	O	O
new	O	O
microsatellite	O	O
markers	O	O
for	O	O
the	O	O
OCRL1	O	O
locus	O	O
,	O	O
and	O	O
we	O	O
detected	O	O
a	O	O
germline	O	O
mosaicism	O	O
in	O	O
one	O	O
family	O	O
.	O	O

This	O	O
observation	O	O
has	O	O
direct	O	O
implications	O	O
for	O	O
genetic	O	O
counseling	O	O
of	O	O
Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
families	O	O
.	O	O

.	O	O

Aminoglycoside	O	O
antibiotics	O	O
restore	O	O
dystrophin	O	O
function	O	O
to	O	O
skeletal	O	O
muscles	O	O
of	O	O
mdx	O	O
mice	O	O
.	O	O

Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
dystrophin	O	O
gene	O	O
,	O	O
leading	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
dystrophin	O	O
protein	O	O
in	O	O
striated	O	O
muscle	O	O
.	O	O

A	O	O
significant	O	O
number	O	O
of	O	O
these	O	O
mutations	O	O
are	O	O
premature	O	O
stop	O	O
codons	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
observation	O	O
that	O	O
aminoglycoside	O	O
treatment	O	O
can	O	O
suppress	O	O
stop	O	O
codons	O	O
in	O	O
cultured	O	O
cells	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
effect	O	O
of	O	O
gentamicin	O	O
on	O	O
cultured	O	O
muscle	O	O
cells	O	O
from	O	O
the	O	O
mdx	O	O
mouse	O	O
-	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
DMD	B-Disease	D020388
that	O	O
possesses	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
in	O	O
the	O	O
dystrophin	O	O
gene	O	O
.	O	O

Exposure	O	O
of	O	O
mdx	O	O
myotubes	O	O
to	O	O
gentamicin	O	O
led	O	O
to	O	O
the	O	O
expression	O	O
and	O	O
localization	O	O
of	O	O
dystrophin	O	O
to	O	O
the	O	O
cell	O	O
membrane	O	O
.	O	O

We	O	O
then	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
differing	O	O
dosages	O	O
of	O	O
gentamicin	O	O
on	O	O
expression	O	O
and	O	O
functional	O	O
protection	O	O
of	O	O
the	O	O
muscles	O	O
of	O	O
mdx	O	O
mice	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
treatment	O	O
regimen	O	O
that	O	O
resulted	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
dystrophin	O	O
in	O	O
the	O	O
cell	O	O
membrane	O	O
in	O	O
all	O	O
striated	O	O
muscles	O	O
examined	O	O
and	O	O
that	O	O
provided	O	O
functional	O	O
protection	O	O
against	O	O
muscular	B-Disease	D014947
injury	I-Disease	D014947
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
our	O	O
results	O	O
are	O	O
the	O	O
first	O	O
to	O	O
demonstrate	O	O
that	O	O
aminoglycosides	O	O
can	O	O
suppress	O	O
stop	O	O
codons	O	O
not	O	O
only	O	O
in	O	O
vitro	O	O
but	O	O
also	O	O
in	O	O
vivo	O	O
.	O	O

Furthermore	O	O
,	O	O
these	O	O
results	O	O
raise	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
novel	O	O
treatment	O	O
regimen	O	O
for	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
and	O	O
other	O	O
diseases	O	O
caused	O	O
by	O	O
premature	O	O
stop	O	O
codon	O	O
mutations	O	O
.	O	O

This	O	O
treatment	O	O
could	O	O
prove	O	O
effective	O	O
in	O	O
up	O	O
to	O	O
15	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
DMD	B-Disease	D020388
.	O	O

.	O	O

Molecular	O	O
and	O	O
metabolic	O	O
basis	O	O
for	O	O
the	O	O
metabolic	B-Disease	D008659
disorder	I-Disease	D008659
normotriglyceridemic	B-Disease	D000012
abetalipoproteinemia	I-Disease	D000012
.	O	O

We	O	O
have	O	O
previously	O	O
described	O	O
a	O	O
disorder	O	O
,	O	O
normotriglyceridemic	B-Disease	D000012
abetalipoproteinemia	I-Disease	D000012
,	O	O
that	O	O
is	O	O
characterized	O	O
by	O	O
the	O	O
virtual	O	O
absence	O	O
of	O	O
plasma	O	O
low	O	O
density	O	O
lipoproteins	O	O
and	O	O
complete	O	O
absence	O	O
of	O	O
apoB	O	O
-	O	O
100	O	O
,	O	O
but	O	O
with	O	O
apparently	O	O
normal	O	O
secretion	O	O
of	O	O
triglyceride	O	O
-	O	O
rich	O	O
lipoproteins	O	O
containing	O	O
apoB	O	O
-	O	O
48	O	O
.	O	O

The	O	O
patients	O	O
plasma	O	O
lipoproteins	O	O
were	O	O
shown	O	O
on	O	O
polyacrylamide	O	O
gels	O	O
and	O	O
by	O	O
antibody	O	O
mapping	O	O
to	O	O
have	O	O
a	O	O
new	O	O
truncated	O	O
apoB	O	O
variant	O	O
,	O	O
apoB	O	O
-	O	O
50	O	O
,	O	O
circulating	O	O
along	O	O
with	O	O
her	O	O
apoB	O	O
-	O	O
48	O	O
.	O	O

We	O	O
have	O	O
found	O	O
this	O	O
individual	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
a	O	O
single	O	O
C	O	O
-	O	O
to	O	O
-	O	O
T	O	O
nucleotide	O	O
substitution	O	O
at	O	O
apoB	O	O
codon	O	O
2252	O	O
,	O	O
which	O	O
produces	O	O
a	O	O
premature	O	O
in	O	O
-	O	O
frame	O	O
stop	O	O
codon	O	O
.	O	O

Thus	O	O
,	O	O
this	O	O
is	O	O
a	O	O
rare	O	O
example	O	O
of	O	O
homozygous	B-Disease	D006995
hypobetalipoproteinemia	I-Disease	D006995
.	O	O

Electron	O	O
photomicrographs	O	O
revealed	O	O
that	O	O
the	O	O
diameters	O	O
of	O	O
particles	O	O
in	O	O
the	O	O
d	O	O
less	O	O
than	O	O
1	O	O
.	O	O

006	O	O
g	O	O
/	O	O
ml	O	O
lipoprotein	O	O
fraction	O	O
,	O	O
in	O	O
both	O	O
the	O	O
postprandial	O	O
and	O	O
postabsorptive	O	O
state	O	O
,	O	O
are	O	O
bimodally	O	O
distributed	O	O
.	O	O

The	O	O
molar	O	O
ratio	O	O
of	O	O
apoE	O	O
to	O	O
apoB	O	O
in	O	O
these	O	O
particles	O	O
is	O	O
3	O	O
.	O	O

5	O	O
1	O	O
,	O	O
similar	O	O
to	O	O
normal	O	O
VLDL	O	O
.	O	O

The	O	O
plasma	O	O
LDL	O	O
interval	O	O
contains	O	O
both	O	O
spherical	O	O
and	O	O
cuboidal	O	O
particles	O	O
.	O	O

Autologous	O	O
reinfusion	O	O
of	O	O
labeled	O	O
d	O	O
less	O	O
than	O	O
1	O	O
.	O	O

006	O	O
g	O	O
/	O	O
ml	O	O
lipoproteins	O	O
showed	O	O
exponential	O	O
disappearance	O	O
from	O	O
plasma	O	O
,	O	O
with	O	O
an	O	O
apparent	O	O
half	O	O
-	O	O
removal	O	O
time	O	O
of	O	O
50	O	O
min	O	O
,	O	O
somewhat	O	O
slower	O	O
than	O	O
for	O	O
normal	O	O
chylomicrons	O	O
but	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
for	O	O
VLDL	O	O
.	O	O

The	O	O
calculated	O	O
production	O	O
rate	O	O
for	O	O
apoB	O	O
was	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
in	O	O
this	O	O
subject	O	O
.	O	O

von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
type	I-Disease	D014842
B	I-Disease	D014842
:	O	O
a	O	O
missense	O	O
mutation	O	O
selectively	O	O
abolishes	O	O
ristocetin	O	O
-	O	O
induced	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
binding	O	O
to	O	O
platelet	O	O
glycoprotein	O	O
Ib	O	O
.	O	O

von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
(	O	O
vWF	O	O
)	O	O
is	O	O
a	O	O
multimeric	O	O
glycoprotein	O	O
that	O	O
mediates	O	O
the	O	O
adhesion	O	O
of	O	O
platelets	O	O
to	O	O
the	O	O
subendothelium	O	O
by	O	O
binding	O	O
to	O	O
platelet	O	O
glycoprotein	O	O
Ib	O	O
.	O	O

For	O	O
human	O	O
vWF	O	O
,	O	O
this	O	O
interaction	O	O
can	O	O
be	O	O
induced	O	O
in	O	O
vitro	O	O
by	O	O
the	O	O
antibiotic	O	O
ristocetin	O	O
or	O	O
the	O	O
snake	O	O
venom	O	O
protein	O	O
botrocetin	O	O
.	O	O

A	O	O
missense	O	O
mutation	O	O
,	O	O
Gly	O	O
-	O	O
561	O	O
-	O	O
-	O	O
>	O	O
Ser	O	O
,	O	O
was	O	O
identified	O	O
within	O	O
the	O	O
proposed	O	O
glycoprotein	O	O
Ib	O	O
binding	O	O
domain	O	O
of	O	O
vWF	O	O
in	O	O
the	O	O
proband	O	O
with	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
type	I-Disease	D014842
B	I-Disease	D014842
,	O	O
a	O	O
unique	O	O
variant	O	O
characterized	O	O
by	O	O
no	O	O
ristocetin	O	O
-	O	O
induced	O	O
,	O	O
but	O	O
normal	O	O
botrocetin	O	O
-	O	O
induced	O	O
,	O	O
binding	O	O
to	O	O
glycoprotein	O	O
Ib	O	O
.	O	O

The	O	O
corresponding	O	O
mutant	O	O
recombinant	O	O
protein	O	O
,	O	O
rvWF	O	O
(	O	O
G561S	O	O
)	O	O
,	O	O
formed	O	O
normal	O	O
multimers	O	O
and	O	O
exhibited	O	O
the	O	O
same	O	O
functional	O	O
defect	O	O
as	O	O
the	O	O
patients	O	O
plasma	O	O
vWF	O	O
,	O	O
confirming	O	O
that	O	O
this	O	O
mutation	O	O
causes	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
type	I-Disease	D014842
B	I-Disease	D014842
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
botrocetin	O	O
and	O	O
ristocetin	O	O
cofactor	O	O
activities	O	O
of	O	O
vWF	O	O
can	O	O
be	O	O
dissociated	O	O
by	O	O
a	O	O
point	O	O
mutation	O	O
and	O	O
confirm	O	O
that	O	O
these	O	O
mediators	O	O
promote	O	O
vWF	O	O
binding	O	O
to	O	O
platelets	O	O
by	O	O
different	O	O
mechanisms	O	O
.	O	O

The	O	O
normal	O	O
botrocetin	O	O
-	O	O
induced	O	O
binding	O	O
and	O	O
the	O	O
defective	O	O
ristocetin	O	O
-	O	O
induced	O	O
binding	O	O
of	O	O
rvWF	O	O
(	O	O
G561S	O	O
)	O	O
suggest	O	O
that	O	O
the	O	O
primary	O	O
defect	O	O
in	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
type	I-Disease	D014842
B	I-Disease	D014842
may	O	O
be	O	O
a	O	O
failure	O	O
of	O	O
normal	O	O
allosteric	O	O
regulation	O	O
of	O	O
the	O	O
glycoprotein	O	O
Ib	O	O
binding	O	O
function	O	O
of	O	O
vWF	O	O
.	O	O

.	O	O

A	O	O
high	O	O
incidence	O	O
of	O	O
BRCA1	O	O
mutations	O	O
in	O	O
20	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
20	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
,	O	O
the	O	O
majority	O	O
of	O	O
which	O	O
show	O	O
positive	O	O
evidence	O	O
of	O	O
linkage	O	O
to	O	O
chromosome	O	O
17q12	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
.	O	O

BRCA1	O	O
mutations	O	O
cosegregating	O	O
with	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
were	O	O
identified	O	O
in	O	O
16	O	O
families	O	O
,	O	O
including	O	O
1	O	O
family	O	O
with	O	O
a	O	O
case	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
.	O	O

Nine	O	O
of	O	O
these	O	O
mutations	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
mutations	O	O
were	O	O
found	O	O
to	O	O
generate	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
leading	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
truncated	O	O
BRCA1	O	O
protein	O	O
of	O	O
2	O	O
%	O	O
-	O	O
88	O	O
%	O	O
of	O	O
the	O	O
expected	O	O
normal	O	O
length	O	O
.	O	O

Two	O	O
mutations	O	O
altered	O	O
the	O	O
RING	O	O
finger	O	O
domain	O	O
.	O	O

Sequencing	O	O
of	O	O
genomic	O	O
DNA	O	O
led	O	O
to	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
BRCA1	O	O
in	O	O
12	O	O
families	O	O
,	O	O
and	O	O
cDNA	O	O
analysis	O	O
revealed	O	O
an	O	O
abnormal	O	O
or	O	O
missing	O	O
BRCA1	O	O
transcript	O	O
in	O	O
4	O	O
of	O	O
the	O	O
8	O	O
remaining	O	O
families	O	O
.	O	O

A	O	O
total	O	O
of	O	O
eight	O	O
mutations	O	O
were	O	O
associated	O	O
with	O	O
a	O	O
reduced	O	O
quantity	O	O
of	O	O
BRCA1	O	O
transcript	O	O
.	O	O

We	O	O
were	O	O
unable	O	O
to	O	O
detect	O	O
BRCA1	O	O
mutations	O	O
in	O	O
4	O	O
of	O	O
the	O	O
20	O	O
families	O	O
,	O	O
but	O	O
only	O	O
1	O	O
of	O	O
these	O	O
was	O	O
clearly	O	O
linked	O	O
to	O	O
BRCA1	O	O
.	O	O

It	O	O
is	O	O
expected	O	O
that	O	O
the	O	O
majority	O	O
of	O	O
clear	O	O
examples	O	O
of	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
syndrome	I-Disease	D061325
will	O	O
be	O	O
associated	O	O
with	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
BRCA1	O	O
.	O	O

.	O	O

Assignment	O	O
of	O	O
the	O	O
human	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
gene	O	O
SGLT1	O	O
to	O	O
chromosome	O	O
22q13	O	O
.	O	O

1	O	O
.	O	O

The	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
gene	O	O
SGLT1	O	O
encodes	O	O
the	O	O
primary	O	O
carrier	O	O
protein	O	O
responsible	O	O
for	O	O
the	O	O
uptake	O	O
of	O	O
the	O	O
dietary	O	O
sugars	O	O
glucose	O	O
and	O	O
galactose	O	O
from	O	O
the	O	O
intestinal	O	O
lumen	O	O
.	O	O

SGLT1	O	O
transport	O	O
activity	O	O
is	O	O
currently	O	O
exploited	O	O
in	O	O
oral	O	O
rehydration	O	O
therapy	O	O
.	O	O

The	O	O
75	O	O
-	O	O
kDa	O	O
glycoprotein	O	O
is	O	O
localized	O	O
in	O	O
the	O	O
brush	O	O
border	O	O
of	O	O
the	O	O
intestinal	O	O
epithelium	O	O
and	O	O
is	O	O
predicted	O	O
to	O	O
comprise	O	O
12	O	O
membrane	O	O
spans	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
with	O	O
the	O	O
autosomal	B-Disease	OMIM:606824
recessive	I-Disease	OMIM:606824
disease	I-Disease	OMIM:606824
glucose	I-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
,	O	O
the	O	O
underlying	O	O
cause	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
SGLT1	O	O
,	O	O
and	O	O
the	O	O
Asp28	O	O
-	O	O
-	O	O
>	O	O
Asn	O	O
change	O	O
was	O	O
demonstrated	O	O
in	O	O
vitro	O	O
to	O	O
eliminate	O	O
SGLT1	O	O
transport	O	O
activity	O	O
.	O	O

The	O	O
SGLT1	O	O
gene	O	O
was	O	O
previously	O	O
shown	O	O
to	O	O
reside	O	O
on	O	O
the	O	O
distal	O	O
q	O	O
arm	O	O
of	O	O
chromosome	O	O
22	O	O
(	O	O
11	O	O
.	O	O

2	O	O
-	O	O
-	O	O
>	O	O
qter	O	O
)	O	O
.	O	O

We	O	O
have	O	O
used	O	O
a	O	O
cosmid	O	O
probe	O	O
for	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
which	O	O
refines	O	O
the	O	O
localization	O	O
to	O	O
22q13	O	O
.	O	O

1	O	O
,	O	O
and	O	O
provide	O	O
an	O	O
example	O	O
of	O	O
the	O	O
utility	O	O
of	O	O
the	O	O
SGLT1	O	O
probe	O	O
as	O	O
a	O	O
diagnostic	O	O
for	O	O
genetic	B-Disease	D030342
diseases	I-Disease	D030342
associated	O	O
with	O	O
translocations	O	O
of	O	O
chromosome	O	O
22	O	O
.	O	O

A	O	O
pseudodeficiency	O	O
allele	O	O
common	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
carriers	O	O
:	O	O
implications	O	O
for	O	O
carrier	O	O
screening	O	O
.	O	O

Deficiency	B-Disease	D013661
of	I-Disease	D013661
beta	I-Disease	D013661
-	I-Disease	D013661
hexosaminidase	I-Disease	D013661
A	I-Disease	D013661
(	O	O
Hex	O	O
A	O	O
)	O	O
activity	O	O
typically	O	O
results	O	O
in	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
.	O	O

However	O	O
,	O	O
healthy	O	O
subjects	O	O
found	O	O
to	O	O
be	O	O
deficient	B-Disease	D013661
in	I-Disease	D013661
Hex	I-Disease	D013661
A	I-Disease	D013661
activity	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
pseudodeficient	O	O
)	O	O
by	O	O
means	O	O
of	O	O
in	O	O
vitro	O	O
biochemical	O	O
tests	O	O
have	O	O
been	O	O
described	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
HEXA	O	O
gene	O	O
of	O	O
one	O	O
pseudodeficient	O	O
subject	O	O
and	O	O
identified	O	O
both	O	O
a	O	O
C739	O	O
-	O	O
to	O	O
-	O	O
T	O	O
substitution	O	O
that	O	O
changes	O	O
Arg247	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Trp	O	O
on	O	O
one	O	O
allele	O	O
and	O	O
a	O	O
previously	O	O
identified	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
mutation	O	O
on	O	O
the	O	O
second	O	O
allele	O	O
.	O	O

Six	O	O
additional	O	O
pseudodeficient	O	O
subjects	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
C739	O	O
-	O	O
to	O	O
-	O	O
T	O	O
mutation	O	O
.	O	O

This	O	O
allele	O	O
accounted	O	O
for	O	O
32	O	O
%	O	O
(	O	O
20	O	O
/	O	O
62	O	O
)	O	O
of	O	O
non	O	O
-	O	O
Jewish	O	O
enzyme	O	O
-	O	O
defined	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
carriers	O	O
but	O	O
for	O	O
none	O	O
of	O	O
36	O	O
Jewish	O	O
enzyme	O	O
-	O	O
defined	O	O
carriers	O	O
who	O	O
did	O	O
not	O	O
have	O	O
one	O	O
of	O	O
three	O	O
known	O	O
mutations	O	O
common	O	O
to	O	O
this	O	O
group	O	O
.	O	O

The	O	O
C739	O	O
-	O	O
to	O	O
-	O	O
T	O	O
allele	O	O
,	O	O
together	O	O
with	O	O
a	O	O
"	O	O
true	O	O
"	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
allele	O	O
,	O	O
causes	O	O
Hex	O	O
A	O	O
pseudodeficiency	O	O
.	O	O

Given	O	O
both	O	O
the	O	O
large	O	O
proportion	O	O
of	O	O
non	O	O
-	O	O
Jewish	O	O
carriers	O	O
with	O	O
this	O	O
allele	O	O
and	O	O
that	O	O
standard	O	O
biochemical	O	O
screening	O	O
cannot	O	O
differentiate	O	O
between	O	O
heterozygotes	O	O
for	O	O
the	O	O
C739	O	O
-	O	O
to	O	O
-	O	O
T	O	O
mutations	O	O
and	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
carriers	O	O
,	O	O
DNA	O	O
testing	O	O
for	O	O
this	O	O
mutation	O	O
in	O	O
at	O	O
-	O	O
risk	O	O
couples	O	O
is	O	O
essential	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
two	O	O
different	O	O
infantile	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
mutations	O	O
in	O	O
a	O	O
Cajun	O	O
population	O	O
.	O	O

A	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
characterize	O	O
the	O	O
mutation	O	O
(	O	O
s	O	O
)	O	O
responsible	O	O
for	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
in	O	O
a	O	O
Cajun	O	O
population	O	O
in	O	O
southwest	O	O
Louisiana	O	O
and	O	O
to	O	O
identify	O	O
the	O	O
origins	O	O
of	O	O
these	O	O
mutations	O	O
.	O	O

Eleven	O	O
of	O	O
12	O	O
infantile	O	O
TSD	B-Disease	D013661
alleles	O	O
examined	O	O
in	O	O
six	O	O
families	O	O
had	O	O
the	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
(	O	O
Hex	O	O
A	O	O
)	O	O
alpha	O	O
-	O	O
subunit	O	O
exon	O	O
11	O	O
insertion	O	O
mutation	O	O
that	O	O
is	O	O
present	O	O
in	O	O
approximately	O	O
70	O	O
%	O	O
of	O	O
Ashkenazi	O	O
Jewish	O	O
TSD	B-Disease	D013661
heterozygotes	O	O
.	O	O

The	O	O
mutation	O	O
in	O	O
the	O	O
remaining	O	O
allele	O	O
was	O	O
a	O	O
single	O	O
-	O	O
base	O	O
transition	O	O
in	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
of	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
intron	O	O
9	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
origins	O	O
of	O	O
these	O	O
two	O	O
mutations	O	O
in	O	O
the	O	O
Cajun	O	O
population	O	O
,	O	O
the	O	O
TSD	B-Disease	D013661
carrier	O	O
status	O	O
was	O	O
enzymatically	O	O
determined	O	O
for	O	O
90	O	O
members	O	O
of	O	O
four	O	O
of	O	O
the	O	O
six	O	O
families	O	O
,	O	O
and	O	O
extensive	O	O
pedigrees	O	O
were	O	O
constructed	O	O
for	O	O
all	O	O
carriers	O	O
.	O	O

A	O	O
single	O	O
ancestral	O	O
couple	O	O
from	O	O
France	O	O
was	O	O
found	O	O
to	O	O
be	O	O
common	O	O
to	O	O
most	O	O
of	O	O
the	O	O
carriers	O	O
of	O	O
the	O	O
exon	O	O
11	O	O
insertion	O	O
.	O	O

Pedigree	O	O
data	O	O
suggest	O	O
that	O	O
this	O	O
mutation	O	O
has	O	O
been	O	O
in	O	O
the	O	O
Cajun	O	O
population	O	O
since	O	O
its	O	O
founding	O	O
over	O	O
2	O	O
centuries	O	O
ago	O	O
and	O	O
that	O	O
it	O	O
may	O	O
be	O	O
widely	O	O
distributed	O	O
within	O	O
the	O	O
population	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
intron	O	O
9	O	O
mutation	O	O
apparently	O	O
was	O	O
introduced	O	O
within	O	O
the	O	O
last	O	O
century	O	O
and	O	O
probably	O	O
is	O	O
limited	O	O
to	O	O
a	O	O
few	O	O
Louisiana	O	O
families	O	O
.	O	O

.	O	O

Canavan	B-Disease	D017825
disease	I-Disease	D017825
:	O	O
genomic	O	O
organization	O	O
and	O	O
localization	O	O
of	O	O
human	O	O
ASPA	O	O
to	O	O
17p13	O	O
-	O	O
ter	O	O
and	O	O
conservation	O	O
of	O	O
the	O	O
ASPA	O	O
gene	O	O
during	O	O
evolution	O	O
.	O	O

Canavan	B-Disease	D017825
disease	I-Disease	D017825
,	O	O
or	O	O
spongy	B-Disease	D017825
degeneration	I-Disease	D017825
of	I-Disease	D017825
the	I-Disease	D017825
brain	I-Disease	D017825
,	O	O
is	O	O
a	O	O
severe	O	O
leukodystrophy	B-Disease	D007966
caused	O	O
by	O	O
the	O	O
deficiency	B-Disease	D017825
of	I-Disease	D017825
aspartoacylase	I-Disease	D017825
(	O	O
ASPA	O	O
)	O	O
.	O	O

Recently	O	O
,	O	O
a	O	O
missense	O	O
mutation	O	O
was	O	O
identified	O	O
in	O	O
human	O	O
ASPA	O	O
coding	O	O
sequence	O	O
from	O	O
patients	O	O
with	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
.	O	O

The	O	O
human	O	O
ASPA	O	O
gene	O	O
has	O	O
been	O	O
cloned	O	O
and	O	O
found	O	O
to	O	O
span	O	O
29	O	O
kb	O	O
of	O	O
the	O	O
genome	O	O
.	O	O

Human	O	O
aspartoacylase	O	O
is	O	O
coded	O	O
by	O	O
six	O	O
exons	O	O
intervened	O	O
by	O	O
five	O	O
introns	O	O
.	O	O

The	O	O
exons	O	O
vary	O	O
from	O	O
94	O	O
(	O	O
exon	O	O
III	O	O
)	O	O
to	O	O
514	O	O
(	O	O
exon	O	O
VI	O	O
)	O	O
bases	O	O
.	O	O

The	O	O
exon	O	O
/	O	O
intron	O	O
splice	O	O
junction	O	O
sites	O	O
follow	O	O
the	O	O
gt	O	O
/	O	O
ag	O	O
consensus	O	O
sequence	O	O
rule	O	O
.	O	O

Southern	O	O
blot	O	O
analysis	O	O
of	O	O
genomic	O	O
DNA	O	O
from	O	O
human	O	O
/	O	O
mouse	O	O
somatic	O	O
cell	O	O
hybrid	O	O
cell	O	O
lines	O	O
localized	O	O
ASPA	O	O
to	O	O
human	O	O
chromosome	O	O
17	O	O
.	O	O

The	O	O
human	O	O
ASPA	O	O
locus	O	O
was	O	O
further	O	O
mapped	O	O
in	O	O
the	O	O
17p13	O	O
-	O	O
ter	O	O
region	O	O
by	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

The	O	O
bovine	O	O
aspa	O	O
gene	O	O
has	O	O
also	O	O
been	O	O
cloned	O	O
,	O	O
and	O	O
its	O	O
exon	O	O
/	O	O
intron	O	O
organization	O	O
is	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
the	O	O
human	O	O
gene	O	O
.	O	O

The	O	O
500	O	O
-	O	O
base	O	O
sequence	O	O
upstream	O	O
of	O	O
the	O	O
initiator	O	O
ATG	O	O
codon	O	O
in	O	O
the	O	O
human	O	O
gene	O	O
and	O	O
that	O	O
in	O	O
the	O	O
bovine	O	O
gene	O	O
are	O	O
77	O	O
%	O	O
identical	O	O
.	O	O

Human	O	O
ASPA	O	O
coding	O	O
sequences	O	O
cross	O	O
-	O	O
hybridize	O	O
with	O	O
genomic	O	O
DNA	O	O
from	O	O
yeast	O	O
,	O	O
chicken	O	O
,	O	O
rabbit	O	O
,	O	O
cow	O	O
,	O	O
dog	O	O
,	O	O
mouse	O	O
,	O	O
rat	O	O
,	O	O
and	O	O
monkey	O	O
.	O	O

The	O	O
specificity	O	O
of	O	O
cross	O	O
-	O	O
species	O	O
hybridization	O	O
of	O	O
coding	O	O
sequences	O	O
suggests	O	O
that	O	O
aspartoacylase	O	O
has	O	O
been	O	O
conserved	O	O
during	O	O
evolution	O	O
.	O	O

It	O	O
should	O	O
now	O	O
be	O	O
possible	O	O
to	O	O
identify	O	O
mutations	O	O
in	O	O
the	O	O
noncoding	O	O
genomic	O	O
sequences	O	O
that	O	O
lead	O	O
to	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
and	O	O
to	O	O
study	O	O
the	O	O
regulation	O	O
of	O	O
ASPA	O	O
.	O	O

.	O	O

Adrenoleukodystrophy	B-Disease	D000326
:	O	O
survey	O	O
of	O	O
303	O	O
cases	O	O
:	O	O
biochemistry	O	O
,	O	O
diagnosis	O	O
,	O	O
and	O	O
therapy	O	O
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
is	O	O
a	O	O
genetically	O	O
determined	O	O
disorder	O	O
associated	O	O
with	O	O
progressive	B-Disease	D003711
central	I-Disease	D003711
demyelination	I-Disease	D003711
and	O	O
adrenal	B-Disease	D000309
cortical	I-Disease	D000309
insufficiency	I-Disease	D000309
.	O	O

All	O	O
affected	O	O
persons	O	O
show	O	O
increased	O	O
levels	O	O
of	O	O
saturated	O	O
unbranched	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
,	O	O
particularly	O	O
hexacosanoate	O	O
(	O	O
C26	O	O
0	O	O
)	O	O
,	O	O
because	O	O
of	O	O
impaired	O	O
capacity	O	O
to	O	O
degrade	O	O
these	O	O
acids	O	O
.	O	O

This	O	O
degradation	O	O
normally	O	O
takes	O	O
place	O	O
in	O	O
a	O	O
subcellular	O	O
organelle	O	O
called	O	O
the	O	O
peroxisome	O	O
,	O	O
and	O	O
ALD	B-Disease	D000326
,	O	O
together	O	O
with	O	O
Zellwegers	B-Disease	D015211
cerebrohepatorenal	I-Disease	D015211
syndrome	I-Disease	D015211
,	O	O
is	O	O
now	O	O
considered	O	O
to	O	O
belong	O	O
to	O	O
the	O	O
newly	O	O
formed	O	O
category	O	O
of	O	O
peroxisomal	B-Disease	D018901
disorders	I-Disease	D018901
.	O	O

Biochemical	O	O
assays	O	O
permit	O	O
prenatal	O	O
diagnosis	O	O
,	O	O
as	O	O
well	O	O
as	O	O
identification	O	O
of	O	O
most	O	O
heterozygotes	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
303	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
in	O	O
217	O	O
kindreds	O	O
.	O	O

These	O	O
patients	O	O
show	O	O
a	O	O
wide	O	O
phenotypic	O	O
variation	O	O
.	O	O

Sixty	O	O
percent	O	O
of	O	O
patients	O	O
had	O	O
childhood	O	O
ALD	B-Disease	D000326
and	O	O
17	O	O
%	O	O
adrenomyeloneuropathy	B-Disease	D000326
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
X	O	O
-	O	O
linked	O	O
,	O	O
with	O	O
the	O	O
gene	O	O
mapped	O	O
to	O	O
Xq28	O	O
.	O	O

Neonatal	B-Disease	OMIM:202370
ALD	I-Disease	OMIM:202370
,	O	O
a	O	O
distinct	O	O
entity	O	O
with	O	O
autosomal	O	O
recessive	O	O
inheritance	O	O
and	O	O
points	O	O
of	O	O
resemblance	O	O
to	O	O
Zellwegers	B-Disease	D015211
syndrome	I-Disease	D015211
,	O	O
accounted	O	O
for	O	O
7	O	O
%	O	O
of	O	O
the	O	O
cases	O	O
.	O	O

Although	O	O
excess	O	O
C26	O	O
0	O	O
in	O	O
the	O	O
brain	O	O
of	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
is	O	O
partially	O	O
of	O	O
dietary	O	O
origin	O	O
,	O	O
dietary	O	O
C26	O	O
0	O	O
restriction	O	O
did	O	O
not	O	O
produce	O	O
clear	O	O
benefit	O	O
.	O	O

Bone	O	O
marrow	O	O
transplant	O	O
lowered	O	O
the	O	O
plasma	O	O
C26	O	O
0	O	O
level	O	O
but	O	O
failed	O	O
to	O	O
arrest	O	O
neurological	O	O
progression	O	O
.	O	O

.	O	O

French	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
patients	O	O
do	O	O
not	O	O
exhibit	O	O
gametic	O	O
segregation	O	O
distortion	O	O
:	O	O
a	O	O
sperm	O	O
typing	O	O
analysis	O	O
.	O	O

Segregation	O	O
distortion	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
occur	O	O
in	O	O
a	O	O
number	O	O
of	O	O
the	O	O
trinucleotide	B-Disease	D030342
repeat	I-Disease	D030342
disorders	I-Disease	D030342
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
sperm	O	O
typing	O	O
study	O	O
performed	O	O
in	O	O
patients	O	O
of	O	O
Japanese	O	O
descent	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
,	O	O
it	O	O
was	O	O
reported	O	O
that	O	O
disease	O	O
alleles	O	O
are	O	O
preferentially	O	O
transmitted	O	O
during	O	O
meiosis	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
sperm	O	O
typing	O	O
study	O	O
of	O	O
five	O	O
MJD	B-Disease	D017827
patients	O	O
of	O	O
French	O	O
descent	O	O
and	O	O
analysis	O	O
of	O	O
the	O	O
pooled	O	O
data	O	O
shows	O	O
a	O	O
ratio	O	O
of	O	O
mutant	O	O
to	O	O
normal	O	O
alleles	O	O
of	O	O
379	O	O
436	O	O
(	O	O
46	O	O
.	O	O

5	O	O
53	O	O
.	O	O

5	O	O
%	O	O
)	O	O
,	O	O
which	O	O
does	O	O
not	O	O
support	O	O
meiotic	O	O
segregation	O	O
distortion	O	O
.	O	O

To	O	O
confirm	O	O
these	O	O
results	O	O
,	O	O
sperm	O	O
typing	O	O
analysis	O	O
was	O	O
also	O	O
performed	O	O
using	O	O
a	O	O
polymorphic	O	O
marker	O	O
,	O	O
D14S1050	O	O
,	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
MJD1	O	O
gene	O	O
.	O	O

Among	O	O
910	O	O
sperm	O	O
analyzed	O	O
,	O	O
the	O	O
allele	O	O
linked	O	O
to	O	O
the	O	O
disease	O	O
chromosome	O	O
was	O	O
detected	O	O
in	O	O
50	O	O
.	O	O

3	O	O
%	O	O
of	O	O
the	O	O
samples	O	O
and	O	O
the	O	O
allele	O	O
linked	O	O
to	O	O
the	O	O
normal	O	O
chromosome	O	O
was	O	O
found	O	O
in	O	O
49	O	O
.	O	O

6	O	O
%	O	O
of	O	O
the	O	O
sperm	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
frequency	O	O
of	O	O
these	O	O
two	O	O
alleles	O	O
is	O	O
not	O	O
significant	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

8423	O	O
)	O	O
.	O	O

Likelihood	O	O
-	O	O
based	O	O
analysis	O	O
of	O	O
segregation	O	O
distortion	O	O
in	O	O
the	O	O
single	O	O
sperm	O	O
data	O	O
using	O	O
the	O	O
SPERMSEG	O	O
program	O	O
also	O	O
showed	O	O
no	O	O
support	O	O
for	O	O
segregation	O	O
distortion	O	O
at	O	O
the	O	O
gamete	O	O
level	O	O
in	O	O
this	O	O
patient	O	O
population	O	O
.	O	O

The	O	O
previous	O	O
report	O	O
on	O	O
the	O	O
Japanese	O	O
patients	O	O
also	O	O
suggested	O	O
that	O	O
disease	O	O
allele	O	O
stability	O	O
may	O	O
be	O	O
influenced	O	O
by	O	O
a	O	O
trans	O	O
effect	O	O
of	O	O
an	O	O
intragenic	O	O
polymorphism	O	O
(	O	O
987	O	O
G	O	O
/	O	O
C	O	O
)	O	O
in	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
.	O	O

All	O	O
of	O	O
the	O	O
French	O	O
patients	O	O
were	O	O
heterozygous	O	O
for	O	O
this	O	O
polymorphism	O	O
.	O	O

However	O	O
,	O	O
analysis	O	O
of	O	O
the	O	O
variance	O	O
in	O	O
repeat	O	O
number	O	O
in	O	O
sperm	O	O
from	O	O
the	O	O
French	O	O
MJD	B-Disease	D017827
patients	O	O
overlapped	O	O
significantly	O	O
with	O	O
the	O	O
variance	O	O
in	O	O
repeat	O	O
number	O	O
observed	O	O
in	O	O
the	O	O
C	O	O
/	O	O
C	O	O
homozygous	O	O
Japanese	O	O
patients	O	O
.	O	O

Nebulin	O	O
seen	O	O
in	O	O
DMD	B-Disease	D020388
males	O	O
including	O	O
one	O	O
patient	O	O
with	O	O
a	O	O
large	O	O
DNA	O	O
deletion	O	O
encompassing	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
nebulin	O	O
in	O	O
a	O	O
muscle	O	O
specimen	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
due	O	O
to	O	O
a	O	O
large	O	O
deletion	O	O
precludes	O	O
the	O	O
possibility	O	O
that	O	O
this	O	O
protein	O	O
is	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
product	O	O
.	O	O

.	O	O

The	O	O
human	O	O
gene	O	O
for	O	O
alkaptonuria	B-Disease	D000474
(	O	O
AKU	B-Disease	D000474
)	O	O
maps	O	O
to	O	O
chromosome	O	O
3q	O	O
.	O	O

Alkaptonuria	B-Disease	D000474
(	O	O
AKU	B-Disease	D000474
;	O	O
McKusick	O	O
no	O	O
.	O	O

203500	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
homogentisic	O	O
acid	O	O
oxidase	O	O
activity	O	O
.	O	O

Patients	O	O
excrete	O	O
large	O	O
amounts	O	O
of	O	O
homogentisic	O	O
acid	O	O
in	O	O
their	O	O
urine	O	O
and	O	O
a	O	O
black	O	O
ochronotic	O	O
pigment	O	O
is	O	O
deposited	O	O
in	O	O
their	O	O
cartilage	O	O
and	O	O
collagenous	O	O
tissues	O	O
.	O	O

Ochronosis	B-Disease	D009794
is	O	O
the	O	O
predominant	O	O
clinical	O	O
complication	O	O
of	O	O
the	O	O
disease	O	O
leading	O	O
to	O	O
ochronotic	B-Disease	D009794	D007592
arthropathy	I-Disease	D009794	D007592
,	O	O
dark	O	O
urine	O	O
,	O	O
pigment	O	O
changes	O	O
of	O	O
the	O	O
skin	O	O
,	O	O
and	O	O
other	O	O
clinical	O	O
features	O	O
.	O	O

A	O	O
mutation	O	O
causing	O	O
alkaptonuria	B-Disease	D000474
in	O	O
the	O	O
mouse	O	O
has	O	O
mapped	O	O
to	O	O
chromosome	O	O
16	O	O
.	O	O

Considering	O	O
conserved	O	O
synteny	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
map	O	O
the	O	O
human	O	O
gene	O	O
to	O	O
chromosome	O	O
3q	O	O
in	O	O
six	O	O
alkaptonuria	B-Disease	D000474
pedigrees	O	O
of	O	O
Slovak	O	O
origin	O	O
.	O	O

.	O	O

The	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
responsible	O	O
for	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
,	O	O
is	O	O
mutated	O	O
in	O	O
human	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
.	O	O

Although	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
is	O	O
the	O	O
most	O	O
common	O	O
cancer	B-Disease	D009369
in	O	O
the	O	O
world	O	O
,	O	O
genetic	O	O
changes	O	O
during	O	O
its	O	O
carcinogenesis	O	O
are	O	O
not	O	O
well	O	O
understood	O	O
.	O	O

Since	O	O
some	O	O
gastric	B-Disease	D013274
cancers	I-Disease	D013274
are	O	O
considered	O	O
to	O	O
originate	O	O
from	O	O
the	O	O
intestinal	O	O
metaplasia	O	O
,	O	O
it	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
,	O	O
the	O	O
mutation	O	O
of	O	O
which	O	O
causes	O	O
adenomatous	B-Disease	D018256
polyps	I-Disease	D018256
in	I-Disease	D018256
the	I-Disease	D018256
colon	I-Disease	D018256
,	O	O
is	O	O
associated	O	O
with	O	O
carcinogenesis	O	O
of	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
.	O	O

Based	O	O
on	O	O
this	O	O
idea	O	O
,	O	O
DNAs	O	O
isolated	O	O
from	O	O
gastric	B-Disease	D013274
cancers	I-Disease	D013274
were	O	O
examined	O	O
by	O	O
means	O	O
of	O	O
a	O	O
RNase	O	O
protection	O	O
analysis	O	O
coupled	O	O
with	O	O
polymerase	O	O
chain	O	O
reaction	O	O
followed	O	O
by	O	O
sequencing	O	O
of	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
products	O	O
.	O	O

By	O	O
screening	O	O
nearly	O	O
one	O	O
-	O	O
half	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
44	O	O
tumors	B-Disease	D009369
,	O	O
somatic	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
three	O	O
tumors	B-Disease	D009369
a	O	O
missense	O	O
mutation	O	O
,	O	O
a	O	O
nonsense	O	O
mutation	O	O
,	O	O
and	O	O
a	O	O
5	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
resulting	O	O
in	O	O
a	O	O
frame	O	O
shift	O	O
which	O	O
causes	O	O
truncation	O	O
of	O	O
the	O	O
gene	O	O
product	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
mutation	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
also	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
during	O	O
the	O	O
carcinogenesis	O	O
of	O	O
at	O	O
least	O	O
some	O	O
gastric	B-Disease	D013274
cancers	I-Disease	D013274
.	O	O

.	O	O

Molecular	O	O
epidemiology	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
heterozygotes	O	O
with	O	O
an	O	O
Arg95Stop	O	O
mutation	O	O
of	O	O
the	O	O
C9	O	O
gene	O	O
in	O	O
Japan	O	O
.	O	O

Deficiency	B-Disease	OMIM:613825
of	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
ninth	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
human	I-Disease	OMIM:613825
complement	I-Disease	OMIM:613825
(	O	O
C9	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
complement	B-Disease	D007153
deficiency	I-Disease	D007153
in	O	O
Japan	O	O
,	O	O
with	O	O
an	O	O
incidence	O	O
of	O	O
approximately	O	O
one	O	O
homozygote	O	O
in	O	O
1000	O	O
,	O	O
but	O	O
is	O	O
very	O	O
rare	O	O
in	O	O
other	O	O
countries	O	O
.	O	O

Genetic	O	O
analyses	O	O
of	O	O
Japanese	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
have	O	O
shown	O	O
that	O	O
a	O	O
C	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transition	O	O
leading	O	O
to	O	O
TGA	O	O
stop	O	O
codon	O	O
for	O	O
Arg95	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
C9	O	O
gene	O	O
(	O	O
Arg95Stop	O	O
)	O	O
is	O	O
common	O	O
in	O	O
Japanese	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

To	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
heterozygous	O	O
carriers	O	O
of	O	O
the	O	O
Arg95Stop	O	O
mutation	O	O
in	O	O
a	O	O
Japanese	O	O
population	O	O
,	O	O
we	O	O
collected	O	O
DNA	O	O
samples	O	O
from	O	O
300	O	O
individuals	O	O
in	O	O
two	O	O
of	O	O
the	O	O
four	O	O
main	O	O
islands	O	O
of	O	O
Japan	O	O
.	O	O

Heterozygote	O	O
detection	O	O
was	O	O
performed	O	O
with	O	O
an	O	O
allele	O	O
-	O	O
specific	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
system	O	O
designed	O	O
to	O	O
detect	O	O
exclusively	O	O
only	O	O
one	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
mutant	O	O
alleles	O	O
,	O	O
followed	O	O
by	O	O
confirmation	O	O
with	O	O
PCR	O	O
/	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

Twenty	O	O
individuals	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
Arg95Stop	O	O
mutation	O	O
.	O	O

None	O	O
was	O	O
homozygous	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
carriers	O	O
of	O	O
the	O	O
Arg95Stop	O	O
mutation	O	O
was	O	O
6	O	O
.	O	O

7	O	O
%	O	O
(	O	O
20	O	O
/	O	O
300	O	O
)	O	O
.	O	O

An	O	O
estimated	O	O
frequency	O	O
(	O	O
0	O	O
.	O	O

12	O	O
%	O	O
)	O	O
of	O	O
complete	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
due	O	O
to	O	O
homozygous	O	O
Arg95Stop	O	O
mutation	O	O
was	O	O
consistent	O	O
with	O	O
frequencies	O	O
determined	O	O
by	O	O
serological	O	O
studies	O	O
Molecular	O	O
analysis	O	O
of	O	O
a	O	O
female	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patient	O	O
.	O	O

We	O	O
report	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
(	O	O
hypoxanthine	B-Disease	D007926
phosphoribosyltransferase	I-Disease	D007926
[	I-Disease	D007926
HPRT	I-Disease	D007926
]	I-Disease	D007926
deficiency	I-Disease	D007926
)	O	O
.	O	O

Cytogenetic	O	O
and	O	O
carrier	O	O
studies	O	O
revealed	O	O
structurally	O	O
normal	O	O
chromosomes	O	O
for	O	O
this	O	O
patient	O	O
and	O	O
her	O	O
parents	O	O
and	O	O
demonstrated	O	O
that	O	O
this	O	O
mutation	O	O
arose	O	O
through	O	O
a	O	O
de	O	O
novo	O	O
gametic	O	O
event	O	O
.	O	O

Comparison	O	O
of	O	O
this	O	O
patients	O	O
DNA	O	O
with	O	O
the	O	O
DNA	O	O
of	O	O
her	O	O
parents	O	O
revealed	O	O
that	O	O
a	O	O
microdeletion	O	O
,	O	O
which	O	O
occurred	O	O
within	O	O
a	O	O
maternal	O	O
gamete	O	O
and	O	O
involved	O	O
the	O	O
entire	O	O
HPRT	O	O
gene	O	O
,	O	O
was	O	O
partially	O	O
responsible	O	O
for	O	O
the	O	O
disease	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

Somatic	O	O
cell	O	O
hybrids	O	O
,	O	O
generated	O	O
to	O	O
separate	O	O
maternal	O	O
and	O	O
paternal	O	O
X	O	O
chromosomes	O	O
,	O	O
showed	O	O
that	O	O
expression	O	O
of	O	O
two	O	O
additional	O	O
X	O	O
-	O	O
linked	O	O
enzymes	O	O
,	O	O
phosphoglycerate	O	O
kinase	O	O
and	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
,	O	O
were	O	O
expressed	O	O
only	O	O
in	O	O
cells	O	O
that	O	O
contained	O	O
the	O	O
maternal	O	O
X	O	O
chromosome	O	O
,	O	O
suggesting	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
functionally	O	O
inactive	O	O
paternal	O	O
X	O	O
chromosome	O	O
.	O	O

Furthermore	O	O
,	O	O
comparison	O	O
of	O	O
methylation	O	O
patterns	O	O
within	O	O
a	O	O
region	O	O
of	O	O
the	O	O
HPRT	O	O
gene	O	O
known	O	O
to	O	O
be	O	O
important	O	O
in	O	O
gene	O	O
regulation	O	O
revealed	O	O
differences	O	O
between	O	O
DNA	O	O
from	O	O
the	O	O
father	O	O
and	O	O
the	O	O
patient	O	O
,	O	O
in	O	O
keeping	O	O
with	O	O
an	O	O
active	O	O
HPRT	O	O
locus	O	O
in	O	O
the	O	O
father	O	O
and	O	O
an	O	O
inactive	O	O
HPRT	O	O
locus	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

Together	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
nonrandom	O	O
inactivation	O	O
of	O	O
the	O	O
cytogenetically	O	O
normal	O	O
paternal	O	O
X	O	O
chromosome	O	O
and	O	O
a	O	O
microdeletion	O	O
of	O	O
the	O	O
HPRT	O	O
gene	O	O
on	O	O
an	O	O
active	O	O
maternal	O	O
X	O	O
chromosome	O	O
were	O	O
responsible	O	O
for	O	O
the	O	O
absence	O	O
of	O	O
HPRT	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

.	O	O

Changes	O	O
at	O	O
P183	O	O
of	O	O
emerin	O	O
weaken	O	O
its	O	O
protein	O	O
-	O	O
protein	O	O
interactions	O	O
resulting	O	O
in	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
.	O	O

Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181	D009136
-	I-Disease	D040181	D009136
linked	I-Disease	D040181	D009136
recessive	I-Disease	D040181	D009136
muscular	I-Disease	D040181	D009136
dystrophy	I-Disease	D040181	D009136
characterized	O	O
by	O	O
early	O	O
contractures	B-Disease	D003286
of	I-Disease	D003286
the	I-Disease	D003286
elbows	I-Disease	D003286
,	I-Disease	D003286
Achilles	I-Disease	D003286
tendons	I-Disease	D003286
and	I-Disease	D003286
spine	I-Disease	D003286
,	O	O
slowly	O	O
progressive	O	O
muscle	B-Disease	D009133
wasting	I-Disease	D009133
and	O	O
weakness	B-Disease	D018908
,	O	O
and	O	O
cardiomyopathy	B-Disease	D009202
associated	O	O
with	O	O
cardiac	B-Disease	OMIM:115080
conduction	I-Disease	OMIM:115080
defects	I-Disease	OMIM:115080
.	O	O

The	O	O
emerin	O	O
gene	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
Xq28	O	O
and	O	O
encodes	O	O
a	O	O
34	O	O
-	O	O
kDa	O	O
serine	O	O
-	O	O
rich	O	O
protein	O	O
,	O	O
emerin	O	O
,	O	O
which	O	O
has	O	O
been	O	O
localized	O	O
to	O	O
the	O	O
nuclear	O	O
envelope	O	O
in	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
tissues	O	O
,	O	O
including	O	O
skeletal	O	O
and	O	O
cardiac	O	O
muscle	O	O
.	O	O

Mutations	O	O
spanning	O	O
the	O	O
emerin	O	O
gene	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
EDMD	B-Disease	D020389
.	O	O

We	O	O
present	O	O
here	O	O
the	O	O
effect	O	O
,	O	O
on	O	O
emerin	O	O
protein	O	O
expression	O	O
,	O	O
of	O	O
two	O	O
missense	O	O
mutations	O	O
identified	O	O
in	O	O
unrelated	O	O
EDMD	B-Disease	D020389
patients	O	O
.	O	O

These	O	O
alterations	O	O
predict	O	O
the	O	O
replacement	O	O
of	O	O
a	O	O
proline	O	O
residue	O	O
at	O	O
position	O	O
183	O	O
with	O	O
either	O	O
a	O	O
histidine	O	O
or	O	O
a	O	O
threonine	O	O
.	O	O

Biochemical	O	O
analysis	O	O
has	O	O
demonstrated	O	O
that	O	O
the	O	O
mobility	O	O
and	O	O
expression	O	O
levels	O	O
of	O	O
the	O	O
mutant	O	O
forms	O	O
of	O	O
emerin	O	O
are	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
emerin	O	O
,	O	O
but	O	O
that	O	O
they	O	O
have	O	O
weakened	O	O
interactions	O	O
with	O	O
nuclear	O	O
lamina	O	O
components	O	O
.	O	O

In	O	O
comparison	O	O
with	O	O
the	O	O
usual	O	O
EDMD	B-Disease	D020389
phenotype	O	O
,	O	O
patients	O	O
with	O	O
P183	O	O
missense	O	O
mutations	O	O
have	O	O
a	O	O
later	O	O
age	O	O
at	O	O
onset	O	O
of	O	O
first	O	O
symptoms	O	O
,	O	O
elbow	B-Disease	D003286
contractures	I-Disease	D003286
,	O	O
ankle	B-Disease	D003286
contractures	I-Disease	D003286
,	O	O
upper	B-Disease	D018908
limb	I-Disease	D018908
weakness	I-Disease	D018908
and	O	O
lower	B-Disease	D018908
limb	I-Disease	D018908
weakness	I-Disease	D018908
,	O	O
but	O	O
there	O	O
is	O	O
no	O	O
difference	O	O
for	O	O
the	O	O
age	O	O
at	O	O
onset	O	O
of	O	O
cardiac	B-Disease	D006331
involvement	I-Disease	D006331
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
protein	O	O
studies	O	O
on	O	O
patients	O	O
with	O	O
missense	O	O
mutations	O	O
resulting	O	O
in	O	O
the	O	O
clinical	O	O
features	O	O
of	O	O
EDMD	B-Disease	D020389
.	O	O

These	O	O
studies	O	O
demonstrate	O	O
the	O	O
importance	O	O
of	O	O
proline	O	O
183	O	O
for	O	O
the	O	O
proper	O	O
structure	O	O
/	O	O
function	O	O
of	O	O
emerin	O	O
.	O	O

.	O	O

Decreased	O	O
expression	O	O
of	O	O
BRCA1	O	O
accelerates	O	O
growth	O	O
and	O	O
is	O	O
often	O	O
present	O	O
during	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
progression	O	O
.	O	O

We	O	O
have	O	O
characterized	O	O
expression	O	O
of	O	O
the	O	O
familial	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
in	O	O
cases	O	O
of	O	O
non	B-Disease	D001943
-	I-Disease	D001943
hereditary	I-Disease	D001943
(	I-Disease	D001943
sporadic	I-Disease	D001943
)	I-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
and	O	O
analyzed	O	O
the	O	O
effect	O	O
of	O	O
antisense	O	O
inhibition	O	O
of	O	O
BRCA1	O	O
on	O	O
the	O	O
proliferative	O	O
rate	O	O
of	O	O
mammary	O	O
epithelial	O	O
cells	O	O
.	O	O

BRCA1	O	O
mRNA	O	O
levels	O	O
are	O	O
markedly	O	O
decreased	O	O
during	O	O
the	O	O
transition	O	O
from	O	O
carcinoma	B-Disease	D002278
in	I-Disease	D002278
situ	I-Disease	D002278
to	O	O
invasive	B-Disease	D009362
cancer	I-Disease	D009362
.	O	O

Experimental	O	O
inhibition	O	O
of	O	O
BRCA1	O	O
expression	O	O
with	O	O
antisense	O	O
oligonucleotides	O	O
produced	O	O
accelerated	O	O
growth	O	O
of	O	O
normal	O	O
and	O	O
malignant	O	O
mammary	O	O
cells	O	O
,	O	O
but	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
non	O	O
-	O	O
mammary	O	O
epithelial	O	O
cells	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
BRCA1	O	O
may	O	O
normally	O	O
serve	O	O
as	O	O
a	O	O
negative	O	O
regulator	O	O
of	O	O
mammary	O	O
epithelial	O	O
cell	O	O
growth	O	O
whose	O	O
function	O	O
is	O	O
compromised	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
either	O	O
by	O	O
direct	O	O
mutation	O	O
or	O	O
alterations	O	O
in	O	O
gene	O	O
expression	O	O
.	O	O

.	O	O

Additional	O	O
copies	O	O
of	O	O
the	O	O
proteolipid	O	O
protein	O	O
gene	O	O
causing	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
arise	O	O
by	O	O
separate	O	O
integration	O	O
into	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O

The	O	O
proteolipid	O	O
protein	O	O
gene	O	O
(	O	O
PLP	O	O
)	O	O
is	O	O
normally	O	O
present	O	O
at	O	O
chromosome	O	O
Xq22	O	O
.	O	O

Mutations	O	O
and	O	O
duplications	O	O
of	O	O
this	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
PMD	B-Disease	OMIM:312080
)	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
two	O	O
new	O	O
families	O	O
in	O	O
which	O	O
males	O	O
affected	O	O
with	O	O
PMD	B-Disease	OMIM:312080
were	O	O
found	O	O
to	O	O
have	O	O
a	O	O
copy	O	O
of	O	O
PLP	O	O
on	O	O
the	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
a	O	O
normal	O	O
copy	O	O
on	O	O
Xq22	O	O
.	O	O

In	O	O
the	O	O
first	O	O
family	O	O
,	O	O
the	O	O
extra	O	O
copy	O	O
was	O	O
first	O	O
detected	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
heterozygosity	O	O
of	O	O
the	O	O
AhaII	O	O
dimorphism	O	O
within	O	O
the	O	O
PLP	O	O
gene	O	O
.	O	O

The	O	O
results	O	O
of	O	O
FISH	O	O
analysis	O	O
showed	O	O
an	O	O
additional	O	O
copy	O	O
of	O	O
PLP	O	O
in	O	O
Xp22	O	O
.	O	O

1	O	O
,	O	O
although	O	O
no	O	O
chromosomal	O	O
rearrangements	O	O
could	O	O
be	O	O
detected	O	O
by	O	O
standard	O	O
karyotype	O	O
analysis	O	O
.	O	O

Another	O	O
three	O	O
affected	O	O
males	O	O
from	O	O
the	O	O
family	O	O
had	O	O
similar	O	O
findings	O	O
.	O	O

In	O	O
a	O	O
second	O	O
unrelated	O	O
family	O	O
with	O	O
signs	O	O
of	O	O
PMD	B-Disease	OMIM:312080
,	O	O
cytogenetic	O	O
analysis	O	O
showed	O	O
a	O	O
pericentric	O	O
inversion	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O

In	O	O
the	O	O
inv	O	O
(	O	O
X	O	O
)	O	O
carried	O	O
by	O	O
several	O	O
affected	O	O
family	O	O
members	O	O
,	O	O
FISH	O	O
showed	O	O
PLP	O	O
signals	O	O
at	O	O
Xp11	O	O
.	O	O

4	O	O
and	O	O
Xq22	O	O
.	O	O

A	O	O
third	O	O
family	O	O
has	O	O
previously	O	O
been	O	O
reported	O	O
,	O	O
in	O	O
which	O	O
affected	O	O
members	O	O
had	O	O
an	O	O
extra	O	O
copy	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
detected	O	O
at	O	O
Xq26	O	O
in	O	O
a	O	O
chromosome	O	O
with	O	O
an	O	O
otherwise	O	O
normal	O	O
banding	O	O
pattern	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
three	O	O
separate	O	O
families	O	O
in	O	O
which	O	O
PLP	O	O
is	O	O
duplicated	O	O
at	O	O
a	O	O
noncontiguous	O	O
site	O	O
suggests	O	O
that	O	O
such	O	O
duplications	O	O
could	O	O
be	O	O
a	O	O
relatively	O	O
common	O	O
but	O	O
previously	O	O
undetected	O	O
cause	O	O
of	O	O
genetic	B-Disease	D030342
disorders	I-Disease	D030342
.	O	O

Linkage	O	O
relationships	O	O
of	O	O
the	O	O
apolipoprotein	O	O
C1	O	O
gene	O	O
and	O	O
a	O	O
cytochrome	O	O
P450	O	O
gene	O	O
(	O	O
CYP2A	O	O
)	O	O
to	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
genetic	O	O
linkage	O	O
of	O	O
two	O	O
markers	O	O
,	O	O
the	O	O
apolipoprotein	O	O
C1	O	O
(	O	O
APOC1	O	O
)	O	O
gene	O	O
and	O	O
a	O	O
cytochrome	O	O
P450	O	O
(	O	O
CYP2A	O	O
)	O	O
gene	O	O
,	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
gene	O	O
for	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

A	O	O
peak	O	O
lod	O	O
score	O	O
of	O	O
9	O	O
.	O	O

29	O	O
at	O	O
2	O	O
cM	O	O
was	O	O
observed	O	O
for	O	O
APOC1	O	O
-	O	O
DM	B-Disease	D009223
,	O	O
with	O	O
a	O	O
lod	O	O
score	O	O
of	O	O
8	O	O
.	O	O

55	O	O
at	O	O
4	O	O
cM	O	O
for	O	O
CYP2A	O	O
-	O	O
DM	B-Disease	D009223
.	O	O

These	O	O
two	O	O
markers	O	O
also	O	O
show	O	O
close	O	O
linkage	O	O
to	O	O
each	O	O
other	O	O
(	O	O
theta	O	O
max	O	O
=	O	O
0	O	O
.	O	O

05	O	O
,	O	O
Zmax	O	O
=	O	O
9	O	O
.	O	O

09	O	O
)	O	O
.	O	O

From	O	O
examination	O	O
of	O	O
the	O	O
genotypes	O	O
of	O	O
the	O	O
recombinant	O	O
individuals	O	O
,	O	O
CYP2A	O	O
appears	O	O
to	O	O
map	O	O
proximal	O	O
to	O	O
DM	B-Disease	D009223
because	O	O
in	O	O
one	O	O
recombinant	O	O
individual	O	O
CYP2A	O	O
,	O	O
APOC2	O	O
and	O	O
CKMM	O	O
had	O	O
all	O	O
recombined	O	O
with	O	O
DM	B-Disease	D009223
.	O	O

Evidence	O	O
from	O	O
another	O	O
CYP2A	O	O
-	O	O
DM	B-Disease	D009223
recombinant	O	O
individual	O	O
places	O	O
CYP2A	O	O
proximal	O	O
to	O	O
APOC2	O	O
and	O	O
CKMM	O	O
.	O	O

Localisation	O	O
of	O	O
CYP2A	O	O
on	O	O
a	O	O
panel	O	O
of	O	O
somatic	O	O
cell	O	O
hybrids	O	O
also	O	O
suggests	O	O
that	O	O
it	O	O
is	O	O
proximal	O	O
to	O	O
DM	B-Disease	D009223
and	O	O
APOC2	O	O
/	O	O
C1	O	O
/	O	O
E	O	O
gene	O	O
cluster	O	O
.	O	O

beta	O	O
-	O	O
galactosidase	O	O
gene	O	O
mutations	O	O
affecting	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
and	O	O
the	O	O
elastin	O	O
-	O	O
binding	O	O
protein	O	O
in	O	O
GM1	B-Disease	D016537
-	I-Disease	D016537
gangliosidosis	I-Disease	D016537
patients	O	O
with	O	O
cardiac	B-Disease	D006331
involvement	I-Disease	D006331
.	O	O

GM1	B-Disease	D016537
-	I-Disease	D016537
gangliosidosis	I-Disease	D016537
is	O	O
a	O	O
lysosomal	B-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
deficiency	B-Disease	D016537
of	I-Disease	D016537
acid	I-Disease	D016537
beta	I-Disease	D016537
-	I-Disease	D016537
galactosidase	I-Disease	D016537
(	O	O
GLB1	O	O
)	O	O
.	O	O

We	O	O
report	O	O
five	O	O
new	O	O
beta	O	O
-	O	O
galactosidase	O	O
gene	O	O
mutations	O	O
in	O	O
nine	O	O
Italian	O	O
patients	O	O
and	O	O
one	O	O
fetus	O	O
,	O	O
segregating	O	O
in	O	O
seven	O	O
unrelated	O	O
families	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
eight	O	O
patients	O	O
with	O	O
the	O	O
infantile	O	O
,	O	O
severe	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
presented	O	O
cardiac	B-Disease	D006331
involvement	I-Disease	D006331
,	O	O
a	O	O
feature	O	O
rarely	O	O
associated	O	O
with	O	O
GM1	B-Disease	D016537
-	I-Disease	D016537
gangliosidosis	I-Disease	D016537
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
the	O	O
patients	O	O
RNA	O	O
and	O	O
DNA	O	O
identified	O	O
two	O	O
new	O	O
RNA	O	O
splicing	O	O
defects	O	O
,	O	O
three	O	O
new	O	O
and	O	O
three	O	O
previously	O	O
described	O	O
amino	O	O
acid	O	O
substitutions	O	O
.	O	O

Interestingly	O	O
,	O	O
all	O	O
patients	O	O
with	O	O
cardiac	B-Disease	D006331
involvement	I-Disease	D006331
were	O	O
homozygous	O	O
for	O	O
one	O	O
of	O	O
these	O	O
mutations	O	O
R59H	O	O
,	O	O
Y591C	O	O
,	O	O
Y591N	O	O
,	O	O
or	O	O
IVS14	O	O
-	O	O
2A	O	O
>	O	O
G	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
all	O	O
other	O	O
patients	O	O
were	O	O
compound	O	O
heterozygous	O	O
for	O	O
one	O	O
of	O	O
the	O	O
following	O	O
mutations	O	O
R201H	O	O
,	O	O
R482H	O	O
,	O	O
G579D	O	O
,	O	O
IVS8	O	O
+	O	O
2T	O	O
>	O	O
C	O	O
.	O	O

Although	O	O
we	O	O
could	O	O
not	O	O
directly	O	O
correlate	O	O
the	O	O
presence	O	O
of	O	O
cardiac	B-Disease	D018376
abnormalities	I-Disease	D018376
with	O	O
specific	O	O
genetic	B-Disease	D020022
lesions	I-Disease	D020022
,	O	O
the	O	O
mutations	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
cardiomyopathy	B-Disease	D009202
fell	O	O
in	O	O
the	O	O
GLB1	O	O
cDNA	O	O
region	O	O
common	O	O
to	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
and	O	O
the	O	O
Hbeta	O	O
-	O	O
Gal	O	O
-	O	O
related	O	O
protein	O	O
,	O	O
also	O	O
known	O	O
as	O	O
the	O	O
elastin	O	O
binding	O	O
protein	O	O
(	O	O
EBP	O	O
)	O	O
.	O	O

Consequently	O	O
,	O	O
both	O	O
molecules	O	O
are	O	O
affected	O	O
by	O	O
the	O	O
mutations	O	O
,	O	O
and	O	O
they	O	O
may	O	O
contribute	O	O
differently	O	O
to	O	O
the	O	O
occurrence	O	O
of	O	O
specific	O	O
clinical	O	O
manifestations	O	O
.	O	O

.	O	O

Exclusion	O	O
of	O	O
linkage	O	O
between	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
and	O	O
the	O	O
human	O	O
serum	O	O
amyloid	O	O
A	O	O
(	O	O
SAA	O	O
)	O	O
gene	O	O
cluster	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
autosomal	O	O
recessive	O	O
trait	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
and	O	O
the	O	O
serum	O	O
amyloid	O	O
A	O	O
(	O	O
SAA	O	O
)	O	O
genes	O	O
by	O	O
comparing	O	O
alleles	O	O
of	O	O
a	O	O
highly	O	O
polymorphic	O	O
dinucleotide	O	O
repeat	O	O
and	O	O
a	O	O
conventional	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
RFLP	O	O
)	O	O
in	O	O
the	O	O
SAA	O	O
gene	O	O
cluster	O	O
in	O	O
Israeli	O	O
FMF	B-Disease	D010505
kindreds	O	O
.	O	O

By	O	O
haplotype	O	O
analysis	O	O
,	O	O
our	O	O
data	O	O
indicate	O	O
a	O	O
minimum	O	O
crossover	O	O
frequency	O	O
of	O	O
22	O	O
%	O	O
between	O	O
the	O	O
SAA	O	O
gene	O	O
marker	O	O
and	O	O
FMF	B-Disease	D010505
.	O	O

By	O	O
conventional	O	O
linkage	O	O
analysis	O	O
this	O	O
eliminates	O	O
a	O	O
minimum	O	O
of	O	O
10	O	O
.	O	O

4	O	O
cM	O	O
including	O	O
and	O	O
surrounding	O	O
the	O	O
SAA	O	O
gene	O	O
cluster	O	O
as	O	O
the	O	O
site	O	O
of	O	O
the	O	O
FMF	B-Disease	D010505
mutation	O	O
although	O	O
SAA	O	O
proteins	O	O
are	O	O
prominent	O	O
physiologic	O	O
markers	O	O
of	O	O
the	O	O
acute	O	O
attacks	O	O
.	O	O

Mice	O	O
deficient	B-Disease	D030342
in	I-Disease	D030342
Six5	I-Disease	D030342
develop	O	O
cataracts	B-Disease	D002386
:	O	O
implications	O	O
for	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

Expansion	O	O
of	O	O
a	O	O
CTG	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
the	O	O
3	O	O
UTR	O	O
of	O	O
the	O	O
gene	O	O
DMPK	O	O
at	O	O
the	O	O
DM1	O	O
locus	O	O
on	O	O
chromosome	O	O
19	O	O
causes	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
a	O	O
dominantly	B-Disease	D030342
inherited	I-Disease	D030342
disease	I-Disease	D030342
characterized	O	O
by	O	O
skeletal	O	O
muscle	B-Disease	D009136
dystrophy	I-Disease	D009136
and	O	O
myotonia	B-Disease	D009222
,	O	O
cataracts	B-Disease	D002386
and	O	O
cardiac	B-Disease	OMIM:115080
conduction	I-Disease	OMIM:115080
defects	I-Disease	OMIM:115080
.	O	O

Targeted	O	O
deletion	O	O
of	O	O
Dm15	O	O
,	O	O
the	O	O
mouse	O	O
orthologue	O	O
of	O	O
human	O	O
DMPK	O	O
,	O	O
produced	O	O
mice	O	O
with	O	O
a	O	O
mild	O	O
myopathy	B-Disease	D009135
and	O	O
cardiac	B-Disease	D006327
conduction	I-Disease	D006327
abnormalities	I-Disease	D006327
,	O	O
but	O	O
without	O	O
other	O	O
features	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
such	O	O
as	O	O
myotonia	B-Disease	D009222
and	O	O
cataracts	B-Disease	D002386
.	O	O

We	O	O
,	O	O
and	O	O
others	O	O
,	O	O
have	O	O
demonstrated	O	O
that	O	O
repeat	O	O
expansion	O	O
decreases	O	O
expression	O	O
of	O	O
the	O	O
adjacent	O	O
gene	O	O
SIX5	O	O
(	O	O
refs	O	O
7	O	O
,	O	O
8	O	O
)	O	O
,	O	O
which	O	O
encodes	O	O
a	O	O
homeodomain	O	O
transcription	O	O
factor	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
SIX5	B-Disease	D030342
deficiency	I-Disease	D030342
contributes	O	O
to	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
phenotype	O	O
,	O	O
we	O	O
disrupted	O	O
mouse	O	O
Six5	O	O
by	O	O
replacing	O	O
the	O	O
first	O	O
exon	O	O
with	O	O
a	O	O
beta	O	O
-	O	O
galactosidase	O	O
reporter	O	O
.	O	O

Six5	O	O
-	O	O
mutant	O	O
mice	O	O
showed	O	O
reporter	O	O
expression	O	O
in	O	O
multiple	O	O
tissues	O	O
,	O	O
including	O	O
the	O	O
developing	O	O
lens	O	O
.	O	O

Homozygous	O	O
mutant	O	O
mice	O	O
had	O	O
no	O	O
apparent	O	O
abnormalities	B-Disease	D009139
of	I-Disease	D009139
skeletal	I-Disease	D009139
muscle	I-Disease	D009139
function	I-Disease	D009139
,	O	O
but	O	O
developed	O	O
lenticular	B-Disease	D002386
opacities	I-Disease	D002386
at	O	O
a	O	O
higher	O	O
rate	O	O
than	O	O
controls	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
SIX5	B-Disease	D030342
deficiency	I-Disease	D030342
contributes	O	O
to	O	O
the	O	O
cataract	B-Disease	D002386
phenotype	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
and	O	O
that	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
represents	O	O
a	O	O
multigenic	B-Disease	D030342
disorder	I-Disease	D030342
.	O	O

.	O	O

Screening	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
patients	O	O
:	O	O
61	O	O
new	O	O
patients	O	O
and	O	O
a	O	O
summary	O	O
of	O	O
150	O	O
unrelated	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
result	O	O
of	O	O
a	O	O
screening	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
in	O	O
61	O	O
new	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
patients	O	O
as	O	O
well	O	O
as	O	O
a	O	O
summary	O	O
of	O	O
the	O	O
results	O	O
of	O	O
150	O	O
patients	O	O
.	O	O

Examination	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
based	O	O
on	O	O
a	O	O
ribonuclease	O	O
protection	O	O
assay	O	O
coupled	O	O
with	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
,	O	O
disclosed	O	O
mutations	O	O
that	O	O
were	O	O
considered	O	O
to	O	O
cause	O	O
significant	O	O
defects	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
product	O	O
in	O	O
97	O	O
of	O	O
150	O	O
unrelated	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

Our	O	O
findings	O	O
revealed	O	O
the	O	O
following	O	O
characteristics	O	O
of	O	O
the	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
APC	B-Disease	D011125
1	O	O
)	O	O
the	O	O
great	O	O
majority	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
found	O	O
to	O	O
truncate	O	O
the	O	O
APC	B-Disease	D011125
product	O	O
;	O	O
2	O	O
)	O	O
almost	O	O
all	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
located	O	O
within	O	O
the	O	O
first	O	O
half	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
;	O	O
3	O	O
)	O	O
no	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
locations	O	O
of	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
and	O	O
extracolonic	O	O
manifestations	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
;	O	O
4	O	O
)	O	O
more	O	O
than	O	O
80	O	O
%	O	O
of	O	O
base	O	O
substitutions	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
were	O	O
from	O	O
cytosine	O	O
to	O	O
other	O	O
nucleotides	O	O
,	O	O
nearly	O	O
one	O	O
-	O	O
third	O	O
of	O	O
which	O	O
occurred	O	O
at	O	O
the	O	O
GpG	O	O
site	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
information	O	O
helpful	O	O
to	O	O
an	O	O
understanding	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
and	O	O
will	O	O
also	O	O
contribute	O	O
to	O	O
presymptomatic	O	O
diagnosis	O	O
of	O	O
members	O	O
in	O	O
FAP	B-Disease	D011125
families	O	O
.	O	O

.	O	O

Hereditary	O	O
deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
in	O	O
association	O	O
with	O	O
discoid	B-Disease	D008179
lupus	I-Disease	D008179
erythematosus	I-Disease	D008179
.	O	O

A	O	O
29	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
discoid	B-Disease	D008179
lupus	I-Disease	D008179
erythematosus	I-Disease	D008179
had	O	O
undetectable	O	O
classic	O	O
pathway	O	O
complement	O	O
activity	O	O
.	O	O

Hypocomplementemia	B-Disease	D007153
was	O	O
due	O	O
to	O	O
selective	O	O
deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
.	O	O

One	O	O
of	O	O
her	O	O
children	O	O
was	O	O
also	O	O
deficient	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
documented	O	O
case	O	O
of	O	O
an	O	O
association	O	O
between	O	O
discoid	B-Disease	D008179
lupus	I-Disease	D008179
erythematosus	I-Disease	D008179
and	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

.	O	O

Isolation	O	O
,	O	O
genomic	O	O
organization	O	O
,	O	O
and	O	O
expression	O	O
analysis	O	O
of	O	O
the	O	O
mouse	O	O
and	O	O
rat	O	O
homologs	O	O
of	O	O
MEFV	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
familial	B-Disease	D010505
mediterranean	I-Disease	D010505
fever	I-Disease	D010505
.	O	O

Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
is	O	O
a	O	O
recessive	B-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
episodes	O	O
of	O	O
fever	B-Disease	D005334
with	O	O
serositis	B-Disease	D012700
or	O	O
synovitis	B-Disease	D013585
.	O	O

Recently	O	O
the	O	O
FMF	B-Disease	D010505
gene	O	O
(	O	O
MEFV	O	O
)	O	O
was	O	O
cloned	O	O
;	O	O
the	O	O
protein	O	O
product	O	O
,	O	O
pyrin	O	O
/	O	O
marenostrin	O	O
,	O	O
is	O	O
thought	O	O
to	O	O
regulate	O	O
inflammation	O	O
in	O	O
myeloid	O	O
cells	O	O
.	O	O

In	O	O
this	O	O
manuscript	O	O
we	O	O
report	O	O
the	O	O
mouse	O	O
and	O	O
rat	O	O
homologs	O	O
of	O	O
MEFV	O	O
.	O	O

The	O	O
murine	O	O
gene	O	O
contains	O	O
ten	O	O
exons	O	O
with	O	O
a	O	O
coding	O	O
sequence	O	O
of	O	O
2304	O	O
bp	O	O
,	O	O
while	O	O
the	O	O
rat	O	O
homolog	O	O
has	O	O
nine	O	O
exons	O	O
with	O	O
a	O	O
coding	O	O
sequence	O	O
of	O	O
2253	O	O
bp	O	O
.	O	O

A	O	O
considerable	O	O
amino	O	O
acid	O	O
sequence	O	O
homology	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
mouse	O	O
and	O	O
human	O	O
(	O	O
47	O	O
.	O	O

6	O	O
%	O	O
identity	O	O
and	O	O
65	O	O
.	O	O

5	O	O
%	O	O
similarity	O	O
)	O	O
and	O	O
between	O	O
the	O	O
mouse	O	O
and	O	O
rat	O	O
genes	O	O
(	O	O
73	O	O
.	O	O

5	O	O
%	O	O
identity	O	O
and	O	O
82	O	O
.	O	O

1	O	O
%	O	O
similarity	O	O
)	O	O
.	O	O

The	O	O
predicted	O	O
rodent	O	O
proteins	O	O
have	O	O
several	O	O
important	O	O
domains	O	O
and	O	O
signals	O	O
found	O	O
in	O	O
human	O	O
pyrin	O	O
,	O	O
including	O	O
a	O	O
B	O	O
-	O	O
box	O	O
zinc	O	O
finger	O	O
domain	O	O
,	O	O
Robbins	O	O
-	O	O
Dingwall	O	O
nuclear	O	O
localization	O	O
signal	O	O
,	O	O
and	O	O
coiled	O	O
-	O	O
coil	O	O
domain	O	O
.	O	O

However	O	O
,	O	O
perhaps	O	O
because	O	O
of	O	O
an	O	O
ancient	O	O
frame	O	O
-	O	O
shift	O	O
mutation	O	O
,	O	O
neither	O	O
the	O	O
mouse	O	O
nor	O	O
the	O	O
rat	O	O
protein	O	O
has	O	O
an	O	O
intact	O	O
C	O	O
-	O	O
terminal	O	O
B30	O	O
.	O	O

2	O	O
domain	O	O
,	O	O
in	O	O
which	O	O
most	O	O
FMF	B-Disease	D010505
-	O	O
associated	O	O
mutations	O	O
have	O	O
been	O	O
found	O	O
in	O	O
human	O	O
MEFV	O	O
.	O	O

Nevertheless	O	O
,	O	O
like	O	O
the	O	O
human	O	O
gene	O	O
,	O	O
mouse	O	O
Mefv	O	O
is	O	O
expressed	O	O
in	O	O
peripheral	O	O
blood	O	O
granulocytes	O	O
but	O	O
not	O	O
lymphocytes	O	O
.	O	O

Consistent	O	O
with	O	O
its	O	O
expression	O	O
in	O	O
granulocytes	O	O
,	O	O
Mefv	O	O
was	O	O
detected	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
the	O	O
primary	O	O
follicles	O	O
and	O	O
marginal	O	O
zones	O	O
of	O	O
the	O	O
splenic	O	O
white	O	O
pulp	O	O
.	O	O

Mefv	O	O
is	O	O
localized	O	O
on	O	O
mouse	O	O
Chromosome	O	O
(	O	O
Chr	O	O
)	O	O
16	O	O
,	O	O
region	O	O
A3	O	O
-	O	O
B1	O	O
,	O	O
extending	O	O
a	O	O
region	O	O
of	O	O
synteny	O	O
with	O	O
human	O	O
Chr	O	O
16p13	O	O
.	O	O

3	O	O
.	O	O

Development	O	O
of	O	O
knockout	O	O
and	O	O
knockin	O	O
mouse	O	O
models	O	O
may	O	O
provide	O	O
further	O	O
insights	O	O
into	O	O
the	O	O
functional	O	O
evolution	O	O
of	O	O
this	O	O
gene	O	O
.	O	O

Analysis	O	O
of	O	O
X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
and	O	O
presumptive	O	O
expression	O	O
of	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
gene	O	O
in	O	O
hematopoietic	O	O
cell	O	O
lineages	O	O
of	O	O
a	O	O
thrombocytopenic	B-Disease	D013921
carrier	O	O
female	O	O
of	O	O
WAS	B-Disease	D014923
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
thrombocytopenic	B-Disease	D013921
female	O	O
belonging	O	O
to	O	O
a	O	O
pedigree	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
.	O	O

Restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
RFLP	O	O
)	O	O
analysis	O	O
with	O	O
probe	O	O
M27	O	O
beta	O	O
,	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
WAS	B-Disease	D014923
gene	O	O
,	O	O
demonstrated	O	O
that	O	O
she	O	O
is	O	O
a	O	O
carrier	O	O
of	O	O
WAS	B-Disease	D014923
.	O	O

Both	O	O
small	O	O
-	O	O
sized	O	O
and	O	O
normal	O	O
-	O	O
sized	O	O
platelets	O	O
were	O	O
present	O	O
,	O	O
suggesting	O	O
that	O	O
,	O	O
unlike	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
WAS	B-Disease	D014923
carriers	O	O
,	O	O
she	O	O
does	O	O
not	O	O
manifest	O	O
nonrandom	O	O
X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
in	O	O
the	O	O
thrombopoietic	O	O
cell	O	O
lineage	O	O
.	O	O

Study	O	O
of	O	O
X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
by	O	O
means	O	O
of	O	O
RFLP	O	O
and	O	O
methylation	O	O
analysis	O	O
demonstrated	O	O
that	O	O
the	O	O
pattern	O	O
of	O	O
X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
was	O	O
nonrandom	O	O
in	O	O
T	O	O
lymphocytes	O	O
,	O	O
but	O	O
random	O	O
in	O	O
granulocytes	O	O
.	O	O

While	O	O
this	O	O
is	O	O
the	O	O
first	O	O
complete	O	O
report	O	O
on	O	O
the	O	O
occurrence	O	O
of	O	O
thrombocytopenia	B-Disease	D013921
in	O	O
a	O	O
carrier	O	O
female	O	O
of	O	O
WAS	B-Disease	D014923
as	O	O
the	O	O
result	O	O
of	O	O
atypical	O	O
lyonization	O	O
,	O	O
it	O	O
also	O	O
suggests	O	O
that	O	O
expression	O	O
of	O	O
the	O	O
WAS	B-Disease	D014923
gene	O	O
occurs	O	O
at	O	O
(	O	O
or	O	O
extends	O	O
up	O	O
to	O	O
)	O	O
a	O	O
later	O	O
stage	O	O
than	O	O
the	O	O
multipotent	O	O
stem	O	O
cell	O	O
along	O	O
the	O	O
hematopoietic	O	O
differentiation	O	O
pathway	O	O
.	O	O

.	O	O

hCds1	O	O
-	O	O
mediated	O	O
phosphorylation	O	O
of	O	O
BRCA1	O	O
regulates	O	O
the	O	O
DNA	O	O
damage	O	O
response	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
(	O	O
ref	O	O
.	O	O

1	O	O
)	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
are	O	O
found	O	O
in	O	O
almost	O	O
all	O	O
of	O	O
the	O	O
families	O	O
with	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancers	I-Disease	D061325
and	O	O
about	O	O
half	O	O
of	O	O
the	O	O
families	O	O
with	O	O
only	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Although	O	O
the	O	O
biochemical	O	O
function	O	O
of	O	O
BRCA1	O	O
is	O	O
not	O	O
well	O	O
understood	O	O
,	O	O
it	O	O
is	O	O
important	O	O
for	O	O
DNA	O	O
damage	O	O
repair	O	O
and	O	O
cell	O	O
-	O	O
cycle	O	O
checkpoint	O	O
.	O	O

BRCA1	O	O
exists	O	O
in	O	O
nuclear	O	O
foci	O	O
but	O	O
is	O	O
hyperphosphorylated	O	O
and	O	O
disperses	O	O
after	O	O
DNA	O	O
damage	O	O
.	O	O

It	O	O
is	O	O
not	O	O
known	O	O
whether	O	O
BRCA1	O	O
phosphorylation	O	O
and	O	O
dispersion	O	O
and	O	O
its	O	O
function	O	O
in	O	O
DNA	O	O
damage	O	O
response	O	O
are	O	O
related	O	O
.	O	O

In	O	O
yeast	O	O
the	O	O
DNA	O	O
damage	O	O
response	O	O
and	O	O
the	O	O
replication	O	O
-	O	O
block	O	O
checkpoint	O	O
are	O	O
mediated	O	O
partly	O	O
through	O	O
the	O	O
Cds1	O	O
kinase	O	O
family	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
the	O	O
human	O	O
Cds1	O	O
kinase	O	O
(	O	O
hCds1	O	O
/	O	O
Chk2	O	O
)	O	O
regulates	O	O
BRCA1	O	O
function	O	O
after	O	O
DNA	O	O
damage	O	O
by	O	O
phosphorylating	O	O
serine	O	O
988	O	O
of	O	O
BRCA1	O	O
.	O	O

We	O	O
show	O	O
that	O	O
hCds1	O	O
and	O	O
BRCA1	O	O
interact	O	O
and	O	O
co	O	O
-	O	O
localize	O	O
within	O	O
discrete	O	O
nuclear	O	O
foci	O	O
but	O	O
separate	O	O
after	O	O
gamma	O	O
irradiation	O	O
.	O	O

Phosphorylation	O	O
of	O	O
BRCA1	O	O
at	O	O
serine	O	O
988	O	O
is	O	O
required	O	O
for	O	O
the	O	O
release	O	O
of	O	O
BRCA1	O	O
from	O	O
hCds1	O	O
.	O	O

This	O	O
phosphorylation	O	O
is	O	O
also	O	O
important	O	O
for	O	O
the	O	O
ability	O	O
of	O	O
BRCA1	O	O
to	O	O
restore	O	O
survival	O	O
after	O	O
DNA	O	O
damage	O	O
in	O	O
the	O	O
BRCA1	O	O
-	O	O
mutated	O	O
cell	O	O
line	O	O
HCC1937	O	O
.	O	O

.	O	O

Ataxin	O	O
-	O	O
3	O	O
with	O	O
an	O	O
altered	O	O
conformation	O	O
that	O	O
exposes	O	O
the	O	O
polyglutamine	O	O
domain	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
nuclear	O	O
matrix	O	O
.	O	O

Spinocerebellar	B-Disease	D017827
ataxia	I-Disease	D017827
type	I-Disease	D017827
-	I-Disease	D017827
3	I-Disease	D017827
or	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
SCA3	B-Disease	D017827
/	O	O
MJD	B-Disease	D017827
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
CAG	B-Disease	D030342
/	I-Disease	D030342
polyglutamine	I-Disease	D030342
repeat	I-Disease	D030342
disease	I-Disease	D030342
family	O	O
.	O	O

In	O	O
this	O	O
family	O	O
of	O	O
disorders	O	O
,	O	O
a	O	O
normally	O	O
polymorphic	O	O
CAG	O	O
repeat	O	O
becomes	O	O
expanded	O	O
,	O	O
resulting	O	O
in	O	O
expression	O	O
of	O	O
an	O	O
expanded	O	O
polyglutamine	O	O
domain	O	O
in	O	O
the	O	O
disease	O	O
gene	O	O
product	O	O
.	O	O

Experimental	O	O
models	O	O
of	O	O
polyglutamine	B-Disease	D030342
disease	I-Disease	D030342
implicate	O	O
the	O	O
nucleus	O	O
in	O	O
pathogenesis	O	O
;	O	O
however	O	O
,	O	O
the	O	O
link	O	O
between	O	O
intranuclear	O	O
expression	O	O
of	O	O
expanded	O	O
polyglutamine	O	O
and	O	O
neuronal	B-Disease	D009461
dysfunction	I-Disease	D009461
remains	O	O
unclear	O	O
.	O	O

Here	O	O
we	O	O
demonstrate	O	O
that	O	O
ataxin	O	O
-	O	O
3	O	O
,	O	O
the	O	O
disease	O	O
protein	O	O
in	O	O
SCA3	B-Disease	D017827
/	O	O
MJD	B-Disease	D017827
,	O	O
adopts	O	O
a	O	O
unique	O	O
conformation	O	O
when	O	O
expressed	O	O
within	O	O
the	O	O
nucleus	O	O
of	O	O
transfected	O	O
cells	O	O
.	O	O

The	O	O
monoclonal	O	O
antibody	O	O
1C2	O	O
is	O	O
known	O	O
preferentially	O	O
to	O	O
bind	O	O
expanded	O	O
polyglutamine	O	O
,	O	O
but	O	O
we	O	O
find	O	O
that	O	O
it	O	O
also	O	O
binds	O	O
a	O	O
fragment	O	O
of	O	O
ataxin	O	O
-	O	O
3	O	O
containing	O	O
a	O	O
normal	O	O
glutamine	O	O
repeat	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
expression	O	O
of	O	O
ataxin	O	O
-	O	O
3	O	O
within	O	O
the	O	O
nucleus	O	O
exposes	O	O
the	O	O
glutamine	O	O
domain	O	O
of	O	O
the	O	O
full	O	O
-	O	O
length	O	O
non	O	O
-	O	O
pathological	O	O
protein	O	O
,	O	O
allowing	O	O
it	O	O
to	O	O
bind	O	O
the	O	O
monoclonal	O	O
antibody	O	O
1C2	O	O
.	O	O

Fractionation	O	O
and	O	O
immunochemical	O	O
experiments	O	O
indicate	O	O
that	O	O
this	O	O
novel	O	O
conformation	O	O
of	O	O
intranuclear	O	O
ataxin	O	O
-	O	O
3	O	O
is	O	O
not	O	O
due	O	O
to	O	O
proteolysis	O	O
,	O	O
suggesting	O	O
instead	O	O
that	O	O
association	O	O
with	O	O
nuclear	O	O
protein	O	O
(	O	O
s	O	O
)	O	O
alters	O	O
the	O	O
structure	O	O
of	O	O
full	O	O
-	O	O
length	O	O
ataxin	O	O
-	O	O
3	O	O
which	O	O
exposes	O	O
the	O	O
polyglutamine	O	O
domain	O	O
.	O	O

This	O	O
conformationally	O	O
altered	O	O
ataxin	O	O
-	O	O
3	O	O
is	O	O
bound	O	O
to	O	O
the	O	O
nuclear	O	O
matrix	O	O
.	O	O

The	O	O
pathological	O	O
form	O	O
of	O	O
ataxin	O	O
-	O	O
3	O	O
with	O	O
an	O	O
expanded	O	O
polyglutamine	O	O
domain	O	O
also	O	O
associates	O	O
with	O	O
the	O	O
nuclear	O	O
matrix	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
an	O	O
early	O	O
event	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
SCA3	B-Disease	D017827
/	O	O
MJD	B-Disease	D017827
may	O	O
be	O	O
an	O	O
altered	O	O
conformation	O	O
of	O	O
ataxin	O	O
-	O	O
3	O	O
within	O	O
the	O	O
nucleus	O	O
that	O	O
exposes	O	O
the	O	O
polyglutamine	O	O
domain	O	O
.	O	O

.	O	O

A	O	O
zinc	O	O
finger	O	O
truncation	O	O
of	O	O
murine	O	O
WT1	O	O
results	O	O
in	O	O
the	O	O
characteristic	O	O
urogenital	B-Disease	D014564
abnormalities	I-Disease	D014564
of	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
.	O	O

The	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
-	O	O
suppressor	O	O
gene	O	O
,	O	O
WT1	O	O
,	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
urogenital	O	O
development	O	O
,	O	O
and	O	O
WT1	B-Disease	D030342
dysfunction	I-Disease	D030342
is	O	O
implicated	O	O
in	O	O
both	O	O
neoplastic	B-Disease	D009369
(	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
,	O	O
mesothelioma	B-Disease	D008654
,	O	O
leukemias	B-Disease	D007938
,	O	O
and	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
)	O	O
and	O	O
nonneoplastic	B-Disease	D004194
(	O	O
glomerulosclerosis	B-Disease	D005921
)	O	O
disease	O	O
.	O	O

The	O	O
analysis	O	O
of	O	O
diseases	O	O
linked	O	O
specifically	O	O
with	O	O
WT1	O	O
mutations	O	O
,	O	O
such	O	O
as	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
(	O	O
DDS	B-Disease	D030321
)	O	O
,	O	O
can	O	O
provide	O	O
valuable	O	O
insight	O	O
concerning	O	O
the	O	O
role	O	O
of	O	O
WT1	O	O
in	O	O
development	O	O
and	O	O
disease	O	O
.	O	O

DDS	B-Disease	D030321
is	O	O
a	O	O
rare	O	O
childhood	O	O
disease	O	O
characterized	O	O
by	O	O
a	O	O
nephropathy	B-Disease	D007674
involving	O	O
mesangial	B-Disease	C537346
sclerosis	I-Disease	C537346
,	O	O
XY	O	O
pseudohermaphroditism	B-Disease	D012734
,	O	O
and	O	O
/	O	O
or	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
(	O	O
WT	B-Disease	D009396
)	O	O
.	O	O

DDS	B-Disease	D030321
patients	O	O
are	O	O
constitutionally	O	O
heterozygous	O	O
for	O	O
exonic	O	O
point	O	O
mutations	O	O
in	O	O
WT1	O	O
,	O	O
which	O	O
include	O	O
mutations	O	O
predicted	O	O
to	O	O
truncate	O	O
the	O	O
protein	O	O
within	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
zinc	O	O
finger	O	O
(	O	O
ZF	O	O
)	O	O
region	O	O
.	O	O

We	O	O
report	O	O
that	O	O
heterozygosity	O	O
for	O	O
a	O	O
targeted	O	O
murine	O	O
Wt1	O	O
allele	O	O
,	O	O
Wt1	O	O
(	O	O
tmT396	O	O
)	O	O
,	O	O
which	O	O
truncates	O	O
ZF3	O	O
at	O	O
codon	O	O
396	O	O
,	O	O
induces	O	O
mesangial	B-Disease	C537346
sclerosis	I-Disease	C537346
characteristic	O	O
of	O	O
DDS	B-Disease	D030321
in	O	O
adult	O	O
heterozygous	O	O
and	O	O
chimeric	O	O
mice	O	O
.	O	O

Male	B-Disease	D005832
genital	I-Disease	D005832
defects	I-Disease	D005832
also	O	O
were	O	O
evident	O	O
and	O	O
there	O	O
was	O	O
a	O	O
single	O	O
case	O	O
of	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
in	O	O
which	O	O
the	O	O
transcript	O	O
of	O	O
the	O	O
nontargeted	O	O
allele	O	O
showed	O	O
an	O	O
exon	O	O
9	O	O
skipping	O	O
event	O	O
,	O	O
implying	O	O
a	O	O
causal	O	O
link	O	O
between	O	O
Wt1	B-Disease	D030342
dysfunction	I-Disease	D030342
and	O	O
Wilms	B-Disease	D009396
tumorigenesis	I-Disease	D009396
in	O	O
mice	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mutant	O	O
WT1	O	O
(	O	O
tmT396	O	O
)	O	O
protein	O	O
accounted	O	O
for	O	O
only	O	O
5	O	O
%	O	O
of	O	O
WT1	O	O
in	O	O
both	O	O
heterozygous	O	O
embryonic	O	O
stem	O	O
cells	O	O
and	O	O
the	O	O
WT	B-Disease	D009396
.	O	O

This	O	O
has	O	O
implications	O	O
regarding	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
the	O	O
mutant	O	O
allele	O	O
exerts	O	O
its	O	O
effect	O	O
.	O	O

Heterogeneity	O	O
of	O	O
"	O	O
Mediterranean	O	O
type	O	O
"	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Spain	O	O
and	O	O
description	O	O
of	O	O
two	O	O
new	O	O
variants	O	O
associated	O	O
with	O	O
favism	B-Disease	D005236
.	O	O

Glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
;	O	O
EC	O	O
1	O	O
.	O	O

1	O	O
.	O	O

1	O	O
.	O	O

49	O	O
from	O	O
thirty	O	O
-	O	O
six	O	O
unrelated	O	O
Spanish	O	O
males	O	O
was	O	O
partially	O	O
purified	O	O
from	O	O
blood	O	O
,	O	O
and	O	O
the	O	O
variants	O	O
were	O	O
characterized	O	O
biochemically	O	O
and	O	O
electrophoretically	O	O
according	O	O
to	O	O
the	O	O
methods	O	O
recommended	O	O
by	O	O
the	O	O
world	O	O
Health	O	O
Organization	O	O
.	O	O

Subjects	O	O
were	O	O
from	O	O
multiple	O	O
geographic	O	O
regions	O	O
within	O	O
Spain	O	O
,	O	O
and	O	O
all	O	O
suffered	O	O
from	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
,	O	O
either	O	O
acute	O	O
(	O	O
34	O	O
cases	O	O
)	O	O
or	O	O
chronic	O	O
nonspherocytic	O	O
(	O	O
2	O	O
cases	O	O
)	O	O
.	O	O

Almost	O	O
all	O	O
the	O	O
variants	O	O
studied	O	O
presented	O	O
residual	O	O
erythrocyte	O	O
G6PD	O	O
activity	O	O
ranging	O	O
from	O	O
0	O	O
to	O	O
10	O	O
%	O	O
of	O	O
normal	O	O
,	O	O
and	O	O
five	O	O
different	O	O
mutants	O	O
were	O	O
responsible	O	O
for	O	O
the	O	O
deficient	O	O
phenotype	O	O
.	O	O

Three	O	O
variants	O	O
were	O	O
similar	O	O
to	O	O
others	O	O
previously	O	O
described	O	O
G6PD	O	O
Mediterranean	O	O
(	O	O
11	O	O
cases	O	O
)	O	O
,	O	O
G6PD	O	O
Athens	O	O
-	O	O
like	O	O
(	O	O
3	O	O
cases	O	O
)	O	O
,	O	O
and	O	O
G6PD	O	O
Union	O	O
(	O	O
2	O	O
cases	O	O
)	O	O
.	O	O

The	O	O
remaining	O	O
variants	O	O
were	O	O
different	O	O
from	O	O
the	O	O
numerous	O	O
variants	O	O
already	O	O
reported	O	O
and	O	O
have	O	O
been	O	O
considered	O	O
as	O	O
new	O	O
mutants	O	O
.	O	O

Provisionally	O	O
they	O	O
are	O	O
called	O	O
G6PD	O	O
Betica	O	O
(	O	O
19	O	O
cases	O	O
)	O	O
and	O	O
G6PD	O	O
Menorca	O	O
(	O	O
1	O	O
case	O	O
)	O	O
.	O	O

The	O	O
present	O	O
study	O	O
constitutes	O	O
the	O	O
first	O	O
attempt	O	O
to	O	O
characterize	O	O
the	O	O
deficient	B-Disease	D005955
G6PD	I-Disease	D005955
variants	O	O
found	O	O
in	O	O
Spain	O	O
and	O	O
supplies	O	O
new	O	O
data	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
molecular	O	O
characteristics	O	O
of	O	O
deficient	O	O
variants	O	O
and	O	O
their	O	O
clinical	O	O
manifestations	O	O
.	O	O

The	O	O
most	O	O
important	O	O
findings	O	O
can	O	O
be	O	O
summarized	O	O
as	O	O
follows	O	O
(	O	O
1	O	O
)	O	O
The	O	O
Spanish	O	O
population	O	O
is	O	O
characterized	O	O
by	O	O
an	O	O
important	O	O
heterogeneity	O	O
in	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

(	O	O
2	O	O
)	O	O
Although	O	O
G6PD	O	O
Mediterranean	O	O
is	O	O
very	O	O
frequent	O	O
,	O	O
it	O	O
presents	O	O
a	O	O
relatively	O	O
high	O	O
degree	O	O
of	O	O
polymorphism	O	O
.	O	O

(	O	O
3	O	O
)	O	O
Favism	B-Disease	D005236
has	O	O
been	O	O
observed	O	O
associated	O	O
with	O	O
all	O	O
kinds	O	O
of	O	O
variants	O	O
described	O	O
here	O	O
.	O	O

(	O	O
4	O	O
)	O	O
G6PD	O	O
Betica	O	O
,	O	O
which	O	O
is	O	O
the	O	O
most	O	O
frequent	O	O
variant	O	O
found	O	O
in	O	O
subjects	O	O
of	O	O
Southern	O	O
Spanish	O	O
origin	O	O
,	O	O
has	O	O
been	O	O
observed	O	O
associated	O	O
with	O	O
favism	B-Disease	D005236
in	O	O
all	O	O
cases	O	O
except	O	O
one	O	O
.	O	O

Early	O	O
onset	O	O
of	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
in	O	O
a	O	O
boy	O	O
with	O	O
emerin	O	O
gene	O	O
deletion	O	O
.	O	O

A	O	O
boy	O	O
developed	O	O
contractures	B-Disease	D003286
of	I-Disease	D003286
the	I-Disease	D003286
Achilles	I-Disease	D003286
tendons	I-Disease	D003286
at	O	O
3	O	O
years	O	O
and	O	O
of	O	O
the	O	O
postcervical	O	O
muscles	O	O
at	O	O
7	O	O
years	O	O
,	O	O
although	O	O
neither	O	O
contractures	B-Disease	D003286
of	I-Disease	D003286
the	I-Disease	D003286
elbows	I-Disease	D003286
nor	O	O
cardiac	B-Disease	D018376
abnormality	I-Disease	D018376
were	O	O
recognized	O	O
by	O	O
the	O	O
age	O	O
of	O	O
9	O	O
years	O	O
.	O	O

Muscle	O	O
computed	O	O
tomography	O	O
scanning	O	O
revealed	O	O
changes	O	O
characteristic	O	O
of	O	O
muscle	O	O
involvement	O	O
.	O	O

Emerin	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
the	O	O
biopsied	O	O
muscle	O	O
,	O	O
and	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
PCR	O	O
-	O	O
based	O	O
genomic	O	O
DNA	O	O
analyses	O	O
of	O	O
the	O	O
emerin	O	O
gene	O	O
demonstrated	O	O
no	O	O
amplification	O	O
product	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

These	O	O
results	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
of	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
,	O	O
and	O	O
reinforce	O	O
the	O	O
necessity	O	O
of	O	O
molecular	O	O
genetic	O	O
diagnosis	O	O
of	O	O
the	O	O
membrane	O	O
protein	O	O
emerin	O	O
in	O	O
younger	O	O
patients	O	O
with	O	O
possible	O	O
EDMD	B-Disease	D020389
before	O	O
appearance	O	O
of	O	O
the	O	O
typical	O	O
symptoms	O	O
,	O	O
to	O	O
avoid	O	O
sudden	B-Disease	D016757
cardiac	I-Disease	D016757
death	I-Disease	D016757
.	O	O

.	O	O

PRAD1	O	O
,	O	O
a	O	O
candidate	O	O
BCL1	O	O
oncogene	O	O
:	O	O
mapping	O	O
and	O	O
expression	O	O
in	O	O
centrocytic	B-Disease	D008223
lymphoma	I-Disease	D008223
.	O	O

Rearrangement	O	O
of	O	O
the	O	O
BCL1	O	O
(	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
1	O	O
)	O	O
region	O	O
on	O	O
chromosome	O	O
11q13	O	O
appears	O	O
to	O	O
be	O	O
highly	O	O
characteristic	O	O
of	O	O
centrocytic	B-Disease	D008223
lymphoma	I-Disease	D008223
and	O	O
also	O	O
is	O	O
found	O	O
infrequently	O	O
in	O	O
other	O	O
B	B-Disease	D016393
-	I-Disease	D016393
cell	I-Disease	D016393
neoplasms	I-Disease	D016393
.	O	O

Rearrangement	O	O
is	O	O
thought	O	O
to	O	O
deregulate	O	O
a	O	O
nearby	O	O
protooncogene	O	O
,	O	O
but	O	O
transcribed	O	O
sequences	O	O
in	O	O
the	O	O
immediate	O	O
vicinity	O	O
of	O	O
BCL1	O	O
breakpoints	O	O
had	O	O
not	O	O
been	O	O
identified	O	O
.	O	O

PRAD1	O	O
,	O	O
previously	O	O
designated	O	O
D11S287E	O	O
,	O	O
was	O	O
identified	O	O
on	O	O
11q13	O	O
as	O	O
a	O	O
chromosomal	O	O
breakpoint	O	O
region	O	O
rearranged	O	O
with	O	O
the	O	O
parathyroid	O	O
hormone	O	O
gene	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
parathyroid	B-Disease	D010282
adenomas	I-Disease	D010282
;	O	O
this	O	O
highly	O	O
conserved	O	O
putative	O	O
oncogene	O	O
,	O	O
which	O	O
encodes	O	O
a	O	O
novel	O	O
cyclin	O	O
,	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
BCL1	O	O
and	O	O
implicated	O	O
also	O	O
in	O	O
subsets	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
squamous	I-Disease	D001943
cell	I-Disease	D001943
neoplasms	I-Disease	D001943
with	O	O
11q13	O	O
amplification	O	O
.	O	O

We	O	O
report	O	O
pulsed	O	O
-	O	O
field	O	O
gel	O	O
electrophoresis	O	O
data	O	O
showing	O	O
BCL1	O	O
and	O	O
PRAD1	O	O
to	O	O
be	O	O
no	O	O
more	O	O
than	O	O
130	O	O
kilobases	O	O
apart	O	O
.	O	O

PRAD1	O	O
mRNA	O	O
is	O	O
abundantly	O	O
expressed	O	O
in	O	O
seven	O	O
of	O	O
seven	O	O
centrocytic	B-Disease	D008223
lymphomas	I-Disease	D008223
(	O	O
Kiel	O	O
classification	O	O
)	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
13	O	O
closely	O	O
related	O	O
but	O	O
noncentrocytic	B-Disease	D008223
lymphomas	I-Disease	D008223
.	O	O

Three	O	O
of	O	O
the	O	O
seven	O	O
centrocytic	B-Disease	D008223
lymphomas	I-Disease	D008223
had	O	O
detectable	O	O
BCL1	O	O
DNA	O	O
rearrangement	O	O
.	O	O

Also	O	O
,	O	O
two	O	O
unusual	O	O
cases	O	O
of	O	O
CLL	O	O
with	O	O
BCL1	O	O
rearrangement	O	O
overexpressed	O	O
PRAD1	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
five	O	O
CLL	O	O
controls	O	O
.	O	O

Thus	O	O
,	O	O
PRAD1	O	O
is	O	O
an	O	O
excellent	O	O
candidate	O	O
"	O	O
BCL1	O	O
oncogene	O	O
.	O	O

"	O	O
Its	O	O
overexpression	O	O
may	O	O
be	O	O
a	O	O
key	O	O
consequence	O	O
of	O	O
rearrangement	O	O
of	O	O
the	O	O
BCL1	O	O
vicinity	O	O
in	O	O
B	B-Disease	D016393
-	I-Disease	D016393
cell	I-Disease	D016393
neoplasms	I-Disease	D016393
and	O	O
a	O	O
unifying	O	O
pathogenetic	O	O
feature	O	O
in	O	O
centrocytic	B-Disease	D008223
lymphoma	I-Disease	D008223
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
:	O	O
increased	O	O
plasma	O	O
content	O	O
of	O	O
saturated	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
.	O	O

With	O	O
a	O	O
new	O	O
method	O	O
we	O	O
measured	O	O
the	O	O
saturated	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
in	O	O
the	O	O
plasma	O	O
of	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
hemizygotes	O	O
,	O	O
ALD	B-Disease	D000326
heterozygotes	O	O
,	O	O
and	O	O
controls	O	O
.	O	O

ALD	B-Disease	D000326
hemizygotes	O	O
showed	O	O
increased	O	O
levels	O	O
of	O	O
hexacosanoate	O	O
(	O	O
C26	O	O
fatty	O	O
acid	O	O
)	O	O
which	O	O
represented	O	O
0	O	O
.	O	O

081	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

0066	O	O
%	O	O
(	O	O
SEM	O	O
)	O	O
of	O	O
total	O	O
fatty	O	O
acids	O	O
,	O	O
compared	O	O
to	O	O
0	O	O
.	O	O

015	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

0032	O	O
%	O	O
in	O	O
the	O	O
controls	O	O
.	O	O

C25	O	O
,	O	O
C24	O	O
,	O	O
and	O	O
C23	O	O
fatty	O	O
acids	O	O
were	O	O
also	O	O
increased	O	O
,	O	O
but	O	O
the	O	O
C22	O	O
and	O	O
C20	O	O
fatty	O	O
acids	O	O
were	O	O
normal	O	O
.	O	O

C26	O	O
levels	O	O
were	O	O
also	O	O
increased	O	O
in	O	O
most	O	O
ALD	B-Disease	D000326
heterozygotes	O	O
,	O	O
with	O	O
a	O	O
mean	O	O
level	O	O
0	O	O
.	O	O

057	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

0063	O	O
%	O	O
of	O	O
total	O	O
fatty	O	O
acids	O	O
.	O	O

The	O	O
technique	O	O
can	O	O
be	O	O
used	O	O
for	O	O
diagnosis	O	O
and	O	O
carrier	O	O
identification	O	O
,	O	O
and	O	O
in	O	O
the	O	O
evaluation	O	O
of	O	O
therapy	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
inhibits	O	O
in	O	O
vitro	O	O
growth	O	O
of	O	O
Plasmodium	O	O
falciparum	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
;	I-Disease	D005955
EC	I-Disease	D005955
1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

49	I-Disease	D005955
)	I-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
red	O	O
blood	O	O
cells	O	O
from	O	O
male	O	O
hemizygotes	O	O
and	O	O
female	O	O
heterozygotes	O	O
from	O	O
the	O	O
island	O	O
of	O	O
Sardinia	O	O
were	O	O
studied	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
support	O	O
growth	O	O
in	O	O
vitro	O	O
of	O	O
the	O	O
malaria	B-Disease	D008288
-	O	O
causing	O	O
organism	O	O
Plasmodium	O	O
falciparum	O	O
.	O	O

Parasite	O	O
growth	O	O
was	O	O
approximately	O	O
one	O	O
-	O	O
third	O	O
of	O	O
normal	O	O
in	O	O
both	O	O
hemi	O	O
-	O	O
and	O	O
heterozygotes	O	O
for	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

In	O	O
Sardinians	O	O
with	O	O
the	O	O
beta	O	O
0	O	O
-	O	O
thalassemia	B-Disease	D013789
trait	O	O
,	O	O
parasite	O	O
growth	O	O
was	O	O
normal	O	O
except	O	O
when	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
occurred	O	O
together	O	O
with	O	O
the	O	O
thalassemia	B-Disease	D013789
trait	O	O
.	O	O

The	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
may	O	O
confer	O	O
a	O	O
selective	O	O
advantage	O	O
in	O	O
a	O	O
malarious	B-Disease	D008288
area	O	O
;	O	O
the	O	O
female	O	O
heterozygote	O	O
may	O	O
be	O	O
at	O	O
a	O	O
particular	O	O
advantage	O	O
because	O	O
resistance	O	O
to	O	O
malaria	B-Disease	D008288
equals	O	O
that	O	O
of	O	O
male	O	O
hemizygotes	O	O
,	O	O
but	O	O
the	O	O
risk	O	O
of	O	O
fatal	B-Disease	D006461
hemolysis	I-Disease	D006461
may	O	O
be	O	O
less	O	O
.	O	O

However	O	O
,	O	O
more	O	O
female	O	O
heterozygotes	O	O
must	O	O
be	O	O
studied	O	O
to	O	O
confirm	O	O
this	O	O
hypothesis	O	O
.	O	O

No	O	O
protective	O	O
effect	O	O
of	O	O
beta	O	O
0	O	O
-	O	O
thalassemia	B-Disease	D013789
trait	O	O
could	O	O
be	O	O
demonstrated	O	O
in	O	O
vitro	O	O
.	O	O

Heterozygous	B-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
associated	O	O
with	O	O
angioedema	B-Disease	D000799
,	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
,	O	O
and	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
,	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
,	O	O
and	O	O
angioedema	B-Disease	D000799
associated	O	O
with	O	O
heterozygous	O	O
complement	B-Disease	OMIM:217000
factor	I-Disease	OMIM:217000
2	I-Disease	OMIM:217000
(	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
)	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

The	O	O
significance	O	O
of	O	O
this	O	O
association	O	O
is	O	O
controversial	O	O
,	O	O
though	O	O
the	O	O
association	O	O
of	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
with	O	O
certain	O	O
histocompatibility	O	O
antigens	O	O
suggests	O	O
possible	O	O
linkage	O	O
to	O	O
immune	O	O
response	O	O
genes	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
heterozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
in	O	O
association	O	O
with	O	O
this	O	O
combination	O	O
of	O	O
autoimmune	B-Disease	D001327
disorders	I-Disease	D001327
,	O	O
and	O	O
we	O	O
discuss	O	O
the	O	O
aetiological	O	O
implications	O	O
.	O	O

.	O	O

Inherited	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
with	O	O
recurrent	O	O
infections	O	O
and	O	O
glomerulonephritis	B-Disease	D005921
.	O	O

A	O	O
10	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Laotian	O	O
boy	O	O
had	O	O
homozygous	O	O
deficiency	B-Disease	OMIM:613779
of	I-Disease	OMIM:613779
the	I-Disease	OMIM:613779
third	I-Disease	OMIM:613779
component	I-Disease	OMIM:613779
of	I-Disease	OMIM:613779
complement	I-Disease	OMIM:613779
and	O	O
recurrent	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
beginning	O	O
at	O	O
age	O	O
5	O	O
months	O	O
.	O	O

Cellular	O	O
and	O	O
humoral	O	O
immunity	O	O
were	O	O
normal	O	O
,	O	O
as	O	O
were	O	O
polymorphonuclear	O	O
leukocyte	O	O
chemotaxis	O	O
and	O	O
bactericidal	O	O
activities	O	O
.	O	O

Serum	O	O
complement	O	O
-	O	O
mediated	O	O
hemolytic	O	O
,	O	O
chemotactic	O	O
,	O	O
and	O	O
opsonic	O	O
activities	O	O
were	O	O
deficient	O	O
.	O	O

In	O	O
vitro	O	O
addition	O	O
of	O	O
purified	O	O
C3	O	O
to	O	O
patient	O	O
serum	O	O
restored	O	O
hemolytic	O	O
complement	O	O
to	O	O
normal	O	O
levels	O	O
,	O	O
and	O	O
plasma	O	O
infusion	O	O
during	O	O
each	O	O
of	O	O
four	O	O
episodes	O	O
of	O	O
pneumonia	B-Disease	D011014
significantly	O	O
enhanced	O	O
serum	O	O
opsonic	O	O
activity	O	O
for	O	O
as	O	O
long	O	O
as	O	O
36	O	O
hours	O	O
.	O	O

A	O	O
renal	O	O
biopsy	O	O
specimen	O	O
revealed	O	O
mesangiopathic	B-Disease	D005921
glomerulonephritis	I-Disease	D005921
,	O	O
although	O	O
significant	O	O
levels	O	O
of	O	O
circulating	O	O
IgG	O	O
immune	O	O
complexes	O	O
were	O	O
not	O	O
detected	O	O
.	O	O

These	O	O
findings	O	O
further	O	O
support	O	O
the	O	O
association	O	O
of	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
with	O	O
immune	B-Disease	D007105
-	I-Disease	D007105
complex	I-Disease	D007105
disease	I-Disease	D007105
and	O	O
suggest	O	O
that	O	O
plasma	O	O
infusion	O	O
may	O	O
be	O	O
an	O	O
adjunct	O	O
to	O	O
antibiotic	O	O
therapy	O	O
in	O	O
the	O	O
management	O	O
of	O	O
severe	O	O
pyogenic	B-Disease	D007239
infections	I-Disease	D007239
in	O	O
patients	O	O
with	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
.	O	O

.	O	O

Southern	O	O
analysis	O	O
reveals	O	O
a	O	O
large	O	O
deletion	O	O
at	O	O
the	O	O
hypoxanthine	O	O
phosphoribosyltransferase	O	O
locus	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

Whole	O	O
genomic	O	O
hprt	O	O
clones	O	O
were	O	O
used	O	O
in	O	O
Southern	O	O
analysis	O	O
to	O	O
screen	O	O
the	O	O
integrity	O	O
of	O	O
the	O	O
hprt	O	O
gene	O	O
in	O	O
a	O	O
family	O	O
that	O	O
includes	O	O
a	O	O
patient	O	O
with	O	O
HPRT	B-Disease	D007926
enzyme	I-Disease	D007926
deficiency	I-Disease	D007926
causal	O	O
to	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

A	O	O
5	O	O
kb	O	O
DNA	O	O
sequence	O	O
deletion	O	O
was	O	O
found	O	O
to	O	O
have	O	O
its	O	O
endpoints	O	O
in	O	O
the	O	O
first	O	O
and	O	O
third	O	O
introns	O	O
.	O	O

The	O	O
probes	O	O
identified	O	O
the	O	O
carrier	O	O
status	O	O
of	O	O
female	O	O
family	O	O
members	O	O
,	O	O
aided	O	O
by	O	O
an	O	O
RFLP	O	O
carried	O	O
by	O	O
the	O	O
mothers	O	O
normal	O	O
X	O	O
-	O	O
chromosome	O	O
.	O	O

.	O	O

Association	O	O
of	O	O
BRCA1	O	O
with	O	O
the	O	O
hRad50	O	O
-	O	O
hMre11	O	O
-	O	O
p95	O	O
complex	O	O
and	O	O
the	O	O
DNA	O	O
damage	O	O
response	O	O
.	O	O

BRCA1	O	O
encodes	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
that	O	O
is	O	O
mutated	O	O
in	O	O
familial	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancers	I-Disease	D061325
.	O	O

Here	O	O
,	O	O
it	O	O
is	O	O
shown	O	O
that	O	O
BRCA1	O	O
interacts	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
with	O	O
hRad50	O	O
,	O	O
which	O	O
forms	O	O
a	O	O
complex	O	O
with	O	O
hMre11	O	O
and	O	O
p95	O	O
/	O	O
nibrin	O	O
.	O	O

Upon	O	O
irradiation	O	O
,	O	O
BRCA1	O	O
was	O	O
detected	O	O
in	O	O
discrete	O	O
foci	O	O
in	O	O
the	O	O
nucleus	O	O
,	O	O
which	O	O
colocalize	O	O
with	O	O
hRad50	O	O
.	O	O

Formation	O	O
of	O	O
irradiation	O	O
-	O	O
induced	O	O
foci	O	O
positive	O	O
for	O	O
BRCA1	O	O
,	O	O
hRad50	O	O
,	O	O
hMre11	O	O
,	O	O
or	O	O
p95	O	O
was	O	O
dramatically	O	O
reduced	O	O
in	O	O
HCC	O	O
/	O	O
1937	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
cells	O	O
carrying	O	O
a	O	O
homozygous	O	O
mutation	O	O
in	O	O
BRCA1	O	O
but	O	O
was	O	O
restored	O	O
by	O	O
transfection	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
BRCA1	O	O
.	O	O

Ectopic	O	O
expression	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
,	O	O
but	O	O
not	O	O
mutated	O	O
,	O	O
BRCA1	O	O
in	O	O
these	O	O
cells	O	O
rendered	O	O
them	O	O
less	O	O
sensitive	O	O
to	O	O
the	O	O
DNA	O	O
damage	O	O
agent	O	O
,	O	O
methyl	O	O
methanesulfonate	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
BRCA1	O	O
is	O	O
important	O	O
for	O	O
the	O	O
cellular	O	O
responses	O	O
to	O	O
DNA	O	O
damage	O	O
that	O	O
are	O	O
mediated	O	O
by	O	O
the	O	O
hRad50	O	O
-	O	O
hMre11	O	O
-	O	O
p95	O	O
complex	O	O
.	O	O

.	O	O

Nebulin	O	O
and	O	O
titin	O	O
expression	O	O
in	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
appears	O	O
normal	O	O
.	O	O

Monoclonal	O	O
antibodies	O	O
which	O	O
recognize	O	O
different	O	O
epitopes	O	O
on	O	O
either	O	O
titin	O	O
or	O	O
nebulin	O	O
show	O	O
normal	O	O
staining	O	O
patterns	O	O
on	O	O
frozen	O	O
sections	O	O
of	O	O
three	O	O
muscle	O	O
biopsies	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

Gel	O	O
electrophoresis	O	O
and	O	O
immunoblotting	O	O
performed	O	O
on	O	O
two	O	O
of	O	O
these	O	O
muscle	O	O
biopsies	O	O
show	O	O
the	O	O
normal	O	O
pattern	O	O
of	O	O
titin	O	O
and	O	O
nebulin	O	O
polypeptides	O	O
.	O	O

Since	O	O
the	O	O
donor	O	O
of	O	O
one	O	O
of	O	O
these	O	O
biopsies	O	O
has	O	O
a	O	O
large	O	O
deletion	O	O
of	O	O
the	O	O
5	O	O
-	O	O
region	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
,	O	O
our	O	O
results	O	O
argue	O	O
against	O	O
the	O	O
recent	O	O
proposal	O	O
that	O	O
nebulin	O	O
is	O	O
the	O	O
gene	O	O
mutated	O	O
in	O	O
DMD	B-Disease	D020388
.	O	O

.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
kinase	O	O
is	O	O
a	O	O
component	O	O
of	O	O
neuromuscular	O	O
junctions	O	O
.	O	O

The	O	O
clinical	O	O
manifestation	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
correlated	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
expansion	O	O
of	O	O
an	O	O
unstable	O	O
[	O	O
CTG	O	O
]	O	O
n	O	O
DNA	O	O
motif	O	O
.	O	O

Recent	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
this	O	O
trinucleotide	O	O
motif	O	O
forms	O	O
part	O	O
of	O	O
the	O	O
last	O	O
,	O	O
3	O	O
untranslated	O	O
exon	O	O
of	O	O
a	O	O
gene	O	O
which	O	O
potentially	O	O
encodes	O	O
multiple	O	O
protein	O	O
isoforms	O	O
of	O	O
a	O	O
serine	O	O
/	O	O
threonine	O	O
protein	O	O
kinase	O	O
(	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
,	O	O
DM	B-Disease	D009223
-	O	O
PK	O	O
)	O	O
.	O	O

We	O	O
report	O	O
here	O	O
on	O	O
the	O	O
development	O	O
of	O	O
antisera	O	O
against	O	O
synthetic	O	O
DM	B-Disease	D009223
-	O	O
PK	O	O
peptide	O	O
antigens	O	O
and	O	O
their	O	O
use	O	O
in	O	O
biochemical	O	O
and	O	O
histochemical	O	O
studies	O	O
.	O	O

Immunoreactive	O	O
DM	B-Disease	D009223
-	O	O
kinase	O	O
protein	O	O
of	O	O
53	O	O
kD	O	O
is	O	O
present	O	O
at	O	O
low	O	O
levels	O	O
in	O	O
skeletal	O	O
and	O	O
cardiac	O	O
muscle	O	O
extracts	O	O
of	O	O
DM	B-Disease	D009223
patients	O	O
and	O	O
normal	O	O
controls	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
revealed	O	O
that	O	O
DM	B-Disease	D009223
-	O	O
PK	O	O
is	O	O
localised	O	O
prominently	O	O
at	O	O
sites	O	O
of	O	O
neuromuscular	O	O
and	O	O
myotendinous	O	O
junctions	O	O
(	O	O
NMJs	O	O
and	O	O
MTJs	O	O
)	O	O
of	O	O
human	O	O
and	O	O
rodent	O	O
skeletal	O	O
muscles	O	O
.	O	O

Furthermore	O	O
,	O	O
very	O	O
low	O	O
levels	O	O
of	O	O
immunoreactive	O	O
DM	B-Disease	D009223
-	O	O
PK	O	O
protein	O	O
are	O	O
present	O	O
in	O	O
the	O	O
sarcoplasm	O	O
of	O	O
predominantly	O	O
type	O	O
I	O	O
fibres	O	O
in	O	O
various	O	O
muscles	O	O
.	O	O

Strikingly	O	O
,	O	O
presence	O	O
of	O	O
the	O	O
protein	O	O
can	O	O
also	O	O
be	O	O
demonstrated	O	O
for	O	O
NMJs	O	O
of	O	O
muscular	O	O
tissues	O	O
of	O	O
adult	O	O
and	O	O
congenital	O	O
cases	O	O
of	O	O
DM	B-Disease	D009223
,	O	O
with	O	O
no	O	O
gross	O	O
changes	O	O
in	O	O
structural	O	O
organisation	O	O
.	O	O

Our	O	O
findings	O	O
provide	O	O
a	O	O
basis	O	O
for	O	O
further	O	O
characterisation	O	O
of	O	O
the	O	O
role	O	O
of	O	O
the	O	O
kinase	O	O
in	O	O
protein	O	O
assembly	O	O
processes	O	O
or	O	O
signal	O	O
mediation	O	O
at	O	O
synaptic	O	O
sites	O	O
and	O	O
ultimately	O	O
for	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
complex	O	O
pathophysiology	O	O
of	O	O
DM	B-Disease	D009223
.	O	O

.	O	O

New	O	O
genetic	O	O
variants	O	O
of	O	O
glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
in	O	O
Italy	O	O
.	O	O

Six	O	O
new	O	O
variants	O	O
of	O	O
human	O	O
erythrocyte	O	O
G6PD	O	O
have	O	O
been	O	O
characterized	O	O
.	O	O

All	O	O
of	O	O
them	O	O
were	O	O
found	O	O
in	O	O
Italian	O	O
males	O	O
and	O	O
all	O	O
were	O	O
associated	O	O
with	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
,	O	O
but	O	O
only	O	O
two	O	O
with	O	O
signs	O	O
of	O	O
haemolysis	B-Disease	D006461
.	O	O

These	O	O
and	O	O
other	O	O
variants	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
which	O	O
must	O	O
thus	O	O
far	O	O
be	O	O
regarded	O	O
as	O	O
sporadic	O	O
,	O	O
are	O	O
found	O	O
to	O	O
map	O	O
in	O	O
parts	O	O
of	O	O
Italy	O	O
where	O	O
common	O	O
types	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
are	O	O
also	O	O
prevalent	O	O
.	O	O

.	O	O

ATM	O	O
-	O	O
heterozygous	O	O
germline	O	O
mutations	O	O
contribute	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
-	O	O
susceptibility	O	O
.	O	O

Approximately	O	O
0	O	O
.	O	O

5	O	O
%	O	O
-	O	O
1	O	O
%	O	O
of	O	O
the	O	O
general	O	O
population	O	O
has	O	O
been	O	O
estimated	O	O
to	O	O
be	O	O
heterozygous	O	O
for	O	O
a	O	O
germline	O	O
mutation	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
the	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
(	O	O
MIM	O	O
208900	O	O
)	O	O
.	O	O

The	O	O
finding	O	O
that	O	O
ATM	O	O
-	O	O
heterozygotes	O	O
have	O	O
an	O	O
increased	O	O
relative	O	O
risk	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
was	O	O
supported	O	O
by	O	O
some	O	O
studies	O	O
but	O	O
not	O	O
confirmed	O	O
by	O	O
others	O	O
.	O	O

In	O	O
view	O	O
of	O	O
this	O	O
discrepancy	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
frequency	O	O
of	O	O
ATM	O	O
germline	O	O
mutations	O	O
in	O	O
a	O	O
selected	O	O
group	O	O
of	O	O
Dutch	O	O
patients	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

We	O	O
have	O	O
analyzed	O	O
ATM	O	O
germline	O	O
mutations	O	O
in	O	O
normal	O	O
blood	O	O
lymphocytes	O	O
,	O	O
using	O	O
the	O	O
protein	O	O
-	O	O
truncation	O	O
test	O	O
followed	O	O
by	O	O
genomic	O	O
-	O	O
sequence	O	O
analysis	O	O
.	O	O

A	O	O
high	O	O
percentage	O	O
of	O	O
ATM	O	O
germline	O	O
mutations	O	O
was	O	O
demonstrated	O	O
among	O	O
patients	O	O
with	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

The	O	O
82	O	O
patients	O	O
included	O	O
in	O	O
this	O	O
study	O	O
had	O	O
developed	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
at	O	O
age	O	O
<	O	O
45	O	O
and	O	O
had	O	O
survived	O	O
>	O	O
/	O	O
=	O	O
5	O	O
years	O	O
(	O	O
mean	O	O
15	O	O
years	O	O
)	O	O
,	O	O
and	O	O
in	O	O
33	O	O
(	O	O
40	O	O
%	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
a	O	O
contralateral	O	O
breast	O	O
tumor	O	O
had	O	O
been	O	O
diagnosed	O	O
.	O	O

Among	O	O
these	O	O
patients	O	O
we	O	O
identified	O	O
seven	O	O
(	O	O
8	O	O
.	O	O

5	O	O
%	O	O
)	O	O
ATM	O	O
germline	O	O
mutations	O	O
,	O	O
of	O	O
which	O	O
five	O	O
are	O	O
distinct	O	O
.	O	O

One	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
(	O	O
IVS10	O	O
-	O	O
6T	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
was	O	O
detected	O	O
three	O	O
times	O	O
in	O	O
our	O	O
series	O	O
.	O	O

Four	O	O
heterozygous	O	O
carriers	O	O
were	O	O
patients	O	O
with	O	O
bilateral	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
mutations	O	O
identified	O	O
in	O	O
this	O	O
study	O	O
are	O	O
"	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
disease	O	O
-	O	O
causing	O	O
"	O	O
mutations	O	O
that	O	O
might	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
heterozygotes	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
ATM	O	O
heterozygotes	O	O
have	O	O
an	O	O
approximately	O	O
ninefold	O	O
-	O	O
increased	O	O
risk	O	O
of	O	O
developing	O	O
a	O	O
type	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
characterized	O	O
by	O	O
frequent	O	O
bilateral	O	O
occurrence	O	O
,	O	O
early	O	O
age	O	O
at	O	O
onset	O	O
,	O	O
and	O	O
long	O	O
-	O	O
term	O	O
survival	O	O
.	O	O

The	O	O
specific	O	O
characteristics	O	O
of	O	O
our	O	O
population	O	O
of	O	O
patients	O	O
may	O	O
explain	O	O
why	O	O
such	O	O
a	O	O
high	O	O
frequency	O	O
was	O	O
not	O	O
found	O	O
in	O	O
other	O	O
series	O	O
.	O	O

Autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
(	O	O
ALPS	B-Disease	D056735
)	O	O
in	O	O
a	O	O
child	O	O
from	O	O
consanguineous	O	O
parents	O	O
:	O	O
a	O	O
dominant	O	O
or	O	O
recessive	O	O
disease	O	O
?	O	O
Autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
(	O	O
ALPS	B-Disease	D056735
)	O	O
is	O	O
characterized	O	O
by	O	O
autoimmune	O	O
features	O	O
and	O	O
lymphoproliferations	O	O
and	O	O
is	O	O
generally	O	O
caused	O	O
by	O	O
defective	O	O
Fas	O	O
-	O	O
mediated	O	O
apoptosis	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
a	O	O
child	O	O
with	O	O
clinical	O	O
features	O	O
of	O	O
ALPS	B-Disease	D056735
without	O	O
detectable	O	O
Fas	O	O
expression	O	O
on	O	O
freshly	O	O
isolated	O	O
blood	O	O
leukocytes	O	O
.	O	O

Detection	O	O
of	O	O
FAS	O	O
transcripts	O	O
via	O	O
real	O	O
-	O	O
time	O	O
quantitative	O	O
PCR	O	O
made	O	O
a	O	O
severe	O	O
transcriptional	O	O
defect	O	O
unlikely	O	O
.	O	O

Sequencing	O	O
of	O	O
the	O	O
FAS	O	O
gene	O	O
revealed	O	O
a	O	O
20	O	O
-	O	O
nucleotide	O	O
duplication	O	O
in	O	O
the	O	O
last	O	O
exon	O	O
affecting	O	O
the	O	O
cytoplasmic	O	O
signaling	O	O
domain	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
homozygous	O	O
for	O	O
this	O	O
mutation	O	O
,	O	O
whereas	O	O
the	O	O
consanguineous	O	O
parents	O	O
and	O	O
the	O	O
siblings	O	O
were	O	O
heterozygous	O	O
.	O	O

The	O	O
patient	O	O
reported	O	O
here	O	O
is	O	O
a	O	O
human	O	O
homologue	O	O
of	O	O
the	O	O
Fas	O	O
-	O	O
null	O	O
mouse	O	O
,	O	O
inasmuch	O	O
as	O	O
she	O	O
carries	O	O
an	O	O
autosomal	O	O
homozygous	O	O
mutation	O	O
in	O	O
the	O	O
FAS	O	O
gene	O	O
and	O	O
she	O	O
shows	O	O
the	O	O
severe	O	O
and	O	O
accelerated	O	O
ALPS	B-Disease	D056735
phenotype	O	O
.	O	O

The	O	O
heterozygous	O	O
family	O	O
members	O	O
did	O	O
not	O	O
have	O	O
the	O	O
ALPS	B-Disease	D056735
phenotype	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
disease	O	O
-	O	O
causing	O	O
FAS	O	O
mutation	O	O
in	O	O
this	O	O
family	O	O
is	O	O
autosomal	O	O
recessive	O	O
.	O	O

.	O	O

A	O	O
prevalent	O	O
mutation	O	O
for	O	O
galactosemia	B-Disease	D005693
among	O	O
black	O	O
Americans	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
define	O	O
the	O	O
mutation	O	O
causing	O	O
galactosemia	B-Disease	D005693
in	O	O
patients	O	O
of	O	O
black	O	O
American	O	O
origin	O	O
who	O	O
have	O	O
no	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
(	O	O
GALT	O	O
)	O	O
activity	O	O
in	O	O
erythrocytes	O	O
but	O	O
good	O	O
clinical	O	O
outcome	O	O
.	O	O

METHODS	O	O
We	O	O
discovered	O	O
a	O	O
mutation	O	O
caused	O	O
by	O	O
a	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
at	O	O
base	O	O
-	O	O
pair	O	O
1158	O	O
of	O	O
the	O	O
GALT	O	O
gene	O	O
that	O	O
results	O	O
in	O	O
a	O	O
serine	O	O
-	O	O
to	O	O
-	O	O
leucine	O	O
substitution	O	O
at	O	O
codon	O	O
135	O	O
(	O	O
S135L	O	O
)	O	O
.	O	O

We	O	O
developed	O	O
a	O	O
method	O	O
with	O	O
which	O	O
to	O	O
screen	O	O
populations	O	O
for	O	O
its	O	O
prevalence	O	O
.	O	O

We	O	O
compared	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
among	O	O
erythrocytes	O	O
,	O	O
leukocytes	O	O
,	O	O
and	O	O
transformed	O	O
lymphoblasts	O	O
,	O	O
as	O	O
well	O	O
as	O	O
total	O	O
body	O	O
oxidation	O	O
of	O	O
D	O	O
-	O	O
(	O	O
13C	O	O
)	O	O
-	O	O
galactose	O	O
to	O	O
13CO2	O	O
among	O	O
three	O	O
genotypes	O	O
for	O	O
GALT	O	O
(	O	O
S135L	O	O
/	O	O
S135L	O	O
,	O	O
Q188R	O	O
/	O	O
Q188R	O	O
,	O	O
and	O	O
Normal	O	O
/	O	O
Normal	O	O
)	O	O
.	O	O

RESULTS	O	O
We	O	O
found	O	O
a	O	O
48	O	O
%	O	O
prevalence	O	O
of	O	O
the	O	O
S135L	O	O
mutation	O	O
among	O	O
17	O	O
black	O	O
American	O	O
patients	O	O
with	O	O
classic	B-Disease	D005693
galactosemia	I-Disease	D005693
and	O	O
a	O	O
1	O	O
%	O	O
prevalence	O	O
in	O	O
a	O	O
population	O	O
of	O	O
50	O	O
black	O	O
Americans	O	O
without	O	O
galactosemia	B-Disease	D005693
.	O	O

The	O	O
S135L	O	O
mutation	O	O
was	O	O
not	O	O
found	O	O
in	O	O
84	O	O
white	O	O
patients	O	O
with	O	O
G	O	O
/	O	O
G	O	O
galactosemia	B-Disease	D005693
nor	O	O
in	O	O
87	O	O
white	O	O
control	O	O
subjects	O	O
without	O	O
galactosemia	B-Disease	D005693
.	O	O

We	O	O
found	O	O
normal	O	O
whole	O	O
body	O	O
oxidation	O	O
of	O	O
D	O	O
-	O	O
(	O	O
13C	O	O
)	O	O
-	O	O
galactose	O	O
by	O	O
the	O	O
patient	O	O
homozygous	O	O
for	O	O
S135L	O	O
and	O	O
various	O	O
degrees	O	O
of	O	O
enzyme	O	O
impairment	O	O
among	O	O
different	O	O
tissues	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
S135L	O	O
mutation	O	O
in	O	O
the	O	O
GALT	O	O
gene	O	O
is	O	O
a	O	O
prevalent	O	O
cause	O	O
of	O	O
galactosemia	B-Disease	D005693
among	O	O
black	O	O
patients	O	O
.	O	O

Because	O	O
GALT	O	O
activity	O	O
varies	O	O
in	O	O
different	O	O
tissues	O	O
of	O	O
patients	O	O
homozygous	O	O
for	O	O
S135L	O	O
,	O	O
they	O	O
may	O	O
have	O	O
a	O	O
better	O	O
clinical	O	O
outcome	O	O
than	O	O
patients	O	O
who	O	O
are	O	O
homozygous	O	O
for	O	O
Q188R	O	O
when	O	O
both	O	O
are	O	O
treated	O	O
from	O	O
infancy	O	O
.	O	O

.	O	O

Constitutive	O	O
and	O	O
regulated	O	O
modes	O	O
of	O	O
splicing	O	O
produce	O	O
six	O	O
major	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
(	O	O
DMPK	O	O
)	O	O
isoforms	O	O
with	O	O
distinct	O	O
properties	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
the	O	O
most	O	O
prevalent	O	O
inherited	B-Disease	D009468	D030342
neuromuscular	I-Disease	D009468	D030342
disease	I-Disease	D009468	D030342
in	O	O
adults	O	O
.	O	O

The	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
is	O	O
a	O	O
CTG	O	O
triplet	O	O
repeat	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
(	O	O
DMPK	O	O
)	O	O
gene	O	O
,	O	O
consisting	O	O
of	O	O
15	O	O
exons	O	O
.	O	O

Using	O	O
a	O	O
transgenic	O	O
DMPK	O	O
-	O	O
overexpressor	O	O
mouse	O	O
model	O	O
,	O	O
we	O	O
demonstrate	O	O
here	O	O
that	O	O
the	O	O
endogenous	O	O
mouse	O	O
DMPK	O	O
gene	O	O
and	O	O
the	O	O
human	O	O
DMPK	O	O
transgene	O	O
produce	O	O
six	O	O
major	O	O
alternatively	O	O
spliced	O	O
mRNAs	O	O
which	O	O
have	O	O
almost	O	O
identical	O	O
cell	O	O
type	O	O
-	O	O
dependent	O	O
distribution	O	O
frequencies	O	O
and	O	O
expression	O	O
patterns	O	O
.	O	O

Use	O	O
of	O	O
a	O	O
cryptic	O	O
5	O	O
splice	O	O
site	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
which	O	O
results	O	O
in	O	O
absence	O	O
or	O	O
presence	O	O
of	O	O
15	O	O
nucleotides	O	O
specifying	O	O
a	O	O
VSGGG	O	O
peptide	O	O
motif	O	O
,	O	O
and	O	O
/	O	O
or	O	O
use	O	O
of	O	O
a	O	O
cryptic	O	O
3	O	O
splice	O	O
site	O	O
in	O	O
exon	O	O
14	O	O
,	O	O
which	O	O
leads	O	O
to	O	O
a	O	O
frameshift	O	O
in	O	O
the	O	O
mRNA	O	O
reading	O	O
frame	O	O
,	O	O
occur	O	O
as	O	O
independent	O	O
stochastic	O	O
events	O	O
in	O	O
all	O	O
tissues	O	O
examined	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
excision	O	O
of	O	O
exons	O	O
13	O	O
/	O	O
14	O	O
that	O	O
causes	O	O
a	O	O
frameshift	O	O
and	O	O
creates	O	O
a	O	O
C	O	O
-	O	O
terminally	O	O
truncated	O	O
protein	O	O
is	O	O
clearly	O	O
cell	O	O
type	O	O
dependent	O	O
and	O	O
occurs	O	O
predominantly	O	O
in	O	O
smooth	O	O
muscle	O	O
.	O	O

We	O	O
generated	O	O
all	O	O
six	O	O
full	O	O
-	O	O
length	O	O
mouse	O	O
cDNAs	O	O
that	O	O
result	O	O
from	O	O
combinations	O	O
of	O	O
these	O	O
three	O	O
major	O	O
splicing	O	O
events	O	O
and	O	O
show	O	O
that	O	O
their	O	O
transfection	O	O
into	O	O
cells	O	O
in	O	O
culture	O	O
leads	O	O
to	O	O
production	O	O
of	O	O
four	O	O
different	O	O
approximately	O	O
74	O	O
kDa	O	O
full	O	O
-	O	O
length	O	O
(	O	O
heart	O	O
-	O	O
,	O	O
skeletal	O	O
muscle	O	O
-	O	O
or	O	O
brain	O	O
-	O	O
specific	O	O
)	O	O
and	O	O
two	O	O
C	O	O
-	O	O
terminally	O	O
truncated	O	O
approximately	O	O
68	O	O
kDa	O	O
(	O	O
smooth	O	O
muscle	O	O
-	O	O
specific	O	O
)	O	O
isoforms	O	O
.	O	O

Information	O	O
on	O	O
DMPK	O	O
mRNA	O	O
and	O	O
protein	O	O
isoform	O	O
expression	O	O
patterns	O	O
will	O	O
be	O	O
useful	O	O
for	O	O
recognizing	O	O
differential	O	O
effects	O	O
of	O	O
(	O	O
CTG	O	O
)	O	O
(	O	O
n	O	O
)	O	O
expansion	O	O
in	O	O
DM	B-Disease	D009223
manifestation	O	O
.	O	O

.	O	O

Linkage	O	O
analysis	O	O
in	O	O
a	O	O
large	O	O
Brazilian	O	O
family	O	O
with	O	O
van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
suggests	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
susceptibility	O	O
locus	O	O
for	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
at	O	O
17p11	O	O
.	O	O

2	O	O
-	O	O
11	O	O
.	O	O

1	O	O
.	O	O

van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
(	O	O
VWS	B-Disease	C536528
)	O	O
,	O	O
which	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
1q32	O	O
-	O	O
41	O	O
,	O	O
is	O	O
characterized	O	O
by	O	O
pits	B-Disease	D008047
and	I-Disease	D008047
/	I-Disease	D008047
or	I-Disease	D008047
sinuses	I-Disease	D008047
of	I-Disease	D008047
the	I-Disease	D008047
lower	I-Disease	D008047
lip	I-Disease	D008047
,	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
/	I-Disease	D002971
palate	I-Disease	D002971
(	O	O
CL	B-Disease	D002971
/	I-Disease	D002971
P	I-Disease	D002971
)	O	O
,	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
(	O	O
CP	B-Disease	D002972
)	O	O
,	O	O
bifid	B-Disease	C531732
uvula	I-Disease	C531732
,	O	O
and	O	O
hypodontia	B-Disease	D000848
(	O	O
H	B-Disease	D000848
)	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
VWS	B-Disease	C536528
,	O	O
which	O	O
has	O	O
incomplete	O	O
penetrance	O	O
,	O	O
is	O	O
highly	O	O
variable	O	O
.	O	O

Both	O	O
the	O	O
occurrence	O	O
of	O	O
CL	B-Disease	D002971
/	I-Disease	D002971
P	I-Disease	D002971
and	O	O
CP	B-Disease	D002972
within	O	O
the	O	O
same	O	O
genealogy	O	O
and	O	O
a	O	O
recurrence	O	O
risk	O	O
<	O	O
40	O	O
%	O	O
for	O	O
CP	B-Disease	D002972
among	O	O
descendants	O	O
with	O	O
VWS	B-Disease	C536528
have	O	O
suggested	O	O
that	O	O
the	O	O
development	O	O
of	O	O
clefts	B-Disease	D002971
in	O	O
this	O	O
syndrome	O	O
is	O	O
influenced	O	O
by	O	O
modifying	O	O
genes	O	O
at	O	O
other	O	O
loci	O	O
.	O	O

To	O	O
test	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
have	O	O
conducted	O	O
linkage	O	O
analysis	O	O
in	O	O
a	O	O
large	O	O
Brazilian	O	O
kindred	O	O
with	O	O
VWS	B-Disease	C536528
,	O	O
considering	O	O
as	O	O
affected	O	O
the	O	O
individuals	O	O
with	O	O
CP	B-Disease	D002972
,	O	O
regardless	O	O
of	O	O
whether	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
other	O	O
clinical	O	O
signs	O	O
of	O	O
VWS	B-Disease	C536528
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
gene	O	O
at	O	O
17p11	O	O
.	O	O

2	O	O
-	O	O
11	O	O
2	O	O
-	O	O
11	O	O
.	O	O

1	O	O
,	O	O
together	O	O
with	O	O
the	O	O
VWS	B-Disease	C536528
gene	O	O
at	O	O
1p32	O	O
-	O	O
41	O	O
,	O	O
enhances	O	O
the	O	O
probability	O	O
of	O	O
CP	B-Disease	D002972
in	O	O
an	O	O
individual	O	O
carrying	O	O
the	O	O
two	O	O
at	O	O
-	O	O
risk	O	O
genes	O	O
.	O	O

If	O	O
this	O	O
hypothesis	O	O
is	O	O
confirmed	O	O
in	O	O
other	O	O
VWS	B-Disease	C536528
pedigrees	O	O
,	O	O
it	O	O
will	O	O
represent	O	O
one	O	O
of	O	O
the	O	O
first	O	O
examples	O	O
of	O	O
a	O	O
gene	O	O
,	O	O
mapped	O	O
through	O	O
linkage	O	O
analysis	O	O
,	O	O
which	O	O
modifies	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
major	O	O
gene	O	O
.	O	O

Diverse	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
gene	O	O
cause	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
and	O	O
mild	O	O
or	O	O
severe	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
;	I-Disease	D005955
EC	I-Disease	D005955
1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

49	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
a	O	O
common	O	O
genetic	B-Disease	D030342
abnormality	I-Disease	D030342
affecting	O	O
an	O	O
estimated	O	O
400	O	O
million	O	O
people	O	O
worldwide	O	O
.	O	O

Clinical	O	O
and	O	O
biochemical	O	O
analyses	O	O
have	O	O
identified	O	O
many	O	O
variants	O	O
exhibiting	O	O
a	O	O
range	O	O
of	O	O
phenotypes	O	O
,	O	O
which	O	O
have	O	O
been	O	O
well	O	O
characterized	O	O
from	O	O
the	O	O
hematological	O	O
point	O	O
of	O	O
view	O	O
.	O	O

However	O	O
,	O	O
until	O	O
now	O	O
,	O	O
their	O	O
precise	O	O
molecular	O	O
basis	O	O
has	O	O
remained	O	O
unknown	O	O
.	O	O

We	O	O
have	O	O
cloned	O	O
and	O	O
sequenced	O	O
seven	O	O
mutant	O	O
G6PD	O	O
alleles	O	O
.	O	O

In	O	O
the	O	O
nondeficient	O	O
polymorphic	O	O
African	O	O
variant	O	O
G6PD	O	O
A	O	O
we	O	O
have	O	O
found	O	O
a	O	O
single	O	O
point	O	O
mutation	O	O
.	O	O

The	O	O
other	O	O
six	O	O
mutants	O	O
investigated	O	O
were	O	O
all	O	O
associated	O	O
with	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
.	O	O

In	O	O
one	O	O
of	O	O
the	O	O
commonest	O	O
,	O	O
G6PD	O	O
Mediterranean	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
favism	B-Disease	D005236
among	O	O
other	O	O
clinical	O	O
manifestations	O	O
,	O	O
a	O	O
single	O	O
amino	O	O
acid	O	O
replacement	O	O
was	O	O
found	O	O
(	O	O
serine	O	O
-	O	O
-	O	O
-	O	O
-	O	O
phenylalanine	O	O
)	O	O
it	O	O
must	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
decreased	O	O
stability	O	O
and	O	O
the	O	O
reduced	O	O
catalytic	O	O
efficiency	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O

Single	O	O
point	O	O
mutations	O	O
were	O	O
also	O	O
found	O	O
in	O	O
G6PD	O	O
Metaponto	O	O
(	O	O
Southern	O	O
Italy	O	O
)	O	O
and	O	O
in	O	O
G6PD	O	O
Ilesha	O	O
(	O	O
Nigeria	O	O
)	O	O
,	O	O
which	O	O
are	O	O
asymptomatic	O	O
,	O	O
and	O	O
in	O	O
G6PD	O	O
Chatham	O	O
,	O	O
which	O	O
was	O	O
observed	O	O
in	O	O
an	O	O
Indian	O	O
boy	O	O
with	O	O
neonatal	B-Disease	D007567
jaundice	I-Disease	D007567
.	O	O

In	O	O
G6PD	O	O
"	O	O
Matera	O	O
,	O	O
"	O	O
which	O	O
is	O	O
now	O	O
known	O	O
to	O	O
be	O	O
the	O	O
same	O	O
as	O	O
G6PD	O	O
A	O	O
-	O	O
,	O	O
two	O	O
separate	O	O
point	O	O
mutations	O	O
were	O	O
found	O	O
,	O	O
one	O	O
of	O	O
which	O	O
is	O	O
the	O	O
same	O	O
as	O	O
in	O	O
G6PD	O	O
A	O	O
.	O	O

In	O	O
G6PD	O	O
Santiago	O	O
,	O	O
a	O	O
de	O	O
novo	O	O
mutation	O	O
(	O	O
glycine	O	O
-	O	O
-	O	O
-	O	O
-	O	O
arginine	O	O
)	O	O
is	O	O
associated	O	O
with	O	O
severe	O	O
chronic	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

The	O	O
mutations	O	O
observed	O	O
show	O	O
a	O	O
striking	O	O
predominance	O	O
of	O	O
C	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
transitions	O	O
,	O	O
with	O	O
CG	O	O
doublets	O	O
involved	O	O
in	O	O
four	O	O
of	O	O
seven	O	O
cases	O	O
.	O	O

Thus	O	O
,	O	O
diverse	O	O
point	O	O
mutations	O	O
may	O	O
account	O	O
largely	O	O
for	O	O
the	O	O
phenotypic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

Increased	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
levels	O	O
caused	O	O
by	O	O
a	O	O
common	O	O
cholesteryl	O	O
-	O	O
ester	O	O
transfer	O	O
protein	O	O
gene	O	O
mutation	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
METHODS	O	O
.	O	O

The	O	O
plasma	O	O
cholesteryl	O	O
-	O	O
ester	O	O
transfer	O	O
protein	O	O
(	O	O
CETP	O	O
)	O	O
catalyzes	O	O
the	O	O
transfer	O	O
of	O	O
cholesteryl	O	O
esters	O	O
from	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
to	O	O
other	O	O
lipoproteins	O	O
.	O	O

We	O	O
recently	O	O
described	O	O
a	O	O
Japanese	O	O
family	O	O
with	O	O
increased	O	O
HDL	O	O
levels	O	O
and	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
due	O	O
to	O	O
a	O	O
splicing	O	O
defect	O	O
of	O	O
the	O	O
CETP	O	O
gene	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
frequency	O	O
and	O	O
phenotype	O	O
of	O	O
this	O	O
condition	O	O
,	O	O
we	O	O
screened	O	O
11	O	O
additional	O	O
families	O	O
with	O	O
high	O	O
HDL	O	O
levels	O	O
by	O	O
means	O	O
of	O	O
a	O	O
radioimmunoassay	O	O
for	O	O
CETP	O	O
and	O	O
DNA	O	O
analysis	O	O
.	O	O

RESULTS	O	O
.	O	O

We	O	O
found	O	O
the	O	O
same	O	O
CETP	O	O
gene	O	O
mutation	O	O
in	O	O
four	O	O
families	O	O
from	O	O
three	O	O
different	O	O
regions	O	O
of	O	O
Japan	O	O
.	O	O

Analysis	O	O
of	O	O
restriction	O	O
-	O	O
fragment	O	O
-	O	O
length	O	O
polymorphisms	O	O
of	O	O
the	O	O
mutant	O	O
CETP	O	O
allele	O	O
showed	O	O
that	O	O
all	O	O
probands	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
identical	O	O
haplotype	O	O
.	O	O

Family	O	O
members	O	O
homozygous	O	O
for	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
had	O	O
moderate	O	O
hypercholesterolemia	B-Disease	D006937
(	O	O
mean	O	O
total	O	O
cholesterol	O	O
level	O	O
[	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
]	O	O
,	O	O
7	O	O
.	O	O

01	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

83	O	O
mmol	O	O
per	O	O
liter	O	O
)	O	O
,	O	O
markedly	O	O
increased	O	O
levels	O	O
of	O	O
HDL	O	O
cholesterol	O	O
(	O	O
4	O	O
.	O	O

24	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

01	O	O
mmol	O	O
per	O	O
liter	O	O
)	O	O
and	O	O
apolipoprotein	O	O
A	O	O
-	O	O
I	O	O
,	O	O
and	O	O
decreased	O	O
levels	O	O
of	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
cholesterol	O	O
(	O	O
1	O	O
.	O	O

99	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

80	O	O
mmol	O	O
per	O	O
liter	O	O
)	O	O
and	O	O
apolipoprotein	O	O
B	O	O
.	O	O

Members	O	O
heterozygous	O	O
for	O	O
the	O	O
deficiency	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
,	O	O
whose	O	O
CETP	O	O
levels	O	O
were	O	O
in	O	O
the	O	O
lower	O	O
part	O	O
of	O	O
the	O	O
normal	O	O
range	O	O
,	O	O
had	O	O
moderately	O	O
increased	O	O
levels	O	O
of	O	O
HDL	O	O
cholesterol	O	O
and	O	O
apolipoprotein	O	O
A	O	O
-	O	O
I	O	O
and	O	O
an	O	O
increased	O	O
ratio	O	O
of	O	O
HDL	O	O
subclass	O	O
2	O	O
to	O	O
HDL	O	O
subclass	O	O
3	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
unaffected	O	O
family	O	O
members	O	O
(	O	O
1	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
)	O	O
.	O	O

CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
was	O	O
not	O	O
found	O	O
in	O	O
six	O	O
unrelated	O	O
subjects	O	O
with	O	O
elevated	O	O
HDL	O	O
cholesterol	O	O
levels	O	O
who	O	O
were	O	O
from	O	O
different	O	O
parts	O	O
of	O	O
the	O	O
United	O	O
States	O	O
.	O	O

CONCLUSIONS	O	O
.	O	O

CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
appears	O	O
to	O	O
be	O	O
a	O	O
frequent	O	O
cause	O	O
of	O	O
increased	O	O
HDL	O	O
levels	O	O
in	O	O
the	O	O
population	O	O
of	O	O
Japan	O	O
,	O	O
possibly	O	O
because	O	O
of	O	O
a	O	O
founder	O	O
effect	O	O
.	O	O

The	O	O
results	O	O
that	O	O
we	O	O
observed	O	O
in	O	O
heterozygotes	O	O
suggest	O	O
that	O	O
CETP	O	O
normally	O	O
plays	O	O
a	O	O
part	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
levels	O	O
of	O	O
HDL	O	O
subclass	O	O
2	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
premature	B-Disease	D050197
atherosclerosis	I-Disease	D050197
in	O	O
the	O	O
families	O	O
with	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
.	O	O

In	O	O
fact	O	O
,	O	O
the	O	O
lipoprotein	O	O
profile	O	O
of	O	O
persons	O	O
with	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
is	O	O
potentially	O	O
antiatherogenic	O	O
and	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
life	O	O
span	O	O
.	O	O

Hereditary	O	O
deficiency	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
and	O	O
recurrent	O	O
meningococcal	B-Disease	D008589
infection	I-Disease	D008589
:	O	O
investigations	O	O
of	O	O
an	O	O
Irish	O	O
family	O	O
using	O	O
a	O	O
novel	O	O
haemolytic	O	O
screening	O	O
assay	O	O
for	O	O
complement	O	O
activity	O	O
and	O	O
C7	O	O
M	O	O
/	O	O
N	O	O
allotyping	O	O
.	O	O

Terminal	B-Disease	D007153
complement	I-Disease	D007153
component	I-Disease	D007153
deficiency	I-Disease	D007153
predisposes	O	O
to	O	O
meningococcal	B-Disease	D008589
infection	I-Disease	D008589
and	O	O
is	O	O
inherited	O	O
in	O	O
an	O	O
autosomal	O	O
co	O	O
-	O	O
dominant	O	O
manner	O	O
.	O	O

An	O	O
Irish	O	O
family	O	O
is	O	O
described	O	O
,	O	O
in	O	O
which	O	O
2	O	O
of	O	O
3	O	O
brothers	O	O
had	O	O
recurrent	O	O
meningococcal	B-Disease	D008589
infection	I-Disease	D008589
.	O	O

A	O	O
novel	O	O
screening	O	O
assay	O	O
was	O	O
used	O	O
to	O	O
investigate	O	O
for	O	O
terminal	B-Disease	D007153
complement	I-Disease	D007153
deficiency	I-Disease	D007153
and	O	O
the	O	O
2	O	O
affected	O	O
brothers	O	O
were	O	O
found	O	O
to	O	O
be	O	O
completely	B-Disease	OMIM:610102
deficient	I-Disease	OMIM:610102
in	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
(	O	O
C7	O	O
)	O	O
.	O	O

Enzyme	O	O
-	O	O
linked	O	O
immunosorbent	O	O
assay	O	O
for	O	O
C7	O	O
revealed	O	O
lower	O	O
than	O	O
normal	O	O
levels	O	O
in	O	O
the	O	O
remaining	O	O
brother	O	O
and	O	O
parents	O	O
.	O	O

C7	O	O
M	O	O
/	O	O
N	O	O
protein	O	O
polymorphism	O	O
allotyping	O	O
,	O	O
used	O	O
to	O	O
investigate	O	O
the	O	O
segregation	O	O
of	O	O
the	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
genes	O	O
,	O	O
showed	O	O
that	O	O
the	O	O
apparently	O	O
complement	O	O
sufficient	O	O
brother	O	O
was	O	O
heterozygous	O	O
C7	B-Disease	OMIM:610102
deficient	I-Disease	OMIM:610102
and	O	O
a	O	O
carrier	O	O
of	O	O
one	O	O
of	O	O
the	O	O
deficiency	O	O
genes	O	O
.	O	O

Complement	O	O
screening	O	O
should	O	O
be	O	O
carried	O	O
out	O	O
in	O	O
any	O	O
individual	O	O
suffering	O	O
recurrent	O	O
meningococcal	B-Disease	D008589
infection	I-Disease	D008589
or	O	O
infection	O	O
with	O	O
an	O	O
uncommon	O	O
meningococcal	B-Disease	D008589
serogroup	O	O
.	O	O

Identification	O	O
of	O	O
complement	B-Disease	D007153
deficient	I-Disease	D007153
patients	O	O
allows	O	O
the	O	O
implementation	O	O
of	O	O
strategies	O	O
to	O	O
prevent	O	O
recurrent	O	O
infection	O	O
.	O	O

.	O	O

Mild	O	O
and	O	O
severe	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
associated	O	O
with	O	O
deletions	O	O
in	O	O
Xp21	O	O
of	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

We	O	O
have	O	O
analysed	O	O
over	O	O
300	O	O
patients	O	O
suffering	O	O
from	O	O
Duchenne	B-Disease	D020388
or	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
or	O	O
BMD	B-Disease	C537666
)	O	O
.	O	O

Deletions	O	O
have	O	O
been	O	O
characterised	O	O
which	O	O
encompass	O	O
either	O	O
the	O	O
pERT87	O	O
(	O	O
DXS164	O	O
)	O	O
locus	O	O
only	O	O
,	O	O
the	O	O
XJ1	O	O
.	O	O

1	O	O
(	O	O
DXS206	O	O
)	O	O
and	O	O
HIP25	O	O
loci	O	O
only	O	O
,	O	O
or	O	O
all	O	O
three	O	O
loci	O	O
.	O	O

These	O	O
loci	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
lie	O	O
within	O	O
the	O	O
DMD	B-Disease	D020388
region	O	O
covering	O	O
several	O	O
hundred	O	O
kilobases	O	O
(	O	O
kb	O	O
)	O	O
of	O	O
DNA	O	O
.	O	O

One	O	O
mildly	O	O
affected	O	O
BMD	B-Disease	C537666
patient	O	O
possesses	O	O
a	O	O
deletion	O	O
of	O	O
at	O	O
least	O	O
110	O	O
kb	O	O
including	O	O
exons	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

Other	O	O
patients	O	O
with	O	O
similar	O	O
exon	O	O
deletions	O	O
,	O	O
or	O	O
smaller	O	O
deletions	O	O
,	O	O
show	O	O
the	O	O
more	O	O
severe	O	O
phenotype	O	O
typical	O	O
of	O	O
DMD	B-Disease	D020388
.	O	O

We	O	O
conclude	O	O
from	O	O
these	O	O
studies	O	O
that	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
clinical	O	O
phenotype	O	O
cannot	O	O
be	O	O
explained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
size	O	O
of	O	O
the	O	O
deletion	O	O
.	O	O

We	O	O
discuss	O	O
this	O	O
in	O	O
the	O	O
context	O	O
of	O	O
candidate	O	O
gene	O	O
sequences	O	O
.	O	O

Meiotic	O	O
segregation	O	O
analysis	O	O
of	O	O
RB1	O	O
alleles	O	O
in	O	O
retinoblastoma	B-Disease	D012175
pedigrees	O	O
by	O	O
use	O	O
of	O	O
single	O	O
-	O	O
sperm	O	O
typing	O	O
.	O	O

In	O	O
hereditary	B-Disease	D012175
retinoblastoma	I-Disease	D012175
,	O	O
different	O	O
epidemiological	O	O
studies	O	O
have	O	O
indicated	O	O
a	O	O
preferential	O	O
paternal	O	O
transmission	O	O
of	O	O
mutant	O	O
retinoblastoma	B-Disease	D012175
alleles	O	O
to	O	O
offspring	O	O
,	O	O
suggesting	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
meiotic	O	O
drive	O	O
.	O	O

To	O	O
investigate	O	O
this	O	O
mechanism	O	O
,	O	O
we	O	O
analyzed	O	O
sperm	O	O
samples	O	O
from	O	O
six	O	O
individuals	O	O
from	O	O
five	O	O
unrelated	O	O
families	O	O
affected	O	O
with	O	O
hereditary	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

Single	O	O
-	O	O
sperm	O	O
typing	O	O
techniques	O	O
were	O	O
performed	O	O
for	O	O
each	O	O
sample	O	O
by	O	O
study	O	O
of	O	O
two	O	O
informative	O	O
short	O	O
tandem	O	O
repeats	O	O
located	O	O
either	O	O
in	O	O
or	O	O
close	O	O
to	O	O
the	O	O
retinoblastoma	B-Disease	D012175
gene	O	O
(	O	O
RB1	O	O
)	O	O
.	O	O

The	O	O
segregation	O	O
probability	O	O
of	O	O
mutant	O	O
RB1	O	O
alleles	O	O
in	O	O
sperm	O	O
samples	O	O
was	O	O
assessed	O	O
by	O	O
use	O	O
of	O	O
the	O	O
SPERMSEG	O	O
program	O	O
,	O	O
which	O	O
includes	O	O
experimental	O	O
parameters	O	O
,	O	O
recombination	O	O
fractions	O	O
between	O	O
the	O	O
markers	O	O
,	O	O
and	O	O
segregation	O	O
parameters	O	O
.	O	O

A	O	O
total	O	O
of	O	O
2	O	O
,	O	O
952	O	O
single	O	O
sperm	O	O
from	O	O
the	O	O
six	O	O
donors	O	O
were	O	O
analyzed	O	O
.	O	O

We	O	O
detected	O	O
a	O	O
significant	O	O
segregation	O	O
distortion	O	O
in	O	O
the	O	O
data	O	O
as	O	O
a	O	O
whole	O	O
(	O	O
P	O	O
=	O	O
.	O	O

0099	O	O
)	O	O
and	O	O
a	O	O
significant	O	O
heterogeneity	O	O
in	O	O
the	O	O
segregation	O	O
rate	O	O
across	O	O
donors	O	O
(	O	O
.	O	O

0092	O	O
)	O	O
.	O	O

Further	O	O
analysis	O	O
shows	O	O
that	O	O
this	O	O
result	O	O
can	O	O
be	O	O
explained	O	O
by	O	O
segregation	O	O
distortion	O	O
in	O	O
favor	O	O
of	O	O
the	O	O
normal	O	O
allele	O	O
in	O	O
one	O	O
donor	O	O
only	O	O
and	O	O
that	O	O
it	O	O
does	O	O
not	O	O
provide	O	O
evidence	O	O
of	O	O
a	O	O
significant	O	O
segregation	O	O
distortion	O	O
in	O	O
the	O	O
other	O	O
donors	O	O
.	O	O

The	O	O
segregation	O	O
distortion	O	O
favoring	O	O
the	O	O
mutant	O	O
RB1	O	O
allele	O	O
does	O	O
not	O	O
seem	O	O
to	O	O
occur	O	O
during	O	O
spermatogenesis	O	O
,	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
meiotic	O	O
drive	O	O
may	O	O
result	O	O
either	O	O
from	O	O
various	O	O
mechanisms	O	O
,	O	O
including	O	O
a	O	O
fertilization	O	O
advantage	O	O
or	O	O
a	O	O
better	O	O
mobility	O	O
in	O	O
sperm	O	O
bearing	O	O
a	O	O
mutant	O	O
RB1	O	O
gene	O	O
,	O	O
or	O	O
from	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
defectively	O	O
imprinted	O	O
gene	O	O
located	O	O
on	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

Functional	O	O
differences	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
product	O	O
are	O	O
associated	O	O
with	O	O
phenotypic	O	O
variation	O	O
in	O	O
patients	O	O
with	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
and	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
(	O	O
DFNB4	B-Disease	OMIM:600791
)	O	O
.	O	O

The	O	O
PDS	B-Disease	C536648
gene	O	O
encodes	O	O
a	O	O
transmembrane	O	O
protein	O	O
,	O	O
known	O	O
as	O	O
pendrin	O	O
,	O	O
which	O	O
functions	O	O
as	O	O
a	O	O
transporter	O	O
of	O	O
iodide	O	O
and	O	O
chloride	O	O
.	O	O

Mutations	O	O
in	O	O
this	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
and	O	O
autosomal	B-Disease	OMIM:600791
recessive	I-Disease	OMIM:600791
non	I-Disease	OMIM:600791
-	I-Disease	OMIM:600791
syndromic	I-Disease	OMIM:600791
hearing	I-Disease	OMIM:600791
loss	I-Disease	OMIM:600791
at	O	O
the	O	O
DFNB4	B-Disease	OMIM:600791
locus	O	O
on	O	O
chromosome	O	O
7q31	O	O
.	O	O

A	O	O
screen	O	O
of	O	O
20	O	O
individuals	O	O
from	O	O
the	O	O
midwestern	O	O
USA	O	O
with	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
and	O	O
dilated	O	O
vestibular	O	O
aqueducts	O	O
identified	O	O
three	O	O
people	O	O
(	O	O
15	O	O
%	O	O
)	O	O
with	O	O
PDS	B-Disease	C536648
mutations	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
PDS	B-Disease	C536648
mutations	O	O
in	O	O
individuals	O	O
with	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
differ	O	O
functionally	O	O
from	O	O
PDS	B-Disease	C536648
mutations	O	O
in	O	O
individuals	O	O
with	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
,	O	O
we	O	O
compared	O	O
three	O	O
common	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
allele	O	O
variants	O	O
(	O	O
L236P	O	O
,	O	O
T416P	O	O
and	O	O
E384G	O	O
)	O	O
,	O	O
with	O	O
three	O	O
PDS	B-Disease	C536648
mutations	O	O
reported	O	O
only	O	O
in	O	O
individuals	O	O
with	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
(	O	O
V480D	O	O
,	O	O
V653A	O	O
and	O	O
I490L	O	O
/	O	O
G497S	O	O
)	O	O
.	O	O

The	O	O
mutations	O	O
associated	O	O
with	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
have	O	O
complete	O	O
loss	O	O
of	O	O
pendrin	O	O
-	O	O
induced	O	O
chloride	O	O
and	O	O
iodide	O	O
transport	O	O
,	O	O
while	O	O
alleles	O	O
unique	O	O
to	O	O
people	O	O
with	O	O
DFNB4	B-Disease	OMIM:600791
are	O	O
able	O	O
to	O	O
transport	O	O
both	O	O
iodide	O	O
and	O	O
chloride	O	O
,	O	O
albeit	O	O
at	O	O
a	O	O
much	O	O
lower	O	O
level	O	O
than	O	O
wild	O	O
-	O	O
type	O	O
pendrin	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
this	O	O
residual	O	O
level	O	O
of	O	O
anion	O	O
transport	O	O
is	O	O
sufficient	O	O
to	O	O
eliminate	O	O
or	O	O
postpone	O	O
the	O	O
onset	O	O
of	O	O
goiter	B-Disease	D006042
in	O	O
individuals	O	O
with	O	O
DFNB4	B-Disease	OMIM:600791
.	O	O

We	O	O
propose	O	O
a	O	O
model	O	O
for	O	O
pendrin	O	O
function	O	O
in	O	O
the	O	O
thyroid	O	O
in	O	O
which	O	O
pendrin	O	O
transports	O	O
iodide	O	O
across	O	O
the	O	O
apical	O	O
membrane	O	O
of	O	O
the	O	O
thyrocyte	O	O
into	O	O
the	O	O
colloid	O	O
space	O	O
.	O	O

.	O	O

Late	O	O
-	O	O
onset	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
:	O	O
molecular	O	O
pathology	O	O
in	O	O
two	O	O
siblings	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
new	O	O
allele	O	O
at	O	O
the	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
locus	O	O
causing	O	O
late	O	O
-	O	O
onset	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
.	O	O

In	O	O
that	O	O
allele	O	O
arginine84	O	O
,	O	O
a	O	O
residue	O	O
that	O	O
is	O	O
highly	O	O
conserved	O	O
in	O	O
the	O	O
arylsulfatase	O	O
gene	O	O
family	O	O
,	O	O
is	O	O
replaced	O	O
by	O	O
glutamine	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
alleles	O	O
that	O	O
cause	O	O
early	O	O
-	O	O
onset	O	O
MLD	B-Disease	D007966
,	O	O
the	O	O
arginine84	O	O
to	O	O
glutamine	O	O
substitution	O	O
is	O	O
associated	O	O
with	O	O
some	O	O
residual	O	O
ARSA	O	O
activity	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
genotypes	O	O
,	O	O
ARSA	O	O
activities	O	O
,	O	O
and	O	O
clinical	O	O
data	O	O
on	O	O
4	O	O
individuals	O	O
carrying	O	O
the	O	O
allele	O	O
of	O	O
81	O	O
patients	O	O
with	O	O
MLD	B-Disease	D007966
examined	O	O
,	O	O
further	O	O
validates	O	O
the	O	O
concept	O	O
that	O	O
different	O	O
degrees	O	O
of	O	O
residual	O	O
ARSA	O	O
activity	O	O
are	O	O
the	O	O
basis	O	O
of	O	O
phenotypical	O	O
variation	O	O
in	O	O
MLD	B-Disease	D007966
.	O	O

.	O	O

Defective	O	O
CD95	O	O
/	O	O
APO	O	O
-	O	O
1	O	O
/	O	O
Fas	O	O
signal	O	O
complex	O	O
formation	O	O
in	O	O
the	O	O
human	O	O
autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
,	I-Disease	D056735
type	I-Disease	D056735
Ia	I-Disease	D056735
.	O	O

Heterozygous	O	O
mutations	O	O
in	O	O
the	O	O
CD95	O	O
(	O	O
APO	O	O
-	O	O
1	O	O
/	O	O
Fas	O	O
)	O	O
receptor	O	O
occur	O	O
in	O	O
most	O	O
individuals	O	O
with	O	O
autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
(	O	O
ALPS	B-Disease	D056735
)	O	O
and	O	O
dominantly	O	O
interfere	O	O
with	O	O
apoptosis	O	O
by	O	O
an	O	O
unknown	O	O
mechanism	O	O
.	O	O

We	O	O
show	O	O
that	O	O
local	O	O
or	O	O
global	O	O
alterations	O	O
in	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
cytoplasmic	O	O
death	O	O
domain	O	O
from	O	O
nine	O	O
independent	O	O
ALPS	B-Disease	D056735
CD95	O	O
death	O	O
-	O	O
domain	O	O
mutations	O	O
result	O	O
in	O	O
a	O	O
failure	O	O
to	O	O
bind	O	O
the	O	O
FADD	O	O
/	O	O
MORT1	O	O
signaling	O	O
protein	O	O
.	O	O

Despite	O	O
heterozygosity	O	O
for	O	O
the	O	O
abnormal	O	O
allele	O	O
,	O	O
lymphocytes	O	O
from	O	O
ALPS	B-Disease	D056735
patients	O	O
showed	O	O
markedly	O	O
decreased	O	O
FADD	O	O
association	O	O
and	O	O
a	O	O
loss	O	O
of	O	O
caspase	O	O
recruitment	O	O
and	O	O
activation	O	O
after	O	O
CD95	O	O
crosslinking	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
intracytoplasmic	O	O
CD95	O	O
mutations	O	O
in	O	O
ALPS	B-Disease	D056735
impair	O	O
apoptosis	O	O
chiefly	O	O
by	O	O
disrupting	O	O
death	O	O
-	O	O
domain	O	O
interactions	O	O
with	O	O
the	O	O
signaling	O	O
protein	O	O
FADD	O	O
/	O	O
MORT1	O	O
.	O	O

.	O	O

Classical	B-Disease	D005693
galactosemia	I-Disease	D005693
and	O	O
mutations	O	O
at	O	O
the	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyl	O	O
transferase	O	O
(	O	O
GALT	O	O
)	O	O
gene	O	O
.	O	O

Classical	B-Disease	D005693
galactosemia	I-Disease	D005693
is	O	O
caused	O	O
by	O	O
a	O	O
deficiency	O	O
in	O	O
activity	O	O
of	O	O
the	O	O
enzyme	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyl	O	O
transferase	O	O
(	O	O
GALT	O	O
)	O	O
,	O	O
which	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
at	O	O
the	O	O
GALT	O	O
gene	O	O
.	O	O

The	O	O
disorder	O	O
exhibits	O	O
considerable	O	O
allelic	O	O
heterogeneity	O	O
and	O	O
,	O	O
at	O	O
the	O	O
end	O	O
of	O	O
1998	O	O
,	O	O
more	O	O
than	O	O
150	O	O
different	O	O
base	O	O
changes	O	O
were	O	O
recorded	O	O
in	O	O
24	O	O
different	O	O
populations	O	O
and	O	O
ethnic	O	O
groups	O	O
in	O	O
15	O	O
countries	O	O
worldwide	O	O
.	O	O

The	O	O
mutations	O	O
most	O	O
frequently	O	O
cited	O	O
are	O	O
Q188R	O	O
,	O	O
K285N	O	O
,	O	O
S135L	O	O
,	O	O
and	O	O
N314D	O	O
.	O	O

Q188R	O	O
is	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
in	O	O
European	O	O
populations	O	O
or	O	O
in	O	O
those	O	O
predominantly	O	O
of	O	O
European	O	O
descent	O	O
.	O	O

Overall	O	O
,	O	O
it	O	O
accounts	O	O
for	O	O
60	O	O
-	O	O
70	O	O
%	O	O
of	O	O
mutant	O	O
chromosomes	O	O
,	O	O
but	O	O
there	O	O
are	O	O
significant	O	O
differences	O	O
in	O	O
its	O	O
relative	O	O
frequency	O	O
in	O	O
individual	O	O
populations	O	O
.	O	O

Individuals	O	O
homoallelic	O	O
for	O	O
Q188R	O	O
tend	O	O
to	O	O
have	O	O
a	O	O
severe	O	O
phenotype	O	O
and	O	O
this	O	O
is	O	O
in	O	O
keeping	O	O
with	O	O
the	O	O
virtually	O	O
complete	O	O
loss	O	O
of	O	O
enzyme	O	O
activity	O	O
observed	O	O
in	O	O
in	O	O
vitro	O	O
expression	O	O
systems	O	O
.	O	O

Globally	O	O
,	O	O
K285N	O	O
is	O	O
rarer	O	O
,	O	O
but	O	O
in	O	O
many	O	O
European	O	O
populations	O	O
it	O	O
can	O	O
be	O	O
found	O	O
on	O	O
25	O	O
-	O	O
40	O	O
%	O	O
of	O	O
mutant	O	O
chromosomes	O	O
.	O	O

It	O	O
is	O	O
invariably	O	O
associated	O	O
with	O	O
a	O	O
severe	O	O
phenotype	O	O
.	O	O

S135L	O	O
is	O	O
found	O	O
almost	O	O
exclusively	O	O
in	O	O
African	O	O
Americans	O	O
.	O	O

In	O	O
vitro	O	O
expression	O	O
results	O	O
are	O	O
discrepant	O	O
,	O	O
but	O	O
some	O	O
individuals	O	O
carrying	O	O
S135L	O	O
appear	O	O
to	O	O
exhibit	O	O
GALT	O	O
activity	O	O
in	O	O
some	O	O
tissues	O	O
.	O	O

Duarte	O	O
1	O	O
(	O	O
or	O	O
Los	O	O
Angeles	O	O
)	O	O
and	O	O
Duarte	O	O
2	O	O
(	O	O
or	O	O
Duarte	O	O
)	O	O
variants	O	O
carry	O	O
the	O	O
same	O	O
amino	O	O
acid	O	O
substitution	O	O
,	O	O
N314D	O	O
,	O	O
even	O	O
though	O	O
D1	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
erythrocyte	O	O
GALT	O	O
activity	O	O
and	O	O
D2	O	O
with	O	O
reduced	O	O
activity	O	O
.	O	O

N314D	O	O
is	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
with	O	O
other	O	O
base	O	O
changes	O	O
that	O	O
differ	O	O
on	O	O
the	O	O
D1	O	O
and	O	O
D2	O	O
alleles	O	O
.	O	O

N314D	O	O
does	O	O
not	O	O
impair	O	O
GALT	O	O
activity	O	O
in	O	O
in	O	O
vitro	O	O
expression	O	O
systems	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
differences	O	O
in	O	O
the	O	O
abundance	O	O
of	O	O
GALT	O	O
protein	O	O
in	O	O
lymphoblastoid	O	O
cells	O	O
lines	O	O
from	O	O
D2	O	O
and	O	O
D1	O	O
individuals	O	O
.	O	O

It	O	O
is	O	O
unclear	O	O
whether	O	O
the	O	O
specific	O	O
molecular	O	O
changes	O	O
that	O	O
distinguish	O	O
the	O	O
D1	O	O
and	O	O
D2	O	O
alleles	O	O
account	O	O
for	O	O
the	O	O
different	O	O
activities	O	O
.	O	O

The	O	O
considerable	O	O
genetic	O	O
heterogeneity	O	O
documented	O	O
to	O	O
date	O	O
undoubtedly	O	O
contributes	O	O
to	O	O
the	O	O
phenotypic	O	O
heterogeneity	O	O
that	O	O
is	O	O
observed	O	O
in	O	O
galactosemia	B-Disease	D005693
.	O	O

The	O	O
additional	O	O
effects	O	O
of	O	O
nonallelic	O	O
variation	O	O
and	O	O
other	O	O
constitutional	O	O
factors	O	O
on	O	O
phenotypic	O	O
variability	O	O
remain	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

.	O	O

X	B-Disease	D041441
-	I-Disease	D041441
linked	I-Disease	D041441
retinoschisis	I-Disease	D041441
with	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
XLRS1	O	O
gene	O	O
.	O	O

BACKGROUND	O	O
X	B-Disease	D041441
-	I-Disease	D041441
linked	I-Disease	D041441
retinoschisis	I-Disease	D041441
(	O	O
XLRS	B-Disease	D041441
)	O	O
is	O	O
a	O	O
relatively	O	O
rare	O	O
vitreoretinal	B-Disease	D058499
dystrophy	I-Disease	D058499
that	O	O
causes	O	O
visual	B-Disease	C531604
loss	I-Disease	C531604
in	O	O
young	O	O
men	O	O
.	O	O

Recently	O	O
,	O	O
a	O	O
gene	O	O
responsible	O	O
for	O	O
this	O	O
disease	O	O
,	O	O
designated	O	O
XLRS1	O	O
,	O	O
was	O	O
identified	O	O
,	O	O
and	O	O
several	O	O
deleterious	O	O
gene	O	O
mutations	O	O
were	O	O
reported	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
analyze	O	O
Japanese	O	O
patients	O	O
clinically	O	O
diagnosed	O	O
as	O	O
having	O	O
XLRS	B-Disease	D041441
formutational	O	O
changes	O	O
in	O	O
the	O	O
XLRS1	O	O
gene	O	O
.	O	O

METHODS	O	O
Ten	O	O
patients	O	O
with	O	O
XLRS	B-Disease	D041441
underwent	O	O
full	O	O
ophthalmologic	O	O
examination	O	O
,	O	O
including	O	O
slitlamp	O	O
biomicroscopy	O	O
and	O	O
dilated	O	O
funduscopy	O	O
.	O	O

Genomic	O	O
DNA	O	O
was	O	O
isolated	O	O
from	O	O
leukocytes	O	O
,	O	O
and	O	O
all	O	O
exons	O	O
of	O	O
the	O	O
XLRS1	O	O
gene	O	O
were	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
analyzed	O	O
using	O	O
a	O	O
direct	O	O
sequencing	O	O
method	O	O
.	O	O

RESULTS	O	O
Point	O	O
mutations	O	O
in	O	O
the	O	O
XLRS1	O	O
gene	O	O
were	O	O
identified	O	O
in	O	O
all	O	O
10	O	O
patients	O	O
.	O	O

The	O	O
mutations	O	O
were	O	O
identical	O	O
in	O	O
each	O	O
of	O	O
2	O	O
pairs	O	O
of	O	O
brothers	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
point	O	O
mutations	O	O
represented	O	O
missense	O	O
mutations	O	O
,	O	O
1	O	O
was	O	O
a	O	O
nonsense	O	O
mutation	O	O
,	O	O
and	O	O
1	O	O
was	O	O
a	O	O
frameshift	O	O
mutation	O	O
.	O	O

Five	O	O
of	O	O
the	O	O
mutations	O	O
are	O	O
newly	O	O
reported	O	O
herein	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
discovery	O	O
of	O	O
new	O	O
point	O	O
mutations	O	O
in	O	O
this	O	O
study	O	O
increases	O	O
the	O	O
available	O	O
information	O	O
regarding	O	O
the	O	O
spectrum	O	O
of	O	O
genetic	B-Disease	D030342
abnormalities	I-Disease	D030342
and	O	O
clinical	O	O
manifestations	O	O
of	O	O
XLRS	B-Disease	D041441
.	O	O

However	O	O
,	O	O
the	O	O
limited	O	O
data	O	O
failed	O	O
to	O	O
reveal	O	O
a	O	O
correlation	O	O
between	O	O
mutation	O	O
and	O	O
disease	O	O
phenotype	O	O
.	O	O

CLINICAL	O	O
RELEVANCE	O	O
Identification	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
XLRS1	O	O
gene	O	O
and	O	O
expanded	O	O
information	O	O
on	O	O
clinical	O	O
manifestations	O	O
will	O	O
facilitate	O	O
early	O	O
diagnosis	O	O
,	O	O
appropriate	O	O
early	O	O
therapy	O	O
,	O	O
and	O	O
genetic	O	O
counseling	O	O
regarding	O	O
the	O	O
prognosis	O	O
of	O	O
XLRS	B-Disease	D041441
.	O	O

.	O	O

Relationship	O	O
among	O	O
genotype	O	O
,	O	O
biochemical	O	O
phenotype	O	O
,	O	O
and	O	O
cognitive	O	O
performance	O	O
in	O	O
females	O	O
with	O	O
phenylalanine	B-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
deficiency	I-Disease	OMIM:261600
:	O	O
report	O	O
from	O	O
the	O	O
Maternal	B-Disease	D017042
Phenylketonuria	I-Disease	D017042
Collaborative	O	O
Study	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
examine	O	O
the	O	O
relationship	O	O
of	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
genotypes	O	O
to	O	O
biochemical	O	O
phenotype	O	O
and	O	O
cognitive	O	O
development	O	O
in	O	O
maternal	B-Disease	D017042
phenylketonuria	I-Disease	D017042
(	O	O
PKU	B-Disease	D010661
)	O	O
.	O	O

METHODOLOGY	O	O
PAH	O	O
gene	O	O
mutations	O	O
were	O	O
examined	O	O
in	O	O
222	O	O
hyperphenylalaninemic	B-Disease	D010661
females	O	O
enrolled	O	O
in	O	O
the	O	O
Maternal	B-Disease	D017042
PKU	I-Disease	D017042
Collaborative	O	O
Study	O	O
(	O	O
MPKUCS	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
84	O	O
different	O	O
mutations	O	O
were	O	O
detected	O	O
,	O	O
and	O	O
complete	O	O
genotype	O	O
was	O	O
obtained	O	O
in	O	O
199	O	O
individuals	O	O
.	O	O

Based	O	O
on	O	O
previous	O	O
knowledge	O	O
about	O	O
mutation	O	O
-	O	O
phenotype	O	O
associations	O	O
,	O	O
78	O	O
of	O	O
the	O	O
mutations	O	O
could	O	O
be	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
four	O	O
classes	O	O
of	O	O
severity	O	O
(	O	O
severe	O	O
PKU	B-Disease	D010661
,	O	O
moderate	O	O
PKU	B-Disease	D010661
,	O	O
mild	O	O
PKU	B-Disease	D010661
,	O	O
and	O	O
mild	B-Disease	D010661
hyperphenylalaninemia	I-Disease	D010661
[	O	O
MHP	B-Disease	D010661
]	O	O
)	O	O
.	O	O

Then	O	O
,	O	O
189	O	O
MPKUCS	O	O
subjects	O	O
were	O	O
grouped	O	O
according	O	O
to	O	O
the	O	O
various	O	O
combinations	O	O
of	O	O
mutation	O	O
classifications	O	O
.	O	O

The	O	O
sample	O	O
sizes	O	O
were	O	O
large	O	O
enough	O	O
for	O	O
statistical	O	O
testing	O	O
in	O	O
four	O	O
groups	O	O
with	O	O
at	O	O
least	O	O
one	O	O
mutation	O	O
that	O	O
completely	O	O
abolishes	O	O
enzyme	O	O
activity	O	O
.	O	O

These	O	O
patients	O	O
are	O	O
considered	O	O
functionally	O	O
hemizygous	O	O
.	O	O

RESULTS	O	O
The	O	O
biochemical	O	O
phenotype	O	O
predicted	O	O
from	O	O
the	O	O
genotype	O	O
in	O	O
functionally	O	O
hemizygous	O	O
patients	O	O
was	O	O
related	O	O
significantly	O	O
to	O	O
the	O	O
assigned	O	O
phenylalanine	O	O
level	O	O
.	O	O

Cognitive	O	O
performance	O	O
(	O	O
IQ	O	O
)	O	O
was	O	O
also	O	O
significantly	O	O
related	O	O
to	O	O
genotype	O	O
.	O	O

The	O	O
IQ	O	O
of	O	O
PAH	B-Disease	OMIM:261600
-	I-Disease	OMIM:261600
deficient	I-Disease	OMIM:261600
mothers	O	O
with	O	O
a	O	O
severe	O	O
PKU	B-Disease	D010661
mutation	O	O
in	O	O
combination	O	O
with	O	O
a	O	O
MHP	B-Disease	D010661
mutation	O	O
or	O	O
a	O	O
mild	O	O
PKU	B-Disease	D010661
mutation	O	O
was	O	O
99	O	O
and	O	O
96	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
the	O	O
IQ	O	O
of	O	O
PKU	B-Disease	D010661
mothers	O	O
with	O	O
two	O	O
severe	O	O
PKU	B-Disease	D010661
mutations	O	O
or	O	O
with	O	O
one	O	O
severe	O	O
and	O	O
one	O	O
moderate	O	O
PKU	B-Disease	D010661
mutation	O	O
was	O	O
83	O	O
and	O	O
84	O	O
,	O	O
respectively	O	O
.	O	O

Of	O	O
the	O	O
patients	O	O
with	O	O
PKU	B-Disease	D010661
,	O	O
92	O	O
%	O	O
had	O	O
been	O	O
treated	O	O
during	O	O
childhood	O	O
.	O	O

Those	O	O
who	O	O
were	O	O
untreated	O	O
or	O	O
treated	O	O
late	O	O
had	O	O
lower	O	O
than	O	O
average	O	O
IQ	O	O
scores	O	O
for	O	O
their	O	O
group	O	O
of	O	O
mutation	O	O
combinations	O	O
.	O	O

Females	O	O
with	O	O
moderate	O	O
or	O	O
mild	O	O
PKU	B-Disease	D010661
who	O	O
were	O	O
treated	O	O
early	O	O
and	O	O
treated	O	O
for	O	O
>	O	O
6	O	O
years	O	O
showed	O	O
IQ	O	O
scores	O	O
10	O	O
points	O	O
above	O	O
average	O	O
for	O	O
their	O	O
group	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
reproductive	O	O
outcome	O	O
in	O	O
maternal	B-Disease	D017042
phenylketonuria	I-Disease	D017042
is	O	O
dependent	O	O
on	O	O
prenatal	O	O
metabolic	O	O
control	O	O
and	O	O
postnatal	O	O
environmental	O	O
circumstances	O	O
.	O	O

Both	O	O
factors	O	O
depend	O	O
on	O	O
the	O	O
intellectual	O	O
resources	O	O
of	O	O
the	O	O
mother	O	O
with	O	O
PKU	B-Disease	D010661
.	O	O

The	O	O
significant	O	O
relationship	O	O
among	O	O
genotype	O	O
,	O	O
biochemical	O	O
phenotype	O	O
,	O	O
and	O	O
cognitive	O	O
performance	O	O
observed	O	O
in	O	O
the	O	O
present	O	O
study	O	O
is	O	O
of	O	O
importance	O	O
for	O	O
the	O	O
development	O	O
of	O	O
an	O	O
optimal	O	O
strategy	O	O
for	O	O
future	O	O
treatment	O	O
of	O	O
females	O	O
with	O	O
PKU	B-Disease	D010661
who	O	O
plan	O	O
pregnancy	O	O
.	O	O

.	O	O

Uncoupling	O	O
of	O	O
hypomyelination	B-Disease	D003711
and	O	O
glial	B-Disease	D004194
cell	I-Disease	D004194
death	I-Disease	D004194
by	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
proteolipid	O	O
protein	O	O
gene	O	O
.	O	O

Proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
;	O	O
M	O	O
(	O	O
r	O	O
)	O	O
30	O	O
,	O	O
000	O	O
)	O	O
is	O	O
a	O	O
highly	O	O
conserved	O	O
major	O	O
polytopic	O	O
membrane	O	O
protein	O	O
in	O	O
myelin	O	O
but	O	O
its	O	O
cellular	O	O
function	O	O
remains	O	O
obscure	O	O
.	O	O

Neurological	O	O
mutant	O	O
mice	O	O
can	O	O
often	O	O
provide	O	O
model	O	O
systems	O	O
for	O	O
human	O	O
genetic	B-Disease	D030342
disorders	I-Disease	D030342
.	O	O

Mutations	O	O
of	O	O
the	O	O
X	O	O
-	O	O
chromosome	O	O
-	O	O
linked	O	O
PLP	O	O
gene	O	O
are	O	O
lethal	O	O
,	O	O
identified	O	O
first	O	O
in	O	O
the	O	O
jimpy	O	O
mouse	O	O
and	O	O
subsequently	O	O
in	O	O
patients	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

The	O	O
unexplained	O	O
phenotype	O	O
of	O	O
these	O	O
mutations	O	O
includes	O	O
degeneration	B-Disease	D056784
and	I-Disease	D056784
premature	I-Disease	D056784
cell	I-Disease	D056784
death	I-Disease	D056784
of	I-Disease	D056784
oligodendrocytes	I-Disease	D056784
with	O	O
associated	O	O
hypomyelination	B-Disease	D003711
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
a	O	O
new	O	O
mouse	O	O
mutant	O	O
rumpshaker	O	O
is	O	O
defined	O	O
by	O	O
the	O	O
amino	O	O
-	O	O
acid	O	O
substitution	O	O
Ile	O	O
-	O	O
to	O	O
-	O	O
Thr	O	O
at	O	O
residue	O	O
186	O	O
in	O	O
a	O	O
membrane	O	O
-	O	O
embedded	O	O
domain	O	O
of	O	O
PLP	O	O
.	O	O

Surprisingly	O	O
,	O	O
rumpshaker	O	O
mice	O	O
,	O	O
although	O	O
myelin	B-Disease	D003711
-	I-Disease	D003711
deficient	I-Disease	D003711
,	O	O
have	O	O
normal	O	O
longevity	O	O
and	O	O
a	O	O
full	O	O
complement	O	O
of	O	O
morphologically	O	O
normal	O	O
oligodendrocytes	O	O
.	O	O

Hypomyelination	B-Disease	D003711
can	O	O
thus	O	O
be	O	O
genetically	O	O
separated	O	O
from	O	O
the	O	O
PLP	O	O
-	O	O
dependent	O	O
oligodendrocyte	B-Disease	D056784
degeneration	I-Disease	D056784
.	O	O

We	O	O
suggest	O	O
that	O	O
PLP	O	O
has	O	O
a	O	O
vital	O	O
function	O	O
in	O	O
glial	O	O
cell	O	O
development	O	O
,	O	O
distinct	O	O
from	O	O
its	O	O
later	O	O
role	O	O
in	O	O
myelin	O	O
assembly	O	O
,	O	O
and	O	O
that	O	O
this	O	O
dichotomy	O	O
of	O	O
action	O	O
may	O	O
explain	O	O
the	O	O
clinical	O	O
spectrum	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

.	O	O

Mutational	O	O
analysis	O	O
of	O	O
the	O	O
HGO	O	O
gene	O	O
in	O	O
Finnish	O	O
alkaptonuria	B-Disease	D000474
patients	O	O
.	O	O

Alkaptonuria	B-Disease	D000474
(	O	O
AKU	B-Disease	D000474
)	O	O
,	O	O
the	O	O
prototypic	O	O
inborn	B-Disease	D008661
error	I-Disease	D008661
of	I-Disease	D008661
metabolism	I-Disease	D008661
,	O	O
has	O	O
recently	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
loss	O	O
of	O	O
function	O	O
mutations	O	O
in	O	O
the	O	O
homogentisate	O	O
-	O	O
1	O	O
,	O	O
2	O	O
-	O	O
dioxygenase	O	O
gene	O	O
(	O	O
HGO	O	O
)	O	O
.	O	O

So	O	O
far	O	O
17	O	O
mutations	O	O
have	O	O
been	O	O
characterised	O	O
in	O	O
AKU	B-Disease	D000474
patients	O	O
of	O	O
different	O	O
ethnic	O	O
origin	O	O
.	O	O

We	O	O
describe	O	O
three	O	O
novel	O	O
mutations	O	O
(	O	O
R58fs	O	O
,	O	O
R330S	O	O
,	O	O
and	O	O
H371R	O	O
)	O	O
and	O	O
one	O	O
common	O	O
AKU	B-Disease	D000474
mutation	O	O
(	O	O
M368V	O	O
)	O	O
,	O	O
detected	O	O
by	O	O
mutational	O	O
and	O	O
polymorphism	O	O
analysis	O	O
of	O	O
the	O	O
HGO	O	O
gene	O	O
in	O	O
five	O	O
Finnish	O	O
AKU	B-Disease	D000474
pedigrees	O	O
.	O	O

The	O	O
three	O	O
novel	O	O
AKU	B-Disease	D000474
mutations	O	O
are	O	O
most	O	O
likely	O	O
specific	O	O
for	O	O
the	O	O
Finnish	O	O
population	O	O
and	O	O
have	O	O
originated	O	O
recently	O	O
.	O	O

.	O	O

Putative	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
gene	O	O
shares	O	O
unexpected	O	O
homology	O	O
with	O	O
ABC	O	O
transporters	O	O
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disease	I-Disease	D040181
affecting	O	O
1	O	O
/	O	O
20	O	O
,	O	O
000	O	O
males	O	O
either	O	O
as	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
in	O	O
childhood	O	O
or	O	O
as	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
in	O	O
adults	O	O
.	O	O

Childhood	O	O
ALD	B-Disease	D000326
is	O	O
the	O	O
more	O	O
severe	O	O
form	O	O
,	O	O
with	O	O
onset	O	O
of	O	O
neurological	O	O
symptoms	O	O
between	O	O
5	O	O
-	O	O
12	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Central	B-Disease	D003711
nervous	I-Disease	D003711
system	I-Disease	D003711
demyelination	I-Disease	D003711
progresses	O	O
rapidly	O	O
and	O	O
death	O	O
occurs	O	O
within	O	O
a	O	O
few	O	O
years	O	O
.	O	O

AMN	B-Disease	D000326
is	O	O
a	O	O
milder	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
with	O	O
onset	O	O
at	O	O
15	O	O
-	O	O
30	O	O
years	O	O
of	O	O
age	O	O
and	O	O
a	O	O
more	O	O
progressive	O	O
course	O	O
.	O	O

Adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
(	O	O
Addisons	B-Disease	D000224
disease	I-Disease	D000224
)	O	O
may	O	O
remain	O	O
the	O	O
only	O	O
clinical	O	O
manifestation	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

The	O	O
principal	O	O
biochemical	O	O
abnormality	O	O
of	O	O
ALD	B-Disease	D000326
is	O	O
the	O	O
accumulation	O	O
of	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
(	O	O
VLCFA	O	O
)	O	O
because	O	O
of	O	O
impaired	O	O
beta	O	O
-	O	O
oxidation	O	O
in	O	O
peroxisomes	O	O
.	O	O

The	O	O
normal	O	O
oxidation	O	O
of	O	O
VLCFA	O	O
-	O	O
CoA	O	O
in	O	O
patients	O	O
fibroblasts	O	O
suggested	O	O
that	O	O
the	O	O
gene	O	O
coding	O	O
for	O	O
the	O	O
VLCFA	O	O
-	O	O
CoA	O	O
synthetase	O	O
could	O	O
be	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
ALD	B-Disease	D000326
.	O	O

Here	O	O
we	O	O
use	O	O
positional	O	O
cloning	O	O
to	O	O
identify	O	O
a	O	O
gene	O	O
partially	O	O
deleted	O	O
in	O	O
6	O	O
of	O	O
85	O	O
independent	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
.	O	O

In	O	O
familial	O	O
cases	O	O
,	O	O
the	O	O
deletions	O	O
segregated	O	O
with	O	O
the	O	O
disease	O	O
.	O	O

An	O	O
identical	O	O
deletion	O	O
was	O	O
detected	O	O
in	O	O
two	O	O
brothers	O	O
presenting	O	O
with	O	O
different	O	O
clinical	O	O
ALD	B-Disease	D000326
phenotypes	O	O
.	O	O

Candidate	O	O
exons	O	O
were	O	O
identified	O	O
by	O	O
computer	O	O
analysis	O	O
of	O	O
genomic	O	O
sequences	O	O
and	O	O
used	O	O
to	O	O
isolate	O	O
complementary	O	O
DNAs	O	O
by	O	O
exon	O	O
connection	O	O
and	O	O
screening	O	O
of	O	O
cDNA	O	O
libraries	O	O
.	O	O

The	O	O
deduced	O	O
protein	O	O
sequence	O	O
shows	O	O
significant	O	O
sequence	O	O
identity	O	O
to	O	O
a	O	O
peroxisomal	O	O
membrane	O	O
protein	O	O
of	O	O
M	O	O
(	O	O
r	O	O
)	O	O
70K	O	O
that	O	O
is	O	O
involved	O	O
in	O	O
peroxisome	O	O
biogenesis	O	O
and	O	O
belongs	O	O
to	O	O
the	O	O
ATP	O	O
-	O	O
binding	O	O
cassette	O	O
superfamily	O	O
of	O	O
transporters	O	O
.	O	O

.	O	O

Cardiac	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
channel	O	O
dysfunction	O	O
in	O	O
Brugada	B-Disease	D053840
syndrome	I-Disease	D053840
is	O	O
aggravated	O	O
by	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
-	O	O
subunit	O	O
.	O	O

BACKGROUND	O	O
Mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
human	O	O
cardiac	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
channel	O	O
alpha	O	O
-	O	O
subunit	O	O
(	O	O
hH1	O	O
)	O	O
are	O	O
responsible	O	O
for	O	O
chromosome	O	O
3	O	O
-	O	O
linked	O	O
congenital	B-Disease	D008133
long	I-Disease	D008133
-	I-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
(	O	O
LQT3	B-Disease	C537034
)	O	O
and	O	O
idiopathic	B-Disease	C537182
ventricular	I-Disease	C537182
fibrillation	I-Disease	C537182
(	O	O
IVF	B-Disease	C537182
)	O	O
.	O	O

An	O	O
auxiliary	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
-	O	O
subunit	O	O
,	O	O
widely	O	O
expressed	O	O
in	O	O
excitable	O	O
tissues	O	O
,	O	O
shifts	O	O
the	O	O
voltage	O	O
dependence	O	O
of	O	O
steady	O	O
-	O	O
state	O	O
inactivation	O	O
toward	O	O
more	O	O
negative	O	O
potentials	O	O
and	O	O
restores	O	O
normal	O	O
gating	O	O
kinetics	O	O
of	O	O
brain	O	O
and	O	O
skeletal	O	O
muscle	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
channels	O	O
expressed	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
but	O	O
has	O	O
little	O	O
if	O	O
any	O	O
functional	O	O
effect	O	O
on	O	O
the	O	O
cardiac	O	O
isoform	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
characterize	O	O
the	O	O
altered	O	O
effects	O	O
of	O	O
a	O	O
human	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
-	O	O
subunit	O	O
(	O	O
hbeta	O	O
(	O	O
1	O	O
)	O	O
)	O	O
on	O	O
the	O	O
heterologously	O	O
expressed	O	O
hH1	O	O
mutation	O	O
(	O	O
T1620M	O	O
)	O	O
previously	O	O
associated	O	O
with	O	O
IVF	B-Disease	C537182
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
When	O	O
expressed	O	O
alone	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
,	O	O
T1620M	O	O
exhibited	O	O
no	O	O
persistent	O	O
currents	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
LQT3	B-Disease	C537034
mutant	O	O
channels	O	O
,	O	O
but	O	O
the	O	O
midpoint	O	O
of	O	O
steady	O	O
-	O	O
state	O	O
inactivation	O	O
(	O	O
V	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
)	O	O
was	O	O
significantly	O	O
shifted	O	O
toward	O	O
more	O	O
positive	O	O
potentials	O	O
than	O	O
for	O	O
wild	O	O
-	O	O
type	O	O
hH1	O	O
.	O	O

Coexpression	O	O
of	O	O
hbeta	O	O
(	O	O
1	O	O
)	O	O
did	O	O
not	O	O
significantly	O	O
alter	O	O
current	O	O
decay	O	O
or	O	O
recovery	O	O
from	O	O
inactivation	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
hH1	O	O
;	O	O
however	O	O
,	O	O
it	O	O
further	O	O
shifted	O	O
the	O	O
V	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
and	O	O
accelerated	O	O
the	O	O
recovery	O	O
from	O	O
inactivation	O	O
of	O	O
T1620M	O	O
.	O	O

Oocyte	O	O
macropatch	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
activation	O	O
kinetics	O	O
of	O	O
T1620M	O	O
were	O	O
normal	O	O
.	O	O

CONCLUSIONS	O	O
It	O	O
is	O	O
suggested	O	O
that	O	O
coexpression	O	O
of	O	O
hbeta	O	O
(	O	O
1	O	O
)	O	O
exposes	O	O
a	O	O
more	O	O
severe	O	O
functional	O	O
defect	O	O
that	O	O
results	O	O
in	O	O
a	O	O
greater	O	O
overlap	O	O
in	O	O
the	O	O
relationship	O	O
between	O	O
channel	O	O
inactivation	O	O
and	O	O
activation	O	O
(	O	O
window	O	O
current	O	O
)	O	O
in	O	O
T1620M	O	O
,	O	O
which	O	O
is	O	O
proposed	O	O
to	O	O
be	O	O
a	O	O
potential	O	O
pathophysiological	O	O
mechanism	O	O
of	O	O
IVF	B-Disease	C537182
in	O	O
vivo	O	O
.	O	O

One	O	O
possible	O	O
explanation	O	O
for	O	O
our	O	O
finding	O	O
is	O	O
an	O	O
altered	O	O
alpha	O	O
-	O	O
/	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
-	O	O
subunit	O	O
association	O	O
in	O	O
the	O	O
mutant	O	O
.	O	O

.	O	O

Autosomal	B-Disease	OMIM:125700
recessive	I-Disease	OMIM:125700
familial	I-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
with	O	O
continued	O	O
secretion	O	O
of	O	O
mutant	O	O
weakly	O	O
active	O	O
vasopressin	O	O
.	O	O

Familial	B-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
post	O	O
-	O	O
natal	O	O
development	O	O
of	O	O
arginine	B-Disease	OMIM:125700
vasopressin	I-Disease	OMIM:125700
(	I-Disease	OMIM:125700
AVP	I-Disease	OMIM:125700
)	I-Disease	OMIM:125700
deficiency	I-Disease	OMIM:125700
due	O	O
to	O	O
mutations	O	O
in	O	O
the	O	O
AVP	O	O
gene	O	O
.	O	O

All	O	O
published	O	O
mutations	O	O
affect	O	O
the	O	O
signal	O	O
peptide	O	O
or	O	O
the	O	O
neurophysin	O	O
-	O	O
II	O	O
carrier	O	O
protein	O	O
and	O	O
are	O	O
presumed	O	O
to	O	O
interfere	O	O
with	O	O
processing	O	O
of	O	O
the	O	O
preprohormone	O	O
,	O	O
leading	O	O
to	O	O
neuronal	B-Disease	D009410
damage	I-Disease	D009410
.	O	O

We	O	O
studied	O	O
an	O	O
unusual	O	O
Palestinian	O	O
family	O	O
consisting	O	O
of	O	O
asymptomatic	O	O
first	O	O
cousin	O	O
parents	O	O
and	O	O
three	O	O
children	O	O
affected	O	O
with	O	O
neurohypophyseal	B-Disease	D020790
diabetes	I-Disease	D020790
insipidus	I-Disease	D020790
,	O	O
suggesting	O	O
autosomal	O	O
recessive	O	O
inheritance	O	O
.	O	O

All	O	O
three	O	O
affected	O	O
children	O	O
were	O	O
homozygous	O	O
and	O	O
the	O	O
parents	O	O
heterozygous	O	O
for	O	O
a	O	O
single	O	O
novel	O	O
mutation	O	O
(	O	O
C301	O	O
-	O	O
>	O	O
T	O	O
)	O	O
in	O	O
exon	O	O
1	O	O
,	O	O
replacing	O	O
Pro7	O	O
of	O	O
mature	O	O
AVP	O	O
with	O	O
Leu	O	O
(	O	O
Leu	O	O
-	O	O
AVP	O	O
)	O	O
.	O	O

Leu	O	O
-	O	O
AVP	O	O
was	O	O
a	O	O
weak	O	O
agonist	O	O
with	O	O
approximately	O	O
30	O	O
-	O	O
fold	O	O
reduced	O	O
binding	O	O
to	O	O
the	O	O
human	O	O
V2	O	O
receptor	O	O
.	O	O

Measured	O	O
by	O	O
radioimmunoassay	O	O
with	O	O
a	O	O
synthetic	O	O
Leu	O	O
-	O	O
AVP	O	O
standard	O	O
,	O	O
serum	O	O
Leu	O	O
-	O	O
AVP	O	O
levels	O	O
were	O	O
elevated	O	O
in	O	O
all	O	O
three	O	O
children	O	O
and	O	O
further	O	O
increased	O	O
during	O	O
water	O	O
deprivation	O	O
to	O	O
as	O	O
high	O	O
as	O	O
30	O	O
times	O	O
normal	O	O
.	O	O

The	O	O
youngest	O	O
child	O	O
(	O	O
2	O	O
years	O	O
old	O	O
)	O	O
was	O	O
only	O	O
mildly	O	O
affected	O	O
but	O	O
had	O	O
Leu	O	O
-	O	O
AVP	O	O
levels	O	O
similar	O	O
to	O	O
her	O	O
severely	O	O
affected	O	O
8	O	O
-	O	O
year	O	O
-	O	O
old	O	O
brother	O	O
,	O	O
suggesting	O	O
that	O	O
unknown	O	O
mechanisms	O	O
may	O	O
partially	O	O
compensate	O	O
for	O	O
a	O	O
deficiency	B-Disease	OMIM:125700
of	I-Disease	OMIM:125700
active	I-Disease	OMIM:125700
AVP	I-Disease	OMIM:125700
in	O	O
very	O	O
young	O	O
children	O	O
.	O	O

.	O	O

Autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
linked	O	O
to	O	O
the	O	O
chromosome	O	O
11p13	O	O
markers	O	O
catalase	O	O
and	O	O
D11S151	O	O
in	O	O
a	O	O
large	O	O
Dutch	O	O
family	O	O
.	O	O

In	O	O
a	O	O
large	O	O
pedigree	O	O
with	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
,	O	O
we	O	O
found	O	O
close	O	O
linkage	O	O
between	O	O
the	O	O
aniridia	B-Disease	D015783
locus	O	O
AN2	O	O
and	O	O
the	O	O
markers	O	O
catalase	O	O
(	O	O
CAT	O	O
)	O	O
(	O	O
zeta	O	O
=	O	O
7	O	O
.	O	O

27	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
)	O	O
and	O	O
D11S151	O	O
(	O	O
zeta	O	O
=	O	O
3	O	O
.	O	O

86	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

10	O	O
)	O	O
flanking	O	O
the	O	O
AN2	O	O
locus	O	O
on	O	O
11p13	O	O
.	O	O

Positive	O	O
lod	O	O
scores	O	O
were	O	O
also	O	O
obtained	O	O
for	O	O
the	O	O
11p13	O	O
-	O	O
-	O	O
-	O	O
-	O	O
11p14	O	O
markers	O	O
D11S16	O	O
and	O	O
FSHB	O	O
with	O	O
the	O	O
linkage	O	O
group	O	O
CAT	O	O
/	O	O
AN2	O	O
/	O	O
D11S151	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
in	O	O
this	O	O
family	O	O
is	O	O
due	O	O
to	O	O
a	O	O
mutation	O	O
at	O	O
the	O	O
AN2	O	O
locus	O	O
on	O	O
11p13	O	O
.	O	O

We	O	O
have	O	O
excluded	O	O
linkage	O	O
(	O	O
zeta	O	O
less	O	O
than	O	O
-	O	O
2	O	O
at	O	O
theta	O	O
less	O	O
than	O	O
0	O	O
.	O	O

18	O	O
)	O	O
between	O	O
the	O	O
aniridia	B-Disease	D015783
and	O	O
the	O	O
chromosome	O	O
2p25	O	O
marker	O	O
D2S1	O	O
(	O	O
linked	O	O
to	O	O
ACP1	O	O
)	O	O
.	O	O

Knobloch	B-Disease	C537209
syndrome	I-Disease	C537209
involving	O	O
midline	B-Disease	C538225
scalp	I-Disease	C538225
defect	I-Disease	C538225
of	I-Disease	C538225
the	I-Disease	C538225
frontal	I-Disease	C538225
region	I-Disease	C538225
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
4	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
Knobloch	B-Disease	C537209
syndrome	I-Disease	C537209
.	O	O

He	O	O
has	O	O
vitreoretinal	B-Disease	D012162
degeneration	I-Disease	D012162
,	O	O
high	B-Disease	D009216
myopia	I-Disease	D009216
,	O	O
cataract	B-Disease	D002386
,	O	O
telecanthus	B-Disease	D030342
,	O	O
hypertelorism	B-Disease	D006972
,	O	O
and	O	O
a	O	O
high	B-Disease	D007569
-	I-Disease	D007569
arched	I-Disease	D007569
palate	I-Disease	D007569
.	O	O

He	O	O
also	O	O
has	O	O
a	O	O
defect	B-Disease	C538225
of	I-Disease	C538225
the	I-Disease	C538225
anterior	I-Disease	C538225
midline	I-Disease	C538225
scalp	I-Disease	C538225
with	O	O
involvement	O	O
of	O	O
the	O	O
frontal	O	O
bone	O	O
as	O	O
documented	O	O
by	O	O
a	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
scan	O	O
.	O	O

The	O	O
brain	O	O
was	O	O
normal	O	O
on	O	O
CT	O	O
scan	O	O
and	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
.	O	O

We	O	O
present	O	O
a	O	O
review	O	O
of	O	O
the	O	O
23	O	O
published	O	O
cases	O	O
with	O	O
this	O	O
syndrome	O	O
.	O	O

Our	O	O
patient	O	O
illustrates	O	O
the	O	O
importance	O	O
of	O	O
investigating	O	O
for	O	O
underlying	O	O
ocular	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
pathology	O	O
whenever	O	O
midline	B-Disease	C538225
scalp	I-Disease	C538225
defects	I-Disease	C538225
are	O	O
present	O	O
.	O	O

.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
:	O	O
phenotypic	O	O
variability	O	O
in	O	O
two	O	O
families	O	O
carrying	O	O
the	O	O
same	O	O
PDS	B-Disease	C536648
missense	O	O
mutation	O	O
.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
comprises	O	O
congenital	B-Disease	D006319
sensorineural	I-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
,	O	O
thyroid	B-Disease	D006042
goiter	I-Disease	D006042
,	O	O
and	O	O
positive	O	O
perchlorate	O	O
discharge	O	O
test	O	O
.	O	O

Recently	O	O
,	O	O
this	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
was	O	O
shown	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
,	O	O
which	O	O
encodes	O	O
an	O	O
anion	O	O
transporter	O	O
called	O	O
pendrin	O	O
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
was	O	O
performed	O	O
in	O	O
two	O	O
consanguineous	O	O
large	O	O
families	O	O
from	O	O
Southern	O	O
Tunisia	O	O
comprising	O	O
a	O	O
total	O	O
of	O	O
23	O	O
individuals	O	O
affected	O	O
with	O	O
profound	O	O
congenital	B-Disease	D003638
deafness	I-Disease	D003638
;	O	O
the	O	O
same	O	O
missense	O	O
mutation	O	O
,	O	O
L445W	O	O
,	O	O
was	O	O
identified	O	O
in	O	O
all	O	O
affected	O	O
individuals	O	O
.	O	O

A	O	O
widened	B-Disease	OMIM:600791
vestibular	I-Disease	OMIM:600791
aqueduct	I-Disease	OMIM:600791
was	O	O
found	O	O
in	O	O
all	O	O
patients	O	O
who	O	O
underwent	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
scan	O	O
exploration	O	O
of	O	O
the	O	O
inner	O	O
ear	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
goiter	B-Disease	D006042
was	O	O
present	O	O
in	O	O
only	O	O
11	O	O
affected	O	O
individuals	O	O
,	O	O
who	O	O
interestingly	O	O
had	O	O
a	O	O
normal	O	O
result	O	O
of	O	O
the	O	O
perchlorate	O	O
discharge	O	O
test	O	O
whenever	O	O
performed	O	O
.	O	O

The	O	O
present	O	O
results	O	O
question	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
perchlorate	O	O
test	O	O
for	O	O
the	O	O
diagnosis	O	O
of	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
and	O	O
support	O	O
the	O	O
use	O	O
of	O	O
a	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
individuals	O	O
with	O	O
severe	O	O
to	O	O
profound	O	O
congenital	B-Disease	D003638
hearing	I-Disease	D003638
loss	I-Disease	D003638
associated	O	O
with	O	O
inner	B-Disease	D007759
ear	I-Disease	D007759
morphological	I-Disease	D007759
anomaly	I-Disease	D007759
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
thyroid	B-Disease	D006042
goiter	I-Disease	D006042
.	O	O

.	O	O

The	O	O
type	O	O
of	O	O
somatic	O	O
mutation	O	O
at	O	O
APC	B-Disease	D011125
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
is	O	O
determined	O	O
by	O	O
the	O	O
site	O	O
of	O	O
the	O	O
germline	O	O
mutation	O	O
:	O	O
a	O	O
new	O	O
facet	O	O
to	O	O
Knudson	O	O
'	O	O
s	O	O
'	O	O
two	O	O
-	O	O
hit	O	O
'	O	O
hypothesis	O	O
.	O	O

APC	B-Disease	D011125
is	O	O
often	O	O
cited	O	O
as	O	O
a	O	O
prime	O	O
example	O	O
of	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
.	O	O

Truncating	O	O
germline	O	O
and	O	O
somatic	O	O
mutations	O	O
(	O	O
or	O	O
,	O	O
infrequently	O	O
,	O	O
allelic	O	O
loss	O	O
)	O	O
occur	O	O
in	O	O
tumors	B-Disease	D009369
in	O	O
FAP	B-Disease	D011125
(	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
)	O	O
.	O	O

Most	O	O
sporadic	B-Disease	D015179
colorectal	I-Disease	D015179
cancers	I-Disease	D015179
also	O	O
have	O	O
two	O	O
APC	B-Disease	D011125
mutations	O	O
.	O	O

Clues	O	O
from	O	O
attenuated	B-Disease	C538265
polyposis	I-Disease	C538265
,	O	O
missense	O	O
germline	O	O
variants	O	O
with	O	O
mild	O	O
disease	O	O
and	O	O
the	O	O
somatic	O	O
mutation	O	O
cluster	O	O
region	O	O
(	O	O
codons	O	O
1	O	O
,	O	O
250	O	O
-	O	O
1	O	O
,	O	O
450	O	O
)	O	O
indicate	O	O
,	O	O
however	O	O
,	O	O
that	O	O
APC	B-Disease	D011125
mutations	O	O
might	O	O
not	O	O
result	O	O
in	O	O
simple	O	O
loss	O	O
of	O	O
protein	O	O
function	O	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
FAP	B-Disease	D011125
patients	O	O
with	O	O
germline	O	O
APC	B-Disease	D011125
mutations	O	O
within	O	O
a	O	O
small	O	O
region	O	O
(	O	O
codons	O	O
1	O	O
,	O	O
194	O	O
-	O	O
1	O	O
,	O	O
392	O	O
at	O	O
most	O	O
)	O	O
mainly	O	O
show	O	O
allelic	O	O
loss	O	O
in	O	O
their	O	O
colorectal	B-Disease	D000236
adenomas	I-Disease	D000236
,	O	O
in	O	O
contrast	O	O
to	O	O
other	O	O
FAP	B-Disease	D011125
patients	O	O
,	O	O
whose	O	O
second	O	O
hits	O	O
tend	O	O
to	O	O
occur	O	O
by	O	O
truncating	O	O
mutations	O	O
in	O	O
the	O	O
mutation	O	O
cluster	O	O
region	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
different	O	O
APC	B-Disease	D011125
mutations	O	O
provide	O	O
cells	O	O
with	O	O
different	O	O
selective	O	O
advantages	O	O
,	O	O
with	O	O
mutations	O	O
close	O	O
to	O	O
codon	O	O
1	O	O
,	O	O
300	O	O
providing	O	O
the	O	O
greatest	O	O
advantage	O	O
.	O	O

Allelic	O	O
loss	O	O
is	O	O
selected	O	O
strongly	O	O
in	O	O
cells	O	O
with	O	O
one	O	O
mutation	O	O
near	O	O
codon	O	O
1	O	O
,	O	O
300	O	O
.	O	O

A	O	O
different	O	O
germline	O	O
-	O	O
somatic	O	O
APC	B-Disease	D011125
mutation	O	O
association	O	O
exists	O	O
in	O	O
FAP	B-Disease	D011125
desmoids	O	O
.	O	O

APC	B-Disease	D011125
is	O	O
not	O	O
,	O	O
therefore	O	O
,	O	O
a	O	O
classical	O	O
tumor	B-Disease	D009369
suppressor	O	O
.	O	O

Our	O	O
findings	O	O
also	O	O
indicate	O	O
a	O	O
new	O	O
mechanism	O	O
for	O	O
disease	O	O
severity	O	O
if	O	O
a	O	O
broader	O	O
spectrum	O	O
of	O	O
mutations	O	O
is	O	O
selected	O	O
in	O	O
tumors	B-Disease	D009369
,	O	O
the	O	O
somatic	O	O
mutation	O	O
rate	O	O
is	O	O
effectively	O	O
higher	O	O
and	O	O
more	O	O
tumors	B-Disease	D009369
grow	O	O
.	O	O

.	O	O

Purification	O	O
of	O	O
human	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
coenzyme	O	O
A	O	O
dehydrogenase	O	O
and	O	O
characterization	O	O
of	O	O
its	O	O
deficiency	O	O
in	O	O
seven	O	O
patients	O	O
.	O	O

Mitochondrial	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
coenzyme	O	O
A	O	O
dehydrogenase	O	O
(	O	O
VLCAD	O	O
)	O	O
was	O	O
purified	O	O
from	O	O
human	O	O
liver	O	O
.	O	O

The	O	O
molecular	O	O
masses	O	O
of	O	O
the	O	O
native	O	O
enzyme	O	O
and	O	O
the	O	O
subunit	O	O
were	O	O
estimated	O	O
to	O	O
be	O	O
154	O	O
and	O	O
70	O	O
kD	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
enzyme	O	O
was	O	O
found	O	O
to	O	O
catalyze	O	O
the	O	O
major	O	O
part	O	O
of	O	O
mitochondrial	O	O
palmitoylcoenzyme	O	O
A	O	O
dehydrogenation	O	O
in	O	O
liver	O	O
,	O	O
heart	O	O
,	O	O
skeletal	O	O
muscle	O	O
,	O	O
and	O	O
skin	O	O
fibroblasts	O	O
(	O	O
89	O	O
-	O	O
97	O	O
,	O	O
86	O	O
-	O	O
99	O	O
,	O	O
96	O	O
-	O	O
99	O	O
,	O	O
and	O	O
78	O	O
-	O	O
87	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Skin	O	O
fibroblasts	O	O
from	O	O
26	O	O
patients	O	O
suspected	O	O
of	O	O
having	O	O
a	O	O
disorder	O	O
of	O	O
mitochondrial	O	O
beta	O	O
-	O	O
oxidation	O	O
were	O	O
analyzed	O	O
for	O	O
VLCAD	O	O
protein	O	O
using	O	O
immunoblotting	O	O
,	O	O
and	O	O
7	O	O
of	O	O
them	O	O
contained	O	O
undetectable	O	O
or	O	O
trace	O	O
levels	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O

The	O	O
seven	O	O
deficient	O	O
fibroblast	O	O
lines	O	O
were	O	O
characterized	O	O
by	O	O
measuring	O	O
acyl	O	O
-	O	O
coenzyme	O	O
A	O	O
dehydrogenation	O	O
activities	O	O
,	O	O
overall	O	O
palmitic	O	O
acid	O	O
oxidation	O	O
,	O	O
and	O	O
VLCAD	O	O
protein	O	O
synthesis	O	O
using	O	O
pulse	O	O
-	O	O
chase	O	O
,	O	O
further	O	O
confirming	O	O
the	O	O
diagnosis	O	O
of	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
.	O	O

These	O	O
results	O	O
suggested	O	O
the	O	O
heterogenous	O	O
nature	O	O
of	O	O
the	O	O
mutations	O	O
causing	O	O
the	O	O
deficiency	O	O
in	O	O
the	O	O
seven	O	O
patients	O	O
.	O	O

Clinically	O	O
,	O	O
all	O	O
patients	O	O
with	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
exhibited	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
.	O	O

At	O	O
least	O	O
four	O	O
of	O	O
them	O	O
presented	O	O
with	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
.	O	O

This	O	O
frequency	O	O
(	O	O
>	O	O
57	O	O
%	O	O
)	O	O
was	O	O
much	O	O
higher	O	O
than	O	O
that	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
other	O	O
disorders	O	O
of	O	O
mitochondrial	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acid	O	O
oxidation	O	O
that	O	O
may	O	O
be	O	O
accompanied	O	O
by	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
in	O	O
infants	O	O
.	O	O

.	O	O

A	O	O
germ	O	O
line	O	O
mutation	O	O
within	O	O
the	O	O
coding	O	O
sequence	O	O
for	O	O
the	O	O
putative	O	O
5	O	O
-	O	O
phosphoribosyl	O	O
-	O	O
1	O	O
-	O	O
pyrophosphate	O	O
binding	O	O
site	O	O
of	O	O
hypoxanthine	O	O
-	O	O
guanine	O	O
phosphoribosyltransferase	O	O
(	O	O
HPRT	O	O
)	O	O
in	O	O
a	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patient	O	O
:	O	O
missense	O	O
mutations	O	O
within	O	O
a	O	O
functionally	O	O
important	O	O
region	O	O
probably	O	O
cause	O	O
disease	O	O
.	O	O

Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
caused	O	O
by	O	O
a	O	O
complete	B-Disease	D007926
deficiency	I-Disease	D007926
of	I-Disease	D007926
hypoxanthine	I-Disease	D007926
guanine	I-Disease	D007926
phosphoribosyltransferase	I-Disease	D007926
(	O	O
HPRT	O	O
)	O	O
is	O	O
the	O	O
result	O	O
of	O	O
a	O	O
heterogeneous	O	O
group	O	O
of	O	O
germ	O	O
line	O	O
mutations	O	O
.	O	O

Identification	O	O
of	O	O
each	O	O
mutant	O	O
gene	O	O
provides	O	O
valuable	O	O
information	O	O
as	O	O
to	O	O
the	O	O
type	O	O
of	O	O
mutation	O	O
that	O	O
occurs	O	O
spontaneously	O	O
.	O	O

We	O	O
report	O	O
here	O	O
a	O	O
newly	O	O
identified	O	O
HPRT	O	O
mutation	O	O
in	O	O
a	O	O
Japanese	O	O
patient	O	O
with	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
.	O	O

This	O	O
gene	O	O
,	O	O
designated	O	O
HPRT	O	O
Tokyo	O	O
,	O	O
had	O	O
a	O	O
single	O	O
nucleotide	O	O
change	O	O
from	O	O
G	O	O
to	O	O
A	O	O
,	O	O
as	O	O
identified	O	O
by	O	O
sequencing	O	O
cDNA	O	O
amplified	O	O
by	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

Allele	O	O
specific	O	O
oligonucleotide	O	O
hybridization	O	O
analysis	O	O
using	O	O
amplified	O	O
genomic	O	O
DNA	O	O
showed	O	O
that	O	O
the	O	O
mutant	O	O
gene	O	O
was	O	O
transmitted	O	O
from	O	O
the	O	O
maternal	O	O
germ	O	O
line	O	O
.	O	O

This	O	O
mutation	O	O
would	O	O
lead	O	O
to	O	O
an	O	O
amino	O	O
acid	O	O
substitution	O	O
of	O	O
Asp	O	O
for	O	O
Gly	O	O
at	O	O
the	O	O
amino	O	O
acid	O	O
position	O	O
140	O	O
located	O	O
within	O	O
the	O	O
putative	O	O
5	O	O
-	O	O
phosphoribosyl	O	O
-	O	O
1	O	O
-	O	O
pyrophosphate	O	O
(	O	O
PRPP	O	O
)	O	O
binding	O	O
region	O	O
.	O	O

Missense	O	O
mutations	O	O
in	O	O
human	O	O
HPRT	B-Disease	D007926
deficient	I-Disease	D007926
patients	O	O
thus	O	O
far	O	O
reported	O	O
tend	O	O
to	O	O
accumulate	O	O
in	O	O
this	O	O
functionally	O	O
active	O	O
region	O	O
.	O	O

However	O	O
,	O	O
a	O	O
comparison	O	O
of	O	O
the	O	O
data	O	O
suggested	O	O
that	O	O
both	O	O
missense	O	O
and	O	O
synonymous	O	O
mutations	O	O
can	O	O
occur	O	O
at	O	O
any	O	O
coding	O	O
sequence	O	O
of	O	O
the	O	O
human	O	O
germ	O	O
line	O	O
HPRT	O	O
gene	O	O
,	O	O
but	O	O
that	O	O
a	O	O
limited	O	O
percentage	O	O
of	O	O
all	O	O
the	O	O
missense	O	O
mutations	O	O
cause	O	O
disease	O	O
.	O	O

The	O	O
probability	O	O
that	O	O
a	O	O
mutation	O	O
will	O	O
cause	O	O
disease	O	O
tends	O	O
to	O	O
be	O	O
higher	O	O
when	O	O
the	O	O
missense	O	O
mutation	O	O
is	O	O
within	O	O
a	O	O
functionally	O	O
important	O	O
sequence	O	O
.	O	O

.	O	O

In	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
correlations	O	O
for	O	O
I65T	O	O
and	O	O
M1V	O	O
mutations	O	O
at	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
locus	O	O
.	O	O

Mutations	O	O
at	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
locus	O	O
are	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
hyperphenylalaninemia	B-Disease	D010661
.	O	O

We	O	O
have	O	O
previously	O	O
described	O	O
four	O	O
mutations	O	O
(	O	O
M1V	O	O
,	O	O
IVS12nt1	O	O
,	O	O
R408W	O	O
,	O	O
and	O	O
S349P	O	O
)	O	O
at	O	O
the	O	O
PAH	O	O
locus	O	O
in	O	O
French	O	O
Canadians	O	O
with	O	O
ancestry	O	O
in	O	O
eastern	O	O
Quebec	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
(	O	O
1	O	O
)	O	O
identification	O	O
of	O	O
another	O	O
mutation	O	O
,	O	O
on	O	O
a	O	O
haplotype	O	O
9	O	O
chromosome	O	O
,	O	O
which	O	O
converts	O	O
codon	O	O
65	O	O
from	O	O
isoleucine	O	O
(	O	O
ATT	O	O
)	O	O
to	O	O
threonine	O	O
(	O	O
ACT	O	O
)	O	O
,	O	O
(	O	O
2	O	O
)	O	O
expression	O	O
analysis	O	O
of	O	O
the	O	O
I65T	O	O
mutation	O	O
in	O	O
COS	O	O
cells	O	O
demonstrating	O	O
75	O	O
%	O	O
loss	O	O
of	O	O
both	O	O
immunoreactive	O	O
protein	O	O
and	O	O
enzyme	O	O
activity	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
expression	O	O
analysis	O	O
of	O	O
the	O	O
most	O	O
prevalent	O	O
PKU	B-Disease	D010661
allele	O	O
(	O	O
M1V	O	O
)	O	O
in	O	O
eastern	O	O
Quebec	O	O
,	O	O
showing	O	O
nondetectable	O	O
levels	O	O
of	O	O
PAH	O	O
protein	O	O
and	O	O
activity	O	O
,	O	O
a	O	O
finding	O	O
compatible	O	O
with	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
translation	O	O
initiation	O	O
codon	O	O
.	O	O

Homozygosity	O	O
for	O	O
M1V	O	O
and	O	O
codominant	O	O
inheritance	O	O
of	O	O
I65T	O	O
/	O	O
R408W	O	O
were	O	O
both	O	O
associated	O	O
with	O	O
classical	B-Disease	D010661
phenylketonuria	I-Disease	D010661
.	O	O

.	O	O

Experimental	O	O
hemochromatosis	B-Disease	D006432
due	O	O
to	O	O
MHC	O	O
class	O	O
I	O	O
HFE	B-Disease	D006432
deficiency	I-Disease	D006432
:	O	O
immune	O	O
status	O	O
and	O	O
iron	O	O
metabolism	O	O
.	O	O

The	O	O
puzzling	O	O
linkage	O	O
between	O	O
genetic	O	O
hemochromatosis	B-Disease	D006432
and	O	O
histocompatibility	O	O
loci	O	O
became	O	O
even	O	O
more	O	O
so	O	O
when	O	O
the	O	O
gene	O	O
involved	O	O
,	O	O
HFE	O	O
,	O	O
was	O	O
identified	O	O
.	O	O

Indeed	O	O
,	O	O
within	O	O
the	O	O
well	O	O
defined	O	O
,	O	O
mainly	O	O
peptide	O	O
-	O	O
binding	O	O
,	O	O
MHC	O	O
class	O	O
I	O	O
family	O	O
of	O	O
molecules	O	O
,	O	O
HFE	O	O
seems	O	O
to	O	O
perform	O	O
an	O	O
unusual	O	O
yet	O	O
essential	O	O
function	O	O
.	O	O

As	O	O
yet	O	O
,	O	O
our	O	O
understanding	O	O
of	O	O
HFE	O	O
function	O	O
in	O	O
iron	O	O
homeostasis	O	O
is	O	O
only	O	O
partial	O	O
;	O	O
an	O	O
even	O	O
more	O	O
open	O	O
question	O	O
is	O	O
its	O	O
possible	O	O
role	O	O
in	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

To	O	O
advance	O	O
on	O	O
both	O	O
of	O	O
these	O	O
avenues	O	O
,	O	O
we	O	O
report	O	O
the	O	O
deletion	O	O
of	O	O
HFE	O	O
alpha1	O	O
and	O	O
alpha2	O	O
putative	O	O
ligand	O	O
binding	O	O
domains	O	O
in	O	O
vivo	O	O
.	O	O

HFE	B-Disease	D006432
-	I-Disease	D006432
deficient	I-Disease	D006432
animals	O	O
were	O	O
analyzed	O	O
for	O	O
a	O	O
comprehensive	O	O
set	O	O
of	O	O
metabolic	O	O
and	O	O
immune	O	O
parameters	O	O
.	O	O

Faithfully	O	O
mimicking	O	O
human	O	O
hemochromatosis	B-Disease	D006432
,	O	O
mice	O	O
homozygous	O	O
for	O	O
this	O	O
deletion	O	O
develop	O	O
iron	O	O
overload	O	O
,	O	O
characterized	O	O
by	O	O
a	O	O
higher	O	O
plasma	O	O
iron	O	O
content	O	O
and	O	O
a	O	O
raised	O	O
transferrin	O	O
saturation	O	O
as	O	O
well	O	O
as	O	O
an	O	O
elevated	O	O
hepatic	O	O
iron	O	O
load	O	O
.	O	O

The	O	O
primary	O	O
defect	O	O
could	O	O
,	O	O
indeed	O	O
,	O	O
be	O	O
traced	O	O
to	O	O
an	O	O
augmented	O	O
duodenal	O	O
iron	O	O
absorption	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
measurement	O	O
of	O	O
the	O	O
gut	O	O
mucosal	O	O
iron	O	O
content	O	O
as	O	O
well	O	O
as	O	O
iron	O	O
regulatory	O	O
proteins	O	O
allows	O	O
a	O	O
more	O	O
informed	O	O
evaluation	O	O
of	O	O
various	O	O
hypotheses	O	O
regarding	O	O
the	O	O
precise	O	O
role	O	O
of	O	O
HFE	O	O
in	O	O
iron	O	O
homeostasis	O	O
.	O	O

Finally	O	O
,	O	O
an	O	O
extensive	O	O
phenotyping	O	O
of	O	O
primary	O	O
and	O	O
secondary	O	O
lymphoid	O	O
organs	O	O
including	O	O
the	O	O
gut	O	O
provides	O	O
no	O	O
compelling	O	O
evidence	O	O
for	O	O
an	O	O
obvious	O	O
immune	O	O
-	O	O
linked	O	O
function	O	O
for	O	O
HFE	O	O
.	O	O

.	O	O

[	O	O
Genetic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
:	O	O
mutant	O	O
alleles	O	O
of	O	O
G6PD	O	O
in	O	O
the	O	O
Shekii	O	O
district	O	O
of	O	O
Azerbaijan	O	O
]	O	O
Examination	O	O
on	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
349	O	O
patients	O	O
of	O	O
Shekii	O	O
district	O	O
hospital	O	O
(	O	O
Azerbaijan	O	O
)	O	O
revealed	O	O
16	O	O
hemi	O	O
-	O	O
,	O	O
4	O	O
homo	O	O
-	O	O
and	O	O
9	O	O
heterozygotic	O	O
carriers	O	O
of	O	O
the	O	O
defect	O	O
.	O	O

Gd	O	O
-	O	O
frequency	O	O
,	O	O
calculated	O	O
from	O	O
the	O	O
data	O	O
obtained	O	O
(	O	O
7	O	O
.	O	O

7	O	O
%	O	O
)	O	O
,	O	O
may	O	O
be	O	O
compared	O	O
to	O	O
neighbouring	O	O
regions	O	O
frequencies	O	O
(	O	O
6	O	O
-	O	O
30	O	O
%	O	O
)	O	O
.	O	O

Carriers	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
are	O	O
residents	O	O
of	O	O
11	O	O
villages	O	O
located	O	O
in	O	O
Alasani	O	O
-	O	O
Aphtalan	O	O
valley	O	O
,	O	O
highly	O	O
endemic	O	O
with	O	O
malaria	B-Disease	D008288
in	O	O
the	O	O
past	O	O
;	O	O
nearly	O	O
all	O	O
marriages	O	O
are	O	O
endogamic	O	O
.	O	O

Physico	O	O
-	O	O
chemical	O	O
and	O	O
kinetic	O	O
study	O	O
of	O	O
10	O	O
mutant	O	O
forms	O	O
of	O	O
G6PD	O	O
,	O	O
according	O	O
to	O	O
WHO	O	O
program	O	O
,	O	O
led	O	O
to	O	O
identification	O	O
of	O	O
5	O	O
variants	O	O
of	O	O
the	O	O
II	O	O
class	O	O
(	O	O
Shekii	O	O
,	O	O
Bideiz	O	O
,	O	O
Shirin	O	O
-	O	O
Bulakh	O	O
,	O	O
Okhut	O	O
I	O	O
and	O	O
Zakataly	O	O
)	O	O
and	O	O
2	O	O
variants	O	O
of	O	O
the	O	O
III	O	O
class	O	O
(	O	O
Okhut	O	O
II	O	O
and	O	O
Martinique	O	O
-	O	O
like	O	O
)	O	O
.	O	O

Resemblance	O	O
of	O	O
the	O	O
majority	O	O
of	O	O
variants	O	O
in	O	O
electrophoretic	O	O
mobility	O	O
and	O	O
the	O	O
level	O	O
of	O	O
erythrocyte	O	O
enzyme	O	O
activity	O	O
permit	O	O
to	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
common	O	O
parental	O	O
mutant	O	O
G6PD	O	O
allele	O	O
distributed	O	O
in	O	O
this	O	O
area	O	O
.	O	O

[	O	O
Gd	O	O
-	O	O
allele	O	O
distribution	O	O
patterns	O	O
in	O	O
Azerbaijan	O	O
.	O	O

III	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
mutant	O	O
forms	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
]	O	O
In	O	O
28	O	O
families	O	O
with	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
living	O	O
in	O	O
3	O	O
settlements	O	O
of	O	O
Shekii	O	O
district	O	O
of	O	O
Azerbaijan	O	O
11	O	O
G6PD	O	O
variants	O	O
of	O	O
II	O	O
and	O	O
III	O	O
classes	O	O
differing	O	O
by	O	O
kinetic	O	O
properties	O	O
were	O	O
identified	O	O
according	O	O
WHO	O	O
program	O	O
.	O	O

9	O	O
of	O	O
them	O	O
are	O	O
characterized	O	O
with	O	O
the	O	O
same	O	O
electrophoretic	O	O
mobility	O	O
.	O	O

Comparison	O	O
of	O	O
G6PD	O	O
spectra	O	O
in	O	O
two	O	O
subpopulations	O	O
and	O	O
in	O	O
a	O	O
mixed	O	O
group	O	O
permits	O	O
to	O	O
make	O	O
a	O	O
conclusion	O	O
about	O	O
existence	O	O
of	O	O
common	O	O
and	O	O
rare	O	O
G6PD	O	O
alleles	O	O
in	O	O
examined	O	O
population	O	O
.	O	O

They	O	O
distribute	O	O
by	O	O
gene	O	O
drift	O	O
supported	O	O
by	O	O
natural	O	O
selection	O	O
.	O	O

Among	O	O
7	O	O
samples	O	O
of	O	O
G6PD	O	O
with	O	O
normal	O	O
and	O	O
increased	O	O
activity	O	O
two	O	O
new	O	O
variants	O	O
of	O	O
IV	O	O
class	O	O
-	O	O
-	O	O
Nukha	O	O
and	O	O
Bash	O	O
-	O	O
Kungut	O	O
-	O	O
-	O	O
were	O	O
found	O	O
.	O	O

.	O	O

Determination	O	O
of	O	O
carrier	O	O
status	O	O
for	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
by	O	O
flow	O	O
cytometric	O	O
analysis	O	O
of	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
expression	O	O
in	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
is	O	O
caused	O	O
by	O	O
defects	O	O
in	O	O
the	O	O
WAS	B-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
gene	O	O
on	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O

Previous	O	O
study	O	O
disclosed	O	O
that	O	O
flow	O	O
cytometric	O	O
analysis	O	O
of	O	O
intracellular	O	O
WASP	O	O
expression	O	O
(	O	O
FCM	O	O
-	O	O
WASP	O	O
analysis	O	O
)	O	O
in	O	O
lymphocytes	O	O
was	O	O
useful	O	O
for	O	O
the	O	O
diagnosis	O	O
of	O	O
WAS	B-Disease	D014923
patients	O	O
.	O	O

Lymphocytes	O	O
from	O	O
all	O	O
WAS	B-Disease	D014923
patients	O	O
showed	O	O
WASPdim	O	O
instead	O	O
of	O	O
WASPbright	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
FCM	O	O
-	O	O
WASP	O	O
analysis	O	O
in	O	O
monocytes	O	O
could	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
the	O	O
WAS	B-Disease	D014923
carrier	O	O
diagnosis	O	O
.	O	O

Monocytes	O	O
from	O	O
all	O	O
nine	O	O
WAS	B-Disease	D014923
carriers	O	O
showed	O	O
varied	O	O
population	O	O
of	O	O
WASPdim	O	O
together	O	O
with	O	O
WASPbright	O	O
.	O	O

None	O	O
of	O	O
control	O	O
individuals	O	O
possessed	O	O
the	O	O
WASPdim	O	O
population	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
lymphocytes	O	O
from	O	O
all	O	O
the	O	O
carriers	O	O
except	O	O
two	O	O
lacked	O	O
the	O	O
WASPdim	O	O
population	O	O
.	O	O

The	O	O
difference	O	O
of	O	O
the	O	O
WASPdim	O	O
population	O	O
in	O	O
monocytes	O	O
and	O	O
lymphocytes	O	O
observed	O	O
in	O	O
WAS	B-Disease	D014923
carriers	O	O
suggests	O	O
that	O	O
WASP	O	O
plays	O	O
a	O	O
more	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
lymphocytes	O	O
than	O	O
in	O	O
that	O	O
of	O	O
monocytes	O	O
.	O	O

The	O	O
present	O	O
studies	O	O
suggest	O	O
that	O	O
a	O	O
skewed	O	O
X	O	O
-	O	O
chromosomal	O	O
inactivation	O	O
pattern	O	O
observed	O	O
in	O	O
WAS	B-Disease	D014923
carrier	O	O
peripheral	O	O
blood	O	O
cells	O	O
is	O	O
not	O	O
fixed	O	O
at	O	O
the	O	O
hemopoietic	O	O
stem	O	O
cell	O	O
level	O	O
but	O	O
progresses	O	O
after	O	O
the	O	O
lineage	O	O
commitment	O	O
.	O	O

.	O	O

Linkage	O	O
of	O	O
DNA	O	O
markers	O	O
at	O	O
Xq28	O	O
to	O	O
adrenoleukodystrophy	B-Disease	D000326
and	O	O
adrenomyeloneuropathy	B-Disease	D000326
present	O	O
within	O	O
the	O	O
same	O	O
family	O	O
.	O	O

We	O	O
present	O	O
a	O	O
large	O	O
kindred	O	O
that	O	O
contained	O	O
patients	O	O
with	O	O
either	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
or	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
.	O	O

The	O	O
pedigree	O	O
clearly	O	O
supported	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
mode	O	O
of	O	O
inheritance	O	O
of	O	O
the	O	O
nonneonatal	O	O
form	O	O
of	O	O
ALD	B-Disease	D000326
/	O	O
AMN	B-Disease	D000326
.	O	O

Analysis	O	O
with	O	O
DNA	O	O
markers	O	O
at	O	O
Xq28	O	O
suggested	O	O
segregation	O	O
of	O	O
both	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
with	O	O
an	O	O
identical	O	O
haplotype	O	O
.	O	O

This	O	O
indicated	O	O
that	O	O
nonneonatal	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
are	O	O
caused	O	O
by	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
same	O	O
gene	O	O
at	O	O
Xq28	O	O
.	O	O

It	O	O
showed	O	O
,	O	O
furthermore	O	O
,	O	O
that	O	O
phenotypic	O	O
differences	O	O
between	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
are	O	O
not	O	O
necessarily	O	O
the	O	O
consequence	O	O
of	O	O
allelic	O	O
heterogeneity	O	O
due	O	O
to	O	O
different	O	O
mutations	O	O
within	O	O
the	O	O
same	O	O
gene	O	O
.	O	O

The	O	O
maximal	O	O
lod	O	O
score	O	O
for	O	O
linkage	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
/	O	O
AMN	B-Disease	D000326
gene	O	O
and	O	O
the	O	O
multiallelic	O	O
anonymous	O	O
DNA	O	O
marker	O	O
at	O	O
DXS52	O	O
was	O	O
3	O	O
.	O	O

0	O	O
at	O	O
a	O	O
recombination	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

00	O	O
.	O	O

This	O	O
made	O	O
a	O	O
prenatal	O	O
or	O	O
presymptomatic	O	O
diagnosis	O	O
and	O	O
heterozygote	O	O
detection	O	O
by	O	O
DNA	O	O
analysis	O	O
with	O	O
this	O	O
marker	O	O
reliable	O	O
.	O	O

Further	O	O
investigation	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
intron	O	O
9	O	O
donor	O	O
splice	O	O
site	O	O
mutation	O	O
frequently	O	O
found	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
patients	O	O
from	O	O
the	O	O
British	O	O
Isles	O	O
.	O	O

In	O	O
a	O	O
previous	O	O
study	O	O
we	O	O
found	O	O
that	O	O
a	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
causing	O	O
mutation	O	O
in	O	O
the	O	O
intron	O	O
9	O	O
donor	O	O
splice	O	O
site	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
occurs	O	O
at	O	O
high	O	O
frequency	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
patients	O	O
and	O	O
carriers	O	O
from	O	O
the	O	O
British	O	O
Isles	O	O
.	O	O

It	O	O
was	O	O
found	O	O
more	O	O
frequently	O	O
in	O	O
subjects	O	O
of	O	O
Irish	O	O
,	O	O
Scottish	O	O
,	O	O
and	O	O
Welsh	O	O
origin	O	O
compared	O	O
with	O	O
English	O	O
origin	O	O
(	O	O
63	O	O
%	O	O
and	O	O
31	O	O
%	O	O
respectively	O	O
)	O	O
.	O	O

We	O	O
have	O	O
now	O	O
tested	O	O
,	O	O
in	O	O
a	O	O
blind	O	O
study	O	O
,	O	O
26	O	O
American	O	O
TSD	B-Disease	D013661
carriers	O	O
and	O	O
28	O	O
non	O	O
-	O	O
carriers	O	O
who	O	O
have	O	O
British	O	O
ancestry	O	O
for	O	O
the	O	O
intron	O	O
9	O	O
splice	O	O
site	O	O
mutation	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
carriers	O	O
and	O	O
none	O	O
of	O	O
the	O	O
controls	O	O
were	O	O
positive	O	O
for	O	O
the	O	O
mutation	O	O
.	O	O

All	O	O
six	O	O
had	O	O
Irish	O	O
ancestry	O	O
,	O	O
compared	O	O
with	O	O
nine	O	O
of	O	O
the	O	O
20	O	O
other	O	O
(	O	O
intron	O	O
9	O	O
mutation	O	O
negative	O	O
)	O	O
TSD	B-Disease	D013661
carriers	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

These	O	O
results	O	O
confirm	O	O
the	O	O
previously	O	O
found	O	O
high	O	O
frequency	O	O
of	O	O
the	O	O
intron	O	O
9	O	O
mutation	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
TSD	B-Disease	D013661
families	O	O
of	O	O
British	O	O
Isles	O	O
,	O	O
particularly	O	O
Irish	O	O
,	O	O
origin	O	O
,	O	O
and	O	O
reinforce	O	O
the	O	O
need	O	O
to	O	O
screen	O	O
such	O	O
families	O	O
for	O	O
this	O	O
mutation	O	O
.	O	O

The	O	O
murine	O	O
homologues	O	O
of	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
gene	O	O
(	O	O
Hdh	O	O
)	O	O
and	O	O
the	O	O
alpha	O	O
-	O	O
adducin	O	O
gene	O	O
(	O	O
Add1	O	O
)	O	O
map	O	O
to	O	O
mouse	O	O
chromosome	O	O
5	O	O
within	O	O
a	O	O
region	O	O
of	O	O
conserved	O	O
synteny	O	O
with	O	O
human	O	O
chromosome	O	O
4p16	O	O
.	O	O

3	O	O
.	O	O

Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
is	O	O
a	O	O
severe	O	O
autosomal	B-Disease	D019636
dominant	I-Disease	D019636
neurodegenerative	I-Disease	D019636
disorder	I-Disease	D019636
associated	O	O
with	O	O
a	O	O
novel	O	O
gene	O	O
(	O	O
IT15	O	O
)	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
reported	O	O
the	O	O
cloning	O	O
of	O	O
Hdh	O	O
,	O	O
the	O	O
murine	O	O
homologue	O	O
of	O	O
IT15	O	O
.	O	O

Here	O	O
,	O	O
using	O	O
an	O	O
interspecific	O	O
backcross	O	O
,	O	O
we	O	O
have	O	O
mapped	O	O
both	O	O
Hdh	O	O
and	O	O
the	O	O
mouse	O	O
homologue	O	O
of	O	O
human	O	O
alpha	O	O
-	O	O
adducin	O	O
(	O	O
Add1	O	O
)	O	O
,	O	O
a	O	O
membrane	O	O
-	O	O
associated	O	O
cytoskeletal	O	O
protein	O	O
gene	O	O
.	O	O

Both	O	O
of	O	O
these	O	O
genes	O	O
map	O	O
in	O	O
the	O	O
same	O	O
position	O	O
on	O	O
mouse	O	O
chromosome	O	O
5	O	O
in	O	O
a	O	O
region	O	O
associated	O	O
with	O	O
ancestral	O	O
chromosomal	O	O
rearrangements	O	O
and	O	O
show	O	O
no	O	O
recombination	O	O
with	O	O
D5H4S43	O	O
,	O	O
D5H4S115	O	O
,	O	O
and	O	O
D5H4S62	O	O
,	O	O
the	O	O
murine	O	O
homologues	O	O
of	O	O
D4S43	O	O
,	O	O
D4S115	O	O
,	O	O
and	O	O
D4S62	O	O
,	O	O
respectively	O	O
.	O	O

Further	O	O
mapping	O	O
studies	O	O
of	O	O
humans	O	O
,	O	O
mice	O	O
,	O	O
and	O	O
other	O	O
mammalian	O	O
species	O	O
should	O	O
reveal	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
rearrangements	O	O
affecting	O	O
this	O	O
chromosomal	O	O
segment	O	O
during	O	O
mammalian	O	O
evolution	O	O
.	O	O

.	O	O

Linkage	O	O
analysis	O	O
of	O	O
the	O	O
apolipoprotein	O	O
C2	O	O
gene	O	O
and	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
on	O	O
human	O	O
chromosome	O	O
19	O	O
reveals	O	O
linkage	O	O
disequilibrium	O	O
in	O	O
a	O	O
French	O	O
-	O	O
Canadian	O	O
population	O	O
.	O	O

The	O	O
gene	O	O
for	O	O
human	O	O
apolipoprotein	O	O
C2	O	O
(	O	O
APOC2	O	O
)	O	O
,	O	O
situated	O	O
on	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
19	O	O
,	O	O
is	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
adult	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
,	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

Six	O	O
APOC2	O	O
RFLPs	O	O
(	O	O
TaqI	O	O
,	O	O
BglI	O	O
,	O	O
BanI	O	O
,	O	O
BamHI	O	O
,	O	O
NcoI	O	O
,	O	O
and	O	O
AvaII	O	O
)	O	O
have	O	O
been	O	O
identified	O	O
to	O	O
date	O	O
.	O	O

We	O	O
have	O	O
conducted	O	O
a	O	O
comprehensive	O	O
DM	B-Disease	D009223
linkage	O	O
study	O	O
utilizing	O	O
all	O	O
six	O	O
RFLPs	O	O
and	O	O
involving	O	O
50	O	O
families	O	O
and	O	O
372	O	O
individuals	O	O
.	O	O

The	O	O
most	O	O
informative	O	O
RFLPs	O	O
are	O	O
,	O	O
in	O	O
descending	O	O
order	O	O
,	O	O
NcoI	O	O
(	O	O
lod	O	O
=	O	O
6	O	O
.	O	O

64	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
BglI	O	O
(	O	O
lod	O	O
=	O	O
6	O	O
.	O	O

12	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
AvaII	O	O
(	O	O
lod	O	O
=	O	O
6	O	O
.	O	O

02	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
,	O	O
BanI	O	O
(	O	O
lod	O	O
=	O	O
5	O	O
.	O	O

76	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

04	O	O
)	O	O
,	O	O
TaqI	O	O
(	O	O
lod	O	O
=	O	O
4	O	O
.	O	O

29	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

06	O	O
)	O	O
,	O	O
and	O	O
BamHI	O	O
(	O	O
lod	O	O
=	O	O
1	O	O
.	O	O

75	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

A	O	O
substantial	O	O
increase	O	O
in	O	O
the	O	O
lod	O	O
scores	O	O
over	O	O
those	O	O
seen	O	O
with	O	O
the	O	O
individual	O	O
RFLPs	O	O
was	O	O
obtained	O	O
when	O	O
the	O	O
linkage	O	O
of	O	O
the	O	O
entire	O	O
APOC2	O	O
haplotype	O	O
(	O	O
composed	O	O
of	O	O
the	O	O
six	O	O
RFLPs	O	O
)	O	O
was	O	O
studied	O	O
(	O	O
lod	O	O
=	O	O
17	O	O
.	O	O

87	O	O
,	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

04	O	O
)	O	O
.	O	O

We	O	O
have	O	O
observed	O	O
significant	O	O
inter	O	O
-	O	O
APOC2	O	O
RFLP	O	O
linkage	O	O
disequilibrium	O	O
.	O	O

Consequently	O	O
,	O	O
the	O	O
three	O	O
most	O	O
informative	O	O
RFLPs	O	O
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
BanI	O	O
,	O	O
TaqI	O	O
,	O	O
and	O	O
either	O	O
BglI	O	O
,	O	O
AvaII	O	O
,	O	O
or	O	O
NcoI	O	O
polymorphisms	O	O
.	O	O

We	O	O
also	O	O
demonstrate	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
DM	B-Disease	D009223
and	O	O
APOC2	O	O
in	O	O
our	O	O
French	O	O
-	O	O
Canadian	O	O
population	O	O
(	O	O
standardized	O	O
disequilibrium	O	O
constant	O	O
phi	O	O
=	O	O
.	O	O

22	O	O
,	O	O
chi	O	O
2	O	O
=	O	O
5	O	O
.	O	O

12	O	O
,	O	O
df	O	O
=	O	O
1	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

04	O	O
)	O	O
.	O	O

This	O	O
represents	O	O
the	O	O
first	O	O
evidence	O	O
of	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
APOC2	O	O
and	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
.	O	O

A	O	O
retrospective	O	O
anonymous	O	O
pilot	O	O
study	O	O
in	O	O
screening	O	O
newborns	O	O
for	O	O
HFE	O	O
mutations	O	O
in	O	O
Scandinavian	O	O
populations	O	O
.	O	O

We	O	O
have	O	O
retrospectively	O	O
analyzed	O	O
837	O	O
random	O	O
anonymized	O	O
dried	O	O
blood	O	O
spot	O	O
(	O	O
DBS	O	O
)	O	O
samples	O	O
from	O	O
neonatal	O	O
screening	O	O
programs	O	O
in	O	O
Scandinavia	O	O
for	O	O
mutations	O	O
in	O	O
HFE	O	O
,	O	O
the	O	O
candidate	O	O
gene	O	O
for	O	O
hemochromatosis	B-Disease	D006432
.	O	O

We	O	O
have	O	O
found	O	O
C282Y	O	O
allele	O	O
frequencies	O	O
of	O	O
2	O	O
.	O	O

3	O	O
%	O	O
(	O	O
+	O	O
2	O	O
.	O	O

0	O	O
%	O	O
)	O	O
(	O	O
-	O	O
1	O	O
.	O	O

3	O	O
%	O	O
)	O	O
in	O	O
Greenland	O	O
,	O	O
4	O	O
.	O	O

5	O	O
%	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
%	O	O
in	O	O
Iceland	O	O
,	O	O
5	O	O
.	O	O

1	O	O
%	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

3	O	O
%	O	O
in	O	O
the	O	O
Faeroe	O	O
Islands	O	O
,	O	O
and	O	O
8	O	O
.	O	O

2	O	O
%	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

7	O	O
%	O	O
in	O	O
Denmark	O	O
.	O	O

The	O	O
high	O	O
prevalence	O	O
of	O	O
HFE	O	O
mutations	O	O
in	O	O
Denmark	O	O
suggests	O	O
that	O	O
population	O	O
screening	O	O
for	O	O
the	O	O
C282Y	O	O
mutation	O	O
could	O	O
be	O	O
highly	O	O
advantageous	O	O
in	O	O
terms	O	O
of	O	O
preventive	O	O
health	O	O
care	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
evaluation	O	O
of	O	O
C282Y	O	O
homozygotes	O	O
and	O	O
H63D	O	O
/	O	O
C282Y	O	O
compound	O	O
heterozygotes	O	O
will	O	O
give	O	O
an	O	O
indication	O	O
of	O	O
the	O	O
penetrance	O	O
of	O	O
the	O	O
mutations	O	O
.	O	O

Hereditary	O	O
TP53	O	O
codon	O	O
292	O	O
and	O	O
somatic	O	O
P16INK4A	O	O
codon	O	O
94	O	O
mutations	O	O
in	O	O
a	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
family	O	O
.	O	O

Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
that	O	O
is	O	O
characterized	O	O
by	O	O
various	O	O
types	O	O
of	O	O
cancer	B-Disease	D009369
in	O	O
childhood	O	O
and	O	O
adult	O	O
cases	O	O
.	O	O

Although	O	O
hereditary	O	O
TP53	O	O
mutation	O	O
is	O	O
very	O	O
rare	O	O
in	O	O
different	O	O
human	O	O
cancers	B-Disease	D009369
,	O	O
it	O	O
has	O	O
been	O	O
frequently	O	O
reported	O	O
in	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
hereditary	O	O
mutations	O	O
of	O	O
TP57KIP2	O	O
,	O	O
P15INK4B	O	O
,	O	O
and	O	O
P16INK4A	O	O
,	O	O
which	O	O
affect	O	O
the	O	O
cell	O	O
cycle	O	O
similar	O	O
to	O	O
TP53	O	O
,	O	O
were	O	O
observed	O	O
in	O	O
some	O	O
types	O	O
of	O	O
cancer	B-Disease	D009369
.	O	O

In	O	O
a	O	O
Turkish	O	O
family	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
,	O	O
we	O	O
analyzed	O	O
the	O	O
mutation	O	O
pattern	O	O
of	O	O
TP53	O	O
,	O	O
P57KIP2	O	O
,	O	O
P15INK4B	O	O
,	O	O
and	O	O
P16INK4A	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
,	O	O
and	O	O
loss	O	O
of	O	O
heterozygosity	O	O
(	O	O
homo	O	O
/	O	O
hemizygous	O	O
deletion	O	O
)	O	O
pattern	O	O
of	O	O
TP53	O	O
and	O	O
P15INK4B	O	O
/	O	O
P16INK4A	O	O
in	O	O
two	O	O
tumor	B-Disease	D009369
tissues	O	O
.	O	O

The	O	O
propositus	O	O
had	O	O
a	O	O
seminoma	B-Disease	D018239
,	O	O
his	O	O
daughter	O	O
a	O	O
medulloblastoma	B-Disease	D008527
,	O	O
and	O	O
one	O	O
of	O	O
his	O	O
healthy	O	O
cousins	O	O
,	O	O
a	O	O
TP53	O	O
codon	O	O
292	O	O
missense	O	O
point	O	O
mutation	O	O
(	O	O
AAA	O	O
-	O	O
-	O	O
>	O	O
ATA	O	O
;	O	O
Lys	O	O
-	O	O
-	O	O
>	O	O
Ile	O	O
)	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
cells	O	O
.	O	O

Tumor	O	O
tissue	O	O
obtained	O	O
from	O	O
the	O	O
propositus	O	O
with	O	O
the	O	O
seminoma	B-Disease	D018239
revealed	O	O
loss	O	O
of	O	O
heterozygosity	O	O
in	O	O
the	O	O
TP53	O	O
gene	O	O
.	O	O

In	O	O
the	O	O
analyses	O	O
of	O	O
tumor	B-Disease	D009369
tissues	O	O
from	O	O
the	O	O
propositus	O	O
and	O	O
his	O	O
daughter	O	O
,	O	O
a	O	O
P16INK4A	O	O
codon	O	O
94	O	O
missense	O	O
point	O	O
mutation	O	O
(	O	O
GCG	O	O
-	O	O
-	O	O
>	O	O
GAG	O	O
;	O	O
Ala	O	O
-	O	O
-	O	O
>	O	O
Glu	O	O
)	O	O
was	O	O
observed	O	O
with	O	O
the	O	O
hereditary	O	O
TP53	O	O
mutation	O	O
.	O	O

P16INK4A	O	O
codon	O	O
94	O	O
mutation	O	O
observed	O	O
in	O	O
our	O	O
family	O	O
is	O	O
a	O	O
novel	O	O
mutation	O	O
in	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
.	O	O

No	O	O
other	O	O
gene	O	O
alteration	O	O
in	O	O
TP53	O	O
,	O	O
P57KIP2	O	O
,	O	O
P15INK4B	O	O
,	O	O
and	O	O
P16INK4A	O	O
was	O	O
observed	O	O
.	O	O

Existence	O	O
of	O	O
the	O	O
P16INK4A	O	O
mutation	O	O
and	O	O
the	O	O
hereditary	O	O
TP53	O	O
mutation	O	O
with	O	O
or	O	O
without	O	O
loss	O	O
of	O	O
heterozygosity	O	O
in	O	O
the	O	O
TP53	O	O
gene	O	O
(	O	O
seminoma	B-Disease	D018239
/	O	O
medulloblastoma	B-Disease	D008527
)	O	O
may	O	O
be	O	O
evidence	O	O
for	O	O
a	O	O
common	O	O
mechanism	O	O
involved	O	O
in	O	O
tumorogenesis	B-Disease	D002471
.	O	O

The	O	O
gene	O	O
alterations	O	O
in	O	O
TP53	O	O
and	O	O
P16INK4A	O	O
genes	O	O
may	O	O
be	O	O
used	O	O
as	O	O
tumor	B-Disease	D009369
markers	O	O
in	O	O
our	O	O
family	O	O
.	O	O

.	O	O

An	O	O
amino	O	O
-	O	O
acid	O	O
substitution	O	O
involved	O	O
in	O	O
phenylketonuria	B-Disease	D010661
is	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
with	O	O
DNA	O	O
haplotype	O	O
2	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
human	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
,	O	O
phenylalanine	O	O
4	O	O
-	O	O
monooxygenase	O	O
,	O	O
EC	O	O
1	O	O
.	O	O

14	O	O
.	O	O

16	O	O
.	O	O

1	O	O
)	O	O
.	O	O

PKU	B-Disease	D010661
is	O	O
a	O	O
common	O	O
inborn	B-Disease	D000592
error	I-Disease	D000592
of	I-Disease	D000592
amino	I-Disease	D000592
-	I-Disease	D000592
acid	I-Disease	D000592
metabolism	I-Disease	D000592
in	O	O
caucasian	O	O
populations	O	O
and	O	O
approximately	O	O
1	O	O
in	O	O
50	O	O
individuals	O	O
are	O	O
carriers	O	O
of	O	O
a	O	O
PKU	B-Disease	D010661
allele	O	O
.	O	O

To	O	O
define	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
PKU	B-Disease	D010661
,	O	O
we	O	O
characterized	O	O
twelve	O	O
restriction	O	O
fragment	O	O
-	O	O
length	O	O
polymorphism	O	O
(	O	O
RFLP	O	O
)	O	O
haplotypes	O	O
of	O	O
the	O	O
PAH	O	O
locus	O	O
in	O	O
the	O	O
northern	O	O
European	O	O
population	O	O
and	O	O
observed	O	O
that	O	O
90	O	O
%	O	O
of	O	O
the	O	O
PKU	B-Disease	D010661
alleles	O	O
in	O	O
this	O	O
population	O	O
are	O	O
confined	O	O
to	O	O
four	O	O
common	O	O
RFLP	O	O
haplotypes	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
reported	O	O
a	O	O
splicing	O	O
mutation	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
that	O	O
is	O	O
associated	O	O
with	O	O
RFLP	O	O
haplotype	O	O
3	O	O
which	O	O
is	O	O
present	O	O
at	O	O
about	O	O
40	O	O
%	O	O
of	O	O
mutant	O	O
alleles	O	O
.	O	O

We	O	O
now	O	O
report	O	O
the	O	O
molecular	B-Disease	D030342
lesion	I-Disease	D030342
associated	O	O
with	O	O
the	O	O
RFLP	O	O
haplotype	O	O
2	O	O
mutant	O	O
allele	O	O
.	O	O

This	O	O
defect	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
C	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transition	O	O
in	O	O
exon	O	O
12	O	O
resulting	O	O
in	O	O
an	O	O
amino	O	O
-	O	O
acid	O	O
substitution	O	O
(	O	O
Arg	O	O
to	O	O
Trp	O	O
)	O	O
at	O	O
residue	O	O
408	O	O
of	O	O
PAH	O	O
.	O	O

Direct	O	O
hybridization	O	O
analysis	O	O
of	O	O
the	O	O
point	O	O
mutation	O	O
using	O	O
a	O	O
specific	O	O
oligonucleotide	O	O
probe	O	O
demonstrated	O	O
that	O	O
this	O	O
mutation	O	O
is	O	O
also	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
with	O	O
RFLP	O	O
haplotype	O	O
2	O	O
alleles	O	O
that	O	O
make	O	O
up	O	O
about	O	O
20	O	O
%	O	O
of	O	O
mutant	O	O
PAH	O	O
genes	O	O
The	O	O
effects	O	O
of	O	O
dystrophin	O	O
gene	O	O
mutations	O	O
on	O	O
the	O	O
ERG	O	O
in	O	O
mice	O	O
and	O	O
humans	O	O
.	O	O

PURPOSE	O	O
.	O	O

The	O	O
authors	O	O
earlier	O	O
findings	O	O
of	O	O
a	O	O
negative	O	O
electroretinogram	O	O
(	O	O
ERG	O	O
)	O	O
in	O	O
a	O	O
boy	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
led	O	O
them	O	O
to	O	O
investigate	O	O
dystrophin	O	O
gene	O	O
deletions	O	O
and	O	O
ERGs	O	O
in	O	O
five	O	O
boys	O	O
with	O	O
DMD	B-Disease	D020388
.	O	O

The	O	O
authors	O	O
wanted	O	O
to	O	O
determined	O	O
whether	O	O
there	O	O
were	O	O
similar	O	O
ERG	O	O
findings	O	O
in	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
DMD	B-Disease	D020388
,	O	O
the	O	O
mdx	O	O
mouse	O	O
.	O	O

METHODS	O	O
.	O	O

Ganzfeld	O	O
ERGs	O	O
were	O	O
recorded	O	O
in	O	O
five	O	O
boys	O	O
with	O	O
DMD	B-Disease	D020388
after	O	O
a	O	O
complete	O	O
ophthalmic	O	O
examination	O	O
.	O	O

The	O	O
dystrophin	O	O
gene	O	O
was	O	O
analyzed	O	O
by	O	O
Southern	O	O
blot	O	O
hybridization	O	O
.	O	O

ERGs	O	O
were	O	O
recorded	O	O
in	O	O
anesthetized	O	O
mdx	O	O
and	O	O
control	O	O
mice	O	O
with	O	O
a	O	O
modified	O	O
Grass	O	O
photostimulator	O	O
(	O	O
Grass	O	O
Instrument	O	O
Company	O	O
,	O	O
Quincy	O	O
,	O	O
MA	O	O
)	O	O
.	O	O

RESULTS	O	O
.	O	O

Ophthalmic	O	O
examinations	O	O
in	O	O
all	O	O
five	O	O
boys	O	O
had	O	O
normal	O	O
findings	O	O
,	O	O
yet	O	O
an	O	O
abnormal	O	O
negative	O	O
ERG	O	O
was	O	O
recorded	O	O
for	O	O
each	O	O
subject	O	O
.	O	O

The	O	O
subjects	O	O
gene	O	O
deletions	O	O
were	O	O
variable	O	O
,	O	O
ranging	O	O
from	O	O
large	O	O
deletions	O	O
to	O	O
no	O	O
detectable	O	O
deletions	O	O
.	O	O

The	O	O
ERGs	O	O
of	O	O
the	O	O
mdx	O	O
mice	O	O
were	O	O
normal	O	O
and	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
from	O	O
those	O	O
of	O	O
the	O	O
control	O	O
mice	O	O
.	O	O

CONCLUSIONS	O	O
.	O	O

The	O	O
authors	O	O
believe	O	O
the	O	O
unique	O	O
ERG	O	O
recorded	O	O
for	O	O
the	O	O
human	O	O
subjects	O	O
is	O	O
a	O	O
manifestation	O	O
of	O	O
DMD	B-Disease	D020388
associated	O	O
with	O	O
defects	O	O
at	O	O
the	O	O
dystrophin	O	O
gene	O	O
locus	O	O
and	O	O
represents	O	O
a	O	O
new	O	O
clinical	O	O
entity	O	O
.	O	O

The	O	O
ERG	O	O
of	O	O
the	O	O
mdx	O	O
mouse	O	O
may	O	O
be	O	O
spared	O	O
for	O	O
several	O	O
reasons	O	O
,	O	O
including	O	O
milder	O	O
effects	O	O
of	O	O
the	O	O
mouse	O	O
gene	O	O
defect	O	O
,	O	O
differences	O	O
in	O	O
muscle	O	O
and	O	O
retinal	O	O
gene	O	O
product	O	O
,	O	O
or	O	O
species	O	O
differences	O	O
in	O	O
the	O	O
biochemical	O	O
role	O	O
of	O	O
dystrophin	O	O
.	O	O

The	O	O
ERG	O	O
shows	O	O
promise	O	O
of	O	O
becoming	O	O
a	O	O
noninvasive	O	O
diagnostic	O	O
tool	O	O
for	O	O
DMD	B-Disease	D020388
and	O	O
its	O	O
milder	O	O
allelic	O	O
forms	O	O
.	O	O

.	O	O

Eight	O	O
novel	O	O
inactivating	O	O
germ	O	O
line	O	O
mutations	O	O
at	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
identified	O	O
by	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
.	O	O

Familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
is	O	O
a	O	O
dominantly	O	O
inherited	O	O
condition	O	O
predisposing	O	O
to	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

The	O	O
recent	O	O
isolation	O	O
of	O	O
the	O	O
responsible	O	O
gene	O	O
(	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
or	O	O
APC	B-Disease	D011125
)	O	O
has	O	O
facilitated	O	O
the	O	O
search	O	O
for	O	O
germ	O	O
line	O	O
mutations	O	O
in	O	O
affected	O	O
individuals	O	O
.	O	O

Previous	O	O
authors	O	O
have	O	O
used	O	O
the	O	O
RNase	O	O
protection	O	O
assay	O	O
and	O	O
the	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphisms	O	O
procedure	O	O
to	O	O
screen	O	O
for	O	O
mutations	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
used	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
(	O	O
DGGE	O	O
)	O	O
.	O	O

DGGE	O	O
analysis	O	O
of	O	O
10	O	O
APC	B-Disease	D011125
exons	O	O
(	O	O
4	O	O
,	O	O
5	O	O
,	O	O
7	O	O
,	O	O
8	O	O
,	O	O
9	O	O
,	O	O
10	O	O
,	O	O
12	O	O
,	O	O
13	O	O
,	O	O
14	O	O
,	O	O
and	O	O
part	O	O
of	O	O
15	O	O
)	O	O
in	O	O
33	O	O
unrelated	O	O
Dutch	O	O
FAP	B-Disease	D011125
patients	O	O
has	O	O
led	O	O
to	O	O
the	O	O
identification	O	O
of	O	O
eight	O	O
novel	O	O
germ	O	O
line	O	O
mutations	O	O
resulting	O	O
in	O	O
stop	O	O
codons	O	O
or	O	O
frameshifts	O	O
.	O	O

The	O	O
results	O	O
reported	O	O
here	O	O
indicate	O	O
that	O	O
(	O	O
1	O	O
)	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
is	O	O
caused	O	O
by	O	O
an	O	O
extremely	O	O
heterogeneous	O	O
spectrum	O	O
of	O	O
point	O	O
mutations	O	O
;	O	O
(	O	O
2	O	O
)	O	O
all	O	O
the	O	O
mutations	O	O
found	O	O
in	O	O
this	O	O
study	O	O
are	O	O
chain	O	O
terminating	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
DGGE	O	O
represents	O	O
a	O	O
rapid	O	O
and	O	O
sensitive	O	O
technique	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
unusually	O	O
large	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

An	O	O
extension	O	O
of	O	O
the	O	O
DGGE	O	O
analysis	O	O
to	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
in	O	O
a	O	O
sufficient	O	O
number	O	O
of	O	O
clinically	O	O
well	O	O
-	O	O
characterized	O	O
,	O	O
unrelated	O	O
patients	O	O
will	O	O
facilitate	O	O
the	O	O
establishment	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
an	O	O
extremely	O	O
heterogeneous	O	O
spectrum	O	O
of	O	O
mutations	O	O
spread	O	O
throughout	O	O
the	O	O
entire	O	O
length	O	O
of	O	O
the	O	O
large	O	O
APC	B-Disease	D011125
gene	O	O
among	O	O
the	O	O
FAP	B-Disease	D011125
patients	O	O
indicates	O	O
that	O	O
this	O	O
approach	O	O
may	O	O
not	O	O
be	O	O
useful	O	O
as	O	O
a	O	O
rapid	O	O
presymptomatic	O	O
diagnostic	O	O
procedure	O	O
in	O	O
a	O	O
routine	O	O
laboratory	O	O
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
above	O	O
DGGE	O	O
approach	O	O
has	O	O
incidentally	O	O
led	O	O
to	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
common	O	O
polymorphism	O	O
in	O	O
exon	O	O
13	O	O
.	O	O

Such	O	O
intragenic	O	O
polymorphisms	O	O
offer	O	O
a	O	O
practical	O	O
approach	O	O
to	O	O
a	O	O
more	O	O
rapid	O	O
procedure	O	O
for	O	O
presymptomatic	O	O
diagnosis	O	O
of	O	O
FAP	B-Disease	D011125
by	O	O
linkage	O	O
analysis	O	O
in	O	O
informative	O	O
families	O	O
.	O	O

.	O	O

Novel	O	O
mutations	O	O
in	O	O
XLRS1	O	O
causing	O	O
retinoschisis	B-Disease	D041441
,	O	O
including	O	O
first	O	O
evidence	O	O
of	O	O
putative	O	O
leader	O	O
sequence	O	O
change	O	O
.	O	O

Juvenile	B-Disease	D041441
retinoschisis	I-Disease	D041441
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
recessive	I-Disease	D040181
disease	I-Disease	D040181
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
XLRS1	O	O
gene	O	O
.	O	O

We	O	O
screened	O	O
31	O	O
new	O	O
unrelated	O	O
patients	O	O
and	O	O
families	O	O
for	O	O
XLRS1	O	O
mutations	O	O
in	O	O
addition	O	O
to	O	O
previously	O	O
reported	O	O
mutations	O	O
for	O	O
60	O	O
of	O	O
our	O	O
families	O	O
(	O	O
Retinoschisis	B-Disease	D041441
Consortium	O	O
,	O	O
Hum	O	O
Mol	O	O
Genet	O	O
1998	O	O
;	O	O
7	O	O
1185	O	O
-	O	O
1192	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
different	O	O
mutations	O	O
including	O	O
12	O	O
novel	O	O
ones	O	O
were	O	O
identified	O	O
in	O	O
28	O	O
patients	O	O
.	O	O

Mutations	O	O
identified	O	O
in	O	O
this	O	O
study	O	O
include	O	O
19	O	O
missense	O	O
mutations	O	O
,	O	O
two	O	O
nonsense	O	O
mutations	O	O
,	O	O
one	O	O
intragenic	O	O
deletion	O	O
,	O	O
four	O	O
microdeletions	O	O
,	O	O
one	O	O
insertion	O	O
,	O	O
and	O	O
one	O	O
intronic	O	O
sequence	O	O
substitution	O	O
that	O	O
is	O	O
likely	O	O
to	O	O
result	O	O
in	O	O
a	O	O
splice	O	O
site	O	O
defect	O	O
.	O	O

Two	O	O
novel	O	O
mutations	O	O
,	O	O
c	O	O
.	O	O

38T	O	O
-	O	O
-	O	O
>	O	O
C	O	O
(	O	O
L13P	O	O
)	O	O
and	O	O
c	O	O
.	O	O

667T	O	O
-	O	O
-	O	O
>	O	O
C	O	O
(	O	O
C223R	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
present	O	O
the	O	O
first	O	O
genetic	O	O
evidence	O	O
for	O	O
the	O	O
functional	O	O
significance	O	O
of	O	O
the	O	O
putative	O	O
leader	O	O
peptide	O	O
sequence	O	O
and	O	O
for	O	O
the	O	O
functional	O	O
significance	O	O
at	O	O
the	O	O
carboxyl	O	O
terminal	O	O
of	O	O
the	O	O
XLRS1	O	O
protein	O	O
beyond	O	O
the	O	O
discoidin	O	O
domain	O	O
.	O	O

Mutations	O	O
in	O	O
25	O	O
of	O	O
the	O	O
families	O	O
were	O	O
localized	O	O
to	O	O
exons	O	O
4	O	O
-	O	O
6	O	O
,	O	O
emphasizing	O	O
the	O	O
critical	O	O
functional	O	O
significance	O	O
of	O	O
the	O	O
discoidin	O	O
domain	O	O
of	O	O
the	O	O
XLRS1	O	O
protein	O	O
Clinical	O	O
use	O	O
of	O	O
DNA	O	O
markers	O	O
linked	O	O
to	O	O
the	O	O
gene	O	O
for	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

Seventy	O	O
families	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
known	O	O
to	O	O
the	O	O
Institute	O	O
of	O	O
Child	O	O
Health	O	O
fall	O	O
into	O	O
three	O	O
categories	O	O
with	O	O
respect	O	O
to	O	O
potential	O	O
linkage	O	O
analysis	O	O
with	O	O
the	O	O
X	O	O
chromosome	O	O
DNA	O	O
markers	O	O
RC8	O	O
and	O	O
L1	O	O
.	O	O

28	O	O
that	O	O
bridge	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

Families	O	O
in	O	O
which	O	O
there	O	O
is	O	O
at	O	O
least	O	O
one	O	O
obligatory	O	O
female	O	O
heterozygote	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
.	O	O

Here	O	O
prediction	O	O
and	O	O
exclusion	O	O
of	O	O
DMD	B-Disease	D020388
gene	O	O
transmission	O	O
may	O	O
be	O	O
possible	O	O
,	O	O
the	O	O
accuracy	O	O
being	O	O
dependent	O	O
on	O	O
the	O	O
closeness	O	O
of	O	O
the	O	O
linkage	O	O
of	O	O
the	O	O
DNA	O	O
marker	O	O
(	O	O
s	O	O
)	O	O
to	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
;	O	O
an	O	O
illustrative	O	O
case	O	O
is	O	O
reported	O	O
.	O	O

Families	O	O
in	O	O
which	O	O
there	O	O
is	O	O
a	O	O
single	O	O
affected	O	O
boy	O	O
,	O	O
who	O	O
also	O	O
has	O	O
one	O	O
or	O	O
more	O	O
healthy	O	O
brothers	O	O
(	O	O
n	O	O
=	O	O
26	O	O
)	O	O
.	O	O

Given	O	O
an	O	O
informative	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
RFLP	O	O
)	O	O
,	O	O
the	O	O
probability	O	O
that	O	O
the	O	O
boy	O	O
represents	O	O
a	O	O
new	O	O
mutation	O	O
can	O	O
be	O	O
reassessed	O	O
;	O	O
it	O	O
is	O	O
also	O	O
possible	O	O
to	O	O
exclude	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
in	O	O
a	O	O
sister	O	O
.	O	O

Families	O	O
with	O	O
a	O	O
single	O	O
affected	O	O
boy	O	O
with	O	O
no	O	O
brother	O	O
(	O	O
n	O	O
=	O	O
30	O	O
)	O	O
.	O	O

Here	O	O
exclusion	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
in	O	O
a	O	O
sister	O	O
may	O	O
be	O	O
possible	O	O
.	O	O

Only	O	O
in	O	O
one	O	O
family	O	O
was	O	O
there	O	O
no	O	O
possibility	O	O
of	O	O
useful	O	O
linkage	O	O
analysis	O	O
.	O	O

The	O	O
linkage	O	O
analysis	O	O
required	O	O
is	O	O
described	O	O
,	O	O
and	O	O
the	O	O
need	O	O
to	O	O
check	O	O
DMD	B-Disease	D020388
families	O	O
for	O	O
informative	O	O
RFLPs	O	O
is	O	O
stressed	O	O
.	O	O

Molecular	O	O
characterization	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
patients	O	O
of	O	O
Chinese	O	O
descent	O	O
and	O	O
identification	O	O
of	O	O
new	O	O
base	O	O
substitutions	O	O
in	O	O
the	O	O
human	O	O
G6PD	O	O
gene	O	O
.	O	O

The	O	O
underlying	O	O
DNA	O	O
changes	O	O
associated	O	O
with	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
Asians	O	O
have	O	O
not	O	O
been	O	O
extensively	O	O
investigated	O	O
.	O	O

To	O	O
fill	O	O
this	O	O
gap	O	O
,	O	O
we	O	O
sequenced	O	O
the	O	O
G6PD	O	O
gene	O	O
of	O	O
43	O	O
G6PD	B-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
Chinese	O	O
whose	O	O
G6PD	O	O
was	O	O
well	O	O
characterized	O	O
biochemically	O	O
.	O	O

DNA	O	O
samples	O	O
were	O	O
obtained	O	O
from	O	O
peripheral	O	O
blood	O	O
of	O	O
these	O	O
individuals	O	O
for	O	O
sequencing	O	O
using	O	O
a	O	O
direct	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
sequencing	O	O
procedure	O	O
.	O	O

From	O	O
these	O	O
43	O	O
samples	O	O
,	O	O
we	O	O
have	O	O
identified	O	O
five	O	O
different	O	O
types	O	O
of	O	O
nucleotide	O	O
substitutions	O	O
in	O	O
the	O	O
G6PD	O	O
gene	O	O
at	O	O
cDNA	O	O
1388	O	O
from	O	O
G	O	O
to	O	O
A	O	O
(	O	O
Arg	O	O
to	O	O
His	O	O
)	O	O
;	O	O
at	O	O
cDNA	O	O
1376	O	O
from	O	O
G	O	O
to	O	O
T	O	O
(	O	O
Arg	O	O
to	O	O
Leu	O	O
)	O	O
;	O	O
at	O	O
cDNA	O	O
1024	O	O
from	O	O
C	O	O
to	O	O
T	O	O
(	O	O
Leu	O	O
to	O	O
Phe	O	O
)	O	O
;	O	O
at	O	O
cDNA	O	O
392	O	O
from	O	O
G	O	O
to	O	O
T	O	O
(	O	O
Gly	O	O
to	O	O
Val	O	O
)	O	O
;	O	O
at	O	O
cDNA	O	O
95	O	O
from	O	O
A	O	O
to	O	O
G	O	O
(	O	O
His	O	O
to	O	O
Arg	O	O
)	O	O
.	O	O

These	O	O
five	O	O
nucleotide	O	O
substitutions	O	O
account	O	O
for	O	O
over	O	O
83	O	O
%	O	O
of	O	O
our	O	O
43	O	O
G6PD	B-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
samples	O	O
and	O	O
these	O	O
substitutions	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
in	O	O
non	O	O
-	O	O
Asians	O	O
.	O	O

The	O	O
substitutions	O	O
found	O	O
at	O	O
cDNA	O	O
392	O	O
and	O	O
cDNA	O	O
1024	O	O
are	O	O
new	O	O
findings	O	O
.	O	O

The	O	O
substitutions	O	O
at	O	O
cDNA	O	O
1376	O	O
and	O	O
1388	O	O
account	O	O
for	O	O
over	O	O
50	O	O
%	O	O
of	O	O
the	O	O
43	O	O
samples	O	O
examined	O	O
indicating	O	O
a	O	O
high	O	O
prevalence	O	O
of	O	O
these	O	O
two	O	O
alleles	O	O
among	O	O
G6PD	B-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
Chinese	O	O
.	O	O

Our	O	O
findings	O	O
add	O	O
support	O	O
to	O	O
the	O	O
notion	O	O
that	O	O
diverse	O	O
point	O	O
mutations	O	O
may	O	O
account	O	O
largely	O	O
for	O	O
much	O	O
of	O	O
the	O	O
phenotypic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

.	O	O

Norrie	B-Disease	C537849
disease	I-Disease	C537849
gene	O	O
:	O	O
characterization	O	O
of	O	O
deletions	O	O
and	O	O
possible	O	O
function	O	O
.	O	O

Positional	O	O
cloning	O	O
experiments	O	O
have	O	O
resulted	O	O
recently	O	O
in	O	O
the	O	O
isolation	O	O
of	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
pseudoglioma	B-Disease	C537849
;	O	O
NDP	B-Disease	C537849
)	O	O
,	O	O
a	O	O
severe	O	O
X	B-Disease	D038901
-	I-Disease	D038901
linked	I-Disease	D038901
neurodevelopmental	I-Disease	D038901
disorder	I-Disease	D038901
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
isolation	O	O
and	O	O
analysis	O	O
of	O	O
human	O	O
genomic	O	O
DNA	O	O
clones	O	O
encompassing	O	O
the	O	O
NDP	B-Disease	C537849
gene	O	O
.	O	O

The	O	O
gene	O	O
spans	O	O
28	O	O
kb	O	O
and	O	O
consists	O	O
of	O	O
3	O	O
exons	O	O
,	O	O
the	O	O
first	O	O
of	O	O
which	O	O
is	O	O
entirely	O	O
contained	O	O
within	O	O
the	O	O
5	O	O
untranslated	O	O
region	O	O
.	O	O

Detailed	O	O
analysis	O	O
of	O	O
genomic	O	O
deletions	O	O
in	O	O
Norrie	B-Disease	C537849
patients	O	O
shows	O	O
that	O	O
they	O	O
are	O	O
heterogeneous	O	O
,	O	O
both	O	O
in	O	O
size	O	O
and	O	O
in	O	O
position	O	O
.	O	O

By	O	O
PCR	O	O
analysis	O	O
,	O	O
we	O	O
found	O	O
that	O	O
expression	O	O
of	O	O
the	O	O
NDP	B-Disease	C537849
gene	O	O
was	O	O
not	O	O
confined	O	O
to	O	O
the	O	O
eye	O	O
or	O	O
to	O	O
the	O	O
brain	O	O
.	O	O

An	O	O
extensive	O	O
DNA	O	O
and	O	O
protein	O	O
sequence	O	O
comparison	O	O
between	O	O
the	O	O
human	O	O
NDP	B-Disease	C537849
gene	O	O
and	O	O
related	O	O
genes	O	O
from	O	O
the	O	O
database	O	O
revealed	O	O
homology	O	O
with	O	O
cysteine	O	O
-	O	O
rich	O	O
protein	O	O
-	O	O
binding	O	O
domains	O	O
of	O	O
immediate	O	O
-	O	O
-	O	O
early	O	O
genes	O	O
implicated	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
proliferation	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
NDP	B-Disease	C537849
is	O	O
a	O	O
molecule	O	O
related	O	O
in	O	O
function	O	O
to	O	O
these	O	O
genes	O	O
and	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
a	O	O
pathway	O	O
that	O	O
regulates	O	O
neural	O	O
cell	O	O
differentiation	O	O
and	O	O
proliferation	O	O
.	O	O

.	O	O

Prenatal	O	O
diagnosis	O	O
of	O	O
Wolman	B-Disease	D015223
disease	I-Disease	D015223
.	O	O

Two	O	O
pregnancies	O	O
at	O	O
risk	O	O
for	O	O
Wolman	B-Disease	D015223
disease	I-Disease	D015223
were	O	O
monitored	O	O
by	O	O
assay	O	O
and	O	O
electrophoresis	O	O
of	O	O
acid	O	O
lipase	O	O
in	O	O
cultured	O	O
amniotic	O	O
-	O	O
fluid	O	O
cells	O	O
.	O	O

Cells	O	O
from	O	O
patient	O	O
1	O	O
had	O	O
5	O	O
%	O	O
of	O	O
control	O	O
levels	O	O
of	O	O
acid	O	O
lipase	O	O
,	O	O
using	O	O
14C	O	O
-	O	O
triolein	O	O
as	O	O
substrate	O	O
;	O	O
however	O	O
,	O	O
when	O	O
artificial	O	O
substrates	O	O
(	O	O
esters	O	O
of	O	O
4	O	O
-	O	O
methylumbelliferone	O	O
and	O	O
p	O	O
-	O	O
nitrophenol	O	O
)	O	O
were	O	O
used	O	O
to	O	O
measure	O	O
acid	O	O
lipase	O	O
,	O	O
these	O	O
cells	O	O
had	O	O
30	O	O
%	O	O
of	O	O
control	O	O
levels	O	O
.	O	O

Electrophoresis	O	O
of	O	O
cell	O	O
extracts	O	O
revealed	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
A	O	O
form	O	O
of	O	O
acid	O	O
lipase	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
Wolman	B-Disease	D015223
disease	I-Disease	D015223
.	O	O

Analysis	O	O
of	O	O
fetal	O	O
tissues	O	O
following	O	O
prostaglandin	O	O
termination	O	O
of	O	O
this	O	O
pregnancy	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
.	O	O

Assay	O	O
of	O	O
fetal	O	O
-	O	O
skin	O	O
fibroblasts	O	O
with	O	O
14C	O	O
-	O	O
triolein	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
artificial	O	O
substrates	O	O
,	O	O
showed	O	O
marked	O	O
deficiency	O	O
of	O	O
acid	O	O
lipase	O	O
activity	O	O
.	O	O

Electrophoresis	O	O
of	O	O
fetal	O	O
-	O	O
tissue	O	O
extracts	O	O
also	O	O
demonstrated	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
A	O	O
form	O	O
of	O	O
acid	O	O
lipase	O	O
.	O	O

Amniotic	O	O
-	O	O
fluid	O	O
cells	O	O
from	O	O
patient	O	O
2	O	O
showed	O	O
normal	O	O
levels	O	O
of	O	O
acid	O	O
lipase	O	O
with	O	O
all	O	O
substrates	O	O
tested	O	O
;	O	O
the	O	O
electrophoretic	O	O
pattern	O	O
of	O	O
acid	O	O
lipase	O	O
was	O	O
normal	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
prenatal	O	O
diagnosis	O	O
of	O	O
Wolman	B-Disease	D015223
disease	I-Disease	D015223
be	O	O
made	O	O
using	O	O
the	O	O
radioassay	O	O
of	O	O
acid	O	O
lipase	O	O
and	O	O
/	O	O
or	O	O
electrophoresis	O	O
.	O	O

.	O	O

Somatic	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
in	O	O
sporadic	B-Disease	D010051
ovarian	I-Disease	D010051
tumours	I-Disease	D010051
.	O	O

The	O	O
BRCA1	O	O
gene	O	O
on	O	O
chromosome	O	O
17q21	O	O
is	O	O
responsible	O	O
for	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
syndrome	I-Disease	D030342
of	O	O
increased	O	O
susceptibility	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
but	O	O
no	O	O
somatic	O	O
mutations	O	O
in	O	O
tumours	B-Disease	D009369
have	O	O
yet	O	O
been	O	O
described	O	O
.	O	O

To	O	O
study	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
BRCA1	O	O
in	O	O
sporadic	O	O
carcinogenesis	O	O
,	O	O
we	O	O
analysed	O	O
the	O	O
genomic	O	O
DNA	O	O
of	O	O
tumour	B-Disease	D009369
and	O	O
normal	O	O
fractions	O	O
of	O	O
47	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
for	O	O
mutations	O	O
in	O	O
BRCA1	O	O
using	O	O
the	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
technique	O	O
.	O	O

We	O	O
now	O	O
describe	O	O
somatic	O	O
mutations	O	O
in	O	O
the	O	O
DNA	O	O
of	O	O
four	O	O
tumours	B-Disease	D009369
which	O	O
also	O	O
had	O	O
loss	O	O
of	O	O
heterozygosity	O	O
(	O	O
LOH	O	O
)	O	O
at	O	O
a	O	O
BRCA1	O	O
intragenic	O	O
marker	O	O
.	O	O

Our	O	O
data	O	O
support	O	O
a	O	O
tumour	B-Disease	D009369
suppressor	O	O
mechanism	O	O
for	O	O
BRCA1	O	O
;	O	O
somatic	O	O
mutations	O	O
and	O	O
LOH	O	O
may	O	O
result	O	O
in	O	O
inactivation	O	O
of	O	O
BRCA1	O	O
in	O	O
at	O	O
least	O	O
a	O	O
small	O	O
number	O	O
of	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
.	O	O

.	O	O

Skewed	O	O
X	O	O
inactivation	O	O
in	O	O
a	O	O
female	O	O
MZ	O	O
twin	O	O
results	O	O
in	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

One	O	O
of	O	O
female	O	O
MZ	O	O
twins	O	O
presented	O	O
with	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
.	O	O

Physical	O	O
examination	O	O
,	O	O
creatine	O	O
phosphokinase	O	O
levels	O	O
,	O	O
and	O	O
muscle	O	O
biopsy	O	O
were	O	O
consistent	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

However	O	O
,	O	O
because	O	O
of	O	O
her	O	O
sex	O	O
she	O	O
was	O	O
diagnosed	O	O
as	O	O
having	O	O
limb	B-Disease	D049288
-	I-Disease	D049288
girdle	I-Disease	D049288
muscular	I-Disease	D049288
dystrophy	I-Disease	D049288
.	O	O

With	O	O
cDNA	O	O
probes	O	O
to	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
,	O	O
a	O	O
gene	O	O
deletion	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
twins	O	O
and	O	O
their	O	O
mother	O	O
.	O	O

The	O	O
de	O	O
novo	O	O
mutation	O	O
which	O	O
arose	O	O
in	O	O
the	O	O
mother	O	O
was	O	O
shown	O	O
by	O	O
novel	O	O
junction	O	O
fragments	O	O
generated	O	O
by	O	O
HindIII	O	O
,	O	O
PstI	O	O
,	O	O
or	O	O
TaqI	O	O
when	O	O
probed	O	O
with	O	O
cDNA8	O	O
.	O	O

Additional	O	O
evidence	O	O
of	O	O
a	O	O
large	O	O
gene	O	O
deletion	O	O
was	O	O
given	O	O
by	O	O
novel	O	O
SfiI	O	O
junction	O	O
fragments	O	O
detected	O	O
by	O	O
probes	O	O
p20	O	O
,	O	O
J	O	O
-	O	O
Bir	O	O
,	O	O
and	O	O
J	O	O
-	O	O
66	O	O
on	O	O
pulsed	O	O
-	O	O
field	O	O
gel	O	O
electrophoresis	O	O
(	O	O
PFGE	O	O
)	O	O
.	O	O

Immunoblot	O	O
analysis	O	O
of	O	O
muscle	O	O
from	O	O
the	O	O
affected	O	O
twin	O	O
showed	O	O
dystrophin	O	O
of	O	O
normal	O	O
size	O	O
but	O	O
of	O	O
reduced	O	O
amount	O	O
.	O	O

Immunofluorescent	O	O
visualization	O	O
of	O	O
dystrophin	O	O
revealed	O	O
foci	O	O
of	O	O
dystrophin	O	O
-	O	O
positive	O	O
fibers	O	O
adjacent	O	O
to	O	O
foci	O	O
of	O	O
dystrophin	O	O
-	O	O
negative	O	O
fibers	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
affected	O	O
twin	O	O
is	O	O
a	O	O
manifesting	O	O
carrier	O	O
of	O	O
an	O	O
abnormal	O	O
DMD	B-Disease	D020388
gene	O	O
,	O	O
her	O	O
myopathy	B-Disease	D009135
being	O	O
a	O	O
direct	O	O
result	O	O
of	O	O
underexpression	O	O
of	O	O
dystrophin	O	O
.	O	O

Cytogenetic	O	O
analysis	O	O
revealed	O	O
normal	O	O
karyotypes	O	O
,	O	O
eliminating	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
translocation	O	O
affecting	O	O
DMD	B-Disease	D020388
gene	O	O
function	O	O
.	O	O

Both	O	O
linkage	O	O
analysis	O	O
and	O	O
DNA	O	O
fingerprint	O	O
analysis	O	O
revealed	O	O
that	O	O
each	O	O
twin	O	O
has	O	O
two	O	O
different	O	O
X	O	O
chromosomes	O	O
,	O	O
eliminating	O	O
the	O	O
possibility	O	O
of	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
as	O	O
a	O	O
mechanism	O	O
for	O	O
DMD	B-Disease	D020388
expression	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
methylation	O	O
differences	O	O
of	O	O
the	O	O
paternal	O	O
and	O	O
maternal	O	O
X	O	O
chromosomes	O	O
in	O	O
these	O	O
MZ	O	O
twins	O	O
,	O	O
we	O	O
propose	O	O
uneven	O	O
lyonization	O	O
(	O	O
X	O	O
chromosome	O	O
inactivation	O	O
)	O	O
as	O	O
the	O	O
underlying	O	O
mechanism	O	O
for	O	O
disease	O	O
expression	O	O
in	O	O
the	O	O
affected	O	O
female	O	O
.	O	O

.	O	O

Coincident	O	O
Kaposi	B-Disease	D012514
sarcoma	I-Disease	D012514
and	O	O
T	B-Disease	D016399
-	I-Disease	D016399
cell	I-Disease	D016399
lymphoma	I-Disease	D016399
in	O	O
a	O	O
patient	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

A	O	O
24	O	O
year	O	O
old	O	O
male	O	O
with	O	O
a	O	O
history	O	O
of	O	O
eczema	B-Disease	D004485
,	O	O
recurrent	O	O
mild	O	O
infections	O	O
,	O	O
and	O	O
thrombocytopenia	B-Disease	D013921
consistent	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
presented	O	O
with	O	O
a	O	O
mediastinal	O	O
mass	O	O
,	O	O
generalized	O	O
lymphadenopathy	B-Disease	D008206
,	O	O
splenomegaly	B-Disease	D013163
,	O	O
and	O	O
severe	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

Studies	O	O
of	O	O
immune	O	O
function	O	O
including	O	O
immunoglobulin	O	O
levels	O	O
and	O	O
T	O	O
-	O	O
cell	O	O
subsets	O	O
were	O	O
normal	O	O
.	O	O

Furthermore	O	O
,	O	O
his	O	O
T	O	O
lymphocytes	O	O
proliferated	O	O
normally	O	O
in	O	O
response	O	O
to	O	O
phytohemagglutinin	O	O
,	O	O
concanavalin	O	O
A	O	O
,	O	O
and	O	O
the	O	O
combination	O	O
of	O	O
neuraminidase	O	O
/	O	O
galactose	O	O
oxidase	O	O
.	O	O

However	O	O
,	O	O
their	O	O
proliferative	O	O
responses	O	O
to	O	O
anti	O	O
-	O	O
CD43	O	O
antibody	O	O
and	O	O
periodate	O	O
were	O	O
diminished	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
clinical	O	O
diagnosis	O	O
of	O	O
WAS	B-Disease	D014923
.	O	O

An	O	O
initial	O	O
inguinal	O	O
lymph	O	O
node	O	O
biopsy	O	O
surprisingly	O	O
revealed	O	O
Kaposi	B-Disease	D012514
sarcoma	I-Disease	D012514
.	O	O

However	O	O
,	O	O
following	O	O
splenectomy	O	O
to	O	O
increase	O	O
the	O	O
platelet	O	O
count	O	O
,	O	O
biopsy	O	O
of	O	O
the	O	O
mediastinal	O	O
mass	O	O
revealed	O	O
T	B-Disease	D016399
-	I-Disease	D016399
cell	I-Disease	D016399
large	I-Disease	D016399
cell	I-Disease	D016399
lymphoma	I-Disease	D016399
.	O	O

Studies	O	O
of	O	O
biopsied	O	O
tissue	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
Epstein	B-Disease	D020031
-	I-Disease	D020031
Barr	I-Disease	D020031
virus	I-Disease	D020031
and	O	O
cytomegalovirus	B-Disease	D003586
were	O	O
negative	O	O
,	O	O
as	O	O
were	O	O
studies	O	O
of	O	O
blood	O	O
,	O	O
including	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
(	O	O
HIV	B-Disease	D015658
)	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
Kaposi	B-Disease	D012514
sarcoma	I-Disease	D012514
arising	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
congenital	B-Disease	D007153
immunodeficiency	I-Disease	D007153
syndrome	I-Disease	D007153
.	O	O

Although	O	O
Kaposi	B-Disease	D012514
sarcoma	I-Disease	D012514
can	O	O
arise	O	O
in	O	O
the	O	O
face	O	O
of	O	O
the	O	O
severe	O	O
immunosuppression	O	O
that	O	O
follows	O	O
allograft	O	O
transplantation	O	O
and	O	O
in	O	O
patients	O	O
infected	O	O
with	O	O
HIV	B-Disease	D015658
,	O	O
we	O	O
postulate	O	O
that	O	O
longevity	O	O
in	O	O
the	O	O
face	O	O
of	O	O
mild	O	O
immunosuppression	O	O
was	O	O
the	O	O
major	O	O
factor	O	O
in	O	O
the	O	O
development	O	O
of	O	O
Kaposi	B-Disease	D012514
sarcoma	I-Disease	D012514
in	O	O
this	O	O
patient	O	O
.	O	O

.	O	O

Treatment	O	O
of	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
:	O	O
effects	O	O
of	O	O
chenodeoxycholic	O	O
acid	O	O
,	O	O
pravastatin	O	O
,	O	O
and	O	O
combined	O	O
use	O	O
.	O	O

Treatments	O	O
by	O	O
oral	O	O
administration	O	O
of	O	O
chenodeoxycholic	O	O
acid	O	O
(	O	O
CDCA	O	O
)	O	O
alone	O	O
,	O	O
3	O	O
-	O	O
hydroxy	O	O
-	O	O
3	O	O
-	O	O
methylglutaryl	O	O
(	O	O
HMG	O	O
)	O	O
CoA	O	O
reductase	O	O
inhibitor	O	O
(	O	O
pravastatin	O	O
)	O	O
alone	O	O
,	O	O
and	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
were	O	O
attempted	O	O
for	O	O
7	O	O
patients	O	O
with	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
.	O	O

CDCA	O	O
treatment	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
300	O	O
mg	O	O
/	O	O
day	O	O
reduced	O	O
serum	O	O
cholestanol	O	O
(	O	O
67	O	O
.	O	O

3	O	O
%	O	O
reduction	O	O
)	O	O
,	O	O
lathosterol	O	O
(	O	O
50	O	O
.	O	O

8	O	O
%	O	O
)	O	O
,	O	O
campesterol	O	O
(	O	O
61	O	O
.	O	O

7	O	O
%	O	O
)	O	O
and	O	O
sitosterol	O	O
(	O	O
12	O	O
.	O	O

7	O	O
%	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
sera	O	O
of	O	O
the	O	O
patients	O	O
changed	O	O
to	O	O
be	O	O
"	O	O
atherogenic	O	O
"	O	O
;	O	O
total	O	O
cholesterol	O	O
,	O	O
triglyceride	O	O
and	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
-	O	O
cholesterol	O	O
were	O	O
increased	O	O
,	O	O
while	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
-	O	O
cholesterol	O	O
was	O	O
decreased	O	O
.	O	O

Contrarily	O	O
,	O	O
pravastatin	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
10	O	O
mg	O	O
/	O	O
day	O	O
improved	O	O
the	O	O
sera	O	O
of	O	O
the	O	O
patients	O	O
to	O	O
be	O	O
markedly	O	O
"	O	O
anti	O	O
-	O	O
atherogenic	O	O
"	O	O
,	O	O
but	O	O
the	O	O
reductions	O	O
of	O	O
cholestanol	O	O
(	O	O
30	O	O
.	O	O

4	O	O
%	O	O
)	O	O
,	O	O
lathosterol	O	O
(	O	O
44	O	O
.	O	O

0	O	O
%	O	O
)	O	O
,	O	O
campesterol	O	O
(	O	O
22	O	O
.	O	O

9	O	O
%	O	O
)	O	O
and	O	O
sitosterol	O	O
(	O	O
9	O	O
.	O	O

6	O	O
%	O	O
)	O	O
were	O	O
inadequate	O	O
.	O	O

Combined	O	O
treatment	O	O
with	O	O
CDCA	O	O
and	O	O
pravastatin	O	O
showed	O	O
good	O	O
overlapping	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
each	O	O
drug	O	O
alone	O	O
.	O	O

The	O	O
sera	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
apparently	O	O
more	O	O
"	O	O
anti	O	O
-	O	O
atherogenic	O	O
"	O	O
than	O	O
those	O	O
after	O	O
CDCA	O	O
treatment	O	O
.	O	O

Serum	O	O
cholestanol	O	O
concentration	O	O
was	O	O
still	O	O
2	O	O
.	O	O

7	O	O
times	O	O
higher	O	O
than	O	O
in	O	O
controls	O	O
,	O	O
but	O	O
the	O	O
serum	O	O
lathosterol	O	O
level	O	O
was	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
enhancement	O	O
of	O	O
overall	O	O
cholesterol	O	O
synthesis	O	O
in	O	O
the	O	O
patients	O	O
was	O	O
sufficiently	O	O
suppressed	O	O
.	O	O

Plant	O	O
sterol	O	O
levels	O	O
were	O	O
also	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
CDCA	O	O
and	O	O
pravastatin	O	O
was	O	O
a	O	O
good	O	O
treatment	O	O
for	O	O
CTX	B-Disease	D019294
,	O	O
based	O	O
on	O	O
the	O	O
improvement	O	O
of	O	O
serum	O	O
lipoprotein	O	O
metabolism	O	O
,	O	O
the	O	O
suppression	O	O
of	O	O
cholesterol	O	O
synthesis	O	O
,	O	O
and	O	O
reductions	O	O
of	O	O
cholestanol	O	O
and	O	O
plant	O	O
sterol	O	O
levels	O	O
.	O	O

In	O	O
all	O	O
of	O	O
7	O	O
patients	O	O
,	O	O
the	O	O
progression	O	O
of	O	O
disease	O	O
was	O	O
arrested	O	O
,	O	O
but	O	O
dramatic	O	O
effects	O	O
on	O	O
clinical	O	O
manifestations	O	O
,	O	O
xanthoma	B-Disease	D014973
,	O	O
and	O	O
electrophysiological	O	O
findings	O	O
could	O	O
not	O	O
be	O	O
found	O	O
after	O	O
the	O	O
treatment	O	O
of	O	O
these	O	O
drugs	O	O
Combined	B-Disease	OMIM:610102
genetic	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
C6	I-Disease	OMIM:610102
and	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
in	O	O
man	O	O
.	O	O

By	O	O
routine	O	O
screening	O	O
of	O	O
sera	O	O
,	O	O
a	O	O
subject	O	O
was	O	O
discovered	O	O
who	O	O
showed	O	O
a	O	O
sub	B-Disease	OMIM:610102
-	I-Disease	OMIM:610102
total	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
C6	I-Disease	OMIM:610102
and	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
.	O	O

No	O	O
clinical	O	O
disease	O	O
was	O	O
associated	O	O
with	O	O
this	O	O
deficiency	O	O
which	O	O
was	O	O
transmitted	O	O
through	O	O
the	O	O
subjects	O	O
family	O	O
as	O	O
a	O	O
single	O	O
genetic	O	O
characteristic	O	O
,	O	O
the	O	O
C6	B-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
being	O	O
associated	O	O
with	O	O
a	O	O
silent	O	O
allele	O	O
at	O	O
the	O	O
structural	O	O
locus	O	O
.	O	O

The	O	O
propositus	O	O
was	O	O
found	O	O
to	O	O
have	O	O
low	O	O
quantities	O	O
of	O	O
an	O	O
abnormal	O	O
C6	O	O
which	O	O
was	O	O
both	O	O
antigenically	O	O
deficient	O	O
and	O	O
smaller	O	O
in	O	O
size	O	O
than	O	O
normal	O	O
C6	O	O
(	O	O
110	O	O
,	O	O
000	O	O
daltons	O	O
compared	O	O
with	O	O
140	O	O
,	O	O
000	O	O
daltons	O	O
)	O	O
and	O	O
small	O	O
quantities	O	O
of	O	O
apparently	O	O
normal	O	O
C7	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
the	O	O
most	O	O
likely	O	O
explanation	O	O
for	O	O
this	O	O
defect	O	O
is	O	O
that	O	O
the	O	O
subject	O	O
has	O	O
a	O	O
structural	O	O
mutation	O	O
in	O	O
his	O	O
C6	O	O
gene	O	O
which	O	O
produces	O	O
hyopsynthesis	O	O
not	O	O
only	O	O
of	O	O
C6	O	O
but	O	O
also	O	O
of	O	O
the	O	O
closely	O	O
linked	O	O
gene	O	O
for	O	O
C7	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
the	O	O
possibility	O	O
that	O	O
C6	O	O
and	O	O
C7	O	O
may	O	O
function	O	O
as	O	O
a	O	O
single	O	O
genetic	O	O
unit	O	O
and	O	O
that	O	O
the	O	O
primary	O	O
transcript	O	O
copied	O	O
from	O	O
the	O	O
genome	O	O
includes	O	O
information	O	O
for	O	O
both	O	O
proteins	O	O
.	O	O

.	O	O

Partial	O	O
deletion	O	O
8q	O	O
without	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
:	O	O
a	O	O
recognisable	O	O
syndrome	O	O
.	O	O

We	O	O
report	O	O
two	O	O
de	O	O
novo	O	O
cases	O	O
of	O	O
del	O	O
(	O	O
8	O	O
)	O	O
(	O	O
pter	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q24	O	O
.	O	O

1	O	O
)	O	O
with	O	O
breakpoints	O	O
involving	O	O
the	O	O
distal	O	O
part	O	O
of	O	O
band	O	O
8q24	O	O
.	O	O

1	O	O
1	O	O
.	O	O

The	O	O
clinical	O	O
features	O	O
were	O	O
similar	O	O
and	O	O
there	O	O
were	O	O
no	O	O
obvious	O	O
stigmata	O	O
of	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
(	O	O
LGS	B-Disease	D015826
)	O	O
.	O	O

There	O	O
are	O	O
three	O	O
other	O	O
cases	O	O
reported	O	O
with	O	O
a	O	O
deletion	O	O
of	O	O
chromosome	O	O
8	O	O
at	O	O
approximately	O	O
the	O	O
same	O	O
breakpoint	O	O
,	O	O
one	O	O
without	O	O
LGS	B-Disease	D015826
and	O	O
some	O	O
similarities	O	O
to	O	O
our	O	O
cases	O	O
,	O	O
the	O	O
other	O	O
two	O	O
with	O	O
LGS	B-Disease	D015826
.	O	O

Our	O	O
findings	O	O
would	O	O
support	O	O
the	O	O
observation	O	O
that	O	O
the	O	O
critical	O	O
segment	O	O
for	O	O
the	O	O
assignment	O	O
of	O	O
LGS	B-Disease	D015826
is	O	O
proximal	O	O
to	O	O
or	O	O
involves	O	O
the	O	O
proximal	O	O
part	O	O
of	O	O
8q24	O	O
.	O	O

1	O	O
,	O	O
but	O	O
a	O	O
review	O	O
of	O	O
published	O	O
reports	O	O
suggests	O	O
that	O	O
the	O	O
aetiology	O	O
of	O	O
LGS	B-Disease	D015826
may	O	O
be	O	O
a	O	O
more	O	O
complex	O	O
issue	O	O
Iron	O	O
-	O	O
dependent	O	O
self	O	O
-	O	O
assembly	O	O
of	O	O
recombinant	O	O
yeast	O	O
frataxin	O	O
:	O	O
implications	O	O
for	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

Frataxin	B-Disease	D005621
deficiency	I-Disease	D005621
is	O	O
the	O	O
primary	O	O
cause	O	O
of	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
,	O	O
an	O	O
autosomal	B-Disease	D030342	D019636
recessive	I-Disease	D030342	D019636
cardiodegenerative	I-Disease	D030342	D019636
and	I-Disease	D030342	D019636
neurodegenerative	I-Disease	D030342	D019636
disease	I-Disease	D030342	D019636
.	O	O

Frataxin	O	O
is	O	O
a	O	O
nuclear	O	O
-	O	O
encoded	O	O
mitochondrial	O	O
protein	O	O
that	O	O
is	O	O
widely	O	O
conserved	O	O
among	O	O
eukaryotes	O	O
.	O	O

Genetic	O	O
inactivation	O	O
of	O	O
the	O	O
yeast	O	O
frataxin	O	O
homologue	O	O
(	O	O
Yfh1p	O	O
)	O	O
results	O	O
in	O	O
mitochondrial	B-Disease	D028361
iron	I-Disease	D028361
accumulation	I-Disease	D028361
and	O	O
hypersensitivity	B-Disease	D004194
to	I-Disease	D004194
oxidative	I-Disease	D004194
stress	I-Disease	D004194
.	O	O

Increased	O	O
iron	O	O
deposition	O	O
and	O	O
evidence	O	O
of	O	O
oxidative	O	O
damage	O	O
have	O	O
also	O	O
been	O	O
observed	O	O
in	O	O
cardiac	O	O
tissue	O	O
and	O	O
cultured	O	O
fibroblasts	O	O
from	O	O
patients	O	O
with	O	O
FRDA	B-Disease	D005621
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
frataxin	O	O
is	O	O
essential	O	O
for	O	O
mitochondrial	O	O
iron	O	O
homeostasis	O	O
and	O	O
protection	O	O
from	O	O
iron	O	O
-	O	O
induced	O	O
formation	O	O
of	O	O
free	O	O
radicals	O	O
.	O	O

The	O	O
functional	O	O
mechanism	O	O
of	O	O
frataxin	O	O
,	O	O
however	O	O
,	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O

We	O	O
have	O	O
expressed	O	O
the	O	O
mature	O	O
form	O	O
of	O	O
Yfh1p	O	O
(	O	O
mYfh1p	O	O
)	O	O
in	O	O
Escherichia	O	O
coli	O	O
and	O	O
have	O	O
analyzed	O	O
its	O	O
function	O	O
in	O	O
vitro	O	O
.	O	O

Isolated	O	O
mYfh1p	O	O
is	O	O
a	O	O
soluble	O	O
monomer	O	O
(	O	O
13	O	O
,	O	O
783	O	O
Da	O	O
)	O	O
that	O	O
contains	O	O
no	O	O
iron	O	O
and	O	O
shows	O	O
no	O	O
significant	O	O
tendency	O	O
to	O	O
self	O	O
-	O	O
associate	O	O
.	O	O

Aerobic	O	O
addition	O	O
of	O	O
ferrous	O	O
iron	O	O
to	O	O
mYfh1p	O	O
results	O	O
in	O	O
assembly	O	O
of	O	O
regular	O	O
spherical	O	O
multimers	O	O
with	O	O
a	O	O
molecular	O	O
mass	O	O
of	O	O
approximately	O	O
1	O	O
.	O	O

1	O	O
MDa	O	O
(	O	O
megadaltons	O	O
)	O	O
and	O	O
a	O	O
diameter	O	O
of	O	O
13	O	O
+	O	O
/	O	O
-	O	O
2	O	O
nm	O	O
.	O	O

Each	O	O
multimer	O	O
consists	O	O
of	O	O
approximately	O	O
60	O	O
subunits	O	O
and	O	O
can	O	O
sequester	O	O
>	O	O
3	O	O
,	O	O
000	O	O
atoms	O	O
of	O	O
iron	O	O
.	O	O

Titration	O	O
of	O	O
mYfh1p	O	O
with	O	O
increasing	O	O
iron	O	O
concentrations	O	O
supports	O	O
a	O	O
stepwise	O	O
mechanism	O	O
of	O	O
multimer	O	O
assembly	O	O
.	O	O

Sequential	O	O
addition	O	O
of	O	O
an	O	O
iron	O	O
chelator	O	O
and	O	O
a	O	O
reducing	O	O
agent	O	O
results	O	O
in	O	O
quantitative	O	O
iron	O	O
release	O	O
with	O	O
concomitant	O	O
disassembly	O	O
of	O	O
the	O	O
multimer	O	O
,	O	O
indicating	O	O
that	O	O
mYfh1p	O	O
sequesters	O	O
iron	O	O
in	O	O
an	O	O
available	O	O
form	O	O
.	O	O

In	O	O
yeast	O	O
mitochondria	O	O
,	O	O
native	O	O
mYfh1p	O	O
exists	O	O
as	O	O
monomer	O	O
and	O	O
a	O	O
higher	O	O
-	O	O
order	O	O
species	O	O
with	O	O
a	O	O
molecular	O	O
weight	O	O
>	O	O
600	O	O
,	O	O
000	O	O
.	O	O

After	O	O
addition	O	O
of	O	O
(	O	O
55	O	O
)	O	O
Fe	O	O
to	O	O
the	O	O
medium	O	O
,	O	O
immunoprecipitates	O	O
of	O	O
this	O	O
species	O	O
contain	O	O
>	O	O
16	O	O
atoms	O	O
of	O	O
(	O	O
55	O	O
)	O	O
Fe	O	O
per	O	O
molecule	O	O
of	O	O
mYfh1p	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
iron	O	O
-	O	O
dependent	O	O
self	O	O
-	O	O
assembly	O	O
of	O	O
recombinant	O	O
mYfh1p	O	O
reflects	O	O
a	O	O
physiological	O	O
role	O	O
for	O	O
frataxin	O	O
in	O	O
mitochondrial	O	O
iron	O	O
sequestration	O	O
and	O	O
bioavailability	O	O
.	O	O

.	O	O

Human	O	O
mutations	O	O
in	O	O
glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
reflect	O	O
evolutionary	O	O
history	O	O
.	O	O

Glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
is	O	O
a	O	O
cytosolic	O	O
enzyme	O	O
encoded	O	O
by	O	O
a	O	O
housekeeping	O	O
X	O	O
-	O	O
linked	O	O
gene	O	O
whose	O	O
main	O	O
function	O	O
is	O	O
to	O	O
produce	O	O
NADPH	O	O
,	O	O
a	O	O
key	O	O
electron	O	O
donor	O	O
in	O	O
the	O	O
defense	O	O
against	O	O
oxidizing	O	O
agents	O	O
and	O	O
in	O	O
reductive	O	O
biosynthetic	O	O
reactions	O	O
.	O	O

Inherited	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
associated	O	O
with	O	O
either	O	O
episodic	B-Disease	D000743
hemolytic	I-Disease	D000743
anemia	I-Disease	D000743
(	O	O
triggered	O	O
by	O	O
fava	O	O
beans	O	O
or	O	O
other	O	O
agents	O	O
)	O	O
or	O	O
life	B-Disease	D000745
-	I-Disease	D000745
long	I-Disease	D000745
hemolytic	I-Disease	D000745
anemia	I-Disease	D000745
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
an	O	O
evolutionary	O	O
analysis	O	O
is	O	O
a	O	O
key	O	O
to	O	O
understanding	O	O
the	O	O
biology	O	O
of	O	O
a	O	O
housekeeping	O	O
gene	O	O
.	O	O

From	O	O
the	O	O
alignment	O	O
of	O	O
the	O	O
amino	O	O
acid	O	O
(	O	O
aa	O	O
)	O	O
sequence	O	O
of	O	O
52	O	O
glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
species	O	O
from	O	O
42	O	O
different	O	O
organisms	O	O
,	O	O
we	O	O
found	O	O
a	O	O
striking	O	O
correlation	O	O
between	O	O
the	O	O
aa	O	O
replacements	O	O
that	O	O
cause	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
humans	O	O
and	O	O
the	O	O
sequence	O	O
conservation	O	O
of	O	O
G6PD	O	O
two	O	O
-	O	O
thirds	O	O
of	O	O
such	O	O
replacements	O	O
are	O	O
in	O	O
highly	O	O
and	O	O
moderately	O	O
conserved	O	O
(	O	O
50	O	O
-	O	O
99	O	O
%	O	O
)	O	O
aa	O	O
;	O	O
relatively	O	O
few	O	O
are	O	O
in	O	O
fully	O	O
conserved	O	O
aa	O	O
(	O	O
where	O	O
they	O	O
might	O	O
be	O	O
lethal	O	O
)	O	O
or	O	O
in	O	O
poorly	O	O
conserved	O	O
aa	O	O
,	O	O
where	O	O
presumably	O	O
they	O	O
simply	O	O
would	O	O
not	O	O
cause	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

This	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
notion	O	O
that	O	O
all	O	O
human	O	O
mutants	O	O
have	O	O
residual	O	O
enzyme	O	O
activity	O	O
and	O	O
that	O	O
null	O	O
mutations	O	O
are	O	O
lethal	O	O
at	O	O
some	O	O
stage	O	O
of	O	O
development	O	O
.	O	O

Comparing	O	O
the	O	O
distribution	O	O
of	O	O
mutations	O	O
in	O	O
a	O	O
human	O	O
housekeeping	O	O
gene	O	O
with	O	O
evolutionary	O	O
conservation	O	O
is	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
pinpointing	O	O
amino	O	O
acid	O	O
residues	O	O
important	O	O
for	O	O
the	O	O
stability	O	O
or	O	O
the	O	O
function	O	O
of	O	O
the	O	O
corresponding	O	O
protein	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
current	O	O
explosive	O	O
increase	O	O
in	O	O
full	O	O
genome	O	O
sequencing	O	O
projects	O	O
,	O	O
this	O	O
tool	O	O
will	O	O
become	O	O
rapidly	O	O
available	O	O
for	O	O
numerous	O	O
other	O	O
genes	O	O
.	O	O

.	O	O

Regionally	O	O
clustered	O	O
APC	B-Disease	D011125
mutations	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
severe	O	O
phenotype	O	O
and	O	O
occur	O	O
at	O	O
a	O	O
high	O	O
frequency	O	O
in	O	O
new	O	O
mutation	O	O
cases	O	O
of	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
.	O	O

Germline	O	O
mutation	O	O
in	O	O
APC	B-Disease	D011125
at	O	O
5q21	O	O
-	O	O
22	O	O
results	O	O
in	O	O
the	O	O
dominantly	O	O
inherited	O	O
syndrome	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
.	O	O

Somatic	O	O
mutation	O	O
in	O	O
this	O	O
gene	O	O
is	O	O
an	O	O
early	O	O
event	O	O
in	O	O
colorectal	O	O
tumourigenesis	O	O
.	O	O

Both	O	O
types	O	O
of	O	O
mutation	O	O
are	O	O
concentrated	O	O
in	O	O
the	O	O
5	O	O
half	O	O
of	O	O
exon	O	O
15	O	O
.	O	O

We	O	O
have	O	O
used	O	O
single	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
and	O	O
heteroduplex	O	O
analysis	O	O
to	O	O
screen	O	O
for	O	O
variants	O	O
in	O	O
this	O	O
region	O	O
of	O	O
the	O	O
gene	O	O
in	O	O
a	O	O
total	O	O
of	O	O
45	O	O
affected	O	O
but	O	O
unrelated	O	O
individuals	O	O
.	O	O

Eighteen	O	O
patients	O	O
had	O	O
no	O	O
family	O	O
history	O	O
of	O	O
the	O	O
disease	O	O
;	O	O
of	O	O
these	O	O
11	O	O
were	O	O
classified	O	O
as	O	O
having	O	O
a	O	O
severe	O	O
phenotype	O	O
,	O	O
based	O	O
on	O	O
an	O	O
early	O	O
age	O	O
at	O	O
presentation	O	O
or	O	O
cancer	B-Disease	D009369
development	O	O
.	O	O

This	O	O
compared	O	O
with	O	O
6	O	O
of	O	O
27	O	O
familial	O	O
cases	O	O
.	O	O

A	O	O
5	O	O
bp	O	O
deletion	O	O
at	O	O
codon	O	O
1309	O	O
reported	O	O
to	O	O
occur	O	O
in	O	O
10	O	O
-	O	O
15	O	O
%	O	O
of	O	O
unselected	O	O
APC	B-Disease	D011125
patients	O	O
worldwide	O	O
,	O	O
was	O	O
found	O	O
in	O	O
5	O	O
of	O	O
the	O	O
18	O	O
new	O	O
mutation	O	O
cases	O	O
and	O	O
4	O	O
of	O	O
the	O	O
27	O	O
familial	O	O
cases	O	O
all	O	O
nine	O	O
were	O	O
classed	O	O
as	O	O
severe	O	O
.	O	O

A	O	O
further	O	O
3	O	O
new	O	O
mutations	O	O
and	O	O
1	O	O
familial	O	O
mutation	O	O
were	O	O
located	O	O
downstream	O	O
from	O	O
codon	O	O
1309	O	O
,	O	O
these	O	O
individuals	O	O
similarly	O	O
being	O	O
classed	O	O
as	O	O
phenotypically	O	O
severe	O	O
.	O	O

In	O	O
contrast	O	O
all	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
mutations	O	O
detected	O	O
in	O	O
affected	O	O
individuals	O	O
with	O	O
an	O	O
average	O	O
phenotype	O	O
were	O	O
located	O	O
prior	O	O
to	O	O
codon	O	O
1309	O	O
.	O	O

The	O	O
frequent	O	O
association	O	O
of	O	O
a	O	O
severe	O	O
phenotype	O	O
with	O	O
fresh	O	O
mutation	O	O
may	O	O
explain	O	O
the	O	O
apparent	O	O
conflict	O	O
of	O	O
a	O	O
high	O	O
mutation	O	O
rate	O	O
(	O	O
20	O	O
-	O	O
30	O	O
%	O	O
)	O	O
in	O	O
a	O	O
condition	O	O
,	O	O
which	O	O
on	O	O
average	O	O
,	O	O
is	O	O
lethal	O	O
at	O	O
a	O	O
post	O	O
-	O	O
reproductive	O	O
age	O	O
.	O	O

.	O	O

Analysis	O	O
of	O	O
alkaptonuria	B-Disease	D000474
(	O	O
AKU	B-Disease	D000474
)	O	O
mutations	O	O
and	O	O
polymorphisms	O	O
reveals	O	O
that	O	O
the	O	O
CCC	O	O
sequence	O	O
motif	O	O
is	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
in	O	O
the	O	O
homogentisate	O	O
1	O	O
,	O	O
2	O	O
dioxygenase	O	O
gene	O	O
(	O	O
HGO	O	O
)	O	O
.	O	O

We	O	O
recently	O	O
showed	O	O
that	O	O
alkaptonuria	B-Disease	D000474
(	O	O
AKU	B-Disease	D000474
)	O	O
is	O	O
caused	O	O
by	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
in	O	O
the	O	O
homogentisate	O	O
1	O	O
,	O	O
2	O	O
dioxygenase	O	O
gene	O	O
(	O	O
HGO	O	O
)	O	O
.	O	O

Herein	O	O
we	O	O
describe	O	O
haplotype	O	O
and	O	O
mutational	O	O
analyses	O	O
of	O	O
HGO	O	O
in	O	O
seven	O	O
new	O	O
AKU	B-Disease	D000474
pedigrees	O	O
.	O	O

These	O	O
analyses	O	O
identified	O	O
two	O	O
novel	O	O
single	O	O
-	O	O
nucleotide	O	O
polymorphisms	O	O
(	O	O
INV4	O	O
+	O	O
31A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
and	O	O
INV11	O	O
+	O	O
18A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
and	O	O
six	O	O
novel	O	O
AKU	B-Disease	D000474
mutations	O	O
(	O	O
INV1	O	O
-	O	O
1G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
,	O	O
W60G	O	O
,	O	O
Y62C	O	O
,	O	O
A122D	O	O
,	O	O
P230T	O	O
,	O	O
and	O	O
D291E	O	O
)	O	O
,	O	O
which	O	O
further	O	O
illustrates	O	O
the	O	O
remarkable	O	O
allelic	O	O
heterogeneity	O	O
found	O	O
in	O	O
AKU	B-Disease	D000474
.	O	O

Reexamination	O	O
of	O	O
all	O	O
29	O	O
mutations	O	O
and	O	O
polymorphisms	O	O
thus	O	O
far	O	O
described	O	O
in	O	O
HGO	O	O
shows	O	O
that	O	O
these	O	O
nucleotide	O	O
changes	O	O
are	O	O
not	O	O
randomly	O	O
distributed	O	O
;	O	O
the	O	O
CCC	O	O
sequence	O	O
motif	O	O
and	O	O
its	O	O
inverted	O	O
complement	O	O
,	O	O
GGG	O	O
,	O	O
are	O	O
preferentially	O	O
mutated	O	O
.	O	O

These	O	O
analyses	O	O
also	O	O
demonstrated	O	O
that	O	O
the	O	O
nucleotide	O	O
substitutions	O	O
in	O	O
HGO	O	O
do	O	O
not	O	O
involve	O	O
CpG	O	O
dinucleotides	O	O
,	O	O
which	O	O
illustrates	O	O
important	O	O
differences	O	O
between	O	O
HGO	O	O
and	O	O
other	O	O
genes	O	O
for	O	O
the	O	O
occurrence	O	O
of	O	O
mutation	O	O
at	O	O
specific	O	O
short	O	O
-	O	O
sequence	O	O
motifs	O	O
.	O	O

Because	O	O
the	O	O
CCC	O	O
sequence	O	O
motifs	O	O
comprise	O	O
a	O	O
significant	O	O
proportion	O	O
(	O	O
34	O	O
.	O	O

5	O	O
%	O	O
)	O	O
of	O	O
all	O	O
mutated	O	O
bases	O	O
that	O	O
have	O	O
been	O	O
observed	O	O
in	O	O
HGO	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
the	O	O
CCC	O	O
triplet	O	O
is	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
in	O	O
HGO	O	O
.	O	O

Further	O	O
evidence	O	O
for	O	O
heterogeneity	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Papua	O	O
New	O	O
Guinea	O	O
.	O	O

Four	O	O
new	O	O
G6PD	O	O
variants	O	O
have	O	O
been	O	O
characterized	O	O
in	O	O
individuals	O	O
from	O	O
Papua	O	O
New	O	O
Guinea	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
the	O	O
previously	O	O
reported	O	O
Markham	O	O
variant	O	O
and	O	O
the	O	O
newly	O	O
characterized	O	O
Salata	O	O
variant	O	O
may	O	O
be	O	O
widely	O	O
distributed	O	O
in	O	O
Papua	O	O
New	O	O
Guinea	O	O
.	O	O

Th	O	O
data	O	O
presented	O	O
here	O	O
together	O	O
with	O	O
those	O	O
of	O	O
previously	O	O
published	O	O
studies	O	O
demonstrate	O	O
a	O	O
degree	O	O
of	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
that	O	O
is	O	O
much	O	O
higher	O	O
than	O	O
that	O	O
in	O	O
other	O	O
regions	O	O
of	O	O
the	O	O
world	O	O
where	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
common	O	O
.	O	O

.	O	O

Overgrowth	B-Disease	D006965
of	I-Disease	D006965
oral	I-Disease	D006965
mucosa	I-Disease	D006965
and	I-Disease	D006965
facial	I-Disease	D006965
skin	I-Disease	D006965
,	O	O
a	O	O
novel	O	O
feature	O	O
of	O	O
aspartylglucosaminuria	B-Disease	D054880
.	O	O

Aspartylglucosaminuria	B-Disease	D054880
(	O	O
AGU	B-Disease	D054880
)	O	O
is	O	O
a	O	O
lysosomal	B-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
deficiency	B-Disease	D054880
of	I-Disease	D054880
aspartylglucosaminidase	I-Disease	D054880
(	O	O
AGA	O	O
)	O	O
.	O	O

The	O	O
main	O	O
symptom	O	O
is	O	O
progressive	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
.	O	O

A	O	O
spectrum	O	O
of	O	O
different	O	O
mutations	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
this	O	O
disease	O	O
,	O	O
one	O	O
missense	O	O
mutation	O	O
(	O	O
Cys163Ser	O	O
)	O	O
being	O	O
responsible	O	O
for	O	O
the	O	O
majority	O	O
of	O	O
Finnish	O	O
cases	O	O
.	O	O

We	O	O
were	O	O
able	O	O
to	O	O
examine	O	O
66	O	O
Finnish	O	O
AGU	B-Disease	D054880
patients	O	O
for	O	O
changes	O	O
in	O	O
the	O	O
oral	O	O
mucosa	O	O
and	O	O
44	O	O
of	O	O
these	O	O
for	O	O
changes	O	O
in	O	O
facial	O	O
skin	O	O
.	O	O

Biopsy	O	O
specimens	O	O
of	O	O
16	O	O
oral	O	O
lesions	O	O
,	O	O
12	O	O
of	O	O
them	O	O
associated	O	O
with	O	O
the	O	O
teeth	O	O
,	O	O
plus	O	O
two	O	O
facial	B-Disease	D013568
lesions	I-Disease	D013568
were	O	O
studied	O	O
histologically	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
for	O	O
AGA	O	O
was	O	O
performed	O	O
on	O	O
15	O	O
oral	O	O
specimens	O	O
.	O	O

Skin	O	O
was	O	O
seborrhoeic	O	O
in	O	O
adolescent	O	O
and	O	O
adult	O	O
patients	O	O
,	O	O
with	O	O
erythema	B-Disease	D017445
of	I-Disease	D017445
the	I-Disease	D017445
facial	I-Disease	D017445
skin	I-Disease	D017445
already	O	O
common	O	O
in	O	O
childhood	O	O
.	O	O

Of	O	O
44	O	O
patients	O	O
,	O	O
nine	O	O
(	O	O
20	O	O
%	O	O
)	O	O
had	O	O
facial	B-Disease	D018322
angiofibromas	I-Disease	D018322
,	O	O
tumours	B-Disease	D009369
primarily	O	O
occurring	O	O
in	O	O
association	O	O
with	O	O
tuberous	B-Disease	D014402
sclerosis	I-Disease	D014402
.	O	O

Oedemic	B-Disease	D007967
buccal	I-Disease	D007967
mucosa	I-Disease	D007967
(	O	O
leucoedema	B-Disease	D007967
)	O	O
and	O	O
gingival	B-Disease	D019214
overgrowths	I-Disease	D019214
were	O	O
more	O	O
frequent	O	O
in	O	O
AGU	B-Disease	D054880
patients	O	O
than	O	O
in	O	O
controls	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Of	O	O
16	O	O
oral	B-Disease	D009059
mucosal	I-Disease	D009059
lesions	I-Disease	D009059
studied	O	O
histologically	O	O
,	O	O
15	O	O
represented	O	O
fibroepithelial	B-Disease	D017573
or	I-Disease	D017573
epithelial	I-Disease	D017573
hyperplasias	I-Disease	D017573
and	O	O
were	O	O
reactive	O	O
in	O	O
nature	O	O
.	O	O

Cytoplasmic	O	O
vacuolisation	O	O
was	O	O
evident	O	O
in	O	O
four	O	O
.	O	O

Immunohistochemically	O	O
,	O	O
expression	O	O
of	O	O
AGA	O	O
in	O	O
AGU	B-Disease	D054880
patients	O	O
mucosal	B-Disease	D009059
lesions	I-Disease	D009059
did	O	O
not	O	O
differ	O	O
from	O	O
that	O	O
seen	O	O
in	O	O
corresponding	O	O
lesions	O	O
of	O	O
normal	O	O
subjects	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
high	O	O
frequency	O	O
of	O	O
mucosal	B-Disease	D009059
overgrowth	I-Disease	D009059
in	O	O
AGU	B-Disease	D054880
patients	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
directly	O	O
associated	O	O
with	O	O
lysosomal	O	O
storage	O	O
or	O	O
with	O	O
alterations	O	O
in	O	O
the	O	O
level	O	O
of	O	O
AGA	O	O
expression	O	O
.	O	O

Molecular	O	O
characterization	O	O
of	O	O
galactosemia	B-Disease	D005693
(	O	O
type	O	O
1	O	O
)	O	O
mutations	O	O
in	O	O
Japanese	O	O
.	O	O

We	O	O
characterized	O	O
two	O	O
novel	O	O
mutations	O	O
of	O	O
the	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
(	O	O
GALT	O	O
)	O	O
gene	O	O
in	O	O
two	O	O
Japanese	O	O
patients	O	O
with	O	O
GALT	B-Disease	D005693
deficiency	I-Disease	D005693
and	O	O
identified	O	O
N314D	O	O
and	O	O
R333W	O	O
mutations	O	O
,	O	O
previously	O	O
found	O	O
in	O	O
Caucasians	O	O
.	O	O

One	O	O
novel	O	O
missense	O	O
mutation	O	O
was	O	O
an	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transition	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
arginine	O	O
by	O	O
histidine	O	O
at	O	O
the	O	O
codon	O	O
231	O	O
(	O	O
R231H	O	O
)	O	O
.	O	O

GALT	O	O
activity	O	O
of	O	O
the	O	O
R231H	O	O
mutant	O	O
construct	O	O
was	O	O
reduced	O	O
to	O	O
15	O	O
%	O	O
of	O	O
normal	O	O
controls	O	O
in	O	O
a	O	O
COS	O	O
cell	O	O
expression	O	O
system	O	O
.	O	O

The	O	O
other	O	O
was	O	O
a	O	O
splicing	O	O
mutation	O	O
,	O	O
an	O	O
A	O	O
-	O	O
to	O	O
-	O	O
G	O	O
transition	O	O
at	O	O
the	O	O
38th	O	O
nucleotide	O	O
in	O	O
exon	O	O
3	O	O
(	O	O
318A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
38	O	O
-	O	O
bp	O	O
deletion	O	O
in	O	O
the	O	O
GALT	O	O
cDNA	O	O
by	O	O
activating	O	O
a	O	O
cryptic	O	O
splice	O	O
acceptor	O	O
site	O	O
.	O	O

In	O	O
seven	O	O
Japanese	O	O
families	O	O
(	O	O
14	O	O
alleles	O	O
for	O	O
classic	O	O
form	O	O
and	O	O
one	O	O
allele	O	O
for	O	O
Duarte	O	O
variant	O	O
)	O	O
with	O	O
GALT	B-Disease	D005693
deficiency	I-Disease	D005693
,	O	O
the	O	O
R231H	O	O
and	O	O
318A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
mutations	O	O
were	O	O
found	O	O
only	O	O
on	O	O
both	O	O
alleles	O	O
of	O	O
the	O	O
proband	O	O
.	O	O

The	O	O
N314D	O	O
and	O	O
R333W	O	O
mutations	O	O
were	O	O
found	O	O
on	O	O
one	O	O
allele	O	O
each	O	O
.	O	O

The	O	O
Q188R	O	O
was	O	O
prevalent	O	O
in	O	O
the	O	O
United	O	O
States	O	O
but	O	O
not	O	O
in	O	O
Japanese	O	O
patients	O	O
.	O	O

The	O	O
N314D	O	O
mutation	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
Duarte	O	O
variant	O	O
in	O	O
Japanese	O	O
persons	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

We	O	O
speculate	O	O
that	O	O
classic	B-Disease	D005693
galactosemia	I-Disease	D005693
mutations	O	O
appear	O	O
to	O	O
differ	O	O
between	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
patients	O	O
.	O	O

Our	O	O
limited	O	O
data	O	O
set	O	O
on	O	O
galactosemia	B-Disease	D005693
mutations	O	O
in	O	O
Japanese	O	O
suggests	O	O
that	O	O
the	O	O
N314D	O	O
GALT	O	O
mutation	O	O
encoding	O	O
the	O	O
Duarte	O	O
variant	O	O
arose	O	O
before	O	O
Asian	O	O
and	O	O
Caucasian	O	O
people	O	O
diverged	O	O
and	O	O
that	O	O
classic	B-Disease	D005693
galactosemia	I-Disease	D005693
mutations	O	O
arose	O	O
and	O	O
/	O	O
or	O	O
accumulated	O	O
after	O	O
the	O	O
divergence	O	O
of	O	O
Asian	O	O
and	O	O
Caucasian	O	O
populations	O	O
.	O	O

.	O	O

Linkage	O	O
disequilibrium	O	O
mapping	O	O
in	O	O
isolated	O	O
founder	O	O
populations	O	O
:	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
in	O	O
Finland	O	O
.	O	O

Linkage	O	O
disequilibrium	O	O
mapping	O	O
in	O	O
isolated	O	O
populations	O	O
provides	O	O
a	O	O
powerful	O	O
tool	O	O
for	O	O
fine	O	O
structure	O	O
localization	O	O
of	O	O
disease	O	O
genes	O	O
.	O	O

Here	O	O
,	O	O
Luria	O	O
and	O	O
Delbrucks	O	O
classical	O	O
methods	O	O
for	O	O
analysing	O	O
bacterial	O	O
cultures	O	O
are	O	O
adapted	O	O
to	O	O
the	O	O
study	O	O
of	O	O
human	O	O
isolated	O	O
founder	O	O
populations	O	O
in	O	O
order	O	O
to	O	O
estimate	O	O
(	O	O
i	O	O
)	O	O
the	O	O
recombination	O	O
fraction	O	O
between	O	O
a	O	O
disease	O	O
locus	O	O
and	O	O
a	O	O
marker	O	O
;	O	O
(	O	O
ii	O	O
)	O	O
the	O	O
expected	O	O
degree	O	O
of	O	O
allelic	O	O
homogeneity	O	O
in	O	O
a	O	O
population	O	O
;	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
the	O	O
mutation	O	O
rate	O	O
of	O	O
marker	O	O
loci	O	O
.	O	O

Using	O	O
these	O	O
methods	O	O
,	O	O
we	O	O
report	O	O
striking	O	O
linkage	O	O
disequilibrium	O	O
for	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
(	O	O
DTD	B-Disease	C536170
)	O	O
in	O	O
Finland	O	O
indicating	O	O
that	O	O
the	O	O
DTD	B-Disease	C536170
gene	O	O
should	O	O
lie	O	O
within	O	O
0	O	O
.	O	O

06	O	O
centimorgans	O	O
(	O	O
or	O	O
about	O	O
60	O	O
kilobases	O	O
)	O	O
of	O	O
the	O	O
CSF1R	O	O
gene	O	O
.	O	O

Predictions	O	O
about	O	O
allelic	O	O
homogeneity	O	O
in	O	O
Finland	O	O
and	O	O
mutation	O	O
rates	O	O
in	O	O
simple	O	O
sequence	O	O
repeats	O	O
are	O	O
confirmed	O	O
by	O	O
independent	O	O
observations	O	O
.	O	O

Mutations	O	O
in	O	O
TNFRSF11A	O	O
,	O	O
affecting	O	O
the	O	O
signal	O	O
peptide	O	O
of	O	O
RANK	O	O
,	O	O
cause	O	O
familial	B-Disease	OMIM:174810
expansile	I-Disease	OMIM:174810
osteolysis	I-Disease	OMIM:174810
.	O	O

Familial	B-Disease	OMIM:174810
expansile	I-Disease	OMIM:174810
osteolysis	I-Disease	OMIM:174810
(	O	O
FEO	B-Disease	OMIM:174810
,	O	O
MIM	O	O
174810	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
,	O	O
autosomal	B-Disease	D001847
dominant	I-Disease	D001847
bone	I-Disease	D001847
disorder	I-Disease	D001847
characterized	O	O
by	O	O
focal	O	O
areas	O	O
of	O	O
increased	B-Disease	D001847
bone	I-Disease	D001847
remodelling	I-Disease	D001847
.	O	O

The	O	O
osteolytic	B-Disease	D030981
lesions	I-Disease	D030981
,	O	O
which	O	O
develop	O	O
usually	O	O
in	O	O
the	O	O
long	O	O
bones	O	O
during	O	O
early	O	O
adulthood	O	O
,	O	O
show	O	O
increased	O	O
osteoblast	O	O
and	O	O
osteoclast	O	O
activity	O	O
.	O	O

Our	O	O
previous	O	O
linkage	O	O
studies	O	O
mapped	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
FEO	B-Disease	OMIM:174810
to	O	O
an	O	O
interval	O	O
of	O	O
less	O	O
than	O	O
5	O	O
cM	O	O
between	O	O
D18S64	O	O
and	O	O
D18S51	O	O
on	O	O
chromosome	O	O
18q21	O	O
.	O	O

2	O	O
-	O	O
21	O	O
2	O	O
-	O	O
21	O	O
.	O	O

3	O	O
in	O	O
a	O	O
large	O	O
Northern	O	O
Irish	O	O
family	O	O
.	O	O

The	O	O
gene	O	O
encoding	O	O
receptor	O	O
activator	O	O
of	O	O
nuclear	O	O
factor	O	O
-	O	O
kappa	O	O
B	O	O
(	O	O
RANK	O	O
;	O	O
ref	O	O
.	O	O

5	O	O
)	O	O
,	O	O
TNFRSF11A	O	O
,	O	O
maps	O	O
to	O	O
this	O	O
region	O	O
.	O	O

RANK	O	O
is	O	O
essential	O	O
in	O	O
osteoclast	O	O
formation	O	O
.	O	O

We	O	O
identified	O	O
two	O	O
heterozygous	O	O
insertion	O	O
mutations	O	O
in	O	O
exon	O	O
1	O	O
of	O	O
TNFRSF11A	O	O
in	O	O
affected	O	O
members	O	O
of	O	O
four	O	O
families	O	O
with	O	O
FEO	B-Disease	OMIM:174810
or	O	O
familial	B-Disease	C538098
Paget	I-Disease	C538098
disease	I-Disease	C538098
of	I-Disease	C538098
bone	I-Disease	C538098
(	O	O
PDB	B-Disease	C538098
)	O	O
.	O	O

One	O	O
was	O	O
a	O	O
duplication	O	O
of	O	O
18	O	O
bases	O	O
and	O	O
the	O	O
other	O	O
a	O	O
duplication	O	O
of	O	O
27	O	O
bases	O	O
,	O	O
both	O	O
of	O	O
which	O	O
affected	O	O
the	O	O
signal	O	O
peptide	O	O
region	O	O
of	O	O
the	O	O
RANK	O	O
molecule	O	O
.	O	O

Expression	O	O
of	O	O
recombinant	O	O
forms	O	O
of	O	O
the	O	O
mutant	O	O
RANK	O	O
proteins	O	O
revealed	O	O
perturbations	O	O
in	O	O
expression	O	O
levels	O	O
and	O	O
lack	O	O
of	O	O
normal	O	O
cleavage	O	O
of	O	O
the	O	O
signal	O	O
peptide	O	O
.	O	O

Both	O	O
mutations	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
RANK	O	O
-	O	O
mediated	O	O
nuclear	O	O
factor	O	O
-	O	O
kappaB	O	O
(	O	O
NF	O	O
-	O	O
kappaB	O	O
)	O	O
signalling	O	O
in	O	O
vitro	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
activating	O	O
mutation	O	O
.	O	O

Adrenoleukodystrophy	O	O
-	O	O
related	O	O
protein	O	O
can	O	O
compensate	O	O
functionally	O	O
for	O	O
adrenoleukodystrophy	B-Disease	D000326
protein	I-Disease	D000326
deficiency	I-Disease	D000326
(	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
:	O	O
implications	O	O
for	O	O
therapy	O	O
.	O	O

Inherited	B-Disease	D030342
defects	I-Disease	D030342
in	O	O
the	O	O
peroxisomal	O	O
ATP	O	O
-	O	O
binding	O	O
cassette	O	O
(	O	O
ABC	O	O
)	O	O
transporter	O	O
adrenoleukodystrophy	B-Disease	D000326
protein	O	O
(	O	O
ALDP	O	O
)	O	O
lead	O	O
to	O	O
the	O	O
lethal	O	O
peroxisomal	B-Disease	D018901
disorder	I-Disease	D018901
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
,	O	O
for	O	O
which	O	O
no	O	O
efficient	O	O
treatment	O	O
has	O	O
been	O	O
established	O	O
so	O	O
far	O	O
.	O	O

Three	O	O
other	O	O
peroxisomal	O	O
ABC	O	O
transporters	O	O
currently	O	O
are	O	O
known	O	O
adrenoleukodystrophy	B-Disease	D000326
-	O	O
related	O	O
protein	O	O
(	O	O
ALDRP	O	O
)	O	O
,	O	O
70	O	O
kDa	O	O
peroxisomal	O	O
membrane	O	O
protein	O	O
(	O	O
PMP70	O	O
)	O	O
and	O	O
PMP70	O	O
-	O	O
related	O	O
protein	O	O
.	O	O

By	O	O
using	O	O
transient	O	O
and	O	O
stable	O	O
overexpression	O	O
of	O	O
human	O	O
cDNAs	O	O
encoding	O	O
ALDP	O	O
and	O	O
its	O	O
closest	O	O
relative	O	O
ALDRP	O	O
,	O	O
we	O	O
could	O	O
restore	O	O
the	O	O
impaired	O	O
peroxisomal	O	O
beta	O	O
-	O	O
oxidation	O	O
in	O	O
fibroblasts	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
patients	O	O
.	O	O

The	O	O
pathognomonic	O	O
accumulation	O	O
of	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
could	O	O
also	O	O
be	O	O
prevented	O	O
by	O	O
overexpression	O	O
of	O	O
ALDRP	O	O
in	O	O
immortalized	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
cells	O	O
.	O	O

Immunofluorescence	O	O
analysis	O	O
demonstrated	O	O
that	O	O
the	O	O
functional	O	O
replacement	O	O
of	O	O
ALDP	O	O
by	O	O
ALDRP	O	O
was	O	O
not	O	O
due	O	O
to	O	O
stabilization	O	O
of	O	O
the	O	O
mutated	O	O
ALDP	O	O
itself	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
restore	O	O
the	O	O
peroxisomal	O	O
beta	O	O
-	O	O
oxidation	O	O
defect	O	O
in	O	O
the	O	O
liver	O	O
of	O	O
ALDP	O	O
-	O	O
deficient	O	O
mice	O	O
by	O	O
stimulation	O	O
of	O	O
ALDRP	O	O
and	O	O
PMP70	O	O
gene	O	O
expression	O	O
through	O	O
a	O	O
dietary	O	O
treatment	O	O
with	O	O
the	O	O
peroxisome	O	O
proliferator	O	O
fenofibrate	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
correction	O	O
of	O	O
the	O	O
biochemical	O	O
defect	O	O
in	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
could	O	O
be	O	O
possible	O	O
by	O	O
drug	O	O
-	O	O
induced	O	O
overexpression	O	O
or	O	O
ectopic	O	O
expression	O	O
of	O	O
ALDRP	O	O
.	O	O

.	O	O

The	O	O
normal	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
allele	O	O
,	O	O
or	O	O
a	O	O
closely	O	O
linked	O	O
gene	O	O
,	O	O
influences	O	O
age	O	O
at	O	O
onset	O	O
of	O	O
HD	B-Disease	D006816
.	O	O

We	O	O
evaluated	O	O
the	O	O
hypothesis	O	O
that	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
is	O	O
influenced	O	O
by	O	O
the	O	O
normal	O	O
HD	B-Disease	D006816
allele	O	O
by	O	O
comparing	O	O
transmission	O	O
patterns	O	O
of	O	O
genetically	O	O
linked	O	O
markers	O	O
at	O	O
the	O	O
D4S10	O	O
locus	O	O
in	O	O
the	O	O
normal	O	O
parent	O	O
against	O	O
age	O	O
at	O	O
onset	O	O
in	O	O
the	O	O
affected	O	O
offspring	O	O
.	O	O

Analysis	O	O
of	O	O
information	O	O
from	O	O
21	O	O
sibships	O	O
in	O	O
14	O	O
kindreds	O	O
showed	O	O
a	O	O
significant	O	O
tendency	O	O
for	O	O
sibs	O	O
who	O	O
have	O	O
similar	O	O
onset	O	O
ages	O	O
to	O	O
share	O	O
the	O	O
same	O	O
D4S10	O	O
allele	O	O
from	O	O
the	O	O
normal	O	O
parent	O	O
.	O	O

Affected	O	O
sibs	O	O
who	O	O
inherited	O	O
different	O	O
D4S10	O	O
alleles	O	O
from	O	O
the	O	O
normal	O	O
parent	O	O
tended	O	O
to	O	O
have	O	O
more	O	O
variable	O	O
ages	O	O
at	O	O
onset	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
HD	B-Disease	D006816
is	O	O
modulated	O	O
by	O	O
the	O	O
normal	O	O
HD	B-Disease	D006816
allele	O	O
or	O	O
by	O	O
a	O	O
closely	O	O
linked	O	O
locus	O	O
.	O	O

.	O	O

Synergistic	O	O
effect	O	O
of	O	O
histone	O	O
hyperacetylation	O	O
and	O	O
DNA	O	O
demethylation	O	O
in	O	O
the	O	O
reactivation	O	O
of	O	O
the	O	O
FMR1	O	O
gene	O	O
.	O	O

Most	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
patients	O	O
have	O	O
expansion	O	O
of	O	O
a	O	O
(	O	O
CGG	O	O
)	O	O
(	O	O
n	O	O
)	O	O
sequence	O	O
with	O	O
>	O	O
200	O	O
repeats	O	O
(	O	O
full	O	O
mutation	O	O
)	O	O
in	O	O
the	O	O
FMR1	O	O
gene	O	O
responsible	O	O
for	O	O
this	O	O
condition	O	O
.	O	O

Hypermethylation	O	O
of	O	O
the	O	O
expanded	O	O
repeat	O	O
and	O	O
of	O	O
the	O	O
FMR1	O	O
promoter	O	O
is	O	O
almost	O	O
always	O	O
present	O	O
and	O	O
apparently	O	O
suppresses	O	O
transcription	O	O
,	O	O
resulting	O	O
in	O	O
absence	O	O
of	O	O
the	O	O
FMR1	O	O
protein	O	O
.	O	O

We	O	O
recently	O	O
showed	O	O
that	O	O
transcriptional	O	O
reactivation	O	O
of	O	O
FMR1	O	O
full	O	O
mutations	O	O
can	O	O
be	O	O
achieved	O	O
by	O	O
inducing	O	O
DNA	O	O
demethylation	O	O
with	O	O
5	O	O
-	O	O
azadeoxycytidine	O	O
(	O	O
5	O	O
-	O	O
azadC	O	O
)	O	O
.	O	O

The	O	O
level	O	O
of	O	O
histone	O	O
acetylation	O	O
is	O	O
another	O	O
important	O	O
factor	O	O
in	O	O
regulating	O	O
gene	O	O
expression	O	O
;	O	O
therefore	O	O
,	O	O
we	O	O
treated	O	O
lymphoblastoid	O	O
cell	O	O
lines	O	O
of	O	O
non	O	O
-	O	O
mosaic	O	O
full	O	O
mutation	O	O
patients	O	O
with	O	O
three	O	O
drugs	O	O
capable	O	O
of	O	O
inducing	O	O
histone	O	O
hyperacetylation	O	O
.	O	O

We	O	O
observed	O	O
a	O	O
consistent	O	O
,	O	O
although	O	O
modest	O	O
,	O	O
reactivation	O	O
of	O	O
the	O	O
FMR1	O	O
gene	O	O
with	O	O
4	O	O
-	O	O
phenylbutyrate	O	O
,	O	O
sodium	O	O
butyrate	O	O
and	O	O
trichostatin	O	O
A	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
.	O	O

However	O	O
,	O	O
we	O	O
report	O	O
that	O	O
combining	O	O
these	O	O
drugs	O	O
with	O	O
5	O	O
-	O	O
azadC	O	O
results	O	O
in	O	O
a	O	O
2	O	O
-	O	O
to	O	O
5	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
FMR1	O	O
mRNA	O	O
levels	O	O
obtained	O	O
with	O	O
5	O	O
-	O	O
azadC	O	O
alone	O	O
,	O	O
thus	O	O
showing	O	O
a	O	O
marked	O	O
synergistic	O	O
effect	O	O
of	O	O
histone	O	O
hyperacetylation	O	O
and	O	O
DNA	O	O
demethylation	O	O
in	O	O
the	O	O
reactivation	O	O
of	O	O
FMR1	O	O
full	O	O
mutations	O	O
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
in	O	O
X	B-Disease	C538243
-	I-Disease	C538243
linked	I-Disease	C538243
amelogenesis	I-Disease	C538243
imperfecta	I-Disease	C538243
.	O	O

The	O	O
AMELX	O	O
gene	O	O
located	O	O
at	O	O
Xp22	O	O
.	O	O

1	O	O
-	O	O
p22	O	O
.	O	O

3	O	O
encodes	O	O
for	O	O
the	O	O
enamel	O	O
protein	O	O
amelogenin	O	O
and	O	O
has	O	O
been	O	O
implicated	O	O
as	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
the	O	O
inherited	B-Disease	D014071
dental	I-Disease	D014071
abnormality	I-Disease	D014071
X	B-Disease	C538243
-	I-Disease	C538243
linked	I-Disease	C538243
amelogenesis	I-Disease	C538243
imperfecta	I-Disease	C538243
(	O	O
XAI	B-Disease	C538243
)	O	O
.	O	O

Three	O	O
families	O	O
with	O	O
XAI	B-Disease	C538243
have	O	O
been	O	O
investigated	O	O
using	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
flanking	O	O
the	O	O
position	O	O
of	O	O
AMELX	O	O
.	O	O

Using	O	O
two	O	O
-	O	O
point	O	O
linkage	O	O
analysis	O	O
,	O	O
linkage	O	O
was	O	O
established	O	O
between	O	O
XAI	B-Disease	C538243
and	O	O
several	O	O
of	O	O
these	O	O
markers	O	O
in	O	O
two	O	O
families	O	O
,	O	O
with	O	O
a	O	O
combined	O	O
lod	O	O
score	O	O
of	O	O
6	O	O
.	O	O

05	O	O
for	O	O
DXS16	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

04	O	O
04	O	O
.	O	O

This	O	O
supports	O	O
the	O	O
involvement	O	O
of	O	O
AMELX	O	O
,	O	O
located	O	O
close	O	O
to	O	O
DXS16	O	O
,	O	O
in	O	O
the	O	O
XAI	B-Disease	C538243
disease	O	O
process	O	O
(	O	O
AIH1	O	O
)	O	O
in	O	O
those	O	O
families	O	O
.	O	O

Using	O	O
multipoint	O	O
linkage	O	O
analysis	O	O
,	O	O
the	O	O
combined	O	O
maximum	O	O
lod	O	O
score	O	O
for	O	O
these	O	O
two	O	O
families	O	O
was	O	O
7	O	O
.	O	O

30	O	O
for	O	O
a	O	O
location	O	O
of	O	O
AIH1	O	O
at	O	O
2	O	O
cM	O	O
distal	O	O
to	O	O
DXS16	O	O
.	O	O

The	O	O
support	O	O
interval	O	O
around	O	O
this	O	O
location	O	O
extended	O	O
about	O	O
8	O	O
cM	O	O
proximal	O	O
to	O	O
DXS92	O	O
,	O	O
and	O	O
the	O	O
AIH1	O	O
location	O	O
could	O	O
not	O	O
be	O	O
precisely	O	O
defined	O	O
by	O	O
multipoint	O	O
mapping	O	O
.	O	O

Study	O	O
of	O	O
recombination	O	O
events	O	O
indicated	O	O
that	O	O
AIH1	O	O
lies	O	O
in	O	O
the	O	O
interval	O	O
between	O	O
DXS143	O	O
and	O	O
DXS85	O	O
.	O	O

There	O	O
was	O	O
significant	O	O
evidence	O	O
against	O	O
linkage	O	O
to	O	O
this	O	O
region	O	O
in	O	O
the	O	O
third	O	O
family	O	O
,	O	O
indicating	O	O
locus	O	O
heterogeneity	O	O
in	O	O
XAI	B-Disease	C538243
.	O	O

Further	O	O
analysis	O	O
with	O	O
markers	O	O
on	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
showed	O	O
evidence	O	O
of	O	O
linkage	O	O
to	O	O
DXS144E	O	O
and	O	O
F9	O	O
with	O	O
no	O	O
recombination	O	O
with	O	O
either	O	O
of	O	O
these	O	O
markers	O	O
.	O	O

Two	O	O
-	O	O
point	O	O
analysis	O	O
gave	O	O
a	O	O
peak	O	O
lod	O	O
score	O	O
at	O	O
DXS144E	O	O
with	O	O
a	O	O
maximum	O	O
lod	O	O
score	O	O
of	O	O
2	O	O
.	O	O

83	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
,	O	O
with	O	O
a	O	O
peak	O	O
lod	O	O
score	O	O
in	O	O
multipoint	O	O
linkage	O	O
analysis	O	O
of	O	O
2	O	O
.	O	O

84	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

The	O	O
support	O	O
interval	O	O
extended	O	O
9	O	O
cM	O	O
proximal	O	O
to	O	O
DXS144E	O	O
and	O	O
14	O	O
cM	O	O
distal	O	O
to	O	O
F9	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
.	O	O

Anonymous	O	O
marker	O	O
loci	O	O
within	O	O
400	O	O
kb	O	O
of	O	O
HLA	O	O
-	O	O
A	O	O
generate	O	O
haplotypes	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
with	O	O
the	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
(	O	O
HFE	O	O
)	O	O
The	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
(	O	O
HFE	O	O
)	O	O
maps	O	O
to	O	O
6p21	O	O
.	O	O

3	O	O
and	O	O
is	O	O
less	O	O
than	O	O
1	O	O
cM	O	O
from	O	O
the	O	O
HLA	O	O
class	O	O
I	O	O
genes	O	O
;	O	O
however	O	O
,	O	O
the	O	O
precise	O	O
physical	O	O
location	O	O
of	O	O
the	O	O
gene	O	O
has	O	O
remained	O	O
elusive	O	O
and	O	O
controversial	O	O
.	O	O

The	O	O
unambiguous	O	O
identification	O	O
of	O	O
a	O	O
crossover	O	O
event	O	O
within	O	O
hemochromatosis	B-Disease	D006432
families	O	O
is	O	O
very	O	O
difficult	O	O
;	O	O
it	O	O
is	O	O
particularly	O	O
hampered	O	O
by	O	O
the	O	O
variability	O	O
of	O	O
the	O	O
phenotypic	O	O
expression	O	O
as	O	O
well	O	O
as	O	O
by	O	O
the	O	O
sex	O	O
-	O	O
and	O	O
age	O	O
-	O	O
related	O	O
penetrance	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

For	O	O
these	O	O
practical	O	O
considerations	O	O
,	O	O
traditional	O	O
linkage	O	O
analysis	O	O
could	O	O
prove	O	O
of	O	O
limited	O	O
value	O	O
in	O	O
further	O	O
refining	O	O
the	O	O
extrapolated	O	O
physical	O	O
position	O	O
of	O	O
HFE	O	O
.	O	O

We	O	O
therefore	O	O
embarked	O	O
upon	O	O
a	O	O
linkage	O	O
-	O	O
disequilibrium	O	O
analysis	O	O
of	O	O
HFE	O	O
and	O	O
normal	O	O
chromosomes	O	O
from	O	O
the	O	O
Brittany	O	O
population	O	O
.	O	O

In	O	O
the	O	O
present	O	O
report	O	O
,	O	O
66	O	O
hemochromatosis	B-Disease	D006432
families	O	O
yielding	O	O
151	O	O
hemochromatosis	B-Disease	D006432
chromosomes	O	O
and	O	O
182	O	O
normal	O	O
chromosomes	O	O
were	O	O
RFLP	O	O
-	O	O
typed	O	O
with	O	O
a	O	O
battery	O	O
of	O	O
probes	O	O
,	O	O
including	O	O
two	O	O
newly	O	O
derived	O	O
polymorphic	O	O
markers	O	O
from	O	O
the	O	O
6	O	O
.	O	O

7	O	O
and	O	O
HLA	O	O
-	O	O
F	O	O
loci	O	O
located	O	O
150	O	O
and	O	O
250	O	O
kb	O	O
telomeric	O	O
to	O	O
HLA	O	O
-	O	O
A	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
a	O	O
strong	O	O
peak	O	O
of	O	O
existing	O	O
linkage	O	O
disequilibrium	O	O
focused	O	O
within	O	O
the	O	O
i82	O	O
-	O	O
to	O	O
-	O	O
6	O	O
.	O	O

7	O	O
interval	O	O
(	O	O
approximately	O	O
250	O	O
kb	O	O
)	O	O
.	O	O

The	O	O
zone	O	O
of	O	O
linkage	O	O
disequilibrium	O	O
is	O	O
flanked	O	O
by	O	O
the	O	O
i97	O	O
locus	O	O
,	O	O
positioned	O	O
30	O	O
kb	O	O
proximal	O	O
to	O	O
i82	O	O
,	O	O
and	O	O
the	O	O
HLA	O	O
-	O	O
F	O	O
gene	O	O
,	O	O
found	O	O
250	O	O
kb	O	O
distal	O	O
to	O	O
HLA	O	O
-	O	O
A	O	O
,	O	O
markers	O	O
of	O	O
which	O	O
display	O	O
no	O	O
significant	O	O
association	O	O
with	O	O
HFE	O	O
.	O	O

These	O	O
data	O	O
support	O	O
the	O	O
possibility	O	O
that	O	O
HFE	O	O
resides	O	O
within	O	O
the	O	O
400	O	O
-	O	O
kb	O	O
expanse	O	O
of	O	O
DNA	O	O
between	O	O
i97	O	O
and	O	O
HLA	O	O
-	O	O
F	O	O
.	O	O

Alternatively	O	O
,	O	O
the	O	O
very	O	O
tight	O	O
association	O	O
of	O	O
HLA	O	O
-	O	O
A3	O	O
and	O	O
allele	O	O
1	O	O
of	O	O
the	O	O
6	O	O
.	O	O

7	O	O
locus	O	O
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
comprised	O	O
by	O	O
the	O	O
major	O	O
ancestral	O	O
or	O	O
founder	O	O
HFE	O	O
haplotype	O	O
in	O	O
Brittany	O	O
,	O	O
supports	O	O
the	O	O
possibility	O	O
that	O	O
the	O	O
disease	O	O
gene	O	O
may	O	O
reside	O	O
immediately	O	O
telomeric	O	O
to	O	O
the	O	O
6	O	O
.	O	O

7	O	O
locus	O	O
within	O	O
the	O	O
linkage	O	O
-	O	O
disequilibrium	O	O
zone	O	O
.	O	O

Additionally	O	O
,	O	O
hemochromatosis	B-Disease	D006432
haplotypes	O	O
possessing	O	O
HLA	O	O
-	O	O
A11	O	O
and	O	O
the	O	O
low	O	O
-	O	O
frequency	O	O
HLA	O	O
-	O	O
F	O	O
polymorphism	O	O
(	O	O
allele	O	O
2	O	O
)	O	O
are	O	O
supportive	O	O
of	O	O
a	O	O
separate	O	O
founder	O	O
chromosome	O	O
containing	O	O
a	O	O
second	O	O
,	O	O
independently	O	O
arising	O	O
mutant	O	O
allele	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
establishment	O	O
of	O	O
a	O	O
likely	O	O
"	O	O
hemochromatosis	B-Disease	D006432
critical	O	O
region	O	O
"	O	O
centromeric	O	O
boundary	O	O
and	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
linkage	O	O
-	O	O
disequilibrium	O	O
zone	O	O
both	O	O
significantly	O	O
contribute	O	O
to	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
DNA	O	O
required	O	O
to	O	O
be	O	O
searched	O	O
for	O	O
novel	O	O
coding	O	O
sequences	O	O
constituting	O	O
the	O	O
HFE	B-Disease	D006432
defect	I-Disease	D006432
Natural	O	O
selection	O	O
of	O	O
hemi	O	O
-	O	O
and	O	O
heterozygotes	O	O
for	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Africa	O	O
by	O	O
resistance	O	O
to	O	O
severe	O	O
malaria	B-Disease	D008288
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
the	O	O
most	O	O
common	O	O
enzymopathy	B-Disease	D008661
of	O	O
humans	O	O
,	O	O
affects	O	O
over	O	O
400	O	O
million	O	O
people	O	O
.	O	O

The	O	O
geographical	O	O
correlation	O	O
of	O	O
its	O	O
distribution	O	O
with	O	O
the	O	O
historical	O	O
endemicity	O	O
of	O	O
malaria	B-Disease	D008288
suggests	O	O
that	O	O
this	O	O
disorder	O	O
has	O	O
risen	O	O
in	O	O
frequency	O	O
through	O	O
natural	O	O
selection	O	O
by	O	O
malaria	B-Disease	D008288
.	O	O

However	O	O
,	O	O
attempts	O	O
to	O	O
confirm	O	O
that	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
protective	O	O
in	O	O
case	O	O
-	O	O
control	O	O
studies	O	O
of	O	O
malaria	B-Disease	D008288
have	O	O
yielded	O	O
conflicting	O	O
results	O	O
.	O	O

Hence	O	O
,	O	O
for	O	O
this	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disorder	I-Disease	D040181
,	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
both	O	O
male	O	O
hemizygotes	O	O
and	O	O
female	O	O
heterozygotes	O	O
are	O	O
protected	O	O
or	O	O
,	O	O
as	O	O
frequently	O	O
suggested	O	O
,	O	O
only	O	O
females	O	O
.	O	O

Furthermore	O	O
,	O	O
how	O	O
much	O	O
protection	O	O
may	O	O
be	O	O
afforded	O	O
is	O	O
unknown	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
,	O	O
in	O	O
two	O	O
large	O	O
case	O	O
-	O	O
control	O	O
studies	O	O
of	O	O
over	O	O
2	O	O
,	O	O
000	O	O
African	O	O
children	O	O
,	O	O
the	O	O
common	O	O
African	O	O
form	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
(	O	O
G6PD	B-Disease	D005955
A	I-Disease	D005955
-	I-Disease	D005955
)	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
46	O	O
-	O	O
58	O	O
%	O	O
reduction	O	O
in	O	O
risk	O	O
of	O	O
severe	O	O
malaria	B-Disease	D008288
for	O	O
both	O	O
female	O	O
heterozygotes	O	O
and	O	O
male	O	O
hemizygotes	O	O
.	O	O

A	O	O
mathematical	O	O
model	O	O
incorporating	O	O
the	O	O
measured	O	O
selective	O	O
advantage	O	O
against	O	O
malaria	B-Disease	D008288
suggests	O	O
that	O	O
a	O	O
counterbalancing	O	O
selective	O	O
disadvantage	O	O
,	O	O
associated	O	O
with	O	O
this	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
,	O	O
has	O	O
retarded	O	O
its	O	O
rise	O	O
in	O	O
frequency	O	O
in	O	O
malaria	B-Disease	D008288
-	O	O
endemic	O	O
regions	O	O
.	O	O

Although	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
now	O	O
regarded	O	O
as	O	O
a	O	O
generally	O	O
benign	O	O
disorder	O	O
,	O	O
in	O	O
earlier	O	O
environmental	O	O
conditions	O	O
it	O	O
could	O	O
have	O	O
been	O	O
significantly	O	O
disadvantageous	O	O
.	O	O

.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
and	O	O
chromosome	O	O
15	O	O
.	O	O

A	O	O
clinical	O	O
discussion	O	O
of	O	O
20	O	O
cases	O	O
.	O	O

A	O	O
chromosome	B-Disease	D002869
15	I-Disease	D002869
anomaly	I-Disease	D002869
was	O	O
observed	O	O
in	O	O
12	O	O
of	O	O
20	O	O
patients	O	O
,	O	O
17	O	O
of	O	O
whom	O	O
were	O	O
clinically	O	O
suspected	O	O
of	O	O
having	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

The	O	O
clinical	O	O
features	O	O
of	O	O
eight	O	O
cases	O	O
with	O	O
15q11	O	O
-	O	O
12	O	O
deletion	O	O
were	O	O
very	O	O
similar	O	O
to	O	O
those	O	O
originally	O	O
described	O	O
in	O	O
PWS	B-Disease	D011218
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
group	O	O
of	O	O
normal	O	O
karyotype	O	O
patients	O	O
is	O	O
heterogeneous	O	O
,	O	O
and	O	O
their	O	O
features	O	O
do	O	O
not	O	O
strictly	O	O
correspond	O	O
to	O	O
the	O	O
clinical	O	O
definition	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

However	O	O
,	O	O
the	O	O
hypothesis	O	O
that	O	O
PWS	B-Disease	D011218
is	O	O
associated	O	O
with	O	O
deletion	O	O
of	O	O
15q11	O	O
-	O	O
12	O	O
can	O	O
neither	O	O
explain	O	O
the	O	O
apparently	O	O
balanced	O	O
translocations	O	O
of	O	O
chromosome	O	O
15	O	O
nor	O	O
account	O	O
for	O	O
the	O	O
small	O	O
supernumerary	O	O
metacentric	O	O
chromosomes	O	O
corresponding	O	O
to	O	O
an	O	O
isochromosome	O	O
15	O	O
for	O	O
band	O	O
15q11	O	O
observed	O	O
in	O	O
some	O	O
cases	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
phenylketonuria	B-Disease	D010661
and	O	O
related	O	O
hyperphenylalaninemias	B-Disease	D010661
:	O	O
mutations	O	O
and	O	O
polymorphisms	O	O
in	O	O
the	O	O
human	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
human	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
producing	O	O
phenylketonuria	B-Disease	D010661
or	O	O
hyperphenylalaninemia	B-Disease	D010661
have	O	O
now	O	O
been	O	O
identified	O	O
in	O	O
many	O	O
patients	O	O
from	O	O
various	O	O
ethnic	O	O
groups	O	O
.	O	O

These	O	O
mutations	O	O
all	O	O
exhibit	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
association	O	O
with	O	O
specific	O	O
restriction	O	O
fragment	O	O
-	O	O
length	O	O
polymorphism	O	O
haplotypes	O	O
at	O	O
the	O	O
PAH	O	O
locus	O	O
.	O	O

About	O	O
50	O	O
of	O	O
these	O	O
mutations	O	O
are	O	O
single	O	O
-	O	O
base	O	O
substitutions	O	O
,	O	O
including	O	O
six	O	O
nonsense	O	O
mutations	O	O
and	O	O
eight	O	O
splicing	O	O
mutations	O	O
,	O	O
with	O	O
the	O	O
remainder	O	O
being	O	O
missense	O	O
mutations	O	O
.	O	O

One	O	O
splicing	O	O
mutation	O	O
results	O	O
in	O	O
a	O	O
3	O	O
amino	O	O
acid	O	O
in	O	O
-	O	O
frame	O	O
insertion	O	O
.	O	O

Two	O	O
or	O	O
3	O	O
large	O	O
deletions	O	O
,	O	O
2	O	O
single	O	O
codon	O	O
deletions	O	O
,	O	O
and	O	O
2	O	O
single	O	O
base	O	O
deletions	O	O
have	O	O
been	O	O
found	O	O
.	O	O

Twelve	O	O
of	O	O
the	O	O
missense	O	O
mutations	O	O
apparently	O	O
result	O	O
from	O	O
the	O	O
methylation	O	O
and	O	O
subsequent	O	O
deamination	O	O
of	O	O
highly	O	O
mutagenic	O	O
CpG	O	O
dinucleotides	O	O
.	O	O

Recurrent	O	O
mutation	O	O
has	O	O
been	O	O
observed	O	O
at	O	O
several	O	O
of	O	O
these	O	O
sites	O	O
,	O	O
producing	O	O
associations	O	O
with	O	O
different	O	O
haplotypes	O	O
in	O	O
different	O	O
populations	O	O
.	O	O

About	O	O
half	O	O
of	O	O
all	O	O
missense	O	O
mutations	O	O
have	O	O
been	O	O
examined	O	O
by	O	O
in	O	O
vitro	O	O
expression	O	O
analysis	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
correlation	O	O
has	O	O
been	O	O
observed	O	O
between	O	O
residual	O	O
PAH	O	O
activity	O	O
and	O	O
disease	O	O
phenotype	O	O
.	O	O

Since	O	O
continuing	O	O
advances	O	O
in	O	O
molecular	O	O
methodologies	O	O
have	O	O
dramatically	O	O
accelerated	O	O
the	O	O
rate	O	O
in	O	O
which	O	O
new	O	O
mutations	O	O
are	O	O
being	O	O
identified	O	O
and	O	O
characterized	O	O
,	O	O
this	O	O
register	O	O
of	O	O
mutations	O	O
will	O	O
be	O	O
updated	O	O
periodically	O	O
.	O	O

.	O	O

The	O	O
intron	O	O
7	O	O
donor	O	O
splice	O	O
site	O	O
transition	O	O
:	O	O
a	O	O
second	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
mutation	O	O
in	O	O
French	O	O
Canada	O	O
.	O	O

Mutations	O	O
at	O	O
the	O	O
hexosaminidase	O	O
A	O	O
(	O	O
HEXA	O	O
)	O	O
gene	O	O
which	O	O
cause	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
have	O	O
elevated	O	O
frequency	O	O
in	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
and	O	O
French	O	O
-	O	O
Canadian	O	O
populations	O	O
.	O	O

We	O	O
report	O	O
a	O	O
novel	O	O
TSD	B-Disease	D013661
allele	O	O
in	O	O
the	O	O
French	O	O
-	O	O
Canadian	O	O
population	O	O
associated	O	O
with	O	O
the	O	O
infantile	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
mutation	O	O
,	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
the	O	O
+	O	O
1	O	O
position	O	O
of	O	O
intron	O	O
7	O	O
,	O	O
abolishes	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
.	O	O

Cultured	O	O
human	O	O
fibroblasts	O	O
from	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
this	O	O
transition	O	O
(	O	O
and	O	O
for	O	O
a	O	O
deletion	O	O
mutation	O	O
)	O	O
produce	O	O
no	O	O
detectable	O	O
HEXA	O	O
mRNA	O	O
.	O	O

The	O	O
intron	O	O
7	O	O
+	O	O
1	O	O
mutation	O	O
occurs	O	O
in	O	O
the	O	O
base	O	O
adjacent	O	O
to	O	O
the	O	O
site	O	O
of	O	O
the	O	O
adult	O	O
-	O	O
onset	O	O
TSD	B-Disease	D013661
mutation	O	O
(	O	O
G805A	O	O
)	O	O
.	O	O

In	O	O
both	O	O
mutations	O	O
a	O	O
restriction	O	O
site	O	O
for	O	O
the	O	O
endonuclease	O	O
EcoRII	O	O
is	O	O
abolished	O	O
.	O	O

Unambiguous	O	O
diagnosis	O	O
,	O	O
therefore	O	O
,	O	O
requires	O	O
allele	O	O
-	O	O
specific	O	O
oligonucleotide	O	O
hybridization	O	O
to	O	O
distinguish	O	O
between	O	O
these	O	O
two	O	O
mutant	O	O
alleles	O	O
.	O	O

The	O	O
intron	O	O
7	O	O
+	O	O
1	O	O
mutation	O	O
has	O	O
been	O	O
detected	O	O
in	O	O
three	O	O
unrelated	O	O
families	O	O
.	O	O

Obligate	O	O
heterozygotes	O	O
for	O	O
the	O	O
intron	O	O
7	O	O
+	O	O
1	O	O
mutation	O	O
were	O	O
born	O	O
in	O	O
the	O	O
Saguenay	O	O
-	O	O
Lac	O	O
-	O	O
St	O	O
-	O	O
Jean	O	O
region	O	O
of	O	O
Quebec	O	O
.	O	O

The	O	O
most	O	O
recent	O	O
ancestors	O	O
common	O	O
to	O	O
obligate	O	O
carriers	O	O
of	O	O
this	O	O
mutation	O	O
were	O	O
from	O	O
the	O	O
Charlevoix	O	O
region	O	O
of	O	O
the	O	O
province	O	O
of	O	O
Quebec	O	O
.	O	O

This	O	O
mutation	O	O
thus	O	O
has	O	O
a	O	O
different	O	O
geographic	O	O
centre	O	O
of	O	O
diffusion	O	O
and	O	O
is	O	O
probably	O	O
less	O	O
common	O	O
than	O	O
the	O	O
exon	O	O
1	O	O
deletion	O	O
TSD	B-Disease	D013661
mutation	O	O
in	O	O
French	O	O
Canadians	O	O
.	O	O

Neither	O	O
mutation	O	O
has	O	O
been	O	O
detected	O	O
in	O	O
France	O	O
,	O	O
the	O	O
ancestral	O	O
homeland	O	O
of	O	O
French	O	O
Canada	O	O
.	O	O

.	O	O

Recessively	O	O
inherited	O	O
multiple	B-Disease	D010009
epiphyseal	I-Disease	D010009
dysplasia	I-Disease	D010009
with	O	O
normal	O	O
stature	O	O
,	O	O
club	B-Disease	D003025
foot	I-Disease	D003025
,	O	O
and	O	O
double	B-Disease	C535504
layered	I-Disease	C535504
patella	I-Disease	C535504
caused	O	O
by	O	O
a	O	O
DTDST	O	O
mutation	O	O
.	O	O

We	O	O
have	O	O
observed	O	O
over	O	O
25	O	O
different	O	O
mutations	O	O
in	O	O
the	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
sulphate	O	O
transporter	O	O
gene	O	O
(	O	O
DTDST	O	O
)	O	O
in	O	O
association	O	O
with	O	O
the	O	O
recessive	B-Disease	D030342
disorders	I-Disease	D030342
achondrogenesis	B-Disease	C536016
1B	I-Disease	C536016
,	O	O
atelosteogenesis	B-Disease	C535395
2	I-Disease	C535395
,	O	O
and	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
.	O	O

The	O	O
c862t	O	O
(	O	O
R279W	O	O
)	O	O
transition	O	O
is	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
in	O	O
non	O	O
-	O	O
Finnish	O	O
patients	O	O
,	O	O
but	O	O
in	O	O
these	O	O
disorders	O	O
it	O	O
is	O	O
usually	O	O
combined	O	O
with	O	O
other	O	O
DTDST	O	O
mutations	O	O
.	O	O

We	O	O
had	O	O
not	O	O
seen	O	O
a	O	O
case	O	O
of	O	O
homozygosity	O	O
for	O	O
c862t	O	O
(	O	O
R279W	O	O
)	O	O
until	O	O
we	O	O
analysed	O	O
DNA	O	O
from	O	O
a	O	O
36	O	O
year	O	O
old	O	O
male	O	O
with	O	O
tall	O	O
-	O	O
normal	O	O
stature	O	O
(	O	O
180	O	O
cm	O	O
)	O	O
who	O	O
asked	O	O
for	O	O
genetic	O	O
counselling	O	O
for	O	O
suspected	O	O
multiple	B-Disease	D010009
epiphyseal	I-Disease	D010009
dysplasia	I-Disease	D010009
.	O	O

He	O	O
was	O	O
treated	O	O
for	O	O
club	B-Disease	D003025
foot	I-Disease	D003025
and	O	O
hip	B-Disease	D006618
dysplasia	I-Disease	D006618
at	O	O
birth	O	O
.	O	O

Skeletal	O	O
changes	O	O
consistent	O	O
with	O	O
multiple	B-Disease	D010009
epiphyseal	I-Disease	D010009
dysplasia	I-Disease	D010009
,	O	O
with	O	O
the	O	O
peculiar	O	O
finding	O	O
of	O	O
a	O	O
double	B-Disease	C535504
layered	I-Disease	C535504
patella	I-Disease	C535504
,	O	O
were	O	O
recognised	O	O
during	O	O
childhood	O	O
.	O	O

Cleft	B-Disease	D002972
palate	I-Disease	D002972
,	O	O
swelling	B-Disease	D004427
of	I-Disease	D004427
the	I-Disease	D004427
ear	I-Disease	D004427
pinna	I-Disease	D004427
,	O	O
and	O	O
hitch	B-Disease	C536903
hiker	I-Disease	C536903
thumb	I-Disease	C536903
were	O	O
absent	O	O
.	O	O

He	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
,	O	O
and	O	O
both	O	O
healthy	O	O
parents	O	O
heterozygous	O	O
,	O	O
for	O	O
the	O	O
R279W	O	O
mutation	O	O
in	O	O
DTDST	O	O
,	O	O
and	O	O
his	O	O
fibroblasts	O	O
showed	O	O
a	O	O
sulphate	O	O
incorporation	O	O
defect	O	O
typical	O	O
of	O	O
DTDST	B-Disease	D030342
disorders	I-Disease	D030342
.	O	O

Counselling	O	O
was	O	O
given	O	O
for	O	O
a	O	O
recessive	B-Disease	D030342
disorder	I-Disease	D030342
,	O	O
thereby	O	O
considerably	O	O
reducing	O	O
the	O	O
probability	O	O
of	O	O
affected	O	O
offspring	O	O
.	O	O

Multiple	B-Disease	D010009
epiphyseal	I-Disease	D010009
dysplasia	I-Disease	D010009
is	O	O
more	O	O
frequently	O	O
caused	O	O
by	O	O
dominant	O	O
mutations	O	O
in	O	O
the	O	O
COMP	O	O
(	O	O
EDM1	B-Disease	OMIM:132400
,	O	O
McKusick	O	O
132400	O	O
)	O	O
and	O	O
COL9A2	O	O
genes	O	O
(	O	O
EDM2	B-Disease	OMIM:600204
,	O	O
McKusick	O	O
600204	O	O
)	O	O
.	O	O

A	O	O
few	O	O
other	O	O
patients	O	O
and	O	O
families	O	O
with	O	O
features	O	O
similar	O	O
to	O	O
our	O	O
proband	O	O
have	O	O
been	O	O
described	O	O
previously	O	O
and	O	O
considered	O	O
to	O	O
have	O	O
autosomal	O	O
recessive	O	O
MED	B-Disease	D010009
(	O	O
EDM4	B-Disease	OMIM:226900
,	O	O
McKusick	O	O
226900	O	O
)	O	O
.	O	O

This	O	O
observation	O	O
confirms	O	O
the	O	O
existence	O	O
of	O	O
this	O	O
entity	O	O
and	O	O
assigns	O	O
it	O	O
to	O	O
the	O	O
phenotypic	O	O
spectrum	O	O
associated	O	O
with	O	O
mutations	O	O
at	O	O
the	O	O
DTDST	O	O
locus	O	O
.	O	O

.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
:	O	O
size	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
dependent	O	O
dynamics	O	O
of	O	O
CTG	O	O
meiotic	O	O
instability	O	O
,	O	O
and	O	O
somatic	O	O
mosaicism	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
a	O	O
progressive	O	O
neuromuscular	B-Disease	D009468
disorder	I-Disease	D009468
which	O	O
results	O	O
from	O	O
elongations	O	O
of	O	O
an	O	O
unstable	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
,	O	O
located	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
.	O	O

A	O	O
correlation	O	O
has	O	O
been	O	O
demonstrated	O	O
between	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
repeat	O	O
number	O	O
of	O	O
this	O	O
sequence	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

However	O	O
,	O	O
the	O	O
clinical	O	O
status	O	O
of	O	O
patients	O	O
cannot	O	O
be	O	O
unambiguously	O	O
ascertained	O	O
solely	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
number	O	O
of	O	O
CTG	O	O
repeats	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
exclusive	O	O
maternal	O	O
inheritance	O	O
of	O	O
the	O	O
congenital	O	O
form	O	O
remains	O	O
unexplained	O	O
.	O	O

Our	O	O
observation	O	O
of	O	O
differently	O	O
sized	O	O
repeats	O	O
in	O	O
various	O	O
DM	B-Disease	D009223
tissues	O	O
from	O	O
the	O	O
same	O	O
individual	O	O
may	O	O
explain	O	O
why	O	O
the	O	O
size	O	O
of	O	O
the	O	O
mutation	O	O
observed	O	O
in	O	O
lymphocytes	O	O
does	O	O
not	O	O
necessarily	O	O
correlate	O	O
with	O	O
the	O	O
severity	O	O
and	O	O
nature	O	O
of	O	O
symptoms	O	O
.	O	O

Through	O	O
a	O	O
molecular	O	O
and	O	O
genetic	O	O
study	O	O
of	O	O
142	O	O
families	O	O
including	O	O
418	O	O
DM	B-Disease	D009223
patients	O	O
,	O	O
we	O	O
have	O	O
investigated	O	O
the	O	O
dynamics	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
meiotic	O	O
instability	O	O
.	O	O

A	O	O
positive	O	O
correlation	O	O
between	O	O
the	O	O
size	O	O
of	O	O
the	O	O
repeat	O	O
and	O	O
the	O	O
intergenerational	O	O
enlargement	O	O
was	O	O
observed	O	O
similarly	O	O
through	O	O
male	O	O
and	O	O
female	O	O
meioses	O	O
for	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

5	O	O
-	O	O
kb	O	O
CTG	O	O
sequences	O	O
.	O	O

Beyond	O	O
0	O	O
.	O	O

5	O	O
kb	O	O
,	O	O
the	O	O
intergenerational	O	O
variation	O	O
was	O	O
more	O	O
important	O	O
through	O	O
female	O	O
meioses	O	O
,	O	O
whereas	O	O
a	O	O
tendency	O	O
to	O	O
compression	O	O
was	O	O
observed	O	O
almost	O	O
exclusively	O	O
in	O	O
male	O	O
meioses	O	O
,	O	O
for	O	O
>	O	O
or	O	O
=	O	O
1	O	O
.	O	O

5	O	O
-	O	O
kb	O	O
fragments	O	O
.	O	O

This	O	O
implies	O	O
a	O	O
size	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
dependent	O	O
meiotic	O	O
instability	O	O
.	O	O

Moreover	O	O
,	O	O
segregation	O	O
analysis	O	O
supports	O	O
the	O	O
hypothesis	O	O
of	O	O
a	O	O
maternal	O	O
as	O	O
well	O	O
as	O	O
a	O	O
familial	O	O
predisposition	O	O
for	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
congenital	O	O
form	O	O
.	O	O

Finally	O	O
,	O	O
this	O	O
analysis	O	O
reveals	O	O
a	O	O
significant	O	O
excess	O	O
of	O	O
transmitting	O	O
grandfathers	O	O
partially	O	O
accounted	O	O
for	O	O
by	O	O
increased	O	O
fertility	O	O
in	O	O
affected	O	O
males	O	O
Fatal	O	O
pyoderma	B-Disease	D017511
gangrenosum	I-Disease	D017511
in	O	O
association	O	O
with	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
.	O	O

Although	O	O
pyoderma	B-Disease	D017511
gangrenosum	I-Disease	D017511
(	O	O
PG	B-Disease	D017511
)	O	O
is	O	O
often	O	O
associated	O	O
with	O	O
systemic	B-Disease	D034721
diseases	I-Disease	D034721
,	O	O
it	O	O
has	O	O
not	O	O
been	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
congenital	B-Disease	D007153
complement	I-Disease	D007153
deficiencies	I-Disease	D007153
.	O	O

We	O	O
describe	O	O
an	O	O
aggressive	O	O
and	O	O
ultimately	O	O
fatal	O	O
case	O	O
of	O	O
PG	B-Disease	D017511
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
congenital	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
.	O	O

Deficiencies	B-Disease	OMIM:610102
of	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
can	O	O
be	O	O
associated	O	O
with	O	O
decreased	O	O
neutrophil	O	O
chemotaxis	O	O
,	O	O
phagocytosis	O	O
,	O	O
and	O	O
opsonization	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
immunologic	B-Disease	D007153
abnormalities	I-Disease	D007153
described	O	O
in	O	O
patients	O	O
with	O	O
PG	B-Disease	D017511
.	O	O

Our	O	O
patients	O	O
decreased	O	O
complement	O	O
level	O	O
,	O	O
if	O	O
not	O	O
directly	O	O
related	O	O
to	O	O
the	O	O
development	O	O
of	O	O
PG	B-Disease	D017511
,	O	O
may	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
aggressive	O	O
nature	O	O
of	O	O
her	O	O
disease	O	O
.	O	O

.	O	O

Emerin	B-Disease	D020389
deficiency	I-Disease	D020389
at	O	O
the	O	O
nuclear	O	O
membrane	O	O
in	O	O
patients	O	O
with	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
.	O	O

Mutations	O	O
in	O	O
the	O	O
STA	O	O
gene	O	O
at	O	O
the	O	O
Xq28	O	O
locus	O	O
have	O	O
been	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
.	O	O

This	O	O
gene	O	O
encodes	O	O
a	O	O
hitherto	O	O
unknown	O	O
protein	O	O
named	O	O
emerin	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
subcellular	O	O
localization	O	O
of	O	O
emerin	O	O
,	O	O
we	O	O
raised	O	O
two	O	O
antisera	O	O
against	O	O
synthetic	O	O
peptide	O	O
fragments	O	O
predicted	O	O
from	O	O
emerin	O	O
cDNA	O	O
.	O	O

Using	O	O
both	O	O
antisera	O	O
,	O	O
we	O	O
found	O	O
positive	O	O
nuclear	O	O
membrane	O	O
staining	O	O
in	O	O
skeletal	O	O
,	O	O
cardiac	O	O
and	O	O
smooth	O	O
muscles	O	O
in	O	O
the	O	O
normal	O	O
controls	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
neuromuscular	B-Disease	D009468
diseases	I-Disease	D009468
other	O	O
than	O	O
EDMD	B-Disease	D020389
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
deficiency	O	O
in	O	O
immunofluorescent	O	O
staining	O	O
of	O	O
skeletal	O	O
and	O	O
cardiac	O	O
muscle	O	O
from	O	O
EDMD	B-Disease	D020389
patients	O	O
was	O	O
observed	O	O
.	O	O

A	O	O
34	O	O
kD	O	O
protein	O	O
is	O	O
immunoreactive	O	O
with	O	O
the	O	O
antisera	O	O
-	O	O
-	O	O
the	O	O
protein	O	O
is	O	O
equivalent	O	O
to	O	O
that	O	O
predicted	O	O
for	O	O
emerin	O	O
.	O	O

Together	O	O
,	O	O
our	O	O
findings	O	O
suggest	O	O
the	O	O
specific	O	O
deficiency	B-Disease	D020389
of	I-Disease	D020389
emerin	I-Disease	D020389
in	O	O
the	O	O
nuclear	O	O
membrane	O	O
of	O	O
muscle	O	O
cells	O	O
in	O	O
patients	O	O
with	O	O
EDMD	B-Disease	D020389
.	O	O

.	O	O

A	O	O
p16INK4a	O	O
-	O	O
insensitive	O	O
CDK4	O	O
mutant	O	O
targeted	O	O
by	O	O
cytolytic	O	O
T	O	O
lymphocytes	O	O
in	O	O
a	O	O
human	O	O
melanoma	B-Disease	D008545
.	O	O

A	O	O
mutated	O	O
cyclin	O	O
-	O	O
dependent	O	O
kinase	O	O
4	O	O
(	O	O
CDK4	O	O
)	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
tumor	B-Disease	D009369
-	O	O
specific	O	O
antigen	O	O
recognized	O	O
by	O	O
HLA	O	O
-	O	O
A2	O	O
.	O	O

1	O	O
-	O	O
restricted	O	O
autologous	O	O
cytolytic	O	O
T	O	O
lymphocytes	O	O
(	O	O
CTLs	O	O
)	O	O
in	O	O
a	O	O
human	O	O
melanoma	B-Disease	D008545
.	O	O

The	O	O
mutated	O	O
CDK4	O	O
allele	O	O
was	O	O
present	O	O
in	O	O
autologous	O	O
cultured	O	O
melanoma	B-Disease	D008545
cells	O	O
and	O	O
metastasis	O	O
tissue	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
patients	O	O
lymphocytes	O	O
.	O	O

The	O	O
mutation	O	O
,	O	O
an	O	O
arginine	O	O
-	O	O
to	O	O
-	O	O
cysteine	O	O
exchange	O	O
at	O	O
residue	O	O
24	O	O
,	O	O
was	O	O
part	O	O
of	O	O
the	O	O
CDK4	O	O
peptide	O	O
recognized	O	O
by	O	O
CTLs	O	O
and	O	O
prevented	O	O
binding	O	O
of	O	O
the	O	O
CDK4	O	O
inhibitor	O	O
p16INK4a	O	O
,	O	O
but	O	O
not	O	O
of	O	O
p21	O	O
or	O	O
of	O	O
p27KIP1	O	O
.	O	O

The	O	O
same	O	O
mutation	O	O
was	O	O
found	O	O
in	O	O
one	O	O
additional	O	O
melanoma	B-Disease	D008545
among	O	O
28	O	O
melanomas	B-Disease	D008545
analyzed	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
mutation	O	O
of	O	O
CDK4	O	O
can	O	O
create	O	O
a	O	O
tumor	B-Disease	D009369
-	O	O
specific	O	O
antigen	O	O
and	O	O
can	O	O
disrupt	O	O
the	O	O
cell	O	O
-	O	O
cycle	O	O
regulation	O	O
exerted	O	O
by	O	O
the	O	O
tumor	B-Disease	D009369
suppressor	O	O
p16INK4a	O	O
.	O	O

.	O	O

Molecular	O	O
analysis	O	O
in	O	O
familial	B-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
:	O	O
early	O	O
diagnosis	O	O
of	O	O
an	O	O
asymptomatic	O	O
carrier	O	O
.	O	O

Familial	B-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
(	O	O
FNDI	B-Disease	OMIM:125700
)	O	O
is	O	O
an	O	O
inherited	O	O
deficiency	B-Disease	OMIM:125700
of	I-Disease	OMIM:125700
the	I-Disease	OMIM:125700
hormone	I-Disease	OMIM:125700
arginine	I-Disease	OMIM:125700
vasopressin	I-Disease	OMIM:125700
(	O	O
AVP	O	O
)	O	O
and	O	O
is	O	O
transmitted	O	O
as	O	O
an	O	O
autosomal	O	O
dominant	O	O
trait	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
have	O	O
analyzed	O	O
the	O	O
AVP	O	O
-	O	O
neurophysin	O	O
II	O	O
(	O	O
AVP	O	O
-	O	O
NPII	O	O
)	O	O
gene	O	O
in	O	O
a	O	O
Spanish	O	O
kindred	O	O
.	O	O

Studies	O	O
were	O	O
performed	O	O
on	O	O
seven	O	O
members	O	O
(	O	O
four	O	O
clinically	O	O
affected	O	O
)	O	O
of	O	O
the	O	O
family	O	O
.	O	O

Patients	O	O
were	O	O
diagnosed	O	O
at	O	O
the	O	O
Hospital	O	O
Universitario	O	O
Gregorio	O	O
Maranon	O	O
(	O	O
Madrid	O	O
,	O	O
Spain	O	O
)	O	O
.	O	O

The	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
AVP	O	O
-	O	O
NPII	O	O
gene	O	O
of	O	O
all	O	O
family	O	O
members	O	O
was	O	O
amplified	O	O
by	O	O
PCR	O	O
and	O	O
sequenced	O	O
.	O	O

All	O	O
affected	O	O
individuals	O	O
presented	O	O
a	O	O
missense	O	O
mutation	O	O
(	O	O
G1757	O	O
-	O	O
-	O	O
>	O	O
A	O	O
)	O	O
that	O	O
replaces	O	O
glycine	O	O
at	O	O
position	O	O
23	O	O
with	O	O
arginine	O	O
within	O	O
the	O	O
NPII	O	O
domain	O	O
.	O	O

The	O	O
substitution	O	O
was	O	O
confirmed	O	O
by	O	O
restriction	O	O
endonuclease	O	O
analysis	O	O
and	O	O
was	O	O
present	O	O
in	O	O
heterozygosis	O	O
.	O	O

Additionally	O	O
,	O	O
one	O	O
of	O	O
the	O	O
asymptomatic	O	O
relatives	O	O
(	O	O
a	O	O
girl	O	O
8	O	O
months	O	O
old	O	O
at	O	O
the	O	O
time	O	O
of	O	O
study	O	O
)	O	O
was	O	O
identified	O	O
as	O	O
carrier	O	O
of	O	O
the	O	O
same	O	O
mutation	O	O
and	O	O
developed	O	O
the	O	O
disease	O	O
3	O	O
months	O	O
later	O	O
.	O	O

The	O	O
alteration	O	O
found	O	O
in	O	O
the	O	O
second	O	O
exon	O	O
of	O	O
the	O	O
gene	O	O
in	O	O
this	O	O
family	O	O
seems	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
disease	O	O
,	O	O
as	O	O
all	O	O
individuals	O	O
harboring	O	O
the	O	O
mutation	O	O
had	O	O
been	O	O
previously	O	O
diagnosed	O	O
or	O	O
have	O	O
eventually	O	O
developed	O	O
FNDI	B-Disease	OMIM:125700
.	O	O

Identification	O	O
of	O	O
the	O	O
molecular	O	O
defect	O	O
underlying	O	O
FNDI	B-Disease	OMIM:125700
in	O	O
affected	O	O
families	O	O
is	O	O
a	O	O
powerful	O	O
tool	O	O
for	O	O
early	O	O
asymptomatic	O	O
diagnosis	O	O
in	O	O
infants	O	O
.	O	O

.	O	O

Sialophorin	O	O
,	O	O
a	O	O
surface	O	O
sialoglycoprotein	O	O
defective	O	O
in	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
,	O	O
is	O	O
involved	O	O
in	O	O
human	O	O
T	O	O
lymphocyte	O	O
proliferation	O	O
.	O	O

The	O	O
mAb	O	O
L10	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
distribution	O	O
and	O	O
the	O	O
function	O	O
of	O	O
sialophorin	O	O
,	O	O
the	O	O
heavily	O	O
glycosylated	O	O
surface	O	O
molecule	O	O
that	O	O
is	O	O
deficient	O	O
/	O	O
defective	O	O
in	O	O
lymphocytes	O	O
of	O	O
patients	O	O
with	O	O
the	O	O
X	B-Disease	D014923
-	I-Disease	D014923
linked	I-Disease	D014923
immunodeficiency	I-Disease	D014923
Wiskott	I-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

Dual	O	O
-	O	O
parameter	O	O
FACS	O	O
analysis	O	O
indicated	O	O
that	O	O
sialophorin	O	O
is	O	O
expressed	O	O
on	O	O
CD4	O	O
+	O	O
and	O	O
CD8	O	O
+	O	O
lymphocytes	O	O
,	O	O
on	O	O
a	O	O
subpopulation	O	O
of	O	O
peripheral	O	O
blood	O	O
B	O	O
lymphocytes	O	O
,	O	O
on	O	O
all	O	O
thymocytes	O	O
,	O	O
and	O	O
on	O	O
a	O	O
subpopulation	O	O
of	O	O
bone	O	O
marrow	O	O
cells	O	O
.	O	O

Functional	O	O
studies	O	O
demonstrated	O	O
that	O	O
L10	O	O
mAb	O	O
stimulates	O	O
the	O	O
proliferation	O	O
of	O	O
peripheral	O	O
blood	O	O
T	O	O
lymphocytes	O	O
as	O	O
measured	O	O
by	O	O
stimulation	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
thymidine	O	O
incorporation	O	O
.	O	O

The	O	O
time	O	O
course	O	O
and	O	O
magnitude	O	O
of	O	O
increased	O	O
[	O	O
3H	O	O
]	O	O
thymidine	O	O
incorporation	O	O
by	O	O
T	O	O
lymphocytes	O	O
in	O	O
response	O	O
to	O	O
L10	O	O
mAb	O	O
paralleled	O	O
that	O	O
induced	O	O
by	O	O
anti	O	O
-	O	O
CD3	O	O
mAb	O	O
.	O	O

Effective	O	O
stimulation	O	O
was	O	O
dependent	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
monocytes	O	O
and	O	O
the	O	O
Fc	O	O
portion	O	O
of	O	O
L10	O	O
mAb	O	O
.	O	O

Stimulation	O	O
of	O	O
lymphocytes	O	O
by	O	O
L10	O	O
,	O	O
like	O	O
stimulation	O	O
by	O	O
anti	O	O
-	O	O
CD3	O	O
mAb	O	O
,	O	O
involves	O	O
increased	O	O
expression	O	O
of	O	O
4F2	O	O
,	O	O
HLA	O	O
-	O	O
DR	O	O
,	O	O
and	O	O
IL	O	O
-	O	O
2	O	O
-	O	O
R	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
sialophorin	O	O
functions	O	O
in	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

.	O	O

Characterization	O	O
of	O	O
the	O	O
rat	O	O
spinocerebellar	B-Disease	D017827
ataxia	I-Disease	D017827
type	I-Disease	D017827
3	I-Disease	D017827
gene	O	O
.	O	O

Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
belongs	O	O
to	O	O
a	O	O
group	O	O
of	O	O
clinically	O	O
and	O	O
genetically	O	O
heterogeneous	O	O
neurodegenerative	B-Disease	D019636
disorders	I-Disease	D019636
characterized	O	O
by	O	O
progressive	B-Disease	D002524
cerebellar	I-Disease	D002524
ataxia	I-Disease	D002524
.	O	O

The	O	O
disease	O	O
-	O	O
causing	O	O
mutation	O	O
has	O	O
recently	O	O
been	O	O
identified	O	O
as	O	O
an	O	O
unstable	O	O
and	O	O
expanded	O	O
(	O	O
CAG	O	O
)	O	O
n	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
a	O	O
novel	O	O
gene	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

In	O	O
Caucasians	O	O
,	O	O
repeat	O	O
expansions	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
have	O	O
also	O	O
been	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
clinically	O	O
distinct	O	O
autosomal	O	O
dominant	O	O
spinocerebellar	B-Disease	D017827
ataxia	I-Disease	D017827
type	I-Disease	D017827
3	I-Disease	D017827
(	O	O
SCA3	B-Disease	D017827
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
biology	O	O
of	O	O
the	O	O
MJD1	O	O
/	O	O
SCA3	B-Disease	D017827
gene	O	O
we	O	O
cloned	O	O
the	O	O
rat	O	O
homologue	O	O
and	O	O
studied	O	O
its	O	O
expression	O	O
.	O	O

The	O	O
rat	O	O
and	O	O
human	O	O
ataxin	O	O
-	O	O
3	O	O
genes	O	O
are	O	O
highly	O	O
homologous	O	O
with	O	O
an	O	O
overall	O	O
sequence	O	O
identity	O	O
of	O	O
approximately	O	O
88	O	O
%	O	O
.	O	O

However	O	O
,	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
end	O	O
of	O	O
the	O	O
putative	O	O
protein	O	O
differs	O	O
strongly	O	O
from	O	O
the	O	O
published	O	O
human	O	O
sequence	O	O
.	O	O

The	O	O
(	O	O
CAG	O	O
)	O	O
n	O	O
block	O	O
in	O	O
the	O	O
rat	O	O
cDNA	O	O
consists	O	O
of	O	O
just	O	O
three	O	O
interrupted	O	O
units	O	O
suggesting	O	O
that	O	O
a	O	O
long	O	O
polyglutamine	O	O
stretch	O	O
is	O	O
not	O	O
essential	O	O
for	O	O
the	O	O
normal	O	O
function	O	O
of	O	O
the	O	O
ataxin	O	O
-	O	O
3	O	O
protein	O	O
in	O	O
rodents	O	O
.	O	O

The	O	O
expression	O	O
pattern	O	O
of	O	O
the	O	O
SCA3	B-Disease	D017827
gene	O	O
in	O	O
various	O	O
rat	O	O
and	O	O
human	O	O
tissues	O	O
was	O	O
investigated	O	O
by	O	O
Northern	O	O
blot	O	O
analyses	O	O
.	O	O

The	O	O
mature	O	O
transcript	O	O
is	O	O
approximately	O	O
6	O	O
kb	O	O
in	O	O
length	O	O
.	O	O

In	O	O
rat	O	O
testis	O	O
,	O	O
a	O	O
smaller	O	O
transcript	O	O
of	O	O
1	O	O
.	O	O

3	O	O
kb	O	O
was	O	O
identified	O	O
.	O	O

Transcription	O	O
of	O	O
rsca3	O	O
was	O	O
detected	O	O
in	O	O
most	O	O
rat	O	O
tissues	O	O
including	O	O
brain	O	O
.	O	O

Analyzing	O	O
the	O	O
expression	O	O
level	O	O
of	O	O
the	O	O
SCA3	B-Disease	D017827
gene	O	O
in	O	O
several	O	O
human	O	O
brain	O	O
sections	O	O
revealed	O	O
no	O	O
significant	O	O
higher	O	O
mRNA	O	O
level	O	O
in	O	O
regions	O	O
predominantly	O	O
affected	O	O
in	O	O
MJD	B-Disease	D017827
.	O	O

Thus	O	O
additional	O	O
molecules	O	O
and	O	O
/	O	O
or	O	O
regulatory	O	O
events	O	O
are	O	O
necessary	O	O
to	O	O
explain	O	O
the	O	O
exclusive	O	O
degeneration	B-Disease	D001927
of	I-Disease	D001927
certain	I-Disease	D001927
brain	I-Disease	D001927
areas	I-Disease	D001927
.	O	O

The	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
PAX3	O	O
/	O	O
FKHR	O	O
fusion	O	O
protein	O	O
is	O	O
a	O	O
transcriptional	O	O
activator	O	O
.	O	O

Chimeric	O	O
transcription	O	O
factors	O	O
,	O	O
created	O	O
by	O	O
gene	O	O
fusions	O	O
as	O	O
the	O	O
result	O	O
of	O	O
chromosomal	O	O
translocations	O	O
,	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
several	O	O
pathologically	O	O
disparate	O	O
solid	B-Disease	D009369
tumors	I-Disease	D009369
.	O	O

The	O	O
PAX3	O	O
/	O	O
FKHR	O	O
fusion	O	O
gene	O	O
,	O	O
formed	O	O
by	O	O
a	O	O
t	O	O
(	O	O
2	O	O
;	O	O
13	O	O
)	O	O
(	O	O
q35	O	O
;	O	O
q14	O	O
)	O	O
in	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
,	O	O
encodes	O	O
a	O	O
hybrid	O	O
protein	O	O
that	O	O
contains	O	O
both	O	O
PAX3	O	O
DNA	O	O
binding	O	O
domains	O	O
,	O	O
the	O	O
paired	O	O
box	O	O
and	O	O
homeodomain	O	O
,	O	O
linked	O	O
to	O	O
the	O	O
bisected	O	O
DNA	O	O
binding	O	O
domain	O	O
of	O	O
FKHR	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
forkhead	O	O
family	O	O
of	O	O
transcription	O	O
factors	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
PAX3	O	O
and	O	O
PAX3	O	O
/	O	O
FKHR	O	O
display	O	O
similar	O	O
,	O	O
but	O	O
not	O	O
identical	O	O
transactivation	O	O
activities	O	O
when	O	O
tested	O	O
with	O	O
model	O	O
Pax	O	O
recognition	O	O
sequences	O	O
.	O	O

No	O	O
functional	O	O
role	O	O
could	O	O
be	O	O
ascribed	O	O
solely	O	O
to	O	O
the	O	O
residual	O	O
FKHR	O	O
binding	O	O
domain	O	O
present	O	O
in	O	O
the	O	O
fusion	O	O
protein	O	O
,	O	O
but	O	O
FKHR	O	O
was	O	O
found	O	O
to	O	O
contribute	O	O
a	O	O
strong	O	O
carboxyl	O	O
terminal	O	O
activation	O	O
domain	O	O
replacing	O	O
the	O	O
one	O	O
located	O	O
in	O	O
the	O	O
unrearranged	O	O
PAX3	O	O
gene	O	O
.	O	O

We	O	O
show	O	O
that	O	O
the	O	O
native	O	O
PAX3	O	O
/	O	O
FKHR	O	O
protein	O	O
present	O	O
in	O	O
tumor	B-Disease	D009369
cells	O	O
with	O	O
this	O	O
translocation	O	O
has	O	O
transcriptional	O	O
characteristics	O	O
similar	O	O
to	O	O
the	O	O
in	O	O
vitro	O	O
expressed	O	O
protein	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
the	O	O
PAX3	O	O
/	O	O
FKHR	O	O
hybrid	O	O
protein	O	O
to	O	O
bind	O	O
DNA	O	O
in	O	O
a	O	O
sequence	O	O
specific	O	O
manner	O	O
and	O	O
to	O	O
transactivate	O	O
the	O	O
expression	O	O
of	O	O
artificial	O	O
reporter	O	O
genes	O	O
suggests	O	O
that	O	O
its	O	O
aberrant	O	O
expression	O	O
could	O	O
subvert	O	O
the	O	O
transcriptional	O	O
programs	O	O
that	O	O
normally	O	O
control	O	O
the	O	O
growth	O	O
,	O	O
differentiation	O	O
,	O	O
and	O	O
survival	O	O
of	O	O
primitive	O	O
myogenic	O	O
precursors	O	O
in	O	O
vivo	O	O
.	O	O

.	O	O

Myotonia	B-Disease	D009224
levior	I-Disease	D009224
is	O	O
a	O	O
chloride	B-Disease	OMIM:160800
channel	I-Disease	OMIM:160800
disorder	I-Disease	OMIM:160800
.	O	O

The	O	O
group	O	O
of	O	O
dominant	B-Disease	C536245
non	I-Disease	C536245
-	I-Disease	C536245
dystrophic	I-Disease	C536245
myotonias	I-Disease	C536245
,	O	O
comprising	O	O
disorders	O	O
characterized	O	O
by	O	O
clinically	O	O
similar	O	O
forms	O	O
of	O	O
myogenic	O	O
muscle	O	O
stiffness	O	O
,	O	O
is	O	O
genetically	O	O
inhomogeneous	O	O
.	O	O

Dominant	B-Disease	D009224
myotonia	I-Disease	D009224
congenita	I-Disease	D009224
(	O	O
Thomsens	B-Disease	D009224
disease	I-Disease	D009224
)	O	O
is	O	O
linked	O	O
to	O	O
CLCN1	O	O
,	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
major	O	O
muscle	O	O
chloride	O	O
channel	O	O
,	O	O
localized	O	O
on	O	O
chromosome	O	O
7q35	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
dominant	B-Disease	D009224
myotonias	I-Disease	D009224
sensitive	O	O
to	O	O
potassium	O	O
are	O	O
caused	O	O
by	O	O
point	O	O
mutations	O	O
in	O	O
SCN4A	O	O
on	O	O
chromosome	O	O
17q	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
alpha	O	O
subunit	O	O
of	O	O
the	O	O
adult	O	O
skeletal	O	O
muscle	O	O
sodium	O	O
channel	O	O
.	O	O

No	O	O
linkage	O	O
or	O	O
molecular	O	O
genetic	O	O
data	O	O
are	O	O
as	O	O
yet	O	O
available	O	O
on	O	O
myotonia	B-Disease	D009224
levior	I-Disease	D009224
characterized	O	O
by	O	O
milder	O	O
symptoms	O	O
and	O	O
later	O	O
onset	O	O
of	O	O
myotonia	B-Disease	D009222
than	O	O
in	O	O
Thomsens	B-Disease	D009224
disease	I-Disease	D009224
,	O	O
and	O	O
absence	O	O
of	O	O
muscle	B-Disease	C536106
hypertrophy	I-Disease	C536106
.	O	O

We	O	O
report	O	O
a	O	O
CLCN1	O	O
Gln	O	O
-	O	O
552	O	O
-	O	O
Arg	O	O
substitution	O	O
for	O	O
a	O	O
family	O	O
with	O	O
dominant	O	O
inheritance	O	O
previously	O	O
diagnosed	O	O
to	O	O
have	O	O
myotonia	B-Disease	D009224
levior	I-Disease	D009224
.	O	O

Thus	O	O
,	O	O
this	O	O
disorder	O	O
appears	O	O
as	O	O
a	O	O
variant	O	O
of	O	O
Thomsens	B-Disease	D009224
disease	I-Disease	D009224
due	O	O
to	O	O
mutations	O	O
leading	O	O
to	O	O
low	O	O
clinical	O	O
expressivity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
report	O	O
a	O	O
novel	O	O
Ile	O	O
-	O	O
290	O	O
-	O	O
Met	O	O
CLCN1	O	O
mutation	O	O
for	O	O
a	O	O
typical	O	O
Thomsen	O	O
pedigree	O	O
.	O	O

In	O	O
another	O	O
family	O	O
previously	O	O
diagnosed	O	O
as	O	O
having	O	O
Thomsens	B-Disease	D009224
disease	I-Disease	D009224
,	O	O
we	O	O
unexpectedly	O	O
found	O	O
a	O	O
CLCN1	O	O
14	O	O
bp	O	O
deletion	O	O
known	O	O
to	O	O
cause	O	O
recessive	B-Disease	D009224
myotonia	I-Disease	D009224
,	O	O
and	O	O
a	O	O
rare	O	O
Trp	O	O
-	O	O
118	O	O
-	O	O
Gly	O	O
polymorphism	O	O
.	O	O

.	O	O

Markedly	O	O
accelerated	O	O
catabolism	O	O
of	O	O
apolipoprotein	O	O
A	O	O
-	O	O
II	O	O
(	O	O
ApoA	O	O
-	O	O
II	O	O
)	O	O
and	O	O
high	O	O
density	O	O
lipoproteins	O	O
containing	O	O
ApoA	O	O
-	O	O
II	O	O
in	O	O
classic	O	O
lecithin	O	O
:	O	O
cholesterol	B-Disease	D007863
acyltransferase	I-Disease	D007863
deficiency	I-Disease	D007863
and	O	O
fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
.	O	O

Classic	B-Disease	D007863
(	I-Disease	D007863
complete	I-Disease	D007863
)	I-Disease	D007863
lecithin	I-Disease	D007863
cholesterol	I-Disease	D007863
acyltransferase	I-Disease	D007863
(	I-Disease	D007863
LCAT	I-Disease	D007863
)	I-Disease	D007863
deficiency	I-Disease	D007863
and	O	O
Fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
(	O	O
partial	B-Disease	D007863
LCAT	I-Disease	D007863
deficiency	I-Disease	D007863
)	O	O
are	O	O
genetic	O	O
syndromes	O	O
associated	O	O
with	O	O
markedly	O	O
decreased	O	O
plasma	O	O
levels	O	O
of	O	O
high	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
cholesterol	O	O
but	O	O
not	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
atherosclerotic	B-Disease	D050197
cardiovascular	I-Disease	D050197
disease	I-Disease	D050197
.	O	O

We	O	O
investigated	O	O
the	O	O
metabolism	O	O
of	O	O
the	O	O
HDL	O	O
apolipoproteins	O	O
(	O	O
apo	O	O
)	O	O
apoA	O	O
-	O	O
I	O	O
and	O	O
apoA	O	O
-	O	O
II	O	O
in	O	O
a	O	O
total	O	O
of	O	O
five	O	O
patients	O	O
with	O	O
LCAT	B-Disease	D007863
deficiency	I-Disease	D007863
,	O	O
one	O	O
with	O	O
classic	B-Disease	D007863
LCAT	I-Disease	D007863
deficiency	I-Disease	D007863
and	O	O
four	O	O
with	O	O
Fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
.	O	O

Plasma	O	O
levels	O	O
of	O	O
apoA	O	O
-	O	O
II	O	O
were	O	O
decreased	O	O
to	O	O
a	O	O
proportionately	O	O
greater	O	O
extent	O	O
(	O	O
23	O	O
%	O	O
of	O	O
normal	O	O
)	O	O
than	O	O
apoA	O	O
-	O	O
I	O	O
(	O	O
30	O	O
%	O	O
of	O	O
normal	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
plasma	O	O
concentrations	O	O
of	O	O
HDL	O	O
particles	O	O
containing	O	O
both	O	O
apoA	O	O
-	O	O
I	O	O
and	O	O
apoA	O	O
-	O	O
II	O	O
(	O	O
LpA	O	O
-	O	O
I	O	O
A	O	O
-	O	O
II	O	O
)	O	O
were	O	O
much	O	O
lower	O	O
(	O	O
18	O	O
%	O	O
of	O	O
normal	O	O
)	O	O
than	O	O
those	O	O
of	O	O
particles	O	O
containing	O	O
only	O	O
apoA	O	O
-	O	O
I	O	O
(	O	O
LpA	O	O
-	O	O
I	O	O
)	O	O
(	O	O
51	O	O
%	O	O
of	O	O
normal	O	O
)	O	O
.	O	O

The	O	O
metabolic	O	O
basis	O	O
for	O	O
the	O	O
low	O	O
levels	O	O
of	O	O
apoA	O	O
-	O	O
II	O	O
and	O	O
LpA	O	O
-	O	O
I	O	O
A	O	O
-	O	O
II	O	O
was	O	O
investigated	O	O
in	O	O
all	O	O
five	O	O
patients	O	O
using	O	O
both	O	O
exogenous	O	O
radiotracer	O	O
and	O	O
endogenous	O	O
stable	O	O
isotope	O	O
labeling	O	O
techniques	O	O
.	O	O

The	O	O
mean	O	O
plasma	O	O
residence	O	O
time	O	O
of	O	O
apoA	O	O
-	O	O
I	O	O
was	O	O
decreased	O	O
at	O	O
2	O	O
.	O	O

08	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

27	O	O
d	O	O
(	O	O
controls	O	O
4	O	O
.	O	O

74	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

65	O	O
days	O	O
)	O	O
;	O	O
however	O	O
,	O	O
the	O	O
residence	O	O
time	O	O
of	O	O
apoA	O	O
-	O	O
II	O	O
was	O	O
even	O	O
shorter	O	O
at	O	O
1	O	O
.	O	O

66	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

24	O	O
d	O	O
(	O	O
controls	O	O
5	O	O
.	O	O

25	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

61	O	O
d	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
catabolism	O	O
of	O	O
apoA	O	O
-	O	O
I	O	O
in	O	O
LpA	O	O
-	O	O
I	O	O
A	O	O
-	O	O
II	O	O
was	O	O
substantially	O	O
faster	O	O
than	O	O
that	O	O
of	O	O
apoA	O	O
-	O	O
I	O	O
in	O	O
LpA	O	O
-	O	O
I	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
genetic	O	O
syndromes	O	O
of	O	O
either	O	O
complete	B-Disease	D007863
or	I-Disease	D007863
partial	I-Disease	D007863
LCAT	I-Disease	D007863
deficiency	I-Disease	D007863
result	O	O
in	O	O
low	O	O
levels	O	O
of	O	O
HDL	O	O
through	O	O
preferential	O	O
hypercatabolism	O	O
of	O	O
apoA	O	O
-	O	O
II	O	O
and	O	O
HDL	O	O
particles	O	O
containing	O	O
apoA	O	O
-	O	O
II	O	O
.	O	O

Because	O	O
LpA	O	O
-	O	O
I	O	O
has	O	O
been	O	O
proposed	O	O
to	O	O
be	O	O
more	O	O
protective	O	O
than	O	O
LpA	O	O
-	O	O
I	O	O
A	O	O
-	O	O
II	O	O
against	O	O
atherosclerosis	B-Disease	D050197
,	O	O
this	O	O
selective	O	O
effect	O	O
on	O	O
the	O	O
metabolism	O	O
of	O	O
LpA	O	O
-	O	O
I	O	O
A	O	O
-	O	O
II	O	O
may	O	O
provide	O	O
a	O	O
potential	O	O
explanation	O	O
why	O	O
patients	O	O
with	O	O
classic	B-Disease	D007863
LCAT	I-Disease	D007863
deficiency	I-Disease	D007863
and	O	O
Fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
are	O	O
not	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
premature	O	O
atherosclerosis	B-Disease	D050197
despite	O	O
markedly	O	O
decreased	O	O
levels	O	O
of	O	O
HDL	O	O
cholesterol	O	O
and	O	O
apoA	O	O
-	O	O
I	O	O
The	O	O
identical	O	O
5	O	O
'	O	O
splice	O	O
-	O	O
site	O	O
acceptor	O	O
mutation	O	O
in	O	O
five	O	O
attenuated	B-Disease	C538265
APC	I-Disease	C538265
families	O	O
from	O	O
Newfoundland	O	O
demonstrates	O	O
a	O	O
founder	O	O
effect	O	O
.	O	O

Inherited	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
predispose	O	O
carriers	O	O
to	O	O
multiple	O	O
adenomatous	B-Disease	D011125
polyps	I-Disease	D011125
of	I-Disease	D011125
the	I-Disease	D011125
colon	I-Disease	D011125
and	I-Disease	D011125
rectum	I-Disease	D011125
and	O	O
to	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Mutations	O	O
located	O	O
at	O	O
the	O	O
extreme	O	O
5	O	O
end	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
however	O	O
,	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
less	O	O
severe	O	O
disease	O	O
known	O	O
as	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
(	O	O
AAPC	B-Disease	C538265
)	O	O
.	O	O

Many	O	O
individuals	O	O
with	O	O
AAPC	B-Disease	C538265
develop	O	O
relatively	O	O
few	O	O
colorectal	B-Disease	D003111
polyps	I-Disease	D003111
but	O	O
are	O	O
still	O	O
at	O	O
high	O	O
risk	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
5	O	O
APC	B-Disease	D011125
germline	O	O
mutation	O	O
in	O	O
five	O	O
separately	O	O
ascertained	O	O
AAPC	B-Disease	C538265
families	O	O
from	O	O
Newfoundland	O	O
,	O	O
Canada	O	O
.	O	O

This	O	O
disease	O	O
-	O	O
causing	O	O
mutation	O	O
is	O	O
a	O	O
single	O	O
basepair	O	O
change	O	O
(	O	O
G	O	O
to	O	O
A	O	O
)	O	O
in	O	O
the	O	O
splice	O	O
-	O	O
acceptor	O	O
region	O	O
of	O	O
APC	B-Disease	D011125
intron	O	O
3	O	O
that	O	O
creates	O	O
a	O	O
mutant	O	O
RNA	O	O
without	O	O
exon	O	O
4	O	O
of	O	O
APC	B-Disease	D011125
.	O	O

The	O	O
observation	O	O
of	O	O
the	O	O
same	O	O
APC	B-Disease	D011125
mutation	O	O
in	O	O
five	O	O
families	O	O
from	O	O
the	O	O
same	O	O
geographic	O	O
area	O	O
demonstrates	O	O
a	O	O
founder	O	O
effect	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
identification	O	O
of	O	O
this	O	O
germline	O	O
mutation	O	O
strengthens	O	O
the	O	O
correlation	O	O
between	O	O
the	O	O
5	O	O
location	O	O
of	O	O
an	O	O
APC	B-Disease	D011125
disease	O	O
-	O	O
causing	O	O
mutation	O	O
and	O	O
the	O	O
attenuated	B-Disease	C538265
polyposis	I-Disease	C538265
phenotype	O	O
.	O	O

.	O	O

Linkage	O	O
of	O	O
aspartylglucosaminuria	B-Disease	D054880
(	O	O
AGU	B-Disease	D054880
)	O	O
to	O	O
marker	O	O
loci	O	O
on	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
4	O	O
.	O	O

Aspartylglucosaminuria	B-Disease	D054880
(	O	O
AGU	B-Disease	D054880
)	O	O
is	O	O
caused	O	O
by	O	O
deficient	O	O
activity	O	O
of	O	O
the	O	O
enzyme	O	O
aspartylglucosaminidase	O	O
(	O	O
AGA	O	O
)	O	O
.	O	O

The	O	O
structural	O	O
gene	O	O
for	O	O
AGA	O	O
has	O	O
been	O	O
assigned	O	O
to	O	O
the	O	O
region	O	O
4q21	O	O
-	O	O
qter	O	O
of	O	O
chromosome	O	O
4	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
map	O	O
position	O	O
of	O	O
the	O	O
AGU	B-Disease	D054880
locus	O	O
in	O	O
relation	O	O
to	O	O
other	O	O
marker	O	O
loci	O	O
on	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
4	O	O
using	O	O
linkage	O	O
analyses	O	O
.	O	O

Restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
alleles	O	O
for	O	O
the	O	O
ADH2	O	O
,	O	O
ADH3	O	O
,	O	O
EGF	O	O
,	O	O
FG	O	O
alpha	O	O
and	O	O
FG	O	O
beta	O	O
loci	O	O
and	O	O
blood	O	O
group	O	O
antigens	O	O
for	O	O
the	O	O
MNS	O	O
locus	O	O
were	O	O
determined	O	O
in	O	O
a	O	O
panel	O	O
of	O	O
12	O	O
Finnish	O	O
AGU	B-Disease	D054880
families	O	O
.	O	O

The	O	O
heterozygous	O	O
family	O	O
members	O	O
were	O	O
identified	O	O
by	O	O
reduced	O	O
activity	O	O
of	O	O
AGA	O	O
in	O	O
lymphocytes	O	O
.	O	O

Linkage	O	O
studies	O	O
were	O	O
performed	O	O
using	O	O
both	O	O
pairwise	O	O
and	O	O
multipoint	O	O
analyses	O	O
.	O	O

Loose	O	O
linkage	O	O
of	O	O
the	O	O
AGU	B-Disease	D054880
locus	O	O
to	O	O
the	O	O
FG	O	O
and	O	O
MNS	O	O
loci	O	O
was	O	O
observed	O	O
(	O	O
z	O	O
=	O	O
1	O	O
.	O	O

16	O	O
,	O	O
z	O	O
=	O	O
1	O	O
.	O	O

39	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Multipoint	O	O
analysis	O	O
to	O	O
the	O	O
fixed	O	O
map	O	O
[	O	O
ADH	O	O
-	O	O
(	O	O
0	O	O
.	O	O

03	O	O
)	O	O
-	O	O
EGF	O	O
-	O	O
(	O	O
0	O	O
.	O	O

35	O	O
)	O	O
-	O	O
FG	O	O
-	O	O
(	O	O
0	O	O
.	O	O

11	O	O
)	O	O
-	O	O
MNS	O	O
]	O	O
suggests	O	O
that	O	O
the	O	O
location	O	O
of	O	O
the	O	O
AGU	B-Disease	D054880
locus	O	O
is	O	O
0	O	O
.	O	O

05	O	O
-	O	O
0	O	O
.	O	O

30	O	O
recombination	O	O
units	O	O
distal	O	O
to	O	O
MNS	O	O
(	O	O
z	O	O
=	O	O
3	O	O
.	O	O

03	O	O
)	O	O
.	O	O

The	O	O
order	O	O
cen	O	O
-	O	O
ADH	O	O
-	O	O
EGF	O	O
-	O	O
FG	O	O
-	O	O
MNS	O	O
-	O	O
AGU	B-Disease	D054880
is	O	O
35	O	O
times	O	O
more	O	O
likely	O	O
than	O	O
the	O	O
next	O	O
best	O	O
order	O	O
cen	O	O
-	O	O
ADH	O	O
-	O	O
EGF	O	O
-	O	O
AGU	B-Disease	D054880
-	O	O
FG	O	O
-	O	O
MNS	O	O
.	O	O

Linkage	O	O
analysis	O	O
in	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
and	O	O
application	O	O
in	O	O
post	O	O
-	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
.	O	O

We	O	O
have	O	O
performed	O	O
linkage	O	O
analysis	O	O
with	O	O
the	O	O
DNA	O	O
markers	O	O
DXS52	O	O
and	O	O
the	O	O
clotting	O	O
factor	O	O
VIII	O	O
gene	O	O
(	O	O
F8C	O	O
)	O	O
,	O	O
in	O	O
several	O	O
large	O	O
families	O	O
with	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
.	O	O

The	O	O
tight	O	O
linkage	O	O
to	O	O
DXS52	O	O
could	O	O
be	O	O
extended	O	O
giving	O	O
a	O	O
maximal	O	O
LOD	O	O
score	O	O
of	O	O
22	O	O
.	O	O

5	O	O
at	O	O
1	O	O
cM	O	O
.	O	O

F8C	O	O
was	O	O
also	O	O
tightly	O	O
linked	O	O
to	O	O
ALD	B-Disease	D000326
with	O	O
a	O	O
maximal	O	O
LOD	O	O
score	O	O
of	O	O
7	O	O
.	O	O

8	O	O
without	O	O
recombination	O	O
.	O	O

Multipoint	O	O
linkage	O	O
analysis	O	O
with	O	O
the	O	O
markers	O	O
DXS304	O	O
,	O	O
DXS52	O	O
,	O	O
and	O	O
F8C	O	O
indicated	O	O
that	O	O
both	O	O
the	O	O
gene	O	O
for	O	O
ALD	B-Disease	D000326
and	O	O
for	O	O
F8C	O	O
are	O	O
distal	O	O
to	O	O
DXS52	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
with	O	O
ALD	B-Disease	D000326
,	O	O
no	O	O
major	O	O
structural	O	O
rearrangement	O	O
in	O	O
the	O	O
Xqter	O	O
region	O	O
was	O	O
observed	O	O
;	O	O
in	O	O
particular	O	O
,	O	O
there	O	O
were	O	O
no	O	O
abnormalities	B-Disease	D003117
in	I-Disease	D003117
the	I-Disease	D003117
vision	I-Disease	D003117
blindness	I-Disease	D003117
genes	I-Disease	D003117
.	O	O

DNA	O	O
analysis	O	O
appeared	O	O
to	O	O
be	O	O
of	O	O
use	O	O
in	O	O
determination	O	O
of	O	O
the	O	O
carrier	O	O
status	O	O
of	O	O
females	O	O
at	O	O
risk	O	O
,	O	O
for	O	O
the	O	O
determination	O	O
of	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
a	O	O
particular	O	O
family	O	O
,	O	O
and	O	O
for	O	O
prenatal	O	O
diagnosis	O	O
.	O	O

Multicentric	O	O
origin	O	O
of	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
(	O	O
HFE	O	O
)	O	O
mutations	O	O
.	O	O

Genetic	B-Disease	D006432
hemochromatosis	I-Disease	D006432
(	O	O
GH	B-Disease	D006432
)	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
a	O	O
disease	O	O
restricted	O	O
to	O	O
those	O	O
of	O	O
European	O	O
ancestry	O	O
.	O	O

In	O	O
northwestern	O	O
Europe	O	O
,	O	O
>	O	O
80	O	O
%	O	O
of	O	O
GH	B-Disease	D006432
patients	O	O
are	O	O
homozygous	O	O
for	O	O
one	O	O
mutation	O	O
,	O	O
the	O	O
substitution	O	O
of	O	O
tyrosine	O	O
for	O	O
cysteine	O	O
at	O	O
position	O	O
282	O	O
(	O	O
C282Y	O	O
)	O	O
in	O	O
the	O	O
unprocessed	O	O
protein	O	O
.	O	O

In	O	O
a	O	O
proportion	O	O
of	O	O
GH	B-Disease	D006432
patients	O	O
,	O	O
two	O	O
mutations	O	O
are	O	O
present	O	O
,	O	O
C282Y	O	O
and	O	O
H63D	O	O
.	O	O

The	O	O
clinical	O	O
significance	O	O
of	O	O
this	O	O
second	O	O
mutation	O	O
is	O	O
such	O	O
that	O	O
it	O	O
appears	O	O
to	O	O
predispose	O	O
1	O	O
%	O	O
-	O	O
2	O	O
%	O	O
of	O	O
compound	O	O
heterozygotes	O	O
to	O	O
expression	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
distribution	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
differ	O	O
,	O	O
C282Y	O	O
being	O	O
limited	O	O
to	O	O
those	O	O
of	O	O
northwestern	O	O
European	O	O
ancestry	O	O
and	O	O
H63D	O	O
being	O	O
found	O	O
at	O	O
allele	O	O
frequencies	O	O
>	O	O
5	O	O
%	O	O
,	O	O
in	O	O
Europe	O	O
,	O	O
in	O	O
countries	O	O
bordering	O	O
the	O	O
Mediterranean	O	O
,	O	O
in	O	O
the	O	O
Middle	O	O
East	O	O
,	O	O
and	O	O
in	O	O
the	O	O
Indian	O	O
subcontinent	O	O
.	O	O

The	O	O
C282Y	O	O
mutation	O	O
occurs	O	O
on	O	O
a	O	O
haplotype	O	O
that	O	O
extends	O	O
<	O	O
/	O	O
=	O	O
6	O	O
Mb	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
mutation	O	O
has	O	O
arisen	O	O
during	O	O
the	O	O
past	O	O
2	O	O
,	O	O
000	O	O
years	O	O
.	O	O

The	O	O
H63D	O	O
mutation	O	O
is	O	O
older	O	O
and	O	O
does	O	O
not	O	O
occur	O	O
on	O	O
such	O	O
a	O	O
large	O	O
extended	O	O
haplotype	O	O
,	O	O
the	O	O
haplotype	O	O
in	O	O
this	O	O
case	O	O
extending	O	O
<	O	O
/	O	O
=	O	O
700	O	O
kb	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
finding	O	O
of	O	O
the	O	O
H63D	O	O
and	O	O
C282Y	O	O
mutations	O	O
on	O	O
new	O	O
haplotypes	O	O
.	O	O

In	O	O
Sri	O	O
Lanka	O	O
we	O	O
have	O	O
found	O	O
H63D	O	O
on	O	O
three	O	O
new	O	O
haplotypes	O	O
and	O	O
have	O	O
found	O	O
C282Y	O	O
on	O	O
one	O	O
new	O	O
haplotype	O	O
,	O	O
demonstrating	O	O
that	O	O
these	O	O
mutations	O	O
have	O	O
arisen	O	O
independently	O	O
on	O	O
this	O	O
island	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
HFE	O	O
gene	O	O
has	O	O
been	O	O
the	O	O
subject	O	O
of	O	O
selection	O	O
pressure	O	O
.	O	O

These	O	O
selection	O	O
pressures	O	O
could	O	O
be	O	O
due	O	O
to	O	O
infectious	B-Disease	D003141
diseases	I-Disease	D003141
,	O	O
environmental	O	O
conditions	O	O
,	O	O
or	O	O
other	O	O
genetic	B-Disease	D030342
disorders	I-Disease	D030342
such	O	O
as	O	O
anemia	B-Disease	D000740
.	O	O

Identification	O	O
and	O	O
localization	O	O
of	O	O
mutations	O	O
at	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
locus	O	O
by	O	O
ribonuclease	O	O
A	O	O
cleavage	O	O
.	O	O

Many	O	O
mutations	O	O
leading	O	O
to	O	O
human	O	O
disease	O	O
are	O	O
the	O	O
result	O	O
of	O	O
single	O	O
DNA	O	O
base	O	O
pair	O	O
changes	O	O
that	O	O
cannot	O	O
be	O	O
identified	O	O
by	O	O
Southern	O	O
analysis	O	O
.	O	O

This	O	O
has	O	O
prompted	O	O
the	O	O
development	O	O
of	O	O
alternative	O	O
assays	O	O
for	O	O
point	O	O
mutation	O	O
detection	O	O
.	O	O

The	O	O
recently	O	O
described	O	O
ribonuclease	O	O
A	O	O
cleavage	O	O
procedure	O	O
,	O	O
with	O	O
a	O	O
polyuridylic	O	O
acid	O	O
-	O	O
paper	O	O
affinity	O	O
chromatography	O	O
step	O	O
,	O	O
has	O	O
been	O	O
used	O	O
to	O	O
identify	O	O
the	O	O
mutational	O	O
lesions	O	O
in	O	O
the	O	O
hypoxanthine	O	O
phosphoribosyltransferase	O	O
(	O	O
HPRT	O	O
)	O	O
messenger	O	O
RNAs	O	O
of	O	O
patients	O	O
with	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
.	O	O

Distinctive	O	O
ribonuclease	O	O
A	O	O
cleavage	O	O
patterns	O	O
were	O	O
identified	O	O
in	O	O
messenger	O	O
RNA	O	O
from	O	O
5	O	O
of	O	O
14	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patients	O	O
who	O	O
were	O	O
chosen	O	O
because	O	O
no	O	O
HPRT	O	O
Southern	O	O
or	O	O
Northern	O	O
blotting	O	O
pattern	O	O
changes	O	O
had	O	O
been	O	O
found	O	O
.	O	O

This	O	O
approach	O	O
now	O	O
allows	O	O
HPRT	O	O
mutation	O	O
detection	O	O
in	O	O
50	O	O
percent	O	O
of	O	O
the	O	O
cases	O	O
of	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
.	O	O

The	O	O
polyuridylic	O	O
acid	O	O
-	O	O
paper	O	O
affinity	O	O
procedure	O	O
provides	O	O
a	O	O
general	O	O
method	O	O
for	O	O
analysis	O	O
of	O	O
low	O	O
abundance	O	O
messenger	O	O
RNAs	O	O
.	O	O

.	O	O

MEFV	O	O
-	O	O
Gene	O	O
analysis	O	O
in	O	O
armenian	O	O
patients	O	O
with	O	O
Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
:	O	O
diagnostic	O	O
value	O	O
and	O	O
unfavorable	O	O
renal	O	O
prognosis	O	O
of	O	O
the	O	O
M694V	O	O
homozygous	O	O
genotype	O	O
-	O	O
genetic	O	O
and	O	O
therapeutic	O	O
implications	O	O
.	O	O

Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
is	O	O
a	O	O
recessively	B-Disease	D030342
inherited	I-Disease	D030342
disorder	I-Disease	D030342
that	O	O
is	O	O
common	O	O
in	O	O
patients	O	O
of	O	O
Armenian	O	O
ancestry	O	O
.	O	O

To	O	O
date	O	O
,	O	O
its	O	O
diagnosis	O	O
,	O	O
which	O	O
can	O	O
be	O	O
made	O	O
only	O	O
retrospectively	O	O
,	O	O
is	O	O
one	O	O
of	O	O
exclusion	O	O
,	O	O
based	O	O
entirely	O	O
on	O	O
nonspecific	O	O
clinical	O	O
signs	O	O
that	O	O
result	O	O
from	O	O
serosal	B-Disease	D007249
inflammation	I-Disease	D007249
and	O	O
that	O	O
may	O	O
lead	O	O
to	O	O
unnecessary	O	O
surgery	O	O
.	O	O

Renal	B-Disease	C538249
amyloidosis	I-Disease	C538249
,	O	O
prevented	O	O
by	O	O
colchicine	O	O
,	O	O
is	O	O
the	O	O
most	O	O
severe	O	O
complication	O	O
of	O	O
FMF	B-Disease	D010505
,	O	O
a	O	O
disorder	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
MEFV	O	O
gene	O	O
.	O	O

To	O	O
evaluate	O	O
the	O	O
diagnostic	O	O
and	O	O
prognostic	O	O
value	O	O
of	O	O
MEFV	O	O
-	O	O
gene	O	O
analysis	O	O
,	O	O
we	O	O
investigated	O	O
90	O	O
Armenian	O	O
FMF	B-Disease	D010505
patients	O	O
from	O	O
77	O	O
unrelated	O	O
families	O	O
that	O	O
were	O	O
not	O	O
selected	O	O
through	O	O
genetic	O	O
-	O	O
linkage	O	O
analysis	O	O
.	O	O

Eight	O	O
mutations	O	O
,	O	O
one	O	O
of	O	O
which	O	O
(	O	O
R408Q	O	O
)	O	O
is	O	O
new	O	O
,	O	O
were	O	O
found	O	O
to	O	O
account	O	O
for	O	O
93	O	O
%	O	O
of	O	O
the	O	O
163	O	O
independent	O	O
FMF	B-Disease	D010505
alleles	O	O
,	O	O
with	O	O
both	O	O
FMF	B-Disease	D010505
alleles	O	O
identified	O	O
in	O	O
89	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
several	O	O
instances	O	O
,	O	O
family	O	O
studies	O	O
provided	O	O
molecular	O	O
evidence	O	O
for	O	O
pseudodominant	O	O
transmission	O	O
and	O	O
incomplete	O	O
penetrance	O	O
of	O	O
the	O	O
disease	O	O
phenotype	O	O
.	O	O

The	O	O
M694V	O	O
homozygous	O	O
genotype	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
higher	O	O
prevalence	O	O
of	O	O
renal	B-Disease	C538249
amyloidosis	I-Disease	C538249
and	O	O
arthritis	B-Disease	D001168
,	O	O
compared	O	O
with	O	O
other	O	O
genotypes	O	O
(	O	O
P	O	O
=	O	O
.	O	O

0002	O	O
and	O	O
P	O	O
=	O	O
.	O	O

006	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
demonstration	O	O
of	O	O
both	O	O
the	O	O
diagnostic	O	O
and	O	O
prognostic	O	O
value	O	O
of	O	O
MEFV	O	O
analysis	O	O
and	O	O
particular	O	O
modes	O	O
of	O	O
inheritance	O	O
should	O	O
lead	O	O
to	O	O
new	O	O
ways	O	O
for	O	O
management	O	O
of	O	O
FMF	B-Disease	D010505
-	O	O
including	O	O
genetic	O	O
counseling	O	O
and	O	O
therapeutic	O	O
decisions	O	O
in	O	O
affected	O	O
families	O	O
.	O	O

Identification	O	O
and	O	O
localization	O	O
of	O	O
huntingtin	O	O
in	O	O
brain	O	O
and	O	O
human	O	O
lymphoblastoid	O	O
cell	O	O
lines	O	O
with	O	O
anti	O	O
-	O	O
fusion	O	O
protein	O	O
antibodies	O	O
.	O	O

The	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
phenotype	O	O
is	O	O
associated	O	O
with	O	O
expansion	O	O
of	O	O
a	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
the	O	O
IT15	O	O
gene	O	O
,	O	O
which	O	O
is	O	O
predicted	O	O
to	O	O
encode	O	O
a	O	O
348	O	O
-	O	O
kDa	O	O
protein	O	O
named	O	O
huntington	O	O
.	O	O

We	O	O
used	O	O
polyclonal	O	O
and	O	O
monoclonal	O	O
anti	O	O
-	O	O
fusion	O	O
protein	O	O
antibodies	O	O
to	O	O
identify	O	O
native	O	O
huntingtin	O	O
in	O	O
rat	O	O
,	O	O
monkey	O	O
,	O	O
and	O	O
human	O	O
.	O	O

Western	O	O
blots	O	O
revealed	O	O
a	O	O
protein	O	O
with	O	O
the	O	O
expected	O	O
molecular	O	O
weight	O	O
which	O	O
is	O	O
present	O	O
in	O	O
the	O	O
soluble	O	O
fraction	O	O
of	O	O
rat	O	O
and	O	O
monkey	O	O
brain	O	O
tissues	O	O
and	O	O
lymphoblastoid	O	O
cells	O	O
from	O	O
control	O	O
cases	O	O
.	O	O

In	O	O
lymphoblastoid	O	O
cell	O	O
lines	O	O
from	O	O
juvenile	O	O
-	O	O
onset	O	O
heterozygote	O	O
HD	B-Disease	D006816
cases	O	O
,	O	O
both	O	O
normal	O	O
and	O	O
mutant	O	O
huntingtin	O	O
are	O	O
expressed	O	O
,	O	O
and	O	O
increasing	O	O
repeat	O	O
expansion	O	O
leads	O	O
to	O	O
lower	O	O
levels	O	O
of	O	O
the	O	O
mutant	O	O
protein	O	O
.	O	O

Immunocytochemistry	O	O
indicates	O	O
that	O	O
huntingtin	O	O
is	O	O
located	O	O
in	O	O
neurons	O	O
throughout	O	O
the	O	O
brain	O	O
,	O	O
with	O	O
the	O	O
highest	O	O
levels	O	O
evident	O	O
in	O	O
larger	O	O
neurons	O	O
.	O	O

In	O	O
the	O	O
human	O	O
striatum	O	O
,	O	O
huntingtin	O	O
is	O	O
enriched	O	O
in	O	O
a	O	O
patch	O	O
-	O	O
like	O	O
distribution	O	O
,	O	O
potentially	O	O
corresponding	O	O
to	O	O
the	O	O
first	O	O
areas	O	O
affected	O	O
in	O	O
HD	B-Disease	D006816
.	O	O

Subcellular	O	O
localization	O	O
of	O	O
huntingtin	O	O
is	O	O
consistent	O	O
with	O	O
a	O	O
cytosolic	O	O
protein	O	O
primarily	O	O
found	O	O
in	O	O
somatodendritic	O	O
regions	O	O
.	O	O

Huntingtin	O	O
appears	O	O
to	O	O
particularly	O	O
associate	O	O
with	O	O
microtubules	O	O
,	O	O
although	O	O
some	O	O
is	O	O
also	O	O
associated	O	O
with	O	O
synaptic	O	O
vesicles	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
localization	O	O
of	O	O
huntingtin	O	O
in	O	O
association	O	O
with	O	O
microtubules	O	O
,	O	O
we	O	O
speculate	O	O
that	O	O
the	O	O
mutation	O	O
impairs	O	O
the	O	O
cytoskeletal	O	O
anchoring	O	O
or	O	O
transport	O	O
of	O	O
mitochondria	O	O
,	O	O
vesicles	O	O
,	O	O
or	O	O
other	O	O
organelles	O	O
or	O	O
molecules	O	O
.	O	O

.	O	O

Correlation	O	O
between	O	O
the	O	O
location	O	O
of	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
and	O	O
the	O	O
number	O	O
of	O	O
colorectal	B-Disease	D003111
polyps	I-Disease	D003111
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
patients	O	O
.	O	O

Recently	O	O
we	O	O
have	O	O
isolated	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
which	O	O
causes	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
,	O	O
and	O	O
its	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
a	O	O
substantial	O	O
number	O	O
of	O	O
FAP	B-Disease	D011125
patients	O	O
have	O	O
been	O	O
identified	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
this	O	O
information	O	O
,	O	O
we	O	O
compared	O	O
the	O	O
location	O	O
of	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
22	O	O
unrelated	O	O
patients	O	O
(	O	O
12	O	O
of	O	O
whom	O	O
have	O	O
been	O	O
reported	O	O
previously	O	O
)	O	O
with	O	O
the	O	O
number	O	O
of	O	O
colorectal	B-Disease	D003111
polyps	I-Disease	D003111
developed	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
;	O	O
17	O	O
were	O	O
sparse	O	O
types	O	O
and	O	O
five	O	O
were	O	O
profuse	O	O
types	O	O
.	O	O

All	O	O
but	O	O
one	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
considered	O	O
to	O	O
cause	O	O
truncation	O	O
of	O	O
the	O	O
gene	O	O
product	O	O
by	O	O
frame	O	O
-	O	O
shift	O	O
due	O	O
to	O	O
deletion	O	O
(	O	O
14	O	O
cases	O	O
)	O	O
or	O	O
nonsense	O	O
mutation	O	O
(	O	O
seven	O	O
cases	O	O
)	O	O
.	O	O

The	O	O
location	O	O
of	O	O
the	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
seems	O	O
to	O	O
correlate	O	O
with	O	O
the	O	O
two	O	O
clinical	O	O
types	O	O
;	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
five	O	O
FAP	B-Disease	D011125
patients	O	O
with	O	O
profuse	O	O
polyps	B-Disease	D011127
were	O	O
observed	O	O
between	O	O
codon	O	O
1250	O	O
and	O	O
codon	O	O
1464	O	O
,	O	O
whereas	O	O
mutations	O	O
in	O	O
17	O	O
FAP	B-Disease	D011125
patients	O	O
with	O	O
fewer	O	O
polyps	B-Disease	D011127
were	O	O
observed	O	O
in	O	O
the	O	O
other	O	O
regions	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

The	O	O
result	O	O
suggests	O	O
that	O	O
the	O	O
number	O	O
of	O	O
colorectal	B-Disease	D003111
polyps	I-Disease	D003111
in	O	O
FAP	B-Disease	D011125
patients	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
difference	O	O
in	O	O
the	O	O
stability	O	O
or	O	O
biological	O	O
function	O	O
of	O	O
the	O	O
truncated	O	O
APC	B-Disease	D011125
protein	O	O
.	O	O

.	O	O

Duchenne	B-Disease	D020388
/	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
:	O	O
correlation	O	O
of	O	O
phenotype	O	O
by	O	O
electroretinography	O	O
with	O	O
sites	O	O
of	O	O
dystrophin	O	O
mutations	O	O
.	O	O

The	O	O
dark	O	O
-	O	O
adapted	O	O
electroretinogram	O	O
(	O	O
ERG	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
)	O	O
shows	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
b	O	O
-	O	O
wave	O	O
amplitude	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
studies	O	O
of	O	O
mouse	O	O
models	O	O
for	O	O
DMD	B-Disease	D020388
show	O	O
position	O	O
-	O	O
specific	O	O
effects	O	O
of	O	O
the	O	O
mutations	O	O
upon	O	O
the	O	O
phenotype	O	O
mice	O	O
with	O	O
5	O	O
defects	O	O
of	O	O
dystrophin	O	O
have	O	O
normal	O	O
ERGs	O	O
,	O	O
those	O	O
with	O	O
defects	O	O
in	O	O
the	O	O
central	O	O
region	O	O
have	O	O
a	O	O
normal	O	O
b	O	O
-	O	O
wave	O	O
amplitude	O	O
associated	O	O
with	O	O
prolonged	O	O
implicit	O	O
times	O	O
for	O	O
both	O	O
the	O	O
b	O	O
-	O	O
wave	O	O
and	O	O
oscillatory	O	O
potentials	O	O
,	O	O
and	O	O
mice	O	O
with	O	O
3	O	O
defects	O	O
have	O	O
a	O	O
phenotype	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
in	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
patients	O	O
.	O	O

The	O	O
mouse	O	O
studies	O	O
suggest	O	O
a	O	O
key	O	O
role	O	O
for	O	O
the	O	O
carboxyl	O	O
terminal	O	O
dystrophin	O	O
isoform	O	O
,	O	O
Dp260	O	O
,	O	O
in	O	O
retinal	O	O
electrophysiology	O	O
.	O	O

We	O	O
have	O	O
undertaken	O	O
a	O	O
systematic	O	O
evaluation	O	O
of	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
patients	O	O
through	O	O
clinical	O	O
examination	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
position	O	O
-	O	O
specific	O	O
effects	O	O
of	O	O
mutations	O	O
noted	O	O
in	O	O
the	O	O
mouse	O	O
are	O	O
present	O	O
in	O	O
man	O	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
,	O	O
in	O	O
man	O	O
,	O	O
a	O	O
wider	O	O
variation	O	O
of	O	O
DMD	B-Disease	D020388
defects	O	O
correlate	O	O
with	O	O
reductions	O	O
in	O	O
the	O	O
b	O	O
-	O	O
wave	O	O
amplitude	O	O
.	O	O

Individuals	O	O
with	O	O
normal	O	O
ERGs	O	O
have	O	O
mutations	O	O
predominantly	O	O
located	O	O
5	O	O
of	O	O
the	O	O
transcript	O	O
initiation	O	O
site	O	O
of	O	O
Dp260	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
most	O	O
important	O	O
determinant	O	O
in	O	O
the	O	O
ERG	O	O
b	O	O
-	O	O
wave	O	O
phenotype	O	O
is	O	O
the	O	O
mutation	O	O
position	O	O
,	O	O
rather	O	O
than	O	O
muscle	B-Disease	D009135
disease	I-Disease	D009135
severity	O	O
.	O	O

Forty	O	O
-	O	O
six	O	O
per	O	O
cent	O	O
of	O	O
patients	O	O
with	O	O
mutations	O	O
5	O	O
of	O	O
the	O	O
Dp260	O	O
transcript	O	O
start	O	O
site	O	O
have	O	O
abnormal	O	O
ERGs	O	O
,	O	O
as	O	O
opposed	O	O
to	O	O
94	O	O
%	O	O
with	O	O
more	O	O
distal	O	O
mutations	O	O
.	O	O

The	O	O
human	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
role	O	O
for	O	O
Dp260	O	O
in	O	O
normal	O	O
retinal	O	O
electrophysiology	O	O
and	O	O
may	O	O
also	O	O
reflect	O	O
the	O	O
expression	O	O
of	O	O
other	O	O
C	O	O
-	O	O
terminal	O	O
dystrophin	O	O
isoforms	O	O
and	O	O
their	O	O
contributions	O	O
to	O	O
retinal	O	O
signal	O	O
transmission	O	O
.	O	O

.	O	O

Molecular	O	O
characterization	O	O
of	O	O
two	O	O
galactosemia	B-Disease	D005693
mutations	O	O
and	O	O
one	O	O
polymorphism	O	O
:	O	O
implications	O	O
for	O	O
structure	O	O
-	O	O
function	O	O
analysis	O	O
of	O	O
human	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
molecular	O	O
characterization	O	O
of	O	O
two	O	O
galactosemia	B-Disease	D005693
mutations	O	O
,	O	O
L74P	O	O
and	O	O
F171S	O	O
,	O	O
and	O	O
one	O	O
polymorphism	O	O
,	O	O
S135L	O	O
,	O	O
in	O	O
human	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
(	O	O
GALT	O	O
)	O	O
.	O	O

Both	O	O
galactosemia	B-Disease	D005693
mutations	O	O
result	O	O
in	O	O
reduced	O	O
enzymatic	O	O
activity	O	O
when	O	O
reconstructed	O	O
in	O	O
the	O	O
cDNA	O	O
and	O	O
overexpressed	O	O
.	O	O

The	O	O
polymorphism	O	O
,	O	O
in	O	O
contrast	O	O
,	O	O
has	O	O
near	O	O
normal	O	O
activity	O	O
.	O	O

Both	O	O
mutations	O	O
affect	O	O
evolutionarily	O	O
conserved	O	O
residues	O	O
,	O	O
suggesting	O	O
that	O	O
they	O	O
are	O	O
functionally	O	O
important	O	O
,	O	O
while	O	O
the	O	O
polymorphism	O	O
occurs	O	O
in	O	O
a	O	O
nonconserved	O	O
domain	O	O
which	O	O
is	O	O
presumably	O	O
not	O	O
critical	O	O
for	O	O
enzymatic	O	O
function	O	O
.	O	O

The	O	O
F171S	O	O
mutation	O	O
is	O	O
close	O	O
to	O	O
the	O	O
putative	O	O
active	O	O
-	O	O
site	O	O
nucleophile	O	O
.	O	O

Our	O	O
data	O	O
further	O	O
support	O	O
the	O	O
notion	O	O
of	O	O
molecular	O	O
heterogeneity	O	O
of	O	O
galactosemia	B-Disease	D005693
and	O	O
suggest	O	O
that	O	O
galactosemia	B-Disease	D005693
mutations	O	O
and	O	O
GALT	O	O
polymorphisms	O	O
may	O	O
be	O	O
useful	O	O
tools	O	O
in	O	O
highlighting	O	O
different	O	O
functional	O	O
domains	O	O
in	O	O
human	O	O
GALT	O	O
.	O	O

.	O	O

Gaucher	B-Disease	D005776
disease	I-Disease	D005776
:	O	O
the	O	O
origins	O	O
of	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
N370S	O	O
and	O	O
84GG	O	O
acid	O	O
beta	O	O
-	O	O
glucosidase	O	O
mutations	O	O
.	O	O

Type	O	O
1	O	O
Gaucher	B-Disease	D005776
disease	I-Disease	D005776
(	O	O
GD	B-Disease	D005776
)	O	O
,	O	O
a	O	O
non	O	O
-	O	O
neuronopathic	O	O
lysosomal	B-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
,	O	O
results	O	O
from	O	O
the	O	O
deficient	O	O
activity	O	O
of	O	O
acid	O	O
beta	O	O
-	O	O
glucosidase	O	O
(	O	O
GBA	O	O
)	O	O
.	O	O

Type	O	O
1	O	O
disease	O	O
is	O	O
panethnic	O	O
but	O	O
is	O	O
more	O	O
prevalent	O	O
in	O	O
individuals	O	O
of	O	O
Ashkenazi	O	O
Jewish	O	O
(	O	O
AJ	O	O
)	O	O
descent	O	O
.	O	O

Of	O	O
the	O	O
causative	O	O
GBA	O	O
mutations	O	O
,	O	O
N370S	O	O
is	O	O
particularly	O	O
frequent	O	O
in	O	O
the	O	O
AJ	O	O
population	O	O
,	O	O
(	O	O
q	O	O
approximately	O	O
.	O	O

03	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
84GG	O	O
insertion	O	O
(	O	O
q	O	O
approximately	O	O
.	O	O

003	O	O
)	O	O
occurs	O	O
exclusively	O	O
in	O	O
the	O	O
Ashkenazim	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
genetic	O	O
history	O	O
of	O	O
these	O	O
mutations	O	O
in	O	O
the	O	O
AJ	O	O
population	O	O
,	O	O
short	O	O
tandem	O	O
repeat	O	O
(	O	O
STR	O	O
)	O	O
markers	O	O
were	O	O
used	O	O
to	O	O
map	O	O
a	O	O
9	O	O
.	O	O

3	O	O
-	O	O
cM	O	O
region	O	O
containing	O	O
the	O	O
GBA	O	O
locus	O	O
and	O	O
to	O	O
genotype	O	O
261	O	O
AJ	O	O
N370S	O	O
chromosomes	O	O
,	O	O
60	O	O
European	O	O
non	O	O
-	O	O
Jewish	O	O
N370S	O	O
chromosomes	O	O
,	O	O
and	O	O
62	O	O
AJ	O	O
84GG	O	O
chromosomes	O	O
.	O	O

A	O	O
highly	O	O
conserved	O	O
haplotype	O	O
at	O	O
four	O	O
markers	O	O
flanking	O	O
GBA	O	O
(	O	O
PKLR	O	O
,	O	O
D1S1595	O	O
,	O	O
D1S2721	O	O
,	O	O
and	O	O
D1S2777	O	O
)	O	O
was	O	O
observed	O	O
on	O	O
both	O	O
the	O	O
AJ	O	O
chromosomes	O	O
and	O	O
the	O	O
non	O	O
-	O	O
Jewish	O	O
N370S	O	O
chromosomes	O	O
,	O	O
suggesting	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
founder	O	O
common	O	O
to	O	O
both	O	O
populations	O	O
.	O	O

Of	O	O
note	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
different	O	O
divergent	O	O
haplotypes	O	O
suggested	O	O
the	O	O
occurrence	O	O
of	O	O
de	O	O
novo	O	O
,	O	O
recurrent	O	O
N370S	O	O
mutations	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
different	O	O
conserved	O	O
haplotype	O	O
at	O	O
these	O	O
markers	O	O
was	O	O
identified	O	O
on	O	O
the	O	O
84GG	O	O
chromosomes	O	O
,	O	O
which	O	O
was	O	O
unique	O	O
to	O	O
the	O	O
AJ	O	O
population	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
linkage	O	O
disequilibrium	O	O
(	O	O
LD	O	O
)	O	O
delta	O	O
values	O	O
,	O	O
the	O	O
non	O	O
-	O	O
Jewish	O	O
European	O	O
N370S	O	O
chromosomes	O	O
had	O	O
greater	O	O
haplotype	O	O
diversity	O	O
and	O	O
less	O	O
LD	O	O
at	O	O
the	O	O
markers	O	O
flanking	O	O
the	O	O
conserved	O	O
haplotype	O	O
than	O	O
did	O	O
the	O	O
AJ	O	O
N370S	O	O
chromosomes	O	O
.	O	O

This	O	O
finding	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
N370S	O	O
mutation	O	O
in	O	O
the	O	O
non	O	O
-	O	O
Jewish	O	O
European	O	O
population	O	O
prior	O	O
to	O	O
the	O	O
founding	O	O
of	O	O
the	O	O
AJ	O	O
population	O	O
.	O	O

Coalescence	O	O
analyses	O	O
for	O	O
the	O	O
N370S	O	O
and	O	O
84GG	O	O
mutations	O	O
estimated	O	O
similar	O	O
coalescence	O	O
times	O	O
,	O	O
of	O	O
48	O	O
and	O	O
55	O	O
.	O	O

5	O	O
generations	O	O
ago	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
results	O	O
of	O	O
these	O	O
studies	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
significant	O	O
bottleneck	O	O
occurring	O	O
in	O	O
the	O	O
AJ	O	O
population	O	O
during	O	O
the	O	O
first	O	O
millennium	O	O
,	O	O
when	O	O
the	O	O
population	O	O
became	O	O
established	O	O
in	O	O
Europe	O	O
.	O	O

Investigation	O	O
of	O	O
thermoregulatory	O	O
characteristics	O	O
in	O	O
patients	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

A	O	O
survey	O	O
instrument	O	O
is	O	O
used	O	O
to	O	O
assess	O	O
temperature	O	O
regulation	O	O
characteristics	O	O
in	O	O
children	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
compared	O	O
to	O	O
3	O	O
control	O	O
groups	O	O
sibs	O	O
of	O	O
PWS	B-Disease	D011218
patients	O	O
(	O	O
SIB	O	O
)	O	O
,	O	O
neurodevelopmentally	B-Disease	D009422
handicapped	I-Disease	D009422
children	O	O
(	O	O
ND	O	O
)	O	O
,	O	O
and	O	O
age	O	O
and	O	O
gender	O	O
matched	O	O
well	O	O
children	O	O
(	O	O
WC	O	O
)	O	O
.	O	O

Significant	O	O
differences	O	O
were	O	O
found	O	O
between	O	O
PWS	B-Disease	D011218
patients	O	O
,	O	O
SIB	O	O
controls	O	O
,	O	O
and	O	O
WC	O	O
controls	O	O
in	O	O
the	O	O
prevalence	O	O
of	O	O
febrile	O	O
convulsions	O	O
,	O	O
fever	O	O
-	O	O
associated	O	O
symptoms	O	O
,	O	O
and	O	O
temperature	O	O
less	O	O
than	O	O
94	O	O
degrees	O	O
F	O	O
.	O	O

No	O	O
differences	O	O
were	O	O
noted	O	O
in	O	O
any	O	O
variable	O	O
between	O	O
the	O	O
PWS	B-Disease	D011218
patients	O	O
and	O	O
the	O	O
ND	O	O
controls	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
abnormalities	O	O
are	O	O
not	O	O
unique	O	O
to	O	O
PWS	B-Disease	D011218
,	O	O
but	O	O
can	O	O
occur	O	O
in	O	O
any	O	O
neurodevelopmentally	B-Disease	D009422
handicapped	I-Disease	D009422
individual	O	O
,	O	O
further	O	O
suggesting	O	O
these	O	O
do	O	O
not	O	O
necessarily	O	O
reflect	O	O
syndrome	O	O
-	O	O
specific	O	O
hypothalamic	B-Disease	D007027
abnormalities	I-Disease	D007027
.	O	O

.	O	O

Abnormal	O	O
high	O	O
density	O	O
lipoproteins	O	O
in	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
.	O	O

The	O	O
plasma	O	O
lipoprotein	O	O
profiles	O	O
and	O	O
high	O	O
density	O	O
lipoproteins	O	O
(	O	O
HDL	O	O
)	O	O
were	O	O
characterized	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
genetic	B-Disease	D030342
disease	I-Disease	D030342
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
.	O	O

Abnormalities	B-Disease	D052456
in	I-Disease	D052456
the	I-Disease	D052456
HDL	I-Disease	D052456
may	O	O
contribute	O	O
to	O	O
their	O	O
increased	O	O
atherogenesis	O	O
and	O	O
excessive	O	O
deposits	O	O
of	O	O
tissue	O	O
sterols	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
low	O	O
or	O	O
low	O	O
-	O	O
normal	O	O
concentrations	O	O
of	O	O
plasma	O	O
cholesterol	O	O
(	O	O
165	O	O
+	O	O
/	O	O
-	O	O
25	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
and	O	O
low	O	O
density	O	O
lipoproteins	O	O
(	O	O
LDL	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
HDL	O	O
-	O	O
cholesterol	O	O
concentration	O	O
in	O	O
the	O	O
CTX	B-Disease	D019294
plasmas	O	O
was	O	O
14	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
about	O	O
one	O	O
-	O	O
third	O	O
the	O	O
normal	O	O
value	O	O
.	O	O

The	O	O
low	O	O
HDL	O	O
-	O	O
cholesterol	O	O
reflects	O	O
a	O	O
low	O	O
concentration	O	O
and	O	O
an	O	O
abnormal	O	O
lipid	O	O
composition	O	O
of	O	O
the	O	O
plasma	O	O
HDL	O	O
.	O	O

Relative	O	O
to	O	O
normal	O	O
HDL	O	O
,	O	O
the	O	O
cholesteryl	O	O
esters	O	O
are	O	O
low	O	O
,	O	O
free	O	O
cholesterol	O	O
and	O	O
phospholipids	O	O
essentially	O	O
normal	O	O
,	O	O
and	O	O
triglycerides	O	O
increased	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
apoprotein	O	O
(	O	O
apo	O	O
)	O	O
to	O	O
total	O	O
cholesterol	O	O
in	O	O
the	O	O
HDL	O	O
of	O	O
CTX	B-Disease	D019294
was	O	O
two	O	O
to	O	O
three	O	O
times	O	O
greater	O	O
than	O	O
normal	O	O
.	O	O

In	O	O
the	O	O
CTX	B-Disease	D019294
HDL	O	O
,	O	O
the	O	O
ratio	O	O
of	O	O
apoAI	O	O
to	O	O
apoAII	O	O
was	O	O
high	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
apoC	O	O
low	O	O
,	O	O
and	O	O
a	O	O
normally	O	O
minor	O	O
form	O	O
of	O	O
apoAI	O	O
increased	O	O
relative	O	O
to	O	O
other	O	O
forms	O	O
.	O	O

The	O	O
HDL	O	O
in	O	O
electron	O	O
micrographs	O	O
appeared	O	O
normal	O	O
morphologically	O	O
and	O	O
in	O	O
particle	O	O
size	O	O
.	O	O

The	O	O
abnormalities	O	O
in	O	O
lipoprotein	O	O
distribution	O	O
profile	O	O
and	O	O
composition	O	O
of	O	O
the	O	O
plasma	O	O
HDL	O	O
result	O	O
from	O	O
metabolic	O	O
defects	O	O
that	O	O
are	O	O
not	O	O
understood	O	O
but	O	O
may	O	O
be	O	O
linked	O	O
to	O	O
the	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
bile	O	O
acid	O	O
synthesis	O	O
in	O	O
CTX	B-Disease	D019294
.	O	O

As	O	O
a	O	O
consequence	O	O
,	O	O
it	O	O
is	O	O
probable	O	O
that	O	O
the	O	O
normal	O	O
functions	O	O
of	O	O
the	O	O
HDL	O	O
,	O	O
possibly	O	O
including	O	O
modulation	O	O
of	O	O
LDL	O	O
-	O	O
cholesterol	O	O
uptake	O	O
and	O	O
the	O	O
removal	O	O
of	O	O
excess	O	O
cholesterol	O	O
from	O	O
peripheral	O	O
tissues	O	O
,	O	O
are	O	O
perturbed	O	O
significantly	O	O
in	O	O
this	O	O
disease	O	O
.	O	O

Splicing	O	O
defects	O	O
in	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
,	O	O
ATM	O	O
:	O	O
underlying	O	O
mutations	O	O
and	O	O
consequences	O	O
.	O	O

Mutations	O	O
resulting	O	O
in	O	O
defective	O	O
splicing	O	O
constitute	O	O
a	O	O
significant	O	O
proportion	O	O
(	O	O
30	O	O
/	O	O
62	O	O
[	O	O
48	O	O
%	O	O
]	O	O
)	O	O
of	O	O
a	O	O
new	O	O
series	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
AT	B-Disease	D001260
)	O	O
that	O	O
were	O	O
detected	O	O
by	O	O
the	O	O
protein	O	O
-	O	O
truncation	O	O
assay	O	O
followed	O	O
by	O	O
sequence	O	O
analysis	O	O
of	O	O
genomic	O	O
DNA	O	O
.	O	O

Fewer	O	O
than	O	O
half	O	O
of	O	O
the	O	O
splicing	O	O
mutations	O	O
involved	O	O
the	O	O
canonical	O	O
AG	O	O
splice	O	O
-	O	O
acceptor	O	O
site	O	O
or	O	O
GT	O	O
splice	O	O
-	O	O
donor	O	O
site	O	O
.	O	O

A	O	O
higher	O	O
percentage	O	O
of	O	O
mutations	O	O
occurred	O	O
at	O	O
less	O	O
stringently	O	O
conserved	O	O
sites	O	O
,	O	O
including	O	O
silent	O	O
mutations	O	O
of	O	O
the	O	O
last	O	O
nucleotide	O	O
of	O	O
exons	O	O
,	O	O
mutations	O	O
in	O	O
nucleotides	O	O
other	O	O
than	O	O
the	O	O
conserved	O	O
AG	O	O
and	O	O
GT	O	O
in	O	O
the	O	O
consensus	O	O
splice	O	O
sites	O	O
,	O	O
and	O	O
creation	O	O
of	O	O
splice	O	O
-	O	O
acceptor	O	O
or	O	O
splice	O	O
-	O	O
donor	O	O
sites	O	O
in	O	O
either	O	O
introns	O	O
or	O	O
exons	O	O
.	O	O

These	O	O
splicing	O	O
mutations	O	O
led	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
consequences	O	O
,	O	O
including	O	O
exon	O	O
skipping	O	O
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O	O
degree	O	O
,	O	O
intron	O	O
retention	O	O
,	O	O
activation	O	O
of	O	O
cryptic	O	O
splice	O	O
sites	O	O
,	O	O
or	O	O
creation	O	O
of	O	O
new	O	O
splice	O	O
sites	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
5	O	O
of	O	O
12	O	O
nonsense	O	O
mutations	O	O
and	O	O
1	O	O
missense	O	O
mutation	O	O
were	O	O
associated	O	O
with	O	O
deletion	O	O
in	O	O
the	O	O
cDNA	O	O
of	O	O
the	O	O
exons	O	O
in	O	O
which	O	O
the	O	O
mutations	O	O
occurred	O	O
.	O	O

No	O	O
ATM	O	O
protein	O	O
was	O	O
detected	O	O
by	O	O
western	O	O
blotting	O	O
in	O	O
any	O	O
AT	B-Disease	D001260
cell	O	O
line	O	O
in	O	O
which	O	O
splicing	O	O
mutations	O	O
were	O	O
identified	O	O
.	O	O

Several	O	O
cases	O	O
of	O	O
exon	O	O
skipping	O	O
in	O	O
both	O	O
normal	O	O
controls	O	O
and	O	O
patients	O	O
for	O	O
whom	O	O
no	O	O
underlying	O	O
defect	O	O
could	O	O
be	O	O
found	O	O
in	O	O
genomic	O	O
DNA	O	O
were	O	O
also	O	O
observed	O	O
,	O	O
suggesting	O	O
caution	O	O
in	O	O
the	O	O
interpretation	O	O
of	O	O
exon	O	O
deletions	O	O
observed	O	O
in	O	O
ATM	O	O
cDNA	O	O
when	O	O
there	O	O
is	O	O
no	O	O
accompanying	O	O
identification	O	O
of	O	O
genomic	O	O
mutations	O	O
.	O	O

.	O	O

Mutations	O	O
of	O	O
the	O	O
cathepsin	O	O
C	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
Papillon	B-Disease	D010214
-	I-Disease	D010214
Lefevre	I-Disease	D010214
syndrome	I-Disease	D010214
.	O	O

Papillon	B-Disease	D010214
-	I-Disease	D010214
Lefevre	I-Disease	D010214
syndrome	I-Disease	D010214
(	O	O
PLS	B-Disease	D010214
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterised	O	O
by	O	O
palmoplantar	B-Disease	D007645
hyperkeratosis	I-Disease	D007645
and	O	O
severe	O	O
early	O	O
onset	O	O
periodontitis	B-Disease	D010518
that	O	O
results	O	O
in	O	O
the	O	O
premature	O	O
loss	O	O
of	O	O
the	O	O
primary	O	O
and	O	O
secondary	O	O
dentitions	O	O
.	O	O

A	O	O
major	O	O
gene	O	O
locus	O	O
for	O	O
PLS	B-Disease	D010214
has	O	O
been	O	O
mapped	O	O
to	O	O
a	O	O
2	O	O
.	O	O

8	O	O
cM	O	O
interval	O	O
on	O	O
chromosome	O	O
11q14	O	O
.	O	O

Correlation	O	O
of	O	O
physical	O	O
and	O	O
genetic	O	O
maps	O	O
of	O	O
this	O	O
interval	O	O
indicate	O	O
it	O	O
includes	O	O
at	O	O
least	O	O
40	O	O
ESTs	O	O
and	O	O
six	O	O
known	O	O
genes	O	O
including	O	O
the	O	O
lysosomal	O	O
protease	O	O
cathepsin	O	O
C	O	O
gene	O	O
(	O	O
CTSC	O	O
)	O	O
.	O	O

The	O	O
CTSC	O	O
message	O	O
is	O	O
expressed	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
immune	O	O
cells	O	O
including	O	O
polymorphonuclear	O	O
leucocytes	O	O
,	O	O
macrophages	O	O
,	O	O
and	O	O
their	O	O
precursors	O	O
.	O	O

By	O	O
RT	O	O
-	O	O
PCR	O	O
,	O	O
we	O	O
found	O	O
CTSC	O	O
is	O	O
also	O	O
expressed	O	O
in	O	O
epithelial	O	O
regions	O	O
commonly	O	O
affected	O	O
by	O	O
PLS	B-Disease	D010214
,	O	O
including	O	O
the	O	O
palms	O	O
,	O	O
soles	O	O
,	O	O
knees	O	O
,	O	O
and	O	O
oral	O	O
keratinised	O	O
gingiva	O	O
.	O	O

The	O	O
4	O	O
.	O	O

7	O	O
kb	O	O
CTSC	O	O
gene	O	O
consists	O	O
of	O	O
two	O	O
exons	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
CTSC	O	O
from	O	O
subjects	O	O
affected	O	O
with	O	O
PLS	B-Disease	D010214
from	O	O
five	O	O
consanguineous	O	O
Turkish	O	O
families	O	O
identified	O	O
four	O	O
different	O	O
mutations	O	O
.	O	O

An	O	O
exon	O	O
1	O	O
nonsense	O	O
mutation	O	O
(	O	O
856C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
)	O	O
introduces	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
at	O	O
amino	O	O
acid	O	O
286	O	O
.	O	O

Three	O	O
exon	O	O
2	O	O
mutations	O	O
were	O	O
identified	O	O
,	O	O
including	O	O
a	O	O
single	O	O
nucleotide	O	O
deletion	O	O
(	O	O
2692delA	O	O
)	O	O
of	O	O
codon	O	O
349	O	O
introducing	O	O
a	O	O
frameshift	O	O
and	O	O
premature	O	O
termination	O	O
codon	O	O
,	O	O
a	O	O
2	O	O
bp	O	O
deletion	O	O
(	O	O
2673	O	O
-	O	O
2674delCT	O	O
)	O	O
that	O	O
results	O	O
in	O	O
introduction	O	O
of	O	O
a	O	O
stop	O	O
codon	O	O
at	O	O
amino	O	O
acid	O	O
343	O	O
,	O	O
and	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
substitution	O	O
in	O	O
codon	O	O
429	O	O
(	O	O
2931G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
)	O	O
introducing	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
.	O	O

All	O	O
PLS	B-Disease	D010214
patients	O	O
were	O	O
homozygous	O	O
for	O	O
cathepsin	O	O
C	O	O
mutations	O	O
inherited	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

Parents	O	O
and	O	O
sibs	O	O
heterozygous	O	O
for	O	O
cathepsin	O	O
C	O	O
mutations	O	O
do	O	O
not	O	O
show	O	O
either	O	O
the	O	O
palmoplantar	B-Disease	D007645
hyperkeratosis	I-Disease	D007645
or	O	O
severe	O	O
early	O	O
onset	O	O
periodontitis	B-Disease	D010518
characteristic	O	O
of	O	O
PLS	B-Disease	D010214
.	O	O

A	O	O
more	O	O
complete	O	O
understanding	O	O
of	O	O
the	O	O
functional	O	O
physiology	O	O
of	O	O
cathepsin	O	O
C	O	O
carries	O	O
significant	O	O
implications	O	O
for	O	O
understanding	O	O
normal	O	O
and	O	O
abnormal	O	O
skin	O	O
development	O	O
and	O	O
periodontal	B-Disease	D010510
disease	I-Disease	D010510
susceptibility	O	O
Identification	O	O
of	O	O
a	O	O
single	O	O
nucleotide	O	O
change	O	O
in	O	O
the	O	O
hypoxanthine	O	O
-	O	O
guanine	O	O
phosphoribosyltransferase	O	O
gene	O	O
(	O	O
HPRTYale	O	O
)	O	O
responsible	O	O
for	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

Complete	O	O
deficiency	B-Disease	D007926
of	I-Disease	D007926
hypoxanthine	I-Disease	D007926
-	I-Disease	D007926
guanine	I-Disease	D007926
phosphoribosyltransferase	I-Disease	D007926
(	O	O
HPRT	O	O
)	O	O
causes	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

Previous	O	O
characterization	O	O
of	O	O
a	O	O
mutant	O	O
form	O	O
of	O	O
HPRT	O	O
,	O	O
HPRTYale	O	O
,	O	O
from	O	O
a	O	O
subject	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
revealed	O	O
normal	O	O
mRNA	O	O
and	O	O
protein	O	O
concentrations	O	O
,	O	O
no	O	O
residual	O	O
catalytic	O	O
activity	O	O
,	O	O
and	O	O
cathodal	O	O
migration	O	O
upon	O	O
PAGE	O	O
.	O	O

We	O	O
have	O	O
cloned	O	O
and	O	O
sequenced	O	O
HPRTYale	O	O
cDNA	O	O
.	O	O

The	O	O
nucleotide	O	O
sequence	O	O
of	O	O
full	O	O
-	O	O
length	O	O
HPRTYale	O	O
cDNA	O	O
revealed	O	O
a	O	O
single	O	O
nucleotide	O	O
substitution	O	O
compared	O	O
with	O	O
normal	O	O
HPRT	O	O
cDNA	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
C	O	O
at	O	O
nucleotide	O	O
position	O	O
211	O	O
.	O	O

This	O	O
transversion	O	O
predicts	O	O
substitution	O	O
of	O	O
arginine	O	O
for	O	O
glycine	O	O
at	O	O
amino	O	O
acid	O	O
position	O	O
71	O	O
,	O	O
explaining	O	O
the	O	O
cathodal	O	O
migration	O	O
of	O	O
HPRTYale	O	O
.	O	O

Chou	O	O
-	O	O
Fasman	O	O
secondary	O	O
structure	O	O
analysis	O	O
predicts	O	O
a	O	O
change	O	O
in	O	O
the	O	O
probability	O	O
of	O	O
beta	O	O
-	O	O
turn	O	O
formation	O	O
in	O	O
the	O	O
region	O	O
containing	O	O
the	O	O
mutation	O	O
.	O	O

Inclusion	O	O
of	O	O
the	O	O
bulky	O	O
arginine	O	O
side	O	O
chain	O	O
in	O	O
place	O	O
of	O	O
glycine	O	O
probably	O	O
disrupts	O	O
protein	O	O
folding	O	O
as	O	O
well	O	O
.	O	O

Cloning	O	O
mutant	O	O
forms	O	O
of	O	O
cDNA	O	O
allows	O	O
identification	O	O
of	O	O
specific	O	O
mutations	O	O
,	O	O
provides	O	O
insight	O	O
into	O	O
mutational	O	O
mechanisms	O	O
,	O	O
and	O	O
facilitates	O	O
structure	O	O
-	O	O
function	O	O
analysis	O	O
of	O	O
mutant	O	O
proteins	O	O
.	O	O

.	O	O

Molecular	O	O
detection	O	O
of	O	O
chromosomal	O	O
translocations	O	O
that	O	O
disrupt	O	O
the	O	O
putative	O	O
retinoblastoma	B-Disease	D012175
susceptibility	O	O
locus	O	O
.	O	O

A	O	O
candidate	O	O
DNA	O	O
sequence	O	O
with	O	O
many	O	O
of	O	O
the	O	O
properties	O	O
predicted	O	O
for	O	O
the	O	O
retinoblastoma	B-Disease	D012175
susceptibility	O	O
(	O	O
RB1	O	O
)	O	O
locus	O	O
has	O	O
been	O	O
cloned	O	O
(	O	O
S	O	O
.	O	O

H	O	O
.	O	O

Friend	O	O
,	O	O
R	O	O
.	O	O

Bernards	O	O
,	O	O
S	O	O
.	O	O

Rogelj	O	O
,	O	O
R	O	O
.	O	O

A	O	O
.	O	O

Weinberg	O	O
,	O	O
J	O	O
.	O	O

M	O	O
.	O	O

Rapaport	O	O
,	O	O
D	O	O
.	O	O

M	O	O
.	O	O

Albert	O	O
,	O	O
and	O	O
T	O	O
.	O	O

P	O	O
.	O	O

Dryja	O	O
,	O	O
Nature	O	O
[	O	O
London	O	O
]	O	O
323	O	O
643	O	O
-	O	O
645	O	O
,	O	O
1986	O	O
)	O	O
.	O	O

The	O	O
large	O	O
size	O	O
of	O	O
this	O	O
gene	O	O
(	O	O
ca	O	O
.	O	O

200	O	O
kilobases	O	O
[	O	O
kb	O	O
]	O	O
)	O	O
and	O	O
its	O	O
multiple	O	O
dispersed	O	O
exons	O	O
(	O	O
Wiggs	O	O
et	O	O
al	O	O
.	O	O

,	O	O
N	O	O
.	O	O

Engl	O	O
.	O	O

J	O	O
.	O	O

Med	O	O
.	O	O

318	O	O
151	O	O
-	O	O
157	O	O
,	O	O
1988	O	O
)	O	O
complicate	O	O
molecular	O	O
screening	O	O
strategies	O	O
important	O	O
in	O	O
prenatal	O	O
and	O	O
presymptomatic	O	O
diagnosis	O	O
and	O	O
in	O	O
carrier	O	O
detection	O	O
.	O	O

Here	O	O
we	O	O
used	O	O
field	O	O
inversion	O	O
gel	O	O
electrophoresis	O	O
(	O	O
FIGE	O	O
)	O	O
to	O	O
construct	O	O
a	O	O
restriction	O	O
map	O	O
of	O	O
approximately	O	O
1	O	O
,	O	O
000	O	O
kb	O	O
of	O	O
DNA	O	O
surrounding	O	O
the	O	O
RB1	O	O
locus	O	O
and	O	O
to	O	O
detect	O	O
the	O	O
translocation	O	O
breakpoints	O	O
in	O	O
three	O	O
retinoblastoma	B-Disease	D012175
patients	O	O
.	O	O

DNA	O	O
probes	O	O
from	O	O
either	O	O
the	O	O
5	O	O
or	O	O
3	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
were	O	O
used	O	O
to	O	O
detect	O	O
a	O	O
250	O	O
-	O	O
kb	O	O
EagI	O	O
restriction	O	O
fragment	O	O
in	O	O
DNA	O	O
from	O	O
unaffected	O	O
individuals	O	O
.	O	O

Both	O	O
probes	O	O
identified	O	O
an	O	O
additional	O	O
hybridizing	O	O
fragment	O	O
in	O	O
the	O	O
DNA	O	O
from	O	O
each	O	O
patient	O	O
,	O	O
permitting	O	O
the	O	O
breakpoints	O	O
in	O	O
all	O	O
three	O	O
to	O	O
be	O	O
mapped	O	O
within	O	O
the	O	O
cloned	O	O
RB1	O	O
gene	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
breakpoint	O	O
in	O	O
one	O	O
translocation	O	O
cell	O	O
line	O	O
allowed	O	O
the	O	O
RB1	O	O
gene	O	O
to	O	O
be	O	O
oriented	O	O
with	O	O
its	O	O
5	O	O
end	O	O
toward	O	O
the	O	O
centromere	O	O
.	O	O

The	O	O
5	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
also	O	O
appeared	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
clustering	O	O
of	O	O
sites	O	O
for	O	O
several	O	O
infrequently	O	O
cleaving	O	O
restriction	O	O
enzymes	O	O
,	O	O
indicating	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
HpaII	O	O
tiny	O	O
fragment	O	O
island	O	O
.	O	O

The	O	O
detection	O	O
and	O	O
mapping	O	O
of	O	O
the	O	O
translocation	O	O
breakpoints	O	O
of	O	O
all	O	O
three	O	O
retinoblastoma	B-Disease	D012175
patients	O	O
to	O	O
within	O	O
the	O	O
putative	O	O
RB1	O	O
gene	O	O
substantiated	O	O
the	O	O
authenticity	O	O
of	O	O
this	O	O
candidate	O	O
sequence	O	O
and	O	O
demonstrated	O	O
the	O	O
utility	O	O
of	O	O
FIGE	O	O
in	O	O
detecting	O	O
chromosomal	O	O
rearrangements	O	O
affecting	O	O
this	O	O
locus	O	O
.	O	O

Constitutional	O	O
mutations	O	O
in	O	O
the	O	O
WT1	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
.	O	O

The	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
is	O	O
characterised	O	O
by	O	O
a	O	O
typical	O	O
nephropathy	B-Disease	D007674
,	O	O
genital	B-Disease	D014564
abnormalities	I-Disease	D014564
and	O	O
also	O	O
predisposes	O	O
to	O	O
the	O	O
development	O	O
of	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
.	O	O

These	O	O
patients	O	O
eventually	O	O
go	O	O
into	O	O
end	O	O
stage	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

A	O	O
candidate	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
gene	O	O
,	O	O
WT1	O	O
,	O	O
from	O	O
the	O	O
11p13	O	O
chromosome	O	O
region	O	O
has	O	O
recently	O	O
been	O	O
cloned	O	O
.	O	O

We	O	O
have	O	O
analysed	O	O
the	O	O
DNA	O	O
sequence	O	O
in	O	O
constitutional	O	O
cells	O	O
from	O	O
eight	O	O
patients	O	O
and	O	O
have	O	O
shown	O	O
heterozygous	O	O
mutations	O	O
in	O	O
six	O	O
of	O	O
them	O	O
.	O	O

Four	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
in	O	O
exon	O	O
9	O	O
,	O	O
all	O	O
resulting	O	O
in	O	O
missense	O	O
mutations	O	O
.	O	O

Three	O	O
were	O	O
at	O	O
nucleotide	O	O
position	O	O
1180	O	O
resulting	O	O
in	O	O
an	O	O
arg	O	O
>	O	O
trp	O	O
amino	O	O
acid	O	O
change	O	O
.	O	O

The	O	O
other	O	O
was	O	O
at	O	O
position	O	O
1186	O	O
converting	O	O
an	O	O
asp	O	O
>	O	O
asn	O	O
in	O	O
the	O	O
predicted	O	O
resultant	O	O
protein	O	O
.	O	O

One	O	O
patient	O	O
had	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
converting	O	O
an	O	O
arg	O	O
>	O	O
his	O	O
.	O	O

A	O	O
single	O	O
base	O	O
pair	O	O
insertion	O	O
at	O	O
nucleotide	O	O
position	O	O
821	O	O
in	O	O
exon	O	O
6	O	O
resulted	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
in	O	O
the	O	O
last	O	O
patient	O	O
.	O	O

We	O	O
were	O	O
unable	O	O
to	O	O
find	O	O
a	O	O
mutation	O	O
in	O	O
one	O	O
patient	O	O
despite	O	O
complete	O	O
sequencing	O	O
of	O	O
the	O	O
genomic	O	O
sequence	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

The	O	O
last	O	O
patient	O	O
carried	O	O
a	O	O
constitutional	O	O
deletion	O	O
of	O	O
the	O	O
11p13	O	O
region	O	O
and	O	O
no	O	O
additional	O	O
mutation	O	O
was	O	O
found	O	O
.	O	O

There	O	O
was	O	O
no	O	O
obvious	O	O
correlation	O	O
between	O	O
the	O	O
type	O	O
of	O	O
mutation	O	O
and	O	O
phenotypic	O	O
expression	O	O
.	O	O

These	O	O
results	O	O
further	O	O
demonstrate	O	O
that	O	O
the	O	O
WT1	O	O
gene	O	O
is	O	O
important	O	O
in	O	O
both	O	O
the	O	O
development	O	O
of	O	O
the	O	O
kidney	O	O
and	O	O
the	O	O
genito	O	O
-	O	O
urinary	O	O
system	O	O
.	O	O

.	O	O

Four	O	O
novel	O	O
PEPD	O	O
alleles	O	O
causing	O	O
prolidase	B-Disease	D056732
deficiency	I-Disease	D056732
.	O	O

Mutations	O	O
at	O	O
the	O	O
PEPD	O	O
locus	O	O
cause	O	O
prolidase	B-Disease	D056732
deficiency	I-Disease	D056732
(	O	O
McKusick	O	O
170100	O	O
)	O	O
,	O	O
a	O	O
rare	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
iminodipeptiduria	B-Disease	D000592
,	O	O
skin	B-Disease	D012883
ulcers	I-Disease	D012883
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
recurrent	O	O
infections	O	O
.	O	O

Four	O	O
PEPD	O	O
mutations	O	O
from	O	O
five	O	O
severely	O	O
affected	O	O
individuals	O	O
were	O	O
characterized	O	O
by	O	O
analysis	O	O
of	O	O
reverse	O	O
-	O	O
transcribed	O	O
,	O	O
PCR	O	O
-	O	O
amplified	O	O
(	O	O
RT	O	O
-	O	O
PCR	O	O
)	O	O
cDNA	O	O
.	O	O

We	O	O
used	O	O
SSCP	O	O
analysis	O	O
on	O	O
four	O	O
overlapping	O	O
cDNA	O	O
fragments	O	O
covering	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
PEPD	O	O
gene	O	O
and	O	O
detected	O	O
abnormal	O	O
SSCP	O	O
bands	O	O
for	O	O
the	O	O
fragment	O	O
spanning	O	O
all	O	O
or	O	O
part	O	O
of	O	O
exons	O	O
13	O	O
-	O	O
15	O	O
in	O	O
three	O	O
of	O	O
the	O	O
probands	O	O
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
the	O	O
mutant	O	O
cDNAs	O	O
showed	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
,	O	O
1342	O	O
substitution	O	O
(	O	O
G448R	O	O
)	O	O
in	O	O
two	O	O
patients	O	O
and	O	O
a	O	O
3	O	O
-	O	O
bp	O	O
deletion	O	O
(	O	O
delta	O	O
E452	O	O
or	O	O
delta	O	O
E453	O	O
)	O	O
in	O	O
another	O	O
.	O	O

In	O	O
the	O	O
other	O	O
two	O	O
probands	O	O
the	O	O
amplified	O	O
products	O	O
were	O	O
of	O	O
reduced	O	O
size	O	O
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
these	O	O
mutant	O	O
cDNAs	O	O
revealed	O	O
a	O	O
deletion	O	O
of	O	O
exon	O	O
5	O	O
in	O	O
one	O	O
patient	O	O
and	O	O
of	O	O
exon	O	O
7	O	O
in	O	O
the	O	O
other	O	O
.	O	O

Intronic	O	O
sequences	O	O
flanking	O	O
exons	O	O
5	O	O
and	O	O
7	O	O
were	O	O
identified	O	O
using	O	O
inverse	O	O
PCR	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O

Conventional	O	O
PCR	O	O
and	O	O
direct	O	O
sequencing	O	O
then	O	O
established	O	O
the	O	O
intron	O	O
-	O	O
exon	O	O
borders	O	O
of	O	O
the	O	O
mutant	O	O
genomic	O	O
DNA	O	O
revealing	O	O
two	O	O
splice	O	O
acceptor	O	O
mutations	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
C	O	O
substitution	O	O
at	O	O
position	O	O
-	O	O
1	O	O
of	O	O
intron	O	O
4	O	O
and	O	O
an	O	O
A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
substitution	O	O
at	O	O
position	O	O
-	O	O
2	O	O
of	O	O
intron	O	O
6	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
severe	O	O
form	O	O
of	O	O
prolidase	B-Disease	D056732
deficiency	I-Disease	D056732
is	O	O
caused	O	O
by	O	O
multiple	O	O
PEPD	O	O
alleles	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
attempt	O	O
to	O	O
begin	O	O
the	O	O
process	O	O
of	O	O
describing	O	O
these	O	O
alleles	O	O
and	O	O
cataloging	O	O
their	O	O
phenotypic	O	O
expression	O	O
.	O	O

.	O	O

Translocation	O	O
t	O	O
(	O	O
5	O	O
;	O	O
11	O	O
)	O	O
(	O	O
q13	O	O
.	O	O

1	O	O
;	O	O
p13	O	O
)	O	O
associated	O	O
with	O	O
familial	O	O
isolated	B-Disease	D015783
aniridia	I-Disease	D015783
.	O	O

A	O	O
father	O	O
and	O	O
daughter	O	O
with	O	O
isolated	B-Disease	D015783
aniridia	I-Disease	D015783
were	O	O
observed	O	O
to	O	O
have	O	O
an	O	O
apparently	O	O
balanced	O	O
,	O	O
reciprocal	O	O
translocation	O	O
involving	O	O
chromosomes	O	O
5	O	O
and	O	O
11	O	O
[	O	O
t	O	O
(	O	O
5	O	O
;	O	O
11	O	O
)	O	O
(	O	O
q13	O	O
.	O	O

1	O	O
;	O	O
p13	O	O
)	O	O
]	O	O
.	O	O

No	O	O
other	O	O
clinical	O	O
characteristics	O	O
often	O	O
associated	O	O
with	O	O
the	O	O
deletion	O	O
of	O	O
11p13	O	O
were	O	O
observed	O	O
in	O	O
this	O	O
family	O	O
.	O	O

This	O	O
finding	O	O
,	O	O
in	O	O
association	O	O
with	O	O
3	O	O
other	O	O
instances	O	O
of	O	O
single	O	O
breaks	O	O
at	O	O
11p13	O	O
and	O	O
aniridia	B-Disease	D015783
,	O	O
supports	O	O
the	O	O
assignment	O	O
of	O	O
AN2	O	O
to	O	O
11p13	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
analysis	O	O
in	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
and	O	O
identification	O	O
of	O	O
a	O	O
missense	O	O
mutation	O	O
associated	O	O
with	O	O
a	O	O
milder	O	O
phenotype	O	O
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
the	O	O
emerin	O	O
gene	O	O
in	O	O
22	O	O
families	O	O
with	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EMD	B-Disease	D020389
)	O	O
revealed	O	O
mutations	O	O
in	O	O
21	O	O
(	O	O
95	O	O
%	O	O
)	O	O
,	O	O
confirming	O	O
that	O	O
emerin	O	O
mutations	O	O
can	O	O
be	O	O
identified	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
families	O	O
with	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
EMD	I-Disease	D020389
.	O	O

Most	O	O
emerin	O	O
mutations	O	O
result	O	O
in	O	O
absence	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

In	O	O
this	O	O
study	O	O
three	O	O
mutations	O	O
(	O	O
a	O	O
missense	O	O
mutation	O	O
Pro183Thr	O	O
and	O	O
two	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
removing	O	O
residues	O	O
95	O	O
-	O	O
99	O	O
and	O	O
236	O	O
-	O	O
241	O	O
,	O	O
respectively	O	O
)	O	O
were	O	O
unusual	O	O
in	O	O
being	O	O
associated	O	O
with	O	O
expression	O	O
of	O	O
mutant	O	O
protein	O	O
.	O	O

The	O	O
phenotype	O	O
in	O	O
these	O	O
families	O	O
was	O	O
compared	O	O
in	O	O
detail	O	O
with	O	O
the	O	O
clinical	O	O
features	O	O
in	O	O
cases	O	O
with	O	O
typical	O	O
null	O	O
mutations	O	O
.	O	O

For	O	O
the	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
.	O	O

In	O	O
the	O	O
family	O	O
with	O	O
the	O	O
missense	O	O
mutation	O	O
the	O	O
phenotype	O	O
was	O	O
milder	O	O
.	O	O

Age	O	O
at	O	O
onset	O	O
was	O	O
later	O	O
for	O	O
first	O	O
symptoms	O	O
and	O	O
for	O	O
development	O	O
of	O	O
ankle	B-Disease	D003286
contractures	I-Disease	D003286
and	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
.	O	O

These	O	O
findings	O	O
have	O	O
diagnostic	O	O
implications	O	O
as	O	O
well	O	O
as	O	O
pointing	O	O
to	O	O
functionally	O	O
important	O	O
regions	O	O
of	O	O
the	O	O
emerin	O	O
protein	O	O
.	O	O

.	O	O

Asef	O	O
,	O	O
a	O	O
link	O	O
between	O	O
the	O	O
tumor	B-Disease	D009369
suppressor	O	O
APC	B-Disease	D011125
and	O	O
G	O	O
-	O	O
protein	O	O
signaling	O	O
.	O	O

The	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
gene	O	O
(	O	O
APC	B-Disease	D011125
)	O	O
is	O	O
mutated	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
and	O	O
in	O	O
sporadic	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
.	O	O

Here	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
product	O	O
is	O	O
shown	O	O
to	O	O
bind	O	O
through	O	O
its	O	O
armadillo	O	O
repeat	O	O
domain	O	O
to	O	O
a	O	O
Rac	O	O
-	O	O
specific	O	O
guanine	O	O
nucleotide	O	O
exchange	O	O
factor	O	O
(	O	O
GEF	O	O
)	O	O
,	O	O
termed	O	O
Asef	O	O
.	O	O

Endogenous	O	O
APC	B-Disease	D011125
colocalized	O	O
with	O	O
Asef	O	O
in	O	O
mouse	O	O
colon	O	O
epithelial	O	O
cells	O	O
and	O	O
neuronal	O	O
cells	O	O
.	O	O

Furthermore	O	O
,	O	O
APC	B-Disease	D011125
enhanced	O	O
the	O	O
GEF	O	O
activity	O	O
of	O	O
Asef	O	O
and	O	O
stimulated	O	O
Asef	O	O
-	O	O
mediated	O	O
cell	O	O
flattening	O	O
,	O	O
membrane	O	O
ruffling	O	O
,	O	O
and	O	O
lamellipodia	O	O
formation	O	O
in	O	O
MDCK	O	O
cells	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
APC	B-Disease	D011125
-	O	O
Asef	O	O
complex	O	O
may	O	O
regulate	O	O
the	O	O
actin	O	O
cytoskeletal	O	O
network	O	O
,	O	O
cell	O	O
morphology	O	O
and	O	O
migration	O	O
,	O	O
and	O	O
neuronal	O	O
function	O	O
.	O	O

.	O	O

Localization	O	O
of	O	O
the	O	O
region	O	O
homologous	O	O
to	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
locus	O	O
on	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
.	O	O

Recent	O	O
progress	O	O
has	O	O
resulted	O	O
in	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
mutated	O	O
in	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
the	I-Disease	D020388
milder	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophies	I-Disease	D020388
being	O	O
cloned	O	O
and	O	O
has	O	O
suggested	O	O
that	O	O
the	O	O
gene	O	O
itself	O	O
extends	O	O
over	O	O
1	O	O
,	O	O
000	O	O
to	O	O
2	O	O
,	O	O
000	O	O
kilobases	O	O
(	O	O
kb	O	O
)	O	O
.	O	O

To	O	O
study	O	O
how	O	O
mutations	O	O
in	O	O
this	O	O
gene	O	O
affect	O	O
muscle	O	O
development	O	O
and	O	O
integrity	O	O
,	O	O
it	O	O
would	O	O
be	O	O
of	O	O
interest	O	O
to	O	O
have	O	O
available	O	O
a	O	O
mouse	O	O
model	O	O
of	O	O
the	O	O
human	O	O
disease	O	O
.	O	O

The	O	O
mouse	O	O
mdx	O	O
mutation	O	O
affects	O	O
muscle	O	O
and	O	O
confers	O	O
a	O	O
mild	O	O
dystrophic	B-Disease	D009136
syndrome	I-Disease	D009136
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
this	O	O
mutation	O	O
is	O	O
equivalent	O	O
to	O	O
Duchenne	B-Disease	D020388
/	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
in	O	O
man	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
the	O	O
use	O	O
of	O	O
two	O	O
sequences	O	O
from	O	O
the	O	O
human	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
that	O	O
cross	O	O
-	O	O
hybridize	O	O
to	O	O
mouse	O	O
X	O	O
-	O	O
linked	O	O
sequences	O	O
to	O	O
localize	O	O
the	O	O
gene	O	O
homologous	O	O
to	O	O
DMD	B-Disease	D020388
in	O	O
the	O	O
mouse	O	O
.	O	O

Both	O	O
sequences	O	O
map	O	O
to	O	O
the	O	O
region	O	O
of	O	O
10	O	O
centimorgan	O	O
lying	O	O
between	O	O
the	O	O
Tabby	O	O
(	O	O
Ta	O	O
)	O	O
and	O	O
St14	O	O
-	O	O
1	O	O
(	O	O
DxPas8	O	O
)	O	O
loci	O	O
,	O	O
close	O	O
to	O	O
the	O	O
phosphorylase	O	O
b	O	O
kinase	O	O
locus	O	O
(	O	O
Phk	O	O
)	O	O
.	O	O

By	O	O
analogy	O	O
with	O	O
the	O	O
human	O	O
X	O	O
-	O	O
chromosome	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
the	O	O
region	O	O
in	O	O
the	O	O
mouse	O	O
around	O	O
the	O	O
G6pd	O	O
and	O	O
St14	O	O
-	O	O
1	O	O
loci	O	O
may	O	O
contain	O	O
two	O	O
genes	O	O
corresponding	O	O
to	O	O
distinct	O	O
human	O	O
myopathies	B-Disease	D009135
Emery	B-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
which	O	O
is	O	O
known	O	O
to	O	O
be	O	O
closely	O	O
linked	O	O
to	O	O
St14	O	O
-	O	O
1	O	O
in	O	O
man	O	O
and	O	O
the	O	O
DMD	B-Disease	D020388
homologue	O	O
described	O	O
here	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
hexosaminidase	B-Disease	D013661
A	I-Disease	D013661
deficiency	I-Disease	D013661
and	O	O
pseudodeficiency	O	O
in	O	O
the	O	O
Berks	O	O
County	O	O
Pennsylvania	O	O
Dutch	O	O
.	O	O

Following	O	O
the	O	O
birth	O	O
of	O	O
two	O	O
infants	O	O
with	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
,	O	O
a	O	O
non	O	O
-	O	O
Jewish	O	O
,	O	O
Pennsylvania	O	O
Dutch	O	O
kindred	O	O
was	O	O
screened	O	O
for	O	O
TSD	B-Disease	D013661
carriers	O	O
using	O	O
the	O	O
biochemical	O	O
assay	O	O
.	O	O

A	O	O
high	O	O
frequency	O	O
of	O	O
individuals	O	O
who	O	O
appeared	O	O
to	O	O
be	O	O
TSD	B-Disease	D013661
heterozygotes	O	O
was	O	O
detected	O	O
(	O	O
Kelly	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1975	O	O
)	O	O
.	O	O

Clinical	O	O
and	O	O
biochemical	O	O
evidence	O	O
suggested	O	O
that	O	O
the	O	O
increased	O	O
carrier	O	O
frequency	O	O
was	O	O
due	O	O
to	O	O
at	O	O
least	O	O
two	O	O
altered	O	O
alleles	O	O
for	O	O
the	O	O
hexosaminidase	O	O
A	O	O
alpha	O	O
-	O	O
subunit	O	O
.	O	O

We	O	O
now	O	O
report	O	O
two	O	O
mutant	O	O
alleles	O	O
in	O	O
this	O	O
Pennsylvania	O	O
Dutch	O	O
kindred	O	O
,	O	O
and	O	O
one	O	O
polymorphism	O	O
.	O	O

One	O	O
allele	O	O
,	O	O
reported	O	O
originally	O	O
in	O	O
a	O	O
French	O	O
TSD	B-Disease	D013661
patient	O	O
(	O	O
Akli	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1991	O	O
)	O	O
,	O	O
is	O	O
a	O	O
GT	O	O
-	O	O
-	O	O
>	O	O
AT	O	O
transition	O	O
at	O	O
the	O	O
donor	O	O
splice	O	O
-	O	O
site	O	O
of	O	O
intron	O	O
9	O	O
.	O	O

The	O	O
second	O	O
,	O	O
a	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
at	O	O
nucleotide	O	O
739	O	O
(	O	O
Arg247Trp	O	O
)	O	O
,	O	O
has	O	O
been	O	O
shown	O	O
by	O	O
Triggs	O	O
-	O	O
Raine	O	O
et	O	O
al	O	O
.	O	O

(	O	O
1992	O	O
)	O	O
to	O	O
be	O	O
a	O	O
clinically	O	O
benign	O	O
"	O	O
pseudodeficient	O	O
"	O	O
allele	O	O
associated	O	O
with	O	O
reduced	O	O
enzyme	O	O
activity	O	O
against	O	O
artificial	O	O
substrate	O	O
.	O	O

Finally	O	O
,	O	O
a	O	O
polymorphism	O	O
[	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
(	O	O
759	O	O
)	O	O
]	O	O
,	O	O
which	O	O
leaves	O	O
valine	O	O
at	O	O
codon	O	O
253	O	O
unchanged	O	O
,	O	O
is	O	O
described	O	O
.	O	O

Gene	O	O
transfer	O	O
and	O	O
expression	O	O
of	O	O
human	O	O
phenylalanine	O	O
hydroxylase	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
genetic	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
the	I-Disease	OMIM:261600
enzyme	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

A	O	O
full	O	O
-	O	O
length	O	O
complementary	O	O
DNA	O	O
clone	O	O
of	O	O
human	O	O
PAH	O	O
was	O	O
inserted	O	O
into	O	O
a	O	O
eukaryotic	O	O
expression	O	O
vector	O	O
and	O	O
transferred	O	O
into	O	O
mouse	O	O
NIH3T3	O	O
cells	O	O
which	O	O
do	O	O
not	O	O
normally	O	O
express	O	O
PAH	O	O
.	O	O

The	O	O
transformed	O	O
mouse	O	O
cells	O	O
expressed	O	O
PAH	O	O
messenger	O	O
RNA	O	O
,	O	O
immunoreactive	O	O
protein	O	O
,	O	O
and	O	O
enzymatic	O	O
activity	O	O
that	O	O
are	O	O
characteristic	O	O
of	O	O
the	O	O
normal	O	O
human	O	O
liver	O	O
products	O	O
,	O	O
demonstrating	O	O
that	O	O
a	O	O
single	O	O
gene	O	O
contains	O	O
all	O	O
of	O	O
the	O	O
necessary	O	O
genetic	O	O
information	O	O
to	O	O
code	O	O
for	O	O
functional	O	O
PAH	O	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
use	O	O
of	O	O
the	O	O
human	O	O
PAH	O	O
probe	O	O
in	O	O
prenatal	O	O
diagnosis	O	O
and	O	O
detection	O	O
of	O	O
carriers	O	O
,	O	O
to	O	O
provide	O	O
new	O	O
opportunities	O	O
for	O	O
the	O	O
biochemical	O	O
characterization	O	O
of	O	O
normal	O	O
and	O	O
mutant	O	O
enzymes	O	O
,	O	O
and	O	O
in	O	O
the	O	O
investigation	O	O
of	O	O
alternative	O	O
genetic	O	O
therapies	O	O
for	O	O
PKU	B-Disease	D010661
.	O	O

.	O	O

Macular	B-Disease	D008268
dystrophy	I-Disease	D008268
associated	O	O
with	O	O
mutations	O	O
at	O	O
codon	O	O
172	O	O
in	O	O
the	O	O
human	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
slow	O	O
gene	O	O
.	O	O

BACKGROUND	O	O
Recently	O	O
,	O	O
mutations	O	O
in	O	O
the	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
slow	O	O
(	O	O
rds	O	O
)	O	O
gene	O	O
which	O	O
codes	O	O
for	O	O
peripherin	O	O
-	O	O
rds	O	O
have	O	O
been	O	O
implicated	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
autosomal	B-Disease	D012174
dominant	I-Disease	D012174
retinitis	I-Disease	D012174
pigmentosa	I-Disease	D012174
.	O	O

Because	O	O
this	O	O
gene	O	O
is	O	O
expressed	O	O
in	O	O
both	O	O
rods	O	O
and	O	O
cones	O	O
,	O	O
mutations	O	O
in	O	O
the	O	O
rds	O	O
gene	O	O
might	O	O
be	O	O
expected	O	O
to	O	O
cause	O	O
degeneration	O	O
affecting	O	O
either	O	O
the	O	O
scotopic	O	O
or	O	O
photopic	O	O
systems	O	O
.	O	O

Mutations	O	O
at	O	O
codon	O	O
172	O	O
of	O	O
the	O	O
rds	O	O
gene	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
three	O	O
families	O	O
with	O	O
autosomal	O	O
dominantly	O	O
inherited	O	O
,	O	O
progressive	O	O
macular	B-Disease	D008268
dystrophy	I-Disease	D008268
.	O	O

METHODS	O	O
Affected	O	O
individuals	O	O
underwent	O	O
ophthalmic	O	O
examination	O	O
,	O	O
scotopic	O	O
perimetry	O	O
,	O	O
dark	O	O
adaptometry	O	O
,	O	O
measurement	O	O
of	O	O
color	O	O
-	O	O
contrast	O	O
sensitivity	O	O
,	O	O
and	O	O
electroretinography	O	O
to	O	O
characterize	O	O
the	O	O
photoreceptor	O	O
dysfunction	O	O
.	O	O

RESULTS	O	O
In	O	O
all	O	O
but	O	O
one	O	O
affected	O	O
member	O	O
,	O	O
symptoms	O	O
of	O	O
progressive	O	O
central	O	O
visual	B-Disease	C531604
loss	I-Disease	C531604
developed	O	O
in	O	O
the	O	O
third	O	O
or	O	O
fourth	O	O
decade	O	O
of	O	O
life	O	O
accompanied	O	O
by	O	O
central	B-Disease	D012607
scotoma	I-Disease	D012607
and	O	O
well	O	O
-	O	O
demarcated	O	O
atrophy	B-Disease	C536309
of	I-Disease	C536309
the	I-Disease	C536309
retinal	I-Disease	C536309
pigment	I-Disease	C536309
epithelium	I-Disease	C536309
and	O	O
choriocapillaris	B-Disease	D008268
of	I-Disease	D008268
the	I-Disease	D008268
macula	I-Disease	D008268
.	O	O

In	O	O
general	O	O
,	O	O
cone	O	O
and	O	O
rod	O	O
thresholds	O	O
were	O	O
elevated	O	O
,	O	O
and	O	O
color	O	O
-	O	O
contrast	O	O
sensitivity	O	O
was	O	O
absent	O	O
in	O	O
the	O	O
central	O	O
visual	O	O
field	O	O
.	O	O

Peripherally	O	O
,	O	O
the	O	O
scotopic	O	O
sensitivities	O	O
were	O	O
normal	O	O
,	O	O
as	O	O
was	O	O
the	O	O
recovery	O	O
from	O	O
bleach	O	O
.	O	O

Cone	O	O
electroretinograms	O	O
were	O	O
diminished	O	O
in	O	O
amplitude	O	O
,	O	O
and	O	O
delayed	O	O
in	O	O
all	O	O
affected	O	O
adults	O	O
except	O	O
one	O	O
.	O	O

Rod	O	O
electroretinograms	O	O
were	O	O
normal	O	O
or	O	O
near	O	O
normal	O	O
in	O	O
amplitude	O	O
,	O	O
and	O	O
had	O	O
normal	O	O
implicit	O	O
times	O	O
.	O	O

Affected	O	O
asymptomatic	O	O
children	O	O
had	O	O
macular	O	O
changes	O	O
,	O	O
abnormal	O	O
color	O	O
-	O	O
contrast	O	O
sensitivity	O	O
,	O	O
and	O	O
reduced	O	O
pattern	O	O
and	O	O
cone	O	O
electroretinograms	O	O
.	O	O

CONCLUSION	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
mutations	O	O
in	O	O
the	O	O
rds	O	O
gene	O	O
can	O	O
be	O	O
expressed	O	O
as	O	O
a	O	O
macular	B-Disease	D008268
dystrophy	I-Disease	D008268
,	O	O
with	O	O
evidence	O	O
of	O	O
primary	O	O
cone	B-Disease	OMIM:180020
dysfunction	I-Disease	OMIM:180020
and	O	O
preservation	O	O
of	O	O
peripheral	O	O
rod	O	O
function	O	O
.	O	O

.	O	O

Glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variants	O	O
:	O	O
Gd	O	O
(	O	O
+	O	O
)	O	O
Alexandra	O	O
associated	O	O
with	O	O
neonatal	B-Disease	D007567
jaundice	I-Disease	D007567
and	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Camperdown	O	O
in	O	O
a	O	O
young	O	O
man	O	O
with	O	O
lamellar	B-Disease	C535342
cataracts	I-Disease	C535342
.	O	O

Two	O	O
male	O	O
subjects	O	O
are	O	O
described	O	O
,	O	O
with	O	O
unusual	O	O
clinical	O	O
presentations	O	O
and	O	O
with	O	O
hitherto	O	O
undescribed	O	O
G6PD	O	O
variants	O	O
.	O	O

The	O	O
first	O	O
,	O	O
of	O	O
Italian	O	O
extraction	O	O
,	O	O
suffered	O	O
from	O	O
severe	O	O
neonatal	B-Disease	D007567
jaundice	I-Disease	D007567
following	O	O
maternal	O	O
ingestion	O	O
of	O	O
fresh	O	O
broad	O	O
beans	O	O
(	O	O
Vicia	O	O
fava	O	O
)	O	O
both	O	O
prenatally	O	O
and	O	O
postnatally	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
enzymatic	O	O
defect	O	O
was	O	O
much	O	O
more	O	O
severe	O	O
in	O	O
the	O	O
neonatal	O	O
period	O	O
than	O	O
on	O	O
retesting	O	O
in	O	O
adolescence	O	O
,	O	O
when	O	O
biochemical	O	O
characterization	O	O
showed	O	O
unique	O	O
features	O	O
which	O	O
justify	O	O
designation	O	O
as	O	O
a	O	O
new	O	O
variant	O	O
Gd	O	O
(	O	O
+	O	O
)	O	O
Alexandra	O	O
.	O	O

The	O	O
second	O	O
patient	O	O
,	O	O
a	O	O
boy	O	O
of	O	O
Maltese	O	O
extraction	O	O
who	O	O
was	O	O
found	O	O
to	O	O
have	O	O
bilateral	B-Disease	C535342
lamellar	I-Disease	C535342
cataracts	I-Disease	C535342
at	O	O
the	O	O
age	O	O
of	O	O
4	O	O
years	O	O
,	O	O
was	O	O
identified	O	O
as	O	O
G6PD	B-Disease	D005955
deficient	I-Disease	D005955
only	O	O
as	O	O
a	O	O
result	O	O
of	O	O
a	O	O
survey	O	O
of	O	O
children	O	O
of	O	O
Mediterranean	O	O
origin	O	O
with	O	O
unexplained	O	O
cataract	B-Disease	D002386
formation	O	O
;	O	O
he	O	O
has	O	O
approximately	O	O
15	O	O
%	O	O
of	O	O
normal	O	O
enzyme	O	O
activity	O	O
,	O	O
with	O	O
another	O	O
unique	O	O
combination	O	O
of	O	O
biochemical	O	O
characteristics	O	O
which	O	O
has	O	O
led	O	O
to	O	O
its	O	O
designation	O	O
as	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Camperdown	O	O
.	O	O

Although	O	O
this	O	O
association	O	O
may	O	O
be	O	O
coincidental	O	O
,	O	O
it	O	O
prompts	O	O
further	O	O
attention	O	O
to	O	O
the	O	O
possibility	O	O
that	O	O
under	O	O
certain	O	O
circumstances	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
may	O	O
favor	O	O
cataract	B-Disease	D002386
formation	O	O
.	O	O

The	O	O
two	O	O
cases	O	O
illustrate	O	O
the	O	O
value	O	O
of	O	O
characterization	O	O
of	O	O
the	O	O
mutant	O	O
enzyme	O	O
whenever	O	O
unexpected	O	O
clinical	O	O
or	O	O
laboratory	O	O
results	O	O
are	O	O
obtained	O	O
.	O	O

.	O	O

DNA	O	O
restriction	O	O
fragments	O	O
associated	O	O
with	O	O
alpha	O	O
1	O	O
-	O	O
antitrypsin	O	O
indicate	O	O
a	O	O
single	O	O
origin	O	O
for	O	O
deficiency	O	O
allele	O	O
PI	O	O
Z	O	O
.	O	O

The	O	O
alpha	O	O
1	O	O
-	O	O
protease	O	O
inhibitor	O	O
,	O	O
or	O	O
alpha	O	O
-	O	O
antitrypsin	O	O
(	O	O
AAT	O	O
)	O	O
,	O	O
a	O	O
major	O	O
plasma	O	O
inhibitor	O	O
of	O	O
leukocyte	O	O
elastase	O	O
and	O	O
bacterial	O	O
proteases	O	O
,	O	O
is	O	O
encoded	O	O
at	O	O
the	O	O
PI	O	O
locus	O	O
on	O	O
chromosome	O	O
14	O	O
(	O	O
14q24	O	O
.	O	O

3	O	O
-	O	O
q32	O	O
.	O	O

1	O	O
)	O	O
.	O	O

A	O	O
deficiency	B-Disease	C531610
of	I-Disease	C531610
AAT	I-Disease	C531610
in	O	O
individuals	O	O
homozygous	O	O
for	O	O
the	O	O
PI	O	O
Z	O	O
allele	O	O
occurs	O	O
in	O	O
about	O	O
1	O	O
in	O	O
2	O	O
,	O	O
000	O	O
-	O	O
8	O	O
,	O	O
000	O	O
caucasians	O	O
and	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
early	O	O
adult	O	O
onset	O	O
emphysema	B-Disease	D004646
and	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
in	O	O
childhood	O	O
.	O	O

We	O	O
have	O	O
now	O	O
used	O	O
DNA	O	O
polymorphisms	O	O
associated	O	O
with	O	O
the	O	O
AAT	O	O
gene	O	O
to	O	O
investigate	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
PI	O	O
Z	O	O
allele	O	O
.	O	O

Using	O	O
two	O	O
genomic	O	O
probes	O	O
extending	O	O
into	O	O
the	O	O
5	O	O
and	O	O
3	O	O
flanking	O	O
regions	O	O
,	O	O
respectively	O	O
,	O	O
we	O	O
have	O	O
identified	O	O
eight	O	O
polymorphic	O	O
restriction	O	O
sites	O	O
.	O	O

Extensive	O	O
linkage	O	O
disequilibrium	O	O
occurs	O	O
throughout	O	O
the	O	O
probed	O	O
region	O	O
with	O	O
the	O	O
PI	O	O
Z	O	O
allele	O	O
,	O	O
but	O	O
not	O	O
with	O	O
normal	O	O
PI	O	O
M	O	O
alleles	O	O
.	O	O

The	O	O
Z	O	O
allele	O	O
occurs	O	O
mainly	O	O
with	O	O
one	O	O
haplotype	O	O
,	O	O
indicating	O	O
a	O	O
single	O	O
,	O	O
relatively	O	O
recent	O	O
,	O	O
origin	O	O
in	O	O
caucasians	O	O
Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
in	O	O
transgenic	O	O
mice	O	O
expressing	O	O
an	O	O
expanded	O	O
CUG	O	O
repeat	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
in	O	O
adult	O	O
humans	O	O
,	O	O
results	O	O
from	O	O
expansion	O	O
of	O	O
a	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
DMPK	O	O
gene	O	O
.	O	O

The	O	O
mutant	O	O
DMPK	O	O
messenger	O	O
RNA	O	O
(	O	O
mRNA	O	O
)	O	O
contains	O	O
an	O	O
expanded	O	O
CUG	O	O
repeat	O	O
and	O	O
is	O	O
retained	O	O
in	O	O
the	O	O
nucleus	O	O
.	O	O

We	O	O
have	O	O
expressed	O	O
an	O	O
untranslated	O	O
CUG	O	O
repeat	O	O
in	O	O
an	O	O
unrelated	O	O
mRNA	O	O
in	O	O
transgenic	O	O
mice	O	O
.	O	O

Mice	O	O
that	O	O
expressed	O	O
expanded	O	O
CUG	O	O
repeats	O	O
developed	O	O
myotonia	B-Disease	D009222
and	O	O
myopathy	B-Disease	D009135
,	O	O
whereas	O	O
mice	O	O
expressing	O	O
a	O	O
nonexpanded	O	O
repeat	O	O
did	O	O
not	O	O
.	O	O

Thus	O	O
,	O	O
transcripts	O	O
with	O	O
expanded	O	O
CUG	O	O
repeats	O	O
are	O	O
sufficient	O	O
to	O	O
generate	O	O
a	O	O
DM	B-Disease	D009223
phenotype	O	O
.	O	O

This	O	O
result	O	O
supports	O	O
a	O	O
role	O	O
for	O	O
RNA	O	O
gain	O	O
of	O	O
function	O	O
in	O	O
disease	O	O
pathogenesis	O	O
.	O	O

.	O	O

Submicroscopic	O	O
deletion	O	O
in	O	O
cousins	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
causes	O	O
a	O	O
grandmatrilineal	O	O
inheritance	O	O
pattern	O	O
:	O	O
effects	O	O
of	O	O
imprinting	O	O
.	O	O

The	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
critical	O	O
region	O	O
on	O	O
15q11	O	O
-	O	O
q13	O	O
is	O	O
subject	O	O
to	O	O
imprinting	O	O
.	O	O

PWS	B-Disease	D011218
becomes	O	O
apparent	O	O
when	O	O
genes	O	O
on	O	O
the	O	O
paternally	O	O
inherited	O	O
chromosome	O	O
are	O	O
not	O	O
expressed	O	O
.	O	O

Familial	B-Disease	D011218
PWS	I-Disease	D011218
is	O	O
rare	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
family	O	O
in	O	O
which	O	O
a	O	O
male	O	O
and	O	O
a	O	O
female	O	O
paternal	O	O
first	O	O
cousin	O	O
both	O	O
have	O	O
PWS	B-Disease	D011218
with	O	O
cytogenetically	O	O
normal	O	O
karyotypes	O	O
.	O	O

Fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
analysis	O	O
shows	O	O
a	O	O
submicroscopic	O	O
deletion	O	O
of	O	O
SNRPN	O	O
,	O	O
but	O	O
not	O	O
the	O	O
closely	O	O
associated	O	O
loci	O	O
D15S10	O	O
,	O	O
D15S11	O	O
,	O	O
D15S63	O	O
,	O	O
and	O	O
GABRB3	O	O
.	O	O

The	O	O
cousins	O	O
fathers	O	O
and	O	O
two	O	O
paternal	O	O
aunts	O	O
have	O	O
the	O	O
same	O	O
deletion	O	O
and	O	O
are	O	O
clinically	O	O
normal	O	O
.	O	O

The	O	O
grandmother	O	O
of	O	O
the	O	O
cousins	O	O
is	O	O
deceased	O	O
and	O	O
not	O	O
available	O	O
for	O	O
study	O	O
,	O	O
and	O	O
their	O	O
grandfather	O	O
is	O	O
not	O	O
deleted	O	O
for	O	O
SNRPN	O	O
.	O	O

DNA	O	O
methylation	O	O
analysis	O	O
of	O	O
D15S63	O	O
is	O	O
consistent	O	O
with	O	O
an	O	O
abnormality	O	O
of	O	O
the	O	O
imprinting	O	O
center	O	O
associated	O	O
with	O	O
PWS	B-Disease	D011218
.	O	O

"	O	O
Grandmatrilineal	O	O
"	O	O
inheritance	O	O
occurs	O	O
when	O	O
a	O	O
woman	O	O
with	O	O
deletion	O	O
of	O	O
an	O	O
imprinted	O	O
,	O	O
paternally	O	O
expressed	O	O
gene	O	O
is	O	O
at	O	O
risk	O	O
of	O	O
having	O	O
affected	O	O
grandchildren	O	O
through	O	O
her	O	O
sons	O	O
.	O	O

In	O	O
this	O	O
case	O	O
,	O	O
PWS	B-Disease	D011218
does	O	O
not	O	O
become	O	O
evident	O	O
as	O	O
long	O	O
as	O	O
the	O	O
deletion	O	O
is	O	O
passed	O	O
through	O	O
the	O	O
matrilineal	O	O
line	O	O
.	O	O

This	O	O
represents	O	O
a	O	O
unique	O	O
inheritance	O	O
pattern	O	O
due	O	O
to	O	O
imprinting	O	O
.	O	O

.	O	O

Expression	O	O
and	O	O
imprinting	O	O
of	O	O
MAGEL2	O	O
suggest	O	O
a	O	O
role	O	O
in	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
willi	I-Disease	D011218
syndrome	I-Disease	D011218
and	O	O
the	O	O
homologous	O	O
murine	O	O
imprinting	O	O
phenotype	O	O
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
is	O	O
caused	O	O
by	O	O
the	O	O
loss	O	O
of	O	O
expression	O	O
of	O	O
imprinted	O	O
genes	O	O
in	O	O
chromosome	O	O
15q11	O	O
-	O	O
q13	O	O
.	O	O

Affected	O	O
individuals	O	O
exhibit	O	O
neonatal	B-Disease	D009123
hypotonia	I-Disease	D009123
,	O	O
developmental	B-Disease	D002658
delay	I-Disease	D002658
and	O	O
childhood	B-Disease	D009765
-	I-Disease	D009765
onset	I-Disease	D009765
obesity	I-Disease	D009765
.	O	O

Necdin	O	O
,	O	O
a	O	O
protein	O	O
implicated	O	O
in	O	O
the	O	O
terminal	O	O
differentiation	O	O
of	O	O
neurons	O	O
,	O	O
is	O	O
the	O	O
only	O	O
PWS	B-Disease	D011218
candidate	O	O
gene	O	O
to	O	O
reduce	O	O
viability	O	O
when	O	O
disrupted	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
characterized	O	O
MAGEL2	O	O
(	O	O
also	O	O
known	O	O
as	O	O
NDNL1	O	O
)	O	O
,	O	O
a	O	O
gene	O	O
with	O	O
51	O	O
%	O	O
amino	O	O
acid	O	O
sequence	O	O
similarity	O	O
to	O	O
necdin	O	O
and	O	O
located	O	O
41	O	O
kb	O	O
distal	O	O
to	O	O
NDN	O	O
in	O	O
the	O	O
PWS	B-Disease	D011218
deletion	O	O
region	O	O
.	O	O

MAGEL2	O	O
is	O	O
expressed	O	O
predominantly	O	O
in	O	O
brain	O	O
,	O	O
the	O	O
primary	O	O
tissue	O	O
affected	O	O
in	O	O
PWS	B-Disease	D011218
and	O	O
in	O	O
several	O	O
fetal	O	O
tissues	O	O
as	O	O
shown	O	O
by	O	O
northern	O	O
blot	O	O
analysis	O	O
.	O	O

MAGEL2	O	O
is	O	O
imprinted	O	O
with	O	O
monoallelic	O	O
expression	O	O
in	O	O
control	O	O
brain	O	O
,	O	O
and	O	O
paternal	O	O
-	O	O
only	O	O
expression	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
as	O	O
demonstrated	O	O
by	O	O
its	O	O
lack	O	O
of	O	O
expression	O	O
in	O	O
brain	O	O
from	O	O
a	O	O
PWS	B-Disease	D011218
-	O	O
affected	O	O
individual	O	O
.	O	O

The	O	O
orthologous	O	O
mouse	O	O
gene	O	O
(	O	O
Magel2	O	O
)	O	O
is	O	O
located	O	O
within	O	O
150	O	O
kb	O	O
of	O	O
NDN	O	O
,	O	O
is	O	O
imprinted	O	O
with	O	O
paternal	O	O
-	O	O
only	O	O
expression	O	O
and	O	O
is	O	O
expressed	O	O
predominantly	O	O
in	O	O
late	O	O
developmental	O	O
stages	O	O
and	O	O
adult	O	O
brain	O	O
as	O	O
shown	O	O
by	O	O
northern	O	O
blotting	O	O
,	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
whole	O	O
-	O	O
mount	O	O
RNA	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

Magel2	O	O
distribution	O	O
partially	O	O
overlaps	O	O
that	O	O
of	O	O
NDN	O	O
,	O	O
with	O	O
strong	O	O
expression	O	O
being	O	O
detected	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
in	O	O
mid	O	O
-	O	O
gestation	O	O
mouse	O	O
embryos	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
,	O	O
although	O	O
loss	O	O
of	O	O
necdin	O	O
expression	O	O
may	O	O
be	O	O
important	O	O
in	O	O
the	O	O
neonatal	O	O
presentation	O	O
of	O	O
PWS	B-Disease	D011218
,	O	O
loss	O	O
of	O	O
MAGEL2	O	O
may	O	O
be	O	O
critical	O	O
to	O	O
abnormalities	B-Disease	D002658
in	I-Disease	D002658
brain	I-Disease	D002658
development	I-Disease	D002658
and	O	O
dysmorphic	B-Disease	D057215
features	I-Disease	D057215
in	O	O
individuals	O	O
with	O	O
PWS	B-Disease	D011218
.	O	O

.	O	O

A	O	O
single	O	O
origin	O	O
of	O	O
phenylketonuria	B-Disease	D010661
in	O	O
Yemenite	O	O
Jews	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
a	O	O
metabolic	B-Disease	D008659
disease	I-Disease	D008659
caused	O	O
by	O	O
recessive	O	O
mutations	O	O
of	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
hepatic	O	O
enzyme	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
PKU	B-Disease	D010661
varies	O	O
widely	O	O
across	O	O
different	O	O
geographic	O	O
areas	O	O
,	O	O
and	O	O
is	O	O
highest	O	O
(	O	O
about	O	O
1	O	O
in	O	O
5	O	O
,	O	O
000	O	O
live	O	O
births	O	O
)	O	O
in	O	O
Ireland	O	O
and	O	O
western	O	O
Scotland	O	O
,	O	O
and	O	O
among	O	O
Yemenite	O	O
Jews	O	O
.	O	O

A	O	O
limited	O	O
number	O	O
of	O	O
point	O	O
mutations	O	O
account	O	O
for	O	O
most	O	O
of	O	O
the	O	O
PKU	B-Disease	D010661
cases	O	O
in	O	O
the	O	O
European	O	O
population	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
a	O	O
single	O	O
molecular	O	O
defect	O	O
-	O	O
-	O	O
a	O	O
deletion	O	O
spanning	O	O
the	O	O
third	O	O
exon	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
-	O	O
-	O	O
is	O	O
responsible	O	O
for	O	O
all	O	O
the	O	O
PKU	B-Disease	D010661
cases	O	O
among	O	O
the	O	O
Yemenite	O	O
Jews	O	O
.	O	O

Examination	O	O
of	O	O
a	O	O
random	O	O
sample	O	O
of	O	O
Yemenite	O	O
Jews	O	O
using	O	O
a	O	O
molecular	O	O
probe	O	O
that	O	O
detects	O	O
the	O	O
carriers	O	O
of	O	O
this	O	O
deletion	O	O
indicated	O	O
a	O	O
high	O	O
frequency	O	O
of	O	O
the	O	O
defective	O	O
gene	O	O
in	O	O
this	O	O
community	O	O
.	O	O

Although	O	O
the	O	O
deleted	O	O
PAH	O	O
gene	O	O
was	O	O
traced	O	O
to	O	O
25	O	O
different	O	O
locations	O	O
throughout	O	O
Yemen	O	O
,	O	O
family	O	O
histories	O	O
and	O	O
official	O	O
documents	O	O
of	O	O
the	O	O
Yemenite	O	O
Jewish	O	O
community	O	O
showed	O	O
that	O	O
the	O	O
common	O	O
ancestor	O	O
of	O	O
all	O	O
the	O	O
carriers	O	O
of	O	O
this	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
lived	O	O
in	O	O
Sana	O	O
,	O	O
the	O	O
capital	O	O
of	O	O
Yemen	O	O
,	O	O
before	O	O
the	O	O
eighteenth	O	O
century	O	O
.	O	O

.	O	O

High	O	O
resolution	O	O
genetic	O	O
analysis	O	O
suggests	O	O
one	O	O
ancestral	O	O
predisposing	O	O
haplotype	O	O
for	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
mutation	O	O
.	O	O

The	O	O
mutation	O	O
causing	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
an	O	O
amplification	O	O
of	O	O
an	O	O
unstable	O	O
trinucleotide	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
in	O	O
over	O	O
99	O	O
%	O	O
of	O	O
the	O	O
global	O	O
DM	B-Disease	D009223
population	O	O
.	O	O

It	O	O
is	O	O
in	O	O
complete	O	O
linkage	O	O
disequilibrium	O	O
with	O	O
an	O	O
Alu	O	O
element	O	O
polymorphism	O	O
within	O	O
the	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
,	O	O
suggesting	O	O
that	O	O
DM	B-Disease	D009223
is	O	O
a	O	O
consequence	O	O
of	O	O
one	O	O
or	O	O
few	O	O
ancestral	O	O
mutations	O	O
.	O	O

A	O	O
recent	O	O
analysis	O	O
utilizing	O	O
this	O	O
polymorphism	O	O
as	O	O
well	O	O
as	O	O
a	O	O
flanking	O	O
dinucleotide	O	O
marker	O	O
,	O	O
suggested	O	O
that	O	O
similar	O	O
to	O	O
Fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
DM	B-Disease	D009223
exhibited	O	O
a	O	O
founder	O	O
effect	O	O
(	O	O
Imbert	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1993	O	O
Nature	O	O
Genet	O	O
.	O	O

4	O	O
,	O	O
72	O	O
-	O	O
76	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
low	O	O
reproductive	O	O
fitness	O	O
of	O	O
individuals	O	O
with	O	O
congenital	O	O
DM	B-Disease	D009223
(	O	O
the	O	O
endpoint	O	O
of	O	O
genetic	O	O
anticipation	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
)	O	O
suggests	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
new	O	O
mutations	O	O
.	O	O

We	O	O
present	O	O
a	O	O
high	O	O
resolution	O	O
genetic	O	O
analysis	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
using	O	O
PCR	O	O
based	O	O
assays	O	O
of	O	O
nine	O	O
polymorphisms	O	O
,	O	O
spanning	O	O
a	O	O
physical	O	O
distance	O	O
of	O	O
30	O	O
kb	O	O
,	O	O
within	O	O
and	O	O
immediately	O	O
flanking	O	O
the	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
.	O	O

The	O	O
persistent	O	O
complete	O	O
allelic	O	O
association	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
with	O	O
all	O	O
these	O	O
polymorphisms	O	O
provides	O	O
further	O	O
support	O	O
to	O	O
previous	O	O
observations	O	O
and	O	O
suggests	O	O
more	O	O
strongly	O	O
that	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
occurred	O	O
on	O	O
the	O	O
background	O	O
of	O	O
a	O	O
particular	O	O
haplotype	O	O
in	O	O
which	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
became	O	O
inherently	O	O
unstable	O	O
and	O	O
therefore	O	O
predisposed	O	O
to	O	O
amplification	O	O
.	O	O

Identification	O	O
and	O	O
rapid	O	O
detection	O	O
of	O	O
three	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
mutations	O	O
in	O	O
the	O	O
Moroccan	O	O
Jewish	O	O
population	O	O
.	O	O

Infantile	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
(	O	O
TSD	B-Disease	D013661
)	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
HEXA	O	O
gene	O	O
that	O	O
result	O	O
in	O	O
the	O	O
complete	O	O
absence	O	O
of	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
activity	O	O
.	O	O

It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
an	O	O
elevated	O	O
frequency	O	O
of	O	O
TSD	B-Disease	D013661
mutations	O	O
exists	O	O
among	O	O
Ashkenazi	O	O
Jews	O	O
.	O	O

More	O	O
recently	O	O
it	O	O
has	O	O
become	O	O
apparent	O	O
that	O	O
elevated	O	O
carrier	O	O
frequencies	O	O
for	O	O
TSD	B-Disease	D013661
also	O	O
occur	O	O
in	O	O
several	O	O
other	O	O
ethnic	O	O
groups	O	O
,	O	O
including	O	O
Moroccan	O	O
Jews	O	O
,	O	O
a	O	O
subgroup	O	O
of	O	O
Sephardic	O	O
Jews	O	O
.	O	O

Elsewhere	O	O
we	O	O
reported	O	O
an	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
of	O	O
one	O	O
of	O	O
the	O	O
two	O	O
adjacent	O	O
phenylalanine	O	O
codons	O	O
at	O	O
position	O	O
304	O	O
or	O	O
305	O	O
(	O	O
delta	O	O
F304	O	O
/	O	O
305	O	O
)	O	O
in	O	O
one	O	O
HEXA	O	O
allele	O	O
of	O	O
a	O	O
Moroccan	O	O
Jewish	O	O
TSD	B-Disease	D013661
patient	O	O
and	O	O
in	O	O
three	O	O
obligate	O	O
carriers	O	O
from	O	O
six	O	O
unrelated	O	O
Moroccan	O	O
Jewish	O	O
families	O	O
.	O	O

We	O	O
have	O	O
now	O	O
identified	O	O
two	O	O
additional	O	O
mutations	O	O
within	O	O
exon	O	O
5	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
that	O	O
account	O	O
for	O	O
the	O	O
remaining	O	O
TSD	B-Disease	D013661
alleles	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
carriers	O	O
.	O	O

One	O	O
of	O	O
the	O	O
mutations	O	O
is	O	O
a	O	O
novel	O	O
C	O	O
-	O	O
to	O	O
-	O	O
G	O	O
transversion	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
replacement	O	O
of	O	O
Tyr180	O	O
by	O	O
a	O	O
stop	O	O
codon	O	O
.	O	O

The	O	O
other	O	O
mutation	O	O
is	O	O
a	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transition	O	O
resulting	O	O
in	O	O
an	O	O
Arg170	O	O
-	O	O
to	O	O
-	O	O
Gln	O	O
substitution	O	O
.	O	O

This	O	O
mutation	O	O
is	O	O
at	O	O
a	O	O
CpG	O	O
site	O	O
in	O	O
a	O	O
Japanese	O	O
infant	O	O
with	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	O	O
and	O	O
was	O	O
described	O	O
elsewhere	O	O
.	O	O

Analysis	O	O
of	O	O
nine	O	O
obligate	O	O
carriers	O	O
from	O	O
seven	O	O
unrelated	O	O
families	O	O
showed	O	O
that	O	O
four	O	O
harbor	O	O
the	O	O
delta	O	O
F304	O	O
/	O	O
305	O	O
mutation	O	O
,	O	O
two	O	O
the	O	O
Arg170	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Gln	O	O
mutation	O	O
,	O	O
and	O	O
one	O	O
the	O	O
Tyr180	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Stop	O	O
mutation	O	O
.	O	O

We	O	O
also	O	O
have	O	O
developed	O	O
rapid	O	O
,	O	O
nonradioactive	O	O
assays	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
each	O	O
mutation	O	O
,	O	O
which	O	O
should	O	O
be	O	O
helpful	O	O
for	O	O
carrier	O	O
screening	O	O
.	O	O

.	O	O

Mapping	O	O
of	O	O
the	O	O
mouse	O	O
homologue	O	O
of	O	O
the	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
gene	O	O
to	O	O
mouse	O	O
chromosome	O	O
8	O	O
.	O	O

ATP7B	O	O
,	O	O
the	O	O
gene	O	O
altered	O	O
in	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
(	O	O
WD	B-Disease	D006527
)	O	O
patients	O	O
,	O	O
lies	O	O
in	O	O
a	O	O
block	O	O
of	O	O
homology	O	O
shared	O	O
between	O	O
human	O	O
chromosome	O	O
13q14	O	O
and	O	O
the	O	O
central	O	O
region	O	O
of	O	O
mouse	O	O
chromosome	O	O
14	O	O
.	O	O

However	O	O
,	O	O
we	O	O
have	O	O
mapped	O	O
the	O	O
murine	O	O
homologue	O	O
of	O	O
ATP7B	O	O
(	O	O
Atp7b	O	O
)	O	O
to	O	O
mouse	O	O
chromosome	O	O
8	O	O
by	O	O
somatic	O	O
cell	O	O
hybrid	O	O
analysis	O	O
.	O	O

Analysis	O	O
of	O	O
80	O	O
interspecific	O	O
backcross	O	O
offspring	O	O
was	O	O
used	O	O
to	O	O
position	O	O
Atp7b	O	O
close	O	O
to	O	O
D8Mit3	O	O
and	O	O
another	O	O
ATPase	O	O
locus	O	O
,	O	O
Atp4b	O	O
,	O	O
on	O	O
mouse	O	O
chromosome	O	O
8	O	O
.	O	O

ATP4B	O	O
lies	O	O
in	O	O
13q34	O	O
and	O	O
is	O	O
separated	O	O
from	O	O
ATP7B	O	O
by	O	O
several	O	O
loci	O	O
whose	O	O
mouse	O	O
homologues	O	O
map	O	O
to	O	O
mouse	O	O
chromosome	O	O
14	O	O
.	O	O

The	O	O
assignment	O	O
of	O	O
Atp7b	O	O
to	O	O
mouse	O	O
chromosome	O	O
8	O	O
identifies	O	O
a	O	O
previously	O	O
unrecognized	O	O
region	O	O
of	O	O
homology	O	O
between	O	O
this	O	O
chromosome	O	O
and	O	O
human	O	O
chromosome	O	O
13	O	O
.	O	O

This	O	O
assignment	O	O
suggests	O	O
a	O	O
possible	O	O
location	O	O
for	O	O
the	O	O
toxic	O	O
milk	O	O
mutation	O	O
in	O	O
the	O	O
mouse	O	O
,	O	O
which	O	O
has	O	O
been	O	O
proposed	O	O
as	O	O
a	O	O
homologue	O	O
of	O	O
WD	B-Disease	D006527
.	O	O

.	O	O

Characteristics	O	O
of	O	O
intergenerational	O	O
contractions	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

In	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
,	O	O
the	O	O
size	O	O
of	O	O
a	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
generally	O	O
increases	O	O
in	O	O
successive	O	O
generations	O	O
with	O	O
clinical	O	O
evidence	O	O
of	O	O
anticipation	O	O
.	O	O

However	O	O
,	O	O
there	O	O
have	O	O
also	O	O
been	O	O
cases	O	O
with	O	O
an	O	O
intergenerational	O	O
contraction	O	O
of	O	O
the	O	O
repeat	O	O
.	O	O

We	O	O
examined	O	O
1	O	O
,	O	O
489	O	O
DM	B-Disease	D009223
parent	O	O
-	O	O
offspring	O	O
pairs	O	O
,	O	O
of	O	O
which	O	O
95	O	O
(	O	O
6	O	O
.	O	O

4	O	O
%	O	O
)	O	O
showed	O	O
such	O	O
contractions	O	O
in	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
(	O	O
PBL	O	O
)	O	O
.	O	O

In	O	O
56	O	O
of	O	O
the	O	O
95	O	O
pairs	O	O
,	O	O
clinical	O	O
data	O	O
allowed	O	O
an	O	O
analysis	O	O
of	O	O
their	O	O
anticipation	O	O
status	O	O
.	O	O

It	O	O
is	O	O
surprising	O	O
that	O	O
anticipation	O	O
occurred	O	O
in	O	O
27	O	O
(	O	O
48	O	O
%	O	O
)	O	O
of	O	O
these	O	O
56	O	O
pairs	O	O
,	O	O
while	O	O
none	O	O
clearly	O	O
showed	O	O
a	O	O
later	O	O
onset	O	O
of	O	O
DM	B-Disease	D009223
in	O	O
the	O	O
symptomatic	O	O
offspring	O	O
.	O	O

The	O	O
contraction	O	O
occurred	O	O
in	O	O
76	O	O
(	O	O
10	O	O
%	O	O
)	O	O
of	O	O
753	O	O
paternal	O	O
transmissions	O	O
and	O	O
in	O	O
19	O	O
(	O	O
3	O	O
%	O	O
)	O	O
of	O	O
736	O	O
maternal	O	O
transmissions	O	O
.	O	O

Anticipation	O	O
was	O	O
observed	O	O
more	O	O
frequently	O	O
in	O	O
maternal	O	O
(	O	O
85	O	O
%	O	O
)	O	O
than	O	O
in	O	O
paternal	O	O
(	O	O
37	O	O
%	O	O
)	O	O
transmissions	O	O
(	O	O
P	O	O
<	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
parental	O	O
repeat	O	O
size	O	O
correlated	O	O
with	O	O
the	O	O
size	O	O
of	O	O
intergenerational	O	O
contraction	O	O
(	O	O
r2	O	O
=	O	O
.	O	O

50	O	O
,	O	O
P	O	O
<	O	O
<	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
the	O	O
slope	O	O
of	O	O
linear	O	O
regression	O	O
was	O	O
steeper	O	O
in	O	O
paternal	O	O
(	O	O
-	O	O
.	O	O

62	O	O
)	O	O
than	O	O
in	O	O
maternal	O	O
(	O	O
-	O	O
.	O	O

30	O	O
)	O	O
transmissions	O	O
(	O	O
P	O	O
<	O	O
<	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Sixteen	O	O
DM	B-Disease	D009223
parents	O	O
had	O	O
multiple	O	O
DM	B-Disease	D009223
offspring	O	O
with	O	O
the	O	O
CTG	O	O
repeat	O	O
contractions	O	O
.	O	O

This	O	O
frequency	O	O
was	O	O
higher	O	O
than	O	O
the	O	O
frequency	O	O
expected	O	O
from	O	O
the	O	O
probability	O	O
of	O	O
the	O	O
repeat	O	O
contractions	O	O
(	O	O
6	O	O
.	O	O

4	O	O
%	O	O
)	O	O
and	O	O
the	O	O
size	O	O
of	O	O
DM	B-Disease	D009223
sib	O	O
population	O	O
(	O	O
1	O	O
.	O	O

54	O	O
DM	B-Disease	D009223
offspring	O	O
per	O	O
DM	B-Disease	D009223
parent	O	O
,	O	O
in	O	O
968	O	O
DM	B-Disease	D009223
parents	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
(	O	O
1	O	O
)	O	O
intergenerational	O	O
contractions	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
in	O	O
leukocyte	O	O
DNA	O	O
frequently	O	O
accompanies	O	O
apparent	O	O
anticipation	O	O
,	O	O
especially	O	O
when	O	O
DM	B-Disease	D009223
is	O	O
maternally	O	O
transmitted	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
paternal	O	O
origin	O	O
of	O	O
the	O	O
repeat	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
repeat	O	O
contraction	O	O
in	O	O
a	O	O
sibling	O	O
increase	O	O
the	O	O
probability	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
contraction	O	O
Splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
may	O	O
result	O	O
in	O	O
intrafamilial	O	O
variability	O	O
for	O	O
deafness	B-Disease	D003638
in	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
is	O	O
a	O	O
recessive	B-Disease	D030342
inherited	I-Disease	D030342
disorder	I-Disease	D030342
that	O	O
consists	O	O
of	O	O
developmental	B-Disease	D015834
abnormalities	I-Disease	D015834
of	I-Disease	D015834
the	I-Disease	D015834
cochlea	I-Disease	D015834
,	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
,	O	O
and	O	O
diffuse	B-Disease	D013959
thyroid	I-Disease	D013959
enlargement	I-Disease	D013959
(	O	O
goiter	B-Disease	D006042
)	O	O
.	O	O

This	O	O
disorder	O	O
may	O	O
account	O	O
for	O	O
up	O	O
to	O	O
10	O	O
%	O	O
of	O	O
cases	O	O
of	O	O
hereditary	B-Disease	D030342	D003638
deafness	I-Disease	D030342	D003638
.	O	O

The	O	O
disease	O	O
gene	O	O
(	O	O
PDS	B-Disease	C536648
)	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
chromosome	O	O
7q22	O	O
-	O	O
q31	O	O
,	O	O
and	O	O
encodes	O	O
a	O	O
chloride	O	O
-	O	O
iodide	O	O
transport	O	O
protein	O	O
.	O	O

We	O	O
performed	O	O
mutation	O	O
analysis	O	O
of	O	O
individual	O	O
exons	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
in	O	O
one	O	O
Spanish	O	O
family	O	O
that	O	O
shows	O	O
intrafamilial	O	O
variability	O	O
of	O	O
the	O	O
deafness	B-Disease	D003638
phenotype	O	O
(	O	O
two	O	O
patients	O	O
with	O	O
profound	O	O
and	O	O
one	O	O
with	O	O
moderate	O	O
-	O	O
severe	O	O
deafness	B-Disease	D003638
)	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
new	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
affecting	O	O
intron	O	O
4	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
,	O	O
at	O	O
nucleotide	O	O
position	O	O
639	O	O
+	O	O
7	O	O
.	O	O

RNA	O	O
analysis	O	O
from	O	O
lymphocytes	O	O
of	O	O
the	O	O
affected	O	O
patients	O	O
showed	O	O
that	O	O
mutation	O	O
639	O	O
+	O	O
7A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
generates	O	O
a	O	O
new	O	O
donor	O	O
splice	O	O
site	O	O
,	O	O
leading	O	O
to	O	O
an	O	O
mRNA	O	O
with	O	O
an	O	O
insertion	O	O
of	O	O
six	O	O
nucleotides	O	O
from	O	O
intron	O	O
4	O	O
of	O	O
PDS	B-Disease	C536648
.	O	O

Since	O	O
the	O	O
newly	O	O
created	O	O
donor	O	O
splice	O	O
site	O	O
is	O	O
likely	O	O
to	O	O
compete	O	O
with	O	O
the	O	O
normal	O	O
one	O	O
,	O	O
variations	O	O
of	O	O
the	O	O
levels	O	O
of	O	O
normal	O	O
and	O	O
aberrant	O	O
transcripts	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
in	O	O
the	O	O
cochlea	O	O
may	O	O
explain	O	O
the	O	O
variability	O	O
in	O	O
the	O	O
deafness	B-Disease	D003638
presentation	O	O
.	O	O

.	O	O

Heterozygous	O	O
loss	O	O
of	O	O
Six5	O	O
in	O	O
mice	O	O
is	O	O
sufficient	O	O
to	O	O
cause	O	O
ocular	O	O
cataracts	B-Disease	D002386
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
an	O	O
autosomal	O	O
dominant	O	O
disorder	O	O
characterized	O	O
by	O	O
skeletal	O	O
muscle	B-Disease	D009133
wasting	I-Disease	D009133
,	O	O
myotonia	B-Disease	D009222
,	O	O
cardiac	B-Disease	D001145
arrhythmia	I-Disease	D001145
,	O	O
hyperinsulinaemia	B-Disease	D006946
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
and	O	O
ocular	O	O
cataracts	B-Disease	D002386
.	O	O

The	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
DM	B-Disease	D009223
is	O	O
a	O	O
CTG	O	O
repeat	O	O
expansion	O	O
located	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
DMPK	O	O
and	O	O
5	O	O
of	O	O
a	O	O
homeodomain	O	O
-	O	O
encoding	O	O
gene	O	O
,	O	O
SIX5	O	O
(	O	O
formerly	O	O
DMAHP	O	O
;	O	O
refs	O	O
2	O	O
-	O	O
5	O	O
)	O	O
.	O	O

There	O	O
are	O	O
three	O	O
mechanisms	O	O
by	O	O
which	O	O
CTG	O	O
expansion	O	O
can	O	O
result	O	O
in	O	O
DM	B-Disease	D009223
.	O	O

First	O	O
,	O	O
repeat	O	O
expansion	O	O
may	O	O
alter	O	O
the	O	O
processing	O	O
or	O	O
transport	O	O
of	O	O
the	O	O
mutant	O	O
DMPK	O	O
mRNA	O	O
and	O	O
consequently	O	O
reduce	O	O
DMPK	O	O
levels	O	O
.	O	O

Second	O	O
,	O	O
CTG	O	O
expansion	O	O
may	O	O
establish	O	O
a	O	O
region	O	O
of	O	O
heterochromatin	O	O
3	O	O
of	O	O
the	O	O
repeat	O	O
sequence	O	O
and	O	O
decrease	O	O
SIX5	O	O
transcription	O	O
.	O	O

Third	O	O
,	O	O
toxic	O	O
effects	O	O
of	O	O
the	O	O
repeat	O	O
expansion	O	O
may	O	O
be	O	O
intrinsic	O	O
to	O	O
the	O	O
repeated	O	O
elements	O	O
at	O	O
the	O	O
level	O	O
of	O	O
DNA	O	O
or	O	O
RNA	O	O
(	O	O
refs	O	O
10	O	O
,	O	O
11	O	O
)	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
loss	O	O
of	O	O
Dm15	O	O
(	O	O
the	O	O
mouse	O	O
DMPK	O	O
homologue	O	O
)	O	O
in	O	O
mice	O	O
produces	O	O
a	O	O
partial	O	O
DM	B-Disease	D009223
phenotype	O	O
characterized	O	O
by	O	O
decreased	O	O
development	O	O
of	O	O
skeletal	O	O
muscle	O	O
force	O	O
and	O	O
cardiac	B-Disease	D001145
conduction	I-Disease	D001145
disorders	I-Disease	D001145
.	O	O

To	O	O
test	O	O
the	O	O
role	O	O
of	O	O
Six5	O	O
loss	O	O
in	O	O
DM	B-Disease	D009223
,	O	O
we	O	O
have	O	O
analysed	O	O
a	O	O
strain	O	O
of	O	O
mice	O	O
in	O	O
which	O	O
Six5	O	O
was	O	O
deleted	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
the	O	O
rate	O	O
and	O	O
severity	O	O
of	O	O
cataract	B-Disease	D002386
formation	O	O
is	O	O
inversely	O	O
related	O	O
to	O	O
Six5	O	O
dosage	O	O
and	O	O
is	O	O
temporally	O	O
progressive	O	O
.	O	O

Six5	O	O
+	O	O
/	O	O
-	O	O
and	O	O
Six5	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
show	O	O
increased	O	O
steady	O	O
-	O	O
state	O	O
levels	O	O
of	O	O
the	O	O
Na	O	O
+	O	O
/	O	O
K	O	O
+	O	O
-	O	O
ATPase	O	O
alpha	O	O
-	O	O
1	O	O
subunit	O	O
and	O	O
decreased	O	O
Dm15	O	O
mRNA	O	O
levels	O	O
.	O	O

Thus	O	O
,	O	O
altered	O	O
ion	O	O
homeostasis	O	O
within	O	O
the	O	O
lens	O	O
may	O	O
contribute	O	O
to	O	O
cataract	B-Disease	D002386
formation	O	O
.	O	O

As	O	O
ocular	O	O
cataracts	B-Disease	D002386
are	O	O
a	O	O
characteristic	O	O
feature	O	O
of	O	O
DM	B-Disease	D009223
,	O	O
these	O	O
results	O	O
demonstrate	O	O
that	O	O
decreased	O	O
SIX5	O	O
transcription	O	O
is	O	O
important	O	O
in	O	O
the	O	O
aetiology	O	O
of	O	O
DM	B-Disease	D009223
.	O	O

Our	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
DM	B-Disease	D009223
is	O	O
a	O	O
contiguous	O	O
gene	O	O
syndrome	O	O
associated	O	O
with	O	O
the	O	O
partial	O	O
loss	O	O
of	O	O
both	O	O
DMPK	O	O
and	O	O
SIX5	O	O
.	O	O

.	O	O

Cis	O	O
and	O	O
trans	O	O
effects	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
mutation	O	O
in	O	O
a	O	O
cell	O	O
culture	O	O
model	O	O
.	O	O

The	O	O
mutation	O	O
causing	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
a	O	O
CTG	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
(	O	O
3	O	O
-	O	O
UTR	O	O
)	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
gene	O	O
(	O	O
DMPK	O	O
)	O	O
,	O	O
but	O	O
the	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
of	O	O
pathogenesis	O	O
remain	O	O
unknown	O	O
.	O	O

Studies	O	O
using	O	O
DM	B-Disease	D009223
patient	O	O
materials	O	O
have	O	O
often	O	O
produced	O	O
confusing	O	O
results	O	O
.	O	O

Therefore	O	O
,	O	O
to	O	O
study	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
in	O	O
a	O	O
controlled	O	O
environment	O	O
,	O	O
we	O	O
have	O	O
established	O	O
a	O	O
cell	O	O
culture	O	O
model	O	O
system	O	O
using	O	O
C2C12	O	O
mouse	O	O
myoblasts	O	O
.	O	O

By	O	O
expressing	O	O
chimeric	O	O
reporter	O	O
constructs	O	O
containing	O	O
a	O	O
reporter	O	O
gene	O	O
fused	O	O
to	O	O
a	O	O
human	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
,	O	O
we	O	O
identified	O	O
both	O	O
cis	O	O
and	O	O
trans	O	O
effects	O	O
that	O	O
are	O	O
mediated	O	O
by	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
a	O	O
mutant	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
,	O	O
with	O	O
as	O	O
few	O	O
as	O	O
57	O	O
CTGs	O	O
,	O	O
had	O	O
a	O	O
negative	O	O
cis	O	O
effect	O	O
on	O	O
protein	O	O
expression	O	O
and	O	O
resulted	O	O
in	O	O
the	O	O
aggregation	O	O
of	O	O
reporter	O	O
transcripts	O	O
into	O	O
discrete	O	O
nuclear	O	O
foci	O	O
.	O	O

We	O	O
determined	O	O
by	O	O
deletion	O	O
analysis	O	O
that	O	O
an	O	O
expanded	O	O
(	O	O
CTG	O	O
)	O	O
(	O	O
n	O	O
)	O	O
tract	O	O
alone	O	O
was	O	O
sufficient	O	O
to	O	O
mediate	O	O
these	O	O
cis	O	O
effects	O	O
.	O	O

Furthermore	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
normal	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
mRNA	O	O
,	O	O
a	O	O
mutant	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
mRNA	O	O
with	O	O
(	O	O
CUG	O	O
)	O	O
(	O	O
200	O	O
)	O	O
selectively	O	O
inhibited	O	O
myogenic	O	O
differentiation	O	O
of	O	O
C2C12	O	O
myoblasts	O	O
.	O	O

Genetic	O	O
analysis	O	O
and	O	O
the	O	O
Cre	O	O
-	O	O
loxP	O	O
system	O	O
were	O	O
used	O	O
to	O	O
clearly	O	O
demonstrate	O	O
that	O	O
the	O	O
myoblast	O	O
fusion	O	O
defect	O	O
could	O	O
be	O	O
rescued	O	O
by	O	O
eliminating	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
mutant	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
transcript	O	O
.	O	O

Characterization	O	O
of	O	O
spontaneous	O	O
deletion	O	O
events	O	O
mapped	O	O
the	O	O
inhibitory	O	O
effect	O	O
to	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
(	O	O
n	O	O
)	O	O
expansion	O	O
and	O	O
/	O	O
or	O	O
the	O	O
3	O	O
end	O	O
of	O	O
the	O	O
DMPK	O	O
3	O	O
-	O	O
UTR	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
evidence	O	O
that	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
acts	O	O
in	O	O
cis	O	O
to	O	O
reduce	O	O
protein	O	O
production	O	O
(	O	O
consistent	O	O
with	O	O
DMPK	B-Disease	D058495
haploinsufficiency	I-Disease	D058495
)	O	O
and	O	O
in	O	O
trans	O	O
as	O	O
a	O	O
riboregulator	O	O
to	O	O
inhibit	O	O
myogenesis	O	O
.	O	O

.	O	O

Intelligence	O	O
quotient	O	O
profile	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
intergenerational	O	O
deficit	O	O
,	O	O
and	O	O
correlation	O	O
with	O	O
CTG	O	O
amplification	O	O
.	O	O

An	O	O
abbreviated	O	O
Wechsler	O	O
Adult	O	O
Intelligence	O	O
Scale	O	O
Revised	O	O
(	O	O
WAIS	O	O
-	O	O
R	O	O
)	O	O
was	O	O
used	O	O
to	O	O
assess	O	O
verbal	O	O
and	O	O
arithmetical	O	O
cognitive	O	O
performance	O	O
in	O	O
55	O	O
subjects	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
,	O	O
covering	O	O
all	O	O
grades	O	O
of	O	O
disease	O	O
severity	O	O
,	O	O
and	O	O
31	O	O
controls	O	O
at	O	O
50	O	O
%	O	O
risk	O	O
of	O	O
inheriting	O	O
DM	B-Disease	D009223
.	O	O

Scaled	O	O
scores	O	O
from	O	O
the	O	O
assessment	O	O
were	O	O
converted	O	O
into	O	O
an	O	O
intelligence	O	O
quotient	O	O
(	O	O
IQ	O	O
)	O	O
estimation	O	O
on	O	O
each	O	O
person	O	O
.	O	O

Significant	O	O
IQ	O	O
differences	O	O
were	O	O
found	O	O
between	O	O
(	O	O
1	O	O
)	O	O
all	O	O
55	O	O
DM	B-Disease	D009223
subjects	O	O
(	O	O
mean	O	O
90	O	O
.	O	O

2	O	O
,	O	O
SD	O	O
16	O	O
.	O	O

1	O	O
)	O	O
and	O	O
31	O	O
controls	O	O
(	O	O
102	O	O
.	O	O

6	O	O
,	O	O
SD	O	O
9	O	O
.	O	O

4	O	O
)	O	O
,	O	O
with	O	O
no	O	O
sex	O	O
differences	O	O
in	O	O
either	O	O
group	O	O
;	O	O
(	O	O
2	O	O
)	O	O
15	O	O
affected	O	O
parents	O	O
(	O	O
99	O	O
.	O	O

3	O	O
,	O	O
SD	O	O
12	O	O
.	O	O

2	O	O
)	O	O
and	O	O
their	O	O
affected	O	O
children	O	O
(	O	O
88	O	O
.	O	O

1	O	O
,	O	O
SD	O	O
17	O	O
.	O	O

2	O	O
)	O	O
,	O	O
where	O	O
significance	O	O
was	O	O
dependent	O	O
on	O	O
parental	O	O
sex	O	O
being	O	O
female	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
15	O	O
pairs	O	O
of	O	O
affected	O	O
sibs	O	O
(	O	O
89	O	O
.	O	O

6	O	O
,	O	O
SD	O	O
13	O	O
.	O	O

2	O	O
)	O	O
and	O	O
their	O	O
normal	O	O
sibs	O	O
(	O	O
100	O	O
.	O	O

2	O	O
,	O	O
SD	O	O
7	O	O
.	O	O

6	O	O
)	O	O
.	O	O

IQ	O	O
steadily	O	O
declined	O	O
as	O	O
(	O	O
1	O	O
)	O	O
the	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
signs	O	O
and	O	O
symptoms	O	O
decreased	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
CTG	O	O
expansion	O	O
size	O	O
increased	O	O
.	O	O

The	O	O
correlation	O	O
appeared	O	O
to	O	O
be	O	O
more	O	O
linear	O	O
with	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

The	O	O
correlation	O	O
of	O	O
IQ	O	O
difference	O	O
and	O	O
CTG	O	O
expansion	O	O
difference	O	O
in	O	O
both	O	O
the	O	O
DM	B-Disease	D009223
parent	O	O
-	O	O
child	O	O
pairs	O	O
and	O	O
normal	O	O
sib	O	O
-	O	O
affected	O	O
sib	O	O
pairs	O	O
was	O	O
poor	O	O
,	O	O
indicating	O	O
that	O	O
CTG	O	O
expansion	O	O
is	O	O
not	O	O
a	O	O
reliable	O	O
predictor	O	O
of	O	O
IQ	O	O
either	O	O
in	O	O
individual	O	O
persons	O	O
or	O	O
families	O	O
.	O	O

Further	O	O
analysis	O	O
of	O	O
cognitive	O	O
function	O	O
in	O	O
DM	B-Disease	D009223
is	O	O
required	O	O
to	O	O
clarify	O	O
specific	O	O
deficits	O	O
characteristic	O	O
of	O	O
this	O	O
patient	O	O
group	O	O
Complement	B-Disease	OMIM:217000
factor	I-Disease	OMIM:217000
2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
:	O	O
a	O	O
clinical	O	O
and	O	O
serological	O	O
family	O	O
study	O	O
.	O	O

Inherited	B-Disease	D007153
complement	I-Disease	D007153
deficiencies	I-Disease	D007153
are	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
connective	O	O
tissue	O	O
diseases	O	O
.	O	O

A	O	O
family	O	O
with	O	O
inherited	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
of	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
factor	I-Disease	OMIM:217000
2	I-Disease	OMIM:217000
(	O	O
C2	O	O
)	O	O
is	O	O
described	O	O
in	O	O
which	O	O
two	O	O
family	O	O
members	O	O
with	O	O
homozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
developed	O	O
cutaneous	B-Disease	D018366
vasculitis	I-Disease	D018366
and	O	O
sicca	B-Disease	D012859
syndrome	I-Disease	D012859
.	O	O

The	O	O
other	O	O
family	O	O
members	O	O
had	O	O
heterozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
and	O	O
each	O	O
member	O	O
had	O	O
the	O	O
HLA	O	O
-	O	O
A25	O	O
,	O	O
B18	O	O
,	O	O
DR2	O	O
(	O	O
w15	O	O
)	O	O
haplotype	O	O
.	O	O

The	O	O
mother	O	O
had	O	O
seropositive	B-Disease	D001172
rheumatoid	I-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

Further	O	O
studies	O	O
showed	O	O
the	O	O
presence	O	O
of	O	O
cryoglobulins	O	O
,	O	O
antibodies	O	O
against	O	O
endothelial	O	O
cells	O	O
,	O	O
and	O	O
anticardiolipin	O	O
antibodies	O	O
.	O	O

.	O	O

Oncogenic	O	O
point	O	O
mutations	O	O
in	O	O
exon	O	O
20	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
in	O	O
families	O	O
showing	O	O
incomplete	O	O
penetrance	O	O
and	O	O
mild	O	O
expression	O	O
of	O	O
the	O	O
retinoblastoma	B-Disease	D012175
phenotype	O	O
.	O	O

The	O	O
retinoblastoma	B-Disease	D012175
-	O	O
predisposition	O	O
gene	O	O
,	O	O
RB1	O	O
,	O	O
segregates	O	O
as	O	O
an	O	O
autosomal	O	O
dominant	O	O
trait	O	O
with	O	O
high	O	O
(	O	O
90	O	O
%	O	O
)	O	O
penetrance	O	O
.	O	O

Certain	O	O
families	O	O
,	O	O
however	O	O
,	O	O
show	O	O
an	O	O
unusual	O	O
low	O	O
-	O	O
penetrance	O	O
phenotype	O	O
with	O	O
many	O	O
individuals	O	O
being	O	O
unaffected	O	O
,	O	O
unilaterally	O	O
affected	O	O
,	O	O
or	O	O
with	O	O
evidence	O	O
of	O	O
spontaneously	O	O
regressed	O	O
tumors	B-Disease	D009369
.	O	O

We	O	O
have	O	O
used	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
and	O	O
PCR	O	O
sequencing	O	O
to	O	O
study	O	O
two	O	O
such	O	O
families	O	O
.	O	O

Mutations	O	O
were	O	O
found	O	O
in	O	O
exon	O	O
20	O	O
of	O	O
RB1	O	O
in	O	O
both	O	O
cases	O	O
.	O	O

In	O	O
one	O	O
family	O	O
a	O	O
C	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
transition	O	O
in	O	O
codon	O	O
661	O	O
converts	O	O
an	O	O
arginine	O	O
(	O	O
CGG	O	O
)	O	O
to	O	O
a	O	O
tryptophan	O	O
(	O	O
TGG	O	O
)	O	O
codon	O	O
.	O	O

In	O	O
this	O	O
family	O	O
,	O	O
incomplete	O	O
penetrance	O	O
and	O	O
mild	O	O
phenotypic	O	O
expression	O	O
were	O	O
observed	O	O
in	O	O
virtually	O	O
all	O	O
patients	O	O
,	O	O
possibly	O	O
indicating	O	O
that	O	O
single	O	O
amino	O	O
acid	O	O
changes	O	O
may	O	O
modify	O	O
protein	O	O
structure	O	O
/	O	O
function	O	O
such	O	O
that	O	O
tumorigenesis	O	O
is	O	O
not	O	O
inevitable	O	O
.	O	O

In	O	O
the	O	O
second	O	O
family	O	O
the	O	O
mutation	O	O
in	O	O
codon	O	O
675	O	O
is	O	O
a	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
transversion	O	O
that	O	O
converts	O	O
a	O	O
glutamine	O	O
(	O	O
GAA	O	O
)	O	O
to	O	O
a	O	O
stop	O	O
(	O	O
TAA	O	O
)	O	O
codon	O	O
.	O	O

However	O	O
,	O	O
this	O	O
mutation	O	O
also	O	O
occurs	O	O
near	O	O
a	O	O
potential	O	O
cryptic	O	O
splice	O	O
acceptor	O	O
site	O	O
,	O	O
raising	O	O
the	O	O
possibility	O	O
of	O	O
alternative	O	O
splicing	O	O
resulting	O	O
in	O	O
a	O	O
less	O	O
severely	O	O
disrupted	O	O
protein	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
R21X	O	O
mutation	O	O
in	O	O
the	O	O
liver	O	O
-	O	O
type	O	O
arginase	O	O
gene	O	O
(	O	O
ARG1	O	O
)	O	O
in	O	O
four	O	O
Portuguese	O	O
patients	O	O
with	O	O
argininemia	B-Disease	D020162
.	O	O

Argininemia	B-Disease	D020162
is	O	O
a	O	O
rare	O	O
autossomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
deficiency	B-Disease	D020162
in	I-Disease	D020162
the	I-Disease	D020162
cytosolic	I-Disease	D020162
liver	I-Disease	D020162
-	I-Disease	D020162
type	I-Disease	D020162
arginase	I-Disease	D020162
enzyme	I-Disease	D020162
(	O	O
L	O	O
-	O	O
arginine	O	O
urea	O	O
-	O	O
hydrolase	O	O
;	O	O
E	O	O
.	O	O

C	O	O
.	O	O

3	O	O
.	O	O

5	O	O
.	O	O

3	O	O
.	O	O

1	O	O
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
molecular	O	O
basis	O	O
for	O	O
argininemia	B-Disease	D020162
in	O	O
four	O	O
unrelated	O	O
Portuguese	O	O
patients	O	O
(	O	O
two	O	O
from	O	O
northern	O	O
Portugal	O	O
and	O	O
two	O	O
from	O	O
Madeira	O	O
Island	O	O
)	O	O
we	O	O
performed	O	O
a	O	O
DNA	O	O
sequence	O	O
analysis	O	O
of	O	O
all	O	O
the	O	O
exons	O	O
and	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
of	O	O
the	O	O
liver	O	O
-	O	O
type	O	O
arginase	O	O
gene	O	O
(	O	O
ARG1	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
a	O	O
newly	O	O
identified	O	O
C	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
in	O	O
codon	O	O
21	O	O
(	O	O
exon	O	O
2	O	O
)	O	O
substituting	O	O
arginine	O	O
for	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
(	O	O
R21X	O	O
CGA	O	O
to	O	O
TGA	O	O
)	O	O
and	O	O
generating	O	O
a	O	O
NlaIII	O	O
restriction	O	O
site	O	O
.	O	O

Restriction	O	O
digestion	O	O
following	O	O
PCR	O	O
amplification	O	O
of	O	O
ARG1	O	O
exon	O	O
2	O	O
confirmed	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
mutation	O	O
.	O	O

A	O	O
mutation	O	O
in	O	O
the	O	O
pleckstrin	O	O
homology	O	O
(	O	O
PH	O	O
)	O	O
domain	O	O
of	O	O
the	O	O
FGD1	O	O
gene	O	O
in	O	O
an	O	O
Italian	O	O
family	O	O
with	O	O
faciogenital	B-Disease	C535331
dysplasia	I-Disease	C535331
(	O	O
Aarskog	B-Disease	C535331
-	I-Disease	C535331
Scott	I-Disease	C535331
syndrome	I-Disease	C535331
)	O	O
.	O	O

Aarskog	B-Disease	C535331
-	I-Disease	C535331
Scott	I-Disease	C535331
Syndrome	I-Disease	C535331
(	O	O
AAS	B-Disease	C535331
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disorder	I-Disease	D040181
characterised	O	O
by	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
and	O	O
multiple	O	O
facial	B-Disease	D019465
,	I-Disease	D019465
limb	I-Disease	D019465
and	I-Disease	D019465
genital	I-Disease	D019465
abnormalities	I-Disease	D019465
.	O	O

A	O	O
gene	O	O
,	O	O
FGD1	O	O
,	O	O
altered	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
AAS	B-Disease	C535331
phenotype	O	O
,	O	O
has	O	O
been	O	O
identified	O	O
and	O	O
found	O	O
to	O	O
encode	O	O
a	O	O
protein	O	O
with	O	O
homology	O	O
to	O	O
Rho	O	O
/	O	O
Rac	O	O
guanine	O	O
nucleotide	O	O
exchange	O	O
factors	O	O
(	O	O
Rho	O	O
/	O	O
Rac	O	O
GEF	O	O
)	O	O
.	O	O

However	O	O
,	O	O
since	O	O
this	O	O
original	O	O
report	O	O
on	O	O
identification	O	O
of	O	O
a	O	O
mutated	O	O
FGD1	O	O
gene	O	O
in	O	O
an	O	O
AAS	B-Disease	C535331
patient	O	O
,	O	O
no	O	O
additional	O	O
mutations	O	O
in	O	O
the	O	O
FGD1	O	O
gene	O	O
have	O	O
been	O	O
described	O	O
.	O	O

We	O	O
analysed	O	O
13	O	O
independent	O	O
patients	O	O
with	O	O
clinical	O	O
diagnosis	O	O
of	O	O
AAS	B-Disease	C535331
.	O	O

One	O	O
patient	O	O
presented	O	O
a	O	O
mutation	O	O
that	O	O
results	O	O
in	O	O
a	O	O
nucleotide	O	O
change	O	O
in	O	O
exon	O	O
10	O	O
of	O	O
the	O	O
FGD1	O	O
gene	O	O
(	O	O
G2559	O	O
>	O	O
A	O	O
)	O	O
substituting	O	O
a	O	O
Gln	O	O
for	O	O
Arg	O	O
in	O	O
position	O	O
610	O	O
.	O	O

The	O	O
mutation	O	O
was	O	O
found	O	O
to	O	O
segregate	O	O
with	O	O
the	O	O
AAS	B-Disease	C535331
phenotype	O	O
in	O	O
affected	O	O
males	O	O
and	O	O
carrier	O	O
females	O	O
in	O	O
the	O	O
family	O	O
of	O	O
this	O	O
patient	O	O
.	O	O

Interestingly	O	O
,	O	O
Arg	O	O
-	O	O
610	O	O
is	O	O
located	O	O
within	O	O
one	O	O
of	O	O
the	O	O
two	O	O
pleckstrin	O	O
homology	O	O
(	O	O
PH	O	O
)	O	O
domains	O	O
of	O	O
the	O	O
FGD1	O	O
gene	O	O
and	O	O
it	O	O
corresponds	O	O
to	O	O
a	O	O
highly	O	O
conserved	O	O
residue	O	O
which	O	O
has	O	O
been	O	O
involved	O	O
in	O	O
InsP	O	O
binding	O	O
in	O	O
PH	O	O
domains	O	O
of	O	O
other	O	O
proteins	O	O
.	O	O

The	O	O
same	O	O
residue	O	O
is	O	O
often	O	O
mutated	O	O
in	O	O
the	O	O
Brutons	O	O
tyrosine	O	O
kinase	O	O
(	O	O
Btk	O	O
)	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
an	O	O
X	B-Disease	OMIM:300755
-	I-Disease	OMIM:300755
linked	I-Disease	OMIM:300755
agammaglobulinemia	I-Disease	OMIM:300755
.	O	O

The	O	O
Arg610Gln	O	O
mutation	O	O
represents	O	O
the	O	O
first	O	O
case	O	O
of	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
PH	O	O
domain	O	O
of	O	O
the	O	O
FGD1	O	O
gene	O	O
and	O	O
additional	O	O
evidence	O	O
that	O	O
mutations	O	O
in	O	O
PH	O	O
domains	O	O
can	O	O
be	O	O
associated	O	O
to	O	O
human	O	O
diseases	O	O
.	O	O

.	O	O

Localization	O	O
of	O	O
histidase	O	O
to	O	O
human	O	O
chromosome	O	O
region	O	O
12q22	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q24	O	O
.	O	O

1	O	O
and	O	O
mouse	O	O
chromosome	O	O
region	O	O
10C2	O	O
-	O	O
-	O	O
-	O	O
-	O	O
D1	O	O
.	O	O

The	O	O
human	O	O
gene	O	O
for	O	O
histidase	O	O
(	O	O
histidine	O	O
ammonia	O	O
-	O	O
lyase	O	O
;	O	O
HAL	O	O
)	O	O
,	O	O
the	O	O
enzyme	O	O
deficient	O	O
in	O	O
histidinemia	B-Disease	C538320
,	O	O
was	O	O
assigned	O	O
to	O	O
human	O	O
chromosome	O	O
12	O	O
by	O	O
Southern	O	O
blot	O	O
analysis	O	O
of	O	O
human	O	O
X	O	O
mouse	O	O
somatic	O	O
cell	O	O
hybrid	O	O
DNA	O	O
.	O	O

The	O	O
gene	O	O
was	O	O
sublocalized	O	O
to	O	O
region	O	O
12q22	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q24	O	O
.	O	O

1	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
using	O	O
a	O	O
human	O	O
histidase	O	O
cDNA	O	O
.	O	O

The	O	O
homologous	O	O
locus	O	O
in	O	O
the	O	O
mouse	O	O
(	O	O
Hal	O	O
)	O	O
was	O	O
mapped	O	O
to	O	O
region	O	O
10C2	O	O
-	O	O
-	O	O
-	O	O
-	O	O
D1	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
using	O	O
a	O	O
cell	O	O
line	O	O
from	O	O
a	O	O
mouse	O	O
homozygous	O	O
for	O	O
a	O	O
1	O	O
.	O	O

10	O	O
Robertsonian	O	O
translocation	O	O
.	O	O

These	O	O
assignments	O	O
extend	O	O
the	O	O
conserved	O	O
syntenic	O	O
region	O	O
between	O	O
human	O	O
chromosome	O	O
12	O	O
and	O	O
mouse	O	O
chromosome	O	O
10	O	O
that	O	O
includes	O	O
the	O	O
genes	O	O
for	O	O
phenylalanine	O	O
hydroxylase	O	O
,	O	O
gamma	O	O
interferon	O	O
,	O	O
peptidase	O	O
,	O	O
and	O	O
citrate	O	O
synthase	O	O
.	O	O

The	O	O
localization	O	O
of	O	O
histidase	O	O
to	O	O
mouse	O	O
chromosome	O	O
10	O	O
suggests	O	O
that	O	O
the	O	O
histidase	O	O
regulatory	O	O
locus	O	O
(	O	O
Hsd	O	O
)	O	O
and	O	O
the	O	O
histidinemia	B-Disease	C538320
mutation	O	O
(	O	O
his	O	O
)	O	O
,	O	O
which	O	O
are	O	O
both	O	O
known	O	O
to	O	O
be	O	O
on	O	O
chromosome	O	O
10	O	O
,	O	O
may	O	O
be	O	O
alleles	O	O
of	O	O
the	O	O
histidase	O	O
structural	O	O
gene	O	O
locus	O	O
.	O	O

Noninvasive	O	O
test	O	O
for	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
using	O	O
hair	O	O
root	O	O
analysis	O	O
.	O	O

Identification	O	O
of	O	O
the	O	O
FMR1	O	O
gene	O	O
and	O	O
the	O	O
repeat	O	O
-	O	O
amplification	O	O
mechanism	O	O
causing	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
led	O	O
to	O	O
development	O	O
of	O	O
reliable	O	O
DNA	O	O
-	O	O
based	O	O
diagnostic	O	O
methods	O	O
,	O	O
including	O	O
Southern	O	O
blot	O	O
hybridization	O	O
and	O	O
PCR	O	O
.	O	O

Both	O	O
methods	O	O
are	O	O
performed	O	O
on	O	O
DNA	O	O
isolated	O	O
from	O	O
peripheral	O	O
blood	O	O
cells	O	O
and	O	O
measure	O	O
the	O	O
repeat	O	O
size	O	O
in	O	O
FMR1	O	O
.	O	O

Using	O	O
an	O	O
immunocytochemical	O	O
technique	O	O
on	O	O
blood	O	O
smears	O	O
,	O	O
we	O	O
recently	O	O
developed	O	O
a	O	O
novel	O	O
test	O	O
for	O	O
identification	O	O
of	O	O
patients	O	O
with	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
.	O	O

This	O	O
method	O	O
,	O	O
also	O	O
called	O	O
"	O	O
antibody	O	O
test	O	O
,	O	O
"	O	O
uses	O	O
monoclonal	O	O
antibodies	O	O
against	O	O
the	O	O
FMR1	O	O
gene	O	O
product	O	O
(	O	O
FMRP	O	O
)	O	O
and	O	O
is	O	O
based	O	O
on	O	O
absence	O	O
of	O	O
FMRP	O	O
in	O	O
patients	O	O
cells	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
a	O	O
new	O	O
diagnostic	O	O
test	O	O
to	O	O
identify	O	O
male	O	O
patients	O	O
with	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
lack	O	O
of	O	O
FMRP	O	O
in	O	O
their	O	O
hair	O	O
roots	O	O
.	O	O

Expression	O	O
of	O	O
FMRP	O	O
in	O	O
hair	O	O
roots	O	O
was	O	O
studied	O	O
by	O	O
use	O	O
of	O	O
an	O	O
FMRP	O	O
-	O	O
specific	O	O
antibody	O	O
test	O	O
,	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
FMRP	O	O
-	O	O
expressing	O	O
hair	O	O
roots	O	O
in	O	O
controls	O	O
and	O	O
in	O	O
male	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
patients	O	O
was	O	O
determined	O	O
.	O	O

Control	O	O
individuals	O	O
showed	O	O
clear	O	O
expression	O	O
of	O	O
FMRP	O	O
in	O	O
nearly	O	O
every	O	O
hair	O	O
root	O	O
,	O	O
whereas	O	O
male	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
patients	O	O
lacked	O	O
expression	O	O
of	O	O
FMRP	O	O
in	O	O
almost	O	O
all	O	O
their	O	O
hair	O	O
roots	O	O
.	O	O

Mentally	B-Disease	D008607
retarded	I-Disease	D008607
female	O	O
patients	O	O
with	O	O
a	O	O
full	O	O
mutation	O	O
showed	O	O
FMRP	O	O
expression	O	O
in	O	O
only	O	O
some	O	O
of	O	O
their	O	O
hair	O	O
roots	O	O
(	O	O
<	O	O
55	O	O
%	O	O
)	O	O
,	O	O
and	O	O
no	O	O
overlap	O	O
with	O	O
normal	O	O
female	O	O
controls	O	O
was	O	O
observed	O	O
.	O	O

The	O	O
advantages	O	O
of	O	O
this	O	O
test	O	O
are	O	O
(	O	O
1	O	O
)	O	O
plucking	O	O
of	O	O
hair	O	O
follicles	O	O
does	O	O
no	O	O
appreciable	O	O
harm	O	O
to	O	O
the	O	O
mentally	B-Disease	D008607
retarded	I-Disease	D008607
patient	O	O
,	O	O
(	O	O
2	O	O
)	O	O
hairs	O	O
can	O	O
be	O	O
sent	O	O
in	O	O
a	O	O
simple	O	O
envelope	O	O
to	O	O
a	O	O
diagnostic	O	O
center	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
result	O	O
of	O	O
the	O	O
test	O	O
is	O	O
available	O	O
within	O	O
5	O	O
h	O	O
of	O	O
plucking	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
this	O	O
test	O	O
enabled	O	O
us	O	O
to	O	O
identify	O	O
two	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
patients	O	O
who	O	O
did	O	O
not	O	O
show	O	O
the	O	O
full	O	O
mutation	O	O
by	O	O
analysis	O	O
of	O	O
DNA	O	O
isolated	O	O
from	O	O
blood	O	O
cells	O	O
.	O	O

.	O	O

Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
:	O	O
detection	O	O
of	O	O
mutations	O	O
Thr181	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Pro	O	O
and	O	O
Leu223	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Pro	O	O
in	O	O
the	O	O
proteolipid	O	O
protein	O	O
gene	O	O
,	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
.	O	O

A	O	O
family	O	O
with	O	O
an	O	O
apparent	O	O
history	O	O
of	O	O
X	O	O
-	O	O
linked	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
presented	O	O
for	O	O
genetic	O	O
counseling	O	O
,	O	O
requesting	O	O
carrier	O	O
detection	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
.	O	O

RFLP	O	O
analysis	O	O
using	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
probe	O	O
was	O	O
uninformative	O	O
in	O	O
this	O	O
family	O	O
.	O	O

A	O	O
prenatal	O	O
diagnosis	O	O
on	O	O
a	O	O
chorionic	O	O
villus	O	O
sample	O	O
(	O	O
CVS	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
of	O	O
a	O	O
variant	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
.	O	O

The	O	O
fetus	O	O
was	O	O
predicted	O	O
to	O	O
be	O	O
unaffected	O	O
.	O	O

Sequencing	O	O
of	O	O
the	O	O
exon	O	O
from	O	O
the	O	O
CVS	O	O
,	O	O
the	O	O
predicted	O	O
-	O	O
carrier	O	O
mother	O	O
,	O	O
and	O	O
the	O	O
obligate	O	O
-	O	O
carrier	O	O
grandmother	O	O
revealed	O	O
an	O	O
A	O	O
-	O	O
to	O	O
-	O	O
C	O	O
change	O	O
at	O	O
nucleotide	O	O
541	O	O
in	O	O
the	O	O
two	O	O
women	O	O
but	O	O
not	O	O
in	O	O
the	O	O
fetus	O	O
.	O	O

As	O	O
this	O	O
change	O	O
results	O	O
in	O	O
a	O	O
Thr	O	O
-	O	O
to	O	O
-	O	O
Pro	O	O
change	O	O
at	O	O
amino	O	O
acid	O	O
181	O	O
in	O	O
a	O	O
region	O	O
of	O	O
the	O	O
gene	O	O
predicted	O	O
to	O	O
be	O	O
part	O	O
of	O	O
a	O	O
transmembrane	O	O
segment	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
this	O	O
was	O	O
the	O	O
mutation	O	O
causing	O	O
the	O	O
disease	O	O
in	O	O
this	O	O
family	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
in	O	O
a	O	O
second	O	O
family	O	O
,	O	O
an	O	O
exon	O	O
5	O	O
variant	O	O
band	O	O
pattern	O	O
on	O	O
SSCP	O	O
analysis	O	O
was	O	O
shown	O	O
by	O	O
sequencing	O	O
to	O	O
be	O	O
due	O	O
to	O	O
a	O	O
T	O	O
-	O	O
to	O	O
-	O	O
C	O	O
change	O	O
at	O	O
nucleotide	O	O
668	O	O
.	O	O

This	O	O
results	O	O
in	O	O
a	O	O
Leu	O	O
-	O	O
to	O	O
-	O	O
Pro	O	O
change	O	O
in	O	O
a	O	O
carrier	O	O
mother	O	O
and	O	O
in	O	O
her	O	O
two	O	O
affected	O	O
sons	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
further	O	O
examples	O	O
of	O	O
mutations	O	O
in	O	O
PLP	O	O
that	O	O
cause	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
and	O	O
illustrate	O	O
the	O	O
value	O	O
of	O	O
SSCP	O	O
in	O	O
genetic	O	O
analysis	O	O
.	O	O

.	O	O

A	O	O
normal	O	O
male	O	O
with	O	O
an	O	O
inherited	O	O
deletion	O	O
of	O	O
one	O	O
exon	O	O
within	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

We	O	O
describe	O	O
two	O	O
brothers	O	O
with	O	O
identical	O	O
inherited	O	O
deletions	O	O
of	O	O
one	O	O
single	O	O
exon	O	O
within	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
;	O	O
one	O	O
brother	O	O
has	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
diagnosed	O	O
at	O	O
11	O	O
years	O	O
of	O	O
age	O	O
,	O	O
whereas	O	O
the	O	O
older	O	O
brother	O	O
is	O	O
normal	O	O
at	O	O
18	O	O
.	O	O

These	O	O
results	O	O
have	O	O
implications	O	O
for	O	O
genetic	O	O
counselling	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
in	O	O
families	O	O
with	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
.	O	O

.	O	O

Small	O	O
deletions	O	O
in	O	O
the	O	O
type	O	O
II	O	O
collagen	O	O
triple	O	O
helix	O	O
produce	O	O
kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
.	O	O

Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
is	O	O
a	O	O
moderately	O	O
severe	O	O
type	B-Disease	C535964
II	I-Disease	C535964
collagenopathy	I-Disease	C535964
,	O	O
characterized	O	O
by	O	O
short	O	O
trunk	O	O
and	O	O
limbs	O	O
,	O	O
kyphoscoliosis	B-Disease	OMIM:610170
,	O	O
midface	B-Disease	OMIM:300194
hypoplasia	I-Disease	OMIM:300194
,	O	O
severe	O	O
myopia	B-Disease	D009216
,	O	O
and	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Mutations	O	O
in	O	O
the	O	O
gene	O	O
that	O	O
encodes	O	O
type	O	O
II	O	O
collagen	O	O
(	O	O
COL2A1	O	O
)	O	O
,	O	O
the	O	O
predominant	O	O
protein	O	O
of	O	O
cartilage	O	O
,	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
a	O	O
number	O	O
of	O	O
individuals	O	O
with	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
.	O	O

All	O	O
but	O	O
two	O	O
of	O	O
these	O	O
previously	O	O
described	O	O
mutations	O	O
cause	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
in	O	O
type	O	O
II	O	O
collagen	O	O
,	O	O
either	O	O
by	O	O
small	O	O
deletions	O	O
in	O	O
the	O	O
gene	O	O
or	O	O
splice	O	O
site	O	O
alterations	O	O
.	O	O

Furthermore	O	O
,	O	O
all	O	O
but	O	O
one	O	O
of	O	O
these	O	O
mutations	O	O
is	O	O
located	O	O
between	O	O
exons	O	O
12	O	O
and	O	O
24	O	O
in	O	O
the	O	O
COL2A1	O	O
gene	O	O
.	O	O

We	O	O
used	O	O
heteroduplex	O	O
analysis	O	O
to	O	O
identify	O	O
sequence	O	O
anomalies	O	O
in	O	O
five	O	O
individuals	O	O
with	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
.	O	O

Sequencing	O	O
of	O	O
the	O	O
index	O	O
patients	O	O
genomic	O	O
DNA	O	O
identified	O	O
four	O	O
new	O	O
dominant	O	O
mutations	O	O
in	O	O
COL2A1	O	O
that	O	O
result	O	O
in	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
a	O	O
21	O	O
-	O	O
bp	O	O
deletion	O	O
in	O	O
exon	O	O
16	O	O
,	O	O
an	O	O
18	O	O
-	O	O
bp	O	O
deletion	O	O
in	O	O
exon	O	O
19	O	O
,	O	O
and	O	O
4	O	O
-	O	O
bp	O	O
deletions	O	O
in	O	O
the	O	O
splice	O	O
donor	O	O
sites	O	O
of	O	O
introns	O	O
14	O	O
and	O	O
20	O	O
.	O	O

A	O	O
previously	O	O
described	O	O
28	O	O
-	O	O
bp	O	O
deletion	O	O
at	O	O
the	O	O
COL2A1	O	O
exon	O	O
12	O	O
-	O	O
intron	O	O
12	O	O
junction	O	O
,	O	O
deleting	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
,	O	O
was	O	O
identified	O	O
in	O	O
the	O	O
fifth	O	O
case	O	O
.	O	O

The	O	O
latter	O	O
three	O	O
mutations	O	O
are	O	O
predicted	O	O
to	O	O
result	O	O
in	O	O
exon	O	O
skipping	O	O
in	O	O
the	O	O
mRNA	O	O
encoded	O	O
from	O	O
the	O	O
mutant	O	O
allele	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
results	O	O
from	O	O
shorter	O	O
type	O	O
II	O	O
collagen	O	O
monomers	O	O
,	O	O
and	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
alteration	O	O
of	O	O
a	O	O
specific	O	O
COL2A1	O	O
domain	O	O
,	O	O
which	O	O
may	O	O
span	O	O
from	O	O
exons	O	O
12	O	O
to	O	O
24	O	O
,	O	O
leads	O	O
to	O	O
the	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
phenotype	O	O
.	O	O

.	O	O

Adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
and	O	O
a	O	O
cytogenetic	O	O
deletion	O	O
of	O	O
chromosome	O	O
5	O	O
resulting	O	O
from	O	O
a	O	O
maternal	O	O
intrachromosomal	O	O
insertion	O	O
.	O	O

We	O	O
present	O	O
the	O	O
clinical	O	O
and	O	O
laboratory	O	O
findings	O	O
in	O	O
an	O	O
institutionalised	O	O
adult	O	O
patient	O	O
originally	O	O
referred	O	O
for	O	O
autism	B-Disease	D001321
.	O	O

A	O	O
high	O	O
risk	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
was	O	O
predicted	O	O
when	O	O
an	O	O
interstitial	O	O
deletion	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
5	O	O
,	O	O
del	O	O
(	O	O
5	O	O
)	O	O
(	O	O
q15q22	O	O
.	O	O

3	O	O
)	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
her	O	O
lymphocytes	O	O
and	O	O
deletion	O	O
of	O	O
the	O	O
MCC	O	O
and	O	O
APC	B-Disease	D011125
genes	O	O
confirmed	O	O
by	O	O
molecular	O	O
analysis	O	O
.	O	O

Adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
and	O	O
carcinoma	B-Disease	D012004
of	I-Disease	D012004
the	I-Disease	D012004
rectum	I-Disease	D012004
were	O	O
subsequently	O	O
diagnosed	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

She	O	O
was	O	O
profoundly	O	O
mentally	B-Disease	D008607
retarded	I-Disease	D008607
,	O	O
autistic	B-Disease	D001321
,	O	O
and	O	O
had	O	O
minor	O	O
dysmorphic	B-Disease	D000013
features	I-Disease	D000013
consistent	O	O
with	O	O
those	O	O
of	O	O
previous	O	O
patients	O	O
with	O	O
similar	O	O
deletions	O	O
.	O	O

The	O	O
deletion	O	O
arose	O	O
as	O	O
a	O	O
result	O	O
of	O	O
recombination	O	O
within	O	O
the	O	O
small	O	O
insertion	O	O
loop	O	O
formed	O	O
at	O	O
meiosis	O	O
by	O	O
the	O	O
direct	O	O
insertion	O	O
(	O	O
dir	O	O
ins	O	O
(	O	O
5	O	O
)	O	O
(	O	O
q22	O	O
.	O	O

3q14	O	O
.	O	O

2q15	O	O
)	O	O
)	O	O
found	O	O
in	O	O
the	O	O
patients	O	O
mother	O	O
.	O	O

This	O	O
family	O	O
further	O	O
confirms	O	O
the	O	O
cytogenetic	O	O
mapping	O	O
of	O	O
both	O	O
MCC	O	O
and	O	O
APC	B-Disease	D011125
genes	O	O
to	O	O
5q22	O	O
and	O	O
comparison	O	O
with	O	O
other	O	O
recent	O	O
cases	O	O
suggests	O	O
that	O	O
both	O	O
genes	O	O
and	O	O
their	O	O
closely	O	O
linked	O	O
markers	O	O
lie	O	O
within	O	O
the	O	O
5q22	O	O
.	O	O

1	O	O
subband	O	O
Somatic	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
:	O	O
mutation	O	O
cluster	O	O
region	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

We	O	O
examined	O	O
somatic	O	O
mutations	O	O
of	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
in	O	O
63	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
(	O	O
16	O	O
adenomas	B-Disease	D000236
and	O	O
47	O	O
carcinomas	B-Disease	D009369
)	O	O
developed	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
and	O	O
non	O	O
-	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
loss	O	O
of	O	O
heterozygosity	O	O
(	O	O
LOH	O	O
)	O	O
at	O	O
the	O	O
APC	B-Disease	D011125
locus	O	O
in	O	O
30	O	O
tumors	B-Disease	D009369
,	O	O
43	O	O
other	O	O
somatic	O	O
mutations	O	O
were	O	O
detected	O	O
.	O	O

Twenty	O	O
-	O	O
one	O	O
of	O	O
them	O	O
were	O	O
point	O	O
mutations	O	O
;	O	O
16	O	O
nonsense	O	O
and	O	O
two	O	O
missense	O	O
mutations	O	O
,	O	O
and	O	O
three	O	O
occurred	O	O
in	O	O
introns	O	O
at	O	O
the	O	O
splicing	O	O
site	O	O
.	O	O

Twenty	O	O
-	O	O
two	O	O
tumors	B-Disease	D009369
had	O	O
frameshift	O	O
mutations	O	O
due	O	O
to	O	O
deletion	O	O
or	O	O
insertion	O	O
;	O	O
nineteen	O	O
of	O	O
them	O	O
were	O	O
deletions	O	O
of	O	O
one	O	O
to	O	O
31	O	O
bp	O	O
and	O	O
three	O	O
were	O	O
a	O	O
1	O	O
-	O	O
bp	O	O
insertion	O	O
.	O	O

One	O	O
tumor	B-Disease	D009369
had	O	O
a	O	O
1	O	O
-	O	O
bp	O	O
deletion	O	O
in	O	O
an	O	O
intron	O	O
near	O	O
the	O	O
splicing	O	O
site	O	O
.	O	O

Hence	O	O
,	O	O
41	O	O
(	O	O
95	O	O
%	O	O
)	O	O
of	O	O
43	O	O
mutations	O	O
resulted	O	O
in	O	O
truncation	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
protein	O	O
.	O	O

Over	O	O
60	O	O
%	O	O
of	O	O
the	O	O
somatic	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
were	O	O
clustered	O	O
within	O	O
a	O	O
small	O	O
region	O	O
of	O	O
exon	O	O
15	O	O
,	O	O
designated	O	O
as	O	O
MCR	O	O
(	O	O
mutation	O	O
cluster	O	O
region	O	O
)	O	O
,	O	O
which	O	O
accounted	O	O
for	O	O
less	O	O
than	O	O
10	O	O
%	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
.	O	O

Combining	O	O
these	O	O
data	O	O
and	O	O
the	O	O
results	O	O
of	O	O
LOH	O	O
,	O	O
more	O	O
than	O	O
80	O	O
%	O	O
of	O	O
tumors	B-Disease	D009369
(	O	O
14	O	O
adenomas	B-Disease	D000236
and	O	O
39	O	O
carcinomas	B-Disease	D009369
)	O	O
had	O	O
at	O	O
least	O	O
one	O	O
mutation	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
of	O	O
which	O	O
more	O	O
than	O	O
60	O	O
%	O	O
(	O	O
9	O	O
adenomas	B-Disease	D000236
and	O	O
23	O	O
carcinomas	B-Disease	D009369
)	O	O
had	O	O
two	O	O
mutations	O	O
.	O	O

These	O	O
results	O	O
strongly	O	O
suggest	O	O
that	O	O
somatic	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
are	O	O
associated	O	O
with	O	O
development	O	O
of	O	O
a	O	O
great	O	O
majority	O	O
of	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
.	O	O

.	O	O

Identification	O	O
of	O	O
an	O	O
altered	O	O
splice	O	O
site	O	O
in	O	O
Ashkenazi	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
.	O	O

Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
resulting	O	O
from	O	O
mutation	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
encoding	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
,	O	O
beta	O	O
-	O	O
N	O	O
-	O	O
acetylhexosaminidase	O	O
A	O	O
(	O	O
ref	O	O
.	O	O

1	O	O
)	O	O
.	O	O

A	O	O
relatively	O	O
high	O	O
frequency	O	O
of	O	O
carriers	O	O
(	O	O
1	O	O
/	O	O
27	O	O
)	O	O
of	O	O
a	O	O
lethal	O	O
,	O	O
infantile	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
is	O	O
found	O	O
in	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
population	O	O
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
yet	O	O
evident	O	O
whether	O	O
this	O	O
has	O	O
resulted	O	O
from	O	O
a	O	O
founder	O	O
effect	O	O
and	O	O
random	O	O
genetic	O	O
drift	O	O
or	O	O
from	O	O
a	O	O
selective	O	O
advantage	O	O
of	O	O
heterozygotes	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
single	O	O
-	O	O
base	O	O
mutation	O	O
in	O	O
a	O	O
cloned	O	O
fragment	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
from	O	O
an	O	O
Ashkenazi	O	O
Jewish	O	O
patient	O	O
.	O	O

This	O	O
change	O	O
,	O	O
the	O	O
substitution	O	O
of	O	O
a	O	O
C	O	O
for	O	O
G	O	O
in	O	O
the	O	O
first	O	O
nucleotide	O	O
of	O	O
intron	O	O
12	O	O
is	O	O
expected	O	O
to	O	O
result	O	O
in	O	O
defective	O	O
splicing	O	O
of	O	O
the	O	O
messenger	O	O
RNA	O	O
.	O	O

A	O	O
test	O	O
for	O	O
the	O	O
mutant	O	O
allele	O	O
based	O	O
on	O	O
amplification	O	O
of	O	O
DNA	O	O
by	O	O
the	O	O
polymerase	O	O
chain	O	O
rection	O	O
and	O	O
cleavage	O	O
of	O	O
a	O	O
DdeI	O	O
restriction	O	O
site	O	O
generated	O	O
by	O	O
the	O	O
mutation	O	O
revealed	O	O
that	O	O
this	O	O
case	O	O
and	O	O
two	O	O
other	O	O
cases	O	O
of	O	O
the	O	O
Ashkenazi	O	O
,	O	O
infantile	O	O
form	O	O
of	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
are	O	O
heterozygous	O	O
for	O	O
two	O	O
different	O	O
mutations	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
multiple	O	O
mutant	O	O
alleles	O	O
warrants	O	O
further	O	O
examination	O	O
of	O	O
the	O	O
selective	O	O
advantage	O	O
hypothesis	O	O
.	O	O

.	O	O

Coats	B-Disease	D058456
'	I-Disease	D058456
disease	I-Disease	D058456
of	O	O
the	O	O
retina	O	O
(	O	O
unilateral	B-Disease	D058456
retinal	I-Disease	D058456
telangiectasis	I-Disease	D058456
)	O	O
caused	O	O
by	O	O
somatic	O	O
mutation	O	O
in	O	O
the	O	O
NDP	O	O
gene	O	O
:	O	O
a	O	O
role	O	O
for	O	O
norrin	O	O
in	O	O
retinal	O	O
angiogenesis	O	O
.	O	O

Coats	B-Disease	D058456
disease	I-Disease	D058456
is	O	O
characterized	O	O
by	O	O
abnormal	B-Disease	D058456
retinal	I-Disease	D058456
vascular	I-Disease	D058456
development	I-Disease	D058456
(	O	O
so	O	O
-	O	O
called	O	O
retinal	B-Disease	D058456
telangiectasis	I-Disease	D058456
)	O	O
which	O	O
results	O	O
in	O	O
massive	O	O
intraretinal	B-Disease	D006949
and	I-Disease	D006949
subretinal	I-Disease	D006949
lipid	I-Disease	D006949
accumulation	I-Disease	D006949
(	O	O
exudative	B-Disease	D012163
retinal	I-Disease	D012163
detachment	I-Disease	D012163
)	O	O
.	O	O

The	O	O
classical	O	O
form	O	O
of	O	O
Coats	B-Disease	D058456
disease	I-Disease	D058456
is	O	O
almost	O	O
invariably	O	O
isolated	O	O
,	O	O
unilateral	O	O
and	O	O
seen	O	O
in	O	O
males	O	O
.	O	O

A	O	O
female	O	O
with	O	O
a	O	O
unilateral	O	O
variant	O	O
of	O	O
Coats	B-Disease	D058456
disease	I-Disease	D058456
gave	O	O
birth	O	O
to	O	O
a	O	O
son	O	O
affected	O	O
by	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
.	O	O

Both	O	O
carried	O	O
a	O	O
missense	O	O
mutation	O	O
within	O	O
the	O	O
NDP	O	O
gene	O	O
on	O	O
chromosome	O	O
Xp11	O	O
.	O	O

2	O	O
2	O	O
.	O	O

Subsequently	O	O
analysis	O	O
of	O	O
the	O	O
retinas	O	O
of	O	O
nine	O	O
enucleated	O	O
eyes	O	O
from	O	O
males	O	O
with	O	O
Coats	B-Disease	D058456
disease	I-Disease	D058456
demonstrated	O	O
in	O	O
one	O	O
a	O	O
somatic	O	O
mutation	O	O
in	O	O
the	O	O
NDP	O	O
gene	O	O
which	O	O
was	O	O
not	O	O
present	O	O
within	O	O
non	O	O
-	O	O
retinal	O	O
tissue	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
Coats	B-Disease	D058456
telangiectasis	I-Disease	D058456
is	O	O
secondary	O	O
to	O	O
somatic	O	O
mutation	O	O
in	O	O
the	O	O
NDP	O	O
gene	O	O
which	O	O
results	O	O
in	O	O
a	O	O
deficiency	B-Disease	C537849
of	I-Disease	C537849
norrin	I-Disease	C537849
(	O	O
the	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
NDP	O	O
gene	O	O
)	O	O
within	O	O
the	O	O
developing	O	O
retina	O	O
.	O	O

This	O	O
supports	O	O
recent	O	O
observations	O	O
that	O	O
the	O	O
protein	O	O
is	O	O
critical	O	O
for	O	O
normal	O	O
retinal	O	O
vasculogenesis	O	O
.	O	O

Trisomy	B-Disease	C538037
15	I-Disease	C538037
with	O	O
loss	O	O
of	O	O
the	O	O
paternal	O	O
15	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
due	O	O
to	O	O
maternal	B-Disease	D024182
disomy	I-Disease	D024182
.	O	O

Uniparental	B-Disease	D024182
disomy	I-Disease	D024182
has	O	O
recently	O	O
been	O	O
recognized	O	O
to	O	O
cause	O	O
human	O	O
disorders	O	O
,	O	O
including	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
particularly	O	O
instructive	O	O
case	O	O
which	O	O
raises	O	O
important	O	O
issues	O	O
concerning	O	O
the	O	O
mechanisms	O	O
producing	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
and	O	O
whose	O	O
evaluation	O	O
provides	O	O
evidence	O	O
that	O	O
trisomy	O	O
may	O	O
precede	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
in	O	O
a	O	O
fetus	O	O
.	O	O

Chorionic	O	O
villus	O	O
sampling	O	O
performed	O	O
for	O	O
advanced	O	O
maternal	O	O
age	O	O
revealed	O	O
trisomy	B-Disease	C538037
15	I-Disease	C538037
in	O	O
all	O	O
direct	O	O
and	O	O
cultured	O	O
cells	O	O
,	O	O
though	O	O
the	O	O
fetus	O	O
appeared	O	O
normal	O	O
.	O	O

Chromosome	O	O
analysis	O	O
of	O	O
amniocytes	O	O
obtained	O	O
at	O	O
15	O	O
wk	O	O
was	O	O
normal	O	O
in	O	O
over	O	O
100	O	O
cells	O	O
studied	O	O
.	O	O

The	O	O
child	O	O
was	O	O
hypotonic	B-Disease	D009123
at	O	O
birth	O	O
,	O	O
and	O	O
high	O	O
-	O	O
resolution	O	O
banding	O	O
failed	O	O
to	O	O
reveal	O	O
the	O	O
deletion	O	O
of	O	O
15q11	O	O
-	O	O
13	O	O
,	O	O
a	O	O
deletion	O	O
which	O	O
is	O	O
found	O	O
in	O	O
50	O	O
%	O	O
-	O	O
70	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
PWS	B-Disease	D011218
.	O	O

Over	O	O
time	O	O
,	O	O
typical	O	O
features	O	O
of	O	O
PWS	B-Disease	D011218
developed	O	O
.	O	O

Molecular	O	O
genetic	O	O
analysis	O	O
using	O	O
probes	O	O
for	O	O
chromosome	O	O
15	O	O
revealed	O	O
maternal	B-Disease	D024182
disomy	I-Disease	D024182
.	O	O

Maternal	O	O
nondisjunction	O	O
with	O	O
fertilization	O	O
of	O	O
a	O	O
disomic	O	O
egg	O	O
by	O	O
a	O	O
normal	O	O
sperm	O	O
,	O	O
followed	O	O
by	O	O
loss	O	O
of	O	O
the	O	O
paternal	O	O
15	O	O
,	O	O
is	O	O
a	O	O
likely	O	O
cause	O	O
of	O	O
confined	O	O
placental	O	O
mosaicism	O	O
and	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
in	O	O
this	O	O
case	O	O
of	O	O
PWS	B-Disease	D011218
,	O	O
and	O	O
advanced	O	O
maternal	O	O
age	O	O
may	O	O
be	O	O
a	O	O
predisposing	O	O
factor	O	O
.	O	O

.	O	O

Genetic	O	O
defect	B-Disease	OMIM:609536
in	I-Disease	OMIM:609536
secretion	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
in	O	O
mice	O	O
.	O	O

A	O	O
genetic	O	O
deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
(	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
)	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement1	I-Disease	OMIM:609536
-	I-Disease	OMIM:609536
3	I-Disease	OMIM:609536
,	O	O
a	O	O
serum	O	O
glycoprotein	O	O
of	O	O
molecular	O	O
weight	O	O
(	O	O
MW	O	O
)	O	O
220	O	O
,	O	O
000	O	O
(	O	O
ref	O	O
.	O	O

4	O	O
)	O	O
,	O	O
has	O	O
been	O	O
found	O	O
in	O	O
39	O	O
%	O	O
of	O	O
inbred	O	O
strains	O	O
of	O	O
mice3	O	O
.	O	O

Sera	O	O
of	O	O
deficient	O	O
mice	O	O
lack	O	O
detectable	O	O
C5	O	O
activity	O	O
and	O	O
protein2	O	O
,	O	O
3	O	O
.	O	O

In	O	O
addition	O	O
deficient	O	O
mice	O	O
produce	O	O
antibody	O	O
to	O	O
mouse	O	O
C5	O	O
when	O	O
injected	O	O
with	O	O
sera	O	O
from	O	O
C5	O	O
sufficient	O	O
(	O	O
normal	O	O
)	O	O
strains	O	O
.	O	O

Levy	O	O
et	O	O
al	O	O
.	O	O

5	O	O
showed	O	O
that	O	O
somatic	O	O
cell	O	O
hybrids	O	O
between	O	O
C5	O	O
deficient	O	O
(	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
old	O	O
line	O	O
)	O	O
macrophages	O	O
and	O	O
either	O	O
C5	O	O
sufficient	O	O
(	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
new	O	O
line	O	O
)	O	O
mouse	O	O
kidney	O	O
or	O	O
chicken	O	O
erythroblasts	O	O
secreted	O	O
haemolytically	O	O
active	O	O
mouse	O	O
C5	O	O
in	O	O
vitro	O	O
.	O	O

Several	O	O
possible	O	O
molecular	O	O
mechanisms	O	O
to	O	O
account	O	O
for	O	O
the	O	O
findings	O	O
were	O	O
considered	O	O
,	O	O
but	O	O
insufficient	O	O
direct	O	O
data	O	O
were	O	O
available	O	O
to	O	O
choose	O	O
among	O	O
them	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
that	O	O
mouse	O	O
(	O	O
CD	O	O
.	O	O

1	O	O
strain	O	O
)	O	O
peritoneal	O	O
cells	O	O
in	O	O
culture	O	O
synthesise	O	O
and	O	O
secrete	O	O
a	O	O
single	O	O
chain	O	O
precursor	O	O
,	O	O
pro	O	O
-	O	O
C5	O	O
(	O	O
MW	O	O
approximately	O	O
210	O	O
,	O	O
000	O	O
)	O	O
,	O	O
of	O	O
the	O	O
two	O	O
-	O	O
chain	O	O
(	O	O
alpha	O	O
chain	O	O
,	O	O
125	O	O
,	O	O
000	O	O
and	O	O
beta	O	O
chain	O	O
83	O	O
,	O	O
000	O	O
MW	O	O
)	O	O
C5	O	O
protein6	O	O
.	O	O

Radiolabelled	O	O
precursor	O	O
C5	O	O
was	O	O
contained	O	O
within	O	O
the	O	O
cells	O	O
and	O	O
was	O	O
secreted	O	O
into	O	O
the	O	O
tissue	O	O
culture	O	O
media	O	O
.	O	O

Using	O	O
similar	O	O
methods	O	O
,	O	O
we	O	O
now	O	O
find	O	O
that	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
in	O	O
each	O	O
of	O	O
five	O	O
different	O	O
mouse	O	O
strains	O	O
(	O	O
AKR	O	O
,	O	O
SWR	O	O
,	O	O
DBA	O	O
/	O	O
2J8	O	O
A	O	O
/	O	O
HeJ	O	O
and	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
old	O	O
line	O	O
)	O	O
is	O	O
due	O	O
to	O	O
a	O	O
failure	O	O
in	O	O
secretion	O	O
of	O	O
C5	O	O
protein	O	O
and	O	O
not	O	O
to	O	O
a	O	O
failure	O	O
in	O	O
biosynthesis	O	O
of	O	O
pro	O	O
-	O	O
C5	O	O
WASP	O	O
gene	O	O
mutations	O	O
in	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
and	O	O
X	B-Disease	OMIM:313900
-	I-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
.	O	O

The	O	O
WASP	O	O
gene	O	O
has	O	O
been	O	O
recently	O	O
cloned	O	O
from	O	O
Xp11	O	O
.	O	O

23	O	O
and	O	O
shown	O	O
to	O	O
be	O	O
mutated	O	O
in	O	O
three	O	O
patients	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
.	O	O

We	O	O
have	O	O
developed	O	O
a	O	O
screening	O	O
protocol	O	O
for	O	O
identifying	O	O
WASP	O	O
gene	O	O
alterations	O	O
in	O	O
genomic	O	O
DNA	O	O
and	O	O
have	O	O
identified	O	O
a	O	O
spectrum	O	O
of	O	O
novel	O	O
mutations	O	O
in	O	O
12	O	O
additional	O	O
unrelated	O	O
families	O	O
.	O	O

These	O	O
missense	O	O
,	O	O
nonsense	O	O
and	O	O
frameshift	O	O
mutations	O	O
involve	O	O
eight	O	O
of	O	O
the	O	O
12	O	O
exons	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Two	O	O
mutations	O	O
creating	O	O
premature	O	O
termination	O	O
codons	O	O
were	O	O
associated	O	O
with	O	O
lack	O	O
of	O	O
detectable	O	O
mRNA	O	O
on	O	O
Northern	O	O
blots	O	O
.	O	O

Four	O	O
amino	O	O
acid	O	O
substitutions	O	O
,	O	O
Leu27Phe	O	O
,	O	O
Thr48Ile	O	O
,	O	O
Val75Met	O	O
and	O	O
Arg477Lys	O	O
,	O	O
were	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
congenital	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
and	O	O
no	O	O
clinically	O	O
evident	O	O
immune	O	O
defect	O	O
indicating	O	O
that	O	O
the	O	O
WASP	O	O
gene	O	O
is	O	O
the	O	O
site	O	O
for	O	O
mutations	O	O
in	O	O
X	B-Disease	OMIM:313900
-	I-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
as	O	O
well	O	O
as	O	O
in	O	O
WAS	B-Disease	D014923
.	O	O

A	O	O
T	O	O
-	O	O
cell	O	O
line	O	O
from	O	O
a	O	O
WAS	B-Disease	D014923
patient	O	O
contained	O	O
two	O	O
independent	O	O
DNA	O	O
alterations	O	O
,	O	O
a	O	O
constitutional	O	O
frameshift	O	O
mutation	O	O
,	O	O
also	O	O
present	O	O
in	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
from	O	O
the	O	O
patient	O	O
,	O	O
and	O	O
compensatory	O	O
splice	O	O
site	O	O
mutation	O	O
unique	O	O
to	O	O
the	O	O
cell	O	O
line	O	O
.	O	O

The	O	O
distribution	O	O
of	O	O
eight	O	O
missense	O	O
mutations	O	O
provides	O	O
valuable	O	O
information	O	O
on	O	O
amino	O	O
acids	O	O
which	O	O
are	O	O
essential	O	O
for	O	O
normal	O	O
protein	O	O
function	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
sites	O	O
in	O	O
the	O	O
first	O	O
two	O	O
exons	O	O
are	O	O
hot	O	O
-	O	O
spots	O	O
for	O	O
mutation	O	O
.	O	O

Detection	O	O
of	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
the	O	O
dystrophin	O	O
gene	O	O
by	O	O
multiple	O	O
SSCP	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
multiplex	O	O
PCR	O	O
with	O	O
the	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
technique	O	O
was	O	O
employed	O	O
to	O	O
screen	O	O
for	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
dystrophin	O	O
gene	O	O
.	O	O

Co	O	O
-	O	O
amplification	O	O
of	O	O
11	O	O
exons	O	O
from	O	O
genomic	O	O
DNA	O	O
of	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
)	O	O
patients	O	O
with	O	O
no	O	O
deletion	O	O
or	O	O
duplication	O	O
was	O	O
performed	O	O
and	O	O
the	O	O
samples	O	O
subjected	O	O
to	O	O
multiple	O	O
SSCP	O	O
analysis	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
a	O	O
Duchenne	B-Disease	D020388
patient	O	O
identified	O	O
by	O	O
this	O	O
approach	O	O
.	O	O

The	O	O
mutation	O	O
introduces	O	O
a	O	O
termination	O	O
codon	O	O
within	O	O
exon	O	O
8	O	O
of	O	O
the	O	O
dystrophin	O	O
gene	O	O
.	O	O

It	O	O
is	O	O
predicted	O	O
to	O	O
cause	O	O
a	O	O
very	O	O
premature	O	O
translational	O	O
termination	O	O
accounting	O	O
for	O	O
the	O	O
severe	O	O
phenotype	O	O
observed	O	O
.	O	O

The	O	O
patient	O	O
inherited	O	O
this	O	O
mutation	O	O
from	O	O
his	O	O
mother	O	O
.	O	O

In	O	O
addition	O	O
the	O	O
analysis	O	O
revealed	O	O
5	O	O
polymorphisms	O	O
useful	O	O
for	O	O
internal	O	O
control	O	O
.	O	O

.	O	O

Molecular	O	O
mechanisms	O	O
of	O	O
oncogenic	O	O
mutations	O	O
in	O	O
tumors	B-Disease	D009369
from	O	O
patients	O	O
with	O	O
bilateral	B-Disease	D012175
and	I-Disease	D012175
unilateral	I-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

The	O	O
RB1	O	O
gene	O	O
from	O	O
12	O	O
human	O	O
retinoblastoma	B-Disease	D012175
tumors	I-Disease	D012175
has	O	O
been	O	O
analyzed	O	O
exon	O	O
-	O	O
by	O	O
-	O	O
exon	O	O
with	O	O
the	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
technique	O	O
.	O	O

Mutations	O	O
were	O	O
found	O	O
in	O	O
all	O	O
tumors	B-Disease	D009369
,	O	O
and	O	O
one	O	O
-	O	O
third	O	O
of	O	O
the	O	O
tumors	B-Disease	D009369
had	O	O
independent	O	O
mutations	O	O
in	O	O
both	O	O
alleles	O	O
neither	O	O
of	O	O
which	O	O
were	O	O
found	O	O
in	O	O
the	O	O
germ	O	O
line	O	O
,	O	O
confirming	O	O
their	O	O
true	O	O
sporadic	O	O
nature	O	O
.	O	O

In	O	O
the	O	O
remaining	O	O
two	O	O
-	O	O
thirds	O	O
of	O	O
the	O	O
tumors	B-Disease	D009369
only	O	O
one	O	O
mutation	O	O
was	O	O
found	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
heterozygosity	O	O
theory	O	O
of	O	O
tumorigenesis	O	O
.	O	O

Point	O	O
mutations	O	O
,	O	O
the	O	O
majority	O	O
of	O	O
which	O	O
were	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transitions	O	O
,	O	O
were	O	O
the	O	O
most	O	O
common	O	O
abnormality	O	O
and	O	O
usually	O	O
resulted	O	O
in	O	O
the	O	O
conversion	O	O
of	O	O
an	O	O
arginine	O	O
codon	O	O
to	O	O
a	O	O
stop	O	O
codon	O	O
.	O	O

Small	O	O
deletions	O	O
were	O	O
the	O	O
second	O	O
most	O	O
common	O	O
abnormality	O	O
and	O	O
most	O	O
often	O	O
created	O	O
a	O	O
downstream	O	O
stop	O	O
codon	O	O
as	O	O
the	O	O
result	O	O
of	O	O
a	O	O
reading	O	O
frameshift	O	O
.	O	O

Deletions	O	O
and	O	O
point	O	O
mutations	O	O
also	O	O
affected	O	O
splice	O	O
junctions	O	O
.	O	O

Direct	O	O
repeats	O	O
were	O	O
present	O	O
at	O	O
the	O	O
breakpoint	O	O
junctions	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
deletions	O	O
,	O	O
supporting	O	O
a	O	O
slipped	O	O
-	O	O
mispairing	O	O
mechanism	O	O
.	O	O

Point	O	O
mutations	O	O
generally	O	O
produced	O	O
DNA	O	O
sequences	O	O
which	O	O
resulted	O	O
in	O	O
perfect	O	O
homology	O	O
with	O	O
endogenous	O	O
sequences	O	O
which	O	O
lay	O	O
within	O	O
14	O	O
bp	O	O
.	O	O

.	O	O

PAX6	O	O
gene	O	O
dosage	O	O
effect	O	O
in	O	O
a	O	O
family	O	O
with	O	O
congenital	B-Disease	D002386
cataracts	I-Disease	D002386
,	O	O
aniridia	B-Disease	D015783
,	O	O
anophthalmia	B-Disease	D000853
and	O	O
central	B-Disease	D009421
nervous	I-Disease	D009421
system	I-Disease	D009421
defects	I-Disease	D009421
.	O	O

The	O	O
human	O	O
eye	O	O
malformation	O	O
aniridia	B-Disease	D015783
results	O	O
from	O	O
haploinsufficiency	B-Disease	OMIM:106210
of	I-Disease	OMIM:106210
PAX6	I-Disease	OMIM:106210
,	O	O
a	O	O
paired	O	O
box	O	O
DNA	O	O
-	O	O
binding	O	O
protein	O	O
.	O	O

To	O	O
study	O	O
this	O	O
dosage	O	O
effect	O	O
,	O	O
we	O	O
characterized	O	O
two	O	O
PAX6	O	O
mutations	O	O
in	O	O
a	O	O
family	O	O
segregating	O	O
aniridia	B-Disease	D015783
and	O	O
a	O	O
milder	O	O
syndrome	O	O
consisting	O	O
of	O	O
congenital	B-Disease	D002386
cataracts	I-Disease	D002386
and	O	O
late	O	O
onset	O	O
corneal	B-Disease	D003317
dystrophy	I-Disease	D003317
.	O	O

The	O	O
nonsense	O	O
mutations	O	O
,	O	O
at	O	O
codons	O	O
103	O	O
and	O	O
353	O	O
,	O	O
truncate	O	O
PAX6	O	O
within	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
paired	O	O
and	O	O
C	O	O
-	O	O
terminal	O	O
PST	O	O
domains	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
wild	O	O
-	O	O
type	O	O
PST	O	O
domain	O	O
activates	O	O
transcription	O	O
autonomously	O	O
and	O	O
the	O	O
mutant	O	O
form	O	O
has	O	O
partial	O	O
activity	O	O
.	O	O

A	O	O
compound	O	O
heterozygote	O	O
had	O	O
severe	O	O
craniofacial	B-Disease	D019465
and	I-Disease	D019465
central	I-Disease	D019465
nervous	I-Disease	D019465
system	I-Disease	D019465
defects	I-Disease	D019465
and	O	O
no	B-Disease	D000853
eyes	I-Disease	D000853
.	O	O

The	O	O
pattern	O	O
of	O	O
malformations	O	O
is	O	O
similar	O	O
to	O	O
that	O	O
in	O	O
homozygous	O	O
Sey	O	O
mice	O	O
and	O	O
suggests	O	O
a	O	O
critical	O	O
role	O	O
for	O	O
PAX6	O	O
in	O	O
controlling	O	O
the	O	O
migration	O	O
and	O	O
differentiation	O	O
of	O	O
specific	O	O
neuronal	O	O
progenitor	O	O
cells	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

.	O	O

Hereditary	B-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
.	O	O

Diagnosis	O	O
and	O	O
HLA	O	O
studies	O	O
in	O	O
a	O	O
French	O	O
-	O	O
Canadian	O	O
family	O	O
.	O	O

The	O	O
serum	O	O
of	O	O
a	O	O
44	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
woman	O	O
of	O	O
French	O	O
-	O	O
Canadian	O	O
descent	O	O
having	O	O
a	O	O
B	O	O
-	O	O
27	O	O
positive	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
was	O	O
deficient	B-Disease	OMIM:610102
in	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
(	O	O
C7	O	O
)	O	O
as	O	O
determined	O	O
by	O	O
hemolytic	O	O
and	O	O
immunochemical	O	O
methods	O	O
.	O	O

No	O	O
inhibitor	O	O
against	O	O
C7	O	O
was	O	O
detected	O	O
,	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
all	O	O
other	O	O
complement	O	O
components	O	O
were	O	O
normal	O	O
.	O	O

No	O	O
deficiency	O	O
in	O	O
the	O	O
opsonic	O	O
activity	O	O
of	O	O
the	O	O
serum	O	O
was	O	O
found	O	O
,	O	O
and	O	O
the	O	O
results	O	O
of	O	O
basic	O	O
coagulation	O	O
studies	O	O
of	O	O
the	O	O
plasma	O	O
were	O	O
normal	O	O
.	O	O

On	O	O
investigation	O	O
of	O	O
the	O	O
patients	O	O
family	O	O
,	O	O
two	O	O
sisters	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
same	O	O
deficiency	O	O
but	O	O
were	O	O
otherwise	O	O
in	O	O
good	O	O
health	O	O
.	O	O

The	O	O
seven	O	O
other	O	O
siblings	O	O
were	O	O
heterozygous	O	O
for	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
,	O	O
while	O	O
the	O	O
paternal	O	O
aunt	O	O
had	O	O
a	O	O
normal	O	O
C7	O	O
level	O	O
.	O	O

In	O	O
the	O	O
third	O	O
generation	O	O
,	O	O
six	O	O
children	O	O
of	O	O
the	O	O
three	O	O
homozygous	O	O
sisters	O	O
and	O	O
five	O	O
children	O	O
of	O	O
heterozygotes	O	O
were	O	O
available	O	O
for	O	O
testing	O	O
.	O	O

Studies	O	O
of	O	O
the	O	O
HLA	O	O
antigens	O	O
in	O	O
all	O	O
the	O	O
22	O	O
subjects	O	O
and	O	O
in	O	O
three	O	O
spouses	O	O
indicated	O	O
no	O	O
close	O	O
linkage	O	O
between	O	O
the	O	O
CM	B-Disease	OMIM:610102
deficienty	I-Disease	OMIM:610102
and	O	O
the	O	O
HLA	O	O
system	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
simultaneous	O	O
occurrence	O	O
of	O	O
two	O	O
hereditary	O	O
complement	B-Disease	OMIM:610102
deficiencies	I-Disease	OMIM:610102
(	I-Disease	OMIM:610102
C2	I-Disease	OMIM:610102
and	I-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
)	I-Disease	OMIM:610102
was	O	O
discovered	O	O
in	O	O
one	O	O
family	O	O
of	O	O
this	O	O
remarkable	O	O
kindred	O	O
.	O	O

.	O	O

Alstrom	B-Disease	D056769
syndrome	I-Disease	D056769
:	O	O
further	O	O
evidence	O	O
for	O	O
linkage	O	O
to	O	O
human	O	O
chromosome	O	O
2p13	O	O
.	O	O

Alstrom	B-Disease	D056769
syndrome	I-Disease	D056769
is	O	O
a	O	O
rare	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
,	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
,	O	O
early	O	O
-	O	O
onset	O	O
obesity	B-Disease	D009765
,	O	O
and	O	O
non	B-Disease	D003924
-	I-Disease	D003924
insulin	I-Disease	D003924
-	I-Disease	D003924
dependent	I-Disease	D003924
diabetes	I-Disease	D003924
mellitus	I-Disease	D003924
.	O	O

The	O	O
gene	O	O
for	O	O
Alstrom	B-Disease	D056769
syndrome	I-Disease	D056769
(	O	O
ALMS1	O	O
)	O	O
has	O	O
been	O	O
previously	O	O
localized	O	O
to	O	O
human	O	O
chromosome	O	O
2p13	O	O
by	O	O
homozygosity	O	O
mapping	O	O
in	O	O
two	O	O
distinct	O	O
isolated	O	O
populations	O	O
-	O	O
French	O	O
Acadian	O	O
and	O	O
North	O	O
African	O	O
.	O	O

Pair	O	O
-	O	O
wise	O	O
analyses	O	O
resulted	O	O
in	O	O
maximum	O	O
lod	O	O
(	O	O
logarithm	O	O
of	O	O
the	O	O
odds	O	O
ratio	O	O
)	O	O
scores	O	O
of	O	O
3	O	O
.	O	O

84	O	O
and	O	O
2	O	O
.	O	O

9	O	O
,	O	O
respectively	O	O
.	O	O

To	O	O
confirm	O	O
these	O	O
findings	O	O
,	O	O
a	O	O
large	O	O
linkage	O	O
study	O	O
was	O	O
performed	O	O
in	O	O
twelve	O	O
additional	O	O
families	O	O
segregating	O	O
for	O	O
Alstrom	B-Disease	D056769
syndrome	I-Disease	D056769
.	O	O

A	O	O
maximum	O	O
two	O	O
-	O	O
point	O	O
lod	O	O
score	O	O
of	O	O
7	O	O
.	O	O

13	O	O
(	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
)	O	O
for	O	O
marker	O	O
D2S2110	O	O
and	O	O
a	O	O
maximum	O	O
cumulative	O	O
multipoint	O	O
lod	O	O
score	O	O
of	O	O
9	O	O
.	O	O

16	O	O
for	O	O
marker	O	O
D2S2110	O	O
were	O	O
observed	O	O
,	O	O
further	O	O
supporting	O	O
linkage	O	O
to	O	O
chromosome	O	O
2p13	O	O
.	O	O

No	O	O
evidence	O	O
of	O	O
genetic	O	O
heterogeneity	O	O
was	O	O
observed	O	O
in	O	O
these	O	O
families	O	O
.	O	O

Meiotic	O	O
recombination	O	O
events	O	O
have	O	O
localized	O	O
the	O	O
critical	O	O
region	O	O
containing	O	O
ALMS1	O	O
to	O	O
a	O	O
6	O	O
.	O	O

1	O	O
-	O	O
cM	O	O
interval	O	O
flanked	O	O
by	O	O
markers	O	O
D2S327	O	O
and	O	O
D2S286	O	O
.	O	O

A	O	O
fine	O	O
resolution	O	O
radiation	O	O
hybrid	O	O
map	O	O
of	O	O
31	O	O
genes	O	O
and	O	O
markers	O	O
has	O	O
been	O	O
constructed	O	O
.	O	O

Haplotype	O	O
and	O	O
multipoint	O	O
linkage	O	O
analysis	O	O
in	O	O
Finnish	O	O
choroideremia	B-Disease	D015794
families	O	O
.	O	O

Multipoint	O	O
linkage	O	O
analysis	O	O
of	O	O
choroideremia	B-Disease	D015794
(	O	O
TCD	B-Disease	D015794
)	O	O
and	O	O
seven	O	O
X	O	O
chromosomal	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
(	O	O
RFLPs	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
18	O	O
Finnish	O	O
TCD	B-Disease	D015794
families	O	O
.	O	O

The	O	O
data	O	O
place	O	O
TCD	B-Disease	D015794
distal	O	O
to	O	O
PGK	O	O
and	O	O
DXS72	O	O
,	O	O
very	O	O
close	O	O
to	O	O
DXYS1	O	O
and	O	O
DXYS5	O	O
(	O	O
Zmax	O	O
=	O	O
24	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
)	O	O
and	O	O
proximal	O	O
to	O	O
DXYS4	O	O
and	O	O
DXYS12	O	O
.	O	O

This	O	O
agrees	O	O
with	O	O
the	O	O
data	O	O
obtained	O	O
from	O	O
other	O	O
linkage	O	O
studies	O	O
and	O	O
from	O	O
physical	O	O
mapping	O	O
.	O	O

All	O	O
the	O	O
TCD	B-Disease	D015794
males	O	O
and	O	O
carrier	O	O
females	O	O
studied	O	O
have	O	O
the	O	O
same	O	O
DXYS1	O	O
allele	O	O
in	O	O
coupling	O	O
with	O	O
TCD	B-Disease	D015794
.	O	O

In	O	O
Northeastern	O	O
Finland	O	O
,	O	O
66	O	O
/	O	O
69	O	O
chromosomes	O	O
carrying	O	O
TCD	B-Disease	D015794
had	O	O
the	O	O
same	O	O
haplotype	O	O
at	O	O
loci	O	O
DXS72	O	O
,	O	O
DXYS1	O	O
,	O	O
DXYS4	O	O
,	O	O
and	O	O
DXYS12	O	O
.	O	O

The	O	O
same	O	O
haplotype	O	O
is	O	O
seen	O	O
in	O	O
only	O	O
15	O	O
/	O	O
99	O	O
chromosomes	O	O
not	O	O
carrying	O	O
TCD	B-Disease	D015794
.	O	O

Moreover	O	O
,	O	O
in	O	O
71	O	O
/	O	O
104	O	O
non	O	O
-	O	O
TCD	B-Disease	D015794
chromosomes	O	O
,	O	O
the	O	O
haplotype	O	O
at	O	O
six	O	O
marker	O	O
loci	O	O
is	O	O
different	O	O
from	O	O
those	O	O
seen	O	O
in	O	O
any	O	O
of	O	O
the	O	O
76	O	O
TCD	B-Disease	D015794
chromosomes	O	O
.	O	O

This	O	O
supports	O	O
the	O	O
previously	O	O
described	O	O
hypothesis	O	O
that	O	O
the	O	O
large	O	O
Northern	O	O
Finnish	O	O
choroideremia	B-Disease	D015794
pedigrees	O	O
,	O	O
comprising	O	O
a	O	O
total	O	O
of	O	O
over	O	O
80	O	O
living	O	O
patients	O	O
representing	O	O
more	O	O
than	O	O
a	O	O
fifth	O	O
of	O	O
all	O	O
TCD	B-Disease	D015794
patients	O	O
described	O	O
worldwide	O	O
,	O	O
carry	O	O
the	O	O
same	O	O
mutation	O	O
.	O	O

These	O	O
linkage	O	O
and	O	O
haplotype	O	O
data	O	O
provide	O	O
improved	O	O
opportunities	O	O
for	O	O
prenatal	O	O
diagnosis	O	O
based	O	O
on	O	O
RFLP	O	O
studies	O	O
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
at	O	O
the	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
locus	O	O
in	O	O
southern	O	O
Italy	O	O
:	O	O
a	O	O
study	O	O
on	O	O
a	O	O
population	O	O
from	O	O
the	O	O
Matera	O	O
district	O	O
.	O	O

Glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
has	O	O
been	O	O
analyzed	O	O
by	O	O
gel	O	O
electrophoresis	O	O
and	O	O
by	O	O
quantitative	O	O
assay	O	O
in	O	O
an	O	O
unselected	O	O
sample	O	O
of	O	O
1524	O	O
schoolboys	O	O
from	O	O
the	O	O
province	O	O
of	O	O
Matera	O	O
(	O	O
Lucania	O	O
)	O	O
in	O	O
southern	O	O
Italy	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
43	O	O
subjects	O	O
with	O	O
a	O	O
G6PD	O	O
variant	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
31	O	O
had	O	O
severe	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
nine	O	O
had	O	O
mild	O	O
to	O	O
moderate	O	O
deficiency	O	O
,	O	O
and	O	O
three	O	O
had	O	O
a	O	O
non	O	O
-	O	O
deficient	O	O
electrophoretic	O	O
variant	O	O
.	O	O

The	O	O
overall	O	O
rate	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
was	O	O
2	O	O
.	O	O

6	O	O
%	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
ranging	O	O
from	O	O
7	O	O
.	O	O

2	O	O
%	O	O
on	O	O
the	O	O
Ionian	O	O
Coast	O	O
to	O	O
zero	O	O
on	O	O
the	O	O
eastern	O	O
side	O	O
of	O	O
the	O	O
Lucanian	O	O
Apennines	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
inversely	O	O
related	O	O
to	O	O
the	O	O
distance	O	O
of	O	O
each	O	O
town	O	O
examined	O	O
from	O	O
the	O	O
Ionian	O	O
Coast	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
geographic	O	O
distribution	O	O
may	O	O
reflect	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
gene	O	O
flow	O	O
from	O	O
Greek	O	O
settlers	O	O
.	O	O

Biochemical	O	O
characterization	O	O
has	O	O
shown	O	O
that	O	O
most	O	O
of	O	O
the	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
this	O	O
population	O	O
is	O	O
accounted	O	O
for	O	O
by	O	O
G6PD	O	O
Mediterranean	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
have	O	O
found	O	O
several	O	O
examples	O	O
of	O	O
two	O	O
other	O	O
known	O	O
polymorphic	O	O
variants	O	O
(	O	O
G6PD	O	O
Cagliari	O	O
and	O	O
G6PD	O	O
A	O	O
-	O	O
)	O	O
;	O	O
three	O	O
new	O	O
polymorphic	O	O
variants	O	O
,	O	O
G6PD	O	O
Metaponto	O	O
(	O	O
class	O	O
III	O	O
)	O	O
,	O	O
G6PD	O	O
Montalbano	O	O
(	O	O
class	O	O
III	O	O
)	O	O
,	O	O
and	O	O
G6PD	O	O
Pisticci	O	O
(	O	O
class	O	O
IV	O	O
)	O	O
;	O	O
and	O	O
two	O	O
sporadic	O	O
variants	O	O
,	O	O
G6PD	O	O
Tursi	O	O
(	O	O
class	O	O
III	O	O
)	O	O
and	O	O
G6PD	O	O
Ferrandina	O	O
(	O	O
class	O	O
II	O	O
)	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
the	O	O
marked	O	O
genetic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
within	O	O
a	O	O
relatively	O	O
narrow	O	O
geographic	O	O
area	O	O
and	O	O
they	O	O
prove	O	O
the	O	O
presence	O	O
in	O	O
the	O	O
Italian	O	O
peninsula	O	O
of	O	O
a	O	O
gene	O	O
(	O	O
GdA	O	O
-	O	O
)	O	O
regarded	O	O
as	O	O
characteristically	O	O
African	O	O
.	O	O

Defective	O	O
CTLA	O	O
-	O	O
4	O	O
cycling	O	O
pathway	O	O
in	O	O
Chediak	B-Disease	D002609
-	I-Disease	D002609
Higashi	I-Disease	D002609
syndrome	I-Disease	D002609
:	O	O
a	O	O
possible	O	O
mechanism	O	O
for	O	O
deregulation	O	O
of	O	O
T	O	O
lymphocyte	O	O
activation	O	O
.	O	O

Cytotoxic	O	O
T	O	O
lymphocyte	O	O
-	O	O
associated	O	O
antigen	O	O
4	O	O
(	O	O
CTLA	O	O
-	O	O
4	O	O
,	O	O
also	O	O
known	O	O
as	O	O
CD152	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
play	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

Its	O	O
membrane	O	O
expression	O	O
is	O	O
highly	O	O
regulated	O	O
by	O	O
endocytosis	O	O
and	O	O
trafficking	O	O
through	O	O
the	O	O
secretory	O	O
lysosome	O	O
pathway	O	O
.	O	O

Chediak	B-Disease	D002609
-	I-Disease	D002609
Higashi	I-Disease	D002609
syndrome	I-Disease	D002609
(	O	O
CHS	B-Disease	D002609
)	O	O
is	O	O
an	O	O
inherited	B-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
lysosomal	O	O
trafficking	O	O
regulator	O	O
gene	O	O
,	O	O
LYST	O	O
.	O	O

It	O	O
results	O	O
in	O	O
defective	O	O
membrane	O	O
targeting	O	O
of	O	O
the	O	O
proteins	O	O
present	O	O
in	O	O
secretory	O	O
lysosomes	O	O
,	O	O
and	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
features	O	O
,	O	O
including	O	O
a	O	O
lymphoproliferative	B-Disease	D008232
syndrome	I-Disease	D008232
with	O	O
hemophagocytosis	B-Disease	D051359
.	O	O

The	O	O
murine	O	O
equivalent	O	O
of	O	O
CHS	B-Disease	D002609
,	O	O
beige	O	O
mice	O	O
,	O	O
present	O	O
similar	O	O
characteristics	O	O
but	O	O
do	O	O
not	O	O
develop	O	O
the	O	O
lymphoproliferative	B-Disease	D008232
syndrome	I-Disease	D008232
.	O	O

We	O	O
show	O	O
herein	O	O
that	O	O
CTLA	O	O
-	O	O
4	O	O
is	O	O
present	O	O
in	O	O
enlarged	O	O
,	O	O
abnormal	O	O
vesicles	O	O
in	O	O
CHS	B-Disease	D002609
T	O	O
cells	O	O
and	O	O
is	O	O
not	O	O
properly	O	O
expressed	O	O
at	O	O
the	O	O
cell	O	O
surface	O	O
after	O	O
T	O	O
cell	O	O
activation	O	O
,	O	O
whereas	O	O
its	O	O
surface	O	O
expression	O	O
is	O	O
not	O	O
impaired	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
proposed	O	O
that	O	O
the	O	O
defective	O	O
surface	O	O
expression	O	O
of	O	O
CTLA	O	O
-	O	O
4	O	O
by	O	O
CHS	B-Disease	D002609
T	O	O
cells	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
lymphoproliferative	B-Disease	D008232
disease	I-Disease	D008232
.	O	O

This	O	O
observation	O	O
may	O	O
provide	O	O
insight	O	O
into	O	O
the	O	O
role	O	O
of	O	O
CTLA	O	O
-	O	O
4	O	O
in	O	O
humans	O	O
.	O	O

.	O	O

Beta	O	O
-	O	O
catenin	O	O
accumulation	O	O
and	O	O
mutation	O	O
of	O	O
the	O	O
CTNNB1	O	O
gene	O	O
in	O	O
hepatoblastoma	B-Disease	D018197
.	O	O

Hepatoblastoma	B-Disease	D018197
is	O	O
a	O	O
rare	O	O
malignant	B-Disease	D008113	D018198
tumor	I-Disease	D008113	D018198
of	I-Disease	D008113	D018198
the	I-Disease	D008113	D018198
liver	I-Disease	D008113	D018198
that	O	O
occurs	O	O
in	O	O
children	O	O
at	O	O
an	O	O
average	O	O
age	O	O
of	O	O
2	O	O
to	O	O
3	O	O
years	O	O
.	O	O

Epidemiologic	O	O
studies	O	O
have	O	O
shown	O	O
an	O	O
increased	O	O
frequency	O	O
of	O	O
this	O	O
tumor	B-Disease	D009369
type	O	O
in	O	O
families	O	O
affected	O	O
by	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
epidemiologic	O	O
data	O	O
,	O	O
molecular	O	O
genetic	O	O
studies	O	O
suggest	O	O
that	O	O
inactivation	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
tumor	I-Disease	D011125
suppressor	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
hepatoblastoma	B-Disease	D018197
tumorigenesis	O	O
.	O	O

A	O	O
major	O	O
function	O	O
of	O	O
APC	O	O
is	O	O
the	O	O
downregulation	O	O
of	O	O
beta	O	O
-	O	O
catenin	O	O
,	O	O
a	O	O
transcription	O	O
-	O	O
activating	O	O
protein	O	O
with	O	O
oncogenic	O	O
potential	O	O
.	O	O

In	O	O
an	O	O
ongoing	O	O
immunohistochemical	O	O
study	O	O
of	O	O
beta	O	O
-	O	O
catenin	O	O
expression	O	O
in	O	O
sporadic	O	O
cases	O	O
of	O	O
tumor	B-Disease	D009369
types	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
,	O	O
we	O	O
observed	O	O
increased	O	O
beta	O	O
-	O	O
catenin	O	O
levels	O	O
in	O	O
the	O	O
cytoplasm	O	O
and	O	O
in	O	O
the	O	O
nuclei	O	O
of	O	O
three	O	O
investigated	O	O
hepatoblastomas	B-Disease	D018197
.	O	O

Sequencing	O	O
of	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
catenin	O	O
gene	O	O
(	O	O
CTNNB1	O	O
)	O	O
revealed	O	O
an	O	O
activating	O	O
mutation	O	O
in	O	O
one	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
samples	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
beta	O	O
-	O	O
catenin	O	O
accumulation	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
hepatoblastoma	B-Disease	D018197
and	O	O
that	O	O
activating	O	O
mutations	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
catenin	O	O
gene	O	O
may	O	O
substitute	O	O
biallelic	O	O
APC	O	O
inactivation	O	O
in	O	O
this	O	O
tumor	B-Disease	D009369
type	O	O
.	O	O

Genes	O	O
Chromosomes	O	O
Cancer	O	O
25	O	O
399	O	O
-	O	O
402	O	O
,	O	O
1999	O	O
.	O	O

.	O	O

Sequence	O	O
of	O	O
DNA	O	O
flanking	O	O
the	O	O
exons	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
,	O	O
and	O	O
identification	O	O
of	O	O
mutations	O	O
in	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
.	O	O

The	O	O
rapid	O	O
identification	O	O
of	O	O
mutations	O	O
causing	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
requires	O	O
the	O	O
capacity	O	O
to	O	O
readily	O	O
screen	O	O
the	O	O
regions	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
most	O	O
likely	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
mutation	O	O
.	O	O

We	O	O
have	O	O
sequenced	O	O
the	O	O
portions	O	O
of	O	O
the	O	O
introns	O	O
flanking	O	O
each	O	O
of	O	O
the	O	O
14	O	O
HEXA	O	O
exons	O	O
in	O	O
order	O	O
to	O	O
specify	O	O
oligonucleotide	O	O
primers	O	O
for	O	O
the	O	O
PCR	O	O
-	O	O
dependent	O	O
amplification	O	O
of	O	O
each	O	O
exon	O	O
and	O	O
splice	O	O
-	O	O
junction	O	O
sequence	O	O
.	O	O

The	O	O
amplified	O	O
products	O	O
were	O	O
analyzed	O	O
,	O	O
by	O	O
electrophoresis	O	O
in	O	O
nondenaturing	O	O
polyacrylamide	O	O
gels	O	O
,	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
either	O	O
heteroduplexes	O	O
,	O	O
derived	O	O
from	O	O
the	O	O
annealing	O	O
of	O	O
normal	O	O
and	O	O
mutant	O	O
DNA	O	O
strands	O	O
,	O	O
or	O	O
single	O	O
-	O	O
strand	O	O
conformational	O	O
polymorphisms	O	O
(	O	O
SSCP	O	O
)	O	O
,	O	O
derived	O	O
from	O	O
the	O	O
renaturation	O	O
of	O	O
single	O	O
-	O	O
stranded	O	O
DNA	O	O
.	O	O

Five	O	O
novel	O	O
mutations	O	O
from	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
patients	O	O
were	O	O
detected	O	O
a	O	O
5	O	O
-	O	O
bp	O	O
deletion	O	O
of	O	O
TCTCC	O	O
in	O	O
IVS	O	O
-	O	O
9	O	O
;	O	O
a	O	O
2	O	O
-	O	O
bp	O	O
deletion	O	O
of	O	O
TG	O	O
in	O	O
exon	O	O
5	O	O
;	O	O
G78	O	O
to	O	O
A	O	O
,	O	O
giving	O	O
a	O	O
stop	O	O
codon	O	O
in	O	O
exon	O	O
1	O	O
;	O	O
G533	O	O
to	O	O
T	O	O
in	O	O
exon	O	O
5	O	O
,	O	O
producing	O	O
the	O	O
third	O	O
amino	O	O
acid	O	O
substitution	O	O
detected	O	O
at	O	O
this	O	O
site	O	O
;	O	O
and	O	O
G	O	O
to	O	O
C	O	O
at	O	O
position	O	O
1	O	O
of	O	O
IVS	O	O
-	O	O
2	O	O
,	O	O
expected	O	O
to	O	O
produce	O	O
abnormal	O	O
splicing	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
two	O	O
mutations	O	O
,	O	O
(	O	O
G1496	O	O
to	O	O
A	O	O
in	O	O
exon	O	O
13	O	O
and	O	O
a	O	O
4	O	O
-	O	O
bp	O	O
insertion	O	O
in	O	O
exon	O	O
11	O	O
)	O	O
that	O	O
have	O	O
previously	O	O
been	O	O
reported	O	O
were	O	O
identified	O	O
.	O	O

.	O	O

In	O	O
vivo	O	O
modulation	O	O
of	O	O
Hmgic	O	O
reduces	O	O
obesity	B-Disease	D009765
.	O	O

The	O	O
HMGI	O	O
family	O	O
of	O	O
proteins	O	O
consists	O	O
of	O	O
three	O	O
members	O	O
,	O	O
HMGIC	O	O
,	O	O
HMGI	O	O
and	O	O
HMGI	O	O
(	O	O
Y	O	O
)	O	O
,	O	O
that	O	O
function	O	O
as	O	O
architectural	O	O
factors	O	O
and	O	O
are	O	O
essential	O	O
components	O	O
of	O	O
the	O	O
enhancesome	O	O
.	O	O

HMGIC	O	O
is	O	O
predominantly	O	O
expressed	O	O
in	O	O
proliferating	O	O
,	O	O
undifferentiated	O	O
mesenchymal	O	O
cells	O	O
and	O	O
is	O	O
not	O	O
detected	O	O
in	O	O
adult	O	O
tissues	O	O
.	O	O

It	O	O
is	O	O
disrupted	O	O
and	O	O
misexpressed	O	O
in	O	O
a	O	O
number	O	O
of	O	O
mesenchymal	B-Disease	D008637
tumour	I-Disease	D008637
cell	O	O
types	O	O
,	O	O
including	O	O
fat	B-Disease	D018205
-	I-Disease	D018205
cell	I-Disease	D018205
tumours	I-Disease	D018205
(	O	O
lipomas	B-Disease	D008067
)	O	O
.	O	O

In	O	O
addition	O	O
Hmgic	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
have	O	O
a	O	O
deficiency	O	O
in	O	O
fat	O	O
tissue	O	O
.	O	O

To	O	O
study	O	O
its	O	O
role	O	O
in	O	O
adipogenesis	O	O
and	O	O
obesity	B-Disease	D009765
,	O	O
we	O	O
examined	O	O
Hmgic	O	O
expression	O	O
in	O	O
the	O	O
adipose	O	O
tissue	O	O
of	O	O
adult	O	O
,	O	O
obese	B-Disease	D009765
mice	O	O
.	O	O

Mice	O	O
with	O	O
a	O	O
partial	B-Disease	OMIM:600698
or	I-Disease	OMIM:600698
complete	I-Disease	OMIM:600698
deficiency	I-Disease	OMIM:600698
of	I-Disease	OMIM:600698
Hmgic	I-Disease	OMIM:600698
resisted	O	O
diet	O	O
-	O	O
induced	O	O
obesity	B-Disease	D009765
.	O	O

Disruption	O	O
of	O	O
Hmgic	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
obesity	B-Disease	D009765
induced	O	O
by	O	O
leptin	B-Disease	OMIM:164160
deficiency	I-Disease	OMIM:164160
(	O	O
Lepob	O	O
/	O	O
Lepob	O	O
)	O	O
in	O	O
a	O	O
gene	O	O
-	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Our	O	O
studies	O	O
implicate	O	O
a	O	O
role	O	O
for	O	O
HMGIC	O	O
in	O	O
fat	O	O
-	O	O
cell	O	O
proliferation	O	O
,	O	O
indicating	O	O
that	O	O
it	O	O
may	O	O
be	O	O
an	O	O
adipose	O	O
-	O	O
specific	O	O
target	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
obesity	B-Disease	D009765
.	O	O

.	O	O

Prenatal	O	O
diagnosis	O	O
by	O	O
FISH	O	O
in	O	O
a	O	O
family	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
caused	O	O
by	O	O
duplication	O	O
of	O	O
PLP	O	O
gene	O	O
.	O	O

A	O	O
diagnosis	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
MIM	O	O
312080	O	O
)	O	O
was	O	O
made	O	O
in	O	O
a	O	O
young	O	O
boy	O	O
.	O	O

No	O	O
mutation	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
had	O	O
been	O	O
found	O	O
.	O	O

The	O	O
boys	O	O
maternal	O	O
aunt	O	O
came	O	O
for	O	O
prenatal	O	O
diagnosis	O	O
when	O	O
16	O	O
+	O	O
weeks	O	O
pregnant	O	O
and	O	O
carrying	O	O
a	O	O
male	O	O
fetus	O	O
.	O	O

Samples	O	O
were	O	O
tested	O	O
for	O	O
duplication	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
,	O	O
by	O	O
interphase	O	O
FISH	O	O
,	O	O
in	O	O
lymphocyte	O	O
preparations	O	O
from	O	O
the	O	O
proband	O	O
,	O	O
his	O	O
aunt	O	O
and	O	O
an	O	O
amniotic	O	O
fluid	O	O
cell	O	O
preparation	O	O
from	O	O
the	O	O
fetus	O	O
.	O	O

The	O	O
proband	O	O
was	O	O
found	O	O
to	O	O
carry	O	O
the	O	O
duplication	O	O
,	O	O
thus	O	O
confirming	O	O
the	O	O
diagnosis	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
,	O	O
but	O	O
neither	O	O
the	O	O
aunt	O	O
nor	O	O
the	O	O
fetus	O	O
carried	O	O
a	O	O
duplication	O	O
.	O	O

.	O	O

Somatic	O	O
rearrangement	O	O
of	O	O
chromosome	O	O
14	O	O
in	O	O
human	O	O
lymphocytes	O	O
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
is	O	O
a	O	O
rare	O	O
genetic	B-Disease	D030342
disorder	I-Disease	D030342
associated	O	O
with	O	O
immune	B-Disease	D007153
deficiency	I-Disease	D007153
,	O	O
chromosome	B-Disease	D043171
instability	I-Disease	D043171
,	O	O
and	O	O
a	O	O
predisposition	O	O
to	O	O
lymphoid	B-Disease	D008223
malignancy	I-Disease	D008223
.	O	O

We	O	O
have	O	O
detected	O	O
chromosomally	O	O
anomalous	O	O
clones	O	O
of	O	O
lymphocytes	O	O
in	O	O
eight	O	O
patients	O	O
with	O	O
this	O	O
disorder	O	O
.	O	O

Chromosome	O	O
banding	O	O
disclosed	O	O
that	O	O
the	O	O
clones	O	O
are	O	O
consistently	O	O
marked	O	O
by	O	O
structural	O	O
rearrangement	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
(	O	O
q	O	O
)	O	O
of	O	O
chromosome	O	O
14	O	O
.	O	O

A	O	O
translocation	O	O
involving	O	O
14q	O	O
was	O	O
found	O	O
in	O	O
clones	O	O
obtained	O	O
from	O	O
seven	O	O
of	O	O
the	O	O
eight	O	O
patients	O	O
whereas	O	O
a	O	O
ring	O	O
14	O	O
chromosome	O	O
was	O	O
found	O	O
in	O	O
a	O	O
clone	O	O
obtained	O	O
from	O	O
the	O	O
other	O	O
.	O	O

These	O	O
findings	O	O
as	O	O
well	O	O
as	O	O
data	O	O
obtained	O	O
by	O	O
others	O	O
for	O	O
patients	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
suggest	O	O
that	O	O
structural	O	O
rearrangement	O	O
of	O	O
14q	O	O
is	O	O
the	O	O
initial	O	O
chromosomal	O	O
change	O	O
in	O	O
lymphocyte	O	O
clones	O	O
of	O	O
patients	O	O
with	O	O
this	O	O
disorder	O	O
.	O	O

Chromosomes	O	O
of	O	O
lymphocytes	O	O
from	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
studied	O	O
before	O	O
and	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
chronic	B-Disease	D015451
lymphocytic	I-Disease	D015451
leukemia	I-Disease	D015451
.	O	O

Before	O	O
leukemia	B-Disease	D007938
was	O	O
diagnosed	O	O
,	O	O
the	O	O
patient	O	O
had	O	O
a	O	O
lymphocyte	O	O
clone	O	O
with	O	O
a	O	O
14q	O	O
translocation	O	O
.	O	O

This	O	O
clone	O	O
appears	O	O
to	O	O
have	O	O
given	O	O
rise	O	O
to	O	O
the	O	O
leukemic	B-Disease	D007938
cells	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
structural	O	O
rearrangement	O	O
of	O	O
14q	O	O
is	O	O
directly	O	O
related	O	O
to	O	O
abnormal	O	O
growth	O	O
of	O	O
lymphocytes	O	O
and	O	O
that	O	O
it	O	O
may	O	O
be	O	O
a	O	O
step	O	O
toward	O	O
the	O	O
development	O	O
of	O	O
lymphoid	B-Disease	D008223
malignancies	I-Disease	D008223
.	O	O

Increasing	O	O
evidence	O	O
,	O	O
provided	O	O
by	O	O
others	O	O
,	O	O
for	O	O
the	O	O
nonrandom	O	O
involvement	O	O
of	O	O
14q	O	O
in	O	O
African	O	O
-	O	O
type	O	O
Burkitts	B-Disease	D002051
lymphoma	I-Disease	D002051
and	O	O
other	O	O
lymphoid	B-Disease	D008223
neoplasms	I-Disease	D008223
further	O	O
strengthens	O	O
this	O	O
hypothesis	O	O
.	O	O

.	O	O

Two	O	O
missense	O	O
mutations	O	O
causing	O	O
mild	O	O
hyperphenylalaninemia	B-Disease	D010661
associated	O	O
with	O	O
DNA	O	O
haplotype	O	O
12	O	O
.	O	O

The	O	O
genetic	B-Disease	D030342
defects	I-Disease	D030342
responsible	O	O
for	O	O
most	O	O
phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
and	O	O
hyperphenylalaninemia	B-Disease	D010661
(	O	O
HPA	B-Disease	D010661
)	O	O
cases	O	O
are	O	O
located	O	O
in	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
gene	O	O
.	O	O

Approximately	O	O
50	O	O
-	O	O
60	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
Caucasians	O	O
and	O	O
are	O	O
reflected	O	O
in	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
clinical	O	O
severities	O	O
.	O	O

Most	O	O
mutations	O	O
are	O	O
linked	O	O
to	O	O
specific	O	O
haplotypes	O	O
,	O	O
as	O	O
defined	O	O
by	O	O
eight	O	O
polymorphic	O	O
restriction	O	O
sites	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
there	O	O
is	O	O
at	O	O
least	O	O
one	O	O
mild	O	O
mutation	O	O
linked	O	O
to	O	O
haplotype	O	O
12	O	O
in	O	O
the	O	O
Swedish	O	O
PKU	B-Disease	D010661
/	O	O
HPA	B-Disease	D010661
population	O	O
,	O	O
since	O	O
7	O	O
of	O	O
8	O	O
patients	O	O
carrying	O	O
haplotype	O	O
12	O	O
had	O	O
mild	O	O
HPA	B-Disease	D010661
.	O	O

Sequence	O	O
analysis	O	O
revealed	O	O
a	O	O
C	O	O
-	O	O
to	O	O
-	O	O
G	O	O
transversion	O	O
at	O	O
the	O	O
second	O	O
base	O	O
of	O	O
codon	O	O
322	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
substitution	O	O
of	O	O
glycine	O	O
for	O	O
alanine	O	O
,	O	O
in	O	O
four	O	O
mutant	O	O
haplotype	O	O
12	O	O
genes	O	O
,	O	O
and	O	O
a	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transition	O	O
at	O	O
the	O	O
second	O	O
base	O	O
of	O	O
codon	O	O
408	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
substitution	O	O
of	O	O
glutamine	O	O
for	O	O
arginine	O	O
,	O	O
in	O	O
another	O	O
three	O	O
mutant	O	O
haplotype	O	O
12	O	O
genes	O	O
.	O	O

These	O	O
mutations	O	O
segregated	O	O
with	O	O
mutant	O	O
haplotype	O	O
12	O	O
alleles	O	O
in	O	O
nuclear	O	O
families	O	O
but	O	O
were	O	O
not	O	O
present	O	O
on	O	O
normal	O	O
or	O	O
other	O	O
mutant	O	O
alleles	O	O
.	O	O

Both	O	O
mutations	O	O
were	O	O
tested	O	O
in	O	O
a	O	O
eukaryotic	O	O
expression	O	O
system	O	O
in	O	O
which	O	O
enzyme	O	O
activities	O	O
of	O	O
different	O	O
mutant	O	O
PAH	O	O
enzymes	O	O
reflect	O	O
the	O	O
relative	O	O
severities	O	O
of	O	O
the	O	O
mutations	O	O
,	O	O
although	O	O
these	O	O
in	O	O
vitro	O	O
activities	O	O
cannot	O	O
be	O	O
translated	O	O
directly	O	O
into	O	O
in	O	O
vivo	O	O
hepatic	O	O
activities	O	O
.	O	O

The	O	O
A322G	O	O
mutant	O	O
PAH	O	O
had	O	O
about	O	O
75	O	O
%	O	O
and	O	O
the	O	O
R408Q	O	O
mutant	O	O
PAH	O	O
about	O	O
55	O	O
%	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
PAH	O	O
enzyme	O	O
activity	O	O
.	O	O

These	O	O
in	O	O
vitro	O	O
activities	O	O
are	O	O
the	O	O
highest	O	O
reported	O	O
for	O	O
mutant	O	O
PAH	O	O
enzymes	O	O
produced	O	O
in	O	O
the	O	O
same	O	O
expression	O	O
system	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
.	O	O

Genomic	O	O
organization	O	O
of	O	O
the	O	O
adrenoleukodystrophy	B-Disease	D000326
gene	O	O
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
,	O	O
the	O	O
most	O	O
frequent	O	O
peroxisomal	B-Disease	D018901
disorder	I-Disease	D018901
,	O	O
is	O	O
a	O	O
severe	O	O
neurodegenerative	B-Disease	D019636
disease	I-Disease	D019636
associated	O	O
with	O	O
an	O	O
impairment	B-Disease	OMIM:300100
of	I-Disease	OMIM:300100
very	I-Disease	OMIM:300100
long	I-Disease	OMIM:300100
chain	I-Disease	OMIM:300100
fatty	I-Disease	OMIM:300100
acids	I-Disease	OMIM:300100
beta	I-Disease	OMIM:300100
-	I-Disease	OMIM:300100
oxidation	I-Disease	OMIM:300100
.	O	O

We	O	O
have	O	O
recently	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
ALD	B-Disease	D000326
,	O	O
located	O	O
in	O	O
Xq28	O	O
.	O	O

It	O	O
encodes	O	O
a	O	O
new	O	O
member	O	O
of	O	O
the	O	O
"	O	O
ABC	O	O
"	O	O
superfamily	O	O
of	O	O
membrane	O	O
-	O	O
associated	O	O
transporters	O	O
that	O	O
shows	O	O
,	O	O
in	O	O
particular	O	O
,	O	O
significant	O	O
homology	O	O
to	O	O
the	O	O
70	O	O
-	O	O
kDa	O	O
peroxisomal	O	O
membrane	O	O
protein	O	O
(	O	O
PMP70	O	O
)	O	O
.	O	O

We	O	O
report	O	O
here	O	O
a	O	O
detailed	O	O
characterization	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
structure	O	O
.	O	O

It	O	O
extends	O	O
over	O	O
21	O	O
kb	O	O
and	O	O
consists	O	O
of	O	O
10	O	O
exons	O	O
.	O	O

To	O	O
facilitate	O	O
the	O	O
detection	O	O
of	O	O
mutations	O	O
in	O	O
ALD	B-Disease	D000326
patients	O	O
,	O	O
we	O	O
have	O	O
determined	O	O
the	O	O
intronic	O	O
sequences	O	O
flanking	O	O
the	O	O
exons	O	O
as	O	O
well	O	O
as	O	O
the	O	O
sequence	O	O
of	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
and	O	O
of	O	O
the	O	O
immediate	O	O
5	O	O
promoter	O	O
region	O	O
.	O	O

Sequences	O	O
present	O	O
in	O	O
distal	O	O
exons	O	O
cross	O	O
-	O	O
hybridize	O	O
strongly	O	O
to	O	O
additional	O	O
sequences	O	O
in	O	O
the	O	O
human	O	O
genome	O	O
.	O	O

The	O	O
ALD	B-Disease	D000326
gene	O	O
has	O	O
been	O	O
positioned	O	O
on	O	O
a	O	O
pulsed	O	O
-	O	O
field	O	O
map	O	O
between	O	O
DXS15	O	O
and	O	O
the	O	O
L1CAM	O	O
gene	O	O
,	O	O
about	O	O
650	O	O
kb	O	O
upstream	O	O
from	O	O
the	O	O
color	O	O
pigment	O	O
genes	O	O
.	O	O

The	O	O
frequent	O	O
occurrence	O	O
of	O	O
color	O	O
vision	O	O
anomalies	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
the	O	O
adult	O	O
onset	O	O
form	O	O
of	O	O
ALD	B-Disease	D000326
)	O	O
thus	O	O
does	O	O
not	O	O
represent	O	O
a	O	O
contiguous	B-Disease	D025063
gene	I-Disease	D025063
syndrome	I-Disease	D025063
but	O	O
a	O	O
secondary	O	O
manifestation	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

.	O	O

BRCA1	O	O
interacts	O	O
with	O	O
components	O	O
of	O	O
the	O	O
histone	O	O
deacetylase	O	O
complex	O	O
.	O	O

Germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
susceptibility	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

BRCA1	O	O
contains	O	O
a	O	O
carboxyl	O	O
-	O	O
terminal	O	O
domain	O	O
(	O	O
BRCT	O	O
)	O	O
that	O	O
is	O	O
shared	O	O
with	O	O
several	O	O
other	O	O
proteins	O	O
involved	O	O
in	O	O
maintaining	O	O
genome	O	O
integrity	O	O
.	O	O

In	O	O
an	O	O
effort	O	O
to	O	O
understand	O	O
the	O	O
function	O	O
of	O	O
BRCA1	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
isolate	O	O
proteins	O	O
that	O	O
interact	O	O
with	O	O
the	O	O
BRCT	O	O
domain	O	O
.	O	O

Purified	O	O
BRCT	O	O
polypeptide	O	O
was	O	O
used	O	O
as	O	O
a	O	O
probe	O	O
to	O	O
screen	O	O
a	O	O
human	O	O
placenta	O	O
cDNA	O	O
expression	O	O
library	O	O
by	O	O
Far	O	O
Western	O	O
analysis	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
BRCA1	O	O
interacts	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
with	O	O
the	O	O
Rb	O	O
-	O	O
binding	O	O
proteins	O	O
,	O	O
RbAp46	O	O
and	O	O
RbAp48	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
Rb	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
BRCT	O	O
domain	O	O
associates	O	O
with	O	O
the	O	O
histone	O	O
deacetylases	O	O
HDAC1	O	O
and	O	O
HDAC2	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
BRCA1	O	O
interacts	O	O
with	O	O
components	O	O
of	O	O
the	O	O
histone	O	O
deacetylase	O	O
complex	O	O
,	O	O
and	O	O
therefore	O	O
may	O	O
explain	O	O
the	O	O
involvement	O	O
of	O	O
BRCA1	O	O
in	O	O
multiple	O	O
processes	O	O
such	O	O
as	O	O
transcription	O	O
,	O	O
DNA	O	O
repair	O	O
,	O	O
and	O	O
recombination	O	O
.	O	O

.	O	O

Deletion	O	O
of	O	O
the	O	O
KIT	O	O
and	O	O
PDGFRA	O	O
genes	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
piebaldism	B-Disease	D016116
.	O	O

We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
human	O	O
piebaldism	B-Disease	D016116
results	O	O
from	O	O
mutations	O	O
of	O	O
the	O	O
KIT	O	O
gene	O	O
,	O	O
which	O	O
encodes	O	O
the	O	O
receptor	O	O
for	O	O
the	O	O
mast	O	O
/	O	O
stem	O	O
cell	O	O
growth	O	O
factor	O	O
and	O	O
is	O	O
located	O	O
in	O	O
chromosome	O	O
segment	O	O
4q12	O	O
.	O	O

Using	O	O
DNA	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
piebaldism	B-Disease	D016116
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
multiple	B-Disease	D000013
congenital	I-Disease	D000013
anomalies	I-Disease	D000013
associated	O	O
with	O	O
a	O	O
46	O	O
,	O	O
XY	O	O
,	O	O
del	O	O
(	O	O
4	O	O
)	O	O
(	O	O
q12q21	O	O
.	O	O

1	O	O
)	O	O
karyotype	O	O
,	O	O
we	O	O
carried	O	O
out	O	O
quantitative	O	O
Southern	O	O
blot	O	O
hybridization	O	O
analyses	O	O
of	O	O
the	O	O
KIT	O	O
gene	O	O
and	O	O
the	O	O
adjacent	O	O
PDGFRA	O	O
(	O	O
platelet	O	O
-	O	O
derived	O	O
growth	O	O
factor	O	O
receptor	O	O
alpha	O	O
subunit	O	O
)	O	O
genes	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
hemizygous	O	O
for	O	O
both	O	O
the	O	O
KIT	O	O
and	O	O
PDGFRA	O	O
genes	O	O
,	O	O
indicating	O	O
that	O	O
both	O	O
of	O	O
these	O	O
genes	O	O
are	O	O
included	O	O
within	O	O
the	O	O
deleted	O	O
region	O	O
.	O	O

Therefore	O	O
,	O	O
deletion	O	O
of	O	O
the	O	O
KIT	O	O
and	O	O
PDGFRA	O	O
genes	O	O
may	O	O
account	O	O
for	O	O
the	O	O
piebald	B-Disease	D016116
phenotype	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

Glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variants	O	O
and	O	O
their	O	O
frequency	O	O
in	O	O
Guangdong	O	O
,	O	O
China	O	O
.	O	O

Erythrocyte	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
was	O	O
characterized	O	O
in	O	O
blood	O	O
samples	O	O
obtained	O	O
from	O	O
97	O	O
randomly	O	O
selected	O	O
males	O	O
with	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
from	O	O
various	O	O
regions	O	O
of	O	O
Guangdong	O	O
Province	O	O
,	O	O
China	O	O
.	O	O

Nine	O	O
new	O	O
variants	O	O
(	O	O
Gd	O	O
Kaiping	O	O
,	O	O
Gd	O	O
Boluo	O	O
,	O	O
Gd	O	O
Huiyang	O	O
,	O	O
Gd	O	O
Gaomin	O	O
,	O	O
Gd	O	O
Qing	O	O
-	O	O
Baijiang	O	O
,	O	O
Gd	O	O
Gaozhou	O	O
,	O	O
Gd	O	O
Huazhou	O	O
,	O	O
Gd	O	O
Nanhai	O	O
,	O	O
and	O	O
Gd	O	O
Guangzhou	O	O
)	O	O
were	O	O
identified	O	O
.	O	O

Of	O	O
the	O	O
31	O	O
variants	O	O
found	O	O
in	O	O
this	O	O
province	O	O
,	O	O
Gd	O	O
Kaiping	O	O
,	O	O
Gd	O	O
Taiwan	O	O
-	O	O
Hakka	O	O
,	O	O
Gd	O	O
Haad	O	O
Yai	O	O
,	O	O
Gd	O	O
Haad	O	O
Yai	O	O
-	O	O
like	O	O
and	O	O
Gd	O	O
Huiyang	O	O
occurred	O	O
most	O	O
frequently	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
each	O	O
variant	O	O
was	O	O
calculated	O	O
.	O	O

The	O	O
results	O	O
demonstrated	O	O
that	O	O
the	O	O
genetic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
was	O	O
high	O	O
in	O	O
this	O	O
area	O	O
.	O	O

.	O	O

A	O	O
common	O	O
molecular	O	O
basis	O	O
for	O	O
rearrangement	B-Disease	D002869
disorders	I-Disease	D002869
on	O	O
chromosome	O	O
22q11	O	O
.	O	O

The	O	O
chromosome	O	O
22q11	O	O
region	O	O
is	O	O
susceptible	O	O
to	O	O
rearrangements	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
congenital	B-Disease	D000013
anomaly	I-Disease	D000013
disorders	I-Disease	D000013
and	O	O
malignant	B-Disease	D018198
tumors	I-Disease	D018198
.	O	O

Three	O	O
congenital	B-Disease	D000013
anomaly	I-Disease	D000013
disorders	I-Disease	D000013
,	O	O
cat	B-Disease	C535918
-	I-Disease	C535918
eye	I-Disease	C535918
syndrome	I-Disease	C535918
,	O	O
der	B-Disease	C535733
(	I-Disease	C535733
)	I-Disease	C535733
syndrome	I-Disease	C535733
and	O	O
velo	B-Disease	D004062
-	I-Disease	D004062
cardio	I-Disease	D004062
-	I-Disease	D004062
facial	I-Disease	D004062
syndrome	I-Disease	D004062
/	O	O
DiGeorge	B-Disease	D004062
syndrome	I-Disease	D004062
(	O	O
VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
)	O	O
are	O	O
associated	O	O
with	O	O
tetrasomy	O	O
,	O	O
trisomy	O	O
or	O	O
monosomy	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
part	O	O
of	O	O
chromosome	O	O
22q11	O	O
.	O	O

VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
is	O	O
the	O	O
most	O	O
common	O	O
syndrome	O	O
associated	O	O
with	O	O
22q11	O	O
rearrangements	O	O
.	O	O

In	O	O
order	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
are	O	O
particular	O	O
regions	O	O
on	O	O
22q11	O	O
that	O	O
are	O	O
prone	O	O
to	O	O
rearrangements	O	O
,	O	O
the	O	O
deletion	O	O
end	O	O
-	O	O
points	O	O
in	O	O
a	O	O
large	O	O
number	O	O
of	O	O
VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
patients	O	O
were	O	O
defined	O	O
by	O	O
haplotype	O	O
analysis	O	O
.	O	O

Most	O	O
VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
patients	O	O
have	O	O
a	O	O
similar	O	O
3	O	O
Mb	O	O
deletion	O	O
,	O	O
some	O	O
have	O	O
a	O	O
nested	O	O
distal	O	O
deletion	O	O
breakpoint	O	O
resulting	O	O
in	O	O
a	O	O
1	O	O
.	O	O

5	O	O
Mb	O	O
deletion	O	O
and	O	O
a	O	O
few	O	O
rare	O	O
patients	O	O
have	O	O
unique	O	O
deletions	O	O
or	O	O
translocations	O	O
.	O	O

The	O	O
high	O	O
prevalence	O	O
of	O	O
the	O	O
disorder	O	O
in	O	O
the	O	O
population	O	O
and	O	O
the	O	O
fact	O	O
that	O	O
most	O	O
cases	O	O
occur	O	O
sporadically	O	O
suggest	O	O
that	O	O
sequences	O	O
at	O	O
or	O	O
near	O	O
the	O	O
breakpoints	O	O
confer	O	O
susceptibility	O	O
to	O	O
chromosome	O	O
rearrangements	O	O
.	O	O

To	O	O
investigate	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
developed	O	O
hamster	O	O
-	O	O
human	O	O
somatic	O	O
hybrid	O	O
cell	O	O
lines	O	O
from	O	O
VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
patients	O	O
with	O	O
all	O	O
three	O	O
classes	O	O
of	O	O
deletions	O	O
and	O	O
we	O	O
now	O	O
show	O	O
that	O	O
the	O	O
breakpoints	O	O
occur	O	O
within	O	O
similar	O	O
low	O	O
copy	O	O
repeats	O	O
,	O	O
termed	O	O
LCR22s	O	O
.	O	O

To	O	O
support	O	O
this	O	O
idea	O	O
further	O	O
,	O	O
we	O	O
identified	O	O
a	O	O
family	O	O
that	O	O
carries	O	O
an	O	O
interstitial	O	O
duplication	O	O
of	O	O
the	O	O
same	O	O
3	O	O
Mb	O	O
region	O	O
that	O	O
is	O	O
deleted	O	O
in	O	O
VCFS	B-Disease	D004062
/	O	O
DGS	B-Disease	D004062
patients	O	O
.	O	O

We	O	O
present	O	O
models	O	O
to	O	O
explain	O	O
how	O	O
the	O	O
LCR22s	O	O
can	O	O
mediate	O	O
different	O	O
homologous	O	O
recombination	O	O
events	O	O
,	O	O
thereby	O	O
generating	O	O
a	O	O
number	O	O
of	O	O
rearrangements	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
congenital	B-Disease	D000013
anomaly	I-Disease	D000013
disorders	I-Disease	D000013
.	O	O

We	O	O
identified	O	O
five	O	O
additional	O	O
copies	O	O
of	O	O
the	O	O
LCR22	O	O
on	O	O
22q11	O	O
that	O	O
may	O	O
mediate	O	O
other	O	O
rearrangements	O	O
leading	O	O
to	O	O
disease	O	O
.	O	O

Typical	O	O
and	O	O
partial	O	O
cat	B-Disease	C535918
eye	I-Disease	C535918
syndrome	I-Disease	C535918
:	O	O
identification	O	O
of	O	O
the	O	O
marker	O	O
chromosome	O	O
by	O	O
FISH	O	O
.	O	O

Three	O	O
children	O	O
are	O	O
reported	O	O
with	O	O
typical	O	O
cat	B-Disease	C535918
eye	I-Disease	C535918
syndrome	I-Disease	C535918
(	O	O
CES	B-Disease	C535918
)	O	O
and	O	O
three	O	O
more	O	O
children	O	O
with	O	O
partial	O	O
CES	B-Disease	C535918
because	O	O
of	O	O
absence	O	O
of	O	O
coloboma	O	O
,	O	O
in	O	O
which	O	O
the	O	O
supernumerary	O	O
marker	O	O
chromosome	O	O
was	O	O
studied	O	O
by	O	O
FISH	O	O
.	O	O

Using	O	O
a	O	O
genomic	O	O
library	O	O
,	O	O
and	O	O
also	O	O
a	O	O
centromeric	O	O
and	O	O
particularly	O	O
a	O	O
cosmid	O	O
probe	O	O
of	O	O
22q11	O	O
,	O	O
partial	O	O
tetrasomy	B-Disease	D058670
was	O	O
shown	O	O
in	O	O
all	O	O
cases	O	O
.	O	O

.	O	O

An	O	O
intrachromosomal	O	O
insertion	O	O
causing	O	O
5q22	O	O
deletion	O	O
and	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
in	O	O
two	O	O
generations	O	O
.	O	O

We	O	O
report	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
FAPC	B-Disease	D011125
)	O	O
with	O	O
epidermoid	B-Disease	D004814
cysts	I-Disease	D004814
,	O	O
osteomata	B-Disease	D010016
,	O	O
and	O	O
areas	O	O
of	O	O
congenital	B-Disease	D012164
hypertrophy	I-Disease	D012164
of	I-Disease	D012164
the	I-Disease	D012164
retinal	I-Disease	D012164
pigment	I-Disease	D012164
epithelium	I-Disease	D012164
(	O	O
CHRPEs	B-Disease	D012164
)	O	O
in	O	O
a	O	O
male	O	O
patient	O	O
and	O	O
his	O	O
maternal	O	O
aunt	O	O
,	O	O
both	O	O
of	O	O
whom	O	O
suffered	O	O
a	O	O
mild	O	O
to	O	O
moderate	O	O
degree	O	O
of	O	O
mental	B-Disease	D008607
handicap	I-Disease	D008607
.	O	O

Both	O	O
had	O	O
an	O	O
interstitial	O	O
deletion	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
5	O	O
(	O	O
del	O	O
(	O	O
5	O	O
)	O	O
(	O	O
q22q23	O	O
.	O	O

2	O	O
)	O	O
)	O	O
.	O	O

Two	O	O
other	O	O
normal	O	O
family	O	O
members	O	O
had	O	O
the	O	O
underlying	O	O
direct	O	O
insertion	O	O
of	O	O
chromosome	O	O
5	O	O
(	O	O
dir	O	O
ins	O	O
(	O	O
5	O	O
)	O	O
(	O	O
q31	O	O
.	O	O

3q22q23	O	O
3q22q23	O	O
.	O	O

2	O	O
)	O	O
)	O	O
.	O	O

Molecular	O	O
genetic	O	O
and	O	O
fluorescent	O	O
hybridisation	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
loci	O	O
D5S37	O	O
and	O	O
D5S98	O	O
are	O	O
outside	O	O
the	O	O
deletion	O	O
whereas	O	O
loci	O	O
detected	O	O
by	O	O
probes	O	O
EF5	O	O
.	O	O

44	O	O
and	O	O
YN5	O	O
.	O	O

48	O	O
are	O	O
lost	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
the	O	O
molecular	O	O
analyses	O	O
indicate	O	O
loss	O	O
of	O	O
one	O	O
allele	O	O
at	O	O
the	O	O
MCC	O	O
and	O	O
APC	B-Disease	D011125
loci	O	O
.	O	O

The	O	O
APC	B-Disease	D011125
gene	O	O
is	O	O
located	O	O
within	O	O
band	O	O
5q22	O	O
.	O	O

Familial	O	O
direct	O	O
insertions	O	O
should	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
recurrent	O	O
microdeletion	O	O
syndromes	O	O
.	O	O

Cloning	O	O
of	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
region	O	O
in	O	O
yeast	O	O
artificial	O	O
chromosomes	O	O
.	O	O

The	O	O
gene	O	O
responsible	O	O
for	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
has	O	O
been	O	O
localized	O	O
to	O	O
a	O	O
2	O	O
.	O	O

5	O	O
million	O	O
base	O	O
pair	O	O
(	O	O
Mb	O	O
)	O	O
region	O	O
between	O	O
the	O	O
loci	O	O
D4S10	O	O
and	O	O
D4S168	O	O
on	O	O
the	O	O
short	O	O
arm	O	O
of	O	O
chromosome	O	O
4	O	O
.	O	O

As	O	O
part	O	O
of	O	O
a	O	O
strategy	O	O
to	O	O
clone	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
its	O	O
chromosomal	O	O
location	O	O
,	O	O
we	O	O
isolated	O	O
genomic	O	O
DNA	O	O
from	O	O
the	O	O
HD	B-Disease	D006816
region	O	O
as	O	O
a	O	O
set	O	O
of	O	O
overlapping	O	O
yeast	O	O
artificial	O	O
chromosome	O	O
(	O	O
YAC	O	O
)	O	O
clones	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
YAC	O	O
clones	O	O
were	O	O
identified	O	O
by	O	O
screening	O	O
human	O	O
YAC	O	O
libraries	O	O
with	O	O
twelve	O	O
PCR	O	O
-	O	O
based	O	O
sequence	O	O
-	O	O
tagged	O	O
sites	O	O
(	O	O
STSs	O	O
)	O	O
from	O	O
the	O	O
region	O	O
.	O	O

We	O	O
assembled	O	O
the	O	O
YAC	O	O
clones	O	O
into	O	O
overlapping	O	O
sets	O	O
by	O	O
hybridizing	O	O
them	O	O
to	O	O
a	O	O
large	O	O
number	O	O
of	O	O
DNA	O	O
probes	O	O
from	O	O
the	O	O
HD	B-Disease	D006816
region	O	O
,	O	O
including	O	O
the	O	O
STSs	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
isolated	O	O
the	O	O
ends	O	O
of	O	O
the	O	O
human	O	O
DNA	O	O
inserts	O	O
of	O	O
most	O	O
of	O	O
the	O	O
YAC	O	O
clones	O	O
to	O	O
assist	O	O
in	O	O
the	O	O
construction	O	O
of	O	O
the	O	O
contig	O	O
.	O	O

Although	O	O
almost	O	O
half	O	O
of	O	O
the	O	O
YACs	O	O
appear	O	O
to	O	O
contain	O	O
chimeric	O	O
inserts	O	O
and	O	O
several	O	O
contain	O	O
internal	O	O
deletions	O	O
or	O	O
other	O	O
rearrangements	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
obtain	O	O
over	O	O
2	O	O
.	O	O

2	O	O
Mb	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
region	O	O
in	O	O
YACs	O	O
,	O	O
including	O	O
one	O	O
continuous	O	O
segment	O	O
of	O	O
2	O	O
.	O	O

0	O	O
Mb	O	O
covering	O	O
the	O	O
region	O	O
that	O	O
most	O	O
likely	O	O
contains	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
.	O	O

Ten	O	O
of	O	O
the	O	O
twenty	O	O
eight	O	O
YAC	O	O
clones	O	O
comprise	O	O
a	O	O
minimal	O	O
set	O	O
spanning	O	O
the	O	O
2	O	O
.	O	O

2	O	O
Mb	O	O
.	O	O

These	O	O
clones	O	O
provide	O	O
reagents	O	O
for	O	O
the	O	O
complete	O	O
characterization	O	O
of	O	O
this	O	O
region	O	O
of	O	O
the	O	O
genome	O	O
and	O	O
for	O	O
the	O	O
eventual	O	O
isolation	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
.	O	O

Three	O	O
novel	O	O
mutations	O	O
in	O	O
five	O	O
unrelated	O	O
subjects	O	O
with	O	O
hereditary	O	O
protein	B-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
type	I-Disease	D018455
I	I-Disease	D018455
.	O	O

A	O	O
panel	O	O
of	O	O
eight	O	O
unrelated	O	O
subjects	O	O
with	O	O
inherited	O	O
type	B-Disease	D018455
I	I-Disease	D018455
protein	I-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
was	O	O
screened	O	O
for	O	O
mutations	O	O
in	O	O
the	O	O
PROS1	O	O
gene	O	O
.	O	O

In	O	O
five	O	O
subjects	O	O
an	O	O
abnormality	O	O
was	O	O
found	O	O
but	O	O
mutations	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
the	O	O
remaining	O	O
three	O	O
subjects	O	O
.	O	O

Two	O	O
subjects	O	O
shared	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
position	O	O
+	O	O
5	O	O
of	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
consensus	O	O
sequence	O	O
of	O	O
intron	O	O
10	O	O
.	O	O

Also	O	O
in	O	O
two	O	O
subjects	O	O
an	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transversion	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
stopcodon	O	O
of	O	O
the	O	O
PROS1	O	O
gene	O	O
;	O	O
this	O	O
transversion	O	O
predicts	O	O
a	O	O
protein	O	O
S	O	O
molecule	O	O
that	O	O
is	O	O
extended	O	O
by	O	O
14	O	O
amino	O	O
acids	O	O
.	O	O

The	O	O
fifth	O	O
subject	O	O
was	O	O
found	O	O
to	O	O
possess	O	O
two	O	O
sequence	O	O
abnormalities	O	O
.	O	O

One	O	O
allele	O	O
carried	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
near	O	O
the	O	O
donor	O	O
splice	O	O
junction	O	O
of	O	O
intron	O	O
2	O	O
,	O	O
but	O	O
this	O	O
abnormality	O	O
is	O	O
probably	O	O
neutral	O	O
,	O	O
since	O	O
it	O	O
was	O	O
inherited	O	O
from	O	O
the	O	O
parent	O	O
with	O	O
normal	O	O
protein	O	O
S	O	O
antigen	O	O
levels	O	O
.	O	O

In	O	O
the	O	O
other	O	O
allele	O	O
a	O	O
single	O	O
T	O	O
insertion	O	O
in	O	O
codon	O	O
-	O	O
25	O	O
was	O	O
found	O	O
.	O	O

Analysis	O	O
of	O	O
platelet	O	O
RNA	O	O
showed	O	O
that	O	O
only	O	O
the	O	O
mRNA	O	O
with	O	O
the	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
mutation	O	O
in	O	O
the	O	O
stopcodon	O	O
is	O	O
present	O	O
in	O	O
amounts	O	O
comparable	O	O
to	O	O
wildtype	O	O
RNA	O	O
.	O	O

mRNA	O	O
from	O	O
the	O	O
alleles	O	O
with	O	O
the	O	O
other	O	O
two	O	O
mutations	O	O
was	O	O
either	O	O
undetectable	O	O
or	O	O
present	O	O
in	O	O
greatly	O	O
reduced	O	O
amounts	O	O
.	O	O

The	O	O
latter	O	O
indicates	O	O
that	O	O
a	O	O
mRNA	O	O
based	O	O
approach	O	O
is	O	O
not	O	O
feasible	O	O
for	O	O
the	O	O
genetic	O	O
analysis	O	O
of	O	O
protein	B-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
type	I-Disease	D018455
I	I-Disease	D018455
.	O	O

.	O	O

A	O	O
potential	O	O
animal	O	O
model	O	O
for	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
through	O	O
introduction	O	O
of	O	O
HPRT	O	O
mutations	O	O
into	O	O
mice	O	O
.	O	O

The	O	O
human	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
is	O	O
a	O	O
rare	O	O
neurological	B-Disease	D009422
and	I-Disease	D009422
behavioural	I-Disease	D009422
disorder	I-Disease	D009422
,	O	O
affecting	O	O
only	O	O
males	O	O
,	O	O
which	O	O
is	O	O
caused	O	O
by	O	O
an	O	O
inherited	B-Disease	D030342
deficiency	I-Disease	D030342
in	O	O
the	O	O
level	O	O
of	O	O
activity	O	O
of	O	O
the	O	O
purine	O	O
salvage	O	O
enzyme	O	O
hypoxanthine	O	O
-	O	O
guanosine	O	O
phosphoribosyl	O	O
transferase	O	O
(	O	O
HPRT	O	O
)	O	O
.	O	O

How	O	O
the	O	O
resulting	O	O
alterations	O	O
in	O	O
purine	O	O
metabolism	O	O
lead	O	O
to	O	O
the	O	O
severe	O	O
symptoms	O	O
characteristic	O	O
of	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patients	O	O
is	O	O
still	O	O
not	O	O
understood	O	O
.	O	O

No	O	O
mutations	O	O
at	O	O
the	O	O
Hprt	O	O
locus	O	O
leading	O	O
to	O	O
loss	O	O
of	O	O
activity	O	O
have	O	O
been	O	O
described	O	O
in	O	O
laboratory	O	O
animals	O	O
.	O	O

To	O	O
derive	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
,	O	O
we	O	O
have	O	O
used	O	O
cultured	O	O
mouse	O	O
embryonic	O	O
stem	O	O
cells	O	O
,	O	O
mutagenized	O	O
by	O	O
retroviral	O	O
insertion	O	O
and	O	O
selected	O	O
for	O	O
loss	O	O
of	O	O
HPRT	O	O
activity	O	O
,	O	O
to	O	O
construct	O	O
chimaeric	O	O
mice	O	O
.	O	O

Two	O	O
clonal	O	O
lines	O	O
carrying	O	O
different	O	O
mutant	O	O
Hprt	O	O
alleles	O	O
have	O	O
given	O	O
rise	O	O
to	O	O
germ	O	O
cells	O	O
in	O	O
chimaeras	O	O
,	O	O
allowing	O	O
the	O	O
derivation	O	O
of	O	O
strains	O	O
of	O	O
mutant	O	O
mice	O	O
having	O	O
the	O	O
same	O	O
biochemical	O	O
defect	O	O
as	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patients	O	O
.	O	O

Male	O	O
mice	O	O
carrying	O	O
the	O	O
mutant	O	O
alleles	O	O
are	O	O
viable	O	O
and	O	O
analysis	O	O
of	O	O
their	O	O
cells	O	O
shows	O	O
a	O	O
total	O	O
lack	O	O
of	O	O
HPRT	O	O
activity	O	O
.	O	O

.	O	O

Duplicational	O	O
mutation	O	O
at	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
locus	O	O
:	O	O
its	O	O
frequency	O	O
,	O	O
distribution	O	O
,	O	O
origin	O	O
,	O	O
and	O	O
phenotypegenotype	O	O
correlation	O	O
.	O	O

Partial	O	O
gene	O	O
deletion	O	O
is	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
mutation	O	O
leading	O	O
to	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
and	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
(	O	O
BMD	B-Disease	C537666
)	O	O
.	O	O

Partial	O	O
gene	O	O
duplication	O	O
has	O	O
also	O	O
been	O	O
recognized	O	O
in	O	O
a	O	O
few	O	O
cases	O	O
.	O	O

We	O	O
have	O	O
conducted	O	O
a	O	O
survey	O	O
for	O	O
duplication	O	O
in	O	O
72	O	O
unrelated	O	O
nondeletion	O	O
patients	O	O
,	O	O
analyzed	O	O
by	O	O
Southern	O	O
blot	O	O
hybridization	O	O
with	O	O
clones	O	O
representing	O	O
the	O	O
entire	O	O
DMD	B-Disease	D020388
cDNA	O	O
.	O	O

With	O	O
careful	O	O
quantitative	O	O
analysis	O	O
of	O	O
hybridization	O	O
band	O	O
intensity	O	O
,	O	O
10	O	O
cases	O	O
were	O	O
found	O	O
to	O	O
carry	O	O
a	O	O
duplication	O	O
of	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
a	O	O
frequency	O	O
of	O	O
14	O	O
%	O	O
for	O	O
nondeletion	O	O
cases	O	O
(	O	O
10	O	O
/	O	O
72	O	O
)	O	O
,	O	O
or	O	O
6	O	O
%	O	O
for	O	O
all	O	O
cases	O	O
(	O	O
10	O	O
/	O	O
181	O	O
)	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
these	O	O
duplications	O	O
has	O	O
been	O	O
characterized	O	O
according	O	O
to	O	O
the	O	O
published	O	O
exon	O	O
-	O	O
containing	O	O
HindIII	O	O
fragment	O	O
map	O	O
,	O	O
and	O	O
in	O	O
six	O	O
of	O	O
the	O	O
10	O	O
duplications	O	O
a	O	O
novel	O	O
restriction	O	O
fragment	O	O
that	O	O
spanned	O	O
the	O	O
duplication	O	O
junction	O	O
was	O	O
detected	O	O
.	O	O

The	O	O
resulting	O	O
translational	O	O
reading	O	O
frame	O	O
of	O	O
mRNA	O	O
has	O	O
been	O	O
predicted	O	O
for	O	O
nine	O	O
duplications	O	O
.	O	O

A	O	O
shift	O	O
of	O	O
the	O	O
reading	O	O
frame	O	O
was	O	O
predicted	O	O
in	O	O
four	O	O
of	O	O
the	O	O
six	O	O
DMD	B-Disease	D020388
cases	O	O
and	O	O
in	O	O
one	O	O
of	O	O
the	O	O
two	O	O
intermediate	O	O
cases	O	O
,	O	O
while	O	O
the	O	O
reading	O	O
frame	O	O
remained	O	O
uninterrupted	O	O
in	O	O
both	O	O
BMD	B-Disease	C537666
cases	O	O
.	O	O

RFLP	O	O
and	O	O
quantitative	O	O
Southern	O	O
blot	O	O
analyses	O	O
revealed	O	O
a	O	O
grandpaternal	O	O
origin	O	O
of	O	O
duplication	O	O
in	O	O
four	O	O
families	O	O
and	O	O
grandmaternal	O	O
origin	O	O
in	O	O
one	O	O
family	O	O
.	O	O

In	O	O
all	O	O
five	O	O
families	O	O
,	O	O
the	O	O
duplication	O	O
was	O	O
found	O	O
to	O	O
originate	O	O
from	O	O
a	O	O
single	O	O
X	O	O
chromosome	O	O
.	O	O

Unequal	O	O
sister	O	O
-	O	O
chromatid	O	O
exchange	O	O
is	O	O
proposed	O	O
to	O	O
be	O	O
the	O	O
mechanism	O	O
for	O	O
the	O	O
formation	O	O
of	O	O
these	O	O
duplications	O	O
.	O	O

.	O	O

Molecular	O	O
evidence	O	O
for	O	O
new	O	O
mutation	O	O
at	O	O
the	O	O
hprt	O	O
locus	O	O
in	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
patients	O	O
.	O	O

Hypoxanthine	O	O
-	O	O
guanine	O	O
phosphoribosyltransferase	O	O
(	O	O
HPRT	O	O
;	O	O
EC2	O	O
.	O	O

4	O	O
.	O	O

2	O	O
.	O	O

8	O	O
)	O	O
,	O	O
which	O	O
functions	O	O
in	O	O
the	O	O
metabolic	O	O
salvage	O	O
of	O	O
purines	O	O
,	O	O
is	O	O
encoded	O	O
by	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
gene	O	O
in	O	O
man	O	O
.	O	O

Partial	O	O
HPRT	B-Disease	OMIM:300323
deficiencies	I-Disease	OMIM:300323
are	O	O
associated	O	O
with	O	O
gouty	B-Disease	D015210
arthritis	I-Disease	D015210
,	O	O
while	O	O
absence	O	O
of	O	O
activity	O	O
results	O	O
in	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
(	O	O
L	B-Disease	D007926
-	I-Disease	D007926
N	I-Disease	D007926
)	O	O
.	O	O

L	B-Disease	D007926
-	I-Disease	D007926
N	I-Disease	D007926
patients	O	O
fail	O	O
to	O	O
reproduce	O	O
and	O	O
the	O	O
heterozygous	O	O
state	O	O
appears	O	O
to	O	O
confer	O	O
no	O	O
selective	O	O
advantage	O	O
.	O	O

Thus	O	O
,	O	O
Haldanes	O	O
principle	O	O
predicts	O	O
that	O	O
new	O	O
mutations	O	O
at	O	O
the	O	O
hprt	O	O
locus	O	O
must	O	O
occur	O	O
frequently	O	O
in	O	O
order	O	O
for	O	O
L	B-Disease	D007926
-	I-Disease	D007926
N	I-Disease	D007926
syndrome	O	O
to	O	O
be	O	O
maintained	O	O
in	O	O
the	O	O
population	O	O
.	O	O

This	O	O
constant	O	O
introduction	O	O
of	O	O
new	O	O
mutations	O	O
would	O	O
be	O	O
expected	O	O
to	O	O
result	O	O
in	O	O
a	O	O
heterogeneous	O	O
collection	O	O
of	O	O
genetic	B-Disease	D020022
lesions	I-Disease	D020022
,	O	O
some	O	O
of	O	O
which	O	O
may	O	O
be	O	O
novel	O	O
.	O	O

As	O	O
we	O	O
report	O	O
here	O	O
,	O	O
the	O	O
mutations	O	O
in	O	O
the	O	O
hprt	O	O
gene	O	O
of	O	O
seven	O	O
L	B-Disease	D007926
-	I-Disease	D007926
N	I-Disease	D007926
patients	O	O
,	O	O
selected	O	O
from	O	O
an	O	O
initial	O	O
survey	O	O
of	O	O
28	O	O
patients	O	O
,	O	O
have	O	O
been	O	O
characterized	O	O
and	O	O
all	O	O
were	O	O
found	O	O
to	O	O
be	O	O
distinctly	O	O
different	O	O
,	O	O
as	O	O
predicted	O	O
.	O	O

The	O	O
origin	O	O
of	O	O
one	O	O
unusual	O	O
mutation	O	O
has	O	O
been	O	O
identified	O	O
by	O	O
analysis	O	O
of	O	O
DNA	O	O
from	O	O
four	O	O
generations	O	O
of	O	O
family	O	O
members	O	O
.	O	O

Further	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
origin	O	O
of	O	O
new	O	O
mutations	O	O
at	O	O
the	O	O
hprt	O	O
locus	O	O
should	O	O
aid	O	O
in	O	O
resolving	O	O
the	O	O
issue	O	O
of	O	O
an	O	O
apparent	O	O
difference	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
hprt	O	O
mutations	O	O
in	O	O
males	O	O
and	O	O
females	O	O
The	O	O
mapping	O	O
of	O	O
a	O	O
cDNA	O	O
from	O	O
the	O	O
human	O	O
X	B-Disease	D020388
-	I-Disease	D020388
linked	I-Disease	D020388
Duchenne	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
to	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
.	O	O

The	O	O
recent	O	O
discovery	O	O
of	O	O
sequences	O	O
at	O	O
the	O	O
site	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
in	O	O
humans	O	O
has	O	O
opened	O	O
up	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
detailed	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
genes	O	O
in	O	O
humans	O	O
and	O	O
in	O	O
related	O	O
mammalian	O	O
species	O	O
.	O	O

Until	O	O
relatively	O	O
recently	O	O
,	O	O
there	O	O
was	O	O
no	O	O
obvious	O	O
mouse	O	O
model	O	O
of	O	O
this	O	O
genetic	B-Disease	D030342
disease	I-Disease	D030342
for	O	O
the	O	O
development	O	O
of	O	O
therapeutic	O	O
strategies	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
a	O	O
mouse	O	O
X	O	O
-	O	O
linked	O	O
mutant	O	O
showing	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
,	O	O
mdx	O	O
,	O	O
has	O	O
provided	O	O
a	O	O
candidate	O	O
mouse	O	O
genetic	O	O
homologue	O	O
to	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
;	O	O
the	O	O
relatively	O	O
mild	O	O
pathological	O	O
features	O	O
of	O	O
mdx	O	O
suggest	O	O
it	O	O
may	O	O
have	O	O
more	O	O
in	O	O
common	O	O
with	O	O
mutations	O	O
of	O	O
the	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
type	O	O
at	O	O
the	O	O
same	O	O
human	O	O
locus	O	O
,	O	O
however	O	O
.	O	O

But	O	O
the	O	O
close	O	O
genetic	O	O
linkage	O	O
of	O	O
mdx	O	O
to	O	O
G6PD	O	O
and	O	O
Hprt	O	O
on	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
,	O	O
coupled	O	O
with	O	O
its	O	O
comparatively	O	O
mild	O	O
pathology	O	O
,	O	O
have	O	O
suggested	O	O
that	O	O
the	O	O
mdx	O	O
mutation	O	O
may	O	O
instead	O	O
correspond	O	O
to	O	O
Emery	B-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
which	O	O
itself	O	O
is	O	O
closely	O	O
linked	O	O
to	O	O
DNA	O	O
markers	O	O
at	O	O
Xq28	O	O
-	O	O
qter	O	O
in	O	O
the	O	O
region	O	O
of	O	O
G6PD	O	O
on	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

Using	O	O
an	O	O
interspecific	O	O
mouse	O	O
domesticus	O	O
/	O	O
spretus	O	O
cross	O	O
,	O	O
segregating	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
markers	O	O
on	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
,	O	O
we	O	O
have	O	O
positioned	O	O
on	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
sequences	O	O
homologous	O	O
to	O	O
a	O	O
DMD	B-Disease	D020388
cDNA	O	O
clone	O	O
.	O	O

These	O	O
sequences	O	O
map	O	O
provocatively	O	O
close	O	O
to	O	O
the	O	O
mdx	O	O
mutation	O	O
and	O	O
unexpectedly	O	O
distant	O	O
from	O	O
sparse	O	O
fur	O	O
,	O	O
spf	O	O
,	O	O
the	O	O
mouse	O	O
homologue	O	O
of	O	O
OTC	O	O
(	O	O
ornithine	O	O
transcarbamylase	O	O
)	O	O
which	O	O
is	O	O
closely	O	O
linked	O	O
to	O	O
DMD	B-Disease	D020388
on	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
the	O	O
alkaptonuria	B-Disease	D000474
mouse	O	O
model	O	O
.	O	O

Alkaptonuria	B-Disease	D000474
(	O	O
aku	B-Disease	D000474
)	O	O
,	O	O
an	O	O
inborn	B-Disease	D008661
error	I-Disease	D008661
of	I-Disease	D008661
metabolism	I-Disease	D008661
caused	O	O
by	O	O
the	O	O
loss	O	O
of	O	O
homogentisate	O	O
1	O	O
,	O	O
2	O	O
-	O	O
dioxygenase	O	O
(	O	O
HGD	O	O
)	O	O
,	O	O
has	O	O
been	O	O
described	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
created	O	O
by	O	O
ethylnitrosourea	O	O
mutagenesis	O	O
but	O	O
the	O	O
mutation	O	O
in	O	O
these	O	O
mice	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
identified	O	O
.	O	O

We	O	O
used	O	O
RT	O	O
-	O	O
PCR	O	O
to	O	O
amplify	O	O
the	O	O
Hgd	O	O
cDNA	O	O
from	O	O
Hgd	O	O
(	O	O
aku	B-Disease	D000474
)	O	O
/	O	O
Hgd	O	O
(	O	O
aku	B-Disease	D000474
)	O	O
mice	O	O
.	O	O

Two	O	O
products	O	O
shorter	O	O
than	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
product	O	O
were	O	O
amplified	O	O
.	O	O

Restriction	O	O
mapping	O	O
and	O	O
DNA	O	O
sequencing	O	O
were	O	O
then	O	O
used	O	O
to	O	O
identify	O	O
the	O	O
Hgd	O	O
(	O	O
aku	B-Disease	D000474
)	O	O
mouse	O	O
mutation	O	O
,	O	O
found	O	O
to	O	O
be	O	O
a	O	O
single	O	O
base	O	O
change	O	O
in	O	O
a	O	O
splice	O	O
donor	O	O
consensus	O	O
sequence	O	O
,	O	O
causing	O	O
exon	O	O
skipping	O	O
and	O	O
frame	O	O
-	O	O
shifted	O	O
products	O	O
.	O	O

This	O	O
base	O	O
change	O	O
allowed	O	O
us	O	O
to	O	O
create	O	O
a	O	O
non	O	O
-	O	O
radioactive	O	O
genotyping	O	O
assay	O	O
for	O	O
this	O	O
allele	O	O
.	O	O

Common	O	O
sequence	O	O
motifs	O	O
at	O	O
the	O	O
rearrangement	O	O
sites	O	O
of	O	O
a	O	O
constitutional	O	O
X	O	O
/	O	O
autosome	O	O
translocation	O	O
and	O	O
associated	O	O
deletion	O	O
.	O	O

Reciprocal	O	O
chromosome	O	O
translocations	O	O
are	O	O
common	O	O
de	O	O
novo	O	O
rearrangements	O	O
that	O	O
occur	O	O
randomly	O	O
throughout	O	O
the	O	O
human	O	O
genome	O	O
.	O	O

To	O	O
learn	O	O
about	O	O
causative	O	O
mechanisms	O	O
,	O	O
we	O	O
have	O	O
cloned	O	O
and	O	O
sequenced	O	O
the	O	O
breakpoints	O	O
of	O	O
a	O	O
cytologically	O	O
balanced	O	O
constitutional	O	O
reciprocal	O	O
translocation	O	O
,	O	O
t	O	O
(	O	O
X	O	O
;	O	O
4	O	O
)	O	O
(	O	O
p21	O	O
.	O	O

2	O	O
;	O	O
q31	O	O
.	O	O

22	O	O
)	O	O
,	O	O
present	O	O
in	O	O
a	O	O
girl	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

Physical	O	O
mapping	O	O
of	O	O
the	O	O
derivative	O	O
chromosomes	O	O
,	O	O
after	O	O
their	O	O
separation	O	O
in	O	O
somatic	O	O
cell	O	O
hybrids	O	O
,	O	O
reveals	O	O
that	O	O
the	O	O
translocation	O	O
disrupts	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
in	O	O
Xp21	O	O
within	O	O
the	O	O
18	O	O
-	O	O
kb	O	O
intron	O	O
16	O	O
.	O	O

Restriction	O	O
mapping	O	O
and	O	O
sequencing	O	O
of	O	O
clones	O	O
that	O	O
span	O	O
both	O	O
translocation	O	O
breakpoints	O	O
as	O	O
well	O	O
as	O	O
the	O	O
corresponding	O	O
normal	O	O
regions	O	O
indicate	O	O
the	O	O
loss	O	O
of	O	O
approximately	O	O
5	O	O
kb	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
derivative	O	O
X	O	O
chromosome	O	O
,	O	O
with	O	O
4	O	O
-	O	O
6	O	O
bp	O	O
deleted	O	O
from	O	O
chromosome	O	O
4	O	O
.	O	O

RFLP	O	O
and	O	O
Southern	O	O
analyses	O	O
indicate	O	O
that	O	O
the	O	O
de	O	O
novo	O	O
translocation	O	O
is	O	O
a	O	O
paternal	O	O
origin	O	O
and	O	O
that	O	O
the	O	O
fathers	O	O
X	O	O
chromosome	O	O
contains	O	O
the	O	O
DNA	O	O
that	O	O
is	O	O
deleted	O	O
in	O	O
the	O	O
derivative	O	O
X	O	O
.	O	O

Most	O	O
likely	O	O
,	O	O
deletion	O	O
and	O	O
translation	O	O
arose	O	O
simultaneously	O	O
from	O	O
a	O	O
complex	O	O
rearrangement	O	O
event	O	O
that	O	O
involves	O	O
three	O	O
chromosomal	O	O
breakpoints	O	O
.	O	O

Short	O	O
regions	O	O
of	O	O
sequence	O	O
homology	O	O
were	O	O
present	O	O
at	O	O
the	O	O
three	O	O
sites	O	O
.	O	O

A	O	O
5	O	O
-	O	O
bp	O	O
sequence	O	O
,	O	O
GGAAT	O	O
,	O	O
found	O	O
exactly	O	O
at	O	O
the	O	O
translocation	O	O
breakpoints	O	O
on	O	O
both	O	O
normal	O	O
chromosomes	O	O
X	O	O
and	O	O
4	O	O
,	O	O
has	O	O
been	O	O
preserved	O	O
only	O	O
on	O	O
the	O	O
der	O	O
(	O	O
4	O	O
)	O	O
chromosome	O	O
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
X	O	O
-	O	O
derived	O	O
sequence	O	O
GGAATCA	O	O
has	O	O
been	O	O
lost	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
der	O	O
(	O	O
X	O	O
)	O	O
chromosome	O	O
,	O	O
as	O	O
it	O	O
matches	O	O
an	O	O
inverted	O	O
GAATCA	O	O
sequence	O	O
present	O	O
on	O	O
the	O	O
opposite	O	O
strand	O	O
exactly	O	O
at	O	O
the	O	O
other	O	O
end	O	O
of	O	O
the	O	O
deleted	O	O
5	O	O
-	O	O
kb	O	O
fragment	O	O
.	O	O

The	O	O
human	O	O
factor	O	O
IX	O	O
gene	O	O
as	O	O
germline	O	O
mutagen	O	O
test	O	O
:	O	O
samples	O	O
from	O	O
Mainland	O	O
China	O	O
have	O	O
the	O	O
putatively	O	O
endogenous	O	O
pattern	O	O
of	O	O
mutation	O	O
.	O	O

Germline	O	O
mutations	O	O
are	O	O
the	O	O
major	O	O
source	O	O
of	O	O
genetic	O	O
variation	O	O
that	O	O
allows	O	O
a	O	O
species	O	O
to	O	O
evolve	O	O
over	O	O
time	O	O
but	O	O
at	O	O
the	O	O
cost	O	O
of	O	O
Mendelian	B-Disease	D030342
disease	I-Disease	D030342
and	O	O
genetic	O	O
predisposition	O	O
to	O	O
multifactorial	B-Disease	D004194
diseases	I-Disease	D004194
.	O	O

Previous	O	O
analyses	O	O
have	O	O
revealed	O	O
that	O	O
the	O	O
pattern	O	O
of	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
factor	O	O
IX	O	O
gene	O	O
(	O	O
F9	O	O
)	O	O
is	O	O
similar	O	O
among	O	O
a	O	O
variety	O	O
of	O	O
ethnically	O	O
and	O	O
geographically	O	O
diverse	O	O
populations	O	O
and	O	O
compatible	O	O
with	O	O
the	O	O
ancient	O	O
pattern	O	O
that	O	O
has	O	O
shaped	O	O
the	O	O
mammalian	O	O
genome	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
compare	O	O
the	O	O
pattern	O	O
of	O	O
germline	O	O
mutation	O	O
in	O	O
a	O	O
population	O	O
of	O	O
hemophilia	B-Disease	D002836
B	I-Disease	D002836
patients	O	O
from	O	O
Mainland	O	O
China	O	O
(	O	O
n	O	O
=	O	O
66	O	O
)	O	O
to	O	O
that	O	O
in	O	O
U	O	O
.	O	O

S	O	O
.	O	O

Caucasians	O	O
,	O	O
Blacks	O	O
,	O	O
and	O	O
Mexican	O	O
Hispanics	O	O
and	O	O
stratify	O	O
by	O	O
disease	O	O
severity	O	O
and	O	O
ethnicity	O	O
.	O	O

The	O	O
similar	O	O
pattern	O	O
of	O	O
germline	O	O
mutation	O	O
in	O	O
all	O	O
ethnic	O	O
groups	O	O
studied	O	O
to	O	O
date	O	O
provides	O	O
additional	O	O
data	O	O
compatible	O	O
with	O	O
the	O	O
inference	O	O
that	O	O
endogenous	O	O
processes	O	O
predominate	O	O
in	O	O
germline	O	O
mutations	O	O
.	O	O

Phenotype	O	O
heterogeneity	O	O
among	O	O
hemizygotes	O	O
in	O	O
a	O	O
family	O	O
biochemically	O	O
screened	O	O
for	O	O
adrenoleukodystrophy	B-Disease	D000326
.	O	O

We	O	O
report	O	O
on	O	O
two	O	O
clinically	O	O
,	O	O
neurologically	O	O
normal	O	O
relatives	O	O
of	O	O
a	O	O
boy	O	O
affected	O	O
by	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
;	O	O
they	O	O
were	O	O
found	O	O
repeatedly	O	O
to	O	O
have	O	O
the	O	O
biochemical	O	O
defect	O	O
of	O	O
an	O	O
ALD	B-Disease	D000326
hemizygote	O	O
.	O	O

The	O	O
assay	O	O
consisted	O	O
in	O	O
the	O	O
determination	O	O
of	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
in	O	O
lyophilized	O	O
and	O	O
reconstituted	O	O
plasma	O	O
.	O	O

While	O	O
no	O	O
evidence	O	O
of	O	O
neurologic	B-Disease	D009422
disease	I-Disease	D009422
(	O	O
leukodystrophy	B-Disease	D007966
or	O	O
myeloneuropathy	B-Disease	D009422
)	O	O
was	O	O
present	O	O
in	O	O
these	O	O
hemizygotes	O	O
,	O	O
adrenocortical	B-Disease	D000224
insufficiency	I-Disease	D000224
provoking	O	O
compensatory	O	O
high	O	O
ACTH	O	O
release	O	O
was	O	O
found	O	O
in	O	O
both	O	O
.	O	O

These	O	O
findings	O	O
should	O	O
be	O	O
taken	O	O
into	O	O
consideration	O	O
when	O	O
counseling	O	O
families	O	O
in	O	O
which	O	O
cases	O	O
with	O	O
clinically	O	O
expressed	O	O
ALD	B-Disease	D000326
are	O	O
represented	O	O
in	O	O
several	O	O
generations	O	O
.	O	O

.	O	O

Novel	O	O
mutations	O	O
of	O	O
the	O	O
ATP7B	O	O
gene	O	O
in	O	O
Japanese	O	O
patients	O	O
with	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Wilson	B-Disease	D006527
disease	I-Disease	D006527
(	O	O
WD	B-Disease	D006527
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
copper	O	O
accumulation	O	O
in	O	O
the	O	O
liver	O	O
,	O	O
brain	O	O
,	O	O
kidneys	O	O
,	O	O
and	O	O
corneas	O	O
,	O	O
and	O	O
culminating	O	O
in	O	O
copper	O	O
toxication	O	O
in	O	O
these	O	O
organs	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
mutations	O	O
of	O	O
the	O	O
responsible	O	O
gene	O	O
,	O	O
ATP7B	O	O
,	O	O
in	O	O
four	O	O
Japanese	O	O
patients	O	O
with	O	O
WD	B-Disease	D006527
.	O	O

By	O	O
direct	O	O
sequencing	O	O
,	O	O
we	O	O
identified	O	O
five	O	O
mutations	O	O
,	O	O
of	O	O
which	O	O
two	O	O
were	O	O
novel	O	O
,	O	O
and	O	O
16	O	O
polymorphisms	O	O
,	O	O
of	O	O
which	O	O
6	O	O
were	O	O
novel	O	O
.	O	O

The	O	O
mutations	O	O
2871delC	O	O
and	O	O
2513delA	O	O
shift	O	O
the	O	O
reading	O	O
frame	O	O
so	O	O
that	O	O
truncated	O	O
abnormal	O	O
protein	O	O
is	O	O
expected	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
these	O	O
mutations	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
hepatic	O	O
-	O	O
type	O	O
of	O	O
early	O	O
onset	O	O
,	O	O
the	O	O
mutations	O	O
A874V	O	O
,	O	O
R778L	O	O
,	O	O
and	O	O
3892delGTC	O	O
were	O	O
either	O	O
missense	O	O
mutations	O	O
or	O	O
in	O	O
frame	O	O
1	O	O
-	O	O
amino	O	O
acid	O	O
deletion	O	O
,	O	O
and	O	O
occurred	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
hepato	O	O
-	O	O
neurologic	O	O
type	O	O
of	O	O
late	O	O
onset	O	O
.	O	O

The	O	O
mutations	O	O
2871delC	O	O
and	O	O
R778L	O	O
have	O	O
been	O	O
previously	O	O
reported	O	O
in	O	O
a	O	O
relatively	O	O
large	O	O
number	O	O
of	O	O
Japanese	O	O
patients	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
R778L	O	O
is	O	O
known	O	O
to	O	O
be	O	O
more	O	O
prevalent	O	O
in	O	O
Asian	O	O
countries	O	O
than	O	O
in	O	O
other	O	O
countries	O	O
of	O	O
the	O	O
world	O	O
.	O	O

Our	O	O
data	O	O
are	O	O
compatible	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
mutations	O	O
tend	O	O
to	O	O
occur	O	O
in	O	O
a	O	O
population	O	O
-	O	O
specific	O	O
manner	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
accumulation	O	O
of	O	O
the	O	O
types	O	O
of	O	O
mutations	O	O
in	O	O
Japanese	O	O
patients	O	O
with	O	O
WD	B-Disease	D006527
will	O	O
facilitate	O	O
the	O	O
fast	O	O
and	O	O
effective	O	O
genetic	O	O
diagnosis	O	O
of	O	O
WD	B-Disease	D006527
in	O	O
Japanese	O	O
patients	O	O
.	O	O

.	O	O

Structural	O	O
analysis	O	O
of	O	O
the	O	O
5	O	O
'	O	O
region	O	O
of	O	O
mouse	O	O
and	O	O
human	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
genes	O	O
reveals	O	O
conservation	O	O
of	O	O
putative	O	O
promoter	O	O
region	O	O
and	O	O
di	O	O
-	O	O
and	O	O
trinucleotide	O	O
polymorphisms	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
cloned	O	O
and	O	O
characterized	O	O
the	O	O
murine	O	O
homologue	O	O
of	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
gene	O	O
and	O	O
shown	O	O
that	O	O
it	O	O
maps	O	O
to	O	O
mouse	O	O
chromosome	O	O
5	O	O
within	O	O
a	O	O
region	O	O
of	O	O
conserved	O	O
synteny	O	O
with	O	O
human	O	O
chromosome	O	O
4p16	O	O
.	O	O

3	O	O
3	O	O
.	O	O

Here	O	O
we	O	O
present	O	O
a	O	O
detailed	O	O
comparison	O	O
of	O	O
the	O	O
sequence	O	O
of	O	O
the	O	O
putative	O	O
promoter	O	O
and	O	O
the	O	O
organization	O	O
of	O	O
the	O	O
5	O	O
genomic	O	O
region	O	O
of	O	O
the	O	O
murine	O	O
(	O	O
Hdh	O	O
)	O	O
and	O	O
human	O	O
HD	B-Disease	D006816
genes	O	O
encompassing	O	O
the	O	O
first	O	O
five	O	O
exons	O	O
.	O	O

We	O	O
show	O	O
that	O	O
in	O	O
this	O	O
region	O	O
these	O	O
two	O	O
genes	O	O
share	O	O
identical	O	O
exon	O	O
boundaries	O	O
,	O	O
but	O	O
have	O	O
different	O	O
-	O	O
size	O	O
introns	O	O
.	O	O

Two	O	O
dinucleotide	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
one	O	O
trinucleotide	O	O
intronic	O	O
polymorphism	O	O
in	O	O
Hdh	O	O
and	O	O
an	O	O
intronic	O	O
CA	O	O
polymorphism	O	O
in	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
were	O	O
identified	O	O
.	O	O

Comparison	O	O
of	O	O
940	O	O
-	O	O
bp	O	O
sequence	O	O
5	O	O
to	O	O
the	O	O
putative	O	O
translation	O	O
start	O	O
site	O	O
reveals	O	O
a	O	O
highly	O	O
conserved	O	O
region	O	O
(	O	O
78	O	O
.	O	O

8	O	O
%	O	O
nucleotide	O	O
identity	O	O
)	O	O
between	O	O
Hdh	O	O
and	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
from	O	O
nucleotide	O	O
-	O	O
56	O	O
to	O	O
-	O	O
206	O	O
(	O	O
of	O	O
Hdh	O	O
)	O	O
.	O	O

Neither	O	O
Hdh	O	O
nor	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
have	O	O
typical	O	O
TATA	O	O
or	O	O
CCAAT	O	O
elements	O	O
,	O	O
but	O	O
both	O	O
show	O	O
one	O	O
putative	O	O
AP2	O	O
binding	O	O
site	O	O
and	O	O
numerous	O	O
potential	O	O
Sp1	O	O
binding	O	O
sites	O	O
.	O	O

The	O	O
high	O	O
sequence	O	O
identity	O	O
between	O	O
Hdh	O	O
and	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
for	O	O
approximately	O	O
200	O	O
bp	O	O
5	O	O
to	O	O
the	O	O
putative	O	O
translation	O	O
start	O	O
site	O	O
indicates	O	O
that	O	O
these	O	O
sequences	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
regulating	O	O
expression	O	O
of	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
gene	O	O
Complement	B-Disease	D007153
deficiency	I-Disease	D007153
and	O	O
nephritis	B-Disease	D009393
.	O	O

A	O	O
report	O	O
of	O	O
a	O	O
family	O	O
.	O	O

A	O	O
family	O	O
is	O	O
described	O	O
in	O	O
which	O	O
three	O	O
children	O	O
had	O	O
homozygous	O	O
deficiency	B-Disease	OMIM:613779
of	I-Disease	OMIM:613779
C3	I-Disease	OMIM:613779
and	O	O
in	O	O
which	O	O
both	O	O
parents	O	O
and	O	O
two	O	O
other	O	O
children	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
C3	O	O
null	O	O
gene	O	O
.	O	O

One	O	O
child	O	O
with	O	O
heterozygous	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
was	O	O
found	O	O
to	O	O
have	O	O
membranoproliferative	O	O
glomerulonephritis	B-Disease	D005921
;	O	O
proteinuria	B-Disease	D011507
and	O	O
/	O	O
or	O	O
microscopical	O	O
haematuria	B-Disease	D006417
was	O	O
present	O	O
in	O	O
all	O	O
three	O	O
homozygous	O	O
C3	B-Disease	OMIM:613779
-	I-Disease	OMIM:613779
deficient	I-Disease	OMIM:613779
children	O	O
.	O	O

All	O	O
children	O	O
with	O	O
homozygous	O	O
or	O	O
heterozygous	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
were	O	O
,	O	O
to	O	O
a	O	O
varying	O	O
degree	O	O
,	O	O
susceptible	O	O
to	O	O
infection	O	O
.	O	O

The	O	O
only	O	O
child	O	O
of	O	O
the	O	O
family	O	O
with	O	O
normal	O	O
complement	O	O
had	O	O
no	O	O
increased	O	O
risk	O	O
of	O	O
infection	O	O
and	O	O
no	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
.	O	O

This	O	O
family	O	O
study	O	O
provides	O	O
further	O	O
support	O	O
for	O	O
the	O	O
proposal	O	O
that	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
predisposes	O	O
to	O	O
nephritis	B-Disease	D009393
.	O	O

.	O	O

Cytogenetic	O	O
investigations	O	O
in	O	O
families	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
.	O	O

Chromosomal	O	O
studies	O	O
were	O	O
performed	O	O
on	O	O
peripheral	O	O
blood	O	O
lymphocytes	O	O
and	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
five	O	O
Israeli	O	O
-	O	O
Moroccan	O	O
families	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
.	O	O

A	O	O
total	O	O
of	O	O
24	O	O
individuals	O	O
,	O	O
including	O	O
seven	O	O
propositi	O	O
,	O	O
was	O	O
investigated	O	O
.	O	O

Among	O	O
the	O	O
probands	O	O
,	O	O
significantly	O	O
elevated	O	O
rates	O	O
of	O	O
chromosome	O	O
damage	O	O
were	O	O
observed	O	O
in	O	O
both	O	O
blood	O	O
and	O	O
skin	O	O
.	O	O

Skin	O	O
fibroblasts	O	O
of	O	O
affected	O	O
individuals	O	O
showed	O	O
several	O	O
orders	O	O
of	O	O
magnitude	O	O
more	O	O
chromosome	O	O
breakage	O	O
than	O	O
lymphocytes	O	O
.	O	O

Increased	O	O
rates	O	O
of	O	O
chromosome	O	O
damage	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
the	O	O
fibroblasts	O	O
of	O	O
some	O	O
phenotypically	O	O
normal	O	O
family	O	O
members	O	O
(	O	O
obligate	O	O
heterozygotes	O	O
and	O	O
sibs	O	O
)	O	O
when	O	O
compared	O	O
to	O	O
normal	O	O
controls	O	O
.	O	O

An	O	O
apparent	O	O
abnormal	O	O
clone	O	O
of	O	O
cells	O	O
,	O	O
possessing	O	O
a	O	O
large	O	O
acrocentric	O	O
marker	O	O
chromosome	O	O
(	O	O
14q	O	O
+	O	O
)	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
varying	O	O
proportions	O	O
among	O	O
cells	O	O
of	O	O
all	O	O
the	O	O
propositi	O	O
(	O	O
2	O	O
-	O	O
5	O	O
%	O	O
of	O	O
lymphocytes	O	O
;	O	O
1	O	O
-	O	O
9	O	O
%	O	O
of	O	O
fibroblasts	O	O
)	O	O
.	O	O

.	O	O

Predominance	O	O
of	O	O
the	O	O
adrenomyeloneuropathy	B-Disease	D000326
phenotype	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
in	O	O
The	O	O
Netherlands	O	O
:	O	O
a	O	O
survey	O	O
of	O	O
30	O	O
kindreds	O	O
.	O	O

X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
is	O	O
an	O	O
inherited	B-Disease	D030342
disorder	I-Disease	D030342
of	O	O
peroxisomal	O	O
beta	O	O
-	O	O
oxidation	O	O
associated	O	O
with	O	O
accumulation	O	O
of	O	O
saturated	O	O
very	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
,	O	O
which	O	O
results	O	O
in	O	O
central	O	O
and	O	O
peripheral	O	O
demyelination	B-Disease	D003711
and	O	O
in	O	O
impaired	B-Disease	D000303
function	I-Disease	D000303
of	I-Disease	D000303
adrenal	I-Disease	D000303
cortex	I-Disease	D000303
and	I-Disease	D000303
testes	I-Disease	D000303
.	O	O

The	O	O
phenotypic	O	O
expression	O	O
is	O	O
highly	O	O
variable	O	O
,	O	O
childhood	B-Disease	D000326
cerebral	I-Disease	D000326
ALD	I-Disease	D000326
(	O	O
CCALD	B-Disease	D000326
)	O	O
and	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
being	O	O
the	O	O
main	O	O
variants	O	O
.	O	O

We	O	O
explored	O	O
the	O	O
30	O	O
Dutch	O	O
kindreds	O	O
well	O	O
known	O	O
to	O	O
the	O	O
Dutch	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
/	O	O
AMN	B-Disease	D000326
Study	O	O
Group	O	O
and	O	O
phenotyped	O	O
77	O	O
male	O	O
patients	O	O
35	O	O
(	O	O
46	O	O
%	O	O
)	O	O
had	O	O
AMN	B-Disease	D000326
and	O	O
24	O	O
(	O	O
31	O	O
%	O	O
)	O	O
CCALD	B-Disease	D000326
or	O	O
adolescent	B-Disease	D000326
cerebral	I-Disease	D000326
ALD	I-Disease	D000326
(	O	O
AdolCALD	B-Disease	D000326
)	O	O
.	O	O

These	O	O
percentages	O	O
differ	O	O
significantly	O	O
from	O	O
previous	O	O
reports	O	O
,	O	O
in	O	O
which	O	O
25	O	O
to	O	O
28	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
developed	O	O
AMN	B-Disease	D000326
and	O	O
53	O	O
to	O	O
57	O	O
%	O	O
CCALD	B-Disease	D000326
or	O	O
AdolCALD	B-Disease	D000326
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
-	O	O
-	O	O
at	O	O
least	O	O
in	O	O
the	O	O
Netherlands	O	O
-	O	O
-	O	O
AMN	B-Disease	D000326
may	O	O
be	O	O
the	O	O
most	O	O
frequent	O	O
phenotype	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
.	O	O

.	O	O

Three	O	O
novel	O	O
aniridia	B-Disease	D015783
mutations	O	O
in	O	O
the	O	O
human	O	O
PAX6	O	O
gene	O	O
.	O	O

Aniridia	B-Disease	D015783
(	O	O
iris	B-Disease	D007499
hypoplasia	I-Disease	D007499
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D005124
dominant	I-Disease	D005124
congenital	I-Disease	D005124
disorder	I-Disease	D005124
of	I-Disease	D005124
the	I-Disease	D005124
eye	I-Disease	D005124
.	O	O

Mutations	O	O
in	O	O
the	O	O
human	O	O
aniridia	B-Disease	D015783
(	O	O
PAX6	O	O
)	O	O
gene	O	O
have	O	O
now	O	O
been	O	O
identified	O	O
in	O	O
many	O	O
patients	O	O
from	O	O
various	O	O
ethnic	O	O
groups	O	O
.	O	O

In	O	O
the	O	O
study	O	O
reported	O	O
here	O	O
we	O	O
describe	O	O
PAX6	O	O
mutations	O	O
in	O	O
one	O	O
sporadic	O	O
and	O	O
five	O	O
familial	O	O
cases	O	O
with	O	O
aniridia	B-Disease	D015783
.	O	O

Of	O	O
the	O	O
four	O	O
different	O	O
mutations	O	O
identified	O	O
,	O	O
one	O	O
was	O	O
identical	O	O
to	O	O
a	O	O
previously	O	O
reported	O	O
mutation	O	O
(	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
at	O	O
codon	O	O
240	O	O
)	O	O
,	O	O
and	O	O
three	O	O
were	O	O
novel	O	O
two	O	O
in	O	O
the	O	O
glycine	O	O
-	O	O
rich	O	O
region	O	O
and	O	O
one	O	O
in	O	O
the	O	O
proline	O	O
/	O	O
serine	O	O
/	O	O
threonine	O	O
-	O	O
rich	O	O
(	O	O
PST	O	O
)	O	O
region	O	O
.	O	O

One	O	O
PAX6	O	O
mutation	O	O
found	O	O
in	O	O
the	O	O
PST	O	O
region	O	O
was	O	O
associated	O	O
with	O	O
cataracts	B-Disease	D002386
in	O	O
an	O	O
aniridia	B-Disease	D015783
family	O	O
.	O	O

Another	O	O
splice	O	O
mutation	O	O
in	O	O
the	O	O
PST	O	O
domain	O	O
occurred	O	O
in	O	O
an	O	O
aniridia	B-Disease	D015783
patient	O	O
with	O	O
anosmia	B-Disease	D000857
(	O	O
inability	O	O
to	O	O
smell	O	O
)	O	O
.	O	O

The	O	O
six	O	O
new	O	O
aniridia	B-Disease	D015783
cases	O	O
reported	O	O
here	O	O
have	O	O
mutations	O	O
predicted	O	O
to	O	O
generate	O	O
incomplete	O	O
PAX6	O	O
proteins	O	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
theory	O	O
that	O	O
human	O	O
aniridia	B-Disease	D015783
is	O	O
caused	O	O
by	O	O
haploinsufficiency	B-Disease	OMIM:106210
of	I-Disease	OMIM:106210
PAX6	I-Disease	OMIM:106210
.	O	O

.	O	O

Hepatoblastoma	B-Disease	D018197
,	O	O
pigmented	B-Disease	D015821
ocular	I-Disease	D015821
fundus	I-Disease	D015821
lesions	I-Disease	D015821
and	O	O
jaw	B-Disease	D007571
lesions	I-Disease	D007571
in	O	O
Gardner	B-Disease	D005736
syndrome	I-Disease	D005736
.	O	O

Hepatoblastoma	B-Disease	D018197
is	O	O
a	O	O
rare	O	O
neoplasm	B-Disease	D009369
of	O	O
infants	O	O
and	O	O
children	O	O
only	O	O
recently	O	O
documented	O	O
in	O	O
association	O	O
with	O	O
hereditary	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
of	I-Disease	D011125
the	I-Disease	D011125
colon	I-Disease	D011125
[	O	O
Kingston	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1983	O	O
]	O	O
.	O	O

We	O	O
report	O	O
four	O	O
children	O	O
with	O	O
hepatoblastoma	B-Disease	D018197
from	O	O
four	O	O
unrelated	O	O
families	O	O
with	O	O
Gardner	B-Disease	D005736
syndrome	I-Disease	D005736
(	O	O
GS	B-Disease	D005736
)	O	O
.	O	O

One	O	O
child	O	O
,	O	O
now	O	O
19	O	O
years	O	O
old	O	O
,	O	O
survived	O	O
after	O	O
a	O	O
resection	O	O
of	O	O
a	O	O
hepatoblastoma	B-Disease	D018197
in	O	O
infancy	O	O
and	O	O
recently	O	O
was	O	O
found	O	O
to	O	O
have	O	O
GS	B-Disease	D005736
.	O	O

He	O	O
has	O	O
an	O	O
associated	O	O
odontoma	B-Disease	D009810
and	O	O
pigmented	B-Disease	D015821
ocular	I-Disease	D015821
fundus	I-Disease	D015821
lesions	I-Disease	D015821
,	O	O
both	O	O
of	O	O
which	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
clinical	O	O
markers	O	O
of	O	O
GS	B-Disease	D005736
.	O	O

Many	O	O
individuals	O	O
in	O	O
these	O	O
four	O	O
GS	B-Disease	D005736
families	O	O
,	O	O
both	O	O
affected	O	O
and	O	O
at	O	O
risk	O	O
,	O	O
have	O	O
osteomatous	B-Disease	D007571
jaw	I-Disease	D007571
lesions	I-Disease	D007571
and	O	O
pigmented	B-Disease	D015821
ocular	I-Disease	D015821
fundus	I-Disease	D015821
lesions	I-Disease	D015821
.	O	O

A	O	O
search	O	O
for	O	O
colonic	B-Disease	D003111
polyps	I-Disease	D003111
should	O	O
be	O	O
made	O	O
in	O	O
families	O	O
of	O	O
infants	O	O
and	O	O
children	O	O
with	O	O
hepatoblastoma	B-Disease	D018197
.	O	O

If	O	O
the	O	O
child	O	O
survives	O	O
,	O	O
he	O	O
or	O	O
she	O	O
should	O	O
be	O	O
monitored	O	O
for	O	O
the	O	O
later	O	O
appearance	O	O
of	O	O
colonic	B-Disease	D003111
polyps	I-Disease	D003111
.	O	O

The	O	O
finding	O	O
of	O	O
jaw	B-Disease	D007571
lesions	I-Disease	D007571
and	O	O
/	O	O
or	O	O
pigmented	B-Disease	D015821
ocular	I-Disease	D015821
fundus	I-Disease	D015821
lesions	I-Disease	D015821
in	O	O
relatives	O	O
at	O	O
risk	O	O
are	O	O
indications	O	O
of	O	O
the	O	O
possible	O	O
presence	O	O
of	O	O
the	O	O
GS	B-Disease	D005736
gene	O	O
.	O	O

Mutation	O	O
spectrum	O	O
in	O	O
the	O	O
CHM	B-Disease	D015794
gene	O	O
of	O	O
Danish	O	O
and	O	O
Swedish	O	O
choroideremia	B-Disease	D015794
patients	O	O
.	O	O

The	O	O
recent	O	O
isolation	O	O
of	O	O
the	O	O
complete	O	O
open	O	O
reading	O	O
frame	O	O
of	O	O
the	O	O
choroideremia	B-Disease	D015794
(	O	O
CHM	B-Disease	D015794
)	O	O
gene	O	O
and	O	O
the	O	O
characterization	O	O
of	O	O
the	O	O
exon	O	O
-	O	O
intron	O	O
boundaries	O	O
has	O	O
paved	O	O
the	O	O
way	O	O
to	O	O
mutation	O	O
detection	O	O
in	O	O
patients	O	O
with	O	O
classical	O	O
choroideremia	B-Disease	D015794
.	O	O

We	O	O
have	O	O
performed	O	O
mutation	O	O
screening	O	O
in	O	O
patients	O	O
from	O	O
15	O	O
Danish	O	O
and	O	O
Swedish	O	O
families	O	O
by	O	O
using	O	O
Southern	O	O
blot	O	O
hybridization	O	O
and	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
SSCP	O	O
)	O	O
technique	O	O
.	O	O

Causative	O	O
mutations	O	O
in	O	O
the	O	O
CHM	B-Disease	D015794
gene	O	O
were	O	O
detected	O	O
in	O	O
at	O	O
least	O	O
12	O	O
families	O	O
,	O	O
indicating	O	O
that	O	O
a	O	O
substantial	O	O
part	O	O
of	O	O
the	O	O
mutations	O	O
can	O	O
be	O	O
identified	O	O
by	O	O
this	O	O
approach	O	O
.	O	O

In	O	O
four	O	O
of	O	O
these	O	O
families	O	O
deletions	O	O
of	O	O
different	O	O
sizes	O	O
were	O	O
found	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
one	O	O
patient	O	O
,	O	O
the	O	O
deletion	O	O
resulted	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
only	O	O
one	O	O
exon	O	O
,	O	O
while	O	O
in	O	O
another	O	O
the	O	O
deletion	O	O
comprised	O	O
the	O	O
entire	O	O
CHM	B-Disease	D015794
gene	O	O
.	O	O

Mapping	O	O
of	O	O
the	O	O
deletion	O	O
endpoints	O	O
in	O	O
these	O	O
four	O	O
patients	O	O
and	O	O
in	O	O
another	O	O
11	O	O
male	O	O
patients	O	O
with	O	O
sizeable	O	O
deletions	O	O
enabled	O	O
us	O	O
to	O	O
construct	O	O
a	O	O
very	O	O
detailed	O	O
map	O	O
of	O	O
intervals	O	O
2	O	O
and	O	O
3	O	O
of	O	O
Xq21	O	O
.	O	O

In	O	O
the	O	O
remaining	O	O
11	O	O
Danish	O	O
and	O	O
Swedish	O	O
families	O	O
at	O	O
least	O	O
8	O	O
causative	O	O
mutations	O	O
were	O	O
found	O	O
by	O	O
PCR	O	O
-	O	O
SSCP	O	O
analysis	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

Interestingly	O	O
,	O	O
all	O	O
CHM	B-Disease	D015794
gene	O	O
mutations	O	O
detected	O	O
thus	O	O
far	O	O
in	O	O
choroideremia	B-Disease	D015794
patients	O	O
give	O	O
rise	O	O
to	O	O
the	O	O
introduction	O	O
of	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
.	O	O

.	O	O

Diverse	O	O
point	O	O
mutations	O	O
result	O	O
in	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
polymorphism	O	O
in	O	O
Taiwan	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
PHOSPHATE	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
;	I-Disease	D005955
EC	I-Disease	D005955
1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

49	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
the	O	O
most	O	O
common	O	O
human	O	O
enzymopathy	B-Disease	D008661
,	O	O
affecting	O	O
more	O	O
than	O	O
200	O	O
million	O	O
people	O	O
worldwide	O	O
.	O	O

Although	O	O
greater	O	O
than	O	O
400	O	O
variants	O	O
have	O	O
been	O	O
described	O	O
based	O	O
on	O	O
clinical	O	O
and	O	O
biochemical	O	O
criteria	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
these	O	O
G6PD	B-Disease	D005955
deficiencies	I-Disease	D005955
.	O	O

Recently	O	O
,	O	O
the	O	O
gene	O	O
that	O	O
encodes	O	O
human	O	O
G6PD	O	O
has	O	O
been	O	O
cloned	O	O
and	O	O
sequenced	O	O
,	O	O
which	O	O
enables	O	O
us	O	O
to	O	O
examine	O	O
directly	O	O
the	O	O
heterogeneity	O	O
of	O	O
G6PD	O	O
at	O	O
the	O	O
DNA	O	O
level	O	O
.	O	O

During	O	O
the	O	O
past	O	O
10	O	O
years	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
G6PD	O	O
activity	O	O
in	O	O
21	O	O
,	O	O
271	O	O
newborn	O	O
Chinese	O	O
infants	O	O
(	O	O
11	O	O
,	O	O
400	O	O
males	O	O
and	O	O
9	O	O
,	O	O
871	O	O
females	O	O
)	O	O
and	O	O
identified	O	O
314	O	O
(	O	O
2	O	O
.	O	O

8	O	O
%	O	O
)	O	O
males	O	O
and	O	O
246	O	O
(	O	O
2	O	O
.	O	O

5	O	O
%	O	O
)	O	O
females	O	O
having	O	O
low	O	O
G6PD	O	O
activity	O	O
.	O	O

The	O	O
G6PD	O	O
gene	O	O
from	O	O
10	O	O
randomly	O	O
selected	O	O
affected	O	O
individuals	O	O
and	O	O
their	O	O
relatives	O	O
was	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
amplified	O	O
,	O	O
subcloned	O	O
,	O	O
and	O	O
sequenced	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
at	O	O
least	O	O
four	O	O
types	O	O
of	O	O
mutation	O	O
are	O	O
responsible	O	O
for	O	O
the	O	O
G6PD	O	O
polymorphism	O	O
in	O	O
Taiwan	O	O
.	O	O

The	O	O
first	O	O
type	O	O
of	O	O
mutation	O	O
(	O	O
487	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
)	O	O
was	O	O
found	O	O
in	O	O
an	O	O
affected	O	O
Chinese	O	O
with	O	O
a	O	O
G	O	O
to	O	O
A	O	O
change	O	O
at	O	O
nucleotide	O	O
487	O	O
,	O	O
which	O	O
results	O	O
in	O	O
a	O	O
(	O	O
163	O	O
)	O	O
Gly	O	O
to	O	O
Ser	O	O
substitution	O	O
.	O	O

The	O	O
second	O	O
type	O	O
of	O	O
mutation	O	O
(	O	O
493	O	O
A	O	O
-	O	O
-	O	O
-	O	O
-	O	O
G	O	O
)	O	O
is	O	O
a	O	O
novel	O	O
mutation	O	O
that	O	O
has	O	O
not	O	O
been	O	O
reported	O	O
in	O	O
any	O	O
other	O	O
ethnic	O	O
group	O	O
and	O	O
was	O	O
identified	O	O
in	O	O
two	O	O
affected	O	O
Chinese	O	O
.	O	O

This	O	O
mutation	O	O
causes	O	O
an	O	O
A	O	O
to	O	O
G	O	O
change	O	O
at	O	O
nucleotide	O	O
position	O	O
493	O	O
,	O	O
producing	O	O
an	O	O
(	O	O
165	O	O
)	O	O
Asn	O	O
to	O	O
Asp	O	O
substitution	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
487	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
and	O	O
493	O	O
A	O	O
-	O	O
-	O	O
-	O	O
-	O	O
G	O	O
mutations	O	O
create	O	O
Alu	O	O
I	O	O
and	O	O
Ava	O	O
II	O	O
recognition	O	O
sites	O	O
,	O	O
respectively	O	O
,	O	O
which	O	O
enabled	O	O
us	O	O
to	O	O
rapidly	O	O
detect	O	O
these	O	O
two	O	O
mutations	O	O
by	O	O
PCR	O	O
/	O	O
restriction	O	O
enzyme	O	O
(	O	O
RE	O	O
)	O	O
digestion	O	O
method	O	O
.	O	O

The	O	O
third	O	O
mutation	O	O
(	O	O
1376	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
)	O	O
was	O	O
found	O	O
in	O	O
four	O	O
affected	O	O
Chinese	O	O
.	O	O

This	O	O
mutation	O	O
causes	O	O
a	O	O
G	O	O
to	O	O
T	O	O
change	O	O
at	O	O
nucleotide	O	O
position	O	O
1376	O	O
that	O	O
results	O	O
in	O	O
an	O	O
(	O	O
459	O	O
)	O	O
Arg	O	O
to	O	O
Leu	O	O
substitution	O	O
.	O	O

The	O	O
1376	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
mutation	O	O
seems	O	O
to	O	O
be	O	O
the	O	O
dominant	O	O
allele	O	O
that	O	O
causes	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Taiwan	O	O
.	O	O

Finally	O	O
,	O	O
two	O	O
affected	O	O
Chinese	O	O
were	O	O
identified	O	O
as	O	O
having	O	O
the	O	O
fourth	O	O
mutation	O	O
(	O	O
1388	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
)	O	O
.	O	O

This	O	O
mutation	O	O
causes	O	O
a	O	O
G	O	O
to	O	O
A	O	O
change	O	O
at	O	O
nucleotide	O	O
1388	O	O
that	O	O
produces	O	O
an	O	O
(	O	O
463	O	O
)	O	O
Arg	O	O
to	O	O
His	O	O
substitution	O	O
.	O	O

Our	O	O
studies	O	O
provide	O	O
the	O	O
direct	O	O
proof	O	O
of	O	O
the	O	O
genetic	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
the	O	O
Chinese	O	O
populations	O	O
of	O	O
Taiwan	O	O
and	O	O
the	O	O
PCR	O	O
/	O	O
RE	O	O
digestion	O	O
method	O	O
is	O	O
suitable	O	O
for	O	O
simultaneous	O	O
detection	O	O
of	O	O
the	O	O
487	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
and	O	O
493	O	O
A	O	O
-	O	O
-	O	O
-	O	O
-	O	O
G	O	O
mutations	O	O
.	O	O

Fas	O	O
preassociation	O	O
required	O	O
for	O	O
apoptosis	O	O
signaling	O	O
and	O	O
dominant	O	O
inhibition	O	O
by	O	O
pathogenic	O	O
mutations	O	O
.	O	O

Heterozygous	O	O
mutations	O	O
encoding	O	O
abnormal	O	O
forms	O	O
of	O	O
the	O	O
death	O	O
receptor	O	O
Fas	O	O
dominantly	O	O
interfere	O	O
with	O	O
Fas	O	O
-	O	O
induced	O	O
lymphocyte	O	O
apoptosis	O	O
in	O	O
human	O	O
autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
.	O	O

This	O	O
effect	O	O
,	O	O
rather	O	O
than	O	O
depending	O	O
on	O	O
ligand	O	O
-	O	O
induced	O	O
receptor	O	O
oligomerization	O	O
,	O	O
was	O	O
found	O	O
to	O	O
stem	O	O
from	O	O
ligand	O	O
-	O	O
independent	O	O
interaction	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
mutant	O	O
Fas	O	O
receptors	O	O
through	O	O
a	O	O
specific	O	O
region	O	O
in	O	O
the	O	O
extracellular	O	O
domain	O	O
.	O	O

Preassociated	O	O
Fas	O	O
complexes	O	O
were	O	O
found	O	O
in	O	O
living	O	O
cells	O	O
by	O	O
means	O	O
of	O	O
fluorescence	O	O
resonance	O	O
energy	O	O
transfer	O	O
between	O	O
variants	O	O
of	O	O
green	O	O
fluorescent	O	O
protein	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
formation	O	O
of	O	O
preassociated	O	O
receptor	O	O
complexes	O	O
is	O	O
necessary	O	O
for	O	O
Fas	O	O
signaling	O	O
and	O	O
dominant	O	O
interference	O	O
in	O	O
human	O	O
disease	O	O
.	O	O

.	O	O

Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
in	O	O
the	O	O
colchicine	O	O
era	O	O
:	O	O
the	O	O
fate	O	O
of	O	O
one	O	O
family	O	O
.	O	O

In	O	O
order	O	O
to	O	O
demonstrate	O	O
the	O	O
effect	O	O
of	O	O
prophylactic	O	O
colchicine	O	O
treatment	O	O
on	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
,	O	O
a	O	O
family	O	O
is	O	O
presented	O	O
with	O	O
6	O	O
out	O	O
of	O	O
9	O	O
siblings	O	O
affected	O	O
by	O	O
FMF	B-Disease	D010505
.	O	O

Each	O	O
patient	O	O
represents	O	O
a	O	O
different	O	O
stage	O	O
of	O	O
the	O	O
amyloidotic	B-Disease	D007674
kidney	I-Disease	D007674
disease	I-Disease	D007674
of	O	O
FMF	B-Disease	D010505
and	O	O
the	O	O
effect	O	O
of	O	O
continuous	O	O
colchicine	O	O
treatment	O	O
on	O	O
its	O	O
course	O	O
.	O	O

Considered	O	O
together	O	O
,	O	O
the	O	O
members	O	O
of	O	O
this	O	O
family	O	O
present	O	O
an	O	O
almost	O	O
complete	O	O
clinical	O	O
,	O	O
genetic	O	O
,	O	O
and	O	O
behavioral	O	O
picture	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

Two	O	O
new	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
mutations	O	O
in	O	O
a	O	O
juvenile	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
patient	O	O
.	O	O

Fragments	O	O
of	O	O
the	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
gene	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
juvenile	O	O
-	O	O
onset	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
were	O	O
amplified	O	O
by	O	O
PCR	O	O
and	O	O
ligated	O	O
into	O	O
MP13	O	O
cloning	O	O
vectors	O	O
.	O	O

Clones	O	O
hybridizing	O	O
with	O	O
cDNA	O	O
for	O	O
human	O	O
ARSA	O	O
were	O	O
selected	O	O
,	O	O
examined	O	O
for	O	O
appropriate	O	O
size	O	O
inserts	O	O
,	O	O
and	O	O
used	O	O
to	O	O
prepare	O	O
single	O	O
-	O	O
stranded	O	O
phage	O	O
DNA	O	O
.	O	O

Examination	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
and	O	O
most	O	O
of	O	O
the	O	O
intronic	O	O
sequence	O	O
revealed	O	O
two	O	O
putative	O	O
disease	O	O
-	O	O
related	O	O
mutations	O	O
.	O	O

One	O	O
,	O	O
a	O	O
point	O	O
mutation	O	O
in	O	O
exon	O	O
3	O	O
,	O	O
resulted	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
isoleucine	O	O
by	O	O
serine	O	O
.	O	O

Introduction	O	O
of	O	O
this	O	O
alteration	O	O
into	O	O
the	O	O
normal	O	O
ARSA	O	O
cDNA	O	O
sequence	O	O
resulted	O	O
in	O	O
a	O	O
substantial	O	O
decrease	O	O
in	O	O
ARSA	O	O
activity	O	O
on	O	O
transient	O	O
expression	O	O
in	O	O
cultured	O	O
baby	O	O
hamster	O	O
kidney	O	O
cells	O	O
.	O	O

About	O	O
5	O	O
%	O	O
of	O	O
the	O	O
control	O	O
expression	O	O
was	O	O
observed	O	O
,	O	O
suggesting	O	O
a	O	O
small	O	O
residual	O	O
activity	O	O
in	O	O
the	O	O
mutated	O	O
ARSA	O	O
.	O	O

The	O	O
second	O	O
mutation	O	O
,	O	O
a	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transition	O	O
,	O	O
occurred	O	O
in	O	O
the	O	O
other	O	O
allele	O	O
and	O	O
resulted	O	O
in	O	O
an	O	O
altered	O	O
splice	O	O
-	O	O
recognition	O	O
sequence	O	O
between	O	O
exon	O	O
7	O	O
and	O	O
the	O	O
following	O	O
intron	O	O
.	O	O

The	O	O
mutation	O	O
also	O	O
resulted	O	O
in	O	O
the	O	O
loss	O	O
of	O	O
a	O	O
restriction	O	O
site	O	O
.	O	O

Apparently	O	O
normal	O	O
levels	O	O
of	O	O
mRNA	O	O
were	O	O
generated	O	O
from	O	O
this	O	O
allele	O	O
,	O	O
but	O	O
no	O	O
ARSA	O	O
activity	O	O
or	O	O
immuno	O	O
-	O	O
cross	O	O
-	O	O
reactive	O	O
material	O	O
could	O	O
be	O	O
detected	O	O
.	O	O

A	O	O
collection	O	O
of	O	O
DNA	O	O
samples	O	O
from	O	O
known	O	O
or	O	O
suspected	O	O
MLD	B-Disease	D007966
patients	O	O
,	O	O
members	O	O
of	O	O
their	O	O
families	O	O
,	O	O
and	O	O
normal	O	O
controls	O	O
was	O	O
screened	O	O
for	O	O
these	O	O
mutations	O	O
.	O	O

Four	O	O
additional	O	O
individuals	O	O
carrying	O	O
each	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
found	O	O
among	O	O
the	O	O
nearly	O	O
100	O	O
MLD	B-Disease	D007966
patients	O	O
in	O	O
the	O	O
sample	O	O
.	O	O

Gene	O	O
segregation	O	O
in	O	O
the	O	O
original	O	O
patients	O	O
family	O	O
was	O	O
consistent	O	O
with	O	O
available	O	O
clinical	O	O
and	O	O
biochemical	O	O
data	O	O
.	O	O

No	O	O
individuals	O	O
homozygous	O	O
for	O	O
either	O	O
of	O	O
these	O	O
two	O	O
mutations	O	O
were	O	O
identified	O	O
.	O	O

However	O	O
,	O	O
combinations	O	O
with	O	O
other	O	O
MLD	B-Disease	D007966
mutations	O	O
suggest	O	O
that	O	O
the	O	O
point	O	O
mutation	O	O
in	O	O
exon	O	O
3	O	O
does	O	O
result	O	O
in	O	O
some	O	O
residual	O	O
enzyme	O	O
activity	O	O
and	O	O
is	O	O
associated	O	O
with	O	O
late	O	O
-	O	O
onset	O	O
forms	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
following	O	O
exon	O	O
7	O	O
produces	O	O
late	O	O
-	O	O
infantile	O	O
MLD	B-Disease	D007966
when	O	O
combined	O	O
with	O	O
other	O	O
enzyme	O	O
-	O	O
null	O	O
mutations	O	O
,	O	O
implying	O	O
that	O	O
it	O	O
is	O	O
completely	O	O
silent	O	O
enzymatically	O	O
.	O	O

.	O	O

Null	O	O
mutation	O	O
of	O	O
the	O	O
murine	O	O
ATP7B	O	O
(	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
)	O	O
gene	O	O
results	O	O
in	O	O
intracellular	B-Disease	C535468
copper	I-Disease	C535468
accumulation	I-Disease	C535468
and	O	O
late	B-Disease	D020518
-	I-Disease	D020518
onset	I-Disease	D020518
hepatic	I-Disease	D020518
nodular	I-Disease	D020518
transformation	I-Disease	D020518
.	O	O

The	O	O
Atp7b	O	O
protein	O	O
is	O	O
a	O	O
copper	O	O
-	O	O
transporting	O	O
ATPase	O	O
expressed	O	O
predominantly	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
in	O	O
most	O	O
other	O	O
tissues	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
ATP7B	O	O
gene	O	O
lead	O	O
to	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
,	O	O
a	O	O
copper	B-Disease	C535468
toxicity	I-Disease	C535468
disorder	I-Disease	C535468
characterized	O	O
by	O	O
dramatic	O	O
build	O	O
-	O	O
up	O	O
of	O	O
intracellular	O	O
hepatic	O	O
copper	O	O
with	O	O
subsequent	O	O
hepatic	B-Disease	D008107
and	I-Disease	D008107
neuro	I-Disease	D008107
-	I-Disease	D008107
logical	I-Disease	D008107
abnormalities	I-Disease	D008107
.	O	O

Using	O	O
homologous	O	O
recombination	O	O
to	O	O
disrupt	O	O
the	O	O
normal	O	O
translation	O	O
of	O	O
ATP7B	O	O
,	O	O
we	O	O
have	O	O
generated	O	O
a	O	O
strain	O	O
of	O	O
mice	O	O
that	O	O
are	O	O
homozygous	O	O
mutants	O	O
(	O	O
null	O	O
)	O	O
for	O	O
the	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
gene	O	O
.	O	O

The	O	O
ATP7B	O	O
null	O	O
mice	O	O
display	O	O
a	O	O
gradual	O	O
accumulation	O	O
of	O	O
hepatic	O	O
copper	O	O
that	O	O
increases	O	O
to	O	O
a	O	O
level	O	O
60	O	O
-	O	O
fold	O	O
greater	O	O
than	O	O
normal	O	O
by	O	O
5	O	O
months	O	O
of	O	O
age	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
copper	O	O
concentration	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
the	O	O
kidney	O	O
,	O	O
brain	O	O
,	O	O
placenta	O	O
and	O	O
lactating	O	O
mammary	O	O
glands	O	O
of	O	O
homo	O	O
-	O	O
zygous	O	O
mutants	O	O
,	O	O
although	O	O
milk	O	O
from	O	O
the	O	O
mutant	O	O
glands	O	O
was	O	O
copper	B-Disease	C535468
deficient	I-Disease	C535468
.	O	O

Morphological	B-Disease	D000013
abnormalities	I-Disease	D000013
resembling	O	O
cirrhosis	B-Disease	D008103
developed	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
the	O	O
livers	O	O
from	O	O
homozygous	O	O
mutants	O	O
older	O	O
than	O	O
7	O	O
months	O	O
of	O	O
age	O	O
.	O	O

Progeny	O	O
of	O	O
the	O	O
homozygous	O	O
mutant	O	O
females	O	O
demonstrated	O	O
neurological	B-Disease	D009461
abnormalities	I-Disease	D009461
and	O	O
growth	B-Disease	D006130
retardation	I-Disease	D006130
characteristic	O	O
of	O	O
copper	B-Disease	C535468
deficiency	I-Disease	C535468
.	O	O

Copper	O	O
concentration	O	O
in	O	O
the	O	O
livers	O	O
of	O	O
the	O	O
newborn	O	O
homozygous	O	O
null	O	O
mutants	O	O
was	O	O
decreased	O	O
dramatically	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
inactivation	O	O
of	O	O
the	O	O
murine	O	O
ATP7B	O	O
gene	O	O
produces	O	O
a	O	O
form	O	O
of	O	O
cirrhotic	B-Disease	D008103
liver	I-Disease	D008103
disease	I-Disease	D008103
that	O	O
resembles	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
in	O	O
humans	O	O
and	O	O
the	O	O
toxic	O	O
milk	O	O
phenotype	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

.	O	O

Adrenoleukodystrophy	B-Disease	D000326
and	O	O
adrenomyeloneuropathy	B-Disease	D000326
associated	O	O
with	O	O
partial	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
in	O	O
three	O	O
generations	O	O
of	O	O
a	O	O
kindred	O	O
.	O	O

Four	O	O
cases	O	O
of	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
and	O	O
one	O	O
case	O	O
of	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
have	O	O
developed	O	O
in	O	O
a	O	O
kindred	O	O
over	O	O
three	O	O
generations	O	O
demonstrating	O	O
that	O	O
AMN	B-Disease	D000326
is	O	O
a	O	O
clinical	O	O
variant	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

Pituitary	O	O
-	O	O
adrenal	O	O
function	O	O
studies	O	O
were	O	O
performed	O	O
in	O	O
10	O	O
family	O	O
members	O	O
,	O	O
including	O	O
two	O	O
affected	O	O
males	O	O
and	O	O
four	O	O
females	O	O
identified	O	O
as	O	O
carriers	O	O
of	O	O
ALD	B-Disease	D000326
/	O	O
AMN	B-Disease	D000326
.	O	O

No	O	O
pituitary	B-Disease	D010900	D000307
-	I-Disease	D010900	D000307
adrenal	I-Disease	D010900	D000307
abnormality	I-Disease	D010900	D000307
was	O	O
found	O	O
in	O	O
the	O	O
carriers	O	O
.	O	O

However	O	O
,	O	O
basal	O	O
morning	O	O
plasma	O	O
adrenocorticotropic	O	O
hormone	O	O
(	O	O
ACTH	O	O
)	O	O
levels	O	O
were	O	O
markedly	O	O
elevated	O	O
in	O	O
the	O	O
two	O	O
males	O	O
with	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
,	O	O
despite	O	O
the	O	O
fact	O	O
that	O	O
they	O	O
had	O	O
no	O	O
clinical	O	O
signs	O	O
of	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
and	O	O
that	O	O
morning	O	O
plasma	O	O
cortisol	O	O
levels	O	O
and	O	O
their	O	O
response	O	O
to	O	O
maximal	O	O
exogenous	O	O
ACTH	O	O
stimulation	O	O
appeared	O	O
to	O	O
be	O	O
normal	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
integrated	O	O
24	O	O
-	O	O
hour	O	O
response	O	O
to	O	O
the	O	O
administration	O	O
were	O	O
also	O	O
subnormal	O	O
in	O	O
these	O	O
two	O	O
cases	O	O
.	O	O

Thus	O	O
,	O	O
people	O	O
with	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
may	O	O
have	O	O
subclinical	O	O
partial	O	O
adrenocrotical	B-Disease	D000224
insufficiency	I-Disease	D000224
.	O	O

No	O	O
other	O	O
endocrinologic	B-Disease	D004700
dysfunction	I-Disease	D004700
was	O	O
identified	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
ALD	B-Disease	D000326
-	O	O
gene	O	O
of	O	O
20	O	O
families	O	O
with	O	O
adrenoleukodystrophy	B-Disease	D000326
/	O	O
adrenomyeloneuropathy	B-Disease	D000326
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
,	O	O
an	O	O
X	B-Disease	D008661
-	I-Disease	D008661
linked	I-Disease	D008661
inherited	I-Disease	D008661
metabolic	I-Disease	D008661
disorder	I-Disease	D008661
,	O	O
is	O	O
the	O	O
most	O	O
frequent	O	O
inborn	B-Disease	D018901
peroxisomal	I-Disease	D018901
disease	I-Disease	D018901
.	O	O

It	O	O
leads	O	O
to	O	O
demyelination	B-Disease	D003711
in	I-Disease	D003711
the	I-Disease	D003711
central	I-Disease	D003711
and	I-Disease	D003711
peripheral	I-Disease	D003711
nervous	I-Disease	D003711
system	I-Disease	D003711
.	O	O

Defective	O	O
beta	O	O
-	O	O
oxidation	O	O
of	O	O
saturated	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
(	O	O
VLCFAs	O	O
;	O	O
C22	O	O
0	O	O
-	O	O
C26	O	O
0	O	O
)	O	O
in	O	O
peroxisomes	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
lead	O	O
to	O	O
an	O	O
accumulation	O	O
of	O	O
VLCFAs	O	O
in	O	O
leukoid	O	O
areas	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
peripheral	O	O
nerves	O	O
,	O	O
adrenal	O	O
gland	O	O
,	O	O
and	O	O
blood	O	O
.	O	O

The	O	O
ALD	B-Disease	D000326
gene	O	O
has	O	O
been	O	O
recently	O	O
identified	O	O
and	O	O
encodes	O	O
a	O	O
745	O	O
-	O	O
amino	O	O
-	O	O
acid	O	O
protein	O	O
.	O	O

We	O	O
screened	O	O
patients	O	O
with	O	O
adrenoleukodystrophy	B-Disease	D000326
/	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
/	O	O
AMN	B-Disease	D000326
)	O	O
from	O	O
20	O	O
kindreds	O	O
for	O	O
mutations	O	O
in	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
.	O	O

Eleven	O	O
missense	O	O
and	O	O
two	O	O
nonsense	O	O
mutations	O	O
,	O	O
five	O	O
deletions	O	O
,	O	O
and	O	O
one	O	O
insertion	O	O
were	O	O
detected	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
eight	O	O
reverse	O	O
transcribed	O	O
fragments	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
-	O	O
gene	O	O
mRNA	O	O
.	O	O

Four	O	O
mutations	O	O
could	O	O
be	O	O
shown	O	O
to	O	O
be	O	O
de	O	O
novo	O	O
.	O	O

All	O	O
mutations	O	O
could	O	O
be	O	O
confirmed	O	O
in	O	O
carriers	O	O
by	O	O
sequencing	O	O
genomic	O	O
DNA	O	O
.	O	O

No	O	O
correlation	O	O
between	O	O
the	O	O
type	O	O
of	O	O
mutation	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
phenotype	O	O
could	O	O
be	O	O
observed	O	O
.	O	O

The	O	O
mutations	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
of	O	O
30	O	O
healthy	O	O
persons	O	O
.	O	O

.	O	O

Gonosomal	O	O
mosaicism	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
patients	O	O
:	O	O
involvement	O	O
of	O	O
mitotic	O	O
events	O	O
in	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
variation	O	O
and	O	O
selection	O	O
against	O	O
extreme	O	O
expansion	O	O
in	O	O
sperm	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
caused	O	O
by	O	O
abnormal	O	O
expansion	O	O
of	O	O
a	O	O
polymorphic	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
,	O	O
located	O	O
in	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
gene	O	O
.	O	O

We	O	O
determined	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
lengths	O	O
in	O	O
a	O	O
broad	O	O
range	O	O
of	O	O
tissue	O	O
DNAs	O	O
from	O	O
patients	O	O
with	O	O
mild	O	O
,	O	O
classical	O	O
,	O	O
or	O	O
congenital	O	O
manifestation	O	O
of	O	O
DM	B-Disease	D009223
.	O	O

Differences	O	O
in	O	O
the	O	O
repeat	O	O
length	O	O
were	O	O
seen	O	O
in	O	O
somatic	O	O
tissues	O	O
from	O	O
single	O	O
DM	B-Disease	D009223
individuals	O	O
and	O	O
twins	O	O
.	O	O

Repeats	O	O
appeared	O	O
to	O	O
expand	O	O
to	O	O
a	O	O
similar	O	O
extent	O	O
in	O	O
tissues	O	O
originating	O	O
from	O	O
the	O	O
same	O	O
embryonal	O	O
origin	O	O
.	O	O

In	O	O
most	O	O
male	O	O
patients	O	O
carrying	O	O
intermediate	O	O
-	O	O
or	O	O
small	O	O
-	O	O
sized	O	O
expansions	O	O
in	O	O
blood	O	O
,	O	O
the	O	O
repeat	O	O
lengths	O	O
covered	O	O
a	O	O
markedly	O	O
wider	O	O
range	O	O
in	O	O
sperm	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
male	O	O
patients	O	O
with	O	O
large	O	O
allele	O	O
expansions	O	O
in	O	O
blood	O	O
(	O	O
>	O	O
700	O	O
CTGs	O	O
)	O	O
had	O	O
similar	O	O
or	O	O
smaller	O	O
repeats	O	O
in	O	O
sperm	O	O
,	O	O
when	O	O
detectable	O	O
.	O	O

Sperm	O	O
alleles	O	O
with	O	O
>	O	O
1	O	O
,	O	O
000	O	O
CTGs	O	O
were	O	O
not	O	O
seen	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
DM	B-Disease	D009223
patients	O	O
can	O	O
be	O	O
considered	O	O
gonosomal	O	O
mosaics	O	O
,	O	O
i	O	O
.	O	O

e	O	O
e	O	O
.	O	O

,	O	O
combined	O	O
somatic	O	O
and	O	O
germ	O	O
-	O	O
line	O	O
tissue	O	O
mosaics	O	O
.	O	O

Most	O	O
remarkably	O	O
,	O	O
we	O	O
observed	O	O
multiple	O	O
cases	O	O
where	O	O
the	O	O
length	O	O
distributions	O	O
of	O	O
intermediate	O	O
-	O	O
or	O	O
small	O	O
-	O	O
sized	O	O
alleles	O	O
in	O	O
fathers	O	O
sperm	O	O
were	O	O
significantly	O	O
different	O	O
from	O	O
that	O	O
in	O	O
their	O	O
offsprings	O	O
blood	O	O
.	O	O

Our	O	O
combined	O	O
findings	O	O
indicate	O	O
that	O	O
intergenerational	O	O
length	O	O
changes	O	O
in	O	O
the	O	O
unstable	O	O
CTG	O	O
repeat	O	O
are	O	O
most	O	O
likely	O	O
to	O	O
occur	O	O
during	O	O
early	O	O
embryonic	O	O
mitotic	O	O
divisions	O	O
in	O	O
both	O	O
somatic	O	O
and	O	O
germ	O	O
-	O	O
line	O	O
tissue	O	O
formation	O	O
.	O	O

Both	O	O
the	O	O
initial	O	O
CTG	O	O
length	O	O
,	O	O
the	O	O
overall	O	O
number	O	O
of	O	O
cell	O	O
divisions	O	O
involved	O	O
in	O	O
tissue	O	O
formation	O	O
,	O	O
and	O	O
perhaps	O	O
a	O	O
specific	O	O
selection	O	O
process	O	O
in	O	O
spermatogenesis	O	O
may	O	O
influence	O	O
the	O	O
dynamics	O	O
of	O	O
this	O	O
process	O	O
.	O	O

A	O	O
model	O	O
explaining	O	O
mitotic	O	O
instability	O	O
and	O	O
sex	O	O
-	O	O
dependent	O	O
segregation	O	O
phenomena	O	O
in	O	O
DM	B-Disease	D009223
manifestation	O	O
is	O	O
discussed	O	O
Combined	O	O
analysis	O	O
of	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
linkage	O	O
to	O	O
1q24	O	O
-	O	O
25	O	O
:	O	O
results	O	O
from	O	O
772	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
families	O	O
from	O	O
the	O	O
International	O	O
Consortium	O	O
for	O	O
Prostate	B-Disease	D011471
Cancer	I-Disease	D011471
Genetics	O	O
.	O	O

A	O	O
previous	O	O
linkage	O	O
study	O	O
provided	O	O
evidence	O	O
for	O	O
a	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
-	O	O
susceptibility	O	O
locus	O	O
at	O	O
1q24	O	O
-	O	O
25	O	O
.	O	O

Subsequent	O	O
reports	O	O
in	O	O
additional	O	O
collections	O	O
of	O	O
families	O	O
have	O	O
yielded	O	O
conflicting	O	O
results	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
evidence	O	O
for	O	O
locus	O	O
heterogeneity	O	O
has	O	O
been	O	O
provided	O	O
by	O	O
the	O	O
identification	O	O
of	O	O
other	O	O
putative	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
loci	O	O
on	O	O
Xq27	O	O
-	O	O
28	O	O
,	O	O
1q42	O	O
-	O	O
43	O	O
,	O	O
and	O	O
1p36	O	O
.	O	O

The	O	O
present	O	O
study	O	O
describes	O	O
a	O	O
combined	O	O
analysis	O	O
for	O	O
six	O	O
markers	O	O
in	O	O
the	O	O
1q24	O	O
-	O	O
25	O	O
region	O	O
in	O	O
772	O	O
families	O	O
affected	O	O
by	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
and	O	O
ascertained	O	O
by	O	O
the	O	O
members	O	O
of	O	O
the	O	O
International	O	O
Consortium	O	O
for	O	O
Prostate	B-Disease	D011471
Cancer	I-Disease	D011471
Genetics	O	O
(	O	O
ICPCG	O	O
)	O	O
from	O	O
North	O	O
America	O	O
,	O	O
Australia	O	O
,	O	O
Finland	O	O
,	O	O
Norway	O	O
,	O	O
Sweden	O	O
,	O	O
and	O	O
the	O	O
United	O	O
Kingdom	O	O
.	O	O

Overall	O	O
,	O	O
there	O	O
was	O	O
some	O	O
evidence	O	O
for	O	O
linkage	O	O
,	O	O
with	O	O
a	O	O
peak	O	O
parametric	O	O
multipoint	O	O
LOD	O	O
score	O	O
assuming	O	O
heterogeneity	O	O
(	O	O
HLOD	O	O
)	O	O
of	O	O
1	O	O
.	O	O

40	O	O
(	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
at	O	O
D1S212	O	O
.	O	O

The	O	O
estimated	O	O
proportion	O	O
of	O	O
families	O	O
(	O	O
alpha	O	O
)	O	O
linked	O	O
to	O	O
the	O	O
locus	O	O
was	O	O
.	O	O

06	O	O
(	O	O
1	O	O
-	O	O
LOD	O	O
support	O	O
interval	O	O
.	O	O

01	O	O
-	O	O
.	O	O

12	O	O
)	O	O
.	O	O

This	O	O
evidence	O	O
was	O	O
not	O	O
observed	O	O
by	O	O
a	O	O
nonparametric	O	O
approach	O	O
,	O	O
presumably	O	O
because	O	O
of	O	O
the	O	O
extensive	O	O
heterogeneity	O	O
.	O	O

Further	O	O
parametric	O	O
analysis	O	O
revealed	O	O
a	O	O
significant	O	O
effect	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
male	O	O
-	O	O
to	O	O
-	O	O
male	O	O
disease	O	O
transmission	O	O
within	O	O
the	O	O
families	O	O
.	O	O

In	O	O
the	O	O
subset	O	O
of	O	O
491	O	O
such	O	O
families	O	O
,	O	O
the	O	O
peak	O	O
HLOD	O	O
was	O	O
2	O	O
.	O	O

In	O	O
the	O	O
subset	O	O
of	O	O
491	O	O
such	O	O
families	O	O
,	O	O
the	O	O
peak	O	O
HLOD	O	O
was	O	O
2	O	O
.	O	O

56	O	O
(	O	O
P	O	O
=	O	O
.	O	O

0006	O	O
)	O	O
and	O	O
alpha	O	O
=	O	O
.	O	O

11	O	O
(	O	O
1	O	O
-	O	O
LOD	O	O
support	O	O
interval	O	O
.	O	O

04	O	O
-	O	O
.	O	O

19	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
HLODs	O	O
of	O	O
0	O	O
in	O	O
the	O	O
remaining	O	O
281	O	O
families	O	O
.	O	O

Within	O	O
the	O	O
families	O	O
with	O	O
male	O	O
-	O	O
to	O	O
-	O	O
male	O	O
disease	O	O
transmission	O	O
,	O	O
alpha	O	O
increased	O	O
with	O	O
the	O	O
early	O	O
mean	O	O
age	O	O
at	O	O
diagnosis	O	O
(	O	O
<	O	O
65	O	O
years	O	O
,	O	O
alpha	O	O
=	O	O
.	O	O

19	O	O
,	O	O
with	O	O
1	O	O
-	O	O
LOD	O	O
support	O	O
interval	O	O
.	O	O

06	O	O
-	O	O
.	O	O

34	O	O
)	O	O
and	O	O
the	O	O
number	O	O
of	O	O
affected	O	O
family	O	O
members	O	O
(	O	O
five	O	O
or	O	O
more	O	O
family	O	O
members	O	O
,	O	O
alpha	O	O
=	O	O
.	O	O

15	O	O
,	O	O
with	O	O
1	O	O
-	O	O
LOD	O	O
support	O	O
interval	O	O
.	O	O

04	O	O
-	O	O
.	O	O

28	O	O
)	O	O
.	O	O

The	O	O
highest	O	O
value	O	O
of	O	O
alpha	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
48	O	O
families	O	O
that	O	O
met	O	O
all	O	O
three	O	O
criteria	O	O
(	O	O
peak	O	O
HLOD	O	O
=	O	O
2	O	O
.	O	O

25	O	O
,	O	O
P	O	O
=	O	O
.	O	O

001	O	O
,	O	O
alpha	O	O
=	O	O
.	O	O

29	O	O
,	O	O
with	O	O
1	O	O
-	O	O
LOD	O	O
support	O	O
interval	O	O
.	O	O

08	O	O
-	O	O
.	O	O

53	O	O
)	O	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
finding	O	O
of	O	O
a	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
-	O	O
susceptibility	O	O
gene	O	O
linked	O	O
to	O	O
1q24	O	O
-	O	O
25	O	O
,	O	O
albeit	O	O
in	O	O
a	O	O
defined	O	O
subset	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
families	O	O
.	O	O

Although	O	O
HPC1	O	O
accounts	O	O
for	O	O
only	O	O
a	O	O
small	O	O
proportion	O	O
of	O	O
all	O	O
families	O	O
affected	O	O
by	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
,	O	O
it	O	O
appears	O	O
to	O	O
play	O	O
a	O	O
more	O	O
prominent	O	O
role	O	O
in	O	O
the	O	O
subset	O	O
of	O	O
families	O	O
with	O	O
several	O	O
members	O	O
affected	O	O
at	O	O
an	O	O
early	O	O
age	O	O
and	O	O
with	O	O
male	O	O
-	O	O
to	O	O
-	O	O
male	O	O
disease	O	O
transmission	O	O
.	O	O

A	O	O
novel	O	O
disease	O	O
with	O	O
deficiency	B-Disease	C536353
of	I-Disease	C536353
mitochondrial	I-Disease	C536353
very	I-Disease	C536353
-	I-Disease	C536353
long	I-Disease	C536353
-	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
CoA	I-Disease	C536353
dehydrogenase	I-Disease	C536353
.	O	O

Palmitoyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
activity	O	O
in	O	O
skin	O	O
fibroblasts	O	O
from	O	O
seven	O	O
patients	O	O
with	O	O
unidentified	O	O
defects	O	O
of	O	O
fatty	O	O
acid	O	O
oxidation	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
presence	O	O
and	O	O
absence	O	O
of	O	O
antibodies	O	O
against	O	O
medium	O	O
-	O	O
chain	O	O
,	O	O
long	O	O
-	O	O
chain	O	O
,	O	O
and	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
dehydrogenases	O	O
(	O	O
VLCAD	O	O
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
patients	O	O
,	O	O
4	O	O
-	O	O
5	O	O
month	O	O
old	O	O
boys	O	O
,	O	O
were	O	O
found	O	O
to	O	O
have	O	O
a	O	O
novel	O	O
disease	O	O
,	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
,	O	O
as	O	O
judged	O	O
from	O	O
the	O	O
results	O	O
of	O	O
very	O	O
low	O	O
palmitoyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
activity	O	O
and	O	O
the	O	O
lack	O	O
of	O	O
immunoreactivity	O	O
toward	O	O
antibody	O	O
raised	O	O
to	O	O
purified	O	O
VLCAD	O	O
.	O	O

.	O	O

Inherited	O	O
WT1	O	O
mutation	O	O
in	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
.	O	O

Patients	O	O
with	O	O
the	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
(	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
,	O	O
genital	B-Disease	D014564
anomalies	I-Disease	D014564
,	O	O
and	O	O
nephropathy	B-Disease	D007674
)	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
carry	O	O
de	O	O
novo	O	O
constitutional	O	O
mutations	O	O
in	O	O
WT1	O	O
,	O	O
the	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
gene	O	O
at	O	O
chromosome	O	O
11p13	O	O
.	O	O

We	O	O
report	O	O
three	O	O
new	O	O
cases	O	O
,	O	O
two	O	O
carrying	O	O
a	O	O
previously	O	O
described	O	O
WT1	O	O
exon	O	O
9	O	O
mutation	O	O
and	O	O
one	O	O
with	O	O
a	O	O
novel	O	O
WT1	O	O
exon	O	O
8	O	O
mutation	O	O
.	O	O

However	O	O
,	O	O
unlike	O	O
patients	O	O
in	O	O
previous	O	O
reports	O	O
,	O	O
one	O	O
of	O	O
our	O	O
three	O	O
patients	O	O
inherited	O	O
the	O	O
affected	O	O
allele	O	O
from	O	O
his	O	O
phenotypically	O	O
unaffected	O	O
father	O	O
.	O	O

This	O	O
observation	O	O
indicates	O	O
that	O	O
the	O	O
WT1	O	O
exon	O	O
9	O	O
mutation	O	O
affecting	O	O
394Arg	O	O
demonstrated	O	O
in	O	O
over	O	O
one	O	O
-	O	O
half	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
the	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
may	O	O
exhibit	O	O
incomplete	O	O
penetrance	O	O
.	O	O

Consequently	O	O
,	O	O
familial	O	O
studies	O	O
in	O	O
patients	O	O
affected	O	O
by	O	O
this	O	O
syndrome	O	O
are	O	O
recommended	O	O
.	O	O

.	O	O

Glucose	B-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
caused	O	O
by	O	O
a	O	O
defect	O	O
in	O	O
the	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
.	O	O

Glucose	B-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
(	O	O
GGM	B-Disease	OMIM:606824
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disease	I-Disease	D030342
manifesting	O	O
within	O	O
the	O	O
first	O	O
weeks	O	O
of	O	O
life	O	O
and	O	O
characterized	O	O
by	O	O
a	O	O
selective	O	O
failure	O	O
to	O	O
absorb	O	O
dietary	O	O
glucose	O	O
and	O	O
galactose	O	O
from	O	O
the	O	O
intestine	O	O
.	O	O

The	O	O
consequent	O	O
severe	O	O
diarrhoea	B-Disease	D003967
and	O	O
dehydration	B-Disease	D003681
are	O	O
usually	O	O
fatal	O	O
unless	O	O
these	O	O
sugars	O	O
are	O	O
eliminated	O	O
from	O	O
the	O	O
diet	O	O
.	O	O

Intestinal	O	O
biopsies	O	O
of	O	O
GGM	B-Disease	OMIM:606824
patients	O	O
have	O	O
revealed	O	O
a	O	O
specific	O	O
defect	O	O
in	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
-	O	O
dependent	O	O
absorption	O	O
of	O	O
glucose	O	O
in	O	O
the	O	O
brush	O	O
border	O	O
.	O	O

Normal	O	O
glucose	O	O
absorption	O	O
is	O	O
mediated	O	O
by	O	O
the	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
in	O	O
the	O	O
brush	O	O
border	O	O
membrane	O	O
of	O	O
the	O	O
intestinal	O	O
epithelium	O	O
.	O	O

Cellular	O	O
influx	O	O
is	O	O
driven	O	O
by	O	O
the	O	O
transmembrane	O	O
Na	O	O
+	O	O
electrochemical	O	O
potential	O	O
gradient	O	O
;	O	O
thereafter	O	O
the	O	O
sugar	O	O
moves	O	O
to	O	O
the	O	O
blood	O	O
across	O	O
the	O	O
basolateral	O	O
membrane	O	O
via	O	O
the	O	O
facilitated	O	O
glucose	O	O
carrier	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
cloned	O	O
and	O	O
sequenced	O	O
a	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
from	O	O
normal	O	O
human	O	O
ileum	O	O
and	O	O
shown	O	O
that	O	O
this	O	O
gene	O	O
,	O	O
SGLT1	O	O
,	O	O
resides	O	O
on	O	O
the	O	O
distal	O	O
q	O	O
arm	O	O
of	O	O
chromosome	O	O
22	O	O
.	O	O

We	O	O
have	O	O
now	O	O
amplified	O	O
SGLT1	O	O
complementary	O	O
DNA	O	O
and	O	O
genomic	O	O
DNA	O	O
from	O	O
members	O	O
of	O	O
a	O	O
family	O	O
affected	O	O
with	O	O
GGM	B-Disease	OMIM:606824
by	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
the	O	O
amplified	O	O
products	O	O
has	O	O
revealed	O	O
a	O	O
single	O	O
missense	O	O
mutation	O	O
in	O	O
SGLT1	O	O
which	O	O
cosegregates	O	O
with	O	O
the	O	O
GGM	B-Disease	OMIM:606824
phenotype	O	O
and	O	O
results	O	O
in	O	O
a	O	O
complete	O	O
loss	O	O
of	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
-	O	O
dependent	O	O
glucose	O	O
transport	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
injected	O	O
with	O	O
this	O	O
complementary	O	O
RNA	O	O
.	O	O

.	O	O

Atm	O	O
and	O	O
Bax	O	O
cooperate	O	O
in	O	O
ionizing	O	O
radiation	O	O
-	O	O
induced	O	O
apoptosis	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
is	O	O
a	O	O
hereditary	B-Disease	D030342
multisystemic	I-Disease	D030342
disease	I-Disease	D030342
resulting	O	O
from	O	O
mutations	O	O
of	O	O
ataxia	B-Disease	D001260
telangiectasia	I-Disease	D001260
,	O	O
mutated	O	O
(	O	O
ATM	O	O
)	O	O
and	O	O
is	O	O
characterized	O	O
by	O	O
neurodegeneration	B-Disease	D019636
,	O	O
cancer	B-Disease	D009369
,	O	O
immune	B-Disease	D007154
defects	I-Disease	D007154
,	O	O
and	O	O
hypersensitivity	B-Disease	D004194
to	I-Disease	D004194
ionizing	I-Disease	D004194
radiation	I-Disease	D004194
.	O	O

The	O	O
molecular	O	O
details	O	O
of	O	O
ATM	O	O
function	O	O
in	O	O
the	O	O
nervous	O	O
system	O	O
are	O	O
unclear	O	O
,	O	O
although	O	O
the	O	O
neurological	B-Disease	D019636
lesion	I-Disease	D019636
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
becomes	O	O
apparent	O	O
early	O	O
in	O	O
life	O	O
,	O	O
suggesting	O	O
a	O	O
developmental	O	O
origin	O	O
.	O	O

The	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
of	O	O
Atm	O	O
-	O	O
null	O	O
mice	O	O
shows	O	O
a	O	O
pronounced	O	O
defect	O	O
in	O	O
apoptosis	O	O
induced	O	O
by	O	O
genotoxic	O	O
stress	O	O
,	O	O
suggesting	O	O
ATM	O	O
functions	O	O
to	O	O
eliminate	O	O
neurons	O	O
with	O	O
excessive	O	O
genomic	O	O
damage	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
the	O	O
death	O	O
effector	O	O
Bax	O	O
is	O	O
required	O	O
for	O	O
a	O	O
large	O	O
proportion	O	O
of	O	O
Atm	O	O
-	O	O
dependent	O	O
apoptosis	O	O
in	O	O
the	O	O
developing	O	O
CNS	O	O
after	O	O
ionizing	O	O
radiation	O	O
(	O	O
IR	O	O
)	O	O
.	O	O

Although	O	O
many	O	O
of	O	O
the	O	O
same	O	O
regions	O	O
of	O	O
the	O	O
CNS	O	O
in	O	O
both	O	O
Bax	O	O
-	O	O
/	O	O
-	O	O
and	O	O
Atm	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
radioresistant	O	O
,	O	O
mice	O	O
nullizygous	O	O
for	O	O
both	O	O
Bax	O	O
and	O	O
Atm	O	O
showed	O	O
additional	O	O
reduction	O	O
in	O	O
IR	O	O
-	O	O
induced	O	O
apoptosis	O	O
in	O	O
the	O	O
CNS	O	O
.	O	O

Therefore	O	O
,	O	O
although	O	O
the	O	O
major	O	O
IR	O	O
-	O	O
induced	O	O
apoptotic	O	O
pathway	O	O
in	O	O
the	O	O
CNS	O	O
requires	O	O
Atm	O	O
and	O	O
Bax	O	O
,	O	O
a	O	O
p53	O	O
-	O	O
dependent	O	O
collateral	O	O
pathway	O	O
exists	O	O
that	O	O
has	O	O
both	O	O
Atm	O	O
-	O	O
and	O	O
Bax	O	O
-	O	O
independent	O	O
branches	O	O
.	O	O

Further	O	O
,	O	O
Atm	O	O
-	O	O
and	O	O
Bax	O	O
-	O	O
dependent	O	O
apoptosis	O	O
in	O	O
the	O	O
CNS	O	O
also	O	O
required	O	O
caspase	O	O
-	O	O
3	O	O
activation	O	O
.	O	O

These	O	O
data	O	O
implicate	O	O
Bax	O	O
and	O	O
caspase	O	O
-	O	O
3	O	O
as	O	O
death	O	O
effectors	O	O
in	O	O
neurodegenerative	O	O
pathways	O	O
.	O	O

.	O	O

Novel	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
mutations	O	O
from	O	O
China	O	O
.	O	O

We	O	O
describe	O	O
three	O	O
HEXA	O	O
mutations	O	O
associated	O	O
with	O	O
infantile	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
in	O	O
three	O	O
unrelated	O	O
nonconsanguineous	O	O
Chinese	O	O
families	O	O
.	O	O

Novel	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
two	O	O
of	O	O
these	O	O
families	O	O
.	O	O

The	O	O
third	O	O
is	O	O
a	O	O
previously	O	O
reported	O	O
mutation	O	O
(	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
nt	O	O
1444	O	O
)	O	O
(	O	O
Nakano	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1988	O	O
)	O	O
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
PCR	O	O
products	O	O
identified	O	O
a	O	O
novel	O	O
insertion	O	O
of	O	O
an	O	O
A	O	O
after	O	O
nt	O	O
547	O	O
in	O	O
family	O	O
1	O	O
.	O	O

This	O	O
change	O	O
generates	O	O
an	O	O
early	O	O
termination	O	O
codon	O	O
6	O	O
bp	O	O
downstream	O	O
from	O	O
the	O	O
insertion	O	O
site	O	O
.	O	O

Allele	O	O
-	O	O
specific	O	O
oligonucleotide	O	O
hybridization	O	O
confirmed	O	O
homozygosity	O	O
in	O	O
the	O	O
proband	O	O
.	O	O

Single	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
analysis	O	O
and	O	O
direct	O	O
sequencing	O	O
of	O	O
amplified	O	O
exon	O	O
13	O	O
revealed	O	O
a	O	O
T	O	O
-	O	O
-	O	O
>	O	O
C	O	O
transition	O	O
at	O	O
nt	O	O
1453	O	O
with	O	O
the	O	O
corresponding	O	O
amino	O	O
acid	O	O
substitution	O	O
W485R	O	O
in	O	O
the	O	O
second	O	O
family	O	O
.	O	O

This	O	O
mutation	O	O
creates	O	O
an	O	O
Fnu4HI	O	O
restriction	O	O
site	O	O
.	O	O

The	O	O
proband	O	O
is	O	O
homozygous	O	O
for	O	O
this	O	O
allele	O	O
.	O	O

When	O	O
the	O	O
site	O	O
-	O	O
specific	O	O
mutagenized	O	O
alpha	O	O
cDNA	O	O
carrying	O	O
the	O	O
T	O	O
-	O	O
-	O	O
>	O	O
C	O	O
transition	O	O
at	O	O
nt	O	O
1453	O	O
was	O	O
expressed	O	O
in	O	O
COS	O	O
1	O	O
cells	O	O
hexosaminidase	O	O
S	O	O
activity	O	O
was	O	O
not	O	O
detectable	O	O
above	O	O
background	O	O
.	O	O

A	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
nt	O	O
1444	O	O
(	O	O
exon	O	O
13	O	O
)	O	O
corresponding	O	O
to	O	O
the	O	O
E482K	O	O
substitution	O	O
was	O	O
found	O	O
in	O	O
the	O	O
third	O	O
family	O	O
.	O	O

This	O	O
mutation	O	O
occurs	O	O
at	O	O
a	O	O
CpG	O	O
dinucleotide	O	O
.	O	O

It	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
an	O	O
Italian	O	O
TSD	B-Disease	D013661
proband	O	O
and	O	O
causes	O	O
defective	O	O
intracellular	O	O
transport	O	O
of	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
from	O	O
the	O	O
rough	O	O
endoplasmic	O	O
reticulum	O	O
to	O	O
the	O	O
Golgi	O	O
apparatus	O	O
.	O	O

Glucose	B-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
and	O	O
incidence	O	O
of	O	O
hematologic	B-Disease	D019337
malignancy	I-Disease	D019337
.	O	O

We	O	O
have	O	O
evaluated	O	O
the	O	O
hypothesis	O	O
of	O	O
a	O	O
negative	O	O
association	O	O
between	O	O
glucose	B-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
and	O	O
cancer	B-Disease	D009369
in	O	O
a	O	O
cohort	O	O
of	O	O
481	O	O
Sardinian	O	O
males	O	O
with	O	O
hematological	B-Disease	D019337
malignancies	I-Disease	D019337
.	O	O

The	O	O
frequency	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
the	O	O
patients	O	O
was	O	O
not	O	O
different	O	O
from	O	O
the	O	O
incidence	O	O
in	O	O
a	O	O
group	O	O
of	O	O
16	O	O
,	O	O
219	O	O
controls	O	O
.	O	O

The	O	O
same	O	O
conclusion	O	O
resulted	O	O
from	O	O
the	O	O
comparison	O	O
of	O	O
the	O	O
frequency	O	O
of	O	O
expression	O	O
of	O	O
the	O	O
GdB	O	O
gene	O	O
in	O	O
23	O	O
heterozygous	O	O
women	O	O
having	O	O
a	O	O
clonal	O	O
hematologic	B-Disease	D006402
disease	I-Disease	D006402
and	O	O
a	O	O
control	O	O
group	O	O
of	O	O
37	O	O
healthy	O	O
heterozygotes	O	O
.	O	O

Therefore	O	O
at	O	O
present	O	O
there	O	O
is	O	O
no	O	O
evidence	O	O
that	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
has	O	O
a	O	O
protective	O	O
effect	O	O
against	O	O
development	O	O
of	O	O
hematologic	B-Disease	D019337
neoplasms	I-Disease	D019337
.	O	O

.	O	O

A	O	O
physical	O	O
map	O	O
and	O	O
candidate	O	O
genes	O	O
in	O	O
the	O	O
BRCA1	O	O
region	O	O
on	O	O
chromosome	O	O
17q12	O	O
-	O	O
21	O	O
.	O	O

We	O	O
have	O	O
constructed	O	O
a	O	O
physical	O	O
map	O	O
of	O	O
a	O	O
4	O	O
cM	O	O
region	O	O
on	O	O
chromosome	O	O
17q12	O	O
-	O	O
21	O	O
that	O	O
contains	O	O
the	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
gene	O	O
BRCA1	O	O
.	O	O

The	O	O
map	O	O
comprises	O	O
a	O	O
contig	O	O
of	O	O
137	O	O
overlapping	O	O
yeast	O	O
artificial	O	O
chromosomes	O	O
and	O	O
P1	O	O
clones	O	O
,	O	O
onto	O	O
which	O	O
we	O	O
have	O	O
placed	O	O
112	O	O
PCR	O	O
markers	O	O
.	O	O

We	O	O
have	O	O
localized	O	O
more	O	O
than	O	O
20	O	O
genes	O	O
on	O	O
this	O	O
map	O	O
,	O	O
ten	O	O
of	O	O
which	O	O
had	O	O
not	O	O
been	O	O
mapped	O	O
to	O	O
the	O	O
region	O	O
previously	O	O
,	O	O
and	O	O
have	O	O
isolated	O	O
30	O	O
cDNA	O	O
clones	O	O
representing	O	O
partial	O	O
sequences	O	O
of	O	O
as	O	O
yet	O	O
unidentified	O	O
genes	O	O
.	O	O

Two	O	O
genes	O	O
that	O	O
lie	O	O
within	O	O
a	O	O
narrow	O	O
region	O	O
defined	O	O
by	O	O
meiotic	O	O
breakpoints	O	O
in	O	O
BRCA1	O	O
patients	O	O
have	O	O
been	O	O
sequenced	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
without	O	O
revealing	O	O
any	O	O
deleterious	O	O
mutations	O	O
.	O	O

These	O	O
new	O	O
reagents	O	O
should	O	O
facilitate	O	O
the	O	O
identification	O	O
of	O	O
BRCA1	O	O
.	O	O

.	O	O

Sulfate	O	O
transport	O	O
is	O	O
not	O	O
impaired	O	O
in	O	O
pendred	B-Disease	C536648
syndrome	I-Disease	C536648
thyrocytes	O	O
.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
is	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
syndromic	B-Disease	D003638
deafness	I-Disease	D003638
,	O	O
characterized	O	O
by	O	O
dyshormonogenic	B-Disease	D006042
goiter	I-Disease	D006042
associated	O	O
with	O	O
sensory	B-Disease	D006319
-	I-Disease	D006319
neural	I-Disease	D006319
deafness	I-Disease	D006319
.	O	O

The	O	O
gene	O	O
responsible	O	O
for	O	O
the	O	O
disease	O	O
(	O	O
PDS	B-Disease	C536648
)	O	O
has	O	O
been	O	O
cloned	O	O
,	O	O
but	O	O
its	O	O
function	O	O
is	O	O
as	O	O
yet	O	O
unknown	O	O
and	O	O
the	O	O
connection	O	O
between	O	O
thyroid	B-Disease	D006042
goiter	I-Disease	D006042
and	O	O
sensory	B-Disease	D006319
-	I-Disease	D006319
neural	I-Disease	D006319
deafness	I-Disease	D006319
remains	O	O
an	O	O
enigma	O	O
.	O	O

PDS	B-Disease	C536648
codes	O	O
for	O	O
a	O	O
novel	O	O
protein	O	O
,	O	O
pendrin	O	O
,	O	O
which	O	O
is	O	O
closely	O	O
related	O	O
to	O	O
a	O	O
number	O	O
of	O	O
sufate	O	O
transporters	O	O
.	O	O

Mechanisms	O	O
by	O	O
which	O	O
abnormal	O	O
sulfate	O	O
transport	O	O
could	O	O
deleteriously	O	O
affect	O	O
iodide	O	O
organification	O	O
have	O	O
been	O	O
proposed	O	O
.	O	O

We	O	O
tested	O	O
sulfate	O	O
transport	O	O
in	O	O
thyrocytes	O	O
obtained	O	O
from	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
patients	O	O
and	O	O
found	O	O
that	O	O
it	O	O
was	O	O
not	O	O
defective	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
pendrin	O	O
in	O	O
fact	O	O
may	O	O
not	O	O
be	O	O
a	O	O
sulfate	O	O
transporter	O	O
,	O	O
and	O	O
emphasizes	O	O
the	O	O
importance	O	O
of	O	O
functional	O	O
studies	O	O
on	O	O
this	O	O
novel	O	O
protein	O	O
.	O	O

.	O	O

Spinal	B-Disease	D014973
xanthomatosis	I-Disease	D014973
:	O	O
a	O	O
variant	O	O
of	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
.	O	O

We	O	O
describe	O	O
seven	O	O
Dutch	O	O
patients	O	O
from	O	O
six	O	O
families	O	O
with	O	O
a	O	O
slowly	O	O
progressive	O	O
,	O	O
mainly	O	O
spinal	B-Disease	D013118
cord	I-Disease	D013118
syndrome	I-Disease	D013118
that	O	O
remained	O	O
for	O	O
many	O	O
years	O	O
the	O	O
sole	O	O
expression	O	O
of	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
.	O	O

MRI	O	O
demonstrated	O	O
white	B-Disease	D002493
matter	I-Disease	D002493
abnormalities	I-Disease	D002493
in	O	O
the	O	O
lateral	O	O
and	O	O
dorsal	O	O
columns	O	O
of	O	O
the	O	O
spinal	O	O
cord	O	O
.	O	O

Post	O	O
-	O	O
mortem	O	O
examination	O	O
of	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
showed	O	O
extensive	O	O
myelin	O	O
loss	O	O
in	O	O
these	O	O
columns	O	O
.	O	O

An	O	O
array	O	O
of	O	O
genotypes	O	O
was	O	O
found	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
spinal	B-Disease	D014973
xanthomatosis	I-Disease	D014973
is	O	O
a	O	O
clinical	O	O
and	O	O
radiological	O	O
separate	O	O
entity	O	O
of	O	O
CTX	B-Disease	D019294
that	O	O
should	O	O
be	O	O
included	O	O
in	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
chronic	B-Disease	D002908	D013118
myelopathy	I-Disease	D002908	D013118
.	O	O

.	O	O

The	O	O
exon	O	O
13	O	O
duplication	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
is	O	O
a	O	O
founder	O	O
mutation	O	O
present	O	O
in	O	O
geographically	O	O
diverse	O	O
populations	O	O
.	O	O

The	O	O
BRCA1	O	O
Exon	O	O
13	O	O
Duplication	O	O
Screening	O	O
Group	O	O
.	O	O

Recently	O	O
,	O	O
a	O	O
6	O	O
-	O	O
kb	O	O
duplication	O	O
of	O	O
exon	O	O
13	O	O
,	O	O
which	O	O
creates	O	O
a	O	O
frameshift	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
,	O	O
has	O	O
been	O	O
described	O	O
in	O	O
three	O	O
unrelated	O	O
U	O	O
.	O	O

S	O	O
S	O	O
.	O	O

families	O	O
of	O	O
European	O	O
ancestry	O	O
and	O	O
in	O	O
one	O	O
Portuguese	O	O
family	O	O
.	O	O

Here	O	O
,	O	O
our	O	O
goal	O	O
was	O	O
to	O	O
estimate	O	O
the	O	O
frequency	O	O
and	O	O
geographic	O	O
diversity	O	O
of	O	O
carriers	O	O
of	O	O
this	O	O
duplication	O	O
.	O	O

To	O	O
do	O	O
this	O	O
,	O	O
a	O	O
collaborative	O	O
screening	O	O
study	O	O
was	O	O
set	O	O
up	O	O
that	O	O
involved	O	O
39	O	O
institutions	O	O
from	O	O
19	O	O
countries	O	O
and	O	O
included	O	O
3	O	O
,	O	O
580	O	O
unrelated	O	O
individuals	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
the	O	O
disease	O	O
and	O	O
934	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
cases	O	O
.	O	O

A	O	O
total	O	O
of	O	O
11	O	O
additional	O	O
families	O	O
carrying	O	O
this	O	O
mutation	O	O
were	O	O
identified	O	O
in	O	O
Australia	O	O
(	O	O
1	O	O
)	O	O
,	O	O
Belgium	O	O
(	O	O
1	O	O
)	O	O
,	O	O
Canada	O	O
(	O	O
1	O	O
)	O	O
,	O	O
Great	O	O
Britain	O	O
(	O	O
6	O	O
)	O	O
,	O	O
and	O	O
the	O	O
United	O	O
States	O	O
(	O	O
2	O	O
)	O	O
.	O	O

Haplotyping	O	O
showed	O	O
that	O	O
they	O	O
are	O	O
likely	O	O
to	O	O
derive	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
,	O	O
possibly	O	O
of	O	O
northern	O	O
British	O	O
origin	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
it	O	O
is	O	O
strongly	O	O
advisable	O	O
,	O	O
for	O	O
laboratories	O	O
carrying	O	O
out	O	O
screening	O	O
either	O	O
in	O	O
English	O	O
-	O	O
speaking	O	O
countries	O	O
or	O	O
in	O	O
countries	O	O
with	O	O
historical	O	O
links	O	O
with	O	O
Britain	O	O
,	O	O
to	O	O
include	O	O
within	O	O
their	O	O
BRCA1	O	O
screening	O	O
protocols	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
based	O	O
assay	O	O
described	O	O
in	O	O
this	O	O
report	O	O
.	O	O

Germline	O	O
mutations	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
in	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
provide	O	O
evidence	O	O
for	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
,	O	O
discovered	O	O
in	O	O
1994	O	O
,	O	O
are	O	O
associated	O	O
with	O	O
an	O	O
80	O	O
-	O	O
90	O	O
%	O	O
lifetime	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

We	O	O
have	O	O
analysed	O	O
60	O	O
families	O	O
with	O	O
a	O	O
history	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
for	O	O
germline	O	O
mutations	O	O
in	O	O
BRCA1	O	O
.	O	O

Twenty	O	O
-	O	O
two	O	O
different	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
32	O	O
families	O	O
(	O	O
53	O	O
%	O	O
)	O	O
,	O	O
of	O	O
which	O	O
14	O	O
are	O	O
previously	O	O
unreported	O	O
.	O	O

We	O	O
observed	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
the	O	O
location	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
the	O	O
gene	O	O
and	O	O
the	O	O
ratio	O	O
of	O	O
breast	B-Disease	D001943
to	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
incidence	O	O
within	O	O
each	O	O
family	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
a	O	O
transition	O	O
in	O	O
risk	O	O
such	O	O
that	O	O
mutations	O	O
in	O	O
the	O	O
3	O	O
third	O	O
of	O	O
the	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
lower	O	O
proportion	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Haplotype	O	O
analysis	O	O
supports	O	O
previous	O	O
data	O	O
which	O	O
suggest	O	O
some	O	O
BRCA1	O	O
mutation	O	O
carriers	O	O
have	O	O
common	O	O
ancestors	O	O
;	O	O
however	O	O
,	O	O
we	O	O
have	O	O
found	O	O
at	O	O
least	O	O
two	O	O
examples	O	O
where	O	O
recurrent	O	O
mutations	O	O
appear	O	O
to	O	O
have	O	O
arisen	O	O
independently	O	O
.	O	O

.	O	O

Inactivation	O	O
of	O	O
the	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
mouse	O	O
gene	O	O
leads	O	O
to	O	O
early	O	O
embryonic	B-Disease	D020964
lethality	I-Disease	D020964
without	O	O
iron	O	O
accumulation	O	O
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
autosomal	B-Disease	D013132
recessive	I-Disease	D013132
ataxia	I-Disease	D013132
,	O	O
is	O	O
caused	O	O
in	O	O
almost	O	O
all	O	O
cases	O	O
by	O	O
homozygous	O	O
intronic	O	O
expansions	O	O
resulting	O	O
in	O	O
the	O	O
loss	O	O
of	O	O
frataxin	O	O
,	O	O
a	O	O
mitochondrial	O	O
protein	O	O
conserved	O	O
through	O	O
evolution	O	O
,	O	O
and	O	O
involved	O	O
in	O	O
mitochondrial	O	O
iron	O	O
homeostasis	O	O
.	O	O

Yeast	O	O
knockout	O	O
models	O	O
,	O	O
and	O	O
histological	O	O
and	O	O
biochemical	O	O
data	O	O
from	O	O
patient	O	O
heart	O	O
biopsies	O	O
or	O	O
autopsies	O	O
indicate	O	O
that	O	O
the	O	O
frataxin	O	O
defect	O	O
causes	O	O
a	O	O
specific	O	O
iron	B-Disease	OMIM:255125
-	I-Disease	OMIM:255125
sulfur	I-Disease	OMIM:255125
protein	I-Disease	OMIM:255125
deficiency	I-Disease	OMIM:255125
and	O	O
mitochondrial	O	O
iron	O	O
accumulation	O	O
leading	O	O
to	O	O
the	O	O
pathological	O	O
changes	O	O
.	O	O

Affected	O	O
human	O	O
tissues	O	O
are	O	O
rarely	O	O
available	O	O
to	O	O
further	O	O
examine	O	O
this	O	O
hypothesis	O	O
.	O	O

To	O	O
study	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
we	O	O
generated	O	O
a	O	O
mouse	O	O
model	O	O
by	O	O
deletion	O	O
of	O	O
exon	O	O
4	O	O
leading	O	O
to	O	O
inactivation	O	O
of	O	O
the	O	O
Frda	B-Disease	D005621
gene	O	O
product	O	O
.	O	O

We	O	O
show	O	O
that	O	O
homozygous	O	O
deletions	O	O
cause	O	O
embryonic	B-Disease	D020964
lethality	I-Disease	D020964
a	O	O
few	O	O
days	O	O
after	O	O
implantation	O	O
,	O	O
demonstrating	O	O
an	O	O
important	O	O
role	O	O
for	O	O
frataxin	O	O
during	O	O
early	O	O
development	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
milder	O	O
phenotype	O	O
in	O	O
humans	O	O
is	O	O
due	O	O
to	O	O
residual	O	O
frataxin	O	O
expression	O	O
associated	O	O
with	O	O
the	O	O
expansion	O	O
mutations	O	O
.	O	O

Surprisingly	O	O
,	O	O
in	O	O
the	O	O
frataxin	O	O
knockout	O	O
mouse	O	O
,	O	O
no	O	O
iron	O	O
accumulation	O	O
was	O	O
observed	O	O
during	O	O
embryonic	O	O
resorption	O	O
,	O	O
suggesting	O	O
that	O	O
cell	O	O
death	O	O
could	O	O
be	O	O
due	O	O
to	O	O
a	O	O
mechanism	O	O
independent	O	O
of	O	O
iron	O	O
accumulation	O	O
.	O	O

.	O	O

A	O	O
glycine250	O	O
-	O	O
-	O	O
>	O	O
aspartate	O	O
substitution	O	O
in	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
hexosaminidase	O	O
A	O	O
causes	O	O
juvenile	O	O
-	O	O
onset	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
in	O	O
a	O	O
Lebanese	O	O
-	O	O
Canadian	O	O
family	O	O
.	O	O

The	O	O
mutation	O	O
causing	O	O
juvenile	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
in	O	O
two	O	O
sibs	O	O
of	O	O
Lebanese	O	O
-	O	O
Maronite	O	O
origin	O	O
is	O	O
described	O	O
.	O	O

An	O	O
mRNA	O	O
-	O	O
containing	O	O
extract	O	O
of	O	O
cultured	O	O
fibroblasts	O	O
obtained	O	O
from	O	O
one	O	O
of	O	O
the	O	O
probands	O	O
was	O	O
used	O	O
as	O	O
a	O	O
template	O	O
to	O	O
amplify	O	O
the	O	O
coding	O	O
sequence	O	O
of	O	O
the	O	O
hexosaminidase	O	O
A	O	O
(	O	O
Hex	O	O
A	O	O
)	O	O
alpha	O	O
-	O	O
subunit	O	O
.	O	O

Sequencing	O	O
of	O	O
amplified	O	O
cDNA	O	O
fragments	O	O
revealed	O	O
a	O	O
single	O	O
alteration	O	O
,	O	O
guanine	O	O
to	O	O
adenine	O	O
at	O	O
nt	O	O
749	O	O
creating	O	O
a	O	O
G250D	O	O
mutation	O	O
.	O	O

The	O	O
mutation	O	O
introduces	O	O
a	O	O
new	O	O
recognition	O	O
site	O	O
for	O	O
the	O	O
restriction	O	O
enzyme	O	O
Eco	O	O
RV	O	O
,	O	O
permitting	O	O
identification	O	O
of	O	O
heterozygotes	O	O
for	O	O
this	O	O
allele	O	O
following	O	O
PCR	O	O
amplification	O	O
and	O	O
Eco	O	O
RV	O	O
digestion	O	O
of	O	O
exon	O	O
7	O	O
sequences	O	O
from	O	O
genomic	O	O
DNA	O	O
templates	O	O
.	O	O

In	O	O
order	O	O
to	O	O
test	O	O
the	O	O
effect	O	O
of	O	O
this	O	O
substitution	O	O
,	O	O
an	O	O
in	O	O
vitro	O	O
mutagenized	O	O
cDNA	O	O
construct	O	O
was	O	O
introduced	O	O
into	O	O
a	O	O
mammalian	O	O
expression	O	O
vector	O	O
and	O	O
transfected	O	O
into	O	O
monkey	O	O
Cos	O	O
-	O	O
1	O	O
cells	O	O
separately	O	O
or	O	O
along	O	O
with	O	O
a	O	O
beta	O	O
-	O	O
cDNA	O	O
expression	O	O
vector	O	O
.	O	O

When	O	O
the	O	O
mutant	O	O
alpha	O	O
-	O	O
cDNA	O	O
was	O	O
the	O	O
only	O	O
gene	O	O
introduced	O	O
into	O	O
COS	O	O
cells	O	O
no	O	O
enzymatic	O	O
activity	O	O
above	O	O
endogenous	O	O
COS	O	O
cell	O	O
activity	O	O
was	O	O
detected	O	O
.	O	O

Cotransfection	O	O
of	O	O
normal	O	O
alpha	O	O
-	O	O
cDNA	O	O
and	O	O
beta	O	O
-	O	O
cDNA	O	O
followed	O	O
by	O	O
immunoprecipitation	O	O
of	O	O
human	O	O
Hex	O	O
A	O	O
resulted	O	O
in	O	O
20	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
the	O	O
ratio	O	O
between	O	O
positive	O	O
and	O	O
negative	O	O
(	O	O
mock	O	O
transfection	O	O
)	O	O
control	O	O
values	O	O
.	O	O

This	O	O
allowed	O	O
the	O	O
detection	O	O
of	O	O
some	O	O
residual	O	O
activity	O	O
(	O	O
12	O	O
%	O	O
of	O	O
the	O	O
positive	O	O
control	O	O
)	O	O
when	O	O
the	O	O
mutant	O	O
alpha	O	O
-	O	O
cDNA	O	O
replaced	O	O
its	O	O
wild	O	O
-	O	O
type	O	O
counterpart	O	O
.	O	O

The	O	O
predicted	O	O
protein	O	O
environment	O	O
in	O	O
which	O	O
the	O	O
mutation	O	O
occurs	O	O
is	O	O
compared	O	O
to	O	O
that	O	O
of	O	O
the	O	O
adult	O	O
-	O	O
onset	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
mutation	O	O
caused	O	O
by	O	O
a	O	O
Gly269	O	O
-	O	O
-	O	O
>	O	O
Ser	O	O
substitution	O	O
in	O	O
exon	O	O
7	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
.	O	O

Restriction	O	O
of	O	O
ocular	O	O
fundus	O	O
lesions	O	O
to	O	O
a	O	O
specific	O	O
subgroup	O	O
of	O	O
APC	B-Disease	D011125
mutations	O	O
in	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
patients	O	O
.	O	O

In	O	O
humans	O	O
,	O	O
alteration	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
APC	B-Disease	D011125
,	O	O
causes	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
,	O	O
a	O	O
condition	O	O
causing	O	O
predisposition	O	O
to	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

The	O	O
syndrome	O	O
inconsistently	O	O
associates	O	O
characteristic	O	O
patches	O	O
of	O	O
congenital	B-Disease	D012164
hypertrophy	I-Disease	D012164
of	I-Disease	D012164
the	I-Disease	D012164
retinal	I-Disease	D012164
pigment	I-Disease	D012164
epithelium	I-Disease	D012164
(	O	O
CHRPE	B-Disease	D012164
)	O	O
.	O	O

Ocular	O	O
examination	O	O
revealed	O	O
that	O	O
patients	O	O
expressing	O	O
CHRPE	B-Disease	D012164
tend	O	O
to	O	O
cluster	O	O
within	O	O
specific	O	O
families	O	O
.	O	O

The	O	O
exact	O	O
APC	B-Disease	D011125
mutation	O	O
was	O	O
identified	O	O
in	O	O
42	O	O
unrelated	O	O
patients	O	O
.	O	O

In	O	O
all	O	O
cases	O	O
these	O	O
mutations	O	O
were	O	O
predicted	O	O
to	O	O
lead	O	O
to	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
truncated	O	O
protein	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
CHRPE	B-Disease	D012164
was	O	O
found	O	O
to	O	O
be	O	O
dependent	O	O
on	O	O
the	O	O
position	O	O
of	O	O
the	O	O
mutation	O	O
along	O	O
the	O	O
coding	O	O
sequence	O	O
.	O	O

CHRPE	B-Disease	D012164
lesions	O	O
are	O	O
almost	O	O
always	O	O
absent	O	O
if	O	O
the	O	O
mutation	O	O
occurs	O	O
before	O	O
exon	O	O
9	O	O
,	O	O
but	O	O
are	O	O
systematically	O	O
present	O	O
if	O	O
it	O	O
occurs	O	O
after	O	O
this	O	O
exon	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
range	O	O
of	O	O
phenotypic	O	O
expression	O	O
observed	O	O
among	O	O
affected	O	O
patients	O	O
may	O	O
result	O	O
in	O	O
part	O	O
from	O	O
different	O	O
allelic	O	O
manifestations	O	O
of	O	O
APC	B-Disease	D011125
mutations	O	O
.	O	O

.	O	O

Linkage	O	O
analysis	O	O
of	O	O
26	O	O
Canadian	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
breast	I-Disease	D001943
-	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
families	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
26	O	O
Canadian	O	O
families	O	O
with	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
for	O	O
linkage	O	O
to	O	O
markers	O	O
flanking	O	O
the	O	O
BRCA1	O	O
gene	O	O
on	O	O
chromosome	O	O
17q12	O	O
-	O	O
q21	O	O
.	O	O

Of	O	O
the	O	O
15	O	O
families	O	O
that	O	O
contain	O	O
cases	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
94	O	O
%	O	O
were	O	O
estimated	O	O
to	O	O
be	O	O
linked	O	O
to	O	O
BRCA1	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
there	O	O
was	O	O
no	O	O
overall	O	O
evidence	O	O
of	O	O
linkage	O	O
in	O	O
the	O	O
group	O	O
of	O	O
10	O	O
families	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
without	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

A	O	O
genetic	O	O
recombinant	O	O
in	O	O
a	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
family	O	O
indicates	O	O
a	O	O
placement	O	O
of	O	O
BRCA1	O	O
telomeric	O	O
to	O	O
D17S776	O	O
,	O	O
and	O	O
helps	O	O
to	O	O
define	O	O
the	O	O
region	O	O
of	O	O
assignment	O	O
of	O	O
the	O	O
cancer	B-Disease	D009369
susceptibility	O	O
gene	O	O
.	O	O

Other	O	O
cancers	B-Disease	D009369
of	O	O
interest	O	O
that	O	O
appeared	O	O
in	O	O
the	O	O
BRCA1	O	O
-	O	O
linked	O	O
families	O	O
included	O	O
primary	B-Disease	D010534
peritoneal	I-Disease	D010534
cancer	I-Disease	D010534
,	O	O
cancer	B-Disease	D009369
of	O	O
the	O	O
fallopian	O	O
tube	O	O
,	O	O
and	O	O
malignant	B-Disease	D008545
melanoma	I-Disease	D008545
.	O	O

.	O	O

Malignant	B-Disease	D009369
neoplasms	I-Disease	D009369
in	O	O
the	O	O
families	O	O
of	O	O
patients	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
syndrome	I-Disease	D030342
associated	O	O
with	O	O
a	O	O
greatly	O	O
increased	O	O
incidence	O	O
of	O	O
malignant	B-Disease	D009369
neoplasms	I-Disease	D009369
in	O	O
homozygous	O	O
affected	O	O
individuals	O	O
.	O	O

Heterozygotes	O	O
for	O	O
the	O	O
gene	O	O
for	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
are	O	O
thought	O	O
to	O	O
comprise	O	O
about	O	O
1	O	O
%	O	O
of	O	O
the	O	O
general	O	O
population	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
know	O	O
whether	O	O
this	O	O
gene	O	O
also	O	O
predisposes	O	O
the	O	O
heterozygous	O	O
carrier	O	O
to	O	O
cancers	B-Disease	D009369
.	O	O

Heterozygous	O	O
carriers	O	O
of	O	O
this	O	O
gene	O	O
are	O	O
common	O	O
among	O	O
the	O	O
close	O	O
relatives	O	O
of	O	O
patients	O	O
with	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
although	O	O
individual	O	O
carriers	O	O
cannot	O	O
be	O	O
identified	O	O
by	O	O
any	O	O
clinical	O	O
criterion	O	O
or	O	O
laboratory	O	O
test	O	O
.	O	O

For	O	O
this	O	O
reason	O	O
,	O	O
we	O	O
compared	O	O
the	O	O
incidence	O	O
of	O	O
death	O	O
from	O	O
malignant	B-Disease	D009369
neoplasms	I-Disease	D009369
in	O	O
2	O	O
families	O	O
of	O	O
patients	O	O
with	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
to	O	O
that	O	O
expected	O	O
in	O	O
a	O	O
random	O	O
sample	O	O
of	O	O
the	O	O
general	O	O
population	O	O
.	O	O

There	O	O
were	O	O
59	O	O
deaths	O	O
from	O	O
malignant	B-Disease	D009369
neoplasms	I-Disease	D009369
in	O	O
relatives	O	O
dying	O	O
before	O	O
age	O	O
75	O	O
,	O	O
compared	O	O
to	O	O
42	O	O
.	O	O

6	O	O
expected	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

For	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
heterozygotes	O	O
younger	O	O
than	O	O
age	O	O
45	O	O
,	O	O
the	O	O
risk	O	O
of	O	O
dying	O	O
from	O	O
a	O	O
malignant	B-Disease	D009369
neoplasm	I-Disease	D009369
was	O	O
estimated	O	O
to	O	O
be	O	O
greater	O	O
than	O	O
5	O	O
times	O	O
the	O	O
risk	O	O
for	O	O
the	O	O
general	O	O
population	O	O
.	O	O

A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
heterozygotes	O	O
may	O	O
comprise	O	O
more	O	O
than	O	O
5	O	O
%	O	O
of	O	O
all	O	O
persons	O	O
dying	O	O
from	O	O
a	O	O
cancer	B-Disease	D009369
before	O	O
age	O	O
45	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
ovarian	B-Disease	D010051
,	I-Disease	D010051
gastric	I-Disease	D010051
,	I-Disease	D010051
and	I-Disease	D010051
biliary	I-Disease	D010051
system	I-Disease	D010051
carcinomas	I-Disease	D010051
and	O	O
of	O	O
leukemia	B-Disease	D007938
and	O	O
lymphoma	B-Disease	D008223
was	O	O
increased	O	O
in	O	O
these	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
families	O	O
.	O	O

Other	O	O
neoplasms	B-Disease	D009369
that	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
this	O	O
gene	O	O
in	O	O
heterozygotes	O	O
include	O	O
pancreatic	B-Disease	D010190
,	I-Disease	D010190
basal	I-Disease	D010190
cell	I-Disease	D010190
,	I-Disease	D010190
colonic	I-Disease	D010190
,	I-Disease	D010190
breast	I-Disease	D010190
,	I-Disease	D010190
and	I-Disease	D010190
cervical	I-Disease	D010190
carcinomas	I-Disease	D010190
.	O	O

Molecular	O	O
genetics	O	O
of	O	O
PKU	B-Disease	D010661
in	O	O
eastern	O	O
Europe	O	O
:	O	O
a	O	O
nonsense	O	O
mutation	O	O
associated	O	O
with	O	O
haplotype	O	O
4	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
a	O	O
genetic	B-Disease	D030342
disorder	I-Disease	D030342
secondary	O	O
to	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

Several	O	O
mutations	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
have	O	O
recently	O	O
been	O	O
reported	O	O
,	O	O
and	O	O
linkage	O	O
disequilibrium	O	O
was	O	O
observed	O	O
between	O	O
RFLP	O	O
haplotypes	O	O
and	O	O
specific	O	O
mutations	O	O
.	O	O

A	O	O
new	O	O
molecular	B-Disease	D030342
lesion	I-Disease	D030342
has	O	O
been	O	O
identified	O	O
in	O	O
exon	O	O
7	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
in	O	O
a	O	O
Hungarian	O	O
PKU	B-Disease	D010661
patient	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
PCR	O	O
-	O	O
amplified	O	O
DNA	O	O
.	O	O

The	O	O
C	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transition	O	O
causes	O	O
the	O	O
substitution	O	O
of	O	O
Arg243	O	O
to	O	O
a	O	O
termination	O	O
codon	O	O
,	O	O
and	O	O
the	O	O
mutant	O	O
allele	O	O
is	O	O
associated	O	O
with	O	O
haplotype	O	O
4	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
.	O	O

The	O	O
mutation	O	O
is	O	O
present	O	O
in	O	O
two	O	O
of	O	O
nine	O	O
mutant	O	O
haplotype	O	O
4	O	O
alleles	O	O
among	O	O
Eastern	O	O
Europeans	O	O
and	O	O
is	O	O
not	O	O
present	O	O
among	O	O
Western	O	O
Europeans	O	O
and	O	O
Asians	O	O
.	O	O

The	O	O
rarity	O	O
of	O	O
this	O	O
mutant	O	O
allele	O	O
and	O	O
its	O	O
restricted	O	O
geographic	O	O
distribution	O	O
suggest	O	O
that	O	O
the	O	O
mutational	O	O
event	O	O
occurred	O	O
recently	O	O
on	O	O
a	O	O
normal	O	O
haplotype	O	O
4	O	O
background	O	O
in	O	O
Eastern	O	O
Europe	O	O
.	O	O

.	O	O

Isolation	O	O
of	O	O
the	O	O
mouse	O	O
homologue	O	O
of	O	O
BRCA1	O	O
and	O	O
genetic	O	O
mapping	O	O
to	O	O
mouse	O	O
chromosome	O	O
11	O	O
.	O	O

The	O	O
BRCA1	O	O
gene	O	O
is	O	O
in	O	O
large	O	O
part	O	O
responsible	O	O
for	O	O
hereditary	B-Disease	D061325
human	I-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
isolation	O	O
of	O	O
the	O	O
murine	O	O
Brca1	O	O
homologue	O	O
cDNA	O	O
clones	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
identified	O	O
genomic	O	O
P1	O	O
clones	O	O
that	O	O
contain	O	O
most	O	O
,	O	O
if	O	O
not	O	O
all	O	O
,	O	O
of	O	O
the	O	O
mouse	O	O
Brca1	O	O
locus	O	O
.	O	O

DNA	O	O
sequence	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
mouse	O	O
and	O	O
human	O	O
coding	O	O
regions	O	O
are	O	O
75	O	O
%	O	O
identical	O	O
at	O	O
the	O	O
nucleotide	O	O
level	O	O
while	O	O
the	O	O
predicted	O	O
amino	O	O
acid	O	O
identity	O	O
is	O	O
only	O	O
58	O	O
%	O	O
.	O	O

A	O	O
DNA	O	O
sequence	O	O
variant	O	O
in	O	O
the	O	O
Brca1	O	O
locus	O	O
was	O	O
identified	O	O
and	O	O
used	O	O
to	O	O
map	O	O
this	O	O
gene	O	O
on	O	O
a	O	O
(	O	O
Mus	O	O
m	O	O
.	O	O

musculus	O	O
Czech	O	O
II	O	O
x	O	O
C57BL	O	O
/	O	O
KsJ	O	O
)	O	O
F1	O	O
x	O	O
C57BL	O	O
/	O	O
KsJ	O	O
intersubspecific	O	O
backcross	O	O
to	O	O
distal	O	O
mouse	O	O
chromosome	O	O
11	O	O
.	O	O

The	O	O
mapping	O	O
of	O	O
this	O	O
gene	O	O
to	O	O
a	O	O
region	O	O
highly	O	O
syntenic	O	O
with	O	O
human	O	O
chromosome	O	O
17	O	O
,	O	O
coupled	O	O
with	O	O
Southern	O	O
and	O	O
Northern	O	O
analyses	O	O
,	O	O
confirms	O	O
that	O	O
we	O	O
isolated	O	O
the	O	O
murine	O	O
Brca1	O	O
homologue	O	O
rather	O	O
than	O	O
a	O	O
related	O	O
RING	O	O
finger	O	O
gene	O	O
.	O	O

The	O	O
isolation	O	O
of	O	O
the	O	O
mouse	O	O
Brca1	O	O
homologue	O	O
will	O	O
facilitate	O	O
the	O	O
creation	O	O
of	O	O
mouse	O	O
models	O	O
for	O	O
germline	O	O
BRCA1	B-Disease	OMIM:604370
defects	I-Disease	OMIM:604370
.	O	O

.	O	O

Human	O	O
deficiency	B-Disease	OMIM:612446
of	I-Disease	OMIM:612446
the	I-Disease	OMIM:612446
sixth	I-Disease	OMIM:612446
component	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
in	O	O
a	O	O
patient	O	O
with	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
and	O	O
no	O	O
haemostasis	B-Disease	D020141
abnormality	I-Disease	D020141
.	O	O

A	O	O
case	O	O
of	O	O
human	O	O
complete	O	O
C6	B-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
is	O	O
reported	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
a	O	O
31	O	O
year	O	O
old	O	O
white	O	O
male	O	O
,	O	O
was	O	O
seen	O	O
on	O	O
the	O	O
occasion	O	O
of	O	O
an	O	O
isolated	O	O
episode	O	O
of	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
.	O	O

Serum	O	O
complement	O	O
hemolytic	O	O
and	O	O
bactericidal	O	O
activities	O	O
were	O	O
lacking	O	O
and	O	O
could	O	O
be	O	O
restored	O	O
to	O	O
normal	O	O
by	O	O
addition	O	O
of	O	O
appropriate	O	O
amounts	O	O
of	O	O
purified	O	O
C6	O	O
.	O	O

No	O	O
hemostatic	B-Disease	D020141
abnormalities	I-Disease	D020141
were	O	O
observed	O	O
.	O	O

.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
:	O	O
refinement	O	O
of	O	O
the	O	O
localization	O	O
on	O	O
Xp	O	O
and	O	O
identification	O	O
of	O	O
another	O	O
closely	O	O
linked	O	O
marker	O	O
locus	O	O
,	O	O
OATL1	O	O
.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
has	O	O
previously	O	O
been	O	O
mapped	O	O
to	O	O
the	O	O
proximal	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
between	O	O
the	O	O
DXS14	O	O
and	O	O
DXS7	O	O
loci	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
further	O	O
segregation	O	O
analysis	O	O
has	O	O
been	O	O
performed	O	O
using	O	O
a	O	O
newly	O	O
identified	O	O
WAS	B-Disease	D014923
family	O	O
as	O	O
well	O	O
as	O	O
an	O	O
additional	O	O
marker	O	O
probe	O	O
,	O	O
HOATL1	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
close	O	O
linkage	O	O
between	O	O
the	O	O
WAS	B-Disease	D014923
and	O	O
OATL1	O	O
loci	O	O
(	O	O
Z	O	O
=	O	O
6	O	O
.	O	O

08	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
)	O	O
and	O	O
localize	O	O
the	O	O
TIMP	O	O
,	O	O
OATL1	O	O
,	O	O
DXS255	O	O
,	O	O
and	O	O
WAS	B-Disease	D014923
loci	O	O
distal	O	O
to	O	O
DXS146	O	O
and	O	O
the	O	O
OATL1	O	O
and	O	O
WAS	B-Disease	D014923
loci	O	O
proximal	O	O
to	O	O
TIMP	O	O
.	O	O

These	O	O
linkage	O	O
data	O	O
narrow	O	O
the	O	O
boundaries	O	O
within	O	O
which	O	O
the	O	O
WAS	B-Disease	D014923
locus	O	O
maps	O	O
to	O	O
the	O	O
chromosomal	O	O
region	O	O
bracketed	O	O
by	O	O
TIMP	O	O
and	O	O
DXS146	O	O
and	O	O
support	O	O
the	O	O
loci	O	O
order	O	O
Xpter	O	O
-	O	O
DXS7	O	O
-	O	O
TIMP	O	O
-	O	O
(	O	O
OATL1	O	O
,	O	O
WAS	B-Disease	D014923
,	O	O
DXS255	O	O
)	O	O
-	O	O
DXS146	O	O
.	O	O

Hereditary	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
of	I-Disease	OMIM:613779
the	I-Disease	OMIM:613779
third	I-Disease	OMIM:613779
component	I-Disease	OMIM:613779
of	I-Disease	OMIM:613779
complement	I-Disease	OMIM:613779
in	O	O
a	O	O
child	O	O
with	O	O
fever	B-Disease	D005334
,	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
and	O	O
arthralgias	B-Disease	D018771
:	O	O
response	O	O
to	O	O
transfusion	O	O
of	O	O
whole	O	O
blood	O	O
.	O	O

A	O	O
previously	O	O
well	O	O
34	O	O
-	O	O
month	O	O
-	O	O
old	O	O
male	O	O
presenting	O	O
with	O	O
fever	B-Disease	D005334
,	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
and	O	O
arthralgias	B-Disease	D018771
was	O	O
found	O	O
to	O	O
lack	O	O
C3	O	O
by	O	O
immunochemical	O	O
(	O	O
undetectable	O	O
)	O	O
and	O	O
hemolytic	O	O
(	O	O
1	O	O
%	O	O
normal	O	O
)	O	O
assays	O	O
.	O	O

No	O	O
infectious	O	O
agent	O	O
could	O	O
be	O	O
demonstrated	O	O
.	O	O

Protein	O	O
levels	O	O
of	O	O
Clq	O	O
.	O	O

C4	O	O
,	O	O
C5	O	O
,	O	O
properdin	O	O
,	O	O
and	O	O
C3b	O	O
-	O	O
INA	O	O
and	O	O
hemolytic	O	O
activities	O	O
of	O	O
complement	O	O
components	O	O
C1	O	O
to	O	O
C9	O	O
except	O	O
C3	O	O
were	O	O
normal	O	O
or	O	O
elevated	O	O
;	O	O
total	O	O
hemolytic	O	O
complement	O	O
activity	O	O
was	O	O
13	O	O
%	O	O
of	O	O
normal	O	O
and	O	O
was	O	O
reconstituted	O	O
by	O	O
purified	O	O
C3	O	O
.	O	O

Properdin	O	O
factor	O	O
B	O	O
was	O	O
702	O	O
(	O	O
normal	O	O
175	O	O
to	O	O
275	O	O
)	O	O
mug	O	O
/	O	O
ml	O	O
,	O	O
and	O	O
was	O	O
not	O	O
cleaver	O	O
upon	O	O
addition	O	O
of	O	O
zymosan	O	O
or	O	O
cobra	O	O
venom	O	O
factor	O	O
.	O	O

The	O	O
serum	O	O
had	O	O
normal	O	O
immune	O	O
adherence	O	O
activity	O	O
,	O	O
but	O	O
was	O	O
deficient	O	O
in	O	O
ability	O	O
to	O	O
opsonize	O	O
Candida	O	O
albicans	O	O
for	O	O
uptake	O	O
and	O	O
Escherichia	O	O
coli	O	O
for	O	O
killing	O	O
by	O	O
neurophils	O	O
,	O	O
generate	O	O
neutrophil	O	O
chemotactic	O	O
factors	O	O
and	O	O
inhibit	O	O
the	O	O
growth	O	O
of	O	O
E	O	O
.	O	O

coli	O	O
;	O	O
these	O	O
activities	O	O
were	O	O
restored	O	O
by	O	O
purified	O	O
C3	O	O
.	O	O

A	O	O
transfusion	O	O
of	O	O
320	O	O
ml	O	O
1	O	O
-	O	O
hour	O	O
-	O	O
old	O	O
normal	O	O
whole	O	O
blood	O	O
on	O	O
the	O	O
fifty	O	O
-	O	O
second	O	O
day	O	O
resulted	O	O
in	O	O
transitory	O	O
elevation	O	O
of	O	O
the	O	O
C3	O	O
level	O	O
to	O	O
25	O	O
mg	O	O
/	O	O
dl	O	O
with	O	O
a	O	O
fall	O	O
-	O	O
off	O	O
(	O	O
approximately	O	O
2	O	O
1	O	O
/	O	O
2	O	O
%	O	O
per	O	O
hour	O	O
)	O	O
to	O	O
undetectable	O	O
levels	O	O
by	O	O
69	O	O
hours	O	O
;	O	O
it	O	O
was	O	O
followed	O	O
by	O	O
disappearance	O	O
of	O	O
the	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
and	O	O
arthralgias	B-Disease	D018771
and	O	O
return	O	O
to	O	O
normal	O	O
of	O	O
the	O	O
previously	O	O
elevated	O	O
temperature	O	O
and	O	O
CRP	O	O
levels	O	O
.	O	O

C3	O	O
levels	O	O
in	O	O
family	O	O
members	O	O
(	O	O
seven	O	O
of	O	O
24	O	O
half	O	O
-	O	O
normal	O	O
)	O	O
,	O	O
lack	O	O
of	O	O
anti	O	O
-	O	O
C3	O	O
activity	O	O
,	O	O
normal	O	O
C3b	O	O
-	O	O
INA	O	O
levels	O	O
and	O	O
a	O	O
normal	O	O
rate	O	O
of	O	O
catabolism	O	O
of	O	O
transfused	O	O
C3	O	O
indicated	O	O
that	O	O
the	O	O
deficiency	O	O
was	O	O
inherited	O	O
with	O	O
autosomal	O	O
codominance	O	O
and	O	O
involved	O	O
decreased	B-Disease	OMIM:613779
synthesis	I-Disease	OMIM:613779
of	I-Disease	OMIM:613779
C3	I-Disease	OMIM:613779
.	O	O

Thus	O	O
,	O	O
this	O	O
child	O	O
is	O	O
a	O	O
unique	O	O
individual	O	O
with	O	O
inherited	B-Disease	OMIM:613779
C3	I-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
presenting	O	O
with	O	O
absence	O	O
of	O	O
repeated	O	O
infections	O	O
,	O	O
whose	O	O
symptoms	O	O
of	O	O
fever	B-Disease	D005334
,	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
and	O	O
arthralgia	B-Disease	D018771
were	O	O
abated	O	O
by	O	O
whole	O	O
blood	O	O
transfusion	O	O
.	O	O

.	O	O

Cloning	O	O
of	O	O
breakpoints	O	O
of	O	O
a	O	O
chromosome	O	O
translocation	O	O
identifies	O	O
the	O	O
AN2	O	O
locus	O	O
.	O	O

Chromosome	O	O
translocations	O	O
involving	O	O
11p13	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
familial	B-Disease	D015783
aniridia	I-Disease	D015783
in	O	O
two	O	O
kindreds	O	O
highlighting	O	O
the	O	O
chromosomal	O	O
localization	O	O
of	O	O
the	O	O
AN2	O	O
locus	O	O
.	O	O

This	O	O
locus	O	O
is	O	O
also	O	O
part	O	O
of	O	O
the	O	O
WAGR	B-Disease	D017624
complex	O	O
(	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
,	O	O
aniridia	B-Disease	D015783
,	O	O
genitourinary	B-Disease	D014564
abnormalities	I-Disease	D014564
,	O	O
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
)	O	O
.	O	O

In	O	O
one	O	O
kindred	O	O
,	O	O
the	O	O
translocation	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
deletion	O	O
,	O	O
and	O	O
probes	O	O
for	O	O
this	O	O
region	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
and	O	O
clone	O	O
the	O	O
breakpoints	O	O
of	O	O
the	O	O
translocation	O	O
in	O	O
the	O	O
second	O	O
kindred	O	O
.	O	O

Comparison	O	O
of	O	O
phage	O	O
restriction	O	O
maps	O	O
exclude	O	O
the	O	O
presence	O	O
of	O	O
any	O	O
sizable	O	O
deletion	O	O
in	O	O
this	O	O
case	O	O
.	O	O

Sequences	O	O
at	O	O
the	O	O
chromosome	O	O
11	O	O
breakpoint	O	O
are	O	O
conserved	O	O
in	O	O
multiple	O	O
species	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
translocation	O	O
falls	O	O
within	O	O
the	O	O
AN2	O	O
gene	O	O
.	O	O

.	O	O

Study	O	O
of	O	O
the	O	O
voltage	O	O
-	O	O
gated	O	O
sodium	O	O
channel	O	O
beta	O	O
1	O	O
subunit	O	O
gene	O	O
(	O	O
SCN1B	O	O
)	O	O
in	O	O
the	O	O
benign	B-Disease	D020936
familial	I-Disease	D020936
infantile	I-Disease	D020936
convulsions	I-Disease	D020936
syndrome	I-Disease	D020936
(	O	O
BFIC	B-Disease	D020936
)	O	O
.	O	O

Benign	B-Disease	D020936
familial	I-Disease	D020936
infantile	I-Disease	D020936
convulsions	I-Disease	D020936
(	O	O
BFIC	B-Disease	D020936
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	B-Disease	D030342	D004827
dominant	I-Disease	D030342	D004827
epilepsy	I-Disease	D030342	D004827
syndrome	I-Disease	D030342	D004827
.	O	O

This	O	O
syndrome	O	O
has	O	O
been	O	O
recently	O	O
described	O	O
in	O	O
Italian	O	O
and	O	O
French	O	O
pedigrees	O	O
.	O	O

Patients	O	O
present	O	O
with	O	O
partial	O	O
,	O	O
then	O	O
generalized	O	O
seizures	O	O
,	O	O
with	O	O
onset	O	O
at	O	O
age	O	O
three	O	O
months	O	O
.	O	O

The	O	O
seizures	O	O
usually	O	O
spontaneously	O	O
cease	O	O
after	O	O
one	O	O
year	O	O
without	O	O
treatment	O	O
,	O	O
leaving	O	O
no	O	O
neurological	B-Disease	D009461
abnormalities	I-Disease	D009461
.	O	O

We	O	O
have	O	O
mapped	O	O
BFIC	B-Disease	D020936
to	O	O
chromosome	O	O
19q	O	O
in	O	O
five	O	O
Italian	O	O
pedigrees	O	O
.	O	O

The	O	O
sodium	O	O
channel	O	O
beta1	O	O
subunit	O	O
gene	O	O
(	O	O
SCN1B	O	O
)	O	O
maps	O	O
to	O	O
this	O	O
candidate	O	O
region	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
one	O	O
Australian	O	O
pedigree	O	O
with	O	O
generalized	O	O
epilepsy	O	O
and	O	O
febrile	O	O
seizures	O	O
"	O	O
plus	O	O
"	O	O
(	O	O
GEFS	O	O
+	O	O
)	O	O
.	O	O

In	O	O
this	O	O
family	O	O
,	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
SCN1B	O	O
cosegregates	O	O
with	O	O
the	O	O
GEFS	O	O
+	O	O
phenotype	O	O
.	O	O

BFIC	B-Disease	D020936
and	O	O
GEFS	O	O
+	O	O
have	O	O
clinical	O	O
features	O	O
in	O	O
common	O	O
,	O	O
therefore	O	O
SCN1B	O	O
is	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
BFIC	B-Disease	D020936
.	O	O

We	O	O
studied	O	O
SCN1B	O	O
exons	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
4	O	O
,	O	O
and	O	O
5	O	O
,	O	O
using	O	O
four	O	O
SSCP	O	O
methods	O	O
in	O	O
10	O	O
Caucasian	O	O
BFIC	B-Disease	D020936
probands	O	O
of	O	O
Western	O	O
Europe	O	O
.	O	O

We	O	O
found	O	O
no	O	O
exon	O	O
variants	O	O
.	O	O

One	O	O
variant	O	O
was	O	O
identified	O	O
in	O	O
intron	O	O
5	O	O
(	O	O
IVS5	O	O
-	O	O
10C	O	O
>	O	O
G	O	O
)	O	O
,	O	O
which	O	O
did	O	O
not	O	O
segregate	O	O
with	O	O
BFIC	B-Disease	D020936
and	O	O
was	O	O
observed	O	O
in	O	O
9	O	O
.	O	O

2	O	O
%	O	O
controls	O	O
.	O	O

A	O	O
second	O	O
variant	O	O
in	O	O
intron	O	O
5	O	O
was	O	O
identified	O	O
(	O	O
IVS5	O	O
+	O	O
30G	O	O
>	O	O
A	O	O
)	O	O
.	O	O

It	O	O
was	O	O
rare	O	O
,	O	O
as	O	O
not	O	O
observed	O	O
in	O	O
controls	O	O
,	O	O
but	O	O
not	O	O
segregating	O	O
with	O	O
the	O	O
BFIC	B-Disease	D020936
phenotype	O	O
.	O	O

Brain	B-Disease	D001927
disease	I-Disease	D001927
and	O	O
molecular	O	O
analysis	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

Abnormal	O	O
amplification	O	O
of	O	O
a	O	O
CTG	O	O
repeat	O	O
on	O	O
chromosome	O	O
19	O	O
is	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

Expansion	O	O
of	O	O
the	O	O
repeat	O	O
has	O	O
been	O	O
correlated	O	O
with	O	O
severity	O	O
of	O	O
several	O	O
clinical	O	O
features	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

We	O	O
performed	O	O
extensive	O	O
cognitive	O	O
testing	O	O
,	O	O
cerebral	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
and	O	O
a	O	O
molecular	O	O
analysis	O	O
in	O	O
28	O	O
cases	O	O
of	O	O
DM	B-Disease	D009223
to	O	O
determine	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
molecular	O	O
defect	O	O
and	O	O
brain	B-Disease	D001927
disease	I-Disease	D001927
.	O	O

Performance	O	O
in	O	O
two	O	O
or	O	O
more	O	O
cognitive	O	O
tests	O	O
was	O	O
pathological	O	O
in	O	O
10	O	O
cases	O	O
.	O	O

Fourteen	O	O
patients	O	O
had	O	O
subcortical	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
lesions	I-Disease	D056784
on	O	O
MRI	O	O
,	O	O
14	O	O
had	O	O
cerebral	B-Disease	D001284
atrophy	I-Disease	D001284
.	O	O

Amplification	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
showed	O	O
a	O	O
strong	O	O
correlation	O	O
with	O	O
cognitive	O	O
test	O	O
deficits	O	O
when	O	O
exceeding	O	O
a	O	O
length	O	O
of	O	O
over	O	O
1000	O	O
trinucleotides	O	O
.	O	O

MRI	O	O
lesions	O	O
were	O	O
associated	O	O
with	O	O
impaired	O	O
psychometric	O	O
performance	O	O
,	O	O
but	O	O
MRI	O	O
and	O	O
molecular	O	O
findings	O	O
were	O	O
only	O	O
weakly	O	O
related	O	O
.	O	O

Disease	O	O
duration	O	O
influenced	O	O
the	O	O
appearance	O	O
and	O	O
amount	O	O
of	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
lesions	I-Disease	D056784
on	O	O
MRI	O	O
.	O	O

Quantification	O	O
of	O	O
CTG	O	O
repeat	O	O
size	O	O
may	O	O
allow	O	O
an	O	O
early	O	O
estimate	O	O
on	O	O
the	O	O
probability	O	O
of	O	O
brain	O	O
involvement	O	O
in	O	O
DM	B-Disease	D009223
;	O	O
cognitive	B-Disease	D003072
dysfunction	I-Disease	D003072
is	O	O
associated	O	O
with	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
lesions	I-Disease	D056784
and	O	O
cerebral	B-Disease	D001284
atrophy	I-Disease	D001284
later	O	O
on	O	O
in	O	O
the	O	O
course	O	O
.	O	O

.	O	O

A	O	O
highly	O	O
accurate	O	O
,	O	O
low	O	O
cost	O	O
test	O	O
for	O	O
BRCA1	O	O
mutations	O	O
.	O	O

The	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
syndrome	I-Disease	D061325
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
frequency	O	O
of	O	O
BRCA1	O	O
mutations	O	O
.	O	O

However	O	O
,	O	O
the	O	O
widespread	O	O
use	O	O
of	O	O
BRCA1	O	O
testing	O	O
has	O	O
been	O	O
limited	O	O
to	O	O
date	O	O
by	O	O
three	O	O
principal	O	O
concerns	O	O
the	O	O
fear	O	O
of	O	O
loss	O	O
of	O	O
health	O	O
and	O	O
life	O	O
insurance	O	O
,	O	O
the	O	O
uncertain	O	O
clinical	O	O
value	O	O
of	O	O
a	O	O
positive	O	O
test	O	O
result	O	O
,	O	O
and	O	O
the	O	O
current	O	O
lack	O	O
of	O	O
an	O	O
inexpensive	O	O
and	O	O
sensitive	O	O
screening	O	O
test	O	O
for	O	O
BRCA1	O	O
mutations	O	O
.	O	O

We	O	O
have	O	O
developed	O	O
an	O	O
inexpensive	O	O
system	O	O
for	O	O
gene	O	O
mutational	O	O
scanning	O	O
,	O	O
based	O	O
on	O	O
a	O	O
combination	O	O
of	O	O
extensive	O	O
multiplex	O	O
PCR	O	O
amplification	O	O
and	O	O
two	O	O
dimensional	O	O
electrophoresis	O	O
.	O	O

The	O	O
efficiency	O	O
of	O	O
this	O	O
system	O	O
,	O	O
as	O	O
a	O	O
screening	O	O
test	O	O
for	O	O
BRCA1	O	O
mutations	O	O
,	O	O
was	O	O
evaluated	O	O
in	O	O
a	O	O
panel	O	O
of	O	O
60	O	O
samples	O	O
from	O	O
high	O	O
risk	O	O
women	O	O
,	O	O
14	O	O
of	O	O
which	O	O
contained	O	O
a	O	O
previously	O	O
identified	O	O
mutation	O	O
in	O	O
BRCA1	O	O
.	O	O

All	O	O
14	O	O
mutations	O	O
were	O	O
identified	O	O
,	O	O
as	O	O
well	O	O
as	O	O
an	O	O
additional	O	O
five	O	O
that	O	O
had	O	O
previously	O	O
escaped	O	O
detection	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
19	O	O
mutations	O	O
,	O	O
a	O	O
total	O	O
of	O	O
15	O	O
different	O	O
polymorphic	O	O
variants	O	O
were	O	O
scored	O	O
,	O	O
most	O	O
of	O	O
which	O	O
were	O	O
recurring	O	O
.	O	O

All	O	O
were	O	O
confirmed	O	O
by	O	O
nucleotide	O	O
sequencing	O	O
.	O	O

The	O	O
cost	O	O
of	O	O
screening	O	O
per	O	O
sample	O	O
was	O	O
calculated	O	O
to	O	O
be	O	O
approximately	O	O
US	O	O
$	O	O
70	O	O
for	O	O
the	O	O
manual	O	O
technique	O	O
used	O	O
in	O	O
this	O	O
study	O	O
,	O	O
and	O	O
may	O	O
be	O	O
reduced	O	O
to	O	O
approximately	O	O
US	O	O
$	O	O
10	O	O
with	O	O
the	O	O
introduction	O	O
of	O	O
commercially	O	O
available	O	O
PCR	O	O
robotics	O	O
and	O	O
fluorescent	O	O
imaging	O	O
.	O	O

Implementation	O	O
of	O	O
this	O	O
method	O	O
of	O	O
mutation	O	O
screening	O	O
in	O	O
the	O	O
research	O	O
and	O	O
clinical	O	O
setting	O	O
should	O	O
permit	O	O
rapid	O	O
accrual	O	O
of	O	O
quantitative	O	O
data	O	O
on	O	O
genotype	O	O
-	O	O
phenotype	O	O
associations	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
diagnostic	O	O
testing	O	O
.	O	O

.	O	O

Germline	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
Korean	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
patients	O	O
.	O	O

We	O	O
extensively	O	O
analyzed	O	O
genomic	O	O
DNA	O	O
and	O	O
messenger	O	O
RNA	O	O
(	O	O
mRNA	O	O
)	O	O
from	O	O
62	O	O
unrelated	O	O
Korean	O	O
patients	O	O
with	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
for	O	O
identification	O	O
of	O	O
germline	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
mutations	O	O
.	O	O

We	O	O
adopted	O	O
both	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
and	O	O
a	O	O
method	O	O
of	O	O
analysis	O	O
involving	O	O
the	O	O
reverse	O	O
transcription	O	O
-	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
RT	O	O
-	O	O
PCR	O	O
)	O	O
followed	O	O
by	O	O
a	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
.	O	O

DNA	O	O
sequencing	O	O
confirmed	O	O
all	O	O
alterations	O	O
represented	O	O
by	O	O
aberrant	O	O
bands	O	O
.	O	O

Germline	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
38	O	O
patients	O	O
(	O	O
61	O	O
%	O	O
)	O	O
.	O	O

Nineteen	O	O
of	O	O
the	O	O
detected	O	O
mutations	O	O
were	O	O
presumed	O	O
to	O	O
be	O	O
novel	O	O
,	O	O
thus	O	O
emphasizing	O	O
the	O	O
heterogeneity	O	O
of	O	O
the	O	O
mutational	O	O
spectrum	O	O
in	O	O
Korean	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

In	O	O
the	O	O
initial	O	O
48	O	O
patients	O	O
,	O	O
SSCP	O	O
analysis	O	O
was	O	O
followed	O	O
by	O	O
PTT	O	O
for	O	O
those	O	O
patients	O	O
for	O	O
whom	O	O
no	O	O
detectable	O	O
mutations	O	O
were	O	O
found	O	O
by	O	O
SSCP	O	O
.	O	O

Using	O	O
this	O	O
combined	O	O
approach	O	O
,	O	O
we	O	O
identified	O	O
germline	O	O
APC	B-Disease	D011125
gene	O	O
mutations	O	O
in	O	O
29	O	O
of	O	O
the	O	O
48	O	O
FAP	B-Disease	D011125
patients	O	O
(	O	O
60	O	O
%	O	O
)	O	O
,	O	O
including	O	O
6	O	O
patients	O	O
in	O	O
whom	O	O
SSCP	O	O
analysis	O	O
failed	O	O
to	O	O
distinguish	O	O
the	O	O
mutant	O	O
allele	O	O
.	O	O

In	O	O
the	O	O
14	O	O
later	O	O
patients	O	O
,	O	O
we	O	O
identified	O	O
truncating	O	O
mutations	O	O
in	O	O
9	O	O
patients	O	O
(	O	O
64	O	O
%	O	O
)	O	O
using	O	O
PTT	O	O
only	O	O
.	O	O

Our	O	O
results	O	O
confirm	O	O
that	O	O
the	O	O
mutation	O	O
detection	O	O
rate	O	O
with	O	O
PTT	O	O
was	O	O
superior	O	O
to	O	O
that	O	O
with	O	O
SSCP	O	O
,	O	O
and	O	O
suggest	O	O
that	O	O
PTT	O	O
would	O	O
be	O	O
a	O	O
more	O	O
practical	O	O
screening	O	O
method	O	O
to	O	O
detect	O	O
germline	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

Homozygosity	O	O
mapping	O	O
in	O	O
a	O	O
family	O	O
with	O	O
microcephaly	B-Disease	D008831
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
to	O	O
a	O	O
Cohen	B-Disease	C536438
syndrome	I-Disease	C536438
region	O	O
on	O	O
8q21	O	O
.	O	O

3	O	O
-	O	O
8q22	O	O
.	O	O

1	O	O
:	O	O
redefining	O	O
a	O	O
clinical	O	O
entity	O	O
.	O	O

A	O	O
syndrome	O	O
of	O	O
microcephaly	B-Disease	D008831
,	O	O
progressive	O	O
postnatal	B-Disease	D006130
growth	I-Disease	D006130
deficiency	I-Disease	D006130
,	O	O
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
was	O	O
observed	O	O
in	O	O
two	O	O
brothers	O	O
and	O	O
their	O	O
cousin	O	O
from	O	O
a	O	O
multiply	O	O
consanguineous	O	O
kindred	O	O
of	O	O
Lebanese	O	O
descent	O	O
.	O	O

Hypotonia	B-Disease	D009123
,	O	O
chorioretinal	B-Disease	 D015862	D058499
dystrophy	I-Disease	 D015862	D058499
,	O	O
and	O	O
myopia	B-Disease	D009216
were	O	O
also	O	O
identified	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
the	O	O
condition	O	O
varied	O	O
among	O	O
the	O	O
closely	O	O
related	O	O
patients	O	O
.	O	O

Because	O	O
of	O	O
absence	O	O
of	O	O
a	O	O
distinctive	O	O
facial	O	O
appearance	O	O
,	O	O
the	O	O
degree	O	O
of	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
,	O	O
the	O	O
initially	O	O
considered	O	O
clinical	O	O
diagnosis	O	O
of	O	O
Cohen	B-Disease	C536438
syndrome	I-Disease	C536438
was	O	O
withdrawn	O	O
and	O	O
a	O	O
novel	O	O
genetic	O	O
entity	O	O
was	O	O
assumed	O	O
.	O	O

Homozygosity	O	O
mapping	O	O
in	O	O
this	O	O
family	O	O
assigned	O	O
the	O	O
gene	O	O
to	O	O
a	O	O
26	O	O
.	O	O

8	O	O
-	O	O
cM	O	O
region	O	O
on	O	O
the	O	O
chromosome	O	O
band	O	O
8q21	O	O
.	O	O

3	O	O
-	O	O
22	O	O
.	O	O

1	O	O
,	O	O
between	O	O
the	O	O
microsatellites	O	O
at	O	O
D8S270	O	O
and	O	O
D8S514	O	O
.	O	O

The	O	O
maximum	O	O
two	O	O
-	O	O
point	O	O
LOD	O	O
score	O	O
was	O	O
found	O	O
for	O	O
marker	O	O
at	O	O
D8S267	O	O
(	O	O
Zmax	O	O
=	O	O
3	O	O
.	O	O

.	O	O

237	O	O
at	O	O
Omax	O	O
=	O	O
0	O	O
.	O	O

00	O	O
)	O	O
.	O	O

Intriguingly	O	O
enough	O	O
,	O	O
the	O	O
identified	O	O
gene	O	O
region	O	O
overlaps	O	O
the	O	O
refined	O	O
gene	O	O
region	O	O
for	O	O
Cohen	B-Disease	C536438
syndrome	I-Disease	C536438
(	O	O
COH1	O	O
)	O	O
[	O	O
Kolehmainen	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1997	O	O
Euro	O	O
J	O	O
Hum	O	O
Genet	O	O
5	O	O
206	O	O
-	O	O
213	O	O
]	O	O
.	O	O

This	O	O
fact	O	O
encourages	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
described	O	O
kindred	O	O
segregates	O	O
for	O	O
a	O	O
variant	O	O
of	O	O
Cohen	B-Disease	C536438
syndrome	I-Disease	C536438
and	O	O
suggests	O	O
a	O	O
redefinition	O	O
of	O	O
its	O	O
phenotype	O	O
Spontaneous	O	O
reversion	O	O
of	O	O
novel	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
mutation	O	O
by	O	O
HPRT	O	O
gene	O	O
rearrangement	O	O
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
an	O	O
unusual	O	O
patient	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
has	O	O
suggested	O	O
that	O	O
the	O	O
mutation	O	O
is	O	O
due	O	O
to	O	O
a	O	O
partial	O	O
HPRT	O	O
gene	O	O
duplication	O	O
.	O	O

We	O	O
now	O	O
report	O	O
the	O	O
cloning	O	O
and	O	O
sequencing	O	O
of	O	O
the	O	O
mutant	O	O
HPRT	O	O
cDNA	O	O
which	O	O
shows	O	O
the	O	O
precise	O	O
duplication	O	O
of	O	O
exons	O	O
2	O	O
and	O	O
3	O	O
.	O	O

This	O	O
mutation	O	O
is	O	O
the	O	O
result	O	O
of	O	O
an	O	O
internal	O	O
duplication	O	O
of	O	O
16	O	O
-	O	O
20	O	O
kilobases	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

The	O	O
structure	O	O
of	O	O
the	O	O
mutant	O	O
gene	O	O
suggests	O	O
that	O	O
the	O	O
duplication	O	O
was	O	O
not	O	O
generated	O	O
by	O	O
a	O	O
single	O	O
unequal	O	O
crossing	O	O
-	O	O
over	O	O
event	O	O
between	O	O
two	O	O
normal	O	O
HPRT	O	O
alleles	O	O
.	O	O

Growth	O	O
of	O	O
Epstein	B-Disease	D020031
-	I-Disease	D020031
Barr	I-Disease	D020031
virus	O	O
-	O	O
transformed	O	O
lymphoblasts	O	O
from	O	O
this	O	O
patient	O	O
in	O	O
selective	O	O
medium	O	O
has	O	O
permitted	O	O
isolation	O	O
of	O	O
spontaneous	O	O
HPRT	O	O
+	O	O
revertants	O	O
of	O	O
this	O	O
mutation	O	O
.	O	O

The	O	O
reversion	O	O
event	O	O
involves	O	O
a	O	O
second	O	O
major	O	O
HPRT	O	O
gene	O	O
rearrangement	O	O
where	O	O
most	O	O
or	O	O
all	O	O
of	O	O
the	O	O
duplicated	O	O
portion	O	O
of	O	O
the	O	O
mutant	O	O
gene	O	O
is	O	O
deleted	O	O
.	O	O

The	O	O
original	O	O
mutation	O	O
therefore	O	O
has	O	O
the	O	O
potential	O	O
for	O	O
spontaneous	O	O
somatic	O	O
reversion	O	O
.	O	O

This	O	O
may	O	O
explain	O	O
the	O	O
relatively	O	O
mild	O	O
symptoms	O	O
of	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	O	O
exhibited	O	O
by	O	O
this	O	O
patient	O	O
.	O	O

.	O	O

Nephropathy	B-Disease	D007674
in	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

Nephropathy	B-Disease	D007674
was	O	O
detected	O	O
in	O	O
five	O	O
of	O	O
32	O	O
patients	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
who	O	O
were	O	O
participating	O	O
in	O	O
a	O	O
study	O	O
of	O	O
transfer	O	O
factor	O	O
(	O	O
TF	O	O
)	O	O
therapy	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
nephropathy	B-Disease	D007674
was	O	O
present	O	O
before	O	O
TF	O	O
and	O	O
did	O	O
not	O	O
appear	O	O
changed	O	O
by	O	O
TF	O	O
therapy	O	O
.	O	O

One	O	O
of	O	O
these	O	O
patients	O	O
subsequently	O	O
developed	O	O
progressive	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
requiring	O	O
dialysis	O	O
beginning	O	O
5	O	O
1	O	O
/	O	O
2	O	O
years	O	O
after	O	O
TF	O	O
therapy	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
decreased	O	O
renal	O	O
function	O	O
appeared	O	O
very	O	O
soon	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
TF	O	O
.	O	O

One	O	O
patient	O	O
showed	O	O
gradually	O	O
decreasing	O	O
renal	O	O
function	O	O
beginning	O	O
after	O	O
two	O	O
years	O	O
of	O	O
TF	O	O
therapy	O	O
.	O	O

An	O	O
additional	O	O
patient	O	O
was	O	O
identified	O	O
who	O	O
died	O	O
with	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
without	O	O
having	O	O
received	O	O
TF	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
occurs	O	O
in	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
more	O	O
frequently	O	O
than	O	O
generally	O	O
recognized	O	O
and	O	O
that	O	O
administration	O	O
of	O	O
TF	O	O
may	O	O
precipitate	O	O
or	O	O
accelerate	O	O
the	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
in	O	O
patients	O	O
with	O	O
this	O	O
syndrome	O	O
.	O	O

.	O	O

Aniridia	B-Disease	D015783
-	O	O
associated	O	O
cytogenetic	O	O
rearrangements	O	O
suggest	O	O
that	O	O
a	O	O
position	O	O
effect	O	O
may	O	O
cause	O	O
the	O	O
mutant	O	O
phenotype	O	O
.	O	O

Current	O	O
evidence	O	O
suggests	O	O
that	O	O
aniridia	B-Disease	D015783
(	O	O
absence	B-Disease	D015783
of	I-Disease	D015783
iris	I-Disease	D015783
)	O	O
is	O	O
caused	O	O
by	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
one	O	O
copy	O	O
of	O	O
the	O	O
PAX6	O	O
gene	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
11p13	O	O
.	O	O

We	O	O
present	O	O
the	O	O
further	O	O
characterisation	O	O
of	O	O
two	O	O
aniridia	B-Disease	D015783
pedigrees	O	O
in	O	O
which	O	O
the	O	O
disease	O	O
segregates	O	O
with	O	O
chromosomal	O	O
rearrangements	O	O
which	O	O
involve	O	O
11p13	O	O
but	O	O
do	O	O
not	O	O
disrupt	O	O
the	O	O
PAX6	O	O
gene	O	O
.	O	O

We	O	O
have	O	O
isolated	O	O
three	O	O
human	O	O
YAC	O	O
clones	O	O
which	O	O
encompass	O	O
the	O	O
PAX6	O	O
locus	O	O
and	O	O
we	O	O
have	O	O
used	O	O
these	O	O
to	O	O
show	O	O
that	O	O
in	O	O
both	O	O
cases	O	O
the	O	O
chromosomal	O	O
breakpoint	O	O
is	O	O
at	O	O
least	O	O
85	O	O
kb	O	O
distal	O	O
of	O	O
the	O	O
3	O	O
end	O	O
of	O	O
PAX6	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
open	O	O
reading	O	O
frame	O	O
of	O	O
PAX6	O	O
is	O	O
apparently	O	O
free	O	O
of	O	O
mutations	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
the	O	O
PAX6	O	O
gene	O	O
on	O	O
the	O	O
rearranged	O	O
chromosome	O	O
11	O	O
is	O	O
in	O	O
an	O	O
inappropriate	O	O
chromatin	O	O
environment	O	O
for	O	O
normal	O	O
expression	O	O
and	O	O
therefore	O	O
that	O	O
a	O	O
position	O	O
effect	O	O
is	O	O
the	O	O
underlying	O	O
mechanism	O	O
of	O	O
disease	O	O
in	O	O
these	O	O
families	O	O
.	O	O

.	O	O

Genetic	O	O
cholesteryl	B-Disease	OMIM:143470
ester	I-Disease	OMIM:143470
transfer	I-Disease	OMIM:143470
protein	I-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
caused	O	O
by	O	O
two	O	O
prevalent	O	O
mutations	O	O
as	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
increased	O	O
levels	O	O
of	O	O
high	O	O
density	O	O
lipoprotein	O	O
cholesterol	O	O
.	O	O

Genetic	O	O
determinants	O	O
of	O	O
HDL	O	O
cholesterol	O	O
(	O	O
HDL	O	O
-	O	O
C	O	O
)	O	O
levels	O	O
in	O	O
the	O	O
general	O	O
population	O	O
are	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
previously	O	O
described	O	O
plasma	O	O
cholesteryl	B-Disease	OMIM:143470
ester	I-Disease	OMIM:143470
transfer	I-Disease	OMIM:143470
protein	I-Disease	OMIM:143470
(	I-Disease	OMIM:143470
CETP	I-Disease	OMIM:143470
)	I-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
due	O	O
to	O	O
an	O	O
intron	O	O
14	O	O
G	O	O
(	O	O
+	O	O
1	O	O
)	O	O
-	O	O
to	O	O
-	O	O
A	O	O
mutation	O	O
(	O	O
Int14	O	O
A	O	O
)	O	O
in	O	O
several	O	O
families	O	O
with	O	O
very	O	O
high	O	O
HDL	O	O
-	O	O
C	O	O
levels	O	O
in	O	O
Japan	O	O
.	O	O

Subjects	O	O
with	O	O
HDL	O	O
-	O	O
C	O	O
>	O	O
or	O	O
=	O	O
100	O	O
mg	O	O
/	O	O
dl	O	O
(	O	O
n	O	O
=	O	O
130	O	O
)	O	O
were	O	O
screened	O	O
by	O	O
PCR	O	O
single	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
analysis	O	O
of	O	O
the	O	O
CETP	O	O
gene	O	O
.	O	O

Two	O	O
other	O	O
mutations	O	O
were	O	O
identified	O	O
by	O	O
DNA	O	O
sequencing	O	O
or	O	O
primer	O	O
-	O	O
mediated	O	O
restriction	O	O
map	O	O
modification	O	O
of	O	O
PCR	O	O
products	O	O
a	O	O
novel	O	O
intron	O	O
14	O	O
splice	O	O
donor	O	O
site	O	O
mutation	O	O
caused	O	O
by	O	O
a	O	O
T	O	O
insertion	O	O
at	O	O
position	O	O
+	O	O
3	O	O
from	O	O
the	O	O
exon14	O	O
/	O	O
intron14	O	O
boundary	O	O
(	O	O
Int14	O	O
T	O	O
)	O	O
and	O	O
a	O	O
missense	O	O
mutation	O	O
(	O	O
Asp442	O	O
to	O	O
Gly	O	O
)	O	O
within	O	O
exon	O	O
15	O	O
(	O	O
D442G	O	O
)	O	O
.	O	O

The	O	O
Int14	O	O
T	O	O
mutation	O	O
was	O	O
only	O	O
found	O	O
in	O	O
one	O	O
family	O	O
.	O	O

However	O	O
,	O	O
the	O	O
D442G	O	O
and	O	O
Int14	O	O
A	O	O
mutations	O	O
were	O	O
highly	O	O
prevalent	O	O
in	O	O
subjects	O	O
with	O	O
HDL	O	O
-	O	O
C	O	O
>	O	O
or	O	O
=	O	O
60	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
with	O	O
combined	O	O
allele	O	O
frequencies	O	O
of	O	O
9	O	O
%	O	O
,	O	O
12	O	O
%	O	O
,	O	O
21	O	O
%	O	O
and	O	O
43	O	O
%	O	O
for	O	O
HDL	O	O
-	O	O
C	O	O
60	O	O
-	O	O
79	O	O
,	O	O
80	O	O
-	O	O
99	O	O
,	O	O
100	O	O
-	O	O
119	O	O
,	O	O
and	O	O
>	O	O
or	O	O
=	O	O
120	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
respectively	O	O
.	O	O

Furthermore	O	O
,	O	O
prevalences	O	O
of	O	O
the	O	O
D442G	O	O
and	O	O
Int14	O	O
A	O	O
mutations	O	O
were	O	O
extremely	O	O
high	O	O
in	O	O
a	O	O
general	O	O
sample	O	O
of	O	O
Japanese	O	O
men	O	O
(	O	O
n	O	O
=	O	O
236	O	O
)	O	O
,	O	O
with	O	O
heterozygote	O	O
frequencies	O	O
of	O	O
7	O	O
%	O	O
and	O	O
2	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

These	O	O
two	O	O
mutations	O	O
accounted	O	O
for	O	O
about	O	O
10	O	O
%	O	O
of	O	O
the	O	O
total	O	O
variance	O	O
of	O	O
HDL	O	O
-	O	O
C	O	O
in	O	O
this	O	O
population	O	O
.	O	O

The	O	O
phenotype	O	O
in	O	O
a	O	O
genetic	O	O
compound	O	O
heterozygote	O	O
(	O	O
Int14	O	O
T	O	O
and	O	O
Int14	O	O
A	O	O
)	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
Int14	O	O
A	O	O
homozygotes	O	O
(	O	O
no	O	O
detectable	O	O
CETP	O	O
and	O	O
markedly	O	O
increased	O	O
HDL	O	O
-	O	O
C	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
Int14	O	O
T	O	O
produces	O	O
a	O	O
null	O	O
allele	O	O
.	O	O

In	O	O
four	O	O
D442G	O	O
homozygotes	O	O
,	O	O
mean	O	O
HDL	O	O
-	O	O
C	O	O
levels	O	O
(	O	O
86	O	O
+	O	O
/	O	O
-	O	O
26	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
were	O	O
lower	O	O
than	O	O
in	O	O
Int14	O	O
A	O	O
homozygotes	O	O
(	O	O
158	O	O
+	O	O
/	O	O
-	O	O
35	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
,	O	O
reflecting	O	O
residual	O	O
CETP	O	O
activity	O	O
in	O	O
plasma	O	O
.	O	O

In	O	O
47	O	O
D442G	O	O
heterozygotes	O	O
,	O	O
mean	O	O
HDL	O	O
-	O	O
C	O	O
levels	O	O
were	O	O
91	O	O
+	O	O
/	O	O
-	O	O
23	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
level	O	O
in	O	O
D442G	O	O
homozygotes	O	O
,	O	O
and	O	O
significantly	O	O
greater	O	O
than	O	O
mean	O	O
HDL	O	O
-	O	O
C	O	O
levels	O	O
in	O	O
Int14	O	O
A	O	O
heterozygotes	O	O
(	O	O
69	O	O
+	O	O
/	O	O
-	O	O
15	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
D442G	O	O
mutation	O	O
acts	O	O
differently	O	O
to	O	O
the	O	O
null	O	O
mutations	O	O
with	O	O
weaker	O	O
effects	O	O
on	O	O
HDL	O	O
in	O	O
the	O	O
homozygous	O	O
state	O	O
and	O	O
stronger	O	O
effects	O	O
in	O	O
the	O	O
heterozygotes	O	O
,	O	O
suggesting	O	O
dominant	O	O
expression	O	O
of	O	O
a	O	O
partially	O	O
defective	O	O
allele	O	O
.	O	O

CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
,	O	O
reflecting	O	O
two	O	O
prevalent	O	O
mutations	O	O
(	O	O
D442G	O	O
and	O	O
Int14	O	O
A	O	O
)	O	O
,	O	O
is	O	O
the	O	O
first	O	O
example	O	O
of	O	O
a	O	O
genetic	B-Disease	D030342
deficiency	I-Disease	D030342
state	O	O
which	O	O
is	O	O
sufficiently	O	O
common	O	O
to	O	O
explain	O	O
a	O	O
significant	O	O
fraction	O	O
of	O	O
the	O	O
variation	O	O
in	O	O
HDL	O	O
-	O	O
C	O	O
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

.	O	O

X	B-Disease	D005955
-	I-Disease	D005955
linked	I-Disease	D005955
glucose	I-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Mus	O	O
musculus	O	O
.	O	O

A	O	O
mouse	O	O
with	O	O
X	B-Disease	D005955
-	I-Disease	D005955
linked	I-Disease	D005955
glucose	I-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
has	O	O
been	O	O
recovered	O	O
in	O	O
offspring	O	O
of	O	O
1	O	O
-	O	O
ethyl	O	O
-	O	O
1	O	O
-	O	O
nitrosourea	O	O
-	O	O
treated	O	O
male	O	O
mice	O	O
.	O	O

The	O	O
activity	O	O
alteration	O	O
was	O	O
detected	O	O
in	O	O
blood	O	O
but	O	O
can	O	O
also	O	O
be	O	O
observed	O	O
in	O	O
other	O	O
tissue	O	O
extracts	O	O
.	O	O

Hemizygous	O	O
,	O	O
heterozygous	O	O
,	O	O
and	O	O
homozygous	O	O
mutants	O	O
have	O	O
,	O	O
respectively	O	O
,	O	O
about	O	O
15	O	O
,	O	O
60	O	O
,	O	O
and	O	O
15	O	O
%	O	O
G6PD	O	O
remaining	O	O
activity	O	O
in	O	O
the	O	O
blood	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
wild	O	O
type	O	O
.	O	O

Erythrocyte	O	O
indices	O	O
did	O	O
not	O	O
show	O	O
differences	O	O
between	O	O
mutants	O	O
and	O	O
wild	O	O
types	O	O
.	O	O

The	O	O
mutation	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
electrophoretic	O	O
migration	O	O
,	O	O
the	O	O
isoelectric	O	O
point	O	O
,	O	O
or	O	O
the	O	O
thermal	O	O
stability	O	O
.	O	O

Kinetic	O	O
properties	O	O
,	O	O
such	O	O
as	O	O
the	O	O
Km	O	O
for	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
or	O	O
for	O	O
NADP	O	O
and	O	O
the	O	O
relative	O	O
utilization	O	O
of	O	O
substrate	O	O
analogues	O	O
,	O	O
showed	O	O
no	O	O
differences	O	O
between	O	O
wild	O	O
types	O	O
and	O	O
mutants	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
relative	O	O
utilization	O	O
of	O	O
deamino	O	O
-	O	O
NADP	O	O
which	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
mutants	O	O
.	O	O

This	O	O
is	O	O
presently	O	O
the	O	O
only	O	O
animal	O	O
model	O	O
for	O	O
X	B-Disease	D005955
-	I-Disease	D005955
linked	I-Disease	D005955
G6PD	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
humans	O	O
.	O	O

.	O	O

Human	O	O
glycine	O	O
decarboxylase	O	O
gene	O	O
(	O	O
GLDC	O	O
)	O	O
and	O	O
its	O	O
highly	O	O
conserved	O	O
processed	O	O
pseudogene	O	O
(	O	O
psiGLDC	O	O
)	O	O
:	O	O
their	O	O
structure	O	O
and	O	O
expression	O	O
,	O	O
and	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
large	O	O
deletion	O	O
in	O	O
a	O	O
family	O	O
with	O	O
nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
.	O	O

Mutations	O	O
in	O	O
the	O	O
glycine	O	O
decarboxylase	O	O
gene	O	O
(	O	O
GLDC	O	O
)	O	O
cause	O	O
nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
(	O	O
NKH	B-Disease	D020158
)	O	O
,	O	O
an	O	O
in	B-Disease	D008661
-	I-Disease	D008661
born	I-Disease	D008661
error	I-Disease	D008661
of	I-Disease	D008661
metabolism	I-Disease	D008661
characterized	O	O
by	O	O
severe	O	O
neurological	B-Disease	D009461
disturbance	I-Disease	D009461
.	O	O

We	O	O
have	O	O
determined	O	O
the	O	O
structure	O	O
of	O	O
GLDC	O	O
and	O	O
of	O	O
its	O	O
pseudogene	O	O
(	O	O
psiGLDC	O	O
)	O	O
and	O	O
studied	O	O
their	O	O
expression	O	O
for	O	O
a	O	O
molecular	O	O
analysis	O	O
of	O	O
NKH	B-Disease	D020158
.	O	O

The	O	O
GLDC	O	O
gene	O	O
spans	O	O
at	O	O
least	O	O
135	O	O
kb	O	O
and	O	O
consists	O	O
of	O	O
25	O	O
exons	O	O
.	O	O

All	O	O
donor	O	O
and	O	O
acceptor	O	O
sites	O	O
adhere	O	O
to	O	O
the	O	O
canonical	O	O
GT	O	O
-	O	O
AG	O	O
rule	O	O
,	O	O
except	O	O
for	O	O
the	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
21	O	O
,	O	O
where	O	O
a	O	O
variant	O	O
form	O	O
GC	O	O
is	O	O
used	O	O
instead	O	O
of	O	O
GT	O	O
.	O	O

The	O	O
transcription	O	O
initiation	O	O
site	O	O
has	O	O
been	O	O
assigned	O	O
to	O	O
a	O	O
residue	O	O
163	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
translation	O	O
initiation	O	O
triplet	O	O
by	O	O
primer	O	O
extension	O	O
analysis	O	O
.	O	O

The	O	O
psiGLDC	O	O
gene	O	O
has	O	O
no	O	O
intron	O	O
and	O	O
shares	O	O
97	O	O
.	O	O

5	O	O
%	O	O
homology	O	O
with	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
functional	O	O
GLDC	O	O
,	O	O
suggesting	O	O
that	O	O
psiGLDC	O	O
is	O	O
a	O	O
processed	O	O
pseudogene	O	O
that	O	O
arose	O	O
from	O	O
the	O	O
GLDC	O	O
transcript	O	O
about	O	O
4	O	O
-	O	O
8	O	O
million	O	O
years	O	O
ago	O	O
.	O	O

RNA	O	O
blotting	O	O
analysis	O	O
has	O	O
revealed	O	O
that	O	O
GLDC	O	O
is	O	O
expressed	O	O
in	O	O
human	O	O
liver	O	O
,	O	O
kidney	O	O
,	O	O
brain	O	O
,	O	O
and	O	O
placenta	O	O
.	O	O

We	O	O
have	O	O
also	O	O
examined	O	O
a	O	O
patient	O	O
with	O	O
NKH	B-Disease	D020158
with	O	O
no	O	O
detectable	O	O
GLDC	O	O
mRNA	O	O
in	O	O
his	O	O
lymphoblasts	O	O
.	O	O

Exons	O	O
1	O	O
-	O	O
3	O	O
of	O	O
the	O	O
functional	O	O
GLDC	O	O
gene	O	O
from	O	O
this	O	O
patient	O	O
are	O	O
not	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
,	O	O
whereas	O	O
those	O	O
from	O	O
control	O	O
subjects	O	O
are	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
a	O	O
large	O	O
homozygous	O	O
deletion	O	O
(	O	O
at	O	O
least	O	O
30	O	O
kb	O	O
)	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
have	O	O
devised	O	O
a	O	O
semi	O	O
-	O	O
quantitative	O	O
PCR	O	O
to	O	O
estimate	O	O
the	O	O
number	O	O
of	O	O
GLDC	O	O
alleles	O	O
by	O	O
using	O	O
psiGLDC	O	O
as	O	O
an	O	O
internal	O	O
control	O	O
and	O	O
have	O	O
confirmed	O	O
the	O	O
homozygosity	O	O
and	O	O
heterozygosity	O	O
of	O	O
the	O	O
deletion	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
his	O	O
parents	O	O
,	O	O
respectively	O	O
.	O	O

Structural	O	O
information	O	O
of	O	O
GLDC	O	O
and	O	O
psiGLDC	O	O
should	O	O
facilitate	O	O
the	O	O
molecular	O	O
analysis	O	O
of	O	O
NKH	B-Disease	D020158
.	O	O

Growth	B-Disease	D006130
retardation	I-Disease	D006130
and	O	O
tumour	B-Disease	D009369
inhibition	O	O
by	O	O
BRCA1	O	O
.	O	O

Inherited	O	O
mutations	O	O
in	O	O
BRCA1	O	O
predispose	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
but	O	O
the	O	O
role	O	O
of	O	O
BRCA1	O	O
in	O	O
sporadic	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
has	O	O
previously	O	O
been	O	O
elusive	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
retroviral	O	O
transfer	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
BRCA1	O	O
gene	O	O
inhibits	O	O
growth	O	O
in	O	O
vitro	O	O
of	O	O
all	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
cell	O	O
lines	O	O
tested	O	O
,	O	O
but	O	O
not	O	O
colon	B-Disease	D003110
or	I-Disease	D003110
lung	I-Disease	D003110
cancer	I-Disease	D003110
cells	O	O
or	O	O
fibroblasts	O	O
.	O	O

Mutant	O	O
BRCA1	O	O
has	O	O
no	O	O
effect	O	O
on	O	O
growth	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
cells	O	O
;	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
cell	O	O
growth	O	O
is	O	O
not	O	O
affected	O	O
by	O	O
BRCA1	O	O
mutations	O	O
in	O	O
the	O	O
5	O	O
portion	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
but	O	O
is	O	O
inhibited	O	O
by	O	O
3	O	O
BRCA1	O	O
mutations	O	O
.	O	O

Development	O	O
of	O	O
MCF	B-Disease	D009369
-	I-Disease	D009369
7	I-Disease	D009369
tumours	I-Disease	D009369
in	O	O
nude	O	O
mice	O	O
is	O	O
inhibited	O	O
when	O	O
MCF	O	O
-	O	O
7	O	O
cells	O	O
are	O	O
transfected	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
,	O	O
but	O	O
not	O	O
mutant	O	O
,	O	O
BRCA1	O	O
.	O	O

Most	O	O
importantly	O	O
,	O	O
among	O	O
mice	O	O
with	O	O
established	O	O
MCF	B-Disease	D009369
-	I-Disease	D009369
7	I-Disease	D009369
tumours	I-Disease	D009369
,	O	O
peritoneal	O	O
treatment	O	O
with	O	O
a	O	O
retroviral	O	O
vector	O	O
expressing	O	O
wild	O	O
-	O	O
type	O	O
BRCA1	O	O
significantly	O	O
inhibits	O	O
tumour	B-Disease	D009369
growth	O	O
and	O	O
increased	O	O
survival	O	O
.	O	O

.	O	O

Striking	O	O
prevalence	O	O
of	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
in	O	O
"	O	O
healthy	O	O
"	O	O
w27	O	O
positive	O	O
males	O	O
and	O	O
females	O	O
.	O	O

Ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
is	O	O
diagnosed	O	O
once	O	O
or	O	O
twice	O	O
in	O	O
each	O	O
1000	O	O
males	O	O
and	O	O
one	O	O
tenth	O	O
as	O	O
frequently	O	O
in	O	O
females	O	O
,	O	O
but	O	O
the	O	O
true	O	O
prevalence	O	O
is	O	O
unknown	O	O
.	O	O

Indentification	O	O
of	O	O
genetic	O	O
marker	O	O
,	O	O
HL	O	O
-	O	O
A	O	O
W27	O	O
,	O	O
for	O	O
susceptible	O	O
persons	O	O
has	O	O
provided	O	O
a	O	O
tool	O	O
facilitating	O	O
epidemiologic	O	O
studies	O	O
and	O	O
allowing	O	O
identification	O	O
of	O	O
"	O	O
control	O	O
"	O	O
populations	O	O
without	O	O
the	O	O
marker	O	O
.	O	O

Evaluation	O	O
by	O	O
postal	O	O
questionnaires	O	O
,	O	O
and	O	O
pelvic	O	O
radiography	O	O
of	O	O
78	O	O
HL	O	O
-	O	O
A	O	O
27W	O	O
-	O	O
positive	O	O
blood	O	O
donors	O	O
selected	O	O
from	O	O
a	O	O
group	O	O
of	O	O
apparently	O	O
healthy	O	O
subjects	O	O
revealed	O	O
14	O	O
who	O	O
satisfied	O	O
the	O	O
criteria	O	O
for	O	O
definite	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
.	O	O

The	O	O
prevalence	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
sexes	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
twenty	O	O
-	O	O
six	O	O
W27	O	O
-	O	O
negative	O	O
controls	O	O
matched	O	O
for	O	O
race	O	O
,	O	O
sex	O	O
,	O	O
and	O	O
age	O	O
failed	O	O
to	O	O
yield	O	O
a	O	O
single	O	O
case	O	O
.	O	O

For	O	O
a	O	O
person	O	O
of	O	O
either	O	O
sex	O	O
with	O	O
HL	O	O
-	O	O
A	O	O
W27	O	O
,	O	O
there	O	O
appears	O	O
to	O	O
be	O	O
about	O	O
a	O	O
20	O	O
per	O	O
cent	O	O
chance	O	O
that	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
will	O	O
develop	O	O
,	O	O
suggesting	O	O
a	O	O
prevalence	O	O
of	O	O
10	O	O
to	O	O
15	O	O
per	O	O
thousand	O	O
.	O	O

Hitherto	O	O
accepted	O	O
figures	O	O
may	O	O
underestimate	O	O
the	O	O
frequency	O	O
by	O	O
a	O	O
factor	O	O
of	O	O
10	O	O
to	O	O
20	O	O
.	O	O

.	O	O

Rapid	O	O
detection	O	O
of	O	O
BRCA1	O	O
mutations	O	O
by	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
.	O	O

More	O	O
than	O	O
75	O	O
%	O	O
of	O	O
the	O	O
reported	O	O
mutations	O	O
in	O	O
the	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
result	O	O
in	O	O
truncated	O	O
proteins	O	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
to	O	O
screen	O	O
for	O	O
mutations	O	O
in	O	O
exon	O	O
11	O	O
,	O	O
which	O	O
encodes	O	O
61	O	O
%	O	O
of	O	O
BRCA1	O	O
.	O	O

In	O	O
45	O	O
patients	O	O
from	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
/	I-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
families	O	O
we	O	O
found	O	O
six	O	O
novel	O	O
mutations	O	O
two	O	O
single	O	O
nucleotide	O	O
insertions	O	O
,	O	O
three	O	O
small	O	O
deletions	O	O
(	O	O
1	O	O
-	O	O
5	O	O
bp	O	O
)	O	O
and	O	O
a	O	O
nonsense	O	O
mutation	O	O
identified	O	O
two	O	O
unrelated	O	O
families	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
amplify	O	O
the	O	O
remaining	O	O
coding	O	O
region	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
using	O	O
lymphocyte	O	O
RNA	O	O
.	O	O

Combined	O	O
with	O	O
PTT	O	O
,	O	O
we	O	O
detected	O	O
aberrantly	O	O
spliced	O	O
products	O	O
affecting	O	O
exons	O	O
5	O	O
and	O	O
6	O	O
in	O	O
one	O	O
of	O	O
two	O	O
BRCA1	O	O
-	O	O
linked	O	O
families	O	O
examined	O	O
.	O	O

The	O	O
protein	O	O
truncation	O	O
test	O	O
promises	O	O
to	O	O
become	O	O
a	O	O
valuable	O	O
technique	O	O
in	O	O
detecting	O	O
BRCA1	O	O
mutations	O	O
.	O	O

.	O	O

New	O	O
variant	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
in	O	O
a	O	O
family	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

A	O	O
C	O	O
-	O	O
-	O	O
greater	O	O
than	O	O
G	O	O
transversion	O	O
has	O	O
been	O	O
found	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
of	O	O
affected	O	O
males	O	O
and	O	O
their	O	O
mother	O	O
in	O	O
a	O	O
single	O	O
sibship	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
PMD	B-Disease	OMIM:312080
)	O	O
.	O	O

The	O	O
transversion	O	O
should	O	O
not	O	O
result	O	O
in	O	O
an	O	O
amino	O	O
acid	O	O
change	O	O
in	O	O
the	O	O
protein	O	O
but	O	O
it	O	O
does	O	O
result	O	O
in	O	O
the	O	O
loss	O	O
of	O	O
a	O	O
HaeIII	O	O
restriction	O	O
endonuclease	O	O
cleavage	O	O
site	O	O
.	O	O

It	O	O
is	O	O
concordant	O	O
with	O	O
the	O	O
disease	O	O
in	O	O
this	O	O
family	O	O
.	O	O

One	O	O
-	O	O
hundred	O	O
-	O	O
ten	O	O
unrelated	O	O
X	O	O
chromosomes	O	O
are	O	O
negative	O	O
for	O	O
this	O	O
mutation	O	O
.	O	O

No	O	O
other	O	O
sequence	O	O
defect	O	O
was	O	O
found	O	O
in	O	O
the	O	O
PLP	O	O
exons	O	O
of	O	O
the	O	O
affected	O	O
males	O	O
.	O	O

The	O	O
cause	O	O
of	O	O
disease	O	O
in	O	O
this	O	O
family	O	O
remains	O	O
unknown	O	O
,	O	O
but	O	O
the	O	O
association	O	O
between	O	O
this	O	O
rare	O	O
mutation	O	O
and	O	O
PMD	B-Disease	OMIM:312080
is	O	O
intriguing	O	O
.	O	O

The	O	O
mutation	O	O
can	O	O
serve	O	O
as	O	O
a	O	O
marker	O	O
for	O	O
following	O	O
segregation	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
.	O	O

.	O	O

Variants	O	O
of	O	O
erythrocyte	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
in	O	O
Bulgarian	O	O
populations	O	O
.	O	O

Ten	O	O
variants	O	O
of	O	O
erythrocyte	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
were	O	O
identified	O	O
in	O	O
22	O	O
patients	O	O
with	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
from	O	O
three	O	O
districts	O	O
of	O	O
Bulgaria	O	O
.	O	O

Corinth	O	O
-	O	O
like	O	O
and	O	O
Fayoum	O	O
-	O	O
like	O	O
variants	O	O
were	O	O
the	O	O
most	O	O
frequent	O	O
;	O	O
Mediterranean	O	O
,	O	O
Ohut	O	O
II	O	O
,	O	O
Kilgore	O	O
,	O	O
Boston	O	O
,	O	O
Poznan	O	O
,	O	O
and	O	O
Panay	O	O
variants	O	O
and	O	O
two	O	O
new	O	O
variants	O	O
,	O	O
Petrich	O	O
and	O	O
Gotze	O	O
Delchev	O	O
,	O	O
were	O	O
each	O	O
found	O	O
in	O	O
one	O	O
or	O	O
two	O	O
carriers	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
revealed	O	O
between	O	O
clinical	O	O
and	O	O
biochemical	O	O
polymorphism	O	O
.	O	O

.	O	O

The	O	O
C282Y	O	O
mutation	O	O
causing	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
does	O	O
not	O	O
produce	O	O
a	O	O
null	O	O
allele	O	O
.	O	O

Targeted	O	O
mutagenesis	O	O
was	O	O
used	O	O
to	O	O
produce	O	O
two	O	O
mutations	O	O
in	O	O
the	O	O
murine	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
(	O	O
Hfe	O	O
)	O	O
locus	O	O
.	O	O

The	O	O
first	O	O
mutation	O	O
deletes	O	O
a	O	O
large	O	O
portion	O	O
of	O	O
the	O	O
coding	O	O
sequence	O	O
,	O	O
generating	O	O
a	O	O
null	O	O
allele	O	O
.	O	O

The	O	O
second	O	O
mutation	O	O
introduces	O	O
a	O	O
missense	O	O
mutation	O	O
(	O	O
C282Y	O	O
)	O	O
into	O	O
the	O	O
Hfe	O	O
locus	O	O
,	O	O
but	O	O
otherwise	O	O
leaves	O	O
the	O	O
gene	O	O
intact	O	O
.	O	O

This	O	O
mutation	O	O
is	O	O
identical	O	O
to	O	O
the	O	O
disease	O	O
-	O	O
causing	O	O
mutation	O	O
in	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
.	O	O

Mice	O	O
carrying	O	O
each	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
were	O	O
bred	O	O
and	O	O
analyzed	O	O
.	O	O

Homozygosity	O	O
for	O	O
either	O	O
mutation	O	O
results	O	O
in	O	O
postnatal	O	O
iron	O	O
loading	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
the	O	O
null	O	O
mutation	O	O
are	O	O
more	O	O
severe	O	O
than	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
C282Y	O	O
mutation	O	O
.	O	O

Mice	O	O
heterozygous	O	O
for	O	O
either	O	O
mutation	O	O
accumulate	O	O
more	O	O
iron	O	O
than	O	O
normal	O	O
controls	O	O
.	O	O

Interestingly	O	O
,	O	O
although	O	O
liver	O	O
iron	O	O
stores	O	O
are	O	O
greatly	O	O
increased	O	O
,	O	O
splenic	O	O
iron	O	O
is	O	O
decreased	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
C282Y	O	O
mutation	O	O
does	O	O
not	O	O
result	O	O
in	O	O
a	O	O
null	O	O
allele	O	O
.	O	O

.	O	O

Regional	O	O
localisation	O	O
of	O	O
the	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
locus	O	O
to	O	O
human	O	O
chromosome	O	O
9q13	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q21	O	O
.	O	O

1	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
assigned	O	O
the	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
locus	O	O
(	O	O
FRDA	O	O
)	O	O
to	O	O
chromosome	O	O
9	O	O
;	O	O
the	O	O
current	O	O
maximal	O	O
lod	O	O
score	O	O
between	O	O
FRDA	O	O
and	O	O
MCT112	O	O
(	O	O
D9S15	O	O
)	O	O
is	O	O
greater	O	O
than	O	O
50	O	O
at	O	O
a	O	O
recombination	O	O
fraction	O	O
of	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

The	O	O
physical	O	O
assignment	O	O
of	O	O
the	O	O
locus	O	O
defined	O	O
by	O	O
MCT112	O	O
,	O	O
and	O	O
hence	O	O
FRDA	O	O
,	O	O
has	O	O
not	O	O
been	O	O
determined	O	O
,	O	O
although	O	O
linkage	O	O
analysis	O	O
of	O	O
MCT112	O	O
with	O	O
other	O	O
chromosome	O	O
9	O	O
markers	O	O
inferred	O	O
a	O	O
location	O	O
close	O	O
to	O	O
the	O	O
centromere	O	O
.	O	O

We	O	O
have	O	O
used	O	O
in	O	O
situ	O	O
hybridisation	O	O
with	O	O
MCT112	O	O
,	O	O
a	O	O
corresponding	O	O
cosmid	O	O
MJ1	O	O
,	O	O
and	O	O
DR47	O	O
(	O	O
D9S5	O	O
)	O	O
,	O	O
coupled	O	O
with	O	O
mapping	O	O
studies	O	O
on	O	O
hybrid	O	O
cell	O	O
panels	O	O
,	O	O
to	O	O
define	O	O
more	O	O
precisely	O	O
the	O	O
location	O	O
of	O	O
the	O	O
disease	O	O
locus	O	O
.	O	O

The	O	O
in	O	O
situ	O	O
location	O	O
of	O	O
all	O	O
three	O	O
probes	O	O
is	O	O
9q13	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q21	O	O
.	O	O

1	O	O
,	O	O
distal	O	O
to	O	O
the	O	O
variable	O	O
heterochromatin	O	O
region	O	O
.	O	O

Physical	O	O
assignment	O	O
of	O	O
FRDA	O	O
will	O	O
allow	O	O
us	O	O
to	O	O
identify	O	O
hybrid	O	O
cell	O	O
lines	O	O
containing	O	O
the	O	O
mutated	O	O
gene	O	O
.	O	O

Mxi1	O	O
mutations	O	O
in	O	O
human	O	O
neurofibrosarcomas	B-Disease	D018319
.	O	O

Mxi1	O	O
is	O	O
thought	O	O
to	O	O
negatively	O	O
regulate	O	O
Myc	O	O
function	O	O
and	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
potential	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
.	O	O

Little	O	O
effort	O	O
has	O	O
yet	O	O
been	O	O
made	O	O
to	O	O
find	O	O
alterations	O	O
involving	O	O
this	O	O
gene	O	O
in	O	O
human	O	O
solid	B-Disease	D009369
tumors	I-Disease	D009369
.	O	O

We	O	O
screened	O	O
31	O	O
human	O	O
gastric	B-Disease	D013274
cancers	I-Disease	D013274
,	O	O
7	O	O
esophageal	B-Disease	D004938
cancers	I-Disease	D004938
,	O	O
85	O	O
bone	B-Disease	D001859
and	I-Disease	D001859
soft	I-Disease	D001859
tissue	I-Disease	D001859
tumors	I-Disease	D001859
of	O	O
various	O	O
types	O	O
,	O	O
including	O	O
4	O	O
neurofibrosarcomas	B-Disease	D018319
.	O	O

We	O	O
also	O	O
examined	O	O
29	O	O
human	O	O
tumor	B-Disease	D009369
cell	O	O
lines	O	O
consisting	O	O
of	O	O
12	O	O
esophageal	B-Disease	D004938
cancers	I-Disease	D004938
,	O	O
7	O	O
glioma	B-Disease	D005910
/	O	O
glioblastomas	B-Disease	D005909
and	O	O
10	O	O
others	O	O
for	O	O
Mxi1	O	O
mutations	O	O
in	O	O
exons	O	O
1	O	O
,	O	O
2	O	O
,	O	O
4	O	O
(	O	O
HLH	O	O
domain	O	O
)	O	O
,	O	O
5	O	O
and	O	O
6	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
SSCP	O	O
)	O	O
and	O	O
subsequent	O	O
sequencing	O	O
revealed	O	O
three	O	O
distinct	O	O
polymorphisms	O	O
in	O	O
the	O	O
intron	O	O
-	O	O
exon	O	O
boundary	O	O
upstream	O	O
from	O	O
exon	O	O
6	O	O
.	O	O

We	O	O
discovered	O	O
a	O	O
missense	O	O
mutation	O	O
,	O	O
GCA	O	O
to	O	O
GTA	O	O
(	O	O
Ala	O	O
54	O	O
Val	O	O
)	O	O
,	O	O
in	O	O
exon	O	O
2	O	O
in	O	O
a	O	O
neurofibrosarcoma	B-Disease	D018319
patient	O	O
(	O	O
case	O	O
1	O	O
)	O	O
,	O	O
two	O	O
missense	O	O
mutations	O	O
,	O	O
AAA	O	O
to	O	O
CAA	O	O
(	O	O
Lys	O	O
118	O	O
Gln	O	O
)	O	O
and	O	O
GAA	O	O
to	O	O
GGA	O	O
(	O	O
Glu	O	O
154	O	O
Gly	O	O
)	O	O
in	O	O
exon	O	O
5	O	O
of	O	O
another	O	O
neurofibrosarcoma	B-Disease	D018319
patient	O	O
(	O	O
case	O	O
2	O	O
)	O	O
,	O	O
and	O	O
3	O	O
amino	O	O
acid	O	O
substitutions	O	O
,	O	O
GTG	O	O
to	O	O
GCG	O	O
(	O	O
Val	O	O
179	O	O
Ala	O	O
)	O	O
,	O	O
GTT	O	O
to	O	O
GCT	O	O
(	O	O
Val	O	O
181	O	O
Ala	O	O
)	O	O
and	O	O
TTC	O	O
to	O	O
CTC	O	O
(	O	O
Phe	O	O
186	O	O
Leu	O	O
)	O	O
,	O	O
in	O	O
a	O	O
third	O	O
neurofibrosarcoma	B-Disease	D018319
patient	O	O
(	O	O
case	O	O
3	O	O
)	O	O
.	O	O

In	O	O
case	O	O
3	O	O
,	O	O
loss	O	O
of	O	O
heterozygosity	O	O
was	O	O
also	O	O
demonstrated	O	O
by	O	O
informative	O	O
(	O	O
TTC	O	O
)	O	O
3	O	O
/	O	O
(	O	O
TTC	O	O
)	O	O
2	O	O
polymorphism	O	O
.	O	O

Our	O	O
data	O	O
demonstrate	O	O
that	O	O
mutations	O	O
occur	O	O
in	O	O
the	O	O
Mxi1	O	O
gene	O	O
in	O	O
neurofibrosarcoma	B-Disease	D018319
.	O	O

Missense	O	O
mutations	O	O
in	O	O
the	O	O
functional	O	O
domain	O	O
of	O	O
Mxi1	O	O
in	O	O
these	O	O
cases	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
neurofibrosarcoma	B-Disease	D018319
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
essential	B-Disease	C538068
fructosuria	I-Disease	C538068
:	O	O
molecular	O	O
cloning	O	O
and	O	O
mutational	O	O
analysis	O	O
of	O	O
human	O	O
ketohexokinase	O	O
(	O	O
fructokinase	O	O
)	O	O
.	O	O

Essential	B-Disease	C538068
fructosuria	I-Disease	C538068
is	O	O
one	O	O
of	O	O
the	O	O
oldest	O	O
known	O	O
inborn	B-Disease	D008661
errors	I-Disease	D008661
of	I-Disease	D008661
metabolism	I-Disease	D008661
.	O	O

It	O	O
is	O	O
a	O	O
benign	O	O
condition	O	O
which	O	O
is	O	O
believed	O	O
to	O	O
result	O	O
from	O	O
deficiency	B-Disease	C538068
of	I-Disease	C538068
hepatic	I-Disease	C538068
fructokinase	I-Disease	C538068
(	O	O
ketohexokinase	O	O
,	O	O
KHK	O	O
,	O	O
E	O	O
.	O	O

C	O	O
.	O	O

2	O	O
.	O	O

7	O	O
.	O	O

1	O	O
.	O	O

3	O	O
)	O	O
.	O	O

This	O	O
enzyme	O	O
catalyses	O	O
the	O	O
first	O	O
step	O	O
of	O	O
metabolism	O	O
of	O	O
dietary	O	O
fructose	O	O
,	O	O
conversion	O	O
of	O	O
fructose	O	O
to	O	O
fructose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
.	O	O

Despite	O	O
the	O	O
early	O	O
recognition	O	O
of	O	O
this	O	O
disorder	O	O
,	O	O
the	O	O
primary	O	O
structure	O	O
of	O	O
human	O	O
KHK	O	O
and	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
essential	B-Disease	C538068
fructosuria	I-Disease	C538068
have	O	O
not	O	O
been	O	O
previously	O	O
defined	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
the	O	O
isolation	O	O
and	O	O
sequencing	O	O
of	O	O
full	O	O
-	O	O
length	O	O
cDNA	O	O
clones	O	O
encoding	O	O
human	O	O
ketohexokinase	O	O
are	O	O
described	O	O
.	O	O

Alternative	O	O
mRNA	O	O
species	O	O
and	O	O
alternative	O	O
KHK	O	O
isozymes	O	O
are	O	O
produced	O	O
by	O	O
alternative	O	O
polyadenylation	O	O
and	O	O
splicing	O	O
of	O	O
the	O	O
KHK	O	O
gene	O	O
.	O	O

The	O	O
KHK	O	O
proteins	O	O
show	O	O
a	O	O
high	O	O
level	O	O
of	O	O
sequence	O	O
conservation	O	O
relative	O	O
to	O	O
rat	O	O
KHK	O	O
.	O	O

Direct	O	O
evidence	O	O
that	O	O
mutation	O	O
of	O	O
the	O	O
KHK	O	O
structural	O	O
gene	O	O
is	O	O
the	O	O
cause	O	O
of	O	O
essential	B-Disease	C538068
fructosuria	I-Disease	C538068
was	O	O
also	O	O
obtained	O	O
.	O	O

In	O	O
a	O	O
well	O	O
-	O	O
characterized	O	O
family	O	O
,	O	O
in	O	O
which	O	O
three	O	O
of	O	O
eight	O	O
siblings	O	O
have	O	O
fructosuria	B-Disease	C538068
,	O	O
all	O	O
affected	O	O
individuals	O	O
are	O	O
compound	O	O
heterozygotes	O	O
for	O	O
two	O	O
mutations	O	O
Gly40Arg	O	O
and	O	O
Ala43Thr	O	O
.	O	O

Both	O	O
mutations	O	O
result	O	O
from	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transitions	O	O
,	O	O
and	O	O
each	O	O
alters	O	O
the	O	O
same	O	O
conserved	O	O
region	O	O
of	O	O
the	O	O
KHK	O	O
protein	O	O
.	O	O

Neither	O	O
mutation	O	O
was	O	O
seen	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
52	O	O
unrelated	O	O
control	O	O
individuals	O	O
.	O	O

An	O	O
additional	O	O
conservative	O	O
amino	O	O
acid	O	O
change	O	O
(	O	O
Val49IIe	O	O
)	O	O
was	O	O
present	O	O
on	O	O
the	O	O
KHK	O	O
allele	O	O
bearing	O	O
Ala43Thr	O	O
Loss	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
product	O	O
causes	O	O
oxidative	O	O
damage	O	O
in	O	O
target	O	O
organs	O	O
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
is	O	O
characterized	O	O
by	O	O
a	O	O
markedly	O	O
increased	O	O
sensitivity	O	O
to	O	O
ionizing	O	O
radiation	O	O
,	O	O
increased	O	O
incidence	O	O
of	O	O
cancer	B-Disease	D009369
,	O	O
and	O	O
neurodegeneration	B-Disease	D019636
,	O	O
especially	O	O
of	O	O
the	O	O
cerebellar	O	O
Purkinje	O	O
cells	O	O
.	O	O

Ionizing	O	O
radiation	O	O
oxidizes	O	O
macromolecules	O	O
and	O	O
causes	O	O
tissue	O	O
damage	O	O
through	O	O
the	O	O
generation	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
(	O	O
ROS	O	O
)	O	O
.	O	O

We	O	O
therefore	O	O
hypothesized	O	O
that	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
is	O	O
due	O	O
to	O	O
oxidative	O	O
damage	O	O
resulting	O	O
from	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
gene	O	O
product	O	O
.	O	O

To	O	O
assess	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
employed	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
the	O	O
mouse	O	O
with	O	O
a	O	O
disrupted	O	O
Atm	O	O
gene	O	O
.	O	O

We	O	O
show	O	O
that	O	O
organs	O	O
which	O	O
develop	O	O
pathologic	O	O
changes	O	O
in	O	O
the	O	O
Atm	O	O
-	O	O
deficient	O	O
mice	O	O
are	O	O
targets	O	O
of	O	O
oxidative	O	O
damage	O	O
,	O	O
and	O	O
that	O	O
cerebellar	O	O
Purkinje	O	O
cells	O	O
are	O	O
particularly	O	O
affected	O	O
.	O	O

These	O	O
observations	O	O
provide	O	O
a	O	O
mechanistic	O	O
basis	O	O
for	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
phenotype	O	O
and	O	O
lay	O	O
a	O	O
rational	O	O
foundation	O	O
for	O	O
therapeutic	O	O
intervention	O	O
.	O	O

.	O	O

Family	O	O
studies	O	O
in	O	O
Bechterew	B-Disease	D013167
'	I-Disease	D013167
s	I-Disease	D013167
syndrome	I-Disease	D013167
(	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
)	O	O
III	O	O
.	O	O

Genetics	O	O
.	O	O

The	O	O
results	O	O
of	O	O
segregation	O	O
analyses	O	O
in	O	O
75	O	O
families	O	O
where	O	O
the	O	O
proband	O	O
had	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
,	O	O
are	O	O
presented	O	O
.	O	O

Of	O	O
the	O	O
278	O	O
adult	O	O
,	O	O
living	O	O
first	O	O
degree	O	O
relatives	O	O
,	O	O
approximately	O	O
85	O	O
%	O	O
cooperated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Clinical	O	O
and	O	O
radiographical	O	O
examinations	O	O
were	O	O
performed	O	O
and	O	O
HLA	O	O
typing	O	O
was	O	O
conducted	O	O
.	O	O

The	O	O
results	O	O
were	O	O
in	O	O
agreement	O	O
with	O	O
our	O	O
hypothesis	O	O
that	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
is	O	O
part	O	O
of	O	O
a	O	O
syndrome	O	O
where	O	O
different	O	O
genetic	O	O
factors	O	O
interact	O	O
.	O	O

Such	O	O
known	O	O
factors	O	O
are	O	O
HLA	O	O
B27	O	O
associated	O	O
disease	O	O
susceptibility	O	O
,	O	O
susceptibility	O	O
to	O	O
psoriatic	B-Disease	D015535
arthropathy	I-Disease	D015535
and	O	O
susceptibility	O	O
to	O	O
entero	B-Disease	C538273	D001168
-	I-Disease	C538273	D001168
arthropathy	I-Disease	C538273	D001168
.	O	O

Radiographical	O	O
sacro	B-Disease	D058566
-	I-Disease	D058566
iliitis	I-Disease	D058566
was	O	O
restricted	O	O
to	O	O
HLA	O	O
B27	O	O
positive	O	O
relatives	O	O
,	O	O
and	O	O
was	O	O
more	O	O
frequently	O	O
found	O	O
in	O	O
relatives	O	O
to	O	O
probands	O	O
with	O	O
psoriasis	B-Disease	D011565
than	O	O
in	O	O
relatives	O	O
to	O	O
probands	O	O
without	O	O
psoriasis	B-Disease	D011565
.	O	O

Environmental	O	O
factors	O	O
(	O	O
intestinal	O	O
bacteria	O	O
)	O	O
are	O	O
known	O	O
to	O	O
trigger	O	O
the	O	O
disease	O	O
at	O	O
least	O	O
in	O	O
some	O	O
persons	O	O
,	O	O
and	O	O
we	O	O
have	O	O
postulated	O	O
that	O	O
all	O	O
or	O	O
most	O	O
of	O	O
them	O	O
have	O	O
the	O	O
predisposition	O	O
to	O	O
develop	O	O
disease	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
syndrome	O	O
has	O	O
a	O	O
multifactorial	O	O
etiology	O	O
.	O	O

The	O	O
phenotypic	O	O
expressions	O	O
of	O	O
the	O	O
different	O	O
genetic	O	O
predispositions	O	O
involved	O	O
,	O	O
include	O	O
sacro	B-Disease	D058566
-	I-Disease	D058566
iliitis	I-Disease	D058566
,	O	O
psoriasis	B-Disease	D011565
,	O	O
acute	B-Disease	D014606
anterior	I-Disease	D014606
uveitis	I-Disease	D014606
,	O	O
peripheral	O	O
arthropathy	B-Disease	D007592
and	O	O
inflammatory	B-Disease	D015212
bowel	I-Disease	D015212
disease	I-Disease	D015212
.	O	O

We	O	O
suggest	O	O
the	O	O
descriptive	O	O
name	O	O
HEREDITARY	B-Disease	D007249	D030342
MULTIFOCAL	I-Disease	D007249	D030342
RELAPSING	I-Disease	D007249	D030342
INFLAMMATION	I-Disease	D007249	D030342
(	O	O
HEMRI	B-Disease	D007249	D030342
)	O	O
for	O	O
this	O	O
syndrome	O	O
.	O	O

Ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
,	O	O
psoriatic	B-Disease	D015535
arthropathy	I-Disease	D015535
and	O	O
entero	B-Disease	C538273	D001168
-	I-Disease	C538273	D001168
arthropathy	I-Disease	C538273	D001168
may	O	O
be	O	O
regarded	O	O
as	O	O
clinical	O	O
sub	O	O
-	O	O
types	O	O
of	O	O
the	O	O
syndrome	O	O
.	O	O

.	O	O

Chromosome	O	O
mapping	O	O
of	O	O
the	O	O
rod	O	O
photoreceptor	O	O
cGMP	O	O
phosphodiesterase	O	O
beta	O	O
-	O	O
subunit	O	O
gene	O	O
in	O	O
mouse	O	O
and	O	O
human	O	O
:	O	O
tight	O	O
linkage	O	O
to	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
region	O	O
(	O	O
4p16	O	O
.	O	O

3	O	O
)	O	O
.	O	O

The	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
mouse	O	O
(	O	O
gene	O	O
symbol	O	O
,	O	O
rd	O	O
)	O	O
is	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
certain	O	O
forms	O	O
of	O	O
human	O	O
hereditary	B-Disease	D015785
retinopathies	I-Disease	D015785
.	O	O

Recent	O	O
findings	O	O
of	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
the	O	O
rd	O	O
mouse	O	O
PDE	O	O
beta	O	O
-	O	O
subunit	O	O
gene	O	O
(	O	O
Pdeb	O	O
)	O	O
prompted	O	O
us	O	O
to	O	O
investigate	O	O
the	O	O
chromosome	O	O
locations	O	O
of	O	O
the	O	O
mouse	O	O
and	O	O
human	O	O
genes	O	O
.	O	O

We	O	O
have	O	O
utilized	O	O
backcross	O	O
analysis	O	O
in	O	O
mice	O	O
to	O	O
verify	O	O
and	O	O
define	O	O
more	O	O
precisely	O	O
the	O	O
location	O	O
of	O	O
the	O	O
Pdeb	O	O
locus	O	O
6	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

3	O	O
cM	O	O
distal	O	O
of	O	O
Mgsa	O	O
on	O	O
mouse	O	O
chromosome	O	O
5	O	O
.	O	O

We	O	O
have	O	O
determined	O	O
that	O	O
the	O	O
human	O	O
gene	O	O
(	O	O
PDEB	O	O
)	O	O
maps	O	O
to	O	O
4p16	O	O
.	O	O

3	O	O
,	O	O
very	O	O
close	O	O
to	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
region	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
comparative	O	O
map	O	O
for	O	O
mice	O	O
and	O	O
humans	O	O
shows	O	O
that	O	O
the	O	O
mouse	O	O
homologue	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
will	O	O
reside	O	O
on	O	O
chromosome	O	O
5	O	O
.	O	O

Linkage	O	O
of	O	O
the	O	O
mouse	O	O
Pdeb	O	O
locus	O	O
with	O	O
other	O	O
homologues	O	O
in	O	O
the	O	O
human	O	O
4p16	O	O
.	O	O

3	O	O
region	O	O
is	O	O
maintained	O	O
but	O	O
gene	O	O
order	O	O
is	O	O
not	O	O
,	O	O
suggesting	O	O
at	O	O
least	O	O
three	O	O
possible	O	O
sites	O	O
for	O	O
the	O	O
corresponding	O	O
mouse	O	O
HD	B-Disease	D006816
gene	O	O
.	O	O

Hereditary	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
in	O	O
man	O	O
.	O	O

II	O	O
.	O	O

Biological	O	O
properties	O	O
of	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
human	O	O
serum	O	O
.	O	O

The	O	O
first	O	O
known	O	O
human	O	O
kindred	O	O
with	O	O
hereditary	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
(	O	O
C5	O	O
)	O	O
was	O	O
documented	O	O
in	O	O
the	O	O
accompanying	O	O
report	O	O
.	O	O

This	O	O
study	O	O
examines	O	O
several	O	O
biological	O	O
properties	O	O
of	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
(	O	O
C5D	B-Disease	OMIM:609536
)	O	O
human	O	O
serum	O	O
,	O	O
particularly	O	O
sera	O	O
obtained	O	O
from	O	O
two	O	O
C5D	B-Disease	OMIM:609536
homozygotes	O	O
.	O	O

The	O	O
proband	O	O
,	O	O
who	O	O
has	O	O
inactive	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
is	O	O
completely	O	O
lacking	O	O
C5	O	O
,	O	O
while	O	O
her	O	O
healthy	O	O
half	O	O
-	O	O
sister	O	O
has	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
normal	O	O
levels	O	O
.	O	O

Both	O	O
sera	O	O
were	O	O
severely	O	O
impaired	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
generate	O	O
chemotactic	O	O
activity	O	O
for	O	O
normal	O	O
human	O	O
neutrophils	O	O
upon	O	O
incubation	O	O
with	O	O
aggregated	O	O
human	O	O
gamma	O	O
-	O	O
globulin	O	O
or	O	O
Escherichia	O	O
coli	O	O
endotoxin	O	O
.	O	O

This	O	O
function	O	O
was	O	O
fully	O	O
restored	O	O
in	O	O
the	O	O
siblings	O	O
serum	O	O
,	O	O
and	O	O
substantially	O	O
improved	O	O
in	O	O
the	O	O
probands	O	O
serum	O	O
,	O	O
by	O	O
addition	O	O
of	O	O
highly	O	O
purified	O	O
human	O	O
C5	O	O
to	O	O
normal	O	O
serum	O	O
concentrations	O	O
.	O	O

Sera	O	O
from	O	O
eight	O	O
family	O	O
members	O	O
who	O	O
were	O	O
apparently	O	O
heterozygous	O	O
for	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
gave	O	O
normal	O	O
chemotactic	O	O
scores	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
C5D	B-Disease	OMIM:609536
serum	O	O
to	O	O
opsonize	O	O
Saccharomyces	O	O
cerevisiae	O	O
(	O	O
bakers	O	O
yeast	O	O
)	O	O
or	O	O
Candida	O	O
albicans	O	O
for	O	O
ingestion	O	O
by	O	O
normal	O	O
neutrophils	O	O
was	O	O
completely	O	O
normal	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
C5D	B-Disease	OMIM:609536
serum	O	O
was	O	O
capable	O	O
of	O	O
promoting	O	O
normal	O	O
phagocytosis	O	O
and	O	O
intracellular	O	O
killing	O	O
of	O	O
Staphylococcus	O	O
aureus	O	O
.	O	O

The	O	O
probands	O	O
serum	O	O
was	O	O
incapable	O	O
of	O	O
mediating	O	O
lysis	O	O
of	O	O
erythrocytes	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
paroxysmal	B-Disease	D006457
nocturnal	I-Disease	D006457
hemoglobinuria	I-Disease	D006457
in	O	O
both	O	O
the	O	O
sucrose	O	O
hemolysia	O	O
and	O	O
acid	O	O
hemolysis	O	O
tests	O	O
,	O	O
and	O	O
also	O	O
lacked	O	O
bactericidal	O	O
activity	O	O
against	O	O
sensitized	O	O
or	O	O
unsensitized	O	O
Salmonella	O	O
typhi	O	O
.	O	O

The	O	O
siblings	O	O
serum	O	O
,	O	O
containing	O	O
only	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
normal	O	O
C5	O	O
,	O	O
effectively	O	O
lysed	O	O
S	O	O
.	O	O

typhi	O	O
,	O	O
but	O	O
only	O	O
at	O	O
eightfold	O	O
lower	O	O
serum	O	O
dilutions	O	O
as	O	O
compared	O	O
to	O	O
normals	O	O
.	O	O

These	O	O
findings	O	O
underscore	O	O
the	O	O
critical	O	O
role	O	O
of	O	O
C5	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
chemotactic	O	O
activity	O	O
and	O	O
in	O	O
cytolytic	O	O
reactions	O	O
,	O	O
as	O	O
opposed	O	O
to	O	O
a	O	O
nonobligatory	O	O
or	O	O
minimal	O	O
role	O	O
in	O	O
opsonization	O	O
,	O	O
at	O	O
least	O	O
for	O	O
the	O	O
organisms	O	O
under	O	O
study	O	O
.	O	O

.	O	O

The	O	O
gene	O	O
for	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
,	O	O
MEFV	O	O
,	O	O
is	O	O
expressed	O	O
in	O	O
early	O	O
leukocyte	O	O
development	O	O
and	O	O
is	O	O
regulated	O	O
in	O	O
response	O	O
to	O	O
inflammatory	O	O
mediators	O	O
.	O	O

Familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
is	O	O
a	O	O
recessive	B-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
episodes	O	O
of	O	O
fever	B-Disease	D005334
and	O	O
neutrophil	B-Disease	D007249
-	I-Disease	D007249
mediated	I-Disease	D007249
serosal	I-Disease	D007249
inflammation	I-Disease	D007249
.	O	O

We	O	O
recently	O	O
identified	O	O
the	O	O
gene	O	O
causing	O	O
FMF	B-Disease	D010505
,	O	O
designated	O	O
MEFV	O	O
,	O	O
and	O	O
found	O	O
it	O	O
to	O	O
be	O	O
expressed	O	O
in	O	O
mature	O	O
neutrophils	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
functions	O	O
as	O	O
an	O	O
inflammatory	O	O
regulator	O	O
.	O	O

To	O	O
facilitate	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
normal	O	O
function	O	O
of	O	O
MEFV	O	O
,	O	O
we	O	O
extended	O	O
our	O	O
previous	O	O
studies	O	O
.	O	O

MEFV	O	O
messenger	O	O
RNA	O	O
was	O	O
detected	O	O
by	O	O
reverse	O	O
transcriptase	O	O
-	O	O
polymerase	O	O
chain	O	O
reaction	O	O
in	O	O
bone	O	O
marrow	O	O
leukocytes	O	O
,	O	O
with	O	O
differential	O	O
expression	O	O
observed	O	O
among	O	O
cells	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

CD34	O	O
hematopoietic	O	O
stem	O	O
-	O	O
cell	O	O
cultures	O	O
induced	O	O
toward	O	O
the	O	O
granulocytic	O	O
lineage	O	O
expressed	O	O
MEFV	O	O
at	O	O
the	O	O
myelocyte	O	O
stage	O	O
,	O	O
concurrently	O	O
with	O	O
lineage	O	O
commitment	O	O
.	O	O

The	O	O
prepromyelocytic	O	O
cell	O	O
line	O	O
HL60	O	O
expressed	O	O
MEFV	O	O
only	O	O
at	O	O
granulocytic	O	O
and	O	O
monocytic	O	O
differentiation	O	O
.	O	O

MEFV	O	O
was	O	O
also	O	O
expressed	O	O
in	O	O
the	O	O
monocytic	O	O
cell	O	O
lines	O	O
U937	O	O
and	O	O
THP	O	O
-	O	O
1	O	O
.	O	O

Among	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
,	O	O
MEFV	O	O
expression	O	O
was	O	O
detected	O	O
in	O	O
neutrophils	O	O
,	O	O
eosinophils	O	O
,	O	O
and	O	O
to	O	O
varying	O	O
degrees	O	O
,	O	O
monocytes	O	O
.	O	O

Consistent	O	O
with	O	O
the	O	O
tissue	O	O
specificity	O	O
of	O	O
expression	O	O
,	O	O
complete	O	O
sequencing	O	O
and	O	O
analysis	O	O
of	O	O
upstream	O	O
regulatory	O	O
regions	O	O
of	O	O
MEFV	O	O
revealed	O	O
homology	O	O
to	O	O
myeloid	O	O
-	O	O
specific	O	O
promoters	O	O
and	O	O
to	O	O
more	O	O
broadly	O	O
expressed	O	O
inflammatory	O	O
promoter	O	O
elements	O	O
.	O	O

In	O	O
vitro	O	O
stimulation	O	O
of	O	O
monocytes	O	O
with	O	O
the	O	O
proinflammatory	O	O
agents	O	O
interferon	O	O
(	O	O
IFN	O	O
)	O	O
gamma	O	O
,	O	O
tumor	B-Disease	D009369
necrosis	O	O
factor	O	O
,	O	O
and	O	O
lipopolysaccharide	O	O
induced	O	O
MEFV	O	O
expression	O	O
,	O	O
whereas	O	O
the	O	O
antiinflammatory	O	O
cytokines	O	O
interleukin	O	O
(	O	O
IL	O	O
)	O	O
4	O	O
,	O	O
IL	O	O
-	O	O
10	O	O
,	O	O
and	O	O
transforming	O	O
growth	O	O
factor	O	O
beta	O	O
inhibited	O	O
such	O	O
expression	O	O
.	O	O

Induction	O	O
by	O	O
IFN	O	O
-	O	O
gamma	O	O
occurred	O	O
rapidly	O	O
and	O	O
was	O	O
resistant	O	O
to	O	O
cycloheximide	O	O
.	O	O

IFN	O	O
-	O	O
alpha	O	O
also	O	O
induced	O	O
MEFV	O	O
expression	O	O
.	O	O

In	O	O
granulocytes	O	O
,	O	O
MEFV	O	O
was	O	O
up	O	O
-	O	O
regulated	O	O
by	O	O
IFN	O	O
-	O	O
gamma	O	O
and	O	O
the	O	O
combination	O	O
of	O	O
IFN	O	O
-	O	O
alpha	O	O
and	O	O
colchicine	O	O
.	O	O

These	O	O
results	O	O
refine	O	O
understanding	O	O
of	O	O
MEFV	O	O
by	O	O
placing	O	O
the	O	O
gene	O	O
in	O	O
the	O	O
myelomonocytic	O	O
-	O	O
specific	O	O
proinflammatory	O	O
pathway	O	O
and	O	O
identifying	O	O
it	O	O
as	O	O
an	O	O
IFN	O	O
-	O	O
gamma	O	O
immediate	O	O
early	O	O
gene	O	O
.	O	O

.	O	O

Spectrum	O	O
of	O	O
hSNF5	O	O
/	O	O
INI1	O	O
somatic	O	O
mutations	O	O
in	O	O
human	O	O
cancer	B-Disease	D009369
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
.	O	O

The	O	O
hSNF5	O	O
/	O	O
INI1	O	O
gene	O	O
which	O	O
encodes	O	O
a	O	O
member	O	O
of	O	O
the	O	O
SWI	O	O
/	O	O
SNF	O	O
chromatin	O	O
ATP	O	O
-	O	O
dependent	O	O
remodeling	O	O
complex	O	O
,	O	O
is	O	O
a	O	O
new	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
localized	O	O
on	O	O
chromosome	O	O
22q11	O	O
.	O	O

2	O	O
and	O	O
recently	O	O
shown	O	O
to	O	O
be	O	O
mutated	O	O
in	O	O
malignant	B-Disease	D018335
rhabdoid	I-Disease	D018335
tumors	I-Disease	D018335
.	O	O

We	O	O
have	O	O
searched	O	O
for	O	O
hSNF5	O	O
/	O	O
INI1	O	O
mutations	O	O
in	O	O
229	O	O
tumors	B-Disease	D009369
of	O	O
various	O	O
origins	O	O
using	O	O
a	O	O
screening	O	O
method	O	O
based	O	O
on	O	O
denaturing	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
.	O	O

A	O	O
total	O	O
of	O	O
31	O	O
homozygous	O	O
deletions	O	O
and	O	O
36	O	O
point	O	O
alterations	O	O
were	O	O
identified	O	O
.	O	O

Point	O	O
mutations	O	O
were	O	O
scattered	O	O
along	O	O
the	O	O
coding	O	O
sequence	O	O
and	O	O
included	O	O
15	O	O
nonsense	O	O
,	O	O
15	O	O
frameshift	O	O
,	O	O
three	O	O
splice	O	O
site	O	O
,	O	O
two	O	O
missense	O	O
and	O	O
one	O	O
editing	O	O
mutations	O	O
.	O	O

Mutations	O	O
were	O	O
retrieved	O	O
in	O	O
most	O	O
rhabdoid	B-Disease	D018335
tumors	I-Disease	D018335
,	O	O
whatever	O	O
their	O	O
sites	O	O
of	O	O
occurrence	O	O
,	O	O
indicating	O	O
the	O	O
common	O	O
pathogenetic	O	O
origin	O	O
of	O	O
these	O	O
tumors	B-Disease	D009369
.	O	O

Recurrent	O	O
hSNF5	O	O
/	O	O
INI1	O	O
alterations	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
choroid	B-Disease	D020288
plexus	I-Disease	D020288
carcinomas	I-Disease	D020288
and	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
central	O	O
primitive	O	O
neuroectodermal	B-Disease	D017599
tumors	I-Disease	D017599
(	O	O
cPNETs	O	O
)	O	O
and	O	O
medulloblastomas	B-Disease	D008527
.	O	O

In	O	O
contrast	O	O
,	O	O
hSNF5	O	O
/	O	O
INI1	O	O
point	O	O
mutations	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
,	O	O
Wilms	B-Disease	D009396
tumors	I-Disease	D009396
,	O	O
gliomas	B-Disease	D005910
,	O	O
ependymomas	B-Disease	D004806
,	O	O
sarcomas	B-Disease	D012509
and	O	O
other	O	O
tumor	B-Disease	D009369
types	O	O
,	O	O
even	O	O
though	O	O
most	O	O
analyzed	O	O
cases	O	O
harbored	O	O
loss	O	O
of	O	O
heterozygosity	O	O
at	O	O
22q11	O	O
.	O	O

2	O	O
loci	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
rhabdoid	B-Disease	D018335
tumors	I-Disease	D018335
,	O	O
choroid	B-Disease	D020288
plexus	I-Disease	D020288
carcinomas	I-Disease	D020288
and	O	O
a	O	O
subset	O	O
of	O	O
medulloblastomas	B-Disease	D008527
and	O	O
cPNETs	O	O
share	O	O
common	O	O
pathways	O	O
of	O	O
oncogenesis	O	O
related	O	O
to	O	O
hSNF5	O	O
/	O	O
INI1	O	O
alteration	O	O
and	O	O
that	O	O
hSNF5	O	O
/	O	O
INI1	O	O
mutations	O	O
define	O	O
a	O	O
genetically	O	O
homogeneous	O	O
family	O	O
of	O	O
highly	O	O
aggressive	O	O
cancers	B-Disease	D009369
mainly	O	O
occurring	O	O
in	O	O
young	O	O
children	O	O
and	O	O
frequently	O	O
,	O	O
but	O	O
not	O	O
always	O	O
,	O	O
exhibiting	O	O
a	O	O
rhabdoid	B-Disease	D018335
phenotype	O	O
Heterogeneity	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Algeria	O	O
.	O	O

Study	O	O
in	O	O
Northern	O	O
Algeria	O	O
with	O	O
description	O	O
of	O	O
five	O	O
new	O	O
variants	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
was	O	O
found	O	O
in	O	O
3	O	O
.	O	O

2	O	O
%	O	O
of	O	O
the	O	O
male	O	O
population	O	O
living	O	O
in	O	O
the	O	O
urban	O	O
area	O	O
of	O	O
Algiers	O	O
.	O	O

The	O	O
deficient	O	O
subjects	O	O
originated	O	O
from	O	O
multiple	O	O
geographic	O	O
regions	O	O
of	O	O
Northern	O	O
Algeria	O	O
,	O	O
with	O	O
prevalence	O	O
of	O	O
individuals	O	O
of	O	O
Berber	O	O
-	O	O
Kabyle	O	O
origin	O	O
.	O	O

Red	O	O
blood	O	O
cell	O	O
G6PD	O	O
was	O	O
partially	O	O
purified	O	O
and	O	O
characterized	O	O
in	O	O
deficient	O	O
males	O	O
from	O	O
17	O	O
families	O	O
,	O	O
and	O	O
six	O	O
different	O	O
variants	O	O
were	O	O
found	O	O
.	O	O

Among	O	O
them	O	O
,	O	O
only	O	O
one	O	O
,	O	O
the	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Kabyle	O	O
variant	O	O
,	O	O
had	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

It	O	O
was	O	O
detected	O	O
in	O	O
nine	O	O
families	O	O
.	O	O

The	O	O
other	O	O
five	O	O
variants	O	O
were	O	O
new	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Laghouat	O	O
(	O	O
four	O	O
cases	O	O
)	O	O
,	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Blida	O	O
(	O	O
one	O	O
case	O	O
)	O	O
,	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Thenia	O	O
(	O	O
one	O	O
case	O	O
)	O	O
,	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Titteri	O	O
(	O	O
one	O	O
case	O	O
)	O	O
,	O	O
and	O	O
Gd	O	O
(	O	O
-	O	O
)	O	O
Alger	O	O
(	O	O
two	O	O
brothers	O	O
)	O	O
.	O	O

Strikingly	O	O
,	O	O
the	O	O
common	O	O
Mediterranean	O	O
variant	O	O
was	O	O
not	O	O
found	O	O
.	O	O

G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
heterogeneous	O	O
in	O	O
northern	O	O
Algeria	O	O
where	O	O
autochtonous	O	O
variants	O	O
seem	O	O
to	O	O
prevail	O	O
.	O	O

The	O	O
Kabyle	O	O
variant	O	O
may	O	O
be	O	O
common	O	O
in	O	O
this	O	O
country	O	O
.	O	O

Fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
without	O	O
CCG	O	O
amplification	O	O
has	O	O
an	O	O
FMR1	O	O
deletion	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
typical	O	O
clinical	O	O
features	O	O
of	O	O
the	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
but	O	O
without	O	O
cytogenetic	O	O
expression	O	O
of	O	O
the	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
or	O	O
an	O	O
amplified	O	O
CCG	O	O
trinucleotide	O	O
repeat	O	O
fragment	O	O
.	O	O

The	O	O
patient	O	O
has	O	O
a	O	O
previously	O	O
uncharacterized	O	O
submicroscopic	O	O
deletion	O	O
encompassing	O	O
the	O	O
CCG	O	O
repeat	O	O
,	O	O
the	O	O
entire	O	O
FMR1	O	O
gene	O	O
and	O	O
about	O	O
2	O	O
.	O	O

5	O	O
megabases	O	O
of	O	O
flanking	O	O
sequences	O	O
.	O	O

This	O	O
finding	O	O
confirms	O	O
that	O	O
the	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
phenotype	O	O
can	O	O
exist	O	O
,	O	O
without	O	O
amplification	O	O
of	O	O
the	O	O
CCG	O	O
repeat	O	O
or	O	O
cytogenetic	O	O
expression	O	O
of	O	O
the	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
,	O	O
and	O	O
that	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
is	O	O
a	O	O
genetically	O	O
homogeneous	O	O
disorder	O	O
involving	O	O
FMR1	O	O
.	O	O

We	O	O
also	O	O
found	O	O
random	O	O
X	O	O
-	O	O
inactivation	O	O
in	O	O
the	O	O
mother	O	O
of	O	O
the	O	O
patient	O	O
who	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
carrier	O	O
of	O	O
this	O	O
deletion	O	O
.	O	O

Confirmation	O	O
of	O	O
linkage	O	O
of	O	O
Van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
to	O	O
chromosome	O	O
1q32	O	O
:	O	O
evidence	O	O
of	O	O
association	O	O
with	O	O
STR	O	O
alleles	O	O
suggests	O	O
possible	O	O
unique	O	O
origin	O	O
of	O	O
the	O	O
disease	O	O
mutation	O	O
.	O	O

Van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
(	O	O
VWS	B-Disease	C536528
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D019465
dominant	I-Disease	D019465
craniofacial	I-Disease	D019465
disorder	I-Disease	D019465
with	O	O
high	O	O
penetrance	O	O
and	O	O
variable	O	O
expression	O	O
.	O	O

Its	O	O
clinical	O	O
features	O	O
are	O	O
variably	O	O
expressed	O	O
,	O	O
but	O	O
include	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
and	O	O
/	O	O
or	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
,	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
and	O	O
hypodontia	B-Disease	D000848
.	O	O

All	O	O
VWS	B-Disease	C536528
families	O	O
studied	O	O
to	O	O
date	O	O
map	O	O
the	O	O
disease	O	O
gene	O	O
to	O	O
a	O	O
<	O	O
2	O	O
cM	O	O
region	O	O
of	O	O
chromosome	O	O
1q32	O	O
,	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
locus	O	O
heterogeneity	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
refine	O	O
the	O	O
localization	O	O
of	O	O
the	O	O
VWS	B-Disease	C536528
gene	O	O
and	O	O
to	O	O
further	O	O
assess	O	O
possible	O	O
heterogeneity	O	O
.	O	O

We	O	O
analyzed	O	O
four	O	O
multiplex	O	O
VWS	B-Disease	C536528
families	O	O
.	O	O

All	O	O
available	O	O
members	O	O
were	O	O
clinically	O	O
assessed	O	O
and	O	O
genotyped	O	O
for	O	O
19	O	O
short	O	O
tandem	O	O
repeat	O	O
markers	O	O
on	O	O
chromosome	O	O
1	O	O
in	O	O
the	O	O
VWS	B-Disease	C536528
candidate	O	O
gene	O	O
region	O	O
.	O	O

We	O	O
performed	O	O
two	O	O
-	O	O
point	O	O
and	O	O
multipoint	O	O
limit	O	O
of	O	O
detection	O	O
(	O	O
LOD	O	O
)	O	O
score	O	O
analyses	O	O
using	O	O
a	O	O
high	O	O
penetrance	O	O
autosomal	O	O
dominant	O	O
model	O	O
.	O	O

All	O	O
families	O	O
showed	O	O
positive	O	O
LOD	O	O
scores	O	O
without	O	O
any	O	O
recombination	O	O
in	O	O
the	O	O
candidate	O	O
region	O	O
.	O	O

The	O	O
largest	O	O
two	O	O
-	O	O
point	O	O
LOD	O	O
score	O	O
was	O	O
5	O	O
.	O	O

87	O	O
87	O	O
.	O	O

Our	O	O
assay	O	O
method	O	O
for	O	O
short	O	O
tandem	O	O
repeat	O	O
(	O	O
STR	O	O
)	O	O
markers	O	O
provided	O	O
highly	O	O
accurate	O	O
size	O	O
estimation	O	O
of	O	O
marker	O	O
allele	O	O
fragment	O	O
sizes	O	O
,	O	O
and	O	O
therefore	O	O
enabled	O	O
us	O	O
to	O	O
determine	O	O
the	O	O
specific	O	O
alleles	O	O
segregating	O	O
with	O	O
the	O	O
VWS	B-Disease	C536528
gene	O	O
in	O	O
each	O	O
of	O	O
our	O	O
four	O	O
families	O	O
.	O	O

We	O	O
observed	O	O
a	O	O
striking	O	O
pattern	O	O
of	O	O
STR	O	O
allele	O	O
sharing	O	O
at	O	O
several	O	O
closely	O	O
linked	O	O
loci	O	O
among	O	O
our	O	O
four	O	O
Caucasian	O	O
VWS	B-Disease	C536528
families	O	O
recruited	O	O
at	O	O
three	O	O
different	O	O
locations	O	O
in	O	O
the	O	O
US	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
unique	O	O
origin	O	O
for	O	O
a	O	O
mutation	O	O
responsible	O	O
for	O	O
many	O	O
or	O	O
most	O	O
cases	O	O
of	O	O
VWS	B-Disease	C536528
.	O	O

The	O	O
carrier	O	O
frequency	O	O
of	O	O
the	O	O
BRCA1	O	O
185delAG	O	O
mutation	O	O
is	O	O
approximately	O	O
1	O	O
percent	O	O
in	O	O
Ashkenazi	O	O
Jewish	O	O
individuals	O	O
.	O	O

Since	O	O
BRCA1	O	O
,	O	O
the	O	O
first	O	O
major	O	O
gene	O	O
responsible	O	O
for	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
was	O	O
cloned	O	O
,	O	O
more	O	O
than	O	O
50	O	O
unique	O	O
mutations	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
the	O	O
germline	O	O
of	O	O
individuals	O	O
with	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

In	O	O
high	O	O
-	O	O
risk	O	O
pedigrees	O	O
,	O	O
female	O	O
carriers	O	O
of	O	O
BRCA1	O	O
mutations	O	O
have	O	O
an	O	O
80	O	O
-	O	O
90	O	O
%	O	O
lifetime	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
and	O	O
a	O	O
40	O	O
-	O	O
50	O	O
%	O	O
risk	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

However	O	O
,	O	O
the	O	O
mutation	O	O
stats	O	O
of	O	O
individuals	O	O
unselected	O	O
for	O	O
breast	B-Disease	D010051
or	I-Disease	D010051
ovarian	I-Disease	D010051
cancer	I-Disease	D010051
has	O	O
not	O	O
been	O	O
determined	O	O
,	O	O
and	O	O
it	O	O
is	O	O
not	O	O
known	O	O
whether	O	O
mutations	O	O
in	O	O
such	O	O
individuals	O	O
confer	O	O
the	O	O
same	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
as	O	O
in	O	O
individuals	O	O
from	O	O
the	O	O
high	O	O
-	O	O
risk	O	O
families	O	O
studied	O	O
so	O	O
far	O	O
.	O	O

Following	O	O
the	O	O
finding	O	O
of	O	O
a	O	O
185delAG	O	O
frameshift	O	O
mutation	O	O
in	O	O
several	O	O
Ashkenazi	O	O
Jewish	O	O
breast	O	O
/	O	O
ovarian	O	O
families	O	O
,	O	O
we	O	O
have	O	O
determined	O	O
the	O	O
frequency	O	O
of	O	O
this	O	O
mutation	O	O
in	O	O
858	O	O
Ashkenazim	O	O
seeking	O	O
genetic	O	O
testing	O	O
for	O	O
conditions	O	O
unrelated	O	O
to	O	O
cancer	B-Disease	D009369
,	O	O
and	O	O
in	O	O
815	O	O
reference	O	O
individuals	O	O
not	O	O
selected	O	O
for	O	O
ethnic	O	O
origin	O	O
.	O	O

We	O	O
observed	O	O
the	O	O
185delAG	O	O
mutation	O	O
in	O	O
0	O	O
.	O	O

9	O	O
%	O	O
of	O	O
Ashkenazim	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
limit	O	O
,	O	O
0	O	O
.	O	O

4	O	O
-	O	O
1	O	O
.	O	O

8	O	O
%	O	O
)	O	O
and	O	O
in	O	O
none	O	O
of	O	O
the	O	O
reference	O	O
samples	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
one	O	O
in	O	O
a	O	O
hundred	O	O
women	O	O
of	O	O
Ashkenazi	O	O
descent	O	O
may	O	O
be	O	O
at	O	O
especially	O	O
high	O	O
risk	O	O
of	O	O
developing	O	O
breast	B-Disease	D010051
and	I-Disease	D010051
/	I-Disease	D010051
or	I-Disease	D010051
ovarian	I-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Targeted	O	O
modification	O	O
of	O	O
the	O	O
apolipoprotein	O	O
B	O	O
gene	O	O
results	O	O
in	O	O
hypobetalipoproteinemia	B-Disease	D006995
and	O	O
developmental	B-Disease	D006130
abnormalities	I-Disease	D006130
in	O	O
mice	O	O
.	O	O

Familial	B-Disease	D052476
hypobetalipoproteinemia	I-Disease	D052476
is	O	O
an	O	O
autosomal	B-Disease	D030342
codominant	I-Disease	D030342
disorder	I-Disease	D030342
resulting	O	O
in	O	O
a	O	O
dramatic	O	O
reduction	O	O
in	O	O
plasma	O	O
concentrations	O	O
of	O	O
apolipoprotein	O	O
(	O	O
apo	O	O
)	O	O
B	O	O
,	O	O
cholesterol	O	O
,	O	O
and	O	O
beta	O	O
-	O	O
migrating	O	O
lipoproteins	O	O
.	O	O

A	O	O
benefit	O	O
of	O	O
hypobetalipoproteinemia	B-Disease	D006995
is	O	O
that	O	O
mildly	O	O
affected	O	O
individuals	O	O
may	O	O
be	O	O
protected	O	O
from	O	O
coronary	B-Disease	D003323
vascular	I-Disease	D003323
disease	I-Disease	D003323
.	O	O

We	O	O
have	O	O
used	O	O
gene	O	O
targeting	O	O
to	O	O
generate	O	O
mice	O	O
with	O	O
a	O	O
modified	O	O
Apob	O	O
allele	O	O
.	O	O

Mice	O	O
containing	O	O
this	O	O
allele	O	O
display	O	O
all	O	O
of	O	O
the	O	O
hallmarks	O	O
of	O	O
human	O	O
hypobetalipoproteinemia	B-Disease	D006995
they	O	O
produce	O	O
a	O	O
truncated	O	O
apoB	O	O
protein	O	O
,	O	O
apoB70	O	O
,	O	O
and	O	O
have	O	O
markedly	O	O
decreased	O	O
plasma	O	O
concentrations	O	O
of	O	O
apoB	O	O
,	O	O
beta	O	O
-	O	O
lipoproteins	O	O
,	O	O
and	O	O
total	O	O
cholesterol	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
mice	O	O
manifest	O	O
several	O	O
characteristics	O	O
that	O	O
are	O	O
occasionally	O	O
observed	O	O
in	O	O
human	O	O
hypobetalipoproteinemia	B-Disease	D006995
,	O	O
including	O	O
reduced	O	O
plasma	O	O
triglyceride	O	O
concentrations	O	O
,	O	O
fasting	O	O
chylomicronemia	B-Disease	OMIM:238600
,	O	O
and	O	O
reduced	O	O
high	O	O
density	O	O
lipoprotein	O	O
cholesterol	O	O
.	O	O

An	O	O
unexpected	O	O
finding	O	O
is	O	O
that	O	O
the	O	O
modified	O	O
Apob	O	O
allele	O	O
is	O	O
strongly	O	O
associated	O	O
with	O	O
exencephalus	B-Disease	D009436
and	O	O
hydrocephalus	B-Disease	D006849
.	O	O

These	O	O
mice	O	O
should	O	O
help	O	O
increase	O	O
our	O	O
understanding	O	O
of	O	O
hypobetalipoproteinemia	B-Disease	D006995
,	O	O
atherogenesis	B-Disease	D050197
,	O	O
and	O	O
the	O	O
etiology	O	O
of	O	O
exencephalus	B-Disease	D009436
and	O	O
hydrocephalus	B-Disease	D006849
.	O	O

.	O	O

Common	O	O
mutations	O	O
in	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
do	O	O
not	O	O
contribute	O	O
to	O	O
early	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
in	O	O
Jewish	O	O
men	O	O
.	O	O

BACKGROUND	O	O
Families	O	O
with	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
hereditary	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
,	O	O
and	O	O
subsequently	O	O
shown	O	O
to	O	O
have	O	O
terminating	O	O
mutations	O	O
in	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
,	O	O
appear	O	O
to	O	O
have	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
among	O	O
male	O	O
relatives	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
common	O	O
germline	O	O
mutations	O	O
of	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
in	O	O
Ashkenazi	O	O
Jewish	O	O
men	O	O
predisposed	O	O
them	O	O
to	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

METHODS	O	O
We	O	O
examined	O	O
genomic	O	O
DNA	O	O
from	O	O
83	O	O
(	O	O
for	O	O
BRCA1	O	O
185delAG	O	O
)	O	O
or	O	O
82	O	O
(	O	O
for	O	O
BRCA2	O	O
6174delT	O	O
)	O	O
Ashkenazi	O	O
Jewish	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
,	O	O
most	O	O
of	O	O
whom	O	O
were	O	O
treated	O	O
at	O	O
a	O	O
relatively	O	O
young	O	O
age	O	O
,	O	O
for	O	O
the	O	O
most	O	O
common	O	O
germline	O	O
mutation	O	O
in	O	O
each	O	O
gene	O	O
seen	O	O
in	O	O
the	O	O
Ashkenazi	O	O
population	O	O
.	O	O

RESULTS	O	O
Our	O	O
study	O	O
should	O	O
have	O	O
been	O	O
able	O	O
to	O	O
detect	O	O
a	O	O
4	O	O
-	O	O
5	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
due	O	O
to	O	O
mutation	O	O
of	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
.	O	O

However	O	O
,	O	O
only	O	O
one	O	O
(	O	O
1	O	O
.	O	O

15	O	O
%	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
-	O	O
3	O	O
.	O	O

6	O	O
%	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
heterozygous	O	O
for	O	O
the	O	O
BRCA1	O	O
mutant	O	O
allele	O	O
,	O	O
and	O	O
only	O	O
two	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
BRCA2	O	O
mutation	O	O
(	O	O
2	O	O
.	O	O

4	O	O
%	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
-	O	O
6	O	O
.	O	O

2	O	O
%	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
incidence	O	O
of	O	O
each	O	O
of	O	O
the	O	O
germline	O	O
mutations	O	O
in	O	O
these	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
closely	O	O
matched	O	O
their	O	O
incidence	O	O
(	O	O
about	O	O
1	O	O
%	O	O
)	O	O
in	O	O
the	O	O
general	O	O
Ashkenazi	O	O
Jewish	O	O
population	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
unlike	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
,	O	O
mutations	O	O
in	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
do	O	O
not	O	O
significantly	O	O
predispose	O	O
men	O	O
to	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
Two	O	O
new	O	O
variants	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
associated	O	O
with	O	O
hereditary	B-Disease	D000746
non	I-Disease	D000746
-	I-Disease	D000746
spherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
:	O	O
G6PD	O	O
Wayne	O	O
and	O	O
G6PD	O	O
Huron	O	O
.	O	O

Two	O	O
new	O	O
deficient	O	O
variants	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
causing	O	O
hereditary	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
(	O	O
HNSHA	B-Disease	D000746
)	O	O
are	O	O
described	O	O
.	O	O

Both	O	O
of	O	O
these	O	O
are	O	O
unique	O	O
and	O	O
they	O	O
have	O	O
been	O	O
named	O	O
G6PD	O	O
Wayne	O	O
and	O	O
G6PD	O	O
Huron	O	O
.	O	O

Patients	O	O
with	O	O
G6PD	O	O
Wayne	O	O
underwent	O	O
splenectomy	O	O
and	O	O
no	O	O
objective	O	O
improvement	O	O
was	O	O
noted	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
G6PD	O	O
Huron	O	O
were	O	O
under	O	O
medical	O	O
observation	O	O
for	O	O
a	O	O
considerable	O	O
period	O	O
of	O	O
time	O	O
without	O	O
the	O	O
diagnosis	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
being	O	O
entertained	O	O
because	O	O
the	O	O
family	O	O
was	O	O
of	O	O
Northern	O	O
European	O	O
origin	O	O
.	O	O

Since	O	O
sporadic	O	O
variants	O	O
of	O	O
G6PD	O	O
causing	O	O
HNSHA	B-Disease	D000746
show	O	O
no	O	O
special	O	O
racial	O	O
predilection	O	O
,	O	O
the	O	O
diagnosis	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
should	O	O
always	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
this	O	O
syndrome	O	O
.	O	O

.	O	O

The	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
gene	O	O
in	O	O
North	O	O
American	O	O
Jewish	O	O
populations	O	O
:	O	O
geographic	O	O
variations	O	O
and	O	O
origin	O	O
.	O	O

From	O	O
data	O	O
collected	O	O
in	O	O
a	O	O
North	O	O
American	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
heterozygote	O	O
screening	O	O
program	O	O
,	O	O
the	O	O
TSD	B-Disease	D013661
carrier	O	O
frequency	O	O
among	O	O
46	O	O
,	O	O
304	O	O
Jewish	O	O
individuals	O	O
was	O	O
found	O	O
to	O	O
be	O	O
.	O	O

0324	O	O
(	O	O
1	O	O
in	O	O
31	O	O
individuals	O	O
)	O	O
.	O	O

This	O	O
frequency	O	O
is	O	O
consistent	O	O
with	O	O
earlier	O	O
estimates	O	O
based	O	O
on	O	O
TSD	B-Disease	D013661
incidence	O	O
data	O	O
.	O	O

TSD	B-Disease	D013661
carrier	O	O
frequencies	O	O
were	O	O
then	O	O
examined	O	O
by	O	O
single	O	O
country	O	O
and	O	O
single	O	O
region	O	O
of	O	O
origin	O	O
in	O	O
28	O	O
,	O	O
029	O	O
Jews	O	O
within	O	O
this	O	O
sample	O	O
for	O	O
whom	O	O
such	O	O
data	O	O
were	O	O
available	O	O
for	O	O
analysis	O	O
.	O	O

Jews	O	O
with	O	O
Polish	O	O
and	O	O
/	O	O
or	O	O
Russian	O	O
ancestry	O	O
constituted	O	O
88	O	O
%	O	O
of	O	O
this	O	O
sample	O	O
and	O	O
had	O	O
a	O	O
TSD	B-Disease	D013661
carrier	O	O
frequency	O	O
of	O	O
.	O	O

0327	O	O
.	O	O

No	O	O
TSD	B-Disease	D013661
carriers	O	O
were	O	O
observed	O	O
among	O	O
the	O	O
166	O	O
Jews	O	O
of	O	O
Near	O	O
Eastern	O	O
origins	O	O
.	O	O

Relative	O	O
to	O	O
Jews	O	O
of	O	O
Polish	O	O
and	O	O
Russian	O	O
origins	O	O
,	O	O
there	O	O
was	O	O
at	O	O
least	O	O
a	O	O
twofold	O	O
increase	O	O
in	O	O
the	O	O
TSD	B-Disease	D013661
carrier	O	O
frequency	O	O
in	O	O
Jews	O	O
of	O	O
Austrian	O	O
,	O	O
Hungarian	O	O
,	O	O
and	O	O
Czechoslovakian	O	O
origins	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

005	O	O
)	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
TSD	B-Disease	D013661
gene	O	O
proliferated	O	O
among	O	O
the	O	O
antecedents	O	O
of	O	O
modern	O	O
Ashkenazi	O	O
Jewry	O	O
after	O	O
the	O	O
Second	O	O
Diaspora	O	O
(	O	O
70	O	O
A	O	O
.	O	O

D	O	O
.	O	O

)	O	O
and	O	O
before	O	O
their	O	O
major	O	O
migrations	O	O
to	O	O
regions	O	O
of	O	O
Poland	O	O
and	O	O
Russia	O	O
(	O	O
before	O	O
1100	O	O
A	O	O
.	O	O

D	O	O
.	O	O

)	O	O
.	O	O

Novel	O	O
inherited	O	O
mutations	O	O
and	O	O
variable	O	O
expressivity	O	O
of	O	O
BRCA1	O	O
alleles	O	O
,	O	O
including	O	O
the	O	O
founder	O	O
mutation	O	O
185delAG	O	O
in	O	O
Ashkenazi	O	O
Jewish	O	O
families	O	O
.	O	O

Thirty	O	O
-	O	O
seven	O	O
families	O	O
with	O	O
four	O	O
or	O	O
more	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
or	O	O
breast	B-Disease	D001943	D010051
and	I-Disease	D001943	D010051
ovarian	I-Disease	D001943	D010051
cancer	I-Disease	D001943	D010051
were	O	O
analyzed	O	O
for	O	O
mutations	O	O
in	O	O
BRCA1	O	O
.	O	O

Twelve	O	O
different	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
,	O	O
four	O	O
novel	O	O
and	O	O
eight	O	O
previously	O	O
observed	O	O
,	O	O
were	O	O
detected	O	O
in	O	O
16	O	O
families	O	O
.	O	O

Five	O	O
families	O	O
of	O	O
Ashkenazi	O	O
Jewish	O	O
descent	O	O
carried	O	O
the	O	O
185delAG	O	O
mutation	O	O
and	O	O
shared	O	O
the	O	O
same	O	O
haplotype	O	O
at	O	O
eight	O	O
polymorphic	O	O
markers	O	O
spanning	O	O
approximately	O	O
850	O	O
kb	O	O
at	O	O
BRCA1	O	O
.	O	O

Expressivity	O	O
of	O	O
185delAG	O	O
in	O	O
these	O	O
families	O	O
varied	O	O
,	O	O
from	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
without	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Mutation	O	O
4184delTCAA	O	O
occurred	O	O
independently	O	O
in	O	O
two	O	O
families	O	O
.	O	O

In	O	O
one	O	O
family	O	O
,	O	O
penetrance	O	O
was	O	O
complete	O	O
,	O	O
with	O	O
females	O	O
developing	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
or	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
and	O	O
the	O	O
male	O	O
carrier	O	O
developing	O	O
prostatic	B-Disease	D011471
cancer	I-Disease	D011471
,	O	O
whereas	O	O
,	O	O
in	O	O
the	O	O
other	O	O
family	O	O
,	O	O
penetrance	O	O
was	O	O
incomplete	O	O
and	O	O
only	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
occurred	O	O
,	O	O
diagnosed	O	O
at	O	O
ages	O	O
38	O	O
-	O	O
81	O	O
years	O	O
.	O	O

Two	O	O
novel	O	O
nonsense	O	O
mutations	O	O
led	O	O
to	O	O
the	O	O
loss	O	O
of	O	O
mutant	O	O
BRCA1	O	O
transcript	O	O
in	O	O
families	O	O
with	O	O
10	O	O
and	O	O
6	O	O
cases	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

A	O	O
665	O	O
-	O	O
nt	O	O
segment	O	O
of	O	O
the	O	O
BRCA1	O	O
3	O	O
-	O	O
UTR	O	O
and	O	O
1	O	O
.	O	O

3	O	O
kb	O	O
of	O	O
genomic	O	O
sequence	O	O
including	O	O
the	O	O
putative	O	O
promoter	O	O
region	O	O
were	O	O
invariant	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
analysis	O	O
in	O	O
13	O	O
families	O	O
without	O	O
coding	O	O
-	O	O
sequence	O	O
mutations	O	O
.	O	O

Overall	O	O
in	O	O
our	O	O
series	O	O
,	O	O
BRCA1	O	O
mutations	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
26	O	O
families	O	O
16	O	O
with	O	O
positive	O	O
BRCA1	O	O
lod	O	O
scores	O	O
,	O	O
7	O	O
with	O	O
negative	O	O
lod	O	O
scores	O	O
(	O	O
reflecting	O	O
multiple	O	O
sporadic	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
)	O	O
,	O	O
and	O	O
3	O	O
not	O	O
tested	O	O
for	O	O
linkage	O	O
.	O	O

Three	O	O
other	O	O
families	O	O
have	O	O
positive	O	O
lod	O	O
scores	O	O
for	O	O
linkage	O	O
to	O	O
BRCA2	O	O
,	O	O
but	O	O
13	O	O
families	O	O
without	O	O
detected	O	O
BRCA1	O	O
mutations	O	O
have	O	O
negative	O	O
lod	O	O
scores	O	O
for	O	O
both	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

Transgenic	O	O
mice	O	O
carrying	O	O
large	O	O
human	O	O
genomic	O	O
sequences	O	O
with	O	O
expanded	O	O
CTG	O	O
repeat	O	O
mimic	O	O
closely	O	O
the	O	O
DM	B-Disease	D009223
CTG	O	O
repeat	O	O
intergenerational	O	O
and	O	O
somatic	O	O
instability	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
CTG	O	O
repeat	O	O
expansion	O	O
in	O	O
the	O	O
3UTR	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
(	O	O
DMPK	O	O
)	O	O
gene	O	O
.	O	O

A	O	O
very	O	O
high	O	O
level	O	O
of	O	O
instability	O	O
is	O	O
observed	O	O
through	O	O
successive	O	O
generations	O	O
and	O	O
the	O	O
size	O	O
of	O	O
the	O	O
repeat	O	O
is	O	O
generally	O	O
correlated	O	O
with	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
and	O	O
with	O	O
age	O	O
at	O	O
onset	O	O
.	O	O

Furthermore	O	O
,	O	O
tissues	O	O
from	O	O
DM	B-Disease	D009223
patients	O	O
exhibit	O	O
somatic	O	O
mosaicism	O	O
that	O	O
increases	O	O
with	O	O
age	O	O
.	O	O

We	O	O
generated	O	O
transgenic	O	O
mice	O	O
carrying	O	O
large	O	O
human	O	O
genomic	O	O
sequences	O	O
with	O	O
20	O	O
,	O	O
55	O	O
or	O	O
>	O	O
300	O	O
CTG	O	O
,	O	O
cloned	O	O
from	O	O
patients	O	O
from	O	O
the	O	O
same	O	O
affected	O	O
DM	B-Disease	D009223
family	O	O
.	O	O

Using	O	O
large	O	O
human	O	O
flanking	O	O
sequences	O	O
and	O	O
a	O	O
large	O	O
amplification	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
the	O	O
intergenerational	O	O
CTG	O	O
repeat	O	O
instability	O	O
is	O	O
reproduced	O	O
in	O	O
mice	O	O
,	O	O
with	O	O
a	O	O
strong	O	O
bias	O	O
towards	O	O
expansions	O	O
and	O	O
with	O	O
the	O	O
same	O	O
sex	O	O
-	O	O
and	O	O
size	O	O
-	O	O
dependent	O	O
characteristics	O	O
as	O	O
in	O	O
humans	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
high	O	O
level	O	O
of	O	O
instability	O	O
,	O	O
increasing	O	O
with	O	O
age	O	O
,	O	O
can	O	O
be	O	O
observed	O	O
in	O	O
tissues	O	O
and	O	O
in	O	O
sperm	O	O
.	O	O

Although	O	O
we	O	O
did	O	O
not	O	O
observe	O	O
dramatic	O	O
expansions	O	O
(	O	O
or	O	O
big	O	O
jumps	O	O
over	O	O
several	O	O
hundred	O	O
CTG	O	O
repeats	O	O
)	O	O
as	O	O
in	O	O
congenital	O	O
forms	O	O
of	O	O
DM	B-Disease	D009223
,	O	O
our	O	O
model	O	O
carrying	O	O
>	O	O
300	O	O
CTG	O	O
is	O	O
the	O	O
first	O	O
to	O	O
show	O	O
instability	O	O
so	O	O
close	O	O
to	O	O
the	O	O
human	O	O
DM	B-Disease	D009223
situation	O	O
.	O	O

Our	O	O
three	O	O
models	O	O
carrying	O	O
different	O	O
sizes	O	O
of	O	O
CTG	O	O
repeat	O	O
provide	O	O
insight	O	O
on	O	O
the	O	O
different	O	O
factors	O	O
modulating	O	O
the	O	O
CTG	O	O
repeat	O	O
instability	O	O
.	O	O

.	O	O

Linkage	O	O
of	O	O
gene	O	O
for	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
and	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
MHC	O	O
in	O	O
man	O	O
.	O	O

Family	O	O
study	O	O
of	O	O
a	O	O
further	O	O
case	O	O
.	O	O

Close	O	O
linkage	O	O
between	O	O
HL	O	O
-	O	O
A	O	O
and	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
was	O	O
first	O	O
reported	O	O
by	O	O
FU	O	O
and	O	O
co	O	O
-	O	O
workers	O	O
in	O	O
1974	O	O
.	O	O

We	O	O
present	O	O
here	O	O
a	O	O
pedigree	O	O
of	O	O
a	O	O
31	O	O
-	O	O
year	O	O
-	O	O
old	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
individual	O	O
with	O	O
clinical	O	O
manifestations	O	O
of	O	O
Hodgkins	B-Disease	D006689
disease	I-Disease	D006689
.	O	O

The	O	O
following	O	O
markers	O	O
were	O	O
tested	O	O
C2	O	O
levels	O	O
,	O	O
factor	O	O
B	O	O
polymorphism	O	O
,	O	O
blood	O	O
groups	O	O
,	O	O
and	O	O
enzyme	O	O
typing	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
close	O	O
linkage	O	O
between	O	O
HL	O	O
-	O	O
A	O	O
and	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
,	O	O
both	O	O
parents	O	O
were	O	O
heterozygous	O	O
for	O	O
Bf	O	O
(	O	O
HL	O	O
-	O	O
A	O	O
linked	O	O
,	O	O
electrophoretic	O	O
variation	O	O
of	O	O
B	O	O
)	O	O
.	O	O

The	O	O
two	O	O
HL	O	O
-	O	O
A	O	O
haplotypes	O	O
closely	O	O
linked	O	O
to	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
are	O	O
different	O	O
2	O	O
,	O	O
W18	O	O
and	O	O
W24	O	O
,	O	O
W18	O	O
.	O	O

They	O	O
share	O	O
,	O	O
however	O	O
,	O	O
the	O	O
SD2	O	O
antigen	O	O
W18	O	O
and	O	O
the	O	O
LD	O	O
type	O	O
7a	O	O
.	O	O

.	O	O

Age	O	O
of	O	O
onset	O	O
in	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
:	O	O
sex	O	O
specific	O	O
influence	O	O
of	O	O
apolipoprotein	O	O
E	O	O
genotype	O	O
and	O	O
normal	O	O
CAG	O	O
repeat	O	O
length	O	O
.	O	O

Age	O	O
of	O	O
onset	O	O
(	O	O
AO	O	O
)	O	O
of	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
is	O	O
known	O	O
to	O	O
be	O	O
correlated	O	O
with	O	O
the	O	O
length	O	O
of	O	O
an	O	O
expanded	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
.	O	O

Apolipoprotein	O	O
E	O	O
(	O	O
APOE	O	O
)	O	O
genotype	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
is	O	O
known	O	O
to	O	O
influence	O	O
AO	O	O
in	O	O
Alzheimer	B-Disease	D000544
disease	I-Disease	D000544
,	O	O
rendering	O	O
the	O	O
APOE	O	O
gene	O	O
a	O	O
likely	O	O
candidate	O	O
to	O	O
affect	O	O
AO	O	O
in	O	O
other	O	O
neurological	B-Disease	D020271
diseases	I-Disease	D020271
too	O	O
.	O	O

We	O	O
therefore	O	O
determined	O	O
APOE	O	O
genotype	O	O
and	O	O
normal	O	O
CAG	O	O
repeat	O	O
length	O	O
in	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
for	O	O
138	O	O
HD	B-Disease	D006816
patients	O	O
who	O	O
were	O	O
previously	O	O
analysed	O	O
with	O	O
respect	O	O
to	O	O
CAG	O	O
repeat	O	O
length	O	O
.	O	O

Genotyping	O	O
for	O	O
APOE	O	O
was	O	O
performed	O	O
blind	O	O
to	O	O
clinical	O	O
information	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
highlighting	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
normal	O	O
repeat	O	O
length	O	O
upon	O	O
AO	O	O
in	O	O
maternally	O	O
inherited	O	O
HD	B-Disease	D006816
and	O	O
in	O	O
male	O	O
patients	O	O
,	O	O
we	O	O
show	O	O
that	O	O
the	O	O
APOE	O	O
epsilon2epsilon3	O	O
genotype	O	O
is	O	O
associated	O	O
with	O	O
significantly	O	O
earlier	O	O
AO	O	O
in	O	O
males	O	O
than	O	O
in	O	O
females	O	O
.	O	O

Such	O	O
a	O	O
sex	O	O
difference	O	O
in	O	O
AO	O	O
was	O	O
not	O	O
apparent	O	O
for	O	O
any	O	O
of	O	O
the	O	O
other	O	O
APOE	O	O
genotypes	O	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
subtle	O	O
differences	O	O
in	O	O
the	O	O
course	O	O
of	O	O
the	O	O
neurodegeneration	B-Disease	D019636
in	O	O
HD	B-Disease	D006816
may	O	O
allow	O	O
interacting	O	O
genes	O	O
to	O	O
exert	O	O
gender	O	O
specific	O	O
effects	O	O
upon	O	O
AO	O	O
.	O	O

Genetic	O	O
linkage	O	O
map	O	O
of	O	O
six	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
around	O	O
the	O	O
gene	O	O
for	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
on	O	O
chromosome	O	O
5	O	O
.	O	O

A	O	O
genetic	O	O
linkage	O	O
map	O	O
of	O	O
six	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
close	O	O
to	O	O
the	O	O
gene	O	O
(	O	O
APC	B-Disease	D011125
)	O	O
for	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
on	O	O
chromosome	O	O
5q	O	O
is	O	O
reported	O	O
.	O	O

One	O	O
hundred	O	O
fifty	O	O
-	O	O
five	O	O
typed	O	O
members	O	O
of	O	O
nine	O	O
FAP	B-Disease	D011125
kindred	O	O
provided	O	O
more	O	O
than	O	O
90	O	O
meioses	O	O
for	O	O
linkage	O	O
analysis	O	O
.	O	O

A	O	O
number	O	O
of	O	O
crucial	O	O
recombination	O	O
events	O	O
have	O	O
been	O	O
identified	O	O
which	O	O
are	O	O
informative	O	O
at	O	O
three	O	O
or	O	O
more	O	O
loci	O	O
,	O	O
allowing	O	O
confident	O	O
ordering	O	O
of	O	O
parts	O	O
of	O	O
the	O	O
map	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
genetic	O	O
heterogeneity	O	O
,	O	O
with	O	O
all	O	O
families	O	O
showing	O	O
linkage	O	O
of	O	O
at	O	O
least	O	O
one	O	O
chromosome	O	O
5	O	O
marker	O	O
to	O	O
the	O	O
gene	O	O
.	O	O

Recombination	O	O
data	O	O
and	O	O
two	O	O
-	O	O
point	O	O
linkage	O	O
analysis	O	O
support	O	O
a	O	O
locus	O	O
order	O	O
of	O	O
centromere	O	O
-	O	O
pi	O	O
227	O	O
-	O	O
C11P11	O	O
-	O	O
ECB27	O	O
-	O	O
L5	O	O
.	O	O

62	O	O
-	O	O
APC	B-Disease	D011125
-	O	O
EF5	O	O
62	O	O
-	O	O
APC	B-Disease	D011125
-	O	O
EF5	O	O
.	O	O

44	O	O
-	O	O
YN5	O	O
44	O	O
-	O	O
YN5	O	O
.	O	O

48	O	O
-	O	O
telomer	O	O
e	O	O
,	O	O
although	O	O
EF5	O	O
.	O	O

44	O	O
could	O	O
lie	O	O
in	O	O
the	O	O
interval	O	O
L5	O	O
.	O	O

62	O	O
-	O	O
APC	B-Disease	D011125
or	O	O
ECB27	O	O
-	O	O
L5	O	O
.	O	O

62	O	O
.	O	O

No	O	O
recombinants	O	O
were	O	O
identified	O	O
between	O	O
APC	B-Disease	D011125
and	O	O
either	O	O
EF5	O	O
.	O	O

44	O	O
or	O	O
YN5	O	O
.	O	O

48	O	O
,	O	O
but	O	O
published	O	O
deletion	O	O
mapping	O	O
in	O	O
colorectal	B-Disease	D015179
carcinomas	I-Disease	D015179
and	O	O
linkage	O	O
analysis	O	O
in	O	O
FAP	B-Disease	D011125
suggest	O	O
that	O	O
YN5	O	O
.	O	O

48	O	O
is	O	O
1	O	O
-	O	O
3	O	O
cM	O	O
from	O	O
APC	B-Disease	D011125
.	O	O

The	O	O
present	O	O
study	O	O
suggests	O	O
that	O	O
YN5	O	O
.	O	O

48	O	O
and	O	O
L5	O	O
.	O	O

62	O	O
delineate	O	O
a	O	O
small	O	O
region	O	O
of	O	O
chromosome	O	O
5	O	O
within	O	O
which	O	O
the	O	O
EF5	O	O
.	O	O

44	O	O
locus	O	O
lies	O	O
very	O	O
close	O	O
to	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

These	O	O
data	O	O
not	O	O
only	O	O
allow	O	O
use	O	O
of	O	O
flanking	O	O
markers	O	O
for	O	O
presymptomatic	O	O
diagnosis	O	O
of	O	O
FAP	B-Disease	D011125
but	O	O
also	O	O
provide	O	O
a	O	O
high	O	O
-	O	O
density	O	O
map	O	O
of	O	O
the	O	O
region	O	O
for	O	O
isolation	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
itself	O	O
and	O	O
for	O	O
further	O	O
assessment	O	O
of	O	O
the	O	O
role	O	O
of	O	O
chromosome	O	O
5	O	O
deletions	O	O
in	O	O
the	O	O
biology	O	O
of	O	O
sporadic	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Detection	O	O
of	O	O
a	O	O
novel	O	O
arginine	O	O
vasopressin	O	O
defect	O	O
by	O	O
dideoxy	O	O
fingerprinting	O	O
.	O	O

Autosomal	B-Disease	OMIM:125700
dominant	I-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
is	O	O
a	O	O
familial	O	O
form	O	O
of	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
.	O	O

This	O	O
disorder	O	O
is	O	O
associated	O	O
with	O	O
variable	O	O
levels	O	O
of	O	O
arginine	O	O
vasopressin	O	O
(	O	O
AVP	O	O
)	O	O
and	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
of	O	O
varying	O	O
severity	O	O
,	O	O
which	O	O
responds	O	O
to	O	O
exogenous	O	O
AVP	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
autosomal	B-Disease	OMIM:125700
dominant	I-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
,	O	O
the	O	O
AVP	O	O
genes	O	O
of	O	O
members	O	O
of	O	O
a	O	O
large	O	O
kindred	O	O
were	O	O
analyzed	O	O
.	O	O

A	O	O
new	O	O
method	O	O
,	O	O
called	O	O
dideoxy	O	O
fingerprinting	O	O
,	O	O
was	O	O
used	O	O
to	O	O
detect	O	O
an	O	O
AVP	O	O
mutation	O	O
that	O	O
was	O	O
characterized	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O

The	O	O
novel	O	O
defect	O	O
found	O	O
changes	O	O
the	O	O
last	O	O
codon	O	O
of	O	O
the	O	O
AVP	O	O
signal	O	O
peptide	O	O
from	O	O
alanine	O	O
to	O	O
threonine	O	O
,	O	O
which	O	O
should	O	O
perturb	O	O
cleavage	O	O
of	O	O
mature	O	O
AVP	O	O
from	O	O
its	O	O
precursor	O	O
protein	O	O
and	O	O
inhibit	O	O
its	O	O
secretion	O	O
or	O	O
action	O	O
.	O	O

.	O	O

Association	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
tumor	I-Disease	D011125
suppressor	O	O
protein	O	O
with	O	O
catenins	O	O
.	O	O

Mutations	O	O
of	O	O
APC	B-Disease	D011125
appear	O	O
to	O	O
initiate	O	O
sporadic	O	O
and	O	O
inherited	O	O
forms	O	O
of	O	O
human	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Although	O	O
these	O	O
mutations	O	O
have	O	O
been	O	O
well	O	O
characterized	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
function	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
product	O	O
.	O	O

Two	O	O
cellular	O	O
proteins	O	O
that	O	O
associate	O	O
with	O	O
APC	B-Disease	D011125
were	O	O
identified	O	O
by	O	O
nucleotide	O	O
sequence	O	O
analysis	O	O
and	O	O
peptide	O	O
mapping	O	O
as	O	O
the	O	O
E	O	O
-	O	O
cadherin	O	O
-	O	O
associated	O	O
proteins	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
catenin	O	O
.	O	O

A	O	O
27	O	O
-	O	O
residue	O	O
fragment	O	O
of	O	O
APC	B-Disease	D011125
containing	O	O
a	O	O
15	O	O
-	O	O
amino	O	O
acid	O	O
repeat	O	O
was	O	O
sufficient	O	O
for	O	O
the	O	O
interaction	O	O
with	O	O
the	O	O
catenins	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
an	O	O
important	O	O
link	O	O
between	O	O
tumor	B-Disease	D009369
initiation	O	O
and	O	O
cell	O	O
adhesion	O	O
.	O	O

.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
is	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
gene	O	O
for	O	O
muscle	O	O
-	O	O
type	O	O
creatine	O	O
kinase	O	O
(	O	O
CKMM	O	O
)	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
genetic	O	O
linkage	O	O
between	O	O
the	O	O
gene	O	O
for	O	O
creatine	O	O
kinase	O	O
muscle	O	O
type	O	O
(	O	O
CKMM	O	O
)	O	O
and	O	O
the	O	O
gene	O	O
for	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

In	O	O
a	O	O
panel	O	O
of	O	O
65	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
families	O	O
from	O	O
Canada	O	O
and	O	O
the	O	O
Netherlands	O	O
,	O	O
a	O	O
maximum	O	O
lod	O	O
score	O	O
(	O	O
Zmax	O	O
)	O	O
of	O	O
22	O	O
.	O	O

8	O	O
at	O	O
a	O	O
recombination	O	O
frequency	O	O
(	O	O
theta	O	O
)	O	O
of	O	O
0	O	O
.	O	O

03	O	O
was	O	O
obtained	O	O
.	O	O

Tight	O	O
linkage	O	O
was	O	O
also	O	O
demonstrated	O	O
for	O	O
CKMM	O	O
and	O	O
the	O	O
gene	O	O
for	O	O
apolipoprotein	O	O
C2	O	O
(	O	O
ApoC2	O	O
)	O	O
.	O	O

This	O	O
establishes	O	O
CKMM	O	O
as	O	O
a	O	O
useful	O	O
marker	O	O
for	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
Discordant	O	O
clinical	O	O
outcome	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
relatives	O	O
showing	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
>	O	O
700	O	O
repeats	O	O
.	O	O

A	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
family	O	O
is	O	O
described	O	O
in	O	O
which	O	O
discordant	O	O
DM	B-Disease	D009223
phenotypes	O	O
were	O	O
found	O	O
in	O	O
the	O	O
children	O	O
of	O	O
two	O	O
affected	O	O
sisters	O	O
with	O	O
similar	O	O
CTG	O	O
expansion	O	O
and	O	O
clinical	O	O
manifestations	O	O
.	O	O

In	O	O
this	O	O
family	O	O
,	O	O
congenital	O	O
as	O	O
well	O	O
as	O	O
early	O	O
severe	O	O
childhood	O	O
and	O	O
later	O	O
childhood	O	O
onset	O	O
DM	B-Disease	D009223
coexist	O	O
.	O	O

This	O	O
observation	O	O
strengthens	O	O
the	O	O
limited	O	O
ability	O	O
of	O	O
lymphocytes	O	O
CTG	O	O
repeat	O	O
number	O	O
analysis	O	O
in	O	O
predicting	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
DM	B-Disease	D009223
patients	O	O
.	O	O

.	O	O

Constitutional	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
gene	O	O
deletions	O	O
detected	O	O
in	O	O
VHL	B-Disease	D006623
families	O	O
by	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
disease	O	O
is	O	O
an	O	O
autosomal	B-Disease	D009386
dominantly	I-Disease	D009386
inherited	I-Disease	D009386
cancer	I-Disease	D009386
syndrome	I-Disease	D009386
predisposing	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
tumor	B-Disease	D009369
types	O	O
that	O	O
include	O	O
retinal	O	O
hemangioblastomas	B-Disease	D018325
,	O	O
hemangioblastomas	B-Disease	D018325
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
,	O	O
pancreatic	B-Disease	D010181
cysts	I-Disease	D010181
and	I-Disease	D010181
tumors	I-Disease	D010181
,	O	O
pheochromocytomas	B-Disease	D010673
,	O	O
endolymphatic	B-Disease	D036821
sac	I-Disease	D036821
tumors	I-Disease	D036821
,	O	O
and	O	O
epididymal	B-Disease	D003537
cystadenomas	I-Disease	D003537
[	O	O
W	O	O
.	O	O

M	O	O
.	O	O

Linehan	O	O
et	O	O
al	O	O
.	O	O

,	O	O
J	O	O
.	O	O

Am	O	O
.	O	O

Med	O	O
.	O	O

Assoc	O	O
.	O	O

,	O	O
273	O	O
564	O	O
-	O	O
570	O	O
,	O	O
1995	O	O
;	O	O
E	O	O
.	O	O

A	O	O
.	O	O

Maher	O	O
and	O	O
W	O	O
.	O	O

G	O	O
.	O	O

Kaelin	O	O
,	O	O
Jr	O	O
.	O	O

,	O	O
Medicine	O	O
(	O	O
Baltimore	O	O
)	O	O
,	O	O
76	O	O
381	O	O
-	O	O
391	O	O
,	O	O
1997	O	O
;	O	O
W	O	O
.	O	O

M	O	O
.	O	O

Linehan	O	O
and	O	O
R	O	O
.	O	O

D	O	O
.	O	O

Klausner	O	O
,	O	O
In	O	O
B	O	O
.	O	O

Vogelstein	O	O
and	O	O
K	O	O
.	O	O

Kinzler	O	O
(	O	O
eds	O	O
.	O	O

)	O	O
,	O	O
The	O	O
Genetic	O	O
Basis	O	O
of	O	O
Human	O	O
Cancer	O	O
,	O	O
pp	O	O
.	O	O

455	O	O
-	O	O
473	O	O
,	O	O
McGraw	O	O
-	O	O
Hill	O	O
,	O	O
1998	O	O
]	O	O
.	O	O

The	O	O
VHL	B-Disease	D006623
gene	O	O
was	O	O
localized	O	O
to	O	O
chromosome	O	O
3p25	O	O
-	O	O
26	O	O
and	O	O
cloned	O	O
[	O	O
F	O	O
.	O	O

Latif	O	O
et	O	O
al	O	O
.	O	O

,	O	O
Science	O	O
(	O	O
Washington	O	O
DC	O	O
)	O	O
,	O	O
260	O	O
1317	O	O
-	O	O
1320	O	O
,	O	O
1993	O	O
]	O	O
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
VHL	B-Disease	D006623
kindreds	O	O
.	O	O

The	O	O
reported	O	O
frequency	O	O
of	O	O
detection	O	O
of	O	O
VHL	B-Disease	D006623
germline	O	O
mutations	O	O
has	O	O
varied	O	O
from	O	O
39	O	O
to	O	O
80	O	O
%	O	O
(	O	O
J	O	O
.	O	O

M	O	O
.	O	O

Whaley	O	O
et	O	O
al	O	O
.	O	O

,	O	O
Am	O	O
.	O	O

J	O	O
.	O	O

Hum	O	O
.	O	O

Genet	O	O
.	O	O

,	O	O
55	O	O
1092	O	O
-	O	O
1102	O	O
,	O	O
1994	O	O
;	O	O
Clinical	O	O
Research	O	O
Group	O	O
for	O	O
Japan	O	O
,	O	O
Hum	O	O
.	O	O

Mol	O	O
.	O	O

Genet	O	O
.	O	O

,	O	O
4	O	O
2233	O	O
-	O	O
2237	O	O
,	O	O
1995	O	O
;	O	O
F	O	O
.	O	O

Chen	O	O
et	O	O
al	O	O
.	O	O

,	O	O
Hum	O	O
.	O	O

Mutat	O	O
.	O	O

,	O	O
5	O	O
66	O	O
-	O	O
75	O	O
,	O	O
1995	O	O
;	O	O
E	O	O
.	O	O

R	O	O
.	O	O

Maher	O	O
et	O	O
al	O	O
.	O	O

,	O	O
J	O	O
.	O	O

Med	O	O
.	O	O

Genet	O	O
.	O	O

,	O	O
33	O	O
328	O	O
-	O	O
332	O	O
,	O	O
1996	O	O
;	O	O
B	O	O
.	O	O

Zbar	O	O
,	O	O
Cancer	O	O
Surv	O	O
.	O	O

,	O	O
25	O	O
219	O	O
-	O	O
232	O	O
,	O	O
1995	O	O
)	O	O
.	O	O

Recently	O	O
a	O	O
quantitative	O	O
Southern	O	O
blotting	O	O
procedure	O	O
was	O	O
found	O	O
to	O	O
improve	O	O
this	O	O
frequency	O	O
(	O	O
C	O	O
.	O	O

Stolle	O	O
et	O	O
al	O	O
.	O	O

,	O	O
Hum	O	O
.	O	O

Mutat	O	O
.	O	O

,	O	O
12	O	O
417	O	O
-	O	O
423	O	O
,	O	O
1998	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
report	O	O
the	O	O
use	O	O
of	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
as	O	O
a	O	O
method	O	O
to	O	O
detect	O	O
and	O	O
characterize	O	O
VHL	B-Disease	D006623
germline	O	O
deletions	O	O
.	O	O

We	O	O
reexamined	O	O
a	O	O
group	O	O
of	O	O
VHL	B-Disease	D006623
patients	O	O
shown	O	O
previously	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
and	O	O
sequencing	O	O
analysis	O	O
not	O	O
to	O	O
harbor	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
VHL	B-Disease	D006623
locus	O	O
.	O	O

We	O	O
found	O	O
constitutional	O	O
deletions	O	O
in	O	O
29	O	O
of	O	O
30	O	O
VHL	B-Disease	D006623
patients	O	O
in	O	O
this	O	O
group	O	O
using	O	O
cosmid	O	O
and	O	O
P1	O	O
probes	O	O
that	O	O
cover	O	O
the	O	O
VHL	B-Disease	D006623
locus	O	O
.	O	O

We	O	O
then	O	O
tested	O	O
six	O	O
phenotypically	O	O
normal	O	O
offspring	O	O
from	O	O
four	O	O
of	O	O
these	O	O
VHL	B-Disease	D006623
families	O	O
two	O	O
were	O	O
found	O	O
to	O	O
carry	O	O
the	O	O
deletion	O	O
and	O	O
the	O	O
other	O	O
four	O	O
were	O	O
deletion	O	O
-	O	O
free	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
germline	O	O
mosaicism	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
was	O	O
identified	O	O
in	O	O
one	O	O
family	O	O
.	O	O

In	O	O
sum	O	O
,	O	O
FISH	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
simple	O	O
and	O	O
reliable	O	O
method	O	O
to	O	O
detect	O	O
VHL	B-Disease	D006623
germline	O	O
deletions	O	O
and	O	O
practically	O	O
useful	O	O
in	O	O
cases	O	O
where	O	O
other	O	O
methods	O	O
of	O	O
screening	O	O
have	O	O
failed	O	O
to	O	O
detect	O	O
a	O	O
VHL	B-Disease	D006623
gene	O	O
abnormality	O	O
Aberrant	O	O
subcellular	O	O
localization	O	O
of	O	O
BRCA1	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

The	O	O
BRCA1	O	O
gene	O	O
product	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
220	O	O
-	O	O
kilodalton	O	O
nuclear	O	O
phosphoprotein	O	O
in	O	O
normal	O	O
cells	O	O
,	O	O
including	O	O
breast	O	O
ductal	O	O
epithelial	O	O
cells	O	O
,	O	O
and	O	O
in	O	O
18	O	O
of	O	O
20	O	O
tumor	B-Disease	D009369
cell	O	O
lines	O	O
derived	O	O
from	O	O
tissues	O	O
other	O	O
than	O	O
breast	O	O
and	O	O
ovary	O	O
.	O	O

In	O	O
16	O	O
of	O	O
17	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
lines	O	O
and	O	O
17	O	O
of	O	O
17	O	O
samples	O	O
of	O	O
cells	O	O
obtained	O	O
from	O	O
malignant	O	O
effusions	O	O
,	O	O
however	O	O
,	O	O
BRCA1	O	O
localized	O	O
mainly	O	O
in	O	O
cytoplasm	O	O
.	O	O

Absence	O	O
of	O	O
BRCA1	O	O
or	O	O
aberrant	O	O
subcellular	O	O
location	O	O
was	O	O
also	O	O
observed	O	O
to	O	O
a	O	O
variable	O	O
extent	O	O
in	O	O
histological	O	O
sections	O	O
of	O	O
many	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
biopsies	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
BRCA1	B-Disease	OMIM:604370
abnormalities	I-Disease	OMIM:604370
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
many	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
,	O	O
sporadic	O	O
as	O	O
well	O	O
as	O	O
familial	O	O
.	O	O

.	O	O

HLA	O	O
B27	O	O
and	O	O
the	O	O
genetics	O	O
of	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
.	O	O

One	O	O
hundred	O	O
and	O	O
twenty	O	O
-	O	O
eight	O	O
of	O	O
145	O	O
patients	O	O
with	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
(	O	O
AS	B-Disease	D013167
)	O	O
were	O	O
found	O	O
to	O	O
be	O	O
HLA	O	O
B27	O	O
positive	O	O
.	O	O

Five	O	O
patients	O	O
had	O	O
evidence	O	O
of	O	O
a	O	O
sero	O	O
-	O	O
negative	O	O
peripheral	B-Disease	D001168
arthritis	I-Disease	D001168
resembling	O	O
peripheral	B-Disease	D015535
psoriatic	I-Disease	D015535
arthritis	I-Disease	D015535
and	O	O
3	O	O
of	O	O
these	O	O
were	O	O
B27	O	O
negative	O	O
.	O	O

One	O	O
further	O	O
B27	O	O
negative	O	O
patients	O	O
had	O	O
a	O	O
sister	O	O
with	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
and	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
and	O	O
a	O	O
mother	O	O
with	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
.	O	O

There	O	O
was	O	O
evidence	O	O
of	O	O
a	O	O
somewhat	O	O
later	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
symptoms	O	O
in	O	O
B27	O	O
negative	O	O
patients	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
interpreted	O	O
as	O	O
suggesting	O	O
some	O	O
degree	O	O
of	O	O
clinical	O	O
and	O	O
genetic	O	O
heterogeneity	O	O
in	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
with	O	O
genes	O	O
for	O	O
psoriasis	B-Disease	D011565
and	O	O
inflammatory	B-Disease	D015212
bowel	I-Disease	D015212
disease	I-Disease	D015212
being	O	O
important	O	O
in	O	O
some	O	O
individuals	O	O
,	O	O
particularly	O	O
those	O	O
who	O	O
are	O	O
B27	O	O
negative	O	O
.	O	O

Twenty	O	O
-	O	O
five	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
with	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
were	O	O
all	O	O
B27	O	O
positive	O	O
.	O	O

The	O	O
only	O	O
instance	O	O
of	O	O
disassociation	O	O
of	O	O
B27	O	O
and	O	O
spondylitis	B-Disease	D013166
in	O	O
a	O	O
family	O	O
was	O	O
where	O	O
the	O	O
proband	O	O
had	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
as	O	O
well	O	O
as	O	O
spondylitis	B-Disease	D013166
.	O	O

Of	O	O
13	O	O
B27	O	O
positive	O	O
fathers	O	O
3	O	O
could	O	O
be	O	O
diagnosed	O	O
as	O	O
having	O	O
definite	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
(	O	O
23	O	O
%	O	O
)	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
thought	O	O
to	O	O
provide	O	O
evidence	O	O
against	O	O
the	O	O
concept	O	O
that	O	O
the	O	O
gene	O	O
for	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
is	O	O
not	O	O
B27	O	O
but	O	O
a	O	O
closely	O	O
linked	O	O
gene	O	O
and	O	O
favour	O	O
the	O	O
occurrence	O	O
of	O	O
an	O	O
environmental	O	O
event	O	O
affecting	O	O
approximately	O	O
one	O	O
-	O	O
fifth	O	O
of	O	O
B27	O	O
positive	O	O
males	O	O
to	O	O
result	O	O
in	O	O
disease	O	O
.	O	O

.	O	O

Late	O	O
infantile	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
in	O	O
Israel	O	O
.	O	O

Metachromatic	B-Disease	D007966
Leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
is	O	O
a	O	O
neurodegenerative	B-Disease	D019636
disease	I-Disease	D019636
in	O	O
which	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
,	O	O
Aryl	O	O
sulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
is	O	O
deficient	O	O
.	O	O

The	O	O
disease	O	O
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
and	O	O
its	O	O
frequency	O	O
is	O	O
estimated	O	O
to	O	O
be	O	O
1	O	O
/	O	O
40	O	O
,	O	O
000	O	O
live	O	O
births	O	O
.	O	O

The	O	O
gene	O	O
of	O	O
ARSA	O	O
has	O	O
been	O	O
cloned	O	O
and	O	O
up	O	O
to	O	O
now	O	O
eight	O	O
mutations	O	O
causing	O	O
MLD	B-Disease	D007966
have	O	O
been	O	O
reported	O	O
.	O	O

Another	O	O
mutation	O	O
,	O	O
PD	O	O
,	O	O
leads	O	O
to	O	O
the	O	O
deficiency	O	O
of	O	O
the	O	O
enzyme	O	O
in	O	O
vitro	O	O
(	O	O
pseudodeficiency	O	O
)	O	O
without	O	O
any	O	O
known	O	O
clinical	O	O
effect	O	O
.	O	O

The	O	O
PD	O	O
mutation	O	O
is	O	O
frequent	O	O
in	O	O
all	O	O
populations	O	O
.	O	O

In	O	O
Israel	O	O
,	O	O
late	O	O
infantile	O	O
MLD	B-Disease	D007966
was	O	O
found	O	O
to	O	O
be	O	O
very	O	O
frequent	O	O
in	O	O
a	O	O
small	O	O
Jewish	O	O
isolate	O	O
,	O	O
the	O	O
Habbanite	O	O
Jews	O	O
(	O	O
1	O	O
/	O	O
75	O	O
live	O	O
births	O	O
)	O	O
.	O	O

The	O	O
molecular	O	O
analysis	O	O
demonstrated	O	O
that	O	O
in	O	O
the	O	O
Habbanite	O	O
population	O	O
,	O	O
the	O	O
mutation	O	O
occurred	O	O
on	O	O
an	O	O
allele	O	O
with	O	O
the	O	O
PD	O	O
mutation	O	O
.	O	O

The	O	O
loss	O	O
of	O	O
ARSA	O	O
activity	O	O
is	O	O
due	O	O
to	O	O
a	O	O
point	O	O
mutation	O	O
C	O	O
>	O	O
T	O	O
leading	O	O
to	O	O
a	O	O
change	O	O
of	O	O
proline	O	O
to	O	O
leucine	O	O
.	O	O

MLD	B-Disease	D007966
is	O	O
also	O	O
frequent	O	O
among	O	O
Moslem	O	O
Arabs	O	O
in	O	O
Jerusalem	O	O
.	O	O

The	O	O
mutation	O	O
is	O	O
a	O	O
transition	O	O
G	O	O
>	O	O
A	O	O
destroying	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
exon	O	O
2	O	O
.	O	O

This	O	O
mutation	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
late	O	O
infantile	O	O
MLD	B-Disease	D007966
from	O	O
different	O	O
ethnic	O	O
groups	O	O
.	O	O

The	O	O
Christian	O	O
Arabs	O	O
in	O	O
Israel	O	O
also	O	O
have	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
the	O	O
disease	O	O
(	O	O
1	O	O
/	O	O
10	O	O
,	O	O
000	O	O
live	O	O
births	O	O
)	O	O
;	O	O
the	O	O
mutation	O	O
in	O	O
this	O	O
population	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O

Knowledge	O	O
of	O	O
the	O	O
different	O	O
mutations	O	O
causing	O	O
MLD	B-Disease	D007966
in	O	O
these	O	O
defined	O	O
populations	O	O
will	O	O
allow	O	O
a	O	O
carrier	O	O
screening	O	O
program	O	O
to	O	O
be	O	O
carried	O	O
out	O	O
and	O	O
prevent	O	O
the	O	O
birth	O	O
of	O	O
additional	O	O
affected	O	O
children	O	O
.	O	O

.	O	O

Genomic	O	O
rearrangements	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
tumor	I-Disease	D011125
-	O	O
suppressor	O	O
gene	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
.	O	O

Germline	O	O
mutations	O	O
of	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	I-Disease	D011125
APC	I-Disease	D011125
)	I-Disease	D011125
tumor	I-Disease	D011125
-	O	O
suppressor	O	O
gene	O	O
result	O	O
in	O	O
the	O	O
hereditary	B-Disease	D015179
colorectal	I-Disease	D015179
cancer	I-Disease	D015179
syndrome	I-Disease	D015179
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
.	O	O

Almost	O	O
all	O	O
APC	B-Disease	D011125
mutations	O	O
that	O	O
have	O	O
been	O	O
identified	O	O
are	O	O
single	O	O
-	O	O
nucleotide	O	O
alterations	O	O
,	O	O
small	O	O
insertions	O	O
,	O	O
or	O	O
small	O	O
deletions	O	O
that	O	O
would	O	O
truncate	O	O
the	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

No	O	O
well	O	O
-	O	O
characterized	O	O
intragenic	O	O
rearrangement	O	O
of	O	O
APC	B-Disease	D011125
has	O	O
been	O	O
described	O	O
,	O	O
and	O	O
the	O	O
prevalence	O	O
of	O	O
this	O	O
type	O	O
of	O	O
mutation	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
is	O	O
not	O	O
clear	O	O
.	O	O

We	O	O
screened	O	O
49	O	O
potential	O	O
FAP	B-Disease	D011125
families	O	O
and	O	O
identified	O	O
26	O	O
different	O	O
germline	O	O
APC	B-Disease	D011125
mutations	O	O
in	O	O
30	O	O
families	O	O
.	O	O

Four	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
genomic	O	O
rearrangements	O	O
resulting	O	O
from	O	O
homologous	O	O
and	O	O
nonhomologous	O	O
recombinations	O	O
mediated	O	O
by	O	O
Alu	O	O
elements	O	O
.	O	O

Two	O	O
of	O	O
these	O	O
four	O	O
rearrangements	O	O
were	O	O
complex	O	O
,	O	O
involving	O	O
deletion	O	O
and	O	O
insertion	O	O
of	O	O
nucleotides	O	O
.	O	O

Of	O	O
these	O	O
four	O	O
rearrangements	O	O
,	O	O
one	O	O
resulted	O	O
in	O	O
the	O	O
deletion	O	O
of	O	O
exons	O	O
11	O	O
and	O	O
12	O	O
and	O	O
two	O	O
others	O	O
resulted	O	O
in	O	O
either	O	O
complete	O	O
or	O	O
partial	O	O
deletion	O	O
of	O	O
exon	O	O
14	O	O
.	O	O

The	O	O
fourth	O	O
rearrangement	O	O
grossly	O	O
altered	O	O
the	O	O
sequence	O	O
within	O	O
intron	O	O
14	O	O
.	O	O

Although	O	O
this	O	O
rearrangement	O	O
did	O	O
not	O	O
affect	O	O
any	O	O
coding	O	O
sequence	O	O
of	O	O
APC	B-Disease	D011125
at	O	O
the	O	O
genomic	O	O
DNA	O	O
level	O	O
,	O	O
it	O	O
caused	O	O
inappropriate	O	O
splicing	O	O
of	O	O
exon	O	O
14	O	O
.	O	O

These	O	O
rearrangements	O	O
were	O	O
initially	O	O
revealed	O	O
by	O	O
analyzing	O	O
cDNAs	O	O
and	O	O
could	O	O
not	O	O
have	O	O
been	O	O
identified	O	O
by	O	O
using	O	O
mutation	O	O
detection	O	O
methods	O	O
that	O	O
screened	O	O
each	O	O
exon	O	O
individually	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
a	O	O
rearrangement	O	O
that	O	O
did	O	O
not	O	O
alter	O	O
any	O	O
coding	O	O
exons	O	O
yet	O	O
affected	O	O
the	O	O
splicing	O	O
further	O	O
underscores	O	O
the	O	O
importance	O	O
of	O	O
using	O	O
cDNA	O	O
for	O	O
mutation	O	O
analysis	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
four	O	O
genomic	O	O
rearrangements	O	O
among	O	O
30	O	O
mutations	O	O
suggests	O	O
that	O	O
genomic	O	O
rearrangements	O	O
are	O	O
frequent	O	O
germline	O	O
APC	B-Disease	D011125
mutations	O	O
.	O	O

.	O	O

Familial	B-Disease	D018567
male	I-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
is	O	O
not	O	O
linked	O	O
to	O	O
the	O	O
BRCA1	O	O
locus	O	O
on	O	O
chromosome	O	O
17q	O	O
.	O	O

Breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
men	O	O
is	O	O
about	O	O
a	O	O
hundredfold	O	O
less	O	O
common	O	O
than	O	O
in	O	O
women	O	O
and	O	O
this	O	O
has	O	O
hindered	O	O
research	O	O
into	O	O
its	O	O
genetic	O	O
basis	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
22	O	O
families	O	O
with	O	O
at	O	O
least	O	O
one	O	O
case	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
for	O	O
linkage	O	O
to	O	O
the	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
locus	O	O
,	O	O
BRCA1	O	O
,	O	O
on	O	O
chromosome	O	O
17q	O	O
.	O	O

We	O	O
found	O	O
strong	O	O
evidence	O	O
against	O	O
linkage	O	O
to	O	O
BRCA1	O	O
(	O	O
lod	O	O
score	O	O
-	O	O
16	O	O
.	O	O

63	O	O
)	O	O
and	O	O
the	O	O
best	O	O
estimate	O	O
of	O	O
the	O	O
proportion	O	O
of	O	O
linked	O	O
families	O	O
was	O	O
0	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
-	O	O
18	O	O
%	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
there	O	O
is	O	O
a	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
other	O	O
than	O	O
BRCA1	O	O
which	O	O
predisposes	O	O
to	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
women	O	O
and	O	O
which	O	O
confers	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
.	O	O

Identification	O	O
of	O	O
additional	O	O
pedigrees	O	O
that	O	O
include	O	O
cases	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
may	O	O
therefore	O	O
facilitate	O	O
the	O	O
mapping	O	O
and	O	O
isolation	O	O
of	O	O
this	O	O
gene	O	O
.	O	O

Evidence	O	O
for	O	O
inter	O	O
-	O	O
generational	O	O
instability	O	O
in	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
and	O	O
for	O	O
conserved	O	O
haplotypes	O	O
at	O	O
flanking	O	O
markers	O	O
amongst	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
(	O	O
CAG	O	O
)	O	O
n	O	O
repeat	O	O
array	O	O
in	O	O
the	O	O
3	O	O
'	O	O
end	O	O
of	O	O
the	O	O
MJD1	O	O
gene	O	O
and	O	O
the	O	O
haplotype	O	O
at	O	O
a	O	O
series	O	O
of	O	O
microsatellite	O	O
markers	O	O
surrounding	O	O
the	O	O
MJD1	O	O
gene	O	O
were	O	O
examined	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
affected	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
.	O	O

Our	O	O
data	O	O
provide	O	O
five	O	O
novel	O	O
observations	O	O
.	O	O

First	O	O
,	O	O
MJD	B-Disease	D017827
is	O	O
associated	O	O
with	O	O
expansion	O	O
fo	O	O
the	O	O
array	O	O
from	O	O
the	O	O
normal	O	O
range	O	O
of	O	O
14	O	O
-	O	O
37	O	O
repeats	O	O
to	O	O
68	O	O
-	O	O
84	O	O
repeats	O	O
in	O	O
most	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
,	O	O
but	O	O
no	O	O
subjects	O	O
were	O	O
observed	O	O
with	O	O
expansions	O	O
intermediate	O	O
in	O	O
size	O	O
between	O	O
those	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
MJD	B-Disease	D017827
affected	O	O
groups	O	O
.	O	O

Second	O	O
,	O	O
the	O	O
expanded	O	O
allele	O	O
associated	O	O
with	O	O
MJD	B-Disease	D017827
displays	O	O
inter	O	O
-	O	O
generational	O	O
instability	O	O
,	O	O
particularly	O	O
in	O	O
male	O	O
meioses	O	O
,	O	O
and	O	O
this	O	O
instability	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
clinical	O	O
phenomenon	O	O
of	O	O
anticipation	O	O
.	O	O

Third	O	O
,	O	O
the	O	O
size	O	O
of	O	O
the	O	O
expanded	O	O
allele	O	O
is	O	O
not	O	O
only	O	O
inversely	O	O
correlated	O	O
with	O	O
the	O	O
age	O	O
-	O	O
of	O	O
-	O	O
onset	O	O
of	O	O
MJD	B-Disease	D017827
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O

738	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
but	O	O
is	O	O
also	O	O
correlated	O	O
with	O	O
the	O	O
frequency	O	O
of	O	O
other	O	O
clinical	O	O
features	O	O
[	O	O
e	O	O
.	O	O

g	O	O
.	O	O

pseudoexophthalmos	O	O
and	O	O
pyramidal	O	O
signs	O	O
were	O	O
more	O	O
frequent	O	O
in	O	O
subjects	O	O
with	O	O
large	O	O
repeats	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
and	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
respectively	O	O
)	O	O
]	O	O
.	O	O

Fourth	O	O
,	O	O
the	O	O
disease	O	O
phenotype	O	O
is	O	O
significantly	O	O
more	O	O
severe	O	O
and	O	O
had	O	O
an	O	O
early	O	O
age	O	O
of	O	O
onset	O	O
(	O	O
16	O	O
years	O	O
)	O	O
in	O	O
a	O	O
subject	O	O
homozygous	O	O
for	O	O
the	O	O
expanded	O	O
allele	O	O
,	O	O
which	O	O
contrasts	O	O
with	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
and	O	O
suggests	O	O
that	O	O
the	O	O
expanded	O	O
allele	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
could	O	O
exert	O	O
its	O	O
effect	O	O
either	O	O
by	O	O
a	O	O
dominant	O	O
negative	O	O
effect	O	O
(	O	O
putatively	O	O
excluded	O	O
in	O	O
HD	B-Disease	D006816
)	O	O
or	O	O
by	O	O
a	O	O
gain	O	O
of	O	O
function	O	O
effect	O	O
as	O	O
proposed	O	O
for	O	O
HD	B-Disease	D006816
.	O	O

Finally	O	O
,	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
affected	O	O
with	O	O
MJD	B-Disease	D017827
share	O	O
haplotypes	O	O
at	O	O
several	O	O
markers	O	O
surrounding	O	O
the	O	O
MJD1	O	O
gene	O	O
,	O	O
which	O	O
are	O	O
uncommon	O	O
in	O	O
the	O	O
normal	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
population	O	O
,	O	O
and	O	O
which	O	O
suggests	O	O
the	O	O
existence	O	O
either	O	O
of	O	O
common	O	O
founders	O	O
in	O	O
these	O	O
populations	O	O
or	O	O
of	O	O
chromosomes	O	O
susceptible	O	O
to	O	O
pathologic	O	O
expansion	O	O
of	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
.	O	O

Familial	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
with	O	O
apparently	O	O
normal	O	O
chromosomes	O	O
.	O	O

We	O	O
report	O	O
on	O	O
4	O	O
sibs	O	O
(	O	O
2F	O	O
,	O	O
2M	O	O
)	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

Diagnosis	O	O
was	O	O
made	O	O
clinically	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
history	O	O
,	O	O
behavior	O	O
,	O	O
and	O	O
physical	O	O
findings	O	O
in	O	O
3	O	O
of	O	O
the	O	O
sibs	O	O
.	O	O

The	O	O
other	O	O
child	O	O
had	O	O
died	O	O
at	O	O
age	O	O
10	O	O
months	O	O
with	O	O
a	O	O
history	O	O
and	O	O
clinical	O	O
findings	O	O
typical	O	O
of	O	O
first	O	O
phase	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

Results	O	O
of	O	O
chromosome	O	O
studies	O	O
on	O	O
the	O	O
parents	O	O
and	O	O
surviving	O	O
sibs	O	O
were	O	O
normal	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
this	O	O
unusual	O	O
familial	O	O
occurrence	O	O
for	O	O
our	O	O
understanding	O	O
of	O	O
PWS	B-Disease	D011218
are	O	O
discussed	O	O
.	O	O

.	O	O

Age	O	O
at	O	O
diagnosis	O	O
as	O	O
an	O	O
indicator	O	O
of	O	O
eligibility	O	O
for	O	O
BRCA1	O	O
DNA	O	O
testing	O	O
in	O	O
familial	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

We	O	O
searched	O	O
for	O	O
criteria	O	O
that	O	O
could	O	O
indicate	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
families	O	O
with	O	O
a	O	O
high	O	O
prior	O	O
probability	O	O
of	O	O
being	O	O
caused	O	O
by	O	O
the	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
locus	O	O
BRCA1	O	O
on	O	O
chromosome	O	O
17	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
linkage	O	O
study	O	O
with	O	O
59	O	O
consecutively	O	O
collected	O	O
Dutch	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
families	O	O
,	O	O
including	O	O
16	O	O
with	O	O
at	O	O
least	O	O
one	O	O
case	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

We	O	O
used	O	O
an	O	O
intake	O	O
cut	O	O
-	O	O
off	O	O
of	O	O
at	O	O
least	O	O
three	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
with	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
/	I-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
at	O	O
any	O	O
age	O	O
.	O	O

Significant	O	O
evidence	O	O
for	O	O
linkage	O	O
was	O	O
found	O	O
only	O	O
among	O	O
the	O	O
13	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
families	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
at	O	O
diagnosis	O	O
of	O	O
less	O	O
than	O	O
45	O	O
years	O	O
.	O	O

An	O	O
unexpectedly	O	O
low	O	O
proportion	O	O
of	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
were	O	O
estimated	O	O
to	O	O
be	O	O
linked	O	O
to	O	O
BRCA1	O	O
,	O	O
which	O	O
could	O	O
be	O	O
due	O	O
to	O	O
a	O	O
founder	O	O
effect	O	O
in	O	O
the	O	O
Dutch	O	O
population	O	O
.	O	O

Given	O	O
the	O	O
expected	O	O
logistical	O	O
problems	O	O
in	O	O
clinical	O	O
management	O	O
now	O	O
that	O	O
BRCA1	O	O
has	O	O
been	O	O
identified	O	O
,	O	O
we	O	O
propose	O	O
an	O	O
interim	O	O
period	O	O
in	O	O
which	O	O
only	O	O
families	O	O
with	O	O
a	O	O
strong	O	O
positive	O	O
family	O	O
history	O	O
for	O	O
early	O	O
onset	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
/	I-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
will	O	O
be	O	O
offered	O	O
BRCA1	O	O
mutation	O	O
testing	O	O
.	O	O

.	O	O

Some	O	O
Mexican	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variants	O	O
revisited	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
appears	O	O
to	O	O
be	O	O
fairly	O	O
common	O	O
in	O	O
Mexico	O	O
.	O	O

We	O	O
have	O	O
now	O	O
examined	O	O
the	O	O
DNA	O	O
of	O	O
three	O	O
previously	O	O
reported	O	O
electrophoretically	O	O
fast	O	O
Mexican	O	O
G6PD	O	O
variants	O	O
,	O	O
-	O	O
G6PD	O	O
Distrito	O	O
Federal	O	O
,	O	O
G6PD	O	O
Tepic	O	O
,	O	O
and	O	O
G6PD	O	O
Castilla	O	O
.	O	O

All	O	O
three	O	O
of	O	O
these	O	O
variants	O	O
,	O	O
believed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
biochemical	O	O
characterization	O	O
and	O	O
population	O	O
origin	O	O
to	O	O
be	O	O
unique	O	O
,	O	O
have	O	O
the	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
transition	O	O
at	O	O
nucleotide	O	O
202	O	O
and	O	O
the	O	O
A	O	O
-	O	O
-	O	O
-	O	O
-	O	O
G	O	O
transition	O	O
at	O	O
nucleotide	O	O
376	O	O
,	O	O
mutations	O	O
that	O	O
we	O	O
now	O	O
recognize	O	O
to	O	O
be	O	O
characteristic	O	O
of	O	O
G6PD	O	O
A	O	O
-	O	O
.	O	O

Two	O	O
other	O	O
Mexican	O	O
males	O	O
with	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
same	O	O
mutation	O	O
.	O	O

All	O	O
five	O	O
have	O	O
the	O	O
(	O	O
NlaIII	O	O
/	O	O
FokI	O	O
/	O	O
PvuII	O	O
/	O	O
PstI	O	O
)	O	O
haplotype	O	O
characteristic	O	O
of	O	O
G6PD	O	O
A	O	O
-	O	O
in	O	O
Africa	O	O
.	O	O

Since	O	O
the	O	O
PvuII	O	O
+	O	O
genotype	O	O
seems	O	O
to	O	O
be	O	O
rare	O	O
in	O	O
Europe	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
all	O	O
of	O	O
these	O	O
G6PD	O	O
A	O	O
-	O	O
genes	O	O
had	O	O
their	O	O
ancient	O	O
origin	O	O
in	O	O
Africa	O	O
,	O	O
although	O	O
in	O	O
many	O	O
of	O	O
the	O	O
Mexican	O	O
patients	O	O
with	O	O
G6PD	O	O
A	O	O
-	O	O
202A	O	O
/	O	O
376G	O	O
the	O	O
gene	O	O
may	O	O
have	O	O
been	O	O
imported	O	O
more	O	O
recently	O	O
from	O	O
Spain	O	O
,	O	O
where	O	O
this	O	O
variant	O	O
,	O	O
formerly	O	O
known	O	O
as	O	O
G6PD	O	O
Betica	O	O
,	O	O
is	O	O
also	O	O
prevalent	O	O
.	O	O

.	O	O

Inactivation	O	O
of	O	O
germline	O	O
mutant	O	O
APC	B-Disease	D011125
alleles	O	O
by	O	O
attenuated	O	O
somatic	O	O
mutations	O	O
:	O	O
a	O	O
molecular	O	O
genetic	O	O
mechanism	O	O
for	O	O
attenuated	B-Disease	C538265
familial	I-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
.	O	O

Germline	O	O
mutations	O	O
of	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	I-Disease	D011125
APC	I-Disease	D011125
)	I-Disease	D011125
tumor	I-Disease	D011125
-	O	O
suppressor	O	O
gene	O	O
result	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
.	O	O

Patients	O	O
with	O	O
FAP	B-Disease	D011125
typically	O	O
develop	O	O
hundreds	O	O
to	O	O
thousands	O	O
of	O	O
benign	B-Disease	D015179
colorectal	I-Disease	D015179
tumors	I-Disease	D015179
and	O	O
early	O	O
-	O	O
onset	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

A	O	O
subset	O	O
of	O	O
germline	O	O
APC	B-Disease	D011125
mutations	O	O
results	O	O
in	O	O
an	O	O
attenuated	B-Disease	C538265
FAP	I-Disease	C538265
(	O	O
AFAP	B-Disease	C538265
)	O	O
phenotype	O	O
,	O	O
in	O	O
which	O	O
patients	O	O
develop	O	O
fewer	O	O
tumors	B-Disease	D009369
and	O	O
develop	O	O
them	O	O
at	O	O
an	O	O
older	O	O
age	O	O
.	O	O

Although	O	O
a	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
between	O	O
the	O	O
locations	O	O
of	O	O
APC	B-Disease	D011125
germline	O	O
mutations	O	O
and	O	O
the	O	O
development	O	O
of	O	O
AFAP	B-Disease	C538265
has	O	O
been	O	O
well	O	O
documented	O	O
,	O	O
the	O	O
mechanism	O	O
for	O	O
AFAP	B-Disease	C538265
has	O	O
not	O	O
been	O	O
well	O	O
defined	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
mechanism	O	O
for	O	O
AFAP	B-Disease	C538265
in	O	O
patients	O	O
carrying	O	O
a	O	O
mutant	O	O
APC	B-Disease	D011125
allele	O	O
(	O	O
APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
)	O	O
that	O	O
has	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
alternatively	O	O
spliced	O	O
region	O	O
of	O	O
exon	O	O
9	O	O
.	O	O

APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
was	O	O
found	O	O
to	O	O
down	O	O
-	O	O
regulate	O	O
beta	O	O
-	O	O
catenin	O	O
-	O	O
regulated	O	O
transcription	O	O
,	O	O
the	O	O
major	O	O
tumor	B-Disease	D009369
-	O	O
suppressor	O	O
function	O	O
of	O	O
APC	B-Disease	D011125
,	O	O
as	O	O
did	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
.	O	O

Mutation	O	O
analysis	O	O
showed	O	O
that	O	O
both	O	O
APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
and	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
alleles	O	O
were	O	O
somatically	O	O
mutated	O	O
in	O	O
most	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
from	O	O
these	O	O
patients	O	O
.	O	O

Functional	O	O
analysis	O	O
showed	O	O
that	O	O
4666insA	O	O
,	O	O
a	O	O
common	O	O
somatic	O	O
mutation	O	O
in	O	O
APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
in	O	O
these	O	O
tumors	B-Disease	D009369
,	O	O
did	O	O
not	O	O
inactivate	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
carriers	O	O
of	O	O
APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
develop	O	O
fewer	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
than	O	O
do	O	O
typical	O	O
patients	O	O
with	O	O
FAP	B-Disease	D011125
because	O	O
somatic	O	O
inactivation	O	O
of	O	O
both	O	O
APC	B-Disease	D011125
alleles	O	O
is	O	O
necessary	O	O
for	O	O
colorectal	O	O
tumorigenesis	O	O
.	O	O

However	O	O
,	O	O
these	O	O
patients	O	O
develop	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
more	O	O
frequently	O	O
than	O	O
does	O	O
the	O	O
general	O	O
population	O	O
because	O	O
APC	B-Disease	D011125
(	O	O
AS9	O	O
)	O	O
is	O	O
inactivated	O	O
by	O	O
mutations	O	O
that	O	O
do	O	O
not	O	O
inactivate	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
.	O	O

.	O	O

Submicroscopic	O	O
deletions	O	O
at	O	O
the	O	O
WAGR	B-Disease	D017624
locus	O	O
,	O	O
revealed	O	O
by	O	O
nonradioactive	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

Fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
with	O	O
biotin	O	O
-	O	O
labeled	O	O
probes	O	O
mapping	O	O
to	O	O
11p13	O	O
has	O	O
been	O	O
used	O	O
for	O	O
the	O	O
molecular	O	O
analysis	O	O
of	O	O
deletions	O	O
of	O	O
the	O	O
WAGR	B-Disease	D017624
(	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
,	O	O
aniridia	B-Disease	D015783
,	O	O
genitourinary	B-Disease	D014564
abnormalities	I-Disease	D014564
,	O	O
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
)	O	O
locus	O	O
.	O	O

We	O	O
have	O	O
detected	O	O
a	O	O
submicroscopic	O	O
11p13	O	O
deletion	O	O
in	O	O
a	O	O
child	O	O
with	O	O
inherited	O	O
aniridia	B-Disease	D015783
who	O	O
subsequently	O	O
presented	O	O
with	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
in	O	O
a	O	O
horseshoe	O	O
kidney	O	O
,	O	O
only	O	O
revealed	O	O
at	O	O
surgery	O	O
.	O	O

The	O	O
mother	O	O
,	O	O
who	O	O
has	O	O
aniridia	B-Disease	D015783
,	O	O
was	O	O
also	O	O
found	O	O
to	O	O
carry	O	O
a	O	O
deletion	O	O
including	O	O
both	O	O
the	O	O
aniridia	B-Disease	D015783
candidate	O	O
gene	O	O
(	O	O
AN2	O	O
)	O	O
and	O	O
the	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
predisposition	O	O
gene	O	O
(	O	O
WT1	O	O
)	O	O
.	O	O

This	O	O
is	O	O
therefore	O	O
a	O	O
rare	O	O
case	O	O
of	O	O
an	O	O
inherited	O	O
WAGR	B-Disease	D017624
deletion	O	O
.	O	O

Wilms	B-Disease	D009396
tumor	I-Disease	D009396
has	O	O
so	O	O
far	O	O
only	O	O
been	O	O
associated	O	O
with	O	O
sporadic	O	O
de	O	O
novo	O	O
aniridia	B-Disease	D015783
cases	O	O
.	O	O

We	O	O
have	O	O
shown	O	O
that	O	O
a	O	O
cosmid	O	O
probe	O	O
for	O	O
a	O	O
candidate	O	O
aniridia	B-Disease	D015783
gene	O	O
,	O	O
homologous	O	O
to	O	O
the	O	O
mouse	O	O
Pax	O	O
-	O	O
6	O	O
gene	O	O
,	O	O
is	O	O
deleted	O	O
in	O	O
cell	O	O
lines	O	O
from	O	O
aniridia	B-Disease	D015783
patients	O	O
with	O	O
previously	O	O
characterized	O	O
deletions	O	O
at	O	O
11p13	O	O
,	O	O
while	O	O
another	O	O
cosmid	O	O
marker	O	O
mapping	O	O
between	O	O
two	O	O
aniridia	B-Disease	D015783
-	O	O
associated	O	O
translocation	O	O
breakpoints	O	O
(	O	O
and	O	O
hence	O	O
a	O	O
second	O	O
candidate	O	O
marker	O	O
)	O	O
is	O	O
present	O	O
on	O	O
both	O	O
chromosomes	O	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
Pax	O	O
-	O	O
6	O	O
homologue	O	O
as	O	O
a	O	O
strong	O	O
candidate	O	O
for	O	O
the	O	O
AN2	O	O
gene	O	O
.	O	O

FISH	O	O
with	O	O
cosmid	O	O
probes	O	O
has	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
fast	O	O
and	O	O
reliable	O	O
technique	O	O
for	O	O
the	O	O
molecular	O	O
analysis	O	O
of	O	O
deletions	O	O
.	O	O

It	O	O
can	O	O
be	O	O
used	O	O
with	O	O
limited	O	O
amounts	O	O
of	O	O
material	O	O
and	O	O
has	O	O
strong	O	O
potential	O	O
for	O	O
clinical	O	O
applications	O	O
.	O	O

.	O	O

Haplotype	O	O
studies	O	O
in	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

In	O	O
51	O	O
families	O	O
with	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
,	O	O
we	O	O
have	O	O
studied	O	O
DNA	O	O
haplotypes	O	O
of	O	O
dinucleotide	O	O
repeat	O	O
polymorphisms	O	O
(	O	O
CA	O	O
repeats	O	O
)	O	O
in	O	O
the	O	O
13q14	O	O
.	O	O

3	O	O
region	O	O
,	O	O
to	O	O
examine	O	O
these	O	O
markers	O	O
for	O	O
association	O	O
with	O	O
the	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
gene	O	O
(	O	O
WND	B-Disease	D006527
)	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
a	O	O
marker	O	O
(	O	O
D13S133	O	O
)	O	O
described	O	O
elsewhere	O	O
,	O	O
we	O	O
have	O	O
developed	O	O
three	O	O
new	O	O
highly	O	O
polymorphic	O	O
markers	O	O
(	O	O
D13S314	O	O
,	O	O
D13S315	O	O
,	O	O
and	O	O
D13S316	O	O
)	O	O
close	O	O
to	O	O
the	O	O
WND	B-Disease	D006527
locus	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
distribution	O	O
of	O	O
marker	O	O
alleles	O	O
at	O	O
the	O	O
loci	O	O
studied	O	O
and	O	O
have	O	O
found	O	O
that	O	O
D13S314	O	O
,	O	O
D13S133	O	O
,	O	O
and	O	O
D13S316	O	O
each	O	O
show	O	O
nonrandom	O	O
distribution	O	O
on	O	O
chromosomes	O	O
carrying	O	O
the	O	O
WND	B-Disease	D006527
mutation	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
haplotypes	O	O
of	O	O
these	O	O
three	O	O
markers	O	O
and	O	O
have	O	O
found	O	O
that	O	O
there	O	O
are	O	O
highly	O	O
significant	O	O
differences	O	O
between	O	O
WND	B-Disease	D006527
and	O	O
normal	O	O
haplotypes	O	O
in	O	O
northern	O	O
European	O	O
families	O	O
.	O	O

These	O	O
findings	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
mutation	O	O
detection	O	O
and	O	O
molecular	O	O
diagnosis	O	O
in	O	O
families	O	O
with	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Growth	O	O
hormone	O	O
treatment	O	O
increases	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
response	O	O
,	O	O
ventilation	O	O
and	O	O
central	O	O
inspiratory	O	O
drive	O	O
in	O	O
children	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

We	O	O
studied	O	O
whether	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
growth	O	O
hormone	O	O
(	O	O
GH	O	O
)	O	O
treatment	O	O
on	O	O
growth	O	O
and	O	O
body	O	O
composition	O	O
in	O	O
PWS	B-Disease	D011218
are	O	O
accompanied	O	O
by	O	O
an	O	O
improvement	O	O
in	O	O
respiratory	O	O
function	O	O
.	O	O

We	O	O
measured	O	O
resting	O	O
ventilation	O	O
,	O	O
airway	O	O
occlusion	O	O
pressure	O	O
(	O	O
P	O	O
(	O	O
0	O	O
.	O	O

1	O	O
)	O	O
)	O	O
and	O	O
ventilatory	O	O
response	O	O
to	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
in	O	O
nine	O	O
children	O	O
,	O	O
aged	O	O
7	O	O
-	O	O
14	O	O
years	O	O
,	O	O
before	O	O
and	O	O
6	O	O
-	O	O
9	O	O
months	O	O
after	O	O
the	O	O
start	O	O
of	O	O
GH	O	O
treatment	O	O
.	O	O

During	O	O
GH	O	O
treatment	O	O
,	O	O
resting	O	O
ventilation	O	O
increased	O	O
by	O	O
26	O	O
%	O	O
,	O	O
P	O	O
(	O	O
0	O	O
.	O	O

1	O	O
)	O	O
by	O	O
72	O	O
%	O	O
and	O	O
the	O	O
response	O	O
to	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
by	O	O
65	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

002	O	O
,	O	O
<	O	O
0	O	O
.	O	O

04	O	O
and	O	O
<	O	O
0	O	O
.	O	O

02	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

This	O	O
observed	O	O
increase	O	O
in	O	O
ventilatory	O	O
output	O	O
was	O	O
not	O	O
correlated	O	O
to	O	O
changes	O	O
in	O	O
body	O	O
mass	O	O
index	O	O
.	O	O

CONCLUSION	O	O
Treatment	O	O
of	O	O
children	O	O
with	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
seems	O	O
to	O	O
have	O	O
a	O	O
stimulatory	O	O
effect	O	O
on	O	O
central	O	O
respiratory	O	O
structures	O	O
.	O	O

The	O	O
observed	O	O
increase	O	O
in	O	O
ventilation	O	O
and	O	O
inspiratory	O	O
drive	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
improved	O	O
activity	O	O
level	O	O
reported	O	O
by	O	O
parents	O	O
of	O	O
PWS	B-Disease	D011218
children	O	O
during	O	O
growth	O	O
hormone	O	O
therapy	O	O
Somatic	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
mutation	O	O
in	O	O
clear	O	O
cell	O	O
papillary	B-Disease	D018292
cystadenoma	I-Disease	D018292
of	I-Disease	D018292
the	I-Disease	D018292
epididymis	I-Disease	D018292
.	O	O

Papillary	B-Disease	D018292
cystadenoma	I-Disease	D018292
of	I-Disease	D018292
the	I-Disease	D018292
epididymis	I-Disease	D018292
is	O	O
an	O	O
uncommon	O	O
benign	O	O
lesion	O	O
that	O	O
may	O	O
occur	O	O
sporadically	O	O
or	O	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
disease	O	O
.	O	O

Neither	O	O
immunohistochemical	O	O
studies	O	O
nor	O	O
molecular	O	O
genetic	O	O
analyses	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
have	O	O
been	O	O
reported	O	O
previously	O	O
for	O	O
this	O	O
lesion	O	O
.	O	O

The	O	O
authors	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
clear	O	O
cell	O	O
papillary	B-Disease	D018292
cystadenoma	I-Disease	D018292
of	I-Disease	D018292
the	I-Disease	D018292
epididymis	I-Disease	D018292
,	O	O
both	O	O
of	O	O
which	O	O
were	O	O
initially	O	O
confused	O	O
with	O	O
metastatic	B-Disease	C538445
renal	I-Disease	C538445
cell	I-Disease	C538445
carcinoma	I-Disease	C538445
.	O	O

Both	O	O
lesions	O	O
showed	O	O
positive	O	O
immunohistochemical	O	O
staining	O	O
for	O	O
low	O	O
and	O	O
intermediate	O	O
molecular	O	O
weight	O	O
keratins	O	O
(	O	O
Cam	O	O
5	O	O
.	O	O

2	O	O
and	O	O
AE1	O	O
/	O	O
AE3	O	O
)	O	O
,	O	O
EMA	O	O
,	O	O
vimentin	O	O
,	O	O
alpha	O	O
1	O	O
-	O	O
antitrypsin	O	O
,	O	O
and	O	O
alpha	O	O
1	O	O
-	O	O
antichymotrypsin	O	O
.	O	O

Each	O	O
was	O	O
negative	O	O
for	O	O
CEA	O	O
.	O	O

Because	O	O
clear	O	O
cell	O	O
papillary	B-Disease	D018292
cystadenoma	I-Disease	D018292
is	O	O
similar	O	O
to	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
histologically	O	O
,	O	O
and	O	O
because	O	O
both	O	O
occur	O	O
as	O	O
components	O	O
of	O	O
the	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	O	O
complex	O	O
,	O	O
the	O	O
authors	O	O
analyzed	O	O
both	O	O
cases	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
.	O	O

A	O	O
somatic	O	O
VHL	B-Disease	D006623
gene	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
one	O	O
of	O	O
the	O	O
two	O	O
tumors	B-Disease	D009369
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
followed	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
.	O	O

Direct	O	O
sequencing	O	O
revealed	O	O
a	O	O
cytosine	O	O
to	O	O
thymine	O	O
transition	O	O
at	O	O
nucleotide	O	O
694	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
replacement	O	O
of	O	O
an	O	O
arginine	O	O
with	O	O
a	O	O
stop	O	O
codon	O	O
after	O	O
the	O	O
sixth	O	O
amino	O	O
acid	O	O
of	O	O
exon	O	O
3	O	O
.	O	O

As	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
is	O	O
believed	O	O
to	O	O
function	O	O
as	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
VHL	B-Disease	D006623
gene	O	O
mutations	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
initiation	O	O
of	O	O
tumorigenesis	O	O
in	O	O
sporadic	O	O
cystadenomas	B-Disease	D003537
of	I-Disease	D003537
the	I-Disease	D003537
epididymis	I-Disease	D003537
.	O	O

An	O	O
evaluation	O	O
of	O	O
genetic	O	O
heterogeneity	O	O
in	O	O
145	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

Breast	B-Disease	D001943
Cancer	I-Disease	D001943
Linkage	O	O
Consortium	O	O
.	O	O

The	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovary	I-Disease	D061325
cancer	I-Disease	D061325
-	I-Disease	D061325
family	I-Disease	D061325
syndrome	I-Disease	D061325
is	O	O
a	O	O
dominant	O	O
predisposition	O	O
to	O	O
cancer	B-Disease	D001943
of	I-Disease	D001943
the	I-Disease	D001943
breast	I-Disease	D001943
and	I-Disease	D001943
ovaries	I-Disease	D001943
which	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
chromosome	O	O
region	O	O
17q12	O	O
-	O	O
q21	O	O
.	O	O

The	O	O
majority	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
of	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovary	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
show	O	O
linkage	O	O
to	O	O
this	O	O
susceptibility	O	O
locus	O	O
,	O	O
designated	O	O
BRCA1	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
results	O	O
of	O	O
a	O	O
linkage	O	O
analysis	O	O
of	O	O
145	O	O
families	O	O
with	O	O
both	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

These	O	O
families	O	O
contain	O	O
either	O	O
a	O	O
total	O	O
of	O	O
three	O	O
or	O	O
more	O	O
cases	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
(	O	O
before	O	O
age	O	O
60	O	O
years	O	O
)	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
or	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

All	O	O
families	O	O
contained	O	O
at	O	O
least	O	O
one	O	O
case	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Overall	O	O
,	O	O
an	O	O
estimated	O	O
76	O	O
%	O	O
of	O	O
the	O	O
145	O	O
families	O	O
are	O	O
linked	O	O
to	O	O
the	O	O
BRCA1	O	O
locus	O	O
.	O	O

None	O	O
of	O	O
the	O	O
13	O	O
families	O	O
with	O	O
cases	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
appear	O	O
to	O	O
be	O	O
linked	O	O
,	O	O
but	O	O
it	O	O
is	O	O
estimated	O	O
that	O	O
92	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
76	O	O
%	O	O
-	O	O
100	O	O
%	O	O
)	O	O
of	O	O
families	O	O
with	O	O
no	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
and	O	O
with	O	O
two	O	O
or	O	O
more	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
are	O	O
linked	O	O
to	O	O
BRCA1	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
-	O	O
family	O	O
syndrome	O	O
is	O	O
genetically	O	O
heterogeneous	O	O
.	O	O

However	O	O
,	O	O
the	O	O
large	O	O
majority	O	O
of	O	O
families	O	O
with	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
with	O	O
two	O	O
or	O	O
more	O	O
cases	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
are	O	O
likely	O	O
to	O	O
be	O	O
due	O	O
to	O	O
BRCA1	O	O
mutations	O	O
.	O	O

.	O	O

Genetic	O	O
analysis	O	O
in	O	O
families	O	O
with	O	O
van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
.	O	O

We	O	O
have	O	O
brought	O	O
together	O	O
information	O	O
on	O	O
864	O	O
affected	O	O
individuals	O	O
in	O	O
164	O	O
families	O	O
(	O	O
including	O	O
three	O	O
new	O	O
pedigrees	O	O
)	O	O
reported	O	O
in	O	O
the	O	O
137	O	O
year	O	O
period	O	O
since	O	O
1845	O	O
when	O	O
Demarquay	O	O
first	O	O
described	O	O
a	O	O
family	O	O
with	O	O
what	O	O
was	O	O
later	O	O
called	O	O
van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
(	O	O
VWS	B-Disease	C536528
)	O	O
.	O	O

Both	O	O
types	O	O
of	O	O
oral	B-Disease	D002971
cleft	I-Disease	D002971
,	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
(	O	O
CP	B-Disease	D002972
)	O	O
and	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
with	O	O
or	O	O
without	O	O
CP	B-Disease	D002972
(	O	O
CLP	B-Disease	D002971
)	O	O
,	O	O
segregate	O	O
in	O	O
these	O	O
families	O	O
together	O	O
with	O	O
lower	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
or	O	O
fistulae	B-Disease	D005402
in	O	O
an	O	O
autosomal	O	O
dominant	O	O
mode	O	O
with	O	O
high	O	O
penetrance	O	O
estimated	O	O
to	O	O
be	O	O
K	O	O
=	O	O
.	O	O

89	O	O
and	O	O
.	O	O

99	O	O
by	O	O
different	O	O
methods	O	O
.	O	O

Cleft	O	O
types	O	O
(	O	O
CLP	B-Disease	D002971
and	O	O
CP	B-Disease	D002972
)	O	O
occur	O	O
in	O	O
VWS	B-Disease	C536528
in	O	O
the	O	O
same	O	O
proportions	O	O
as	O	O
in	O	O
the	O	O
general	O	O
non	O	O
-	O	O
VWS	B-Disease	C536528
population	O	O
,	O	O
ie	O	O
,	O	O
about	O	O
twice	O	O
as	O	O
many	O	O
cleft	O	O
-	O	O
bearing	O	O
individuals	O	O
have	O	O
CLP	B-Disease	D002971
as	O	O
have	O	O
CP	B-Disease	D002972
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
we	O	O
do	O	O
not	O	O
find	O	O
the	O	O
usually	O	O
observed	O	O
excess	O	O
of	O	O
females	O	O
with	O	O
CP	B-Disease	D002972
and	O	O
excess	O	O
of	O	O
males	O	O
with	O	O
CLP	B-Disease	D002971
;	O	O
in	O	O
VWS	B-Disease	C536528
the	O	O
sex	O	O
ratios	O	O
are	O	O
more	O	O
nearly	O	O
equal	O	O
.	O	O

Lip	B-Disease	C536528
pits	I-Disease	C536528
also	O	O
are	O	O
equally	O	O
distributed	O	O
between	O	O
the	O	O
sexes	O	O
.	O	O

Affected	O	O
males	O	O
and	O	O
females	O	O
are	O	O
equally	O	O
likely	O	O
to	O	O
transmit	O	O
VWS	B-Disease	C536528
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
an	O	O
excess	O	O
of	O	O
less	O	O
severely	O	O
affected	O	O
individuals	O	O
among	O	O
transmitters	O	O
and	O	O
a	O	O
deficiency	O	O
of	O	O
more	O	O
severely	O	O
affected	O	O
,	O	O
brought	O	O
about	O	O
by	O	O
a	O	O
proband	O	O
bias	O	O
and	O	O
differential	O	O
fecundity	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
VWS	B-Disease	C536528
is	O	O
significantly	O	O
modified	O	O
by	O	O
the	O	O
genetic	O	O
background	O	O
More	O	O
extreme	O	O
phenotypes	O	O
in	O	O
parents	O	O
tend	O	O
to	O	O
produce	O	O
more	O	O
extreme	O	O
expression	O	O
in	O	O
their	O	O
children	O	O
.	O	O

For	O	O
a	O	O
VWS	B-Disease	C536528
gene	O	O
carrier	O	O
the	O	O
relative	O	O
risk	O	O
of	O	O
transmitting	O	O
a	O	O
cleft	O	O
is	O	O
26	O	O
.	O	O

45	O	O
%	O	O
;	O	O
that	O	O
of	O	O
transmitting	O	O
lower	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
is	O	O
23	O	O
.	O	O

55	O	O
%	O	O
.	O	O

Three	O	O
pedigrees	O	O
of	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
in	O	O
the	O	O
literature	O	O
show	O	O
no	O	O
clefts	O	O
among	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
affected	O	O
individuals	O	O
.	O	O

Control	O	O
of	O	O
gene	O	O
expression	O	O
in	O	O
VWS	B-Disease	C536528
in	O	O
the	O	O
three	O	O
target	O	O
tissues	O	O
appears	O	O
to	O	O
be	O	O
independent	O	O
and	O	O
separately	O	O
designated	O	O
.	O	O

Mutation	O	O
rate	O	O
of	O	O
the	O	O
VWS	B-Disease	C536528
gene	O	O
is	O	O
calculated	O	O
to	O	O
be	O	O
1	O	O
.	O	O

8	O	O
X	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
Molecular	O	O
and	O	O
phenotypic	O	O
analysis	O	O
of	O	O
patients	O	O
with	O	O
deletions	O	O
within	O	O
the	O	O
deletion	O	O
-	O	O
rich	O	O
region	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
.	O	O

Eighty	O	O
unrelated	O	O
individuals	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
or	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
(	O	O
BMD	B-Disease	C537666
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
deletions	O	O
in	O	O
the	O	O
major	O	O
deletion	O	O
-	O	O
rich	O	O
region	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
.	O	O

This	O	O
region	O	O
includes	O	O
the	O	O
last	O	O
five	O	O
exons	O	O
detected	O	O
by	O	O
cDNA5b	O	O
-	O	O
7	O	O
,	O	O
all	O	O
exons	O	O
detected	O	O
by	O	O
cDNA8	O	O
,	O	O
and	O	O
the	O	O
first	O	O
two	O	O
exons	O	O
detected	O	O
by	O	O
cDNA9	O	O
.	O	O

These	O	O
80	O	O
individuals	O	O
account	O	O
for	O	O
approximately	O	O
75	O	O
%	O	O
of	O	O
109	O	O
deletions	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
detected	O	O
among	O	O
181	O	O
patients	O	O
analyzed	O	O
with	O	O
the	O	O
entire	O	O
dystrophin	O	O
cDNA	O	O
.	O	O

Endpoints	O	O
for	O	O
many	O	O
of	O	O
these	O	O
deletions	O	O
were	O	O
further	O	O
characterized	O	O
using	O	O
two	O	O
genomic	O	O
probes	O	O
,	O	O
p20	O	O
(	O	O
DXS269	O	O
;	O	O
Wapenaar	O	O
et	O	O
al	O	O
.	O	O

)	O	O
and	O	O
GMGX11	O	O
(	O	O
DXS239	O	O
;	O	O
present	O	O
paper	O	O
)	O	O
.	O	O

Clinical	O	O
findings	O	O
are	O	O
presented	O	O
for	O	O
all	O	O
80	O	O
patients	O	O
allowing	O	O
a	O	O
correlation	O	O
of	O	O
phenotypic	O	O
severity	O	O
with	O	O
the	O	O
genotype	O	O
.	O	O

Thirty	O	O
-	O	O
eight	O	O
independent	O	O
patients	O	O
were	O	O
old	O	O
enough	O	O
to	O	O
be	O	O
classified	O	O
as	O	O
DMD	B-Disease	D020388
,	O	O
BMD	B-Disease	C537666
,	O	O
or	O	O
intermediate	O	O
phenotype	O	O
and	O	O
had	O	O
deletions	O	O
of	O	O
exons	O	O
with	O	O
sequenced	O	O
intron	O	O
/	O	O
exon	O	O
boundaries	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
eight	O	O
BMD	B-Disease	C537666
patients	O	O
and	O	O
one	O	O
intermediate	O	O
patient	O	O
had	O	O
gene	O	O
deletions	O	O
predicted	O	O
to	O	O
leave	O	O
the	O	O
reading	O	O
frame	O	O
intact	O	O
,	O	O
while	O	O
21	O	O
DMD	B-Disease	D020388
patients	O	O
,	O	O
7	O	O
intermediate	O	O
patients	O	O
,	O	O
and	O	O
1	O	O
BMD	B-Disease	C537666
patient	O	O
had	O	O
gene	O	O
deletions	O	O
predicted	O	O
to	O	O
disrupt	O	O
the	O	O
reading	O	O
frame	O	O
.	O	O

Thus	O	O
,	O	O
with	O	O
two	O	O
exceptions	O	O
,	O	O
frameshift	O	O
deletions	O	O
of	O	O
the	O	O
gene	O	O
resulted	O	O
in	O	O
more	O	O
severe	O	O
phenotype	O	O
than	O	O
did	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
.	O	O

This	O	O
is	O	O
in	O	O
agreement	O	O
with	O	O
recent	O	O
findings	O	O
by	O	O
Baumbach	O	O
et	O	O
al	O	O
.	O	O

and	O	O
Koenig	O	O
et	O	O
al	O	O
.	O	O

but	O	O
is	O	O
in	O	O
contrast	O	O
to	O	O
findings	O	O
,	O	O
by	O	O
Malhotra	O	O
et	O	O
al	O	O
.	O	O

at	O	O
the	O	O
5	O	O
'	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Proteolipoprotein	O	O
gene	O	O
analysis	O	O
in	O	O
82	O	O
patients	O	O
with	O	O
sporadic	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
Disease	I-Disease	OMIM:312080
:	O	O
duplications	O	O
,	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
originate	O	O
more	O	O
frequently	O	O
in	O	O
male	O	O
germ	O	O
cells	O	O
,	O	O
but	O	O
point	O	O
mutations	O	O
do	O	O
not	O	O
.	O	O

The	O	O
Clinical	O	O
European	O	O
Network	O	O
on	O	O
Brain	B-Disease	D020279
Dysmyelinating	I-Disease	D020279
Disease	I-Disease	D020279
.	O	O

Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
Disease	I-Disease	OMIM:312080
(	O	O
PMD	B-Disease	D020371
)	O	O
is	O	O
an	O	O
X	B-Disease	D020279
-	I-Disease	D020279
linked	I-Disease	D020279
developmental	I-Disease	D020279
defect	I-Disease	D020279
of	I-Disease	D020279
myelination	I-Disease	D020279
affecting	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
and	O	O
segregating	O	O
with	O	O
the	O	O
proteolipoprotein	O	O
(	O	O
PLP	O	O
)	O	O
locus	O	O
.	O	O

Investigating	O	O
82	O	O
strictly	O	O
selected	O	O
sporadic	O	O
cases	O	O
of	O	O
PMD	B-Disease	D020371
,	O	O
we	O	O
found	O	O
PLP	O	O
mutations	O	O
in	O	O
77	O	O
%	O	O
;	O	O
complete	O	O
PLP	O	O
-	O	O
gene	O	O
duplications	O	O
were	O	O
the	O	O
most	O	O
frequent	O	O
abnormality	O	O
(	O	O
62	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
point	O	O
mutations	O	O
in	O	O
coding	O	O
or	O	O
splice	O	O
-	O	O
site	O	O
regions	O	O
of	O	O
the	O	O
gene	O	O
were	O	O
involved	O	O
less	O	O
frequently	O	O
(	O	O
38	O	O
%	O	O
)	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
maternal	O	O
status	O	O
of	O	O
56	O	O
cases	O	O
to	O	O
determine	O	O
the	O	O
origin	O	O
of	O	O
both	O	O
types	O	O
of	O	O
PLP	O	O
mutation	O	O
,	O	O
since	O	O
this	O	O
is	O	O
relevant	O	O
to	O	O
genetic	O	O
counseling	O	O
.	O	O

In	O	O
the	O	O
22	O	O
point	O	O
mutations	O	O
,	O	O
68	O	O
%	O	O
of	O	O
mothers	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
mutation	O	O
,	O	O
a	O	O
value	O	O
identical	O	O
to	O	O
the	O	O
two	O	O
-	O	O
thirds	O	O
of	O	O
carrier	O	O
mothers	O	O
that	O	O
would	O	O
be	O	O
expected	O	O
if	O	O
there	O	O
were	O	O
an	O	O
equal	O	O
mutation	O	O
rate	O	O
in	O	O
male	O	O
and	O	O
female	O	O
germ	O	O
cells	O	O
.	O	O

In	O	O
sharp	O	O
contrast	O	O
,	O	O
among	O	O
the	O	O
34	O	O
duplicated	O	O
cases	O	O
,	O	O
91	O	O
%	O	O
of	O	O
mothers	O	O
were	O	O
carriers	O	O
,	O	O
a	O	O
value	O	O
significantly	O	O
(	O	O
chi2	O	O
=	O	O
9	O	O
.	O	O

20	O	O
,	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
in	O	O
favor	O	O
of	O	O
a	O	O
male	O	O
bias	O	O
,	O	O
with	O	O
an	O	O
estimation	O	O
of	O	O
the	O	O
male	O	O
/	O	O
female	O	O
mutation	O	O
frequency	O	O
(	O	O
k	O	O
)	O	O
of	O	O
9	O	O
.	O	O

3	O	O
3	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
observed	O	O
the	O	O
occurrence	O	O
of	O	O
de	O	O
novo	O	O
mutations	O	O
between	O	O
parental	O	O
and	O	O
grandparental	O	O
generations	O	O
in	O	O
17	O	O
three	O	O
-	O	O
generation	O	O
families	O	O
,	O	O
which	O	O
allowed	O	O
a	O	O
direct	O	O
estimation	O	O
of	O	O
the	O	O
k	O	O
value	O	O
(	O	O
k	O	O
=	O	O
11	O	O
)	O	O
.	O	O

Again	O	O
,	O	O
a	O	O
significant	O	O
male	O	O
mutation	O	O
imbalance	O	O
was	O	O
observed	O	O
only	O	O
for	O	O
the	O	O
duplications	O	O
.	O	O

Haplotype	O	O
analysis	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
in	O	O
Turkish	O	O
phenylketonuria	B-Disease	D010661
families	O	O
.	O	O

We	O	O
have	O	O
estimated	O	O
the	O	O
haplotype	O	O
distribution	O	O
of	O	O
mutant	O	O
and	O	O
normal	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
alleles	O	O
for	O	O
17	O	O
Turkish	O	O
phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
families	O	O
20	O	O
normal	O	O
and	O	O
27	O	O
mutated	O	O
PAH	O	O
alleles	O	O
could	O	O
be	O	O
identified	O	O
.	O	O

Of	O	O
the	O	O
latter	O	O
,	O	O
the	O	O
most	O	O
prevalent	O	O
were	O	O
associated	O	O
with	O	O
haplotype	O	O
6	O	O
(	O	O
29	O	O
.	O	O

6	O	O
%	O	O
)	O	O
,	O	O
1	O	O
(	O	O
18	O	O
.	O	O

5	O	O
%	O	O
)	O	O
and	O	O
36	O	O
(	O	O
11	O	O
.	O	O

1	O	O
%	O	O
)	O	O
,	O	O
while	O	O
the	O	O
normal	O	O
alleles	O	O
were	O	O
preferentially	O	O
associated	O	O
with	O	O
haplotype	O	O
1	O	O
(	O	O
20	O	O
%	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
19	O	O
different	O	O
haplotypes	O	O
observed	O	O
,	O	O
5	O	O
have	O	O
not	O	O
been	O	O
described	O	O
previously	O	O
.	O	O

The	O	O
haplotype	O	O
distribution	O	O
differed	O	O
significantly	O	O
from	O	O
that	O	O
of	O	O
the	O	O
Northern	O	O
European	O	O
population	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
eight	O	O
polymorphic	O	O
sites	O	O
were	O	O
in	O	O
association	O	O
with	O	O
PKU	B-Disease	D010661
.	O	O

No	O	O
deletions	O	O
of	O	O
exon	O	O
sequences	O	O
were	O	O
found	O	O
in	O	O
the	O	O
families	O	O
analysed	O	O
.	O	O

Cloning	O	O
of	O	O
human	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
coenzyme	O	O
A	O	O
dehydrogenase	O	O
and	O	O
molecular	O	O
characterization	O	O
of	O	O
its	O	O
deficiency	O	O
in	O	O
two	O	O
patients	O	O
.	O	O

Two	O	O
overlapping	O	O
cDNA	O	O
clones	O	O
(	O	O
1	O	O
,	O	O
991	O	O
bp	O	O
and	O	O
736	O	O
bp	O	O
,	O	O
respectively	O	O
)	O	O
encoding	O	O
the	O	O
precursor	O	O
of	O	O
human	O	O
mitochondrial	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
coenzyme	O	O
A	O	O
dehydrogenase	O	O
(	O	O
VLCAD	O	O
)	O	O
were	O	O
cloned	O	O
and	O	O
sequenced	O	O
.	O	O

The	O	O
cDNA	O	O
inserts	O	O
of	O	O
these	O	O
clones	O	O
together	O	O
encompass	O	O
a	O	O
region	O	O
of	O	O
2	O	O
,	O	O
177	O	O
bases	O	O
,	O	O
encoding	O	O
the	O	O
entire	O	O
protein	O	O
of	O	O
655	O	O
amino	O	O
acids	O	O
,	O	O
including	O	O
a	O	O
40	O	O
-	O	O
amino	O	O
acid	O	O
leader	O	O
peptide	O	O
and	O	O
a	O	O
615	O	O
-	O	O
amino	O	O
acid	O	O
mature	O	O
polypeptide	O	O
.	O	O

PCR	O	O
-	O	O
amplified	O	O
VLCAD	O	O
cDNAs	O	O
were	O	O
sequenced	O	O
in	O	O
cultured	O	O
fibroblasts	O	O
from	O	O
two	O	O
VLCAD	B-Disease	C536353
-	I-Disease	C536353
deficient	I-Disease	C536353
patients	O	O
.	O	O

In	O	O
both	O	O
patients	O	O
,	O	O
a	O	O
105	O	O
-	O	O
bp	O	O
deletion	O	O
encompassing	O	O
bases	O	O
1078	O	O
-	O	O
1182	O	O
in	O	O
VLCAD	O	O
cDNA	O	O
was	O	O
identified	O	O
.	O	O

The	O	O
deletion	O	O
seems	O	O
to	O	O
occur	O	O
due	O	O
to	O	O
exon	O	O
skipping	O	O
during	O	O
processing	O	O
of	O	O
VLCAD	O	O
pre	O	O
-	O	O
mRNA	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
demonstration	O	O
of	O	O
a	O	O
mutation	O	O
causing	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
.	O	O

Quantitative	O	O
cDNA	O	O
expression	O	O
of	O	O
normal	O	O
human	O	O
VLCAD	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
patients	O	O
fibroblasts	O	O
,	O	O
using	O	O
vaccinia	O	O
viral	O	O
system	O	O
,	O	O
which	O	O
demonstrated	O	O
that	O	O
the	O	O
deficiency	B-Disease	C536353
of	I-Disease	C536353
the	I-Disease	C536353
normal	I-Disease	C536353
VLCAD	I-Disease	C536353
protein	I-Disease	C536353
causes	O	O
impaired	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acid	O	O
beta	O	O
-	O	O
oxidation	O	O
activity	O	O
in	O	O
the	O	O
patients	O	O
fibroblasts	O	O
.	O	O

In	O	O
patient	O	O
fibroblasts	O	O
,	O	O
raising	O	O
VLCAD	O	O
activity	O	O
to	O	O
approximately	O	O
20	O	O
%	O	O
of	O	O
normal	O	O
control	O	O
fibroblast	O	O
activity	O	O
raised	O	O
palmitic	O	O
acid	O	O
beta	O	O
-	O	O
oxidation	O	O
flux	O	O
to	O	O
the	O	O
level	O	O
found	O	O
in	O	O
control	O	O
fibroblasts	O	O
,	O	O
which	O	O
may	O	O
offer	O	O
important	O	O
information	O	O
for	O	O
the	O	O
rational	O	O
design	O	O
of	O	O
future	O	O
somatic	O	O
gene	O	O
therapy	O	O
for	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
.	O	O

.	O	O

Mutations	O	O
in	O	O
the	O	O
RB1	O	O
gene	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
transcription	O	O
.	O	O

Inactivation	O	O
of	O	O
both	O	O
alleles	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
during	O	O
normal	O	O
retinal	O	O
development	O	O
initiates	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
retinoblastoma	B-Disease	D012175
(	I-Disease	D012175
RB	I-Disease	D012175
)	I-Disease	D012175
tumor	I-Disease	D012175
.	O	O

To	O	O
identify	O	O
the	O	O
mutations	O	O
which	O	O
inactivate	O	O
RB1	O	O
,	O	O
21	O	O
RB	B-Disease	D012175
tumors	I-Disease	D012175
isolated	O	O
from	O	O
19	O	O
patients	O	O
were	O	O
analyzed	O	O
with	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
or	O	O
an	O	O
RNase	O	O
protection	O	O
assay	O	O
or	O	O
both	O	O
.	O	O

Mutations	O	O
were	O	O
identified	O	O
in	O	O
13	O	O
of	O	O
21	O	O
RB	B-Disease	D012175
tumors	I-Disease	D012175
;	O	O
in	O	O
8	O	O
tumors	B-Disease	D009369
,	O	O
the	O	O
precise	O	O
errors	O	O
in	O	O
nucleotide	O	O
sequence	O	O
were	O	O
characterized	O	O
.	O	O

Each	O	O
of	O	O
four	O	O
germ	O	O
line	O	O
mutations	O	O
involved	O	O
a	O	O
small	O	O
deletion	O	O
or	O	O
duplication	O	O
,	O	O
while	O	O
three	O	O
somatic	O	O
mutations	O	O
were	O	O
point	O	O
mutations	O	O
leading	O	O
to	O	O
splice	O	O
alterations	O	O
and	O	O
loss	O	O
of	O	O
an	O	O
exon	O	O
from	O	O
the	O	O
mature	O	O
RB1	O	O
mRNA	O	O
.	O	O

We	O	O
were	O	O
unable	O	O
to	O	O
detect	O	O
expression	O	O
of	O	O
the	O	O
mutant	O	O
allele	O	O
in	O	O
lymphoblasts	O	O
of	O	O
three	O	O
bilaterally	O	O
affected	O	O
patients	O	O
,	O	O
although	O	O
the	O	O
mutation	O	O
was	O	O
present	O	O
in	O	O
the	O	O
genomic	O	O
DNA	O	O
and	O	O
transcripts	O	O
containing	O	O
the	O	O
mutations	O	O
were	O	O
obvious	O	O
in	O	O
the	O	O
RB	B-Disease	D012175
tumors	I-Disease	D012175
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
normal	O	O
RB1	O	O
allele	O	O
.	O	O

The	O	O
variations	O	O
in	O	O
the	O	O
level	O	O
of	O	O
expression	O	O
of	O	O
mutant	O	O
transcripts	O	O
suggest	O	O
deregulation	O	O
of	O	O
RB1	O	O
transcription	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
functional	O	O
RB1	O	O
gene	O	O
product	O	O
.	O	O

.	O	O

Resolution	O	O
of	O	O
the	O	O
two	O	O
loci	O	O
for	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
,	O	O
AN1	O	O
and	O	O
AN2	O	O
,	O	O
to	O	O
a	O	O
single	O	O
locus	O	O
on	O	O
chromosome	O	O
11p13	O	O
.	O	O

Two	O	O
distinct	O	O
loci	O	O
have	O	O
been	O	O
proposed	O	O
for	O	O
aniridia	B-Disease	D015783
;	O	O
AN1	O	O
for	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
on	O	O
chromosome	O	O
2p	O	O
and	O	O
AN2	O	O
for	O	O
the	O	O
aniridia	B-Disease	D015783
in	O	O
the	O	O
WAGR	B-Disease	D017624
contiguous	I-Disease	D017624
gene	I-Disease	D017624
syndrome	I-Disease	D017624
on	O	O
chromosome	O	O
11p13	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
the	O	O
kindred	O	O
segregating	O	O
for	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
,	O	O
which	O	O
suggested	O	O
linkage	O	O
to	O	O
acid	O	O
phosphatase	O	O
-	O	O
1	O	O
(	O	O
ACP1	O	O
)	O	O
and	O	O
led	O	O
to	O	O
the	O	O
assignment	O	O
of	O	O
the	O	O
AN1	O	O
locus	O	O
on	O	O
chromosome	O	O
2p	O	O
,	O	O
has	O	O
been	O	O
updated	O	O
and	O	O
expanded	O	O
.	O	O

Linkage	O	O
analysis	O	O
between	O	O
the	O	O
aniridia	B-Disease	D015783
phenotype	O	O
and	O	O
ACP1	O	O
does	O	O
not	O	O
support	O	O
the	O	O
original	O	O
linkage	O	O
results	O	O
,	O	O
excluding	O	O
linkage	O	O
up	O	O
to	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

17	O	O
with	O	O
Z	O	O
=	O	O
-	O	O
2	O	O
.	O	O

Tests	O	O
for	O	O
linkage	O	O
to	O	O
other	O	O
chromosome	O	O
2p	O	O
markers	O	O
.	O	O

APOB	O	O
,	O	O
D2S71	O	O
,	O	O
D2S5	O	O
,	O	O
and	O	O
D2S1	O	O
,	O	O
also	O	O
excluded	O	O
linkage	O	O
to	O	O
aniridia	B-Disease	D015783
.	O	O

Markers	O	O
that	O	O
have	O	O
been	O	O
isolated	O	O
from	O	O
the	O	O
chromosome	O	O
11p13	O	O
region	O	O
were	O	O
then	O	O
analyzed	O	O
in	O	O
this	O	O
aniridia	B-Disease	D015783
family	O	O
.	O	O

Two	O	O
RFLPs	O	O
at	O	O
the	O	O
D11S323	O	O
locus	O	O
give	O	O
significant	O	O
evidence	O	O
for	O	O
linkage	O	O
.	O	O

The	O	O
PvuII	O	O
polymorphism	O	O
detected	O	O
by	O	O
probe	O	O
p5S1	O	O
.	O	O

6	O	O
detects	O	O
no	O	O
recombinants	O	O
,	O	O
with	O	O
a	O	O
maximum	O	O
lod	O	O
score	O	O
of	O	O
Z	O	O
=	O	O
6	O	O
.	O	O

97	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
00	O	O
.	O	O

The	O	O
HaeIII	O	O
polymorphism	O	O
detected	O	O
by	O	O
the	O	O
probe	O	O
p5BE1	O	O
.	O	O

2	O	O
gives	O	O
a	O	O
maximum	O	O
lod	O	O
score	O	O
of	O	O
Z	O	O
=	O	O
2	O	O
.	O	O

57	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
00	O	O
.	O	O

Locus	O	O
D11S325	O	O
gives	O	O
a	O	O
lod	O	O
score	O	O
of	O	O
Z	O	O
=	O	O
1	O	O
.	O	O

53	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
00	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
a	O	O
locus	O	O
for	O	O
aniridia	B-Disease	D015783
(	O	O
AN1	O	O
)	O	O
on	O	O
chromosome	O	O
2p	O	O
has	O	O
been	O	O
misassigned	O	O
and	O	O
that	O	O
this	O	O
autosomal	O	O
dominant	O	O
aniridia	B-Disease	D015783
family	O	O
is	O	O
segregating	O	O
for	O	O
an	O	O
aniridia	B-Disease	D015783
mutation	O	O
linked	O	O
to	O	O
markers	O	O
in	O	O
the	O	O
11p13	O	O
region	O	O
.	O	O

GT	O	O
to	O	O
AT	O	O
transition	O	O
at	O	O
a	O	O
splice	O	O
donor	O	O
site	O	O
causes	O	O
skipping	O	O
of	O	O
the	O	O
preceding	O	O
exon	O	O
in	O	O
phenylketonuria	B-Disease	D010661
.	O	O

Classical	B-Disease	D010661
Phenylketonuria	I-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
human	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

We	O	O
isolated	O	O
several	O	O
mutant	O	O
PAH	O	O
cDNA	O	O
clones	O	O
from	O	O
a	O	O
PKU	B-Disease	D010661
carrier	O	O
individual	O	O
and	O	O
showed	O	O
that	O	O
they	O	O
contained	O	O
an	O	O
internal	O	O
116	O	O
base	O	O
pair	O	O
deletion	O	O
,	O	O
corresponding	O	O
precisely	O	O
to	O	O
exon	O	O
12	O	O
of	O	O
the	O	O
human	O	O
chromosomal	O	O
PAH	O	O
gene	O	O
.	O	O

The	O	O
deletion	O	O
causes	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
truncated	O	O
protein	O	O
lacking	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
52	O	O
amino	O	O
acids	O	O
.	O	O

Gene	O	O
transfer	O	O
and	O	O
expression	O	O
studies	O	O
using	O	O
the	O	O
mutant	O	O
PAH	O	O
cDNA	O	O
indicated	O	O
that	O	O
the	O	O
deletion	O	O
abolishes	O	O
PAH	O	O
activity	O	O
in	O	O
the	O	O
cell	O	O
as	O	O
a	O	O
result	O	O
of	O	O
protein	O	O
instability	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
the	O	O
deletion	O	O
,	O	O
the	O	O
mutant	O	O
chromosomal	O	O
PAH	O	O
gene	O	O
was	O	O
isolated	O	O
from	O	O
this	O	O
individual	O	O
and	O	O
shown	O	O
to	O	O
contain	O	O
a	O	O
GT	O	O
-	O	O
-	O	O
greater	O	O
than	O	O
AT	O	O
substitution	O	O
at	O	O
the	O	O
5	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
12	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
consequence	O	O
of	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
mutation	O	O
in	O	O
the	O	O
human	O	O
liver	O	O
is	O	O
the	O	O
skipping	O	O
of	O	O
the	O	O
preceding	O	O
exon	O	O
during	O	O
RNA	O	O
splicing	O	O
.	O	O

.	O	O

Clinical	O	O
and	O	O
molecular	O	O
genetic	O	O
analysis	O	O
of	O	O
19	O	O
Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
kindreds	O	O
demonstrating	O	O
a	O	O
wide	O	O
spectrum	O	O
of	O	O
mutations	O	O
in	O	O
WFS1	O	O
.	O	O

Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
is	O	O
an	O	O
autosomal	B-Disease	D020271
recessive	I-Disease	D020271
neurodegenerative	I-Disease	D020271
disorder	I-Disease	D020271
characterized	O	O
by	O	O
juvenile	B-Disease	D003922
-	I-Disease	D003922
onset	I-Disease	D003922
diabetes	I-Disease	D003922
mellitus	I-Disease	D003922
and	O	O
progressive	O	O
optic	B-Disease	D009896
atrophy	I-Disease	D009896
.	O	O

mtDNA	O	O
deletions	O	O
have	O	O
been	O	O
described	O	O
,	O	O
and	O	O
a	O	O
gene	O	O
(	O	O
WFS1	O	O
)	O	O
recently	O	O
has	O	O
been	O	O
identified	O	O
,	O	O
on	O	O
chromosome	O	O
4p16	O	O
,	O	O
encoding	O	O
a	O	O
predicted	O	O
890	O	O
amino	O	O
acid	O	O
transmembrane	O	O
protein	O	O
.	O	O

Direct	O	O
DNA	O	O
sequencing	O	O
was	O	O
done	O	O
to	O	O
screen	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
WFS1	O	O
gene	O	O
in	O	O
30	O	O
patients	O	O
from	O	O
19	O	O
British	O	O
kindreds	O	O
with	O	O
Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
.	O	O

DNA	O	O
was	O	O
also	O	O
screened	O	O
for	O	O
structural	O	O
rearrangements	O	O
(	O	O
deletions	O	O
and	O	O
duplications	O	O
)	O	O
and	O	O
point	O	O
mutations	O	O
in	O	O
mtDNA	O	O
.	O	O

No	O	O
pathogenic	O	O
mtDNA	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
our	O	O
cohort	O	O
.	O	O

We	O	O
identified	O	O
24	O	O
mutations	O	O
in	O	O
the	O	O
WFS1	O	O
gene	O	O
8	O	O
nonsense	O	O
mutations	O	O
,	O	O
8	O	O
missense	O	O
mutations	O	O
,	O	O
3	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
,	O	O
1	O	O
in	O	O
-	O	O
frame	O	O
insertion	O	O
,	O	O
and	O	O
4	O	O
frameshift	O	O
mutations	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
23	O	O
were	O	O
novel	O	O
mutations	O	O
,	O	O
and	O	O
most	O	O
occurred	O	O
in	O	O
exon	O	O
8	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
patients	O	O
were	O	O
compound	O	O
heterozygotes	O	O
for	O	O
two	O	O
mutations	O	O
,	O	O
and	O	O
there	O	O
was	O	O
no	O	O
common	O	O
founder	O	O
mutation	O	O
.	O	O

The	O	O
data	O	O
were	O	O
also	O	O
analyzed	O	O
for	O	O
genotype	O	O
-	O	O
phenotype	O	O
relationships	O	O
.	O	O

Although	O	O
some	O	O
interesting	O	O
cases	O	O
were	O	O
noted	O	O
,	O	O
consideration	O	O
of	O	O
the	O	O
small	O	O
sample	O	O
size	O	O
and	O	O
frequency	O	O
of	O	O
each	O	O
mutation	O	O
indicated	O	O
no	O	O
clear	O	O
-	O	O
cut	O	O
correlations	O	O
between	O	O
any	O	O
of	O	O
the	O	O
observed	O	O
mutations	O	O
and	O	O
disease	O	O
severity	O	O
.	O	O

There	O	O
were	O	O
no	O	O
obvious	O	O
mutation	O	O
hot	O	O
spots	O	O
or	O	O
clusters	O	O
.	O	O

Hence	O	O
,	O	O
molecular	O	O
screening	O	O
for	O	O
Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
in	O	O
affected	O	O
families	O	O
and	O	O
for	O	O
Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
-	O	O
carrier	O	O
status	O	O
in	O	O
subjects	O	O
with	O	O
psychiatric	B-Disease	D001523
disorders	I-Disease	D001523
or	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
will	O	O
require	O	O
complete	O	O
analysis	O	O
of	O	O
exon	O	O
8	O	O
and	O	O
upstream	O	O
exons	O	O
.	O	O

.	O	O

Maternal	B-Disease	D024182
uniparental	I-Disease	D024182
disomy	I-Disease	D024182
for	I-Disease	D024182
chromosome	I-Disease	D024182
14	I-Disease	D024182
in	O	O
a	O	O
boy	O	O
with	O	O
a	O	O
normal	O	O
karyotype	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
boy	O	O
with	O	O
a	O	O
maternal	B-Disease	D024182
uniparental	I-Disease	D024182
disomy	I-Disease	D024182
for	I-Disease	D024182
chromosome	I-Disease	D024182
14	I-Disease	D024182
(	O	O
UPD	B-Disease	D024182
(	O	O
14	O	O
)	O	O
)	O	O
.	O	O

At	O	O
7	O	O
years	O	O
of	O	O
age	O	O
he	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
by	O	O
the	O	O
paediatrician	O	O
because	O	O
of	O	O
symptoms	O	O
of	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

He	O	O
showed	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
,	O	O
obesity	B-Disease	D009765
,	O	O
mild	O	O
developmental	B-Disease	D002658
delay	I-Disease	D002658
,	O	O
cryptorchidism	B-Disease	D003456
,	O	O
and	O	O
some	O	O
mild	O	O
dysmorphic	B-Disease	D000013
features	I-Disease	D000013
.	O	O

The	O	O
history	O	O
further	O	O
indicated	O	O
intrauterine	B-Disease	D005317
growth	I-Disease	D005317
retardation	I-Disease	D005317
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
pregnancy	O	O
.	O	O

His	O	O
mother	O	O
was	O	O
44	O	O
years	O	O
of	O	O
age	O	O
at	O	O
the	O	O
time	O	O
of	O	O
his	O	O
birth	O	O
.	O	O

After	O	O
birth	O	O
he	O	O
showed	O	O
hypotonia	B-Disease	D009123
with	O	O
poor	O	O
sucking	O	O
,	O	O
for	O	O
which	O	O
gavage	O	O
feeding	O	O
was	O	O
needed	O	O
.	O	O

Motor	O	O
development	O	O
was	O	O
delayed	O	O
.	O	O

After	O	O
1	O	O
year	O	O
he	O	O
became	O	O
obese	B-Disease	D009765
despite	O	O
a	O	O
normal	O	O
appetite	O	O
.	O	O

Recurrent	O	O
middle	B-Disease	D010033
ear	I-Disease	D010033
infections	I-Disease	D010033
,	O	O
a	O	O
high	O	O
pain	O	O
threshold	O	O
,	O	O
and	O	O
a	O	O
great	O	O
skill	O	O
with	O	O
jigsaw	O	O
puzzles	O	O
were	O	O
reported	O	O
.	O	O

There	O	O
were	O	O
no	O	O
behavioural	O	O
problems	O	O
or	O	O
sleep	O	O
disturbance	O	O
.	O	O

Chromosomal	O	O
analysis	O	O
was	O	O
normal	O	O
(	O	O
46	O	O
,	O	O
XY	O	O
)	O	O
.	O	O

DNA	O	O
analysis	O	O
for	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
showed	O	O
no	O	O
abnormalities	O	O
.	O	O

Two	O	O
years	O	O
later	O	O
he	O	O
was	O	O
re	O	O
-	O	O
examined	O	O
because	O	O
we	O	O
thought	O	O
his	O	O
features	O	O
fitted	O	O
the	O	O
PWS	B-Disease	D011218
-	O	O
like	O	O
phenotype	O	O
associated	O	O
with	O	O
maternal	O	O
UPD	B-Disease	D024182
(	O	O
14	O	O
)	O	O
.	O	O

At	O	O
that	O	O
time	O	O
precocious	O	O
puberty	O	O
was	O	O
evident	O	O
.	O	O

DNA	O	O
analysis	O	O
showed	O	O
maternal	B-Disease	D024182
heterodisomy	I-Disease	D024182
for	O	O
chromosome	O	O
14	O	O
.	O	O

In	O	O
all	O	O
the	O	O
previously	O	O
described	O	O
11	O	O
cases	O	O
with	O	O
maternal	O	O
UPD	B-Disease	D024182
(	O	O
14	O	O
)	O	O
,	O	O
a	O	O
Robertsonian	O	O
translocation	O	O
involving	O	O
chromosome	O	O
14	O	O
was	O	O
detected	O	O
cytogenetically	O	O
before	O	O
DNA	O	O
analysis	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
diagnosis	O	O
of	O	O
maternal	O	O
UPD	B-Disease	D024182
(	O	O
14	O	O
)	O	O
based	O	O
on	O	O
clinical	O	O
features	O	O
.	O	O

This	O	O
finding	O	O
underlines	O	O
the	O	O
importance	O	O
of	O	O
DNA	O	O
analysis	O	O
for	O	O
maternal	O	O
UPD	B-Disease	D024182
(	O	O
14	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
similar	O	O
PWS	B-Disease	D011218
-	O	O
like	O	O
phenotype	O	O
even	O	O
without	O	O
previous	O	O
identification	O	O
of	O	O
a	O	O
Robertsonian	O	O
translocation	O	O
involving	O	O
chromosome	O	O
14	O	O
.	O	O

.	O	O

Detection	O	O
of	O	O
eight	O	O
BRCA1	O	O
mutations	O	O
in	O	O
10	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
,	O	O
including	O	O
1	O	O
family	O	O
with	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
.	O	O

Genetic	O	O
epidemiological	O	O
evidence	O	O
suggests	O	O
that	O	O
mutations	O	O
in	O	O
BRCA1	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
approximately	O	O
one	O	O
half	O	O
of	O	O
early	O	O
onset	O	O
familial	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
and	O	O
the	O	O
majority	O	O
of	O	O
familial	B-Disease	D061325
breast	I-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

The	O	O
recent	O	O
cloning	O	O
of	O	O
BRCA1	O	O
allows	O	O
for	O	O
the	O	O
direct	O	O
detection	O	O
of	O	O
mutations	O	O
,	O	O
but	O	O
the	O	O
feasibility	O	O
of	O	O
presymptomatic	O	O
screening	O	O
for	O	O
cancer	B-Disease	D009369
susceptibility	O	O
is	O	O
unknown	O	O
.	O	O

We	O	O
analyzed	O	O
genomic	O	O
DNA	O	O
from	O	O
one	O	O
affected	O	O
individual	O	O
from	O	O
each	O	O
of	O	O
24	O	O
families	O	O
with	O	O
at	O	O
least	O	O
three	O	O
cases	O	O
of	O	O
ovarian	B-Disease	D010051
or	I-Disease	D010051
breast	I-Disease	D010051
cancer	I-Disease	D010051
,	O	O
using	O	O
SSCP	O	O
assays	O	O
.	O	O

Variant	O	O
SSCP	O	O
bands	O	O
were	O	O
subcloned	O	O
and	O	O
sequenced	O	O
.	O	O

Allele	O	O
-	O	O
specific	O	O
oligonucleotide	O	O
hybridization	O	O
was	O	O
used	O	O
to	O	O
verify	O	O
sequence	O	O
changes	O	O
and	O	O
to	O	O
screen	O	O
DNA	O	O
from	O	O
control	O	O
individuals	O	O
.	O	O

Six	O	O
frameshift	O	O
and	O	O
two	O	O
missense	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
10	O	O
different	O	O
families	O	O
.	O	O

A	O	O
frameshift	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
male	O	O
proband	O	O
affected	O	O
with	O	O
both	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
prostate	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

A	O	O
40	O	O
-	O	O
bp	O	O
deletion	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
intra	B-Disease	D000008	D002277
-	I-Disease	D000008	D002277
abdominal	I-Disease	D000008	D002277
carcinomatosis	I-Disease	D000008	D002277
1	O	O
year	O	O
after	O	O
prophylactic	O	O
oophorectomy	O	O
.	O	O

Mutations	O	O
were	O	O
detected	O	O
throughout	O	O
the	O	O
gene	O	O
,	O	O
and	O	O
only	O	O
one	O	O
was	O	O
detected	O	O
in	O	O
more	O	O
than	O	O
a	O	O
single	O	O
family	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
further	O	O
evidence	O	O
that	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
can	O	O
occur	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
a	O	O
wide	O	O
array	O	O
of	O	O
BRCA1	O	O
mutations	O	O
.	O	O

These	O	O
results	O	O
suggests	O	O
that	O	O
development	O	O
of	O	O
a	O	O
screening	O	O
test	O	O
for	O	O
BRCA1	O	O
mutations	O	O
will	O	O
be	O	O
technically	O	O
challenging	O	O
.	O	O

The	O	O
finding	O	O
of	O	O
a	O	O
mutation	O	O
in	O	O
a	O	O
family	O	O
with	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
,	O	O
not	O	O
previously	O	O
thought	O	O
to	O	O
be	O	O
related	O	O
to	O	O
BRCA1	O	O
,	O	O
also	O	O
illustrates	O	O
the	O	O
potential	O	O
difficulties	O	O
of	O	O
genetic	O	O
counseling	O	O
for	O	O
individuals	O	O
known	O	O
to	O	O
carry	O	O
mutations	O	O
.	O	O

.	O	O

Color	B-Disease	D003117
vision	I-Disease	D003117
defects	I-Disease	D003117
in	O	O
adrenomyeloneuropathy	B-Disease	D000326
.	O	O

The	O	O
relationship	O	O
between	O	O
abnormal	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
and	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
was	O	O
investigated	O	O
in	O	O
27	O	O
AMN	B-Disease	D000326
patients	O	O
and	O	O
31	O	O
age	O	O
-	O	O
matched	O	O
controls	O	O
by	O	O
using	O	O
the	O	O
Farnsworth	O	O
-	O	O
Munsell	O	O
100	O	O
Hue	O	O
test	O	O
.	O	O

Twelve	O	O
(	O	O
44	O	O
%	O	O
)	O	O
of	O	O
27	O	O
patients	O	O
showed	O	O
test	O	O
scores	O	O
significantly	O	O
above	O	O
normal	O	O
.	O	O

The	O	O
axes	O	O
of	O	O
bipolarity	O	O
determined	O	O
by	O	O
the	O	O
testing	O	O
differed	O	O
widely	O	O
between	O	O
the	O	O
patients	O	O
with	O	O
abnormal	O	O
scores	O	O
,	O	O
compatible	O	O
with	O	O
the	O	O
notion	O	O
that	O	O
different	O	O
alterations	O	O
in	O	O
visual	O	O
pigment	O	O
genes	O	O
occur	O	O
in	O	O
different	O	O
AMN	B-Disease	D000326
kindreds	O	O
.	O	O

These	O	O
observations	O	O
confirm	O	O
our	O	O
earlier	O	O
impression	O	O
that	O	O
the	O	O
frequency	O	O
of	O	O
abnormal	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
is	O	O
increased	O	O
in	O	O
these	O	O
kindreds	O	O
,	O	O
and	O	O
it	O	O
supports	O	O
our	O	O
contentions	O	O
that	O	O
(	O	O
1	O	O
)	O	O
AMN	B-Disease	D000326
(	O	O
and	O	O
its	O	O
companion	O	O
,	O	O
adrenoleukodystrophy	B-Disease	D000326
)	O	O
are	O	O
very	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
visual	O	O
pigment	O	O
loci	O	O
at	O	O
Xq28	O	O
and	O	O
(	O	O
2	O	O
)	O	O
this	O	O
proximity	O	O
might	O	O
provide	O	O
the	O	O
opportunity	O	O
to	O	O
observe	O	O
contiguous	B-Disease	D025063
gene	I-Disease	D025063
defects	I-Disease	D025063
.	O	O

.	O	O

Patterns	O	O
of	O	O
exon	O	O
deletions	O	O
in	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

A	O	O
panel	O	O
of	O	O
patients	O	O
with	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
and	O	O
BMD	B-Disease	C537666
)	O	O
has	O	O
been	O	O
screened	O	O
with	O	O
the	O	O
cDNA	O	O
probes	O	O
Cf56a	O	O
and	O	O
Cf23a	O	O
,	O	O
which	O	O
detect	O	O
exons	O	O
in	O	O
the	O	O
central	O	O
part	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

One	O	O
or	O	O
more	O	O
exons	O	O
were	O	O
deleted	O	O
in	O	O
60	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
deletions	O	O
were	O	O
mapped	O	O
and	O	O
prove	O	O
to	O	O
be	O	O
heterogeneous	O	O
in	O	O
size	O	O
and	O	O
extent	O	O
,	O	O
particularly	O	O
in	O	O
DMD	B-Disease	D020388
.	O	O

Deletions	O	O
specific	O	O
to	O	O
DMD	B-Disease	D020388
and	O	O
to	O	O
BMD	B-Disease	C537666
are	O	O
described	O	O
.	O	O

Half	O	O
of	O	O
all	O	O
BMD	B-Disease	C537666
patients	O	O
have	O	O
a	O	O
deletion	O	O
of	O	O
one	O	O
particular	O	O
small	O	O
group	O	O
of	O	O
exons	O	O
;	O	O
smaller	O	O
deletions	O	O
within	O	O
this	O	O
same	O	O
group	O	O
produce	O	O
the	O	O
more	O	O
severe	O	O
DMD	B-Disease	D020388
.	O	O

.	O	O

The	O	O
LEC	O	O
rat	O	O
has	O	O
a	O	O
deletion	O	O
in	O	O
the	O	O
copper	O	O
transporting	O	O
ATPase	O	O
gene	O	O
homologous	O	O
to	O	O
the	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
gene	O	O
.	O	O

The	O	O
Long	O	O
-	O	O
Evans	O	O
Cinnamon	O	O
(	O	O
LEC	O	O
)	O	O
rat	O	O
shows	O	O
similarity	O	O
to	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
in	O	O
many	O	O
clinical	O	O
and	O	O
biochemical	O	O
features	O	O
.	O	O

We	O	O
have	O	O
cloned	O	O
cDNAs	O	O
for	O	O
the	O	O
rat	O	O
gene	O	O
(	O	O
Atp7b	O	O
)	O	O
homologous	O	O
to	O	O
the	O	O
human	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
gene	O	O
(	O	O
ATP7B	O	O
)	O	O
and	O	O
have	O	O
used	O	O
them	O	O
to	O	O
identify	O	O
a	O	O
partial	O	O
deletion	O	O
in	O	O
the	O	O
Atp7b	O	O
gene	O	O
in	O	O
the	O	O
LEC	O	O
rat	O	O
.	O	O

The	O	O
deletion	O	O
removes	O	O
at	O	O
least	O	O
900	O	O
bp	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
at	O	O
the	O	O
3	O	O
end	O	O
,	O	O
includes	O	O
the	O	O
crucial	O	O
ATP	O	O
binding	O	O
domain	O	O
and	O	O
extends	O	O
downstream	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
convincing	O	O
evidence	O	O
for	O	O
defining	O	O
the	O	O
LEC	O	O
rat	O	O
as	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

This	O	O
model	O	O
will	O	O
be	O	O
important	O	O
for	O	O
studying	O	O
liver	O	O
pathophysiology	O	O
,	O	O
for	O	O
developing	O	O
therapy	O	O
for	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
and	O	O
for	O	O
studying	O	O
the	O	O
pathway	O	O
of	O	O
copper	O	O
transport	O	O
and	O	O
its	O	O
possible	O	O
interaction	O	O
with	O	O
other	O	O
heavy	O	O
metals	O	O
.	O	O

.	O	O

Detection	O	O
of	O	O
a	O	O
new	O	O
submicroscopic	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
deletion	O	O
interval	O	O
with	O	O
a	O	O
novel	O	O
DNA	O	O
probe	O	O
isolated	O	O
by	O	O
differential	O	O
Alu	O	O
PCR	O	O
fingerprint	O	O
cloning	O	O
.	O	O

Differential	O	O
Alu	O	O
PCR	O	O
fingerprint	O	O
cloning	O	O
was	O	O
used	O	O
to	O	O
isolate	O	O
a	O	O
DNA	O	O
probe	O	O
from	O	O
the	O	O
Xp11	O	O
.	O	O

4	O	O
-	O	O
-	O	O
>	O	O
p11	O	O
.	O	O

21	O	O
region	O	O
of	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

This	O	O
novel	O	O
sequence	O	O
,	O	O
cpXr318	O	O
(	O	O
DXS742	O	O
)	O	O
,	O	O
detects	O	O
a	O	O
new	O	O
submicroscopic	O	O
deletion	O	O
interval	O	O
at	O	O
the	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
locus	O	O
(	O	O
NDP	O	O
)	O	O
.	O	O

Combining	O	O
our	O	O
data	O	O
with	O	O
the	O	O
consensus	O	O
genetic	O	O
map	O	O
of	O	O
the	O	O
proximal	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
,	O	O
we	O	O
propose	O	O
the	O	O
physical	O	O
order	O	O
Xcen	O	O
-	O	O
DXS14	O	O
-	O	O
DXS255	O	O
-	O	O
(	O	O
DXS426	O	O
,	O	O
TIMP	O	O
)	O	O
-	O	O
(	O	O
DXS742	O	O
-	O	O
(	O	O
[	O	O
MAOB	O	O
-	O	O
MAOA	O	O
-	O	O
DXS7	O	O
]	O	O
,	O	O
NDP	O	O
)	O	O
-	O	O
DXS77	O	O
-	O	O
DXS228	O	O
)	O	O
-	O	O
DXS209	O	O
-	O	O
DXS148	O	O
-	O	O
DXS196	O	O
-	O	O
+	O	O
+	O	O
+	O	O
Xpter	O	O
.	O	O

The	O	O
cpXr318	O	O
probe	O	O
and	O	O
a	O	O
subclone	O	O
from	O	O
a	O	O
cosmid	O	O
corresponding	O	O
to	O	O
the	O	O
DXS7	O	O
locus	O	O
were	O	O
converted	O	O
into	O	O
sequence	O	O
-	O	O
tagged	O	O
sites	O	O
.	O	O

Finally	O	O
,	O	O
DXS742	O	O
,	O	O
DSX7	O	O
,	O	O
DXS77	O	O
,	O	O
and	O	O
MAOA	O	O
were	O	O
integrated	O	O
into	O	O
a	O	O
physical	O	O
map	O	O
spanning	O	O
the	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
locus	O	O
Genetic	O	O
analysis	O	O
of	O	O
a	O	O
Japanese	O	O
family	O	O
with	O	O
normotriglyceridemic	B-Disease	D000012
abetalipoproteinemia	I-Disease	D000012
indicates	O	O
a	O	O
lack	O	O
of	O	O
linkage	O	O
to	O	O
the	O	O
apolipoprotein	O	O
B	O	O
gene	O	O
.	O	O

Normotriglyceridemic	B-Disease	D000012
abetalipoproteinemia	I-Disease	D000012
is	O	O
a	O	O
rare	O	O
familial	B-Disease	D009358
disorder	I-Disease	D009358
characterized	O	O
by	O	O
an	O	O
isolated	O	O
deficiency	B-Disease	OMIM:200100
of	I-Disease	OMIM:200100
apoB	I-Disease	OMIM:200100
-	I-Disease	OMIM:200100
100	I-Disease	OMIM:200100
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
a	O	O
patient	O	O
with	O	O
this	O	O
disease	O	O
,	O	O
who	O	O
had	O	O
normal	O	O
apoB	O	O
-	O	O
48	O	O
but	O	O
no	O	O
apoB	O	O
-	O	O
100	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
genetic	B-Disease	D030342
abnormalities	I-Disease	D030342
in	O	O
this	O	O
family	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
linkage	O	O
of	O	O
apoB	O	O
gene	O	O
using	O	O
three	O	O
genetic	O	O
markers	O	O
.	O	O

The	O	O
proband	O	O
and	O	O
her	O	O
affected	O	O
brother	O	O
showed	O	O
completely	O	O
different	O	O
apoB	O	O
gene	O	O
alleles	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
apoB	O	O
gene	O	O
itself	O	O
is	O	O
not	O	O
related	O	O
to	O	O
this	O	O
disorder	O	O
in	O	O
this	O	O
family	O	O
.	O	O

By	O	O
contrast	O	O
,	O	O
an	O	O
American	O	O
case	O	O
had	O	O
a	O	O
point	O	O
substitution	O	O
in	O	O
the	O	O
apoB	O	O
gene	O	O
generating	O	O
an	O	O
in	O	O
-	O	O
frame	O	O
stop	O	O
codon	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
disorder	O	O
can	O	O
be	O	O
caused	O	O
by	O	O
defect	O	O
(	O	O
s	O	O
)	O	O
of	O	O
either	O	O
an	O	O
apoB	O	O
gene	O	O
or	O	O
other	O	O
genes	O	O
.	O	O

.	O	O

Founder	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
in	O	O
Polish	O	O
families	O	O
with	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

We	O	O
have	O	O
undertaken	O	O
a	O	O
hospital	O	O
-	O	O
based	O	O
study	O	O
,	O	O
to	O	O
identify	O	O
possible	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
founder	O	O
mutations	O	O
in	O	O
the	O	O
Polish	O	O
population	O	O
.	O	O

The	O	O
study	O	O
group	O	O
consisted	O	O
of	O	O
66	O	O
Polish	O	O
families	O	O
with	O	O
cancer	B-Disease	D009369
who	O	O
have	O	O
at	O	O
least	O	O
three	O	O
related	O	O
females	O	O
affected	O	O
with	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
and	O	O
who	O	O
had	O	O
cancer	B-Disease	D009369
diagnosed	O	O
,	O	O
in	O	O
at	O	O
least	O	O
one	O	O
of	O	O
the	O	O
three	O	O
affected	O	O
females	O	O
,	O	O
at	O	O
age	O	O
<	O	O
50	O	O
years	O	O
.	O	O

A	O	O
total	O	O
of	O	O
26	O	O
families	O	O
had	O	O
both	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
,	O	O
4	O	O
families	O	O
had	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
only	O	O
,	O	O
and	O	O
36	O	O
families	O	O
had	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
only	O	O
.	O	O

Genomic	O	O
DNA	O	O
was	O	O
prepared	O	O
from	O	O
the	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
of	O	O
at	O	O
least	O	O
one	O	O
affected	O	O
woman	O	O
from	O	O
each	O	O
family	O	O
.	O	O

The	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
was	O	O
screened	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
germline	O	O
mutations	O	O
,	O	O
by	O	O
use	O	O
of	O	O
SSCP	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
observed	O	O
variants	O	O
.	O	O

Mutations	O	O
were	O	O
found	O	O
in	O	O
35	O	O
(	O	O
53	O	O
%	O	O
)	O	O
of	O	O
the	O	O
66	O	O
families	O	O
studied	O	O
.	O	O

All	O	O
but	O	O
one	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
detected	O	O
within	O	O
the	O	O
BRCA1	O	O
gene	O	O
.	O	O

BRCA1	B-Disease	OMIM:604370
abnormalities	I-Disease	OMIM:604370
were	O	O
identified	O	O
in	O	O
all	O	O
four	O	O
families	O	O
with	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
only	O	O
,	O	O
in	O	O
67	O	O
%	O	O
of	O	O
27	O	O
families	O	O
with	O	O
both	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
,	O	O
and	O	O
in	O	O
34	O	O
%	O	O
of	O	O
35	O	O
families	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
only	O	O
.	O	O

The	O	O
single	O	O
family	O	O
with	O	O
a	O	O
BRCA2	O	O
mutation	O	O
had	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
syndrome	O	O
.	O	O

Seven	O	O
distinct	O	O
mutations	O	O
were	O	O
identified	O	O
;	O	O
five	O	O
of	O	O
these	O	O
occurred	O	O
in	O	O
two	O	O
or	O	O
more	O	O
families	O	O
.	O	O

In	O	O
total	O	O
,	O	O
recurrent	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
33	O	O
(	O	O
94	O	O
%	O	O
)	O	O
of	O	O
the	O	O
35	O	O
families	O	O
with	O	O
detected	O	O
mutations	O	O
.	O	O

Three	O	O
BRCA1	B-Disease	OMIM:604370
abnormalities	I-Disease	OMIM:604370
-	O	O
5382insC	O	O
,	O	O
C61G	O	O
,	O	O
and	O	O
4153delA	O	O
-	O	O
accounted	O	O
for	O	O
51	O	O
%	O	O
,	O	O
20	O	O
%	O	O
,	O	O
and	O	O
11	O	O
%	O	O
of	O	O
the	O	O
identified	O	O
mutations	O	O
,	O	O
respectively	O	O
.	O	O

.	O	O

New	O	O
founder	O	O
haplotypes	O	O
at	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
locus	O	O
in	O	O
southern	O	O
Africa	O	O
.	O	O

The	O	O
association	O	O
between	O	O
normal	O	O
alleles	O	O
at	O	O
the	O	O
CTG	O	O
repeat	O	O
and	O	O
two	O	O
nearby	O	O
polymorphisms	O	O
in	O	O
the	O	O
myotonin	O	O
protein	O	O
kinase	O	O
gene	O	O
,	O	O
the	O	O
Alu	O	O
insertion	O	O
/	O	O
deletion	O	O
polymorphism	O	O
and	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
kinase	O	O
(	O	O
DMK	O	O
)	O	O
(	O	O
G	O	O
/	O	O
T	O	O
)	O	O
intron	O	O
9	O	O
/	O	O
HinfI	O	O
polymorphism	O	O
,	O	O
has	O	O
been	O	O
analyzed	O	O
in	O	O
South	O	O
African	O	O
Negroids	O	O
,	O	O
a	O	O
population	O	O
in	O	O
which	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
has	O	O
not	O	O
been	O	O
described	O	O
.	O	O

South	O	O
African	O	O
Negroids	O	O
have	O	O
a	O	O
CTG	O	O
allelic	O	O
distribution	O	O
that	O	O
is	O	O
significantly	O	O
different	O	O
from	O	O
that	O	O
in	O	O
Caucasoids	O	O
and	O	O
Japanese	O	O
the	O	O
CTG	O	O
repeat	O	O
lengths	O	O
of	O	O
>	O	O
or	O	O
=	O	O
19	O	O
are	O	O
very	O	O
rare	O	O
.	O	O

The	O	O
striking	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
specific	O	O
alleles	O	O
at	O	O
the	O	O
Alu	O	O
polymorphism	O	O
(	O	O
Alu	O	O
(	O	O
ins	O	O
)	O	O
and	O	O
Alu	O	O
(	O	O
del	O	O
)	O	O
)	O	O
,	O	O
the	O	O
HinfI	O	O
polymorphism	O	O
(	O	O
HinfI	O	O
-	O	O
1	O	O
and	O	O
HinfI	O	O
-	O	O
2	O	O
)	O	O
,	O	O
and	O	O
the	O	O
CTG	O	O
repeat	O	O
polymorphism	O	O
seen	O	O
in	O	O
Caucasoid	O	O
(	O	O
Europeans	O	O
and	O	O
Canadians	O	O
)	O	O
populations	O	O
was	O	O
also	O	O
found	O	O
in	O	O
the	O	O
South	O	O
African	O	O
Negroid	O	O
population	O	O
.	O	O

Numerous	O	O
haplotypes	O	O
,	O	O
not	O	O
previously	O	O
described	O	O
in	O	O
Europeans	O	O
,	O	O
were	O	O
,	O	O
however	O	O
,	O	O
found	O	O
.	O	O

It	O	O
thus	O	O
seems	O	O
likely	O	O
that	O	O
only	O	O
a	O	O
small	O	O
number	O	O
of	O	O
these	O	O
"	O	O
African	O	O
"	O	O
chromosomes	O	O
were	O	O
present	O	O
in	O	O
the	O	O
progenitors	O	O
of	O	O
all	O	O
non	O	O
-	O	O
African	O	O
peoples	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
support	O	O
for	O	O
the	O	O
"	O	O
out	O	O
of	O	O
Africa	O	O
"	O	O
model	O	O
for	O	O
the	O	O
origin	O	O
of	O	O
modern	O	O
humans	O	O
and	O	O
suggest	O	O
that	O	O
the	O	O
rare	O	O
ancestral	O	O
DM	B-Disease	D009223
mutation	O	O
event	O	O
may	O	O
have	O	O
occurred	O	O
after	O	O
the	O	O
migration	O	O
from	O	O
Africa	O	O
,	O	O
hence	O	O
the	O	O
absence	O	O
of	O	O
DM	B-Disease	D009223
in	O	O
sub	O	O
-	O	O
Saharan	O	O
Negroid	O	O
peoples	O	O
.	O	O

.	O	O

Marked	O	O
phenotypic	O	O
heterogeneity	O	O
associated	O	O
with	O	O
expansion	O	O
of	O	O
a	O	O
CAG	O	O
repeat	O	O
sequence	O	O
at	O	O
the	O	O
spinocerebellar	B-Disease	D017827
ataxia	I-Disease	D017827
3	I-Disease	D017827
/	I-Disease	D017827
Machado	I-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
locus	O	O
.	O	O

The	O	O
spinocerebellar	B-Disease	D017827
ataxia	I-Disease	D017827
3	I-Disease	D017827
locus	O	O
(	O	O
SCA3	B-Disease	D017827
)	O	O
for	O	O
type	B-Disease	OMIM:109150
I	I-Disease	OMIM:109150
autosomal	I-Disease	OMIM:109150
dominant	I-Disease	OMIM:109150
cerebellar	I-Disease	OMIM:109150
ataxia	I-Disease	OMIM:109150
(	O	O
ADCA	B-Disease	OMIM:109150
type	I-Disease	OMIM:109150
I	I-Disease	OMIM:109150
)	O	O
,	O	O
a	O	O
clinically	O	O
and	O	O
genetically	O	O
heterogeneous	O	O
group	O	O
of	O	O
neurodegenerative	B-Disease	D019636
disorders	I-Disease	D019636
,	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
chromosome	O	O
14q32	O	O
.	O	O

1	O	O
1	O	O
.	O	O

ADCA	B-Disease	OMIM:109150
type	I-Disease	OMIM:109150
I	I-Disease	OMIM:109150
patients	O	O
from	O	O
families	O	O
segregating	O	O
SCA3	B-Disease	D017827
share	O	O
clinical	O	O
features	O	O
in	O	O
common	O	O
with	O	O
those	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
,	O	O
the	O	O
gene	O	O
of	O	O
which	O	O
maps	O	O
to	O	O
the	O	O
same	O	O
region	O	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
the	O	O
disease	O	O
gene	O	O
segregating	O	O
in	O	O
each	O	O
of	O	O
three	O	O
French	O	O
ADCA	B-Disease	OMIM:109150
type	I-Disease	OMIM:109150
I	I-Disease	OMIM:109150
kindreds	O	O
and	O	O
in	O	O
a	O	O
French	O	O
family	O	O
with	O	O
neuropathological	O	O
findings	O	O
suggesting	O	O
the	O	O
ataxochoreic	O	O
form	O	O
of	O	O
dentatorubropallidoluysian	B-Disease	OMIM:125370
atrophy	I-Disease	OMIM:125370
carries	O	O
an	O	O
expanded	O	O
CAG	O	O
repeat	O	O
sequence	O	O
located	O	O
at	O	O
the	O	O
same	O	O
locus	O	O
as	O	O
that	O	O
for	O	O
MJD	B-Disease	D017827
.	O	O

Analysis	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
these	O	O
families	O	O
shows	O	O
a	O	O
strong	O	O
negative	O	O
correlation	O	O
between	O	O
size	O	O
of	O	O
the	O	O
expanded	O	O
CAG	O	O
repeat	O	O
and	O	O
age	O	O
at	O	O
onset	O	O
of	O	O
clinical	O	O
disease	O	O
.	O	O

Instability	O	O
of	O	O
the	O	O
expanded	O	O
triplet	O	O
repeat	O	O
was	O	O
not	O	O
found	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
sex	O	O
of	O	O
the	O	O
parent	O	O
transmitting	O	O
the	O	O
mutation	O	O
.	O	O

Evidence	O	O
was	O	O
found	O	O
for	O	O
somatic	O	O
and	O	O
gonadal	O	O
mosaicism	O	O
for	O	O
alleles	O	O
carrying	O	O
expanded	O	O
trinucleotide	O	O
repeats	O	O
.	O	O

The	O	O
red	O	O
-	O	O
green	O	O
visual	O	O
pigment	O	O
gene	O	O
region	O	O
in	O	O
adrenoleukodystrophy	B-Disease	D000326
.	O	O

Although	O	O
recent	O	O
data	O	O
established	O	O
that	O	O
a	O	O
specific	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acyl	O	O
-	O	O
CoA	O	O
synthetase	O	O
is	O	O
defective	O	O
in	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
,	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
is	O	O
still	O	O
unidentified	O	O
.	O	O

The	O	O
ALD	B-Disease	D000326
locus	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
Xq28	O	O
,	O	O
like	O	O
the	O	O
red	O	O
and	O	O
green	O	O
color	O	O
pigment	O	O
genes	O	O
.	O	O

Abnormal	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
has	O	O
been	O	O
observed	O	O
in	O	O
12	O	O
of	O	O
27	O	O
patients	O	O
with	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
,	O	O
a	O	O
milder	O	O
form	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

Furthermore	O	O
,	O	O
rearrangements	O	O
of	O	O
the	O	O
color	O	O
vision	O	O
gene	O	O
cluster	O	O
were	O	O
found	O	O
in	O	O
four	O	O
of	O	O
eight	O	O
ALD	B-Disease	D000326
kindreds	O	O
.	O	O

This	O	O
led	O	O
us	O	O
to	O	O
propose	O	O
that	O	O
a	O	O
single	O	O
DNA	O	O
rearrangement	O	O
could	O	O
underlie	O	O
both	O	O
ALD	B-Disease	D000326
and	O	O
abnormal	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
in	O	O
these	O	O
patients	O	O
.	O	O

Study	O	O
of	O	O
34	O	O
French	O	O
ALD	B-Disease	D000326
patients	O	O
failed	O	O
to	O	O
reveal	O	O
a	O	O
higher	O	O
than	O	O
expected	O	O
frequency	O	O
of	O	O
green	O	O
/	O	O
red	O	O
visual	O	O
pigment	O	O
rearrangements	O	O
3	O	O
to	O	O
the	O	O
red	O	O
/	O	O
green	O	O
color	O	O
vision	O	O
gene	O	O
complex	O	O
.	O	O

The	O	O
previous	O	O
report	O	O
of	O	O
such	O	O
rearrangements	O	O
was	O	O
based	O	O
on	O	O
small	O	O
numbers	O	O
and	O	O
lack	O	O
of	O	O
knowledge	O	O
that	O	O
the	O	O
frequency	O	O
of	O	O
"	O	O
abnormal	O	O
"	O	O
color	O	O
vision	O	O
arrays	O	O
on	O	O
molecular	O	O
analysis	O	O
was	O	O
twice	O	O
as	O	O
high	O	O
as	O	O
expected	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
frequency	O	O
of	O	O
phenotypic	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
defects	I-Disease	D003117
.	O	O

The	O	O
red	O	O
/	O	O
green	O	O
color	O	O
pigment	O	O
(	O	O
R	O	O
/	O	O
GCP	O	O
)	O	O
region	O	O
was	O	O
studied	O	O
by	O	O
pulsed	O	O
-	O	O
field	O	O
gel	O	O
electrophoresis	O	O
in	O	O
14	O	O
of	O	O
these	O	O
patients	O	O
,	O	O
and	O	O
we	O	O
did	O	O
not	O	O
find	O	O
any	O	O
fragment	O	O
size	O	O
difference	O	O
between	O	O
the	O	O
patients	O	O
and	O	O
normal	O	O
individuals	O	O
who	O	O
have	O	O
the	O	O
same	O	O
number	O	O
of	O	O
pigment	O	O
genes	O	O
.	O	O

The	O	O
R	O	O
/	O	O
GCP	O	O
region	O	O
was	O	O
also	O	O
analyzed	O	O
in	O	O
29	O	O
French	O	O
and	O	O
seven	O	O
North	O	O
American	O	O
ALD	B-Disease	D000326
patients	O	O
by	O	O
using	O	O
six	O	O
genomic	O	O
DNA	O	O
probes	O	O
,	O	O
isolated	O	O
from	O	O
a	O	O
cosmid	O	O
walk	O	O
,	O	O
that	O	O
flank	O	O
the	O	O
color	O	O
vision	O	O
genes	O	O
.	O	O

No	O	O
deletions	O	O
were	O	O
found	O	O
with	O	O
probes	O	O
that	O	O
lie	O	O
3	O	O
of	O	O
the	O	O
green	O	O
pigment	O	O
genes	O	O
.	O	O

One	O	O
of	O	O
the	O	O
eight	O	O
previously	O	O
reported	O	O
ALD	B-Disease	D000326
individuals	O	O
has	O	O
a	O	O
long	O	O
deletion	O	O
5	O	O
of	O	O
the	O	O
red	O	O
pigment	O	O
gene	O	O
,	O	O
a	O	O
deletion	O	O
causing	O	O
blue	O	O
cone	O	O
monochromacy	O	O
.	O	O

This	O	O
finding	O	O
and	O	O
the	O	O
previous	O	O
findings	O	O
of	O	O
a	O	O
45	O	O
%	O	O
frequency	O	O
of	O	O
phenotypic	B-Disease	D003117
color	I-Disease	D003117
vision	I-Disease	D003117
defects	I-Disease	D003117
in	O	O
patients	O	O
with	O	O
AMN	B-Disease	D000326
may	O	O
suggest	O	O
that	O	O
the	O	O
ALD	B-Disease	D000326
/	O	O
AMN	B-Disease	D000326
gene	O	O
lies	O	O
5	O	O
to	O	O
the	O	O
red	O	O
pigment	O	O
gene	O	O
and	O	O
that	O	O
the	O	O
frequent	O	O
phenotypic	O	O
color	B-Disease	D003117
vision	I-Disease	D003117
anomalies	I-Disease	D003117
owe	O	O
their	O	O
origin	O	O
to	O	O
deleted	O	O
DNA	O	O
that	O	O
includes	O	O
regulatory	O	O
genes	O	O
for	O	O
color	O	O
vision	O	O
.	O	O

It	O	O
is	O	O
possible	O	O
,	O	O
however	O	O
,	O	O
that	O	O
phenotypic	O	O
color	B-Disease	D003117
vision	I-Disease	D003117
anomalies	I-Disease	D003117
in	O	O
AMN	B-Disease	D000326
may	O	O
be	O	O
phenocopies	O	O
secondary	O	O
to	O	O
retinal	O	O
or	O	O
neural	O	O
involvement	O	O
by	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
single	O	O
case	O	O
of	O	O
blue	O	O
cone	O	O
monochromacy	O	O
may	O	O
therefore	O	O
be	O	O
a	O	O
fortuitous	O	O
coincidence	O	O
of	O	O
two	O	O
diseases	O	O
.	O	O

.	O	O

Haim	B-Disease	C537627
-	I-Disease	C537627
Munk	I-Disease	C537627
syndrome	I-Disease	C537627
and	O	O
Papillon	B-Disease	D010214
-	I-Disease	D010214
Lefevre	I-Disease	D010214
syndrome	I-Disease	D010214
are	O	O
allelic	O	O
mutations	O	O
in	O	O
cathepsin	O	O
C	O	O
.	O	O

Of	O	O
the	O	O
many	O	O
palmoplantar	B-Disease	D007645
keratoderma	I-Disease	D007645
(	I-Disease	D007645
PPK	I-Disease	D007645
)	I-Disease	D007645
conditions	I-Disease	D007645
,	O	O
only	O	O
Papillon	B-Disease	D010214
-	I-Disease	D010214
Lefevre	I-Disease	D010214
syndrome	I-Disease	D010214
(	O	O
PLS	B-Disease	D010214
)	O	O
and	O	O
Haim	B-Disease	C537627
-	I-Disease	C537627
Munk	I-Disease	C537627
syndrome	I-Disease	C537627
(	O	O
HMS	B-Disease	C537627
)	O	O
are	O	O
associated	O	O
with	O	O
premature	O	O
periodontal	O	O
destruction	O	O
.	O	O

Although	O	O
both	O	O
PLS	B-Disease	D010214
and	O	O
HMS	B-Disease	C537627
share	O	O
the	O	O
cardinal	O	O
features	O	O
of	O	O
PPK	B-Disease	D007645
and	O	O
severe	O	O
periodontitis	B-Disease	D010518
,	O	O
a	O	O
number	O	O
of	O	O
additional	O	O
findings	O	O
are	O	O
reported	O	O
in	O	O
HMS	B-Disease	C537627
including	O	O
arachnodactyly	B-Disease	D054119
,	O	O
acro	B-Disease	D030981
-	I-Disease	D030981
osteolysis	I-Disease	D030981
,	O	O
atrophic	B-Disease	D009260
changes	I-Disease	D009260
of	I-Disease	D009260
the	I-Disease	D009260
nails	I-Disease	D009260
,	O	O
and	O	O
a	O	O
radiographic	B-Disease	D006226
deformity	I-Disease	D006226
of	I-Disease	D006226
the	I-Disease	D006226
fingers	I-Disease	D006226
.	O	O

While	O	O
PLS	B-Disease	D010214
cases	O	O
have	O	O
been	O	O
identified	O	O
throughout	O	O
the	O	O
world	O	O
,	O	O
HMS	B-Disease	C537627
has	O	O
only	O	O
been	O	O
described	O	O
among	O	O
descendants	O	O
of	O	O
a	O	O
religious	O	O
isolate	O	O
originally	O	O
from	O	O
Cochin	O	O
,	O	O
India	O	O
.	O	O

Parental	O	O
consanguinity	O	O
is	O	O
a	O	O
characteristic	O	O
of	O	O
many	O	O
cases	O	O
of	O	O
both	O	O
conditions	O	O
.	O	O

Although	O	O
autosomal	O	O
recessive	O	O
transmission	O	O
of	O	O
PLS	B-Disease	D010214
is	O	O
evident	O	O
,	O	O
a	O	O
more	O	O
"	O	O
complex	O	O
"	O	O
autosomal	O	O
recessive	O	O
pattern	O	O
of	O	O
inheritance	O	O
with	O	O
phenotypic	O	O
influences	O	O
from	O	O
a	O	O
closely	O	O
linked	O	O
modifying	O	O
locus	O	O
has	O	O
been	O	O
hypothesised	O	O
for	O	O
HMS	B-Disease	C537627
.	O	O

Recently	O	O
,	O	O
mutations	O	O
of	O	O
the	O	O
cathepsin	O	O
C	O	O
gene	O	O
have	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
underlying	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
PLS	B-Disease	D010214
.	O	O

To	O	O
determine	O	O
if	O	O
a	O	O
cathepsin	O	O
C	O	O
mutation	O	O
is	O	O
also	O	O
responsible	O	O
for	O	O
HMS	B-Disease	C537627
,	O	O
we	O	O
sequenced	O	O
the	O	O
gene	O	O
in	O	O
affected	O	O
and	O	O
unaffected	O	O
subjects	O	O
from	O	O
the	O	O
Cochin	O	O
isolate	O	O
in	O	O
which	O	O
both	O	O
the	O	O
PLS	B-Disease	D010214
and	O	O
HMS	B-Disease	C537627
phenotypes	O	O
appear	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
identification	O	O
of	O	O
a	O	O
mutation	O	O
of	O	O
cathepsin	O	O
C	O	O
(	O	O
exon	O	O
6	O	O
,	O	O
2127A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
that	O	O
changes	O	O
a	O	O
highly	O	O
conserved	O	O
amino	O	O
acid	O	O
in	O	O
the	O	O
cathepsin	O	O
C	O	O
peptide	O	O
.	O	O

This	O	O
mutation	O	O
segregates	O	O
with	O	O
HMS	B-Disease	C537627
in	O	O
four	O	O
nuclear	O	O
families	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
shared	O	O
common	O	O
haplotype	O	O
for	O	O
genetic	O	O
loci	O	O
flanking	O	O
the	O	O
cathepsin	O	O
C	O	O
gene	O	O
suggests	O	O
that	O	O
affected	O	O
subjects	O	O
descended	O	O
from	O	O
the	O	O
Cochin	O	O
isolate	O	O
are	O	O
homozygous	O	O
for	O	O
a	O	O
mutation	O	O
inherited	O	O
"	O	O
identical	O	O
by	O	O
descent	O	O
"	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

This	O	O
finding	O	O
supports	O	O
simple	O	O
autosomal	O	O
recessive	O	O
inheritance	O	O
for	O	O
HMS	B-Disease	C537627
in	O	O
these	O	O
families	O	O
.	O	O

We	O	O
also	O	O
report	O	O
a	O	O
mutation	O	O
of	O	O
the	O	O
same	O	O
exon	O	O
6	O	O
CTSC	O	O
codon	O	O
(	O	O
2126C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
)	O	O
in	O	O
a	O	O
Turkish	O	O
family	O	O
with	O	O
classical	O	O
PLS	B-Disease	D010214
.	O	O

These	O	O
findings	O	O
provide	O	O
evidence	O	O
that	O	O
PLS	B-Disease	D010214
and	O	O
HMS	B-Disease	C537627
are	O	O
allelic	O	O
variants	O	O
of	O	O
cathepsin	O	O
C	O	O
gene	O	O
mutations	O	O
.	O	O

.	O	O

X	O	O
inactivation	O	O
and	O	O
somatic	O	O
cell	O	O
selection	O	O
rescue	O	O
female	O	O
mice	O	O
carrying	O	O
a	O	O
Piga	O	O
-	O	O
null	O	O
mutation	O	O
.	O	O

A	O	O
somatic	O	O
mutation	O	O
in	O	O
the	O	O
X	O	O
linked	O	O
PIGA	O	O
gene	O	O
is	O	O
responsible	O	O
for	O	O
the	O	O
deficiency	B-Disease	C537277
of	I-Disease	C537277
glycosyl	I-Disease	C537277
phosphatidylinositol	I-Disease	C537277
(	I-Disease	C537277
GPI	I-Disease	C537277
)	I-Disease	C537277
-	I-Disease	C537277
anchored	I-Disease	C537277
proteins	I-Disease	C537277
on	O	O
blood	O	O
cells	O	O
from	O	O
patients	O	O
with	O	O
paroxysmal	B-Disease	D006457
nocturnal	I-Disease	D006457
hemoglobinuria	I-Disease	D006457
.	O	O

No	O	O
inherited	O	O
form	O	O
of	O	O
GPI	B-Disease	C537277
-	I-Disease	C537277
anchor	I-Disease	C537277
deficiency	I-Disease	C537277
has	O	O
been	O	O
described	O	O
.	O	O

Because	O	O
conventional	O	O
Piga	O	O
gene	O	O
knockout	O	O
is	O	O
associated	O	O
with	O	O
high	O	O
embryonic	B-Disease	D020964
lethality	I-Disease	D020964
in	O	O
chimeric	O	O
mice	O	O
,	O	O
we	O	O
used	O	O
the	O	O
Cre	O	O
/	O	O
loxP	O	O
system	O	O
.	O	O

We	O	O
generated	O	O
mice	O	O
in	O	O
which	O	O
two	O	O
loxP	O	O
sites	O	O
flank	O	O
part	O	O
of	O	O
Piga	O	O
exon	O	O
2	O	O
.	O	O

After	O	O
crossbreeding	O	O
with	O	O
female	O	O
mice	O	O
of	O	O
the	O	O
EIIa	O	O
-	O	O
cre	O	O
strain	O	O
,	O	O
the	O	O
floxed	O	O
allele	O	O
undergoes	O	O
Cre	O	O
-	O	O
mediated	O	O
recombination	O	O
with	O	O
high	O	O
efficiency	O	O
during	O	O
early	O	O
embryonic	O	O
development	O	O
.	O	O

Because	O	O
of	O	O
X	O	O
chromosome	O	O
inactivation	O	O
,	O	O
female	O	O
offspring	O	O
are	O	O
mosaic	O	O
for	O	O
cells	O	O
that	O	O
express	O	O
or	O	O
lack	O	O
GPI	O	O
-	O	O
linked	O	O
proteins	O	O
.	O	O

Analysis	O	O
of	O	O
mosaic	O	O
mice	O	O
showed	O	O
that	O	O
in	O	O
heart	O	O
,	O	O
lung	O	O
,	O	O
kidney	O	O
,	O	O
brain	O	O
,	O	O
and	O	O
liver	O	O
,	O	O
mainly	O	O
wild	O	O
-	O	O
type	O	O
Piga	O	O
is	O	O
active	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
tissues	O	O
require	O	O
GPI	O	O
-	O	O
linked	O	O
proteins	O	O
.	O	O

The	O	O
salient	O	O
exceptions	O	O
were	O	O
spleen	O	O
,	O	O
thymus	O	O
,	O	O
and	O	O
red	O	O
blood	O	O
cells	O	O
,	O	O
which	O	O
had	O	O
almost	O	O
equal	O	O
numbers	O	O
of	O	O
cells	O	O
expressing	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
or	O	O
the	O	O
recombined	O	O
allele	O	O
,	O	O
implying	O	O
that	O	O
GPI	O	O
-	O	O
linked	O	O
proteins	O	O
are	O	O
not	O	O
essential	O	O
for	O	O
the	O	O
derivation	O	O
of	O	O
these	O	O
tissues	O	O
.	O	O

PIGA	O	O
(	O	O
-	O	O
)	O	O
cells	O	O
had	O	O
no	O	O
growth	O	O
advantage	O	O
,	O	O
suggesting	O	O
that	O	O
other	O	O
factors	O	O
are	O	O
needed	O	O
for	O	O
their	O	O
clonal	O	O
dominance	O	O
in	O	O
patients	O	O
with	O	O
paroxysmal	B-Disease	D006457
nocturnal	I-Disease	D006457
hemoglobinuria	I-Disease	D006457
.	O	O

.	O	O

The	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
gene	O	O
maps	O	O
to	O	O
a	O	O
150	O	O
kb	O	O
region	O	O
on	O	O
chromosome	O	O
Xp11	O	O
.	O	O

3	O	O
.	O	O

Norrie	B-Disease	C537849
disease	I-Disease	C537849
is	O	O
a	O	O
human	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
recessive	I-Disease	D040181
disorder	I-Disease	D040181
of	O	O
unknown	O	O
etiology	O	O
characterized	O	O
by	O	O
congenital	B-Disease	D057130
blindness	I-Disease	D057130
,	O	O
sensory	B-Disease	D006319
neural	I-Disease	D006319
deafness	I-Disease	D006319
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
.	O	O

This	O	O
disease	O	O
gene	O	O
was	O	O
previously	O	O
linked	O	O
to	O	O
the	O	O
DXS7	O	O
(	O	O
L1	O	O
.	O	O

28	O	O
)	O	O
locus	O	O
and	O	O
the	O	O
MAO	O	O
genes	O	O
in	O	O
band	O	O
Xp11	O	O
.	O	O

3	O	O
3	O	O
.	O	O

We	O	O
report	O	O
here	O	O
fine	O	O
physical	O	O
mapping	O	O
of	O	O
the	O	O
obligate	O	O
region	O	O
containing	O	O
the	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
gene	O	O
(	O	O
NDP	O	O
)	O	O
defined	O	O
by	O	O
a	O	O
recombination	O	O
and	O	O
by	O	O
the	O	O
smallest	O	O
submicroscopic	O	O
chromosomal	O	O
deletion	O	O
associated	O	O
with	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
identified	O	O
to	O	O
date	O	O
.	O	O

Analysis	O	O
,	O	O
using	O	O
in	O	O
addition	O	O
two	O	O
overlapping	O	O
YAC	O	O
clones	O	O
from	O	O
this	O	O
region	O	O
,	O	O
allowed	O	O
orientation	O	O
of	O	O
the	O	O
MAOA	O	O
and	O	O
MAOB	O	O
genes	O	O
in	O	O
a	O	O
5	O	O
-	O	O
3	O	O
-	O	O
3	O	O
-	O	O
5	O	O
configuration	O	O
.	O	O

A	O	O
recombination	O	O
event	O	O
between	O	O
a	O	O
(	O	O
GT	O	O
)	O	O
n	O	O
polymorphism	O	O
in	O	O
intron	O	O
2	O	O
of	O	O
the	O	O
MAOB	O	O
gene	O	O
and	O	O
the	O	O
NDP	O	O
locus	O	O
,	O	O
in	O	O
a	O	O
family	O	O
previously	O	O
reported	O	O
to	O	O
have	O	O
a	O	O
recombination	O	O
between	O	O
DXS7	O	O
and	O	O
NDP	O	O
,	O	O
delineates	O	O
a	O	O
flanking	O	O
marker	O	O
telomeric	O	O
to	O	O
this	O	O
disease	O	O
gene	O	O
.	O	O

An	O	O
anonymous	O	O
DNA	O	O
probe	O	O
,	O	O
dc12	O	O
,	O	O
present	O	O
in	O	O
one	O	O
of	O	O
the	O	O
YACs	O	O
and	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
submicroscopic	O	O
deletion	O	O
which	O	O
includes	O	O
MAOA	O	O
and	O	O
MAOB	O	O
but	O	O
not	O	O
L1	O	O
.	O	O

28	O	O
,	O	O
serves	O	O
as	O	O
a	O	O
flanking	O	O
marker	O	O
centromeric	O	O
to	O	O
the	O	O
disease	O	O
gene	O	O
.	O	O

An	O	O
Alu	O	O
-	O	O
PCR	O	O
fragment	O	O
from	O	O
the	O	O
right	O	O
arm	O	O
of	O	O
the	O	O
MAO	O	O
YAC	O	O
(	O	O
YMAO	O	O
.	O	O

AluR	O	O
)	O	O
is	O	O
not	O	O
deleted	O	O
in	O	O
this	O	O
patient	O	O
and	O	O
also	O	O
delineates	O	O
the	O	O
centromeric	O	O
extent	O	O
of	O	O
the	O	O
obligate	O	O
disease	O	O
region	O	O
.	O	O

The	O	O
apparent	O	O
order	O	O
of	O	O
these	O	O
loci	O	O
is	O	O
telomere	O	O
.	O	O

DXS7	O	O
-	O	O
MAOA	O	O
-	O	O
MAOB	O	O
-	O	O
NDP	O	O
-	O	O
dc12	O	O
-	O	O
YMAO	O	O
DXS7	O	O
-	O	O
MAOA	O	O
-	O	O
MAOB	O	O
-	O	O
NDP	O	O
-	O	O
dc12	O	O
-	O	O
YMAO	O	O
.	O	O

AluR	O	O
.	O	O

centromere	O	O
.	O	O

Together	O	O
these	O	O
data	O	O
define	O	O
the	O	O
obligate	O	O
region	O	O
containing	O	O
the	O	O
NDP	O	O
gene	O	O
to	O	O
a	O	O
chromosomal	O	O
segment	O	O
less	O	O
than	O	O
150	O	O
kb	O	O
.	O	O

Molecular	O	O
genetics	O	O
of	O	O
the	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
Mediterranean	O	O
variant	O	O
and	O	O
description	O	O
of	O	O
a	O	O
new	O	O
G6PD	O	O
mutant	O	O
,	O	O
G6PD	O	O
Andalus1361A	O	O
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
;	I-Disease	D005955
E	I-Disease	D005955
.	I-Disease	D005955

C	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

1	I-Disease	D005955
.	I-Disease	D005955

49	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
the	O	O
most	O	O
common	O	O
human	O	O
enzymopathy	B-Disease	D008661
;	O	O
more	O	O
than	O	O
300	O	O
different	O	O
biochemical	O	O
variants	O	O
of	O	O
the	O	O
enzyme	O	O
have	O	O
been	O	O
described	O	O
.	O	O

In	O	O
many	O	O
parts	O	O
of	O	O
the	O	O
world	O	O
the	O	O
Mediterranean	O	O
type	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
prevalent	O	O
.	O	O

However	O	O
,	O	O
G6PD	O	O
Mediterranean	O	O
has	O	O
come	O	O
to	O	O
be	O	O
regarded	O	O
as	O	O
a	O	O
generic	O	O
term	O	O
applied	O	O
to	O	O
similar	O	O
G6PD	O	O
mutations	O	O
thought	O	O
,	O	O
however	O	O
,	O	O
to	O	O
represent	O	O
a	O	O
somewhat	O	O
heterogeneous	O	O
group	O	O
.	O	O

A	O	O
C	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
mutation	O	O
at	O	O
nucleotide	O	O
563	O	O
of	O	O
G6PD	O	O
Mediterranean	O	O
has	O	O
been	O	O
identified	O	O
by	O	O
Vulliamy	O	O
et	O	O
al	O	O
.	O	O

,	O	O
and	O	O
the	O	O
same	O	O
mutation	O	O
has	O	O
been	O	O
found	O	O
by	O	O
De	O	O
Vita	O	O
et	O	O
al	O	O
.	O	O

in	O	O
G6PD	O	O
Mediterranean	O	O
,	O	O
G6PD	O	O
Sassari	O	O
,	O	O
and	O	O
G6PD	O	O
Cagliari	O	O
.	O	O

The	O	O
latter	O	O
subjects	O	O
had	O	O
an	O	O
additional	O	O
mutation	O	O
,	O	O
at	O	O
nucleotide	O	O
1311	O	O
,	O	O
that	O	O
did	O	O
not	O	O
produce	O	O
a	O	O
coding	O	O
change	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
genomic	O	O
DNA	O	O
of	O	O
five	O	O
patients	O	O
-	O	O
-	O	O
four	O	O
of	O	O
Spanish	O	O
origin	O	O
and	O	O
one	O	O
of	O	O
Jewish	O	O
origin	O	O
-	O	O
-	O	O
having	O	O
enzymatically	O	O
documented	O	O
G6PD	O	O
Mediterranean	O	O
.	O	O

All	O	O
had	O	O
both	O	O
the	O	O
mutation	O	O
at	O	O
nucleotide	O	O
563	O	O
and	O	O
that	O	O
at	O	O
nucleotide	O	O
1311	O	O
.	O	O

A	O	O
sixth	O	O
sample	O	O
,	O	O
resembling	O	O
G6PD	O	O
Mediterranean	O	O
kinetically	O	O
but	O	O
with	O	O
a	O	O
slightly	O	O
rapid	O	O
electrophoretic	O	O
mobility	O	O
,	O	O
was	O	O
designated	O	O
G6PD	O	O
Andalus	O	O
and	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
different	O	O
mutation	O	O
,	O	O
a	O	O
G	O	O
-	O	O
-	O	O
-	O	O
-	O	O
A	O	O
transition	O	O
at	O	O
nucleotide	O	O
1361	O	O
,	O	O
producing	O	O
an	O	O
arginine	O	O
-	O	O
to	O	O
-	O	O
histidine	O	O
substitution	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
G6PD	O	O
Mediterranean	O	O
is	O	O
,	O	O
after	O	O
all	O	O
,	O	O
relatively	O	O
homogeneous	O	O
.	O	O

Small	O	O
nuclear	O	O
ribonucleoprotein	O	O
polypeptide	O	O
N	O	O
(	O	O
SNRPN	O	O
)	O	O
,	O	O
an	O	O
expressed	O	O
gene	O	O
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
critical	O	O
region	O	O
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
is	O	O
associated	O	O
with	O	O
paternally	O	O
derived	O	O
chromosomal	O	O
deletions	O	O
in	O	O
region	O	O
15q11	O	O
-	O	O
13	O	O
or	O	O
with	O	O
maternal	B-Disease	C538037
disomy	I-Disease	C538037
for	I-Disease	C538037
chromosome	I-Disease	C538037
15	I-Disease	C538037
.	O	O

Therefore	O	O
,	O	O
loss	O	O
of	O	O
the	O	O
expressed	O	O
paternal	O	O
alleles	O	O
of	O	O
maternally	O	O
imprinted	O	O
genes	O	O
must	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
PWS	B-Disease	D011218
phenotype	O	O
.	O	O

We	O	O
have	O	O
mapped	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
small	O	O
nuclear	O	O
RNA	O	O
associated	O	O
polypeptide	O	O
SmN	O	O
(	O	O
SNRPN	O	O
)	O	O
to	O	O
human	O	O
chromosome	O	O
15q12	O	O
and	O	O
a	O	O
processed	O	O
pseudogene	O	O
SNRPNP1	O	O
to	O	O
chromosome	O	O
region	O	O
6pter	O	O
-	O	O
p21	O	O
.	O	O

Furthermore	O	O
,	O	O
SNRPN	O	O
was	O	O
mapped	O	O
to	O	O
the	O	O
minimal	O	O
deletion	O	O
interval	O	O
that	O	O
is	O	O
critical	O	O
for	O	O
PWS	B-Disease	D011218
.	O	O

The	O	O
fact	O	O
that	O	O
the	O	O
mouse	O	O
Snrpn	O	O
gene	O	O
is	O	O
maternally	O	O
imprinted	O	O
in	O	O
brain	O	O
suggests	O	O
that	O	O
loss	O	O
of	O	O
the	O	O
paternally	O	O
derived	O	O
SNRPN	O	O
allele	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
PWS	B-Disease	D011218
phenotype	O	O
.	O	O

.	O	O

Increased	O	O
incidence	O	O
of	O	O
cancer	B-Disease	D009369
in	O	O
patients	O	O
with	O	O
cartilage	B-Disease	C535916
-	I-Disease	C535916
hair	I-Disease	C535916
hypoplasia	I-Disease	C535916
.	O	O

OBJECTIVE	O	O
Previous	O	O
reports	O	O
have	O	O
suggested	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
among	O	O
patients	O	O
with	O	O
cartilage	B-Disease	C535916
-	I-Disease	C535916
hair	I-Disease	C535916
hypoplasia	I-Disease	C535916
(	O	O
CHH	B-Disease	C535916
)	O	O
.	O	O

This	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
further	O	O
evaluate	O	O
this	O	O
risk	O	O
among	O	O
patients	O	O
with	O	O
CHH	B-Disease	C535916
and	O	O
their	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
One	O	O
hundred	O	O
twenty	O	O
-	O	O
two	O	O
patients	O	O
with	O	O
CHH	B-Disease	C535916
were	O	O
identified	O	O
through	O	O
2	O	O
countrywide	O	O
epidemiologic	O	O
surveys	O	O
in	O	O
1974	O	O
and	O	O
in	O	O
1986	O	O
.	O	O

Their	O	O
parents	O	O
and	O	O
nonaffected	O	O
siblings	O	O
were	O	O
identified	O	O
through	O	O
the	O	O
Population	O	O
Register	O	O
Center	O	O
.	O	O

This	O	O
cohort	O	O
underwent	O	O
follow	O	O
-	O	O
up	O	O
for	O	O
cancer	B-Disease	D009369
incidence	O	O
through	O	O
the	O	O
Finnish	O	O
Cancer	O	O
Registry	O	O
to	O	O
the	O	O
end	O	O
of	O	O
1995	O	O
.	O	O

RESULTS	O	O
A	O	O
statistically	O	O
significant	O	O
excess	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
was	O	O
seen	O	O
among	O	O
the	O	O
patients	O	O
with	O	O
CHH	B-Disease	C535916
(	O	O
standardized	O	O
incidence	O	O
ratio	O	O
6	O	O
.	O	O

9	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
2	O	O
.	O	O

3	O	O
to	O	O
16	O	O
)	O	O
,	O	O
which	O	O
was	O	O
mainly	O	O
attributable	O	O
to	O	O
non	B-Disease	D008228
-	I-Disease	D008228
Hodgkins	I-Disease	D008228
lymphoma	I-Disease	D008228
(	O	O
standardized	O	O
incidence	O	O
ratio	O	O
90	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
18	O	O
to	O	O
264	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
significant	O	O
excess	O	O
risk	O	O
of	O	O
basal	B-Disease	D002280
cell	I-Disease	D002280
carcinoma	I-Disease	D002280
was	O	O
seen	O	O
(	O	O
standardized	O	O
incidence	O	O
ratio	O	O
35	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
7	O	O
.	O	O

2	O	O
to	O	O
102	O	O
)	O	O
.	O	O

The	O	O
cancer	B-Disease	D009369
incidence	O	O
among	O	O
the	O	O
siblings	O	O
or	O	O
the	O	O
parents	O	O
did	O	O
not	O	O
differ	O	O
from	O	O
the	O	O
average	O	O
cancer	B-Disease	D009369
incidence	O	O
in	O	O
the	O	O
Finnish	O	O
population	O	O
.	O	O

CONCLUSIONS	O	O
This	O	O
study	O	O
confirms	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
,	O	O
especially	O	O
non	B-Disease	D008228
-	I-Disease	D008228
Hodgkins	I-Disease	D008228
lymphoma	I-Disease	D008228
,	O	O
probably	O	O
attributable	O	O
to	O	O
defective	O	O
immunity	O	O
,	O	O
among	O	O
patients	O	O
with	O	O
CHH	B-Disease	C535916
.	O	O

Genetic	O	O
polymorphism	O	O
of	O	O
G6PD	O	O
in	O	O
a	O	O
Bulgarian	O	O
population	O	O
.	O	O

Considerable	O	O
genetic	O	O
heterogeneity	O	O
in	O	O
G6PD	O	O
was	O	O
found	O	O
in	O	O
the	O	O
Bulgarian	O	O
population	O	O
-	O	O
14	O	O
G6PD	O	O
variants	O	O
isolated	O	O
from	O	O
117	O	O
hemizygous	O	O
carriers	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

Of	O	O
these	O	O
,	O	O
G6PD	O	O
Mediterranean	O	O
type	O	O
was	O	O
a	O	O
polymorphic	O	O
variant	O	O
and	O	O
G6PD	O	O
Corinth	O	O
occurred	O	O
with	O	O
high	O	O
frequency	O	O
.	O	O

Two	O	O
new	O	O
variants	O	O
were	O	O
identified	O	O
-	O	O
G6PD	O	O
Rudosem	O	O
and	O	O
G6PD	O	O
Nedelino	O	O
.	O	O

In	O	O
a	O	O
selected	O	O
group	O	O
of	O	O
78	O	O
subjects	O	O
with	O	O
clinical	O	O
manifestations	O	O
,	O	O
four	O	O
variants	O	O
were	O	O
established	O	O
G6PD	O	O
Mediterranian	O	O
,	O	O
G6PD	O	O
Corinth	O	O
,	O	O
G6PD	O	O
Seattle	O	O
and	O	O
G6PD	O	O
Ohut	O	O
II	O	O
.	O	O

.	O	O

A	O	O
genetic	O	O
etiology	O	O
for	O	O
DiGeorge	B-Disease	D004062
syndrome	I-Disease	D004062
:	O	O
consistent	O	O
deletions	O	O
and	O	O
microdeletions	O	O
of	O	O
22q11	O	O
.	O	O

DiGeorge	B-Disease	D004062
syndrome	I-Disease	D004062
(	O	O
DGS	B-Disease	D004062
)	O	O
,	O	O
a	O	O
developmental	O	O
field	O	O
defect	O	O
of	O	O
the	O	O
third	O	O
and	O	O
fourth	O	O
pharyngeal	O	O
pouches	O	O
,	O	O
is	O	O
characterized	O	O
by	O	O
aplasia	B-Disease	C536288
or	I-Disease	C536288
hypoplasia	I-Disease	C536288
of	I-Disease	C536288
the	I-Disease	C536288
thymus	I-Disease	C536288
and	I-Disease	C536288
parathyroid	I-Disease	C536288
glands	I-Disease	C536288
and	O	O
by	O	O
conotruncal	B-Disease	C535464
cardiac	I-Disease	C535464
malformations	I-Disease	C535464
.	O	O

Cytogenetic	O	O
studies	O	O
support	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
DGS	B-Disease	D004062
critical	O	O
region	O	O
in	O	O
band	O	O
22q11	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
report	O	O
the	O	O
results	O	O
of	O	O
clinical	O	O
,	O	O
cytogenetic	O	O
,	O	O
and	O	O
molecular	O	O
studies	O	O
of	O	O
14	O	O
patients	O	O
with	O	O
DGS	B-Disease	D004062
.	O	O

Chromosome	O	O
analysis	O	O
,	O	O
utilizing	O	O
high	O	O
-	O	O
resolution	O	O
banding	O	O
techniques	O	O
,	O	O
detected	O	O
interstitial	O	O
deletions	O	O
in	O	O
five	O	O
probands	O	O
and	O	O
was	O	O
inconclusive	O	O
for	O	O
a	O	O
deletion	O	O
in	O	O
three	O	O
probands	O	O
.	O	O

The	O	O
remaining	O	O
six	O	O
patients	O	O
had	O	O
normal	O	O
karyotypes	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
molecular	O	O
analysis	O	O
detected	O	O
DNA	O	O
deletions	O	O
in	O	O
all	O	O
14	O	O
probands	O	O
.	O	O

Two	O	O
of	O	O
10	O	O
loci	O	O
tested	O	O
,	O	O
D22S75	O	O
and	O	O
D22S259	O	O
,	O	O
are	O	O
deleted	O	O
in	O	O
all	O	O
14	O	O
patients	O	O
.	O	O

A	O	O
third	O	O
locus	O	O
,	O	O
D22S66	O	O
,	O	O
is	O	O
deleted	O	O
in	O	O
the	O	O
eight	O	O
DGS	B-Disease	D004062
probands	O	O
tested	O	O
.	O	O

Physical	O	O
mapping	O	O
using	O	O
somatic	O	O
cell	O	O
hybrids	O	O
places	O	O
D22S66	O	O
between	O	O
D22S75	O	O
and	O	O
D22S259	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
should	O	O
be	O	O
deleted	O	O
in	O	O
the	O	O
remaining	O	O
six	O	O
cases	O	O
.	O	O

Parent	O	O
-	O	O
of	O	O
-	O	O
origin	O	O
studies	O	O
were	O	O
performed	O	O
in	O	O
five	O	O
families	O	O
.	O	O

Four	O	O
probands	O	O
failed	O	O
to	O	O
inherit	O	O
a	O	O
maternal	O	O
allele	O	O
,	O	O
and	O	O
one	O	O
failed	O	O
to	O	O
inherit	O	O
a	O	O
paternal	O	O
allele	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
these	O	O
families	O	O
,	O	O
and	O	O
of	O	O
six	O	O
maternally	O	O
and	O	O
five	O	O
paternally	O	O
derived	O	O
unbalanced	O	O
-	O	O
translocation	O	O
DGS	B-Disease	D004062
probands	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
parent	O	O
of	O	O
origin	O	O
or	O	O
imprinting	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
DGS	B-Disease	D004062
.	O	O

Deletion	O	O
of	O	O
the	O	O
same	O	O
three	O	O
loci	O	O
in	O	O
all	O	O
14	O	O
DGS	B-Disease	D004062
probands	O	O
begins	O	O
to	O	O
delineate	O	O
the	O	O
region	O	O
of	O	O
chromosome	O	O
22	O	O
critical	O	O
for	O	O
DGS	B-Disease	D004062
and	O	O
confirms	O	O
the	O	O
hypothesis	O	O
that	O	O
submicroscopic	O	O
deletions	O	O
of	O	O
22q11	O	O
are	O	O
etiologic	O	O
in	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
cases	O	O
.	O	O

.	O	O

Characterisation	O	O
of	O	O
a	O	O
new	O	O
rare	O	O
fragile	O	O
site	O	O
easily	O	O
confused	O	O
with	O	O
the	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
.	O	O

A	O	O
new	O	O
fragile	O	O
site	O	O
(	O	O
FRAXE	O	O
)	O	O
in	O	O
Xq28	O	O
is	O	O
described	O	O
.	O	O

It	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
typical	O	O
folate	O	O
sensitive	O	O
fragile	O	O
site	O	O
.	O	O

The	O	O
fragile	O	O
site	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
it	O	O
does	O	O
not	O	O
give	O	O
abnormal	O	O
results	O	O
when	O	O
subjected	O	O
to	O	O
Southern	O	O
analysis	O	O
with	O	O
probe	O	O
pfxa3	O	O
which	O	O
detects	O	O
the	O	O
unstable	O	O
DNA	O	O
sequence	O	O
characteristic	O	O
of	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	O	O
.	O	O

In	O	O
situ	O	O
hybridization	O	O
mapping	O	O
locates	O	O
the	O	O
fragile	O	O
site	O	O
between	O	O
150	O	O
kb	O	O
and	O	O
600	O	O
kb	O	O
distal	O	O
to	O	O
FRAXA	O	O
.	O	O

The	O	O
distinction	O	O
between	O	O
the	O	O
two	O	O
fragile	O	O
sites	O	O
is	O	O
important	O	O
clinically	O	O
since	O	O
cytogenetic	O	O
detection	O	O
of	O	O
FRAXE	O	O
,	O	O
without	O	O
molecular	O	O
analysis	O	O
,	O	O
could	O	O
result	O	O
in	O	O
misdiagnosis	O	O
of	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	O	O
.	O	O

.	O	O

BRCA1	O	O
mutations	O	O
in	O	O
primary	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
carcinomas	I-Disease	D001943
.	O	O

Loss	O	O
of	O	O
heterozygosity	O	O
data	O	O
from	O	O
familial	B-Disease	D009386
tumors	I-Disease	D009386
suggest	O	O
that	O	O
BRCA1	O	O
,	O	O
a	O	O
gene	O	O
that	O	O
confers	O	O
susceptibility	O	O
to	O	O
ovarian	B-Disease	D010051
and	I-Disease	D010051
early	I-Disease	D010051
-	I-Disease	D010051
onset	I-Disease	D010051
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
encodes	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
.	O	O

The	O	O
BRCA1	O	O
region	O	O
is	O	O
also	O	O
subject	O	O
to	O	O
allelic	O	O
loss	O	O
in	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
,	O	O
an	O	O
indication	O	O
that	O	O
BRCA1	O	O
mutations	O	O
may	O	O
occur	O	O
somatically	O	O
in	O	O
these	O	O
tumors	B-Disease	D009369
.	O	O

The	O	O
BRCA1	O	O
coding	O	O
region	O	O
was	O	O
examined	O	O
for	O	O
mutations	O	O
in	O	O
primary	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
tumors	I-Disease	D001943
that	O	O
show	O	O
allele	O	O
loss	O	O
at	O	O
the	O	O
BRCA1	O	O
locus	O	O
.	O	O

Mutations	O	O
were	O	O
detected	O	O
in	O	O
3	O	O
of	O	O
32	O	O
breast	O	O
and	O	O
1	O	O
of	O	O
12	O	O
ovarian	B-Disease	D010051
carcinomas	I-Disease	D010051
;	O	O
all	O	O
four	O	O
mutations	O	O
were	O	O
germline	O	O
alterations	O	O
and	O	O
occurred	O	O
in	O	O
early	O	O
-	O	O
onset	O	O
cancers	B-Disease	D009369
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
mutation	O	O
of	O	O
BRCA1	O	O
may	O	O
not	O	O
be	O	O
critical	O	O
in	O	O
the	O	O
development	O	O
of	O	O
the	O	O
majority	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
that	O	O
arise	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
mutant	O	O
germline	O	O
allele	O	O
.	O	O

.	O	O

Genomic	O	O
structure	O	O
of	O	O
the	O	O
EWS	O	O
gene	O	O
and	O	O
its	O	O
relationship	O	O
to	O	O
EWSR1	O	O
,	O	O
a	O	O
site	O	O
of	O	O
tumor	B-Disease	D009369
-	O	O
associated	O	O
chromosome	O	O
translocation	O	O
.	O	O

The	O	O
EWS	O	O
gene	O	O
has	O	O
been	O	O
identified	O	O
based	O	O
on	O	O
its	O	O
location	O	O
at	O	O
the	O	O
chromosome	O	O
22	O	O
breakpoint	O	O
of	O	O
the	O	O
t	O	O
(	O	O
11	O	O
;	O	O
22	O	O
)	O	O
(	O	O
q24	O	O
;	O	O
q12	O	O
)	O	O
translocation	O	O
that	O	O
characterizes	O	O
Ewing	B-Disease	D012512
sarcoma	I-Disease	D012512
and	O	O
related	O	O
neuroectodermal	B-Disease	D017599
tumors	I-Disease	D017599
.	O	O

The	O	O
EWS	O	O
gene	O	O
spans	O	O
about	O	O
40	O	O
kb	O	O
of	O	O
DNA	O	O
and	O	O
is	O	O
encoded	O	O
by	O	O
17	O	O
exons	O	O
.	O	O

The	O	O
nucleotide	O	O
sequence	O	O
of	O	O
the	O	O
exons	O	O
is	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
the	O	O
previously	O	O
described	O	O
cDNA	O	O
.	O	O

The	O	O
first	O	O
7	O	O
exons	O	O
encode	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
domain	O	O
of	O	O
EWS	O	O
,	O	O
which	O	O
consists	O	O
of	O	O
a	O	O
repeated	O	O
degenerated	O	O
polypeptide	O	O
of	O	O
7	O	O
to	O	O
12	O	O
residues	O	O
rich	O	O
in	O	O
tyrosine	O	O
,	O	O
serine	O	O
,	O	O
threonine	O	O
,	O	O
glycine	O	O
,	O	O
and	O	O
glutamine	O	O
.	O	O

Exons	O	O
11	O	O
,	O	O
12	O	O
,	O	O
and	O	O
13	O	O
encode	O	O
the	O	O
putative	O	O
RNA	O	O
binding	O	O
domain	O	O
.	O	O

The	O	O
three	O	O
glycine	O	O
-	O	O
and	O	O
arginine	O	O
-	O	O
rich	O	O
motifs	O	O
of	O	O
the	O	O
gene	O	O
are	O	O
mainly	O	O
encoded	O	O
by	O	O
exons	O	O
8	O	O
-	O	O
9	O	O
,	O	O
14	O	O
,	O	O
and	O	O
16	O	O
.	O	O

The	O	O
DNA	O	O
sequence	O	O
in	O	O
the	O	O
5	O	O
region	O	O
of	O	O
the	O	O
gene	O	O
has	O	O
features	O	O
of	O	O
a	O	O
CpG	O	O
-	O	O
rich	O	O
island	O	O
and	O	O
lacks	O	O
canonical	O	O
promoter	O	O
elements	O	O
,	O	O
such	O	O
as	O	O
TATA	O	O
and	O	O
CCAAT	O	O
consensus	O	O
sequences	O	O
.	O	O

Positions	O	O
of	O	O
the	O	O
chromosome	O	O
22	O	O
breakpoints	O	O
were	O	O
determined	O	O
for	O	O
19	O	O
Ewing	B-Disease	D012512
tumors	I-Disease	D012512
.	O	O

They	O	O
were	O	O
localized	O	O
in	O	O
introns	O	O
7	O	O
or	O	O
8	O	O
in	O	O
18	O	O
cases	O	O
and	O	O
in	O	O
intron	O	O
10	O	O
in	O	O
1	O	O
case	O	O
.	O	O

.	O	O

PAX6	O	O
mutations	O	O
in	O	O
aniridia	B-Disease	D015783
.	O	O

Aniridia	B-Disease	D015783
is	O	O
a	O	O
congenital	B-Disease	D005124
malformation	I-Disease	D005124
of	I-Disease	D005124
the	I-Disease	D005124
eye	I-Disease	D005124
,	O	O
chiefly	O	O
characterised	O	O
by	O	O
iris	B-Disease	D007499
hypoplasia	I-Disease	D007499
,	O	O
which	O	O
can	O	O
cause	O	O
blindness	B-Disease	D001766
.	O	O

The	O	O
PAX6	O	O
gene	O	O
was	O	O
isolated	O	O
as	O	O
a	O	O
candidate	O	O
aniridia	B-Disease	D015783
gene	O	O
by	O	O
positional	O	O
cloning	O	O
from	O	O
the	O	O
smallest	O	O
region	O	O
of	O	O
overlap	O	O
of	O	O
aniridia	B-Disease	D015783
-	O	O
associated	O	O
deletions	O	O
.	O	O

Subsequently	O	O
PAX6	O	O
intragenic	O	O
mutations	O	O
were	O	O
demonstrated	O	O
in	O	O
Smalleye	O	O
,	O	O
a	O	O
mouse	O	O
mutant	O	O
which	O	O
is	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
aniridia	B-Disease	D015783
,	O	O
and	O	O
six	O	O
human	O	O
aniridia	B-Disease	D015783
patients	O	O
.	O	O

In	O	O
this	O	O
paper	O	O
we	O	O
describe	O	O
four	O	O
additional	O	O
PAX6	O	O
point	O	O
mutations	O	O
in	O	O
aniridia	B-Disease	D015783
patients	O	O
,	O	O
both	O	O
sporadic	O	O
and	O	O
familial	O	O
.	O	O

These	O	O
mutations	O	O
highlight	O	O
regions	O	O
of	O	O
the	O	O
gene	O	O
which	O	O
are	O	O
essential	O	O
for	O	O
normal	O	O
PAX6	O	O
function	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
frequency	O	O
at	O	O
which	O	O
we	O	O
have	O	O
found	O	O
PAX6	O	O
mutations	O	O
suggests	O	O
that	O	O
lesions	O	O
in	O	O
PAX6	O	O
will	O	O
account	O	O
for	O	O
most	O	O
cases	O	O
of	O	O
aniridia	B-Disease	D015783
.	O	O

.	O	O

Mutations	O	O
in	O	O
the	O	O
PAX6	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
hereditary	O	O
aniridia	B-Disease	D015783
.	O	O

The	O	O
14	O	O
exons	O	O
of	O	O
the	O	O
PAX6	O	O
gene	O	O
have	O	O
been	O	O
analysed	O	O
exon	O	O
-	O	O
by	O	O
-	O	O
exon	O	O
using	O	O
SSCP	O	O
in	O	O
6	O	O
aniridia	B-Disease	D015783
families	O	O
.	O	O

In	O	O
each	O	O
family	O	O
band	O	O
shifts	O	O
were	O	O
observed	O	O
on	O	O
the	O	O
SSCP	O	O
gels	O	O
for	O	O
only	O	O
one	O	O
exon	O	O
and	O	O
direct	O	O
PCR	O	O
-	O	O
sequencing	O	O
revealed	O	O
mutations	O	O
in	O	O
each	O	O
case	O	O
.	O	O

Two	O	O
mutations	O	O
involved	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transitions	O	O
in	O	O
CGAarg	O	O
codons	O	O
in	O	O
exons	O	O
9	O	O
and	O	O
11	O	O
.	O	O

Another	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
converted	O	O
a	O	O
CAG	O	O
-	O	O
glutamine	O	O
to	O	O
a	O	O
TAG	O	O
-	O	O
stop	O	O
in	O	O
exon	O	O
7	O	O
.	O	O

Small	O	O
insertions	O	O
created	O	O
frameshifts	O	O
which	O	O
produced	O	O
downstream	O	O
stop	O	O
codons	O	O
in	O	O
another	O	O
two	O	O
patients	O	O
and	O	O
an	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
mutation	O	O
disrupted	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
exon	O	O
5	O	O
in	O	O
the	O	O
remaining	O	O
family	O	O
.	O	O

Thus	O	O
,	O	O
complete	O	O
inactivation	O	O
of	O	O
the	O	O
PAX6	O	O
gene	O	O
is	O	O
predicted	O	O
in	O	O
all	O	O
cases	O	O
.	O	O

Analysis	O	O
of	O	O
other	O	O
affected	O	O
members	O	O
of	O	O
the	O	O
families	O	O
showed	O	O
that	O	O
,	O	O
in	O	O
each	O	O
case	O	O
,	O	O
all	O	O
affected	O	O
individuals	O	O
carried	O	O
the	O	O
same	O	O
family	O	O
-	O	O
specific	O	O
mutation	O	O
.	O	O

One	O	O
polymorphism	O	O
was	O	O
found	O	O
in	O	O
exon	O	O
7	O	O
.	O	O

This	O	O
data	O	O
strongly	O	O
supports	O	O
the	O	O
candidature	O	O
of	O	O
PAX6	O	O
as	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
hereditary	O	O
aniridia	B-Disease	D015783
.	O	O

.	O	O

Locus	O	O
heterogeneity	O	O
in	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
autosomal	B-Disease	OMIM:610743
recessive	I-Disease	OMIM:610743
ataxia	I-Disease	OMIM:610743
.	O	O

The	O	O
disease	O	O
locus	O	O
was	O	O
assigned	O	O
to	O	O
chromosome	O	O
9	O	O
and	O	O
the	O	O
disease	O	O
gene	O	O
,	O	O
STM7	O	O
/	O	O
X25	O	O
,	O	O
has	O	O
been	O	O
isolated	O	O
.	O	O

To	O	O
date	O	O
most	O	O
data	O	O
suggest	O	O
locus	O	O
homogeneity	O	O
in	O	O
FRDA	B-Disease	D005621
.	O	O

We	O	O
now	O	O
provide	O	O
strong	O	O
evidence	O	O
of	O	O
a	O	O
second	O	O
FRDA	B-Disease	D005621
locus	O	O
.	O	O

Studying	O	O
two	O	O
siblings	O	O
with	O	O
FRDA	B-Disease	D005621
from	O	O
two	O	O
families	O	O
we	O	O
did	O	O
not	O	O
detect	O	O
a	O	O
mutation	O	O
in	O	O
STM7	O	O
/	O	O
X25	O	O
.	O	O

Haplotype	O	O
analysis	O	O
of	O	O
the	O	O
STM7	O	O
/	O	O
X25	O	O
region	O	O
of	O	O
chromosome	O	O
9	O	O
demonstrated	O	O
that	O	O
the	O	O
relevant	O	O
portion	O	O
of	O	O
chromosome	O	O
9	O	O
differs	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

Although	O	O
the	O	O
patients	O	O
studied	O	O
had	O	O
typical	O	O
FRDA	B-Disease	D005621
,	O	O
one	O	O
sibpair	O	O
had	O	O
the	O	O
uncommon	O	O
symptom	O	O
of	O	O
retained	O	O
tendon	O	O
reflexes	O	O
.	O	O

In	O	O
order	O	O
to	O	O
investigate	O	O
whether	O	O
retained	O	O
tendon	O	O
reflexes	O	O
are	O	O
characteristic	O	O
of	O	O
FRDA	B-Disease	D005621
caused	O	O
by	O	O
the	O	O
second	O	O
locus	O	O
,	O	O
FRDA2	O	O
,	O	O
we	O	O
studied	O	O
an	O	O
unrelated	O	O
FRDA	B-Disease	D005621
patient	O	O
with	O	O
retained	O	O
tendon	O	O
reflexes	O	O
.	O	O

The	O	O
observation	O	O
of	O	O
typical	O	O
mutations	O	O
in	O	O
STM7	O	O
/	O	O
X25	O	O
(	O	O
GAA	O	O
expansions	O	O
)	O	O
in	O	O
this	O	O
patient	O	O
demonstrates	O	O
that	O	O
the	O	O
two	O	O
genetically	O	O
different	O	O
forms	O	O
of	O	O
FRDA	B-Disease	D005621
cannot	O	O
be	O	O
distinguished	O	O
clinically	O	O
.	O	O

.	O	O

Haploinsufficiency	B-Disease	OMIM:602482
of	I-Disease	OMIM:602482
the	I-Disease	OMIM:602482
transcription	I-Disease	OMIM:602482
factors	I-Disease	OMIM:602482
FOXC1	I-Disease	OMIM:602482
and	I-Disease	OMIM:602482
FOXC2	I-Disease	OMIM:602482
results	O	O
in	O	O
aberrant	O	O
ocular	O	O
development	O	O
.	O	O

Anterior	B-Disease	C537775
segment	I-Disease	C537775
developmental	I-Disease	C537775
disorders	I-Disease	C537775
,	O	O
including	O	O
Axenfeld	B-Disease	C535679
-	I-Disease	C535679
Rieger	I-Disease	C535679
anomaly	I-Disease	C535679
(	O	O
ARA	B-Disease	C535679
)	O	O
,	O	O
variably	O	O
associate	O	O
with	O	O
harmfully	O	O
elevated	O	O
intraocular	O	O
pressure	O	O
(	O	O
IOP	O	O
)	O	O
,	O	O
which	O	O
causes	O	O
glaucoma	B-Disease	D005901
.	O	O

Clinically	O	O
observed	O	O
dysgenesis	O	O
does	O	O
not	O	O
correlate	O	O
with	O	O
IOP	O	O
,	O	O
however	O	O
,	O	O
and	O	O
the	O	O
etiology	O	O
of	O	O
glaucoma	B-Disease	D005901
development	O	O
is	O	O
not	O	O
understood	O	O
.	O	O

The	O	O
forkhead	O	O
transcription	O	O
factor	O	O
genes	O	O
Foxc1	O	O
(	O	O
formerly	O	O
Mf1	O	O
)	O	O
and	O	O
Foxc2	O	O
(	O	O
formerly	O	O
Mfh1	O	O
)	O	O
are	O	O
expressed	O	O
in	O	O
the	O	O
mesenchyme	O	O
from	O	O
which	O	O
the	O	O
ocular	O	O
drainage	O	O
structures	O	O
derive	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
human	O	O
homolog	O	O
of	O	O
Foxc1	O	O
,	O	O
FKHL7	O	O
,	O	O
cause	O	O
dominant	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
defects	I-Disease	C537775
and	O	O
glaucoma	B-Disease	D005901
in	O	O
various	O	O
families	O	O
.	O	O

We	O	O
show	O	O
that	O	O
Foxc1	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
have	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
abnormalities	I-Disease	C537775
similar	O	O
to	O	O
those	O	O
reported	O	O
in	O	O
human	O	O
patients	O	O
.	O	O

These	O	O
abnormalities	O	O
include	O	O
small	O	O
or	O	O
absent	O	O
Schlemms	O	O
canal	O	O
,	O	O
aberrantly	O	O
developed	O	O
trabecular	O	O
meshwork	O	O
,	O	O
iris	B-Disease	D007499
hypoplasia	I-Disease	D007499
,	O	O
severely	O	O
eccentric	O	O
pupils	O	O
and	O	O
displaced	O	O
Schwalbes	O	O
line	O	O
.	O	O

The	O	O
penetrance	O	O
of	O	O
clinically	O	O
obvious	O	O
abnormalities	O	O
varies	O	O
with	O	O
genetic	O	O
background	O	O
.	O	O

In	O	O
some	O	O
affected	O	O
eyes	O	O
,	O	O
collagen	O	O
bundles	O	O
were	O	O
half	O	O
normal	O	O
diameter	O	O
,	O	O
or	O	O
collagen	O	O
and	O	O
elastic	O	O
tissue	O	O
were	O	O
very	O	O
sparse	O	O
.	O	O

Thus	O	O
,	O	O
abnormalities	O	O
in	O	O
extracellular	O	O
matrix	O	O
synthesis	O	O
or	O	O
organization	O	O
may	O	O
contribute	O	O
to	O	O
development	O	O
of	O	O
the	O	O
ocular	O	O
phenotypes	O	O
.	O	O

Despite	O	O
the	O	O
abnormalities	O	O
in	O	O
ocular	O	O
drainage	O	O
structures	O	O
in	O	O
Foxc1	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
IOP	O	O
was	O	O
normal	O	O
in	O	O
almost	O	O
all	O	O
mice	O	O
analyzed	O	O
,	O	O
on	O	O
all	O	O
genetic	O	O
backgrounds	O	O
and	O	O
at	O	O
all	O	O
ages	O	O
.	O	O

Similar	O	O
abnormalities	O	O
were	O	O
found	O	O
in	O	O
Foxc2	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
but	O	O
no	O	O
disease	O	O
-	O	O
associated	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
human	O	O
homolog	O	O
FKHL14	O	O
in	O	O
32	O	O
ARA	B-Disease	C535679
patients	O	O
.	O	O

Foxc1	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
and	O	O
Foxc2	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
are	O	O
useful	O	O
models	O	O
for	O	O
studying	O	O
anterior	O	O
segment	O	O
development	O	O
and	O	O
its	O	O
anomalies	O	O
,	O	O
and	O	O
may	O	O
allow	O	O
identification	O	O
of	O	O
genes	O	O
that	O	O
interact	O	O
with	O	O
Foxc1	O	O
and	O	O
Foxc2	O	O
(	O	O
or	O	O
FKHL7	O	O
and	O	O
FKHL14	O	O
)	O	O
to	O	O
produce	O	O
a	O	O
phenotype	O	O
with	O	O
elevated	O	O
IOP	O	O
and	O	O
glaucoma	B-Disease	D005901
.	O	O

.	O	O

The	O	O
dermatofibrosarcoma	B-Disease	C538219
protuberans	I-Disease	C538219
-	O	O
associated	O	O
collagen	O	O
type	O	O
Ialpha1	O	O
/	O	O
platelet	O	O
-	O	O
derived	O	O
growth	O	O
factor	O	O
(	O	O
PDGF	O	O
)	O	O
B	O	O
-	O	O
chain	O	O
fusion	O	O
gene	O	O
generates	O	O
a	O	O
transforming	O	O
protein	O	O
that	O	O
is	O	O
processed	O	O
to	O	O
functional	O	O
PDGF	O	O
-	O	O
BB	O	O
.	O	O

Dermatofibrosarcoma	B-Disease	C538219
protuberans	I-Disease	C538219
(	O	O
DFSP	B-Disease	C538219
)	O	O
displays	O	O
chromosomal	O	O
rearrangements	O	O
involving	O	O
chromosome	O	O
17	O	O
and	O	O
22	O	O
,	O	O
which	O	O
fuse	O	O
the	O	O
collagen	O	O
type	O	O
Ialpha1	O	O
(	O	O
COLIA1	O	O
)	O	O
gene	O	O
to	O	O
the	O	O
platelet	O	O
-	O	O
derived	O	O
growth	O	O
factor	O	O
(	O	O
PDGF	O	O
)	O	O
B	O	O
-	O	O
chain	O	O
(	O	O
PDGFB	O	O
)	O	O
gene	O	O
.	O	O

To	O	O
characterize	O	O
the	O	O
functional	O	O
and	O	O
structural	O	O
properties	O	O
of	O	O
the	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
fusion	O	O
protein	O	O
,	O	O
we	O	O
generated	O	O
a	O	O
stable	O	O
NIH3T3	O	O
cell	O	O
line	O	O
that	O	O
contained	O	O
a	O	O
tumor	B-Disease	D009369
-	O	O
derived	O	O
chimeric	O	O
gene	O	O
resulting	O	O
from	O	O
a	O	O
COIA1	O	O
intron	O	O
7	O	O
-	O	O
PDGFB	O	O
intron	O	O
1	O	O
fusion	O	O
.	O	O

Expression	O	O
of	O	O
the	O	O
fusion	O	O
protein	O	O
led	O	O
to	O	O
morphological	O	O
transformation	O	O
and	O	O
increased	O	O
growth	O	O
rate	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

The	O	O
PDGF	O	O
receptor	O	O
kinase	O	O
inhibitor	O	O
CGP57148B	O	O
reversed	O	O
the	O	O
transformed	O	O
phenotype	O	O
and	O	O
reduced	O	O
the	O	O
growth	O	O
rate	O	O
of	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
-	O	O
expressing	O	O
cells	O	O
but	O	O
had	O	O
no	O	O
effects	O	O
on	O	O
control	O	O
cells	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
dimeric	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
precursors	O	O
was	O	O
demonstrated	O	O
through	O	O
PDGFB	O	O
immunoprecipitations	O	O
of	O	O
metabolically	O	O
labeled	O	O
cells	O	O
and	O	O
also	O	O
by	O	O
PDGFB	O	O
immunoprecipitations	O	O
followed	O	O
by	O	O
immunoblotting	O	O
with	O	O
COLIA1	O	O
antibodies	O	O
.	O	O

Pulse	O	O
-	O	O
chase	O	O
studies	O	O
demonstrated	O	O
that	O	O
the	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
precursor	O	O
was	O	O
processed	O	O
to	O	O
an	O	O
end	O	O
product	O	O
that	O	O
was	O	O
indistinguishable	O	O
from	O	O
wild	O	O
-	O	O
type	O	O
PDGF	O	O
-	O	O
BB	O	O
.	O	O

Finally	O	O
,	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
-	O	O
expressing	O	O
cells	O	O
generated	O	O
tumors	B-Disease	D009369
after	O	O
s	O	O
.	O	O

c	O	O
c	O	O
.	O	O

injection	O	O
into	O	O
nude	O	O
mice	O	O
,	O	O
and	O	O
tumor	B-Disease	D009369
growth	O	O
was	O	O
reduced	O	O
by	O	O
treatment	O	O
with	O	O
CGP57148B	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
COLIA1	O	O
/	O	O
PDGFB	O	O
fusion	O	O
associated	O	O
with	O	O
DFSP	B-Disease	C538219
contributes	O	O
to	O	O
tumor	B-Disease	D009369
development	O	O
through	O	O
ectopic	O	O
production	O	O
of	O	O
PDGF	O	O
-	O	O
BB	O	O
and	O	O
the	O	O
formation	O	O
of	O	O
an	O	O
autocrine	O	O
loop	O	O
.	O	O

Our	O	O
findings	O	O
,	O	O
thus	O	O
,	O	O
suggest	O	O
that	O	O
PDGF	O	O
receptors	O	O
could	O	O
be	O	O
a	O	O
target	O	O
for	O	O
pharmacological	O	O
treatment	O	O
of	O	O
DFSP	B-Disease	C538219
and	O	O
giant	B-Disease	C538219
cell	I-Disease	C538219
fibroblastoma	I-Disease	C538219
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

,	O	O
through	O	O
the	O	O
use	O	O
of	O	O
PDGF	O	O
receptor	O	O
kinase	O	O
inhibitors	O	O
such	O	O
as	O	O
CGP57148B	O	O
.	O	O

Founder	O	O
effect	O	O
of	O	O
a	O	O
prevalent	O	O
phenylketonuria	B-Disease	D010661
mutation	O	O
in	O	O
the	O	O
Oriental	O	O
population	O	O
.	O	O

A	O	O
missense	O	O
mutation	O	O
has	O	O
been	O	O
identified	O	O
in	O	O
the	O	O
human	O	O
phenylalanine	O	O
hydroxylase	O	O
[	O	O
PAH	O	O
;	O	O
phenylalanine	O	O
4	O	O
-	O	O
monooxygenase	O	O
;	O	O
L	O	O
-	O	O
phenylalanine	O	O
,	O	O
tetrahydrobiopterin	O	O
oxygen	O	O
oxidoreductase	O	O
(	O	O
4	O	O
-	O	O
hydroxylating	O	O
)	O	O
,	O	O
EC	O	O
1	O	O
.	O	O

14	O	O
.	O	O

16	O	O
.	O	O

1	O	O
]	O	O
gene	O	O
in	O	O
a	O	O
Chinese	O	O
patient	O	O
with	O	O
classic	O	O
phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
.	O	O

A	O	O
G	O	O
-	O	O
to	O	O
-	O	O
C	O	O
transition	O	O
at	O	O
the	O	O
second	O	O
base	O	O
of	O	O
codon	O	O
413	O	O
in	O	O
exon	O	O
12	O	O
of	O	O
the	O	O
gene	O	O
results	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
Pro413	O	O
for	O	O
Arg413	O	O
in	O	O
the	O	O
mutant	O	O
protein	O	O
.	O	O

This	O	O
mutation	O	O
(	O	O
R413P	O	O
)	O	O
results	O	O
in	O	O
negligible	O	O
enzymatic	O	O
activity	O	O
when	O	O
expressed	O	O
in	O	O
heterologous	O	O
mammalian	O	O
cells	O	O
and	O	O
is	O	O
compatible	O	O
with	O	O
a	O	O
classic	O	O
PKU	B-Disease	D010661
phenotype	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

Population	O	O
genetic	O	O
studies	O	O
reveal	O	O
that	O	O
this	O	O
mutation	O	O
is	O	O
tightly	O	O
linked	O	O
to	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
haplotype	O	O
4	O	O
,	O	O
which	O	O
is	O	O
the	O	O
predominant	O	O
haplotype	O	O
of	O	O
the	O	O
PAH	O	O
locus	O	O
in	O	O
the	O	O
Oriental	O	O
population	O	O
.	O	O

It	O	O
accounts	O	O
for	O	O
13	O	O
.	O	O

8	O	O
%	O	O
of	O	O
northern	O	O
Chinese	O	O
and	O	O
27	O	O
%	O	O
of	O	O
Japanese	O	O
PKU	B-Disease	D010661
alleles	O	O
,	O	O
but	O	O
it	O	O
is	O	O
rare	O	O
in	O	O
southern	O	O
Chinese	O	O
(	O	O
2	O	O
.	O	O

2	O	O
%	O	O
)	O	O
and	O	O
is	O	O
absent	O	O
in	O	O
the	O	O
Caucasian	O	O
population	O	O
.	O	O

The	O	O
data	O	O
demonstrate	O	O
unambiguously	O	O
that	O	O
the	O	O
mutation	O	O
occurred	O	O
after	O	O
racial	O	O
divergence	O	O
of	O	O
Orientals	O	O
and	O	O
Caucasians	O	O
and	O	O
suggest	O	O
that	O	O
the	O	O
allele	O	O
has	O	O
spread	O	O
throughout	O	O
the	O	O
Orient	O	O
by	O	O
a	O	O
founder	O	O
effect	O	O
.	O	O

Previous	O	O
protein	O	O
polymorphism	O	O
studies	O	O
in	O	O
eastern	O	O
Asia	O	O
have	O	O
led	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
"	O	O
northern	O	O
Mongoloids	O	O
"	O	O
represented	O	O
a	O	O
founding	O	O
population	O	O
in	O	O
Asia	O	O
.	O	O

Our	O	O
results	O	O
are	O	O
compatible	O	O
with	O	O
this	O	O
hypothesis	O	O
in	O	O
that	O	O
the	O	O
PKU	B-Disease	D010661
mutation	O	O
might	O	O
have	O	O
occurred	O	O
in	O	O
northern	O	O
Mongoloids	O	O
and	O	O
subsequently	O	O
spread	O	O
to	O	O
the	O	O
Chinese	O	O
and	O	O
Japanese	O	O
populations	O	O
.	O	O

Late	O	O
-	O	O
onset	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
:	O	O
a	O	O
subset	O	O
with	O	O
distinct	O	O
clinical	O	O
,	O	O
demographic	O	O
,	O	O
and	O	O
molecular	O	O
genetic	O	O
characteristics	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
prevalence	O	O
and	O	O
characterize	O	O
demographic	O	O
,	O	O
clinical	O	O
,	O	O
and	O	O
genetic	O	O
features	O	O
of	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
of	O	O
late	O	O
onset	O	O
,	O	O
all	O	O
patients	O	O
experiencing	O	O
their	O	O
first	O	O
FMF	B-Disease	D010505
attack	O	O
at	O	O
age	O	O
40	O	O
years	O	O
or	O	O
more	O	O
were	O	O
identified	O	O
using	O	O
the	O	O
computerized	O	O
registry	O	O
of	O	O
our	O	O
FMF	B-Disease	D010505
clinic	O	O
,	O	O
and	O	O
then	O	O
thoroughly	O	O
interviewed	O	O
and	O	O
examined	O	O
.	O	O

The	O	O
control	O	O
group	O	O
consisted	O	O
of	O	O
40	O	O
consecutive	O	O
FMF	B-Disease	D010505
patients	O	O
,	O	O
who	O	O
arrived	O	O
at	O	O
the	O	O
FMF	B-Disease	D010505
clinic	O	O
for	O	O
their	O	O
regular	O	O
follow	O	O
-	O	O
up	O	O
visit	O	O
and	O	O
were	O	O
40	O	O
years	O	O
of	O	O
age	O	O
or	O	O
older	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
examination	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
in	O	O
patients	O	O
and	O	O
controls	O	O
was	O	O
determined	O	O
using	O	O
a	O	O
modified	O	O
score	O	O
,	O	O
developed	O	O
previously	O	O
.	O	O

Mutational	O	O
analysis	O	O
in	O	O
the	O	O
FMF	B-Disease	D010505
gene	O	O
was	O	O
performed	O	O
using	O	O
a	O	O
commercial	O	O
kit	O	O
.	O	O

Only	O	O
20	O	O
of	O	O
4000	O	O
(	O	O
0	O	O
.	O	O

5	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
late	O	O
-	O	O
onset	O	O
FMF	B-Disease	D010505
.	O	O

These	O	O
patients	O	O
were	O	O
mostly	O	O
men	O	O
,	O	O
of	O	O
non	O	O
-	O	O
North	O	O
African	O	O
origin	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

All	O	O
had	O	O
abdominal	O	O
attacks	O	O
and	O	O
in	O	O
most	O	O
these	O	O
were	O	O
the	O	O
only	O	O
manifestation	O	O
of	O	O
their	O	O
disease	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
001	O	O
.	O	O

None	O	O
had	O	O
chronic	O	O
or	O	O
prolonged	O	O
manifestations	O	O
of	O	O
FMF	B-Disease	D010505
,	O	O
for	O	O
example	O	O
,	O	O
amyloidosis	B-Disease	D000686
,	O	O
chronic	B-Disease	D001168
arthritis	I-Disease	D001168
,	O	O
or	O	O
protracted	O	O
myalgia	B-Disease	D059352
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
.	O	O

The	O	O
response	O	O
to	O	O
treatment	O	O
was	O	O
good	O	O
despite	O	O
using	O	O
low	O	O
colchicine	O	O
dose	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
.	O	O

The	O	O
overall	O	O
severity	O	O
score	O	O
indicated	O	O
a	O	O
mild	O	O
disease	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
.	O	O

Mutational	O	O
analysis	O	O
revealed	O	O
absence	O	O
of	O	O
M694V	O	O
homozygosity	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
,	O	O
compared	O	O
to	O	O
our	O	O
regular	O	O
FMF	B-Disease	D010505
population	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
onset	O	O
of	O	O
FMF	B-Disease	D010505
in	O	O
a	O	O
late	O	O
age	O	O
defines	O	O
a	O	O
milder	O	O
form	O	O
of	O	O
disease	O	O
with	O	O
typical	O	O
clinical	O	O
,	O	O
demographic	O	O
,	O	O
and	O	O
molecular	O	O
genetic	O	O
characteristics	O	O
Structure	O	O
of	O	O
the	O	O
human	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
gene	O	O
SGLT1	O	O
.	O	O

Intestinal	O	O
uptake	O	O
of	O	O
dietary	O	O
glucose	O	O
and	O	O
galactose	O	O
is	O	O
mediated	O	O
by	O	O
the	O	O
SGLT1	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
of	O	O
the	O	O
brush	O	O
border	O	O
.	O	O

An	O	O
SGLT1	O	O
missense	O	O
mutation	O	O
underlies	O	O
hereditary	B-Disease	OMIM:606824
glucose	I-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
,	O	O
characterized	O	O
by	O	O
potentially	O	O
fatal	O	O
diarrhea	B-Disease	D003967
;	O	O
conversely	O	O
,	O	O
oral	O	O
rehydration	O	O
therapy	O	O
exploits	O	O
normal	O	O
transport	O	O
to	O	O
alleviate	O	O
life	O	O
-	O	O
threatening	O	O
diarrhea	B-Disease	D003967
of	O	O
infectious	O	O
origin	O	O
.	O	O

We	O	O
have	O	O
mapped	O	O
the	O	O
entire	O	O
human	O	O
SGLT1	O	O
Na	O	O
+	O	O
/	O	O
glucose	O	O
cotransporter	O	O
gene	O	O
from	O	O
cosmid	O	O
and	O	O
lambda	O	O
phage	O	O
clones	O	O
representing	O	O
a	O	O
genomic	O	O
region	O	O
of	O	O
112	O	O
kilobases	O	O
.	O	O

Transcription	O	O
initiation	O	O
occurred	O	O
from	O	O
a	O	O
site	O	O
27	O	O
base	O	O
pairs	O	O
3	O	O
of	O	O
a	O	O
TATAA	O	O
sequence	O	O
.	O	O

All	O	O
exon	O	O
-	O	O
flanking	O	O
regions	O	O
were	O	O
sequenced	O	O
,	O	O
and	O	O
the	O	O
entire	O	O
112	O	O
-	O	O
kilobase	O	O
region	O	O
mapped	O	O
with	O	O
four	O	O
restriction	O	O
enzymes	O	O
.	O	O

SGLT1	O	O
is	O	O
comprised	O	O
of	O	O
15	O	O
exons	O	O
(	O	O
spanning	O	O
72	O	O
kilobases	O	O
)	O	O
;	O	O
a	O	O
possible	O	O
evolutionary	O	O
origin	O	O
from	O	O
a	O	O
six	O	O
-	O	O
membrane	O	O
-	O	O
span	O	O
ancestral	O	O
precursor	O	O
via	O	O
a	O	O
gene	O	O
duplication	O	O
event	O	O
is	O	O
suggested	O	O
from	O	O
comparison	O	O
of	O	O
exons	O	O
against	O	O
protein	O	O
secondary	O	O
structure	O	O
and	O	O
from	O	O
sequence	O	O
considerations	O	O
.	O	O

A	O	O
new	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
1	O	O
causing	O	O
glucose	B-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
is	O	O
also	O	O
described	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
-	O	O
dependent	O	O
cotransporter	O	O
gene	O	O
structure	O	O
reported	O	O
.	O	O

These	O	O
data	O	O
facilitate	O	O
the	O	O
search	O	O
for	O	O
new	O	O
glucose	B-Disease	OMIM:606824
/	I-Disease	OMIM:606824
galactose	I-Disease	OMIM:606824
malabsorption	I-Disease	OMIM:606824
-	O	O
related	O	O
mutations	O	O
in	O	O
this	O	O
important	O	O
gene	O	O
and	O	O
provide	O	O
a	O	O
basis	O	O
for	O	O
future	O	O
evolutionary	O	O
comparisons	O	O
with	O	O
other	O	O
Na	O	O
(	O	O
+	O	O
)	O	O
-	O	O
dependent	O	O
cotransporters	O	O
.	O	O

.	O	O

ATM	O	O
phosphorylates	O	O
p95	O	O
/	O	O
nbs1	O	O
in	O	O
an	O	O
S	O	O
-	O	O
phase	O	O
checkpoint	O	O
pathway	O	O
.	O	O

The	O	O
rare	B-Disease	D035583
diseases	I-Disease	D035583
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
AT	B-Disease	D001260
)	O	O
,	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
,	O	O
and	O	O
Nijmegen	B-Disease	D049932
breakage	I-Disease	D049932
syndrome	I-Disease	D049932
(	O	O
NBS	B-Disease	D049932
)	O	O
,	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
p95	O	O
/	O	O
nbs1	O	O
gene	O	O
,	O	O
share	O	O
a	O	O
variety	O	O
of	O	O
phenotypic	B-Disease	D004194
abnormalities	I-Disease	D004194
such	O	O
as	O	O
chromosomal	B-Disease	D043171
instability	I-Disease	D043171
,	O	O
radiation	O	O
sensitivity	O	O
and	O	O
defects	O	O
in	O	O
cell	O	O
-	O	O
cycle	O	O
checkpoints	O	O
in	O	O
response	O	O
to	O	O
ionizing	O	O
radiation	O	O
.	O	O

The	O	O
ATM	O	O
gene	O	O
encodes	O	O
a	O	O
protein	O	O
kinase	O	O
that	O	O
is	O	O
activated	O	O
by	O	O
ionizing	O	O
radiation	O	O
or	O	O
radiomimetic	O	O
drugs	O	O
,	O	O
whereas	O	O
p95	O	O
/	O	O
nbs1	O	O
is	O	O
part	O	O
of	O	O
a	O	O
protein	O	O
complex	O	O
that	O	O
is	O	O
involved	O	O
in	O	O
responses	O	O
to	O	O
DNA	O	O
double	O	O
-	O	O
strand	O	O
breaks	O	O
.	O	O

Here	O	O
,	O	O
because	O	O
of	O	O
the	O	O
similarities	O	O
between	O	O
AT	B-Disease	D001260
and	O	O
NBS	B-Disease	D049932
,	O	O
we	O	O
evaluated	O	O
the	O	O
functional	O	O
interactions	O	O
between	O	O
ATM	O	O
and	O	O
p95	O	O
/	O	O
nbs1	O	O
.	O	O

Activation	O	O
of	O	O
the	O	O
ATM	O	O
kinase	O	O
by	O	O
ionizing	O	O
radiation	O	O
and	O	O
induction	O	O
of	O	O
ATM	O	O
-	O	O
dependent	O	O
responses	O	O
in	O	O
NBS	B-Disease	D049932
cells	O	O
indicated	O	O
that	O	O
p95	O	O
/	O	O
nbs1	O	O
may	O	O
not	O	O
be	O	O
required	O	O
for	O	O
signalling	O	O
to	O	O
ATM	O	O
after	O	O
ionizing	O	O
radiation	O	O
.	O	O

However	O	O
,	O	O
p95	O	O
/	O	O
nbs1	O	O
was	O	O
phosphorylated	O	O
on	O	O
serine	O	O
343	O	O
in	O	O
an	O	O
ATM	O	O
-	O	O
dependent	O	O
manner	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
after	O	O
ionizing	O	O
radiation	O	O
.	O	O

A	O	O
p95	O	O
/	O	O
nbs1	O	O
construct	O	O
mutated	O	O
at	O	O
the	O	O
ATM	O	O
phosphorylation	O	O
site	O	O
abrogated	O	O
an	O	O
S	O	O
-	O	O
phase	O	O
checkpoint	O	O
induced	O	O
by	O	O
ionizing	O	O
radiation	O	O
in	O	O
normal	O	O
cells	O	O
and	O	O
failed	O	O
to	O	O
compensate	O	O
for	O	O
this	O	O
functional	O	O
deficiency	O	O
in	O	O
NBS	B-Disease	D049932
cells	O	O
.	O	O

These	O	O
observations	O	O
link	O	O
ATM	O	O
and	O	O
p95	O	O
/	O	O
nbs1	O	O
in	O	O
a	O	O
common	O	O
signalling	O	O
pathway	O	O
and	O	O
provide	O	O
an	O	O
explanation	O	O
for	O	O
phenotypic	O	O
similarities	O	O
in	O	O
these	O	O
two	O	O
diseases	O	O
.	O	O

.	O	O

Two	O	O
distinct	O	O
mutations	O	O
at	O	O
a	O	O
single	O	O
BamHI	O	O
site	O	O
in	O	O
phenylketonuria	B-Disease	D010661
.	O	O

Classical	B-Disease	D010661
phenylketonuria	I-Disease	D010661
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disease	I-Disease	D030342
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

The	O	O
abolition	O	O
of	O	O
an	O	O
invariant	O	O
BamHI	O	O
site	O	O
located	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
(	O	O
exon	O	O
7	O	O
)	O	O
led	O	O
to	O	O
the	O	O
recognition	O	O
of	O	O
two	O	O
new	O	O
point	O	O
mutations	O	O
at	O	O
codon	O	O
272	O	O
and	O	O
273	O	O
(	O	O
272gly	O	O
-	O	O
-	O	O
-	O	O
-	O	O
stop	O	O
and	O	O
273ser	O	O
-	O	O
-	O	O
-	O	O
-	O	O
phe	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Both	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
north	O	O
eastern	O	O
France	O	O
or	O	O
Belgium	O	O
and	O	O
occurred	O	O
on	O	O
the	O	O
background	O	O
of	O	O
RFLP	O	O
haplotype	O	O
7	O	O
alleles	O	O
.	O	O

The	O	O
present	O	O
study	O	O
supports	O	O
the	O	O
view	O	O
that	O	O
the	O	O
clinical	O	O
heterogeneity	O	O
in	O	O
PKU	B-Disease	D010661
is	O	O
accounted	O	O
for	O	O
by	O	O
the	O	O
large	O	O
variety	O	O
of	O	O
mutant	O	O
genotypes	O	O
associated	O	O
with	O	O
PAH	B-Disease	OMIM:261600
deficiencies	I-Disease	OMIM:261600
.	O	O

.	O	O

Functional	O	O
link	O	O
between	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
and	O	O
Nijmegen	B-Disease	D049932
breakage	I-Disease	D049932
syndrome	I-Disease	D049932
gene	O	O
products	O	O
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
and	O	O
Nijmegen	B-Disease	D049932
breakage	I-Disease	D049932
syndrome	I-Disease	D049932
(	O	O
NBS	B-Disease	D049932
)	O	O
are	O	O
recessive	B-Disease	D030342
genetic	I-Disease	D030342
disorders	I-Disease	D030342
with	O	O
susceptibility	O	O
to	O	O
cancer	B-Disease	D009369
and	O	O
similar	O	O
cellular	O	O
phenotypes	O	O
.	O	O

The	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
designated	O	O
ATM	O	O
,	O	O
is	O	O
a	O	O
member	O	O
of	O	O
a	O	O
family	O	O
of	O	O
kinases	O	O
characterized	O	O
by	O	O
a	O	O
carboxy	O	O
-	O	O
terminal	O	O
phosphatidylinositol	O	O
3	O	O
-	O	O
kinase	O	O
-	O	O
like	O	O
domain	O	O
.	O	O

The	O	O
NBS1	O	O
protein	O	O
is	O	O
specifically	O	O
mutated	O	O
in	O	O
patients	O	O
with	O	O
Nijmegen	B-Disease	D049932
breakage	I-Disease	D049932
syndrome	I-Disease	D049932
and	O	O
forms	O	O
a	O	O
complex	O	O
with	O	O
the	O	O
DNA	O	O
repair	O	O
proteins	O	O
Rad50	O	O
and	O	O
Mrel1	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
phosphorylation	O	O
of	O	O
NBS1	O	O
,	O	O
induced	O	O
by	O	O
ionizing	O	O
radiation	O	O
,	O	O
requires	O	O
catalytically	O	O
active	O	O
ATM	O	O
.	O	O

Complexes	O	O
containing	O	O
ATM	O	O
and	O	O
NBS1	O	O
exist	O	O
in	O	O
vivo	O	O
in	O	O
both	O	O
untreated	O	O
cells	O	O
and	O	O
cells	O	O
treated	O	O
with	O	O
ionizing	O	O
radiation	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
two	O	O
residues	O	O
of	O	O
NBS1	O	O
,	O	O
Ser	O	O
278	O	O
and	O	O
Ser	O	O
343	O	O
that	O	O
are	O	O
phosphorylated	O	O
in	O	O
vitro	O	O
by	O	O
ATM	O	O
and	O	O
whose	O	O
modification	O	O
in	O	O
vivo	O	O
is	O	O
essential	O	O
for	O	O
the	O	O
cellular	O	O
response	O	O
to	O	O
DNA	O	O
damage	O	O
.	O	O

This	O	O
response	O	O
includes	O	O
S	O	O
-	O	O
phase	O	O
checkpoint	O	O
activation	O	O
,	O	O
formation	O	O
of	O	O
the	O	O
NBS1	O	O
/	O	O
Mrel1	O	O
/	O	O
Rad50	O	O
nuclear	O	O
foci	O	O
and	O	O
rescue	O	O
of	O	O
hypersensitivity	B-Disease	D004194
to	I-Disease	D004194
ionizing	I-Disease	D004194
radiation	I-Disease	D004194
.	O	O

Together	O	O
,	O	O
these	O	O
results	O	O
demonstrate	O	O
a	O	O
biochemical	O	O
link	O	O
between	O	O
cell	O	O
-	O	O
cycle	O	O
checkpoints	O	O
activated	O	O
by	O	O
DNA	O	O
damage	O	O
and	O	O
DNA	O	O
repair	O	O
in	O	O
two	O	O
genetic	B-Disease	D030342
diseases	I-Disease	D030342
with	O	O
overlapping	O	O
phenotypes	O	O
.	O	O

.	O	O

Structure	O	O
and	O	O
genomic	O	O
sequence	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
kinase	O	O
)	O	O
gene	O	O
.	O	O

The	O	O
mutation	O	O
causing	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
has	O	O
recently	O	O
been	O	O
identified	O	O
as	O	O
an	O	O
unstable	O	O
CTG	O	O
trinucleotide	O	O
repeat	O	O
located	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
a	O	O
gene	O	O
encoding	O	O
for	O	O
a	O	O
protein	O	O
with	O	O
putative	O	O
serine	O	O
-	O	O
threonine	O	O
protein	O	O
kinase	O	O
activity	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
present	O	O
the	O	O
genomic	O	O
sequences	O	O
of	O	O
the	O	O
human	O	O
and	O	O
murine	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
these	O	O
sequences	O	O
with	O	O
each	O	O
other	O	O
and	O	O
with	O	O
known	O	O
cDNA	O	O
sequences	O	O
from	O	O
both	O	O
species	O	O
,	O	O
led	O	O
us	O	O
to	O	O
predict	O	O
a	O	O
translation	O	O
initiation	O	O
codon	O	O
,	O	O
as	O	O
well	O	O
as	O	O
determine	O	O
the	O	O
organization	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
.	O	O

Several	O	O
polymorphisms	O	O
within	O	O
the	O	O
human	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
and	O	O
PCR	O	O
assays	O	O
to	O	O
detect	O	O
two	O	O
of	O	O
these	O	O
are	O	O
described	O	O
.	O	O

The	O	O
complete	O	O
sequence	O	O
and	O	O
characterization	O	O
of	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
kinase	O	O
gene	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
identification	O	O
of	O	O
novel	O	O
polymorphisms	O	O
within	O	O
the	O	O
gene	O	O
,	O	O
represent	O	O
an	O	O
important	O	O
step	O	O
in	O	O
a	O	O
further	O	O
understanding	O	O
of	O	O
the	O	O
genetics	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
and	O	O
the	O	O
molecular	O	O
biology	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
novel	O	O
imprinted	O	O
transcripts	O	O
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
and	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
deletion	O	O
region	O	O
:	O	O
further	O	O
evidence	O	O
for	O	O
regional	O	O
imprinting	O	O
control	O	O
.	O	O

Deletions	O	O
and	O	O
other	O	O
abnormalities	O	O
of	O	O
human	O	O
chromosome	O	O
15q11	O	O
-	O	O
q13	O	O
are	O	O
associated	O	O
with	O	O
two	O	O
developmental	O	O
disorders	O	O
,	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
and	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
(	O	O
AS	B-Disease	D017204
)	O	O
.	O	O

Loss	O	O
of	O	O
expression	O	O
of	O	O
imprinted	O	O
,	O	O
paternally	O	O
expressed	O	O
genes	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
PWS	B-Disease	D011218
.	O	O

However	O	O
,	O	O
the	O	O
number	O	O
of	O	O
imprinted	O	O
genes	O	O
that	O	O
contribute	O	O
to	O	O
PWS	B-Disease	D011218
,	O	O
and	O	O
the	O	O
range	O	O
over	O	O
which	O	O
the	O	O
imprinting	O	O
signal	O	O
acts	O	O
to	O	O
silence	O	O
one	O	O
copy	O	O
of	O	O
the	O	O
gene	O	O
in	O	O
a	O	O
parent	O	O
-	O	O
of	O	O
-	O	O
origin	O	O
-	O	O
specific	O	O
manner	O	O
,	O	O
are	O	O
unknown	O	O
.	O	O

To	O	O
identify	O	O
additional	O	O
imprinted	O	O
genes	O	O
that	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
PWS	B-Disease	D011218
phenotype	O	O
and	O	O
to	O	O
understand	O	O
the	O	O
regional	O	O
control	O	O
of	O	O
imprinting	O	O
in	O	O
15q11	O	O
-	O	O
q13	O	O
,	O	O
we	O	O
have	O	O
constructed	O	O
an	O	O
imprinted	O	O
transcript	O	O
map	O	O
of	O	O
the	O	O
PWS	B-Disease	D011218
-	O	O
AS	B-Disease	D017204
deletion	O	O
interval	O	O
.	O	O

The	O	O
imprinting	O	O
status	O	O
of	O	O
22	O	O
expressed	O	O
sequence	O	O
tags	O	O
derived	O	O
from	O	O
the	O	O
radiation	O	O
-	O	O
hybrid	O	O
human	O	O
transcript	O	O
maps	O	O
or	O	O
physical	O	O
maps	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
reverse	O	O
transcriptase	O	O
-	O	O
PCR	O	O
assay	O	O
and	O	O
correlated	O	O
with	O	O
the	O	O
position	O	O
of	O	O
the	O	O
transcripts	O	O
on	O	O
the	O	O
physical	O	O
map	O	O
.	O	O

Seven	O	O
new	O	O
paternally	O	O
expressed	O	O
transcripts	O	O
localize	O	O
to	O	O
an	O	O
approximately	O	O
1	O	O
.	O	O

5	O	O
-	O	O
Mb	O	O
domain	O	O
surrounding	O	O
the	O	O
SNRPN	O	O
-	O	O
associated	O	O
imprinting	O	O
center	O	O
,	O	O
which	O	O
already	O	O
includes	O	O
four	O	O
imprinted	O	O
,	O	O
paternally	O	O
expressed	O	O
genes	O	O
.	O	O

All	O	O
other	O	O
tested	O	O
new	O	O
transcripts	O	O
in	O	O
the	O	O
deletion	O	O
region	O	O
were	O	O
expressed	O	O
from	O	O
both	O	O
alleles	O	O
.	O	O

A	O	O
domain	O	O
of	O	O
exclusive	O	O
paternal	O	O
expression	O	O
surrounding	O	O
the	O	O
imprinting	O	O
center	O	O
suggests	O	O
strong	O	O
regional	O	O
control	O	O
of	O	O
the	O	O
imprinting	O	O
process	O	O
.	O	O

This	O	O
study	O	O
provides	O	O
the	O	O
means	O	O
for	O	O
further	O	O
investigation	O	O
of	O	O
additional	O	O
genes	O	O
that	O	O
cause	O	O
or	O	O
modify	O	O
the	O	O
phenotypes	O	O
associated	O	O
with	O	O
rearrangements	O	O
of	O	O
15q11	O	O
-	O	O
q13	O	O
.	O	O

Penetrances	O	O
of	O	O
BRCA1	O	O
1675delA	O	O
and	O	O
1135insA	O	O
with	O	O
respect	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

For	O	O
genetic	O	O
counseling	O	O
and	O	O
predictive	O	O
testing	O	O
in	O	O
families	O	O
with	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
penetrances	O	O
and	O	O
expressions	O	O
of	O	O
the	O	O
underlying	O	O
mutations	O	O
should	O	O
be	O	O
known	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
two	O	O
BRCA1	O	O
founder	O	O
mutations	O	O
in	O	O
the	O	O
Norwegian	O	O
population	O	O
.	O	O

Index	O	O
cases	O	O
for	O	O
the	O	O
present	O	O
study	O	O
were	O	O
found	O	O
two	O	O
different	O	O
ways	O	O
through	O	O
a	O	O
series	O	O
of	O	O
consecutive	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
and	O	O
through	O	O
our	O	O
family	O	O
cancer	B-Disease	D009369
clinic	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
.	O	O

Altogether	O	O
,	O	O
20	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
BRCA1	O	O
1675delA	O	O
,	O	O
and	O	O
10	O	O
had	O	O
1135insA	O	O
.	O	O

Their	O	O
relatives	O	O
were	O	O
described	O	O
with	O	O
respect	O	O
to	O	O
absence	O	O
/	O	O
presence	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
/	I-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Of	O	O
133	O	O
living	O	O
female	O	O
relatives	O	O
,	O	O
83	O	O
(	O	O
62	O	O
%	O	O
)	O	O
were	O	O
tested	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
mutation	O	O
.	O	O

No	O	O
difference	O	O
,	O	O
in	O	O
penetrance	O	O
and	O	O
expression	O	O
,	O	O
between	O	O
the	O	O
two	O	O
mutations	O	O
were	O	O
found	O	O
,	O	O
whereas	O	O
differences	O	O
according	O	O
to	O	O
method	O	O
of	O	O
ascertainment	O	O
were	O	O
seen	O	O
.	O	O

The	O	O
overall	O	O
findings	O	O
were	O	O
that	O	O
disease	O	O
started	O	O
to	O	O
occur	O	O
at	O	O
age	O	O
30	O	O
years	O	O
and	O	O
that	O	O
by	O	O
age	O	O
50	O	O
years	O	O
48	O	O
%	O	O
of	O	O
the	O	O
mutation	O	O
-	O	O
carrying	O	O
women	O	O
had	O	O
experienced	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
/	I-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

More	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
than	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
were	O	O
recorded	O	O
.	O	O

Both	O	O
penetrance	O	O
and	O	O
expression	O	O
(	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
vs	O	O
.	O	O

ovarian	B-Disease	D010051
cancer	I-Disease	D010051
)	O	O
were	O	O
different	O	O
from	O	O
those	O	O
in	O	O
reports	O	O
of	O	O
the	O	O
Ashkenazi	O	O
founder	O	O
mutations	O	O
.	O	O

Whether	O	O
the	O	O
reported	O	O
differences	O	O
reflect	O	O
true	O	O
differences	O	O
and	O	O
/	O	O
or	O	O
methodological	O	O
problems	O	O
is	O	O
discussed	O	O
.	O	O

An	O	O
observed	O	O
excess	O	O
of	O	O
mutation	O	O
carriers	O	O
could	O	O
not	O	O
be	O	O
accounted	O	O
for	O	O
by	O	O
methodological	O	O
problems	O	O
;	O	O
possible	O	O
explanations	O	O
were	O	O
a	O	O
"	O	O
true	O	O
"	O	O
low	O	O
penetrance	O	O
or	O	O
preferential	O	O
segregation	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
subtotal	B-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
.	O	O

A	O	O
carboxy	O	O
-	O	O
terminally	O	O
truncated	O	O
but	O	O
functionally	O	O
active	O	O
C6	O	O
.	O	O

Individuals	O	O
with	O	O
subtotal	B-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
possess	O	O
a	O	O
C6	O	O
molecule	O	O
that	O	O
is	O	O
14	O	O
%	O	O
shorter	O	O
than	O	O
normal	O	O
C6	O	O
and	O	O
present	O	O
in	O	O
low	O	O
but	O	O
detectable	O	O
concentrations	O	O
(	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
mean	O	O
)	O	O
.	O	O

We	O	O
now	O	O
show	O	O
that	O	O
this	O	O
dysmorphic	O	O
C6	O	O
is	O	O
bactericidally	O	O
active	O	O
and	O	O
lacks	O	O
an	O	O
epitope	O	O
that	O	O
was	O	O
mapped	O	O
to	O	O
the	O	O
most	O	O
carboxy	O	O
-	O	O
terminal	O	O
part	O	O
of	O	O
C6	O	O
using	O	O
C6	O	O
cDNA	O	O
fragments	O	O
expressed	O	O
as	O	O
fusion	O	O
proteins	O	O
in	O	O
the	O	O
pUEX	O	O
expression	O	O
system	O	O
.	O	O

We	O	O
thus	O	O
predicted	O	O
that	O	O
the	O	O
abnormal	O	O
C6	O	O
molecule	O	O
might	O	O
be	O	O
carboxy	O	O
-	O	O
terminally	O	O
truncated	O	O
and	O	O
sought	O	O
a	O	O
mutation	O	O
in	O	O
an	O	O
area	O	O
approximately	O	O
14	O	O
%	O	O
from	O	O
the	O	O
carboxy	O	O
-	O	O
terminal	O	O
end	O	O
of	O	O
the	O	O
coding	O	O
sequence	O	O
.	O	O

By	O	O
sequencing	O	O
PCR	O	O
-	O	O
amplified	O	O
products	O	O
from	O	O
this	O	O
region	O	O
,	O	O
we	O	O
found	O	O
,	O	O
in	O	O
three	O	O
individuals	O	O
from	O	O
two	O	O
families	O	O
,	O	O
a	O	O
mutation	O	O
that	O	O
might	O	O
plausibly	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
defect	O	O
.	O	O

All	O	O
three	O	O
have	O	O
an	O	O
abnormal	O	O
5	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
15	O	O
,	O	O
which	O	O
would	O	O
probably	O	O
prevent	O	O
splicing	O	O
.	O	O

An	O	O
in	O	O
-	O	O
frame	O	O
stop	O	O
codon	O	O
is	O	O
found	O	O
17	O	O
codons	O	O
downstream	O	O
from	O	O
the	O	O
intron	O	O
boundary	O	O
,	O	O
which	O	O
would	O	O
lead	O	O
to	O	O
a	O	O
truncated	O	O
polypeptide	O	O
13	O	O
.	O	O

5	O	O
%	O	O
smaller	O	O
than	O	O
normal	O	O
C6	O	O
.	O	O

This	O	O
result	O	O
was	O	O
unexpected	O	O
,	O	O
as	O	O
earlier	O	O
studies	O	O
mapped	O	O
the	O	O
C5b	O	O
binding	O	O
site	O	O
,	O	O
or	O	O
a	O	O
putative	O	O
enzymatic	O	O
region	O	O
,	O	O
to	O	O
this	O	O
part	O	O
of	O	O
C6	O	O
.	O	O

Interestingly	O	O
,	O	O
all	O	O
three	O	O
subjects	O	O
were	O	O
probably	O	O
heterozygous	O	O
for	O	O
both	O	O
subtotal	B-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
and	I-Disease	OMIM:612446
complete	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
.	O	O

Mutations	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
in	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
:	O	O
definition	O	O
of	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
VHL	B-Disease	D006623
patients	O	O
to	O	O
develop	O	O
an	O	O
RCC	B-Disease	D002292
.	O	O

To	O	O
investigate	O	O
the	O	O
nature	O	O
of	O	O
somatic	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
mutations	O	O
,	O	O
we	O	O
analyzed	O	O
173	O	O
primary	O	O
sporadic	O	O
human	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
for	O	O
mutations	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
tumor	O	O
suppressor	O	O
gene	O	O
,	O	O
using	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
and	O	O
single	O	O
-	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
analysis	O	O
(	O	O
SSCP	O	O
)	O	O
of	O	O
DNA	O	O
.	O	O

We	O	O
detected	O	O
abnormal	O	O
SSCP	O	O
pattern	O	O
in	O	O
73	O	O
samples	O	O
.	O	O

After	O	O
sequencing	O	O
,	O	O
we	O	O
identified	O	O
microdeletions	O	O
in	O	O
58	O	O
%	O	O
of	O	O
cases	O	O
,	O	O
microinsertions	O	O
in	O	O
17	O	O
%	O	O
,	O	O
nonsense	O	O
mutations	O	O
in	O	O
8	O	O
%	O	O
,	O	O
and	O	O
missense	O	O
mutations	O	O
in	O	O
17	O	O
%	O	O
.	O	O

Among	O	O
these	O	O
mutations	O	O
,	O	O
50	O	O
%	O	O
correspond	O	O
to	O	O
new	O	O
mutations	O	O
.	O	O

VHL	B-Disease	D006623
mutations	O	O
were	O	O
found	O	O
only	O	O
in	O	O
the	O	O
nonpapillary	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
(	O	O
RCC	B-Disease	D002292
)	O	O
subtype	O	O
,	O	O
as	O	O
previously	O	O
reported	O	O
.	O	O

To	O	O
compare	O	O
somatic	O	O
and	O	O
germline	O	O
mutations	O	O
,	O	O
we	O	O
used	O	O
the	O	O
VHL	B-Disease	D006623
database	O	O
,	O	O
which	O	O
includes	O	O
507	O	O
mutations	O	O
.	O	O

The	O	O
study	O	O
of	O	O
mutational	O	O
events	O	O
revealed	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
somatic	O	O
and	O	O
germline	O	O
mutations	O	O
with	O	O
mutations	O	O
leading	O	O
to	O	O
truncated	O	O
proteins	O	O
observed	O	O
in	O	O
78	O	O
%	O	O
of	O	O
somatic	O	O
mutations	O	O
vs	O	O
only	O	O
37	O	O
%	O	O
in	O	O
germline	O	O
mutations	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

We	O	O
postulated	O	O
that	O	O
a	O	O
specific	O	O
pattern	O	O
of	O	O
VHL	B-Disease	D006623
mutations	O	O
is	O	O
associated	O	O
with	O	O
sporadic	B-Disease	D002292
RCC	I-Disease	D002292
.	O	O

This	O	O
pattern	O	O
corresponds	O	O
to	O	O
mutations	O	O
leading	O	O
mainly	O	O
to	O	O
truncated	O	O
proteins	O	O
with	O	O
few	O	O
specific	O	O
missense	O	O
mutations	O	O
.	O	O

We	O	O
then	O	O
analyzed	O	O
the	O	O
occurrence	O	O
of	O	O
RCC	B-Disease	D002292
in	O	O
VHL	B-Disease	D006623
families	O	O
,	O	O
based	O	O
on	O	O
the	O	O
nature	O	O
of	O	O
mutations	O	O
.	O	O

We	O	O
observed	O	O
RCC	B-Disease	D002292
in	O	O
at	O	O
least	O	O
one	O	O
member	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
families	O	O
in	O	O
77	O	O
%	O	O
of	O	O
cases	O	O
with	O	O
mutations	O	O
leading	O	O
to	O	O
truncated	O	O
proteins	O	O
versus	O	O
55	O	O
%	O	O
in	O	O
cases	O	O
with	O	O
missense	O	O
mutations	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
mutations	O	O
resulting	O	O
in	O	O
truncated	O	O
proteins	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
RCC	B-Disease	D002292
in	O	O
VHL	B-Disease	D006623
patients	O	O
Evidence	O	O
for	O	O
inter	O	O
-	O	O
generational	O	O
instability	O	O
in	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
and	O	O
for	O	O
conserved	O	O
haplotypes	O	O
at	O	O
flanking	O	O
markers	O	O
amongst	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
(	O	O
CAG	O	O
)	O	O
n	O	O
repeat	O	O
array	O	O
in	O	O
the	O	O
3	O	O
'	O	O
end	O	O
of	O	O
the	O	O
MJD1	O	O
gene	O	O
and	O	O
the	O	O
haplotype	O	O
at	O	O
a	O	O
series	O	O
of	O	O
microsatellite	O	O
markers	O	O
surrounding	O	O
the	O	O
MJD1	O	O
gene	O	O
were	O	O
examined	O	O
in	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
affected	O	O
with	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
.	O	O

Our	O	O
data	O	O
provide	O	O
five	O	O
novel	O	O
observations	O	O
.	O	O

First	O	O
,	O	O
MJD	B-Disease	D017827
is	O	O
associated	O	O
with	O	O
expansion	O	O
fo	O	O
the	O	O
array	O	O
from	O	O
the	O	O
normal	O	O
range	O	O
of	O	O
14	O	O
-	O	O
37	O	O
repeats	O	O
to	O	O
68	O	O
-	O	O
84	O	O
repeats	O	O
in	O	O
most	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
,	O	O
but	O	O
no	O	O
subjects	O	O
were	O	O
observed	O	O
with	O	O
expansions	O	O
intermediate	O	O
in	O	O
size	O	O
between	O	O
those	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
MJD	B-Disease	D017827
affected	O	O
groups	O	O
.	O	O

Second	O	O
,	O	O
the	O	O
expanded	O	O
allele	O	O
associated	O	O
with	O	O
MJD	B-Disease	D017827
displays	O	O
inter	O	O
-	O	O
generational	O	O
instability	O	O
,	O	O
particularly	O	O
in	O	O
male	O	O
meioses	O	O
,	O	O
and	O	O
this	O	O
instability	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
clinical	O	O
phenomenon	O	O
of	O	O
anticipation	O	O
.	O	O

Third	O	O
,	O	O
the	O	O
size	O	O
of	O	O
the	O	O
expanded	O	O
allele	O	O
is	O	O
not	O	O
only	O	O
inversely	O	O
correlated	O	O
with	O	O
the	O	O
age	O	O
-	O	O
of	O	O
-	O	O
onset	O	O
of	O	O
MJD	B-Disease	D017827
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O

738	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
but	O	O
is	O	O
also	O	O
correlated	O	O
with	O	O
the	O	O
frequency	O	O
of	O	O
other	O	O
clinical	O	O
features	O	O
[	O	O
e	O	O
.	O	O

g	O	O
.	O	O

pseudoexophthalmos	O	O
and	O	O
pyramidal	O	O
signs	O	O
were	O	O
more	O	O
frequent	O	O
in	O	O
subjects	O	O
with	O	O
large	O	O
repeats	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
and	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
respectively	O	O
)	O	O
]	O	O
.	O	O

Fourth	O	O
,	O	O
the	O	O
disease	O	O
phenotype	O	O
is	O	O
significantly	O	O
more	O	O
severe	O	O
and	O	O
had	O	O
an	O	O
early	O	O
age	O	O
of	O	O
onset	O	O
(	O	O
16	O	O
years	O	O
)	O	O
in	O	O
a	O	O
subject	O	O
homozygous	O	O
for	O	O
the	O	O
expanded	O	O
allele	O	O
,	O	O
which	O	O
contrasts	O	O
with	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
and	O	O
suggests	O	O
that	O	O
the	O	O
expanded	O	O
allele	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
could	O	O
exert	O	O
its	O	O
effect	O	O
either	O	O
by	O	O
a	O	O
dominant	O	O
negative	O	O
effect	O	O
(	O	O
putatively	O	O
excluded	O	O
in	O	O
HD	B-Disease	D006816
)	O	O
or	O	O
by	O	O
a	O	O
gain	O	O
of	O	O
function	O	O
effect	O	O
as	O	O
proposed	O	O
for	O	O
HD	B-Disease	D006816
.	O	O

Finally	O	O
,	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
subjects	O	O
affected	O	O
with	O	O
MJD	B-Disease	D017827
share	O	O
haplotypes	O	O
at	O	O
several	O	O
markers	O	O
surrounding	O	O
the	O	O
MJD1	O	O
gene	O	O
,	O	O
which	O	O
are	O	O
uncommon	O	O
in	O	O
the	O	O
normal	O	O
Japanese	O	O
and	O	O
Caucasian	O	O
population	O	O
,	O	O
and	O	O
which	O	O
suggests	O	O
the	O	O
existence	O	O
either	O	O
of	O	O
common	O	O
founders	O	O
in	O	O
these	O	O
populations	O	O
or	O	O
of	O	O
chromosomes	O	O
susceptible	O	O
to	O	O
pathologic	O	O
expansion	O	O
of	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
MJD1	O	O
gene	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
:	O	O
the	O	O
role	O	O
of	O	O
the	O	O
CUG	O	O
triplet	O	O
repeats	O	O
in	O	O
splicing	O	O
of	O	O
a	O	O
novel	O	O
DMPK	O	O
exon	O	O
and	O	O
altered	O	O
cytoplasmic	O	O
DMPK	O	O
mRNA	O	O
isoform	O	O
ratios	O	O
.	O	O

The	O	O
mechanism	O	O
by	O	O
which	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
UTR	O	O
of	O	O
the	O	O
DMPK	O	O
gene	O	O
causes	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
unknown	O	O
.	O	O

We	O	O
identified	O	O
four	O	O
RNA	O	O
splicing	O	O
factors	O	O
-	O	O
-	O	O
hnRNP	O	O
C	O	O
,	O	O
U2AF	O	O
(	O	O
U2	O	O
auxiliary	O	O
factor	O	O
)	O	O
,	O	O
PTB	O	O
(	O	O
polypyrimidine	O	O
tract	O	O
binding	O	O
protein	O	O
)	O	O
,	O	O
and	O	O
PSF	O	O
(	O	O
PTB	O	O
associated	O	O
splicing	O	O
factor	O	O
)	O	O
-	O	O
-	O	O
that	O	O
bind	O	O
to	O	O
two	O	O
short	O	O
regions	O	O
3	O	O
of	O	O
the	O	O
(	O	O
CUG	O	O
)	O	O
n	O	O
,	O	O
and	O	O
found	O	O
a	O	O
novel	O	O
3	O	O
DMPK	O	O
exon	O	O
resulting	O	O
in	O	O
an	O	O
mRNA	O	O
lacking	O	O
the	O	O
repeats	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
the	O	O
(	O	O
CUG	O	O
)	O	O
n	O	O
is	O	O
an	O	O
essential	O	O
cis	O	O
acting	O	O
element	O	O
for	O	O
this	O	O
splicing	O	O
event	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
(	O	O
CUG	O	O
)	O	O
n	O	O
containing	O	O
mRNAs	O	O
,	O	O
the	O	O
novel	O	O
isoform	O	O
is	O	O
not	O	O
retained	O	O
in	O	O
the	O	O
nucleus	O	O
in	O	O
DM	B-Disease	D009223
cells	O	O
,	O	O
resulting	O	O
in	O	O
imbalances	O	O
in	O	O
relative	O	O
levels	O	O
of	O	O
cytoplasmic	O	O
DMPK	O	O
mRNA	O	O
isoforms	O	O
and	O	O
a	O	O
new	O	O
dominant	O	O
effect	O	O
of	O	O
the	O	O
mutation	O	O
on	O	O
DMPK	O	O
.	O	O

.	O	O

Mechanism	O	O
of	O	O
increased	O	O
iron	O	O
absorption	O	O
in	O	O
murine	O	O
model	O	O
of	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
:	O	O
increased	O	O
duodenal	O	O
expression	O	O
of	O	O
the	O	O
iron	O	O
transporter	O	O
DMT1	O	O
.	O	O

Hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
(	O	O
HH	B-Disease	D006432
)	O	O
is	O	O
a	O	O
common	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
tissue	O	O
iron	O	O
deposition	O	O
secondary	O	O
to	O	O
excessive	O	O
dietary	O	O
iron	O	O
absorption	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
that	O	O
HFE	O	O
,	O	O
the	O	O
protein	O	O
defective	O	O
in	O	O
HH	B-Disease	D006432
,	O	O
was	O	O
physically	O	O
associated	O	O
with	O	O
the	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
in	O	O
duodenal	O	O
crypt	O	O
cells	O	O
and	O	O
proposed	O	O
that	O	O
mutations	O	O
in	O	O
HFE	O	O
attenuate	O	O
the	O	O
uptake	O	O
of	O	O
transferrin	O	O
-	O	O
bound	O	O
iron	O	O
from	O	O
plasma	O	O
by	O	O
duodenal	O	O
crypt	O	O
cells	O	O
,	O	O
leading	O	O
to	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
transporters	O	O
for	O	O
dietary	O	O
iron	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
HFE	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
have	O	O
increased	O	O
duodenal	O	O
expression	O	O
of	O	O
the	O	O
divalent	O	O
metal	O	O
transporter	O	O
(	O	O
DMT1	O	O
)	O	O
.	O	O

By	O	O
4	O	O
weeks	O	O
of	O	O
age	O	O
,	O	O
the	O	O
HFE	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
demonstrated	O	O
iron	O	O
loading	O	O
when	O	O
compared	O	O
with	O	O
HFE	O	O
+	O	O
/	O	O
+	O	O
littermates	O	O
,	O	O
with	O	O
elevated	O	O
transferrin	O	O
saturations	O	O
(	O	O
68	O	O
.	O	O

4	O	O
%	O	O
vs	O	O
.	O	O

49	O	O
.	O	O

8	O	O
%	O	O
)	O	O
and	O	O
elevated	O	O
liver	O	O
iron	O	O
concentrations	O	O
(	O	O
985	O	O
micrograms	O	O
vs	O	O
.	O	O

381	O	O
micrograms	O	O
)	O	O
.	O	O

By	O	O
using	O	O
Northern	O	O
blot	O	O
analyses	O	O
,	O	O
we	O	O
quantitated	O	O
duodenal	O	O
expression	O	O
of	O	O
both	O	O
classes	O	O
of	O	O
DMT1	O	O
transcripts	O	O
one	O	O
containing	O	O
an	O	O
iron	O	O
responsive	O	O
element	O	O
(	O	O
IRE	O	O
)	O	O
,	O	O
called	O	O
DMT1	O	O
(	O	O
IRE	O	O
)	O	O
,	O	O
and	O	O
one	O	O
containing	O	O
no	O	O
IRE	O	O
,	O	O
called	O	O
DMT1	O	O
(	O	O
non	O	O
-	O	O
IRE	O	O
)	O	O
.	O	O

The	O	O
positive	O	O
control	O	O
for	O	O
DMT1	O	O
up	O	O
-	O	O
regulation	O	O
was	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
dietary	B-Disease	D018798
iron	I-Disease	D018798
deficiency	I-Disease	D018798
that	O	O
demonstrated	O	O
greatly	O	O
increased	O	O
levels	O	O
of	O	O
duodenal	O	O
DMT1	O	O
(	O	O
IRE	O	O
)	O	O
mRNA	O	O
.	O	O

HFE	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
also	O	O
demonstrated	O	O
an	O	O
increase	O	O
in	O	O
duodenal	O	O
DMT1	O	O
(	O	O
IRE	O	O
)	O	O
mRNA	O	O
(	O	O
average	O	O
7	O	O
.	O	O

7	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
despite	O	O
their	O	O
elevated	O	O
transferrin	O	O
saturation	O	O
and	O	O
hepatic	O	O
iron	O	O
content	O	O
.	O	O

Duodenal	O	O
expression	O	O
of	O	O
DMT1	O	O
(	O	O
non	O	O
-	O	O
IRE	O	O
)	O	O
was	O	O
not	O	O
increased	O	O
,	O	O
nor	O	O
was	O	O
hepatic	O	O
expression	O	O
of	O	O
DMT1	O	O
increased	O	O
.	O	O

These	O	O
data	O	O
support	O	O
the	O	O
model	O	O
for	O	O
HH	B-Disease	D006432
in	O	O
which	O	O
HFE	O	O
mutations	O	O
lead	O	O
to	O	O
inappropriately	O	O
low	O	O
crypt	O	O
cell	O	O
iron	O	O
,	O	O
with	O	O
resultant	O	O
stabilization	O	O
of	O	O
DMT1	O	O
(	O	O
IRE	O	O
)	O	O
mRNA	O	O
,	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
DMT1	O	O
,	O	O
and	O	O
increased	O	O
absorption	O	O
of	O	O
dietary	O	O
iron	O	O
.	O	O

Yeast	O	O
artificial	O	O
chromosomes	O	O
for	O	O
the	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
familial	B-Disease	D011125
polyposis	I-Disease	D011125
APC	I-Disease	D011125
gene	O	O
region	O	O
.	O	O

Two	O	O
yeast	O	O
artificial	O	O
chromosomes	O	O
(	O	O
YACs	O	O
)	O	O
spanning	O	O
a	O	O
total	O	O
distance	O	O
of	O	O
1	O	O
.	O	O

1	O	O
megabase	O	O
pairs	O	O
of	O	O
DNA	O	O
around	O	O
the	O	O
MCC	O	O
(	O	O
for	O	O
mutated	O	O
in	O	O
colorectal	B-Disease	D015179
carcinoma	I-Disease	D015179
)	O	O
and	O	O
APC	B-Disease	D011125
(	O	O
for	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
)	O	O
genes	O	O
at	O	O
5q21	O	O
have	O	O
been	O	O
isolated	O	O
and	O	O
characterized	O	O
.	O	O

Starting	O	O
from	O	O
the	O	O
MCC	O	O
gene	O	O
,	O	O
a	O	O
strategy	O	O
was	O	O
undertaken	O	O
to	O	O
identify	O	O
constitutional	O	O
submicroscopic	O	O
deletions	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
patients	O	O
that	O	O
might	O	O
considerably	O	O
narrow	O	O
down	O	O
the	O	O
position	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
YACs	O	O
identified	O	O
by	O	O
the	O	O
MCC	O	O
gene	O	O
were	O	O
screened	O	O
across	O	O
a	O	O
chromosome	O	O
5	O	O
-	O	O
specific	O	O
cosmid	O	O
library	O	O
to	O	O
provide	O	O
a	O	O
source	O	O
of	O	O
DNA	O	O
probes	O	O
for	O	O
genomic	O	O
scanning	O	O
.	O	O

The	O	O
cosmids	O	O
isolated	O	O
from	O	O
these	O	O
experiments	O	O
were	O	O
used	O	O
to	O	O
screen	O	O
a	O	O
panel	O	O
of	O	O
somatic	O	O
cell	O	O
hybrids	O	O
containing	O	O
chromosome	O	O
5	O	O
segregated	O	O
from	O	O
patients	O	O
suspected	O	O
to	O	O
carry	O	O
putative	O	O
interstitial	O	O
deletions	O	O
.	O	O

This	O	O
screening	O	O
approach	O	O
led	O	O
to	O	O
the	O	O
confirmation	O	O
of	O	O
a	O	O
small	O	O
heterozygous	O	O
deletion	O	O
in	O	O
a	O	O
polyposis	B-Disease	D011125
patient	O	O
that	O	O
overlaps	O	O
one	O	O
of	O	O
the	O	O
two	O	O
isolated	O	O
YACs	O	O
.	O	O

This	O	O
YAC	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
contain	O	O
the	O	O
entire	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
a	O	O
significant	O	O
portion	O	O
of	O	O
DNA	O	O
flanking	O	O
the	O	O
5	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
and	O	O
should	O	O
therefore	O	O
prove	O	O
a	O	O
valuable	O	O
resource	O	O
for	O	O
functional	O	O
studies	O	O
by	O	O
transfer	O	O
to	O	O
colorectal	B-Disease	D015179
tumor	I-Disease	D015179
-	O	O
derived	O	O
cell	O	O
lines	O	O
.	O	O

Analbuminemia	B-Disease	OMIM:103600
in	O	O
an	O	O
American	O	O
Indian	O	O
girl	O	O
.	O	O

Analbuminemia	B-Disease	OMIM:103600
was	O	O
fortuitously	O	O
detected	O	O
in	O	O
a	O	O
nonedematous	O	O
12	O	O
-	O	O
year	O	O
-	O	O
old	O	O
American	O	O
Indian	O	O
girl	O	O
with	O	O
atopic	B-Disease	D003876
dermatitis	I-Disease	D003876
,	O	O
mild	O	O
bronchial	B-Disease	D001249
asthma	I-Disease	D001249
,	O	O
a	O	O
mild	O	O
seizure	B-Disease	D004827
disorder	I-Disease	D004827
,	O	O
and	O	O
hyperlipoproteinemia	B-Disease	D006951
with	O	O
a	O	O
corneal	B-Disease	D001112
arcus	I-Disease	D001112
.	O	O

Immunologic	O	O
methods	O	O
revealed	O	O
trace	O	O
amounts	O	O
(	O	O
17	O	O
mg	O	O
/	O	O
100	O	O
ml	O	O
)	O	O
of	O	O
apparently	O	O
normal	O	O
serum	O	O
albumin	O	O
.	O	O

The	O	O
patients	O	O
parents	O	O
were	O	O
remotely	O	O
related	O	O
.	O	O

The	O	O
pedigree	O	O
and	O	O
clinical	O	O
findings	O	O
were	O	O
compatible	O	O
with	O	O
autosomal	O	O
recessive	O	O
transmission	O	O
of	O	O
analbuminemia	B-Disease	OMIM:103600
.	O	O

Heterozygotes	O	O
had	O	O
subnormal	O	O
levels	O	O
of	O	O
serum	O	O
albumin	O	O
.	O	O

The	O	O
Gc	O	O
-	O	O
locus	O	O
is	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
structural	O	O
albumin	O	O
locus	O	O
.	O	O

Gc	O	O
-	O	O
protein	O	O
levels	O	O
were	O	O
normal	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
together	O	O
with	O	O
normal	O	O
chromosomal	O	O
banding	O	O
studies	O	O
make	O	O
it	O	O
unlikely	O	O
that	O	O
a	O	O
chromosomal	O	O
deletion	O	O
caused	O	O
analbuminemia	B-Disease	OMIM:103600
.	O	O

Gc	O	O
-	O	O
types	O	O
in	O	O
the	O	O
family	O	O
were	O	O
compatible	O	O
with	O	O
,	O	O
but	O	O
did	O	O
not	O	O
prove	O	O
,	O	O
linkage	O	O
of	O	O
analbuminemia	B-Disease	OMIM:103600
to	O	O
the	O	O
Gc	O	O
-	O	O
locus	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
a	O	O
"	O	O
thalassemia	B-Disease	D013789
"	O	O
-	O	O
like	O	O
mutation	O	O
for	O	O
this	O	O
disorder	O	O
.	O	O

.	O	O

Treatment	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
with	O	O
growth	O	O
hormone	O	O
inhibitors	O	O
.	O	O

A	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
therapeutic	O	O
trial	O	O
with	O	O
the	O	O
drug	O	O
mazindol	O	O
,	O	O
a	O	O
growth	O	O
hormone	O	O
inhibitor	O	O
,	O	O
was	O	O
performed	O	O
in	O	O
a	O	O
pair	O	O
of	O	O
7	O	O
1	O	O
/	O	O
2	O	O
year	O	O
-	O	O
old	O	O
monozygotic	O	O
twins	O	O
,	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

The	O	O
rationale	O	O
for	O	O
this	O	O
trial	O	O
was	O	O
based	O	O
on	O	O
a	O	O
patient	O	O
(	O	O
reported	O	O
previously	O	O
)	O	O
affected	O	O
simultaneously	O	O
with	O	O
DMD	B-Disease	D020388
and	O	O
growth	B-Disease	OMIM:262400
hormone	I-Disease	OMIM:262400
(	I-Disease	OMIM:262400
GH	I-Disease	OMIM:262400
)	I-Disease	OMIM:262400
deficiency	I-Disease	OMIM:262400
,	O	O
who	O	O
is	O	O
showing	O	O
a	O	O
benign	O	O
course	O	O
of	O	O
the	O	O
dystrophic	B-Disease	D009136
process	I-Disease	D009136
and	O	O
is	O	O
still	O	O
walking	O	O
at	O	O
18	O	O
years	O	O
.	O	O

One	O	O
of	O	O
the	O	O
twins	O	O
received	O	O
2	O	O
mg	O	O
of	O	O
mazindol	O	O
daily	O	O
,	O	O
while	O	O
the	O	O
other	O	O
received	O	O
a	O	O
placebo	O	O
.	O	O

The	O	O
assessment	O	O
,	O	O
repeated	O	O
every	O	O
2	O	O
months	O	O
,	O	O
included	O	O
weight	O	O
and	O	O
height	O	O
measurements	O	O
,	O	O
functional	O	O
and	O	O
motor	O	O
ability	O	O
tests	O	O
,	O	O
ergometry	O	O
and	O	O
determinations	O	O
of	O	O
serum	O	O
enzymes	O	O
and	O	O
GH	O	O
levels	O	O
.	O	O

After	O	O
one	O	O
year	O	O
of	O	O
trial	O	O
the	O	O
code	O	O
was	O	O
broken	O	O
and	O	O
it	O	O
was	O	O
seen	O	O
that	O	O
the	O	O
twin	O	O
under	O	O
placebo	O	O
treatment	O	O
was	O	O
strikingly	O	O
worse	O	O
than	O	O
his	O	O
brother	O	O
,	O	O
the	O	O
progression	O	O
of	O	O
whose	O	O
condition	O	O
was	O	O
practically	O	O
arrested	O	O
.	O	O

These	O	O
results	O	O
strongly	O	O
suggest	O	O
that	O	O
treatment	O	O
with	O	O
a	O	O
GH	O	O
inhibitor	O	O
is	O	O
beneficial	O	O
for	O	O
DMD	B-Disease	D020388
patients	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
WASP	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
and	O	O
isolated	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
reveals	O	O
allelic	O	O
heterogeneity	O	O
at	O	O
the	O	O
WAS	B-Disease	D014923
locus	O	O
.	O	O

Mutation	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
the	O	O
recently	O	O
isolated	O	O
WASP	O	O
protein	O	O
has	O	O
now	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
responsible	O	O
for	O	O
the	O	O
X	B-Disease	D014923
-	I-Disease	D014923
linked	I-Disease	D014923
Wiskott	I-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
,	O	O
a	O	O
primary	O	O
immunodeficiency	B-Disease	D007153
disease	I-Disease	D007153
associated	O	O
with	O	O
extensive	O	O
phenotypic	O	O
variability	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
range	O	O
of	O	O
WASP	O	O
mutations	O	O
responsible	O	O
for	O	O
WAS	B-Disease	D014923
,	O	O
we	O	O
used	O	O
PCR	O	O
-	O	O
SSCP	O	O
analysis	O	O
to	O	O
screen	O	O
for	O	O
WASP	O	O
gene	O	O
mutation	O	O
in	O	O
19	O	O
unrelated	O	O
boys	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
classical	O	O
or	O	O
attenuated	O	O
WAS	B-Disease	D014923
or	O	O
isolated	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
.	O	O

All	O	O
19	O	O
patients	O	O
had	O	O
WASP	O	O
mutations	O	O
,	O	O
each	O	O
of	O	O
which	O	O
localized	O	O
to	O	O
the	O	O
initial	O	O
three	O	O
or	O	O
terminal	O	O
three	O	O
exons	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
and	O	O
the	O	O
majority	O	O
of	O	O
which	O	O
were	O	O
unique	O	O
in	O	O
each	O	O
case	O	O
.	O	O

However	O	O
,	O	O
a	O	O
missense	O	O
mutation	O	O
which	O	O
results	O	O
in	O	O
substitution	O	O
of	O	O
the	O	O
arginine	O	O
at	O	O
WAS	B-Disease	D014923
codon	O	O
86	O	O
was	O	O
identified	O	O
in	O	O
three	O	O
boys	O	O
with	O	O
severe	O	O
WAS	B-Disease	D014923
as	O	O
well	O	O
as	O	O
in	O	O
one	O	O
boy	O	O
presenting	O	O
with	O	O
thrombocytopenia	B-Disease	D013921
alone	O	O
.	O	O

While	O	O
the	O	O
three	O	O
mutations	O	O
found	O	O
in	O	O
the	O	O
isolated	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
patients	O	O
leave	O	O
the	O	O
reading	O	O
frame	O	O
intact	O	O
,	O	O
about	O	O
one	O	O
-	O	O
half	O	O
of	O	O
the	O	O
gene	O	O
alterations	O	O
detected	O	O
in	O	O
both	O	O
severe	O	O
and	O	O
attenuated	O	O
WAS	B-Disease	D014923
patients	O	O
result	O	O
in	O	O
frameshifted	O	O
transcript	O	O
and	O	O
premature	O	O
translation	O	O
termination	O	O
.	O	O

These	O	O
findings	O	O
therefore	O	O
confirm	O	O
the	O	O
association	O	O
of	O	O
WAS	B-Disease	D014923
with	O	O
WASP	O	O
mutation	O	O
and	O	O
identify	O	O
WASP	O	O
mutation	O	O
as	O	O
a	O	O
cause	O	O
for	O	O
isolated	O	O
congenital	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
in	O	O
males	O	O
.	O	O

While	O	O
the	O	O
WASP	O	O
gene	O	O
defects	O	O
responsible	O	O
for	O	O
isolated	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
and	O	O
other	O	O
mild	O	O
presentations	O	O
of	O	O
WAS	B-Disease	D014923
do	O	O
not	O	O
appear	O	O
distinct	O	O
from	O	O
those	O	O
resulting	O	O
in	O	O
severe	O	O
WAS	B-Disease	D014923
,	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
analysis	O	O
of	O	O
WASP	O	O
gene	O	O
mutation	O	O
provides	O	O
a	O	O
valuable	O	O
tool	O	O
for	O	O
distinguishing	O	O
the	O	O
spectrum	O	O
of	O	O
WAS	B-Disease	D014923
patients	O	O
and	O	O
the	O	O
subset	O	O
of	O	O
males	O	O
with	O	O
isolated	B-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
who	O	O
represent	O	O
mild	O	O
cases	O	O
of	O	O
WAS	B-Disease	D014923
.	O	O

.	O	O

Huntington	B-Disease	D006816
disease	I-Disease	D006816
without	O	O
CAG	O	O
expansion	O	O
:	O	O
phenocopies	O	O
or	O	O
errors	O	O
in	O	O
assignment	O	O
?	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
expanded	O	O
CAG	O	O
repeat	O	O
within	O	O
a	O	O
novel	O	O
gene	O	O
on	O	O
4p16	O	O
.	O	O

3	O	O
(	O	O
IT15	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
30	O	O
of	O	O
1	O	O
,	O	O
022	O	O
affected	O	O
persons	O	O
(	O	O
2	O	O
.	O	O

9	O	O
%	O	O
of	O	O
our	O	O
cohort	O	O
)	O	O
did	O	O
not	O	O
have	O	O
an	O	O
expanded	O	O
CAG	O	O
in	O	O
the	O	O
disease	O	O
range	O	O
.	O	O

The	O	O
reasons	O	O
for	O	O
not	O	O
observing	O	O
expansion	O	O
in	O	O
affected	O	O
individuals	O	O
are	O	O
important	O	O
for	O	O
determining	O	O
the	O	O
sensitivity	O	O
of	O	O
using	O	O
repeat	O	O
length	O	O
both	O	O
for	O	O
diagnosis	O	O
of	O	O
affected	O	O
patients	O	O
and	O	O
for	O	O
predictive	O	O
testing	O	O
programs	O	O
and	O	O
may	O	O
have	O	O
biological	O	O
relevance	O	O
for	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
molecular	O	O
mechanism	O	O
underlying	O	O
HD	B-Disease	D006816
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
majority	O	O
(	O	O
18	O	O
)	O	O
of	O	O
the	O	O
individuals	O	O
with	O	O
normal	O	O
sized	O	O
alleles	O	O
represent	O	O
misdiagnosis	O	O
,	O	O
sample	O	O
mix	O	O
-	O	O
up	O	O
,	O	O
or	O	O
clerical	O	O
error	O	O
.	O	O

The	O	O
remaining	O	O
12	O	O
patients	O	O
represent	O	O
possible	O	O
phenocopies	O	O
for	O	O
HD	B-Disease	D006816
.	O	O

In	O	O
at	O	O
least	O	O
four	O	O
cases	O	O
,	O	O
family	O	O
studies	O	O
of	O	O
these	O	O
phenocopies	O	O
excluded	O	O
4p16	O	O
.	O	O

3	O	O
as	O	O
the	O	O
region	O	O
responsible	O	O
for	O	O
the	O	O
phenotype	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
that	O	O
are	O	O
other	O	O
than	O	O
CAG	O	O
expansion	O	O
have	O	O
not	O	O
been	O	O
excluded	O	O
for	O	O
the	O	O
remaining	O	O
eight	O	O
cases	O	O
;	O	O
however	O	O
,	O	O
in	O	O
as	O	O
many	O	O
as	O	O
seven	O	O
of	O	O
these	O	O
persons	O	O
,	O	O
retrospective	O	O
review	O	O
of	O	O
these	O	O
patients	O	O
clinical	O	O
features	O	O
identified	O	O
characteristics	O	O
not	O	O
typical	O	O
for	O	O
HD	B-Disease	D006816
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
on	O	O
rare	O	O
occasions	O	O
mutations	O	O
in	O	O
other	O	O
,	O	O
as	O	O
-	O	O
yet	O	O
-	O	O
undefined	O	O
genes	O	O
can	O	O
present	O	O
with	O	O
a	O	O
clinical	O	O
phenotype	O	O
very	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
HD	B-Disease	D006816
Allelic	O	O
exclusion	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
in	O	O
platelets	O	O
and	O	O
T	O	O
lymphocytes	O	O
from	O	O
a	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
carrier	O	O
.	O	O

An	O	O
obligate	O	O
carrier	O	O
of	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
who	O	O
was	O	O
also	O	O
heterozygous	O	O
for	O	O
the	O	O
A	O	O
and	O	O
B	O	O
types	O	O
of	O	O
X	O	O
-	O	O
linked	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
was	O	O
found	O	O
.	O	O

With	O	O
her	O	O
it	O	O
became	O	O
possible	O	O
to	O	O
determine	O	O
whether	O	O
allelic	O	O
exclusion	O	O
occurs	O	O
in	O	O
particular	O	O
cell	O	O
-	O	O
types	O	O
of	O	O
the	O	O
WAS	B-Disease	D014923
carrier	O	O
.	O	O

If	O	O
so	O	O
,	O	O
the	O	O
remaining	O	O
cells	O	O
of	O	O
a	O	O
particular	O	O
cell	O	O
-	O	O
type	O	O
would	O	O
express	O	O
only	O	O
the	O	O
normal	O	O
X	O	O
chromosome	O	O
and	O	O
only	O	O
one	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
isoenzyme	O	O
would	O	O
be	O	O
demonstrable	O	O
.	O	O

This	O	O
carrier	O	O
had	O	O
only	O	O
the	O	O
B	O	O
isoenzyme	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
in	O	O
platelets	O	O
and	O	O
thymus	O	O
-	O	O
derived	O	O
T	O	O
lymphocytes	O	O
,	O	O
although	O	O
both	O	O
isoenzymes	O	O
A	O	O
and	O	O
B	O	O
were	O	O
present	O	O
in	O	O
erythrocytes	O	O
and	O	O
neutrophils	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
selection	O	O
against	O	O
the	O	O
WAS	B-Disease	D014923
gene	O	O
occurs	O	O
in	O	O
platelets	O	O
and	O	O
thymus	O	O
-	O	O
derived	O	O
T	O	O
lymphocytes	O	O
and	O	O
that	O	O
the	O	O
defects	O	O
associated	O	O
with	O	O
WAS	B-Disease	D014923
expressed	O	O
in	O	O
these	O	O
cell	O	O
-	O	O
types	O	O
may	O	O
be	O	O
implicated	O	O
in	O	O
the	O	O
genesis	O	O
of	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

.	O	O

A	O	O
novel	O	O
mutation	O	O
in	O	O
the	O	O
sodium	O	O
/	O	O
iodide	O	O
symporter	O	O
gene	O	O
in	O	O
the	O	O
largest	O	O
family	O	O
with	O	O
iodide	B-Disease	OMIM:274400
transport	I-Disease	OMIM:274400
defect	I-Disease	OMIM:274400
.	O	O

We	O	O
previously	O	O
reported	O	O
nine	O	O
children	O	O
with	O	O
an	O	O
autosomally	O	O
recessive	O	O
form	O	O
of	O	O
congenital	B-Disease	D003409
hypothyroidism	I-Disease	D003409
due	O	O
to	O	O
an	O	O
iodide	B-Disease	OMIM:274400
transport	I-Disease	OMIM:274400
defect	I-Disease	OMIM:274400
in	O	O
a	O	O
large	O	O
Hutterite	O	O
family	O	O
with	O	O
extensive	O	O
consanguinity	O	O
living	O	O
in	O	O
central	O	O
Canada	O	O
.	O	O

Since	O	O
the	O	O
original	O	O
report	O	O
,	O	O
we	O	O
have	O	O
diagnosed	O	O
congenital	B-Disease	D003409
hypothyroidism	I-Disease	D003409
by	O	O
newborn	O	O
TSH	O	O
screening	O	O
in	O	O
9	O	O
additional	O	O
children	O	O
from	O	O
the	O	O
family	O	O
.	O	O

We	O	O
performed	O	O
direct	O	O
sequencing	O	O
of	O	O
the	O	O
PCR	O	O
products	O	O
of	O	O
each	O	O
NIS	O	O
(	O	O
sodium	O	O
/	O	O
iodide	O	O
symporter	O	O
)	O	O
gene	O	O
exon	O	O
with	O	O
flanking	O	O
introns	O	O
amplified	O	O
from	O	O
genomic	O	O
DNA	O	O
extracted	O	O
from	O	O
peripheral	O	O
blood	O	O
cells	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
novel	O	O
NIS	O	O
gene	O	O
mutation	O	O
,	O	O
G395R	O	O
(	O	O
Gly395	O	O
-	O	O
-	O	O
>	O	O
Arg	O	O
;	O	O
GGA	O	O
-	O	O
-	O	O
>	O	O
AGA	O	O
)	O	O
,	O	O
in	O	O
10	O	O
patients	O	O
examined	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

All	O	O
of	O	O
the	O	O
parents	O	O
tested	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
mutation	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
patients	O	O
were	O	O
homozygous	O	O
.	O	O

The	O	O
mutation	O	O
was	O	O
located	O	O
in	O	O
the	O	O
10th	O	O
transmembrane	O	O
helix	O	O
.	O	O

Expression	O	O
experiments	O	O
by	O	O
transfection	O	O
of	O	O
the	O	O
mutant	O	O
NIS	O	O
complimentary	O	O
DNA	O	O
into	O	O
COS	O	O
-	O	O
7	O	O
cells	O	O
showed	O	O
no	O	O
perchlorate	O	O
-	O	O
sensitive	O	O
iodide	O	O
uptake	O	O
,	O	O
confirming	O	O
that	O	O
the	O	O
mutation	O	O
is	O	O
the	O	O
direct	O	O
cause	O	O
of	O	O
the	O	O
iodide	B-Disease	OMIM:274400
transport	I-Disease	OMIM:274400
defect	I-Disease	OMIM:274400
in	O	O
these	O	O
patients	O	O
.	O	O

A	O	O
patient	O	O
who	O	O
showed	O	O
an	O	O
intermediate	O	O
saliva	O	O
/	O	O
serum	O	O
technetium	O	O
ratio	O	O
(	O	O
14	O	O
.	O	O

0	O	O
;	O	O
normal	O	O
,	O	O
>	O	O
or	O	O
=	O	O
20	O	O
)	O	O
and	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
a	O	O
partial	O	O
or	O	O
less	O	O
severe	O	O
defect	O	O
in	O	O
the	O	O
previous	O	O
report	O	O
(	O	O
IX	O	O
-	O	O
24	O	O
)	O	O
did	O	O
not	O	O
have	O	O
a	O	O
NIS	O	O
gene	O	O
mutation	O	O
.	O	O

It	O	O
is	O	O
now	O	O
possible	O	O
to	O	O
use	O	O
gene	O	O
diagnostics	O	O
of	O	O
this	O	O
unique	O	O
NIS	O	O
mutation	O	O
to	O	O
identify	O	O
patients	O	O
with	O	O
congenital	B-Disease	D003409
hypothyroidism	I-Disease	D003409
due	O	O
to	O	O
an	O	O
iodide	B-Disease	OMIM:274400
transport	I-Disease	OMIM:274400
defect	I-Disease	OMIM:274400
in	O	O
this	O	O
family	O	O
and	O	O
to	O	O
determine	O	O
the	O	O
carrier	O	O
state	O	O
of	O	O
potential	O	O
parents	O	O
for	O	O
genetic	O	O
counseling	O	O
and	O	O
arranging	O	O
rapid	O	O
and	O	O
early	O	O
diagnosis	O	O
of	O	O
their	O	O
infants	O	O
.	O	O

Determination	O	O
of	O	O
the	O	O
mutations	O	O
responsible	O	O
for	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
in	O	O
17	O	O
subjects	O	O
.	O	O

Hypoxanthine	O	O
-	O	O
-	O	O
guanine	O	O
phosphoribosyltransferase	O	O
(	O	O
HPRT	O	O
)	O	O
is	O	O
a	O	O
purine	O	O
salvage	O	O
enzyme	O	O
that	O	O
catalyzes	O	O
the	O	O
conversion	O	O
of	O	O
hypoxanthine	O	O
to	O	O
inosine	O	O
monophosphate	O	O
and	O	O
guanine	O	O
to	O	O
guanosine	O	O
monophosphate	O	O
.	O	O

Previous	O	O
studies	O	O
of	O	O
mutant	O	O
HPRT	O	O
proteins	O	O
analyzed	O	O
at	O	O
the	O	O
molecular	O	O
level	O	O
have	O	O
shown	O	O
a	O	O
significant	O	O
heterogeneity	O	O
.	O	O

This	O	O
investigation	O	O
further	O	O
verifies	O	O
this	O	O
heterogeneity	O	O
and	O	O
identifies	O	O
insertions	O	O
,	O	O
deletions	O	O
,	O	O
and	O	O
point	O	O
mutations	O	O
.	O	O

The	O	O
direct	O	O
sequencing	O	O
of	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
amplified	O	O
product	O	O
of	O	O
reverse	O	O
-	O	O
transcribed	O	O
HPRT	O	O
mRNA	O	O
enabled	O	O
the	O	O
rapid	O	O
identification	O	O
of	O	O
the	O	O
mutations	O	O
found	O	O
in	O	O
17	O	O
previously	O	O
uncharacterized	O	O
cell	O	O
lines	O	O
derived	O	O
from	O	O
patients	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

.	O	O

A	O	O
new	O	O
CT	O	O
pattern	O	O
in	O	O
adrenoleukodystrophy	B-Disease	D000326
.	O	O

A	O	O
new	O	O
CT	O	O
pattern	O	O
was	O	O
observed	O	O
in	O	O
2	O	O
patients	O	O
with	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
.	O	O

This	O	O
pattern	O	O
,	O	O
which	O	O
the	O	O
authors	O	O
call	O	O
Type	O	O
II	O	O
,	O	O
is	O	O
characterized	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
posterior	O	O
periventricular	O	O
areas	O	O
of	O	O
decreased	O	O
attenuation	O	O
around	O	O
the	O	O
trigone	O	O
on	O	O
non	O	O
-	O	O
contrast	O	O
scans	O	O
after	O	O
contrast	O	O
infusion	O	O
,	O	O
however	O	O
,	O	O
there	O	O
is	O	O
striking	O	O
enhancement	O	O
of	O	O
various	O	O
white	O	O
-	O	O
matter	O	O
structures	O	O
(	O	O
tracts	O	O
or	O	O
fiber	O	O
systems	O	O
)	O	O
such	O	O
as	O	O
the	O	O
internal	O	O
capsules	O	O
,	O	O
corpus	O	O
callosum	O	O
,	O	O
corona	O	O
radiata	O	O
,	O	O
forceps	O	O
major	O	O
,	O	O
and	O	O
cerebral	O	O
peduncles	O	O
.	O	O

This	O	O
is	O	O
different	O	O
from	O	O
numerous	O	O
previous	O	O
descriptions	O	O
of	O	O
the	O	O
CT	O	O
pattern	O	O
in	O	O
ALD	B-Disease	D000326
.	O	O

Type	B-Disease	D000326
II	I-Disease	D000326
ALD	I-Disease	D000326
does	O	O
not	O	O
appear	O	O
to	O	O
have	O	O
been	O	O
seen	O	O
in	O	O
any	O	O
other	O	O
leukoencephalopathy	B-Disease	D056784
and	O	O
is	O	O
probably	O	O
specific	O	O
for	O	O
a	O	O
phenotypic	O	O
variant	O	O
or	O	O
an	O	O
evolving	O	O
stage	O	O
of	O	O
ALD	B-Disease	D000326
.	O	O

.	O	O

Genetic	O	O
analysis	O	O
,	O	O
phenotypic	O	O
diagnosis	O	O
,	O	O
and	O	O
risk	O	O
of	O	O
venous	B-Disease	D020246
thrombosis	I-Disease	D020246
in	O	O
families	O	O
with	O	O
inherited	O	O
deficiencies	B-Disease	D018455
of	I-Disease	D018455
protein	I-Disease	D018455
S	I-Disease	D018455
.	O	O

Protein	B-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
is	O	O
a	O	O
recognized	O	O
risk	O	O
factor	O	O
for	O	O
venous	B-Disease	D020246
thrombosis	I-Disease	D020246
.	O	O

Of	O	O
all	O	O
the	O	O
inherited	O	O
thrombophilic	B-Disease	D019851
conditions	I-Disease	D019851
,	O	O
it	O	O
remains	O	O
the	O	O
most	O	O
difficult	O	O
to	O	O
diagnose	O	O
because	O	O
of	O	O
phenotypic	O	O
variability	O	O
,	O	O
which	O	O
can	O	O
lead	O	O
to	O	O
inconclusive	O	O
results	O	O
.	O	O

We	O	O
have	O	O
overcome	O	O
this	O	O
problem	O	O
by	O	O
studying	O	O
a	O	O
cohort	O	O
of	O	O
patients	O	O
from	O	O
a	O	O
single	O	O
center	O	O
where	O	O
the	O	O
diagnosis	O	O
was	O	O
confirmed	O	O
at	O	O
the	O	O
genetic	O	O
level	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
index	O	O
patients	O	O
with	O	O
protein	B-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
and	O	O
a	O	O
PROS1	B-Disease	OMIM:612336
gene	I-Disease	OMIM:612336
defect	I-Disease	OMIM:612336
were	O	O
studied	O	O
,	O	O
together	O	O
with	O	O
109	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
.	O	O

To	O	O
avoid	O	O
selection	O	O
bias	O	O
,	O	O
we	O	O
confined	O	O
analysis	O	O
of	O	O
total	O	O
and	O	O
free	O	O
protein	O	O
S	O	O
levels	O	O
and	O	O
thrombotic	O	O
risk	O	O
to	O	O
the	O	O
patients	O	O
relatives	O	O
.	O	O

In	O	O
this	O	O
group	O	O
of	O	O
relatives	O	O
,	O	O
a	O	O
low	O	O
free	O	O
protein	O	O
S	O	O
level	O	O
was	O	O
the	O	O
most	O	O
reliable	O	O
predictor	O	O
of	O	O
a	O	O
PROS1	B-Disease	OMIM:612336
gene	I-Disease	OMIM:612336
defect	I-Disease	OMIM:612336
(	O	O
sensitivity	O	O
97	O	O
.	O	O

7	O	O
%	O	O
,	O	O
specificity	O	O
100	O	O
%	O	O
)	O	O
.	O	O

First	O	O
-	O	O
degree	O	O
relatives	O	O
with	O	O
a	O	O
PROS1	B-Disease	OMIM:612336
gene	I-Disease	OMIM:612336
defect	I-Disease	OMIM:612336
had	O	O
a	O	O
5	O	O
.	O	O

0	O	O
-	O	O
fold	O	O
higher	O	O
risk	O	O
of	O	O
thrombosis	B-Disease	D013927
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

5	O	O
-	O	O
16	O	O
.	O	O

8	O	O
)	O	O
than	O	O
those	O	O
with	O	O
a	O	O
normal	O	O
PROS1	O	O
gene	O	O
and	O	O
no	O	O
other	O	O
recognized	O	O
thrombophilic	B-Disease	D019851
defect	I-Disease	D019851
.	O	O

Although	O	O
pregnancy	O	O
/	O	O
puerperium	O	O
and	O	O
immobility	O	O
/	O	O
trauma	B-Disease	D014947
were	O	O
important	O	O
precipitating	O	O
factors	O	O
for	O	O
thrombosis	B-Disease	D013927
,	O	O
almost	O	O
half	O	O
of	O	O
the	O	O
events	O	O
were	O	O
spontaneous	O	O
.	O	O

Relatives	O	O
with	O	O
splice	O	O
-	O	O
site	O	O
or	O	O
major	O	O
structural	O	O
defects	B-Disease	OMIM:612336
in	I-Disease	OMIM:612336
the	I-Disease	OMIM:612336
PROS1	I-Disease	OMIM:612336
gene	I-Disease	OMIM:612336
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
had	O	O
a	O	O
thrombotic	O	O
event	O	O
and	O	O
had	O	O
significantly	O	O
lower	O	O
total	O	O
and	O	O
free	O	O
protein	O	O
S	O	O
levels	O	O
than	O	O
those	O	O
relatives	O	O
having	O	O
missense	O	O
mutations	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
persons	O	O
with	O	O
PROS1	B-Disease	OMIM:612336
gene	I-Disease	OMIM:612336
defects	I-Disease	OMIM:612336
and	O	O
protein	B-Disease	D018455
S	I-Disease	D018455
deficiency	I-Disease	D018455
are	O	O
at	O	O
increased	O	O
risk	O	O
of	O	O
thrombosis	B-Disease	D013927
and	O	O
that	O	O
free	O	O
protein	O	O
S	O	O
estimation	O	O
offers	O	O
the	O	O
most	O	O
reliable	O	O
way	O	O
of	O	O
diagnosing	O	O
the	O	O
deficiency	O	O
.	O	O

(	O	O
Blood	O	O
.	O	O

2000	O	O
;	O	O
95	O	O
1935	O	O
-	O	O
1941	O	O
)	O	O
.	O	O

Severe	O	O
clinical	O	O
expression	O	O
in	O	O
X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
.	O	O

X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
is	O	O
a	O	O
relatively	O	O
rare	O	O
benign	B-Disease	D009468
neuromuscular	I-Disease	D009468
disorder	I-Disease	D009468
which	O	O
can	O	O
vary	O	O
remarkably	O	O
in	O	O
onset	O	O
,	O	O
course	O	O
and	O	O
severity	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
a	O	O
TCTAC	O	O
deletion	O	O
spanning	O	O
the	O	O
nucleotides	O	O
631	O	O
-	O	O
635	O	O
of	O	O
the	O	O
emerin	O	O
gene	O	O
caused	O	O
an	O	O
unusually	O	O
severe	O	O
disease	O	O
phenotype	O	O
including	O	O
loss	B-Disease	D051346
of	I-Disease	D051346
ambulation	I-Disease	D051346
and	O	O
severe	O	O
muscle	B-Disease	D009133
wasting	I-Disease	D009133
in	O	O
two	O	O
affected	O	O
brothers	O	O
.	O	O

The	O	O
same	O	O
mutation	O	O
has	O	O
been	O	O
reported	O	O
previously	O	O
in	O	O
an	O	O
unrelated	O	O
family	O	O
showing	O	O
a	O	O
significantly	O	O
milder	O	O
phenotype	O	O
.	O	O

The	O	O
interfamilial	O	O
heterogeneity	O	O
in	O	O
distribution	O	O
and	O	O
in	O	O
severity	O	O
of	O	O
the	O	O
features	O	O
in	O	O
the	O	O
two	O	O
families	O	O
point	O	O
to	O	O
environmental	O	O
or	O	O
genetic	O	O
modification	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
clinical	O	O
variability	O	O
in	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
.	O	O

.	O	O

The	O	O
gene	O	O
for	O	O
spinal	B-Disease	D013132
cerebellar	I-Disease	D013132
ataxia	I-Disease	D013132
3	O	O
(	O	O
SCA3	O	O
)	O	O
is	O	O
located	O	O
in	O	O
a	O	O
region	O	O
of	O	O
approximately	O	O
3	O	O
cM	O	O
on	O	O
chromosome	O	O
14q24	O	O
.	O	O

3	O	O
-	O	O
q32	O	O
.	O	O

2	O	O
.	O	O

SCA3	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
spinal	B-Disease	D013132
cerebellar	I-Disease	D013132
ataxia	I-Disease	D013132
3	O	O
,	O	O
was	O	O
recently	O	O
mapped	O	O
to	O	O
a	O	O
15	O	O
-	O	O
cM	O	O
interval	O	O
between	O	O
D14S67	O	O
and	O	O
D14S81	O	O
on	O	O
chromosome	O	O
14q	O	O
,	O	O
by	O	O
linkage	O	O
analysis	O	O
in	O	O
two	O	O
families	O	O
of	O	O
French	O	O
ancestry	O	O
.	O	O

The	O	O
SCA3	O	O
candidate	O	O
region	O	O
has	O	O
now	O	O
been	O	O
refined	O	O
by	O	O
linkage	O	O
analysis	O	O
with	O	O
four	O	O
new	O	O
microsatellite	O	O
markers	O	O
(	O	O
D14S256	O	O
,	O	O
D14S291	O	O
,	O	O
D14S280	O	O
,	O	O
and	O	O
AFM343vf1	O	O
)	O	O
in	O	O
the	O	O
same	O	O
two	O	O
families	O	O
,	O	O
in	O	O
which	O	O
19	O	O
additional	O	O
individuals	O	O
were	O	O
genotyped	O	O
,	O	O
and	O	O
in	O	O
a	O	O
third	O	O
French	O	O
family	O	O
.	O	O

Combined	O	O
two	O	O
-	O	O
point	O	O
linkage	O	O
analyses	O	O
show	O	O
that	O	O
the	O	O
new	O	O
markers	O	O
,	O	O
D14S280	O	O
and	O	O
AFM343vf1	O	O
,	O	O
are	O	O
tightly	O	O
linked	O	O
to	O	O
the	O	O
SCA3	O	O
locus	O	O
,	O	O
with	O	O
maximal	O	O
lod	O	O
scores	O	O
,	O	O
at	O	O
recombination	O	O
fraction	O	O
,	O	O
(	O	O
theta	O	O
)	O	O
=	O	O
.	O	O

00	O	O
,	O	O
of	O	O
7	O	O
.	O	O

05	O	O
and	O	O
13	O	O
.	O	O

70	O	O
,	O	O
respectively	O	O
.	O	O

Combined	O	O
multipoint	O	O
and	O	O
recombinant	O	O
haplotype	O	O
analyses	O	O
localize	O	O
the	O	O
SCA3	O	O
locus	O	O
to	O	O
a	O	O
3	O	O
-	O	O
cM	O	O
interval	O	O
flanked	O	O
by	O	O
D14S291	O	O
and	O	O
D14S81	O	O
.	O	O

The	O	O
same	O	O
allele	O	O
for	O	O
D14S280	O	O
segregates	O	O
with	O	O
the	O	O
disease	O	O
locus	O	O
in	O	O
the	O	O
three	O	O
kindreds	O	O
.	O	O

This	O	O
allele	O	O
is	O	O
frequent	O	O
in	O	O
the	O	O
French	O	O
population	O	O
,	O	O
however	O	O
,	O	O
and	O	O
linkage	O	O
disequilibrium	O	O
is	O	O
not	O	O
clearly	O	O
established	O	O
.	O	O

The	O	O
SCA3	O	O
locus	O	O
remains	O	O
within	O	O
the	O	O
29	O	O
-	O	O
cM	O	O
region	O	O
on	O	O
14q24	O	O
.	O	O

3	O	O
-	O	O
q32	O	O
.	O	O

2	O	O
containing	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
,	O	O
which	O	O
is	O	O
clinically	O	O
related	O	O
to	O	O
the	O	O
phenotype	O	O
determined	O	O
by	O	O
SCA3	O	O
,	O	O
but	O	O
it	O	O
cannot	O	O
yet	O	O
be	O	O
concluded	O	O
that	O	O
both	O	O
diseases	O	O
result	O	O
from	O	O
alterations	O	O
of	O	O
the	O	O
same	O	O
gene	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
and	O	O
childhood	O	O
-	O	O
onset	O	O
Tourette	B-Disease	D005879
syndrome	I-Disease	D005879
.	O	O

A	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
childhood	O	O
-	O	O
onset	O	O
Tourette	B-Disease	D005879
syndrome	I-Disease	D005879
(	O	O
TS	B-Disease	D005879
)	O	O
developed	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
.	O	O

We	O	O
believe	O	O
this	O	O
to	O	O
be	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
childhood	O	O
-	O	O
onset	O	O
TS	B-Disease	D005879
with	O	O
adult	O	O
onset	O	O
HD	B-Disease	D006816
.	O	O

Discovery	O	O
of	O	O
other	O	O
cases	O	O
with	O	O
both	O	O
disorders	O	O
may	O	O
provide	O	O
clues	O	O
to	O	O
the	O	O
pathophysiology	O	O
of	O	O
both	O	O
conditions	O	O
.	O	O

.	O	O

The	O	O
protein	O	O
deficient	O	O
in	O	O
Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
is	O	O
a	O	O
phosphatidylinositol	O	O
-	O	O
4	O	O
,	O	O
5	O	O
-	O	O
bisphosphate	O	O
5	O	O
-	O	O
phosphatase	O	O
.	O	O

Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
,	O	O
also	O	O
known	O	O
as	O	O
oculocerebrorenal	B-Disease	D009800
syndrome	I-Disease	D009800
,	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
X	O	O
chromosome	O	O
-	O	O
encoded	O	O
OCRL	O	O
gene	O	O
.	O	O

The	O	O
OCRL	O	O
protein	O	O
is	O	O
51	O	O
%	O	O
identical	O	O
to	O	O
inositol	O	O
polyphosphate	O	O
5	O	O
-	O	O
phosphatase	O	O
II	O	O
(	O	O
5	O	O
-	O	O
phosphatase	O	O
II	O	O
)	O	O
from	O	O
human	O	O
platelets	O	O
over	O	O
a	O	O
span	O	O
of	O	O
744	O	O
aa	O	O
,	O	O
suggesting	O	O
that	O	O
OCRL	O	O
may	O	O
be	O	O
a	O	O
similar	O	O
enzyme	O	O
.	O	O

We	O	O
engineered	O	O
a	O	O
construct	O	O
of	O	O
the	O	O
OCRL	O	O
cDNA	O	O
that	O	O
encodes	O	O
amino	O	O
acids	O	O
homologous	O	O
to	O	O
the	O	O
platelet	O	O
5	O	O
-	O	O
phosphatase	O	O
for	O	O
expression	O	O
in	O	O
baculovirus	O	O
-	O	O
infected	O	O
Sf9	O	O
insect	O	O
cells	O	O
.	O	O

This	O	O
cDNA	O	O
encodes	O	O
aa	O	O
264	O	O
-	O	O
968	O	O
of	O	O
the	O	O
OCRL	O	O
protein	O	O
.	O	O

The	O	O
recombinant	O	O
protein	O	O
was	O	O
found	O	O
to	O	O
catalyze	O	O
the	O	O
reactions	O	O
also	O	O
carried	O	O
out	O	O
by	O	O
platelet	O	O
5	O	O
-	O	O
phosphatase	O	O
II	O	O
.	O	O

Thus	O	O
OCRL	O	O
converts	O	O
inositol	O	O
1	O	O
,	O	O
4	O	O
,	O	O
5	O	O
-	O	O
trisphosphate	O	O
to	O	O
inositol	O	O
1	O	O
,	O	O
4	O	O
-	O	O
bisphosphate	O	O
,	O	O
and	O	O
it	O	O
converts	O	O
inositol	O	O
1	O	O
,	O	O
3	O	O
,	O	O
4	O	O
,	O	O
5	O	O
-	O	O
tetrakisphosphate	O	O
to	O	O
inositol	O	O
1	O	O
,	O	O
3	O	O
,	O	O
4	O	O
-	O	O
trisphosphate	O	O
.	O	O

Most	O	O
important	O	O
,	O	O
the	O	O
enzyme	O	O
converts	O	O
phosphatidylinositol	O	O
4	O	O
,	O	O
5	O	O
-	O	O
bisphosphate	O	O
to	O	O
phosphatidylinositol	O	O
4	O	O
-	O	O
phosphate	O	O
.	O	O

The	O	O
relative	O	O
ability	O	O
of	O	O
OCRL	O	O
to	O	O
catalyze	O	O
the	O	O
three	O	O
reactions	O	O
is	O	O
different	O	O
from	O	O
that	O	O
of	O	O
5	O	O
-	O	O
phosphatase	O	O
II	O	O
and	O	O
from	O	O
that	O	O
of	O	O
another	O	O
5	O	O
-	O	O
phosphatase	O	O
isoenzyme	O	O
from	O	O
platelets	O	O
,	O	O
5	O	O
-	O	O
phosphatase	O	O
I	O	O
.	O	O

The	O	O
recombinant	O	O
OCRL	O	O
protein	O	O
hydrolyzes	O	O
the	O	O
phospholipid	O	O
substrate	O	O
10	O	O
-	O	O
to	O	O
30	O	O
-	O	O
fold	O	O
better	O	O
than	O	O
5	O	O
-	O	O
phosphatase	O	O
II	O	O
,	O	O
and	O	O
5	O	O
-	O	O
phosphatase	O	O
I	O	O
does	O	O
not	O	O
cleave	O	O
the	O	O
lipid	O	O
at	O	O
all	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
OCRL	O	O
functions	O	O
as	O	O
a	O	O
phosphatidylinositol	O	O
4	O	O
,	O	O
5	O	O
-	O	O
bisphosphate	O	O
5	O	O
-	O	O
phosphatase	O	O
in	O	O
OCRL	O	O
-	O	O
expressing	O	O
Sf9	O	O
cells	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
OCRL	O	O
is	O	O
mainly	O	O
a	O	O
lipid	O	O
phosphatase	O	O
that	O	O
may	O	O
control	O	O
cellular	O	O
levels	O	O
of	O	O
a	O	O
critical	O	O
metabolite	O	O
,	O	O
phosphatidylinositol	O	O
4	O	O
,	O	O
5	O	O
-	O	O
bisphosphate	O	O
.	O	O

Deficiency	O	O
of	O	O
this	O	O
enzyme	O	O
apparently	O	O
causes	O	O
the	O	O
protean	O	O
manifestations	O	O
of	O	O
Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
.	O	O

.	O	O

Microdeletions	O	O
at	O	O
chromosome	O	O
bands	O	O
1q32	O	O
-	O	O
q41	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
Van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
.	O	O

Van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
(	O	O
VWS	B-Disease	C536528
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
comprising	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
and	O	O
/	O	O
or	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
and	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
.	O	O

We	O	O
reported	O	O
previously	O	O
a	O	O
family	O	O
whose	O	O
underlying	O	O
mutation	O	O
is	O	O
a	O	O
500	O	O
-	O	O
800	O	O
kb	O	O
deletion	O	O
localized	O	O
to	O	O
chromosome	O	O
bands	O	O
1q32	O	O
-	O	O
q41	O	O
[	O	O
Sander	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1994	O	O
Hum	O	O
Mol	O	O
Genet	O	O
3	O	O
576	O	O
-	O	O
578	O	O
]	O	O
.	O	O

Along	O	O
with	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
/	O	O
palate	O	O
and	O	O
lip	B-Disease	C536528
pits	I-Disease	C536528
,	O	O
affected	O	O
relatives	O	O
exhibit	O	O
developmental	B-Disease	D006130
delays	I-Disease	D006130
,	O	O
suggesting	O	O
that	O	O
the	O	O
function	O	O
of	O	O
a	O	O
gene	O	O
nearby	O	O
may	O	O
also	O	O
be	O	O
disrupted	O	O
.	O	O

To	O	O
further	O	O
localize	O	O
the	O	O
VWS	B-Disease	C536528
gene	O	O
we	O	O
searched	O	O
for	O	O
other	O	O
deletions	O	O
that	O	O
cause	O	O
VWS	B-Disease	C536528
.	O	O

An	O	O
allele	O	O
loss	O	O
assay	O	O
was	O	O
performed	O	O
using	O	O
a	O	O
novel	O	O
highly	O	O
polymorphic	O	O
marker	O	O
,	O	O
D1S3753	O	O
.	O	O

From	O	O
a	O	O
panel	O	O
of	O	O
37	O	O
unrelated	O	O
individuals	O	O
,	O	O
we	O	O
detected	O	O
an	O	O
allele	O	O
loss	O	O
in	O	O
one	O	O
family	O	O
,	O	O
indicating	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
deletion	O	O
.	O	O

In	O	O
this	O	O
family	O	O
,	O	O
the	O	O
phenotype	O	O
in	O	O
three	O	O
generations	O	O
of	O	O
affected	O	O
individuals	O	O
was	O	O
confined	O	O
to	O	O
the	O	O
cardinal	O	O
signs	O	O
of	O	O
VWS	B-Disease	C536528
.	O	O

Surprisingly	O	O
,	O	O
mapping	O	O
of	O	O
the	O	O
new	O	O
deletion	O	O
showed	O	O
that	O	O
it	O	O
extended	O	O
0	O	O
.	O	O

2	O	O
-	O	O
1	O	O
Mb	O	O
beyond	O	O
the	O	O
proximal	O	O
breakpoint	O	O
for	O	O
the	O	O
deletion	O	O
described	O	O
previously	O	O
.	O	O

No	O	O
deletions	O	O
were	O	O
detected	O	O
in	O	O
seven	O	O
cases	O	O
of	O	O
popliteal	B-Disease	OMIM:119500
pterygia	I-Disease	OMIM:119500
syndrome	I-Disease	OMIM:119500
,	O	O
76	O	O
cases	O	O
of	O	O
mixed	O	O
syndromic	B-Disease	D002971
forms	I-Disease	D002971
of	I-Disease	D002971
cleft	I-Disease	D002971
lip	I-Disease	D002971
and	I-Disease	D002971
palate	I-Disease	D002971
,	O	O
and	O	O
178	O	O
cases	O	O
of	O	O
nonsyndromic	B-Disease	OMIM:119530
cleft	I-Disease	OMIM:119530
lip	I-Disease	OMIM:119530
and	I-Disease	OMIM:119530
palate	I-Disease	OMIM:119530
.	O	O

Mucopolysaccharidosis	B-Disease	OMIM:253000
type	I-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
:	O	O
common	O	O
double	O	O
deletion	O	O
in	O	O
the	O	O
N	O	O
-	O	O
acetylgalactosamine	O	O
-	O	O
6	O	O
-	O	O
sulfatase	O	O
gene	O	O
(	O	O
GALNS	O	O
)	O	O
.	O	O

Mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
(	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	D009085
in	I-Disease	D009085
N	I-Disease	D009085
-	I-Disease	D009085
acetylgalactosamine	I-Disease	D009085
-	I-Disease	D009085
6	I-Disease	D009085
-	I-Disease	D009085
sulfatase	I-Disease	D009085
(	O	O
GALNS	O	O
)	O	O
.	O	O

We	O	O
found	O	O
two	O	O
separate	O	O
deletions	O	O
of	O	O
nearly	O	O
8	O	O
.	O	O

0	O	O
and	O	O
6	O	O
.	O	O

0	O	O
kb	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
,	O	O
including	O	O
some	O	O
exons	O	O
.	O	O

There	O	O
are	O	O
Alu	O	O
repetitive	O	O
elements	O	O
near	O	O
the	O	O
breakpoints	O	O
of	O	O
the	O	O
8	O	O
.	O	O

0	O	O
-	O	O
kb	O	O
deletion	O	O
,	O	O
and	O	O
this	O	O
deletion	O	O
resulted	O	O
from	O	O
an	O	O
Alu	O	O
-	O	O
Alu	O	O
recombination	O	O
.	O	O

The	O	O
other	O	O
6	O	O
.	O	O

0	O	O
-	O	O
kb	O	O
deletion	O	O
involved	O	O
illegitimate	O	O
recombinational	O	O
events	O	O
between	O	O
incomplete	O	O
short	O	O
direct	O	O
repeats	O	O
of	O	O
8	O	O
bp	O	O
at	O	O
deletion	O	O
breakpoints	O	O
.	O	O

The	O	O
same	O	O
rearrangement	O	O
has	O	O
been	O	O
observed	O	O
in	O	O
a	O	O
heteroallelic	O	O
state	O	O
in	O	O
four	O	O
unrelated	O	O
patients	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
documentation	O	O
of	O	O
a	O	O
common	O	O
double	O	O
deletion	O	O
a	O	O
gene	O	O
that	O	O
is	O	O
not	O	O
a	O	O
member	O	O
of	O	O
a	O	O
gene	O	O
cluster	O	O
.	O	O

Segregation	O	O
analysis	O	O
of	O	O
a	O	O
marker	O	O
localised	O	O
Xp21	O	O
.	O	O

2	O	O
-	O	O
Xp21	O	O
.	O	O

3	O	O
in	O	O
Duchenne	B-Disease	D020388
and	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
families	O	O
.	O	O

A	O	O
DNA	O	O
marker	O	O
C7	O	O
,	O	O
localised	O	O
Xp21	O	O
.	O	O

1	O	O
-	O	O
Xp21	O	O
.	O	O

3	O	O
,	O	O
has	O	O
been	O	O
studied	O	O
in	O	O
kindreds	O	O
segregating	O	O
for	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
and	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
(	O	O
BMD	B-Disease	C537666
)	O	O
.	O	O

In	O	O
DMD	B-Disease	D020388
families	O	O
four	O	O
crossovers	O	O
were	O	O
observed	O	O
in	O	O
38	O	O
informative	O	O
meioses	O	O
between	O	O
C7	O	O
and	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
(	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

12	O	O
,	O	O
z	O	O
max	O	O
=	O	O
+	O	O
2	O	O
.	O	O

72	O	O
)	O	O
.	O	O

In	O	O
BMD	B-Disease	C537666
families	O	O
no	O	O
recombinants	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
16	O	O
informative	O	O
meioses	O	O
studied	O	O
.	O	O

These	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
localisation	O	O
of	O	O
the	O	O
mutations	O	O
in	O	O
these	O	O
disorders	O	O
being	O	O
in	O	O
the	O	O
same	O	O
region	O	O
of	O	O
Xp21	O	O
.	O	O

Studies	O	O
in	O	O
families	O	O
also	O	O
segregating	O	O
for	O	O
the	O	O
DNA	O	O
marker	O	O
754	O	O
support	O	O
the	O	O
previously	O	O
reported	O	O
physical	O	O
order	O	O
of	O	O
these	O	O
loci	O	O
as	O	O
X	O	O
centromere	O	O
-	O	O
754	O	O
-	O	O
DMD	B-Disease	D020388
-	O	O
BMD	B-Disease	C537666
-	O	O
C7	O	O
-	O	O
X	O	O
telomere	O	O
.	O	O

A	O	O
recombination	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

11	O	O
(	O	O
z	O	O
max	O	O
=	O	O
+	O	O
5	O	O
.	O	O

58	O	O
)	O	O
was	O	O
found	O	O
between	O	O
DMD	B-Disease	D020388
-	O	O
754	O	O
by	O	O
combining	O	O
our	O	O
previously	O	O
published	O	O
data	O	O
with	O	O
the	O	O
data	O	O
presented	O	O
here	O	O
.	O	O

C7	O	O
and	O	O
754	O	O
thus	O	O
provide	O	O
good	O	O
bridging	O	O
markers	O	O
for	O	O
the	O	O
diagnosis	O	O
of	O	O
DMD	B-Disease	D020388
and	O	O
BMD	B-Disease	C537666
Genetic	O	O
analysis	O	O
of	O	O
the	O	O
BRCA1	O	O
region	O	O
in	O	O
a	O	O
large	O	O
breast	O	O
/	O	O
ovarian	O	O
family	O	O
:	O	O
refinement	O	O
of	O	O
the	O	O
minimal	O	O
region	O	O
containing	O	O
BRCA1	O	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
a	O	O
single	O	O
multi	O	O
-	O	O
affected	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
pedigree	O	O
(	O	O
BOV3	O	O
)	O	O
and	O	O
have	O	O
shown	O	O
consistent	O	O
inheritance	O	O
of	O	O
markers	O	O
on	O	O
chromosome	O	O
17q	O	O
with	O	O
the	O	O
disease	O	O
confirming	O	O
that	O	O
this	O	O
family	O	O
is	O	O
due	O	O
to	O	O
the	O	O
BRCA1	O	O
gene	O	O
.	O	O

Analysis	O	O
of	O	O
17q	O	O
haplotypes	O	O
shows	O	O
a	O	O
recombination	O	O
event	O	O
in	O	O
a	O	O
bilateral	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
case	O	O
which	O	O
suggests	O	O
that	O	O
the	O	O
BRCA1	O	O
gene	O	O
lies	O	O
distal	O	O
to	O	O
D17S857	O	O
;	O	O
D17S857	O	O
is	O	O
thus	O	O
the	O	O
new	O	O
proximal	O	O
boundary	O	O
for	O	O
the	O	O
region	O	O
containing	O	O
BRCA1	O	O
.	O	O

Combining	O	O
this	O	O
information	O	O
with	O	O
previously	O	O
published	O	O
mapping	O	O
information	O	O
suggests	O	O
that	O	O
BRCA1	O	O
is	O	O
contained	O	O
in	O	O
a	O	O
region	O	O
estimated	O	O
at	O	O
1	O	O
-	O	O
1	O	O
.	O	O

5	O	O
Mb	O	O
in	O	O
length	O	O
.	O	O

All	O	O
seven	O	O
breast	B-Disease	D001943
tumour	I-Disease	D001943
/	O	O
blood	O	O
pairs	O	O
examined	O	O
from	O	O
this	O	O
family	O	O
show	O	O
loss	O	O
of	O	O
heterozygosity	O	O
in	O	O
the	O	O
tumours	B-Disease	D009369
.	O	O

The	O	O
allel	O	O
retained	O	O
in	O	O
each	O	O
tumour	B-Disease	D009369
was	O	O
from	O	O
the	O	O
disease	O	O
-	O	O
bearing	O	O
chromosome	O	O
implicating	O	O
BRCA1	O	O
as	O	O
a	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
.	O	O

We	O	O
have	O	O
sequenced	O	O
the	O	O
17	O	O
beta	O	O
-	O	O
oestradiol	O	O
dehydrogenase	O	O
genes	O	O
(	O	O
EDH17B1	O	O
and	O	O
EDH17B2	O	O
)	O	O
which	O	O
have	O	O
been	O	O
suggested	O	O
as	O	O
candidate	O	O
genes	O	O
for	O	O
BRCA1	O	O
in	O	O
four	O	O
members	O	O
of	O	O
this	O	O
family	O	O
.	O	O

No	O	O
germline	O	O
mutations	O	O
were	O	O
detected	O	O
.	O	O

A	O	O
point	O	O
mutation	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
Met	O	O
on	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
integrin	O	O
leads	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
new	O	O
human	O	O
platelet	O	O
alloantigen	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
and	O	O
affects	O	O
collagen	O	O
-	O	O
induced	O	O
aggregation	O	O
.	O	O

A	O	O
new	O	O
platelet	O	O
-	O	O
specific	O	O
alloantigen	O	O
,	O	O
termed	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
,	O	O
was	O	O
identified	O	O
in	O	O
a	O	O
severe	O	O
case	O	O
of	O	O
neonatal	B-Disease	D054098
alloimmune	I-Disease	D054098
thrombocytopenia	I-Disease	D054098
.	O	O

The	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
alloantigen	O	O
is	O	O
of	O	O
low	O	O
frequency	O	O
(	O	O
1	O	O
/	O	O
400	O	O
)	O	O
in	O	O
the	O	O
German	O	O
population	O	O
.	O	O

Immunochemical	O	O
studies	O	O
demonstrated	O	O
that	O	O
the	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
epitopes	O	O
reside	O	O
on	O	O
platelet	O	O
glycoprotein	O	O
(	O	O
GP	O	O
)	O	O
Ia	O	O
.	O	O

Nucleotide	O	O
sequence	O	O
analysis	O	O
of	O	O
GPIa	O	O
cDNA	O	O
derived	O	O
from	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
-	O	O
positive	O	O
platelets	O	O
showed	O	O
C	O	O
(	O	O
2531	O	O
)	O	O
-	O	O
-	O	O
>	O	O
T	O	O
(	O	O
2531	O	O
)	O	O
point	O	O
mutation	O	O
,	O	O
resulting	O	O
in	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
Met	O	O
dimorphism	O	O
.	O	O

Analysis	O	O
of	O	O
genomic	O	O
DNA	O	O
from	O	O
22	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
-	O	O
negative	O	O
normal	O	O
individuals	O	O
showed	O	O
that	O	O
the	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
is	O	O
encoded	O	O
by	O	O
ACG	O	O
(	O	O
2532	O	O
)	O	O
(	O	O
90	O	O
.	O	O

9	O	O
%	O	O
)	O	O
or	O	O
ACA	O	O
(	O	O
2532	O	O
)	O	O
(	O	O
9	O	O
.	O	O

1	O	O
%	O	O
)	O	O
.	O	O

To	O	O
establish	O	O
a	O	O
DNA	O	O
typing	O	O
technique	O	O
,	O	O
we	O	O
elucidated	O	O
the	O	O
organization	O	O
of	O	O
the	O	O
GPIa	O	O
gene	O	O
adjacent	O	O
to	O	O
the	O	O
polymorphic	O	O
bases	O	O
.	O	O

The	O	O
introns	O	O
(	O	O
421	O	O
bp	O	O
and	O	O
1	O	O
.	O	O

2	O	O
kb	O	O
)	O	O
encompass	O	O
a	O	O
142	O	O
-	O	O
bp	O	O
exon	O	O
with	O	O
the	O	O
2	O	O
polymorphic	O	O
bases	O	O
2531	O	O
and	O	O
2532	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
analysis	O	O
on	O	O
DNA	O	O
derived	O	O
from	O	O
100	O	O
donors	O	O
using	O	O
the	O	O
restriction	O	O
enzyme	O	O
Mae	O	O
III	O	O
showed	O	O
that	O	O
the	O	O
Met	O	O
(	O	O
799	O	O
)	O	O
form	O	O
of	O	O
GPIa	O	O
is	O	O
restricted	O	O
to	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
(	O	O
+	O	O
)	O	O
phenotype	O	O
.	O	O

Analysis	O	O
of	O	O
stable	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
transfectants	O	O
expressing	O	O
allele	O	O
-	O	O
specific	O	O
recombinant	O	O
forms	O	O
of	O	O
GPIa	O	O
showed	O	O
that	O	O
anti	O	O
-	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
exclusively	O	O
reacted	O	O
with	O	O
the	O	O
Glu	O	O
(	O	O
505	O	O
)	O	O
Met	O	O
(	O	O
799	O	O
)	O	O
,	O	O
but	O	O
not	O	O
with	O	O
the	O	O
Glu	O	O
(	O	O
505	O	O
)	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
and	O	O
the	O	O
Lys	O	O
(	O	O
505	O	O
)	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
isoforms	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
anti	O	O
-	O	O
Br	O	O
(	O	O
a	O	O
)	O	O
(	O	O
HPA	O	O
-	O	O
5b	O	O
)	O	O
only	O	O
recognized	O	O
the	O	O
Lys	O	O
(	O	O
505	O	O
)	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
form	O	O
,	O	O
whereas	O	O
anti	O	O
-	O	O
Br	O	O
(	O	O
b	O	O
)	O	O
(	O	O
HPA	O	O
-	O	O
5a	O	O
)	O	O
reacted	O	O
with	O	O
both	O	O
Glu	O	O
(	O	O
505	O	O
)	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
and	O	O
Glu	O	O
(	O	O
505	O	O
)	O	O
Met	O	O
(	O	O
799	O	O
)	O	O
isoforms	O	O
.	O	O

These	O	O
results	O	O
demonstrated	O	O
that	O	O
the	O	O
Met	O	O
(	O	O
799	O	O
)	O	O
is	O	O
responsible	O	O
for	O	O
formation	O	O
of	O	O
the	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
alloantigenic	O	O
determinants	O	O
,	O	O
whereas	O	O
amino	O	O
acid	O	O
505	O	O
(	O	O
Lys	O	O
or	O	O
Glu	O	O
)	O	O
specifically	O	O
controls	O	O
the	O	O
expression	O	O
of	O	O
Br	O	O
(	O	O
a	O	O
)	O	O
and	O	O
Br	O	O
(	O	O
b	O	O
)	O	O
epitopes	O	O
,	O	O
respectively	O	O
.	O	O

Platelet	O	O
aggregation	O	O
responses	O	O
of	O	O
Sit	O	O
(	O	O
a	O	O
)	O	O
(	O	O
+	O	O
)	O	O
individuals	O	O
were	O	O
diminished	O	O
in	O	O
response	O	O
to	O	O
collagen	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
Thr	O	O
(	O	O
799	O	O
)	O	O
Met	O	O
mutation	O	O
affects	O	O
the	O	O
function	O	O
of	O	O
the	O	O
GPIa	O	O
/	O	O
IIa	O	O
complex	O	O
Estimation	O	O
of	O	O
the	O	O
male	O	O
to	O	O
female	O	O
ratio	O	O
of	O	O
mutation	O	O
rates	O	O
from	O	O
the	O	O
segregation	O	O
of	O	O
X	O	O
-	O	O
chromosomal	O	O
DNA	O	O
haplotypes	O	O
in	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
families	O	O
.	O	O

A	O	O
novel	O	O
procedure	O	O
is	O	O
presented	O	O
to	O	O
estimate	O	O
the	O	O
ratio	O	O
of	O	O
male	O	O
to	O	O
female	O	O
mutation	O	O
rates	O	O
for	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

X	O	O
-	O	O
specific	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
are	O	O
used	O	O
to	O	O
establish	O	O
DNA	O	O
haplotypes	O	O
in	O	O
three	O	O
-	O	O
generation	O	O
DMD	B-Disease	D020388
families	O	O
.	O	O

From	O	O
the	O	O
proportion	O	O
of	O	O
DMD	B-Disease	D020388
patients	O	O
who	O	O
have	O	O
inherited	O	O
their	O	O
maternal	O	O
grandfathers	O	O
X	O	O
chromosome	O	O
,	O	O
the	O	O
ratio	O	O
of	O	O
mutation	O	O
rates	O	O
can	O	O
be	O	O
calculated	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
classical	O	O
methods	O	O
,	O	O
the	O	O
proposed	O	O
procedure	O	O
is	O	O
not	O	O
restricted	O	O
to	O	O
sporadic	O	O
or	O	O
familiar	O	O
cases	O	O
nor	O	O
is	O	O
any	O	O
information	O	O
on	O	O
the	O	O
carrier	O	O
status	O	O
of	O	O
female	O	O
relatives	O	O
required	O	O
.	O	O

.	O	O

Genetic	O	O
analysis	O	O
of	O	O
an	O	O
inherited	O	O
deficiency	B-Disease	OMIM:613779
of	I-Disease	OMIM:613779
the	I-Disease	OMIM:613779
third	I-Disease	OMIM:613779
component	I-Disease	OMIM:613779
of	I-Disease	OMIM:613779
complement	I-Disease	OMIM:613779
in	O	O
Brittany	O	O
spaniel	O	O
dogs	O	O
.	O	O

Genetically	O	O
determined	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
in	O	O
Brittany	O	O
spaniel	O	O
dogs	O	O
shares	O	O
a	O	O
number	O	O
of	O	O
biochemical	O	O
and	O	O
clinical	O	O
characteristics	O	O
with	O	O
the	O	O
human	O	O
disorder	O	O
.	O	O

In	O	O
humans	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
is	O	O
a	O	O
null	O	O
gene	O	O
that	O	O
is	O	O
allelic	O	O
to	O	O
the	O	O
structural	O	O
gene	O	O
for	O	O
C3	O	O
and	O	O
is	O	O
not	O	O
linked	O	O
to	O	O
the	O	O
major	O	O
histocompatibility	O	O
locus	O	O
.	O	O

The	O	O
current	O	O
study	O	O
used	O	O
allotype	O	O
analysis	O	O
of	O	O
canine	O	O
C3	O	O
in	O	O
order	O	O
to	O	O
demonstrate	O	O
that	O	O
the	O	O
gene	O	O
for	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
in	O	O
these	O	O
dogs	O	O
is	O	O
also	O	O
a	O	O
null	O	O
gene	O	O
allelic	O	O
to	O	O
the	O	O
structural	O	O
gene	O	O
for	O	O
C3	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
preliminary	O	O
pedigree	O	O
analysis	O	O
suggests	O	O
that	O	O
the	O	O
gene	O	O
for	O	O
canine	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
is	O	O
apparently	O	O
not	O	O
closely	O	O
linked	O	O
to	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
of	O	O
the	O	O
dog	O	O
.	O	O

Thus	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
in	O	O
Brittany	O	O
spaniel	O	O
dogs	O	O
not	O	O
only	O	O
shares	O	O
biochemical	O	O
and	O	O
clinical	O	O
features	O	O
with	O	O
C3	B-Disease	OMIM:613779
deficiency	I-Disease	OMIM:613779
in	O	O
humans	O	O
,	O	O
but	O	O
also	O	O
shares	O	O
some	O	O
genetic	O	O
characteristics	O	O
with	O	O
the	O	O
human	O	O
disorder	O	O
.	O	O

.	O	O

A	O	O
novel	O	O
frameshift	O	O
mutation	O	O
in	O	O
the	O	O
McLeod	B-Disease	OMIM:300842
syndrome	I-Disease	OMIM:300842
gene	O	O
in	O	O
a	O	O
Japanese	O	O
family	O	O
.	O	O

We	O	O
report	O	O
a	O	O
novel	O	O
mutation	O	O
in	O	O
the	O	O
XK	O	O
gene	O	O
(	O	O
XK	O	O
)	O	O
in	O	O
a	O	O
Japanese	O	O
patient	O	O
with	O	O
McLeod	B-Disease	OMIM:300842
syndrome	I-Disease	OMIM:300842
.	O	O

A	O	O
50	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
showed	O	O
progressive	O	O
muscular	B-Disease	D009133
atrophy	I-Disease	D009133
,	O	O
choreic	B-Disease	D002819
movement	I-Disease	D002819
,	O	O
elevated	O	O
level	O	O
of	O	O
serum	O	O
creatinine	O	O
kinase	O	O
,	O	O
and	O	O
acanthocytosis	B-Disease	D000012
.	O	O

The	O	O
expression	O	O
level	O	O
of	O	O
all	O	O
the	O	O
Kell	O	O
antigens	O	O
in	O	O
erythrocyte	O	O
was	O	O
decreased	O	O
and	O	O
molecular	O	O
analysis	O	O
revealed	O	O
a	O	O
single	O	O
-	O	O
base	O	O
(	O	O
T	O	O
)	O	O
deletion	O	O
at	O	O
the	O	O
nucleotide	O	O
position	O	O
1095	O	O
in	O	O
XK	O	O
.	O	O

This	O	O
deletion	O	O
caused	O	O
a	O	O
frameshift	O	O
in	O	O
translation	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
at	O	O
the	O	O
amino	O	O
acid	O	O
position	O	O
408	O	O
.	O	O

We	O	O
conclude	O	O
this	O	O
single	O	O
-	O	O
base	O	O
deletion	O	O
causes	O	O
defective	O	O
Kx	O	O
protein	O	O
,	O	O
which	O	O
is	O	O
responsible	O	O
for	O	O
the	O	O
McLeod	B-Disease	OMIM:300842
phenotype	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

.	O	O

Alpha	O	O
-	O	O
cardiac	O	O
actin	O	O
is	O	O
a	O	O
novel	O	O
disease	O	O
gene	O	O
in	O	O
familial	B-Disease	D024741
hypertrophic	I-Disease	D024741
cardiomyopathy	I-Disease	D024741
.	O	O

We	O	O
identified	O	O
the	O	O
alpha	O	O
-	O	O
cardiac	O	O
actin	O	O
gene	O	O
(	O	O
ACTC	O	O
)	O	O
as	O	O
a	O	O
novel	O	O
disease	O	O
gene	O	O
in	O	O
a	O	O
pedigree	O	O
suffering	O	O
from	O	O
familial	B-Disease	D024741
hypertrophic	I-Disease	D024741
cardiomyopathy	I-Disease	D024741
(	O	O
FHC	B-Disease	D024741
)	O	O
.	O	O

Linkage	O	O
analyses	O	O
excluded	O	O
all	O	O
the	O	O
previously	O	O
reported	O	O
FHC	B-Disease	D024741
loci	O	O
as	O	O
possible	O	O
disease	O	O
loci	O	O
in	O	O
the	O	O
family	O	O
studied	O	O
,	O	O
with	O	O
lod	O	O
scores	O	O
varying	O	O
between	O	O
-	O	O
2	O	O
.	O	O

5	O	O
and	O	O
-	O	O
6	O	O
.	O	O

0	O	O
0	O	O
.	O	O

Further	O	O
linkage	O	O
analyses	O	O
of	O	O
plausible	O	O
candidate	O	O
genes	O	O
highly	O	O
expressed	O	O
in	O	O
the	O	O
adult	O	O
human	O	O
heart	O	O
identified	O	O
ACTC	O	O
as	O	O
the	O	O
most	O	O
likely	O	O
disease	O	O
gene	O	O
,	O	O
showing	O	O
a	O	O
maximal	O	O
lod	O	O
score	O	O
of	O	O
3	O	O
.	O	O

6	O	O
6	O	O
.	O	O

Mutation	O	O
analysis	O	O
of	O	O
ACTC	O	O
revealed	O	O
an	O	O
Ala295Ser	O	O
mutation	O	O
in	O	O
exon	O	O
5	O	O
close	O	O
to	O	O
2	O	O
missense	O	O
mutations	O	O
recently	O	O
described	O	O
to	O	O
cause	O	O
the	O	O
inherited	O	O
form	O	O
of	O	O
idiopathic	B-Disease	C536277
dilated	I-Disease	C536277
cardiomyopathy	I-Disease	C536277
(	O	O
IDC	B-Disease	C536277
)	O	O
.	O	O

The	O	O
EWS	O	O
gene	O	O
,	O	O
involved	O	O
in	O	O
Ewing	B-Disease	D012512
family	I-Disease	D012512
of	I-Disease	D012512
tumors	I-Disease	D012512
,	O	O
malignant	B-Disease	D008545
melanoma	I-Disease	D008545
of	I-Disease	D008545
soft	I-Disease	D008545
parts	I-Disease	D008545
and	O	O
desmoplastic	B-Disease	D058405
small	I-Disease	D058405
round	I-Disease	D058405
cell	I-Disease	D058405
tumors	I-Disease	D058405
,	O	O
codes	O	O
for	O	O
an	O	O
RNA	O	O
binding	O	O
protein	O	O
with	O	O
novel	O	O
regulatory	O	O
domains	O	O
.	O	O

The	O	O
EWS	O	O
gene	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
band	O	O
q12	O	O
of	O	O
human	O	O
chromosome	O	O
22	O	O
,	O	O
is	O	O
involved	O	O
in	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
human	O	O
solid	B-Disease	D009369
tumors	I-Disease	D009369
including	O	O
Ewing	B-Disease	D012512
sarcoma	I-Disease	D012512
,	O	O
related	O	O
primitive	O	O
neuroectodermal	B-Disease	D017599
tumors	I-Disease	D017599
,	O	O
malignant	B-Disease	D008545
melanoma	I-Disease	D008545
of	I-Disease	D008545
soft	I-Disease	D008545
parts	I-Disease	D008545
and	O	O
desmoplastic	B-Disease	D058405
small	I-Disease	D058405
round	I-Disease	D058405
cell	I-Disease	D058405
tumors	I-Disease	D058405
.	O	O

In	O	O
these	O	O
tumors	B-Disease	D009369
,	O	O
the	O	O
EWS	O	O
is	O	O
fused	O	O
to	O	O
genes	O	O
encoding	O	O
transcriptional	O	O
activators	O	O
/	O	O
repressors	O	O
,	O	O
like	O	O
Fli	O	O
-	O	O
1	O	O
or	O	O
erg	O	O
or	O	O
ATF	O	O
1	O	O
or	O	O
wt1	O	O
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
function	O	O
of	O	O
the	O	O
EWS	O	O
protein	O	O
,	O	O
we	O	O
cloned	O	O
the	O	O
EWS	O	O
cDNA	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
this	O	O
cDNA	O	O
revealed	O	O
differential	O	O
splicing	O	O
involving	O	O
two	O	O
exons	O	O
encoding	O	O
72	O	O
amino	O	O
acids	O	O
.	O	O

Both	O	O
alternatively	O	O
spliced	O	O
transcripts	O	O
,	O	O
EWS	O	O
and	O	O
EWS	O	O
-	O	O
b	O	O
,	O	O
are	O	O
expressed	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
cells	O	O
.	O	O

Because	O	O
EWS	O	O
proteins	O	O
contain	O	O
putative	O	O
conserved	O	O
RNA	O	O
binding	O	O
motifs	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
RNA	O	O
binding	O	O
properties	O	O
of	O	O
the	O	O
EWS	O	O
protein	O	O
.	O	O

The	O	O
EWS	O	O
-	O	O
b	O	O
protein	O	O
binds	O	O
to	O	O
RNA	O	O
in	O	O
vitro	O	O
and	O	O
,	O	O
specifically	O	O
,	O	O
to	O	O
poly	O	O
G	O	O
and	O	O
poly	O	O
U	O	O
.	O	O

The	O	O
RNA	O	O
binding	O	O
activity	O	O
was	O	O
localized	O	O
to	O	O
the	O	O
carboxy	O	O
terminal	O	O
86	O	O
amino	O	O
acids	O	O
,	O	O
which	O	O
constitute	O	O
RGG	O	O
box	O	O
.	O	O

Thus	O	O
the	O	O
amino	O	O
terminal	O	O
domain	O	O
of	O	O
EWS	O	O
(	O	O
NTD	O	O
-	O	O
EWS	O	O
)	O	O
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
chromosome	O	O
translocation	O	O
may	O	O
regulate	O	O
the	O	O
specificity	O	O
of	O	O
RNA	O	O
binding	O	O
activity	O	O
of	O	O
EWS	O	O
.	O	O

An	O	O
EWS	O	O
-	O	O
erg	O	O
chimeric	O	O
protein	O	O
,	O	O
which	O	O
is	O	O
found	O	O
in	O	O
Ewings	B-Disease	D012512
sarcoma	I-Disease	D012512
cells	O	O
,	O	O
functions	O	O
as	O	O
a	O	O
transcriptional	O	O
activator	O	O
.	O	O

Mutational	O	O
analysis	O	O
of	O	O
EWS	O	O
-	O	O
erg	O	O
chimeric	O	O
protein	O	O
revealed	O	O
that	O	O
NTD	O	O
-	O	O
EWS	O	O
functions	O	O
as	O	O
a	O	O
regulatory	O	O
domain	O	O
for	O	O
the	O	O
transcriptional	O	O
activation	O	O
properties	O	O
of	O	O
EWS	O	O
-	O	O
erg	O	O
chimeric	O	O
protein	O	O
.	O	O

.	O	O

A	O	O
mutation	O	O
common	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
:	O	O
frequency	O	O
and	O	O
RNA	O	O
studies	O	O
.	O	O

Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
resulting	O	O
from	O	O
mutation	O	O
of	O	O
the	O	O
HEXA	O	O
gene	O	O
encoding	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
the	O	O
lysosomal	O	O
enzyme	O	O
,	O	O
beta	O	O
-	O	O
N	O	O
-	O	O
acetylhexosaminidase	O	O
A	O	O
(	O	O
Hex	O	O
A	O	O
)	O	O
.	O	O

We	O	O
have	O	O
discovered	O	O
that	O	O
a	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
mutation	O	O
,	O	O
IVS	O	O
-	O	O
9	O	O
+	O	O
1	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
,	O	O
first	O	O
detected	O	O
by	O	O
Akli	O	O
et	O	O
al	O	O
.	O	O

(	O	O
Genomics	O	O
11	O	O
124	O	O
-	O	O
134	O	O
,	O	O
1991	O	O
)	O	O
,	O	O
is	O	O
a	O	O
common	O	O
disease	O	O
allele	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
Caucasians	O	O
(	O	O
10	O	O
/	O	O
58	O	O
alleles	O	O
examined	O	O
)	O	O
.	O	O

A	O	O
PCR	O	O
-	O	O
based	O	O
diagnostic	O	O
test	O	O
,	O	O
which	O	O
detects	O	O
an	O	O
NlaIII	O	O
site	O	O
generated	O	O
by	O	O
the	O	O
mutation	O	O
,	O	O
revealed	O	O
a	O	O
frequency	O	O
among	O	O
enzyme	O	O
-	O	O
defined	O	O
carriers	O	O
of	O	O
9	O	O
/	O	O
64	O	O
(	O	O
14	O	O
%	O	O
)	O	O
.	O	O

Most	O	O
of	O	O
those	O	O
carrying	O	O
the	O	O
allele	O	O
trace	O	O
their	O	O
origins	O	O
to	O	O
the	O	O
United	O	O
Kingdom	O	O
,	O	O
Ireland	O	O
,	O	O
or	O	O
Western	O	O
Europe	O	O
.	O	O

It	O	O
was	O	O
not	O	O
identified	O	O
among	O	O
12	O	O
Black	O	O
American	O	O
TSD	B-Disease	D013661
alleles	O	O
or	O	O
in	O	O
any	O	O
of	O	O
18	O	O
Ashkenazi	O	O
Jewish	O	O
,	O	O
enzyme	O	O
-	O	O
defined	O	O
carriers	O	O
who	O	O
did	O	O
not	O	O
carry	O	O
any	O	O
of	O	O
the	O	O
mutations	O	O
common	O	O
to	O	O
this	O	O
population	O	O
.	O	O

No	O	O
normally	O	O
spliced	O	O
RNA	O	O
was	O	O
detected	O	O
in	O	O
PCR	O	O
products	O	O
generated	O	O
from	O	O
reverse	O	O
transcription	O	O
of	O	O
RNA	O	O
carrying	O	O
the	O	O
IVS	O	O
-	O	O
9	O	O
mutation	O	O
.	O	O

Instead	O	O
,	O	O
the	O	O
low	O	O
levels	O	O
of	O	O
mRNA	O	O
from	O	O
this	O	O
allele	O	O
were	O	O
comprised	O	O
of	O	O
aberrant	O	O
species	O	O
resulting	O	O
from	O	O
the	O	O
use	O	O
of	O	O
either	O	O
of	O	O
two	O	O
cryptic	O	O
donor	O	O
sites	O	O
,	O	O
one	O	O
truncating	O	O
exon	O	O
9	O	O
and	O	O
the	O	O
other	O	O
within	O	O
IVS	O	O
-	O	O
9	O	O
,	O	O
spliced	O	O
to	O	O
exon	O	O
10	O	O
.	O	O

Numerous	O	O
additional	O	O
splice	O	O
products	O	O
were	O	O
detected	O	O
,	O	O
most	O	O
involving	O	O
skipping	O	O
of	O	O
one	O	O
or	O	O
more	O	O
surrounding	O	O
exons	O	O
.	O	O

Together	O	O
with	O	O
a	O	O
recently	O	O
identified	O	O
allele	O	O
responsible	O	O
for	O	O
Hex	O	O
A	O	O
pseudodeficiency	O	O
(	O	O
Triggs	O	O
-	O	O
Raine	O	O
et	O	O
al	O	O
.	O	O

Am	O	O
J	O	O
Hum	O	O
Genet	O	O
,	O	O
1992	O	O
)	O	O
,	O	O
these	O	O
two	O	O
alleles	O	O
accounted	O	O
for	O	O
almost	O	O
50	O	O
%	O	O
(	O	O
29	O	O
/	O	O
64	O	O
)	O	O
of	O	O
TSD	B-Disease	D013661
or	O	O
carrier	O	O
alleles	O	O
ascertained	O	O
by	O	O
enzyme	O	O
screening	O	O
tests	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
Caucasians	O	O
.	O	O

.	O	O

Characterization	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
region	O	O
predicts	O	O
multiple	O	O
protein	O	O
isoform	O	O
-	O	O
encoding	O	O
mRNAs	O	O
.	O	O

The	O	O
mutation	O	O
underlying	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
an	O	O
expansion	O	O
of	O	O
a	O	O
polymorphic	O	O
CTG	O	O
-	O	O
repeat	O	O
in	O	O
a	O	O
gene	O	O
encoding	O	O
protein	O	O
kinase	O	O
activity	O	O
.	O	O

Brain	O	O
and	O	O
heart	O	O
transcripts	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
-	O	O
kinase	O	O
(	O	O
DMR	O	O
-	O	O
B15	O	O
)	O	O
gene	O	O
are	O	O
subject	O	O
to	O	O
alternative	O	O
RNA	O	O
splicing	O	O
in	O	O
both	O	O
human	O	O
and	O	O
mouse	O	O
.	O	O

The	O	O
unstable	O	O
[	O	O
CTG	O	O
]	O	O
5	O	O
-	O	O
30	O	O
motif	O	O
is	O	O
found	O	O
uniquely	O	O
in	O	O
humans	O	O
,	O	O
although	O	O
the	O	O
flanking	O	O
nucleotides	O	O
are	O	O
also	O	O
present	O	O
in	O	O
mouse	O	O
.	O	O

Characterization	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
region	O	O
of	O	O
both	O	O
species	O	O
reveals	O	O
another	O	O
active	O	O
gene	O	O
(	O	O
DMR	O	O
-	O	O
N9	O	O
)	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
the	O	O
kinase	O	O
gene	O	O
.	O	O

DMR	O	O
-	O	O
N9	O	O
transcripts	O	O
,	O	O
mainly	O	O
expressed	O	O
in	O	O
brain	O	O
and	O	O
testis	O	O
,	O	O
possess	O	O
a	O	O
single	O	O
,	O	O
large	O	O
open	O	O
reading	O	O
frame	O	O
,	O	O
but	O	O
the	O	O
function	O	O
of	O	O
its	O	O
protein	O	O
product	O	O
is	O	O
unknown	O	O
.	O	O

Clinical	O	O
manifestation	O	O
of	O	O
DM	B-Disease	D009223
may	O	O
be	O	O
caused	O	O
by	O	O
the	O	O
expanded	O	O
CTG	O	O
-	O	O
repeat	O	O
compromising	O	O
the	O	O
(	O	O
alternative	O	O
)	O	O
expression	O	O
of	O	O
DM	B-Disease	D009223
-	O	O
kinase	O	O
or	O	O
DMR	O	O
-	O	O
N9	O	O
proteins	O	O
.	O	O

.	O	O

Paroxysmal	B-Disease	D006457
nocturnal	I-Disease	D006457
haemoglobinuria	I-Disease	D006457
with	O	O
coexisting	O	O
deficiency	B-Disease	OMIM:613825
of	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
ninth	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
complement	I-Disease	OMIM:613825
:	O	O
lack	O	O
of	O	O
massive	O	O
haemolytic	B-Disease	D006461
attack	I-Disease	D006461
.	O	O

A	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
paroxysmal	B-Disease	D006457
nocturnal	I-Disease	D006457
haemoglobinuria	I-Disease	D006457
(	O	O
PNH	B-Disease	D006457
)	O	O
was	O	O
found	O	O
to	O	O
have	O	O
an	O	O
inherited	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
in	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
ninth	I-Disease	OMIM:613825
complement	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
(	O	O
C9	O	O
)	O	O
.	O	O

In	O	O
complement	O	O
-	O	O
sensitivity	O	O
lysis	O	O
tests	O	O
,	O	O
80	O	O
%	O	O
of	O	O
her	O	O
erythrocytes	O	O
were	O	O
markedly	O	O
complement	O	O
-	O	O
sensitive	O	O
(	O	O
PNH	B-Disease	D006457
-	O	O
III	O	O
)	O	O
.	O	O

Laser	O	O
cytofluorimetry	O	O
with	O	O
a	O	O
monoclonal	O	O
antibody	O	O
against	O	O
decay	O	O
-	O	O
accelerating	O	O
factor	O	O
(	O	O
DAF	O	O
)	O	O
revealed	O	O
that	O	O
95	O	O
%	O	O
of	O	O
her	O	O
erythrocytes	O	O
were	O	O
DAF	O	O
-	O	O
negative	O	O
.	O	O

Surprisingly	O	O
,	O	O
she	O	O
has	O	O
suffered	O	O
only	O	O
mild	O	O
haemolysis	B-Disease	D006461
and	O	O
has	O	O
never	O	O
experienced	O	O
massive	O	O
spontaneous	O	O
haemolysis	B-Disease	D006461
.	O	O

Gross	O	O
haemoglobinuria	B-Disease	D006456
and	O	O
jaundice	B-Disease	D007565
occurred	O	O
only	O	O
after	O	O
receiving	O	O
postoperative	O	O
transfusion	O	O
of	O	O
whole	O	O
blood	O	O
.	O	O

In	O	O
her	O	O
serum	O	O
,	O	O
C9	O	O
was	O	O
not	O	O
detectable	O	O
either	O	O
by	O	O
immunological	O	O
or	O	O
by	O	O
functional	O	O
assays	O	O
.	O	O

Both	O	O
the	O	O
Ham	O	O
test	O	O
and	O	O
the	O	O
sugar	O	O
water	O	O
test	O	O
using	O	O
normal	O	O
human	O	O
serum	O	O
or	O	O
plasma	O	O
yielded	O	O
marked	O	O
haemolysis	B-Disease	D006461
of	O	O
the	O	O
patients	O	O
erythrocytes	O	O
.	O	O

When	O	O
the	O	O
patients	O	O
serum	O	O
or	O	O
plasma	O	O
was	O	O
used	O	O
,	O	O
only	O	O
a	O	O
trace	O	O
of	O	O
lysis	O	O
was	O	O
detected	O	O
.	O	O

Addition	O	O
of	O	O
purified	O	O
human	O	O
C9	O	O
to	O	O
her	O	O
plasma	O	O
fully	O	O
restored	O	O
haemolysis	B-Disease	D006461
.	O	O

These	O	O
observations	O	O
indicated	O	O
that	O	O
C9	O	O
may	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
haemolytic	B-Disease	D006461
attacks	I-Disease	D006461
in	O	O
patients	O	O
with	O	O
PNH	B-Disease	D006457
and	O	O
that	O	O
characteristic	O	O
haemolysis	B-Disease	D006461
in	O	O
PNH	B-Disease	D006457
may	O	O
be	O	O
tempered	O	O
by	O	O
coexisting	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

.	O	O

BRCA1	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
human	O	O
SWI	O	O
/	O	O
SNF	O	O
-	O	O
related	O	O
complex	O	O
:	O	O
linking	O	O
chromatin	O	O
remodeling	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
predispose	O	O
individuals	O	O
to	O	O
breast	B-Disease	D010051
and	I-Disease	D010051
ovarian	I-Disease	D010051
cancers	I-Disease	D010051
.	O	O

Using	O	O
a	O	O
combination	O	O
of	O	O
affinity	O	O
-	O	O
and	O	O
conventional	O	O
chromatographic	O	O
techniques	O	O
,	O	O
we	O	O
have	O	O
isolated	O	O
a	O	O
predominant	O	O
form	O	O
of	O	O
a	O	O
multiprotein	O	O
BRCA1	O	O
-	O	O
containing	O	O
complex	O	O
from	O	O
human	O	O
cells	O	O
displaying	O	O
chromatin	O	O
-	O	O
remodeling	O	O
activity	O	O
.	O	O

Mass	O	O
spectrometric	O	O
sequencing	O	O
of	O	O
components	O	O
of	O	O
this	O	O
complex	O	O
indicated	O	O
that	O	O
BRCA1	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
SWI	O	O
/	O	O
SNF	O	O
-	O	O
related	O	O
complex	O	O
.	O	O

We	O	O
show	O	O
that	O	O
BRCA1	O	O
can	O	O
directly	O	O
interact	O	O
with	O	O
the	O	O
BRG1	O	O
subunit	O	O
of	O	O
the	O	O
SWI	O	O
/	O	O
SNF	O	O
complex	O	O
.	O	O

Moreover	O	O
,	O	O
p53	O	O
-	O	O
mediated	O	O
stimulation	O	O
of	O	O
transcription	O	O
by	O	O
BRCA1	O	O
was	O	O
completely	O	O
abrogated	O	O
by	O	O
either	O	O
a	O	O
dominant	O	O
-	O	O
negative	O	O
mutant	O	O
of	O	O
BRG1	O	O
or	O	O
the	O	O
cancer	B-Disease	D009369
-	O	O
causing	O	O
deletion	O	O
in	O	O
exon	O	O
11	O	O
of	O	O
BRCA1	O	O
.	O	O

These	O	O
findings	O	O
reveal	O	O
a	O	O
direct	O	O
function	O	O
for	O	O
BRCA1	O	O
in	O	O
transcriptional	O	O
control	O	O
through	O	O
modulation	O	O
of	O	O
chromatin	O	O
structure	O	O
.	O	O

.	O	O

Germinal	O	O
mosaicism	O	O
in	O	O
a	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
family	O	O
:	O	O
implications	O	O
for	O	O
genetic	O	O
counselling	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
describe	O	O
a	O	O
three	O	O
-	O	O
generation	O	O
family	O	O
in	O	O
which	O	O
two	O	O
siblings	O	O
were	O	O
affected	O	O
by	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

Immunohistochemical	O	O
analysis	O	O
of	O	O
muscle	O	O
dystrophin	O	O
and	O	O
haplotype	O	O
analysis	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
revealed	O	O
that	O	O
the	O	O
X	O	O
chromosome	O	O
carrying	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
was	O	O
transmitted	O	O
from	O	O
the	O	O
healthy	O	O
maternal	O	O
grandfather	O	O
to	O	O
his	O	O
three	O	O
daughters	O	O
,	O	O
including	O	O
the	O	O
probands	O	O
mother	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
grandfather	O	O
was	O	O
a	O	O
germinal	O	O
mosaic	O	O
for	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

The	O	O
definition	O	O
of	O	O
the	O	O
carrier	O	O
status	O	O
in	O	O
two	O	O
possible	O	O
carriers	O	O
led	O	O
us	O	O
to	O	O
give	O	O
accurate	O	O
genetic	O	O
counselling	O	O
and	O	O
to	O	O
prevent	O	O
the	O	O
birth	O	O
of	O	O
an	O	O
affected	O	O
boy	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
demonstrate	O	O
the	O	O
usefulness	O	O
of	O	O
haplotype	O	O
analysis	O	O
and	O	O
immunohistochemical	O	O
muscle	O	O
dystrophin	O	O
studies	O	O
to	O	O
detect	O	O
hidden	O	O
germinal	O	O
mosaicism	O	O
and	O	O
to	O	O
improve	O	O
genetic	O	O
counselling	O	O
.	O	O

.	O	O

Centrosome	O	O
amplification	O	O
and	O	O
a	O	O
defective	O	O
G2	O	O
-	O	O
M	O	O
cell	O	O
cycle	O	O
checkpoint	O	O
induce	O	O
genetic	O	O
instability	O	O
in	O	O
BRCA1	O	O
exon	O	O
11	O	O
isoform	O	O
-	O	O
deficient	O	O
cells	O	O
.	O	O

Germline	O	O
mutations	O	O
of	O	O
the	O	O
Brca1	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
predispose	O	O
women	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancers	I-Disease	D061325
.	O	O

To	O	O
study	O	O
mechanisms	O	O
underlying	O	O
BRCA1	O	O
-	O	O
related	O	O
tumorigenesis	O	O
,	O	O
we	O	O
derived	O	O
mouse	O	O
embryonic	O	O
fibroblast	O	O
cells	O	O
carrying	O	O
a	O	O
targeted	O	O
deletion	O	O
of	O	O
exon	O	O
11	O	O
of	O	O
the	O	O
Brca1	O	O
gene	O	O
.	O	O

We	O	O
show	O	O
that	O	O
the	O	O
mutant	O	O
cells	O	O
maintain	O	O
an	O	O
intact	O	O
G1	O	O
-	O	O
S	O	O
cell	O	O
cycle	O	O
checkpoint	O	O
and	O	O
proliferate	O	O
poorly	O	O
.	O	O

However	O	O
,	O	O
a	O	O
defective	O	O
G2	O	O
-	O	O
M	O	O
checkpoint	O	O
in	O	O
these	O	O
cells	O	O
is	O	O
accompanied	O	O
by	O	O
extensive	O	O
chromosomal	B-Disease	D002869
abnormalities	I-Disease	D002869
.	O	O

Mutant	O	O
fibroblasts	O	O
contain	O	O
multiple	O	O
,	O	O
functional	O	O
centrosomes	O	O
,	O	O
which	O	O
lead	O	O
to	O	O
unequal	O	O
chromosome	O	O
segregation	O	O
,	O	O
abnormal	O	O
nuclear	O	O
division	O	O
,	O	O
and	O	O
aneuploidy	B-Disease	D000782
.	O	O

These	O	O
data	O	O
uncover	O	O
an	O	O
essential	O	O
role	O	O
of	O	O
BRCA1	O	O
in	O	O
maintaining	O	O
genetic	O	O
stability	O	O
through	O	O
the	O	O
regulation	O	O
of	O	O
centrosome	O	O
duplication	O	O
and	O	O
the	O	O
G2	O	O
-	O	O
M	O	O
checkpoint	O	O
and	O	O
provide	O	O
a	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
role	O	O
of	O	O
BRCA1	O	O
in	O	O
tumorigenesis	O	O
.	O	O

.	O	O

Aberrant	O	O
splicing	O	O
of	O	O
phenylalanine	O	O
hydroxylase	O	O
mRNA	O	O
:	O	O
the	O	O
major	O	O
cause	O	O
for	O	O
phenylketonuria	B-Disease	D010661
in	O	O
parts	O	O
of	O	O
southern	O	O
Europe	O	O
.	O	O

We	O	O
report	O	O
a	O	O
mutation	O	O
within	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
gene	O	O
that	O	O
causes	O	O
aberrant	O	O
splicing	O	O
of	O	O
the	O	O
mRNA	O	O
and	O	O
that	O	O
is	O	O
in	O	O
tight	O	O
association	O	O
with	O	O
chromosomal	O	O
haplotypes	O	O
6	O	O
,	O	O
10	O	O
,	O	O
and	O	O
36	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
high	O	O
frequency	O	O
of	O	O
these	O	O
particular	O	O
haplotypes	O	O
in	O	O
Bulgaria	O	O
,	O	O
Italy	O	O
,	O	O
and	O	O
Turkey	O	O
,	O	O
it	O	O
appears	O	O
to	O	O
be	O	O
one	O	O
of	O	O
the	O	O
more	O	O
frequent	O	O
defects	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
causing	O	O
classical	O	O
phenylketonuria	B-Disease	D010661
in	O	O
this	O	O
part	O	O
of	O	O
Europe	O	O
.	O	O

The	O	O
mutation	O	O
is	O	O
a	O	O
G	O	O
to	O	O
A	O	O
transition	O	O
at	O	O
position	O	O
546	O	O
in	O	O
intron	O	O
10	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
,	O	O
11	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
intron	O	O
10	O	O
/	O	O
exon	O	O
11	O	O
boundary	O	O
.	O	O

It	O	O
activates	O	O
a	O	O
cryptic	O	O
splice	O	O
site	O	O
and	O	O
results	O	O
in	O	O
an	O	O
in	O	O
-	O	O
frame	O	O
insertion	O	O
of	O	O
9	O	O
nucleotides	O	O
between	O	O
exon	O	O
10	O	O
and	O	O
exon	O	O
11	O	O
of	O	O
the	O	O
processed	O	O
mRNA	O	O
.	O	O

Normal	O	O
amounts	O	O
of	O	O
liver	O	O
PAH	O	O
protein	O	O
are	O	O
present	O	O
in	O	O
homozygous	O	O
patients	O	O
,	O	O
but	O	O
no	O	O
catalytic	O	O
activity	O	O
can	O	O
be	O	O
detected	O	O
.	O	O

This	O	O
loss	O	O
of	O	O
enzyme	O	O
activity	O	O
is	O	O
probably	O	O
caused	O	O
by	O	O
conformational	O	O
changes	O	O
resulting	O	O
from	O	O
the	O	O
insertion	O	O
of	O	O
three	O	O
additional	O	O
amino	O	O
acids	O	O
(	O	O
Gly	O	O
-	O	O
Leu	O	O
-	O	O
Gln	O	O
)	O	O
between	O	O
the	O	O
normal	O	O
sequences	O	O
encoded	O	O
by	O	O
exon	O	O
10	O	O
and	O	O
exon	O	O
11	O	O
.	O	O

.	O	O

Biochemical	O	O
and	O	O
structural	O	O
analysis	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
N	O	O
-	O	O
acetylgalactosamine	O	O
-	O	O
6	O	O
-	O	O
sulfate	O	O
sulfatase	O	O
causing	O	O
mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
phenotypes	O	O
.	O	O

Mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
(	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
;	O	O
OMIM	O	O
#	O	O
253000	O	O
)	O	O
,	O	O
a	O	O
lysosomal	B-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:253000
of	I-Disease	OMIM:253000
N	I-Disease	OMIM:253000
-	I-Disease	OMIM:253000
acetylgalactosamine	I-Disease	OMIM:253000
-	I-Disease	OMIM:253000
6	I-Disease	OMIM:253000
-	I-Disease	OMIM:253000
sulfate	I-Disease	OMIM:253000
sulfatase	I-Disease	OMIM:253000
(	O	O
GALNS	O	O
)	O	O
,	O	O
has	O	O
variable	O	O
clinical	O	O
phenotypes	O	O
.	O	O

To	O	O
date	O	O
we	O	O
have	O	O
identified	O	O
65	O	O
missense	O	O
mutations	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
from	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
patients	O	O
,	O	O
but	O	O
the	O	O
correlation	O	O
between	O	O
genotype	O	O
and	O	O
phenotype	O	O
has	O	O
remained	O	O
unclear	O	O
.	O	O

We	O	O
studied	O	O
17	O	O
missense	O	O
mutations	O	O
using	O	O
biochemical	O	O
approaches	O	O
and	O	O
32	O	O
missense	O	O
mutations	O	O
,	O	O
using	O	O
structural	O	O
analyses	O	O
.	O	O

Fifteen	O	O
missense	O	O
mutations	O	O
and	O	O
two	O	O
newly	O	O
engineered	O	O
active	O	O
site	O	O
mutations	O	O
(	O	O
C79S	O	O
,	O	O
C79T	O	O
)	O	O
were	O	O
characterized	O	O
by	O	O
transient	O	O
expression	O	O
analysis	O	O
.	O	O

Mutant	O	O
proteins	O	O
,	O	O
except	O	O
for	O	O
C79S	O	O
and	O	O
C79T	O	O
,	O	O
were	O	O
destabilized	O	O
and	O	O
detected	O	O
as	O	O
insoluble	O	O
precursor	O	O
forms	O	O
while	O	O
the	O	O
C79S	O	O
and	O	O
C79T	O	O
mutants	O	O
were	O	O
of	O	O
a	O	O
soluble	O	O
mature	O	O
size	O	O
.	O	O

Mutants	O	O
found	O	O
in	O	O
the	O	O
severe	O	O
phenotype	O	O
had	O	O
no	O	O
activity	O	O
.	O	O

Mutants	O	O
found	O	O
in	O	O
the	O	O
mild	O	O
phenotype	O	O
had	O	O
a	O	O
considerable	O	O
residual	O	O
activity	O	O
(	O	O
1	O	O
.	O	O

3	O	O
-	O	O
13	O	O
.	O	O

3	O	O
%	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
GALNS	O	O
activity	O	O
)	O	O
.	O	O

Sulfatases	O	O
,	O	O
including	O	O
GALNS	O	O
,	O	O
are	O	O
members	O	O
of	O	O
a	O	O
highly	O	O
conserved	O	O
gene	O	O
family	O	O
sharing	O	O
an	O	O
extensive	O	O
sequence	O	O
homology	O	O
.	O	O

Thus	O	O
,	O	O
a	O	O
tertiary	O	O
structural	O	O
model	O	O
of	O	O
human	O	O
GALNS	O	O
was	O	O
constructed	O	O
from	O	O
the	O	O
X	O	O
-	O	O
ray	O	O
crystal	O	O
structure	O	O
of	O	O
N	O	O
-	O	O
acetylgalacto	O	O
-	O	O
samine	O	O
-	O	O
4	O	O
-	O	O
sulfatase	O	O
and	O	O
arylsulfatase	O	O
A	O	O
,	O	O
using	O	O
homology	O	O
modeling	O	O
,	O	O
and	O	O
32	O	O
missense	O	O
mutations	O	O
were	O	O
investigated	O	O
.	O	O

Consequently	O	O
,	O	O
we	O	O
propose	O	O
that	O	O
there	O	O
are	O	O
at	O	O
least	O	O
three	O	O
different	O	O
reasons	O	O
for	O	O
the	O	O
severe	O	O
phenotype	O	O
(	O	O
i	O	O
)	O	O
destruction	O	O
of	O	O
the	O	O
hydrophobic	O	O
core	O	O
or	O	O
modification	O	O
of	O	O
the	O	O
packing	O	O
;	O	O
(	O	O
ii	O	O
)	O	O
removal	O	O
of	O	O
a	O	O
salt	O	O
bridge	O	O
to	O	O
destabilize	O	O
the	O	O
entire	O	O
conformation	O	O
;	O	O
(	O	O
iii	O	O
)	O	O
modification	O	O
of	O	O
the	O	O
active	O	O
site	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
mild	O	O
mutations	O	O
were	O	O
mostly	O	O
located	O	O
on	O	O
the	O	O
surface	O	O
of	O	O
the	O	O
GALNS	O	O
protein	O	O
.	O	O

These	O	O
studies	O	O
shed	O	O
further	O	O
light	O	O
on	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
of	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
and	O	O
structure	O	O
-	O	O
function	O	O
relationship	O	O
in	O	O
the	O	O
sulfatase	O	O
family	O	O
.	O	O

Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
:	O	O
cellular	O	O
impairments	O	O
and	O	O
their	O	O
implication	O	O
for	O	O
carrier	O	O
detection	O	O
.	O	O

A	O	O
family	O	O
in	O	O
which	O	O
two	O	O
male	O	O
siblings	O	O
were	O	O
affected	O	O
with	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
was	O	O
studied	O	O
using	O	O
G	O	O
-	O	O
6	O	O
-	O	O
PD	O	O
isoenzymes	O	O
as	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
marker	O	O
in	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
nature	O	O
of	O	O
cellular	O	O
abnormalities	O	O
.	O	O

Isolated	O	O
peripheral	O	O
blood	O	O
cell	O	O
types	O	O
from	O	O
the	O	O
doubly	O	O
heterozygous	O	O
mother	O	O
of	O	O
the	O	O
affected	O	O
males	O	O
seemingly	O	O
failed	O	O
to	O	O
express	O	O
the	O	O
G	O	O
-	O	O
6	O	O
-	O	O
PD	O	O
allele	O	O
in	O	O
cis	O	O
position	O	O
with	O	O
the	O	O
WAS	B-Disease	D014923
allele	O	O
while	O	O
her	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
expressed	O	O
both	O	O
G	O	O
-	O	O
6	O	O
-	O	O
PD	O	O
alleles	O	O
.	O	O

Additionally	O	O
,	O	O
a	O	O
histogram	O	O
analysis	O	O
of	O	O
platelet	O	O
size	O	O
revealed	O	O
a	O	O
single	O	O
population	O	O
of	O	O
abnormally	O	O
small	O	O
platelets	O	O
in	O	O
the	O	O
affected	O	O
propositus	O	O
,	O	O
whereas	O	O
the	O	O
heterozygous	O	O
mother	O	O
had	O	O
no	O	O
appreciable	O	O
small	O	O
platelet	O	O
subpopulation	O	O
.	O	O

In	O	O
vitro	O	O
culture	O	O
of	O	O
hemopoietic	O	O
progenitor	O	O
cells	O	O
of	O	O
the	O	O
heterozygous	O	O
mother	O	O
showed	O	O
that	O	O
the	O	O
majority	O	O
of	O	O
progenitor	O	O
cells	O	O
did	O	O
not	O	O
express	O	O
the	O	O
WAS	B-Disease	D014923
allele	O	O
.	O	O

However	O	O
,	O	O
a	O	O
small	O	O
number	O	O
of	O	O
cells	O	O
expressing	O	O
the	O	O
G	O	O
-	O	O
6	O	O
-	O	O
PD	O	O
type	O	O
linked	O	O
with	O	O
the	O	O
WAS	B-Disease	D014923
allele	O	O
were	O	O
detected	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
the	O	O
latter	O	O
progenitors	O	O
was	O	O
significantly	O	O
higher	O	O
among	O	O
more	O	O
primitive	O	O
progenitors	O	O
(	O	O
those	O	O
giving	O	O
rise	O	O
to	O	O
later	O	O
appearing	O	O
colonies	O	O
)	O	O
.	O	O

This	O	O
observation	O	O
suggests	O	O
that	O	O
selection	O	O
against	O	O
cells	O	O
expressing	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
defect	I-Disease	D014923
takes	O	O
place	O	O
in	O	O
the	O	O
hemopoietic	O	O
system	O	O
of	O	O
the	O	O
heterozygous	O	O
female	O	O
and	O	O
offers	O	O
a	O	O
possible	O	O
means	O	O
of	O	O
carrier	O	O
detection	O	O
in	O	O
some	O	O
women	O	O
.	O	O

Linkage	O	O
studies	O	O
in	O	O
this	O	O
family	O	O
revealed	O	O
one	O	O
example	O	O
of	O	O
probable	O	O
recombination	O	O
between	O	O
the	O	O
loci	O	O
for	O	O
WAS	B-Disease	D014923
and	O	O
G	O	O
-	O	O
6	O	O
-	O	O
PD	O	O
among	O	O
three	O	O
informative	O	O
subjects	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
two	O	O
loci	O	O
may	O	O
not	O	O
be	O	O
closely	O	O
linked	O	O
on	O	O
the	O	O
X	O	O
-	O	O
chromosome	O	O
.	O	O

.	O	O

Familial	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
the	I-Disease	OMIM:610102
seventh	I-Disease	OMIM:610102
component	I-Disease	OMIM:610102
of	I-Disease	OMIM:610102
complement	I-Disease	OMIM:610102
associated	O	O
with	O	O
recurrent	O	O
meningococcal	B-Disease	D008589
infections	I-Disease	D008589
.	O	O

We	O	O
describe	O	O
an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
suffering	O	O
from	O	O
recurrent	B-Disease	D008581	D012008
meningitis	I-Disease	D008581	D012008
with	O	O
a	O	O
complete	O	O
absence	O	O
of	O	O
the	O	O
seventh	O	O
component	O	O
of	O	O
complement	O	O
(	O	O
C7	O	O
)	O	O
.	O	O

Diagnosis	O	O
was	O	O
established	O	O
by	O	O
haemolytic	O	O
titration	O	O
and	O	O
western	O	O
blotting	O	O
.	O	O

The	O	O
patients	O	O
serum	O	O
lacked	O	O
the	O	O
85	O	O
kDa	O	O
C7	O	O
chain	O	O
.	O	O

Haemolytic	O	O
activity	O	O
of	O	O
serum	O	O
was	O	O
reconstituted	O	O
with	O	O
either	O	O
pooled	O	O
normal	O	O
human	O	O
serum	O	O
or	O	O
with	O	O
purified	O	O
C7	O	O
.	O	O

The	O	O
relatives	O	O
(	O	O
parents	O	O
and	O	O
one	O	O
sister	O	O
)	O	O
had	O	O
half	O	O
-	O	O
normal	O	O
levels	O	O
of	O	O
both	O	O
immunochemically	O	O
and	O	O
functionally	O	O
determined	O	O
C7	O	O
,	O	O
indicating	O	O
a	O	O
heterozygous	O	O
state	O	O
for	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
.	O	O

.	O	O

Non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
associated	O	O
with	O	O
enlarged	B-Disease	OMIM:600791
vestibular	I-Disease	OMIM:600791
aqueduct	I-Disease	OMIM:600791
is	O	O
caused	O	O
by	O	O
PDS	B-Disease	C536648
mutations	O	O
.	O	O

Enlarged	B-Disease	OMIM:600791
vestibular	I-Disease	OMIM:600791
aqueduct	I-Disease	OMIM:600791
(	O	O
EVA	B-Disease	OMIM:600791
)	O	O
,	O	O
known	O	O
as	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
inner	B-Disease	D007759
ear	I-Disease	D007759
abnormality	I-Disease	D007759
,	O	O
has	O	O
recently	O	O
been	O	O
of	O	O
particular	O	O
genetic	O	O
interest	O	O
because	O	O
this	O	O
anomaly	O	O
is	O	O
inherited	O	O
in	O	O
a	O	O
recessive	O	O
manner	O	O
.	O	O

The	O	O
locus	O	O
for	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
sensorineural	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
with	O	O
EVA	B-Disease	OMIM:600791
has	O	O
been	O	O
mapped	O	O
to	O	O
the	O	O
same	O	O
chromosomal	O	O
region	O	O
,	O	O
7q31	O	O
,	O	O
as	O	O
the	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
locus	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
seven	O	O
mutations	O	O
in	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
(	O	O
PDS	B-Disease	C536648
)	O	O
,	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
,	O	O
have	O	O
been	O	O
found	O	O
in	O	O
families	O	O
of	O	O
non	B-Disease	C537845
-	I-Disease	C537845
syndromic	I-Disease	C537845
sensorineural	I-Disease	C537845
hearing	I-Disease	C537845
loss	I-Disease	C537845
with	O	O
EVA	B-Disease	OMIM:600791
.	O	O

One	O	O
family	O	O
is	O	O
homozygous	O	O
,	O	O
three	O	O
families	O	O
are	O	O
compound	O	O
heterozygotes	O	O
,	O	O
and	O	O
two	O	O
families	O	O
are	O	O
heterozygous	O	O
but	O	O
with	O	O
no	O	O
other	O	O
mutation	O	O
detected	O	O
.	O	O

The	O	O
present	O	O
results	O	O
provide	O	O
evidence	O	O
that	O	O
mutations	O	O
in	O	O
PDS	B-Disease	C536648
cause	O	O
both	O	O
syndromic	B-Disease	D034381
and	I-Disease	D034381
non	I-Disease	D034381
-	I-Disease	D034381
syndromic	I-Disease	D034381
hearing	I-Disease	D034381
loss	I-Disease	D034381
.	O	O

.	O	O

Deletions	O	O
of	O	O
a	O	O
DNA	O	O
sequence	O	O
in	O	O
retinoblastomas	B-Disease	D012175
and	O	O
mesenchymal	B-Disease	C535700
tumors	I-Disease	C535700
:	O	O
organization	O	O
of	O	O
the	O	O
sequence	O	O
and	O	O
its	O	O
encoded	O	O
protein	O	O
.	O	O

Retinoblastoma	B-Disease	D012175
is	O	O
a	O	O
childhood	B-Disease	D009369
tumor	I-Disease	D009369
that	O	O
can	O	O
arise	O	O
because	O	O
of	O	O
mutant	O	O
alleles	O	O
acquired	O	O
as	O	O
somatic	O	O
or	O	O
germinal	O	O
mutations	O	O
.	O	O

The	O	O
mutant	O	O
allele	O	O
can	O	O
be	O	O
carried	O	O
in	O	O
the	O	O
germ	O	O
line	O	O
.	O	O

The	O	O
mutations	O	O
creating	O	O
these	O	O
alleles	O	O
act	O	O
by	O	O
inactivating	O	O
copies	O	O
of	O	O
a	O	O
recessive	O	O
oncogene	O	O
located	O	O
within	O	O
band	O	O
q14	O	O
of	O	O
chromosome	O	O
13	O	O
and	O	O
termed	O	O
the	O	O
RB1	O	O
locus	O	O
.	O	O

We	O	O
have	O	O
reported	O	O
isolation	O	O
of	O	O
a	O	O
cDNA	O	O
fragment	O	O
that	O	O
recognizes	O	O
chromosomal	O	O
sequences	O	O
possessing	O	O
many	O	O
of	O	O
the	O	O
attributes	O	O
of	O	O
the	O	O
retinoblastoma	B-Disease	D012175
gene	O	O
associated	O	O
with	O	O
the	O	O
RB1	O	O
locus	O	O
.	O	O

We	O	O
now	O	O
report	O	O
that	O	O
this	O	O
segment	O	O
is	O	O
additionally	O	O
the	O	O
target	O	O
of	O	O
somatic	O	O
mutations	O	O
in	O	O
mesenchymal	B-Disease	C535700
tumors	I-Disease	C535700
among	O	O
patients	O	O
having	O	O
no	O	O
apparent	O	O
predisposition	O	O
to	O	O
retinoblastoma	B-Disease	D012175
and	O	O
no	O	O
previous	O	O
evidence	O	O
of	O	O
retinoblastoma	B-Disease	D012175
.	O	O

These	O	O
tumors	B-Disease	D009369
provide	O	O
additional	O	O
evidence	O	O
that	O	O
the	O	O
cloned	O	O
sequences	O	O
are	O	O
representative	O	O
of	O	O
a	O	O
gene	O	O
that	O	O
is	O	O
a	O	O
frequent	O	O
target	O	O
of	O	O
inactivation	O	O
during	O	O
tumorigenesis	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
this	O	O
cDNA	O	O
provides	O	O
little	O	O
insight	O	O
into	O	O
its	O	O
normal	O	O
functional	O	O
role	O	O
.	O	O

.	O	O

Genetically	O	O
determined	O	O
low	O	O
C4	O	O
:	O	O
a	O	O
predisposing	O	O
factor	O	O
to	O	O
autoimmune	B-Disease	D006521
chronic	I-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
.	O	O

Of	O	O
26	O	O
patients	O	O
with	O	O
autoimmune	B-Disease	D006521
chronic	I-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
(	O	O
CAH	B-Disease	D006521
)	O	O
starting	O	O
in	O	O
childhood	O	O
18	O	O
(	O	O
69	O	O
%	O	O
)	O	O
had	O	O
low	O	O
C4	O	O
and	O	O
5	O	O
(	O	O
19	O	O
%	O	O
)	O	O
had	O	O
low	O	O
C3	O	O
serum	O	O
levels	O	O
.	O	O

Impaired	O	O
hepatic	O	O
synthesis	O	O
and	O	O
immune	O	O
-	O	O
consumption	O	O
were	O	O
unlikely	O	O
since	O	O
transferrin	O	O
levels	O	O
were	O	O
normal	O	O
in	O	O
all	O	O
patients	O	O
,	O	O
albumin	O	O
levels	O	O
were	O	O
persistently	O	O
low	O	O
in	O	O
only	O	O
3	O	O
,	O	O
and	O	O
only	O	O
3	O	O
had	O	O
raised	O	O
levels	O	O
of	O	O
activation	O	O
fragment	O	O
C3d	O	O
.	O	O

C4d	O	O
was	O	O
normal	O	O
in	O	O
all	O	O
patients	O	O
studied	O	O
.	O	O

In	O	O
the	O	O
families	O	O
of	O	O
12	O	O
probands	O	O
with	O	O
low	O	O
C4	O	O
,	O	O
7	O	O
parents	O	O
had	O	O
low	O	O
C4	O	O
and	O	O
2	O	O
had	O	O
levels	O	O
which	O	O
were	O	O
at	O	O
the	O	O
lower	O	O
limit	O	O
of	O	O
normal	O	O
.	O	O

5	O	O
of	O	O
10	O	O
siblings	O	O
from	O	O
5	O	O
families	O	O
had	O	O
low	O	O
C4	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
low	O	O
C4	O	O
levels	O	O
in	O	O
CAH	B-Disease	D006521
are	O	O
genetically	O	O
determined	O	O
.	O	O

C4	O	O
phenotyping	O	O
in	O	O
20	O	O
patients	O	O
and	O	O
in	O	O
26	O	O
parents	O	O
showed	O	O
that	O	O
90	O	O
%	O	O
and	O	O
81	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
had	O	O
null	O	O
allotypes	O	O
at	O	O
either	O	O
the	O	O
C4A	O	O
or	O	O
C4B	O	O
locus	O	O
compared	O	O
with	O	O
59	O	O
%	O	O
in	O	O
controls	O	O
,	O	O
indicating	O	O
that	O	O
defective	O	O
expression	O	O
of	O	O
structural	O	O
genes	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
observed	O	O
C4	B-Disease	OMIM:614380	OMIM:614379
deficiency	I-Disease	OMIM:614380	OMIM:614379
.	O	O

.	O	O

Tight	O	O
linkage	O	O
between	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
and	O	O
apolipoprotein	O	O
E	O	O
genes	O	O
revealed	O	O
with	O	O
allele	O	O
-	O	O
specific	O	O
oligonucleotides	O	O
.	O	O

In	O	O
16	O	O
families	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
a	O	O
novel	O	O
approach	O	O
based	O	O
on	O	O
use	O	O
of	O	O
allele	O	O
-	O	O
specific	O	O
oligonucleotides	O	O
has	O	O
been	O	O
employed	O	O
to	O	O
study	O	O
the	O	O
linkage	O	O
relationship	O	O
between	O	O
the	O	O
apolipoprotein	O	O
E	O	O
(	O	O
APOE	O	O
)	O	O
gene	O	O
and	O	O
DM	B-Disease	D009223
.	O	O

Synthetic	O	O
oligonucleotides	O	O
,	O	O
designed	O	O
to	O	O
discriminate	O	O
between	O	O
APOE	O	O
alleles	O	O
epsilon	O	O
3	O	O
and	O	O
epsilon	O	O
4	O	O
,	O	O
enabled	O	O
us	O	O
to	O	O
distinguish	O	O
heterozygous	O	O
carriers	O	O
in	O	O
a	O	O
hybridization	O	O
assay	O	O
.	O	O

In	O	O
a	O	O
subset	O	O
of	O	O
families	O	O
,	O	O
the	O	O
relevant	O	O
segment	O	O
of	O	O
the	O	O
APOE	O	O
gene	O	O
was	O	O
enzymatically	O	O
amplified	O	O
to	O	O
increase	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
method	O	O
.	O	O

For	O	O
DM	B-Disease	D009223
and	O	O
APOE	O	O
,	O	O
a	O	O
maximum	O	O
lod	O	O
score	O	O
(	O	O
zmax	O	O
of	O	O
7	O	O
.	O	O

47	O	O
was	O	O
obtained	O	O
at	O	O
a	O	O
recombination	O	O
frequency	O	O
(	O	O
theta	O	O
)	O	O
of	O	O
0	O	O
.	O	O

047	O	O
(	O	O
male	O	O
theta	O	O
=	O	O
female	O	O
theta	O	O
)	O	O
.	O	O

No	O	O
recombination	O	O
(	O	O
maximum	O	O
lod	O	O
score	O	O
of	O	O
5	O	O
.	O	O

61	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

0	O	O
)	O	O
was	O	O
found	O	O
between	O	O
APOE	O	O
and	O	O
the	O	O
apolipoprotein	O	O
CII	O	O
(	O	O
APOC2	O	O
)	O	O
gene	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
APOC2	O	O
,	O	O
APOE	O	O
is	O	O
a	O	O
useful	O	O
marker	O	O
for	O	O
presymptomatic	O	O
DM	B-Disease	D009223
diagnosis	O	O
.	O	O

Confirmation	O	O
of	O	O
BRCA1	O	O
by	O	O
analysis	O	O
of	O	O
germline	O	O
mutations	O	O
linked	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
in	O	O
ten	O	O
families	O	O
.	O	O

We	O	O
provide	O	O
genetic	O	O
evidence	O	O
supporting	O	O
the	O	O
identity	O	O
of	O	O
the	O	O
candidate	O	O
gene	O	O
for	O	O
BRCA1	O	O
through	O	O
the	O	O
characterization	O	O
of	O	O
germline	O	O
mutations	O	O
in	O	O
63	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
and	O	O
10	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
patients	O	O
in	O	O
ten	O	O
families	O	O
with	O	O
cancer	B-Disease	D009369
linked	O	O
to	O	O
chromosome	O	O
17q21	O	O
.	O	O

Nine	O	O
different	O	O
mutations	O	O
were	O	O
detected	O	O
by	O	O
screening	O	O
BRCA1	O	O
DNA	O	O
and	O	O
RNA	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

Seven	O	O
mutations	O	O
lead	O	O
to	O	O
protein	O	O
truncations	O	O
at	O	O
sites	O	O
throughout	O	O
the	O	O
gene	O	O
.	O	O

One	O	O
missense	O	O
mutation	O	O
(	O	O
which	O	O
occurred	O	O
independently	O	O
in	O	O
two	O	O
families	O	O
)	O	O
leads	O	O
to	O	O
loss	O	O
of	O	O
a	O	O
cysteine	O	O
in	O	O
the	O	O
zinc	O	O
binding	O	O
domain	O	O
.	O	O

An	O	O
intronic	O	O
single	O	O
basepair	O	O
substitution	O	O
destroys	O	O
an	O	O
acceptor	O	O
site	O	O
and	O	O
activates	O	O
a	O	O
cryptic	O	O
splice	O	O
site	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
59	O	O
basepair	O	O
insertion	O	O
and	O	O
chain	O	O
termination	O	O
.	O	O

The	O	O
four	O	O
families	O	O
with	O	O
both	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
had	O	O
chain	O	O
termination	O	O
mutations	O	O
in	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
half	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

.	O	O

Genetic	O	O
instability	O	O
in	O	O
human	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
cell	O	O
lines	O	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
the	O	O
stability	O	O
of	O	O
microsatellites	O	O
in	O	O
cell	O	O
lines	O	O
derived	O	O
from	O	O
human	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
and	O	O
found	O	O
that	O	O
5	O	O
out	O	O
of	O	O
10	O	O
of	O	O
the	O	O
ovarian	B-Disease	D010051
tumor	I-Disease	D010051
cell	O	O
lines	O	O
are	O	O
genetically	O	O
unstable	O	O
at	O	O
the	O	O
majority	O	O
of	O	O
the	O	O
loci	O	O
analyzed	O	O
.	O	O

In	O	O
clones	O	O
and	O	O
subclones	O	O
derived	O	O
serially	O	O
from	O	O
one	O	O
of	O	O
these	O	O
cell	O	O
lines	O	O
(	O	O
2774	O	O
;	O	O
serous	B-Disease	D018284
cystadenocarcinoma	I-Disease	D018284
)	O	O
,	O	O
a	O	O
very	O	O
high	O	O
proportion	O	O
of	O	O
microsatellites	O	O
distributed	O	O
in	O	O
many	O	O
different	O	O
regions	O	O
of	O	O
the	O	O
genome	O	O
change	O	O
their	O	O
size	O	O
in	O	O
a	O	O
mercurial	O	O
fashion	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
genomic	O	O
instability	O	O
in	O	O
ovarian	B-Disease	D010051
tumors	I-Disease	D010051
is	O	O
a	O	O
dynamic	O	O
and	O	O
ongoing	O	O
process	O	O
whose	O	O
high	O	O
frequency	O	O
may	O	O
have	O	O
been	O	O
previously	O	O
underestimated	O	O
by	O	O
PCR	O	O
-	O	O
based	O	O
allelotyping	O	O
of	O	O
bulk	O	O
tumor	B-Disease	D009369
tissue	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
the	O	O
source	O	O
of	O	O
the	O	O
genetic	O	O
instability	O	O
in	O	O
one	O	O
ovarian	B-Disease	D010051
tumor	I-Disease	D010051
as	O	O
a	O	O
point	O	O
mutation	O	O
(	O	O
R524P	O	O
)	O	O
in	O	O
the	O	O
human	O	O
mismatch	O	O
-	O	O
repair	O	O
gene	O	O
MSH2	O	O
(	O	O
Salmonella	O	O
MutS	O	O
homologue	O	O
)	O	O
,	O	O
which	O	O
has	O	O
recently	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
hereditary	B-Disease	D003123
nonpolyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
.	O	O

Patient	O	O
2774	O	O
was	O	O
a	O	O
38	O	O
-	O	O
year	O	O
-	O	O
old	O	O
heterozygote	O	O
,	O	O
and	O	O
her	O	O
normal	O	O
tissue	O	O
carried	O	O
both	O	O
mutant	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
alleles	O	O
of	O	O
the	O	O
human	O	O
MSH2	O	O
gene	O	O
.	O	O

However	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
was	O	O
lost	O	O
at	O	O
some	O	O
point	O	O
early	O	O
during	O	O
tumorigenesis	O	O
so	O	O
that	O	O
DNA	O	O
isolated	O	O
either	O	O
from	O	O
the	O	O
patients	O	O
ovarian	B-Disease	D010051
tumor	I-Disease	D010051
or	O	O
from	O	O
the	O	O
2774	O	O
cell	O	O
line	O	O
carries	O	O
only	O	O
the	O	O
mutant	O	O
allele	O	O
of	O	O
the	O	O
human	O	O
MSH2	O	O
gene	O	O
.	O	O

The	O	O
genetic	O	O
instability	O	O
observed	O	O
in	O	O
the	O	O
tumor	B-Disease	D009369
and	O	O
cell	O	O
line	O	O
DNA	O	O
,	O	O
together	O	O
with	O	O
the	O	O
germ	O	O
-	O	O
line	O	O
mutation	O	O
in	O	O
a	O	O
mismatch	O	O
-	O	O
repair	O	O
gene	O	O
,	O	O
suggest	O	O
that	O	O
the	O	O
MSH2	O	O
gene	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
onset	O	O
and	O	O
/	O	O
or	O	O
progression	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

.	O	O

Retroviral	O	O
-	O	O
mediated	O	O
gene	O	O
transfer	O	O
of	O	O
human	O	O
phenylalanine	O	O
hydroxylase	O	O
into	O	O
NIH	O	O
3T3	O	O
and	O	O
hepatoma	B-Disease	D006528
cells	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
caused	O	O
by	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
the	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
enzyme	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

A	O	O
full	O	O
-	O	O
length	O	O
human	O	O
PAH	O	O
cDNA	O	O
sequence	O	O
has	O	O
been	O	O
inserted	O	O
into	O	O
pzip	O	O
-	O	O
neoSV	O	O
(	O	O
X	O	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
retroviral	O	O
vector	O	O
containing	O	O
the	O	O
bacterial	O	O
neo	O	O
gene	O	O
.	O	O

The	O	O
recombinant	O	O
has	O	O
been	O	O
transfected	O	O
into	O	O
psi	O	O
2	O	O
cells	O	O
,	O	O
which	O	O
provide	O	O
synthesis	O	O
of	O	O
the	O	O
retroviral	O	O
capsid	O	O
.	O	O

Recombinant	O	O
virus	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
of	O	O
the	O	O
transfected	O	O
psi	O	O
2	O	O
cells	O	O
,	O	O
which	O	O
is	O	O
capable	O	O
of	O	O
transmitting	O	O
the	O	O
human	O	O
PAH	O	O
gene	O	O
into	O	O
mouse	O	O
NIH	O	O
3T3	O	O
cells	O	O
by	O	O
infection	O	O
leading	O	O
to	O	O
stable	O	O
incorporation	O	O
of	O	O
the	O	O
recombinant	O	O
provirus	O	O
.	O	O

Infected	O	O
cells	O	O
express	O	O
PAH	O	O
mRNA	O	O
,	O	O
immunoreactive	O	O
PAH	O	O
protein	O	O
,	O	O
and	O	O
exhibit	O	O
pterin	O	O
-	O	O
dependent	O	O
phenylalanine	O	O
hydroxylase	O	O
activity	O	O
.	O	O

The	O	O
recombinant	O	O
virus	O	O
is	O	O
also	O	O
capable	O	O
of	O	O
infecting	O	O
a	O	O
mouse	O	O
hepatoma	B-Disease	D006528
cell	O	O
line	O	O
that	O	O
does	O	O
not	O	O
normally	O	O
synthesize	O	O
PAH	O	O
.	O	O

PAH	O	O
activity	O	O
is	O	O
present	O	O
in	O	O
the	O	O
cellular	O	O
extracts	O	O
and	O	O
the	O	O
entire	O	O
hydroxylation	O	O
system	O	O
is	O	O
reconstituted	O	O
in	O	O
the	O	O
hepatoma	B-Disease	D006528
cells	O	O
infected	O	O
with	O	O
the	O	O
recombinant	O	O
viruses	O	O
.	O	O

Thus	O	O
,	O	O
recombinant	O	O
viruses	O	O
containing	O	O
human	O	O
PAH	O	O
cDNA	O	O
provide	O	O
a	O	O
means	O	O
for	O	O
introducing	O	O
functional	O	O
PAH	O	O
into	O	O
mammalian	O	O
cells	O	O
of	O	O
hepatic	O	O
origin	O	O
and	O	O
can	O	O
potentially	O	O
be	O	O
introduced	O	O
into	O	O
whole	O	O
animals	O	O
as	O	O
a	O	O
model	O	O
for	O	O
somatic	O	O
gene	O	O
therapy	O	O
for	O	O
PKU	B-Disease	D010661
.	O	O

.	O	O

Characterisation	O	O
of	O	O
molecular	O	O
defects	O	O
in	O	O
X	B-Disease	C538243
-	I-Disease	C538243
linked	I-Disease	C538243
amelogenesis	I-Disease	C538243
imperfecta	I-Disease	C538243
(	O	O
AIH1	B-Disease	C538243
)	O	O
.	O	O

Amelogenins	O	O
are	O	O
an	O	O
heterogenous	O	O
family	O	O
of	O	O
proteins	O	O
produced	O	O
by	O	O
ameloblasts	O	O
of	O	O
the	O	O
enamel	O	O
organ	O	O
during	O	O
tooth	O	O
development	O	O
.	O	O

Disturbances	O	O
of	O	O
enamel	O	O
formation	O	O
occur	O	O
in	O	O
amelogenesis	B-Disease	D000567
imperfecta	I-Disease	D000567
,	O	O
a	O	O
clinically	O	O
heterogenous	O	O
group	O	O
of	O	O
inherited	B-Disease	D030342
disorders	I-Disease	D030342
characterised	O	O
by	O	O
defective	O	O
enamel	O	O
biomineralisation	O	O
.	O	O

An	O	O
amelogenin	O	O
gene	O	O
,	O	O
AMGX	O	O
,	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
the	O	O
short	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
(	O	O
Xp22	O	O
.	O	O

1	O	O
-	O	O
p22	O	O
.	O	O

3	O	O
)	O	O
and	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
molecular	O	O
pathology	O	O
of	O	O
X	B-Disease	C538243
-	I-Disease	C538243
linked	I-Disease	C538243
amelogenesis	I-Disease	C538243
imperfecta	I-Disease	C538243
(	O	O
AIH1	B-Disease	C538243
)	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
three	O	O
families	O	O
exhibiting	O	O
AIH1	B-Disease	C538243
and	O	O
screened	O	O
the	O	O
AMGX	O	O
gene	O	O
for	O	O
mutations	O	O
using	O	O
single	O	O
-	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
analysis	O	O
and	O	O
DNA	O	O
sequencing	O	O
.	O	O

Three	O	O
novel	O	O
mutations	O	O
were	O	O
identified	O	O
a	O	O
C	O	O
-	O	O
T	O	O
substitution	O	O
in	O	O
exon	O	O
5	O	O
,	O	O
and	O	O
a	O	O
G	O	O
-	O	O
T	O	O
substitution	O	O
and	O	O
single	O	O
cytosine	O	O
deletion	O	O
in	O	O
exon	O	O
6	O	O
,	O	O
confirming	O	O
the	O	O
existence	O	O
of	O	O
extensive	O	O
allelic	O	O
heterogeneity	O	O
in	O	O
this	O	O
condition	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
family	O	O
-	O	O
specific	O	O
mutations	O	O
will	O	O
enable	O	O
early	O	O
identification	O	O
of	O	O
affected	O	O
individuals	O	O
and	O	O
correlation	O	O
of	O	O
clinical	O	O
phenotype	O	O
with	O	O
genotype	O	O
will	O	O
facilitate	O	O
an	O	O
objective	O	O
system	O	O
of	O	O
disease	O	O
classification	O	O
.	O	O

The	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
gene	O	O
encodes	O	O
a	O	O
chloride	O	O
-	O	O
iodide	O	O
transport	O	O
protein	O	O
.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
is	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
syndromic	B-Disease	D003638
deafness	I-Disease	D003638
and	O	O
characterized	O	O
by	O	O
congenital	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
and	O	O
goitre	B-Disease	D006042
.	O	O

This	O	O
disorder	O	O
was	O	O
mapped	O	O
to	O	O
chromosome	O	O
7	O	O
and	O	O
the	O	O
gene	O	O
causing	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
(	O	O
PDS	B-Disease	C536648
)	O	O
was	O	O
subsequently	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
.	O	O

PDS	B-Disease	C536648
encodes	O	O
a	O	O
putative	O	O
transmembrane	O	O
protein	O	O
designated	O	O
pendrin	O	O
.	O	O

Pendrin	O	O
is	O	O
closely	O	O
related	O	O
to	O	O
a	O	O
family	O	O
of	O	O
sulfate	O	O
transport	O	O
proteins	O	O
that	O	O
includes	O	O
the	O	O
rat	O	O
sulfate	O	O
-	O	O
anion	O	O
transporter	O	O
(	O	O
encoded	O	O
by	O	O
Sat	O	O
-	O	O
1	O	O
;	O	O
29	O	O
%	O	O
amino	O	O
acid	O	O
sequence	O	O
identity	O	O
)	O	O
,	O	O
the	O	O
human	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
sulfate	O	O
transporter	O	O
(	O	O
encoded	O	O
by	O	O
DTD	O	O
;	O	O
32	O	O
%	O	O
)	O	O
and	O	O
the	O	O
human	O	O
sulfate	O	O
transporter	O	O
downregulated	O	O
in	O	O
adenoma	B-Disease	D000236
(	O	O
encoded	O	O
by	O	O
DRA	O	O
;	O	O
45	O	O
%	O	O
)	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
this	O	O
homology	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
slightly	O	O
modified	O	O
sulfate	O	O
-	O	O
transporter	O	O
signature	O	O
sequence	O	O
comprising	O	O
its	O	O
putative	O	O
second	O	O
transmembrane	O	O
domain	O	O
,	O	O
pendrin	O	O
has	O	O
been	O	O
proposed	O	O
to	O	O
function	O	O
as	O	O
a	O	O
sulfate	O	O
transporter	O	O
.	O	O

We	O	O
were	O	O
unable	O	O
to	O	O
detect	O	O
evidence	O	O
of	O	O
sulfate	O	O
transport	O	O
following	O	O
the	O	O
expression	O	O
of	O	O
pendrin	O	O
in	O	O
Xenopus	O	O
laevis	O	O
oocytes	O	O
by	O	O
microinjection	O	O
of	O	O
PDS	B-Disease	C536648
cRNA	O	O
or	O	O
in	O	O
Sf9	O	O
cells	O	O
following	O	O
infection	O	O
with	O	O
PDS	B-Disease	C536648
-	O	O
recombinant	O	O
baculovirus	O	O
.	O	O

The	O	O
rates	O	O
of	O	O
transport	O	O
for	O	O
iodide	O	O
and	O	O
chloride	O	O
were	O	O
significantly	O	O
increased	O	O
following	O	O
the	O	O
expression	O	O
of	O	O
pendrin	O	O
in	O	O
both	O	O
cell	O	O
systems	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
pendrin	O	O
functions	O	O
as	O	O
a	O	O
transporter	O	O
of	O	O
chloride	O	O
and	O	O
iodide	O	O
,	O	O
but	O	O
not	O	O
sulfate	O	O
,	O	O
and	O	O
may	O	O
provide	O	O
insight	O	O
into	O	O
thyroid	O	O
physiology	O	O
and	O	O
the	O	O
pathophysiology	O	O
of	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
.	O	O

.	O	O

Linkage	O	O
relationship	O	O
of	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
,	O	O
HLA	O	O
and	O	O
glyoxalase	O	O
I	O	O
loci	O	O
.	O	O

Immunogenetic	O	O
analysis	O	O
of	O	O
a	O	O
homozygous	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
individual	O	O
and	O	O
family	O	O
members	O	O
demonstrated	O	O
linkage	O	O
of	O	O
HLA	O	O
-	O	O
A25	O	O
,	O	O
B18	O	O
and	O	O
C2o	O	O
.	O	O

HLA	O	O
-	O	O
D	O	O
typing	O	O
showed	O	O
that	O	O
5	O	O
members	O	O
typed	O	O
with	O	O
homozygous	O	O
Dw2	O	O
typing	O	O
cells	O	O
from	O	O
an	O	O
individual	O	O
with	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
but	O	O
not	O	O
with	O	O
Dw2	O	O
typing	O	O
cells	O	O
from	O	O
2	O	O
individuals	O	O
with	O	O
normal	O	O
C2	O	O
.	O	O

The	O	O
homozygous	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficient	I-Disease	OMIM:217000
propositus	O	O
and	O	O
brother	O	O
were	O	O
HLA	O	O
-	O	O
A	O	O
and	O	O
B	O	O
homozygous	O	O
but	O	O
heterozygous	O	O
at	O	O
the	O	O
HLA	O	O
-	O	O
D	O	O
and	O	O
glyoxalase	O	O
I	O	O
loci	O	O
.	O	O

Therefore	O	O
,	O	O
in	O	O
this	O	O
family	O	O
,	O	O
the	O	O
C2o	O	O
gene	O	O
is	O	O
linked	O	O
with	O	O
two	O	O
distinct	O	O
haplotypes	O	O
HLA	O	O
-	O	O
A25	O	O
,	O	O
B18	O	O
,	O	O
Dw2	O	O
,	O	O
GLO1	O	O
and	O	O
HLA	O	O
-	O	O
A25	O	O
,	O	O
B18	O	O
,	O	O
D	O	O
unknown	O	O
,	O	O
GL02	O	O
.	O	O

These	O	O
results	O	O
could	O	O
be	O	O
explained	O	O
by	O	O
an	O	O
ancestral	O	O
recombinant	O	O
event	O	O
,	O	O
which	O	O
occurred	O	O
between	O	O
the	O	O
C2o	O	O
locus	O	O
and	O	O
HLA	O	O
-	O	O
D	O	O
locus	O	O
in	O	O
which	O	O
C2o	O	O
segregated	O	O
with	O	O
HLA	O	O
-	O	O
B	O	O
.	O	O

This	O	O
would	O	O
suggest	O	O
that	O	O
the	O	O
locus	O	O
for	O	O
the	O	O
C2o	O	O
gene	O	O
maps	O	O
between	O	O
HLA	O	O
-	O	O
B	O	O
and	O	O
HLA	O	O
-	O	O
D	O	O
on	O	O
the	O	O
sixth	O	O
chromosome	O	O
.	O	O

.	O	O

A	O	O
71	O	O
-	O	O
kilodalton	O	O
protein	O	O
is	O	O
a	O	O
major	O	O
product	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
in	O	O
brain	O	O
and	O	O
other	O	O
nonmuscle	O	O
tissues	O	O
.	O	O

The	O	O
known	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
products	O	O
,	O	O
the	O	O
muscle	O	O
-	O	O
and	O	O
brain	O	O
-	O	O
type	O	O
dystrophin	O	O
isoforms	O	O
,	O	O
are	O	O
427	O	O
-	O	O
kDa	O	O
proteins	O	O
translated	O	O
from	O	O
14	O	O
-	O	O
kilobase	O	O
(	O	O
kb	O	O
)	O	O
mRNAs	O	O
.	O	O

Recently	O	O
we	O	O
described	O	O
a	O	O
6	O	O
.	O	O

5	O	O
-	O	O
kb	O	O
mRNA	O	O
that	O	O
also	O	O
is	O	O
transcribed	O	O
from	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

Cloning	O	O
and	O	O
in	O	O
vitro	O	O
transcription	O	O
and	O	O
translation	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
show	O	O
that	O	O
the	O	O
6	O	O
.	O	O

5	O	O
-	O	O
kb	O	O
mRNA	O	O
encodes	O	O
a	O	O
70	O	O
.	O	O

8	O	O
-	O	O
kDa	O	O
protein	O	O
that	O	O
is	O	O
a	O	O
major	O	O
product	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
.	O	O

It	O	O
contains	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
and	O	O
the	O	O
cysteine	O	O
-	O	O
rich	O	O
domains	O	O
of	O	O
dystrophin	O	O
,	O	O
seven	O	O
additional	O	O
amino	O	O
acids	O	O
at	O	O
the	O	O
N	O	O
terminus	O	O
,	O	O
and	O	O
some	O	O
modifications	O	O
formed	O	O
by	O	O
alternative	O	O
splicing	O	O
in	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
domain	O	O
.	O	O

It	O	O
lacks	O	O
the	O	O
entire	O	O
large	O	O
domain	O	O
of	O	O
spectrin	O	O
-	O	O
like	O	O
repeats	O	O
and	O	O
the	O	O
actin	O	O
-	O	O
binding	O	O
N	O	O
-	O	O
terminal	O	O
domain	O	O
of	O	O
dystrophin	O	O
.	O	O

This	O	O
protein	O	O
is	O	O
the	O	O
major	O	O
DMD	B-Disease	D020388
gene	O	O
product	O	O
in	O	O
brain	O	O
and	O	O
other	O	O
nonmuscle	O	O
tissues	O	O
but	O	O
is	O	O
undetectable	O	O
in	O	O
skeletal	O	O
muscle	O	O
extracts	O	O
.	O	O

Histidinemia	B-Disease	C538320
.	O	O

Classical	O	O
and	O	O
atypical	O	O
form	O	O
in	O	O
siblings	O	O
.	O	O

Two	O	O
brothers	O	O
,	O	O
6	O	O
and	O	O
13	O	O
years	O	O
old	O	O
,	O	O
had	O	O
histidinemia	B-Disease	C538320
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
clinical	O	O
and	O	O
biochemical	O	O
observations	O	O
,	O	O
the	O	O
younger	O	O
boy	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
a	O	O
classical	O	O
type	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
while	O	O
the	O	O
older	O	O
boy	O	O
had	O	O
an	O	O
atypical	O	O
form	O	O
characterized	O	O
by	O	O
partial	O	O
impairment	O	O
of	O	O
the	O	O
skin	O	O
histidase	O	O
activity	O	O
and	O	O
a	O	O
moderately	O	O
prolonged	O	O
half	O	O
-	O	O
life	O	O
of	O	O
blood	O	O
histidine	O	O
.	O	O

The	O	O
mother	O	O
is	O	O
a	O	O
heterozygous	O	O
carrier	O	O
,	O	O
while	O	O
the	O	O
father	O	O
and	O	O
sister	O	O
seem	O	O
to	O	O
be	O	O
normal	O	O
.	O	O

.	O	O

Hypoxanthine	B-Disease	OMIM:300323
-	I-Disease	OMIM:300323
guanine	I-Disease	OMIM:300323
phosphoribosyltransferase	I-Disease	OMIM:300323
deficiency	I-Disease	OMIM:300323
:	O	O
analysis	O	O
of	O	O
HPRT	O	O
mutations	O	O
by	O	O
direct	O	O
sequencing	O	O
and	O	O
allele	O	O
-	O	O
specific	O	O
amplification	O	O
.	O	O

The	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
is	O	O
a	O	O
severe	O	O
X	B-Disease	D040181
chromosome	I-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
human	I-Disease	D040181
disease	I-Disease	D040181
caused	O	O
by	O	O
a	O	O
virtual	O	O
absence	B-Disease	D007926
of	I-Disease	D007926
hypoxanthine	I-Disease	D007926
-	I-Disease	D007926
guanine	I-Disease	D007926
phosphoribosyltransferase	I-Disease	D007926
(	I-Disease	D007926
HPRT	I-Disease	D007926
)	I-Disease	D007926
activity	I-Disease	D007926
.	O	O

A	O	O
partial	O	O
deficiency	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
this	O	O
enzyme	O	O
can	O	O
result	O	O
in	O	O
gouty	B-Disease	D015210
arthritis	I-Disease	D015210
.	O	O

To	O	O
determine	O	O
the	O	O
genetic	O	O
basis	O	O
for	O	O
reduction	O	O
or	O	O
loss	O	O
of	O	O
enzyme	O	O
activity	O	O
,	O	O
we	O	O
have	O	O
amplified	O	O
and	O	O
sequenced	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
HPRT	O	O
cDNA	O	O
from	O	O
four	O	O
patients	O	O
one	O	O
with	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
(	O	O
HPRTPerth	O	O
)	O	O
and	O	O
three	O	O
with	O	O
partial	B-Disease	OMIM:300323
deficiencies	I-Disease	OMIM:300323
of	I-Disease	OMIM:300323
HPRT	I-Disease	OMIM:300323
activity	I-Disease	OMIM:300323
,	O	O
which	O	O
have	O	O
been	O	O
designated	O	O
HPRTUrangan	O	O
,	O	O
HPRTSwan	O	O
and	O	O
HPRTToowong	O	O
.	O	O

In	O	O
all	O	O
four	O	O
patients	O	O
,	O	O
the	O	O
only	O	O
mutation	O	O
identified	O	O
was	O	O
a	O	O
single	O	O
base	O	O
substitution	O	O
in	O	O
exons	O	O
2	O	O
or	O	O
3	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
,	O	O
which	O	O
in	O	O
each	O	O
case	O	O
predicts	O	O
a	O	O
single	O	O
amino	O	O
acid	O	O
substitution	O	O
in	O	O
the	O	O
translated	O	O
protein	O	O
.	O	O

Each	O	O
base	O	O
change	O	O
was	O	O
confirmed	O	O
by	O	O
allele	O	O
-	O	O
specific	O	O
amplification	O	O
of	O	O
the	O	O
patients	O	O
genomic	O	O
DNA	O	O
.	O	O

It	O	O
is	O	O
interesting	O	O
to	O	O
note	O	O
that	O	O
the	O	O
mutation	O	O
found	O	O
for	O	O
HPRTPerth	O	O
is	O	O
identical	O	O
to	O	O
that	O	O
reported	O	O
for	O	O
HPRTFlint	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
the	O	O
two	O	O
mutations	O	O
are	O	O
de	O	O
novo	O	O
events	O	O
.	O	O

.	O	O

Sjogren	B-Disease	D016111
-	I-Disease	D016111
Larsson	I-Disease	D016111
syndrome	I-Disease	D016111
.	O	O

Impaired	O	O
fatty	O	O
alcohol	O	O
oxidation	O	O
in	O	O
cultured	O	O
fibroblasts	O	O
due	O	O
to	O	O
deficient	O	O
fatty	O	O
alcohol	O	O
:	O	O
nicotinamide	O	O
adenine	O	O
dinucleotide	O	O
oxidoreductase	O	O
activity	O	O
.	O	O

Lipid	O	O
metabolism	O	O
was	O	O
studied	O	O
in	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
patients	O	O
with	O	O
the	O	O
inherited	B-Disease	D030342
disorder	I-Disease	D030342
,	O	O
Sjogren	B-Disease	D016111
-	I-Disease	D016111
Larsson	I-Disease	D016111
syndrome	I-Disease	D016111
(	O	O
SLS	B-Disease	D016111
)	O	O
.	O	O

Intact	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
incubated	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
[	O	O
1	O	O
-	O	O
14C	O	O
]	O	O
palmitate	O	O
accumulated	O	O
more	O	O
radioactive	O	O
hexadecanol	O	O
than	O	O
did	O	O
normal	O	O
cells	O	O
,	O	O
whereas	O	O
incorporation	O	O
of	O	O
radioactivity	O	O
into	O	O
other	O	O
cellular	O	O
lipids	O	O
was	O	O
unaltered	O	O
.	O	O

The	O	O
hexadecanol	O	O
content	O	O
of	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
was	O	O
abnormally	O	O
elevated	O	O
.	O	O

Hexadecanol	O	O
accumulation	O	O
was	O	O
not	O	O
due	O	O
to	O	O
increased	O	O
fatty	O	O
alcohol	O	O
synthesis	O	O
nor	O	O
its	O	O
deficient	O	O
utilization	O	O
for	O	O
glycerol	O	O
ether	O	O
synthesis	O	O
.	O	O

The	O	O
half	O	O
-	O	O
life	O	O
of	O	O
intracellular	O	O
hexadecanol	O	O
loaded	O	O
into	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
was	O	O
increased	O	O
(	O	O
70	O	O
min	O	O
)	O	O
compared	O	O
with	O	O
normal	O	O
(	O	O
15	O	O
min	O	O
)	O	O
,	O	O
and	O	O
intact	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
showed	O	O
impaired	O	O
oxidation	O	O
of	O	O
[	O	O
14C	O	O
]	O	O
-	O	O
hexadecanol	O	O
to	O	O
fatty	O	O
acid	O	O
.	O	O

Fatty	O	O
alcohol	O	O
NAD	O	O
+	O	O
oxidoreductase	O	O
,	O	O
the	O	O
enzyme	O	O
catalyzing	O	O
this	O	O
reaction	O	O
,	O	O
was	O	O
deficient	O	O
in	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
.	O	O

Mean	O	O
total	O	O
activity	O	O
in	O	O
SLS	B-Disease	D016111
fibroblasts	O	O
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
was	O	O
13	O	O
%	O	O
of	O	O
that	O	O
in	O	O
normal	O	O
fibroblasts	O	O
,	O	O
and	O	O
palmitoyl	O	O
CoA	O	O
-	O	O
inhibitable	O	O
activity	O	O
was	O	O
1	O	O
%	O	O
of	O	O
normal	O	O
.	O	O

Fibroblasts	O	O
from	O	O
two	O	O
obligate	O	O
SLS	B-Disease	D016111
heterozygotes	O	O
had	O	O
enzyme	O	O
activities	O	O
intermediate	O	O
between	O	O
that	O	O
in	O	O
normal	O	O
fibroblasts	O	O
and	O	O
individuals	O	O
with	O	O
SLS	B-Disease	D016111
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
primary	O	O
defect	O	O
in	O	O
SLS	B-Disease	D016111
is	O	O
deficiency	B-Disease	D016111
of	I-Disease	D016111
fatty	I-Disease	D016111
alcohol	I-Disease	D016111
NAD	I-Disease	D016111
+	I-Disease	D016111
oxidoreductase	I-Disease	D016111
.	O	O

SLS	B-Disease	D016111
represents	O	O
the	O	O
first	O	O
inherited	B-Disease	D030342
disorder	I-Disease	D030342
in	O	O
man	O	O
associated	O	O
with	O	O
an	O	O
isolated	O	O
abnormality	B-Disease	D005235
in	I-Disease	D005235
fatty	I-Disease	D005235
alcohol	I-Disease	D005235
metabolism	I-Disease	D005235
.	O	O

.	O	O

Glycerol	O	O
as	O	O
a	O	O
correlate	O	O
of	O	O
impaired	B-Disease	D018149
glucose	I-Disease	D018149
tolerance	I-Disease	D018149
:	O	O
dissection	O	O
of	O	O
a	O	O
complex	O	O
system	O	O
by	O	O
use	O	O
of	O	O
a	O	O
simple	O	O
genetic	O	O
trait	O	O
.	O	O

Glycerol	O	O
kinase	O	O
(	O	O
GK	O	O
)	O	O
represents	O	O
the	O	O
primary	O	O
entry	O	O
of	O	O
glycerol	O	O
into	O	O
glucose	O	O
and	O	O
triglyceride	O	O
metabolism	O	O
.	O	O

Impaired	B-Disease	D018149
glucose	I-Disease	D018149
tolerance	I-Disease	D018149
(	O	O
IGT	B-Disease	D018149
)	O	O
and	O	O
hypertriglyceridemia	B-Disease	D015228
are	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
and	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
.	O	O

The	O	O
relationship	O	O
between	O	O
glycerol	O	O
and	O	O
the	O	O
risk	O	O
of	O	O
IGT	B-Disease	D018149
,	O	O
however	O	O
,	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
therefore	O	O
undertook	O	O
the	O	O
study	O	O
of	O	O
fasting	O	O
plasma	O	O
glycerol	O	O
levels	O	O
in	O	O
a	O	O
cohort	O	O
of	O	O
1	O	O
,	O	O
056	O	O
unrelated	O	O
men	O	O
and	O	O
women	O	O
of	O	O
French	O	O
-	O	O
Canadian	O	O
descent	O	O
.	O	O

Family	O	O
screening	O	O
in	O	O
the	O	O
initial	O	O
cohort	O	O
identified	O	O
18	O	O
men	O	O
from	O	O
five	O	O
families	O	O
with	O	O
severe	O	O
hyperglycerolemia	B-Disease	C538138
(	O	O
values	O	O
above	O	O
2	O	O
.	O	O

0	O	O
mmol	O	O
/	O	O
liter	O	O
)	O	O
and	O	O
demonstrated	O	O
an	O	O
X	O	O
-	O	O
linked	O	O
pattern	O	O
of	O	O
inheritance	O	O
.	O	O

Linkage	O	O
analysis	O	O
of	O	O
the	O	O
data	O	O
from	O	O
12	O	O
microsatellite	O	O
markers	O	O
surrounding	O	O
the	O	O
Xp21	O	O
.	O	O

3	O	O
GK	O	O
gene	O	O
resulted	O	O
in	O	O
a	O	O
peak	O	O
LOD	O	O
score	O	O
of	O	O
3	O	O
.	O	O

46	O	O
,	O	O
centered	O	O
around	O	O
marker	O	O
DXS8039	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
since	O	O
all	O	O
of	O	O
the	O	O
families	O	O
originated	O	O
in	O	O
a	O	O
population	O	O
with	O	O
a	O	O
proven	O	O
founder	O	O
effect	O	O
-	O	O
the	O	O
Saguenay	O	O
Lac	O	O
-	O	O
St	O	O
.	O	O

-	O	O
Jean	O	O
region	O	O
of	O	O
Quebec	O	O
-	O	O
a	O	O
common	O	O
disease	O	O
haplotype	O	O
was	O	O
sought	O	O
.	O	O

Indeed	O	O
,	O	O
a	O	O
six	O	O
-	O	O
marker	O	O
haplotype	O	O
extending	O	O
over	O	O
a	O	O
region	O	O
of	O	O
5	O	O
.	O	O

5	O	O
cM	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
families	O	O
.	O	O

Resequencing	O	O
of	O	O
the	O	O
GK	O	O
gene	O	O
in	O	O
family	O	O
members	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
N288D	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
10	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
a	O	O
highly	O	O
conserved	O	O
asparagine	O	O
residue	O	O
by	O	O
a	O	O
negatively	O	O
charged	O	O
aspartic	O	O
acid	O	O
.	O	O

Assignment	O	O
of	O	O
the	O	O
aspartylglucosaminidase	O	O
gene	O	O
(	O	O
AGA	O	O
)	O	O
to	O	O
4q33	O	O
-	O	O
-	O	O
-	O	O
-	O	O
q35	O	O
based	O	O
on	O	O
decreased	O	O
activity	O	O
in	O	O
a	O	O
girl	O	O
with	O	O
a	O	O
46	O	O
,	O	O
XX	O	O
,	O	O
del	O	O
(	O	O
4	O	O
)	O	O
(	O	O
q33	O	O
)	O	O
karyotype	O	O
.	O	O

Aspartylglucosaminuria	B-Disease	D054880
(	O	O
AGU	B-Disease	D054880
)	O	O
is	O	O
a	O	O
recessive	O	O
autosomally	O	O
inherited	O	O
lysosomal	B-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
due	O	O
to	O	O
deficiency	B-Disease	D054880
of	I-Disease	D054880
the	I-Disease	D054880
enzyme	I-Disease	D054880
aspartylglucosaminidase	I-Disease	D054880
(	O	O
AGA	O	O
)	O	O
.	O	O

The	O	O
structural	O	O
gene	O	O
for	O	O
this	O	O
human	O	O
enzyme	O	O
(	O	O
AGA	O	O
)	O	O
has	O	O
been	O	O
assigned	O	O
to	O	O
the	O	O
region	O	O
4q21	O	O
-	O	O
-	O	O
-	O	O
-	O	O
qter	O	O
.	O	O

We	O	O
determined	O	O
the	O	O
AGA	O	O
activity	O	O
in	O	O
cultured	O	O
fibroblasts	O	O
of	O	O
a	O	O
girl	O	O
with	O	O
a	O	O
46	O	O
,	O	O
XX	O	O
,	O	O
del	O	O
(	O	O
4	O	O
)	O	O
(	O	O
q33	O	O
)	O	O
karyotype	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
girl	O	O
is	O	O
a	O	O
hemizygote	O	O
for	O	O
AGA	O	O
,	O	O
permitting	O	O
the	O	O
assignment	O	O
of	O	O
human	O	O
AGA	O	O
to	O	O
the	O	O
region	O	O
4q33	O	O
-	O	O
-	O	O
-	O	O
-	O	O
qter	O	O
.	O	O

.	O	O

Mutations	O	O
in	O	O
the	O	O
fibrinogen	O	O
aalpha	O	O
gene	O	O
account	O	O
for	O	O
the	O	O
majority	O	O
of	O	O
cases	O	O
of	O	O
congenital	B-Disease	C531603
afibrinogenemia	I-Disease	C531603
.	O	O

Congenital	B-Disease	C531603
afibrinogenemia	I-Disease	C531603
is	O	O
a	O	O
rare	O	O
,	O	O
autosomal	B-Disease	D030342
,	I-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
the	O	O
complete	O	O
absence	O	O
of	O	O
detectable	O	O
fibrinogen	O	O
.	O	O

We	O	O
previously	O	O
identified	O	O
the	O	O
first	O	O
causative	O	O
mutations	O	O
in	O	O
a	O	O
nonconsanguineous	O	O
Swiss	O	O
family	O	O
;	O	O
the	O	O
4	O	O
affected	O	O
persons	O	O
have	O	O
homozygous	O	O
deletions	O	O
of	O	O
approximately	O	O
11	O	O
kb	O	O
of	O	O
the	O	O
fibrinogen	O	O
alpha	O	O
(	O	O
FGA	O	O
)	O	O
gene	O	O
.	O	O

Haplotype	O	O
data	O	O
implied	O	O
that	O	O
these	O	O
deletions	O	O
occurred	O	O
on	O	O
distinct	O	O
ancestral	O	O
chromosomes	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
region	O	O
may	O	O
be	O	O
susceptible	O	O
to	O	O
deletion	O	O
by	O	O
a	O	O
common	O	O
mechanism	O	O
.	O	O

We	O	O
subsequently	O	O
showed	O	O
that	O	O
all	O	O
the	O	O
deletions	O	O
were	O	O
identical	O	O
to	O	O
the	O	O
base	O	O
pair	O	O
and	O	O
probably	O	O
resulted	O	O
from	O	O
a	O	O
nonhomologous	O	O
recombination	O	O
mediated	O	O
by	O	O
7	O	O
-	O	O
bp	O	O
direct	O	O
repeats	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
collected	O	O
data	O	O
on	O	O
13	O	O
additional	O	O
unrelated	O	O
patients	O	O
to	O	O
identify	O	O
the	O	O
causative	O	O
mutations	O	O
and	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
the	O	O
11	O	O
-	O	O
kb	O	O
deletion	O	O
.	O	O

A	O	O
common	O	O
recurrent	O	O
mutation	O	O
,	O	O
at	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
of	O	O
FGA	O	O
intron	O	O
4	O	O
(	O	O
IVS4	O	O
+	O	O
1	O	O
G	O	O
>	O	O
T	O	O
)	O	O
,	O	O
accounted	O	O
for	O	O
14	O	O
of	O	O
the	O	O
26	O	O
(	O	O
54	O	O
%	O	O
)	O	O
alleles	O	O
.	O	O

One	O	O
patient	O	O
was	O	O
heterozygous	O	O
for	O	O
the	O	O
previously	O	O
identified	O	O
deletion	O	O
.	O	O

Three	O	O
more	O	O
frameshift	O	O
mutations	O	O
,	O	O
2	O	O
nonsense	O	O
mutations	O	O
,	O	O
and	O	O
a	O	O
second	O	O
splice	O	O
site	O	O
mutation	O	O
were	O	O
also	O	O
identified	O	O
.	O	O

Consequently	O	O
,	O	O
86	O	O
%	O	O
of	O	O
afibrinogenemia	B-Disease	D000347
alleles	O	O
analyzed	O	O
to	O	O
date	O	O
have	O	O
truncating	O	O
mutations	O	O
of	O	O
FGA	O	O
,	O	O
though	O	O
mutations	O	O
in	O	O
all	O	O
3	O	O
fibrinogen	O	O
genes	O	O
,	O	O
FGG	O	O
,	O	O
FGA	O	O
,	O	O
and	O	O
FGB	O	O
,	O	O
might	O	O
be	O	O
predicted	O	O
to	O	O
cause	O	O
congenital	B-Disease	C531603
afibrinogenemia	I-Disease	C531603
.	O	O

.	O	O

Utilization	O	O
of	O	O
purines	O	O
by	O	O
an	O	O
HPRT	O	O
variant	O	O
in	O	O
an	O	O
intelligent	O	O
,	O	O
nonmutilative	O	O
patient	O	O
with	O	O
features	O	O
of	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

The	O	O
patient	O	O
,	O	O
H	O	O
.	O	O

Chr	O	O
.	O	O

B	O	O
.	O	O

,	O	O
was	O	O
among	O	O
the	O	O
first	O	O
reported	O	O
with	O	O
hyperuricemia	B-Disease	D033461
and	O	O
central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
symptoms	I-Disease	D002493
.	O	O

He	O	O
has	O	O
been	O	O
found	O	O
to	O	O
have	O	O
a	O	O
variant	O	O
of	O	O
hypoxanthine	O	O
guanine	O	O
phosphoribosyl	O	O
transferase	O	O
(	O	O
HPRT	O	O
;	O	O
E	O	O
.	O	O

C	O	O
.	O	O

2	O	O
.	O	O

4	O	O
.	O	O

2	O	O
.	O	O

8	O	O
)	O	O
distinct	O	O
from	O	O
the	O	O
enzyme	O	O
present	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

The	O	O
patient	O	O
had	O	O
chroeoathetosis	B-Disease	C537181
,	O	O
spasticity	B-Disease	D009128
,	O	O
dysarthric	B-Disease	D004401
speech	I-Disease	D004401
,	O	O
and	O	O
hyperuricemia	B-Disease	D033461
.	O	O

However	O	O
,	O	O
his	O	O
intelligence	O	O
was	O	O
normal	O	O
and	O	O
he	O	O
had	O	O
no	O	O
evidence	O	O
of	O	O
self	O	O
-	O	O
mutilation	O	O
.	O	O

There	O	O
was	O	O
no	O	O
activity	O	O
of	O	O
HPRT	O	O
in	O	O
the	O	O
lysates	O	O
of	O	O
erythrocytes	O	O
and	O	O
cultured	O	O
fibroblasts	O	O
when	O	O
analyzed	O	O
in	O	O
the	O	O
usual	O	O
manner	O	O
.	O	O

Using	O	O
a	O	O
newly	O	O
developed	O	O
method	O	O
for	O	O
the	O	O
study	O	O
of	O	O
purine	O	O
metabolism	O	O
in	O	O
intact	O	O
cultured	O	O
cells	O	O
,	O	O
this	O	O
patient	O	O
was	O	O
found	O	O
to	O	O
metabolize	O	O
some	O	O
9	O	O
%	O	O
of	O	O
8	O	O
-	O	O
14C	O	O
-	O	O
hypoxanthine	O	O
,	O	O
and	O	O
90	O	O
%	O	O
of	O	O
the	O	O
isotope	O	O
utilized	O	O
was	O	O
converted	O	O
to	O	O
adenine	O	O
and	O	O
guanine	O	O
nucleotides	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
cells	O	O
from	O	O
patients	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
were	O	O
virtually	O	O
completely	O	O
unable	O	O
to	O	O
convert	O	O
hypoxanthine	O	O
to	O	O
nucleotides	O	O
.	O	O

The	O	O
patients	O	O
fibroblasts	O	O
were	O	O
even	O	O
more	O	O
efficient	O	O
in	O	O
the	O	O
metabolism	O	O
of	O	O
8	O	O
-	O	O
14C	O	O
-	O	O
guanine	O	O
,	O	O
which	O	O
was	O	O
utilized	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
27	O	O
%	O	O
,	O	O
over	O	O
80	O	O
%	O	O
of	O	O
which	O	O
was	O	O
converted	O	O
to	O	O
guanine	O	O
and	O	O
adenine	O	O
nucleotides	O	O
.	O	O

The	O	O
growth	O	O
of	O	O
the	O	O
cultured	O	O
fibroblasts	O	O
of	O	O
this	O	O
patient	O	O
was	O	O
intermediate	O	O
in	O	O
media	O	O
containing	O	O
hypoxanthine	O	O
aminopterin	O	O
thymidine	O	O
(	O	O
HAT	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
growth	O	O
of	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
cells	O	O
was	O	O
inhibited	O	O
and	O	O
normal	O	O
cells	O	O
grew	O	O
normally	O	O
.	O	O

Similarly	O	O
in	O	O
8	O	O
-	O	O
azaguanine	O	O
,	O	O
6	O	O
-	O	O
thioguanine	O	O
,	O	O
and	O	O
8	O	O
-	O	O
azahypoxanthine	O	O
,	O	O
the	O	O
growth	O	O
of	O	O
the	O	O
patients	O	O
cells	O	O
was	O	O
intermediate	O	O
between	O	O
normal	O	O
and	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
cells	O	O
.	O	O

These	O	O
observations	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
genetic	O	O
heterogeneity	O	O
among	O	O
patients	O	O
with	O	O
disorders	O	O
in	O	O
purine	O	O
metabolism	O	O
involving	O	O
the	O	O
HPRT	O	O
gene	O	O
.	O	O

They	O	O
document	O	O
that	O	O
this	O	O
famous	O	O
patient	O	O
did	O	O
not	O	O
have	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
Canavan	B-Disease	D017825
disease	I-Disease	D017825
:	O	O
mutations	O	O
among	O	O
Jewish	O	O
and	O	O
non	O	O
-	O	O
Jewish	O	O
patients	O	O
.	O	O

Canavan	B-Disease	D017825
disease	I-Disease	D017825
is	O	O
an	O	O
autosomal	B-Disease	D007966
recessive	I-Disease	D007966
leukodystrophy	I-Disease	D007966
caused	O	O
by	O	O
the	O	O
deficiency	B-Disease	D017825
of	I-Disease	D017825
aspartoacylase	I-Disease	D017825
(	O	O
ASPA	O	O
)	O	O
.	O	O

Sixty	O	O
-	O	O
four	O	O
probands	O	O
were	O	O
analyzed	O	O
for	O	O
mutations	O	O
in	O	O
the	O	O
ASPA	O	O
gene	O	O
.	O	O

Three	O	O
point	O	O
mutations	O	O
-	O	O
-	O	O
693C	O	O
-	O	O
-	O	O
>	O	O
A	O	O
,	O	O
854A	O	O
-	O	O
-	O	O
>	O	O
C	O	O
,	O	O
and	O	O
914C	O	O
-	O	O
-	O	O
>	O	O
A	O	O
-	O	O
-	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
.	O	O

The	O	O
693C	O	O
-	O	O
-	O	O
>	O	O
A	O	O
and	O	O
914C	O	O
-	O	O
-	O	O
>	O	O
A	O	O
base	O	O
changes	O	O
,	O	O
resulting	O	O
in	O	O
nonsense	O	O
tyr231	O	O
-	O	O
-	O	O
>	O	O
ter	O	O
and	O	O
missense	O	O
ala305	O	O
-	O	O
-	O	O
>	O	O
glu	O	O
mutations	O	O
,	O	O
respectively	O	O
,	O	O
lead	O	O
to	O	O
complete	O	O
loss	O	O
of	O	O
ASPA	O	O
activity	O	O
in	O	O
in	O	O
vitro	O	O
expression	O	O
studies	O	O
.	O	O

The	O	O
854A	O	O
-	O	O
-	O	O
>	O	O
C	O	O
transversion	O	O
converted	O	O
glu	O	O
to	O	O
ala	O	O
in	O	O
codon	O	O
285	O	O
.	O	O

The	O	O
glu285	O	O
-	O	O
-	O	O
>	O	O
ala	O	O
mutant	O	O
ASPA	O	O
has	O	O
2	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
activity	O	O
expressed	O	O
by	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
enzyme	O	O
.	O	O

A	O	O
fourth	O	O
mutation	O	O
,	O	O
433	O	O
-	O	O
-	O	O
2	O	O
(	O	O
A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
transition	O	O
,	O	O
was	O	O
identified	O	O
at	O	O
the	O	O
splice	O	O
-	O	O
acceptor	O	O
site	O	O
in	O	O
intron	O	O
2	O	O
.	O	O

The	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
would	O	O
lead	O	O
to	O	O
skipping	O	O
of	O	O
exon	O	O
3	O	O
,	O	O
accompanied	O	O
by	O	O
a	O	O
frameshift	O	O
,	O	O
and	O	O
thus	O	O
would	O	O
produce	O	O
aberrant	O	O
ASPA	O	O
.	O	O

Of	O	O
the	O	O
128	O	O
unrelated	O	O
Canavan	B-Disease	D017825
chromosomes	O	O
analyzed	O	O
,	O	O
88	O	O
were	O	O
from	O	O
probands	O	O
of	O	O
Ashkenazi	O	O
Jewish	O	O
descent	O	O
.	O	O

The	O	O
glu285	O	O
-	O	O
-	O	O
>	O	O
ala	O	O
mutation	O	O
was	O	O
predominant	O	O
(	O	O
82	O	O
.	O	O

9	O	O
%	O	O
)	O	O
in	O	O
this	O	O
population	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
tyr231	O	O
-	O	O
-	O	O
>	O	O
ter	O	O
(	O	O
14	O	O
.	O	O

8	O	O
%	O	O
)	O	O
and	O	O
433	O	O
-	O	O
-	O	O
2	O	O
(	O	O
A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
(	O	O
1	O	O
.	O	O

1	O	O
%	O	O
)	O	O
mutations	O	O
.	O	O

The	O	O
three	O	O
mutations	O	O
account	O	O
for	O	O
98	O	O
.	O	O

8	O	O
%	O	O
of	O	O
the	O	O
Canavan	B-Disease	D017825
chromosomes	O	O
of	O	O
Ashkenazi	O	O
Jewish	O	O
origin	O	O
.	O	O

The	O	O
ala305	O	O
-	O	O
-	O	O
>	O	O
glu	O	O
mutation	O	O
was	O	O
found	O	O
exclusively	O	O
in	O	O
non	O	O
-	O	O
Jewish	O	O
probands	O	O
of	O	O
European	O	O
descent	O	O
and	O	O
constituted	O	O
60	O	O
%	O	O
of	O	O
the	O	O
40	O	O
mutant	O	O
chromosomes	O	O
.	O	O

Predominant	O	O
occurrence	O	O
of	O	O
certain	O	O
mutations	O	O
among	O	O
Ashkenazi	O	O
Jewish	O	O
and	O	O
non	O	O
-	O	O
Jewish	O	O
patients	O	O
with	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
would	O	O
suggest	O	O
a	O	O
founding	O	O
-	O	O
father	O	O
effect	O	O
in	O	O
propagation	O	O
of	O	O
these	O	O
mutant	O	O
chromosomes	O	O
Identification	O	O
of	O	O
deletion	O	O
mutations	O	O
and	O	O
three	O	O
new	O	O
genes	O	O
at	O	O
the	O	O
familial	B-Disease	D011125
polyposis	I-Disease	D011125
locus	O	O
.	O	O

Small	O	O
(	O	O
100	O	O
-	O	O
260	O	O
kb	O	O
)	O	O
,	O	O
nested	O	O
deletions	O	O
were	O	O
characterized	O	O
in	O	O
DNA	O	O
from	O	O
two	O	O
unrelated	O	O
patients	O	O
with	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
.	O	O

Three	O	O
candidate	O	O
genes	O	O
located	O	O
within	O	O
the	O	O
deleted	O	O
region	O	O
were	O	O
ascertained	O	O
and	O	O
a	O	O
previous	O	O
candidate	O	O
gene	O	O
,	O	O
MCC	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
located	O	O
outside	O	O
the	O	O
deleted	O	O
region	O	O
.	O	O

One	O	O
of	O	O
the	O	O
new	O	O
genes	O	O
contained	O	O
sequence	O	O
identical	O	O
to	O	O
SRP19	O	O
,	O	O
the	O	O
gene	O	O
coding	O	O
for	O	O
the	O	O
19	O	O
kd	O	O
component	O	O
of	O	O
the	O	O
ribosomal	O	O
signal	O	O
recognition	O	O
particle	O	O
.	O	O

The	O	O
second	O	O
,	O	O
provisionally	O	O
designated	O	O
DP1	O	O
(	O	O
deleted	O	O
in	O	O
polyposis	O	O
1	O	O
)	O	O
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
transcribed	O	O
in	O	O
the	O	O
same	O	O
orientation	O	O
as	O	O
MCC	O	O
.	O	O

Two	O	O
other	O	O
cDNAs	O	O
,	O	O
DP2	O	O
and	O	O
DP3	O	O
,	O	O
were	O	O
found	O	O
to	O	O
overlap	O	O
,	O	O
forming	O	O
a	O	O
single	O	O
gene	O	O
,	O	O
DP2	O	O
.	O	O

5	O	O
,	O	O
that	O	O
is	O	O
transcribed	O	O
in	O	O
the	O	O
same	O	O
orientation	O	O
as	O	O
SRP19	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
families	O	O
with	O	O
deletions	O	O
in	O	O
the	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
gene	O	O
.	O	O

Von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	I-Disease	D006623
VHL	I-Disease	D006623
)	I-Disease	D006623
disease	I-Disease	D006623
is	O	O
a	O	O
hereditary	B-Disease	D009386
tumor	I-Disease	D009386
syndrome	I-Disease	D009386
characterized	O	O
by	O	O
predisposition	O	O
for	O	O
bilateral	B-Disease	D018325
and	I-Disease	D018325
multi	I-Disease	D018325
-	I-Disease	D018325
centric	I-Disease	D018325
hemangioblastoma	I-Disease	D018325
in	O	O
the	O	O
retina	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
pheochromocytoma	B-Disease	D010673
,	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
,	O	O
and	O	O
cysts	B-Disease	D052177
in	I-Disease	D052177
the	I-Disease	D052177
kidney	I-Disease	D052177
,	I-Disease	D052177
pancreas	I-Disease	D052177
,	I-Disease	D052177
and	I-Disease	D052177
epididymis	I-Disease	D052177
.	O	O

We	O	O
describe	O	O
five	O	O
families	O	O
for	O	O
which	O	O
direct	O	O
sequencing	O	O
of	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
had	O	O
failed	O	O
to	O	O
identify	O	O
the	O	O
family	O	O
-	O	O
specific	O	O
mutation	O	O
.	O	O

Further	O	O
molecular	O	O
analysis	O	O
revealed	O	O
deletions	O	O
involving	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
in	O	O
each	O	O
of	O	O
these	O	O
families	O	O
.	O	O

In	O	O
four	O	O
families	O	O
,	O	O
partial	O	O
deletions	O	O
of	O	O
one	O	O
or	O	O
more	O	O
exons	O	O
were	O	O
detected	O	O
by	O	O
Southern	O	O
blot	O	O
analysis	O	O
.	O	O

In	O	O
the	O	O
fifth	O	O
family	O	O
,	O	O
FISH	O	O
analysis	O	O
demonstrated	O	O
the	O	O
deletion	O	O
of	O	O
the	O	O
entire	O	O
VHL	B-Disease	D006623
gene	O	O
.	O	O

Our	O	O
results	O	O
show	O	O
that	O	O
(	O	O
quantitative	O	O
)	O	O
Southern	O	O
blot	O	O
analysis	O	O
is	O	O
a	O	O
sensitive	O	O
method	O	O
for	O	O
detecting	O	O
germline	O	O
deletions	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
and	O	O
should	O	O
be	O	O
implemented	O	O
in	O	O
routine	O	O
DNA	O	O
diagnosis	O	O
for	O	O
VHL	B-Disease	D006623
disease	O	O
.	O	O

Our	O	O
data	O	O
support	O	O
the	O	O
previously	O	O
established	O	O
observation	O	O
that	O	O
families	O	O
with	O	O
a	O	O
germline	O	O
deletion	O	O
have	O	O
a	O	O
low	O	O
risk	O	O
for	O	O
pheochromocytoma	B-Disease	D010673
.	O	O

Further	O	O
unraveling	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
VHL	B-Disease	D006623
disease	O	O
has	O	O
revealed	O	O
that	O	O
families	O	O
with	O	O
a	O	O
full	O	O
or	O	O
partial	O	O
deletion	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
exhibit	O	O
a	O	O
phenotype	O	O
with	O	O
a	O	O
preponderance	O	O
of	O	O
central	B-Disease	D018325
nervous	I-Disease	D018325
system	I-Disease	D018325
hemangioblastoma	I-Disease	D018325
.	O	O

.	O	O

Understanding	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
.	O	O

Fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
a	O	O
common	O	O
form	O	O
of	O	O
inherited	B-Disease	D038901
mental	I-Disease	D038901
retardation	I-Disease	D038901
,	O	O
is	O	O
mainly	O	O
caused	O	O
by	O	O
massive	O	O
expansion	O	O
of	O	O
CGG	O	O
triplet	O	O
repeats	O	O
located	O	O
in	O	O
the	O	O
5	O	O
-	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
fragile	B-Disease	OMIM:300624
X	I-Disease	OMIM:300624
mental	I-Disease	OMIM:300624
retardation	I-Disease	OMIM:300624
-	O	O
1	O	O
(	O	O
FMR1	O	O
)	O	O
gene	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
fragile	B-Disease	D005600
X	I-Disease	D005600
syndrome	I-Disease	D005600
,	O	O
the	O	O
expanded	O	O
CGG	O	O
triplet	O	O
repeats	O	O
are	O	O
hypermethylated	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
FMR1	O	O
gene	O	O
is	O	O
repressed	O	O
,	O	O
which	O	O
leads	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
FMR1	O	O
protein	O	O
(	O	O
FMRP	O	O
)	O	O
and	O	O
subsequent	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
.	O	O

FMRP	O	O
is	O	O
an	O	O
RNA	O	O
-	O	O
binding	O	O
protein	O	O
that	O	O
shuttles	O	O
between	O	O
the	O	O
nucleus	O	O
and	O	O
cytoplasm	O	O
.	O	O

This	O	O
protein	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
protein	O	O
translation	O	O
as	O	O
it	O	O
is	O	O
found	O	O
associated	O	O
with	O	O
polyribosomes	O	O
and	O	O
the	O	O
rough	O	O
endoplasmic	O	O
reticulum	O	O
.	O	O

We	O	O
discuss	O	O
here	O	O
the	O	O
recent	O	O
progress	O	O
made	O	O
towards	O	O
understanding	O	O
the	O	O
molecular	O	O
mechanism	O	O
of	O	O
CGG	O	O
repeat	O	O
expansion	O	O
and	O	O
physiological	O	O
function	O	O
(	O	O
s	O	O
)	O	O
of	O	O
FMRP	O	O
.	O	O

These	O	O
studies	O	O
will	O	O
not	O	O
only	O	O
help	O	O
to	O	O
illuminate	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
the	O	O
general	O	O
class	O	O
of	O	O
human	O	O
diseases	O	O
with	O	O
trinucleotide	O	O
repeat	O	O
expansion	O	O
but	O	O
also	O	O
provide	O	O
an	O	O
avenue	O	O
to	O	O
understand	O	O
aspects	O	O
of	O	O
human	O	O
cognition	O	O
and	O	O
intelligence	O	O
.	O	O

.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Papua	O	O
New	O	O
Guinea	O	O
.	O	O

The	O	O
description	O	O
of	O	O
13	O	O
new	O	O
variants	O	O
.	O	O

A	O	O
total	O	O
of	O	O
362	O	O
males	O	O
from	O	O
various	O	O
regions	O	O
of	O	O
Papua	O	O
New	O	O
Guinea	O	O
were	O	O
screened	O	O
for	O	O
red	O	O
cell	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
activity	O	O
.	O	O

Twenty	O	O
-	O	O
six	O	O
G6PD	B-Disease	D005955
deficient	I-Disease	D005955
individuals	O	O
were	O	O
identified	O	O
.	O	O

Biochemical	O	O
characterization	O	O
of	O	O
G6PD	O	O
purified	O	O
from	O	O
these	O	O
subjects	O	O
has	O	O
revealed	O	O
13	O	O
new	O	O
variants	O	O
and	O	O
several	O	O
copies	O	O
of	O	O
previously	O	O
described	O	O
forms	O	O
of	O	O
G6PD	O	O
.	O	O

This	O	O
study	O	O
illustrates	O	O
the	O	O
extreme	O	O
heterogeneity	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
among	O	O
the	O	O
people	O	O
of	O	O
Papua	O	O
New	O	O
Guinea	O	O
.	O	O

.	O	O

Regional	O	O
mapping	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
and	O	O
the	O	O
phenylketonuria	B-Disease	D010661
locus	O	O
in	O	O
the	O	O
human	O	O
genome	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
of	O	O
amino	O	O
acid	O	O
metabolism	O	O
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
the	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
enzyme	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
;	O	O
phenylalanine	O	O
4	O	O
-	O	O
monooxygenase	O	O
,	O	O
EC	O	O
1	O	O
.	O	O

14	O	O
.	O	O

16	O	O
.	O	O

1	O	O
)	O	O
.	O	O

A	O	O
cDNA	O	O
clone	O	O
for	O	O
human	O	O
PAH	O	O
has	O	O
previously	O	O
been	O	O
used	O	O
to	O	O
assign	O	O
the	O	O
corresponding	O	O
gene	O	O
to	O	O
human	O	O
chromosome	O	O
12	O	O
.	O	O

To	O	O
define	O	O
the	O	O
regional	O	O
map	O	O
position	O	O
of	O	O
the	O	O
disease	O	O
locus	O	O
and	O	O
the	O	O
PAH	O	O
gene	O	O
on	O	O
human	O	O
chromosome	O	O
12	O	O
,	O	O
DNA	O	O
was	O	O
isolated	O	O
from	O	O
human	O	O
-	O	O
hamster	O	O
somatic	O	O
cell	O	O
hybrids	O	O
with	O	O
various	O	O
deletions	O	O
of	O	O
human	O	O
chromosome	O	O
12	O	O
and	O	O
was	O	O
analyzed	O	O
by	O	O
Southern	O	O
blot	O	O
analysis	O	O
using	O	O
the	O	O
human	O	O
cDNA	O	O
PAH	O	O
clone	O	O
as	O	O
a	O	O
hybridization	O	O
probe	O	O
.	O	O

From	O	O
these	O	O
results	O	O
,	O	O
together	O	O
with	O	O
detailed	O	O
biochemical	O	O
and	O	O
cytogenetic	O	O
characterization	O	O
of	O	O
the	O	O
hybrid	O	O
cells	O	O
,	O	O
the	O	O
region	O	O
on	O	O
chromosome	O	O
12	O	O
containing	O	O
the	O	O
human	O	O
PAH	O	O
gene	O	O
has	O	O
been	O	O
defined	O	O
as	O	O
12q14	O	O
.	O	O

3	O	O
-	O	O
-	O	O
-	O	O
-	O	O
qter	O	O
3	O	O
-	O	O
-	O	O
-	O	O
-	O	O
qter	O	O
.	O	O

The	O	O
PAH	O	O
map	O	O
position	O	O
on	O	O
chromosome	O	O
12	O	O
was	O	O
further	O	O
localized	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
of	O	O
125I	O	O
-	O	O
labeled	O	O
human	O	O
PAH	O	O
cDNA	O	O
to	O	O
chromosomes	O	O
prepared	O	O
from	O	O
a	O	O
human	O	O
lymphoblastoid	O	O
cell	O	O
line	O	O
.	O	O

Results	O	O
of	O	O
these	O	O
experiments	O	O
demonstrated	O	O
that	O	O
the	O	O
region	O	O
on	O	O
chromosome	O	O
12	O	O
containing	O	O
the	O	O
PAH	O	O
gene	O	O
and	O	O
the	O	O
PKU	B-Disease	D010661
locus	O	O
in	O	O
man	O	O
is	O	O
12q22	O	O
-	O	O
-	O	O
-	O	O
-	O	O
12q24	O	O
.	O	O

1	O	O
.	O	O

These	O	O
results	O	O
not	O	O
only	O	O
provide	O	O
a	O	O
regionalized	O	O
map	O	O
position	O	O
for	O	O
a	O	O
major	O	O
human	O	O
disease	O	O
locus	O	O
but	O	O
also	O	O
can	O	O
serve	O	O
as	O	O
a	O	O
reference	O	O
point	O	O
for	O	O
linkage	O	O
analysis	O	O
with	O	O
other	O	O
DNA	O	O
markers	O	O
on	O	O
human	O	O
chromosome	O	O
12	O	O
Total	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
of	I-Disease	OMIM:143470
plasma	I-Disease	OMIM:143470
cholesteryl	I-Disease	OMIM:143470
ester	I-Disease	OMIM:143470
transfer	I-Disease	OMIM:143470
protein	I-Disease	OMIM:143470
in	O	O
subjects	O	O
homozygous	O	O
and	O	O
heterozygous	O	O
for	O	O
the	O	O
intron	O	O
14	O	O
splicing	O	O
defect	O	O
.	O	O

The	O	O
molecular	O	O
basis	O	O
of	O	O
cholesteryl	B-Disease	OMIM:143470
ester	I-Disease	OMIM:143470
transfer	I-Disease	OMIM:143470
protein	I-Disease	OMIM:143470
(	I-Disease	OMIM:143470
CETP	I-Disease	OMIM:143470
)	I-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
was	O	O
investigated	O	O
in	O	O
4	O	O
unrelated	O	O
CETP	B-Disease	OMIM:143470
-	I-Disease	OMIM:143470
deficient	I-Disease	OMIM:143470
families	O	O
.	O	O

The	O	O
high	O	O
density	O	O
lipoprotein	O	O
-	O	O
cholesterol	O	O
levels	O	O
of	O	O
the	O	O
probands	O	O
exceeded	O	O
150	O	O
mg	O	O
/	O	O
dl	O	O
.	O	O

The	O	O
plasma	O	O
of	O	O
the	O	O
probands	O	O
was	O	O
totally	O	O
deficient	O	O
in	O	O
CETP	O	O
activity	O	O
and	O	O
mass	O	O
.	O	O

The	O	O
genomic	O	O
DNA	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
amplified	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
using	O	O
two	O	O
oligonucleotide	O	O
primers	O	O
located	O	O
in	O	O
the	O	O
intron	O	O
12	O	O
and	O	O
14	O	O
of	O	O
the	O	O
CETP	O	O
gene	O	O
,	O	O
and	O	O
the	O	O
amplified	O	O
products	O	O
were	O	O
directly	O	O
sequenced	O	O
.	O	O

Two	O	O
patients	O	O
were	O	O
homozygous	O	O
for	O	O
a	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
change	O	O
at	O	O
the	O	O
5	O	O
-	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
the	O	O
intron	O	O
14	O	O
.	O	O

The	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
change	O	O
would	O	O
cause	O	O
impaired	O	O
splicing	O	O
of	O	O
pre	O	O
-	O	O
messenger	O	O
RNA	O	O
.	O	O

The	O	O
other	O	O
two	O	O
probands	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
mutation	O	O
,	O	O
but	O	O
totally	O	O
lacked	O	O
CETP	O	O
.	O	O

Their	O	O
lipoprotein	O	O
patterns	O	O
were	O	O
also	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
the	O	O
two	O	O
homozygotes	O	O
.	O	O

Thus	O	O
,	O	O
other	O	O
genetic	B-Disease	D030342
defects	I-Disease	D030342
or	O	O
metabolic	O	O
factors	O	O
influencing	O	O
CETP	O	O
expression	O	O
are	O	O
implicated	O	O
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
mutation	O	O
may	O	O
be	O	O
common	O	O
in	O	O
human	O	O
plasma	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
.	O	O

Furthermore	O	O
,	O	O
there	O	O
could	O	O
be	O	O
compound	O	O
heterozygotes	O	O
who	O	O
totally	O	O
lack	O	O
plasma	O	O
CETP	O	O
and	O	O
have	O	O
lipoprotein	O	O
profiles	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
homozygotes	O	O
.	O	O

.	O	O

Heterogeneity	O	O
of	O	O
type	B-Disease	D056725
I	I-Disease	D056725
von	I-Disease	D056725
Willebrand	I-Disease	D056725
disease	I-Disease	D056725
:	O	O
evidence	O	O
for	O	O
a	O	O
subgroup	O	O
with	O	O
an	O	O
abnormal	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
.	O	O

Type	B-Disease	D056725
I	I-Disease	D056725
von	I-Disease	D056725
Willebrand	I-Disease	D056725
disease	I-Disease	D056725
(	O	O
vWD	B-Disease	D014842
)	O	O
is	O	O
characterized	O	O
by	O	O
equally	O	O
low	O	O
plasma	O	O
concentrations	O	O
of	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
antigen	O	O
(	O	O
vWF	O	O
Ag	O	O
)	O	O
and	O	O
ristocetin	O	O
cofactor	O	O
(	O	O
RiCof	O	O
)	O	O
and	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
all	O	O
vWF	O	O
multimers	O	O
in	O	O
sodium	O	O
dodecyl	O	O
sulfate	O	O
(	O	O
SDS	O	O
)	O	O
-	O	O
agarose	O	O
gel	O	O
electrophoresis	O	O
.	O	O

For	O	O
17	O	O
patients	O	O
(	O	O
13	O	O
kindreds	O	O
)	O	O
diagnosed	O	O
with	O	O
these	O	O
criteria	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
the	O	O
platelet	O	O
contents	O	O
of	O	O
vWF	O	O
Ag	O	O
and	O	O
RiCof	O	O
and	O	O
the	O	O
changes	O	O
of	O	O
these	O	O
in	O	O
plasma	O	O
after	O	O
DDAVP	O	O
infusion	O	O
.	O	O

Platelet	O	O
vWF	O	O
Ag	O	O
and	O	O
RiCof	O	O
were	O	O
normal	O	O
in	O	O
four	O	O
kindreds	O	O
(	O	O
called	O	O
"	O	O
platelet	O	O
normal	O	O
"	O	O
subgroup	O	O
)	O	O
;	O	O
following	O	O
1	O	O
-	O	O
deamino	O	O
-	O	O
8	O	O
-	O	O
D	O	O
-	O	O
arginine	O	O
vasopressin	O	O
;	O	O
plasma	O	O
vWF	O	O
Ag	O	O
,	O	O
RiCof	O	O
and	O	O
the	O	O
bleeding	O	O
time	O	O
(	O	O
BT	O	O
)	O	O
became	O	O
normal	O	O
.	O	O

In	O	O
six	O	O
kindreds	O	O
,	O	O
platelet	O	O
vWF	O	O
Ag	O	O
and	O	O
RiCof	O	O
were	O	O
equally	O	O
low	O	O
(	O	O
platelet	O	O
low	O	O
)	O	O
;	O	O
after	O	O
DDAVP	O	O
,	O	O
plasma	O	O
vWF	O	O
Ag	O	O
and	O	O
RiCof	O	O
remained	O	O
low	O	O
,	O	O
and	O	O
the	O	O
BT	O	O
was	O	O
prolonged	O	O
.	O	O

In	O	O
three	O	O
additional	O	O
kindreds	O	O
,	O	O
platelets	O	O
contained	O	O
normal	O	O
concentrations	O	O
of	O	O
vWF	O	O
Ag	O	O
,	O	O
but	O	O
RiCof	O	O
was	O	O
very	O	O
low	O	O
(	O	O
platelet	O	O
discordant	O	O
)	O	O
;	O	O
even	O	O
though	O	O
a	O	O
complete	O	O
set	O	O
of	O	O
multimers	O	O
was	O	O
found	O	O
in	O	O
plasma	O	O
and	O	O
platelets	O	O
,	O	O
there	O	O
was	O	O
a	O	O
relatively	O	O
small	O	O
amount	O	O
of	O	O
large	O	O
multimers	O	O
.	O	O

After	O	O
DDAVP	O	O
,	O	O
plasma	O	O
vWF	O	O
Ag	O	O
became	O	O
normal	O	O
,	O	O
but	O	O
RiCof	O	O
remained	O	O
low	O	O
and	O	O
the	O	O
BT	O	O
was	O	O
very	O	O
prolonged	O	O
.	O	O

These	O	O
findings	O	O
demonstrated	O	O
that	O	O
there	O	O
can	O	O
be	O	O
an	O	O
abnormal	O	O
vWF	O	O
(	O	O
RiCof	O	O
less	O	O
than	O	O
vWF	O	O
Ag	O	O
)	O	O
even	O	O
in	O	O
type	B-Disease	D056725
I	I-Disease	D056725
vWD	I-Disease	D056725
,	O	O
coexisting	O	O
with	O	O
a	O	O
complete	O	O
set	O	O
of	O	O
vWF	O	O
multimers	O	O
(	O	O
platelet	O	O
discordant	O	O
)	O	O
;	O	O
that	O	O
the	O	O
abnormal	O	O
vWF	O	O
can	O	O
be	O	O
shown	O	O
more	O	O
clearly	O	O
in	O	O
platelets	O	O
than	O	O
in	O	O
plasma	O	O
or	O	O
else	O	O
in	O	O
plasma	O	O
after	O	O
DDAVP	O	O
infusion	O	O
;	O	O
and	O	O
that	O	O
DDAVP	O	O
normalizes	O	O
the	O	O
BT	O	O
only	O	O
in	O	O
those	O	O
patients	O	O
with	O	O
normal	O	O
platelet	O	O
levels	O	O
of	O	O
both	O	O
vWF	O	O
Ag	O	O
and	O	O
RiCof	O	O
(	O	O
platelet	O	O
normal	O	O
)	O	O
.	O	O

.	O	O

Characterization	O	O
of	O	O
a	O	O
YAC	O	O
containing	O	O
part	O	O
or	O	O
all	O	O
of	O	O
the	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
locus	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
from	O	O
pulsed	O	O
-	O	O
field	O	O
gel	O	O
electrophoresis	O	O
(	O	O
PFGE	O	O
)	O	O
that	O	O
the	O	O
monoamine	O	O
oxidase	O	O
genes	O	O
A	O	O
and	O	O
B	O	O
(	O	O
MAOA	O	O
&	O	O
MAOB	O	O
)	O	O
and	O	O
DXS7	O	O
loci	O	O
are	O	O
physically	O	O
very	O	O
close	O	O
.	O	O

We	O	O
have	O	O
therefore	O	O
extended	O	O
studies	O	O
on	O	O
their	O	O
relationship	O	O
through	O	O
the	O	O
characterisation	O	O
of	O	O
a	O	O
650	O	O
kb	O	O
YAC	O	O
isolated	O	O
using	O	O
L1	O	O
.	O	O

28	O	O
(	O	O
recognising	O	O
the	O	O
DXS7	O	O
locus	O	O
)	O	O
as	O	O
a	O	O
probe	O	O
.	O	O

Restriction	O	O
mapping	O	O
of	O	O
the	O	O
YAC	O	O
indicates	O	O
that	O	O
it	O	O
contains	O	O
both	O	O
MAOA	O	O
and	O	O
MAOB	O	O
genes	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
DXS7	O	O
locus	O	O
.	O	O

The	O	O
map	O	O
derived	O	O
from	O	O
the	O	O
YL1	O	O
.	O	O

28	O	O
-	O	O
YAC	O	O
is	O	O
compatible	O	O
both	O	O
with	O	O
the	O	O
map	O	O
from	O	O
an	O	O
independently	O	O
derived	O	O
YAC	O	O
carrying	O	O
MAOA	O	O
and	O	O
B	O	O
genes	O	O
and	O	O
with	O	O
the	O	O
long	O	O
range	O	O
genomic	O	O
map	O	O
for	O	O
the	O	O
region	O	O
.	O	O

A	O	O
series	O	O
of	O	O
subclones	O	O
prepared	O	O
from	O	O
a	O	O
phage	O	O
library	O	O
(	O	O
lambda	O	O
DASH	O	O
II	O	O
)	O	O
of	O	O
the	O	O
YAC	O	O
have	O	O
been	O	O
characterised	O	O
and	O	O
have	O	O
been	O	O
employed	O	O
to	O	O
determine	O	O
the	O	O
end	O	O
point	O	O
of	O	O
the	O	O
deletion	O	O
of	O	O
a	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
NDP	B-Disease	C537849
)	O	O
patient	O	O
who	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
lack	O	O
both	O	O
DXS7	O	O
and	O	O
MAO	O	O
coding	O	O
sequences	O	O
.	O	O

The	O	O
pattern	O	O
of	O	O
retention	O	O
of	O	O
subclones	O	O
in	O	O
the	O	O
deletion	O	O
patient	O	O
place	O	O
the	O	O
end	O	O
point	O	O
of	O	O
the	O	O
deletion	O	O
within	O	O
30	O	O
-	O	O
130	O	O
kb	O	O
of	O	O
the	O	O
proximal	O	O
end	O	O
of	O	O
the	O	O
YAC	O	O
.	O	O

By	O	O
combining	O	O
the	O	O
data	O	O
with	O	O
established	O	O
recombination	O	O
analysis	O	O
,	O	O
we	O	O
provide	O	O
evidence	O	O
that	O	O
all	O	O
or	O	O
part	O	O
of	O	O
the	O	O
NDP	B-Disease	C537849
lies	O	O
in	O	O
the	O	O
interval	O	O
of	O	O
approximately	O	O
250kb	O	O
within	O	O
the	O	O
YAC	O	O
.	O	O

Identification	O	O
of	O	O
mutations	O	O
in	O	O
Danish	O	O
choroideremia	B-Disease	D015794
families	O	O
.	O	O

We	O	O
have	O	O
searched	O	O
for	O	O
mutations	O	O
in	O	O
the	O	O
choroideremia	B-Disease	D015794
gene	O	O
(	O	O
CHM	B-Disease	D015794
)	O	O
in	O	O
patients	O	O
from	O	O
12	O	O
Danish	O	O
families	O	O
in	O	O
which	O	O
CHM	B-Disease	D015794
is	O	O
segregating	O	O
.	O	O

Employing	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
,	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
,	O	O
and	O	O
direct	O	O
DNA	O	O
sequencing	O	O
,	O	O
different	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
6	O	O
patients	O	O
.	O	O

All	O	O
the	O	O
mutations	O	O
will	O	O
interfere	O	O
with	O	O
the	O	O
correct	O	O
translation	O	O
of	O	O
the	O	O
mRNA	O	O
predicting	O	O
a	O	O
truncated	O	O
protein	O	O
or	O	O
no	O	O
gene	O	O
product	O	O
at	O	O
all	O	O
.	O	O

.	O	O

G130V	O	O
,	O	O
a	O	O
common	O	O
FRDA	B-Disease	D005621
point	O	O
mutation	O	O
,	O	O
appears	O	O
to	O	O
have	O	O
arisen	O	O
from	O	O
a	O	O
common	O	O
founder	O	O
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
inherited	B-Disease	D013132
ataxia	I-Disease	D013132
.	O	O

About	O	O
98	O	O
%	O	O
of	O	O
mutant	O	O
alleles	O	O
have	O	O
an	O	O
expansion	O	O
of	O	O
a	O	O
GAA	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
intron	O	O
1	O	O
of	O	O
the	O	O
affected	O	O
gene	O	O
,	O	O
FRDA	B-Disease	D005621
.	O	O

The	O	O
other	O	O
2	O	O
%	O	O
are	O	O
point	O	O
mutations	O	O
.	O	O

Of	O	O
the	O	O
17	O	O
point	O	O
mutations	O	O
so	O	O
far	O	O
described	O	O
,	O	O
three	O	O
appear	O	O
to	O	O
be	O	O
more	O	O
common	O	O
.	O	O

One	O	O
of	O	O
these	O	O
is	O	O
the	O	O
G130V	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
FRDA	B-Disease	D005621
.	O	O

G130V	O	O
,	O	O
when	O	O
present	O	O
with	O	O
an	O	O
expanded	O	O
GAA	O	O
repeat	O	O
on	O	O
the	O	O
other	O	O
allele	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
atypical	O	O
FRDA	B-Disease	D005621
phenotype	O	O
.	O	O

Haplotype	O	O
analysis	O	O
was	O	O
undertaken	O	O
on	O	O
the	O	O
four	O	O
families	O	O
who	O	O
have	O	O
been	O	O
described	O	O
with	O	O
this	O	O
mutation	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
a	O	O
common	O	O
founder	O	O
for	O	O
this	O	O
mutation	O	O
.	O	O

Although	O	O
marked	O	O
differences	O	O
in	O	O
extragenic	O	O
marker	O	O
haplotypes	O	O
were	O	O
seen	O	O
in	O	O
one	O	O
family	O	O
,	O	O
similar	O	O
intragenic	O	O
haplotyping	O	O
suggests	O	O
the	O	O
same	O	O
mutation	O	O
founder	O	O
for	O	O
this	O	O
family	O	O
with	O	O
the	O	O
differences	O	O
explicable	O	O
by	O	O
two	O	O
recombination	O	O
events	O	O
.	O	O

.	O	O

Frequency	O	O
of	O	O
exon	O	O
15	O	O
missense	O	O
mutation	O	O
(	O	O
442D	O	O
:	O	O
G	O	O
)	O	O
in	O	O
cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
gene	O	O
in	O	O
hyperalphalipoproteinemic	B-Disease	OMIM:143470
Japanese	O	O
subjects	O	O
.	O	O

Cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
(	O	O
CETP	O	O
)	O	O
transfers	O	O
cholesteryl	O	O
ester	O	O
from	O	O
high	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
to	O	O
apo	O	O
B	O	O
-	O	O
containing	O	O
lipoproteins	O	O
.	O	O

The	O	O
hyperalphalipoproteinemia	B-Disease	OMIM:143470
caused	O	O
by	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
is	O	O
fairly	O	O
common	O	O
in	O	O
Japan	O	O
and	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
mutations	O	O
in	O	O
the	O	O
CETP	O	O
gene	O	O
is	O	O
the	O	O
splicing	O	O
defect	O	O
of	O	O
the	O	O
intron	O	O
14	O	O
,	O	O
the	O	O
allelic	O	O
frequency	O	O
of	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
0	O	O
.	O	O

0049	O	O
in	O	O
the	O	O
Japanese	O	O
general	O	O
population	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
have	O	O
reported	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
15	O	O
of	O	O
the	O	O
CETP	O	O
gene	O	O
(	O	O
442D	O	O
G	O	O
)	O	O
,	O	O
showing	O	O
a	O	O
dominant	O	O
effect	O	O
on	O	O
the	O	O
CETP	O	O
activity	O	O
and	O	O
HDL	O	O
-	O	O
cholesterol	O	O
level	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
frequency	O	O
of	O	O
this	O	O
new	O	O
mutation	O	O
in	O	O
Japanese	O	O
hyperalphalipoproteinemic	B-Disease	OMIM:143470
(	O	O
HDL	O	O
-	O	O
cholesterol	O	O
>	O	O
or	O	O
=	O	O
100	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
subjects	O	O
.	O	O

A	O	O
rapid	O	O
and	O	O
easy	O	O
screening	O	O
method	O	O
for	O	O
this	O	O
new	O	O
mutation	O	O
was	O	O
developed	O	O
using	O	O
a	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
-	O	O
mediated	O	O
site	O	O
-	O	O
directed	O	O
mutagenesis	O	O
.	O	O

Among	O	O
117	O	O
Japanese	O	O
hyperalphalipoproteinemic	B-Disease	OMIM:143470
subjects	O	O
(	O	O
HDL	O	O
-	O	O
cholesterol	O	O
;	O	O
116	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
16	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
S	O	O
.	O	O

D	O	O
.	O	O

)	O	O
without	O	O
the	O	O
intron	O	O
14	O	O
splice	O	O
defect	O	O
,	O	O
three	O	O
homozygotes	O	O
(	O	O
2	O	O
.	O	O

5	O	O
%	O	O
)	O	O
and	O	O
34	O	O
heterozygotes	O	O
(	O	O
29	O	O
.	O	O

1	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
442D	O	O
G	O	O
mutation	O	O
.	O	O

The	O	O
relative	O	O
allelic	O	O
frequency	O	O
of	O	O
this	O	O
mutation	O	O
was	O	O
calculated	O	O
to	O	O
be	O	O
0	O	O
.	O	O

17	O	O
.	O	O

One	O	O
of	O	O
the	O	O
homozygotes	O	O
for	O	O
the	O	O
442D	O	O
G	O	O
mutation	O	O
was	O	O
the	O	O
patient	O	O
previously	O	O
described	O	O
by	O	O
us	O	O
as	O	O
having	O	O
hyperalphalipoproteinemia	B-Disease	OMIM:143470
with	O	O
corneal	B-Disease	D003318
opacity	I-Disease	D003318
and	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
.	O	O

This	O	O
was	O	O
the	O	O
first	O	O
reported	O	O
subject	O	O
homozygous	O	O
for	O	O
the	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
who	O	O
also	O	O
demonstrated	O	O
atherosclerotic	B-Disease	D050197
symptoms	I-Disease	D050197
.	O	O

In	O	O
homozygous	O	O
subjects	O	O
,	O	O
CETP	O	O
activity	O	O
ranged	O	O
from	O	O
37	O	O
%	O	O
to	O	O
62	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
value	O	O
,	O	O
which	O	O
was	O	O
consistent	O	O
with	O	O
the	O	O
results	O	O
obtained	O	O
from	O	O
the	O	O
transient	O	O
expression	O	O
experiment	O	O
previously	O	O
reported	O	O
;	O	O
however	O	O
,	O	O
the	O	O
specific	O	O
activity	O	O
of	O	O
CETP	O	O
was	O	O
not	O	O
as	O	O
low	O	O
as	O	O
expected	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Fibroblast	O	O
growth	O	O
factor	O	O
homologous	O	O
factor	O	O
2	O	O
(	O	O
FHF2	O	O
)	O	O
:	O	O
gene	O	O
structure	O	O
,	O	O
expression	O	O
and	O	O
mapping	O	O
to	O	O
the	O	O
Borjeson	B-Disease	C536575
-	I-Disease	C536575
Forssman	I-Disease	C536575
-	I-Disease	C536575
Lehmann	I-Disease	C536575
syndrome	I-Disease	C536575
region	O	O
in	O	O
Xq26	O	O
delineated	O	O
by	O	O
a	O	O
duplication	O	O
breakpoint	O	O
in	O	O
a	O	O
BFLS	B-Disease	C536575
-	O	O
like	O	O
patient	O	O
.	O	O

Borjeson	B-Disease	C536575
-	I-Disease	C536575
Forssman	I-Disease	C536575
-	I-Disease	C536575
Lehmann	I-Disease	C536575
syndrome	I-Disease	C536575
(	O	O
BFLS	B-Disease	C536575
)	O	O
is	O	O
a	O	O
syndromal	O	O
X	B-Disease	D038901
-	I-Disease	D038901
linked	I-Disease	D038901
mental	I-Disease	D038901
retardation	I-Disease	D038901
,	O	O
which	O	O
maps	O	O
by	O	O
linkage	O	O
to	O	O
the	O	O
q26	O	O
region	O	O
of	O	O
the	O	O
human	O	O
X	O	O
chromosome	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
male	O	O
patient	O	O
with	O	O
BFLS	B-Disease	C536575
-	O	O
like	O	O
features	O	O
and	O	O
a	O	O
duplication	O	O
,	O	O
46	O	O
,	O	O
Y	O	O
,	O	O
dup	O	O
(	O	O
X	O	O
)	O	O
(	O	O
q26q28	O	O
)	O	O
,	O	O
inherited	O	O
from	O	O
his	O	O
phenotypically	O	O
normal	O	O
mother	O	O
.	O	O

Fluorescence	O	O
in	O	O
situ	O	O
hybridisation	O	O
using	O	O
yeast	O	O
artificial	O	O
chromosome	O	O
clones	O	O
from	O	O
Xq26	O	O
localised	O	O
the	O	O
duplication	O	O
breakpoint	O	O
to	O	O
an	O	O
approximately	O	O
400	O	O
-	O	O
kb	O	O
interval	O	O
in	O	O
the	O	O
Xq26	O	O
.	O	O

3	O	O
region	O	O
between	O	O
DXS155	O	O
and	O	O
DXS294	O	O
/	O	O
DXS730	O	O
.	O	O

Database	O	O
searches	O	O
and	O	O
analysis	O	O
of	O	O
available	O	O
genomic	O	O
DNA	O	O
sequence	O	O
from	O	O
the	O	O
region	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
fibroblast	O	O
growth	O	O
factor	O	O
homologous	O	O
factor	O	O
gene	O	O
,	O	O
FHF2	O	O
,	O	O
within	O	O
the	O	O
duplication	O	O
breakpoint	O	O
interval	O	O
.	O	O

The	O	O
gene	O	O
structure	O	O
of	O	O
FHF2	O	O
was	O	O
determined	O	O
and	O	O
two	O	O
new	O	O
exons	O	O
were	O	O
identified	O	O
,	O	O
including	O	O
a	O	O
new	O	O
5	O	O
end	O	O
exon	O	O
,	O	O
1B	O	O
.	O	O

FHF2	O	O
is	O	O
a	O	O
large	O	O
gene	O	O
extending	O	O
over	O	O
approximately	O	O
200	O	O
kb	O	O
in	O	O
Xq26	O	O
.	O	O

3	O	O
and	O	O
is	O	O
composed	O	O
of	O	O
at	O	O
least	O	O
seven	O	O
exons	O	O
.	O	O

It	O	O
shows	O	O
tissue	O	O
-	O	O
specific	O	O
alternative	O	O
splicing	O	O
and	O	O
alternative	O	O
transcription	O	O
starts	O	O
.	O	O

Northern	O	O
blot	O	O
hybridisation	O	O
showed	O	O
highest	O	O
expression	O	O
in	O	O
brain	O	O
and	O	O
skeletal	O	O
muscle	O	O
.	O	O

The	O	O
FHF2	O	O
gene	O	O
localisation	O	O
and	O	O
tissue	O	O
-	O	O
specific	O	O
expression	O	O
pattern	O	O
suggest	O	O
it	O	O
to	O	O
be	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
familial	O	O
cases	O	O
of	O	O
the	O	O
BFLS	B-Disease	C536575
syndrome	O	O
and	O	O
other	O	O
syndromal	O	O
and	O	O
non	O	O
-	O	O
specific	O	O
forms	O	O
of	O	O
X	B-Disease	D038901
-	I-Disease	D038901
linked	I-Disease	D038901
mental	I-Disease	D038901
retardation	I-Disease	D038901
mapping	O	O
to	O	O
the	O	O
region	O	O
.	O	O

Illegitimate	O	O
transcription	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
in	O	O
lymphocytes	O	O
for	O	O
identification	O	O
of	O	O
mutations	O	O
in	O	O
phenylketonuria	B-Disease	D010661
.	O	O

Taking	O	O
advantage	O	O
of	O	O
the	O	O
illegitimate	O	O
transcription	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
gene	O	O
,	O	O
we	O	O
have	O	O
been	O	O
able	O	O
to	O	O
analyse	O	O
the	O	O
PAH	O	O
cDNA	O	O
sequence	O	O
of	O	O
hyperphenylalaninemic	B-Disease	D010661
children	O	O
in	O	O
circulating	O	O
lymphocytes	O	O
.	O	O

Using	O	O
this	O	O
approach	O	O
,	O	O
we	O	O
have	O	O
also	O	O
identified	O	O
3	O	O
novel	O	O
mutations	O	O
in	O	O
cDNA	O	O
from	O	O
liver	O	O
and	O	O
lymphocytes	O	O
of	O	O
two	O	O
patients	O	O
.	O	O

One	O	O
mutation	O	O
,	O	O
detected	O	O
by	O	O
the	O	O
abnormal	O	O
pattern	O	O
of	O	O
migration	O	O
of	O	O
an	O	O
amplified	O	O
fragment	O	O
,	O	O
is	O	O
a	O	O
C	O	O
to	O	O
T	O	O
transition	O	O
in	O	O
the	O	O
splice	O	O
acceptor	O	O
site	O	O
of	O	O
intron	O	O
10	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
the	O	O
skipping	O	O
of	O	O
exon	O	O
11	O	O
with	O	O
the	O	O
premature	O	O
termination	O	O
of	O	O
RNA	O	O
translation	O	O
downstream	O	O
from	O	O
exon	O	O
12	O	O
(	O	O
-	O	O
3	O	O
IVS10	O	O
)	O	O
.	O	O

The	O	O
other	O	O
two	O	O
mutations	O	O
are	O	O
missense	O	O
mutations	O	O
in	O	O
exons	O	O
10	O	O
and	O	O
11	O	O
(	O	O
respectively	O	O
,	O	O
L333F	O	O
and	O	O
E390G	O	O
)	O	O
.	O	O

The	O	O
present	O	O
study	O	O
supports	O	O
the	O	O
view	O	O
that	O	O
circulating	O	O
lymphocytes	O	O
give	O	O
easy	O	O
access	O	O
to	O	O
PAH	O	O
gene	O	O
transcripts	O	O
whose	O	O
nucleotide	O	O
sequence	O	O
is	O	O
identical	O	O
to	O	O
that	O	O
reported	O	O
in	O	O
liver	O	O
and	O	O
therefore	O	O
represent	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
molecular	O	O
genetic	O	O
studies	O	O
in	O	O
phenylketonuria	B-Disease	D010661
.	O	O

.	O	O

Function	O	O
of	O	O
an	O	O
axonal	O	O
chemoattractant	O	O
modulated	O	O
by	O	O
metalloprotease	O	O
activity	O	O
.	O	O

The	O	O
axonal	O	O
chemoattractant	O	O
netrin	O	O
-	O	O
1	O	O
guides	O	O
spinal	O	O
commissural	O	O
axons	O	O
by	O	O
activating	O	O
its	O	O
receptor	O	O
DCC	O	O
(	O	O
Deleted	O	O
in	O	O
Colorectal	B-Disease	D015179
Cancer	I-Disease	D015179
)	O	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
chemical	O	O
inhibitors	O	O
of	O	O
metalloproteases	O	O
potentiate	O	O
netrin	O	O
-	O	O
mediated	O	O
axon	O	O
outgrowth	O	O
in	O	O
vitro	O	O
.	O	O

We	O	O
have	O	O
also	O	O
found	O	O
that	O	O
DCC	O	O
is	O	O
a	O	O
substrate	O	O
for	O	O
metalloprotease	O	O
-	O	O
dependent	O	O
ectodomain	O	O
shedding	O	O
,	O	O
and	O	O
that	O	O
the	O	O
inhibitors	O	O
block	O	O
proteolytic	O	O
processing	O	O
of	O	O
DCC	O	O
and	O	O
cause	O	O
an	O	O
increase	O	O
in	O	O
DCC	O	O
protein	O	O
levels	O	O
on	O	O
axons	O	O
within	O	O
spinal	O	O
cord	O	O
explants	O	O
.	O	O

Thus	O	O
,	O	O
potentiation	O	O
of	O	O
netrin	O	O
activity	O	O
by	O	O
inhibitors	O	O
may	O	O
result	O	O
from	O	O
stabilization	O	O
of	O	O
DCC	O	O
on	O	O
the	O	O
axons	O	O
,	O	O
and	O	O
proteolytic	O	O
activity	O	O
may	O	O
regulate	O	O
axon	O	O
migration	O	O
by	O	O
controlling	O	O
the	O	O
number	O	O
of	O	O
functional	O	O
extracellular	O	O
axon	O	O
guidance	O	O
receptors	O	O
.	O	O

.	O	O

Choroideremia	B-Disease	D015794
:	O	O
close	O	O
linkage	O	O
to	O	O
DXYS1	O	O
and	O	O
DXYS12	O	O
demonstrated	O	O
by	O	O
segregation	O	O
analysis	O	O
and	O	O
historical	O	O
-	O	O
genealogical	O	O
evidence	O	O
.	O	O

Linkage	O	O
studies	O	O
using	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
were	O	O
conducted	O	O
in	O	O
the	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disorder	I-Disease	D040181
,	O	O
choroideremia	B-Disease	D015794
,	O	O
designated	O	O
TCD	B-Disease	C531652
for	O	O
Progressive	B-Disease	C531652
Tapeto	I-Disease	C531652
-	I-Disease	C531652
Choroidal	I-Disease	C531652
Dystrophy	I-Disease	C531652
.	O	O

Previously	O	O
demonstrated	O	O
close	O	O
linkage	O	O
with	O	O
locus	O	O
DXYS1	O	O
was	O	O
confirmed	O	O
(	O	O
lod	O	O
11	O	O
.	O	O

44	O	O
at	O	O
0	O	O
recombination	O	O
distance	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
locus	O	O
DXYS12	O	O
was	O	O
found	O	O
to	O	O
be	O	O
closely	O	O
linked	O	O
with	O	O
TCD	B-Disease	C531652
(	O	O
lod	O	O
3	O	O
.	O	O

31	O	O
at	O	O
0	O	O
recombination	O	O
distance	O	O
)	O	O
.	O	O

The	O	O
disease	O	O
mainly	O	O
occurs	O	O
in	O	O
three	O	O
large	O	O
kindreds	O	O
in	O	O
remote	O	O
Northern	O	O
Finland	O	O
.	O	O

While	O	O
formal	O	O
genealogical	O	O
proof	O	O
is	O	O
lacking	O	O
,	O	O
all	O	O
presently	O	O
living	O	O
(	O	O
more	O	O
than	O	O
80	O	O
affected	O	O
males	O	O
and	O	O
120	O	O
carrier	O	O
females	O	O
)	O	O
probably	O	O
originate	O	O
from	O	O
a	O	O
common	O	O
founder	O	O
couple	O	O
born	O	O
in	O	O
1644	O	O
and	O	O
1646	O	O
,	O	O
twelve	O	O
generations	O	O
ago	O	O
.	O	O

All	O	O
36	O	O
patients	O	O
and	O	O
48	O	O
carriers	O	O
tested	O	O
from	O	O
the	O	O
three	O	O
kindreds	O	O
had	O	O
the	O	O
same	O	O
haplotype	O	O
(	O	O
TCD	B-Disease	C531652
/	O	O
DXYS1	O	O
,	O	O
11kb	O	O
/	O	O
DXYS12	O	O
,	O	O
1	O	O
.	O	O

6kb	O	O
)	O	O
.	O	O

Given	O	O
that	O	O
at	O	O
least	O	O
105	O	O
female	O	O
meioses	O	O
transmitting	O	O
TCD	B-Disease	C531652
have	O	O
occurred	O	O
since	O	O
1650	O	O
in	O	O
these	O	O
kindreds	O	O
,	O	O
extremely	O	O
close	O	O
linkage	O	O
between	O	O
TCD	B-Disease	C531652
,	O	O
DXYS1	O	O
and	O	O
DXYS12	O	O
is	O	O
suggested	O	O
.	O	O

The	O	O
above	O	O
haplotype	O	O
is	O	O
a	O	O
very	O	O
useful	O	O
diagnostic	O	O
tool	O	O
in	O	O
these	O	O
TCD	B-Disease	C531652
families	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
our	O	O
historical	O	O
-	O	O
genealogical	O	O
approach	O	O
to	O	O
linkage	O	O
analysis	O	O
may	O	O
be	O	O
possible	O	O
elsewhere	O	O
in	O	O
similar	O	O
isolated	O	O
populations	O	O
Functional	O	O
consequences	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
early	O	O
growth	O	O
response	O	O
2	O	O
gene	O	O
(	O	O
EGR2	O	O
)	O	O
correlate	O	O
with	O	O
severity	O	O
of	O	O
human	O	O
myelinopathies	B-Disease	D011115
.	O	O

The	O	O
early	O	O
growth	O	O
response	O	O
2	O	O
gene	O	O
(	O	O
EGR2	O	O
)	O	O
is	O	O
a	O	O
Cys2His2zinc	O	O
finger	O	O
transcription	O	O
factor	O	O
which	O	O
is	O	O
thought	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
peripheral	O	O
nervous	O	O
system	O	O
myelination	O	O
.	O	O

This	O	O
idea	O	O
is	O	O
based	O	O
partly	O	O
on	O	O
the	O	O
phenotype	O	O
of	O	O
homozygous	O	O
Krox20	O	O
(	O	O
Egr2	O	O
)	O	O
knockout	O	O
mice	O	O
,	O	O
which	O	O
display	O	O
hypomyelination	B-Disease	D010523
of	I-Disease	D010523
the	I-Disease	D010523
PNS	I-Disease	D010523
and	O	O
a	O	O
block	O	O
of	O	O
Schwann	O	O
cells	O	O
at	O	O
an	O	O
early	O	O
stage	O	O
of	O	O
differentiation	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
human	O	O
EGR2	O	O
gene	O	O
have	O	O
recently	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
inherited	B-Disease	C548028
peripheral	I-Disease	C548028
neuropathies	I-Disease	C548028
Charcot	B-Disease	D002607
-	I-Disease	D002607
Marie	I-Disease	D002607
-	I-Disease	D002607
Tooth	I-Disease	D002607
type	I-Disease	D002607
1	I-Disease	D002607
,	O	O
Dejerine	B-Disease	C538392
-	I-Disease	C538392
Sottas	I-Disease	C538392
syndrome	I-Disease	C538392
and	O	O
congenital	B-Disease	OMIM:605253
hypomyelinating	I-Disease	OMIM:605253
neuropathy	I-Disease	OMIM:605253
.	O	O

Three	O	O
of	O	O
the	O	O
four	O	O
EGR2	O	O
mutations	O	O
are	O	O
dominant	O	O
and	O	O
occur	O	O
within	O	O
the	O	O
zinc	O	O
finger	O	O
DNA	O	O
-	O	O
binding	O	O
domain	O	O
.	O	O

The	O	O
fourth	O	O
mutation	O	O
is	O	O
recessive	O	O
and	O	O
affects	O	O
the	O	O
inhibitory	O	O
domain	O	O
(	O	O
R1	O	O
)	O	O
that	O	O
binds	O	O
the	O	O
NAB	O	O
transcriptional	O	O
co	O	O
-	O	O
repressors	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
DNA	O	O
-	O	O
binding	O	O
assays	O	O
and	O	O
transcriptional	O	O
analysis	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
functional	O	O
consequences	O	O
of	O	O
these	O	O
mutations	O	O
.	O	O

The	O	O
zinc	O	O
finger	O	O
mutations	O	O
affect	O	O
DNA	O	O
binding	O	O
and	O	O
the	O	O
amount	O	O
of	O	O
residual	O	O
binding	O	O
directly	O	O
correlates	O	O
with	O	O
disease	O	O
severity	O	O
.	O	O

The	O	O
R1	O	O
domain	O	O
mutation	O	O
prevents	O	O
interaction	O	O
of	O	O
EGR2	O	O
with	O	O
the	O	O
NAB	O	O
co	O	O
-	O	O
repressors	O	O
and	O	O
thereby	O	O
increases	O	O
transcriptional	O	O
activity	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
insight	O	O
into	O	O
the	O	O
possible	O	O
disease	O	O
mechanisms	O	O
underlying	O	O
EGR2	O	O
mutations	O	O
and	O	O
the	O	O
reason	O	O
for	O	O
varying	O	O
severity	O	O
and	O	O
differences	O	O
in	O	O
inheritance	O	O
patterns	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
human	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
:	O	O
analysis	O	O
of	O	O
platelet	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
mRNA	O	O
.	O	O

von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
(	O	O
vWD	B-Disease	D014842
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
inherited	B-Disease	D025861
bleeding	I-Disease	D025861
disorder	I-Disease	D025861
in	O	O
humans	O	O
,	O	O
can	O	O
result	O	O
from	O	O
either	O	O
a	O	O
quantitative	O	O
or	O	O
a	O	O
qualitative	O	O
defect	O	O
in	O	O
the	O	O
adhesive	O	O
glycoprotein	O	O
,	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
(	O	O
vWF	O	O
)	O	O
.	O	O

Molecular	O	O
studies	O	O
of	O	O
vWD	B-Disease	D014842
have	O	O
been	O	O
limited	O	O
by	O	O
the	O	O
large	O	O
size	O	O
of	O	O
the	O	O
vWF	O	O
gene	O	O
and	O	O
difficulty	O	O
in	O	O
obtaining	O	O
the	O	O
vWF	O	O
mRNA	O	O
from	O	O
patients	O	O
.	O	O

By	O	O
use	O	O
of	O	O
an	O	O
adaptation	O	O
of	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
vWF	O	O
mRNA	O	O
was	O	O
amplified	O	O
and	O	O
sequenced	O	O
from	O	O
peripheral	O	O
blood	O	O
platelets	O	O
.	O	O

A	O	O
silent	O	O
vWF	O	O
allele	O	O
was	O	O
identified	O	O
,	O	O
resulting	O	O
from	O	O
a	O	O
cis	O	O
defect	O	O
in	O	O
vWF	O	O
mRNA	O	O
transcription	O	O
or	O	O
processing	O	O
.	O	O

In	O	O
two	O	O
type	B-Disease	D056728
IIA	I-Disease	D056728
vWD	I-Disease	D056728
patients	O	O
,	O	O
two	O	O
different	O	O
but	O	O
adjacent	O	O
missense	O	O
mutations	O	O
were	O	O
identified	O	O
,	O	O
the	O	O
locations	O	O
of	O	O
which	O	O
may	O	O
identify	O	O
an	O	O
important	O	O
vWF	O	O
functional	O	O
domain	O	O
.	O	O

Expression	O	O
in	O	O
heterologous	O	O
cells	O	O
of	O	O
recombinant	O	O
vWF	O	O
containing	O	O
one	O	O
of	O	O
these	O	O
latter	O	O
mutations	O	O
reproduced	O	O
the	O	O
characteristic	O	O
structural	O	O
abnormality	O	O
seen	O	O
in	O	O
type	B-Disease	D056728
IIA	I-Disease	D056728
vWD	I-Disease	D056728
plasma	O	O
.	O	O

.	O	O

A	O	O
transgene	O	O
insertion	O	O
creating	O	O
a	O	O
heritable	O	O
chromosome	O	O
deletion	O	O
mouse	O	O
model	O	O
of	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
and	I-Disease	D011218
angelman	I-Disease	D011218
syndromes	I-Disease	D011218
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
and	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
(	O	O
AS	B-Disease	D017204
)	O	O
result	O	O
from	O	O
the	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
imprinted	O	O
genes	O	O
in	O	O
human	O	O
chromosome	O	O
15q11	O	O
-	O	O
q13	O	O
.	O	O

The	O	O
central	O	O
part	O	O
of	O	O
mouse	O	O
chromosome	O	O
7	O	O
is	O	O
homologous	O	O
to	O	O
human	O	O
15q11	O	O
-	O	O
q13	O	O
,	O	O
with	O	O
conservation	O	O
of	O	O
both	O	O
gene	O	O
order	O	O
and	O	O
imprinted	O	O
features	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
characterization	O	O
of	O	O
a	O	O
transgene	O	O
insertion	O	O
(	O	O
Epstein	O	O
-	O	O
Barr	O	O
virus	O	O
Latent	O	O
Membrane	O	O
Protein	O	O
2A	O	O
,	O	O
LMP2A	O	O
)	O	O
into	O	O
mouse	O	O
chromosome	O	O
7C	O	O
,	O	O
which	O	O
has	O	O
resulted	O	O
in	O	O
mouse	O	O
models	O	O
for	O	O
PWS	B-Disease	D011218
and	O	O
AS	B-Disease	D017204
dependent	O	O
on	O	O
the	O	O
sex	O	O
of	O	O
the	O	O
transmitting	O	O
parent	O	O
.	O	O

Epigenotype	O	O
(	O	O
allelic	O	O
expression	O	O
and	O	O
DNA	O	O
methylation	O	O
)	O	O
and	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
analyses	O	O
indicate	O	O
that	O	O
the	O	O
transgene	O	O
-	O	O
induced	O	O
mutation	O	O
has	O	O
generated	O	O
a	O	O
complete	O	O
deletion	O	O
of	O	O
the	O	O
PWS	B-Disease	D011218
/	O	O
AS	B-Disease	D017204
-	O	O
homologous	O	O
region	O	O
but	O	O
has	O	O
not	O	O
deleted	O	O
flanking	O	O
loci	O	O
.	O	O

Because	O	O
the	O	O
intact	O	O
chromosome	O	O
7	O	O
,	O	O
opposite	O	O
the	O	O
deleted	O	O
homolog	O	O
,	O	O
maintains	O	O
the	O	O
correct	O	O
imprint	O	O
in	O	O
somatic	O	O
cells	O	O
of	O	O
PWS	B-Disease	D011218
and	O	O
AS	B-Disease	D017204
mice	O	O
and	O	O
establishes	O	O
the	O	O
correct	O	O
imprint	O	O
in	O	O
male	O	O
and	O	O
female	O	O
germ	O	O
cells	O	O
of	O	O
AS	B-Disease	D017204
mice	O	O
,	O	O
homologous	O	O
association	O	O
and	O	O
replication	O	O
asynchrony	O	O
are	O	O
not	O	O
part	O	O
of	O	O
the	O	O
imprinting	O	O
mechanism	O	O
.	O	O

This	O	O
heritable	O	O
-	O	O
deletion	O	O
mouse	O	O
model	O	O
will	O	O
be	O	O
particularly	O	O
useful	O	O
for	O	O
the	O	O
identification	O	O
of	O	O
the	O	O
etiological	O	O
genes	O	O
and	O	O
mechanisms	O	O
,	O	O
phenotypic	O	O
basis	O	O
,	O	O
and	O	O
investigation	O	O
of	O	O
therapeutic	O	O
approaches	O	O
for	O	O
PWS	B-Disease	D011218
.	O	O

.	O	O

Transgenic	O	O
mice	O	O
expressing	O	O
a	O	O
truncated	O	O
form	O	O
of	O	O
the	O	O
high	O	O
mobility	O	O
group	O	O
I	O	O
-	O	O
C	O	O
protein	O	O
develop	O	O
adiposity	O	O
and	O	O
an	O	O
abnormally	O	O
high	O	O
prevalence	O	O
of	O	O
lipomas	B-Disease	D008067
.	O	O

Chromosomal	O	O
translocations	O	O
in	O	O
human	O	O
lipomas	B-Disease	D008067
frequently	O	O
create	O	O
fusion	O	O
transcripts	O	O
encoding	O	O
high	O	O
mobility	O	O
group	O	O
(	O	O
HMG	O	O
)	O	O
I	O	O
-	O	O
C	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
and	O	O
C	O	O
-	O	O
terminal	O	O
sequences	O	O
from	O	O
different	O	O
presumed	O	O
transcription	O	O
factors	O	O
,	O	O
suggesting	O	O
a	O	O
potential	O	O
role	O	O
for	O	O
HMG	O	O
I	O	O
-	O	O
C	O	O
in	O	O
the	O	O
development	O	O
of	O	O
lipomas	B-Disease	D008067
.	O	O

To	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
the	O	O
HMG	O	O
I	O	O
-	O	O
C	O	O
component	O	O
,	O	O
the	O	O
three	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
of	O	O
HMG	O	O
I	O	O
-	O	O
C	O	O
have	O	O
now	O	O
been	O	O
expressed	O	O
in	O	O
transgenic	O	O
mice	O	O
.	O	O

Despite	O	O
the	O	O
ubiquitous	O	O
expression	O	O
of	O	O
the	O	O
truncated	O	O
HMG	O	O
I	O	O
-	O	O
C	O	O
protein	O	O
,	O	O
the	O	O
transgenic	O	O
mice	O	O
develop	O	O
a	O	O
selective	O	O
abundance	O	O
of	O	O
fat	O	O
tissue	O	O
early	O	O
in	O	O
life	O	O
,	O	O
show	O	O
marked	O	O
adipose	B-Disease	D007249
tissue	I-Disease	D007249
inflammation	I-Disease	D007249
,	O	O
and	O	O
have	O	O
an	O	O
abnormally	O	O
high	O	O
incidence	O	O
of	O	O
lipomas	B-Disease	D008067
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
that	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
of	O	O
HMG	O	O
I	O	O
-	O	O
C	O	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
C	O	O
-	O	O
terminal	O	O
fusion	O	O
partner	O	O
,	O	O
are	O	O
sufficient	O	O
to	O	O
perturb	O	O
adipogenesis	O	O
and	O	O
predispose	O	O
to	O	O
lipomas	B-Disease	D008067
.	O	O

We	O	O
provide	O	O
data	O	O
supporting	O	O
the	O	O
central	O	O
utility	O	O
of	O	O
this	O	O
animal	O	O
model	O	O
as	O	O
a	O	O
tool	O	O
to	O	O
understand	O	O
the	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
the	O	O
development	O	O
of	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
kind	O	O
of	O	O
human	O	O
benign	B-Disease	D009369
tumors	I-Disease	D009369
.	O	O

.	O	O

A	O	O
common	O	O
MSH2	O	O
mutation	O	O
in	O	O
English	O	O
and	O	O
North	O	O
American	O	O
HNPCC	B-Disease	D003123
families	O	O
:	O	O
origin	O	O
,	O	O
phenotypic	O	O
expression	O	O
,	O	O
and	O	O
sex	O	O
specific	O	O
differences	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

The	O	O
frequency	O	O
,	O	O
origin	O	O
,	O	O
and	O	O
phenotypic	O	O
expression	O	O
of	O	O
a	O	O
germline	O	O
MSH2	O	O
gene	O	O
mutation	O	O
previously	O	O
identified	O	O
in	O	O
seven	O	O
kindreds	O	O
with	O	O
hereditary	B-Disease	D003123
non	I-Disease	D003123
-	I-Disease	D003123
polyposis	I-Disease	D003123
cancer	I-Disease	D003123
syndrome	I-Disease	D003123
(	O	O
HNPCC	B-Disease	D003123
)	O	O
was	O	O
investigated	O	O
.	O	O

The	O	O
mutation	O	O
(	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
at	O	O
nt943	O	O
+	O	O
3	O	O
)	O	O
disrupts	O	O
the	O	O
3	O	O
splice	O	O
site	O	O
of	O	O
exon	O	O
5	O	O
leading	O	O
to	O	O
the	O	O
deletion	O	O
of	O	O
this	O	O
exon	O	O
from	O	O
MSH2	O	O
mRNA	O	O
and	O	O
represents	O	O
the	O	O
only	O	O
frequent	O	O
MSH2	O	O
mutation	O	O
so	O	O
far	O	O
reported	O	O
.	O	O

Although	O	O
this	O	O
mutation	O	O
was	O	O
initially	O	O
detected	O	O
in	O	O
four	O	O
of	O	O
33	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
families	O	O
analysed	O	O
from	O	O
eastern	O	O
England	O	O
,	O	O
more	O	O
extensive	O	O
analysis	O	O
has	O	O
reduced	O	O
the	O	O
frequency	O	O
to	O	O
four	O	O
of	O	O
52	O	O
(	O	O
8	O	O
%	O	O
)	O	O
English	O	O
HNPCC	B-Disease	D003123
kindreds	O	O
analysed	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
MSH2	O	O
mutation	O	O
was	O	O
identified	O	O
in	O	O
10	O	O
of	O	O
20	O	O
(	O	O
50	O	O
%	O	O
)	O	O
separately	O	O
identified	O	O
colorectal	B-Disease	D015179
families	O	O
from	O	O
Newfoundland	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
origin	O	O
of	O	O
this	O	O
mutation	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
families	O	O
from	O	O
England	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
,	O	O
Newfoundland	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
and	O	O
the	O	O
United	O	O
States	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
haplotype	O	O
analysis	O	O
using	O	O
microsatellite	O	O
markers	O	O
linked	O	O
to	O	O
MSH2	O	O
was	O	O
performed	O	O
.	O	O

Within	O	O
the	O	O
English	O	O
and	O	O
US	O	O
families	O	O
there	O	O
was	O	O
little	O	O
evidence	O	O
for	O	O
a	O	O
recent	O	O
common	O	O
origin	O	O
of	O	O
the	O	O
MSH2	O	O
splice	O	O
site	O	O
mutation	O	O
in	O	O
most	O	O
families	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
common	O	O
haplotype	O	O
was	O	O
identified	O	O
at	O	O
the	O	O
two	O	O
flanking	O	O
markers	O	O
(	O	O
CA5	O	O
and	O	O
D2S288	O	O
)	O	O
in	O	O
eight	O	O
of	O	O
the	O	O
Newfoundland	O	O
families	O	O
.	O	O

These	O	O
findings	O	O
suggested	O	O
a	O	O
founder	O	O
effect	O	O
within	O	O
Newfoundland	O	O
similar	O	O
to	O	O
that	O	O
reported	O	O
by	O	O
others	O	O
for	O	O
two	O	O
MLH1	O	O
mutations	O	O
in	O	O
Finnish	O	O
HNPCC	B-Disease	D003123
families	O	O
.	O	O

We	O	O
calculated	O	O
age	O	O
related	O	O
risks	O	O
of	O	O
all	O	O
,	O	O
colorectal	B-Disease	D015179
,	O	O
endometrial	O	O
,	O	O
and	O	O
ovarian	O	O
cancers	B-Disease	D009369
in	O	O
nt943	O	O
+	O	O
3	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
MSH2	O	O
mutation	O	O
carriers	O	O
(	O	O
n	O	O
=	O	O
76	O	O
)	O	O
for	O	O
all	O	O
patients	O	O
and	O	O
for	O	O
men	O	O
and	O	O
women	O	O
separately	O	O
.	O	O

For	O	O
both	O	O
sexes	O	O
combined	O	O
,	O	O
the	O	O
penetrances	O	O
at	O	O
age	O	O
60	O	O
years	O	O
for	O	O
all	O	O
cancers	B-Disease	D009369
and	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
were	O	O
0	O	O
.	O	O

86	O	O
and	O	O
0	O	O
.	O	O

57	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
was	O	O
significantly	O	O
higher	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
in	O	O
males	O	O
than	O	O
females	O	O
(	O	O
0	O	O
.	O	O

63	O	O
v	O	O
0	O	O
.	O	O

30	O	O
and	O	O
0	O	O
.	O	O

84	O	O
v	O	O
0	O	O
.	O	O

44	O	O
at	O	O
ages	O	O
50	O	O
and	O	O
60	O	O
years	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

For	O	O
females	O	O
there	O	O
was	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
(	O	O
0	O	O
.	O	O

5	O	O
at	O	O
age	O	O
60	O	O
years	O	O
)	O	O
and	O	O
premenopausal	B-Disease	D010051
ovarian	I-Disease	D010051
cancer	I-Disease	D010051
(	O	O
0	O	O
.	O	O

2	O	O
at	O	O
50	O	O
years	O	O
)	O	O
.	O	O

These	O	O
intersex	O	O
differences	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
risks	O	O
have	O	O
implications	O	O
for	O	O
screening	O	O
programmes	O	O
and	O	O
for	O	O
attempts	O	O
to	O	O
identify	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
susceptibility	O	O
modifiers	O	O
.	O	O

Novel	O	O
mutation	O	O
at	O	O
the	O	O
initiation	O	O
codon	O	O
in	O	O
the	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
gene	O	O
in	O	O
two	O	O
Japanese	O	O
families	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
new	O	O
mutation	O	O
of	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
ND	B-Disease	C537849
)	O	O
gene	O	O
in	O	O
two	O	O
Japanese	O	O
males	O	O
from	O	O
unrelated	O	O
families	O	O
;	O	O
they	O	O
showed	O	O
typical	O	O
ocular	O	O
features	O	O
of	O	O
ND	B-Disease	C537849
but	O	O
no	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
or	O	O
hearing	B-Disease	D034381
impairment	I-Disease	D034381
.	O	O

A	O	O
mutation	O	O
was	O	O
found	O	O
in	O	O
both	O	O
patients	O	O
at	O	O
the	O	O
initiation	O	O
codon	O	O
of	O	O
exon	O	O
2	O	O
of	O	O
the	O	O
ND	B-Disease	C537849
gene	O	O
(	O	O
ATG	O	O
to	O	O
GTG	O	O
)	O	O
,	O	O
with	O	O
otherwise	O	O
normal	O	O
nucleotide	O	O
sequences	O	O
.	O	O

Their	O	O
mothers	O	O
had	O	O
the	O	O
normal	O	O
and	O	O
mutant	O	O
types	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
which	O	O
was	O	O
expected	O	O
for	O	O
heterozygotes	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
mutation	O	O
of	O	O
the	O	O
initiation	O	O
codon	O	O
would	O	O
cause	O	O
the	O	O
failure	O	O
of	O	O
ND	B-Disease	C537849
gene	O	O
expression	O	O
or	O	O
a	O	O
defect	O	O
in	O	O
translation	O	O
thereby	O	O
truncating	O	O
the	O	O
amino	O	O
terminus	O	O
of	O	O
ND	B-Disease	C537849
protein	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
rarity	O	O
and	O	O
marked	O	O
heterogeneity	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
ND	B-Disease	C537849
gene	O	O
,	O	O
the	O	O
present	O	O
apparently	O	O
unrelated	O	O
Japanese	O	O
families	O	O
who	O	O
have	O	O
lived	O	O
in	O	O
the	O	O
same	O	O
area	O	O
for	O	O
over	O	O
two	O	O
centuries	O	O
presumably	O	O
share	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
mutation	O	O
.	O	O

.	O	O

Haplotype	O	O
and	O	O
phenotype	O	O
analysis	O	O
of	O	O
six	O	O
recurrent	O	O
BRCA1	O	O
mutations	O	O
in	O	O
61	O	O
families	O	O
:	O	O
results	O	O
of	O	O
an	O	O
international	O	O
study	O	O
.	O	O

Several	O	O
BRCA1	O	O
mutations	O	O
have	O	O
now	O	O
been	O	O
found	O	O
to	O	O
occur	O	O
in	O	O
geographically	O	O
diverse	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

To	O	O
investigate	O	O
mutation	O	O
origin	O	O
and	O	O
mutation	O	O
-	O	O
specific	O	O
phenotypes	O	O
due	O	O
to	O	O
BRCA1	O	O
,	O	O
we	O	O
constructed	O	O
a	O	O
haplotype	O	O
of	O	O
nine	O	O
polymorphic	O	O
markers	O	O
within	O	O
or	O	O
immediately	O	O
flanking	O	O
the	O	O
BRCA1	O	O
locus	O	O
in	O	O
a	O	O
set	O	O
of	O	O
61	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
selected	O	O
for	O	O
having	O	O
one	O	O
of	O	O
six	O	O
recurrent	O	O
BRCA1	O	O
mutations	O	O
.	O	O

Tests	O	O
of	O	O
both	O	O
mutations	O	O
and	O	O
family	O	O
-	O	O
specific	O	O
differences	O	O
in	O	O
age	O	O
at	O	O
diagnosis	O	O
were	O	O
not	O	O
significant	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
the	O	O
six	O	O
mutations	O	O
in	O	O
the	O	O
relative	O	O
proportions	O	O
of	O	O
cases	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
was	O	O
suggestive	O	O
of	O	O
an	O	O
effect	O	O
(	O	O
P	O	O
=	O	O
.	O	O

069	O	O
)	O	O
,	O	O
with	O	O
57	O	O
%	O	O
of	O	O
women	O	O
presumed	O	O
affected	O	O
because	O	O
of	O	O
the	O	O
1294	O	O
del	O	O
40	O	O
BRCA1	O	O
mutation	O	O
having	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
compared	O	O
with	O	O
14	O	O
%	O	O
of	O	O
affected	O	O
women	O	O
with	O	O
the	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
intron	O	O
5	O	O
of	O	O
BRCA1	O	O
.	O	O

For	O	O
the	O	O
BRCA1	O	O
mutations	O	O
studied	O	O
here	O	O
,	O	O
the	O	O
individual	O	O
mutations	O	O
are	O	O
estimated	O	O
to	O	O
have	O	O
arisen	O	O
9	O	O
-	O	O
170	O	O
generations	O	O
ago	O	O
.	O	O

In	O	O
general	O	O
,	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
haplotype	O	O
conservation	O	O
across	O	O
the	O	O
region	O	O
was	O	O
observed	O	O
,	O	O
with	O	O
haplotype	O	O
differences	O	O
most	O	O
often	O	O
due	O	O
to	O	O
mutations	O	O
in	O	O
the	O	O
short	O	O
-	O	O
tandem	O	O
-	O	O
repeat	O	O
markers	O	O
,	O	O
although	O	O
some	O	O
likely	O	O
instances	O	O
of	O	O
recombination	O	O
also	O	O
were	O	O
observed	O	O
.	O	O

For	O	O
several	O	O
of	O	O
the	O	O
instances	O	O
,	O	O
there	O	O
was	O	O
evidence	O	O
for	O	O
multiple	O	O
,	O	O
independent	O	O
,	O	O
BRCA1	O	O
mutational	O	O
events	O	O
.	O	O

A	O	O
new	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variant	O	O
(	O	O
G6PD	O	O
Nagano	O	O
)	O	O
associated	O	O
with	O	O
congenital	B-Disease	D000745
hemolytic	I-Disease	D000745
anemia	I-Disease	D000745
.	O	O

A	O	O
new	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
variant	O	O
associated	O	O
with	O	O
chronic	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
was	O	O
reported	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
a	O	O
6	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Japanese	O	O
male	O	O
,	O	O
was	O	O
noticed	O	O
to	O	O
have	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
soon	O	O
after	O	O
birth	O	O
,	O	O
and	O	O
a	O	O
diagnosis	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
was	O	O
made	O	O
at	O	O
the	O	O
age	O	O
of	O	O
2	O	O
.	O	O

He	O	O
had	O	O
episodes	O	O
of	O	O
hemolytic	B-Disease	D006461
crisis	I-Disease	D006461
several	O	O
times	O	O
after	O	O
upper	B-Disease	D012141
respiratory	I-Disease	D012141
infection	I-Disease	D012141
.	O	O

G6PD	O	O
activity	O	O
of	O	O
the	O	O
patient	O	O
was	O	O
5	O	O
.	O	O

5	O	O
%	O	O
of	O	O
normal	O	O
.	O	O

The	O	O
enzymatic	O	O
characteristics	O	O
were	O	O
examined	O	O
when	O	O
he	O	O
was	O	O
5	O	O
years	O	O
old	O	O
,	O	O
and	O	O
his	O	O
G6PD	O	O
showed	O	O
faster	O	O
-	O	O
than	O	O
-	O	O
normal	O	O
electrophoretic	O	O
mobility	O	O
,	O	O
low	O	O
Km	O	O
G6P	O	O
,	O	O
high	O	O
Km	O	O
NADP	O	O
,	O	O
low	O	O
Ki	O	O
NADPH	O	O
,	O	O
normal	O	O
utilization	O	O
of	O	O
substrate	O	O
analogues	O	O
,	O	O
heat	O	O
instability	O	O
,	O	O
and	O	O
a	O	O
normal	O	O
pH	O	O
optimum	O	O
curve	O	O
.	O	O

From	O	O
these	O	O
results	O	O
,	O	O
this	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
new	O	O
variant	O	O
and	O	O
was	O	O
designated	O	O
G6PD	O	O
Nagano	O	O
.	O	O

Infection	O	O
-	O	O
induced	O	O
hemolysis	B-Disease	D006461
and	O	O
chronic	B-Disease	D000745
hemolytic	I-Disease	D000745
anemia	I-Disease	D000745
seem	O	O
to	O	O
be	O	O
due	O	O
to	O	O
markedly	O	O
impaired	O	O
enzyme	O	O
activity	O	O
and	O	O
thermal	O	O
instability	O	O
.	O	O

Craniofrontonasal	B-Disease	C536456
dysplasia	I-Disease	C536456
.	O	O

We	O	O
report	O	O
on	O	O
nine	O	O
patients	O	O
with	O	O
craniofrontonasal	B-Disease	C536456
dysplasia	I-Disease	C536456
(	O	O
CFND	B-Disease	C536456
)	O	O
.	O	O

Seven	O	O
classical	O	O
cases	O	O
had	O	O
facial	O	O
features	O	O
suggestive	O	O
of	O	O
frontonasal	B-Disease	C538065
dysplasia	I-Disease	C538065
and	O	O
coronal	B-Disease	C537369
craniosynostosis	I-Disease	C537369
.	O	O

Extracranial	B-Disease	D009139
abnormalities	I-Disease	D009139
such	O	O
as	O	O
brittle	B-Disease	D009260
nails	I-Disease	D009260
with	I-Disease	D009260
prominent	I-Disease	D009260
longitudinal	I-Disease	D009260
grooves	I-Disease	D009260
or	O	O
syndactyly	B-Disease	D013576
of	I-Disease	D013576
fingers	I-Disease	D013576
and	I-Disease	D013576
toes	I-Disease	D013576
were	O	O
observed	O	O
in	O	O
individual	O	O
patients	O	O
.	O	O

In	O	O
two	O	O
families	O	O
the	O	O
father	O	O
of	O	O
classical	O	O
cases	O	O
showed	O	O
a	O	O
milder	O	O
pattern	O	O
of	O	O
abnormalities	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
diagnosis	O	O
.	O	O

We	O	O
present	O	O
a	O	O
2	O	O
-	O	O
to	O	O
13	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
on	O	O
our	O	O
patients	O	O
.	O	O

Hypotonia	B-Disease	D009123
and	O	O
laxity	B-Disease	C535884
of	I-Disease	C535884
joints	I-Disease	C535884
are	O	O
common	O	O
and	O	O
may	O	O
necessitate	O	O
supportive	O	O
measures	O	O
.	O	O

Mild	O	O
developmental	B-Disease	D002658
delay	I-Disease	D002658
was	O	O
noted	O	O
in	O	O
three	O	O
out	O	O
of	O	O
six	O	O
classical	O	O
cases	O	O
studied	O	O
in	O	O
detail	O	O
.	O	O

Unlike	O	O
almost	O	O
all	O	O
other	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
disorders	I-Disease	D040181
,	O	O
clinical	O	O
expression	O	O
in	O	O
CFND	B-Disease	C536456
is	O	O
generally	O	O
much	O	O
more	O	O
severe	O	O
in	O	O
females	O	O
than	O	O
in	O	O
males	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
previous	O	O
reports	O	O
of	O	O
this	O	O
condition	O	O
,	O	O
one	O	O
of	O	O
our	O	O
severely	O	O
affected	O	O
cases	O	O
is	O	O
a	O	O
male	O	O
.	O	O

.	O	O

A	O	O
new	O	O
mutation	O	O
in	O	O
the	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
gene	O	O
in	O	O
a	O	O
German	O	O
family	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

A	O	O
C	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transition	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
was	O	O
found	O	O
in	O	O
2	O	O
affected	O	O
males	O	O
and	O	O
two	O	O
obligate	O	O
carriers	O	O
in	O	O
a	O	O
German	O	O
family	O	O
with	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

The	O	O
mutation	O	O
,	O	O
which	O	O
causes	O	O
loss	O	O
of	O	O
an	O	O
HphI	O	O
site	O	O
and	O	O
changes	O	O
amino	O	O
acid	O	O
155	O	O
from	O	O
threonine	O	O
to	O	O
isoleucine	O	O
,	O	O
was	O	O
absent	O	O
from	O	O
108	O	O
normal	O	O
chromosomes	O	O
.	O	O

There	O	O
are	O	O
5	O	O
concordances	O	O
and	O	O
1	O	O
discrepancy	O	O
between	O	O
these	O	O
results	O	O
and	O	O
those	O	O
obtained	O	O
by	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
in	O	O
this	O	O
family	O	O
.	O	O

.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
and	O	O
X	B-Disease	OMIM:313900
-	I-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
congenital	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
are	O	O
caused	O	O
by	O	O
mutations	O	O
of	O	O
the	O	O
same	O	O
gene	O	O
.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
recessive	I-Disease	D040181
disorder	I-Disease	D040181
characterized	O	O
by	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
small	O	O
platelets	O	O
,	O	O
eczema	B-Disease	D004485
,	O	O
recurrent	O	O
infections	O	O
,	O	O
and	O	O
immunodeficiency	B-Disease	D007153
.	O	O

Besides	O	O
the	O	O
classic	O	O
WAS	B-Disease	D014923
phenotype	O	O
,	O	O
there	O	O
is	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
congenital	B-Disease	OMIM:313900
X	I-Disease	OMIM:313900
-	I-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
(	O	O
XLT	B-Disease	OMIM:313900
)	O	O
who	O	O
have	O	O
small	O	O
platelets	O	O
but	O	O
only	O	O
transient	O	O
eczema	B-Disease	D004485
,	O	O
if	O	O
any	O	O
,	O	O
and	O	O
minimal	O	O
immune	B-Disease	D007153
deficiency	I-Disease	D007153
.	O	O

Because	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
WAS	B-Disease	D014923
has	O	O
been	O	O
sequenced	O	O
,	O	O
it	O	O
was	O	O
possible	O	O
to	O	O
correlate	O	O
the	O	O
WAS	B-Disease	D014923
phenotypes	O	O
with	O	O
WAS	B-Disease	D014923
gene	O	O
mutations	O	O
.	O	O

Using	O	O
a	O	O
fingerprinting	O	O
screening	O	O
technique	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
approximate	O	O
location	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
13	O	O
unrelated	O	O
WAS	B-Disease	D014923
patients	O	O
with	O	O
mild	O	O
to	O	O
severe	O	O
clinical	O	O
symptoms	O	O
.	O	O

Direct	O	O
sequence	O	O
analysis	O	O
of	O	O
cDNA	O	O
and	O	O
genomic	O	O
DNA	O	O
obtained	O	O
from	O	O
patient	O	O
-	O	O
derived	O	O
cell	O	O
lines	O	O
showed	O	O
12	O	O
unique	O	O
mutations	O	O
distributed	O	O
throughout	O	O
the	O	O
WAS	B-Disease	D014923
gene	O	O
,	O	O
including	O	O
insertions	O	O
,	O	O
deletions	O	O
,	O	O
and	O	O
point	O	O
mutations	O	O
resulting	O	O
in	O	O
amino	O	O
acid	O	O
substitutions	O	O
,	O	O
termination	O	O
,	O	O
exon	O	O
skipping	O	O
,	O	O
or	O	O
splicing	O	O
defects	O	O
.	O	O

Of	O	O
4	O	O
unrelated	O	O
patients	O	O
with	O	O
the	O	O
XLT	B-Disease	OMIM:313900
phenotype	O	O
,	O	O
3	O	O
had	O	O
missense	O	O
mutations	O	O
affecting	O	O
exon	O	O
2	O	O
and	O	O
1	O	O
had	O	O
a	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
affecting	O	O
exon	O	O
9	O	O
.	O	O

Patients	O	O
with	O	O
classic	O	O
WAS	B-Disease	D014923
had	O	O
more	O	O
complex	O	O
mutations	O	O
,	O	O
resulting	O	O
in	O	O
termination	O	O
codons	O	O
,	O	O
frameshift	O	O
,	O	O
and	O	O
early	O	O
termination	O	O
.	O	O

These	O	O
findings	O	O
provide	O	O
direct	O	O
evidence	O	O
that	O	O
XLT	B-Disease	OMIM:313900
and	O	O
WAS	B-Disease	D014923
are	O	O
caused	O	O
by	O	O
mutations	O	O
of	O	O
the	O	O
same	O	O
gene	O	O
and	O	O
suggest	O	O
that	O	O
severe	O	O
clinical	O	O
phenotypes	O	O
are	O	O
associated	O	O
with	O	O
complex	O	O
mutations	O	O
.	O	O

.	O	O

A	O	O
3	O	O
-	O	O
base	O	O
pair	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
results	O	O
in	O	O
a	O	O
kinetic	O	O
variant	O	O
of	O	O
phenylketonuria	B-Disease	D010661
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disease	I-Disease	D030342
due	O	O
to	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
a	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
enzyme	I-Disease	OMIM:261600
,	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
PAH	O	O
activity	O	O
results	O	O
in	O	O
typical	O	O
PKU	B-Disease	D010661
while	O	O
persistence	O	O
of	O	O
a	O	O
residual	O	O
enzyme	O	O
activity	O	O
gives	O	O
rise	O	O
to	O	O
variant	O	O
forms	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

We	O	O
report	O	O
here	O	O
a	O	O
3	O	O
-	O	O
base	O	O
pair	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
of	O	O
the	O	O
PAH	O	O
gene	O	O
(	O	O
delta	O	O
194	O	O
)	O	O
in	O	O
a	O	O
mild	O	O
variant	O	O
,	O	O
with	O	O
markedly	O	O
reduced	O	O
affinity	O	O
of	O	O
the	O	O
enzyme	O	O
for	O	O
phenylalanine	O	O
(	O	O
Km	O	O
=	O	O
160	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
we	O	O
provide	O	O
functional	O	O
evidence	O	O
for	O	O
responsibility	O	O
of	O	O
the	O	O
deletion	O	O
in	O	O
the	O	O
mutant	O	O
phenotype	O	O
.	O	O

Since	O	O
the	O	O
deletion	O	O
was	O	O
located	O	O
in	O	O
the	O	O
third	O	O
exon	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
which	O	O
presents	O	O
no	O	O
homology	O	O
with	O	O
other	O	O
hydroxylases	O	O
,	O	O
we	O	O
suggest	O	O
that	O	O
exon	O	O
3	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
specificity	O	O
of	O	O
the	O	O
enzyme	O	O
for	O	O
phenylalanine	O	O
.	O	O

Finally	O	O
,	O	O
since	O	O
none	O	O
of	O	O
the	O	O
98	O	O
PKU	B-Disease	D010661
patients	O	O
tested	O	O
were	O	O
found	O	O
to	O	O
carry	O	O
this	O	O
particular	O	O
deletion	O	O
,	O	O
our	O	O
study	O	O
suggests	O	O
that	O	O
this	O	O
molecular	O	O
event	O	O
probably	O	O
occurred	O	O
recently	O	O
on	O	O
the	O	O
background	O	O
of	O	O
a	O	O
haplotype	O	O
2	O	O
gene	O	O
in	O	O
Portugal	O	O
.	O	O

.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
:	O	O
an	O	O
overview	O	O
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
,	O	O
an	O	O
autosomal	B-Disease	D020271
recessive	I-Disease	D020271
neurodegenerative	I-Disease	D020271
disease	I-Disease	D020271
,	O	O
is	O	O
the	O	O
most	O	O
common	O	O
of	O	O
the	O	O
inherited	B-Disease	D013132
ataxias	I-Disease	D013132
.	O	O

The	O	O
recent	O	O
discovery	O	O
of	O	O
the	O	O
gene	O	O
that	O	O
is	O	O
mutated	O	O
in	O	O
this	O	O
condition	O	O
,	O	O
FRDA	B-Disease	D005621
,	O	O
has	O	O
led	O	O
to	O	O
rapid	O	O
advances	O	O
in	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
pathogenesis	O	O
of	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

About	O	O
98	O	O
%	O	O
of	O	O
mutant	O	O
alleles	O	O
have	O	O
an	O	O
expansion	O	O
of	O	O
a	O	O
GAA	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
intron	O	O
1	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

This	O	O
leads	O	O
to	O	O
reduced	O	O
levels	O	O
of	O	O
the	O	O
protein	O	O
,	O	O
frataxin	O	O
.	O	O

There	O	O
is	O	O
mounting	O	O
evidence	O	O
to	O	O
suggest	O	O
that	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
is	O	O
the	O	O
result	O	O
of	O	O
accumulation	O	O
of	O	O
iron	O	O
in	O	O
mitochondria	O	O
leading	O	O
to	O	O
excess	O	O
production	O	O
of	O	O
free	O	O
radicals	O	O
,	O	O
which	O	O
then	O	O
results	O	O
in	O	O
cellular	O	O
damage	O	O
and	O	O
death	O	O
.	O	O

Currently	O	O
there	O	O
is	O	O
no	O	O
known	O	O
treatment	O	O
that	O	O
alters	O	O
the	O	O
natural	O	O
course	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
discovery	O	O
of	O	O
the	O	O
FRDA	B-Disease	D005621
gene	O	O
and	O	O
its	O	O
possible	O	O
function	O	O
has	O	O
raised	O	O
hope	O	O
that	O	O
rational	O	O
therapeutic	O	O
strategies	O	O
will	O	O
be	O	O
developed	O	O
.	O	O

.	O	O

Clinical	O	O
and	O	O
molecular	O	O
genetics	O	O
of	O	O
primary	B-Disease	D020821
dystonias	I-Disease	D020821
.	O	O

Primary	B-Disease	D020821
dystonias	I-Disease	D020821
are	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
with	O	O
dystonia	B-Disease	D004421
as	O	O
a	O	O
major	O	O
symptom	O	O
.	O	O

They	O	O
are	O	O
frequently	O	O
inherited	O	O
as	O	O
Mendelian	O	O
traits	O	O
.	O	O

There	O	O
are	O	O
at	O	O
least	O	O
eight	O	O
clinically	O	O
distinct	O	O
autosomal	O	O
dominant	O	O
and	O	O
two	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
forms	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
pedigree	O	O
analyses	O	O
suggest	O	O
the	O	O
occurrence	O	O
of	O	O
an	O	O
autosomal	O	O
recessive	O	O
variant	O	O
.	O	O

The	O	O
clinical	O	O
classification	O	O
is	O	O
increasingly	O	O
being	O	O
replaced	O	O
by	O	O
a	O	O
genetic	O	O
one	O	O
.	O	O

To	O	O
date	O	O
gene	O	O
loci	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
at	O	O
least	O	O
six	O	O
autosomal	O	O
dominant	O	O
forms	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
in	O	O
idiopathic	B-Disease	D004422
torsion	I-Disease	D004422
dystonia	I-Disease	D004422
(	O	O
9q34	O	O
)	O	O
,	O	O
focal	B-Disease	D020821
dystonia	I-Disease	D020821
(	O	O
18p	O	O
)	O	O
,	O	O
adult	O	O
-	O	O
onset	O	O
idiopathic	B-Disease	D004422
torsion	I-Disease	D004422
dystonia	I-Disease	D004422
of	O	O
mixed	O	O
type	O	O
(	O	O
8p21	O	O
-	O	O
q22	O	O
)	O	O
,	O	O
dopa	B-Disease	C538007
-	I-Disease	C538007
responsive	I-Disease	C538007
dystonia	I-Disease	C538007
(	O	O
14q22	O	O
.	O	O

1	O	O
-	O	O
q22	O	O
.	O	O

2	O	O
)	O	O
,	O	O
and	O	O
paroxysmal	B-Disease	C537181
dystonic	I-Disease	C537181
choreoathetosis	I-Disease	C537181
(	O	O
2q25	O	O
-	O	O
q33	O	O
;	O	O
1p21	O	O
-	O	O
p13	O	O
.	O	O

3	O	O
)	O	O
.	O	O

Gene	O	O
loci	O	O
in	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
forms	O	O
have	O	O
been	O	O
assigned	O	O
to	O	O
Xq13	O	O
.	O	O

1	O	O
in	O	O
the	O	O
X	B-Disease	OMIM:314250
-	I-Disease	OMIM:314250
linked	I-Disease	OMIM:314250
dystonia	I-Disease	OMIM:314250
parkinsonism	I-Disease	OMIM:314250
syndrome	I-Disease	OMIM:314250
and	O	O
to	O	O
Xq22	O	O
in	O	O
X	B-Disease	OMIM:304500
-	I-Disease	OMIM:304500
linked	I-Disease	OMIM:304500
sensorineural	I-Disease	OMIM:304500
deafness	I-Disease	OMIM:304500
,	O	O
dystonia	B-Disease	D004421
,	O	O
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
.	O	O

The	O	O
disease	O	O
genes	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
two	O	O
autosomal	O	O
dominant	O	O
forms	O	O
and	O	O
in	O	O
one	O	O
X	O	O
-	O	O
linked	O	O
recessive	O	O
form	O	O
.	O	O

Mutations	O	O
in	O	O
a	O	O
gene	O	O
coding	O	O
for	O	O
an	O	O
ATP	O	O
-	O	O
binding	O	O
protein	O	O
were	O	O
detected	O	O
in	O	O
idiopathic	B-Disease	D004422
torsion	I-Disease	D004422
dystonia	I-Disease	D004422
(	O	O
DYT1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
GTP	O	O
cyclohydrolase	O	O
1	O	O
gene	O	O
is	O	O
mutated	O	O
in	O	O
dopa	B-Disease	C538007
-	I-Disease	C538007
responsive	I-Disease	C538007
dystonia	I-Disease	C538007
(	O	O
DYT5	O	O
)	O	O
.	O	O

In	O	O
sensorineural	B-Disease	D006319
deafness	I-Disease	D006319
,	O	O
dystonia	B-Disease	D004421
,	O	O
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
the	O	O
gene	O	O
DDP	O	O
coding	O	O
for	O	O
a	O	O
polypeptide	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

This	O	O
article	O	O
reviews	O	O
the	O	O
clinical	O	O
and	O	O
molecular	O	O
genetics	O	O
of	O	O
primary	B-Disease	D020821
dystonias	I-Disease	D020821
,	O	O
critically	O	O
discusses	O	O
present	O	O
findings	O	O
,	O	O
and	O	O
proposes	O	O
referring	O	O
to	O	O
the	O	O
known	O	O
forms	O	O
,	O	O
most	O	O
of	O	O
which	O	O
can	O	O
be	O	O
distinguished	O	O
by	O	O
genetic	O	O
criteria	O	O
,	O	O
as	O	O
dystonias	B-Disease	D020821
1	I-Disease	D020821
-	I-Disease	D020821
12	I-Disease	D020821
.	O	O

Clinical	O	O
and	O	O
genetic	O	O
study	O	O
of	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
in	O	O
an	O	O
Australian	O	O
population	O	O
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
FRDA	B-Disease	D005621
gene	O	O
that	O	O
encodes	O	O
a	O	O
210	O	O
-	O	O
amino	O	O
acid	O	O
protein	O	O
called	O	O
frataxin	O	O
.	O	O

An	O	O
expansion	O	O
of	O	O
a	O	O
GAA	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
intron	O	O
1	O	O
of	O	O
the	O	O
gene	O	O
is	O	O
present	O	O
in	O	O
more	O	O
than	O	O
95	O	O
%	O	O
of	O	O
mutant	O	O
alleles	O	O
.	O	O

Of	O	O
the	O	O
83	O	O
people	O	O
we	O	O
studied	O	O
who	O	O
have	O	O
mutations	O	O
in	O	O
FRDA	B-Disease	D005621
,	O	O
78	O	O
are	O	O
homozygous	O	O
for	O	O
an	O	O
expanded	O	O
GAA	O	O
repeat	O	O
;	O	O
the	O	O
other	O	O
five	O	O
patients	O	O
have	O	O
an	O	O
expansion	O	O
in	O	O
one	O	O
allele	O	O
and	O	O
a	O	O
point	O	O
mutation	O	O
in	O	O
the	O	O
other	O	O
.	O	O

Here	O	O
we	O	O
present	O	O
a	O	O
detailed	O	O
clinical	O	O
and	O	O
genetic	O	O
study	O	O
of	O	O
a	O	O
subset	O	O
of	O	O
51	O	O
patients	O	O
homozygous	O	O
for	O	O
an	O	O
expansion	O	O
of	O	O
the	O	O
GAA	O	O
repeat	O	O
.	O	O

We	O	O
found	O	O
a	O	O
correlation	O	O
between	O	O
the	O	O
size	O	O
of	O	O
the	O	O
smaller	O	O
of	O	O
the	O	O
two	O	O
expanded	O	O
alleles	O	O
and	O	O
age	O	O
at	O	O
onset	O	O
,	O	O
age	O	O
into	O	O
wheelchair	O	O
,	O	O
scoliosis	B-Disease	D012600
,	O	O
impaired	O	O
vibration	O	O
sense	O	O
,	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
foot	B-Disease	D005530
deformity	I-Disease	D005530
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
correlation	O	O
between	O	O
the	O	O
size	O	O
of	O	O
the	O	O
smaller	O	O
allele	O	O
and	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
,	O	O
loss	B-Disease	D020886
of	I-Disease	D020886
proprioception	I-Disease	D020886
,	O	O
or	O	O
bladder	B-Disease	D001745
symptoms	I-Disease	D001745
.	O	O

The	O	O
larger	O	O
allele	O	O
size	O	O
correlated	O	O
with	O	O
bladder	B-Disease	D001745
symptoms	I-Disease	D001745
and	O	O
the	O	O
presence	O	O
of	O	O
foot	B-Disease	D005530
deformity	I-Disease	D005530
.	O	O

The	O	O
duration	O	O
of	O	O
disease	O	O
is	O	O
correlated	O	O
with	O	O
wheelchair	O	O
use	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
diabetes	B-Disease	D003920
,	O	O
scoliosis	B-Disease	D012600
,	O	O
bladder	B-Disease	D001745
symptoms	I-Disease	D001745
and	O	O
impaired	B-Disease	D020886
proprioception	I-Disease	D020886
,	O	O
and	O	O
vibration	O	O
sense	O	O
but	O	O
no	O	O
other	O	O
complications	O	O
studied	O	O
.	O	O

.	O	O

Recurrent	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
with	O	O
absence	B-Disease	OMIM:612446
of	I-Disease	OMIM:612446
the	I-Disease	OMIM:612446
sixth	I-Disease	OMIM:612446
component	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
:	O	O
an	O	O
evaluation	O	O
of	O	O
underlying	O	O
immunologic	O	O
mechanisms	O	O
.	O	O

A	O	O
51	O	O
/	O	O
2	O	O
-	O	O
year	O	O
-	O	O
old	O	O
black	O	O
girl	O	O
with	O	O
recurrent	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
and	O	O
absence	B-Disease	OMIM:612446
of	I-Disease	OMIM:612446
the	I-Disease	OMIM:612446
sixth	I-Disease	OMIM:612446
component	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
(	O	O
C6	O	O
)	O	O
is	O	O
reported	O	O
.	O	O

To	O	O
explore	O	O
the	O	O
pathogenesis	O	O
of	O	O
recurrent	O	O
neisserial	B-Disease	D016870
infections	I-Disease	D016870
in	O	O
C6	B-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
,	O	O
a	O	O
detailed	O	O
analysis	O	O
of	O	O
her	O	O
immune	O	O
competence	O	O
was	O	O
conducted	O	O
.	O	O

Her	O	O
serum	O	O
had	O	O
normal	O	O
chemotactic	O	O
,	O	O
opsonic	O	O
,	O	O
alternative	O	O
complement	O	O
pathway	O	O
,	O	O
and	O	O
specific	O	O
antibody	O	O
activity	O	O
,	O	O
but	O	O
lacked	O	O
complement	O	O
-	O	O
mediated	O	O
bacteriolytic	O	O
activity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
her	O	O
C6	B-Disease	OMIM:612446
-	I-Disease	OMIM:612446
deficient	I-Disease	OMIM:612446
serum	O	O
was	O	O
indistinguishable	O	O
from	O	O
normal	O	O
serum	O	O
in	O	O
a	O	O
complement	O	O
-	O	O
dependent	O	O
assay	O	O
of	O	O
phagocyte	O	O
bactericidal	O	O
activity	O	O
.	O	O

Absent	O	O
bacteriolysis	O	O
remains	O	O
the	O	O
only	O	O
consistent	O	O
defect	O	O
associated	O	O
with	O	O
recurrent	O	O
neisserial	B-Disease	D016870
infections	I-Disease	D016870
and	O	O
absence	O	O
of	O	O
one	O	O
of	O	O
the	O	O
late	O	O
-	O	O
acting	O	O
complement	O	O
components	O	O
.	O	O

.	O	O

Mutation	O	O
of	O	O
the	O	O
sterol	O	O
27	O	O
-	O	O
hydroxylase	O	O
gene	O	O
(	O	O
CYP27	O	O
)	O	O
results	O	O
in	O	O
truncation	O	O
of	O	O
mRNA	O	O
expressed	O	O
in	O	O
leucocytes	O	O
in	O	O
a	O	O
Japanese	O	O
family	O	O
with	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
.	O	O

OBJECTIVES	O	O
A	O	O
Japanese	O	O
family	O	O
with	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
was	O	O
investigated	O	O
for	O	O
a	O	O
sequence	O	O
alteration	O	O
in	O	O
the	O	O
sterol	O	O
27	O	O
-	O	O
hydroxylase	O	O
gene	O	O
(	O	O
CYP27	O	O
)	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
CYP27	O	O
has	O	O
been	O	O
mostly	O	O
explored	O	O
using	O	O
cultured	O	O
fibroblasts	O	O
,	O	O
prompting	O	O
the	O	O
examination	O	O
of	O	O
the	O	O
transcripts	O	O
from	O	O
blood	O	O
leucocytes	O	O
as	O	O
a	O	O
simple	O	O
and	O	O
rapid	O	O
technique	O	O
.	O	O

METHODS	O	O
An	O	O
alteration	O	O
in	O	O
CYP27	O	O
of	O	O
the	O	O
proband	O	O
was	O	O
searched	O	O
for	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
SSCP	O	O
)	O	O
analysis	O	O
and	O	O
subsequent	O	O
sequencing	O	O
.	O	O

Samples	O	O
of	O	O
RNA	O	O
were	O	O
subjected	O	O
to	O	O
reverse	O	O
transcription	O	O
PCR	O	O
(	O	O
RT	O	O
-	O	O
PCR	O	O
)	O	O
and	O	O
the	O	O
product	O	O
of	O	O
the	O	O
proband	O	O
was	O	O
amplified	O	O
with	O	O
nested	O	O
primers	O	O
and	O	O
sequenced	O	O
.	O	O

RESULTS	O	O
A	O	O
homozygous	O	O
G	O	O
to	O	O
A	O	O
transition	O	O
at	O	O
the	O	O
5	O	O
end	O	O
of	O	O
intron	O	O
7	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

In	O	O
RT	O	O
-	O	O
PCR	O	O
analysis	O	O
,	O	O
only	O	O
a	O	O
truncated	O	O
transcript	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
patient	O	O
,	O	O
whereas	O	O
both	O	O
normal	O	O
and	O	O
truncated	O	O
transcripts	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
siblings	O	O
.	O	O

The	O	O
sequencing	O	O
of	O	O
the	O	O
patients	O	O
cDNA	O	O
fragment	O	O
disclosed	O	O
a	O	O
direct	O	O
conjuction	O	O
of	O	O
exon	O	O
6	O	O
and	O	O
exon	O	O
8	O	O
.	O	O

CONCLUSION	O	O
The	O	O
mutation	O	O
at	O	O
splice	O	O
donor	O	O
site	O	O
and	O	O
the	O	O
truncation	O	O
of	O	O
mRNA	O	O
were	O	O
identical	O	O
with	O	O
those	O	O
of	O	O
a	O	O
recently	O	O
reported	O	O
Italian	O	O
patient	O	O
,	O	O
although	O	O
different	O	O
in	O	O
symptomatology	O	O
.	O	O

The	O	O
application	O	O
of	O	O
blood	O	O
leucocytes	O	O
can	O	O
be	O	O
a	O	O
simple	O	O
technique	O	O
on	O	O
analysing	O	O
a	O	O
constructive	O	O
abnormality	B-Disease	OMIM:213700
of	I-Disease	OMIM:213700
CYP27	I-Disease	OMIM:213700
mRNA	O	O
.	O	O

.	O	O

Frequent	O	O
detection	O	O
of	O	O
codon	O	O
877	O	O
mutation	O	O
in	O	O
the	O	O
androgen	O	O
receptor	O	O
gene	O	O
in	O	O
advanced	B-Disease	D011471
prostate	I-Disease	D011471
cancers	I-Disease	D011471
.	O	O

Prostatic	O	O
tissue	O	O
specimens	O	O
derived	O	O
from	O	O
transurethral	O	O
resections	O	O
of	O	O
patients	O	O
with	O	O
metastatic	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
were	O	O
analyzed	O	O
for	O	O
genetic	O	O
alterations	O	O
in	O	O
the	O	O
hormone	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
the	O	O
androgen	O	O
receptor	O	O
(	O	O
AR	O	O
)	O	O
gene	O	O
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
derived	O	O
DNAs	O	O
of	O	O
6	O	O
of	O	O
24	O	O
specimens	O	O
revealed	O	O
a	O	O
codon	O	O
877	O	O
mutation	O	O
(	O	O
ACT	O	O
-	O	O
-	O	O
>	O	O
GCT	O	O
,	O	O
Thr	O	O
-	O	O
-	O	O
>	O	O
Ala	O	O
)	O	O
in	O	O
the	O	O
hormone	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
the	O	O
AR	O	O
gene	O	O
.	O	O

This	O	O
same	O	O
AR	O	O
mutation	O	O
has	O	O
been	O	O
reported	O	O
previously	O	O
in	O	O
a	O	O
metastatic	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
cell	O	O
line	O	O
,	O	O
LNCaP	O	O
,	O	O
where	O	O
this	O	O
mutation	O	O
confers	O	O
upon	O	O
the	O	O
AR	O	O
an	O	O
altered	O	O
ligand	O	O
-	O	O
binding	O	O
specificity	O	O
which	O	O
is	O	O
stimulated	O	O
by	O	O
estrogens	O	O
,	O	O
progestagens	O	O
,	O	O
and	O	O
antiandrogens	O	O
.	O	O

It	O	O
is	O	O
possible	O	O
that	O	O
analogous	O	O
to	O	O
an	O	O
activated	O	O
/	O	O
altered	O	O
growth	O	O
factor	O	O
receptor	O	O
oncogene	O	O
,	O	O
codon	O	O
877	O	O
mutant	O	O
AR	O	O
with	O	O
altered	O	O
ligand	O	O
binding	O	O
may	O	O
provide	O	O
a	O	O
selective	O	O
growth	O	O
advantage	O	O
in	O	O
the	O	O
genesis	O	O
of	O	O
a	O	O
subset	O	O
of	O	O
advanced	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
.	O	O

Although	O	O
estrogens	O	O
are	O	O
used	O	O
infrequently	O	O
,	O	O
antiandrogens	O	O
are	O	O
used	O	O
increasingly	O	O
in	O	O
hormonal	O	O
therapy	O	O
for	O	O
patients	O	O
with	O	O
advanced	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
.	O	O

The	O	O
stimulatory	O	O
effect	O	O
of	O	O
these	O	O
therapeutic	O	O
agents	O	O
on	O	O
the	O	O
codon	O	O
877	O	O
mutant	O	O
AR	O	O
further	O	O
suggests	O	O
that	O	O
this	O	O
frequently	O	O
observed	O	O
AR	O	O
mutation	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
treatment	O	O
refractory	O	O
disease	O	O
.	O	O

.	O	O

ATM	O	O
-	O	O
dependent	O	O
phosphorylation	O	O
of	O	O
nibrin	O	O
in	O	O
response	O	O
to	O	O
radiation	O	O
exposure	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
gene	O	O
ATM	O	O
are	O	O
responsible	O	O
for	O	O
the	O	O
genetic	B-Disease	D030342
disorder	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
cerebellar	B-Disease	D002526
dysfunction	I-Disease	D002526
,	O	O
radiosensitivity	O	O
,	O	O
chromosomal	O	O
instability	O	O
and	O	O
cancer	B-Disease	D009369
predisposition	O	O
.	O	O

Both	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
phenotype	O	O
and	O	O
the	O	O
similarity	O	O
of	O	O
the	O	O
ATM	O	O
protein	O	O
to	O	O
other	O	O
DNA	O	O
-	O	O
damage	O	O
sensors	O	O
suggests	O	O
a	O	O
role	O	O
for	O	O
ATM	O	O
in	O	O
biochemical	O	O
pathways	O	O
involved	O	O
in	O	O
the	O	O
recognition	O	O
,	O	O
signalling	O	O
and	O	O
repair	O	O
of	O	O
DNA	O	O
double	O	O
-	O	O
strand	O	O
breaks	O	O
(	O	O
DSBs	O	O
)	O	O
.	O	O

There	O	O
are	O	O
strong	O	O
parallels	O	O
between	O	O
the	O	O
pattern	O	O
of	O	O
radiosensitivity	O	O
,	O	O
chromosomal	O	O
instability	O	O
and	O	O
cancer	B-Disease	D009369
predisposition	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
and	O	O
that	O	O
in	O	O
patients	O	O
with	O	O
Nijmegen	B-Disease	D049932
breakage	I-Disease	D049932
syndrome	I-Disease	D049932
(	O	O
NBS	B-Disease	D049932
)	O	O
.	O	O

The	O	O
protein	O	O
defective	O	O
in	O	O
NBS	B-Disease	D049932
,	O	O
nibrin	O	O
(	O	O
encoded	O	O
by	O	O
NBS1	O	O
)	O	O
,	O	O
forms	O	O
a	O	O
complex	O	O
with	O	O
MRE11	O	O
and	O	O
RAD50	O	O
(	O	O
refs	O	O
1	O	O
,	O	O
2	O	O
)	O	O
.	O	O

This	O	O
complex	O	O
localizes	O	O
to	O	O
DSBs	O	O
within	O	O
30	O	O
minutes	O	O
after	O	O
cellular	O	O
exposure	O	O
to	O	O
ionizing	O	O
radiation	O	O
(	O	O
IR	O	O
)	O	O
and	O	O
is	O	O
observed	O	O
in	O	O
brightly	O	O
staining	O	O
nuclear	O	O
foci	O	O
after	O	O
a	O	O
longer	O	O
period	O	O
of	O	O
time	O	O
.	O	O

The	O	O
overlap	O	O
between	O	O
clinical	O	O
and	O	O
cellular	O	O
phenotypes	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
and	O	O
NBS	B-Disease	D049932
suggests	O	O
that	O	O
ATM	O	O
and	O	O
nibrin	O	O
may	O	O
function	O	O
in	O	O
the	O	O
same	O	O
biochemical	O	O
pathway	O	O
.	O	O

Here	O	O
we	O	O
demonstrate	O	O
that	O	O
nibrin	O	O
is	O	O
phosphorylated	O	O
within	O	O
one	O	O
hour	O	O
of	O	O
treatment	O	O
of	O	O
cells	O	O
with	O	O
IR	O	O
.	O	O

This	O	O
response	O	O
is	O	O
abrogated	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
cells	O	O
that	O	O
either	O	O
do	O	O
not	O	O
express	O	O
ATM	O	O
protein	O	O
or	O	O
express	O	O
near	O	O
full	O	O
-	O	O
length	O	O
mutant	O	O
protein	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
ATM	O	O
physically	O	O
interacts	O	O
with	O	O
and	O	O
phosphorylates	O	O
nibrin	O	O
on	O	O
serine	O	O
343	O	O
both	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
.	O	O

Phosphorylation	O	O
of	O	O
this	O	O
site	O	O
appears	O	O
to	O	O
be	O	O
functionally	O	O
important	O	O
because	O	O
mutated	O	O
nibrin	O	O
(	O	O
S343A	O	O
)	O	O
does	O	O
not	O	O
completely	O	O
complement	O	O
radiosensitivity	O	O
in	O	O
NBS	B-Disease	D049932
cells	O	O
.	O	O

ATM	O	O
phosphorylation	O	O
of	O	O
nibrin	O	O
does	O	O
not	O	O
affect	O	O
nibrin	O	O
-	O	O
MRE11	O	O
-	O	O
RAD50	O	O
association	O	O
as	O	O
revealed	O	O
by	O	O
radiation	O	O
-	O	O
induced	O	O
foci	O	O
formation	O	O
.	O	O

Our	O	O
data	O	O
provide	O	O
a	O	O
biochemical	O	O
explanation	O	O
for	O	O
the	O	O
similarity	O	O
in	O	O
phenotype	O	O
between	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
and	O	O
NBS	B-Disease	D049932
.	O	O

.	O	O

Detection	O	O
of	O	O
an	O	O
unstable	O	O
fragment	O	O
of	O	O
DNA	O	O
specific	O	O
to	O	O
individuals	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
adult	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
,	O	O
with	O	O
a	O	O
prevalence	O	O
of	O	O
2	O	O
-	O	O
14	O	O
per	O	O
100	O	O
,	O	O
000	O	O
individuals	O	O
.	O	O

The	O	O
disease	O	O
is	O	O
characterized	O	O
by	O	O
progressive	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
and	O	O
sustained	B-Disease	D009120
muscle	I-Disease	D009120
contraction	I-Disease	D009120
,	O	O
often	O	O
with	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
accompanying	O	O
symptoms	O	O
.	O	O

The	O	O
age	O	O
at	O	O
onset	O	O
and	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
show	O	O
extreme	O	O
variation	O	O
,	O	O
both	O	O
within	O	O
and	O	O
between	O	O
families	O	O
.	O	O

Despite	O	O
its	O	O
clinical	O	O
variability	O	O
,	O	O
this	O	O
dominant	O	O
condition	O	O
segregates	O	O
as	O	O
a	O	O
single	O	O
locus	O	O
at	O	O
chromosome	O	O
19q13	O	O
.	O	O

3	O	O
in	O	O
every	O	O
population	O	O
studied	O	O
.	O	O

It	O	O
is	O	O
flanked	O	O
by	O	O
the	O	O
tightly	O	O
linked	O	O
genetic	O	O
markers	O	O
ERCC1	O	O
proximally	O	O
and	O	O
D19S51	O	O
distally	O	O
;	O	O
these	O	O
define	O	O
the	O	O
DM	B-Disease	D009223
critical	O	O
region	O	O
.	O	O

We	O	O
report	O	O
the	O	O
isolation	O	O
of	O	O
an	O	O
expressed	O	O
sequence	O	O
from	O	O
this	O	O
region	O	O
which	O	O
detects	O	O
a	O	O
DNA	O	O
fragment	O	O
that	O	O
is	O	O
larger	O	O
in	O	O
affected	O	O
individuals	O	O
than	O	O
in	O	O
normal	O	O
siblings	O	O
or	O	O
unaffected	O	O
controls	O	O
.	O	O

The	O	O
size	O	O
of	O	O
this	O	O
fragment	O	O
varies	O	O
between	O	O
affected	O	O
siblings	O	O
,	O	O
and	O	O
increases	O	O
in	O	O
size	O	O
through	O	O
generations	O	O
in	O	O
parallel	O	O
with	O	O
increasing	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
this	O	O
unstable	O	O
DNA	O	O
sequence	O	O
is	O	O
the	O	O
molecular	O	O
feature	O	O
that	O	O
underlies	O	O
DM	B-Disease	D009223
.	O	O

Detection	O	O
of	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
and	O	O
second	O	O
recurrent	O	O
mutation	O	O
in	O	O
the	O	O
CACNA1A	O	O
gene	O	O
in	O	O
individuals	O	O
with	O	O
EA	B-Disease	C535506
-	I-Disease	C535506
2	I-Disease	C535506
and	O	O
FHM	B-Disease	D020325
.	O	O

Mutations	O	O
in	O	O
the	O	O
brain	O	O
specific	O	O
P	O	O
/	O	O
Q	O	O
type	O	O
Ca2	O	O
+	O	O
channel	O	O
alpha1	O	O
subunit	O	O
gene	O	O
,	O	O
CACNA1A	O	O
,	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
three	O	O
clinically	O	O
distinct	O	O
disorders	O	O
,	O	O
viz	O	O
.	O	O

episodic	B-Disease	C535506
ataxia	I-Disease	C535506
type	I-Disease	C535506
2	I-Disease	C535506
(	O	O
EA	B-Disease	C535506
-	I-Disease	C535506
2	I-Disease	C535506
)	O	O
,	O	O
familial	B-Disease	D020325
hemiplegic	I-Disease	D020325
migraine	I-Disease	D020325
(	O	O
FHM	B-Disease	D020325
)	O	O
and	O	O
spinocerebellar	B-Disease	OMIM:183086
ataxia	I-Disease	OMIM:183086
6	I-Disease	OMIM:183086
(	O	O
SCA6	B-Disease	OMIM:183086
)	O	O
.	O	O

For	O	O
individuals	O	O
with	O	O
EA	B-Disease	C535506
-	I-Disease	C535506
2	I-Disease	C535506
,	O	O
the	O	O
mutations	O	O
described	O	O
thus	O	O
far	O	O
are	O	O
presumed	O	O
to	O	O
result	O	O
in	O	O
a	O	O
truncated	O	O
protein	O	O
product	O	O
.	O	O

Several	O	O
different	O	O
missense	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
FHM	B-Disease	D020325
.	O	O

At	O	O
least	O	O
two	O	O
of	O	O
these	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
on	O	O
two	O	O
different	O	O
chromosome	O	O
19p13	O	O
haplotypes	O	O
and	O	O
thus	O	O
represent	O	O
recurrent	O	O
mutations	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
have	O	O
screened	O	O
several	O	O
individuals	O	O
for	O	O
mutations	O	O
in	O	O
all	O	O
47	O	O
exons	O	O
in	O	O
the	O	O
CACNA1A	O	O
gene	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
analysis	O	O
.	O	O

We	O	O
have	O	O
characterised	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
,	O	O
G5260A	O	O
,	O	O
in	O	O
exon	O	O
32	O	O
in	O	O
a	O	O
family	O	O
segregating	O	O
for	O	O
EA	B-Disease	C535506
-	I-Disease	C535506
2	I-Disease	C535506
.	O	O

The	O	O
consequence	O	O
of	O	O
this	O	O
mutation	O	O
is	O	O
an	O	O
amino	O	O
acid	O	O
substitution	O	O
at	O	O
a	O	O
highly	O	O
conserved	O	O
position	O	O
within	O	O
the	O	O
CACNA1A	O	O
gene	O	O
.	O	O

This	O	O
represents	O	O
the	O	O
first	O	O
point	O	O
mutation	O	O
not	O	O
resulting	O	O
in	O	O
a	O	O
proposed	O	O
truncated	O	O
protein	O	O
.	O	O

Furthermore	O	O
,	O	O
this	O	O
mutation	O	O
has	O	O
been	O	O
detected	O	O
in	O	O
a	O	O
family	O	O
member	O	O
with	O	O
mild	O	O
clinical	O	O
signs	O	O
including	O	O
only	O	O
migraine	B-Disease	D008881
.	O	O

Additionally	O	O
,	O	O
a	O	O
second	O	O
previously	O	O
identified	O	O
recurrent	O	O
muta	O	O
tion	O	O
,	O	O
C2272T	O	O
,	O	O
in	O	O
exon	O	O
16	O	O
has	O	O
been	O	O
discovered	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
FHM	B-Disease	D020325
.	O	O

.	O	O

Dominant	O	O
negative	O	O
effect	O	O
of	O	O
the	O	O
APC1309	O	O
mutation	O	O
:	O	O
a	O	O
possible	O	O
explanation	O	O
for	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
.	O	O

Inactivation	O	O
of	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
product	O	O
initiates	O	O
colorectal	O	O
tumorigenesis	O	O
.	O	O

Patients	O	O
with	O	O
familial	B-Disease	D011125
APC	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
carry	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
and	O	O
develop	O	O
multiple	O	O
colorectal	B-Disease	D003123
adenomas	I-Disease	D003123
and	O	O
subsequent	O	O
carcinomas	B-Disease	D009369
early	O	O
in	O	O
life	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
correlates	O	O
with	O	O
the	O	O
position	O	O
of	O	O
the	O	O
inherited	O	O
APC	B-Disease	D011125
mutation	O	O
(	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
)	O	O
.	O	O

Together	O	O
with	O	O
the	O	O
fact	O	O
that	O	O
both	O	O
germ	O	O
-	O	O
line	O	O
and	O	O
sporadic	O	O
APC	B-Disease	D011125
mutations	O	O
cluster	O	O
in	O	O
the	O	O
central	O	O
region	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
this	O	O
points	O	O
to	O	O
a	O	O
dominant	O	O
negative	O	O
effect	O	O
of	O	O
certain	O	O
APC	B-Disease	D011125
mutants	O	O
.	O	O

Loss	O	O
of	O	O
APC	B-Disease	D011125
function	O	O
was	O	O
recently	O	O
shown	O	O
to	O	O
result	O	O
in	O	O
enhanced	O	O
beta	O	O
-	O	O
catenin	O	O
-	O	O
/	O	O
Tcf	O	O
-	O	O
mediated	O	O
transcription	O	O
in	O	O
colon	O	O
epithelial	O	O
cells	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
provide	O	O
experimental	O	O
evidence	O	O
for	O	O
a	O	O
dominant	O	O
negative	O	O
effect	O	O
of	O	O
APC	B-Disease	D011125
gene	O	O
products	O	O
associated	O	O
with	O	O
severe	O	O
polyposis	B-Disease	D044483
.	O	O

Wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
activity	O	O
in	O	O
beta	O	O
-	O	O
catenin	O	O
-	O	O
/	O	O
Tcf	O	O
-	O	O
mediated	O	O
transcription	O	O
was	O	O
strongly	O	O
inhibited	O	O
by	O	O
a	O	O
mutant	O	O
APC	B-Disease	D011125
that	O	O
is	O	O
truncated	O	O
at	O	O
codon	O	O
1309	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
mutant	O	O
APC	B-Disease	D011125
gene	O	O
products	O	O
that	O	O
are	O	O
associated	O	O
with	O	O
attenuated	B-Disease	C538265
polyposis	I-Disease	C538265
(	O	O
codon	O	O
386	O	O
or	O	O
1465	O	O
)	O	O
interfered	O	O
only	O	O
weakly	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
activity	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
a	O	O
molecular	O	O
explanation	O	O
for	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
and	O	O
support	O	O
the	O	O
idea	O	O
that	O	O
colorectal	B-Disease	D015179
tumor	I-Disease	D015179
growth	O	O
might	O	O
be	O	O
,	O	O
in	O	O
part	O	O
,	O	O
driven	O	O
by	O	O
selection	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
mutation	O	O
cluster	O	O
region	O	O
.	O	O

.	O	O

Mutation	O	O
of	O	O
the	O	O
KIT	O	O
(	O	O
mast	O	O
/	O	O
stem	O	O
cell	O	O
growth	O	O
factor	O	O
receptor	O	O
)	O	O
protooncogene	O	O
in	O	O
human	O	O
piebaldism	B-Disease	D016116
.	O	O

Piebaldism	B-Disease	D016116
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
genetic	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
cogenital	O	O
patches	O	O
of	O	O
skin	O	O
and	O	O
hair	O	O
from	O	O
which	O	O
melanocytes	O	O
are	O	O
completely	O	O
absent	O	O
.	O	O

A	O	O
similar	O	O
disorder	O	O
of	O	O
mouse	O	O
,	O	O
dominant	O	O
white	O	O
spotting	O	O
(	O	O
W	O	O
)	O	O
,	O	O
results	O	O
from	O	O
mutations	O	O
of	O	O
the	O	O
c	O	O
-	O	O
Kit	O	O
protooncogene	O	O
,	O	O
which	O	O
encodes	O	O
and	O	O
receptor	O	O
for	O	O
mast	O	O
/	O	O
stem	O	O
cell	O	O
growth	O	O
factor	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
KIT	O	O
gene	O	O
mutation	O	O
in	O	O
a	O	O
proband	O	O
with	O	O
classic	O	O
autosomal	O	O
dominant	O	O
piebaldism	B-Disease	D016116
.	O	O

This	O	O
mutation	O	O
results	O	O
in	O	O
a	O	O
Gly	O	O
-	O	O
-	O	O
-	O	O
-	O	O
Arg	O	O
substitution	O	O
at	O	O
codon	O	O
664	O	O
,	O	O
within	O	O
the	O	O
tyrosine	O	O
kinase	O	O
domain	O	O
.	O	O

This	O	O
substitution	O	O
was	O	O
not	O	O
seen	O	O
in	O	O
any	O	O
normal	O	O
individuals	O	O
and	O	O
was	O	O
completely	O	O
linked	O	O
to	O	O
the	O	O
piebald	B-Disease	D016116
phenotype	O	O
in	O	O
the	O	O
probands	O	O
family	O	O
.	O	O

Piebaldism	B-Disease	D016116
in	O	O
this	O	O
family	O	O
thus	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
human	O	O
homologue	O	O
to	O	O
dominant	O	O
white	O	O
spotting	O	O
(	O	O
W	O	O
)	O	O
of	O	O
the	O	O
mouse	O	O
.	O	O

.	O	O

An	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
missense	O	O
mutation	O	O
(	O	O
T274M	O	O
)	O	O
causing	O	O
late	B-Disease	D007966
-	I-Disease	D007966
infantile	I-Disease	D007966
metachromatic	I-Disease	D007966
leukodystrophy	I-Disease	D007966
.	O	O

Metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D016464
recessive	I-Disease	D016464
lysosomal	I-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	D007966
of	I-Disease	D007966
arylsulfatase	I-Disease	D007966
A	I-Disease	D007966
(	O	O
ARSA	O	O
;	O	O
EC	O	O
3	O	O
.	O	O

1	O	O
.	O	O

6	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
8	O	O
ARSA	O	O
exons	O	O
and	O	O
adjacent	O	O
intron	O	O
boundaries	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
late	B-Disease	D007966
-	I-Disease	D007966
infantile	I-Disease	D007966
metachromatic	I-Disease	D007966
leukodystrophy	I-Disease	D007966
were	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
amplified	O	O
in	O	O
seven	O	O
discrete	O	O
reactions	O	O
.	O	O

Amplified	O	O
ARSA	O	O
exons	O	O
were	O	O
analysed	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
sequence	O	O
alterations	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
,	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
of	O	O
PCR	O	O
products	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
a	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
in	O	O
exon	O	O
IV	O	O
that	O	O
results	O	O
in	O	O
the	O	O
substitution	O	O
of	O	O
a	O	O
highly	O	O
conserved	O	O
threonine	O	O
residue	O	O
at	O	O
amino	O	O
acid	O	O
274	O	O
with	O	O
a	O	O
methionine	O	O
(	O	O
T274M	O	O
)	O	O
.	O	O

Analysis	O	O
of	O	O
a	O	O
further	O	O
29	O	O
MLD	B-Disease	D007966
patients	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
five	O	O
additional	O	O
homozygotes	O	O
for	O	O
T274M	O	O
.	O	O

All	O	O
6	O	O
T274M	O	O
homozygotes	O	O
(	O	O
representing	O	O
four	O	O
families	O	O
)	O	O
were	O	O
of	O	O
Lebanese	O	O
descent	O	O
,	O	O
and	O	O
all	O	O
were	O	O
known	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
consanguineous	O	O
marriages	O	O
.	O	O

The	O	O
altered	O	O
amino	O	O
acid	O	O
is	O	O
rigidly	O	O
conserved	O	O
among	O	O
10	O	O
sulfatases	O	O
from	O	O
Escherichia	O	O
coli	O	O
to	O	O
humans	O	O
;	O	O
therefore	O	O
,	O	O
it	O	O
is	O	O
most	O	O
likely	O	O
that	O	O
the	O	O
resultant	O	O
mutant	O	O
protein	O	O
will	O	O
have	O	O
little	O	O
or	O	O
no	O	O
enzyme	O	O
activity	O	O
.	O	O

This	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
very	O	O
low	O	O
ARSA	O	O
activity	O	O
measured	O	O
in	O	O
these	O	O
patients	O	O
and	O	O
their	O	O
uniformly	O	O
severe	O	O
clinical	O	O
presentation	O	O
Mutations	O	O
in	O	O
the	O	O
gene	O	O
for	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
in	O	O
patients	O	O
with	O	O
different	O	O
clinical	O	O
phenotypes	O	O
.	O	O

Recently	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
most	O	O
common	O	O
peroxisomal	B-Disease	D018901
disorder	I-Disease	D018901
,	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
,	O	O
has	O	O
been	O	O
described	O	O
encoding	O	O
a	O	O
peroxisomal	O	O
membrane	O	O
transporter	O	O
protein	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
entire	O	O
protein	O	O
-	O	O
coding	O	O
sequence	O	O
of	O	O
this	O	O
gene	O	O
by	O	O
reverse	O	O
-	O	O
transcription	O	O
PCR	O	O
,	O	O
SSCP	O	O
,	O	O
and	O	O
DNA	O	O
sequencing	O	O
in	O	O
five	O	O
patients	O	O
with	O	O
different	O	O
clinical	O	O
expression	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
and	O	O
in	O	O
their	O	O
female	O	O
relatives	O	O
;	O	O
these	O	O
clinical	O	O
expressions	O	O
were	O	O
cerebral	O	O
childhood	O	O
ALD	B-Disease	D000326
,	O	O
adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
,	O	O
and	O	O
"	O	O
Addison	B-Disease	D000224
disease	I-Disease	D000224
only	I-Disease	D000224
"	O	O
(	O	O
ADO	B-Disease	D000224
)	O	O
phenotype	O	O
.	O	O

In	O	O
the	O	O
three	O	O
patients	O	O
exhibiting	O	O
the	O	O
classical	O	O
picture	O	O
of	O	O
severe	O	O
childhood	O	O
ALD	B-Disease	D000326
we	O	O
identified	O	O
in	O	O
the	O	O
5	O	O
portion	O	O
of	O	O
the	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
gene	O	O
a	O	O
38	O	O
-	O	O
bp	O	O
deletion	O	O
that	O	O
causes	O	O
a	O	O
frameshift	O	O
mutation	O	O
,	O	O
a	O	O
3	O	O
-	O	O
bp	O	O
deletion	O	O
leading	O	O
to	O	O
a	O	O
deletion	O	O
of	O	O
an	O	O
amino	O	O
acid	O	O
in	O	O
the	O	O
ATP	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
protein	O	O
,	O	O
and	O	O
a	O	O
missense	O	O
mutation	O	O
.	O	O

In	O	O
the	O	O
patient	O	O
with	O	O
the	O	O
clinical	O	O
phenotype	O	O
of	O	O
AMN	B-Disease	D000326
,	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
codon	O	O
212	O	O
,	O	O
along	O	O
with	O	O
a	O	O
second	O	O
site	O	O
mutation	O	O
at	O	O
codon	O	O
178	O	O
,	O	O
was	O	O
observed	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
patient	O	O
with	O	O
the	O	O
ADO	B-Disease	D000224
phenotype	O	O
revealed	O	O
a	O	O
further	O	O
missense	O	O
mutation	O	O
at	O	O
a	O	O
highly	O	O
conserved	O	O
position	O	O
in	O	O
the	O	O
ALDP	O	O
/	O	O
PMP70	O	O
comparison	O	O
.	O	O

The	O	O
disruptive	O	O
nature	O	O
of	O	O
two	O	O
mutations	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
the	O	O
frameshift	O	O
and	O	O
the	O	O
nonsense	O	O
mutation	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
biochemically	O	O
proved	O	O
childhood	O	O
ALD	B-Disease	D000326
and	O	O
AMN	B-Disease	D000326
further	O	O
strongly	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
alterations	O	O
in	O	O
this	O	O
gene	O	O
play	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
.	O	O

Since	O	O
the	O	O
current	O	O
biochemical	O	O
techniques	O	O
for	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
carrier	O	O
detection	O	O
in	O	O
affected	O	O
families	O	O
lack	O	O
sufficient	O	O
reliability	O	O
,	O	O
our	O	O
procedure	O	O
described	O	O
for	O	O
systematic	O	O
mutation	O	O
scanning	O	O
is	O	O
also	O	O
capable	O	O
of	O	O
improving	O	O
genetic	O	O
counseling	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
Atelosteogenesis	B-Disease	C535395
type	I-Disease	C535395
II	I-Disease	C535395
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
sulfate	O	O
-	O	O
transporter	O	O
gene	O	O
(	O	O
DTDST	O	O
)	O	O
:	O	O
evidence	O	O
for	O	O
a	O	O
phenotypic	O	O
series	O	O
involving	O	O
three	O	O
chondrodysplasias	B-Disease	D010009
.	O	O

Atelosteogenesis	B-Disease	C535395
type	I-Disease	C535395
II	I-Disease	C535395
(	O	O
AO	B-Disease	C535395
II	I-Disease	C535395
)	O	O
is	O	O
a	O	O
neonatally	O	O
lethal	O	O
chondrodysplasia	B-Disease	D010009
whose	O	O
clinical	O	O
and	O	O
histological	O	O
characteristics	O	O
resemble	O	O
those	O	O
of	O	O
another	O	O
chondrodysplasia	B-Disease	D010009
,	O	O
the	O	O
much	O	O
less	O	O
severe	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
(	O	O
DTD	B-Disease	C536170
)	O	O
.	O	O

The	O	O
similarity	O	O
suggests	O	O
a	O	O
shared	O	O
pathogenesis	O	O
involving	O	O
lesions	O	O
in	O	O
the	O	O
same	O	O
biochemical	O	O
pathway	O	O
and	O	O
perhaps	O	O
the	O	O
same	O	O
gene	O	O
.	O	O

DTD	B-Disease	C536170
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
recently	O	O
identified	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
sulfate	O	O
-	O	O
transporter	O	O
gene	O	O
(	O	O
DTDST	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
AOII	B-Disease	C535395
patients	O	O
also	O	O
have	O	O
DTDST	O	O
mutations	O	O
,	O	O
which	O	O
lead	O	O
to	O	O
defective	O	O
uptake	O	O
of	O	O
inorganic	O	O
sulfate	O	O
and	O	O
insufficient	O	O
sulfation	O	O
of	O	O
macromolecules	O	O
by	O	O
patient	O	O
mesenchymal	O	O
cells	O	O
in	O	O
vitro	O	O
.	O	O

Together	O	O
with	O	O
our	O	O
recent	O	O
observation	O	O
that	O	O
a	O	O
third	O	O
even	O	O
more	O	O
severe	O	O
chondrodysplasia	B-Disease	D010009
,	O	O
achondrogenesis	O	O
type	O	O
IB	O	O
,	O	O
is	O	O
also	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
DTDST	O	O
,	O	O
these	O	O
results	O	O
demonstrate	O	O
a	O	O
phenotypic	O	O
series	O	O
of	O	O
three	O	O
chondrodysplasias	B-Disease	D010009
of	O	O
increasing	O	O
severity	O	O
caused	O	O
by	O	O
lesions	O	O
in	O	O
a	O	O
single	O	O
sulfate	O	O
-	O	O
transporter	O	O
gene	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
the	O	O
phenotype	O	O
appears	O	O
to	O	O
be	O	O
correlated	O	O
with	O	O
the	O	O
predicted	O	O
effect	O	O
of	O	O
the	O	O
mutations	O	O
on	O	O
the	O	O
residual	O	O
activity	O	O
of	O	O
the	O	O
DTDST	O	O
protein	O	O
.	O	O

.	O	O

Emerin	B-Disease	D020389
,	I-Disease	D020389
deficiency	I-Disease	D020389
of	O	O
which	O	O
causes	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
,	O	O
is	O	O
localized	O	O
at	O	O
the	O	O
inner	O	O
nuclear	O	O
membrane	O	O
.	O	O

X	B-Disease	D020389
-	I-Disease	D020389
linked	I-Disease	D020389
recessive	I-Disease	D020389
Emery	I-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
is	O	O
an	O	O
inherited	B-Disease	D009135	D030342
muscle	I-Disease	D009135	D030342
disorder	I-Disease	D009135	D030342
characterized	O	O
by	O	O
the	O	O
clinical	O	O
triad	O	O
of	O	O
progressive	O	O
wasting	B-Disease	D019282
of	I-Disease	D019282
humero	I-Disease	D019282
-	I-Disease	D019282
peroneal	I-Disease	D019282
muscles	I-Disease	D019282
,	O	O
early	O	O
contractures	B-Disease	D003286
of	I-Disease	D003286
the	I-Disease	D003286
elbows	I-Disease	D003286
,	I-Disease	D003286
Achilles	I-Disease	D003286
tendons	I-Disease	D003286
and	I-Disease	D003286
postcervical	I-Disease	D003286
muscles	I-Disease	D003286
,	O	O
and	O	O
cardiac	B-Disease	D006327
conduction	I-Disease	D006327
block	I-Disease	D006327
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
.	O	O

The	O	O
gene	O	O
for	O	O
EDMD	B-Disease	D020389
on	O	O
Xq28	O	O
encodes	O	O
a	O	O
novel	O	O
protein	O	O
named	O	O
emerin	O	O
that	O	O
localizes	O	O
at	O	O
the	O	O
nuclear	O	O
membrane	O	O
of	O	O
skeletal	O	O
,	O	O
cardiac	O	O
and	O	O
smooth	O	O
muscles	O	O
and	O	O
some	O	O
other	O	O
non	O	O
-	O	O
muscle	O	O
tissues	O	O
.	O	O

To	O	O
investigate	O	O
a	O	O
possible	O	O
physiological	O	O
role	O	O
for	O	O
emerin	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
ultrastructural	O	O
localization	O	O
of	O	O
the	O	O
protein	O	O
in	O	O
human	O	O
skeletal	O	O
muscle	O	O
and	O	O
HeLa	O	O
cells	O	O
,	O	O
using	O	O
ultrathin	O	O
cryosections	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
immune	O	O
-	O	O
labeled	O	O
colloidal	O	O
gold	O	O
particles	O	O
were	O	O
localized	O	O
on	O	O
the	O	O
nucleoplasmic	O	O
surface	O	O
of	O	O
the	O	O
inner	O	O
nuclear	O	O
membrane	O	O
,	O	O
but	O	O
not	O	O
on	O	O
the	O	O
nuclear	O	O
pore	O	O
.	O	O

Emerin	O	O
stayed	O	O
on	O	O
the	O	O
cytoplasmic	O	O
surface	O	O
of	O	O
the	O	O
nuclear	O	O
lamina	O	O
,	O	O
even	O	O
after	O	O
detergent	O	O
treatment	O	O
that	O	O
solubilizes	O	O
membrane	O	O
lipids	O	O
and	O	O
washes	O	O
out	O	O
membrane	O	O
proteins	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
emerin	O	O
anchors	O	O
at	O	O
the	O	O
inner	O	O
nuclear	O	O
membrane	O	O
through	O	O
the	O	O
hydrophobic	O	O
stretch	O	O
,	O	O
and	O	O
protrudes	O	O
from	O	O
the	O	O
hydrophilic	O	O
region	O	O
to	O	O
the	O	O
nucleoplasm	O	O
where	O	O
it	O	O
interacts	O	O
with	O	O
the	O	O
nuclear	O	O
lamina	O	O
.	O	O

We	O	O
speculate	O	O
that	O	O
emerin	O	O
contributes	O	O
to	O	O
maintain	O	O
the	O	O
nuclear	O	O
structure	O	O
and	O	O
stability	O	O
,	O	O
as	O	O
well	O	O
as	O	O
nuclear	O	O
functions	O	O
,	O	O
particularly	O	O
in	O	O
muscle	O	O
tissues	O	O
that	O	O
have	O	O
severe	O	O
stress	O	O
with	O	O
rigorous	O	O
contraction	O	O
-	O	O
relaxation	O	O
movements	O	O
and	O	O
calcium	O	O
flux	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
common	O	O
PEX1	O	O
mutation	O	O
in	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
.	O	O

The	O	O
Zellweger	B-Disease	D015211
spectrum	I-Disease	D015211
of	I-Disease	D015211
disease	I-Disease	D015211
,	O	O
encompassing	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
and	O	O
the	O	O
progressively	O	O
milder	O	O
phenotypes	O	O
of	O	O
neonatal	B-Disease	OMIM:202370
adrenoleukodystrophy	I-Disease	OMIM:202370
and	O	O
infantile	B-Disease	D052919
Refsum	I-Disease	D052919
disease	I-Disease	D052919
,	O	O
is	O	O
due	O	O
to	O	O
a	O	O
failure	O	O
to	O	O
form	O	O
functional	O	O
peroxisomes	O	O
.	O	O

Cell	O	O
fusion	O	O
complementation	O	O
studies	O	O
demonstrated	O	O
that	O	O
these	O	O
diseases	O	O
are	O	O
genetically	O	O
heterogeneous	O	O
,	O	O
with	O	O
two	O	O
-	O	O
thirds	O	O
of	O	O
all	O	O
patients	O	O
lying	O	O
within	O	O
a	O	O
single	O	O
complementation	O	O
group	O	O
,	O	O
CG1	O	O
.	O	O

Molecular	O	O
genetic	O	O
and	O	O
cell	O	O
biology	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
PEX1	O	O
is	O	O
deficient	O	O
in	O	O
many	O	O
CG1	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
previous	O	O
studies	O	O
have	O	O
focused	O	O
on	O	O
mildly	O	O
affected	O	O
patients	O	O
and	O	O
there	O	O
is	O	O
still	O	O
no	O	O
report	O	O
of	O	O
two	O	O
mutant	O	O
PEX1	O	O
alleles	O	O
in	O	O
any	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
patient	O	O
.	O	O

Furthermore	O	O
,	O	O
mutations	O	O
in	O	O
the	O	O
PMP70	O	O
gene	O	O
have	O	O
also	O	O
been	O	O
identified	O	O
in	O	O
two	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
patients	O	O
from	O	O
CG1	O	O
,	O	O
raising	O	O
the	O	O
possibility	O	O
that	O	O
CG1	O	O
patients	O	O
may	O	O
represent	O	O
a	O	O
mixture	O	O
of	O	O
PEX1	O	O
-	O	O
deficient	O	O
and	O	O
PMP70	O	O
-	O	O
deficient	O	O
individuals	O	O
.	O	O

To	O	O
address	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
disease	O	O
in	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
patients	O	O
from	O	O
CG1	O	O
,	O	O
we	O	O
examined	O	O
all	O	O
24	O	O
PEX1	O	O
exons	O	O
in	O	O
four	O	O
patients	O	O
,	O	O
including	O	O
both	O	O
patients	O	O
that	O	O
have	O	O
mutations	O	O
in	O	O
PMP70	O	O
.	O	O

PEX1	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
all	O	O
four	O	O
patients	O	O
,	O	O
including	O	O
a	O	O
1	O	O
-	O	O
bp	O	O
insertion	O	O
(	O	O
c	O	O
.	O	O

2097insT	O	O
)	O	O
in	O	O
exon	O	O
13	O	O
that	O	O
was	O	O
present	O	O
in	O	O
three	O	O
of	O	O
the	O	O
four	O	O
patients	O	O
.	O	O

Subsequent	O	O
studies	O	O
demonstrated	O	O
that	O	O
this	O	O
mutation	O	O
is	O	O
present	O	O
in	O	O
one	O	O
-	O	O
half	O	O
of	O	O
all	O	O
CG1	O	O
patients	O	O
and	O	O
correlates	O	O
with	O	O
the	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
phenotype	O	O
.	O	O

As	O	O
this	O	O
mutation	O	O
leads	O	O
to	O	O
a	O	O
loss	O	O
of	O	O
protein	O	O
function	O	O
its	O	O
frequency	O	O
makes	O	O
it	O	O
the	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
,	O	O
helping	O	O
to	O	O
explain	O	O
the	O	O
high	O	O
percentage	O	O
of	O	O
patients	O	O
that	O	O
belong	O	O
to	O	O
CG1	O	O
.	O	O

Polymorphisms	O	O
of	O	O
the	O	O
CYP2D6	O	O
gene	O	O
increase	O	O
susceptibility	O	O
to	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
.	O	O

Ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
(	O	O
AS	B-Disease	D013167
)	O	O
is	O	O
a	O	O
common	O	O
and	O	O
highly	O	O
familial	O	O
rheumatic	B-Disease	D012216
disorder	I-Disease	D012216
.	O	O

The	O	O
sibling	O	O
recurrence	O	O
risk	O	O
ratio	O	O
for	O	O
the	O	O
disease	O	O
is	O	O
63	O	O
and	O	O
heritability	O	O
assessed	O	O
in	O	O
twins	O	O
>	O	O
90	O	O
%	O	O
.	O	O

Although	O	O
MHC	O	O
genes	O	O
,	O	O
including	O	O
HLA	O	O
-	O	O
B27	O	O
,	O	O
contribute	O	O
only	O	O
20	O	O
-	O	O
50	O	O
%	O	O
of	O	O
the	O	O
genetic	O	O
risk	O	O
for	O	O
the	O	O
disease	O	O
,	O	O
no	O	O
non	O	O
-	O	O
MHC	O	O
gene	O	O
has	O	O
yet	O	O
been	O	O
convincingly	O	O
demonstrated	O	O
to	O	O
influence	O	O
either	O	O
susceptibility	O	O
to	O	O
the	O	O
disease	O	O
or	O	O
its	O	O
phenotypic	O	O
expression	O	O
.	O	O

Previous	O	O
linkage	O	O
and	O	O
association	O	O
studies	O	O
have	O	O
suggested	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
susceptibility	O	O
gene	O	O
for	O	O
AS	B-Disease	D013167
close	O	O
to	O	O
,	O	O
or	O	O
within	O	O
,	O	O
the	O	O
cytochrome	O	O
P450	O	O
2D6	O	O
gene	O	O
(	O	O
CYP2D6	O	O
,	O	O
debrisoquine	O	O
hydroxylase	O	O
)	O	O
located	O	O
at	O	O
chromosome	O	O
22q13	O	O
.	O	O

1	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
linkage	O	O
study	O	O
of	O	O
chromosome	O	O
22	O	O
in	O	O
200	O	O
families	O	O
with	O	O
AS	B-Disease	D013167
affected	O	O
sibling	O	O
-	O	O
pairs	O	O
.	O	O

Association	O	O
of	O	O
alleles	O	O
of	O	O
the	O	O
CYP2D6	O	O
gene	O	O
was	O	O
examined	O	O
by	O	O
both	O	O
case	O	O
-	O	O
control	O	O
and	O	O
within	O	O
-	O	O
family	O	O
means	O	O
.	O	O

For	O	O
case	O	O
-	O	O
control	O	O
studies	O	O
,	O	O
617	O	O
unrelated	O	O
individuals	O	O
with	O	O
AS	B-Disease	D013167
(	O	O
361	O	O
probands	O	O
from	O	O
sibling	O	O
-	O	O
pair	O	O
and	O	O
parent	O	O
-	O	O
case	O	O
trio	O	O
families	O	O
and	O	O
256	O	O
unrelated	O	O
non	O	O
-	O	O
familial	O	O
sporadic	O	O
cases	O	O
)	O	O
and	O	O
402	O	O
healthy	O	O
ethnically	O	O
matched	O	O
controls	O	O
were	O	O
employed	O	O
.	O	O

For	O	O
within	O	O
-	O	O
family	O	O
association	O	O
studies	O	O
,	O	O
361	O	O
families	O	O
including	O	O
161	O	O
parent	O	O
-	O	O
case	O	O
trios	O	O
and	O	O
200	O	O
affected	O	O
sibling	O	O
-	O	O
pair	O	O
families	O	O
were	O	O
employed	O	O
.	O	O

Homozygosity	O	O
for	O	O
poor	O	O
metabolizer	O	O
alleles	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
AS	B-Disease	D013167
.	O	O

Heterozygosity	O	O
for	O	O
the	O	O
most	O	O
frequent	O	O
poor	O	O
metabolizer	O	O
allele	O	O
(	O	O
CYP2D6	O	O
*	O	O
4	O	O
)	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
increased	O	O
susceptibility	O	O
to	O	O
AS	B-Disease	D013167
.	O	O

Significant	O	O
within	O	O
-	O	O
family	O	O
association	O	O
of	O	O
CYP2D6	O	O
*	O	O
4	O	O
alleles	O	O
and	O	O
AS	B-Disease	D013167
was	O	O
demonstrated	O	O
.	O	O

Weak	O	O
linkage	O	O
was	O	O
also	O	O
demonstrated	O	O
between	O	O
CYP2D6	O	O
and	O	O
AS	B-Disease	D013167
.	O	O

We	O	O
postulate	O	O
that	O	O
altered	O	O
metabolism	O	O
of	O	O
a	O	O
natural	O	O
toxin	O	O
or	O	O
antigen	O	O
by	O	O
the	O	O
CYP2D6	O	O
gene	O	O
may	O	O
increase	O	O
susceptibility	O	O
to	O	O
AS	B-Disease	D013167
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
the	O	O
genotype	O	O
-	O	O
phenotype	O	O
relationship	O	O
in	O	O
factor	B-Disease	D005171
X	I-Disease	D005171
deficiency	I-Disease	D005171
.	O	O

Factor	B-Disease	D005171
X	I-Disease	D005171
deficiency	I-Disease	D005171
is	O	O
a	O	O
rare	O	O
haemorrhagic	B-Disease	D006474
condition	I-Disease	D006474
,	O	O
normally	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
,	O	O
in	O	O
which	O	O
a	O	O
variable	O	O
clinical	O	O
presentation	O	O
correlates	O	O
poorly	O	O
with	O	O
laboratory	O	O
phenotype	O	O
.	O	O

The	O	O
factor	O	O
X	O	O
(	O	O
F10	O	O
)	O	O
genes	O	O
of	O	O
14	O	O
unrelated	O	O
individuals	O	O
with	O	O
factor	B-Disease	D005171
X	I-Disease	D005171
deficiency	I-Disease	D005171
(	O	O
12	O	O
familial	O	O
and	O	O
two	O	O
sporadic	O	O
cases	O	O
)	O	O
were	O	O
sequenced	O	O
yielding	O	O
a	O	O
total	O	O
of	O	O
13	O	O
novel	O	O
mutations	O	O
.	O	O

Family	O	O
studies	O	O
were	O	O
performed	O	O
in	O	O
order	O	O
to	O	O
distinguish	O	O
the	O	O
contributions	O	O
of	O	O
individual	O	O
mutant	O	O
F10	O	O
alleles	O	O
to	O	O
the	O	O
clinical	O	O
and	O	O
laboratory	O	O
phenotypes	O	O
.	O	O

Missense	O	O
mutations	O	O
were	O	O
studied	O	O
by	O	O
means	O	O
of	O	O
molecular	O	O
modelling	O	O
,	O	O
whereas	O	O
single	O	O
basepair	O	O
substitutions	O	O
in	O	O
splice	O	O
sites	O	O
and	O	O
the	O	O
5	O	O
flanking	O	O
region	O	O
were	O	O
examined	O	O
by	O	O
in	O	O
vitro	O	O
splicing	O	O
assay	O	O
and	O	O
luciferase	O	O
reporter	O	O
gene	O	O
assay	O	O
respectively	O	O
.	O	O

The	O	O
deletion	O	O
allele	O	O
of	O	O
a	O	O
novel	O	O
hexanucleotide	O	O
insertion	O	O
/	O	O
deletion	O	O
polymorphism	O	O
in	O	O
the	O	O
F10	O	O
gene	O	O
promoter	O	O
region	O	O
was	O	O
shown	O	O
by	O	O
reporter	O	O
gene	O	O
assay	O	O
,	O	O
to	O	O
reduce	O	O
promoter	O	O
activity	O	O
by	O	O
approximately	O	O
20	O	O
%	O	O
.	O	O

One	O	O
family	O	O
manifesting	O	O
an	O	O
autosomal	O	O
dominant	O	O
pattern	O	O
of	O	O
inheritance	O	O
possessed	O	O
three	O	O
clinically	O	O
affected	O	O
members	O	O
who	O	O
were	O	O
heterozygous	O	O
for	O	O
a	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
that	O	O
was	O	O
predicted	O	O
to	O	O
lead	O	O
to	O	O
the	O	O
production	O	O
of	O	O
a	O	O
truncated	O	O
protein	O	O
product	O	O
.	O	O

A	O	O
model	O	O
which	O	O
accounts	O	O
for	O	O
the	O	O
dominant	O	O
negative	O	O
effect	O	O
of	O	O
this	O	O
lesion	O	O
is	O	O
presented	O	O
.	O	O

Variation	O	O
in	O	O
the	O	O
antigen	O	O
level	O	O
of	O	O
heterozygous	O	O
relatives	O	O
of	O	O
probands	O	O
was	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
higher	O	O
between	O	O
families	O	O
than	O	O
within	O	O
families	O	O
,	O	O
consistent	O	O
with	O	O
the	O	O
view	O	O
that	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
F10	O	O
lesion	O	O
(	O	O
s	O	O
)	O	O
segregating	O	O
in	O	O
a	O	O
given	O	O
family	O	O
is	O	O
a	O	O
prime	O	O
determinant	O	O
of	O	O
the	O	O
laboratory	O	O
phenotype	O	O
.	O	O

By	O	O
contrast	O	O
,	O	O
no	O	O
such	O	O
relationship	O	O
could	O	O
be	O	O
discerned	O	O
between	O	O
laboratory	O	O
phenotype	O	O
and	O	O
polymorphism	O	O
genotype	O	O
.	O	O

.	O	O

Restoration	O	O
of	O	O
photoreceptor	O	O
ultrastructure	O	O
and	O	O
function	O	O
in	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
slow	O	O
mice	O	O
by	O	O
gene	O	O
therapy	O	O
.	O	O

The	O	O
gene	O	O
Prph2	O	O
encodes	O	O
a	O	O
photoreceptor	O	O
-	O	O
specific	O	O
membrane	O	O
glycoprotein	O	O
,	O	O
peripherin	O	O
-	O	O
2	O	O
(	O	O
also	O	O
known	O	O
as	O	O
peripherin	O	O
/	O	O
rds	O	O
)	O	O
,	O	O
which	O	O
is	O	O
inserted	O	O
into	O	O
the	O	O
rims	O	O
of	O	O
photoreceptor	O	O
outer	O	O
segment	O	O
discs	O	O
in	O	O
a	O	O
complex	O	O
with	O	O
rom	O	O
-	O	O
1	O	O
(	O	O
ref	O	O
.	O	O

2	O	O
)	O	O
.	O	O

The	O	O
complex	O	O
is	O	O
necessary	O	O
for	O	O
the	O	O
stabilization	O	O
of	O	O
the	O	O
discs	O	O
,	O	O
which	O	O
are	O	O
renewed	O	O
constantly	O	O
throughout	O	O
life	O	O
,	O	O
and	O	O
which	O	O
contain	O	O
the	O	O
visual	O	O
pigments	O	O
necessary	O	O
for	O	O
photon	O	O
capture	O	O
.	O	O

Mutations	O	O
in	O	O
Prph2	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
result	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
photoreceptor	B-Disease	D058499
dystrophies	I-Disease	D058499
,	O	O
including	O	O
autosomal	B-Disease	D012174
dominant	I-Disease	D012174
retinitis	I-Disease	D012174
pigmentosa	I-Disease	D012174
and	O	O
macular	B-Disease	D008268
dystrophy	I-Disease	D008268
.	O	O

A	O	O
common	O	O
feature	O	O
of	O	O
these	O	O
diseases	O	O
is	O	O
the	O	O
loss	O	O
of	O	O
photoreceptor	O	O
function	O	O
,	O	O
also	O	O
seen	O	O
in	O	O
the	O	O
retinal	B-Disease	D012162
degeneration	I-Disease	D012162
slow	O	O
(	O	O
rds	O	O
or	O	O
Prph2	O	O
Rd2	O	O
/	O	O
Rd2	O	O
)	O	O
mouse	O	O
,	O	O
which	O	O
is	O	O
homozygous	O	O
for	O	O
a	O	O
null	O	O
mutation	O	O
in	O	O
Prph2	O	O
.	O	O

It	O	O
is	O	O
characterized	O	O
by	O	O
a	O	O
complete	O	O
failure	O	O
to	O	O
develop	O	O
photoreceptor	O	O
discs	O	O
and	O	O
outer	O	O
segments	O	O
,	O	O
downregulation	O	O
of	O	O
rhodopsin	O	O
and	O	O
apoptotic	O	O
loss	O	O
of	O	O
photoreceptor	O	O
cells	O	O
.	O	O

The	O	O
electroretinograms	O	O
(	O	O
ERGs	O	O
)	O	O
of	O	O
Prph2Rd2	O	O
/	O	O
Rd2	O	O
mice	O	O
have	O	O
greatly	O	O
diminished	O	O
a	O	O
-	O	O
wave	O	O
and	O	O
b	O	O
-	O	O
wave	O	O
amplitudes	O	O
,	O	O
which	O	O
decline	O	O
to	O	O
virtually	O	O
undetectable	O	O
concentrations	O	O
by	O	O
two	O	O
months	O	O
.	O	O

Subretinal	O	O
injection	O	O
of	O	O
recombinant	O	O
adeno	O	O
-	O	O
associated	O	O
virus	O	O
(	O	O
AAV	O	O
)	O	O
encoding	O	O
a	O	O
Prph2	O	O
transgene	O	O
results	O	O
in	O	O
stable	O	O
generation	O	O
of	O	O
outer	O	O
segment	O	O
structures	O	O
and	O	O
formation	O	O
of	O	O
new	O	O
stacks	O	O
of	O	O
discs	O	O
containing	O	O
both	O	O
perpherin	O	O
-	O	O
2	O	O
and	O	O
rhodopsin	O	O
,	O	O
which	O	O
in	O	O
many	O	O
cases	O	O
are	O	O
morphologically	O	O
similar	O	O
to	O	O
normal	O	O
outer	O	O
segments	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
re	O	O
-	O	O
establishment	O	O
of	O	O
the	O	O
structural	O	O
integrity	O	O
of	O	O
the	O	O
photoreceptor	O	O
layer	O	O
also	O	O
results	O	O
in	O	O
electrophysiological	O	O
correction	O	O
.	O	O

These	O	O
studies	O	O
demonstrate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
a	O	O
complex	O	O
ultrastructural	O	O
cell	O	O
defect	O	O
can	O	O
be	O	O
corrected	O	O
both	O	O
morphologically	O	O
and	O	O
functionally	O	O
by	O	O
in	O	O
vivo	O	O
gene	O	O
transfer	O	O
.	O	O

.	O	O

Phenylalanine	O	O
hydroxylase	O	O
gene	O	O
haplotypes	O	O
in	O	O
Polynesians	O	O
:	O	O
evolutionary	O	O
origins	O	O
and	O	O
absence	O	O
of	O	O
alleles	O	O
associated	O	O
with	O	O
severe	O	O
phenylketonuria	B-Disease	D010661
.	O	O

A	O	O
total	O	O
of	O	O
630	O	O
haplotypes	O	O
for	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
gene	O	O
locus	O	O
were	O	O
established	O	O
in	O	O
five	O	O
groups	O	O
of	O	O
Polynesians	O	O
comprising	O	O
Samoans	O	O
,	O	O
Tongans	O	O
,	O	O
Cook	O	O
Islanders	O	O
,	O	O
Maori	O	O
,	O	O
and	O	O
Niueans	O	O
.	O	O

Considerable	O	O
genetic	O	O
continuity	O	O
was	O	O
demonstrated	O	O
between	O	O
these	O	O
widely	O	O
dispersed	O	O
populations	O	O
,	O	O
since	O	O
three	O	O
common	O	O
haplotypes	O	O
(	O	O
4	O	O
,	O	O
1	O	O
,	O	O
and	O	O
7	O	O
)	O	O
constituted	O	O
over	O	O
95	O	O
%	O	O
of	O	O
alleles	O	O
.	O	O

A	O	O
control	O	O
group	O	O
of	O	O
individuals	O	O
from	O	O
Southeast	O	O
Asia	O	O
shared	O	O
the	O	O
same	O	O
major	O	O
haplotypes	O	O
,	O	O
4	O	O
,	O	O
1	O	O
,	O	O
and	O	O
7	O	O
,	O	O
with	O	O
Polynesians	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
further	O	O
support	O	O
for	O	O
the	O	O
theories	O	O
of	O	O
genetic	O	O
homogeneity	O	O
and	O	O
of	O	O
Asian	O	O
affinities	O	O
of	O	O
the	O	O
Polynesian	O	O
precursor	O	O
populations	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
severe	O	O
phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
in	O	O
both	O	O
Polynesians	O	O
and	O	O
Southeast	O	O
Asians	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
lack	O	O
of	O	O
PAH	O	O
haplotypes	O	O
2	O	O
and	O	O
3	O	O
,	O	O
on	O	O
which	O	O
the	O	O
severe	O	O
PKU	B-Disease	D010661
mutants	O	O
have	O	O
arisen	O	O
among	O	O
Caucasians	O	O
.	O	O

.	O	O

cDNA	O	O
microarrays	O	O
detect	O	O
activation	O	O
of	O	O
a	O	O
myogenic	O	O
transcription	O	O
program	O	O
by	O	O
the	O	O
PAX3	O	O
-	O	O
FKHR	O	O
fusion	O	O
oncogene	O	O
.	O	O

Alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
is	O	O
an	O	O
aggressive	O	O
pediatric	B-Disease	D019042
cancer	I-Disease	D019042
of	I-Disease	D019042
striated	I-Disease	D019042
muscle	I-Disease	D019042
characterized	O	O
in	O	O
60	O	O
%	O	O
of	O	O
cases	O	O
by	O	O
a	O	O
t	O	O
(	O	O
2	O	O
;	O	O
13	O	O
)	O	O
(	O	O
q35	O	O
;	O	O
q14	O	O
)	O	O
.	O	O

This	O	O
results	O	O
in	O	O
the	O	O
fusion	O	O
of	O	O
PAX3	O	O
,	O	O
a	O	O
developmental	O	O
transcription	O	O
factor	O	O
required	O	O
for	O	O
limb	O	O
myogenesis	O	O
,	O	O
with	O	O
FKHR	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
forkhead	O	O
family	O	O
of	O	O
transcription	O	O
factors	O	O
.	O	O

The	O	O
resultant	O	O
PAX3	O	O
-	O	O
FKHR	O	O
gene	O	O
possesses	O	O
transforming	O	O
properties	O	O
;	O	O
however	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
this	O	O
chimeric	O	O
oncogene	O	O
on	O	O
gene	O	O
expression	O	O
are	O	O
largely	O	O
unknown	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
actions	O	O
of	O	O
these	O	O
transcription	O	O
factors	O	O
,	O	O
both	O	O
Pax3	O	O
and	O	O
PAX3	O	O
-	O	O
FKHR	O	O
were	O	O
introduced	O	O
into	O	O
NIH	O	O
3T3	O	O
cells	O	O
,	O	O
and	O	O
the	O	O
resultant	O	O
gene	O	O
expression	O	O
changes	O	O
were	O	O
analyzed	O	O
with	O	O
a	O	O
murine	O	O
cDNA	O	O
microarray	O	O
containing	O	O
2	O	O
,	O	O
225	O	O
elements	O	O
.	O	O

We	O	O
found	O	O
that	O	O
PAX3	O	O
-	O	O
FKHR	O	O
but	O	O
not	O	O
PAX3	O	O
activated	O	O
a	O	O
myogenic	O	O
transcription	O	O
program	O	O
including	O	O
the	O	O
induction	O	O
of	O	O
transcription	O	O
factors	O	O
MyoD	O	O
,	O	O
Myogenin	O	O
,	O	O
Six1	O	O
,	O	O
and	O	O
Slug	O	O
as	O	O
well	O	O
as	O	O
a	O	O
battery	O	O
of	O	O
genes	O	O
involved	O	O
in	O	O
several	O	O
aspects	O	O
of	O	O
muscle	O	O
function	O	O
.	O	O

Notable	O	O
among	O	O
this	O	O
group	O	O
were	O	O
the	O	O
growth	O	O
factor	O	O
gene	O	O
Igf2	O	O
and	O	O
its	O	O
binding	O	O
protein	O	O
Igfbp5	O	O
.	O	O

Relevance	O	O
of	O	O
this	O	O
model	O	O
was	O	O
suggested	O	O
by	O	O
verification	O	O
that	O	O
three	O	O
of	O	O
these	O	O
genes	O	O
(	O	O
IGFBP5	O	O
,	O	O
HSIX1	O	O
,	O	O
and	O	O
Slug	O	O
)	O	O
were	O	O
also	O	O
expressed	O	O
in	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
cell	O	O
lines	O	O
.	O	O

This	O	O
study	O	O
utilizes	O	O
cDNA	O	O
microarrays	O	O
to	O	O
elucidate	O	O
the	O	O
pattern	O	O
of	O	O
gene	O	O
expression	O	O
induced	O	O
by	O	O
an	O	O
oncogenic	O	O
transcription	O	O
factor	O	O
and	O	O
demonstrates	O	O
the	O	O
profound	O	O
myogenic	O	O
properties	O	O
of	O	O
PAX3	O	O
-	O	O
FKHR	O	O
in	O	O
NIH	O	O
3T3	O	O
cells	O	O
.	O	O

.	O	O

Re	O	O
-	O	O
evaluation	O	O
of	O	O
the	O	O
sublocalization	O	O
of	O	O
esterase	O	O
D	O	O
and	O	O
its	O	O
relation	O	O
to	O	O
the	O	O
retinoblastoma	B-Disease	D012175
locus	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

In	O	O
situ	O	O
hybridization	O	O
of	O	O
a	O	O
cDNA	O	O
probe	O	O
for	O	O
the	O	O
esterase	O	O
D	O	O
gene	O	O
(	O	O
ESD	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
on	O	O
human	O	O
chromosomes	O	O
.	O	O

The	O	O
probe	O	O
hybridized	O	O
most	O	O
strongly	O	O
to	O	O
13q14	O	O
.	O	O

2	O	O
and	O	O
13q14	O	O
.	O	O

3	O	O
.	O	O

This	O	O
observation	O	O
raises	O	O
doubts	O	O
concerning	O	O
the	O	O
most	O	O
recently	O	O
published	O	O
assignment	O	O
of	O	O
ESD	O	O
to	O	O
13q14	O	O
.	O	O

1	O	O
.	O	O

A	O	O
deletion	O	O
in	O	O
an	O	O
individual	O	O
with	O	O
retinoblastoma	B-Disease	D012175
was	O	O
reported	O	O
to	O	O
separate	O	O
the	O	O
closely	O	O
linked	O	O
ESD	O	O
and	O	O
retinoblastoma	B-Disease	D012175
(	O	O
RB1	O	O
)	O	O
loci	O	O
,	O	O
placing	O	O
ESD	O	O
proximal	O	O
to	O	O
RB1	O	O
.	O	O

Quantitative	O	O
in	O	O
situ	O	O
hybridization	O	O
studies	O	O
of	O	O
this	O	O
deletion	O	O
do	O	O
not	O	O
confirm	O	O
this	O	O
interpretation	O	O
.	O	O

Rather	O	O
,	O	O
they	O	O
suggest	O	O
that	O	O
ESD	O	O
is	O	O
missing	O	O
from	O	O
the	O	O
deleted	O	O
chromosome	O	O
13	O	O
and	O	O
duplicated	O	O
on	O	O
the	O	O
normal	O	O
homolog	O	O
.	O	O

From	O	O
these	O	O
findings	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
the	O	O
deletion	O	O
in	O	O
this	O	O
individual	O	O
cannot	O	O
be	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
orientation	O	O
nor	O	O
the	O	O
sublocalization	O	O
of	O	O
ESD	O	O
and	O	O
RB1	O	O
within	O	O
the	O	O
13q14	O	O
region	O	O
.	O	O

The	O	O
DNA	O	O
double	O	O
-	O	O
strand	O	O
break	O	O
repair	O	O
gene	O	O
hMRE11	O	O
is	O	O
mutated	O	O
in	O	O
individuals	O	O
with	O	O
an	O	O
ataxia	B-Disease	OMIM:604391
-	I-Disease	OMIM:604391
telangiectasia	I-Disease	OMIM:604391
-	I-Disease	OMIM:604391
like	I-Disease	OMIM:604391
disorder	I-Disease	OMIM:604391
.	O	O

We	O	O
show	O	O
that	O	O
hypomorphic	O	O
mutations	O	O
in	O	O
hMRE11	O	O
,	O	O
but	O	O
not	O	O
in	O	O
ATM	O	O
,	O	O
are	O	O
present	O	O
in	O	O
certain	O	O
individuals	O	O
with	O	O
an	O	O
ataxia	B-Disease	OMIM:604391
-	I-Disease	OMIM:604391
telangiectasia	I-Disease	OMIM:604391
-	I-Disease	OMIM:604391
like	I-Disease	OMIM:604391
disorder	I-Disease	OMIM:604391
(	O	O
ATLD	B-Disease	OMIM:604391
)	O	O
.	O	O

The	O	O
cellular	O	O
features	O	O
resulting	O	O
from	O	O
these	O	O
hMRE11	O	O
mutations	O	O
are	O	O
similar	O	O
to	O	O
those	O	O
seen	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
as	O	O
well	O	O
as	O	O
NBS	B-Disease	D049932
and	O	O
include	O	O
hypersensitivity	B-Disease	D004194
to	I-Disease	D004194
ionizing	I-Disease	D004194
radiation	I-Disease	D004194
,	O	O
radioresistant	O	O
DNA	O	O
synthesis	O	O
,	O	O
and	O	O
abrogation	O	O
of	O	O
ATM	O	O
-	O	O
dependent	O	O
events	O	O
,	O	O
such	O	O
as	O	O
the	O	O
activation	O	O
of	O	O
Jun	O	O
kinase	O	O
following	O	O
exposure	O	O
to	O	O
gamma	O	O
irradiation	O	O
.	O	O

Although	O	O
the	O	O
mutant	O	O
hMre11	O	O
proteins	O	O
retain	O	O
some	O	O
ability	O	O
to	O	O
interact	O	O
with	O	O
hRad50	O	O
and	O	O
Nbs1	O	O
,	O	O
formation	O	O
of	O	O
ionizing	O	O
radiation	O	O
-	O	O
induced	O	O
hMre11	O	O
and	O	O
Nbs1	O	O
foci	O	O
was	O	O
absent	O	O
in	O	O
hMRE11	O	O
mutant	O	O
cells	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
ATM	O	O
and	O	O
the	O	O
hMre11	O	O
/	O	O
hRad50	O	O
/	O	O
Nbs1	O	O
protein	O	O
complex	O	O
act	O	O
in	O	O
the	O	O
same	O	O
DNA	O	O
damage	O	O
response	O	O
pathway	O	O
and	O	O
link	O	O
hMre11	O	O
to	O	O
the	O	O
complex	O	O
pathology	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
.	O	O

.	O	O

Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
expression	O	O
in	O	O
normal	O	O
and	O	O
diseased	O	O
human	O	O
muscle	O	O
.	O	O

A	O	O
probe	O	O
for	O	O
the	O	O
5	O	O
end	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
was	O	O
used	O	O
to	O	O
study	O	O
expression	O	O
of	O	O
the	O	O
gene	O	O
in	O	O
normal	O	O
human	O	O
muscle	O	O
,	O	O
myogenic	O	O
cell	O	O
cultures	O	O
,	O	O
and	O	O
muscle	O	O
from	O	O
patients	O	O
with	O	O
DMD	B-Disease	D020388
.	O	O

Expression	O	O
was	O	O
found	O	O
in	O	O
RNA	O	O
from	O	O
normal	O	O
fetal	O	O
muscle	O	O
,	O	O
adult	O	O
cardiac	O	O
and	O	O
skeletal	O	O
muscle	O	O
,	O	O
and	O	O
cultured	O	O
muscle	O	O
after	O	O
myoblast	O	O
fusion	O	O
.	O	O

In	O	O
DMD	B-Disease	D020388
muscle	O	O
,	O	O
expression	O	O
of	O	O
this	O	O
portion	O	O
of	O	O
the	O	O
gene	O	O
was	O	O
also	O	O
revealed	O	O
by	O	O
in	O	O
situ	O	O
RNA	O	O
hybridization	O	O
,	O	O
particularly	O	O
in	O	O
regenerating	O	O
muscle	O	O
fibers	O	O
.	O	O

.	O	O

Localisation	O	O
of	O	O
the	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
gene	O	O
on	O	O
the	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
by	O	O
linkage	O	O
to	O	O
cloned	O	O
DNA	O	O
sequences	O	O
.	O	O

A	O	O
linkage	O	O
study	O	O
in	O	O
30	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
(	O	O
BMD	B-Disease	C537666
)	O	O
kindreds	O	O
using	O	O
three	O	O
cloned	O	O
DNA	O	O
sequences	O	O
from	O	O
the	O	O
X	O	O
chromosome	O	O
which	O	O
demonstrate	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
(	O	O
RFLPs	O	O
)	O	O
,	O	O
suggests	O	O
that	O	O
the	O	O
BMD	B-Disease	C537666
gene	O	O
is	O	O
located	O	O
on	O	O
the	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
,	O	O
in	O	O
the	O	O
p21	O	O
region	O	O
.	O	O

The	O	O
genes	O	O
for	O	O
Becker	B-Disease	D020388
and	I-Disease	D020388
Duchenne	I-Disease	D020388
dystrophies	I-Disease	D020388
must	O	O
therefore	O	O
be	O	O
closely	O	O
linked	O	O
,	O	O
if	O	O
not	O	O
allelic	O	O
,	O	O
and	O	O
any	O	O
future	O	O
DNA	O	O
probes	O	O
found	O	O
to	O	O
be	O	O
of	O	O
practical	O	O
use	O	O
in	O	O
one	O	O
disorder	O	O
should	O	O
be	O	O
equally	O	O
applicable	O	O
to	O	O
the	O	O
other	O	O
.	O	O

The	O	O
linkage	O	O
analysis	O	O
also	O	O
provides	O	O
data	O	O
on	O	O
the	O	O
frequency	O	O
of	O	O
recombination	O	O
along	O	O
the	O	O
short	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
,	O	O
and	O	O
across	O	O
the	O	O
centromeric	O	O
region	O	O
.	O	O

.	O	O

Age	O	O
of	O	O
the	O	O
intronic	O	O
GAA	O	O
triplet	O	O
repeat	O	O
expansion	O	O
mutation	O	O
in	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
,	O	O
the	O	O
most	O	O
frequently	O	O
inherited	B-Disease	D013132
ataxia	I-Disease	D013132
,	O	O
is	O	O
due	O	O
in	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
cases	O	O
to	O	O
a	O	O
large	O	O
expansion	O	O
of	O	O
an	O	O
intronic	O	O
GAA	O	O
repeat	O	O
.	O	O

Using	O	O
linkage	O	O
disequilibrium	O	O
analysis	O	O
based	O	O
on	O	O
haplotype	O	O
data	O	O
of	O	O
seven	O	O
polymorphic	O	O
markers	O	O
close	O	O
to	O	O
the	O	O
frataxin	O	O
gene	O	O
,	O	O
the	O	O
age	O	O
of	O	O
FRDA	B-Disease	D005621
founding	O	O
mutational	O	O
event	O	O
(	O	O
s	O	O
)	O	O
is	O	O
estimated	O	O
to	O	O
be	O	O
at	O	O
least	O	O
682	O	O
+	O	O
/	O	O
-	O	O
203	O	O
generations	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
564	O	O
-	O	O
801	O	O
g	O	O
)	O	O
,	O	O
a	O	O
dating	O	O
which	O	O
is	O	O
consistent	O	O
with	O	O
little	O	O
or	O	O
no	O	O
negative	O	O
selection	O	O
and	O	O
provides	O	O
further	O	O
evidence	O	O
for	O	O
an	O	O
ancient	O	O
spread	O	O
of	O	O
a	O	O
pre	O	O
-	O	O
mutation	O	O
(	O	O
at	O	O
-	O	O
risk	O	O
alleles	O	O
)	O	O
in	O	O
western	O	O
Europe	O	O
.	O	O

.	O	O

The	O	O
human	O	O
MAGEL2	O	O
gene	O	O
and	O	O
its	O	O
mouse	O	O
homologue	O	O
are	O	O
paternally	O	O
expressed	O	O
and	O	O
mapped	O	O
to	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
region	O	O
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	O	O
(	O	O
PWS	B-Disease	D011218
)	O	O
is	O	O
a	O	O
complex	O	O
neurogenetic	B-Disease	D020271
disorder	I-Disease	D020271
.	O	O

The	O	O
phenotype	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
contiguous	B-Disease	D025063
gene	I-Disease	D025063
syndrome	I-Disease	D025063
involving	O	O
genes	O	O
which	O	O
are	O	O
paternally	O	O
expressed	O	O
only	O	O
,	O	O
located	O	O
in	O	O
the	O	O
human	O	O
15q11	O	O
-	O	O
q13	O	O
region	O	O
.	O	O

Four	O	O
mouse	O	O
models	O	O
of	O	O
PWS	B-Disease	D011218
have	O	O
been	O	O
reported	O	O
but	O	O
these	O	O
do	O	O
not	O	O
definitively	O	O
allow	O	O
the	O	O
delineation	O	O
of	O	O
the	O	O
critical	O	O
region	O	O
and	O	O
the	O	O
associated	O	O
genes	O	O
involved	O	O
in	O	O
the	O	O
aetiology	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

Moreover	O	O
,	O	O
targeted	O	O
mutagenesis	O	O
of	O	O
mouse	O	O
homologues	O	O
of	O	O
the	O	O
human	O	O
candidate	O	O
PWS	B-Disease	D011218
genes	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
result	O	O
in	O	O
any	O	O
of	O	O
the	O	O
features	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

Therefore	O	O
,	O	O
the	O	O
isolation	O	O
of	O	O
new	O	O
genes	O	O
in	O	O
this	O	O
region	O	O
remains	O	O
crucial	O	O
for	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

In	O	O
this	O	O
manuscript	O	O
,	O	O
we	O	O
report	O	O
the	O	O
characterization	O	O
of	O	O
MAGEL2	O	O
and	O	O
its	O	O
mouse	O	O
homologue	O	O
Magel2	O	O
.	O	O

These	O	O
are	O	O
located	O	O
in	O	O
the	O	O
human	O	O
15q11	O	O
-	O	O
q13	O	O
and	O	O
mouse	O	O
7C	O	O
regions	O	O
,	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
NDN	O	O
/	O	O
Ndn	O	O
.	O	O

By	O	O
northern	O	O
blot	O	O
analysis	O	O
we	O	O
did	O	O
not	O	O
detect	O	O
any	O	O
expression	O	O
of	O	O
MAGEL2	O	O
/	O	O
Magel2	O	O
but	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
analysis	O	O
,	O	O
specific	O	O
expression	O	O
was	O	O
detected	O	O
in	O	O
fetal	O	O
and	O	O
adult	O	O
brain	O	O
and	O	O
in	O	O
placenta	O	O
.	O	O

Both	O	O
genes	O	O
are	O	O
intronless	O	O
with	O	O
tandem	O	O
direct	O	O
repeat	O	O
sequences	O	O
contained	O	O
within	O	O
a	O	O
CpG	O	O
island	O	O
in	O	O
the	O	O
5	O	O
-	O	O
untranscribed	O	O
region	O	O
.	O	O

The	O	O
transcripts	O	O
encode	O	O
putative	O	O
proteins	O	O
that	O	O
are	O	O
homologous	O	O
to	O	O
the	O	O
MAGE	O	O
proteins	O	O
and	O	O
NDN	O	O
.	O	O

Moreover	O	O
,	O	O
MAGEL2	O	O
/	O	O
Magel2	O	O
are	O	O
expressed	O	O
only	O	O
from	O	O
the	O	O
paternal	O	O
allele	O	O
in	O	O
brain	O	O
,	O	O
suggesting	O	O
a	O	O
potential	O	O
role	O	O
in	O	O
the	O	O
aetiology	O	O
of	O	O
PWS	B-Disease	D011218
and	O	O
its	O	O
mouse	O	O
model	O	O
,	O	O
respectively	O	O
.	O	O

.	O	O

Multiple	O	O
origins	O	O
for	O	O
phenylketonuria	B-Disease	D010661
in	O	O
Europe	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
,	O	O
a	O	O
disorder	B-Disease	D000592
of	I-Disease	D000592
amino	I-Disease	D000592
acid	I-Disease	D000592
metabolism	I-Disease	D000592
prevalent	O	O
among	O	O
Caucasians	O	O
and	O	O
other	O	O
ethnic	O	O
groups	O	O
,	O	O
is	O	O
caused	O	O
primarily	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
the	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
enzyme	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

PKU	B-Disease	D010661
is	O	O
a	O	O
highly	O	O
heterogeneous	O	O
disorder	O	O
,	O	O
with	O	O
more	O	O
than	O	O
60	O	O
molecular	O	O
lesions	O	O
identified	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
.	O	O

The	O	O
haplotype	O	O
associations	O	O
,	O	O
relative	O	O
frequencies	O	O
,	O	O
and	O	O
distributions	O	O
of	O	O
five	O	O
prevalent	O	O
PAH	O	O
mutations	O	O
(	O	O
R158Q	O	O
,	O	O
R261Q	O	O
,	O	O
IVS10nt546	O	O
,	O	O
R408W	O	O
,	O	O
and	O	O
IVS12n1	O	O
)	O	O
were	O	O
established	O	O
in	O	O
a	O	O
comprehensive	O	O
European	O	O
sample	O	O
population	O	O
and	O	O
subsequently	O	O
were	O	O
examined	O	O
to	O	O
determine	O	O
the	O	O
potential	O	O
roles	O	O
of	O	O
several	O	O
genetic	O	O
mechanisms	O	O
in	O	O
explaining	O	O
the	O	O
present	O	O
distribution	O	O
of	O	O
the	O	O
major	O	O
PKU	B-Disease	D010661
alleles	O	O
.	O	O

Each	O	O
of	O	O
these	O	O
five	O	O
mutations	O	O
was	O	O
strongly	O	O
associated	O	O
with	O	O
only	O	O
one	O	O
of	O	O
the	O	O
more	O	O
than	O	O
70	O	O
chromosomal	O	O
haplotypes	O	O
defined	O	O
by	O	O
eight	O	O
RFLPs	O	O
in	O	O
or	O	O
near	O	O
the	O	O
PAH	O	O
gene	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
each	O	O
of	O	O
these	O	O
mutations	O	O
arose	O	O
through	O	O
a	O	O
single	O	O
founding	O	O
event	O	O
that	O	O
occurred	O	O
within	O	O
time	O	O
periods	O	O
ranging	O	O
from	O	O
several	O	O
hundred	O	O
to	O	O
several	O	O
thousand	O	O
years	O	O
ago	O	O
.	O	O

From	O	O
the	O	O
significant	O	O
differences	O	O
observed	O	O
in	O	O
the	O	O
relative	O	O
frequencies	O	O
and	O	O
distributions	O	O
of	O	O
these	O	O
five	O	O
alleles	O	O
throughout	O	O
Europe	O	O
,	O	O
four	O	O
of	O	O
these	O	O
putative	O	O
founding	O	O
events	O	O
could	O	O
be	O	O
localized	O	O
to	O	O
specific	O	O
ethnic	O	O
subgroups	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
there	O	O
were	O	O
multiple	O	O
,	O	O
geographically	O	O
and	O	O
ethnically	O	O
distinct	O	O
origins	O	O
for	O	O
PKU	B-Disease	D010661
within	O	O
the	O	O
European	O	O
population	O	O
.	O	O

.	O	O

Autoinhibition	O	O
and	O	O
activation	O	O
mechanisms	O	O
of	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
.	O	O

The	O	O
Rho	O	O
-	O	O
family	O	O
GTPase	O	O
,	O	O
Cdc42	O	O
,	O	O
can	O	O
regulate	O	O
the	O	O
actin	O	O
cytoskeleton	O	O
through	O	O
activation	O	O
of	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
family	O	O
members	O	O
.	O	O

Activation	O	O
relieves	O	O
an	O	O
autoinhibitory	O	O
contact	O	O
between	O	O
the	O	O
GTPase	O	O
-	O	O
binding	O	O
domain	O	O
and	O	O
the	O	O
carboxy	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
WASP	O	O
proteins	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
autoinhibited	O	O
structure	O	O
of	O	O
the	O	O
GTPase	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
WASP	O	O
,	O	O
which	O	O
can	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
region	O	O
or	O	O
by	O	O
organic	O	O
co	O	O
-	O	O
solvents	O	O
.	O	O

In	O	O
the	O	O
autoinhibited	O	O
complex	O	O
,	O	O
intramolecular	O	O
interactions	O	O
with	O	O
the	O	O
GTPase	O	O
-	O	O
binding	O	O
domain	O	O
occlude	O	O
residues	O	O
of	O	O
the	O	O
C	O	O
terminus	O	O
that	O	O
regulate	O	O
the	O	O
Arp2	O	O
/	O	O
3	O	O
actin	O	O
-	O	O
nucleating	O	O
complex	O	O
.	O	O

Binding	O	O
of	O	O
Cdc42	O	O
to	O	O
the	O	O
GTPase	O	O
-	O	O
binding	O	O
domain	O	O
causes	O	O
a	O	O
dramatic	O	O
conformational	O	O
change	O	O
,	O	O
resulting	O	O
in	O	O
disruption	O	O
of	O	O
the	O	O
hydrophobic	O	O
core	O	O
and	O	O
release	O	O
of	O	O
the	O	O
C	O	O
terminus	O	O
,	O	O
enabling	O	O
its	O	O
interaction	O	O
with	O	O
the	O	O
actin	O	O
regulatory	O	O
machinery	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
intrinsically	O	O
unstructured	O	O
peptides	O	O
such	O	O
as	O	O
the	O	O
GTPase	O	O
-	O	O
binding	O	O
domain	O	O
of	O	O
WASP	O	O
can	O	O
be	O	O
induced	O	O
into	O	O
distinct	O	O
structural	O	O
and	O	O
functional	O	O
states	O	O
depending	O	O
on	O	O
context	O	O
.	O	O

.	O	O

Localisation	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
to	O	O
between	O	O
DXS7	O	O
and	O	O
DXS426	O	O
on	O	O
Xp	O	O
.	O	O

A	O	O
highly	O	O
informative	O	O
microsatellite	O	O
marker	O	O
,	O	O
DXS426	O	O
,	O	O
which	O	O
maps	O	O
proximal	O	O
to	O	O
DXS7	O	O
in	O	O
the	O	O
interval	O	O
Xp11	O	O
.	O	O

4	O	O
-	O	O
Xp11	O	O
4	O	O
-	O	O
Xp11	O	O
.	O	O

23	O	O
,	O	O
has	O	O
been	O	O
used	O	O
to	O	O
refine	O	O
further	O	O
the	O	O
localisation	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
NDP	B-Disease	C537849
)	O	O
.	O	O

The	O	O
results	O	O
from	O	O
a	O	O
multiply	O	O
informative	O	O
crossover	O	O
localize	O	O
the	O	O
NDP	B-Disease	C537849
gene	O	O
proximal	O	O
to	O	O
DXS7	O	O
.	O	O

In	O	O
conjunction	O	O
with	O	O
information	O	O
from	O	O
2	O	O
NDP	B-Disease	C537849
patients	O	O
who	O	O
have	O	O
a	O	O
deletion	O	O
for	O	O
DXS7	O	O
but	O	O
not	O	O
for	O	O
DSX426	O	O
,	O	O
our	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
NDP	B-Disease	C537849
gene	O	O
lies	O	O
between	O	O
DXS7	O	O
and	O	O
DXS426	O	O
on	O	O
proximal	O	O
Xp	O	O
.	O	O

Molecular	O	O
basis	O	O
of	O	O
human	O	O
mitochondrial	O	O
very	B-Disease	C536353
-	I-Disease	C536353
long	I-Disease	C536353
-	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
CoA	I-Disease	C536353
dehydrogenase	I-Disease	C536353
deficiency	I-Disease	C536353
causing	O	O
cardiomyopathy	B-Disease	D009202
and	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
in	O	O
childhood	O	O
.	O	O

beta	O	O
-	O	O
Oxidation	O	O
of	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
provides	O	O
the	O	O
major	O	O
source	O	O
of	O	O
energy	O	O
in	O	O
the	O	O
heart	O	O
.	O	O

Defects	O	O
in	O	O
enzymes	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
oxidation	O	O
pathway	O	O
cause	O	O
sudden	B-Disease	D003645
,	I-Disease	D003645
unexplained	I-Disease	D003645
death	I-Disease	D003645
in	O	O
childhood	O	O
,	O	O
acute	O	O
hepatic	B-Disease	D006501
encephalopathy	I-Disease	D006501
or	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
,	O	O
skeletal	B-Disease	D009135
myopathy	I-Disease	D009135
,	O	O
and	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

Very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
[	O	O
VLCAD	O	O
;	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
-	O	O
acyl	O	O
-	O	O
CoA	O	O
(	O	O
acceptor	O	O
)	O	O
2	O	O
,	O	O
3	O	O
-	O	O
oxidoreductase	O	O
,	O	O
EC	O	O
1	O	O
.	O	O

3	O	O
3	O	O
.	O	O

99	O	O
99	O	O
.	O	O

13	O	O
]	O	O
catalyzes	O	O
the	O	O
first	O	O
step	O	O
in	O	O
beta	O	O
-	O	O
oxidation	O	O
.	O	O

We	O	O
have	O	O
isolated	O	O
the	O	O
human	O	O
VLCAD	O	O
cDNA	O	O
and	O	O
gene	O	O
and	O	O
determined	O	O
the	O	O
complete	O	O
nucleotide	O	O
sequences	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
amplification	O	O
of	O	O
VLCAD	O	O
mRNA	O	O
and	O	O
genomic	O	O
exons	O	O
defined	O	O
the	O	O
molecular	O	O
defects	O	O
in	O	O
two	O	O
patients	O	O
with	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
who	O	O
presented	O	O
with	O	O
unexplained	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

In	O	O
one	O	O
,	O	O
a	O	O
homozygous	O	O
mutation	O	O
in	O	O
the	O	O
consensus	O	O
dinucleotide	O	O
of	O	O
the	O	O
donor	O	O
splice	O	O
site	O	O
(	O	O
g	O	O
+	O	O
1	O	O
-	O	O
-	O	O
>	O	O
a	O	O
)	O	O
was	O	O
associated	O	O
with	O	O
universal	O	O
skipping	O	O
of	O	O
the	O	O
prior	O	O
exon	O	O
(	O	O
exon	O	O
11	O	O
)	O	O
.	O	O

The	O	O
second	O	O
patient	O	O
was	O	O
a	O	O
compound	O	O
heterozygote	O	O
,	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
,	O	O
C1837	O	O
-	O	O
-	O	O
>	O	O
T	O	O
,	O	O
changing	O	O
the	O	O
arginine	O	O
at	O	O
residue	O	O
613	O	O
to	O	O
tryptophan	O	O
on	O	O
one	O	O
allele	O	O
and	O	O
a	O	O
single	O	O
base	O	O
deletion	O	O
at	O	O
the	O	O
intron	O	O
-	O	O
exon	O	O
6	O	O
boundary	O	O
as	O	O
the	O	O
second	O	O
mutation	O	O
.	O	O

This	O	O
initial	O	O
delineation	O	O
of	O	O
human	O	O
mutations	O	O
in	O	O
VLCAD	O	O
suggests	O	O
that	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
reduces	O	O
myocardial	O	O
fatty	O	O
acid	O	O
beta	O	O
-	O	O
oxidation	O	O
and	O	O
energy	O	O
production	O	O
and	O	O
is	O	O
associated	O	O
with	O	O
cardiomyopathy	B-Disease	D009202
and	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
in	O	O
childhood	O	O
.	O	O

An	O	O
error	O	O
in	O	O
dystrophin	O	O
mRNA	O	O
processing	O	O
in	O	O
golden	B-Disease	D009136
retriever	I-Disease	D009136
muscular	I-Disease	D009136
dystrophy	I-Disease	D009136
,	O	O
an	O	O
animal	O	O
homologue	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

Golden	B-Disease	D009136
retriever	I-Disease	D009136
muscular	I-Disease	D009136
dystrophy	I-Disease	D009136
(	O	O
GRMD	B-Disease	D009136
)	O	O
is	O	O
a	O	O
spontaneous	O	O
,	O	O
X	O	O
-	O	O
linked	O	O
,	O	O
progressively	O	O
fatal	O	O
disease	O	O
of	O	O
dogs	O	O
and	O	O
is	O	O
also	O	O
a	O	O
homologue	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

Two	O	O
-	O	O
thirds	O	O
of	O	O
DMD	B-Disease	D020388
patients	O	O
carry	O	O
detectable	O	O
deletions	O	O
in	O	O
their	O	O
dystrophin	O	O
gene	O	O
.	O	O

The	O	O
defect	O	O
underlying	O	O
the	O	O
remaining	O	O
one	O	O
-	O	O
third	O	O
of	O	O
DMD	B-Disease	D020388
patients	O	O
is	O	O
undetermined	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
canine	O	O
dystrophin	O	O
gene	O	O
in	O	O
normal	O	O
and	O	O
GRMD	B-Disease	D009136
dogs	O	O
has	O	O
failed	O	O
to	O	O
demonstrate	O	O
any	O	O
detectable	O	O
loss	O	O
of	O	O
exons	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
have	O	O
demonstrated	O	O
a	O	O
RNA	O	O
processing	O	O
error	O	O
in	O	O
GRMD	B-Disease	D009136
that	O	O
results	O	O
from	O	O
a	O	O
single	O	O
base	O	O
change	O	O
in	O	O
the	O	O
3	O	O
consensus	O	O
splice	O	O
site	O	O
of	O	O
intron	O	O
6	O	O
.	O	O

The	O	O
seventh	O	O
exon	O	O
is	O	O
then	O	O
skipped	O	O
,	O	O
which	O	O
predicts	O	O
a	O	O
termination	O	O
of	O	O
the	O	O
dystrophin	O	O
reading	O	O
frame	O	O
within	O	O
its	O	O
N	O	O
-	O	O
terminal	O	O
domain	O	O
in	O	O
exon	O	O
8	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
example	O	O
of	O	O
dystrophin	B-Disease	OMIM:310200
deficiency	I-Disease	OMIM:310200
caused	O	O
by	O	O
a	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
.	O	O

.	O	O

Serum	O	O
amyloid	O	O
A	O	O
and	O	O
P	O	O
protein	O	O
genes	O	O
in	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
.	O	O

Two	O	O
recent	O	O
studies	O	O
have	O	O
suggested	O	O
the	O	O
involvement	O	O
of	O	O
serum	O	O
amyloid	O	O
A	O	O
(	O	O
SAA	O	O
)	O	O
and	O	O
P	O	O
(	O	O
APCS	O	O
)	O	O
genes	O	O
in	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
MEF	B-Disease	D010505
)	O	O
.	O	O

To	O	O
test	O	O
the	O	O
role	O	O
of	O	O
SAA	O	O
and	O	O
APCS	O	O
in	O	O
MEF	B-Disease	D010505
and	O	O
MEF	B-Disease	D010505
-	O	O
amyloidosis	B-Disease	D000686
,	O	O
we	O	O
studied	O	O
17	O	O
informative	O	O
families	O	O
(	O	O
15	O	O
Armenians	O	O
,	O	O
2	O	O
non	O	O
-	O	O
Ashkenazi	O	O
Jews	O	O
)	O	O
and	O	O
8	O	O
MEF	B-Disease	D010505
patients	O	O
with	O	O
amyloidosis	B-Disease	D000686
using	O	O
a	O	O
candidate	O	O
gene	O	O
approach	O	O
.	O	O

No	O	O
evidence	O	O
for	O	O
any	O	O
MEF	B-Disease	D010505
-	O	O
associated	O	O
polymorphism	O	O
was	O	O
found	O	O
in	O	O
any	O	O
of	O	O
the	O	O
41	O	O
Armenian	O	O
and	O	O
Jewish	O	O
MEF	B-Disease	D010505
patients	O	O
tested	O	O
.	O	O

Our	O	O
family	O	O
studies	O	O
allowed	O	O
us	O	O
to	O	O
rule	O	O
out	O	O
tight	O	O
linkage	O	O
between	O	O
SAA	O	O
and	O	O
MEF	B-Disease	D010505
(	O	O
lod	O	O
score	O	O
=	O	O
-	O	O
2	O	O
.	O	O

16	O	O
,	O	O
theta	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
0	O	O
.	O	O

06	O	O
)	O	O
.	O	O

For	O	O
APCS	O	O
we	O	O
found	O	O
that	O	O
the	O	O
allele	O	O
frequency	O	O
in	O	O
the	O	O
MEF	B-Disease	D010505
-	O	O
amyloidosis	B-Disease	D000686
patients	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
in	O	O
18	O	O
unrelated	O	O
MEF	B-Disease	D010505
patients	O	O
without	O	O
amyloidosis	B-Disease	D000686
and	O	O
their	O	O
33	O	O
healthy	O	O
parents	O	O
.	O	O

Glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variants	O	O
from	O	O
Italian	O	O
subjects	O	O
associated	O	O
with	O	O
severe	B-Disease	D007567
neonatal	I-Disease	D007567
jaundice	I-Disease	D007567
.	O	O

Screening	O	O
for	O	O
the	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
was	O	O
carried	O	O
out	O	O
at	O	O
the	O	O
Maternity	O	O
Division	O	O
of	O	O
the	O	O
Galliera	O	O
Hospital	O	O
in	O	O
Genoa	O	O
,	O	O
Italy	O	O
.	O	O

Two	O	O
groups	O	O
of	O	O
subjects	O	O
with	O	O
hyperbilirubinaemia	B-Disease	D006932
of	O	O
non	O	O
-	O	O
immunological	O	O
origin	O	O
were	O	O
examined	O	O
(	O	O
a	O	O
)	O	O
302	O	O
newborn	O	O
babies	O	O
of	O	O
Sardinian	O	O
extraction	O	O
(	O	O
on	O	O
cord	O	O
blood	O	O
)	O	O
and	O	O
(	O	O
b	O	O
)	O	O
201	O	O
newborn	O	O
babies	O	O
of	O	O
south	O	O
Italian	O	O
ancestry	O	O
(	O	O
on	O	O
peripheral	O	O
blood	O	O
)	O	O
.	O	O

Among	O	O
503	O	O
subjects	O	O
,	O	O
43	O	O
showed	O	O
an	O	O
enzyme	O	O
deficiency	O	O
;	O	O
in	O	O
39	O	O
the	O	O
defect	O	O
was	O	O
of	O	O
the	O	O
Mediterranean	O	O
type	O	O
.	O	O

In	O	O
one	O	O
case	O	O
,	O	O
previously	O	O
described	O	O
,	O	O
the	O	O
enzyme	O	O
was	O	O
of	O	O
the	O	O
A	O	O
-	O	O
type	O	O
.	O	O

In	O	O
the	O	O
remaining	O	O
cases	O	O
three	O	O
different	O	O
variants	O	O
were	O	O
identified	O	O
.	O	O

In	O	O
the	O	O
present	O	O
work	O	O
these	O	O
three	O	O
cases	O	O
,	O	O
each	O	O
with	O	O
severe	B-Disease	D007567
neonatal	I-Disease	D007567
jaundice	I-Disease	D007567
,	O	O
are	O	O
reported	O	O
.	O	O

Their	O	O
parents	O	O
originated	O	O
from	O	O
Calabria	O	O
,	O	O
from	O	O
Sardinia	O	O
and	O	O
from	O	O
Sicily	O	O
.	O	O

The	O	O
abnormal	O	O
enzymes	O	O
are	O	O
respectively	O	O
designated	O	O
as	O	O
GdDcbrousse	O	O
-	O	O
like	O	O
,	O	O
GdGallura	O	O
and	O	O
GdAgrigento	O	O
.	O	O

.	O	O

Loss	O	O
of	O	O
normal	O	O
allele	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
an	O	O
adrenocortical	B-Disease	D018268
carcinoma	I-Disease	D018268
from	O	O
a	O	O
patient	O	O
with	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
.	O	O

Endocrine	B-Disease	D004701
neoplasms	I-Disease	D004701
have	O	O
been	O	O
reported	O	O
occasionally	O	O
in	O	O
patients	O	O
with	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
.	O	O

An	O	O
adrenocorotical	B-Disease	D018268
carcinoma	I-Disease	D018268
was	O	O
studied	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
FAP	B-Disease	D011125
.	O	O

Loss	O	O
of	O	O
heterozygosity	O	O
(	O	O
LOH	O	O
)	O	O
in	O	O
the	O	O
region	O	O
close	O	O
to	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
was	O	O
detected	O	O
in	O	O
this	O	O
carcinoma	B-Disease	D002277
,	O	O
and	O	O
evidence	O	O
was	O	O
obtained	O	O
that	O	O
there	O	O
was	O	O
a	O	O
loss	O	O
of	O	O
the	O	O
normal	O	O
allele	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
demonstration	O	O
of	O	O
LOH	O	O
at	O	O
the	O	O
APC	B-Disease	D011125
locus	O	O
in	O	O
adrenocortical	B-Disease	D018268
tumors	I-Disease	D018268
.	O	O

The	O	O
present	O	O
results	O	O
and	O	O
our	O	O
previous	O	O
data	O	O
on	O	O
LOH	O	O
in	O	O
a	O	O
recurring	O	O
desmoid	B-Disease	C535944
tumor	I-Disease	C535944
suggest	O	O
that	O	O
the	O	O
heterozygous	O	O
mutant	O	O
/	O	O
wild	O	O
-	O	O
type	O	O
condition	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
may	O	O
give	O	O
rise	O	O
to	O	O
benign	B-Disease	D009369
tumors	I-Disease	D009369
,	O	O
and	O	O
that	O	O
functional	O	O
loss	O	O
of	O	O
this	O	O
gene	O	O
leads	O	O
to	O	O
development	O	O
of	O	O
tumors	B-Disease	D009369
not	O	O
only	O	O
in	O	O
the	O	O
colon	O	O
but	O	O
also	O	O
in	O	O
other	O	O
various	O	O
parts	O	O
of	O	O
the	O	O
body	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

.	O	O

Heterozygous	O	O
C2	B-Disease	OMIM:217000
-	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
and	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
.	O	O

Complement	B-Disease	D007153
deficiency	I-Disease	D007153
states	O	O
in	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
(	O	O
MG	B-Disease	D009157
)	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
19	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
typical	O	O
MG	B-Disease	D009157
and	O	O
heterozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
,	O	O
along	O	O
with	O	O
HLA	O	O
typing	O	O
of	O	O
the	O	O
patient	O	O
and	O	O
her	O	O
immediate	O	O
family	O	O
.	O	O

.	O	O

Large	O	O
heterozygous	O	O
deletion	O	O
masquerading	O	O
as	O	O
homozygous	O	O
missense	O	O
mutation	O	O
:	O	O
a	O	O
pitfall	O	O
in	O	O
diagnostic	O	O
mutation	O	O
analysis	O	O
.	O	O

The	O	O
clinical	O	O
use	O	O
of	O	O
molecular	O	O
analyses	O	O
in	O	O
recessive	B-Disease	D030342
disorders	I-Disease	D030342
relies	O	O
on	O	O
the	O	O
exact	O	O
characterization	O	O
of	O	O
both	O	O
mutant	O	O
alleles	O	O
in	O	O
the	O	O
affected	O	O
patient	O	O
.	O	O

This	O	O
can	O	O
be	O	O
problematic	O	O
when	O	O
only	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
is	O	O
examined	O	O
or	O	O
when	O	O
relevant	O	O
DNA	O	O
alterations	O	O
are	O	O
not	O	O
recognized	O	O
by	O	O
standard	O	O
methods	O	O
.	O	O

We	O	O
present	O	O
a	O	O
child	O	O
in	O	O
whom	O	O
phenylketonuria	B-Disease	D010661
was	O	O
apparently	O	O
caused	O	O
by	O	O
homozygosity	O	O
for	O	O
the	O	O
mutation	O	O
E390G	O	O
in	O	O
exon	O	O
11	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
gene	O	O
.	O	O

However	O	O
,	O	O
the	O	O
clinical	O	O
severity	O	O
of	O	O
the	O	O
disease	O	O
was	O	O
not	O	O
quite	O	O
as	O	O
mild	O	O
as	O	O
expected	O	O
,	O	O
the	O	O
mutation	O	O
was	O	O
not	O	O
identified	O	O
in	O	O
the	O	O
father	O	O
despite	O	O
confirmed	O	O
paternity	O	O
,	O	O
and	O	O
the	O	O
paternal	O	O
allele	O	O
showed	O	O
a	O	O
highly	O	O
unusual	O	O
pattern	O	O
of	O	O
polymorphic	O	O
markers	O	O
in	O	O
the	O	O
PAH	O	O
gene	O	O
.	O	O

Presence	O	O
of	O	O
a	O	O
large	O	O
deletion	O	O
involving	O	O
exons	O	O
9	O	O
,	O	O
10	O	O
and	O	O
11	O	O
of	O	O
the	O	O
phenylalanine	O	O
hydroxylase	O	O
gene	O	O
was	O	O
confirmed	O	O
by	O	O
long	O	O
-	O	O
range	O	O
PCR	O	O
.	O	O

Diagnostic	O	O
DNA	O	O
analyses	O	O
should	O	O
include	O	O
a	O	O
comprehensive	O	O
examination	O	O
of	O	O
the	O	O
whole	O	O
relevant	O	O
gene	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
confirmation	O	O
of	O	O
carrier	O	O
status	O	O
in	O	O
both	O	O
parents	O	O
.	O	O

.	O	O

Two	O	O
point	O	O
mutations	O	O
are	O	O
responsible	O	O
for	O	O
G6PD	O	O
polymorphism	O	O
in	O	O
Sardinia	O	O
.	O	O

The	O	O
human	O	O
X	O	O
-	O	O
linked	O	O
gene	O	O
encoding	O	O
glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
is	O	O
highly	O	O
polymorphic	O	O
;	O	O
more	O	O
than	O	O
300	O	O
G6PD	O	O
variants	O	O
have	O	O
been	O	O
identified	O	O
.	O	O

G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
different	O	O
geographical	O	O
areas	O	O
appears	O	O
to	O	O
have	O	O
arisen	O	O
through	O	O
independent	O	O
mutational	O	O
events	O	O
,	O	O
but	O	O
within	O	O
the	O	O
same	O	O
population	O	O
it	O	O
may	O	O
also	O	O
be	O	O
heterogeneous	O	O
.	O	O

One	O	O
example	O	O
is	O	O
the	O	O
island	O	O
of	O	O
Sardinia	O	O
,	O	O
where	O	O
careful	O	O
clinical	O	O
and	O	O
biochemical	O	O
studies	O	O
have	O	O
identified	O	O
four	O	O
different	O	O
G6PD	O	O
variants	O	O
.	O	O

We	O	O
cloned	O	O
and	O	O
sequenced	O	O
the	O	O
four	O	O
G6PD	O	O
variants	O	O
from	O	O
Sardinia	O	O
and	O	O
found	O	O
that	O	O
only	O	O
two	O	O
mutations	O	O
are	O	O
responsible	O	O
for	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
this	O	O
area	O	O
one	O	O
mutation	O	O
is	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
G6PD	B-Disease	D005955
Seattle	I-Disease	D005955
-	I-Disease	D005955
like	I-Disease	D005955
phenotype	I-Disease	D005955
,	O	O
a	O	O
milder	O	O
form	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
;	O	O
the	O	O
other	O	O
mutation	O	O
is	O	O
responsible	O	O
for	O	O
all	O	O
forms	O	O
of	O	O
very	O	O
severe	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
Sardinia	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
in	O	O
the	O	O
Mediterranean	O	O
.	O	O

.	O	O

Familial	B-Disease	D008179
discoid	I-Disease	D008179
lupus	I-Disease	D008179
erythematosus	I-Disease	D008179
associated	O	O
with	O	O
heterozygote	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

Two	O	O
siblings	O	O
with	O	O
chronic	B-Disease	D008179
discoid	I-Disease	D008179
lupus	I-Disease	D008179
erythematosus	I-Disease	D008179
and	O	O
several	O	O
family	O	O
members	O	O
were	O	O
found	O	O
with	O	O
heterozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

An	O	O
association	O	O
with	O	O
histocompatibility	O	O
markers	O	O
HLA	O	O
-	O	O
B18	O	O
and	O	O
HLA	O	O
-	O	O
Dw2	O	O
was	O	O
demonstrated	O	O
,	O	O
and	O	O
the	O	O
slow	O	O
allotype	O	O
of	O	O
factor	O	O
B	O	O
was	O	O
present	O	O
.	O	O

Linkage	O	O
studies	O	O
in	O	O
this	O	O
family	O	O
suggested	O	O
a	O	O
close	O	O
linkage	O	O
between	O	O
the	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
gene	O	O
and	O	O
genes	O	O
coding	O	O
for	O	O
B18	O	O
,	O	O
Dw2	O	O
,	O	O
and	O	O
BfS	O	O
antigens	O	O
.	O	O

One	O	O
HLA	O	O
-	O	O
ACB	O	O
/	O	O
DBf	O	O
recombinant	O	O
was	O	O
observed	O	O
showing	O	O
closer	O	O
linkage	O	O
between	O	O
HLA	O	O
-	O	O
D	O	O
and	O	O
Bf	O	O
than	O	O
between	O	O
HLA	O	O
-	O	O
B	O	O
and	O	O
Bf	O	O
.	O	O

.	O	O

A	O	O
strong	O	O
candidate	O	O
for	O	O
the	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
BRCA1	O	O
.	O	O

A	O	O
strong	O	O
candidate	O	O
for	O	O
the	O	O
17q	O	O
-	O	O
linked	O	O
BRCA1	O	O
gene	O	O
,	O	O
which	O	O
influences	O	O
susceptibility	O	O
to	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
has	O	O
been	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
methods	O	O
.	O	O

Probable	O	O
predisposing	O	O
mutations	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
five	O	O
of	O	O
eight	O	O
kindreds	O	O
presumed	O	O
to	O	O
segregate	O	O
BRCA1	O	O
susceptibility	O	O
alleles	O	O
.	O	O

The	O	O
mutations	O	O
include	O	O
an	O	O
11	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
,	O	O
a	O	O
1	O	O
-	O	O
base	O	O
pair	O	O
insertion	O	O
,	O	O
a	O	O
stop	O	O
codon	O	O
,	O	O
a	O	O
missense	O	O
substitution	O	O
,	O	O
and	O	O
an	O	O
inferred	O	O
regulatory	O	O
mutation	O	O
.	O	O

The	O	O
BRCA1	O	O
gene	O	O
is	O	O
expressed	O	O
in	O	O
numerous	O	O
tissues	O	O
,	O	O
including	O	O
breast	O	O
and	O	O
ovary	O	O
,	O	O
and	O	O
encodes	O	O
a	O	O
predicted	O	O
protein	O	O
of	O	O
1863	O	O
amino	O	O
acids	O	O
.	O	O

This	O	O
protein	O	O
contains	O	O
a	O	O
zinc	O	O
finger	O	O
domain	O	O
in	O	O
its	O	O
amino	O	O
-	O	O
terminal	O	O
region	O	O
,	O	O
but	O	O
is	O	O
otherwise	O	O
unrelated	O	O
to	O	O
previously	O	O
described	O	O
proteins	O	O
.	O	O

Identification	O	O
of	O	O
BRCA1	O	O
should	O	O
facilitate	O	O
early	O	O
diagnosis	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
in	O	O
some	O	O
individuals	O	O
as	O	O
well	O	O
as	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
biology	O	O
.	O	O

.	O	O

Recombinations	O	O
in	O	O
individuals	O	O
homozygous	O	O
by	O	O
descent	O	O
localize	O	O
the	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
locus	O	O
in	O	O
a	O	O
cloned	O	O
450	O	O
-	O	O
kb	O	O
interval	O	O
.	O	O

The	O	O
locus	O	O
for	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
,	O	O
a	O	O
severe	O	O
neurodegenerative	B-Disease	D019636
disease	I-Disease	D019636
,	O	O
is	O	O
tightly	O	O
linked	O	O
to	O	O
markers	O	O
D9S5	O	O
and	O	O
D9S15	O	O
,	O	O
and	O	O
analysis	O	O
of	O	O
rare	O	O
recombination	O	O
events	O	O
has	O	O
suggested	O	O
the	O	O
order	O	O
cen	O	O
-	O	O
FRDA	B-Disease	D005621
-	O	O
D9S5	O	O
-	O	O
D9S15	O	O
-	O	O
qter	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
construction	O	O
of	O	O
a	O	O
YAC	O	O
contig	O	O
extending	O	O
800	O	O
kb	O	O
centromeric	O	O
to	O	O
D9S5	O	O
and	O	O
the	O	O
isolation	O	O
of	O	O
five	O	O
new	O	O
microsatellite	O	O
markers	O	O
from	O	O
this	O	O
region	O	O
.	O	O

In	O	O
order	O	O
to	O	O
map	O	O
these	O	O
markers	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
FRDA	B-Disease	D005621
locus	O	O
,	O	O
all	O	O
within	O	O
a	O	O
1	O	O
-	O	O
cM	O	O
confidence	O	O
interval	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
increase	O	O
the	O	O
genetic	O	O
information	O	O
of	O	O
available	O	O
FRDA	B-Disease	D005621
families	O	O
by	O	O
considering	O	O
homozygosity	O	O
by	O	O
descent	O	O
and	O	O
association	O	O
with	O	O
founder	O	O
haplotypes	O	O
in	O	O
isolated	O	O
populations	O	O
.	O	O

This	O	O
approach	O	O
allowed	O	O
us	O	O
to	O	O
identify	O	O
one	O	O
phase	O	O
-	O	O
known	O	O
recombination	O	O
and	O	O
one	O	O
probable	O	O
historic	O	O
recombination	O	O
on	O	O
haplotypes	O	O
from	O	O
Reunion	O	O
Island	O	O
patients	O	O
,	O	O
both	O	O
of	O	O
which	O	O
place	O	O
three	O	O
of	O	O
the	O	O
five	O	O
markers	O	O
proximal	O	O
to	O	O
FRDA	B-Disease	D005621
.	O	O

This	O	O
represents	O	O
the	O	O
first	O	O
identification	O	O
of	O	O
close	O	O
FRDA	B-Disease	D005621
flanking	O	O
markers	O	O
on	O	O
the	O	O
centromeric	O	O
side	O	O
.	O	O

The	O	O
two	O	O
other	O	O
markers	O	O
allowed	O	O
us	O	O
to	O	O
narrow	O	O
the	O	O
breakpoint	O	O
of	O	O
a	O	O
previously	O	O
identified	O	O
distal	O	O
recombination	O	O
that	O	O
is	O	O
>	O	O
180	O	O
kb	O	O
from	O	O
D9S5	O	O
(	O	O
26P	O	O
)	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
the	O	O
results	O	O
place	O	O
the	O	O
FRDA	B-Disease	D005621
locus	O	O
in	O	O
a	O	O
450	O	O
-	O	O
kb	O	O
interval	O	O
,	O	O
which	O	O
is	O	O
small	O	O
enough	O	O
for	O	O
direct	O	O
search	O	O
of	O	O
candidate	O	O
genes	O	O
.	O	O

A	O	O
detailed	O	O
rare	O	O
cutter	O	O
restriction	O	O
map	O	O
and	O	O
a	O	O
cosmid	O	O
contig	O	O
covering	O	O
this	O	O
interval	O	O
were	O	O
constructed	O	O
and	O	O
should	O	O
facilitate	O	O
the	O	O
search	O	O
of	O	O
genes	O	O
in	O	O
this	O	O
region	O	O
.	O	O

.	O	O

Further	O	O
mapping	O	O
of	O	O
an	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
locus	O	O
to	O	O
the	O	O
chromosome	O	O
11q23	O	O
region	O	O
.	O	O

We	O	O
recently	O	O
mapped	O	O
the	O	O
gene	O	O
for	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
group	O	O
A	O	O
(	O	O
ATA	O	O
)	O	O
to	O	O
chromosome	O	O
11q22	O	O
-	O	O
23	O	O
by	O	O
linkage	O	O
analysis	O	O
,	O	O
using	O	O
the	O	O
genetic	O	O
markers	O	O
THY1	O	O
and	O	O
pYNB3	O	O
.	O	O

12	O	O
(	O	O
D11S144	O	O
)	O	O
.	O	O

The	O	O
most	O	O
likely	O	O
order	O	O
was	O	O
cent	O	O
-	O	O
AT	B-Disease	D001260
-	O	O
S144	O	O
-	O	O
THY1	O	O
.	O	O

The	O	O
present	O	O
paper	O	O
describes	O	O
further	O	O
mapping	O	O
of	O	O
the	O	O
AT	B-Disease	D001260
locus	O	O
by	O	O
means	O	O
of	O	O
a	O	O
panel	O	O
of	O	O
10	O	O
markers	O	O
that	O	O
span	O	O
approximately	O	O
60	O	O
cM	O	O
in	O	O
the	O	O
11q22	O	O
-	O	O
23	O	O
region	O	O
centered	O	O
around	O	O
S144	O	O
and	O	O
THY1	O	O
.	O	O

Location	O	O
scores	O	O
indicate	O	O
that	O	O
three	O	O
contiguous	O	O
subsegments	O	O
within	O	O
the	O	O
[	O	O
S144	O	O
-	O	O
THY1	O	O
]	O	O
segment	O	O
,	O	O
as	O	O
well	O	O
as	O	O
three	O	O
contiguous	O	O
segments	O	O
telomeric	O	O
to	O	O
THY1	O	O
,	O	O
are	O	O
each	O	O
unlikely	O	O
to	O	O
contain	O	O
the	O	O
AT	B-Disease	D001260
locus	O	O
,	O	O
while	O	O
the	O	O
more	O	O
centromeric	O	O
[	O	O
STMY	O	O
-	O	O
S144	O	O
]	O	O
segment	O	O
is	O	O
most	O	O
likely	O	O
to	O	O
contain	O	O
the	O	O
AT	B-Disease	D001260
locus	O	O
.	O	O

These	O	O
data	O	O
,	O	O
together	O	O
with	O	O
recent	O	O
refinements	O	O
in	O	O
the	O	O
linkage	O	O
and	O	O
physical	O	O
maps	O	O
of	O	O
11q22	O	O
-	O	O
23	O	O
,	O	O
place	O	O
the	O	O
AT	B-Disease	D001260
locus	O	O
at	O	O
11q23	O	O
.	O	O

Proliferation	O	O
-	O	O
related	O	O
expression	O	O
of	O	O
p19	O	O
/	O	O
nm23	O	O
nucleoside	O	O
diphosphate	O	O
kinase	O	O
.	O	O

High	O	O
level	O	O
expression	O	O
of	O	O
the	O	O
nm23	O	O
-	O	O
H1	O	O
gene	O	O
,	O	O
which	O	O
encodes	O	O
for	O	O
a	O	O
nucleoside	O	O
diphosphate	O	O
kinase	O	O
,	O	O
has	O	O
been	O	O
found	O	O
to	O	O
correlate	O	O
with	O	O
diminished	O	O
metastasis	O	O
in	O	O
some	O	O
tumors	B-Disease	D009369
but	O	O
not	O	O
in	O	O
others	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
identified	O	O
the	O	O
protein	O	O
product	O	O
of	O	O
the	O	O
nm23	O	O
-	O	O
H1	O	O
gene	O	O
in	O	O
two	O	O
-	O	O
dimensional	O	O
electrophoretic	O	O
gels	O	O
and	O	O
have	O	O
designated	O	O
it	O	O
p19	O	O
/	O	O
nm23	O	O
.	O	O

In	O	O
neuroblastoma	B-Disease	D009447
,	O	O
higher	O	O
levels	O	O
of	O	O
p19	O	O
/	O	O
nm23	O	O
,	O	O
which	O	O
are	O	O
associated	O	O
with	O	O
amplification	O	O
of	O	O
the	O	O
N	O	O
-	O	O
myc	O	O
oncogene	O	O
,	O	O
large	O	O
tumor	B-Disease	D009369
mass	O	O
,	O	O
and	O	O
metastasis	O	O
,	O	O
were	O	O
observed	O	O
in	O	O
advanced	O	O
stage	O	O
tumors	B-Disease	D009369
compared	O	O
with	O	O
limited	O	O
stage	O	O
disease	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
variable	O	O
expression	O	O
of	O	O
nm23	O	O
-	O	O
H1	O	O
in	O	O
different	O	O
tumors	B-Disease	D009369
,	O	O
we	O	O
have	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
amounts	O	O
of	O	O
the	O	O
protein	O	O
and	O	O
cell	O	O
proliferation	O	O
.	O	O

The	O	O
levels	O	O
of	O	O
p19	O	O
/	O	O
nm23	O	O
were	O	O
compared	O	O
between	O	O
resting	O	O
and	O	O
mitotically	O	O
stimulated	O	O
normal	O	O
human	O	O
PBLs	O	O
and	O	O
in	O	O
leukemia	B-Disease	D007938
cells	O	O
.	O	O

The	O	O
amount	O	O
of	O	O
p19	O	O
/	O	O
nm23	O	O
increased	O	O
in	O	O
normal	O	O
lymphocytes	O	O
in	O	O
response	O	O
to	O	O
mitotic	O	O
stimulation	O	O
and	O	O
paralleled	O	O
the	O	O
increase	O	O
in	O	O
DNA	O	O
synthesis	O	O
.	O	O

In	O	O
leukemia	B-Disease	D007938
cells	O	O
obtained	O	O
from	O	O
patients	O	O
with	O	O
different	O	O
subtypes	O	O
of	O	O
acute	B-Disease	D007938
leukemia	I-Disease	D007938
,	O	O
p19	O	O
/	O	O
nm23	O	O
levels	O	O
were	O	O
also	O	O
increased	O	O
relative	O	O
to	O	O
resting	O	O
normal	O	O
lymphocytes	O	O
.	O	O

Treatment	O	O
of	O	O
mitotically	O	O
stimulated	O	O
lymphocytes	O	O
with	O	O
cyclosporin	O	O
,	O	O
which	O	O
inhibits	O	O
proliferation	O	O
,	O	O
blocked	O	O
the	O	O
increase	O	O
in	O	O
p19	O	O
/	O	O
nm23	O	O
;	O	O
treatment	O	O
of	O	O
the	O	O
leukemia	B-Disease	D007938
cell	O	O
line	O	O
HL	O	O
-	O	O
60	O	O
with	O	O
dimethylsulfoxide	O	O
,	O	O
which	O	O
induces	O	O
terminal	O	O
differentiation	O	O
,	O	O
resulted	O	O
in	O	O
diminished	O	O
levels	O	O
of	O	O
p19	O	O
/	O	O
nm23	O	O
.	O	O

Our	O	O
data	O	O
therefore	O	O
provide	O	O
evidence	O	O
that	O	O
nm23	O	O
-	O	O
H1	O	O
expression	O	O
is	O	O
related	O	O
to	O	O
cell	O	O
proliferative	O	O
activity	O	O
.	O	O

.	O	O

Carrier	O	O
detection	O	O
of	O	O
pyruvate	B-Disease	D015324
carboxylase	I-Disease	D015324
deficiency	I-Disease	D015324
in	O	O
fibroblasts	O	O
and	O	O
lymphocytes	O	O
.	O	O

Pyruvate	O	O
carboxylase	O	O
(	O	O
E	O	O
.	O	O

C	O	O
.	O	O

6	O	O
.	O	O

4	O	O
.	O	O

1	O	O
.	O	O

1	O	O
)	O	O
activity	O	O
was	O	O
determined	O	O
in	O	O
the	O	O
circulating	O	O
peripheral	O	O
lymphocytes	O	O
and	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
the	O	O
family	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
hepatic	O	O
,	O	O
cerebral	O	O
,	O	O
renal	O	O
cortical	O	O
,	O	O
leukocyte	O	O
,	O	O
and	O	O
fibroblast	O	O
pyruvate	B-Disease	D015324
carboxylase	I-Disease	D015324
deficiency	I-Disease	D015324
(	O	O
PC	B-Disease	D015324
Portland	I-Disease	D015324
deficiency	I-Disease	D015324
)	O	O
.	O	O

Lymphocyte	O	O
activities	O	O
were	O	O
mother	O	O
,	O	O
33	O	O
-	O	O
-	O	O
39	O	O
%	O	O
;	O	O
father	O	O
,	O	O
11	O	O
-	O	O
-	O	O
29	O	O
%	O	O
;	O	O
brother	O	O
,	O	O
82	O	O
-	O	O
-	O	O
103	O	O
%	O	O
;	O	O
and	O	O
sister	O	O
,	O	O
38	O	O
-	O	O
-	O	O
48	O	O
%	O	O
of	O	O
the	O	O
lowest	O	O
normal	O	O
.	O	O

Fibroblasts	O	O
from	O	O
the	O	O
patients	O	O
mother	O	O
and	O	O
father	O	O
had	O	O
42	O	O
and	O	O
34	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
of	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
lowest	O	O
normal	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
the	O	O
disease	O	O
is	O	O
inherited	O	O
in	O	O
an	O	O
autosomal	O	O
recessive	O	O
manner	O	O
and	O	O
that	O	O
lymphocytes	O	O
and	O	O
fibroblasts	O	O
can	O	O
be	O	O
used	O	O
to	O	O
detect	O	O
carriers	O	O
.	O	O

Neither	O	O
pyruvate	O	O
carboxylase	O	O
nor	O	O
mitochondrial	O	O
PEPCK	O	O
activity	O	O
in	O	O
lymphocytes	O	O
was	O	O
increased	O	O
by	O	O
a	O	O
21	O	O
-	O	O
hr	O	O
fast	O	O
.	O	O

Complex	B-Disease	C538138
glycerol	I-Disease	C538138
kinase	I-Disease	C538138
deficiency	I-Disease	C538138
:	O	O
molecular	O	O
-	O	O
genetic	O	O
,	O	O
cytogenetic	O	O
,	O	O
and	O	O
clinical	O	O
studies	O	O
of	O	O
five	O	O
Japanese	O	O
patients	O	O
.	O	O

Five	O	O
male	O	O
Japanese	O	O
patients	O	O
with	O	O
complex	B-Disease	C538138
glycerol	I-Disease	C538138
kinase	I-Disease	C538138
deficiency	I-Disease	C538138
(	O	O
CGKD	B-Disease	C538138
)	O	O
and	O	O
their	O	O
relatives	O	O
were	O	O
studied	O	O
clinically	O	O
,	O	O
cytogenetically	O	O
,	O	O
and	O	O
molecular	O	O
-	O	O
genetically	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
or	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
congenital	B-Disease	D000312
adrenal	I-Disease	D000312
hypoplasia	I-Disease	D000312
,	O	O
and	O	O
glycerol	B-Disease	C538138
kinase	I-Disease	C538138
deficiency	I-Disease	C538138
.	O	O

High	O	O
-	O	O
resolution	O	O
GTG	O	O
-	O	O
banded	O	O
chromosomes	O	O
showed	O	O
a	O	O
microdeletion	O	O
in	O	O
the	O	O
Xp21	O	O
region	O	O
in	O	O
all	O	O
four	O	O
patients	O	O
examined	O	O
and	O	O
in	O	O
all	O	O
five	O	O
mothers	O	O
.	O	O

Southern	O	O
hybridizations	O	O
,	O	O
after	O	O
digestions	O	O
by	O	O
restriction	O	O
endonucleases	O	O
,	O	O
with	O	O
various	O	O
cloned	O	O
DNAs	O	O
(	O	O
D2	O	O
,	O	O
99	O	O
-	O	O
6	O	O
,	O	O
B24	O	O
,	O	O
C7	O	O
,	O	O
L1	O	O
-	O	O
4	O	O
,	O	O
cDMD13	O	O
-	O	O
14	O	O
,	O	O
J66	O	O
-	O	O
HI	O	O
,	O	O
P20	O	O
,	O	O
J	O	O
-	O	O
Bir	O	O
,	O	O
ERT87	O	O
-	O	O
30	O	O
,	O	O
ERT87	O	O
-	O	O
15	O	O
,	O	O
ERT87	O	O
-	O	O
8	O	O
,	O	O
ERT87	O	O
-	O	O
1	O	O
,	O	O
XJ	O	O
-	O	O
1	O	O
.	O	O

1	O	O
,	O	O
754	O	O
,	O	O
cx5	O	O
.	O	O

7	O	O
,	O	O
and	O	O
OTC	O	O
-	O	O
1	O	O
)	O	O
that	O	O
are	O	O
located	O	O
around	O	O
Xp21	O	O
also	O	O
showed	O	O
a	O	O
deletion	O	O
in	O	O
the	O	O
genome	O	O
of	O	O
all	O	O
patients	O	O
and	O	O
mothers	O	O
.	O	O

Although	O	O
the	O	O
deletion	O	O
differed	O	O
in	O	O
size	O	O
among	O	O
patients	O	O
,	O	O
a	O	O
segment	O	O
commonly	O	O
absent	O	O
was	O	O
located	O	O
between	O	O
the	O	O
genomic	O	O
sequences	O	O
corresponding	O	O
to	O	O
L1	O	O
-	O	O
4	O	O
and	O	O
cDMD13	O	O
-	O	O
14	O	O
.	O	O

This	O	O
finding	O	O
indicated	O	O
that	O	O
the	O	O
gene	O	O
coding	O	O
for	O	O
glycerol	O	O
kinase	O	O
(	O	O
GK	O	O
)	O	O
is	O	O
located	O	O
within	O	O
this	O	O
segment	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
the	O	O
clinical	O	O
manifestations	O	O
of	O	O
the	O	O
present	O	O
five	O	O
patients	O	O
and	O	O
reported	O	O
CGKD	B-Disease	C538138
or	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
patients	O	O
with	O	O
DNA	O	O
deletion	O	O
suggests	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
certain	O	O
gene	O	O
responsible	O	O
for	O	O
gonadotropin	B-Disease	C535764
deficiency	I-Disease	C535764
(	O	O
GTD	B-Disease	C535764
)	O	O
.	O	O

The	O	O
result	O	O
of	O	O
the	O	O
present	O	O
study	O	O
and	O	O
results	O	O
of	O	O
previous	O	O
studies	O	O
suggest	O	O
that	O	O
genes	O	O
for	O	O
ornithine	O	O
transcarbamylase	O	O
(	O	O
OTC	O	O
)	O	O
,	O	O
DMD	B-Disease	D020388
,	O	O
and	O	O
GK	O	O
and	O	O
putative	O	O
genes	O	O
responsible	O	O
for	O	O
congenital	B-Disease	D000312
adrenal	I-Disease	D000312
hypoplasia	I-Disease	D000312
(	O	O
AHC	B-Disease	D000312
)	O	O
and	O	O
GTD	B-Disease	C535764
are	O	O
arranged	O	O
from	O	O
telomere	O	O
to	O	O
centromere	O	O
as	O	O
pter	O	O
-	O	O
-	O	O
GTD	B-Disease	C535764
-	O	O
-	O	O
AHC	B-Disease	D000312
-	O	O
-	O	O
GK	O	O
-	O	O
-	O	O
DMD	B-Disease	D020388
-	O	O
-	O	O
OTC	O	O
-	O	O
-	O	O
cen	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
and	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
in	O	O
the	O	O
same	O	O
patient	O	O
.	O	O

We	O	O
report	O	O
on	O	O
the	O	O
first	O	O
patient	O	O
identified	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
and	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
.	O	O

The	O	O
family	O	O
of	O	O
the	O	O
propositus	O	O
had	O	O
a	O	O
strong	O	O
history	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
and	O	O
there	O	O
was	O	O
an	O	O
intrafamilial	O	O
pathological	O	O
expansion	O	O
of	O	O
the	O	O
responsible	O	O
CTG	O	O
repeat	O	O
between	O	O
the	O	O
mildly	O	O
affected	O	O
mother	O	O
(	O	O
160	O	O
repeats	O	O
;	O	O
normal	O	O
27	O	O
repeats	O	O
)	O	O
and	O	O
her	O	O
more	O	O
severely	O	O
affected	O	O
son	O	O
(	O	O
650	O	O
repeats	O	O
)	O	O
,	O	O
and	O	O
his	O	O
sister	O	O
(	O	O
650	O	O
repeats	O	O
)	O	O
.	O	O

The	O	O
propositus	O	O
was	O	O
an	O	O
isolated	O	O
case	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
with	O	O
marked	O	O
dystrophin	B-Disease	OMIM:310200
deficiency	I-Disease	OMIM:310200
in	O	O
muscle	O	O
biopsy	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
still	O	O
ambulatory	O	O
post	O	O
age	O	O
16	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
could	O	O
interfere	O	O
to	O	O
some	O	O
extent	O	O
with	O	O
the	O	O
progression	O	O
of	O	O
Duchenne	B-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

However	O	O
,	O	O
other	O	O
interpretations	O	O
are	O	O
possible	O	O
.	O	O

Twelve	O	O
percent	O	O
of	O	O
dystrophin	O	O
revertant	O	O
fibers	O	O
as	O	O
observed	O	O
by	O	O
immunohistochemistry	O	O
could	O	O
be	O	O
sufficient	O	O
to	O	O
ameliorate	O	O
typical	O	O
DMD	B-Disease	D020388
clinical	O	O
severity	O	O
,	O	O
or	O	O
the	O	O
patient	O	O
may	O	O
present	O	O
a	O	O
somatic	O	O
mosaic	O	O
.	O	O

The	O	O
pathophysiological	O	O
interactions	O	O
of	O	O
these	O	O
two	O	O
unlinked	O	O
disorders	O	O
are	O	O
discussed	O	O
at	O	O
the	O	O
clinical	O	O
and	O	O
histopathological	O	O
levels	O	O
.	O	O

.	O	O

Autosomal	O	O
recessive	O	O
transmission	O	O
of	O	O
hemophilia	B-Disease	D006467
A	I-Disease	D006467
due	O	O
to	O	O
a	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
mutation	O	O
.	O	O

The	O	O
differential	O	O
diagnosis	O	O
of	O	O
the	O	O
genetic	B-Disease	D025861
bleeding	I-Disease	D025861
disorders	I-Disease	D025861
,	O	O
hemophilia	B-Disease	D006467
A	I-Disease	D006467
and	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	O	O
,	O	O
is	O	O
occasionally	O	O
confounded	O	O
by	O	O
the	O	O
close	O	O
molecular	O	O
relationship	O	O
of	O	O
coagulation	O	O
factor	O	O
VIII	O	O
and	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
(	O	O
vWF	O	O
)	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
the	O	O
autosomal	O	O
inheritance	O	O
of	O	O
a	O	O
hemophilia	B-Disease	D006467
A	I-Disease	D006467
phenotype	O	O
due	O	O
to	O	O
a	O	O
mutation	O	O
of	O	O
vWF	O	O
that	O	O
results	O	O
in	O	O
defective	O	O
factor	O	O
VIII	O	O
binding	O	O
.	O	O

The	O	O
proband	O	O
was	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
low	O	O
levels	O	O
of	O	O
factor	O	O
VIII	O	O
activity	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
amplification	O	O
and	O	O
DNA	O	O
sequencing	O	O
were	O	O
employed	O	O
to	O	O
examine	O	O
exons	O	O
encoding	O	O
the	O	O
putative	O	O
factor	O	O
VIII	O	O
binding	O	O
domain	O	O
of	O	O
vWF	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
a	O	O
single	O	O
point	O	O
mutation	O	O
causing	O	O
a	O	O
Thr	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
substitution	O	O
at	O	O
amino	O	O
acid	O	O
position	O	O
28	O	O
in	O	O
the	O	O
mature	O	O
vWF	O	O
subunit	O	O
.	O	O

The	O	O
phenotypic	O	O
expression	O	O
of	O	O
the	O	O
mutation	O	O
was	O	O
determined	O	O
to	O	O
be	O	O
recessive	O	O
because	O	O
heterozygous	O	O
family	O	O
members	O	O
were	O	O
clinically	O	O
unaffected	O	O
.	O	O

Recombinant	O	O
vWF	O	O
containing	O	O
the	O	O
observed	O	O
amino	O	O
acid	O	O
substitution	O	O
was	O	O
expressed	O	O
in	O	O
COS	O	O
-	O	O
1	O	O
cells	O	O
.	O	O

The	O	O
mutant	O	O
vWF	O	O
was	O	O
processed	O	O
and	O	O
secreted	O	O
normally	O	O
,	O	O
and	O	O
was	O	O
functionally	O	O
equivalent	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
vWF	O	O
in	O	O
its	O	O
ability	O	O
to	O	O
bind	O	O
to	O	O
platelets	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mutant	O	O
failed	O	O
to	O	O
bind	O	O
factor	O	O
VIII	O	O
,	O	O
demonstrating	O	O
that	O	O
the	O	O
mutation	O	O
was	O	O
functionally	O	O
related	O	O
to	O	O
the	O	O
observed	O	O
hemophilia	B-Disease	D006467
phenotype	O	O
.	O	O

The	O	O
family	O	O
we	O	O
describe	O	O
demonstrates	O	O
the	O	O
recessive	O	O
inheritance	O	O
of	O	O
a	O	O
recently	O	O
recognized	O	O
class	O	O
of	O	O
genetic	B-Disease	D025861
bleeding	I-Disease	D025861
disorders	I-Disease	D025861
,	O	O
we	O	O
call	O	O
"	O	O
autosomal	O	O
hemophilia	B-Disease	D006467
.	O	O

"	O	O
We	O	O
conclude	O	O
that	O	O
vWF	O	O
mutation	O	O
may	O	O
be	O	O
an	O	O
under	O	O
recognized	O	O
cause	O	O
of	O	O
hemophilia	B-Disease	D006467
,	O	O
especially	O	O
in	O	O
cases	O	O
where	O	O
the	O	O
inheritance	O	O
pattern	O	O
is	O	O
not	O	O
consistent	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
transmission	O	O
.	O	O

Determination	O	O
of	O	O
30	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
mutations	O	O
,	O	O
including	O	O
15	O	O
not	O	O
previously	O	O
described	O	O
.	O	O

X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
Adrenoleukodystrophy	I-Disease	D000326
(	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
)	O	O
is	O	O
the	O	O
most	O	O
frequent	O	O
peroxisomal	B-Disease	D018901
disease	I-Disease	D018901
.	O	O

It	O	O
mainly	O	O
involves	O	O
the	O	O
nervous	O	O
system	O	O
white	O	O
matter	O	O
,	O	O
adrenal	O	O
cortex	O	O
and	O	O
testes	O	O
.	O	O

Several	O	O
distinct	O	O
clinical	O	O
phenotypes	O	O
are	O	O
known	O	O
.	O	O

The	O	O
principal	O	O
biochemical	O	O
abnormality	O	O
is	O	O
the	O	O
accumulation	O	O
of	O	O
saturated	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
fatty	O	O
acids	O	O
(	O	O
VLCFAs	O	O
>	O	O
C22	O	O
0	O	O
,	O	O
mainly	O	O
C26	O	O
0	O	O
)	O	O
,	O	O
which	O	O
is	O	O
due	O	O
to	O	O
impaired	O	O
capacity	O	O
for	O	O
beta	O	O
-	O	O
oxidation	O	O
in	O	O
peroxisomes	O	O
.	O	O

Diagnosis	O	O
is	O	O
usually	O	O
based	O	O
on	O	O
the	O	O
VLCFA	O	O
levels	O	O
in	O	O
plasma	O	O
or	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
in	O	O
both	O	O
patients	O	O
and	O	O
carriers	O	O
.	O	O

In	O	O
0	O	O
.	O	O

1	O	O
%	O	O
of	O	O
affected	O	O
males	O	O
,	O	O
however	O	O
,	O	O
the	O	O
plasma	O	O
C26	O	O
0	O	O
level	O	O
is	O	O
borderline	O	O
normal	O	O
,	O	O
and	O	O
15	O	O
%	O	O
of	O	O
obligate	O	O
female	O	O
carriers	O	O
have	O	O
normal	O	O
results	O	O
.	O	O

Effective	O	O
mutation	O	O
detection	O	O
in	O	O
these	O	O
families	O	O
is	O	O
therefore	O	O
fundamental	O	O
to	O	O
unambiguously	O	O
determine	O	O
the	O	O
genetic	O	O
status	O	O
of	O	O
each	O	O
individual	O	O
at	O	O
risk	O	O
.	O	O

Of	O	O
particular	O	O
concern	O	O
are	O	O
female	O	O
members	O	O
of	O	O
kindreds	O	O
segregating	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
mutations	O	O
,	O	O
because	O	O
normal	O	O
VLCFA	O	O
levels	O	O
do	O	O
not	O	O
guarantee	O	O
lack	O	O
of	O	O
carrier	O	O
status	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
fast	O	O
method	O	O
for	O	O
detection	O	O
of	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
mutations	O	O
.	O	O

The	O	O
method	O	O
is	O	O
based	O	O
on	O	O
SSCP	O	O
analysis	O	O
of	O	O
nested	O	O
PCR	O	O
fragments	O	O
followed	O	O
by	O	O
sequence	O	O
-	O	O
determination	O	O
reactions	O	O
.	O	O

Using	O	O
this	O	O
methodology	O	O
we	O	O
have	O	O
found	O	O
X	B-Disease	D000326
-	I-Disease	D000326
ALD	I-Disease	D000326
mutations	O	O
in	O	O
30	O	O
kindreds	O	O
,	O	O
including	O	O
15	O	O
not	O	O
previously	O	O
reported	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
in	O	O
families	O	O
with	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

We	O	O
analysed	O	O
50	O	O
probands	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
for	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
BRCA1	O	O
candidate	O	O
gene	O	O
,	O	O
using	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
analysis	O	O
on	O	O
PCR	O	O
-	O	O
amplified	O	O
genomic	O	O
DNA	O	O
.	O	O

A	O	O
total	O	O
of	O	O
eight	O	O
putative	O	O
disease	O	O
-	O	O
causing	O	O
alterations	O	O
were	O	O
identified	O	O
four	O	O
of	O	O
these	O	O
are	O	O
frameshifts	O	O
and	O	O
two	O	O
are	O	O
nonsense	O	O
mutations	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
found	O	O
two	O	O
missense	O	O
mutations	O	O
,	O	O
one	O	O
of	O	O
which	O	O
changes	O	O
the	O	O
final	O	O
cysteine	O	O
of	O	O
the	O	O
BRCA1	O	O
zinc	O	O
finger	O	O
motif	O	O
to	O	O
glycine	O	O
.	O	O

These	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
tumour	B-Disease	D009369
suppressor	O	O
model	O	O
,	O	O
and	O	O
support	O	O
the	O	O
notion	O	O
that	O	O
this	O	O
candidate	O	O
gene	O	O
is	O	O
in	O	O
fact	O	O
BRCA1	O	O
.	O	O

The	O	O
heterogeneity	O	O
of	O	O
mutations	O	O
,	O	O
coupled	O	O
with	O	O
the	O	O
large	O	O
size	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
indicates	O	O
that	O	O
clinical	O	O
application	O	O
of	O	O
BRCA1	O	O
mutation	O	O
testing	O	O
will	O	O
be	O	O
technically	O	O
challenging	O	O
.	O	O

.	O	O

Screening	O	O
for	O	O
carriers	O	O
of	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
among	O	O
Ashkenazi	O	O
Jews	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
DNA	O	O
-	O	O
based	O	O
and	O	O
enzyme	O	O
-	O	O
based	O	O
tests	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
METHODS	O	O
.	O	O

The	O	O
prevention	O	O
of	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
GM2	B-Disease	D013661
gangliosidosis	I-Disease	D013661
,	I-Disease	D013661
type	I-Disease	D013661
1	I-Disease	D013661
)	O	O
depends	O	O
on	O	O
the	O	O
identification	O	O
of	O	O
carriers	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
this	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
.	O	O

We	O	O
compared	O	O
the	O	O
enzyme	O	O
-	O	O
based	O	O
test	O	O
widely	O	O
used	O	O
in	O	O
screening	O	O
for	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
with	O	O
a	O	O
test	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
DNA	O	O
.	O	O

We	O	O
developed	O	O
methods	O	O
to	O	O
detect	O	O
the	O	O
three	O	O
mutations	O	O
in	O	O
the	O	O
HEXA	O	O
gene	O	O
that	O	O
occur	O	O
with	O	O
high	O	O
frequency	O	O
among	O	O
Ashkenazi	O	O
Jews	O	O
two	O	O
mutations	O	O
cause	O	O
infantile	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
,	O	O
and	O	O
the	O	O
third	O	O
causes	O	O
the	O	O
adult	O	O
-	O	O
onset	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

DNA	O	O
segments	O	O
containing	O	O
these	O	O
mutation	O	O
sites	O	O
were	O	O
amplified	O	O
with	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
analyzed	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
mutations	O	O
.	O	O

RESULTS	O	O
.	O	O

Among	O	O
62	O	O
Ashkenazi	O	O
obligate	O	O
carriers	O	O
of	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
,	O	O
the	O	O
three	O	O
specific	O	O
mutations	O	O
accounted	O	O
for	O	O
all	O	O
but	O	O
one	O	O
of	O	O
the	O	O
mutant	O	O
alleles	O	O
(	O	O
98	O	O
percent	O	O
)	O	O
.	O	O

In	O	O
216	O	O
Ashkenazi	O	O
carriers	O	O
identified	O	O
by	O	O
the	O	O
enzyme	O	O
test	O	O
,	O	O
DNA	O	O
analysis	O	O
showed	O	O
that	O	O
177	O	O
(	O	O
82	O	O
percent	O	O
)	O	O
had	O	O
one	O	O
of	O	O
the	O	O
identified	O	O
mutations	O	O
.	O	O

Of	O	O
the	O	O
177	O	O
,	O	O
79	O	O
percent	O	O
had	O	O
the	O	O
exon	O	O
11	O	O
insertion	O	O
mutation	O	O
,	O	O
18	O	O
percent	O	O
had	O	O
the	O	O
intron	O	O
12	O	O
splice	O	O
-	O	O
junction	O	O
mutation	O	O
,	O	O
and	O	O
3	O	O
percent	O	O
had	O	O
the	O	O
less	O	O
severe	O	O
exon	O	O
7	O	O
mutation	O	O
associated	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
disease	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
enzyme	O	O
tests	O	O
in	O	O
the	O	O
39	O	O
subjects	O	O
(	O	O
18	O	O
percent	O	O
)	O	O
who	O	O
were	O	O
defined	O	O
as	O	O
carriers	O	O
but	O	O
in	O	O
whom	O	O
DNA	O	O
analysis	O	O
did	O	O
not	O	O
identify	O	O
a	O	O
mutant	O	O
allele	O	O
were	O	O
probably	O	O
false	O	O
positive	O	O
(	O	O
although	O	O
there	O	O
remains	O	O
some	O	O
possibility	O	O
of	O	O
unidentified	O	O
mutations	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
of	O	O
152	O	O
persons	O	O
defined	O	O
as	O	O
noncarriers	O	O
by	O	O
the	O	O
enzyme	O	O
-	O	O
based	O	O
test	O	O
,	O	O
1	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
carrier	O	O
by	O	O
DNA	O	O
analysis	O	O
(	O	O
i	O	O
.	O	O

e	O	O
e	O	O
.	O	O

,	O	O
a	O	O
false	O	O
negative	O	O
enzyme	O	O
-	O	O
test	O	O
result	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
.	O	O

The	O	O
increased	O	O
specificity	O	O
and	O	O
predictive	O	O
value	O	O
of	O	O
the	O	O
DNA	O	O
-	O	O
based	O	O
test	O	O
make	O	O
it	O	O
a	O	O
useful	O	O
adjunct	O	O
to	O	O
the	O	O
diagnostic	O	O
tests	O	O
currently	O	O
used	O	O
to	O	O
screen	O	O
for	O	O
carriers	O	O
of	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
.	O	O

Adrenoleukodystrophy	B-Disease	D000326
gene	O	O
encodes	O	O
an	O	O
80	O	O
kDa	O	O
membrane	O	O
protein	O	O
.	O	O

An	O	O
antibody	O	O
against	O	O
the	O	O
synthetic	O	O
C	O	O
-	O	O
terminal	O	O
peptides	O	O
deduced	O	O
from	O	O
the	O	O
cDNA	O	O
of	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
was	O	O
produced	O	O
to	O	O
characterize	O	O
the	O	O
product	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
.	O	O

The	O	O
antibody	O	O
reacted	O	O
with	O	O
the	O	O
80	O	O
kDa	O	O
band	O	O
protein	O	O
in	O	O
control	O	O
fibroblasts	O	O
,	O	O
while	O	O
no	O	O
bands	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
fibroblasts	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
ALD	B-Disease	D000326
(	O	O
#	O	O
163	O	O
)	O	O
,	O	O
in	O	O
which	O	O
mRNA	O	O
of	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
was	O	O
undetectable	O	O
based	O	O
on	O	O
Northern	O	O
blot	O	O
analysis	O	O
.	O	O

The	O	O
293T	O	O
cells	O	O
transfected	O	O
with	O	O
the	O	O
full	O	O
-	O	O
coding	O	O
cDNA	O	O
inserted	O	O
in	O	O
the	O	O
expression	O	O
vector	O	O
produced	O	O
a	O	O
new	O	O
80	O	O
kDa	O	O
protein	O	O
,	O	O
as	O	O
detected	O	O
by	O	O
Western	O	O
blot	O	O
.	O	O

In	O	O
an	O	O
immunocytological	O	O
study	O	O
,	O	O
the	O	O
staining	O	O
was	O	O
in	O	O
a	O	O
punctate	O	O
pattern	O	O
,	O	O
in	O	O
the	O	O
normal	O	O
fibroblasts	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
punctate	O	O
staining	O	O
in	O	O
the	O	O
#	O	O
163	O	O
cells	O	O
.	O	O

These	O	O
data	O	O
thus	O	O
indicate	O	O
that	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
encodes	O	O
an	O	O
80	O	O
kDa	O	O
membrane	O	O
protein	O	O
.	O	O

.	O	O

Preferential	O	O
germline	O	O
mutation	O	O
of	O	O
the	O	O
paternal	O	O
allele	O	O
in	O	O
retinoblastoma	B-Disease	D012175
.	O	O

The	O	O
event	O	O
triggering	O	O
malignant	O	O
proliferation	O	O
in	O	O
70	O	O
%	O	O
of	O	O
retinoblastoma	B-Disease	D012175
tumours	B-Disease	D009369
is	O	O
loss	O	O
of	O	O
heterozygosity	O	O
for	O	O
chromosome	O	O
13q14	O	O
,	O	O
whereby	O	O
the	O	O
normal	O	O
retinoblastoma	B-Disease	D012175
gene	O	O
(	O	O
RB1	O	O
)	O	O
allele	O	O
is	O	O
lost	O	O
and	O	O
an	O	O
already	O	O
mutated	O	O
RB1	O	O
allele	O	O
remains	O	O
in	O	O
the	O	O
tumour	B-Disease	D009369
.	O	O

The	O	O
first	O	O
allele	O	O
suffers	O	O
a	O	O
mutational	O	O
event	O	O
-	O	O
-	O	O
deletion	O	O
,	O	O
duplication	O	O
or	O	O
point	O	O
mutation	O	O
(	O	O
manuscript	O	O
in	O	O
preparation	O	O
)	O	O
-	O	O
-	O	O
either	O	O
in	O	O
the	O	O
germ	O	O
line	O	O
(	O	O
all	O	O
bilateral	O	O
patients	O	O
)	O	O
or	O	O
in	O	O
a	O	O
somatic	O	O
retinal	O	O
cell	O	O
(	O	O
most	O	O
unilateral	O	O
patients	O	O
)	O	O
.	O	O

Most	O	O
bilateral	O	O
patients	O	O
have	O	O
no	O	O
family	O	O
history	O	O
of	O	O
retinoblastoma	B-Disease	D012175
and	O	O
are	O	O
presumed	O	O
to	O	O
have	O	O
new	O	O
germline	O	O
mutations	O	O
which	O	O
arose	O	O
in	O	O
the	O	O
egg	O	O
,	O	O
sperm	O	O
or	O	O
early	O	O
embryo	O	O
.	O	O

We	O	O
have	O	O
determined	O	O
the	O	O
parental	O	O
origin	O	O
of	O	O
the	O	O
retained	O	O
allele	O	O
in	O	O
nine	O	O
retinoblastoma	B-Disease	D012175
tumours	B-Disease	D009369
from	O	O
eight	O	O
unrelated	O	O
non	O	O
-	O	O
familial	O	O
cases	O	O
by	O	O
using	O	O
RB1	O	O
-	O	O
linked	O	O
genetic	O	O
markers	O	O
.	O	O

Six	O	O
tumours	B-Disease	D009369
retained	O	O
the	O	O
paternal	O	O
allele	O	O
and	O	O
three	O	O
retained	O	O
the	O	O
maternal	O	O
allele	O	O
.	O	O

Of	O	O
the	O	O
three	O	O
unilateral	B-Disease	D009369
tumours	I-Disease	D009369
,	O	O
only	O	O
one	O	O
retained	O	O
the	O	O
paternal	O	O
RB1	O	O
allele	O	O
.	O	O

Thus	O	O
,	O	O
there	O	O
is	O	O
no	O	O
evidence	O	O
that	O	O
the	O	O
paternal	O	O
RB1	O	O
allele	O	O
is	O	O
preferentially	O	O
retained	O	O
in	O	O
retinoblastoma	B-Disease	D012175
,	O	O
as	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
be	O	O
the	O	O
case	O	O
in	O	O
osteosarcoma	B-Disease	D012516
.	O	O

By	O	O
contrast	O	O
,	O	O
tumours	B-Disease	D009369
from	O	O
four	O	O
of	O	O
the	O	O
five	O	O
bilateral	O	O
patients	O	O
retained	O	O
the	O	O
paternal	O	O
RB1	O	O
allele	O	O
.	O	O

This	O	O
suggests	O	O
either	O	O
that	O	O
new	O	O
germline	O	O
RB1	O	O
mutations	O	O
arise	O	O
more	O	O
frequently	O	O
during	O	O
spermatogenesis	O	O
than	O	O
during	O	O
oogenesis	O	O
,	O	O
or	O	O
that	O	O
imprinting	O	O
in	O	O
the	O	O
early	O	O
embryo	O	O
affects	O	O
chromosomal	O	O
susceptibility	O	O
to	O	O
mutation	O	O
.	O	O

.	O	O

Mutations	O	O
at	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
locus	O	O
and	O	O
clinical	O	O
phenotypes	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
.	O	O

Mutations	O	O
at	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
locus	O	O
on	O	O
chromosome	O	O
band	O	O
11q22	O	O
cause	O	O
a	O	O
distinctive	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
syndrome	I-Disease	D030342
in	O	O
homozygotes	O	O
and	O	O
predispose	O	O
heterozygotes	O	O
to	O	O
cancer	B-Disease	D009369
,	O	O
ischemic	B-Disease	D017202
heart	I-Disease	D017202
disease	I-Disease	D017202
,	O	O
and	O	O
early	O	O
mortality	O	O
.	O	O

PCR	O	O
amplification	O	O
from	O	O
genomic	O	O
DNA	O	O
and	O	O
automated	O	O
sequencing	O	O
of	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
(	O	O
66	O	O
exons	O	O
)	O	O
and	O	O
splice	O	O
junctions	O	O
detected	O	O
77	O	O
mutations	O	O
(	O	O
85	O	O
%	O	O
)	O	O
in	O	O
90	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
chromosomes	O	O
.	O	O

Heteroduplex	O	O
analysis	O	O
detected	O	O
another	O	O
42	O	O
mutations	O	O
at	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
locus	O	O
.	O	O

Out	O	O
of	O	O
a	O	O
total	O	O
of	O	O
71	O	O
unique	O	O
mutations	O	O
,	O	O
50	O	O
were	O	O
found	O	O
only	O	O
in	O	O
a	O	O
single	O	O
family	O	O
,	O	O
and	O	O
51	O	O
had	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

Most	O	O
(	O	O
58	O	O
/	O	O
71	O	O
,	O	O
82	O	O
%	O	O
)	O	O
mutations	O	O
were	O	O
frameshift	O	O
and	O	O
nonsense	O	O
mutations	O	O
that	O	O
are	O	O
predicted	O	O
to	O	O
cause	O	O
truncation	O	O
of	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
protein	O	O
;	O	O
the	O	O
less	O	O
common	O	O
mutation	O	O
types	O	O
were	O	O
missense	O	O
(	O	O
9	O	O
/	O	O
71	O	O
,	O	O
13	O	O
%	O	O
)	O	O
,	O	O
splicing	O	O
(	O	O
3	O	O
/	O	O
71	O	O
,	O	O
4	O	O
%	O	O
)	O	O
and	O	O
one	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
,	O	O
2546	O	O
3	O	O
(	O	O
1	O	O
/	O	O
71	O	O
,	O	O
1	O	O
%	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
survival	O	O
and	O	O
height	O	O
distribution	O	O
of	O	O
134	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
specific	O	O
mutations	O	O
present	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

Patients	O	O
homozygous	O	O
for	O	O
a	O	O
single	O	O
truncating	O	O
mutation	O	O
,	O	O
typically	O	O
near	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
or	O	O
heterozygous	O	O
for	O	O
the	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
2546	O	O
3	O	O
,	O	O
were	O	O
shorter	O	O
and	O	O
had	O	O
significantly	O	O
shorter	O	O
survival	O	O
than	O	O
those	O	O
heterozygous	O	O
for	O	O
a	O	O
splice	O	O
site	O	O
or	O	O
missense	O	O
mutation	O	O
,	O	O
or	O	O
heterozygous	O	O
for	O	O
two	O	O
truncating	O	O
mutations	O	O
.	O	O

Alterations	O	O
of	O	O
the	O	O
length	O	O
or	O	O
amino	O	O
acid	O	O
composition	O	O
of	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
gene	O	O
product	O	O
affect	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
clinical	O	O
phenotype	O	O
in	O	O
different	O	O
ways	O	O
.	O	O

Mutation	O	O
analysis	O	O
at	O	O
the	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
locus	O	O
may	O	O
help	O	O
estimate	O	O
the	O	O
prognosis	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
.	O	O

.	O	O

Anticipation	O	O
resulting	O	O
in	O	O
elimination	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
gene	O	O
:	O	O
a	O	O
follow	O	O
up	O	O
study	O	O
of	O	O
one	O	O
extended	O	O
family	O	O
.	O	O

We	O	O
have	O	O
re	O	O
-	O	O
examined	O	O
an	O	O
extended	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
family	O	O
,	O	O
previously	O	O
described	O	O
in	O	O
1955	O	O
,	O	O
in	O	O
order	O	O
to	O	O
study	O	O
the	O	O
long	O	O
term	O	O
effects	O	O
of	O	O
anticipation	O	O
in	O	O
DM	B-Disease	D009223
and	O	O
in	O	O
particular	O	O
the	O	O
implications	O	O
for	O	O
families	O	O
affected	O	O
by	O	O
this	O	O
disease	O	O
.	O	O

This	O	O
follow	O	O
up	O	O
study	O	O
provides	O	O
data	O	O
on	O	O
35	O	O
gene	O	O
carriers	O	O
and	O	O
46	O	O
asymptomatic	O	O
at	O	O
risk	O	O
family	O	O
members	O	O
in	O	O
five	O	O
generations	O	O
.	O	O

Clinical	O	O
anticipation	O	O
,	O	O
defined	O	O
as	O	O
the	O	O
cascade	O	O
of	O	O
mild	O	O
,	O	O
adult	O	O
,	O	O
childhood	O	O
,	O	O
or	O	O
congenital	B-Disease	D030342
disease	I-Disease	D030342
in	O	O
subsequent	O	O
generations	O	O
,	O	O
appeared	O	O
to	O	O
be	O	O
a	O	O
relentless	O	O
process	O	O
,	O	O
occurring	O	O
in	O	O
all	O	O
affected	O	O
branches	O	O
of	O	O
the	O	O
family	O	O
.	O	O

The	O	O
cascade	O	O
was	O	O
found	O	O
to	O	O
proceed	O	O
asynchronously	O	O
in	O	O
the	O	O
different	O	O
branches	O	O
,	O	O
mainly	O	O
because	O	O
of	O	O
an	O	O
unequal	O	O
number	O	O
of	O	O
generations	O	O
with	O	O
mild	O	O
disease	O	O
.	O	O

The	O	O
transition	O	O
from	O	O
the	O	O
mild	O	O
to	O	O
the	O	O
adult	O	O
type	O	O
was	O	O
associated	O	O
with	O	O
transmission	O	O
through	O	O
a	O	O
male	O	O
parent	O	O
.	O	O

Stable	O	O
transmission	O	O
of	O	O
the	O	O
asymptomatic	O	O
/	O	O
mild	O	O
phenotype	O	O
showed	O	O
a	O	O
female	O	O
transmission	O	O
bias	O	O
.	O	O

We	O	O
further	O	O
examined	O	O
the	O	O
extent	O	O
and	O	O
causes	O	O
of	O	O
gene	O	O
loss	O	O
in	O	O
this	O	O
pedigree	O	O
.	O	O

Gene	O	O
loss	O	O
in	O	O
the	O	O
patient	O	O
group	O	O
was	O	O
complete	O	O
,	O	O
owing	O	O
to	O	O
infertility	B-Disease	D007246
of	O	O
the	O	O
male	O	O
patients	O	O
with	O	O
adult	O	O
onset	O	O
disease	O	O
and	O	O
the	O	O
fact	O	O
that	O	O
mentally	B-Disease	D008607
retarded	I-Disease	D008607
patients	O	O
did	O	O
not	O	O
procreate	O	O
.	O	O

Out	O	O
of	O	O
the	O	O
46	O	O
at	O	O
risk	O	O
subjects	O	O
in	O	O
the	O	O
two	O	O
youngest	O	O
generations	O	O
,	O	O
only	O	O
one	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
full	O	O
mutation	O	O
.	O	O

This	O	O
is	O	O
the	O	O
only	O	O
subject	O	O
who	O	O
may	O	O
transmit	O	O
the	O	O
gene	O	O
to	O	O
the	O	O
sixth	O	O
generation	O	O
.	O	O

No	O	O
protomutation	O	O
carriers	O	O
were	O	O
found	O	O
in	O	O
the	O	O
fourth	O	O
and	O	O
fifth	O	O
generations	O	O
.	O	O

Therefore	O	O
it	O	O
is	O	O
highly	O	O
probable	O	O
that	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
will	O	O
be	O	O
eliminated	O	O
from	O	O
this	O	O
pedigree	O	O
within	O	O
one	O	O
generation	O	O
.	O	O

The	O	O
high	O	O
population	O	O
frequency	O	O
of	O	O
DM	B-Disease	D009223
can	O	O
at	O	O
present	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
contribution	O	O
of	O	O
asymptomatic	O	O
cases	O	O
in	O	O
the	O	O
younger	O	O
generations	O	O
of	O	O
known	O	O
families	O	O
,	O	O
but	O	O
is	O	O
probably	O	O
caused	O	O
by	O	O
the	O	O
events	O	O
in	O	O
the	O	O
ancestral	O	O
generations	O	O
.	O	O

.	O	O

Exon	O	O
9	O	O
mutations	O	O
in	O	O
the	O	O
WT1	O	O
gene	O	O
,	O	O
without	O	O
influencing	O	O
KTS	O	O
splice	O	O
isoforms	O	O
,	O	O
are	O	O
also	O	O
responsible	O	O
for	O	O
Frasier	B-Disease	D052159
syndrome	I-Disease	D052159
.	O	O

We	O	O
report	O	O
new	O	O
mutations	O	O
in	O	O
exon	O	O
9	O	O
of	O	O
the	O	O
WT1	O	O
gene	O	O
that	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
ratio	O	O
of	O	O
+	O	O
/	O	O
-	O	O
KTS	O	O
splice	O	O
isoforms	O	O
in	O	O
two	O	O
unrelated	O	O
patients	O	O
with	O	O
Frasier	B-Disease	D052159
syndrome	I-Disease	D052159
(	O	O
FS	B-Disease	D052159
)	O	O
.	O	O

The	O	O
mutation	O	O
of	O	O
intron	O	O
9	O	O
inducing	O	O
defective	O	O
alternative	O	O
splicing	O	O
was	O	O
reported	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
this	O	O
syndrome	O	O
.	O	O

The	O	O
mutations	O	O
found	O	O
in	O	O
our	O	O
cases	O	O
occurred	O	O
in	O	O
the	O	O
same	O	O
exon	O	O
of	O	O
the	O	O
WT1	O	O
gene	O	O
as	O	O
detected	O	O
in	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
(	O	O
DDS	B-Disease	D030321
)	O	O
and	O	O
could	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
previously	O	O
proposed	O	O
mechanism	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
two	O	O
syndromes	O	O
originate	O	O
from	O	O
the	O	O
same	O	O
WT1	B-Disease	D009396
gene	I-Disease	D009396
abnormality	I-Disease	D009396
.	O	O

From	O	O
a	O	O
molecular	O	O
biological	O	O
point	O	O
of	O	O
view	O	O
,	O	O
we	O	O
concluded	O	O
that	O	O
the	O	O
two	O	O
diseases	O	O
were	O	O
not	O	O
separable	O	O
,	O	O
and	O	O
that	O	O
FS	B-Disease	D052159
should	O	O
be	O	O
included	O	O
as	O	O
an	O	O
atypical	O	O
form	O	O
of	O	O
DDS	B-Disease	D030321
.	O	O

.	O	O

Deficit	O	O
of	O	O
in	O	O
vivo	O	O
mitochondrial	O	O
ATP	O	O
production	O	O
in	O	O
patients	O	O
with	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
(	O	O
FRDA	B-Disease	D005621
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
of	O	O
the	O	O
inherited	B-Disease	D013132
ataxias	I-Disease	D013132
,	O	O
is	O	O
an	O	O
autosomal	B-Disease	D019636
recessive	I-Disease	D019636
degenerative	I-Disease	D019636
disorder	I-Disease	D019636
,	O	O
characterized	O	O
clinically	O	O
by	O	O
onset	O	O
before	O	O
the	O	O
age	O	O
of	O	O
25	O	O
of	O	O
progressive	B-Disease	D020234
gait	I-Disease	D020234
and	I-Disease	D020234
limb	I-Disease	D020234
ataxia	I-Disease	D020234
,	O	O
absence	B-Disease	D012021
of	I-Disease	D012021
deep	I-Disease	D012021
tendon	I-Disease	D012021
reflexes	I-Disease	D012021
,	O	O
extensor	B-Disease	D001405
plantar	I-Disease	D001405
responses	I-Disease	D001405
,	O	O
and	O	O
loss	B-Disease	D053421
of	I-Disease	D053421
position	I-Disease	D053421
and	I-Disease	D053421
vibration	I-Disease	D053421
sense	I-Disease	D053421
in	O	O
the	O	O
lower	O	O
limbs	O	O
.	O	O

FRDA	B-Disease	D005621
is	O	O
caused	O	O
by	O	O
a	O	O
GAA	O	O
triplet	O	O
expansion	O	O
in	O	O
the	O	O
first	O	O
intron	O	O
of	O	O
the	O	O
FRDA	B-Disease	D005621
gene	O	O
on	O	O
chromosome	O	O
9q13	O	O
in	O	O
97	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
FRDA	B-Disease	D005621
gene	O	O
encodes	O	O
a	O	O
widely	O	O
expressed	O	O
210	O	O
-	O	O
aa	O	O
protein	O	O
,	O	O
frataxin	O	O
,	O	O
which	O	O
is	O	O
located	O	O
in	O	O
mitochondria	O	O
and	O	O
is	O	O
severely	O	O
reduced	O	O
in	O	O
FRDA	B-Disease	D005621
patients	O	O
.	O	O

Frataxin	O	O
function	O	O
is	O	O
still	O	O
unknown	O	O
but	O	O
the	O	O
knockout	O	O
of	O	O
the	O	O
yeast	O	O
frataxin	O	O
homologue	O	O
gene	O	O
(	O	O
YFH1	O	O
)	O	O
showed	O	O
a	O	O
severe	O	O
defect	O	O
of	O	O
mitochondrial	O	O
respiration	O	O
and	O	O
loss	O	O
of	O	O
mtDNA	O	O
associated	O	O
with	O	O
elevated	O	O
intramitochondrial	O	O
iron	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
in	O	O
vivo	O	O
evidence	O	O
of	O	O
impaired	O	O
mitochondrial	O	O
respiration	O	O
in	O	O
skeletal	O	O
muscle	O	O
of	O	O
FRDA	B-Disease	D005621
patients	O	O
.	O	O

Using	O	O
phosphorus	O	O
magnetic	O	O
resonance	O	O
spectroscopy	O	O
we	O	O
demonstrated	O	O
a	O	O
maximum	O	O
rate	O	O
of	O	O
muscle	O	O
mitochondrial	O	O
ATP	O	O
production	O	O
(	O	O
V	O	O
(	O	O
max	O	O
)	O	O
)	O	O
below	O	O
the	O	O
normal	O	O
range	O	O
in	O	O
all	O	O
12	O	O
FRDA	B-Disease	D005621
patients	O	O
and	O	O
a	O	O
strong	O	O
negative	O	O
correlation	O	O
between	O	O
mitochondrial	O	O
V	O	O
(	O	O
max	O	O
)	O	O
and	O	O
the	O	O
number	O	O
of	O	O
GAA	O	O
repeats	O	O
in	O	O
the	O	O
smaller	O	O
allele	O	O
.	O	O

Our	O	O
results	O	O
show	O	O
that	O	O
FRDA	B-Disease	D005621
is	O	O
a	O	O
nuclear	O	O
-	O	O
encoded	O	O
mitochondrial	B-Disease	D028361
disorder	I-Disease	D028361
affecting	O	O
oxidative	O	O
phosphorylation	O	O
and	O	O
give	O	O
a	O	O
rationale	O	O
for	O	O
treatments	O	O
aimed	O	O
to	O	O
improve	O	O
mitochondrial	O	O
function	O	O
in	O	O
this	O	O
condition	O	O
.	O	O

.	O	O

Chronic	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
(	O	O
CNSHA	B-Disease	D000746
)	O	O
and	O	O
glucose	B-Disease	D005955
6	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
a	O	O
patient	O	O
with	O	O
familial	B-Disease	D028227
amyloidotic	I-Disease	D028227
polyneuropathy	I-Disease	D028227
(	O	O
FAP	B-Disease	D028227
)	O	O
.	O	O

Molecular	O	O
study	O	O
of	O	O
a	O	O
new	O	O
variant	O	O
(	O	O
G6PD	O	O
Clinic	O	O
)	O	O
with	O	O
markedly	O	O
acidic	O	O
pH	O	O
optimum	O	O
.	O	O

A	O	O
new	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
G6PD	O	O
)	O	O
variant	O	O
with	O	O
severe	O	O
erythrocytic	B-Disease	D005955
G6PD	I-Disease	D005955
deficiency	I-Disease	D005955
and	O	O
a	O	O
unique	O	O
pH	O	O
optimum	O	O
is	O	O
described	O	O
in	O	O
a	O	O
young	O	O
patient	O	O
with	O	O
chronic	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
(	O	O
CNSHA	B-Disease	D000746
)	O	O
and	O	O
familial	B-Disease	D028227
amyloidotic	I-Disease	D028227
polyneuropathy	I-Disease	D028227
(	O	O
FAP	B-Disease	D028227
)	O	O
.	O	O

Chronic	B-Disease	D006461
hemolysis	I-Disease	D006461
was	O	O
present	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
infections	O	O
,	O	O
oxidant	O	O
drugs	O	O
or	O	O
ingestion	O	O
of	O	O
faba	O	O
beans	O	O
.	O	O

Residual	O	O
enzyme	O	O
activity	O	O
was	O	O
about	O	O
2	O	O
.	O	O

6	O	O
%	O	O
and	O	O
63	O	O
%	O	O
of	O	O
normal	O	O
activity	O	O
in	O	O
erythrocytes	O	O
and	O	O
leucocytes	O	O
,	O	O
respectively	O	O
.	O	O

A	O	O
molecular	O	O
study	O	O
using	O	O
standard	O	O
methods	O	O
showed	O	O
G6PD	O	O
in	O	O
the	O	O
patient	O	O
to	O	O
have	O	O
normal	O	O
electrophoretic	O	O
mobility	O	O
(	O	O
at	O	O
pH	O	O
7	O	O
.	O	O

0	O	O
,	O	O
8	O	O
.	O	O

0	O	O
and	O	O
8	O	O
.	O	O

8	O	O
)	O	O
,	O	O
normal	O	O
apparent	O	O
affinity	O	O
for	O	O
substrates	O	O
(	O	O
Km	O	O
,	O	O
G6P	O	O
and	O	O
NADP	O	O
)	O	O
and	O	O
a	O	O
slightly	O	O
abnormal	O	O
utilization	O	O
of	O	O
substrate	O	O
analogues	O	O
(	O	O
decreased	O	O
deamino	O	O
-	O	O
NADP	O	O
and	O	O
increased	O	O
2	O	O
-	O	O
deoxyglucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
utilization	O	O
)	O	O
.	O	O

Heat	O	O
stability	O	O
was	O	O
found	O	O
to	O	O
be	O	O
markedly	O	O
decreased	O	O
(	O	O
8	O	O
%	O	O
of	O	O
residual	O	O
activity	O	O
after	O	O
20	O	O
min	O	O
of	O	O
incubation	O	O
at	O	O
46	O	O
degrees	O	O
C	O	O
)	O	O
and	O	O
a	O	O
particular	O	O
characteristic	O	O
of	O	O
this	O	O
enzyme	O	O
was	O	O
a	O	O
biphasic	O	O
pH	O	O
curve	O	O
with	O	O
a	O	O
greatly	O	O
increased	O	O
activity	O	O
at	O	O
low	O	O
pH	O	O
.	O	O

Although	O	O
molecular	O	O
characteristics	O	O
of	O	O
this	O	O
variant	O	O
closely	O	O
resemble	O	O
those	O	O
of	O	O
G6PD	O	O
Bangkok	O	O
and	O	O
G6PD	O	O
Duarte	O	O
,	O	O
it	O	O
can	O	O
be	O	O
distinguished	O	O
from	O	O
these	O	O
and	O	O
all	O	O
other	O	O
previously	O	O
reported	O	O
variants	O	O
by	O	O
virtue	O	O
of	O	O
its	O	O
unusual	O	O
pH	O	O
curve	O	O
.	O	O

Therefore	O	O
the	O	O
present	O	O
variant	O	O
has	O	O
been	O	O
designated	O	O
G6PD	O	O
Clinic	O	O
to	O	O
distinguish	O	O
it	O	O
from	O	O
other	O	O
G6PD	O	O
variants	O	O
previously	O	O
described	O	O
Regional	O	O
localization	O	O
of	O	O
polymorphic	O	O
DNA	O	O
loci	O	O
on	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
using	O	O
deletions	O	O
associated	O	O
with	O	O
choroideremia	B-Disease	D015794
.	O	O

In	O	O
two	O	O
unrelated	O	O
families	O	O
,	O	O
males	O	O
have	O	O
been	O	O
identified	O	O
who	O	O
suffer	O	O
from	O	O
choroideremia	B-Disease	D015794
and	O	O
at	O	O
the	O	O
same	O	O
time	O	O
have	O	O
an	O	O
interstitial	O	O
deletion	O	O
on	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O

By	O	O
high	O	O
-	O	O
resolution	O	O
banding	O	O
we	O	O
have	O	O
characterized	O	O
the	O	O
deletion	O	O
chromosomes	O	O
as	O	O
del	O	O
(	O	O
X	O	O
)	O	O
(	O	O
q21	O	O
.	O	O

1	O	O
-	O	O
q21	O	O
1	O	O
-	O	O
q21	O	O
.	O	O

33	O	O
)	O	O
and	O	O
del	O	O
(	O	O
X	O	O
)	O	O
(	O	O
q21	O	O
.	O	O

2	O	O
-	O	O
q21	O	O
2	O	O
-	O	O
q21	O	O
.	O	O

31	O	O
)	O	O
respectively	O	O
.	O	O

By	O	O
Southern	O	O
blot	O	O
analysis	O	O
we	O	O
have	O	O
mapped	O	O
ten	O	O
different	O	O
polymorphic	O	O
DNA	O	O
loci	O	O
relative	O	O
to	O	O
the	O	O
position	O	O
of	O	O
the	O	O
deletion	O	O
and	O	O
the	O	O
choroideremia	B-Disease	D015794
locus	O	O
TCD	O	O
.	O	O

One	O	O
probe	O	O
,	O	O
p31	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
cover	O	O
one	O	O
of	O	O
the	O	O
breakpoints	O	O
of	O	O
the	O	O
smallest	O	O
deletion	O	O
.	O	O

The	O	O
following	O	O
order	O	O
of	O	O
the	O	O
loci	O	O
was	O	O
suggested	O	O
by	O	O
deletion	O	O
mapping	O	O
cen	O	O
-	O	O
DXS106	O	O
-	O	O
DXS72	O	O
-	O	O
TCD	O	O
-	O	O
(	O	O
DXYS1	O	O
/	O	O
DXYS23	O	O
/	O	O
DXYS5	O	O
)	O	O
-	O	O
DXYS2	O	O
-	O	O
(	O	O
DXYS12	O	O
/	O	O
DXS3	O	O
)	O	O
-	O	O
(	O	O
DXS17	O	O
/	O	O
DXS101	O	O
)	O	O
-	O	O
Xqter	O	O
.	O	O

A	O	O
de	O	O
novo	O	O
unbalanced	O	O
reciprocal	O	O
translocation	O	O
identified	O	O
as	O	O
paternal	O	O
in	O	O
origin	O	O
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

Interstitial	O	O
cytogenetic	O	O
deletions	O	O
involving	O	O
the	O	O
paternally	O	O
derived	O	O
chromosome	O	O
15q11	O	O
-	O	O
13	O	O
have	O	O
been	O	O
described	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

We	O	O
report	O	O
a	O	O
child	O	O
with	O	O
PWS	B-Disease	D011218
and	O	O
a	O	O
de	O	O
novo	O	O
unbalanced	O	O
karyotype	O	O
-	O	O
45	O	O
,	O	O
XY	O	O
,	O	O
-	O	O
9	O	O
,	O	O
-	O	O
15	O	O
,	O	O
+	O	O
der	O	O
(	O	O
9	O	O
)	O	O
t	O	O
(	O	O
9	O	O
;	O	O
15	O	O
)	O	O
(	O	O
q34	O	O
;	O	O
q13	O	O
)	O	O
.	O	O

Molecular	O	O
studies	O	O
with	O	O
the	O	O
DNA	O	O
probe	O	O
pML34	O	O
confirmed	O	O
that	O	O
only	O	O
a	O	O
single	O	O
Prader	B-Disease	D011218
Willi	I-Disease	D011218
critical	O	O
region	O	O
(	O	O
PWCR	O	O
15q11	O	O
.	O	O

2	O	O
-	O	O
q12	O	O
)	O	O
copy	O	O
was	O	O
present	O	O
.	O	O

Hybridisation	O	O
of	O	O
patient	O	O
and	O	O
parental	O	O
DNA	O	O
with	O	O
the	O	O
multi	O	O
-	O	O
allelic	O	O
probe	O	O
CMW1	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
pter	O	O
-	O	O
15q13	O	O
,	O	O
showed	O	O
that	O	O
the	O	O
chromosome	O	O
involved	O	O
in	O	O
the	O	O
translocation	O	O
was	O	O
paternal	O	O
in	O	O
origin	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
example	O	O
of	O	O
a	O	O
paternally	O	O
-	O	O
derived	O	O
PWCR	O	O
allele	O	O
loss	O	O
caused	O	O
by	O	O
an	O	O
unbalanced	O	O
translocation	O	O
that	O	O
has	O	O
arisen	O	O
de	O	O
novo	O	O
.	O	O

Clinicopathologic	O	O
features	O	O
of	O	O
BRCA	B-Disease	OMIM:604370
-	I-Disease	OMIM:604370
linked	I-Disease	OMIM:604370
and	I-Disease	OMIM:604370
sporadic	I-Disease	OMIM:604370
ovarian	I-Disease	OMIM:604370
cancer	I-Disease	OMIM:604370
.	O	O

CONTEXT	O	O
Most	O	O
hereditary	B-Disease	D061325
ovarian	I-Disease	D061325
cancers	I-Disease	D061325
are	O	O
associated	O	O
with	O	O
germline	O	O
mutations	O	O
in	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
.	O	O

Attempts	O	O
to	O	O
define	O	O
the	O	O
clinical	O	O
significance	O	O
of	O	O
BRCA	O	O
mutation	O	O
status	O	O
in	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
have	O	O
produced	O	O
conflicting	O	O
results	O	O
,	O	O
especially	O	O
regarding	O	O
survival	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
whether	O	O
hereditary	B-Disease	D061325
ovarian	I-Disease	D061325
cancers	I-Disease	D061325
have	O	O
distinct	O	O
clinical	O	O
and	O	O
pathological	O	O
features	O	O
compared	O	O
with	O	O
sporadic	B-Disease	D010051
(	I-Disease	D010051
nonhereditary	I-Disease	D010051
)	I-Disease	D010051
ovarian	I-Disease	D010051
cancers	I-Disease	D010051
.	O	O

DESIGN	O	O
AND	O	O
SETTING	O	O
Retrospective	O	O
cohort	O	O
study	O	O
of	O	O
a	O	O
consecutive	O	O
series	O	O
of	O	O
933	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
diagnosed	O	O
and	O	O
treated	O	O
at	O	O
our	O	O
institution	O	O
,	O	O
which	O	O
is	O	O
a	O	O
comprehensive	O	O
cancer	B-Disease	D009369
center	O	O
as	O	O
designated	O	O
by	O	O
the	O	O
National	O	O
Cancer	B-Disease	D009369
Institute	O	O
,	O	O
over	O	O
a	O	O
12	O	O
-	O	O
year	O	O
period	O	O
(	O	O
December	O	O
1986	O	O
to	O	O
August	O	O
1998	O	O
)	O	O
.	O	O

PATIENTS	O	O
The	O	O
study	O	O
was	O	O
restricted	O	O
to	O	O
patients	O	O
of	O	O
Jewish	O	O
origin	O	O
because	O	O
of	O	O
the	O	O
ease	O	O
of	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
genotyping	O	O
in	O	O
this	O	O
ethnic	O	O
group	O	O
.	O	O

From	O	O
the	O	O
189	O	O
patients	O	O
who	O	O
identified	O	O
themselves	O	O
as	O	O
Jewish	O	O
,	O	O
88	O	O
hereditary	O	O
cases	O	O
were	O	O
identified	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
germline	O	O
founder	O	O
mutation	O	O
in	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
.	O	O

The	O	O
remaining	O	O
101	O	O
cases	O	O
from	O	O
the	O	O
same	O	O
series	O	O
not	O	O
associated	O	O
with	O	O
a	O	O
BRCA	O	O
mutation	O	O
and	O	O
2	O	O
additional	O	O
groups	O	O
(	O	O
Gynecologic	O	O
Oncology	O	O
Group	O	O
protocols	O	O
52	O	O
and	O	O
111	O	O
)	O	O
with	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
from	O	O
clinical	O	O
trials	O	O
(	O	O
for	O	O
the	O	O
survival	O	O
analysis	O	O
)	O	O
were	O	O
included	O	O
for	O	O
comparison	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
Age	O	O
at	O	O
diagnosis	O	O
,	O	O
surgical	O	O
stage	O	O
,	O	O
histologic	O	O
cell	O	O
type	O	O
and	O	O
grade	O	O
,	O	O
and	O	O
surgical	O	O
outcome	O	O
;	O	O
and	O	O
response	O	O
to	O	O
chemotherapy	O	O
and	O	O
survival	O	O
for	O	O
advanced	O	O
-	O	O
stage	O	O
(	O	O
II	O	O
and	O	O
IV	O	O
)	O	O
cases	O	O
.	O	O

RESULTS	O	O
Hereditary	B-Disease	D009369
cancers	I-Disease	D009369
were	O	O
rarely	O	O
diagnosed	O	O
before	O	O
age	O	O
40	O	O
years	O	O
and	O	O
were	O	O
common	O	O
after	O	O
age	O	O
60	O	O
years	O	O
,	O	O
with	O	O
mean	O	O
age	O	O
at	O	O
diagnosis	O	O
being	O	O
significantly	O	O
younger	O	O
for	O	O
BRCA1	O	O
-	O	O
vs	O	O
BRCA2	O	O
-	O	O
linked	O	O
patients	O	O
(	O	O
54	O	O
vs	O	O
62	O	O
years	O	O
;	O	O
P	O	O
=	O	O
.	O	O

04	O	O
)	O	O
.	O	O

Histology	O	O
,	O	O
grade	O	O
,	O	O
stage	O	O
,	O	O
and	O	O
success	O	O
of	O	O
cytoreductive	O	O
surgery	O	O
were	O	O
similar	O	O
for	O	O
hereditary	O	O
and	O	O
sporadic	O	O
cases	O	O
.	O	O

The	O	O
hereditary	O	O
group	O	O
had	O	O
a	O	O
longer	O	O
disease	O	O
-	O	O
free	O	O
interval	O	O
following	O	O
primary	O	O
chemotherapy	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
nonhereditary	O	O
group	O	O
,	O	O
with	O	O
a	O	O
median	O	O
time	O	O
to	O	O
recurrence	O	O
of	O	O
14	O	O
months	O	O
and	O	O
7	O	O
months	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Those	O	O
with	O	O
hereditary	B-Disease	D009369
cancers	I-Disease	D009369
had	O	O
improved	O	O
survival	O	O
compared	O	O
with	O	O
the	O	O
nonhereditary	O	O
group	O	O
(	O	O
P	O	O
=	O	O
.	O	O

004	O	O
)	O	O
.	O	O

For	O	O
stage	B-Disease	D009369
III	I-Disease	D009369
cancers	I-Disease	D009369
,	O	O
BRCA	O	O
mutation	O	O
status	O	O
was	O	O
an	O	O
independent	O	O
prognostic	O	O
variable	O	O
(	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Although	O	O
BRCA	B-Disease	OMIM:604370
-	I-Disease	OMIM:604370
associated	I-Disease	OMIM:604370
hereditary	I-Disease	OMIM:604370
ovarian	I-Disease	OMIM:604370
cancers	I-Disease	OMIM:604370
in	O	O
this	O	O
population	O	O
have	O	O
surgical	O	O
and	O	O
pathological	O	O
characteristics	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
sporadic	B-Disease	D009369
cancers	I-Disease	D009369
,	O	O
advanced	B-Disease	D009386
-	I-Disease	D009386
stage	I-Disease	D009386
hereditary	I-Disease	D009386
cancer	I-Disease	D009386
patients	O	O
survive	O	O
longer	O	O
than	O	O
nonhereditary	B-Disease	D009369
cancer	I-Disease	D009369
patients	O	O
.	O	O

Age	O	O
penetrance	O	O
is	O	O
greater	O	O
for	O	O
BRCA1	B-Disease	OMIM:604370
-	I-Disease	OMIM:604370
linked	I-Disease	OMIM:604370
than	I-Disease	OMIM:604370
for	I-Disease	OMIM:604370
BRCA2	I-Disease	OMIM:604370
-	I-Disease	OMIM:604370
linked	I-Disease	OMIM:604370
cancers	I-Disease	OMIM:604370
in	O	O
this	O	O
population	O	O
.	O	O

Germline	O	O
intronic	O	O
and	O	O
exonic	O	O
mutations	O	O
in	O	O
the	O	O
Wilms	B-Disease	D009396
'	I-Disease	D009396
tumour	I-Disease	D009396
gene	O	O
(	O	O
WT1	O	O
)	O	O
affecting	O	O
urogenital	O	O
development	O	O
.	O	O

Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
is	O	O
a	O	O
rare	O	O
human	O	O
developmental	B-Disease	D002658
disorder	I-Disease	D002658
affecting	O	O
the	O	O
urogenital	O	O
system	O	O
and	O	O
leading	O	O
to	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
intersex	B-Disease	D012734
disorders	I-Disease	D012734
and	O	O
Wilms	B-Disease	D009396
tumour	I-Disease	D009396
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
four	O	O
individuals	O	O
with	O	O
this	O	O
syndrome	O	O
are	O	O
described	O	O
carrying	O	O
germline	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
Wilms	B-Disease	D009396
tumour	I-Disease	D009396
suppressor	O	O
gene	O	O
,	O	O
WT1	O	O
.	O	O

Three	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
in	O	O
the	O	O
zinc	O	O
finger	O	O
domains	O	O
of	O	O
WT1	O	O
.	O	O

The	O	O
fourth	O	O
occurred	O	O
within	O	O
intron	O	O
9	O	O
,	O	O
preventing	O	O
splicing	O	O
at	O	O
one	O	O
of	O	O
the	O	O
alternatively	O	O
chosen	O	O
splice	O	O
donor	O	O
sites	O	O
of	O	O
exon	O	O
9	O	O
when	O	O
assayed	O	O
in	O	O
vitro	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
genetic	O	O
evidence	O	O
for	O	O
distinct	O	O
functional	O	O
roles	O	O
of	O	O
the	O	O
WT1	O	O
isoforms	O	O
in	O	O
urogenital	O	O
development	O	O
.	O	O

.	O	O

Analysis	O	O
of	O	O
deletions	O	O
in	O	O
DNA	O	O
from	O	O
patients	O	O
with	O	O
Becker	B-Disease	D020388
and	I-Disease	D020388
Duchenne	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
recessive	I-Disease	D040181
genetic	I-Disease	D040181
disorder	I-Disease	D040181
for	O	O
which	O	O
the	O	O
biochemical	O	O
defect	O	O
is	O	O
as	O	O
yet	O	O
unknown	O	O
.	O	O

Recently	O	O
,	O	O
two	O	O
cloned	O	O
segments	O	O
of	O	O
human	O	O
X	O	O
-	O	O
chromosome	O	O
DNA	O	O
have	O	O
been	O	O
described	O	O
which	O	O
detect	O	O
structural	O	O
alterations	O	O
within	O	O
or	O	O
near	O	O
the	O	O
genetic	O	O
locus	O	O
responsible	O	O
for	O	O
the	O	O
disorder	O	O
.	O	O

Both	O	O
of	O	O
these	O	O
cloned	O	O
segments	O	O
were	O	O
described	O	O
as	O	O
tightly	O	O
linked	O	O
to	O	O
the	O	O
locus	O	O
and	O	O
were	O	O
capable	O	O
of	O	O
detecting	O	O
deletions	O	O
in	O	O
the	O	O
DNA	O	O
of	O	O
boys	O	O
affected	O	O
with	O	O
DMD	B-Disease	D020388
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
determine	O	O
more	O	O
precisely	O	O
the	O	O
occurrence	O	O
of	O	O
these	O	O
deletions	O	O
within	O	O
a	O	O
large	O	O
population	O	O
of	O	O
DMD	B-Disease	D020388
patients	O	O
and	O	O
the	O	O
accuracy	O	O
of	O	O
one	O	O
of	O	O
the	O	O
segments	O	O
,	O	O
DXS164	O	O
(	O	O
pERT87	O	O
)	O	O
,	O	O
in	O	O
determining	O	O
the	O	O
inheritance	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
X	O	O
chromosome	O	O
,	O	O
the	O	O
subclones	O	O
1	O	O
,	O	O
8	O	O
and	O	O
15	O	O
were	O	O
made	O	O
available	O	O
to	O	O
many	O	O
investigators	O	O
throughout	O	O
the	O	O
world	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
the	O	O
combined	O	O
results	O	O
of	O	O
more	O	O
than	O	O
20	O	O
research	O	O
laboratories	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
occurrence	O	O
of	O	O
deletions	O	O
at	O	O
the	O	O
DXS164	O	O
locus	O	O
in	O	O
DNA	O	O
samples	O	O
isolated	O	O
from	O	O
patients	O	O
with	O	O
DMD	B-Disease	D020388
and	O	O
Becker	B-Disease	C537666
muscular	I-Disease	C537666
dystrophy	I-Disease	C537666
(	O	O
BMD	B-Disease	C537666
)	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
DXS164	O	O
locus	O	O
apparently	O	O
recombines	O	O
with	O	O
DMD	B-Disease	D020388
5	O	O
%	O	O
of	O	O
the	O	O
time	O	O
,	O	O
but	O	O
is	O	O
probably	O	O
located	O	O
between	O	O
independent	O	O
sites	O	O
of	O	O
mutation	O	O
which	O	O
yield	O	O
DMD	B-Disease	D020388
.	O	O

The	O	O
breakpoints	O	O
of	O	O
some	O	O
deletions	O	O
are	O	O
delineated	O	O
within	O	O
the	O	O
DXS164	O	O
locus	O	O
,	O	O
and	O	O
it	O	O
is	O	O
evident	O	O
that	O	O
the	O	O
deletions	O	O
at	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
are	O	O
frequent	O	O
and	O	O
extremely	O	O
large	O	O
.	O	O

.	O	O

Additional	O	O
case	O	O
of	O	O
female	O	O
monozygotic	O	O
twins	O	O
discordant	O	O
for	O	O
the	O	O
clinical	O	O
manifestations	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
due	O	O
to	O	O
opposite	O	O
X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
.	O	O

A	O	O
pair	O	O
of	O	O
female	O	O
monozygotic	O	O
(	O	O
MZ	O	O
)	O	O
twins	O	O
,	O	O
heterozygous	O	O
carriers	O	O
for	O	O
a	O	O
deletion	O	O
in	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
and	O	O
discordant	O	O
for	O	O
the	O	O
clinical	O	O
manifestations	O	O
of	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
,	O	O
were	O	O
analyzed	O	O
by	O	O
molecular	O	O
studies	O	O
,	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
and	O	O
methylation	O	O
pattern	O	O
of	O	O
X	O	O
chromosomes	O	O
to	O	O
search	O	O
for	O	O
opposite	O	O
X	O	O
inactivation	O	O
as	O	O
an	O	O
explanation	O	O
of	O	O
their	O	O
clinical	O	O
discordance	O	O
.	O	O

Results	O	O
in	O	O
lymphocytes	O	O
and	O	O
skin	O	O
fibroblast	O	O
cell	O	O
lines	O	O
suggest	O	O
a	O	O
partial	O	O
mirror	O	O
inactivation	O	O
with	O	O
the	O	O
normal	O	O
X	O	O
chromosome	O	O
preferentially	O	O
active	O	O
in	O	O
the	O	O
unaffected	O	O
twin	O	O
,	O	O
and	O	O
the	O	O
maternal	O	O
deleted	O	O
X	O	O
chromosome	O	O
preferentially	O	O
active	O	O
in	O	O
the	O	O
affected	O	O
twin	O	O
.	O	O

A	O	O
review	O	O
shows	O	O
that	O	O
MZ	O	O
female	O	O
twins	O	O
discordant	O	O
for	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
diseases	I-Disease	D040181
are	O	O
not	O	O
uncommon	O	O
.	O	O

Twinning	O	O
and	O	O
X	O	O
inactivation	O	O
may	O	O
be	O	O
interrelated	O	O
and	O	O
could	O	O
explain	O	O
the	O	O
female	O	O
twins	O	O
discordant	O	O
for	O	O
X	O	O
-	O	O
linked	O	O
traits	O	O
.	O	O

.	O	O

Analbuminemia	B-Disease	OMIM:103600
in	O	O
a	O	O
neonate	O	O
.	O	O

A	O	O
small	O	O
-	O	O
for	O	O
-	O	O
gestational	O	O
-	O	O
age	O	O
infant	O	O
,	O	O
found	O	O
to	O	O
have	O	O
analbuminemia	B-Disease	OMIM:103600
in	O	O
the	O	O
neonatal	O	O
period	O	O
,	O	O
is	O	O
reported	O	O
and	O	O
the	O	O
twelve	O	O
cases	O	O
recorded	O	O
in	O	O
the	O	O
world	O	O
literature	O	O
are	O	O
reviewed	O	O
.	O	O

Patients	O	O
lacking	O	O
this	O	O
serum	O	O
protein	O	O
are	O	O
essentially	O	O
asymptomatic	O	O
,	O	O
apart	O	O
from	O	O
minimal	O	O
ankle	B-Disease	D016512
edema	I-Disease	D016512
and	O	O
ease	B-Disease	D005221
of	I-Disease	D005221
fatigue	I-Disease	D005221
.	O	O

Apparent	O	O
compensatory	O	O
mechanisms	O	O
which	O	O
come	O	O
into	O	O
play	O	O
when	O	O
serum	O	O
albumin	O	O
is	O	O
low	O	O
include	O	O
prolonged	O	O
half	O	O
-	O	O
life	O	O
of	O	O
albumin	O	O
and	O	O
transferrin	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
globulins	O	O
,	O	O
beta	O	O
lipoprotein	O	O
,	O	O
and	O	O
glycoproteins	O	O
,	O	O
arterial	B-Disease	D007022
hypotension	I-Disease	D007022
with	O	O
reduced	O	O
capillary	O	O
hydrostatic	O	O
pressure	O	O
,	O	O
and	O	O
the	O	O
ability	O	O
to	O	O
respond	O	O
with	O	O
rapid	O	O
sodium	O	O
and	O	O
chloride	O	O
diuresis	O	O
in	O	O
response	O	O
to	O	O
small	O	O
volume	O	O
changes	O	O
.	O	O

Examination	O	O
of	O	O
plasma	O	O
amino	O	O
acids	O	O
,	O	O
an	O	O
investigation	O	O
not	O	O
previously	O	O
reported	O	O
,	O	O
revealed	O	O
an	O	O
extremely	O	O
low	O	O
plasma	O	O
tryptophan	O	O
level	O	O
,	O	O
a	O	O
finding	O	O
which	O	O
may	O	O
be	O	O
important	O	O
in	O	O
view	O	O
of	O	O
the	O	O
role	O	O
of	O	O
tryptophan	O	O
in	O	O
albumin	O	O
synthesis	O	O
.	O	O

.	O	O

Homozygous	O	O
presence	O	O
of	O	O
the	O	O
crossover	O	O
(	O	O
fusion	O	O
gene	O	O
)	O	O
mutation	O	O
identified	O	O
in	O	O
a	O	O
type	B-Disease	D005776
II	I-Disease	D005776
Gaucher	I-Disease	D005776
disease	I-Disease	D005776
fetus	O	O
:	O	O
is	O	O
this	O	O
analogous	O	O
to	O	O
the	O	O
Gaucher	O	O
knock	O	O
-	O	O
out	O	O
mouse	O	O
model	O	O
?	O	O
Gaucher	B-Disease	D005776
disease	I-Disease	D005776
(	O	O
GD	B-Disease	D005776
)	O	O
is	O	O
an	O	O
inherited	O	O
deficiency	B-Disease	D005776
of	I-Disease	D005776
beta	I-Disease	D005776
-	I-Disease	D005776
glucocerebrosidase	I-Disease	D005776
(	O	O
EC	O	O
3	O	O
.	O	O

1	O	O
.	O	O

2	O	O
.	O	O

45	O	O
,	O	O
gene	O	O
symbol	O	O
GBA	O	O
)	O	O
.	O	O

In	O	O
type	B-Disease	D005776
I	I-Disease	D005776
GD	I-Disease	D005776
,	O	O
the	O	O
CNS	O	O
is	O	O
not	O	O
involved	O	O
(	O	O
nonneuronopathic	O	O
)	O	O
,	O	O
whereas	O	O
in	O	O
type	B-Disease	D005776
II	I-Disease	D005776
GD	I-Disease	D005776
(	O	O
acute	O	O
neuronopathic	O	O
)	O	O
CNS	O	O
involvement	O	O
is	O	O
early	O	O
and	O	O
rapidly	O	O
progressive	O	O
,	O	O
while	O	O
in	O	O
type	B-Disease	D005776
III	I-Disease	D005776
GD	I-Disease	D005776
(	O	O
subacute	O	O
neuronopathic	O	O
)	O	O
CNS	O	O
involvement	O	O
occurs	O	O
later	O	O
and	O	O
is	O	O
slowly	O	O
progressive	O	O
.	O	O

The	O	O
T6433C	O	O
(	O	O
L444P	O	O
)	O	O
substitution	O	O
is	O	O
prevalent	O	O
in	O	O
type	B-Disease	D005776
GD	I-Disease	D005776
II	I-Disease	D005776
.	O	O

It	O	O
may	O	O
occur	O	O
alone	O	O
as	O	O
a	O	O
single	O	O
base	O	O
-	O	O
pair	O	O
mutation	O	O
but	O	O
often	O	O
is	O	O
found	O	O
as	O	O
part	O	O
of	O	O
a	O	O
complex	O	O
allele	O	O
containing	O	O
additional	O	O
GBA	O	O
nucleotide	O	O
substitutions	O	O
,	O	O
G6468C	O	O
(	O	O
A456P	O	O
)	O	O
and	O	O
G6482C	O	O
(	O	O
V460V	O	O
)	O	O
,	O	O
without	O	O
(	O	O
recNciI	O	O
)	O	O
or	O	O
with	O	O
(	O	O
recTL	O	O
)	O	O
G5957C	O	O
(	O	O
D409H	O	O
)	O	O
.	O	O

This	O	O
complex	O	O
allele	O	O
is	O	O
presumed	O	O
to	O	O
have	O	O
formed	O	O
by	O	O
recombination	O	O
(	O	O
crossover	O	O
,	O	O
fusion	O	O
)	O	O
of	O	O
the	O	O
structural	O	O
gene	O	O
with	O	O
the	O	O
pseudogene	O	O
,	O	O
which	O	O
contains	O	O
the	O	O
mutated	O	O
sequences	O	O
.	O	O

Two	O	O
complex	O	O
alleles	O	O
have	O	O
never	O	O
been	O	O
demonstrated	O	O
to	O	O
coexist	O	O
in	O	O
any	O	O
individual	O	O
.	O	O

We	O	O
devised	O	O
a	O	O
selective	O	O
PCR	O	O
method	O	O
for	O	O
the	O	O
specific	O	O
amplification	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
/	O	O
or	O	O
fusion	O	O
gene	O	O
.	O	O

Using	O	O
this	O	O
procedure	O	O
we	O	O
demonstrated	O	O
the	O	O
fusion	O	O
gene	O	O
in	O	O
homozygous	O	O
form	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
in	O	O
a	O	O
Macedonian	O	O
/	O	O
Ashkenazi	O	O
Jewish	O	O
GD	B-Disease	D005776
type	O	O
II	O	O
fetus	O	O
.	O	O

Both	O	O
parents	O	O
were	O	O
carriers	O	O
of	O	O
the	O	O
recombination	O	O
.	O	O

This	O	O
was	O	O
confirmed	O	O
by	O	O
direct	O	O
sequence	O	O
analysis	O	O
.	O	O

A	O	O
previous	O	O
conceptus	O	O
in	O	O
this	O	O
family	O	O
was	O	O
stillborn	B-Disease	D005313
at	O	O
36	O	O
weeks	O	O
,	O	O
with	O	O
features	O	O
of	O	O
severe	O	O
type	B-Disease	D005776
II	I-Disease	D005776
GD	I-Disease	D005776
.	O	O

Neonates	O	O
showing	O	O
a	O	O
severe	O	O
clinical	O	O
phenotype	O	O
,	O	O
analogous	O	O
to	O	O
the	O	O
early	O	O
neonatal	O	O
lethal	O	O
disease	O	O
occurring	O	O
in	O	O
mice	O	O
homozygous	O	O
for	O	O
a	O	O
null	O	O
allele	O	O
produced	O	O
by	O	O
targeted	O	O
disruption	O	O
of	O	O
GBA	O	O
,	O	O
have	O	O
been	O	O
described	O	O
elsewhere	O	O
,	O	O
but	O	O
the	O	O
specific	O	O
mutations	O	O
in	O	O
these	O	O
cases	O	O
have	O	O
not	O	O
yet	O	O
been	O	O
characterized	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Decrease	O	O
in	O	O
GTP	O	O
cyclohydrolase	O	O
I	O	O
gene	O	O
expression	O	O
caused	O	O
by	O	O
inactivation	O	O
of	O	O
one	O	O
allele	O	O
in	O	O
hereditary	B-Disease	D020821
progressive	I-Disease	D020821
dystonia	I-Disease	D020821
with	O	O
marked	O	O
diurnal	O	O
fluctuation	O	O
.	O	O

Hereditary	B-Disease	D020821
progressive	I-Disease	D020821
dystonia	I-Disease	D020821
with	O	O
marked	O	O
diurnal	O	O
fluctuation	O	O
(	O	O
HPD	B-Disease	D020821
;	O	O
dopa	B-Disease	C538007
-	I-Disease	C538007
responsive	I-Disease	C538007
dystonia	I-Disease	C538007
,	O	O
DRD	B-Disease	C538007
)	O	O
have	O	O
been	O	O
recently	O	O
found	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
the	O	O
GTP	O	O
cyclohydrolase	O	O
I	O	O
(	O	O
GCH1	O	O
)	O	O
gene	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
quantified	O	O
the	O	O
mRNA	O	O
level	O	O
of	O	O
GCH1	O	O
in	O	O
phytohemagglutinin	O	O
(	O	O
PHA	O	O
)	O	O
-	O	O
stimulated	O	O
mononuclear	O	O
blood	O	O
cells	O	O
from	O	O
one	O	O
Japanese	O	O
family	O	O
that	O	O
do	O	O
not	O	O
have	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
or	O	O
splice	O	O
junctions	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
the	O	O
amounts	O	O
of	O	O
the	O	O
GCH1	O	O
mRNA	O	O
were	O	O
decreased	O	O
to	O	O
about	O	O
40	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
level	O	O
in	O	O
both	O	O
patients	O	O
and	O	O
carriers	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
GCH1	O	O
mRNA	O	O
was	O	O
transcribed	O	O
from	O	O
only	O	O
one	O	O
allele	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
other	O	O
allele	O	O
was	O	O
in	O	O
an	O	O
inactive	O	O
state	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
some	O	O
novel	O	O
mutations	O	O
should	O	O
exist	O	O
on	O	O
one	O	O
of	O	O
the	O	O
alleles	O	O
in	O	O
some	O	O
unknown	O	O
region	O	O
of	O	O
the	O	O
GCH1	O	O
gene	O	O
,	O	O
and	O	O
may	O	O
decrease	O	O
the	O	O
GCH1	O	O
mRNA	O	O
causing	O	O
the	O	O
HPD	B-Disease	D020821
/	O	O
DRD	B-Disease	C538007
symptoms	O	O
.	O	O

.	O	O

Novel	O	O
mutations	O	O
in	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
gene	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
transcriptional	O	O
,	O	O
translational	O	O
,	O	O
and	O	O
clinical	O	O
phenotypes	O	O
.	O	O

Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
is	O	O
an	O	O
X	B-Disease	D053632
-	I-Disease	D053632
linked	I-Disease	D053632
recessive	I-Disease	D053632
immunodeficiency	I-Disease	D053632
characterized	O	O
by	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
eczema	B-Disease	D004485
,	O	O
and	O	O
recurrent	O	O
infections	O	O
,	O	O
and	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
WAS	B-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
gene	O	O
.	O	O

WASP	O	O
contains	O	O
several	O	O
functional	O	O
domains	O	O
through	O	O
which	O	O
it	O	O
interacts	O	O
with	O	O
proteins	O	O
involved	O	O
in	O	O
intracellular	O	O
signaling	O	O
and	O	O
regulation	O	O
of	O	O
the	O	O
actin	O	O
cytoskeleton	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
17	O	O
WASP	O	O
gene	O	O
mutations	O	O
were	O	O
identified	O	O
,	O	O
12	O	O
of	O	O
which	O	O
are	O	O
novel	O	O
.	O	O

DNA	O	O
of	O	O
affected	O	O
males	O	O
and	O	O
obligate	O	O
carriers	O	O
was	O	O
PCR	O	O
amplified	O	O
and	O	O
analyzed	O	O
by	O	O
SSCA	O	O
,	O	O
heteroduplex	O	O
analysis	O	O
,	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
the	O	O
mutations	O	O
at	O	O
the	O	O
mRNA	O	O
and	O	O
protein	O	O
level	O	O
were	O	O
ascertained	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
Western	O	O
blot	O	O
analyses	O	O
.	O	O

All	O	O
missense	O	O
mutations	O	O
were	O	O
located	O	O
in	O	O
exons	O	O
1	O	O
-	O	O
4	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
nonsense	O	O
,	O	O
frameshift	O	O
and	O	O
splice	O	O
site	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
exons	O	O
6	O	O
-	O	O
11	O	O
.	O	O

Mutations	O	O
that	O	O
alter	O	O
splice	O	O
sites	O	O
led	O	O
to	O	O
the	O	O
synthesis	O	O
of	O	O
several	O	O
types	O	O
of	O	O
mRNAs	O	O
,	O	O
a	O	O
fraction	O	O
of	O	O
which	O	O
represented	O	O
the	O	O
normally	O	O
spliced	O	O
product	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
normally	O	O
spliced	O	O
transcripts	O	O
was	O	O
correlated	O	O
with	O	O
a	O	O
milder	O	O
phenotype	O	O
.	O	O

When	O	O
one	O	O
such	O	O
case	O	O
was	O	O
studied	O	O
by	O	O
Western	O	O
blotting	O	O
,	O	O
reduced	O	O
amounts	O	O
of	O	O
normal	O	O
-	O	O
size	O	O
WASP	O	O
were	O	O
present	O	O
.	O	O

In	O	O
other	O	O
cases	O	O
as	O	O
well	O	O
,	O	O
a	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
amount	O	O
of	O	O
normal	O	O
or	O	O
mutant	O	O
WASP	O	O
present	O	O
and	O	O
the	O	O
phenotypes	O	O
of	O	O
the	O	O
affected	O	O
individuals	O	O
.	O	O

No	O	O
protein	O	O
was	O	O
detected	O	O
in	O	O
two	O	O
individuals	O	O
with	O	O
severe	O	O
WAS	B-Disease	D014923
.	O	O

Reduced	O	O
levels	O	O
of	O	O
a	O	O
normal	O	O
-	O	O
size	O	O
WASP	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
were	O	O
seen	O	O
in	O	O
two	O	O
individuals	O	O
with	O	O
XLT	B-Disease	OMIM:313900
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
mutation	O	O
analysis	O	O
at	O	O
the	O	O
DNA	O	O
level	O	O
is	O	O
not	O	O
sufficient	O	O
for	O	O
predicting	O	O
clinical	O	O
course	O	O
.	O	O

Studies	O	O
at	O	O
the	O	O
transcript	O	O
and	O	O
protein	O	O
level	O	O
are	O	O
needed	O	O
for	O	O
a	O	O
better	O	O
assessment	O	O
.	O	O

.	O	O

Incidence	O	O
and	O	O
characteristics	O	O
of	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variants	O	O
in	O	O
Japan	O	O
.	O	O

A	O	O
total	O	O
of	O	O
3000	O	O
men	O	O
living	O	O
in	O	O
Yamaguchi	O	O
were	O	O
screened	O	O
for	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
using	O	O
Beutlers	O	O
spot	O	O
test	O	O
and	O	O
three	O	O
types	O	O
of	O	O
starch	O	O
gel	O	O
electrophoresis	O	O
.	O	O

These	O	O
electrophoresis	O	O
used	O	O
a	O	O
phosphate	O	O
buffer	O	O
system	O	O
at	O	O
pH	O	O
7	O	O
.	O	O

0	O	O
,	O	O
a	O	O
TRIS	O	O
-	O	O
EDTA	O	O
-	O	O
borate	O	O
buffer	O	O
system	O	O
at	O	O
pH	O	O
8	O	O
.	O	O

6	O	O
,	O	O
and	O	O
a	O	O
TRIS	O	O
-	O	O
hydrochloride	O	O
buffer	O	O
system	O	O
at	O	O
pH	O	O
8	O	O
.	O	O

.	O	O

Fifteen	O	O
G6PD	B-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
variants	O	O
were	O	O
found	O	O
at	O	O
the	O	O
rate	O	O
of	O	O
0	O	O
.	O	O

5	O	O
%	O	O
and	O	O
classified	O	O
into	O	O
four	O	O
groups	O	O
.	O	O

As	O	O
new	O	O
variants	O	O
,	O	O
G6PD	O	O
Konan	O	O
,	O	O
Kamiube	O	O
,	O	O
and	O	O
Kiwa	O	O
were	O	O
identified	O	O
.	O	O

These	O	O
three	O	O
variants	O	O
had	O	O
a	O	O
mild	O	O
to	O	O
moderate	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
and	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
clinical	O	O
signs	O	O
.	O	O

G6PD	O	O
Konan	O	O
had	O	O
fast	O	O
electrophoretic	O	O
mobility	O	O
as	O	O
compared	O	O
with	O	O
normal	O	O
levels	O	O
,	O	O
G6PD	O	O
Kiwa	O	O
had	O	O
slightly	O	O
elevated	O	O
electrophoretic	O	O
mobility	O	O
,	O	O
and	O	O
G6PD	O	O
Kamiube	O	O
had	O	O
normal	O	O
electrophoretic	O	O
mobility	O	O
.	O	O

These	O	O
three	O	O
variants	O	O
had	O	O
normal	O	O
levels	O	O
of	O	O
Km	O	O
G6P	O	O
,	O	O
Km	O	O
NADP	O	O
,	O	O
and	O	O
Ki	O	O
NADPH	O	O
,	O	O
normal	O	O
utilizations	O	O
of	O	O
both	O	O
2	O	O
-	O	O
deoxy	O	O
-	O	O
G6P	O	O
and	O	O
deamino	O	O
-	O	O
NAPD	O	O
,	O	O
normal	O	O
heat	O	O
stability	O	O
,	O	O
and	O	O
a	O	O
normal	O	O
pH	O	O
curve	O	O
.	O	O

The	O	O
other	O	O
variant	O	O
was	O	O
G6PD	O	O
Ube	O	O
,	O	O
which	O	O
we	O	O
had	O	O
previously	O	O
found	O	O
in	O	O
Yamaguchi	O	O
(	O	O
Nakashima	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1977	O	O
)	O	O
.	O	O

One	O	O
boy	O	O
with	O	O
G6PD	O	O
Ube	O	O
was	O	O
Korean	O	O
Difference	O	O
in	O	O
methylation	O	O
patterns	O	O
within	O	O
the	O	O
D15S9	O	O
region	O	O
of	O	O
chromosome	O	O
15q11	O	O
-	O	O
13	O	O
in	O	O
first	O	O
cousins	O	O
with	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
and	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

Abnormalities	O	O
of	O	O
chromosome	O	O
region	O	O
15q11	O	O
-	O	O
13	O	O
are	O	O
associated	O	O
with	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
(	O	O
AS	B-Disease	D017204
)	O	O
and	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

Differences	O	O
between	O	O
the	O	O
methylation	O	O
patterns	O	O
of	O	O
the	O	O
region	O	O
of	O	O
chromosome	O	O
15q11	O	O
-	O	O
13	O	O
which	O	O
hybridizes	O	O
to	O	O
the	O	O
highly	O	O
conserved	O	O
DNA	O	O
,	O	O
DN34	O	O
,	O	O
in	O	O
normal	O	O
individuals	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
AS	B-Disease	D017204
and	O	O
PWS	B-Disease	D011218
have	O	O
been	O	O
described	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
family	O	O
in	O	O
which	O	O
first	O	O
cousins	O	O
are	O	O
affected	O	O
by	O	O
AS	B-Disease	D017204
and	O	O
PWS	B-Disease	D011218
as	O	O
a	O	O
result	O	O
of	O	O
a	O	O
familial	O	O
paracentric	O	O
inversion	O	O
of	O	O
15q11	O	O
-	O	O
q13	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
studies	O	O
on	O	O
this	O	O
family	O	O
demonstrate	O	O
the	O	O
differences	O	O
in	O	O
the	O	O
methylation	O	O
patterns	O	O
in	O	O
the	O	O
2	O	O
conditions	O	O
and	O	O
the	O	O
phenomenon	O	O
of	O	O
genomic	O	O
imprinting	O	O
,	O	O
whereby	O	O
genetic	O	O
information	O	O
is	O	O
expressed	O	O
differently	O	O
dependent	O	O
on	O	O
the	O	O
parent	O	O
of	O	O
origin	O	O
.	O	O

.	O	O

Mutations	O	O
in	O	O
the	O	O
candidate	O	O
gene	O	O
for	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
.	O	O

Recently	O	O
,	O	O
we	O	O
and	O	O
others	O	O
have	O	O
isolated	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
X	B-Disease	C537849
linked	I-Disease	C537849
Norrie	I-Disease	C537849
disease	I-Disease	C537849
(	O	O
ND	B-Disease	C537849
)	O	O
which	O	O
was	O	O
found	O	O
to	O	O
be	O	O
deleted	O	O
or	O	O
disrupted	O	O
in	O	O
several	O	O
patients	O	O
.	O	O

As	O	O
a	O	O
prerequisite	O	O
for	O	O
the	O	O
identification	O	O
of	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
ND	B-Disease	C537849
gene	O	O
we	O	O
have	O	O
established	O	O
the	O	O
exon	O	O
-	O	O
intron	O	O
structure	O	O
of	O	O
this	O	O
gene	O	O
.	O	O

In	O	O
17	O	O
unrelated	O	O
patients	O	O
and	O	O
15	O	O
controls	O	O
,	O	O
PCR	O	O
products	O	O
derived	O	O
from	O	O
the	O	O
promoter	O	O
region	O	O
,	O	O
exons	O	O
1	O	O
and	O	O
2	O	O
as	O	O
well	O	O
as	O	O
the	O	O
coding	O	O
part	O	O
of	O	O
exon	O	O
3	O	O
were	O	O
analysed	O	O
with	O	O
the	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
technique	O	O
.	O	O

In	O	O
12	O	O
patients	O	O
altered	O	O
PCR	O	O
fragments	O	O
were	O	O
detected	O	O
which	O	O
were	O	O
studied	O	O
in	O	O
detail	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O

Eleven	O	O
different	O	O
mutations	O	O
were	O	O
found	O	O
,	O	O
and	O	O
all	O	O
but	O	O
one	O	O
are	O	O
likely	O	O
to	O	O
give	O	O
rise	O	O
to	O	O
significant	O	O
structural	O	O
changes	O	O
in	O	O
the	O	O
predicted	O	O
protein	O	O
.	O	O

These	O	O
findings	O	O
,	O	O
and	O	O
the	O	O
absence	O	O
of	O	O
functionally	O	O
relevant	O	O
base	O	O
changes	O	O
in	O	O
healthy	O	O
controls	O	O
,	O	O
emphasize	O	O
the	O	O
causal	O	O
role	O	O
of	O	O
this	O	O
candidate	O	O
gene	O	O
in	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
and	O	O
pave	O	O
the	O	O
way	O	O
for	O	O
reliable	O	O
diagnosis	O	O
and	O	O
carrier	O	O
detection	O	O
.	O	O

.	O	O

A	O	O
single	O	O
amino	O	O
acid	O	O
substitution	O	O
(	O	O
G103D	O	O
)	O	O
in	O	O
the	O	O
type	O	O
II	O	O
collagen	O	O
triple	O	O
helix	O	O
produces	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
.	O	O

Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
is	O	O
a	O	O
moderately	O	O
severe	O	O
chondrodysplasia	B-Disease	D010009
phenotype	O	O
that	O	O
results	O	O
from	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
for	O	O
type	O	O
II	O	O
collagen	O	O
,	O	O
COL2A1	O	O
.	O	O

Characteristics	O	O
of	O	O
the	O	O
disorder	O	O
include	O	O
a	O	O
short	B-Disease	D006130
trunk	I-Disease	D006130
and	I-Disease	D006130
extremities	I-Disease	D006130
,	O	O
mid	B-Disease	D019767
-	I-Disease	D019767
face	I-Disease	D019767
hypoplasia	I-Disease	D019767
,	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
,	O	O
myopia	B-Disease	D009216
,	O	O
retinal	B-Disease	D012163
detachment	I-Disease	D012163
,	O	O
and	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Recently	O	O
,	O	O
deletions	O	O
of	O	O
all	O	O
or	O	O
part	O	O
of	O	O
exon	O	O
12	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
individuals	O	O
with	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
,	O	O
suggesting	O	O
that	O	O
mutations	O	O
within	O	O
this	O	O
region	O	O
of	O	O
the	O	O
protein	O	O
may	O	O
primarily	O	O
result	O	O
in	O	O
the	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
phenotype	O	O
.	O	O

We	O	O
used	O	O
SSCP	O	O
to	O	O
analyze	O	O
an	O	O
amplified	O	O
genomic	O	O
DNA	O	O
fragment	O	O
containing	O	O
exon	O	O
12	O	O
from	O	O
seven	O	O
individuals	O	O
with	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
.	O	O

An	O	O
abnormality	O	O
was	O	O
identified	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

DNA	O	O
sequence	O	O
analysis	O	O
demonstrated	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
heterozygous	O	O
for	O	O
a	O	O
G	O	O
to	O	O
A	O	O
transition	O	O
that	O	O
implied	O	O
substitution	O	O
of	O	O
glycine103	O	O
of	O	O
the	O	O
triple	O	O
helical	O	O
domain	O	O
by	O	O
aspartate	O	O
.	O	O

The	O	O
mutation	O	O
was	O	O
not	O	O
observed	O	O
in	O	O
DNA	O	O
from	O	O
either	O	O
of	O	O
the	O	O
clinically	O	O
unaffected	O	O
parents	O	O
of	O	O
the	O	O
proband	O	O
.	O	O

Protein	O	O
microsequencing	O	O
demonstrated	O	O
expression	O	O
of	O	O
the	O	O
abnormal	O	O
allele	O	O
in	O	O
cartilage	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
point	O	O
mutations	O	O
which	O	O
result	O	O
in	O	O
single	O	O
amino	O	O
acid	O	O
substitutions	O	O
can	O	O
produce	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
and	O	O
further	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
alteration	O	O
of	O	O
a	O	O
domain	O	O
,	O	O
which	O	O
includes	O	O
the	O	O
region	O	O
encoded	O	O
by	O	O
exon	O	O
12	O	O
,	O	O
in	O	O
the	O	O
type	O	O
II	O	O
collagen	O	O
protein	O	O
leads	O	O
to	O	O
this	O	O
disorder	O	O
.	O	O

.	O	O

Linkage	O	O
analysis	O	O
of	O	O
5	O	O
novel	O	O
van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
kindreds	O	O
to	O	O
1q32	O	O
-	O	O
q41	O	O
markers	O	O
further	O	O
supports	O	O
locus	O	O
homogeneity	O	O
of	O	O
the	O	O
disease	O	O
trait	O	O
.	O	O

van	B-Disease	C536528
der	I-Disease	C536528
Woude	I-Disease	C536528
syndrome	I-Disease	C536528
(	O	O
vWS	B-Disease	C536528
,	O	O
MIM	O	O
119300	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
autosomal	B-Disease	C536528
dominant	I-Disease	C536528
clefting	I-Disease	C536528
condition	I-Disease	C536528
with	O	O
cardinal	O	O
features	O	O
of	O	O
mucous	B-Disease	D009078
cysts	I-Disease	D009078
(	O	O
lower	B-Disease	C536528
-	I-Disease	C536528
lip	I-Disease	C536528
pits	I-Disease	C536528
)	O	O
and	O	O
clefts	B-Disease	D002971
to	I-Disease	D002971
the	I-Disease	D002971
lip	I-Disease	D002971
and	I-Disease	D002971
/	I-Disease	D002971
or	I-Disease	D002971
palate	I-Disease	D002971
.	O	O

The	O	O
vWS	B-Disease	C536528
gene	O	O
has	O	O
been	O	O
assigned	O	O
to	O	O
a	O	O
locus	O	O
in	O	O
1q32	O	O
-	O	O
q41	O	O
by	O	O
linkage	O	O
analysis	O	O
and	O	O
physical	O	O
mapping	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
5	O	O
novel	O	O
vWS	B-Disease	C536528
families	O	O
through	O	O
probands	O	O
attended	O	O
for	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
and	I-Disease	D002971
/	I-Disease	D002971
or	I-Disease	D002971
palate	I-Disease	D002971
repair	O	O
at	O	O
the	O	O
Department	O	O
of	O	O
Maxillofacial	O	O
Surgery	O	O
of	O	O
Hopital	O	O
Trousseau	O	O
,	O	O
Paris	O	O
,	O	O
in	O	O
order	O	O
to	O	O
tentatively	O	O
refine	O	O
the	O	O
genetic	O	O
map	O	O
of	O	O
the	O	O
vWS	B-Disease	C536528
region	O	O
in	O	O
1q32	O	O
-	O	O
q41	O	O
and	O	O
possibly	O	O
identify	O	O
unlinked	O	O
pedigrees	O	O
.	O	O

Linkage	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
6	O	O
microsatellite	O	O
markers	O	O
(	O	O
D1S249	O	O
,	O	O
D1S425	O	O
,	O	O
D1S491	O	O
,	O	O
D1S205	O	O
,	O	O
D1S414	O	O
,	O	O
D1S425	O	O
)	O	O
,	O	O
yielding	O	O
a	O	O
maximum	O	O
cumulative	O	O
LOD	O	O
score	O	O
of	O	O
Z	O	O
=	O	O
3	O	O
.	O	O

27	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

00	O	O
for	O	O
D1S245	O	O
.	O	O

The	O	O
innermost	O	O
four	O	O
markers	O	O
were	O	O
found	O	O
to	O	O
be	O	O
tightly	O	O
linked	O	O
to	O	O
one	O	O
another	O	O
,	O	O
with	O	O
no	O	O
evidence	O	O
for	O	O
recombination	O	O
.	O	O

Our	O	O
results	O	O
support	O	O
linkage	O	O
of	O	O
vWS	B-Disease	C536528
within	O	O
a	O	O
region	O	O
of	O	O
tightly	O	O
linked	O	O
markers	O	O
and	O	O
do	O	O
not	O	O
favour	O	O
locus	O	O
heterogeneity	O	O
of	O	O
the	O	O
disease	O	O
trait	O	O
.	O	O

Hypopigmentation	B-Disease	D017496
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

Cutaneous	B-Disease	D010859
and	I-Disease	D010859
ocular	I-Disease	D010859
pigmentation	I-Disease	D010859
were	O	O
evaluated	O	O
in	O	O
29	O	O
individuals	O	O
with	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

Criteria	O	O
for	O	O
hypopigmentation	B-Disease	D017496
included	O	O
the	O	O
presence	O	O
of	O	O
type	O	O
I	O	O
or	O	O
II	O	O
skin	O	O
,	O	O
the	O	O
lightest	O	O
skin	O	O
type	O	O
in	O	O
the	O	O
family	O	O
by	O	O
history	O	O
,	O	O
and	O	O
iris	O	O
translucency	O	O
on	O	O
globe	O	O
transillumination	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
these	O	O
criteria	O	O
,	O	O
48	O	O
%	O	O
of	O	O
the	O	O
PWS	B-Disease	D011218
individuals	O	O
were	O	O
hypopigmented	B-Disease	D017496
.	O	O

The	O	O
presence	O	O
of	O	O
hypopigmentation	B-Disease	D017496
correlated	O	O
with	O	O
a	O	O
small	O	O
interstitial	O	O
deletion	O	O
on	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
15	O	O
;	O	O
however	O	O
,	O	O
this	O	O
deletion	O	O
was	O	O
also	O	O
found	O	O
in	O	O
individuals	O	O
who	O	O
did	O	O
not	O	O
meet	O	O
the	O	O
full	O	O
criteria	O	O
for	O	O
hypopigmentation	B-Disease	D017496
.	O	O

Hairbulb	O	O
tyrosinase	O	O
activity	O	O
and	O	O
glutathione	O	O
content	O	O
,	O	O
as	O	O
well	O	O
as	O	O
urine	O	O
cysteinyldopa	O	O
excretion	O	O
,	O	O
were	O	O
low	O	O
in	O	O
PWS	B-Disease	D011218
individuals	O	O
with	O	O
and	O	O
without	O	O
hypopigmentation	B-Disease	D017496
and	O	O
did	O	O
not	O	O
separate	O	O
these	O	O
two	O	O
groups	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
hypopigmentation	B-Disease	D017496
is	O	O
found	O	O
in	O	O
a	O	O
significant	O	O
proportion	O	O
of	O	O
individuals	O	O
with	O	O
PWS	B-Disease	D011218
and	O	O
that	O	O
the	O	O
hypopigmentation	B-Disease	D017496
may	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
deletion	O	O
of	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
15	O	O
.	O	O

The	O	O
mechanism	O	O
for	O	O
the	O	O
hypopigmentation	B-Disease	D017496
is	O	O
unknown	O	O
.	O	O

.	O	O

Deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
in	O	O
human	O	O
subjects	O	O
.	O	O

Clinical	O	O
,	O	O
genetic	O	O
and	O	O
immunologic	O	O
studies	O	O
in	O	O
a	O	O
large	O	O
kindred	O	O
.	O	O

The	O	O
discovery	O	O
of	O	O
a	O	O
large	O	O
kindred	O	O
with	O	O
a	O	O
heritable	O	O
deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
(	O	O
C5	O	O
)	O	O
has	O	O
permitted	O	O
the	O	O
accumulation	O	O
of	O	O
new	O	O
clinical	O	O
,	O	O
genetic	O	O
and	O	O
immunologic	O	O
data	O	O
concerning	O	O
the	O	O
role	O	O
of	O	O
C5	O	O
in	O	O
human	O	O
subjects	O	O
.	O	O

The	O	O
proband	O	O
,	O	O
who	O	O
has	O	O
had	O	O
nine	O	O
episodes	O	O
of	O	O
disseminated	O	O
gonococcal	B-Disease	D006069
infection	I-Disease	D006069
,	O	O
has	O	O
a	O	O
hemolytic	O	O
C5	O	O
level	O	O
of	O	O
approximately	O	O
0	O	O
.	O	O

5	O	O
per	O	O
cent	O	O
of	O	O
normal	O	O
.	O	O

No	O	O
C5	O	O
protein	O	O
was	O	O
detectable	O	O
,	O	O
but	O	O
low	O	O
levels	O	O
of	O	O
functional	O	O
C5	O	O
activity	O	O
could	O	O
be	O	O
found	O	O
using	O	O
a	O	O
sensitive	O	O
bactericidal	O	O
assay	O	O
.	O	O

The	O	O
probands	O	O
twin	O	O
as	O	O
well	O	O
as	O	O
another	O	O
sister	O	O
also	O	O
had	O	O
extremely	O	O
low	O	O
levels	O	O
of	O	O
hemolytic	O	O
C5	O	O
(	O	O
approximately	O	O
0	O	O
.	O	O

5	O	O
per	O	O
cent	O	O
normal	O	O
)	O	O
,	O	O
but	O	O
both	O	O
these	O	O
subjects	O	O
have	O	O
been	O	O
healthy	O	O
.	O	O

Hemolytic	O	O
complement	O	O
and	O	O
bacteriolytic	O	O
activity	O	O
could	O	O
be	O	O
restored	O	O
by	O	O
the	O	O
addition	O	O
of	O	O
purified	O	O
C5	O	O
.	O	O

No	O	O
chemotactic	O	O
activity	O	O
for	O	O
polymorphonuclear	O	O
leukocytes	O	O
could	O	O
be	O	O
generated	O	O
in	O	O
the	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
serums	O	O
upon	O	O
activation	O	O
of	O	O
either	O	O
the	O	O
classic	O	O
or	O	O
alternative	O	O
pathways	O	O
,	O	O
again	O	O
demonstrating	O	O
the	O	O
importance	O	O
of	O	O
C5	O	O
in	O	O
human	O	O
subjects	O	O
for	O	O
the	O	O
production	O	O
of	O	O
chemotactic	O	O
factors	O	O
.	O	O

The	O	O
chemotactic	O	O
responsiveness	O	O
of	O	O
the	O	O
patients	O	O
polymorphonuclear	O	O
leukocytes	O	O
and	O	O
monocytes	O	O
to	O	O
preformed	O	O
chemotactic	O	O
factors	O	O
was	O	O
not	O	O
depressed	O	O
.	O	O

Twenty	O	O
-	O	O
two	O	O
of	O	O
32	O	O
other	O	O
family	O	O
members	O	O
from	O	O
three	O	O
generations	O	O
had	O	O
depressed	O	O
whole	O	O
hemolytic	O	O
complement	O	O
levels	O	O
.	O	O

In	O	O
19	O	O
of	O	O
30	O	O
family	O	O
members	O	O
,	O	O
levels	O	O
of	O	O
hemolytic	O	O
C5	O	O
ranged	O	O
from	O	O
13	O	O
to	O	O
64	O	O
per	O	O
cent	O	O
of	O	O
normal	O	O
.	O	O

No	O	O
linkage	O	O
for	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
and	O	O
the	O	O
A	O	O
or	O	O
B	O	O
loci	O	O
of	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
could	O	O
be	O	O
found	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
an	O	O
autosomal	O	O
codominant	O	O
mode	O	O
of	O	O
inheritance	O	O
of	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

Deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
is	O	O
compatible	O	O
with	O	O
good	O	O
health	O	O
,	O	O
but	O	O
it	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
repeated	O	O
disseminated	O	O
gonococcal	B-Disease	D006069
infection	I-Disease	D006069
A	O	O
new	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
variant	O	O
,	O	O
G6PD	O	O
Orissa	O	O
(	O	O
44	O	O
Ala	O	O
-	O	O
-	O	O
>	O	O
Gly	O	O
)	O	O
,	O	O
is	O	O
the	O	O
major	O	O
polymorphic	O	O
variant	O	O
in	O	O
tribal	O	O
populations	O	O
in	O	O
India	O	O
.	O	O

Deficiency	B-Disease	D005955
of	I-Disease	D005955
glucose	I-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	O	O
G6PD	O	O
)	O	O
is	O	O
usually	O	O
found	O	O
at	O	O
high	O	O
frequencies	O	O
in	O	O
areas	O	O
of	O	O
the	O	O
world	O	O
where	O	O
malaria	B-Disease	D008288
has	O	O
been	O	O
endemic	O	O
.	O	O

The	O	O
frequency	O	O
and	O	O
genetic	O	O
basis	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
have	O	O
been	O	O
studied	O	O
in	O	O
Africa	O	O
,	O	O
around	O	O
the	O	O
Mediterranean	O	O
,	O	O
and	O	O
in	O	O
the	O	O
Far	O	O
East	O	O
,	O	O
but	O	O
little	O	O
such	O	O
information	O	O
is	O	O
available	O	O
about	O	O
the	O	O
situation	O	O
in	O	O
India	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
extent	O	O
of	O	O
heterogeneity	O	O
of	O	O
G6PD	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
several	O	O
different	O	O
Indian	O	O
populations	O	O
by	O	O
screening	O	O
for	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
followed	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
deficient	O	O
alleles	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
varies	O	O
between	O	O
3	O	O
%	O	O
and	O	O
15	O	O
%	O	O
in	O	O
different	O	O
tribal	O	O
and	O	O
urban	O	O
groups	O	O
.	O	O

Remarkably	O	O
,	O	O
a	O	O
previously	O	O
unreported	O	O
deficient	O	O
variant	O	O
,	O	O
G6PD	O	O
Orissa	O	O
(	O	O
44	O	O
Ala	O	O
-	O	O
-	O	O
>	O	O
Gly	O	O
)	O	O
,	O	O
is	O	O
responsible	O	O
for	O	O
most	O	O
of	O	O
the	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
tribal	O	O
Indian	O	O
populations	O	O
but	O	O
is	O	O
not	O	O
found	O	O
in	O	O
urban	O	O
populations	O	O
,	O	O
where	O	O
most	O	O
of	O	O
the	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
is	O	O
due	O	O
to	O	O
the	O	O
G6PD	O	O
Mediterranean	O	O
(	O	O
188	O	O
Ser	O	O
-	O	O
-	O	O
>	O	O
Phe	O	O
)	O	O
variant	O	O
.	O	O

The	O	O
KmNADP	O	O
of	O	O
G6PD	O	O
Orissa	O	O
is	O	O
fivefold	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
normal	O	O
enzyme	O	O
.	O	O

This	O	O
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
fact	O	O
that	O	O
the	O	O
alanine	O	O
residue	O	O
that	O	O
is	O	O
replaced	O	O
by	O	O
glycine	O	O
is	O	O
part	O	O
of	O	O
a	O	O
putative	O	O
coenzyme	O	O
-	O	O
binding	O	O
site	O	O
.	O	O

.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
Wilms	B-Disease	D009396
'	I-Disease	D009396
tumor	I-Disease	D009396
suppressor	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
abnormal	O	O
urogenital	O	O
development	O	O
in	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
.	O	O

Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
is	O	O
a	O	O
rare	O	O
human	O	O
condition	O	O
in	O	O
which	O	O
severe	O	O
urogenital	B-Disease	D014564
aberrations	I-Disease	D014564
result	O	O
in	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
pseudohermaphroditism	B-Disease	D012734
,	O	O
and	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
(	O	O
nephroblastoma	B-Disease	D009396
)	O	O
.	O	O

To	O	O
investigate	O	O
its	O	O
possible	O	O
role	O	O
,	O	O
we	O	O
have	O	O
analyzed	O	O
the	O	O
coding	O	O
exons	O	O
of	O	O
the	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
suppressor	O	O
gene	O	O
(	O	O
WT1	O	O
)	O	O
for	O	O
germline	O	O
mutations	O	O
.	O	O

In	O	O
ten	O	O
independent	O	O
cases	O	O
of	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
,	O	O
point	O	O
mutations	O	O
in	O	O
the	O	O
zinc	O	O
finger	O	O
domains	O	O
of	O	O
one	O	O
WT1	O	O
gene	O	O
copy	O	O
were	O	O
found	O	O
.	O	O

Nine	O	O
of	O	O
these	O	O
mutations	O	O
are	O	O
found	O	O
within	O	O
exon	O	O
9	O	O
(	O	O
zinc	O	O
finger	O	O
III	O	O
)	O	O
;	O	O
the	O	O
remaining	O	O
mutation	O	O
is	O	O
in	O	O
exon	O	O
8	O	O
(	O	O
zinc	O	O
finger	O	O
II	O	O
)	O	O
.	O	O

These	O	O
mutations	O	O
directly	O	O
affect	O	O
DNA	O	O
sequence	O	O
recognition	O	O
.	O	O

In	O	O
two	O	O
families	O	O
analyzed	O	O
,	O	O
the	O	O
mutations	O	O
were	O	O
shown	O	O
to	O	O
arise	O	O
de	O	O
novo	O	O
.	O	O

Wilms	B-Disease	D009396
tumors	I-Disease	D009396
from	O	O
three	O	O
individuals	O	O
and	O	O
one	O	O
juvenile	O	O
granulosa	O	O
cell	O	O
tumor	B-Disease	D009369
demonstrate	O	O
reduction	O	O
to	O	O
homozygosity	O	O
for	O	O
the	O	O
mutated	O	O
WT1	O	O
allele	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
evidence	O	O
of	O	O
a	O	O
direct	O	O
role	O	O
for	O	O
WT1	O	O
in	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
and	O	O
thus	O	O
urogenital	O	O
system	O	O
development	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
feline	O	O
beta	B-Disease	D016538
-	I-Disease	D016538
glucuronidase	I-Disease	D016538
deficiency	I-Disease	D016538
:	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
mucopolysaccharidosis	B-Disease	D016538
VII	I-Disease	D016538
.	O	O

A	O	O
family	O	O
of	O	O
domestic	O	O
cats	O	O
was	O	O
found	O	O
that	O	O
exhibited	O	O
clinical	O	O
and	O	O
biochemical	O	O
abnormalities	O	O
consistent	O	O
with	O	O
mucopolysaccharidosis	B-Disease	D016538
VII	I-Disease	D016538
,	O	O
an	O	O
autosomal	B-Disease	D016464
recessive	I-Disease	D016464
lysosomal	I-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
beta	B-Disease	D016538
-	I-Disease	D016538
glucuronidase	I-Disease	D016538
deficiency	I-Disease	D016538
.	O	O

beta	O	O
-	O	O
Glucuronidase	O	O
activity	O	O
was	O	O
undetectable	O	O
in	O	O
affected	O	O
cat	O	O
fibroblasts	O	O
and	O	O
restored	O	O
by	O	O
retroviral	O	O
gene	O	O
transfer	O	O
of	O	O
rat	O	O
beta	O	O
-	O	O
glucuronidase	O	O
cDNA	O	O
.	O	O

beta	O	O
-	O	O
Glucuronidase	O	O
mRNA	O	O
was	O	O
normal	O	O
in	O	O
affected	O	O
cat	O	O
testis	O	O
by	O	O
Northern	O	O
blot	O	O
analysis	O	O
.	O	O

Normal	O	O
feline	O	O
beta	O	O
-	O	O
glucuronidase	O	O
cDNA	O	O
was	O	O
cloned	O	O
and	O	O
characterized	O	O
,	O	O
and	O	O
amplified	O	O
from	O	O
affected	O	O
cat	O	O
fibroblasts	O	O
by	O	O
reverse	O	O
transcription	O	O
coupled	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

There	O	O
was	O	O
a	O	O
G	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transition	O	O
in	O	O
the	O	O
affected	O	O
cat	O	O
cDNA	O	O
that	O	O
predicted	O	O
an	O	O
E351K	O	O
substitution	O	O
,	O	O
destroyed	O	O
a	O	O
BssSI	O	O
site	O	O
,	O	O
and	O	O
eliminated	O	O
GUSB	O	O
enzymatic	O	O
activity	O	O
in	O	O
expression	O	O
studies	O	O
.	O	O

Multiple	O	O
species	O	O
comparison	O	O
and	O	O
the	O	O
crystal	O	O
structure	O	O
of	O	O
human	O	O
beta	O	O
-	O	O
glucuronidase	O	O
indicated	O	O
that	O	O
E351	O	O
is	O	O
a	O	O
highly	O	O
conserved	O	O
residue	O	O
most	O	O
likely	O	O
essential	O	O
in	O	O
maintenance	O	O
of	O	O
the	O	O
enzymes	O	O
conformation	O	O
.	O	O

BssSI	O	O
digestion	O	O
of	O	O
polymerase	O	O
chain	O	O
reaction	O	O
products	O	O
amplified	O	O
from	O	O
genomic	O	O
DNA	O	O
indicated	O	O
that	O	O
affected	O	O
cats	O	O
were	O	O
homozygous	O	O
and	O	O
cats	O	O
with	O	O
half	O	O
-	O	O
normal	O	O
beta	O	O
-	O	O
glucuronidase	O	O
activity	O	O
were	O	O
heterozygous	O	O
for	O	O
the	O	O
missense	O	O
mutation	O	O
.	O	O

Carriers	O	O
identified	O	O
in	O	O
this	O	O
manner	O	O
produced	O	O
affected	O	O
kittens	O	O
in	O	O
prospective	O	O
breedings	O	O
,	O	O
and	O	O
a	O	O
feline	O	O
MPS	B-Disease	D016538
VII	I-Disease	D016538
breeding	O	O
colony	O	O
has	O	O
been	O	O
established	O	O
.	O	O

.	O	O

Loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
in	O	O
the	O	O
cathepsin	O	O
C	O	O
gene	O	O
result	O	O
in	O	O
periodontal	B-Disease	D010510
disease	I-Disease	D010510
and	O	O
palmoplantar	B-Disease	D007645
keratosis	I-Disease	D007645
.	O	O

Papillon	B-Disease	D010214
-	I-Disease	D010214
Lefevre	I-Disease	D010214
syndrome	I-Disease	D010214
,	O	O
or	O	O
keratosis	B-Disease	D007645
palmoplantaris	I-Disease	D007645
with	O	O
periodontopathia	B-Disease	D010510
(	O	O
PLS	B-Disease	D010214
,	O	O
MIM	O	O
245000	O	O
)	O	O
,	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
that	O	O
is	O	O
mainly	O	O
ascertained	O	O
by	O	O
dentists	O	O
because	O	O
of	O	O
the	O	O
severe	O	O
periodontitis	B-Disease	D010518
that	O	O
afflicts	O	O
patients	O	O
.	O	O

Both	O	O
the	O	O
deciduous	O	O
and	O	O
permanent	O	O
dentitions	O	O
are	O	O
affected	O	O
,	O	O
resulting	O	O
in	O	O
premature	O	O
tooth	B-Disease	D016388
loss	I-Disease	D016388
.	O	O

Palmoplantar	B-Disease	D007645
keratosis	I-Disease	D007645
,	O	O
varying	O	O
from	O	O
mild	O	O
psoriasiform	O	O
scaly	O	O
skin	O	O
to	O	O
overt	O	O
hyperkeratosis	B-Disease	D017488
,	O	O
typically	O	O
develops	O	O
within	O	O
the	O	O
first	O	O
three	O	O
years	O	O
of	O	O
life	O	O
.	O	O

Keratosis	B-Disease	D007642
also	O	O
affects	O	O
other	O	O
sites	O	O
such	O	O
as	O	O
elbows	O	O
and	O	O
knees	O	O
.	O	O

Most	O	O
PLS	B-Disease	D010214
patients	O	O
display	O	O
both	O	O
periodontitis	B-Disease	D010518
and	O	O
hyperkeratosis	B-Disease	D017488
.	O	O

Some	O	O
patients	O	O
have	O	O
only	O	O
palmoplantar	B-Disease	D007645
keratosis	I-Disease	D007645
or	O	O
periodontitis	B-Disease	D010518
,	O	O
and	O	O
in	O	O
rare	O	O
individuals	O	O
the	O	O
periodontitis	B-Disease	D010518
is	O	O
mild	O	O
and	O	O
of	O	O
late	O	O
onset	O	O
.	O	O

The	O	O
PLS	B-Disease	D010214
locus	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
chromosome	O	O
11q14	O	O
-	O	O
q21	O	O
(	O	O
refs	O	O
7	O	O
,	O	O
8	O	O
,	O	O
9	O	O
)	O	O
.	O	O

Using	O	O
homozygosity	O	O
mapping	O	O
in	O	O
eight	O	O
small	O	O
consanguineous	O	O
families	O	O
,	O	O
we	O	O
have	O	O
narrowed	O	O
the	O	O
candidate	O	O
region	O	O
to	O	O
a	O	O
1	O	O
.	O	O

2	O	O
-	O	O
cM	O	O
interval	O	O
between	O	O
D11S4082	O	O
and	O	O
D11S931	O	O
.	O	O

The	O	O
gene	O	O
(	O	O
CTSC	O	O
)	O	O
encoding	O	O
the	O	O
lysosomal	O	O
protease	O	O
cathepsin	O	O
C	O	O
(	O	O
or	O	O
dipeptidyl	O	O
aminopeptidase	O	O
I	O	O
)	O	O
lies	O	O
within	O	O
this	O	O
interval	O	O
.	O	O

We	O	O
defined	O	O
the	O	O
genomic	O	O
structure	O	O
of	O	O
CTSC	O	O
and	O	O
found	O	O
mutations	O	O
in	O	O
all	O	O
eight	O	O
families	O	O
.	O	O

In	O	O
two	O	O
of	O	O
these	O	O
families	O	O
we	O	O
used	O	O
a	O	O
functional	O	O
assay	O	O
to	O	O
demonstrate	O	O
an	O	O
almost	O	O
total	O	O
loss	O	O
of	O	O
cathepsin	O	O
C	O	O
activity	O	O
in	O	O
PLS	B-Disease	D010214
patients	O	O
and	O	O
reduced	O	O
activity	O	O
in	O	O
obligate	O	O
carriers	O	O
.	O	O

Brca1	B-Disease	OMIM:604370
deficiency	I-Disease	OMIM:604370
results	O	O
in	O	O
early	O	O
embryonic	B-Disease	D020964
lethality	I-Disease	D020964
characterized	O	O
by	O	O
neuroepithelial	B-Disease	D018302
abnormalities	I-Disease	D018302
.	O	O

The	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
has	O	O
been	O	O
cloned	O	O
and	O	O
shown	O	O
to	O	O
encode	O	O
a	O	O
zinc	O	O
-	O	O
finger	O	O
protein	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

Mutations	O	O
in	O	O
BRCA1	O	O
account	O	O
for	O	O
at	O	O
least	O	O
80	O	O
%	O	O
of	O	O
families	O	O
with	O	O
both	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
as	O	O
well	O	O
as	O	O
some	O	O
non	O	O
-	O	O
familial	O	O
sporadic	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
.	O	O

The	O	O
loss	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
BRCA1	O	O
in	O	O
tumours	B-Disease	D009369
of	O	O
individuals	O	O
carrying	O	O
one	O	O
nonfunctional	O	O
BRCA1	O	O
allele	O	O
suggests	O	O
that	O	O
BRCA1	O	O
encodes	O	O
a	O	O
tumour	B-Disease	D009369
suppressor	O	O
that	O	O
may	O	O
inhibit	O	O
the	O	O
proliferation	O	O
of	O	O
mammary	O	O
epithelial	O	O
cells	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
BRCA1	O	O
in	O	O
normal	O	O
tissue	O	O
growth	O	O
and	O	O
differentiation	O	O
,	O	O
and	O	O
to	O	O
generate	O	O
a	O	O
potential	O	O
model	O	O
for	O	O
the	O	O
cancer	B-Disease	D009369
susceptibility	O	O
associated	O	O
with	O	O
loss	O	O
of	O	O
BRCA1	O	O
function	O	O
,	O	O
we	O	O
have	O	O
created	O	O
a	O	O
mouse	O	O
line	O	O
carrying	O	O
a	O	O
mutation	O	O
in	O	O
one	O	O
Brca1	O	O
allele	O	O
.	O	O

Analysis	O	O
of	O	O
mice	O	O
homozygous	O	O
for	O	O
the	O	O
mutant	O	O
allele	O	O
indicate	O	O
that	O	O
Brca1	O	O
is	O	O
critical	O	O
for	O	O
normal	O	O
development	O	O
,	O	O
as	O	O
these	O	O
mice	O	O
died	O	O
in	O	O
utero	O	O
between	O	O
10	O	O
and	O	O
13	O	O
days	O	O
of	O	O
gestation	O	O
(	O	O
E10	O	O
-	O	O
E13	O	O
)	O	O
.	O	O

Abnormalities	O	O
in	O	O
Brca1	B-Disease	OMIM:604370
-	I-Disease	OMIM:604370
deficient	I-Disease	OMIM:604370
embryos	O	O
were	O	O
most	O	O
evident	O	O
in	O	O
the	O	O
neural	O	O
tube	O	O
,	O	O
with	O	O
40	O	O
%	O	O
of	O	O
the	O	O
embryos	O	O
presenting	O	O
with	O	O
varying	O	O
degrees	O	O
of	O	O
spina	B-Disease	D016135
bifida	I-Disease	D016135
and	O	O
anencephaly	B-Disease	D000757
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
neuroepithelium	O	O
in	O	O
Brca1	B-Disease	OMIM:604370
-	I-Disease	OMIM:604370
deficient	I-Disease	OMIM:604370
embryos	O	O
appeared	O	O
disorganized	O	O
,	O	O
with	O	O
signs	O	O
of	O	O
both	O	O
rapid	O	O
proliferation	O	O
and	O	O
excessive	O	O
cell	O	O
death	O	O
.	O	O

.	O	O

X	B-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
recessive	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
.	O	O

A	O	O
Saudi	O	O
Arab	O	O
boy	O	O
presented	O	O
in	O	O
early	O	O
childhood	O	O
with	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
morphologically	O	O
large	O	O
and	O	O
normal	O	O
sized	O	O
platelets	O	O
,	O	O
increased	O	O
mean	O	O
platelet	O	O
volume	O	O
,	O	O
and	O	O
a	O	O
hypermegakaryocytic	O	O
bone	O	O
marrow	O	O
.	O	O

There	O	O
was	O	O
no	O	O
clinical	O	O
and	O	O
laboratory	O	O
evidence	O	O
of	O	O
any	O	O
significant	O	O
immunological	B-Disease	D007154
abnormalities	I-Disease	D007154
.	O	O

Similar	O	O
findings	O	O
in	O	O
two	O	O
other	O	O
brothers	O	O
suggested	O	O
strongly	O	O
that	O	O
they	O	O
were	O	O
all	O	O
suffering	O	O
from	O	O
an	O	O
X	B-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
recessive	I-Disease	OMIM:313900
thrombocytopenic	I-Disease	OMIM:313900
disorder	I-Disease	OMIM:313900
.	O	O

Results	O	O
of	O	O
DNA	O	O
analysis	O	O
with	O	O
the	O	O
probe	O	O
M27	O	O
beta	O	O
are	O	O
consistent	O	O
with	O	O
X	O	O
linkage	O	O
and	O	O
indicate	O	O
also	O	O
that	O	O
the	O	O
locus	O	O
of	O	O
the	O	O
relevant	O	O
gene	O	O
lies	O	O
close	O	O
to	O	O
or	O	O
is	O	O
identical	O	O
to	O	O
the	O	O
locus	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
.	O	O

Because	O	O
of	O	O
various	O	O
features	O	O
which	O	O
include	O	O
the	O	O
presence	O	O
of	O	O
large	O	O
and	O	O
normal	O	O
sized	O	O
platelets	O	O
(	O	O
rather	O	O
than	O	O
small	O	O
platelets	O	O
)	O	O
and	O	O
freedom	O	O
from	O	O
significant	O	O
immune	B-Disease	D007154
deficiencies	I-Disease	D007154
,	O	O
it	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
X	B-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
recessive	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
in	O	O
this	O	O
family	O	O
is	O	O
an	O	O
isolated	O	O
entity	O	O
quite	O	O
distinct	O	O
from	O	O
the	O	O
classical	O	O
WAS	B-Disease	D014923
phenotype	O	O
.	O	O

However	O	O
,	O	O
a	O	O
modified	O	O
expression	O	O
of	O	O
the	O	O
WAS	B-Disease	D014923
gene	O	O
producing	O	O
a	O	O
mild	O	O
phenotypic	O	O
variant	O	O
cannot	O	O
be	O	O
excluded	O	O
entirely	O	O
.	O	O

.	O	O

Genetics	O	O
of	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
:	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
with	O	O
high	O	O
gene	O	O
frequency	O	O
in	O	O
Sephardim	O	O
of	O	O
Moroccan	O	O
origin	O	O
.	O	O

We	O	O
described	O	O
6	O	O
patients	O	O
(	O	O
from	O	O
3	O	O
families	O	O
)	O	O
affected	O	O
with	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
.	O	O

All	O	O
are	O	O
Sephardic	O	O
Jews	O	O
of	O	O
Moroccan	O	O
extraction	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
small	O	O
number	O	O
of	O	O
CTX	B-Disease	D019294
patients	O	O
diagnosed	O	O
in	O	O
the	O	O
world	O	O
(	O	O
a	O	O
total	O	O
of	O	O
50	O	O
including	O	O
our	O	O
6	O	O
patients	O	O
)	O	O
,	O	O
we	O	O
are	O	O
probably	O	O
dealing	O	O
with	O	O
an	O	O
ethnic	O	O
subgroup	O	O
with	O	O
a	O	O
high	O	O
CTX	B-Disease	D019294
gene	O	O
frequency	O	O
,	O	O
which	O	O
we	O	O
have	O	O
estimated	O	O
to	O	O
be	O	O
1	O	O
/	O	O
108	O	O
.	O	O

Since	O	O
there	O	O
are	O	O
differences	O	O
in	O	O
expression	O	O
in	O	O
this	O	O
disease	O	O
,	O	O
we	O	O
recommend	O	O
cholestanol	O	O
study	O	O
in	O	O
cases	O	O
of	O	O
undiagnosed	O	O
cataract	B-Disease	D002386
or	O	O
tendinous	B-Disease	D014973
xanthomas	I-Disease	D014973
in	O	O
childhood	O	O
or	O	O
early	O	O
adolescence	O	O
.	O	O

The	O	O
diagnosis	O	O
in	O	O
CTX	B-Disease	D019294
is	O	O
important	O	O
not	O	O
only	O	O
for	O	O
genetic	O	O
counseling	O	O
,	O	O
but	O	O
also	O	O
in	O	O
veiw	O	O
of	O	O
possible	O	O
treatment	O	O
.	O	O

.	O	O

A	O	O
missense	O	O
mutation	O	O
in	O	O
the	O	O
cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
gene	O	O
with	O	O
possible	O	O
dominant	O	O
effects	O	O
on	O	O
plasma	O	O
high	O	O
density	O	O
lipoproteins	O	O
.	O	O

Plasma	O	O
HDL	O	O
are	O	O
a	O	O
negative	O	O
risk	O	O
factor	O	O
for	O	O
atherosclerosis	B-Disease	D050197
.	O	O

Cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
(	O	O
CETP	O	O
;	O	O
476	O	O
amino	O	O
acids	O	O
)	O	O
transfers	O	O
cholesteryl	O	O
ester	O	O
from	O	O
HDL	O	O
to	O	O
other	O	O
lipoproteins	O	O
.	O	O

Subjects	O	O
with	O	O
homozygous	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
caused	O	O
by	O	O
a	O	O
gene	O	O
splicing	O	O
defect	O	O
have	O	O
markedly	O	O
elevated	O	O
HDL	O	O
;	O	O
however	O	O
,	O	O
heterozygotes	O	O
have	O	O
only	O	O
mild	O	O
increases	O	O
in	O	O
HDL	O	O
.	O	O

We	O	O
describe	O	O
two	O	O
probands	O	O
with	O	O
a	O	O
CETP	O	O
missense	O	O
mutation	O	O
(	O	O
442	O	O
D	O	O
G	O	O
)	O	O
.	O	O

Although	O	O
heterozygous	O	O
,	O	O
they	O	O
have	O	O
threefold	O	O
increases	O	O
in	O	O
HDL	O	O
concentration	O	O
and	O	O
markedly	O	O
decreased	O	O
plasma	O	O
CETP	O	O
mass	O	O
and	O	O
activity	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
mutation	O	O
has	O	O
dominant	O	O
effects	O	O
on	O	O
CETP	O	O
and	O	O
HDL	O	O
in	O	O
vivo	O	O
.	O	O

Cellular	O	O
expression	O	O
of	O	O
mutant	O	O
cDNA	O	O
results	O	O
in	O	O
secretion	O	O
of	O	O
only	O	O
30	O	O
%	O	O
of	O	O
wild	O	O
type	O	O
CETP	O	O
activity	O	O
.	O	O

Moreover	O	O
,	O	O
coexpression	O	O
of	O	O
wild	O	O
type	O	O
and	O	O
mutant	O	O
cDNAs	O	O
leads	O	O
to	O	O
inhibition	O	O
of	O	O
wild	O	O
type	O	O
secretion	O	O
and	O	O
activity	O	O
.	O	O

The	O	O
dominant	O	O
effects	O	O
of	O	O
the	O	O
CETP	O	O
missense	O	O
mutation	O	O
during	O	O
cellular	O	O
expression	O	O
probably	O	O
explains	O	O
why	O	O
the	O	O
probands	O	O
have	O	O
markedly	O	O
increased	O	O
HDL	O	O
in	O	O
the	O	O
heterozygous	O	O
state	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
the	O	O
active	O	O
molecular	O	O
species	O	O
of	O	O
CETP	O	O
may	O	O
be	O	O
multimeric	O	O
.	O	O

.	O	O

Huntington	B-Disease	D006816
disease	I-Disease	D006816
:	O	O
no	O	O
evidence	O	O
for	O	O
locus	O	O
heterogeneity	O	O
.	O	O

A	O	O
total	O	O
of	O	O
63	O	O
families	O	O
with	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
were	O	O
examined	O	O
for	O	O
linkage	O	O
between	O	O
HD	B-Disease	D006816
and	O	O
G8	O	O
(	O	O
D4S10	O	O
)	O	O
.	O	O

The	O	O
families	O	O
included	O	O
57	O	O
Caucasian	O	O
,	O	O
four	O	O
Black	O	O
American	O	O
,	O	O
and	O	O
two	O	O
Japanese	O	O
.	O	O

The	O	O
combined	O	O
maximum	O	O
lod	O	O
score	O	O
was	O	O
87	O	O
.	O	O

69	O	O
at	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

04	O	O
(	O	O
99	O	O
%	O	O
confidence	O	O
interval	O	O
0	O	O
.	O	O

018	O	O
-	O	O
0	O	O
.	O	O

071	O	O
)	O	O
.	O	O

The	O	O
maximum	O	O
frequency	O	O
of	O	O
recombination	O	O
was	O	O
0	O	O
.	O	O

03	O	O
in	O	O
males	O	O
and	O	O
0	O	O
.	O	O

05	O	O
in	O	O
females	O	O
.	O	O

Fifty	O	O
-	O	O
seven	O	O
families	O	O
gave	O	O
positive	O	O
lod	O	O
scores	O	O
;	O	O
five	O	O
small	O	O
families	O	O
gave	O	O
mildly	O	O
negative	O	O
lod	O	O
scores	O	O
.	O	O

The	O	O
maximum	O	O
likelihood	O	O
estimate	O	O
of	O	O
alpha	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
linked	O	O
loci	O	O
,	O	O
was	O	O
1	O	O
.	O	O

0	O	O
with	O	O
a	O	O
lower	O	O
99	O	O
%	O	O
confidence	O	O
interval	O	O
of	O	O
0	O	O
.	O	O

88	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
there	O	O
is	O	O
only	O	O
one	O	O
HD	B-Disease	D006816
locus	O	O
,	O	O
although	O	O
a	O	O
second	O	O
rare	O	O
locus	O	O
cannot	O	O
be	O	O
ruled	O	O
out	O	O
.	O	O

Homozygous	O	O
and	O	O
heterozygous	O	O
deletions	O	O
of	O	O
the	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
gene	O	O
in	O	O
patients	O	O
and	O	O
carriers	O	O
of	O	O
severe	B-Disease	D056729
von	I-Disease	D056729
Willebrand	I-Disease	D056729
disease	I-Disease	D056729
.	O	O

Severe	B-Disease	D056729
von	I-Disease	D056729
Willebrand	I-Disease	D056729
disease	I-Disease	D056729
is	O	O
characterized	O	O
by	O	O
undetectable	O	O
or	O	O
trace	O	O
quantities	O	O
of	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
in	O	O
plasma	O	O
and	O	O
tissue	O	O
stores	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
genomic	O	O
DNA	O	O
of	O	O
10	O	O
affected	O	O
individuals	O	O
from	O	O
six	O	O
families	O	O
with	O	O
this	O	O
disorder	O	O
using	O	O
probes	O	O
from	O	O
the	O	O
5	O	O
and	O	O
3	O	O
ends	O	O
of	O	O
the	O	O
vWF	O	O
cDNA	O	O
and	O	O
with	O	O
a	O	O
probe	O	O
extending	O	O
from	O	O
the	O	O
5	O	O
end	O	O
into	O	O
the	O	O
central	O	O
region	O	O
.	O	O

Southern	O	O
blots	O	O
of	O	O
restriction	O	O
endonuclease	O	O
digests	O	O
and	O	O
gene	O	O
dosage	O	O
analysis	O	O
measurements	O	O
carried	O	O
out	O	O
with	O	O
quantitative	O	O
slot	O	O
blots	O	O
of	O	O
undigested	O	O
genomic	O	O
DNA	O	O
separated	O	O
these	O	O
patients	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
first	O	O
group	O	O
consisted	O	O
of	O	O
a	O	O
family	O	O
with	O	O
complete	O	O
homozygous	O	O
deletions	O	O
of	O	O
the	O	O
vWF	O	O
gene	O	O
in	O	O
the	O	O
four	O	O
probands	O	O
.	O	O

Gene	O	O
dosage	O	O
analysis	O	O
was	O	O
consistent	O	O
with	O	O
heterozygous	O	O
deletions	O	O
in	O	O
both	O	O
of	O	O
the	O	O
asymptomatic	O	O
parents	O	O
and	O	O
four	O	O
asymptomatic	O	O
siblings	O	O
of	O	O
this	O	O
kindred	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

The	O	O
second	O	O
group	O	O
was	O	O
comprised	O	O
of	O	O
a	O	O
family	O	O
in	O	O
which	O	O
there	O	O
was	O	O
a	O	O
complete	O	O
heterozygous	O	O
deletion	O	O
of	O	O
the	O	O
vWF	O	O
gene	O	O
in	O	O
the	O	O
proband	O	O
and	O	O
one	O	O
asymptomatic	O	O
parent	O	O
,	O	O
suggesting	O	O
that	O	O
a	O	O
different	O	O
type	O	O
of	O	O
genetic	B-Disease	D030342
abnormality	I-Disease	D030342
was	O	O
inherited	O	O
from	O	O
the	O	O
other	O	O
parent	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
patient	O	O
appeared	O	O
to	O	O
be	O	O
doubly	O	O
heterozygous	O	O
for	O	O
interacting	O	O
genetic	B-Disease	D030342
abnormalities	I-Disease	D030342
affecting	O	O
vWF	O	O
expression	O	O
.	O	O

In	O	O
the	O	O
third	O	O
group	O	O
,	O	O
no	O	O
gene	O	O
deletions	O	O
could	O	O
be	O	O
detected	O	O
.	O	O

Alloantibodies	O	O
developed	O	O
only	O	O
in	O	O
the	O	O
kindred	O	O
with	O	O
homozygous	O	O
deletions	O	O
.	O	O

These	O	O
techniques	O	O
should	O	O
prove	O	O
useful	O	O
in	O	O
identifying	O	O
carriers	O	O
of	O	O
severe	B-Disease	D056729
von	I-Disease	D056729
Willebrand	I-Disease	D056729
disease	I-Disease	D056729
and	O	O
also	O	O
in	O	O
defining	O	O
patients	O	O
predictably	O	O
at	O	O
risk	O	O
of	O	O
developing	O	O
alloantibodies	O	O
to	O	O
vWF	O	O
.	O	O

Spectrum	O	O
of	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
RB1	O	O
gene	O	O
:	O	O
a	O	O
study	O	O
of	O	O
232	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D012175
and	I-Disease	D012175
non	I-Disease	D012175
hereditary	I-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
RB1	O	O
gene	O	O
confer	O	O
hereditary	O	O
predisposition	O	O
to	O	O
retinoblastoma	B-Disease	D012175
.	O	O

We	O	O
have	O	O
performed	O	O
a	O	O
mutation	O	O
survey	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
in	O	O
232	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D012175
or	I-Disease	D012175
non	I-Disease	D012175
hereditary	I-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

We	O	O
systematically	O	O
explored	O	O
all	O	O
27	O	O
exons	O	O
and	O	O
flanking	O	O
sequences	O	O
as	O	O
well	O	O
as	O	O
the	O	O
promotor	O	O
.	O	O

All	O	O
types	O	O
of	O	O
point	O	O
mutations	O	O
are	O	O
represented	O	O
and	O	O
are	O	O
found	O	O
unequally	O	O
distributed	O	O
along	O	O
the	O	O
RB1	O	O
gene	O	O
sequence	O	O
.	O	O

In	O	O
the	O	O
population	O	O
we	O	O
studied	O	O
,	O	O
exons	O	O
3	O	O
,	O	O
8	O	O
,	O	O
18	O	O
and	O	O
19	O	O
are	O	O
preferentially	O	O
altered	O	O
.	O	O

The	O	O
range	O	O
of	O	O
frequency	O	O
of	O	O
detection	O	O
of	O	O
germline	O	O
mutations	O	O
is	O	O
about	O	O
20	O	O
%	O	O
,	O	O
indicating	O	O
that	O	O
other	O	O
mechanisms	O	O
of	O	O
inactivation	O	O
of	O	O
RB1	O	O
should	O	O
be	O	O
involved	O	O
.	O	O

The	O	O
spectrum	O	O
of	O	O
mutations	O	O
presented	O	O
here	O	O
should	O	O
help	O	O
to	O	O
improve	O	O
the	O	O
clinical	O	O
management	O	O
of	O	O
retinoblastoma	B-Disease	D012175
and	O	O
to	O	O
understand	O	O
the	O	O
molecular	O	O
mechanisms	O	O
leading	O	O
to	O	O
tumorigenesis	O	O
.	O	O

.	O	O

Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
:	O	O
an	O	O
X	B-Disease	D020279
-	I-Disease	D020279
linked	I-Disease	D020279
neurologic	I-Disease	D020279
disorder	I-Disease	D020279
of	I-Disease	D020279
myelin	I-Disease	D020279
metabolism	I-Disease	D020279
with	O	O
a	O	O
novel	O	O
mutation	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
proteolipid	O	O
protein	O	O
.	O	O

The	O	O
nosology	O	O
of	O	O
the	O	O
inborn	B-Disease	D020279
errors	I-Disease	D020279
of	I-Disease	D020279
myelin	I-Disease	D020279
metabolism	I-Disease	D020279
has	O	O
been	O	O
stymied	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
molecular	O	O
genetic	O	O
analysis	O	O
.	O	O

Historically	O	O
,	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
has	O	O
encompassed	O	O
a	O	O
host	O	O
of	O	O
neurologic	B-Disease	D009422
disorders	I-Disease	D009422
that	O	O
present	O	O
with	O	O
a	O	O
deficit	B-Disease	D003711
of	I-Disease	D003711
myelin	I-Disease	D003711
,	O	O
the	O	O
membrane	O	O
elaborated	O	O
by	O	O
glial	O	O
cells	O	O
that	O	O
encircles	O	O
and	O	O
successively	O	O
enwraps	O	O
axons	O	O
.	O	O

We	O	O
describe	O	O
here	O	O
a	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
pedigree	O	O
of	O	O
the	O	O
classical	O	O
type	O	O
,	O	O
with	O	O
X	O	O
-	O	O
linked	O	O
inheritance	O	O
,	O	O
a	O	O
typical	O	O
clinical	O	O
progression	O	O
,	O	O
and	O	O
a	O	O
pathologic	O	O
loss	O	O
of	O	O
myelinating	O	O
cells	O	O
and	O	O
myelin	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

To	O	O
discriminate	O	O
variants	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
,	O	O
a	O	O
set	O	O
of	O	O
oligonucleotide	O	O
primers	O	O
was	O	O
constructed	O	O
to	O	O
polymerase	O	O
-	O	O
chain	O	O
-	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
amplify	O	O
and	O	O
sequence	O	O
the	O	O
gene	O	O
encoding	O	O
proteolipid	O	O
protein	O	O
(	O	O
PLP	O	O
)	O	O
,	O	O
a	O	O
structural	O	O
protein	O	O
that	O	O
comprises	O	O
half	O	O
of	O	O
the	O	O
protein	O	O
of	O	O
the	O	O
myelin	O	O
sheath	O	O
.	O	O

The	O	O
PLP	O	O
gene	O	O
in	O	O
one	O	O
of	O	O
two	O	O
affected	O	O
males	O	O
and	O	O
the	O	O
carrier	O	O
mother	O	O
of	O	O
this	O	O
family	O	O
exhibited	O	O
a	O	O
single	O	O
base	O	O
difference	O	O
in	O	O
the	O	O
more	O	O
than	O	O
2	O	O
kb	O	O
of	O	O
the	O	O
PLP	O	O
gene	O	O
sequenced	O	O
,	O	O
a	O	O
C	O	O
-	O	O
-	O	O
-	O	O
-	O	O
T	O	O
transition	O	O
that	O	O
would	O	O
create	O	O
a	O	O
serine	O	O
substitution	O	O
for	O	O
proline	O	O
at	O	O
the	O	O
carboxy	O	O
end	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

Our	O	O
results	O	O
delineate	O	O
the	O	O
clinical	O	O
features	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
,	O	O
define	O	O
the	O	O
possible	O	O
molecular	O	O
pathology	O	O
of	O	O
this	O	O
dysmyelinating	B-Disease	D003711
disorder	I-Disease	D003711
,	O	O
and	O	O
address	O	O
the	O	O
molecular	O	O
classification	O	O
of	O	O
inborn	B-Disease	D020279
errors	I-Disease	D020279
of	I-Disease	D020279
myelin	I-Disease	D020279
metabolism	I-Disease	D020279
.	O	O

Patients	O	O
with	O	O
the	O	O
classical	O	O
form	O	O
(	O	O
type	O	O
I	O	O
)	O	O
and	O	O
the	O	O
more	O	O
severely	O	O
affected	O	O
,	O	O
connatal	O	O
variant	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
type	O	O
II	O	O
)	O	O
would	O	O
be	O	O
predicted	O	O
to	O	O
display	O	O
mutation	O	O
at	O	O
the	O	O
PLP	O	O
locus	O	O
.	O	O

The	O	O
other	O	O
variants	O	O
(	O	O
types	O	O
III	O	O
-	O	O
VI	O	O
)	O	O
,	O	O
which	O	O
have	O	O
sometimes	O	O
been	O	O
categorized	O	O
as	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
,	O	O
may	O	O
represent	O	O
mutations	O	O
in	O	O
genes	O	O
encoding	O	O
other	O	O
structural	O	O
myelin	O	O
proteins	O	O
or	O	O
proteins	O	O
critical	O	O
to	O	O
myelination	O	O
.	O	O

.	O	O

CAG	O	O
expansions	O	O
in	O	O
a	O	O
novel	O	O
gene	O	O
for	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
at	O	O
chromosome	O	O
14q32	O	O
.	O	O

1	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
novel	O	O
gene	O	O
containing	O	O
CAG	O	O
repeats	O	O
and	O	O
mapped	O	O
it	O	O
to	O	O
chromosome	O	O
14q32	O	O
.	O	O

1	O	O
,	O	O
the	O	O
genetic	O	O
locus	O	O
for	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
.	O	O

In	O	O
normal	O	O
individuals	O	O
the	O	O
gene	O	O
contains	O	O
between	O	O
13	O	O
and	O	O
36	O	O
CAG	O	O
repeats	O	O
,	O	O
whereas	O	O
most	O	O
of	O	O
the	O	O
clinically	O	O
diagnosed	O	O
patients	O	O
and	O	O
all	O	O
of	O	O
the	O	O
affected	O	O
members	O	O
of	O	O
a	O	O
family	O	O
with	O	O
the	O	O
clinical	O	O
and	O	O
pathological	O	O
diagnosis	O	O
of	O	O
MJD	B-Disease	D017827
show	O	O
expansion	O	O
of	O	O
the	O	O
repeat	O	O
-	O	O
number	O	O
(	O	O
from	O	O
68	O	O
-	O	O
79	O	O
)	O	O
.	O	O

Southern	O	O
blot	O	O
analyses	O	O
and	O	O
genomic	O	O
cloning	O	O
demonstrates	O	O
the	O	O
existence	O	O
of	O	O
related	O	O
genes	O	O
.	O	O

These	O	O
results	O	O
raise	O	O
the	O	O
possibility	O	O
that	O	O
similar	O	O
abnormalities	O	O
in	O	O
related	O	O
genes	O	O
may	O	O
give	O	O
rise	O	O
to	O	O
diseases	O	O
similar	O	O
to	O	O
MJD	B-Disease	D017827
.	O	O

Conservation	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
in	O	O
mice	O	O
and	O	O
humans	O	O
.	O	O

A	O	O
portion	O	O
of	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
transcript	O	O
from	O	O
human	O	O
fetal	O	O
skeletal	O	O
muscle	O	O
and	O	O
mouse	O	O
adult	O	O
heart	O	O
was	O	O
sequenced	O	O
,	O	O
representing	O	O
approximately	O	O
25	O	O
percent	O	O
of	O	O
the	O	O
total	O	O
,	O	O
14	O	O
-	O	O
kb	O	O
DMD	B-Disease	D020388
transcript	O	O
.	O	O

The	O	O
nucleic	O	O
acid	O	O
and	O	O
predicted	O	O
amino	O	O
acid	O	O
sequences	O	O
from	O	O
the	O	O
two	O	O
species	O	O
are	O	O
nearly	O	O
90	O	O
percent	O	O
homologous	O	O
.	O	O

The	O	O
amino	O	O
acid	O	O
sequence	O	O
that	O	O
is	O	O
predicted	O	O
from	O	O
this	O	O
portion	O	O
of	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
indicates	O	O
that	O	O
the	O	O
protein	O	O
product	O	O
might	O	O
serve	O	O
a	O	O
structural	O	O
role	O	O
in	O	O
muscle	O	O
,	O	O
but	O	O
the	O	O
abundance	O	O
and	O	O
tissue	O	O
distribution	O	O
of	O	O
the	O	O
messenger	O	O
RNA	O	O
suggests	O	O
that	O	O
the	O	O
DMD	B-Disease	D020388
protein	O	O
is	O	O
not	O	O
nebulin	O	O
.	O	O

.	O	O

Deficiency	B-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
murine	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
(	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
)	I-Disease	OMIM:609536
.	O	O

A	O	O
2	O	O
-	O	O
base	O	O
pair	O	O
gene	O	O
deletion	O	O
in	O	O
a	O	O
5	O	O
'	O	O
-	O	O
exon	O	O
.	O	O

To	O	O
ascertain	O	O
the	O	O
molecular	O	O
mechanism	O	O
that	O	O
causes	O	O
murine	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
,	O	O
genomic	O	O
and	O	O
cDNA	O	O
libraries	O	O
were	O	O
constructed	O	O
from	O	O
mouse	O	O
liver	O	O
DNA	O	O
and	O	O
mRNA	O	O
employing	O	O
the	O	O
congenic	O	O
strains	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
nSnJ	O	O
and	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
oSnJ	O	O
that	O	O
are	O	O
sufficient	O	O
and	O	O
deficient	B-Disease	OMIM:609536
for	I-Disease	OMIM:609536
C5	I-Disease	OMIM:609536
,	O	O
respectively	O	O
.	O	O

Genomic	O	O
fragments	O	O
were	O	O
isolated	O	O
which	O	O
correspond	O	O
to	O	O
PvuII	O	O
and	O	O
HindIII	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
associated	O	O
with	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

Sequence	O	O
analyses	O	O
demonstrated	O	O
that	O	O
each	O	O
of	O	O
these	O	O
polymorphisms	O	O
resulted	O	O
from	O	O
single	O	O
base	O	O
pair	O	O
substitutions	O	O
and	O	O
that	O	O
neither	O	O
substitution	O	O
would	O	O
probably	O	O
cause	O	O
or	O	O
contribute	O	O
to	O	O
the	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

Sequence	O	O
analyses	O	O
of	O	O
C5	O	O
sufficient	O	O
and	O	O
deficient	O	O
cDNAs	O	O
revealed	O	O
a	O	O
2	O	O
base	O	O
-	O	O
pair	O	O
deletion	O	O
in	O	O
the	O	O
deficient	O	O
cDNAs	O	O
.	O	O

The	O	O
"	O	O
TA	O	O
"	O	O
deletion	O	O
was	O	O
located	O	O
near	O	O
the	O	O
5	O	O
end	O	O
of	O	O
the	O	O
cDNA	O	O
.	O	O

This	O	O
deletion	O	O
shifts	O	O
the	O	O
reading	O	O
frame	O	O
of	O	O
the	O	O
C5	O	O
mRNA	O	O
so	O	O
that	O	O
the	O	O
termination	O	O
codon	O	O
UGA	O	O
is	O	O
present	O	O
4	O	O
base	O	O
pairs	O	O
downstream	O	O
from	O	O
the	O	O
deletion	O	O
.	O	O

Genomic	O	O
DNA	O	O
was	O	O
amplified	O	O
and	O	O
sequenced	O	O
corresponding	O	O
to	O	O
the	O	O
area	O	O
surrounding	O	O
the	O	O
2	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
.	O	O

Six	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
strains	O	O
,	O	O
A	O	O
/	O	O
HeJ	O	O
,	O	O
AKR	O	O
/	O	O
J	O	O
,	O	O
DBA	O	O
/	O	O
2J	O	O
,	O	O
NZB	O	O
/	O	O
B1NJ	O	O
,	O	O
SWR	O	O
/	O	O
J	O	O
,	O	O
and	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
oSnJ	O	O
,	O	O
and	O	O
four	O	O
C5	O	O
-	O	O
sufficient	O	O
strains	O	O
,	O	O
Balb	O	O
/	O	O
CJ	O	O
,	O	O
C57Bl	O	O
/	O	O
6J	O	O
,	O	O
DBA	O	O
/	O	O
1J	O	O
,	O	O
and	O	O
B10	O	O
.	O	O

D2	O	O
/	O	O
nSnJ	O	O
,	O	O
were	O	O
analyzed	O	O
.	O	O

The	O	O
sequencing	O	O
data	O	O
revealed	O	O
that	O	O
the	O	O
2	O	O
base	O	O
pairs	O	O
were	O	O
deleted	O	O
from	O	O
the	O	O
C5	O	O
gene	O	O
of	O	O
each	O	O
deficient	O	O
mouse	O	O
tested	O	O
but	O	O
not	O	O
from	O	O
the	O	O
C5	O	O
gene	O	O
of	O	O
any	O	O
sufficient	O	O
mouse	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
1	O	O
)	O	O
there	O	O
is	O	O
an	O	O
identical	O	O
2	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
in	O	O
an	O	O
exon	O	O
of	O	O
the	O	O
C5	O	O
gene	O	O
in	O	O
several	O	O
different	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
mouse	O	O
strains	O	O
;	O	O
2	O	O
)	O	O
the	O	O
mRNA	O	O
transcribed	O	O
from	O	O
the	O	O
C5D	O	O
gene	O	O
retains	O	O
this	O	O
deletion	O	O
;	O	O
and	O	O
3	O	O
)	O	O
this	O	O
mutation	O	O
should	O	O
result	O	O
in	O	O
C5	B-Disease	OMIM:609536
protein	I-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

Recurrent	O	O
meningitis	B-Disease	D008581
in	O	O
a	O	O
patient	O	O
with	O	O
congenital	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
complement	I-Disease	OMIM:613825
.	O	O

First	O	O
case	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
in	O	O
Europe	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
first	O	O
cases	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
in	O	O
Europe	O	O
that	O	O
were	O	O
detected	O	O
in	O	O
a	O	O
Swiss	O	O
family	O	O
,	O	O
of	O	O
which	O	O
two	O	O
members	O	O
-	O	O
-	O	O
one	O	O
with	O	O
a	O	O
complete	O	O
deficiency	O	O
and	O	O
the	O	O
other	O	O
with	O	O
approximately	O	O
half	O	O
-	O	O
normal	O	O
C9	O	O
levels	O	O
-	O	O
-	O	O
experienced	O	O
bacterial	B-Disease	D016920
meningitis	I-Disease	D016920
.	O	O

The	O	O
index	O	O
patient	O	O
,	O	O
a	O	O
56	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
man	O	O
with	O	O
a	O	O
history	O	O
of	O	O
purulent	B-Disease	D008586
meningitis	I-Disease	D008586
at	O	O
the	O	O
age	O	O
of	O	O
23	O	O
years	O	O
,	O	O
presented	O	O
with	O	O
an	O	O
acute	B-Disease	D008585
meningococcal	I-Disease	D008585
meningitis	I-Disease	D008585
.	O	O

No	O	O
impairment	B-Disease	D007153
of	I-Disease	D007153
cellular	I-Disease	D007153
immunity	I-Disease	D007153
or	O	O
immunoglobulin	B-Disease	D004406
deficiency	I-Disease	D004406
could	O	O
be	O	O
found	O	O
.	O	O

Complement	O	O
assays	O	O
showed	O	O
a	O	O
complete	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
,	O	O
while	O	O
the	O	O
other	O	O
individual	O	O
component	O	O
levels	O	O
were	O	O
normal	O	O
and	O	O
the	O	O
hemolytic	O	O
activity	O	O
(	O	O
measured	O	O
using	O	O
the	O	O
CH50	O	O
assay	O	O
)	O	O
was	O	O
only	O	O
slightly	O	O
reduced	O	O
.	O	O

A	O	O
family	O	O
study	O	O
revealed	O	O
complete	B-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
in	O	O
the	O	O
patients	O	O
healthy	O	O
brother	O	O
and	O	O
half	O	O
-	O	O
normal	O	O
C9	O	O
concentrations	O	O
in	O	O
his	O	O
sister	O	O
,	O	O
his	O	O
son	O	O
(	O	O
who	O	O
also	O	O
had	O	O
experienced	O	O
an	O	O
episode	O	O
of	O	O
bacterial	B-Disease	D016920
meningitis	I-Disease	D016920
)	O	O
,	O	O
and	O	O
his	O	O
niece	O	O
,	O	O
consistent	O	O
with	O	O
an	O	O
inherited	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

This	O	O
first	O	O
case	O	O
of	O	O
recurrent	B-Disease	D008581	D012008
meningitis	I-Disease	D008581	D012008
in	O	O
a	O	O
white	O	O
patient	O	O
with	O	O
complete	B-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
suggests	O	O
that	O	O
this	O	O
complement	B-Disease	D007153
defect	I-Disease	D007153
may	O	O
also	O	O
be	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
bacterial	B-Disease	D016870
,	I-Disease	D016870
especially	I-Disease	D016870
neisserial	I-Disease	D016870
,	I-Disease	D016870
infections	I-Disease	D016870
.	O	O

.	O	O

Bone	O	O
marrow	O	O
transplant	O	O
in	O	O
adrenoleukodystrophy	B-Disease	D000326
.	O	O

An	O	O
allogeneic	O	O
bone	O	O
marrow	O	O
transplant	O	O
(	O	O
BMT	O	O
)	O	O
from	O	O
a	O	O
normal	O	O
HLA	O	O
identical	O	O
sibling	O	O
donor	O	O
was	O	O
performed	O	O
in	O	O
a	O	O
13	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
rapidly	O	O
progressive	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
.	O	O

Engraftment	O	O
and	O	O
complete	O	O
hematologic	O	O
recovery	O	O
occurred	O	O
within	O	O
4	O	O
weeks	O	O
,	O	O
but	O	O
neurologic	B-Disease	D019636
deterioration	I-Disease	D019636
continued	O	O
.	O	O

The	O	O
patient	O	O
died	O	O
of	O	O
an	O	O
adenovirus	B-Disease	D000257
infection	I-Disease	D000257
141	O	O
days	O	O
after	O	O
BMT	O	O
.	O	O

ALD	B-Disease	D000326
is	O	O
characterized	O	O
by	O	O
abnormally	O	O
high	O	O
plasma	O	O
levels	O	O
of	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
(	O	O
VLCFA	O	O
)	O	O
as	O	O
a	O	O
result	O	O
of	O	O
impaired	O	O
capacity	O	O
to	O	O
degrade	O	O
them	O	O
.	O	O

Ten	O	O
days	O	O
after	O	O
BMT	O	O
,	O	O
the	O	O
white	O	O
blood	O	O
cell	O	O
VLCFA	O	O
levels	O	O
and	O	O
enzyme	O	O
activity	O	O
became	O	O
normal	O	O
;	O	O
after	O	O
3	O	O
months	O	O
,	O	O
there	O	O
was	O	O
progressive	O	O
reduction	O	O
of	O	O
plasma	O	O
VLCFA	O	O
to	O	O
levels	O	O
only	O	O
slightly	O	O
above	O	O
normal	O	O
.	O	O

.	O	O

Increased	O	O
incidence	O	O
of	O	O
cataracts	B-Disease	D002386
in	O	O
male	O	O
subjects	O	O
deficient	B-Disease	D005955
in	I-Disease	D005955
glucose	I-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
.	O	O

Glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
RBCs	O	O
was	O	O
found	O	O
significantly	O	O
more	O	O
frequently	O	O
in	O	O
210	O	O
male	O	O
cataractous	B-Disease	D002386
patients	O	O
than	O	O
in	O	O
672	O	O
control	O	O
subjects	O	O
of	O	O
Sardinian	O	O
origin	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
the	O	O
deficiency	O	O
was	O	O
increasingly	O	O
higher	O	O
in	O	O
presenile	O	O
cataracts	B-Disease	D002386
.	O	O

In	O	O
the	O	O
G6PD	B-Disease	D005955
-	I-Disease	D005955
deficient	I-Disease	D005955
group	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
cortical	B-Disease	D002386
and	I-Disease	D002386
total	I-Disease	D002386
cataracts	I-Disease	D002386
was	O	O
also	O	O
increased	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
decrease	O	O
of	O	O
the	O	O
G6PD	O	O
activity	O	O
in	O	O
the	O	O
lens	O	O
,	O	O
which	O	O
accompanies	O	O
its	O	O
deficiency	O	O
in	O	O
the	O	O
erythrocyte	O	O
,	O	O
might	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
cataracto	O	O
-	O	O
genesis	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

Moreover	O	O
,	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
should	O	O
be	O	O
added	O	O
to	O	O
other	O	O
conditions	O	O
,	O	O
such	O	O
as	O	O
the	O	O
galactosemic	B-Disease	OMIM:230400
states	O	O
and	O	O
riboflavin	B-Disease	D012257
deficiency	I-Disease	D012257
,	O	O
where	O	O
cataracts	B-Disease	D002386
represent	O	O
a	O	O
sensitive	O	O
indicator	O	O
of	O	O
metabolic	B-Disease	D008659
abnormalities	I-Disease	D008659
of	O	O
the	O	O
RBC	O	O
.	O	O

.	O	O

Von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
maps	O	O
to	O	O
the	O	O
region	O	O
of	O	O
chromosome	O	O
3	O	O
associated	O	O
with	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
.	O	O

Von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
with	O	O
inherited	O	O
susceptibility	O	O
to	O	O
various	O	O
forms	O	O
of	O	O
cancer	B-Disease	D009369
,	O	O
including	O	O
hemangioblastomas	B-Disease	D018325
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
phaeochromocytomas	B-Disease	D010673
,	O	O
pancreatic	B-Disease	OMIM:260350
malignancies	I-Disease	OMIM:260350
,	O	O
and	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

Renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
constitute	O	O
a	O	O
particularly	O	O
frequent	O	O
cause	O	O
of	O	O
death	O	O
in	O	O
this	O	O
disorder	O	O
,	O	O
occurring	O	O
as	O	O
bilateral	B-Disease	D009369
and	I-Disease	D009369
multifocal	I-Disease	D009369
tumours	I-Disease	D009369
,	O	O
and	O	O
presenting	O	O
at	O	O
an	O	O
earlier	O	O
age	O	O
than	O	O
in	O	O
sporadic	O	O
,	O	O
non	O	O
-	O	O
familial	O	O
cases	O	O
of	O	O
this	O	O
tumour	B-Disease	D009369
type	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
is	O	O
linked	O	O
to	O	O
the	O	O
locus	O	O
encoding	O	O
the	O	O
human	O	O
homologoue	O	O
of	O	O
the	O	O
RAF1	O	O
oncogene	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
chromosome	O	O
3p25	O	O
(	O	O
ref	O	O
.	O	O

4	O	O
)	O	O
.	O	O

Crossovers	O	O
with	O	O
the	O	O
VHL	B-Disease	D006623
locus	O	O
suggest	O	O
that	O	O
the	O	O
defect	O	O
responsible	O	O
for	O	O
the	O	O
VHL	B-Disease	D006623
phenotype	O	O
is	O	O
not	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
RAF1	O	O
gene	O	O
itself	O	O
.	O	O

An	O	O
alternative	O	O
or	O	O
prior	O	O
event	O	O
to	O	O
oncogene	O	O
activation	O	O
in	O	O
tumour	B-Disease	D009369
formation	O	O
may	O	O
be	O	O
the	O	O
inactivation	O	O
of	O	O
a	O	O
putative	O	O
tumour	B-Disease	D009369
suppressor	O	O
which	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
both	O	O
the	O	O
inherited	B-Disease	D009369
and	I-Disease	D009369
sporadic	I-Disease	D009369
forms	I-Disease	D009369
of	I-Disease	D009369
the	I-Disease	D009369
cancer	I-Disease	D009369
.	O	O

Sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
have	O	O
previously	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
regions	O	O
on	O	O
chromosome	O	O
3p	O	O
(	O	O
refs	O	O
5	O	O
,	O	O
6	O	O
)	O	O
.	O	O

Consequently	O	O
,	O	O
sporadic	O	O
and	O	O
VHL	B-Disease	D006623
-	O	O
associated	O	O
forms	O	O
of	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
might	O	O
both	O	O
result	O	O
from	O	O
alterations	O	O
causing	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
same	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
on	O	O
this	O	O
chromosome	O	O
.	O	O

.	O	O

Tightly	O	O
linked	O	O
flanking	O	O
markers	O	O
for	O	O
the	O	O
Lowe	B-Disease	D009800
oculocerebrorenal	I-Disease	D009800
syndrome	I-Disease	D009800
,	O	O
with	O	O
application	O	O
to	O	O
carrier	O	O
assessment	O	O
.	O	O

The	O	O
Lowe	B-Disease	D009800
oculocerebrorenal	I-Disease	D009800
syndrome	I-Disease	D009800
(	O	O
OCRL	B-Disease	D009800
)	O	O
is	O	O
characterized	O	O
by	O	O
congenital	O	O
cataract	B-Disease	D002386
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
and	O	O
defective	B-Disease	D015499
renal	I-Disease	D015499
tubular	I-Disease	D015499
function	I-Disease	D015499
.	O	O

A	O	O
map	O	O
assignment	O	O
of	O	O
OCRL	B-Disease	D009800
to	O	O
Xq24	O	O
-	O	O
q26	O	O
has	O	O
been	O	O
made	O	O
previously	O	O
by	O	O
linkage	O	O
analysis	O	O
with	O	O
DXS42	O	O
at	O	O
Xq24	O	O
-	O	O
q26	O	O
(	O	O
theta	O	O
=	O	O
0	O	O
,	O	O
z	O	O
=	O	O
5	O	O
.	O	O

09	O	O
)	O	O
and	O	O
with	O	O
DXS10	O	O
at	O	O
Xq26	O	O
(	O	O
theta	O	O
=	O	O
0	O	O
,	O	O
z	O	O
=	O	O
6	O	O
.	O	O

45	O	O
)	O	O
.	O	O

Two	O	O
additional	O	O
families	O	O
were	O	O
studied	O	O
and	O	O
three	O	O
additional	O	O
polymorphisms	O	O
were	O	O
identified	O	O
at	O	O
DXS42	O	O
by	O	O
using	O	O
a	O	O
35	O	O
-	O	O
kb	O	O
sequence	O	O
isolated	O	O
with	O	O
the	O	O
probe	O	O
detecting	O	O
the	O	O
original	O	O
polymorphism	O	O
at	O	O
DXS42	O	O
.	O	O

With	O	O
additional	O	O
OCRL	B-Disease	D009800
families	O	O
made	O	O
informative	O	O
for	O	O
DXS42	O	O
,	O	O
theta	O	O
remained	O	O
0	O	O
with	O	O
z	O	O
=	O	O
6	O	O
.	O	O

63	O	O
;	O	O
and	O	O
for	O	O
DXS10	O	O
theta	O	O
=	O	O
0	O	O
.	O	O

03	O	O
and	O	O
z	O	O
=	O	O
7	O	O
.	O	O

07	O	O
.	O	O

Evidence	O	O
for	O	O
placing	O	O
OCRL	B-Disease	D009800
at	O	O
Xq25	O	O
also	O	O
comes	O	O
from	O	O
a	O	O
female	O	O
with	O	O
Lowe	B-Disease	D009800
syndrome	I-Disease	D009800
and	O	O
an	O	O
X	O	O
;	O	O
3	O	O
translocation	O	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
Xq25	O	O
breakpoint	O	O
in	O	O
this	O	O
patient	O	O
to	O	O
determine	O	O
the	O	O
position	O	O
of	O	O
OCRL	B-Disease	D009800
relative	O	O
to	O	O
the	O	O
two	O	O
linked	O	O
markers	O	O
.	O	O

Each	O	O
derivative	O	O
chromosome	O	O
was	O	O
isolated	O	O
away	O	O
from	O	O
its	O	O
normal	O	O
counterpart	O	O
in	O	O
somatic	O	O
cell	O	O
hybrids	O	O
.	O	O

DXS42	O	O
was	O	O
mapped	O	O
to	O	O
the	O	O
derivative	O	O
chromosome	O	O
X	O	O
containing	O	O
Xpterq25	O	O
,	O	O
and	O	O
DXS10	O	O
was	O	O
mapped	O	O
to	O	O
the	O	O
derivative	O	O
chromosome	O	O
3	O	O
containing	O	O
Xq25	O	O
-	O	O
qter	O	O
.	O	O

The	O	O
markers	O	O
DXS10	O	O
and	O	O
DXS42	O	O
therefore	O	O
show	O	O
tight	O	O
linkage	O	O
with	O	O
OCRL	B-Disease	D009800
in	O	O
six	O	O
families	O	O
and	O	O
flank	O	O
the	O	O
Xq25	O	O
breakpoint	O	O
in	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
an	O	O
X	O	O
;	O	O
3	O	O
translocation	O	O
.	O	O

Linkage	O	O
analysis	O	O
with	O	O
flanking	O	O
markers	O	O
was	O	O
used	O	O
to	O	O
assess	O	O
OCRL	B-Disease	D009800
carrier	O	O
status	O	O
in	O	O
women	O	O
at	O	O
risk	O	O
.	O	O

Results	O	O
,	O	O
when	O	O
compared	O	O
with	O	O
carrier	O	O
determination	O	O
by	O	O
ophthalmologic	O	O
examination	O	O
,	O	O
indicated	O	O
that	O	O
the	O	O
slit	O	O
-	O	O
lamp	O	O
exam	O	O
can	O	O
be	O	O
a	O	O
sensitive	O	O
and	O	O
specific	O	O
method	O	O
of	O	O
carrier	O	O
determination	O	O
in	O	O
many	O	O
cases	O	O
Abnormal	O	O
development	O	O
of	O	O
Purkinje	O	O
cells	O	O
and	O	O
lymphocytes	O	O
in	O	O
Atm	O	O
mutant	O	O
mice	O	O
.	O	O

Motor	B-Disease	D002524
incoordination	I-Disease	D002524
,	O	O
immune	B-Disease	D007154
deficiencies	I-Disease	D007154
,	O	O
and	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
are	O	O
the	O	O
characteristic	O	O
features	O	O
of	O	O
the	O	O
hereditary	B-Disease	D030342
disease	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
,	O	O
which	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
.	O	O

Through	O	O
gene	O	O
targeting	O	O
,	O	O
we	O	O
have	O	O
generated	O	O
a	O	O
line	O	O
of	O	O
Atm	O	O
mutant	O	O
mice	O	O
,	O	O
Atm	O	O
(	O	O
y	O	O
/	O	O
y	O	O
)	O	O
mice	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
other	O	O
Atm	O	O
mutant	O	O
mice	O	O
,	O	O
Atm	O	O
(	O	O
y	O	O
/	O	O
y	O	O
)	O	O
mice	O	O
show	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
thymic	B-Disease	D013953
lymphoma	I-Disease	D013953
and	O	O
survive	O	O
beyond	O	O
a	O	O
few	O	O
months	O	O
of	O	O
age	O	O
.	O	O

Atm	O	O
(	O	O
y	O	O
/	O	O
y	O	O
)	O	O
mice	O	O
exhibit	O	O
deficits	O	O
in	O	O
motor	O	O
learning	O	O
indicative	O	O
of	O	O
cerebellar	B-Disease	D002526
dysfunction	I-Disease	D002526
.	O	O

Even	O	O
though	O	O
we	O	O
found	O	O
no	O	O
gross	O	O
cerebellar	B-Disease	D013132
degeneration	I-Disease	D013132
in	O	O
older	O	O
Atm	O	O
(	O	O
y	O	O
/	O	O
y	O	O
)	O	O
animals	O	O
,	O	O
ectopic	O	O
and	O	O
abnormally	O	O
differentiated	O	O
Purkinje	O	O
cells	O	O
were	O	O
apparent	O	O
in	O	O
mutant	O	O
mice	O	O
of	O	O
all	O	O
ages	O	O
.	O	O

These	O	O
findings	O	O
establish	O	O
that	O	O
some	O	O
neuropathological	B-Disease	D009422
abnormalities	I-Disease	D009422
seen	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
also	O	O
are	O	O
present	O	O
in	O	O
Atm	O	O
mutant	O	O
mice	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
report	O	O
a	O	O
previously	O	O
unrecognized	O	O
effect	O	O
of	O	O
Atm	B-Disease	OMIM:208900
deficiency	I-Disease	OMIM:208900
on	O	O
development	O	O
or	O	O
maintenance	O	O
of	O	O
CD4	O	O
(	O	O
+	O	O
)	O	O
8	O	O
(	O	O
+	O	O
)	O	O
thymocytes	O	O
.	O	O

We	O	O
discuss	O	O
these	O	O
findings	O	O
in	O	O
the	O	O
context	O	O
of	O	O
the	O	O
hypothesis	O	O
that	O	O
abnormal	O	O
development	O	O
of	O	O
Purkinje	O	O
cells	O	O
and	O	O
lymphocytes	O	O
contributes	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
.	O	O

.	O	O

Both	O	O
mutations	O	O
in	O	O
G6PD	O	O
A	O	O
-	O	O
are	O	O
necessary	O	O
to	O	O
produce	O	O
the	O	O
G6PD	B-Disease	D005955
deficient	I-Disease	D005955
phenotype	O	O
.	O	O

The	O	O
high	O	O
prevalence	O	O
of	O	O
glucose	B-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
African	O	O
populations	O	O
is	O	O
due	O	O
almost	O	O
entirely	O	O
to	O	O
the	O	O
enzyme	O	O
variant	O	O
A	O	O
-	O	O
,	O	O
which	O	O
differs	O	O
from	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
G6PD	O	O
B	O	O
by	O	O
two	O	O
amino	O	O
acid	O	O
replacements	O	O
,	O	O
68	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
and	O	O
126	O	O
Asn	O	O
-	O	O
-	O	O
>	O	O
Asp	O	O
.	O	O

The	O	O
non	O	O
-	O	O
deficient	O	O
polymorphic	O	O
variant	O	O
G6PD	O	O
A	O	O
contains	O	O
only	O	O
the	O	O
mutation	O	O
126	O	O
Asn	O	O
-	O	O
-	O	O
>	O	O
Asp	O	O
.	O	O

The	O	O
frequencies	O	O
of	O	O
the	O	O
G6PD	O	O
A	O	O
and	O	O
of	O	O
the	O	O
G6PD	O	O
A	O	O
-	O	O
genes	O	O
in	O	O
parts	O	O
of	O	O
Africa	O	O
are	O	O
both	O	O
about	O	O
0	O	O
.	O	O

2	O	O
.	O	O

The	O	O
68	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
mutation	O	O
has	O	O
not	O	O
been	O	O
found	O	O
in	O	O
a	O	O
B	O	O
background	O	O
.	O	O

This	O	O
could	O	O
be	O	O
because	O	O
the	O	O
68	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
mutation	O	O
happened	O	O
to	O	O
arise	O	O
in	O	O
an	O	O
A	O	O
gene	O	O
in	O	O
the	O	O
first	O	O
instance	O	O
,	O	O
or	O	O
because	O	O
the	O	O
68	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
mutation	O	O
alone	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
cause	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
.	O	O

We	O	O
have	O	O
approached	O	O
this	O	O
question	O	O
by	O	O
producing	O	O
G6PD	O	O
B	O	O
,	O	O
A	O	O
,	O	O
A	O	O
-	O	O
,	O	O
and	O	O
G6PD	O	O
68	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Met	O	O
in	O	O
a	O	O
bacterial	O	O
expression	O	O
system	O	O
and	O	O
analysing	O	O
their	O	O
biochemical	O	O
properties	O	O
.	O	O

With	O	O
each	O	O
single	O	O
mutation	O	O
we	O	O
found	O	O
a	O	O
slight	O	O
decrease	O	O
in	O	O
both	O	O
the	O	O
specific	O	O
activity	O	O
and	O	O
the	O	O
yield	O	O
of	O	O
enzyme	O	O
when	O	O
compared	O	O
to	O	O
G6PD	O	O
B	O	O
.	O	O

When	O	O
both	O	O
mutations	O	O
were	O	O
introduced	O	O
together	O	O
,	O	O
there	O	O
was	O	O
a	O	O
roughly	O	O
additive	O	O
effect	O	O
on	O	O
specific	O	O
activity	O	O
,	O	O
but	O	O
a	O	O
much	O	O
more	O	O
drastic	O	O
effect	O	O
on	O	O
enzyme	O	O
yield	O	O
(	O	O
4	O	O
%	O	O
of	O	O
normal	O	O
)	O	O
.	O	O

This	O	O
synergistic	O	O
effect	O	O
was	O	O
also	O	O
demonstrated	O	O
on	O	O
thermal	O	O
stability	O	O
,	O	O
especially	O	O
at	O	O
low	O	O
NADP	O	O
concentrations	O	O
.	O	O

Comparable	O	O
results	O	O
were	O	O
produced	O	O
when	O	O
the	O	O
replacement	O	O
119	O	O
Gln	O	O
-	O	O
-	O	O
>	O	O
Glu	O	O
was	O	O
studied	O	O
instead	O	O
of	O	O
126	O	O
Asn	O	O
-	O	O
-	O	O
>	O	O
Asp	O	O
.	O	O

We	O	O
infer	O	O
that	O	O
the	O	O
coexistence	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
is	O	O
responsible	O	O
for	O	O
enzyme	B-Disease	D005955
deficiency	I-Disease	D005955
in	I-Disease	D005955
G6PD	I-Disease	D005955
A	O	O
-	O	O
because	O	O
they	O	O
act	O	O
synergistically	O	O
in	O	O
causing	O	O
instability	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O

Detection	O	O
of	O	O
98	O	O
%	O	O
of	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
gene	O	O
deletions	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

We	O	O
describe	O	O
oligonucleotide	O	O
primer	O	O
sequences	O	O
that	O	O
can	O	O
be	O	O
used	O	O
to	O	O
amplify	O	O
eight	O	O
exons	O	O
plus	O	O
the	O	O
muscle	O	O
promoter	O	O
of	O	O
the	O	O
dystrophin	O	O
gene	O	O
in	O	O
a	O	O
single	O	O
multiplex	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
.	O	O

When	O	O
used	O	O
in	O	O
conjunction	O	O
with	O	O
an	O	O
existing	O	O
primer	O	O
set	O	O
,	O	O
these	O	O
two	O	O
multiplex	O	O
reactions	O	O
detect	O	O
about	O	O
98	O	O
%	O	O
of	O	O
deletions	O	O
in	O	O
patients	O	O
with	O	O
Duchenne	B-Disease	D020388
or	I-Disease	D020388
Becker	I-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
,	O	O
BMD	B-Disease	C537666
)	O	O
.	O	O

Furthermore	O	O
,	O	O
these	O	O
primers	O	O
amplify	O	O
most	O	O
of	O	O
the	O	O
exons	O	O
in	O	O
the	O	O
deletion	O	O
prone	O	O
"	O	O
hot	O	O
spot	O	O
"	O	O
region	O	O
around	O	O
exons	O	O
44	O	O
to	O	O
53	O	O
,	O	O
allowing	O	O
determination	O	O
of	O	O
deletion	O	O
endpoints	O	O
and	O	O
prediction	O	O
of	O	O
mutational	O	O
effects	O	O
on	O	O
the	O	O
translational	O	O
reading	O	O
frame	O	O
.	O	O

Thus	O	O
,	O	O
use	O	O
of	O	O
these	O	O
PCR	O	O
-	O	O
based	O	O
assays	O	O
will	O	O
allow	O	O
deletion	O	O
detection	O	O
and	O	O
prenatal	O	O
diagnosis	O	O
for	O	O
most	O	O
DMD	B-Disease	D020388
/	O	O
BMD	B-Disease	C537666
patients	O	O
in	O	O
a	O	O
fraction	O	O
of	O	O
the	O	O
time	O	O
required	O	O
for	O	O
Southern	O	O
blot	O	O
analysis	O	O
.	O	O

.	O	O

Recombination	O	O
events	O	O
that	O	O
locate	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
distal	O	O
to	O	O
APOC2	O	O
on	O	O
19q	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
a	O	O
recombination	O	O
in	O	O
an	O	O
individual	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
which	O	O
placed	O	O
the	O	O
markers	O	O
D19S19	O	O
and	O	O
APOC2	O	O
on	O	O
the	O	O
same	O	O
side	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
.	O	O

Haplotyping	O	O
of	O	O
this	O	O
family	O	O
with	O	O
more	O	O
recently	O	O
characterized	O	O
probes	O	O
which	O	O
are	O	O
either	O	O
tightly	O	O
linked	O	O
to	O	O
DM	B-Disease	D009223
or	O	O
distal	O	O
to	O	O
the	O	O
linkage	O	O
group	O	O
at	O	O
q13	O	O
.	O	O

2	O	O
shows	O	O
that	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
is	O	O
distal	O	O
to	O	O
APOC2	O	O
.	O	O

This	O	O
is	O	O
confirmed	O	O
by	O	O
other	O	O
recombinants	O	O
where	O	O
DM	B-Disease	D009223
segregates	O	O
with	O	O
distal	O	O
probes	O	O
.	O	O

Additional	O	O
marker	O	O
to	O	O
marker	O	O
recombinations	O	O
in	O	O
unaffected	O	O
individuals	O	O
are	O	O
reported	O	O
and	O	O
support	O	O
the	O	O
order	O	O
and	O	O
orientation	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
linkage	O	O
group	O	O
as	O	O
pter	O	O
-	O	O
(	O	O
INSR	O	O
,	O	O
LDLR	O	O
,	O	O
S9	O	O
)	O	O
-	O	O
(	O	O
S19	O	O
,	O	O
BCL3	O	O
,	O	O
APOC2	O	O
)	O	O
-	O	O
(	O	O
CKMM	O	O
,	O	O
DM	B-Disease	D009223
)	O	O
-	O	O
(	O	O
S22	O	O
,	O	O
+	O	O
+	O	O
+	O	O
PRKCG	O	O
)	O	O
-	O	O
qter	O	O
.	O	O

The	O	O
data	O	O
presented	O	O
here	O	O
cannot	O	O
determine	O	O
whether	O	O
DM	B-Disease	D009223
is	O	O
proximal	O	O
or	O	O
distal	O	O
to	O	O
CKMM	O	O
.	O	O

The	O	O
consequences	O	O
of	O	O
this	O	O
probe	O	O
order	O	O
for	O	O
antenatal	O	O
diagnosis	O	O
and	O	O
future	O	O
research	O	O
aiming	O	O
to	O	O
isolate	O	O
the	O	O
gene	O	O
which	O	O
is	O	O
affected	O	O
in	O	O
DM	B-Disease	D009223
are	O	O
discussed	O	O
.	O	O

New	O	O
mutations	O	O
,	O	O
polymorphisms	O	O
,	O	O
and	O	O
rare	O	O
variants	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
detected	O	O
by	O	O
a	O	O
novel	O	O
SSCP	O	O
strategy	O	O
.	O	O

The	O	O
gene	O	O
for	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
,	O	O
ATM	O	O
,	O	O
spans	O	O
about	O	O
150	O	O
kb	O	O
of	O	O
genomic	O	O
DNA	O	O
.	O	O

ATM	O	O
mutations	O	O
are	O	O
found	O	O
along	O	O
the	O	O
entire	O	O
gene	O	O
,	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
.	O	O

Using	O	O
DNA	O	O
as	O	O
the	O	O
starting	O	O
material	O	O
,	O	O
we	O	O
screened	O	O
the	O	O
ATM	O	O
gene	O	O
in	O	O
92	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
,	O	O
using	O	O
an	O	O
optimized	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
technique	O	O
that	O	O
detected	O	O
all	O	O
previously	O	O
known	O	O
mutations	O	O
in	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
segments	O	O
being	O	O
analyzed	O	O
.	O	O

To	O	O
expedite	O	O
screening	O	O
,	O	O
we	O	O
sequentially	O	O
loaded	O	O
the	O	O
SSCP	O	O
gels	O	O
with	O	O
three	O	O
different	O	O
sets	O	O
of	O	O
PCR	O	O
products	O	O
that	O	O
were	O	O
pretested	O	O
to	O	O
avoid	O	O
overlapping	O	O
patterns	O	O
.	O	O

Many	O	O
of	O	O
the	O	O
DNA	O	O
changes	O	O
we	O	O
detected	O	O
were	O	O
intragenic	O	O
polymorphisms	O	O
.	O	O

Of	O	O
an	O	O
expected	O	O
177	O	O
unknown	O	O
mutations	O	O
,	O	O
we	O	O
detected	O	O
approximately	O	O
70	O	O
%	O	O
,	O	O
mostly	O	O
protein	O	O
truncating	O	O
mutations	O	O
(	O	O
that	O	O
would	O	O
have	O	O
been	O	O
detectable	O	O
by	O	O
protein	O	O
truncation	O	O
testing	O	O
if	O	O
RNA	O	O
starting	O	O
material	O	O
had	O	O
been	O	O
available	O	O
)	O	O
.	O	O

Mutations	O	O
have	O	O
now	O	O
been	O	O
defined	O	O
for	O	O
every	O	O
exon	O	O
of	O	O
the	O	O
ATM	O	O
gene	O	O
.	O	O

Herein	O	O
,	O	O
we	O	O
present	O	O
35	O	O
new	O	O
mutations	O	O
and	O	O
34	O	O
new	O	O
intragenic	O	O
polymorphisms	O	O
or	O	O
rare	O	O
variants	O	O
within	O	O
the	O	O
ATM	O	O
gene	O	O
.	O	O

This	O	O
is	O	O
the	O	O
most	O	O
comprehensive	O	O
compilation	O	O
of	O	O
ATM	O	O
polymorphisms	O	O
assembled	O	O
to	O	O
date	O	O
.	O	O

Defining	O	O
polymorphic	O	O
sites	O	O
as	O	O
well	O	O
as	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
will	O	O
be	O	O
of	O	O
great	O	O
importance	O	O
in	O	O
designing	O	O
automated	O	O
methods	O	O
for	O	O
detecting	O	O
mutations	O	O
.	O	O

.	O	O

Chromosome	O	O
breakage	O	O
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
and	I-Disease	D011218
Angelman	I-Disease	D011218
syndromes	I-Disease	D011218
involves	O	O
recombination	O	O
between	O	O
large	O	O
,	O	O
transcribed	O	O
repeats	O	O
at	O	O
proximal	O	O
and	O	O
distal	O	O
breakpoints	O	O
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
and	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
(	O	O
AS	B-Disease	D017204
)	O	O
are	O	O
distinct	O	O
neurobehavioral	B-Disease	D019954
disorders	I-Disease	D019954
that	O	O
most	O	O
often	O	O
arise	O	O
from	O	O
a	O	O
4	O	O
-	O	O
Mb	O	O
deletion	O	O
of	O	O
chromosome	O	O
15q11	O	O
-	O	O
q13	O	O
during	O	O
paternal	O	O
or	O	O
maternal	O	O
gametogenesis	O	O
,	O	O
respectively	O	O
.	O	O

At	O	O
a	O	O
de	O	O
novo	O	O
frequency	O	O
of	O	O
approximately	O	O
.	O	O

67	O	O
-	O	O
1	O	O
/	O	O
10	O	O
,	O	O
000	O	O
births	O	O
,	O	O
these	O	O
deletions	O	O
represent	O	O
a	O	O
common	O	O
structural	O	O
chromosome	O	O
change	O	O
in	O	O
the	O	O
human	O	O
genome	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
mechanism	O	O
underlying	O	O
these	O	O
events	O	O
,	O	O
we	O	O
characterized	O	O
the	O	O
regions	O	O
that	O	O
contain	O	O
two	O	O
proximal	O	O
breakpoint	O	O
clusters	O	O
and	O	O
a	O	O
distal	O	O
cluster	O	O
.	O	O

Novel	O	O
DNA	O	O
sequences	O	O
potentially	O	O
associated	O	O
with	O	O
the	O	O
breakpoints	O	O
were	O	O
positionally	O	O
cloned	O	O
from	O	O
YACs	O	O
within	O	O
or	O	O
near	O	O
these	O	O
regions	O	O
.	O	O

Analyses	O	O
of	O	O
rodent	O	O
-	O	O
human	O	O
somatic	O	O
-	O	O
cell	O	O
hybrids	O	O
,	O	O
YAC	O	O
contigs	O	O
,	O	O
and	O	O
FISH	O	O
of	O	O
normal	O	O
or	O	O
rearranged	O	O
chromosomes	O	O
15	O	O
identified	O	O
duplicated	O	O
sequences	O	O
(	O	O
the	O	O
END	O	O
repeats	O	O
)	O	O
at	O	O
or	O	O
near	O	O
the	O	O
breakpoints	O	O
.	O	O

The	O	O
END	O	O
-	O	O
repeat	O	O
units	O	O
are	O	O
derived	O	O
from	O	O
large	O	O
genomic	O	O
duplications	O	O
of	O	O
a	O	O
novel	O	O
gene	O	O
(	O	O
HERC2	O	O
)	O	O
,	O	O
many	O	O
copies	O	O
of	O	O
which	O	O
are	O	O
transcriptionally	O	O
active	O	O
in	O	O
germline	O	O
tissues	O	O
.	O	O

One	O	O
of	O	O
five	O	O
PWS	B-Disease	D011218
/	O	O
AS	B-Disease	D017204
patients	O	O
analyzed	O	O
to	O	O
date	O	O
has	O	O
an	O	O
identifiable	O	O
,	O	O
rearranged	O	O
HERC2	O	O
transcript	O	O
derived	O	O
from	O	O
the	O	O
deletion	O	O
event	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
the	O	O
END	O	O
repeats	O	O
flanking	O	O
15q11	O	O
-	O	O
q13	O	O
mediate	O	O
homologous	O	O
recombination	O	O
resulting	O	O
in	O	O
deletion	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
propose	O	O
that	O	O
active	O	O
transcription	O	O
of	O	O
these	O	O
repeats	O	O
in	O	O
male	O	O
and	O	O
female	O	O
germ	O	O
cells	O	O
may	O	O
facilitate	O	O
the	O	O
homologous	O	O
recombination	O	O
process	O	O
.	O	O

A	O	O
4	O	O
-	O	O
megabase	O	O
YAC	O	O
contig	O	O
that	O	O
spans	O	O
the	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
region	O	O
on	O	O
human	O	O
chromosome	O	O
8q24	O	O
.	O	O

1	O	O
:	O	O
use	O	O
in	O	O
refining	O	O
the	O	O
location	O	O
of	O	O
the	O	O
trichorhinophalangeal	B-Disease	OMIM:190350
syndrome	I-Disease	OMIM:190350
and	O	O
multiple	O	O
exostoses	O	O
genes	O	O
(	O	O
TRPS1	O	O
and	O	O
EXT1	O	O
)	O	O
.	O	O

We	O	O
have	O	O
constructed	O	O
a	O	O
physical	O	O
map	O	O
covering	O	O
over	O	O
4	O	O
Mb	O	O
of	O	O
human	O	O
chromosome	O	O
8q24	O	O
.	O	O

1	O	O
and	O	O
used	O	O
this	O	O
map	O	O
to	O	O
refine	O	O
the	O	O
locations	O	O
of	O	O
the	O	O
genes	O	O
responsible	O	O
for	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
.	O	O

The	O	O
map	O	O
is	O	O
composed	O	O
of	O	O
overlapping	O	O
YAC	O	O
clones	O	O
that	O	O
were	O	O
identified	O	O
and	O	O
ordered	O	O
in	O	O
relation	O	O
to	O	O
sequence	O	O
tagged	O	O
sites	O	O
mapped	O	O
to	O	O
the	O	O
Langer	O	O
-	O	O
Giedion	O	O
chromosomal	O	O
region	O	O
on	O	O
somatic	O	O
cell	O	O
hybrids	O	O
.	O	O

The	O	O
minimal	O	O
region	O	O
of	O	O
overlap	O	O
of	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
deletions	O	O
,	O	O
previously	O	O
identified	O	O
by	O	O
analysis	O	O
of	O	O
15	O	O
patients	O	O
,	O	O
was	O	O
placed	O	O
on	O	O
the	O	O
map	O	O
by	O	O
analysis	O	O
of	O	O
2	O	O
patients	O	O
whose	O	O
deletions	O	O
define	O	O
the	O	O
endpoints	O	O
.	O	O

The	O	O
chromosome	O	O
8	O	O
breakpoint	O	O
of	O	O
a	O	O
balanced	O	O
t	O	O
(	O	O
8	O	O
;	O	O
9	O	O
)	O	O
(	O	O
q24	O	O
.	O	O

11	O	O
;	O	O
q33	O	O
.	O	O

3	O	O
)	O	O
translocation	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
trichorhinophalangeal	B-Disease	OMIM:190350
syndrome	I-Disease	OMIM:190350
(	O	O
TRPS	B-Disease	OMIM:190350
I	O	O
)	O	O
was	O	O
found	O	O
to	O	O
be	O	O
located	O	O
just	O	O
within	O	O
the	O	O
proximal	O	O
end	O	O
of	O	O
the	O	O
minimal	O	O
deletion	O	O
region	O	O
.	O	O

A	O	O
deletion	O	O
of	O	O
8q24	O	O
.	O	O

11	O	O
-	O	O
q24	O	O
.	O	O

3	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
multiple	O	O
exostoses	O	O
was	O	O
found	O	O
to	O	O
overlap	O	O
the	O	O
distal	O	O
end	O	O
of	O	O
the	O	O
LGS	B-Disease	D015826
deletion	O	O
region	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
EXT1	O	O
gene	O	O
is	O	O
distal	O	O
to	O	O
the	O	O
TRPS1	O	O
gene	O	O
and	O	O
supporting	O	O
the	O	O
hypothesis	O	O
that	O	O
Langer	B-Disease	D015826
-	I-Disease	D015826
Giedion	I-Disease	D015826
syndrome	I-Disease	D015826
is	O	O
due	O	O
to	O	O
loss	O	O
of	O	O
functional	O	O
copies	O	O
of	O	O
both	O	O
the	O	O
TRPS1	O	O
and	O	O
the	O	O
EXT1	O	O
genes	O	O
Genetic	O	O
mapping	O	O
of	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
syndrome	I-Disease	D061325
to	O	O
a	O	O
small	O	O
interval	O	O
on	O	O
chromosome	O	O
17q12	O	O
-	O	O
21	O	O
:	O	O
exclusion	O	O
of	O	O
candidate	O	O
genes	O	O
EDH17B2	O	O
and	O	O
RARA	O	O
.	O	O

A	O	O
susceptibility	O	O
gene	O	O
for	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
BRCA1	O	O
,	O	O
has	O	O
been	O	O
assigned	O	O
by	O	O
linkage	O	O
analysis	O	O
to	O	O
chromosome	O	O
17q21	O	O
.	O	O

Candidate	O	O
genes	O	O
in	O	O
this	O	O
region	O	O
include	O	O
EDH17B2	O	O
,	O	O
which	O	O
encodes	O	O
estradiol	O	O
17	O	O
beta	O	O
-	O	O
hydroxysteroid	O	O
dehydrogenase	O	O
II	O	O
(	O	O
17	O	O
beta	O	O
-	O	O
HSD	O	O
II	O	O
)	O	O
,	O	O
and	O	O
RARA	O	O
,	O	O
the	O	O
gene	O	O
for	O	O
retinoic	O	O
acid	O	O
receptor	O	O
alpha	O	O
.	O	O

We	O	O
have	O	O
typed	O	O
22	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
breast	I-Disease	D001943
-	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
families	O	O
with	O	O
eight	O	O
polymorphisms	O	O
from	O	O
the	O	O
chromosome	O	O
17q12	O	O
-	O	O
21	O	O
region	O	O
,	O	O
including	O	O
two	O	O
in	O	O
the	O	O
EDH17B2	O	O
gene	O	O
.	O	O

Genetic	O	O
recombination	O	O
with	O	O
the	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
trait	O	O
excludes	O	O
RARA	O	O
from	O	O
further	O	O
consideration	O	O
as	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
BRCA1	O	O
.	O	O

Both	O	O
BRCA1	O	O
and	O	O
EDH17B2	O	O
map	O	O
to	O	O
a	O	O
6	O	O
cM	O	O
interval	O	O
(	O	O
between	O	O
THRA1	O	O
and	O	O
D17S579	O	O
)	O	O
and	O	O
no	O	O
recombination	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
genes	O	O
.	O	O

However	O	O
,	O	O
direct	O	O
sequencing	O	O
of	O	O
overlapping	O	O
PCR	O	O
products	O	O
containing	O	O
the	O	O
entire	O	O
EDH17B2	O	O
gene	O	O
in	O	O
four	O	O
unrelated	O	O
affected	O	O
women	O	O
did	O	O
not	O	O
uncover	O	O
any	O	O
sequence	O	O
variation	O	O
,	O	O
other	O	O
than	O	O
previously	O	O
described	O	O
polymorphisms	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
EDH17B2	O	O
gene	O	O
,	O	O
therefore	O	O
do	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
syndrome	I-Disease	D061325
.	O	O

Single	O	O
meiotic	O	O
crossovers	O	O
in	O	O
affected	O	O
women	O	O
suggest	O	O
that	O	O
BRCA1	O	O
is	O	O
flanked	O	O
by	O	O
the	O	O
loci	O	O
RARA	O	O
and	O	O
D17S78	O	O
.	O	O

.	O	O

Hereditary	B-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
associated	O	O
with	O	O
common	O	O
variable	O	O
immunodeficiency	B-Disease	D007153
.	O	O

Homozygous	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
in	O	O
a	O	O
19	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
was	O	O
associated	O	O
with	O	O
variable	O	O
immunodeficiency	B-Disease	D007153
manifested	O	O
by	O	O
marked	O	O
hypoimmunoglobulinemia	B-Disease	D007153
and	O	O
impaired	O	O
antibody	O	O
responses	O	O
,	O	O
normal	O	O
circulating	O	O
B	O	O
lymphocytes	O	O
,	O	O
and	O	O
subnormal	O	O
T	O	O
-	O	O
cell	O	O
functions	O	O
.	O	O

Neither	O	O
antilymphocytic	O	O
autoantibodies	O	O
nor	O	O
chromosomal	B-Disease	D002869
abnormalities	I-Disease	D002869
were	O	O
found	O	O
.	O	O

Serum	O	O
immunoglobulin	O	O
levels	O	O
were	O	O
within	O	O
normal	O	O
limits	O	O
in	O	O
his	O	O
parents	O	O
and	O	O
brother	O	O
who	O	O
were	O	O
heterozygous	O	O
for	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

The	O	O
patients	O	O
lymphocytes	O	O
were	O	O
homozygous	O	O
at	O	O
the	O	O
HLA	O	O
-	O	O
D	O	O
locus	O	O
but	O	O
expressed	O	O
an	O	O
antigen	O	O
different	O	O
from	O	O
DW2	O	O
.	O	O

.	O	O

Isolation	O	O
of	O	O
molecular	O	O
probes	O	O
associated	O	O
with	O	O
the	O	O
chromosome	O	O
15	O	O
instability	O	O
in	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
.	O	O

Flow	O	O
cytometry	O	O
and	O	O
recombinant	O	O
DNA	O	O
techniques	O	O
have	O	O
been	O	O
used	O	O
to	O	O
obtain	O	O
reagents	O	O
for	O	O
a	O	O
molecular	O	O
analysis	O	O
of	O	O
the	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

HindIII	O	O
total	O	O
-	O	O
digest	O	O
libraries	O	O
were	O	O
prepared	O	O
in	O	O
lambda	O	O
phage	O	O
Charon	O	O
21A	O	O
from	O	O
flow	O	O
-	O	O
sorted	O	O
inverted	O	O
duplicated	O	O
no	O	O
.	O	O

15	O	O
human	O	O
chromosomes	O	O
and	O	O
propagated	O	O
on	O	O
recombination	O	O
-	O	O
proficient	O	O
(	O	O
LE392	O	O
)	O	O
and	O	O
recBC	O	O
-	O	O
,	O	O
sbcB	O	O
-	O	O
(	O	O
DB1257	O	O
)	O	O
bacteria	O	O
.	O	O

Twelve	O	O
distinct	O	O
chromosome	O	O
15	O	O
-	O	O
specific	O	O
probes	O	O
have	O	O
been	O	O
isolated	O	O
.	O	O

Eight	O	O
localized	O	O
to	O	O
the	O	O
region	O	O
15q11	O	O
-	O	O
-	O	O
-	O	O
-	O	O
13	O	O
.	O	O

Four	O	O
of	O	O
these	O	O
eight	O	O
sublocalized	O	O
to	O	O
band	O	O
15q11	O	O
.	O	O

2	O	O
and	O	O
are	O	O
shown	O	O
to	O	O
be	O	O
deleted	O	O
in	O	O
DNA	O	O
of	O	O
one	O	O
of	O	O
two	O	O
patients	O	O
examined	O	O
with	O	O
the	O	O
PWS	B-Disease	D011218
.	O	O

Heteroduplex	O	O
analysis	O	O
of	O	O
two	O	O
of	O	O
these	O	O
clones	O	O
,	O	O
which	O	O
grew	O	O
on	O	O
DB1257	O	O
but	O	O
not	O	O
on	O	O
LE392	O	O
,	O	O
revealed	O	O
stem	O	O
-	O	O
loop	O	O
structures	O	O
in	O	O
the	O	O
inserts	O	O
,	O	O
indicative	O	O
of	O	O
inverted	O	O
,	O	O
repeated	O	O
DNA	O	O
elements	O	O
.	O	O

Such	O	O
DNA	O	O
repeats	O	O
might	O	O
account	O	O
for	O	O
some	O	O
of	O	O
the	O	O
cloning	O	O
instability	O	O
of	O	O
DNA	O	O
segments	O	O
from	O	O
proximal	O	O
15q	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
genetic	O	O
and	O	O
physical	O	O
instability	O	O
associated	O	O
with	O	O
the	O	O
repeated	O	O
sequences	O	O
we	O	O
have	O	O
isolated	O	O
from	O	O
band	O	O
15q11	O	O
.	O	O

2	O	O
may	O	O
elucidate	O	O
the	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
instability	O	O
of	O	O
this	O	O
chromosomal	O	O
region	O	O
in	O	O
patients	O	O
with	O	O
the	O	O
PWS	B-Disease	D011218
or	O	O
other	O	O
diseases	O	O
associated	O	O
with	O	O
chromosomal	B-Disease	D002869
abnormalities	I-Disease	D002869
in	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
human	O	O
chromosome	O	O
15	O	O
Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
:	O	O
evidence	O	O
for	O	O
a	O	O
possible	O	O
dominant	O	O
-	O	O
negative	O	O
RNA	O	O
mutation	O	O
.	O	O

The	O	O
trinucleotide	O	O
expansion	O	O
mutation	O	O
causing	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
is	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
a	O	O
protein	O	O
kinase	O	O
gene	O	O
.	O	O

The	O	O
molecular	O	O
mechanisms	O	O
by	O	O
which	O	O
the	O	O
expanded	O	O
repeat	O	O
causes	O	O
the	O	O
clinically	O	O
variable	O	O
and	O	O
multisystemic	B-Disease	D004194
disease	I-Disease	D004194
,	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
are	O	O
not	O	O
understood	O	O
.	O	O

It	O	O
has	O	O
been	O	O
particularly	O	O
difficult	O	O
to	O	O
rationalize	O	O
the	O	O
dominant	O	O
inheritance	O	O
with	O	O
the	O	O
fact	O	O
that	O	O
the	O	O
expansion	O	O
mutation	O	O
lies	O	O
outside	O	O
of	O	O
the	O	O
protein	O	O
-	O	O
encoding	O	O
gene	O	O
elements	O	O
,	O	O
and	O	O
should	O	O
not	O	O
be	O	O
translated	O	O
into	O	O
protein	O	O
.	O	O

Here	O	O
we	O	O
use	O	O
muscle	O	O
biopsies	O	O
from	O	O
classical	O	O
adult	O	O
-	O	O
onset	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
patients	O	O
to	O	O
study	O	O
the	O	O
accumulation	O	O
of	O	O
transcripts	O	O
from	O	O
both	O	O
the	O	O
normal	O	O
and	O	O
expanded	O	O
DM	B-Disease	D009223
kinase	O	O
genes	O	O
in	O	O
patient	O	O
muscle	O	O
,	O	O
and	O	O
compare	O	O
the	O	O
results	O	O
to	O	O
normal	O	O
and	O	O
myopathic	B-Disease	D009135
controls	O	O
.	O	O

We	O	O
found	O	O
relatively	O	O
small	O	O
decreases	O	O
of	O	O
DM	B-Disease	D009223
kinase	O	O
RNA	O	O
in	O	O
the	O	O
total	O	O
RNA	O	O
pool	O	O
from	O	O
muscle	O	O
;	O	O
however	O	O
,	O	O
these	O	O
reductions	O	O
were	O	O
not	O	O
disease	O	O
specific	O	O
.	O	O

Analysis	O	O
of	O	O
poly	O	O
(	O	O
A	O	O
)	O	O
+	O	O
RNA	O	O
showed	O	O
dramatic	O	O
decreases	O	O
of	O	O
both	O	O
the	O	O
mutant	O	O
and	O	O
normal	O	O
DM	B-Disease	D009223
kinase	O	O
RNAs	O	O
,	O	O
and	O	O
these	O	O
changes	O	O
were	O	O
disease	O	O
-	O	O
specific	O	O
.	O	O

Our	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
novel	O	O
molecular	O	O
pathogenetic	O	O
mechanism	O	O
for	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
both	O	O
the	O	O
normal	O	O
and	O	O
expanded	O	O
DM	B-Disease	D009223
kinase	O	O
genes	O	O
are	O	O
transcribed	O	O
in	O	O
patient	O	O
muscle	O	O
,	O	O
but	O	O
the	O	O
abnormal	O	O
expansion	O	O
-	O	O
containing	O	O
RNA	O	O
has	O	O
a	O	O
dominant	O	O
effect	O	O
on	O	O
RNA	O	O
metabolism	O	O
by	O	O
preventing	O	O
the	O	O
accumulation	O	O
of	O	O
poly	O	O
(	O	O
A	O	O
)	O	O
+	O	O
RNA	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
the	O	O
expansion	O	O
mutation	O	O
to	O	O
alter	O	O
accumulation	O	O
of	O	O
poly	O	O
(	O	O
A	O	O
)	O	O
+	O	O
RNA	O	O
in	O	O
trans	O	O
suggests	O	O
that	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
may	O	O
be	O	O
the	O	O
first	O	O
example	O	O
of	O	O
a	O	O
dominant	O	O
-	O	O
negative	O	O
mutation	O	O
manifested	O	O
at	O	O
the	O	O
RNA	O	O
level	O	O
.	O	O

.	O	O

Isolation	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
McLeod	B-Disease	OMIM:300842
syndrome	I-Disease	OMIM:300842
that	O	O
encodes	O	O
a	O	O
novel	O	O
membrane	O	O
transport	O	O
protein	O	O
.	O	O

McLeod	B-Disease	OMIM:300842
syndrome	I-Disease	OMIM:300842
is	O	O
an	O	O
X	B-Disease	D040181
-	I-Disease	D040181
linked	I-Disease	D040181
multisystem	I-Disease	D040181
disorder	I-Disease	D040181
characterized	O	O
by	O	O
abnormalities	O	O
in	O	O
the	O	O
neuromuscular	O	O
and	O	O
hematopoietic	O	O
systems	O	O
.	O	O

We	O	O
have	O	O
assembled	O	O
a	O	O
cosmid	O	O
contig	O	O
of	O	O
360	O	O
kb	O	O
that	O	O
encompasses	O	O
the	O	O
McLeod	B-Disease	OMIM:300842
gene	O	O
locus	O	O
.	O	O

A	O	O
50	O	O
kb	O	O
deletion	O	O
was	O	O
detected	O	O
by	O	O
screening	O	O
DNA	O	O
from	O	O
patients	O	O
with	O	O
radiolabeled	O	O
whole	O	O
cosmids	O	O
,	O	O
and	O	O
two	O	O
transcription	O	O
units	O	O
were	O	O
identified	O	O
within	O	O
this	O	O
deletion	O	O
.	O	O

The	O	O
mRNA	O	O
expression	O	O
pattern	O	O
of	O	O
one	O	O
of	O	O
them	O	O
,	O	O
designated	O	O
as	O	O
XK	O	O
,	O	O
correlates	O	O
closely	O	O
to	O	O
the	O	O
McLeod	B-Disease	OMIM:300842
phenotype	O	O
.	O	O

XK	O	O
encodes	O	O
a	O	O
novel	O	O
protein	O	O
with	O	O
structural	O	O
characteristics	O	O
of	O	O
prokaryotic	O	O
and	O	O
eukaryotic	O	O
membrane	O	O
transport	O	O
proteins	O	O
.	O	O

Nucleotide	O	O
sequence	O	O
analysis	O	O
of	O	O
XK	O	O
from	O	O
two	O	O
unrelated	O	O
McLeod	B-Disease	OMIM:300842
patients	O	O
has	O	O
identified	O	O
point	O	O
mutations	O	O
at	O	O
conserved	O	O
splice	O	O
donor	O	O
and	O	O
acceptor	O	O
sites	O	O
.	O	O

These	O	O
findings	O	O
provide	O	O
direct	O	O
evidence	O	O
that	O	O
XK	O	O
is	O	O
responsible	O	O
for	O	O
McLeod	B-Disease	OMIM:300842
syndrome	I-Disease	OMIM:300842
.	O	O

.	O	O

Molecular	O	O
basis	O	O
of	O	O
very	B-Disease	C536353
long	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
CoA	I-Disease	C536353
dehydrogenase	I-Disease	C536353
deficiency	I-Disease	C536353
in	O	O
three	O	O
Israeli	O	O
patients	O	O
:	O	O
identification	O	O
of	O	O
a	O	O
complex	O	O
mutant	O	O
allele	O	O
with	O	O
P65L	O	O
and	O	O
K247Q	O	O
mutations	O	O
,	O	O
the	O	O
former	O	O
being	O	O
an	O	O
exonic	O	O
mutation	O	O
causing	O	O
exon	O	O
3	O	O
skipping	O	O
.	O	O

Very	B-Disease	C536353
long	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
CoA	I-Disease	C536353
dehydrogenase	I-Disease	C536353
(	I-Disease	C536353
VLCAD	I-Disease	C536353
)	I-Disease	C536353
deficiency	I-Disease	C536353
is	O	O
a	O	O
life	O	O
-	O	O
threatening	O	O
disorder	O	O
of	O	O
mitochondrial	O	O
fatty	O	O
acid	O	O
beta	O	O
-	O	O
oxidation	O	O
.	O	O

We	O	O
identified	O	O
four	O	O
novel	O	O
mutations	O	O
in	O	O
three	O	O
unrelated	O	O
patients	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
the	O	O
severe	O	O
childhood	O	O
form	O	O
of	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
with	O	O
early	O	O
onset	O	O
and	O	O
high	O	O
mortality	O	O
.	O	O

Immunoblot	O	O
analysis	O	O
revealed	O	O
that	O	O
VLCAD	O	O
protein	O	O
was	O	O
undetectable	O	O
in	O	O
patients	O	O
2	O	O
and	O	O
3	O	O
,	O	O
whereas	O	O
normal	O	O
-	O	O
size	O	O
VLCAD	O	O
protein	O	O
and	O	O
an	O	O
aberrant	O	O
form	O	O
of	O	O
VLCAD	O	O
(	O	O
4kDa	O	O
smaller	O	O
)	O	O
were	O	O
detected	O	O
in	O	O
patient	O	O
1	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
null	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
patients	O	O
2	O	O
and	O	O
3	O	O
patient	O	O
2	O	O
is	O	O
homozygous	O	O
for	O	O
a	O	O
frameshift	O	O
mutation	O	O
,	O	O
del	O	O
4	O	O
bp	O	O
at	O	O
798	O	O
-	O	O
801	O	O
,	O	O
and	O	O
patient	O	O
3	O	O
is	O	O
homozygous	O	O
for	O	O
a	O	O
nonsense	O	O
mutation	O	O
65C	O	O
>	O	O
A	O	O
(	O	O
S22X	O	O
)	O	O
.	O	O

Patient	O	O
1	O	O
was	O	O
homozygous	O	O
for	O	O
a	O	O
complex	O	O
mutant	O	O
allele	O	O
containing	O	O
two	O	O
alterations	O	O
,	O	O
including	O	O
a	O	O
194C	O	O
>	O	O
T	O	O
transition	O	O
(	O	O
P65L	O	O
)	O	O
and	O	O
739A	O	O
>	O	O
C	O	O
transversion	O	O
(	O	O
K247Q	O	O
)	O	O
;	O	O
in	O	O
the	O	O
case	O	O
of	O	O
P65L	O	O
,	O	O
the	O	O
amino	O	O
acid	O	O
change	O	O
does	O	O
not	O	O
reduce	O	O
enzyme	O	O
activity	O	O
.	O	O

However	O	O
,	O	O
the	O	O
nucleotide	O	O
change	O	O
resulted	O	O
in	O	O
exon	O	O
3	O	O
skipping	O	O
,	O	O
whereas	O	O
the	O	O
latter	O	O
K247Q	O	O
mutation	O	O
had	O	O
a	O	O
drastic	O	O
effect	O	O
on	O	O
enzyme	O	O
activity	O	O
.	O	O

We	O	O
verified	O	O
these	O	O
events	O	O
by	O	O
in	O	O
vivo	O	O
splicing	O	O
experiments	O	O
and	O	O
transient	O	O
expression	O	O
analysis	O	O
of	O	O
mutant	O	O
cDNAs	O	O
.	O	O

The	O	O
P65L	O	O
mutation	O	O
locates	O	O
11	O	O
bases	O	O
upstream	O	O
of	O	O
a	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
3	O	O
.	O	O

This	O	O
is	O	O
an	O	O
example	O	O
of	O	O
an	O	O
exonic	O	O
mutation	O	O
which	O	O
affects	O	O
exon	O	O
-	O	O
splicing	O	O
.	O	O

.	O	O

Amino	O	O
-	O	O
terminal	O	O
fragments	O	O
of	O	O
mutant	O	O
huntingtin	O	O
show	O	O
selective	O	O
accumulation	O	O
in	O	O
striatal	O	O
neurons	O	O
and	O	O
synaptic	O	O
toxicity	O	O
.	O	O

Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
is	O	O
caused	O	O
by	O	O
expansion	O	O
of	O	O
a	O	O
glutamine	O	O
repeat	O	O
in	O	O
the	O	O
amino	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
huntingtin	O	O
.	O	O

Despite	O	O
its	O	O
widespread	O	O
expression	O	O
,	O	O
mutant	O	O
huntingtin	O	O
induces	O	O
selective	O	O
neuronal	O	O
loss	O	O
in	O	O
striatal	O	O
neurons	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
,	O	O
in	O	O
mutant	O	O
mice	O	O
expressing	O	O
HD	B-Disease	D006816
repeats	O	O
,	O	O
the	O	O
production	O	O
and	O	O
aggregation	O	O
of	O	O
N	O	O
-	O	O
terminal	O	O
huntingtin	O	O
fragments	O	O
preferentially	O	O
occur	O	O
in	O	O
HD	B-Disease	D006816
-	O	O
affected	O	O
neurons	O	O
and	O	O
their	O	O
processes	O	O
and	O	O
axonal	O	O
terminals	O	O
.	O	O

N	O	O
-	O	O
terminal	O	O
fragments	O	O
of	O	O
mutant	O	O
huntingtin	O	O
form	O	O
aggregates	O	O
and	O	O
induce	O	O
neuritic	B-Disease	D009410
degeneration	I-Disease	D009410
in	O	O
cultured	O	O
striatal	O	O
neurons	O	O
.	O	O

N	O	O
-	O	O
terminal	O	O
mutant	O	O
huntingtin	O	O
also	O	O
binds	O	O
to	O	O
synaptic	O	O
vesicles	O	O
and	O	O
inhibits	O	O
their	O	O
glutamate	O	O
uptake	O	O
in	O	O
vitro	O	O
.	O	O

The	O	O
specific	O	O
processing	O	O
and	O	O
accumulation	O	O
of	O	O
toxic	O	O
fragments	O	O
of	O	O
N	O	O
-	O	O
terminal	O	O
huntingtin	O	O
in	O	O
HD	B-Disease	D006816
-	O	O
affected	O	O
striatal	O	O
neurons	O	O
,	O	O
especially	O	O
in	O	O
their	O	O
neuronal	O	O
processes	O	O
and	O	O
axonal	O	O
terminals	O	O
,	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
selective	O	O
neuropathology	O	O
of	O	O
HD	B-Disease	D006816
.	O	O

.	O	O

Phenotypic	O	O
variation	O	O
including	O	O
retinitis	B-Disease	D012174
pigmentosa	I-Disease	D012174
,	O	O
pattern	B-Disease	D008268
dystrophy	I-Disease	D008268
,	O	O
and	O	O
fundus	B-Disease	C535804
flavimaculatus	I-Disease	C535804
in	O	O
a	O	O
single	O	O
family	O	O
with	O	O
a	O	O
deletion	O	O
of	O	O
codon	O	O
153	O	O
or	O	O
154	O	O
of	O	O
the	O	O
peripherin	O	O
/	O	O
RDS	O	O
gene	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
Mutations	O	O
of	O	O
the	O	O
peripherin	O	O
/	O	O
RDS	O	O
gene	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
autosomal	B-Disease	D012174
dominant	I-Disease	D012174
retinitis	I-Disease	D012174
pigmentosa	I-Disease	D012174
,	O	O
pattern	B-Disease	D008268
macular	I-Disease	D008268
dystrophy	I-Disease	D008268
,	O	O
and	O	O
retinitis	B-Disease	OMIM:136880
punctata	I-Disease	OMIM:136880
albescens	I-Disease	OMIM:136880
.	O	O

We	O	O
report	O	O
herein	O	O
the	O	O
occurrence	O	O
of	O	O
three	O	O
separate	O	O
phenotypes	O	O
within	O	O
a	O	O
single	O	O
family	O	O
with	O	O
a	O	O
novel	O	O
3	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
of	O	O
codon	O	O
153	O	O
or	O	O
154	O	O
of	O	O
the	O	O
peripherin	O	O
/	O	O
RDS	O	O
gene	O	O
.	O	O

DESIGN	O	O
Case	O	O
reports	O	O
with	O	O
clinical	O	O
features	O	O
,	O	O
fluorescein	O	O
angiography	O	O
,	O	O
kinetic	O	O
perimetry	O	O
,	O	O
electrophysiological	O	O
studies	O	O
,	O	O
and	O	O
molecular	O	O
genetics	O	O
.	O	O

SETTING	O	O
University	O	O
medical	O	O
centers	O	O
.	O	O

PATIENTS	O	O
A	O	O
75	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
,	O	O
her	O	O
two	O	O
daughters	O	O
(	O	O
aged	O	O
44	O	O
and	O	O
50	O	O
years	O	O
)	O	O
,	O	O
and	O	O
her	O	O
49	O	O
-	O	O
year	O	O
-	O	O
old	O	O
son	O	O
were	O	O
screened	O	O
for	O	O
peripherin	O	O
/	O	O
RDS	O	O
mutations	O	O
because	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
multiple	O	O
phenotypes	O	O
within	O	O
the	O	O
same	O	O
family	O	O
.	O	O

RESULTS	O	O
The	O	O
mother	O	O
presented	O	O
at	O	O
age	O	O
63	O	O
years	O	O
with	O	O
a	O	O
profoundly	O	O
abnormal	O	O
electroretinogram	O	O
(	O	O
ERG	O	O
)	O	O
and	O	O
adult	O	O
-	O	O
onset	O	O
retinitis	B-Disease	D012174
pigmentosa	I-Disease	D012174
that	O	O
progressed	O	O
dramatically	O	O
over	O	O
12	O	O
years	O	O
,	O	O
with	O	O
marked	O	O
loss	O	O
of	O	O
peripheral	O	O
visual	O	O
field	O	O
.	O	O

One	O	O
daughter	O	O
developed	O	O
pattern	B-Disease	D008268
macular	I-Disease	D008268
dystrophy	I-Disease	D008268
at	O	O
age	O	O
31	O	O
years	O	O
.	O	O

At	O	O
age	O	O
44	O	O
years	O	O
,	O	O
her	O	O
ERG	O	O
was	O	O
moderately	O	O
abnormal	O	O
but	O	O
her	O	O
clinical	O	O
disease	O	O
was	O	O
limited	O	O
to	O	O
the	O	O
macula	O	O
.	O	O

Another	O	O
daughter	O	O
presented	O	O
at	O	O
age	O	O
42	O	O
years	O	O
with	O	O
macular	B-Disease	D008268
degeneration	I-Disease	D008268
and	O	O
over	O	O
10	O	O
years	O	O
developed	O	O
the	O	O
clinical	O	O
picture	O	O
of	O	O
fundus	B-Disease	C535804
flavimaculatus	I-Disease	C535804
.	O	O

Her	O	O
peripheral	O	O
visual	O	O
field	O	O
was	O	O
preserved	O	O
but	O	O
her	O	O
ERG	O	O
was	O	O
moderately	O	O
abnormal	O	O
.	O	O

The	O	O
son	O	O
had	O	O
onset	O	O
of	O	O
macular	B-Disease	D008268
degeneration	I-Disease	D008268
at	O	O
age	O	O
44	O	O
years	O	O
.	O	O

Pericentral	B-Disease	D012607
scotomas	I-Disease	D012607
were	O	O
present	O	O
and	O	O
the	O	O
ERG	O	O
was	O	O
markedly	O	O
abnormal	O	O
.	O	O

Fluorescein	O	O
angiography	O	O
revealed	O	O
punctate	O	O
pigment	O	O
epithelial	O	O
transmission	O	O
defects	O	O
.	O	O

CONCLUSIONS	O	O
A	O	O
3	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
of	O	O
codon	O	O
153	O	O
or	O	O
154	O	O
of	O	O
the	O	O
peripherin	O	O
/	O	O
RDS	O	O
gene	O	O
can	O	O
produce	O	O
clinically	O	O
disparate	O	O
phenotypes	O	O
even	O	O
within	O	O
the	O	O
same	O	O
family	O	O
.	O	O

.	O	O

Missense	O	O
mutation	O	O
in	O	O
the	O	O
alternative	O	O
splice	O	O
region	O	O
of	O	O
the	O	O
PAX6	O	O
gene	O	O
in	O	O
eye	B-Disease	D005124
anomalies	I-Disease	D005124
.	O	O

The	O	O
PAX6	O	O
gene	O	O
is	O	O
involved	O	O
in	O	O
ocular	O	O
morphogenesis	O	O
,	O	O
and	O	O
PAX6	O	O
mutations	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
various	O	O
types	O	O
of	O	O
ocular	B-Disease	D005124
anomalies	I-Disease	D005124
,	O	O
including	O	O
aniridia	B-Disease	D015783
,	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
,	O	O
corneal	B-Disease	D003317
dystrophy	I-Disease	D003317
,	O	O
congenital	B-Disease	D002386
cataract	I-Disease	D002386
,	O	O
and	O	O
foveal	B-Disease	OMIM:136520
hypoplasia	I-Disease	OMIM:136520
.	O	O

The	O	O
gene	O	O
encodes	O	O
a	O	O
transcriptional	O	O
regulator	O	O
that	O	O
recognizes	O	O
target	O	O
genes	O	O
through	O	O
its	O	O
paired	O	O
-	O	O
type	O	O
DNA	O	O
-	O	O
binding	O	O
domain	O	O
.	O	O

The	O	O
paired	O	O
domain	O	O
is	O	O
composed	O	O
of	O	O
two	O	O
distinct	O	O
DNA	O	O
-	O	O
binding	O	O
subdomains	O	O
,	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
subdomain	O	O
(	O	O
NTS	O	O
)	O	O
and	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
subdomain	O	O
(	O	O
CTS	O	O
)	O	O
,	O	O
which	O	O
bind	O	O
respective	O	O
consensus	O	O
DNA	O	O
sequences	O	O
.	O	O

The	O	O
human	O	O
PAX6	O	O
gene	O	O
produces	O	O
two	O	O
alternative	O	O
splice	O	O
isoforms	O	O
that	O	O
have	O	O
the	O	O
distinct	O	O
structure	O	O
of	O	O
the	O	O
paired	O	O
domain	O	O
.	O	O

The	O	O
insertion	O	O
,	O	O
into	O	O
the	O	O
NTS	O	O
,	O	O
of	O	O
14	O	O
additional	O	O
amino	O	O
acids	O	O
encoded	O	O
by	O	O
exon	O	O
5a	O	O
abolishes	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
activity	O	O
of	O	O
the	O	O
NTS	O	O
and	O	O
unmasks	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
ability	O	O
of	O	O
the	O	O
CTS	O	O
.	O	O

Thus	O	O
,	O	O
exon	O	O
5a	O	O
appears	O	O
to	O	O
function	O	O
as	O	O
a	O	O
molecular	O	O
switch	O	O
that	O	O
specifies	O	O
target	O	O
genes	O	O
.	O	O

We	O	O
ascertained	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
in	O	O
four	O	O
pedigrees	O	O
with	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
,	O	O
congenital	B-Disease	D002386
cataract	I-Disease	D002386
,	O	O
Axenfeldt	B-Disease	C535679
anomaly	I-Disease	C535679
,	O	O
and	O	O
/	O	O
or	O	O
foveal	B-Disease	OMIM:136520
hypoplasia	I-Disease	OMIM:136520
,	O	O
which	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
is	O	O
the	O	O
first	O	O
mutation	O	O
identified	O	O
in	O	O
the	O	O
splice	O	O
-	O	O
variant	O	O
region	O	O
.	O	O

A	O	O
T	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
the	O	O
20th	O	O
nucleotide	O	O
position	O	O
of	O	O
exon	O	O
5a	O	O
results	O	O
in	O	O
a	O	O
Val	O	O
-	O	O
-	O	O
>	O	O
Asp	O	O
(	O	O
GTC	O	O
-	O	O
-	O	O
>	O	O
GAC	O	O
)	O	O
substitution	O	O
at	O	O
the	O	O
7th	O	O
codon	O	O
of	O	O
the	O	O
alternative	O	O
splice	O	O
region	O	O
.	O	O

Functional	O	O
analyses	O	O
demonstrated	O	O
that	O	O
the	O	O
V54D	O	O
mutation	O	O
slightly	O	O
increased	O	O
NTS	O	O
binding	O	O
and	O	O
decreased	O	O
CTS	O	O
transactivation	O	O
activity	O	O
to	O	O
almost	O	O
half	O	O
.	O	O

.	O	O

A	O	O
detailed	O	O
multipoint	O	O
map	O	O
of	O	O
human	O	O
chromosome	O	O
4	O	O
provides	O	O
evidence	O	O
for	O	O
linkage	O	O
heterogeneity	O	O
and	O	O
position	O	O
-	O	O
specific	O	O
recombination	O	O
rates	O	O
.	O	O

Utilizing	O	O
the	O	O
CEPH	O	O
reference	O	O
panel	O	O
and	O	O
genotypic	O	O
data	O	O
for	O	O
53	O	O
markers	O	O
,	O	O
we	O	O
have	O	O
constructed	O	O
a	O	O
20	O	O
-	O	O
locus	O	O
multipoint	O	O
genetic	O	O
map	O	O
of	O	O
human	O	O
chromosome	O	O
4	O	O
.	O	O

New	O	O
RFLPs	O	O
are	O	O
reported	O	O
for	O	O
four	O	O
loci	O	O
.	O	O

The	O	O
map	O	O
integrates	O	O
a	O	O
high	O	O
-	O	O
resolution	O	O
genetic	O	O
map	O	O
of	O	O
4p16	O	O
into	O	O
a	O	O
continuous	O	O
map	O	O
extending	O	O
to	O	O
4q31	O	O
and	O	O
an	O	O
unlinked	O	O
cluster	O	O
of	O	O
three	O	O
loci	O	O
at	O	O
4q35	O	O
.	O	O

The	O	O
20	O	O
linked	O	O
markers	O	O
form	O	O
a	O	O
continuous	O	O
linkage	O	O
group	O	O
of	O	O
152	O	O
cM	O	O
in	O	O
males	O	O
and	O	O
202	O	O
cM	O	O
in	O	O
females	O	O
.	O	O

Likely	O	O
genetic	O	O
locations	O	O
are	O	O
provided	O	O
for	O	O
25	O	O
polymorphic	O	O
anonymous	O	O
sequences	O	O
and	O	O
28	O	O
gene	O	O
-	O	O
specific	O	O
RFLPs	O	O
.	O	O

The	O	O
map	O	O
was	O	O
constructed	O	O
employing	O	O
the	O	O
LINKAGE	O	O
and	O	O
CRIMAP	O	O
computational	O	O
methodologies	O	O
to	O	O
build	O	O
the	O	O
multipoint	O	O
map	O	O
via	O	O
a	O	O
stepwise	O	O
algorithm	O	O
.	O	O

A	O	O
detailed	O	O
10	O	O
-	O	O
point	O	O
map	O	O
of	O	O
the	O	O
4p16	O	O
region	O	O
constructed	O	O
from	O	O
the	O	O
CEPH	O	O
panel	O	O
provides	O	O
evidence	O	O
for	O	O
heterogeneity	O	O
in	O	O
the	O	O
linkage	O	O
maps	O	O
constructed	O	O
from	O	O
families	O	O
segregating	O	O
for	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
.	O	O

It	O	O
additionally	O	O
provides	O	O
evidence	O	O
for	O	O
position	O	O
-	O	O
specific	O	O
recombination	O	O
frequencies	O	O
in	O	O
the	O	O
telomeric	O	O
region	O	O
of	O	O
4p	O	O
.	O	O

.	O	O

The	O	O
murine	O	O
homolog	O	O
of	O	O
the	O	O
human	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
Brca1	O	O
maps	O	O
to	O	O
mouse	O	O
chromosome	O	O
11D	O	O
.	O	O

The	O	O
recently	O	O
cloned	O	O
human	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
is	O	O
located	O	O
on	O	O
human	O	O
chromosome	O	O
17q21	O	O
.	O	O

We	O	O
have	O	O
isolated	O	O
murine	O	O
genomic	O	O
clones	O	O
containing	O	O
Brca1	O	O
as	O	O
a	O	O
first	O	O
step	O	O
in	O	O
generating	O	O
a	O	O
mouse	O	O
model	O	O
for	O	O
the	O	O
loss	O	O
of	O	O
BRCA1	O	O
function	O	O
.	O	O

A	O	O
mouse	O	O
genomic	O	O
library	O	O
was	O	O
screened	O	O
using	O	O
probes	O	O
corresponding	O	O
to	O	O
exon	O	O
11	O	O
of	O	O
the	O	O
human	O	O
BRCA1	O	O
gene	O	O
.	O	O

Two	O	O
overlapping	O	O
mouse	O	O
clones	O	O
were	O	O
identified	O	O
that	O	O
hybridized	O	O
to	O	O
human	O	O
BRCA1	O	O
exons	O	O
9	O	O
-	O	O
12	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
1	O	O
.	O	O

4	O	O
kb	O	O
of	O	O
the	O	O
region	O	O
of	O	O
these	O	O
clones	O	O
corresponding	O	O
to	O	O
part	O	O
of	O	O
human	O	O
exon	O	O
11	O	O
revealed	O	O
72	O	O
%	O	O
nucleic	O	O
acid	O	O
identity	O	O
but	O	O
only	O	O
50	O	O
%	O	O
amino	O	O
acid	O	O
identity	O	O
with	O	O
the	O	O
human	O	O
gene	O	O
.	O	O

The	O	O
longest	O	O
of	O	O
the	O	O
mouse	O	O
Brca1	O	O
genomic	O	O
clones	O	O
maps	O	O
to	O	O
chromosome	O	O
11D	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
two	O	O
-	O	O
color	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
.	O	O

The	O	O
synteny	O	O
to	O	O
human	O	O
chromosome	O	O
17	O	O
was	O	O
confirmed	O	O
by	O	O
cohybridization	O	O
with	O	O
the	O	O
mouse	O	O
probe	O	O
for	O	O
the	O	O
NF1	O	O
-	O	O
gene	O	O
.	O	O

This	O	O
comparative	O	O
study	O	O
confirms	O	O
that	O	O
the	O	O
relative	O	O
location	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
has	O	O
been	O	O
conserved	O	O
between	O	O
mice	O	O
and	O	O
humans	O	O
.	O	O

High	O	O
residual	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
activity	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
late	B-Disease	D007966
-	I-Disease	D007966
infantile	I-Disease	D007966
metachromatic	I-Disease	D007966
leukodystrophy	I-Disease	D007966
.	O	O

We	O	O
identified	O	O
a	O	O
patient	O	O
suffering	O	O
from	O	O
late	B-Disease	D007966
-	I-Disease	D007966
infantile	I-Disease	D007966
metachromatic	I-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
who	O	O
has	O	O
a	O	O
residual	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
activity	O	O
of	O	O
about	O	O
10	O	O
%	O	O
.	O	O

Fibroblasts	O	O
of	O	O
the	O	O
patient	O	O
show	O	O
significant	O	O
sulfatide	O	O
degradation	O	O
activity	O	O
exceeding	O	O
that	O	O
of	O	O
adult	B-Disease	D007966
MLD	I-Disease	D007966
patients	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
ARSA	O	O
gene	O	O
in	O	O
this	O	O
patient	O	O
revealed	O	O
heterozygosity	O	O
for	O	O
two	O	O
new	O	O
mutant	O	O
alleles	O	O
in	O	O
one	O	O
allele	O	O
,	O	O
deletion	O	O
of	O	O
C	O	O
447	O	O
in	O	O
exon	O	O
2	O	O
leads	O	O
to	O	O
a	O	O
frameshift	O	O
and	O	O
to	O	O
a	O	O
premature	O	O
stop	O	O
codon	O	O
at	O	O
amino	O	O
acid	O	O
position	O	O
105	O	O
;	O	O
in	O	O
the	O	O
second	O	O
allele	O	O
,	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
in	O	O
exon	O	O
5	O	O
causes	O	O
a	O	O
Gly309	O	O
-	O	O
-	O	O
>	O	O
Ser	O	O
substitution	O	O
.	O	O

Transient	O	O
expression	O	O
of	O	O
the	O	O
mutant	O	O
Ser309	O	O
-	O	O
ARSA	O	O
resulted	O	O
in	O	O
only	O	O
13	O	O
%	O	O
enzyme	O	O
activity	O	O
of	O	O
that	O	O
observed	O	O
in	O	O
cells	O	O
expressing	O	O
normal	O	O
ARSA	O	O
.	O	O

The	O	O
mutant	O	O
ARSA	O	O
is	O	O
correctly	O	O
targeted	O	O
to	O	O
the	O	O
lysosomes	O	O
but	O	O
is	O	O
unstable	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
in	O	O
contrast	O	O
to	O	O
previous	O	O
results	O	O
showing	O	O
that	O	O
the	O	O
late	B-Disease	D007966
-	I-Disease	D007966
infantile	I-Disease	D007966
type	I-Disease	D007966
of	I-Disease	D007966
MLD	I-Disease	D007966
is	O	O
always	O	O
associated	O	O
with	O	O
the	O	O
complete	O	O
absence	O	O
of	O	O
ARSA	O	O
activity	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
the	O	O
mutant	O	O
ARSA	O	O
protein	O	O
may	O	O
be	O	O
influenced	O	O
by	O	O
particular	O	O
features	O	O
of	O	O
oligodendrocytes	O	O
,	O	O
such	O	O
that	O	O
the	O	O
level	O	O
of	O	O
mutant	O	O
enzyme	O	O
is	O	O
lower	O	O
in	O	O
these	O	O
cells	O	O
than	O	O
in	O	O
others	O	O
.	O	O

.	O	O

De	O	O
novo	O	O
deletions	O	O
of	O	O
SNRPN	O	O
exon	O	O
1	O	O
in	O	O
early	O	O
human	O	O
and	O	O
mouse	O	O
embryos	O	O
result	O	O
in	O	O
a	O	O
paternal	O	O
to	O	O
maternal	O	O
imprint	O	O
switch	O	O
.	O	O

Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
is	O	O
a	O	O
neurogenetic	B-Disease	D020271
disease	I-Disease	D020271
characterized	O	O
by	O	O
infantile	B-Disease	D009123
hypotonia	I-Disease	D009123
,	O	O
gonadal	B-Disease	D006058
hypoplasia	I-Disease	D006058
,	O	O
obsessive	O	O
behaviour	O	O
and	O	O
neonatal	O	O
feeding	O	O
difficulties	O	O
followed	O	O
by	O	O
hyperphagia	B-Disease	D006963
,	O	O
leading	O	O
to	O	O
profound	O	O
obesity	B-Disease	D009765
.	O	O

PWS	B-Disease	D011218
is	O	O
due	O	O
to	O	O
a	O	O
lack	O	O
of	O	O
paternal	O	O
genetic	O	O
information	O	O
at	O	O
15q11	O	O
-	O	O
q13	O	O
(	O	O
ref	O	O
.	O	O

2	O	O
)	O	O
.	O	O

Five	O	O
imprinted	O	O
,	O	O
paternally	O	O
expressed	O	O
genes	O	O
map	O	O
to	O	O
the	O	O
PWS	B-Disease	D011218
region	O	O
,	O	O
MKRN3	O	O
(	O	O
ref	O	O
.	O	O

3	O	O
)	O	O
,	O	O
NDN	O	O
(	O	O
ref	O	O
.	O	O

4	O	O
)	O	O
,	O	O
NDNL1	O	O
(	O	O
ref	O	O
.	O	O

5	O	O
)	O	O
,	O	O
SNRPN	O	O
(	O	O
refs	O	O
6	O	O
-	O	O
8	O	O
)	O	O
and	O	O
IPW	O	O
(	O	O
ref	O	O
.	O	O

9	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
two	O	O
poorly	O	O
characterized	O	O
framents	O	O
designated	O	O
PAR	O	O
-	O	O
1	O	O
and	O	O
PAR	O	O
-	O	O
5	O	O
(	O	O
ref	O	O
.	O	O

10	O	O
)	O	O
.	O	O

Imprinting	O	O
of	O	O
this	O	O
region	O	O
involves	O	O
a	O	O
bipartite	O	O
imprinting	O	O
centre	O	O
(	O	O
IC	O	O
)	O	O
,	O	O
which	O	O
overlaps	O	O
SNRPN	O	O
(	O	O
refs	O	O
10	O	O
,	O	O
11	O	O
)	O	O
.	O	O

Deletion	O	O
of	O	O
the	O	O
SNRPN	O	O
promoter	O	O
/	O	O
exon	O	O
1	O	O
region	O	O
(	O	O
the	O	O
PWS	B-Disease	D011218
IC	O	O
element	O	O
)	O	O
appears	O	O
to	O	O
impair	O	O
the	O	O
establishment	O	O
of	O	O
the	O	O
paternal	O	O
imprint	O	O
in	O	O
the	O	O
male	O	O
germ	O	O
line	O	O
and	O	O
leads	O	O
to	O	O
PWS	B-Disease	D011218
.	O	O

Here	O	O
we	O	O
report	O	O
a	O	O
PWS	B-Disease	D011218
family	O	O
in	O	O
which	O	O
the	O	O
father	O	O
is	O	O
mosaic	O	O
for	O	O
an	O	O
IC	O	O
deletion	O	O
on	O	O
his	O	O
paternal	O	O
chromosome	O	O
.	O	O

The	O	O
deletion	O	O
chromosome	O	O
has	O	O
acquired	O	O
a	O	O
maternal	O	O
methylation	O	O
imprint	O	O
in	O	O
his	O	O
somatic	O	O
cells	O	O
.	O	O

We	O	O
have	O	O
made	O	O
identical	O	O
findings	O	O
in	O	O
chimaeric	O	O
mice	O	O
generated	O	O
from	O	O
two	O	O
independent	O	O
embryonic	O	O
stem	O	O
(	O	O
ES	O	O
)	O	O
cell	O	O
lines	O	O
harbouring	O	O
a	O	O
similar	O	O
deletion	O	O
.	O	O

Our	O	O
studies	O	O
demonstrate	O	O
that	O	O
the	O	O
PWS	B-Disease	D011218
IC	O	O
element	O	O
is	O	O
not	O	O
only	O	O
required	O	O
for	O	O
the	O	O
establishment	O	O
of	O	O
the	O	O
paternal	O	O
imprint	O	O
,	O	O
but	O	O
also	O	O
for	O	O
its	O	O
postzygotic	O	O
maintenance	O	O
.	O	O

.	O	O

Molecular	O	O
characterization	O	O
of	O	O
two	O	O
galactosemia	B-Disease	D005693
mutations	O	O
:	O	O
correlation	O	O
of	O	O
mutations	O	O
with	O	O
highly	O	O
conserved	O	O
domains	O	O
in	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyl	O	O
transferase	O	O
.	O	O

Galactosemia	B-Disease	D005693
is	O	O
an	O	O
autosomal	B-Disease	D005693
recessive	I-Disease	D005693
disorder	I-Disease	D005693
of	I-Disease	D005693
human	I-Disease	D005693
galactose	I-Disease	D005693
metabolism	I-Disease	D005693
caused	O	O
by	O	O
deficiency	B-Disease	D005693
of	I-Disease	D005693
the	I-Disease	D005693
enzyme	I-Disease	D005693
galactose	I-Disease	D005693
-	I-Disease	D005693
1	I-Disease	D005693
-	I-Disease	D005693
phosphate	I-Disease	D005693
uridyl	I-Disease	D005693
transferase	I-Disease	D005693
(	O	O
GALT	O	O
)	O	O
.	O	O

The	O	O
molecular	O	O
basis	O	O
of	O	O
this	O	O
disorder	O	O
is	O	O
at	O	O
present	O	O
not	O	O
well	O	O
understood	O	O
.	O	O

We	O	O
report	O	O
here	O	O
two	O	O
missense	O	O
mutations	O	O
which	O	O
result	O	O
in	O	O
low	O	O
or	O	O
undetectable	O	O
enzymatic	O	O
activity	O	O
.	O	O

First	O	O
,	O	O
we	O	O
identified	O	O
at	O	O
nucleotide	O	O
591	O	O
a	O	O
transition	O	O
which	O	O
substitutes	O	O
glutamine	O	O
188	O	O
by	O	O
arginine	O	O
.	O	O

The	O	O
mutated	O	O
glutamine	O	O
is	O	O
not	O	O
only	O	O
highly	O	O
conserved	O	O
in	O	O
evolution	O	O
(	O	O
conserved	O	O
also	O	O
in	O	O
Escherichia	O	O
coli	O	O
and	O	O
Saccharomyces	O	O
cerevisiae	O	O
)	O	O
,	O	O
but	O	O
is	O	O
also	O	O
two	O	O
amino	O	O
acid	O	O
residues	O	O
downstream	O	O
from	O	O
the	O	O
active	O	O
site	O	O
histidine	O	O
-	O	O
proline	O	O
-	O	O
histidine	O	O
triad	O	O
and	O	O
results	O	O
in	O	O
about	O	O
10	O	O
%	O	O
of	O	O
normal	O	O
enzymatic	O	O
activity	O	O
.	O	O

The	O	O
arginine	O	O
188	O	O
mutation	O	O
is	O	O
the	O	O
most	O	O
common	O	O
galactosemia	B-Disease	D005693
mutation	O	O
characterized	O	O
to	O	O
date	O	O
.	O	O

It	O	O
accounts	O	O
for	O	O
one	O	O
-	O	O
fourth	O	O
of	O	O
the	O	O
galactosemia	B-Disease	D005693
alleles	O	O
studied	O	O
.	O	O

Second	O	O
,	O	O
we	O	O
report	O	O
the	O	O
substitution	O	O
of	O	O
arginine	O	O
333	O	O
by	O	O
tryptophan	O	O
,	O	O
caused	O	O
by	O	O
a	O	O
transition	O	O
at	O	O
nucleotide	O	O
1025	O	O
.	O	O

The	O	O
area	O	O
surrounding	O	O
this	O	O
missense	O	O
mutation	O	O
is	O	O
the	O	O
most	O	O
highly	O	O
conserved	O	O
domain	O	O
in	O	O
the	O	O
homologous	O	O
enzymes	O	O
from	O	O
E	O	O
.	O	O

coli	O	O
,	O	O
yeast	O	O
,	O	O
and	O	O
humans	O	O
,	O	O
and	O	O
this	O	O
mutation	O	O
results	O	O
in	O	O
undetectable	O	O
enzymatic	O	O
activity	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
is	O	O
a	O	O
severe	O	O
mutation	O	O
.	O	O

This	O	O
second	O	O
mutation	O	O
appears	O	O
to	O	O
be	O	O
rare	O	O
,	O	O
since	O	O
it	O	O
was	O	O
found	O	O
only	O	O
in	O	O
the	O	O
patient	O	O
we	O	O
sequenced	O	O
.	O	O

Our	O	O
data	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
the	O	O
heterogeneity	O	O
of	O	O
galactosemia	B-Disease	D005693
at	O	O
the	O	O
molecular	O	O
level	O	O
,	O	O
heterogeneity	O	O
which	O	O
might	O	O
be	O	O
related	O	O
to	O	O
the	O	O
variable	O	O
clinical	O	O
outcome	O	O
observed	O	O
in	O	O
this	O	O
disorder	O	O
.	O	O

.	O	O

Neurophysiologic	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
long	O	O
-	O	O
term	O	O
dietary	O	O
treatment	O	O
in	O	O
adult	O	O
-	O	O
onset	O	O
adrenoleukodystrophy	B-Disease	D000326
.	O	O

OBJECTIVE	O	O
To	O	O
monitor	O	O
the	O	O
effects	O	O
of	O	O
dietary	O	O
treatment	O	O
in	O	O
adult	O	O
-	O	O
onset	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
by	O	O
means	O	O
of	O	O
somatosensory	O	O
evoked	O	O
potentials	O	O
(	O	O
SEPs	O	O
)	O	O
and	O	O
motor	O	O
evoked	O	O
potentials	O	O
(	O	O
MEPs	O	O
)	O	O
.	O	O

BACKGROUND	O	O
SEPs	O	O
and	O	O
MEPs	O	O
have	O	O
proved	O	O
useful	O	O
in	O	O
revealing	O	O
signs	O	O
of	O	O
progressively	O	O
severe	O	O
,	O	O
central	O	O
dying	B-Disease	D016472
-	I-Disease	D016472
back	I-Disease	D016472
axonopathy	I-Disease	D016472
in	O	O
early	O	O
stages	O	O
of	O	O
adult	O	O
-	O	O
onset	O	O
ALD	B-Disease	D000326
.	O	O

METHODS	O	O
Eight	O	O
patients	O	O
with	O	O
adult	O	O
-	O	O
onset	O	O
ALD	B-Disease	D000326
underwent	O	O
clinical	O	O
examination	O	O
,	O	O
brain	O	O
and	O	O
spine	O	O
MRI	O	O
,	O	O
and	O	O
SEP	O	O
and	O	O
MEP	O	O
studies	O	O
before	O	O
and	O	O
after	O	O
3	O	O
years	O	O
of	O	O
Lorenzos	O	O
oil	O	O
dietary	O	O
therapy	O	O
.	O	O

RESULTS	O	O
Before	O	O
treatment	O	O
,	O	O
brain	O	O
MRI	O	O
was	O	O
normal	O	O
in	O	O
five	O	O
patients	O	O
.	O	O

Three	O	O
of	O	O
these	O	O
patients	O	O
had	O	O
pure	O	O
spinal	B-Disease	D016472
SEP	I-Disease	D016472
abnormalities	I-Disease	D016472
and	O	O
in	O	O
the	O	O
remaining	O	O
two	O	O
patients	O	O
SEPs	O	O
showed	O	O
signs	O	O
of	O	O
involvement	O	O
of	O	O
both	O	O
the	O	O
spinal	O	O
and	O	O
cerebral	O	O
somatosensory	O	O
tracts	O	O
.	O	O

After	O	O
treatment	O	O
,	O	O
the	O	O
three	O	O
patients	O	O
with	O	O
pure	O	O
spinal	B-Disease	D016472
abnormalities	I-Disease	D016472
showed	O	O
clinical	O	O
and	O	O
neurophysiologic	O	O
worsening	O	O
,	O	O
whereas	O	O
the	O	O
two	O	O
patients	O	O
with	O	O
a	O	O
more	O	O
advanced	O	O
stage	O	O
of	O	O
disease	O	O
(	O	O
exhibited	O	O
by	O	O
SEPs	O	O
)	O	O
showed	O	O
substantially	O	O
unchanged	O	O
clinical	O	O
and	O	O
neurophysiologic	O	O
features	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
abnormal	O	O
brain	O	O
MRI	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
treatment	O	O
showed	O	O
clinical	O	O
and	O	O
neurophysiologic	O	O
worsening	O	O
.	O	O

CONCLUSIONS	O	O
Lorenzos	O	O
oil	O	O
therapy	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
patients	O	O
with	O	O
evidence	O	O
of	O	O
inflammatory	B-Disease	D004660
brain	I-Disease	D004660
lesions	I-Disease	D004660
.	O	O

Moreover	O	O
,	O	O
in	O	O
patients	O	O
without	O	O
clear	O	O
signs	O	O
of	O	O
inflammatory	O	O
damage	O	O
,	O	O
this	O	O
treatment	O	O
does	O	O
not	O	O
modify	O	O
significantly	O	O
the	O	O
natural	O	O
course	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

However	O	O
,	O	O
because	O	O
effective	O	O
treatments	O	O
should	O	O
begin	O	O
before	O	O
the	O	O
onset	O	O
of	O	O
severe	O	O
neurologic	O	O
symptoms	O	O
,	O	O
SEPs	O	O
and	O	O
MEPs	O	O
should	O	O
be	O	O
considered	O	O
to	O	O
evaluate	O	O
the	O	O
effectiveness	O	O
of	O	O
other	O	O
experimental	O	O
treatments	O	O
in	O	O
the	O	O
patient	O	O
with	O	O
a	O	O
negative	O	O
brain	O	O
MRI	O	O
.	O	O

The	O	O
molecular	O	O
basis	O	O
of	O	O
Sjogren	B-Disease	D016111
-	I-Disease	D016111
Larsson	I-Disease	D016111
syndrome	I-Disease	D016111
:	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
fatty	O	O
aldehyde	O	O
dehydrogenase	O	O
gene	O	O
.	O	O

Sjogren	B-Disease	D016111
-	I-Disease	D016111
Larsson	I-Disease	D016111
syndrome	I-Disease	D016111
(	O	O
SLS	B-Disease	D016111
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
ichthyosis	B-Disease	D007057
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
spasticity	B-Disease	D009128
,	O	O
and	O	O
deficient	B-Disease	D016111
activity	I-Disease	D016111
of	I-Disease	D016111
fatty	I-Disease	D016111
aldehyde	I-Disease	D016111
dehydrogenase	I-Disease	D016111
(	O	O
FALDH	O	O
)	O	O
.	O	O

To	O	O
define	O	O
the	O	O
molecular	O	O
defects	O	O
causing	O	O
SLS	B-Disease	D016111
,	O	O
we	O	O
performed	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
FALDH	O	O
gene	O	O
in	O	O
probands	O	O
from	O	O
63	O	O
kindreds	O	O
with	O	O
SLS	B-Disease	D016111
.	O	O

Among	O	O
these	O	O
patients	O	O
,	O	O
49	O	O
different	O	O
mutations	O	O
-	O	O
including	O	O
10	O	O
deletions	O	O
,	O	O
2	O	O
insertions	O	O
,	O	O
22	O	O
amino	O	O
acid	O	O
substitutions	O	O
,	O	O
3	O	O
nonsense	O	O
mutations	O	O
,	O	O
9	O	O
splice	O	O
-	O	O
site	O	O
defects	O	O
,	O	O
and	O	O
3	O	O
complex	O	O
mutations	O	O
-	O	O
were	O	O
found	O	O
.	O	O

All	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
SLS	B-Disease	D016111
were	O	O
found	O	O
to	O	O
carry	O	O
mutations	O	O
.	O	O

Nineteen	O	O
of	O	O
the	O	O
missense	O	O
mutations	O	O
resulted	O	O
in	O	O
a	O	O
severe	O	O
reduction	O	O
of	O	O
FALDH	O	O
enzyme	O	O
catalytic	O	O
activity	O	O
when	O	O
expressed	O	O
in	O	O
mammalian	O	O
cells	O	O
,	O	O
but	O	O
one	O	O
mutation	O	O
(	O	O
798G	O	O
-	O	O
-	O	O
>	O	O
C	O	O
[	O	O
K266N	O	O
]	O	O
)	O	O
seemed	O	O
to	O	O
have	O	O
a	O	O
greater	O	O
effect	O	O
on	O	O
mRNA	O	O
stability	O	O
.	O	O

The	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
led	O	O
to	O	O
exon	O	O
skipping	O	O
or	O	O
utilization	O	O
of	O	O
cryptic	O	O
acceptor	O	O
-	O	O
splice	O	O
sites	O	O
.	O	O

Thirty	O	O
-	O	O
seven	O	O
mutations	O	O
were	O	O
private	O	O
,	O	O
and	O	O
12	O	O
mutations	O	O
were	O	O
seen	O	O
in	O	O
two	O	O
or	O	O
more	O	O
probands	O	O
of	O	O
European	O	O
or	O	O
Middle	O	O
Eastern	O	O
descent	O	O
.	O	O

Four	O	O
single	O	O
-	O	O
nucleotide	O	O
polymorphisms	O	O
(	O	O
SNPs	O	O
)	O	O
were	O	O
found	O	O
in	O	O
the	O	O
FALDH	O	O
gene	O	O
.	O	O

At	O	O
least	O	O
four	O	O
of	O	O
the	O	O
common	O	O
mutations	O	O
(	O	O
551C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
,	O	O
682C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
,	O	O
733G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
,	O	O
and	O	O
798	O	O
+	O	O
1delG	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
multiple	O	O
SNP	O	O
haplotypes	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
mutations	O	O
originated	O	O
independently	O	O
on	O	O
more	O	O
than	O	O
one	O	O
occasion	O	O
or	O	O
were	O	O
ancient	O	O
SLS	B-Disease	D016111
genes	O	O
that	O	O
had	O	O
undergone	O	O
intragenic	O	O
recombination	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
SLS	B-Disease	D016111
is	O	O
caused	O	O
by	O	O
a	O	O
strikingly	O	O
heterogeneous	O	O
group	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
FALDH	O	O
gene	O	O
and	O	O
provide	O	O
a	O	O
framework	O	O
for	O	O
understanding	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
SLS	B-Disease	D016111
and	O	O
the	O	O
development	O	O
of	O	O
DNA	O	O
-	O	O
based	O	O
diagnostic	O	O
tests	O	O
.	O	O

.	O	O

Severe	B-Disease	D005955
-	I-Disease	D005955
glucose	I-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
associated	O	O
with	O	O
chronic	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
,	O	O
granulocyte	B-Disease	D007960
dysfunction	I-Disease	D007960
,	O	O
and	O	O
increased	O	O
susceptibility	O	O
to	O	O
infections	O	O
:	O	O
description	O	O
of	O	O
a	O	O
new	O	O
molecular	O	O
variant	O	O
(	O	O
G6PD	O	O
Barcelona	O	O
)	O	O
.	O	O

Molecular	O	O
,	O	O
kinetic	O	O
,	O	O
and	O	O
functional	O	O
studies	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
erythrocytes	O	O
and	O	O
leukocytes	O	O
in	O	O
a	O	O
Spanish	O	O
male	O	O
with	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
congenital	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
(	O	O
CNSHA	B-Disease	D000746
)	O	O
,	O	O
and	O	O
increased	O	O
susceptibility	O	O
to	O	O
infections	O	O
.	O	O

G6PD	O	O
activity	O	O
was	O	O
absent	O	O
in	O	O
patients	O	O
red	O	O
cells	O	O
and	O	O
was	O	O
about	O	O
2	O	O
%	O	O
of	O	O
normal	O	O
in	O	O
leukocytes	O	O
.	O	O

Molecular	O	O
studies	O	O
using	O	O
standard	O	O
methods	O	O
(	O	O
WHO	O	O
,	O	O
1967	O	O
)	O	O
showed	O	O
G6PD	O	O
in	O	O
the	O	O
patient	O	O
to	O	O
have	O	O
a	O	O
slightly	O	O
fast	O	O
electrophoretic	O	O
mobility	O	O
at	O	O
pH	O	O
8	O	O
.	O	O

0	O	O
with	O	O
otherwise	O	O
normal	O	O
properties	O	O
(	O	O
heat	O	O
stability	O	O
at	O	O
46	O	O
degrees	O	O
C	O	O
,	O	O
apparent	O	O
affinity	O	O
for	O	O
substrates	O	O
,	O	O
optimum	O	O
pH	O	O
,	O	O
and	O	O
utilization	O	O
of	O	O
substrate	O	O
analogues	O	O
)	O	O
.	O	O

Other	O	O
tests	O	O
showed	O	O
the	O	O
patients	O	O
granulocytes	O	O
to	O	O
engulf	O	O
latex	O	O
particles	O	O
normally	O	O
,	O	O
but	O	O
to	O	O
have	O	O
impaired	O	O
reduction	O	O
of	O	O
nitroblue	O	O
tetrazolium	O	O
and	O	O
ferricytochrome	O	O
-	O	O
c	O	O
as	O	O
well	O	O
as	O	O
reduced	O	O
iodination	O	O
.	O	O

Chemotaxis	O	O
and	O	O
random	O	O
migration	O	O
of	O	O
the	O	O
patients	O	O
granulocytes	O	O
were	O	O
normal	O	O
as	O	O
were	O	O
myeloperoxidase	O	O
,	O	O
leukocyte	O	O
alkaline	O	O
phosphatase	O	O
(	O	O
LAP	O	O
)	O	O
,	O	O
and	O	O
ultrastructural	O	O
features	O	O
.	O	O

The	O	O
molecular	O	O
characteristics	O	O
of	O	O
G6PD	O	O
in	O	O
the	O	O
patient	O	O
differed	O	O
from	O	O
those	O	O
of	O	O
all	O	O
previously	O	O
reported	O	O
variants	O	O
associated	O	O
with	O	O
CNSHA	B-Disease	D000746
,	O	O
so	O	O
the	O	O
present	O	O
variant	O	O
was	O	O
provisionally	O	O
called	O	O
G6PD	O	O
Barcelona	O	O
to	O	O
distinguish	O	O
it	O	O
from	O	O
other	O	O
G6PD	O	O
variants	O	O
previously	O	O
described	O	O
.	O	O

Possible	O	O
mechanisms	O	O
for	O	O
the	O	O
severe	O	O
deficiency	B-Disease	D005955
of	I-Disease	D005955
G6PD	I-Disease	D005955
in	O	O
erythrocytes	O	O
and	O	O
granulocytes	O	O
was	O	O
investigated	O	O
by	O	O
studies	O	O
on	O	O
the	O	O
immunologic	O	O
specific	O	O
activity	O	O
of	O	O
the	O	O
mutant	O	O
enzyme	O	O
.	O	O

Mutations	O	O
at	O	O
the	O	O
PAX6	O	O
locus	O	O
are	O	O
found	O	O
in	O	O
heterogeneous	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
malformations	I-Disease	C537775
including	O	O
Peters	B-Disease	C537884
'	I-Disease	C537884
anomaly	I-Disease	C537884
.	O	O

Mutation	O	O
or	O	O
deletion	O	O
of	O	O
the	O	O
PAX6	O	O
gene	O	O
underlies	O	O
many	O	O
cases	O	O
of	O	O
aniridia	B-Disease	D015783
.	O	O

Three	O	O
lines	O	O
of	O	O
evidence	O	O
now	O	O
converge	O	O
to	O	O
implicate	O	O
PAX6	O	O
more	O	O
widely	O	O
in	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
malformations	I-Disease	C537775
including	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
.	O	O

First	O	O
,	O	O
a	O	O
child	O	O
with	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
is	O	O
deleted	O	O
for	O	O
one	O	O
copy	O	O
of	O	O
PAX6	O	O
.	O	O

Second	O	O
,	O	O
affected	O	O
members	O	O
of	O	O
a	O	O
family	O	O
with	O	O
dominantly	O	O
inherited	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
malformations	I-Disease	C537775
,	O	O
including	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
are	O	O
heterozygous	O	O
for	O	O
an	O	O
R26G	O	O
mutation	O	O
in	O	O
the	O	O
PAX6	O	O
paired	O	O
box	O	O
.	O	O

Third	O	O
,	O	O
a	O	O
proportion	O	O
of	O	O
Sey	O	O
/	O	O
+	O	O
Smalleye	O	O
mice	O	O
,	O	O
heterozygous	O	O
for	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
murine	O	O
Pax	O	O
-	O	O
6	O	O
,	O	O
have	O	O
an	O	O
ocular	O	O
phenotype	O	O
resembling	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
.	O	O

We	O	O
therefore	O	O
propose	O	O
that	O	O
a	O	O
variety	O	O
of	O	O
anterior	B-Disease	C537775
segment	I-Disease	C537775
anomalies	I-Disease	C537775
may	O	O
be	O	O
associated	O	O
with	O	O
PAX6	O	O
mutations	O	O
.	O	O

.	O	O

In	O	O
Swedish	O	O
families	O	O
with	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
,	O	O
linkage	O	O
to	O	O
the	O	O
HPC1	O	O
locus	O	O
on	O	O
chromosome	O	O
1q24	O	O
-	O	O
25	O	O
is	O	O
restricted	O	O
to	O	O
families	O	O
with	O	O
early	O	O
-	O	O
onset	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

Prostate	B-Disease	D011471
cancer	I-Disease	D011471
clusters	O	O
in	O	O
some	O	O
families	O	O
,	O	O
and	O	O
an	O	O
estimated	O	O
5	O	O
%	O	O
-	O	O
10	O	O
%	O	O
of	O	O
all	O	O
cases	O	O
are	O	O
estimated	O	O
to	O	O
result	O	O
from	O	O
inheritance	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
-	O	O
susceptibility	O	O
genes	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
evidence	O	O
of	O	O
linkage	O	O
to	O	O
the	O	O
1q24	O	O
-	O	O
25	O	O
region	O	O
(	O	O
HPC1	O	O
)	O	O
in	O	O
91	O	O
North	O	O
American	O	O
and	O	O
Swedish	O	O
families	O	O
each	O	O
with	O	O
multiple	O	O
cases	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
(	O	O
Smith	O	O
et	O	O
al	O	O
.	O	O

1996	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
report	O	O
we	O	O
analyze	O	O
40	O	O
(	O	O
12	O	O
original	O	O
and	O	O
28	O	O
newly	O	O
identified	O	O
)	O	O
Swedish	O	O
families	O	O
with	O	O
hereditary	B-Disease	C537243
prostate	I-Disease	C537243
cancer	I-Disease	C537243
(	O	O
HPC	B-Disease	C537243
)	O	O
that	O	O
,	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
40	O	O
markers	O	O
spanning	O	O
a	O	O
25	O	O
-	O	O
cM	O	O
interval	O	O
within	O	O
1q24	O	O
-	O	O
25	O	O
,	O	O
have	O	O
evidence	O	O
of	O	O
linkage	O	O
.	O	O

In	O	O
the	O	O
complete	O	O
set	O	O
of	O	O
families	O	O
,	O	O
a	O	O
maximum	O	O
two	O	O
-	O	O
point	O	O
LOD	O	O
score	O	O
of	O	O
1	O	O
.	O	O

10	O	O
was	O	O
observed	O	O
at	O	O
D1S413	O	O
(	O	O
at	O	O
a	O	O
recombination	O	O
fraction	O	O
[	O	O
theta	O	O
]	O	O
of	O	O
.	O	O

1	O	O
)	O	O
,	O	O
with	O	O
a	O	O
maximum	O	O
NPL	O	O
(	O	O
nonparametric	O	O
linkage	O	O
)	O	O
Z	O	O
score	O	O
of	O	O
1	O	O
.	O	O

64	O	O
at	O	O
D1S202	O	O
(	O	O
P	O	O
=	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
evidence	O	O
of	O	O
linkage	O	O
to	O	O
this	O	O
region	O	O
originated	O	O
almost	O	O
exclusively	O	O
from	O	O
the	O	O
subset	O	O
of	O	O
12	O	O
early	O	O
-	O	O
onset	O	O
(	O	O
age	O	O
<	O	O
65	O	O
years	O	O
)	O	O
families	O	O
,	O	O
which	O	O
yielded	O	O
a	O	O
maximum	O	O
LOD	O	O
score	O	O
of	O	O
2	O	O
.	O	O

38	O	O
at	O	O
D1S413	O	O
(	O	O
straight	O	O
theta	O	O
=	O	O
0	O	O
)	O	O
and	O	O
an	O	O
NPL	O	O
Z	O	O
score	O	O
of	O	O
1	O	O
.	O	O

95	O	O
at	O	O
D1S422	O	O
(	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
.	O	O

Estimates	O	O
from	O	O
heterogeneity	O	O
tests	O	O
suggest	O	O
that	O	O
,	O	O
within	O	O
Sweden	O	O
,	O	O
as	O	O
many	O	O
as	O	O
50	O	O
%	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
families	O	O
had	O	O
evidence	O	O
of	O	O
linkage	O	O
to	O	O
the	O	O
HPC1	O	O
region	O	O
.	O	O

These	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
of	O	O
linkage	O	O
to	O	O
HPC1	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
families	O	O
with	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
,	O	O
particularly	O	O
those	O	O
with	O	O
an	O	O
early	O	O
age	O	O
at	O	O
diagnosis	O	O
.	O	O

Localisation	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
locus	O	O
to	O	O
19q13	O	O
.	O	O

2	O	O
-	O	O
19q13	O	O
.	O	O

3	O	O
and	O	O
its	O	O
relationship	O	O
to	O	O
twelve	O	O
polymorphic	O	O
loci	O	O
on	O	O
19q	O	O
.	O	O

The	O	O
order	O	O
of	O	O
fourteen	O	O
polymorphic	O	O
markers	O	O
localised	O	O
to	O	O
the	O	O
long	O	O
arm	O	O
of	O	O
human	O	O
chromosome	O	O
19	O	O
has	O	O
been	O	O
established	O	O
by	O	O
multipoint	O	O
mapping	O	O
in	O	O
a	O	O
set	O	O
of	O	O
40	O	O
CEPH	O	O
(	O	O
Centre	O	O
dEtude	O	O
de	O	O
Polymorphisme	O	O
Humain	O	O
,	O	O
Paris	O	O
)	O	O
reference	O	O
families	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
linkage	O	O
relationship	O	O
of	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
locus	O	O
to	O	O
twelve	O	O
of	O	O
these	O	O
markers	O	O
as	O	O
studied	O	O
in	O	O
45	O	O
families	O	O
with	O	O
DM	B-Disease	D009223
.	O	O

The	O	O
resulting	O	O
genetic	O	O
map	O	O
is	O	O
supported	O	O
by	O	O
the	O	O
localisation	O	O
of	O	O
the	O	O
DNA	O	O
markers	O	O
in	O	O
a	O	O
panel	O	O
of	O	O
somatic	O	O
cell	O	O
hybrids	O	O
.	O	O

Ten	O	O
of	O	O
the	O	O
twelve	O	O
markers	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
proximal	O	O
to	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
and	O	O
two	O	O
,	O	O
PRKCG	O	O
and	O	O
D19S22	O	O
,	O	O
distal	O	O
but	O	O
at	O	O
distances	O	O
of	O	O
approximately	O	O
25	O	O
cM	O	O
and	O	O
15	O	O
cM	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
closest	O	O
proximal	O	O
markers	O	O
are	O	O
APOC2	O	O
(	O	O
apolipoprotein	O	O
C	O	O
-	O	O
II	O	O
)	O	O
and	O	O
CKM	O	O
(	O	O
creatine	O	O
kinase	O	O
,	O	O
muscle	O	O
)	O	O
approximately	O	O
3	O	O
cM	O	O
and	O	O
2	O	O
cM	O	O
from	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
order	O	O
APOC2	O	O
-	O	O
CKM	O	O
-	O	O
DM	B-Disease	D009223
.	O	O

The	O	O
distance	O	O
between	O	O
APOC2	O	O
,	O	O
CKM	O	O
and	O	O
DM	B-Disease	D009223
(	O	O
of	O	O
the	O	O
order	O	O
of	O	O
2	O	O
million	O	O
base	O	O
pairs	O	O
)	O	O
and	O	O
their	O	O
known	O	O
orientation	O	O
should	O	O
permit	O	O
directional	O	O
chromosome	O	O
walking	O	O
and	O	O
jumping	O	O
.	O	O

The	O	O
data	O	O
presented	O	O
here	O	O
should	O	O
enable	O	O
us	O	O
to	O	O
determine	O	O
whether	O	O
or	O	O
not	O	O
new	O	O
markers	O	O
are	O	O
distal	O	O
to	O	O
APOC2	O	O
/	O	O
CKM	O	O
and	O	O
thus	O	O
potentially	O	O
flank	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
.	O	O

.	O	O

A	O	O
recurrent	O	O
expansion	O	O
of	O	O
a	O	O
maternal	O	O
allele	O	O
with	O	O
36	O	O
CAG	O	O
repeats	O	O
causes	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
in	O	O
two	O	O
sisters	O	O
.	O	O

Large	O	O
intergenerational	O	O
repeat	O	O
expansions	O	O
of	O	O
the	O	O
CAG	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
have	O	O
been	O	O
well	O	O
documented	O	O
for	O	O
the	O	O
male	O	O
germline	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
recurrent	O	O
large	O	O
expansion	O	O
of	O	O
a	O	O
maternal	O	O
allele	O	O
with	O	O
36	O	O
CAG	O	O
repeats	O	O
(	O	O
to	O	O
66	O	O
and	O	O
57	O	O
repeats	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
two	O	O
daughters	O	O
)	O	O
associated	O	O
with	O	O
onset	O	O
of	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
in	O	O
the	O	O
second	O	O
and	O	O
third	O	O
decade	O	O
in	O	O
a	O	O
family	O	O
without	O	O
history	O	O
of	O	O
HD	B-Disease	D006816
.	O	O

Our	O	O
findings	O	O
give	O	O
evidence	O	O
of	O	O
a	O	O
gonadal	O	O
mosaicism	O	O
in	O	O
the	O	O
unaffected	O	O
mother	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
large	O	O
expansions	O	O
also	O	O
occur	O	O
in	O	O
the	O	O
female	O	O
germline	O	O
and	O	O
that	O	O
a	O	O
negative	O	O
selection	O	O
of	O	O
oocytes	O	O
with	O	O
long	O	O
repeats	O	O
might	O	O
explain	O	O
the	O	O
different	O	O
instability	O	O
behavior	O	O
of	O	O
the	O	O
male	O	O
and	O	O
the	O	O
female	O	O
germlines	O	O
.	O	O

.	O	O

Germline	O	O
E	O	O
-	O	O
cadherin	O	O
gene	O	O
(	O	O
CDH1	O	O
)	O	O
mutations	O	O
predispose	O	O
to	O	O
familial	B-Disease	D013274
gastric	I-Disease	D013274
cancer	I-Disease	D013274
and	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Inherited	O	O
mutations	O	O
in	O	O
the	O	O
E	O	O
-	O	O
cadherin	O	O
gene	O	O
(	O	O
CDH1	O	O
)	O	O
were	O	O
described	O	O
recently	O	O
in	O	O
three	O	O
Maori	O	O
kindreds	O	O
with	O	O
familial	B-Disease	D013274
gastric	I-Disease	D013274
cancer	I-Disease	D013274
.	O	O

Familial	B-Disease	D013274
gastric	I-Disease	D013274
cancer	I-Disease	D013274
is	O	O
genetically	O	O
heterogeneous	O	O
and	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
what	O	O
proportion	O	O
of	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
susceptibility	O	O
in	O	O
non	O	O
-	O	O
Maori	O	O
populations	O	O
is	O	O
due	O	O
to	O	O
germline	O	O
CDH1	O	O
mutations	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
screened	O	O
eight	O	O
familial	B-Disease	D013274
gastric	I-Disease	D013274
cancer	I-Disease	D013274
kindreds	O	O
of	O	O
British	O	O
and	O	O
Irish	O	O
origin	O	O
for	O	O
germline	O	O
CDH1	O	O
mutations	O	O
,	O	O
by	O	O
SSCP	O	O
analysis	O	O
of	O	O
all	O	O
16	O	O
exons	O	O
and	O	O
flanking	O	O
sequences	O	O
.	O	O

Each	O	O
family	O	O
contained	O	O
(	O	O
i	O	O
)	O	O
two	O	O
cases	O	O
of	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
in	O	O
first	O	O
degree	O	O
relatives	O	O
with	O	O
one	O	O
affected	O	O
before	O	O
age	O	O
50	O	O
years	O	O
;	O	O
or	O	O
(	O	O
ii	O	O
)	O	O
three	O	O
or	O	O
more	O	O
cases	O	O
of	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
.	O	O

Novel	O	O
germline	O	O
CDH1	O	O
mutations	O	O
(	O	O
a	O	O
nonsense	O	O
and	O	O
a	O	O
splice	O	O
site	O	O
)	O	O
were	O	O
detected	O	O
in	O	O
two	O	O
families	O	O
(	O	O
25	O	O
%	O	O
)	O	O
.	O	O

Both	O	O
mutations	O	O
were	O	O
predicted	O	O
to	O	O
truncate	O	O
the	O	O
E	O	O
-	O	O
cadherin	O	O
protein	O	O
in	O	O
the	O	O
signal	O	O
peptide	O	O
domain	O	O
.	O	O

In	O	O
one	O	O
family	O	O
there	O	O
was	O	O
evidence	O	O
of	O	O
non	O	O
-	O	O
penetrance	O	O
and	O	O
susceptibility	O	O
to	O	O
both	O	O
gastric	B-Disease	D015179
and	I-Disease	D015179
colorectal	I-Disease	D015179
cancer	I-Disease	D015179
;	O	O
thus	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
six	O	O
cases	O	O
of	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
,	O	O
a	O	O
CDH1	O	O
mutation	O	O
carrier	O	O
developed	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
at	O	O
age	O	O
30	O	O
years	O	O
.	O	O

We	O	O
have	O	O
confirmed	O	O
that	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
CDH1	O	O
gene	O	O
cause	O	O
familial	B-Disease	D013274
gastric	I-Disease	D013274
cancer	I-Disease	D013274
in	O	O
non	O	O
-	O	O
Maori	O	O
populations	O	O
.	O	O

However	O	O
,	O	O
only	O	O
a	O	O
minority	O	O
of	O	O
familial	O	O
gastric	B-Disease	D013274
cancers	I-Disease	D013274
can	O	O
be	O	O
accounted	O	O
for	O	O
by	O	O
CDH1	O	O
mutations	O	O
.	O	O

Loss	O	O
of	O	O
E	O	O
-	O	O
cadherin	O	O
function	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
sporadic	O	O
colorectal	B-Disease	D015179
and	I-Disease	D015179
other	I-Disease	D015179
cancers	I-Disease	D015179
,	O	O
and	O	O
our	O	O
findings	O	O
provide	O	O
evidence	O	O
that	O	O
germline	O	O
CDH1	O	O
mutations	O	O
predispose	O	O
to	O	O
early	O	O
onset	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Thus	O	O
,	O	O
CDH1	O	O
should	O	O
be	O	O
investigated	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
inherited	O	O
susceptibility	O	O
to	O	O
both	O	O
gastric	B-Disease	D015179
and	I-Disease	D015179
colorectal	I-Disease	D015179
cancers	I-Disease	D015179
.	O	O

Germinal	O	O
mosaicism	O	O
in	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
pedigree	O	O
where	O	O
the	O	O
disease	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
molecular	O	O
deletion	O	O
within	O	O
the	O	O
DMD	B-Disease	D020388
locus	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
meiotic	O	O
segregation	O	O
products	O	O
of	O	O
the	O	O
common	O	O
female	O	O
ancestor	O	O
using	O	O
marker	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
(	O	O
RFLPs	O	O
)	O	O
detected	O	O
by	O	O
probes	O	O
that	O	O
lie	O	O
within	O	O
this	O	O
deletion	O	O
.	O	O

These	O	O
studies	O	O
show	O	O
that	O	O
this	O	O
female	O	O
has	O	O
transmitted	O	O
three	O	O
distinct	O	O
types	O	O
of	O	O
X	O	O
chromosome	O	O
to	O	O
her	O	O
offspring	O	O
.	O	O

This	O	O
observation	O	O
may	O	O
be	O	O
explained	O	O
by	O	O
postulating	O	O
that	O	O
the	O	O
mutation	O	O
arose	O	O
as	O	O
a	O	O
postzygotic	O	O
deletion	O	O
within	O	O
this	O	O
common	O	O
ancestor	O	O
,	O	O
who	O	O
was	O	O
consequently	O	O
germinally	O	O
mosaic	O	O
.	O	O

.	O	O

Expression	O	O
of	O	O
the	O	O
murine	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
in	O	O
muscle	O	O
and	O	O
brain	O	O
.	O	O

Complementary	O	O
DNA	O	O
clones	O	O
were	O	O
isolated	O	O
that	O	O
represent	O	O
the	O	O
5	O	O
terminal	O	O
2	O	O
.	O	O

5	O	O
kilobases	O	O
of	O	O
the	O	O
murine	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
Dmd	O	O
)	O	O
messenger	O	O
RNA	O	O
(	O	O
mRNA	O	O
)	O	O
.	O	O

Mouse	O	O
Dmd	O	O
mRNA	O	O
was	O	O
detectable	O	O
in	O	O
skeletal	O	O
and	O	O
cardiac	O	O
muscle	O	O
and	O	O
at	O	O
a	O	O
level	O	O
approximately	O	O
90	O	O
percent	O	O
lower	O	O
in	O	O
brain	O	O
.	O	O

Dmd	O	O
mRNA	O	O
is	O	O
also	O	O
present	O	O
,	O	O
but	O	O
at	O	O
much	O	O
lower	O	O
than	O	O
normal	O	O
levels	O	O
,	O	O
in	O	O
both	O	O
the	O	O
muscle	O	O
and	O	O
brain	O	O
of	O	O
three	O	O
different	O	O
strains	O	O
of	O	O
dystrophic	B-Disease	D020388
mdx	O	O
mice	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
Dmd	O	O
mRNA	O	O
in	O	O
brain	O	O
raises	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
relation	O	O
between	O	O
human	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
gene	O	O
expression	O	O
and	O	O
the	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
found	O	O
in	O	O
some	O	O
DMD	B-Disease	D020388
males	O	O
.	O	O

These	O	O
results	O	O
also	O	O
provide	O	O
evidence	O	O
that	O	O
the	O	O
mdx	O	O
mutations	O	O
are	O	O
allelic	O	O
variants	O	O
of	O	O
mouse	O	O
Dmd	O	O
gene	O	O
mutations	O	O
.	O	O

Human	O	O
peroxisomal	O	O
targeting	O	O
signal	O	O
-	O	O
1	O	O
receptor	O	O
restores	O	O
peroxisomal	O	O
protein	O	O
import	O	O
in	O	O
cells	O	O
from	O	O
patients	O	O
with	O	O
fatal	O	O
peroxisomal	B-Disease	D018901
disorders	I-Disease	D018901
.	O	O

Two	O	O
peroxisomal	O	O
targeting	O	O
signals	O	O
,	O	O
PTS1	O	O
and	O	O
PTS2	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
import	O	O
of	O	O
proteins	O	O
into	O	O
the	O	O
peroxisome	O	O
matrix	O	O
.	O	O

Human	O	O
patients	O	O
with	O	O
fatal	O	O
generalized	O	O
peroxisomal	B-Disease	D018901
deficiency	I-Disease	D018901
disorders	I-Disease	D018901
fall	O	O
into	O	O
at	O	O
least	O	O
nine	O	O
genetic	O	O
complementation	O	O
groups	O	O
.	O	O

Cells	O	O
from	O	O
many	O	O
of	O	O
these	O	O
patients	O	O
are	O	O
deficient	O	O
in	O	O
the	O	O
import	O	O
of	O	O
PTS1	O	O
-	O	O
containing	O	O
proteins	O	O
,	O	O
but	O	O
the	O	O
causes	O	O
of	O	O
the	O	O
protein	O	O
-	O	O
import	O	O
defect	O	O
in	O	O
these	O	O
patients	O	O
are	O	O
unknown	O	O
.	O	O

We	O	O
have	O	O
cloned	O	O
and	O	O
sequenced	O	O
the	O	O
human	O	O
cDNA	O	O
homologue	O	O
(	O	O
PTS1R	O	O
)	O	O
of	O	O
the	O	O
Pichia	O	O
pastoris	O	O
PAS8	O	O
gene	O	O
,	O	O
the	O	O
PTS1	O	O
receptor	O	O
(	O	O
McCollum	O	O
,	O	O
D	O	O
.	O	O

,	O	O
E	O	O
.	O	O

Monosov	O	O
,	O	O
and	O	O
S	O	O
.	O	O

Subramani	O	O
.	O	O

1993	O	O
.	O	O

J	O	O
.	O	O

Cell	O	O
Biol	O	O
.	O	O

121	O	O
761	O	O
-	O	O
774	O	O
)	O	O
.	O	O

The	O	O
PTS1R	O	O
mRNA	O	O
is	O	O
expressed	O	O
in	O	O
all	O	O
human	O	O
tissues	O	O
examined	O	O
.	O	O

Antibodies	O	O
to	O	O
the	O	O
human	O	O
PTS1R	O	O
recognize	O	O
this	O	O
protein	O	O
in	O	O
human	O	O
,	O	O
monkey	O	O
,	O	O
rat	O	O
,	O	O
and	O	O
hamster	O	O
cells	O	O
.	O	O

The	O	O
protein	O	O
is	O	O
localized	O	O
mainly	O	O
in	O	O
the	O	O
cytosol	O	O
but	O	O
is	O	O
also	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
peroxisomes	O	O
.	O	O

Part	O	O
of	O	O
the	O	O
peroxisomal	O	O
PTS1R	O	O
protein	O	O
is	O	O
tightly	O	O
bound	O	O
to	O	O
the	O	O
peroxisomal	O	O
membrane	O	O
.	O	O

Antibodies	O	O
to	O	O
PTS1R	O	O
inhibit	O	O
peroxisomal	O	O
protein	O	O
-	O	O
import	O	O
of	O	O
PTS1	O	O
-	O	O
containing	O	O
proteins	O	O
in	O	O
a	O	O
permeabilized	O	O
CHO	O	O
cell	O	O
system	O	O
.	O	O

In	O	O
vitro	O	O
-	O	O
translated	O	O
PTS1R	O	O
protein	O	O
specifically	O	O
binds	O	O
a	O	O
serine	O	O
-	O	O
lysine	O	O
-	O	O
leucine	O	O
-	O	O
peptide	O	O
.	O	O

A	O	O
PAS8	O	O
-	O	O
PTS1R	O	O
fusion	O	O
protein	O	O
complements	O	O
the	O	O
P	O	O
.	O	O

pastoris	O	O
pas8	O	O
mutant	O	O
.	O	O

The	O	O
PTS1R	O	O
cDNA	O	O
also	O	O
complements	O	O
the	O	O
PTS1	B-Disease	OMIM:202370
protein	I-Disease	OMIM:202370
-	I-Disease	OMIM:202370
import	I-Disease	OMIM:202370
defect	I-Disease	OMIM:202370
in	O	O
skin	O	O
fibroblasts	O	O
from	O	O
patients	O	O
-	O	O
-	O	O
belonging	O	O
to	O	O
complementation	O	O
group	O	O
two	O	O
-	O	O
-	O	O
diagnosed	O	O
as	O	O
having	O	O
neonatal	B-Disease	OMIM:202370
adrenoleukodystrophy	I-Disease	OMIM:202370
or	O	O
Zellweger	B-Disease	D015211
syndrome	I-Disease	D015211
.	O	O

The	O	O
PTS1R	O	O
gene	O	O
has	O	O
been	O	O
localized	O	O
to	O	O
a	O	O
chromosomal	O	O
location	O	O
where	O	O
no	O	O
other	O	O
peroxisomal	B-Disease	D018901
disorder	I-Disease	D018901
genes	O	O
are	O	O
known	O	O
to	O	O
map	O	O
.	O	O

Our	O	O
findings	O	O
represent	O	O
the	O	O
only	O	O
case	O	O
in	O	O
which	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
the	O	O
protein	B-Disease	D008661
-	I-Disease	D008661
import	I-Disease	D008661
deficiency	I-Disease	D008661
in	O	O
human	O	O
peroxisomal	B-Disease	D018901
disorders	I-Disease	D018901
is	O	O
understood	O	O
.	O	O

